<SEC-DOCUMENT>0001213900-25-062110.txt : 20250708
<SEC-HEADER>0001213900-25-062110.hdr.sgml : 20250708
<ACCEPTANCE-DATETIME>20250708171236
ACCESSION NUMBER:		0001213900-25-062110
CONFORMED SUBMISSION TYPE:	F-4/A
PUBLIC DOCUMENT COUNT:		141
FILED AS OF DATE:		20250708
DATE AS OF CHANGE:		20250708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282351
		FILM NUMBER:		251111683

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-4/A
<SEQUENCE>1
<FILENAME>ea0248138-f4a9_scisparc.htm
<DESCRIPTION>AMENDMENT NO. 9 TO FORM F-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 20:39:34 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sprcy="http://trpx.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="-keep: true">As filed with the
Securities and Exchange Commission on July 8, 2025</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No.&#160;333-282351</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-85099">Amendment No. 9</ix:nonNumeric> to</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span style="-sec-ix-hidden: hidden-fact-0">F-4</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REGISTRATION STATEMENT </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Under </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>The Securities Act of 1933 </i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-84"><b>SciSparc Ltd.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-top: 0.2pt; padding-right: 0.2pt; padding-left: 0.2pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-85100">Israel</ix:nonNumeric></b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt 0.2pt 1.5pt; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-top: 0.2pt; padding-right: 0.2pt; padding-left: 0.2pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>2834</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt 0.2pt 1.5pt; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-top: 0.2pt; padding-right: 0.2pt; padding-left: 0.2pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Not Applicable</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; text-align: center; vertical-align: top"><b>(State or Other Jurisdiction of<br/> Incorporation or Organization)</b></td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; vertical-align: bottom">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(Primary Standard Industrial<br/> Classification Code Number)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; vertical-align: bottom">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; text-align: center; vertical-align: top"><b>(I.R.S.&#160;Employer <br/> Identification Number)</b></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-85101">20 Raul Wallenberg Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-85102">Tower A</ix:nonNumeric>,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-85103">Tel Aviv</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-85104">6971916</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-85105">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-85106">(+972)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-85107">(3) 717-5777</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address, including zip code, and telephone
number, including area code, of Registrant&#8217;s principal executive offices) </b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-160"><b>Puglisi &amp; Associates</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-85108">850 Library Ave.</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-85109">Suite 204</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-85110">Newark</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressStateOrProvince" id="ixv-85111">DE</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-85112">19711</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-85113">(302)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-85114">738-6680</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Please send copies of all communications to:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; text-align: center; vertical-align: top; width: 24%"><b>Shachar
    Hadar, Adv. <br/>
    Matthew Rudolph, Adv.<br/>
    Meitar | Law Offices<br/>
    16 Abba Hillel Silver Rd. <br/>
    Ramat Gan 52506, Israel <br/>
    Tel: (+972) (3) 610-3100</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; text-align: center; vertical-align: top; width: 23%"><b>Oded
    Har-Even, Esq. <br/>
    Howard Berkenblit, Esq. <br/>
    Sullivan &amp; Worcester LLP<br/>
    1251 Avenue of the Americas <br/>
    New York, NY 10020 <br/>
    Tel: (212) 660-3000</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 23%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>David
                                            Huberman, Esq.<br/>
                                            Greenberg Traurig, P.A.<br/>
                                            One Azrieli Center<br/>
                                            Round Tower, 30<sup>th</sup>&#160;floor<br/>
                                            132 Menachem Begin Rd<br/>
                                            Tel Aviv 6701101<br/>
                                            Telephone: 312.364.1633</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.2pt; vertical-align: top; width: 24%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Gregory
                                            Irgo, Adv.<br/>
                                            Ido Zaborof, Adv.<br/>
                                            Lipa Meir &amp; Co., <br/>
                                            Advocates<br/>
                                            2 Weizmann St.,<br/>
                                            Tel Aviv 6423902, Israel<br/>
                                            Tel: (+972) (3) 607 0603</b></p>
</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effectiveness of this registration statement and
the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this Form is filed
to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If applicable, place
an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Exchange Act&#160;Rule&#160;13e-4(i)&#160;(Cross-Border
Issuer Tender Offer) <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Exchange Act&#160;Rule&#160;14d-1(d)&#160;(Cross-Border
Third-Party Tender Offer) <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Emerging growth company
<ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-291"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)
of the Securities Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&#160;a further amendment
that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the
Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"><b>&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 8pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="color: Red"><b>The
information in this proxy statement/prospectus is not complete and may be changed. SciSparc may not sell its securities pursuant to the
proposed transactions until the Registration Statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus
is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where
the offer or sale is not permitted.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="color: Red"><b>&#160;</b></span></p><div>

</div><p style="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Preliminary Proxy
Statement, Subject to Completion dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2025</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: red"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg" style="height: 108.75pt; width: 108.75pt"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PROPOSED MERGER<br/>
YOUR VOTE IS VERY IMPORTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">To the Shareholders of SciSparc
Ltd.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">You are cordially invited
to attend a special meeting of the shareholders of SciSparc Ltd., or SciSparc, an Israeli limited company, which we refer to as &#8220;we,&#8221;
&#8220;SciSparc,&#8221; or the &#8220;Company,&#8221; which will be held at 3:00 p.m., local time, on August 25, 2025, at the Company&#8217;s
offices, at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel, unless postponed or adjourned to a later date. This is an important
meeting that affects your investment in SciSparc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, SciSparc
and AutoMax Motors Ltd., an Israeli limited company, or AutoMax, entered into an Agreement and Plan of Merger as amended on August 14,
2024, November 26, 2024, March 27, 2025, and on May 8, 2025 or the Merger Agreement, pursuant to which SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of SciSparc, or Merger Sub, will merge with and into AutoMax, with AutoMax surviving as a
wholly-owned subsidiary of SciSparc. Ordinary shares, as well as pre-funded warrants exercisable into ordinary shares, of SciSparc will
be issued to AutoMax&#8217;s shareholders at the effective time of such merger, or the Merger. The final exchange ratio, or the Exchange
Ratio, has been determined pursuant to a formula described in more detail in the Merger Agreement and later in this proxy statement/prospectus.
Under the Exchange Ratio formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders, and
M.R.M Merhavit Holding &amp; Management Ltd, or the Advisor, in connection with the Merger, are expected to own approximately 49.99%
of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions, and as further defined in the Merger Agreement,
and SciSparc&#8217;s shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis,
subject to certain exceptions. The Merger has been unanimously approved by the boards of directors of both companies and will be presented
for approval by the shareholders of AutoMax. On August 14, 2024, the parties entered into an addendum to the Merger Agreement, or the
Merger Agreement Addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by August
30, 2024, was deferred to November 30, 2024. On November 26, 2024, the parties entered into a second addendum to the Merger Agreement,
or the Merger Agreement Second Addendum, pursuant to which the right to terminate the Merger Agreement, if the Merger was not consummated
by November 30, 2024, was deferred to March 31, 2025. On March 27, 2025, the parties entered into a third addendum to the Merger Agreement,
or the Merger Agreement Third Addendum, pursuant to which the right to terminate the Merger Agreement, if the Merger was not consummated
by March 31, 2025, was deferred to September 30, 2025, and the definition of &#8220;Exchange Ratio&#8221; was revised to remove the rounding
to four decimal places of the Exchange Ratio. On May 8, 2025, the parties entered into a fourth addendum to the Merger Agreement, or
the Merger Agreement Fourth Addendum, pursuant to which the definition of &#8220;Bondholders&#8221; was revised to include holders of
AutoMax&#8217;s Series C Bonds. The Merger is expected to close in the third quarter of 2025, subject to the approval of SciSparc&#8217;s
shareholders, approval of the AutoMax shareholders, including a separate approval by AutoMax shareholders who are not controlling shareholders
of AutoMax or SciSparc, and court approval (as further detailed under &#8220;Regulatory Approvals&#8221;), as well as other customary
conditions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the effective time of
the Merger, the officers of SciSparc will include Mr. Oz Adler, Chief Executive Officer and Chief Financial Officer and Dr. Adi Zuloff-Shani,
Chief Technology Officer. In addition, each of Mr. Alon Dayan, Mr. Lior Vider and Mr. Itschak Shrem will resign from SciSparc&#8217;s
board of directors upon the effective time of the Merger. In accordance with the Merger Agreement and subject to the approval by the
SciSparc shareholders of Proposal No. 1 at the Special Meeting and immediately upon the resignation of Mr. Dayan and Mr. Vider from SciSparc&#8217;s
board of directors in accordance with the terms of the Merger Agreement, AutoMax&#8217;s designees to SciSparc&#8217;s board of directors
will be assigned to two separate classes, whereby one such designee will be assigned to Class I with a term of office expiring at the
annual general meeting of SciSparc to be held in 2027 and the other such designee will be assigned to Class III with a term of office
expiring at the annual general meeting of SciSparc to be held in 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s ordinary
shares are currently listed on the Nasdaq Capital Market under the symbol &#8220;SPRC.&#8221; Prior to consummation of the Merger, SciSparc
intends to file an additional listing application with Nasdaq, as required by Nasdaq to effect the additional listing of SciSparc&#8217;s
ordinary shares issuable in connection with the Merger. After completion of the Merger, SciSparc will continue to trade on the Nasdaq
Capital Market under SciSparc&#8217;s existing name, SciSparc Ltd., and existing trading symbol, &#8220;SPRC&#8221;. The closing price
of SciSparc&#8217;s ordinary shares on Nasdaq as of July 3, 2025, the latest practicable date before the date of this prospectus, was
$6.60.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is holding a special
meeting of shareholders, or the Special Meeting, for the following purposes, as more fully described in the accompanying proxy statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. To approve the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
indemnification agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, or the Indemnification
Agreement, effective upon the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement
with all office holders of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed
to the board of directors of SciSparc;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, chairman of the board
of directors, or Chairman, and President, contingent upon the approval and the closing of the Merger; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We know of no other matters
to be submitted at the Special Meeting other than as specified herein. If any other business is properly brought before the Special Meeting,
the persons named as proxies may vote in respect thereof in accordance with their best judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After
                                            careful consideration, SciSparc&#8217;s board of directors has determined that the Merger
                                            is fair to and in the best interests of SciSparc and its shareholders, has approved the Merger
                                            Agreement, the Merger, the issuance of ordinary shares and the pre-funded warrants of SciSparc
                                            to AutoMax&#8217;s shareholders pursuant to the terms of the Merger Agreement, the approval
                                            of form of Indemnification Agreement, the approval of a one-time cash bonus to SciSparc&#8217;s
                                            Chief Executive Officer, Chairman and President, contingent upon the approval and the closing
                                            of the Merger, the appointment of each of Tomer Levy and Yaarah Alfi to serve on the SciSparc
                                            board of directors upon of the effective time of the Merger, the ratification of the class
                                            structure of the SciSparc board of directors, and the other actions contemplated by the Merger
                                            Agreement, and has determined to recommend that the SciSparc shareholders vote to approve
                                            each of the proposals set forth in this proxy statement/prospectus. Accordingly, SciSparc&#8217;s
                                            board of directors unanimously recommends that the SciSparc shareholders vote FOR each of
                                            the Proposals Nos. 1 through 4 described above.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Your vote is very important,
regardless of the number of shares you own.</b> Whether or not you expect to attend the Special Meeting in person, please complete, date,
sign and promptly return the accompanying proxy card in the enclosed postage paid envelope to ensure that your shares will be represented
and voted at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More information about SciSparc,
AutoMax and the proposed transactions is contained in this proxy statement/prospectus. SciSparc urges you to read this proxy statement/prospectus
carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;<b><span style="text-decoration:underline">RISK FACTORS</span></b>&#8221;
BEGINNING ON PAGE 11.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is excited about
the opportunities the Merger brings to its shareholders, and thanks you for your consideration and continued support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">/s/ Amitay Weiss</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay
    Weiss</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman
    of the Board</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>None of the Securities and Exchange Commission,
the Israel Securities Authority or any state securities commission has approved or disapproved the Merger described in this proxy statement/prospectus
or the SciSparc ordinary shares and pre-funded warrants to be issued in connection with the Merger or passed upon the adequacy or accuracy
of this proxy statement/prospectus. Any representation to the contrary is a criminal offense.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying proxy
statement is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, and is first being mailed to SciSparc shareholders on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PRELIMINARY PROXY STATEMENT,
SUBJECT TO COMPLETION<br/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>SCISPARC LTD.<br/>
20 RAUL WALLENBERG ST.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>TOWER A, 2<sup>ND</sup> FLOOR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>TEL AVIV 6971916 ISRAEL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b style="-keep: true">NOTICE OF SPECIAL MEETING
OF SHAREHOLDERS</b><b><br/>
<span style="-keep: true">TO BE HELD ON AUGUST 25, 2025</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Dear Shareholders of SciSparc
Ltd.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">You are cordially invited
to attend the Special Meeting of the shareholders of SciSparc Ltd., or SciSparc, to be held at 3:00 p.m., local time, on August 25, 2025,
at&#160;the Company&#8217;s offices, at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel, for the following purposes:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. To approve the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, upon the effective
time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all office holders of SciSparc
to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of directors of
SciSparc;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President,
contingent upon the approval and the closing of the Merger; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We know of no other matters
to be submitted at the Special Meeting other than as specified herein. If any other business is properly brought before the Special Meeting,
the persons named as proxies may vote in respect thereof in accordance with their best judgment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Israeli law, one or
more shareholders holding at least 1% of the voting rights at the Special Meeting of the shareholders may request that the board of directors
include a matter in the agenda of a Special Meeting of the shareholders to be convened in the future, provided that it is appropriate
to discuss such a matter at the Special Meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel,
a matter relating to the appointment or removal of a director may only be requested by one or more shareholders holding at least 5% of
the voting rights at the Special Meeting of the shareholders. SciSparc&#8217;s Amended and Restated Articles of Association contain procedural
guidelines and disclosure items with respect to the submission of shareholder proposals for special meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The board of directors
of SciSparc has fixed August 4, 2025 as the record date for the determination of shareholders entitled to notice of, and to vote at,
the Special Meeting and any adjournment or postponement thereof. Only holders of record of ordinary shares of SciSparc at the close of
business on the record date are entitled to notice of, and to vote at, the Special Meeting. At the close of business on the record date,
SciSparc had ordinary shares outstanding and entitled to vote.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Your vote is important.
The affirmative vote of a simple majority of shareholders present (in person or by proxy) and voting (not including abstentions) is required
for approval of Proposals Nos. 1 and 4. The approval of each of Proposals Nos. 2, and 3, require the affirmative vote of a simple majority,
plus either (i)&#160;a simple majority of shares voted at the Special Meeting,&#160;<i>excluding</i>&#160;the shares of controlling shareholders,
if any, and of shareholders who have a personal interest in the approval of the resolution (each, an &#8220;Interested Shareholder&#8221;),
or (ii)&#160;the total number of shares of non-controlling shareholders and of shareholders who do not have a personal interest in the
resolution voting against approval of the resolution does not exceed two&#160;percent (2%) of the outstanding voting power in SciSparc.&#160;We
encourage you to read this proxy statement/prospectus carefully. If you have any questions or need assistance voting your shares, please
contact our Chief Executive Officer:</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Oz Adler</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>20 Raul Wallenberg St., Tower A, 2<sup>nd </sup>Floor,
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel Aviv Israel, 6971916</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>+972-3-7175777</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Even if you plan to attend
the Special Meeting in person, SciSparc requests that you sign and return the enclosed proxy card or grant your proxy by telephone or
through the Internet to ensure that your shares will be represented at the Special Meeting if you are unable to attend.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By Order of the Board of Directors
    of</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amitay
    Weiss</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman of the Board</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2025</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE SCISPARC BOARD OF
DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, SCISPARC
AND ITS SHAREHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE SCISPARC BOARD OF DIRECTORS RECOMMENDS THAT SCISPARC SHAREHOLDERS VOTE
&#8220;FOR&#8221; EACH SUCH PROPOSAL.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>REFERENCES TO ADDITIONAL
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This proxy statement/prospectus
incorporates important business and financial information about SciSparc that is not included in or delivered with this document. You
may obtain this information without charge through the Securities and Exchange Commission, or the SEC, website (www.sec.gov) or upon
your written or oral request by contacting the Chief Financial Officer of SciSparc Ltd., at 20 Raul Wallenberg St., Tower A, 2<sup>nd
</sup>Floor, Tel Aviv Israel, 6971916, or by calling +972-3-7175777.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>To facilitate timely
delivery of these documents, any request should be made no later than August 12, 2025 to receive them before the Special Meeting.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For additional details about
where you can find information about SciSparc, please see the section entitled &#8220;<i>Where You Can Find More Information</i>&#8221;
in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ABOUT THIS DOCUMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc Ltd., which we
refer to herein as the &#8220;Company,&#8221; &#8220;SciSparc,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221; is providing
these proxy materials in connection with the solicitation by our board of directors of proxies to be voted at a Special Meeting of our
shareholders to be held on August 25, 2025, commencing at 3:00 p.m., local time, at the Company&#8217;s offices, at 20 Raul Wallenberg
Street, Tower A, Tel Aviv 6971916 Israel, or at any adjournment or postponement thereof. This proxy statement/prospectus and the enclosed
proxy card will be mailed to each shareholder entitled to notice of, and to vote at, the Special Meeting of shareholders commencing on
or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are cautioned not
to rely on any information other than the information contained in or incorporated by reference into this proxy statement/prospectus.
No one has been authorized to provide you with information that is different from that contained in or incorporated by reference into
this proxy statement/prospectus. This proxy statement/prospectus is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. You should not assume that the information contained
in this proxy statement/prospectus is accurate as of any other date, nor should you assume that the information incorporated by reference
into this proxy statement/prospectus is accurate as of any date other than the date of such incorporated document. The mailing of this
proxy statement/prospectus to our shareholders will not create any implication to the contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Effective as of
market open on July 3, 2025, SciSparc effected a one-for-twenty-one (1-for-21) reverse share split, or the Reverse Split, of its
issued and outstanding ordinary shares, no par value per share. Unless the context expressly indicates otherwise, all references to
SciSparc&#8217;s share capital, including share and per share amounts referred to in this proxy statement/prospectus, are presented
after giving effect to the Reverse Split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>This proxy statement/prospectus
does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction
in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 90%; text-align: right"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 9.5pt"><b>Page</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_001"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">QUESTIONS
    AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">ii</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_002"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">SUMMARY</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">1</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_003"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">MARKET
    PRICE AND DIVIDEND INFORMATION</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">10</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_004"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">RISK
    FACTORS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">11</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_005"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">FORWARD-LOOKING
    STATEMENTS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">83</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_006"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THE
    SPECIAL MEETING OF SCISPARC SHAREHOLDERS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">85</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_007"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THE
    MERGER</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">88</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_008"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THE
    MERGER AGREEMENT</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">109</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_009"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AGREEMENTS
    RELATED TO THE MERGER</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">131</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_010"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">MATTERS
    BEING SUBMITTED TO A VOTE OF SCISPARC SHAREHOLDERS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">133</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_011"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">SCISPARC
    BUSINESS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">138</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_012"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AUTOMAX
    BUSINESS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">175</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_013"><span style="font-family: Times New Roman, Times, Serif">SCISPARC
    MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">188</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_014"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AUTOMAX
    MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">198</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_015"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">DIRECTORS
    AND OFFICERS OF SCISPARC FOLLOWING THE MERGER</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">204</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_016"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">RELATED
    PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">210</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_017"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">UNAUDITED
    PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">216</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_018"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">NOTES
    TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">219</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_019"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">Description
    of SHARE Capital</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">223</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_020"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">COMPARISON
    OF SHAREHOLDER RIGHTS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">230</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_021"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">PRINCIPAL
    SHAREHOLDERS OF SCISPARC</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">234</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_022"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">PRINCIPAL
    SHAREHOLDERS OF AUTOMAX</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">236</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_023"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">PRINCIPAL
    SHAREHOLDERS OF Combined company</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">238</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_024"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">LEGAL
    MATTERS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">240</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_025">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">240</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_026"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">WHERE
    YOU CAN FIND MORE INFORMATION</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">240</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt"><a href="#m_027"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">HOUSEHOLDING
    OF PROXY MATERIALS</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">241</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><a href="#f-1_001"><span style="font-size: 9.5pt">SCISPARC
    LTD. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><a href="#au_001">AUTOMAX MOTORS
    LTD. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase"><a href="#B_001">ANNEX
    A AGREEMENT AND PLAN OF MERGER AND ADDENDUMS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">A-1</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase"><a href="#B_002">ANNEX
    B FORM OF automax SHAREHOLDER SUPPORT AGREEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">B-1</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase"><a href="#B_004">ANNEX
    C INDEMNIFICATION AGREEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">C-1</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase"><a href="#B_006">ANNEX
    D SCISPARC&#8217;S AMENDED AND RESTATED Articles of association</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">D-1</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 9.5pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9.5pt; text-transform: uppercase"><a href="#B_007">ANNEX
    E tRANSLATION OF VALUATION REPORT OF E.D.B. Consulting and investments Ltd</a>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 9.5pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">E-1</td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase"></p><div>


</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">QUESTIONS
AND ANSWERS ABOUT THE SPECIAL MEETING AND THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following section provides
answers to frequently asked questions about the Merger and other matters relating to the Special Meeting. This section, however, provides
only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced
sections. SciSparc urges its shareholders to read this document in its entirety prior to making any decision.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, SciSparc
and AutoMax entered into the Merger Agreement, pursuant to which Merger Sub will merge with and into AutoMax, with AutoMax surviving
as a wholly-owned subsidiary of SciSparc. Ordinary shares of SciSparc will be issued to AutoMax&#8217;s shareholders at the effective
time of such merger, or the Merger. The Exchange Ratio will be determined pursuant to a formula described in more detail in the Merger
Agreement and later in this proxy statement/prospectus. Under the Exchange Ratio formula described in the Merger Agreement, immediately
following the Merger, AutoMax&#8217;s shareholders, and the Advisor in connection with the Merger, are expected to own approximately
49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions, and as further defined in the Merger
Agreement, and SciSparc&#8217;s shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital on a fully-diluted
basis, subject to certain exceptions. The Merger has been unanimously approved by the boards of directors of both companies and will
be presented for approval by the shareholders of AutoMax, including a separate approval by AutoMax&#8217;s shareholders who are not controlling
shareholders of AutoMax or SciSparc. On August 14, 2024, the parties entered into the Merger Agreement Addendum, pursuant to which the
rights to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024. On
November 26, 2024, the parties entered into the Merger Agreement Second Addendum, pursuant to which the right to terminate the Merger
Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025. On March 27, 2025, the parties entered
into the Merger Agreement Third Addendum, pursuant to which the right to terminate the Merger Agreement, if the Merger was not consummated
by March 31, 2025, was deferred to September 30, 2025, and the definition of &#8220;Exchange Ratio&#8221; was revised to remove the rounding
to four decimal places of the Exchange Ratio. On May 8, 2025, the parties entered into the Merger Agreement Fourth Addendum, pursuant
to which the definition of &#8220;Bondholders&#8221; was revised to include holders of AutoMax&#8217;s Series C Bonds. The Merger is
expected to close during the third quarter of 2025, subject to the approval of the shareholders of SciSparc, approval of AutoMax shareholders,
and court approval, as detailed in section entitled &#8220;<i>Regulatory Approvals</i>&#8221; in this proxy statement/prospectus, as
well as other customary conditions. Since the Merger is subject to a number of conditions, neither SciSparc nor AutoMax can anticipate
either the timing of the closing of the Merger or whether it will occur at all.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">At the effective time
of the Merger, SciSparc anticipates that per each AutoMax ordinary share AutoMax shareholders will receive the number of SciSparc&#8217;s
outstanding shares on fully-diluted basis, subject to certain exceptions, divided by 0.5001, multiplied by 0.4749, divided by the number
of AutoMax&#8217;s outstanding shares, excluding dormant shares, (minus SciSparc&#8217;s holdings in AutoMax), so, that in any event,
AutoMax shareholders (other than SciSparc), together with the Advisor in connection with the Merger, shall own approximately 49.99% of
SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions. Under the Exchange Ratio formula described in
the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders, together with its Advisor in connection with the
Merger, are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected to
own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more complete description
of the Merger, please see the section entitled &#8220;<i>The Merger Agreement</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What will happen to SciSparc if, for any
reason, the Merger does not close?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, for any reason, the Merger
does not close, the SciSparc board of directors may, following the termination of the Merger Agreement, elect to, among other things,
attempt to complete another strategic transaction similar to the Merger, attempt to sell or otherwise dispose of certain assets of SciSparc
or continue to operate the business of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Why are the two companies proposing to merge?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax believe
that the Merger will result in a combined company that will maximize shareholder value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s board of
directors considered a number of factors that supported its decision to approve the Merger Agreement. In the course of its deliberations,
SciSparc&#8217;s board of directors also considered a variety of risks and other countervailing factors related to entering into the
Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a discussion of SciSparc&#8217;s
reasons for the Merger, please see the section entitled &#8220;<i>The Merger &#8211; Reasons for the Merger.</i>&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the anticipated business of the combined
company?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc anticipates to continue
its current business activities as the parent company, while AutoMax&#8217;s current business activities will continue to be carried
out by AutoMax as a wholly-owned subsidiary of SciSparc.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Why am I receiving these materials?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are receiving these proxy
materials because you have been identified as a shareholder of SciSparc as of the record date, and you are entitled to vote at the Special
Meeting to approve the matters described in this proxy statement/prospectus. This proxy statement/prospectus contains important information
about the proposed Merger and the Special Meeting and you should read it carefully and in its entirety. The enclosed voting materials
allow you to authorize a proxy to vote your SciSparc ordinary shares without attending the Special Meeting. As promptly as practicable,
please complete, sign, date and mail your proxy card in the pre-addressed postage-paid envelope provided or call the toll-free telephone
number listed on your proxy card or access the Internet Web site described in the instructions on the enclosed proxy card.</p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What am I voting on?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are five matters scheduled
for a vote at the Special Meeting:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The approval of the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective upon
the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all office holders
of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of
directors of SciSparc;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President,
contingent upon the approval and closing of the Merger; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent
upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the
effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is required to consummate the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To
                                            consummate the Merger, Proposals Nos. 1, 2, 3, and 4 must be approved at the Special Meeting,
                                            or at any permitted adjournment thereof, by the requisite holders of SciSparc ordinary shares
                                            on the record date for the Special Meeting. The Merger will not occur if Proposals Nos. 1,
                                            2, 3, and 4 are not approved by SciSparc&#8217;s shareholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the requirement
of obtaining such shareholder approvals, each of the other closing conditions set forth in the Merger Agreement must be satisfied or
waived.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more complete description
of the closing conditions under the Merger Agreement, we urge you to read the section entitled &#8220;<i>The Merger Agreement &#8211;
Conditions to the Completion of the Merger</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Are there any federal or state regulatory
requirements that must be complied with or federal or state regulatory approvals or clearances that must be obtained in connection with
the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither SciSparc nor AutoMax
is required to make any filings or obtain any approvals or clearances from any antitrust regulatory authorities in the United States
or other countries to consummate the Merger. In the United States, SciSparc must comply with applicable federal and state securities
laws and Nasdaq rules and regulations in connection with the issuance of the shares in connection with the Merger, including the filing
with the SEC of this proxy statement/prospectus. In addition, in connection with the Merger, AutoMax has obtained a Withholding Tax Ruling
and a 104H Tax Ruling from the tax authorities in Israel; both SciSparc and AutoMax are required to comply with the provisions thereunder.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What will AutoMax shareholders receive in
the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
AutoMax shareholders will be entitled to receive SciSparc ordinary shares and pre-funded warrants exercisable into ordinary shares of
SciSparc in exchange for AutoMax ordinary shares in an amount to be calculated by the application of an Exchange Ratio formula in the
Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, in accordance
with the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive to
account for changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary
shares issued pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and
could vary significantly from the market value of the SciSparc ordinary shares on the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, AutoMax shareholders will receive SciSparc ordinary shares in exchange for AutoMax shares held by them in an amount equal
to the number of AutoMax shares held by each AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will
receive pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued
in connection with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary
share (after aggregating all fractional SciSparc ordinary shares issuable to such shareholder) will receive such amount rounded to the
nearest whole number of SciSparc ordinary shares.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (other than SciSparc, which
currently holds shares in AutoMax) and its Advisor are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s
shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital on a fully-diluted basis (subject to certain
exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Exchange Ratio is
the result of the following calculation: the number of the SciSparc outstanding shares on a fully-diluted basis (subject to certain exceptions)
divided by 0.5001, multiplied by 0.4749, then divided by the number of the AutoMax outstanding shares ,excluding dormant shares, less
the number of the AutoMax ordinary shares held by SciSparc; so that, in any event, immediately following the effective time, holders
of AutoMax outstanding shares (and its Advisor, but other than SciSparc), will hold together 49.99% of SciSparc&#8217;s share capital,
on a fully-diluted basis (subject to certain exceptions), immediately following the effective time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For example, if the Merger
was consummated as of July 3, 2025, then based on 535,197 SciSparc outstanding shares (including pre-funded warrants to exercise up to
628 SciSparc ordinary shares) and 98,691,969 AutoMax outstanding shares (excluding dormant shares and 5,000,000 AutoMax shares held by
SciSparc), each AutoMax shareholder would have been entitled to receive 0.00514956 SciSparc shares, equal to $0.03398708, based on the
closing price of SciSparc ordinary shares on Nasdaq on July 3, 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more complete description
of what AutoMax shareholders will receive in the Merger, please see the sections entitled &#8220;<i>Market Price and Dividend Information</i>&#8221;
and &#8220;<i>The Merger Agreement &#8211;&#8201;Merger Consideration</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the AutoMax Shareholder Support Agreement?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution
of the Merger Agreement, certain shareholders of AutoMax entered into a shareholder support agreement, or the AutoMax Shareholder Support
Agreement, covering approximately 55.56% of the outstanding shares of AutoMax. The AutoMax Shareholder Support Agreement provides, among
other things, that the shareholders who are party to the AutoMax Shareholder Support Agreement will vote all of the shares of AutoMax
held by them in favor of the adoption of the Merger Agreement, the approval of the Merger and the other transactions contemplated by
the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What are AutoMax&#8217;s payment obligations
under the loan agreements?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax entered
into two loan agreements: (i) the Bridge Loan, as amended by the Amended Bridge Loan, the Second Amendment and the Third Amendment, and
(ii) the Additional Loan Agreement (as such terms are defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Bridge Loan, as
amended, SciSparc made available a $4.25 million loan to AutoMax, or the Loan Amount, under which SciSparc will be entitled to be paid
the due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated), of the Loan Amount, accruing from the
period beginning on December 1, 2024 and ending on the effective date of the Merger. The Loan Amount was set off against the obligation
of SciSparc to pay the Closing Financing (for more information, see &#8220;What is the closing financing?&#8221; on page iv). However,
if the Merger Agreement is terminated, the Loan Amount shall be repaid on the three-month anniversary of the termination thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Additional Loan
Agreement, SciSparc extended to AutoMax a loan in the amount of $2 million, or the Additional Loan Amount. The Additional Loan Amount
is due and payable on a monthly basis, as follows: (i) beginning on each month subsequent to February 24, 2025, AutoMax shall pay $50,000,
or the Monthly Payment, plus the interest of 8% per annum accrued on the outstanding Additional Loan Amount up to the payment date; and
(ii) upon the consummation of the Merger, the remaining interest on the Additional Loan Amount shall be cancelled and forgiven, and AutoMax
shall continue making Monthly Payments towards the remaining outstanding and due Additional Loan Amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What is the closing financing?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the Merger Agreement,
SciSparc has agreed to transfer to AutoMax a total of $4.25 million at the closing, less any amount due by AutoMax to SciSparc under
any loan agreement between the parties, or the Closing Financing Amount. As of the date of his prospectus, SciSparc has advanced to AutoMax
the aggregate amount of the Closing Financing Amount, $4.25 million, as a loan, under the Bridge Loan (as defined below) and its amendments
thereto, to enable AutoMax to have sufficient cashflow to further develop its operations. As a result of AutoMax receiving the entire
Closing Financing Amount, SciSparc will have no obligations to transfer additional financing amounts to AutoMax at the closing of the
Merger. On the closing date of the Merger, SciSparc will be due interest at a rate of 7% per annum (or 9% per annum if the Merger is
not consummated), of the Loan Amount, from the period starting December 1, 2024 and ending on the effective date of the Merger. In consideration
for the Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned
subsidiary AutoMax Direct Import Ltd. (formerly known as AutoMax Leasing Ltd.), which it wholly owns, or AutoMax Direct Import, in favor
of SciSparc.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Did SciSparc&#8217;s board of directors obtain
a&#160;third-party fairness opinion in determining whether or not to proceed with the Merger?</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No. SciSparc&#8217;s board
of directors did not obtain a third-party fairness opinion. However, SciSparc&#8217;s board of directors obtained an independent third-party
valuation report from E.D.B. Consulting and Investments Ltd., or E.D.B. SciSparc&#8217;s board of directors ensured that the third-party
valuation met all necessary regulatory and legal standards, as there was no legal requirement under Israeli law to obtain a fairness
opinion in connection with the approval of the Merger. The board of directors of SciSparc also considered the cost implications, as fairness
opinions can be expensive, and determined that the third-party valuation provided sufficient information at a lower cost. SciSparc&#8217;s
board of directors believed that the valuation, conducted by a reputable independent firm with industry expertise, offered comprehensive
and reliable data adequate for making an informed decision about the Merger. For more information see &#8220;<i>Summary &#8212; Valuation
Report of E.D.B. Consulting and Investments Ltd</i>&#8221;.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>What will happen to AutoMax&#8217;s outstanding
options, warrants, Series B bonds, and Series C bonds in the Merger?</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of AutoMax&#8217;s Series B Bonds, or the Series B Bonds, and the Series B Bonds trust deed, dated February 23, 2022, or the Series B
Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual installments, which will be paid
annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on February 28, 2023 constituted 10%
of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February 28, 2024, constituted 15% of the
aggregate principal amount of the Series B Bonds, the third payment, that was made on February 28, 2025, constituted 30% of the aggregate
principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute 45% of the aggregate
principal amount of the Series B Bonds. Following the closing of the Merger the Series B Bonds will remain outstanding and subject to
repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B Bonds bear interest at a rate of 5.9% per annum.
As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal amount of Series B Bonds remains outstanding and
will therefore become a liability of the combined company following the completion of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On May 19, 2025, AutoMax&#8217;s
Series C Bonds, or the Series C Bonds, were issued and began trading on the Tel-Aviv Stock Exchange Ltd., or TASE. According to the terms
of the Series C Bonds and the Series C Bonds trust deed, dated May 14, 2025, or the Series C Bonds Trust Deed, the Series C Bonds are
due for repayment in four (4) unequal annual installments, which will be paid annually from December 31, 2026 until December 31, 2029,
such that the first payment will constitute 5% of the principal, the second and third payments will constitute 10% each of the principal,
and the fourth payment will constitute 75% of the principal. The Series C Bonds bear fixed annual interest at a rate of 8% per annum.
The interest will be paid on each June 30 and December 31, from 2026 to 2029. As of July 3, 2025, NIS 74,353 thousand, approximately
($20,260 thousand) in principal amount of Series C Bonds remains outstanding and will therefore become a liability of the combined company
following the completion of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Will holders of the SciSparc ordinary shares
issued in the Merger be able to sell those shares without restriction?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
                                            sale of the SciSparc ordinary shares and pre-funded warrants issued as consideration in the
                                            Merger are being registered under the Securities Act of 1933, as amended, or the Securities
                                            Act, pursuant to the registration statement of which this prospectus forms a part, and will
                                            be able to be sold without restriction following the consummation of the Merger for so long
                                            as such registration statement remains effective, other than shares held by affiliates that
                                            will be subject to resale restrictions as control securities under Rule 144.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who will be the directors of SciSparc following
the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At and immediately after
the effective time of the Merger, the board of directors of SciSparc is expected to be composed of the individuals set forth in the table
below. The directors shall serve until their respective successors are duly elected or appointed and qualified or their earlier death,
resignation or removal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; width: 35%; text-indent: 0pt"><b>Designee</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; width: 10%"><b>Age</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; width: 53%"><b>Position(s)</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><i>AutoMax Designees
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Yaarah Alfi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Financial
    Officer of AutoMax, director nominee of SciSparc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Tomer Levy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">VP
    Business Development and Headquarters, director of AutoMax, director nominee of SciSparc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt; vertical-align: top"><span style="font-size: 10pt"><i>SciSparc
    Designees</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Amitay Weiss</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chairman of SciSparc&#8217;s
    board of directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Amnon Ben Shay</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Moshe Revach</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Liat Sidi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who will be the executive officers of SciSparc
immediately following the Merger?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following the
Merger, the executive management team of SciSparc is expected to be composed as set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; text-align: left; vertical-align: bottom; width: 25%; text-indent: 0pt"><b>Name</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center; width: 1%; text-indent: 0pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 27%; text-indent: 0pt"><b>Position
    with SciSparc</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center; width: 1%; text-indent: 0pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 35%; text-indent: 0pt"><b>Current
    Position</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; text-align: center; width: 1%; text-indent: 0pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; vertical-align: bottom; width: 10%; text-indent: 0pt"><b>Age</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Oz Adler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive
    Officer and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive
    Officer and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Technology
    Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Technology
    Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">56</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>What interests do the current officers and directors of SciSparc
have in the merger?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In considering the recommendation
of SciSparc&#8217;s board of directors to vote in favor of the Merger, shareholders should be aware that, aside from their interests
as shareholders, certain of SciSparc&#8217;s directors and officers have interests in the Merger that differ from, or extend beyond,
those of SciSparc&#8217;s shareholders generally. SciSparc&#8217;s directors were aware of and considered these interests, among other
matters, in evaluating the Merger and in recommending to shareholders that they approve the Merger. Shareholders should take these interests
into account in deciding whether to approve the Merger. These interests include, among other things, the fact that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Each
                                            of Amnon Ben Shay, Moshe Revach and Liat Sidi will continue to be a director of the combined
                                            company after the effective time of the Merger, and, following the closing of the Merger,
                                            will be eligible to be compensated as a non-employee director of the combined company pursuant
                                            to the compensation policy of SciSparc;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Subject
                                            to the approval of SciSparc shareholders by the requisite majority, as described further
                                            in this prospectus, SciSparc&#8217;s Chief Executive Officer, Chairman and President will
                                            each be entitled to receive a one-time cash bonus, subject to and upon the closing of the
                                            Merger;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant
                                            to the Merger Agreement and form of Indemnification Agreement, SciSparc&#8217;s directors
                                            and executive officers are entitled to continued indemnification, expense advancement and
                                            insurance coverage; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Mr. Amitay Weiss, the Chairman
    of SciSparc&#8217;s board of directors, serves as the chairman of AutoMax&#8217;s board of directors. Pursuant to the terms of the
    Merger Agreement, Mr. Amitay Weiss will continue to be a director of the combined company after the closing of the Merger and will
    receive compensation as a director and be entitled to continued indemnification. In addition, if approved by SciSparc shareholders,
    Mr. Amitay Weiss will be entitled to receive a one-time cash bonus of $150,000 as the Chairman of SciSparc upon the closing of the
    Merger. These interests may present him with actual or potential conflicts of interest. Mr. Amitay Weiss recused himself from the
    decision of approving the Merger and did not participate in the discussion or voting on the matter due to his personal interest.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>What is the one-time bonus to be granted to SciSparc&#8217;s Chief
Executive Officer, Chairman and President?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is proposing that
in connection with, and subject to, the closing of the Merger, Mr. Oz Adler, SciSparc&#8217;s Chief Executive Officer, shall receive
a cash bonus in the amount of $315,000. In addition, SciSparc is proposing that Mr. Amitay Weiss, SciSparc&#8217;s Chairman of the board
of directors, shall receive a cash bonus in the amount of $150,000, and Mr. Itschak Shrem, SciSparc&#8217;s President, shall receive
a cash bonus in the amount of $50,000, in connection with, and subject to, the closing of the Merger.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc&#8217;s
reasons for granting the above mentioned bonuses include providing an appropriate award for advancing SciSparc&#8217;s Restructuring
Plan (as defined below), including the recipients&#8217; individual contributions to the execution of the Merger Agreement and incentivizing
individual excellence and corporate performance. For more information see the section titled &#8220;<i>Proposal No. 3 &#8211; Approval
of a one-time cash bonus to the SciSparc </i></span><i>Chief Executive Officer, Chairman and President</i><span style="background-color: white">.&#8221;
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What are the material Israeli income tax
consequences of the Merger to me?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are urged to consult
with your own tax advisor for a full understanding of the tax consequences of the Merger to you, including the consequences under any
applicable, state, local, foreign or other tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more detailed description
of the material Israeli tax consequences of the Merger, see the section entitled &#8220;<i>The Merger &#8211; Certain Material Israeli
Income Tax Consequences of the Merger.</i>&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>What are the material U.S. federal income
tax consequences of the Merger to me?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger, AutoMax
will merge with and into SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of SciSparc, and former shareholders
of AutoMax will receive voting ordinary shares (and in some cases pre-funded warrants to acquire SciSparc voting ordinary shares) of
SciSparc. It is the opinion of SciSparc&#8217;s U.S. federal tax counsel that the Merger as structured is a reverse triangular merger
that meets the requirements of a &#8220;reorganization&#8221; as in Section 368(a)(1)(A) of the Internal Revenue Code of 1986, as amended,
or the Code, as augmented by the provisions of Section 368(a)(2)(E) of the Code.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are urged to consult
with your own tax advisor for a full understanding of the tax consequences of the Merger to you, including the consequences under any
applicable, state, local, foreign or other tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more detailed description
of the material U.S. federal income tax consequences of the Merger, see the section entitled &#8220;Material U.S. Federal Income Tax
Considerations to U.S. Holders.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true">What is the Reverse
Split?</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Effective
as of market open on July 3, 2025, SciSparc effected a one-for-twenty-one (1-for-21) reverse share split, of its issued and outstanding
ordinary shares, no par value per share. The Reverse Split was approved by SciSparc&#8217;s shareholders at its annual meeting of shareholders
held on October 23, 2024, to be effected at the board of directors&#8217; discretion within approved parameters. Accordingly, the board
of directors approved a 1-for-21 ratio. The Reverse Split did not result in an adjustment to the authorized share capital of SciSparc
under its Amended and Restated Articles of Association, as approved by SciSparc&#8217;s shareholders on June 26, 2025, which, as of the
date hereof consists of 2,000,000,000 ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
addition, on June 26, 2025, SciSparc&#8217;s shareholders approved a framework for a reverse split of the issued and outstanding ordinary
shares in the range of a ratio of between 1:2 and 1:250, to be effected at the discretion of, at such ratio within the approved range
and by such number of increments, and on such dates, as may be determined by SciSparc&#8217;s board of directors within 18 months following
the date of approval.&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a SciSparc shareholder, how does the
SciSparc board of directors recommend that I vote?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
careful consideration, the SciSparc board of directors recommends that SciSparc shareholders vote:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221;
                                            Proposal No. 1 to approve the consummation of the Merger and the other transactions contemplated
                                            by the Merger Agreement, including the issuance of SciSparc ordinary shares and the pre-funded
                                            warrants at the effective time of the Merger to the shareholders of AutoMax;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221;
                                            Proposal No. 2 to approve the form of Indemnification Agreement for directors and officers
                                            of SciSparc;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p><div>

</div><table cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221;
    Proposal No. 3, subject to and contingent upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s
    Chief Executive Officer, Chairman and President, contingent upon the approval and closing of the Merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FOR&#8221;
    Proposal No. 4, subject to and contingent upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve
    on the SciSparc board of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board
    of directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">What
risks should I consider in deciding whether to vote in favor of the matters set forth above?</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully review
the section of this proxy statement/prospectus entitled &#8220;Risk Factors,&#8221; which sets forth certain risks and uncertainties
related to the Merger, risks and uncertainties to which SciSparc&#8217;s business will be subject, risks and uncertainties to which SciSparc,
as an independent company, is subject and risks and uncertainties to which AutoMax, as an independent company, is subject.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When do you expect the Merger to be consummated?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc anticipates that
the Merger will occur as promptly as practicable after the Special Meeting to be held on August 25, 2025 and following satisfaction or
waiver of all closing conditions, but cannot predict the exact timing. For a more complete description of the closing conditions under
the Merger Agreement, please see the section entitled &#8220;<i>The Merger Agreement &#8211;Conditions to the Completion of the Merger</i>&#8221;
in this proxy statement/prospectus.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What do I need to do now?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc urges you to read
this proxy statement/prospectus carefully, including its annexes, and to consider how the Merger affects you.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a shareholder
of record of SciSparc, you may provide your proxy instructions in one of two different ways. First, you can mail your signed proxy card
in the enclosed return envelope. Second, you may also provide your proxy instructions via telephone or the Internet by following the
instructions on your proxy card or instruction form. Please provide your proxy instructions only once, unless you are revoking a previously
delivered proxy instruction, and as soon as possible so that your shares can be voted at the Special Meeting. The laws of Israel, under
which SciSparc is incorporated, permit electronically transmitted proxies, provided that each such proxy contains or is submitted with
information from which it can determine that the proxy was authorized by the shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The telephone and Internet
voting procedures below are designed to authenticate shareholders&#8217; identities, to allow shareholders to grant a proxy to vote their
shares and to confirm that shareholders&#8217; instructions have been recorded properly. Shareholders granting a proxy to vote via the
Internet should understand there may be costs associated with electronic access, such as usage charges from Internet access providers
and telephone companies, that must be borne by the shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether you hold your shares
directly as the shareholder of record or beneficially in &#8220;street name,&#8221; you may vote your shares by proxy without attending
the Special Meeting. Depending on how you hold your shares, you may vote your shares in one of the following ways:</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">Shareholders
of Record: For Shares Registered in Your Name</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>By
                                            telephone or over the Internet</i>. You may vote your shares by telephone or via the Internet
                                            by following the instructions provided on your proxy card. If you vote by telephone or via
                                            the Internet, you do not need to return a proxy card by mail. If you have Internet access,
                                            we encourage you to record your vote on the Internet. It is convenient, reduces the use of
                                            natural resources and saves significant postage and processing costs. In addition, when you
                                            vote via the Internet or by phone prior to the Special Meeting&#8217;s date, your vote is
                                            recorded immediately and there is no risk that postal delays will cause your vote to arrive
                                            late and therefore not be counted.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>By
                                            Mail</i>. If you received printed proxy materials, you may submit your vote by completing,
                                            signing and dating each proxy card received and returning it in the prepaid envelope. Sign
                                            your name exactly as it appears on the proxy card.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>In
                                            person at the Special Meeting</i>. You may vote your shares in person at the Special Meeting.
                                            Even if you plan to attend the Special Meeting in person, we recommend that you also submit
                                            your proxy card or voting instructions or vote by telephone or via the Internet by the applicable
                                            deadline so that your vote will be counted if you later decide not to attend the Special
                                            Meeting.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Beneficial
Shareholders: For Shares Registered in the Name of a Broker or Bank</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most beneficial owners whose
ordinary shares are held in &#8220;street name&#8221; receive instructions for granting proxies from their banks, brokers or other agents,
rather than using SciSparc&#8217;s proxy card. If you are a beneficial owner of your shares, you should have received a Voting Instruction
Form from the broker or other nominee holding your shares. You should follow the voting instructions provided by your broker or nominee
in order to instruct your broker or other nominee on how to vote your shares. The availability of telephone and Internet voting will
depend on the voting process of the broker or nominee. Shares held beneficially may be voted in person at the Special Meeting only if
you contact the broker or nominee giving you the right to vote the shares and obtain a legal proxy from such broker or nominee.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">General
Information for All Shares Voted Via the Internet or By Telephone</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Votes submitted by telephone
or via the Internet must be received by 11:59 p.m., Eastern Time on August 12, 2025. Submitting your proxy by telephone or via the Internet
will not affect your right to vote in person should you decide to attend the Special Meeting.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who can vote at the Special Meeting?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, on the record date,
your SciSparc ordinary shares are registered directly in your name with the SciSparc transfer agent, you are considered to be the shareholder
of record with respect to those shares, and the proxy materials and proxy card are being sent directly to you by SciSparc. If you are
a SciSparc shareholder of record, you may attend the Special Meeting of SciSparc shareholders and vote your shares in person. Even if
you plan to attend the Special Meeting in person, SciSparc requests that you sign and return the enclosed proxy to ensure that your shares
will be represented at the Special Meeting if you are unable to attend.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, on the record date, your
ordinary shares are held in a brokerage account or by another nominee, you are considered the beneficial owner of ordinary shares held
in &#8220;street name,&#8221; and the proxy materials are being forwarded to you by your broker or other nominee together with a voting
instruction card. As the beneficial owner, you are also invited to attend the Special Meeting of SciSparc shareholders. Because a beneficial
owner is not the shareholder of record, you may not vote these shares in person at the Special Meeting unless you obtain a proxy from
the broker, trustee or nominee that holds your shares, giving you the right to vote the shares at the Special Meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">How are votes counted?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Votes
                                            will be counted in the Special Meeting, including votes &#8220;For&#8221; and &#8220;Against,&#8221;
                                            abstentions and, if applicable, broker non-votes. Abstentions will have no effect and will
                                            not be counted towards the vote total with respect to Proposals Nos. 1 through 4. Broker
                                            non-votes will not be counted towards the vote total for any proposal.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What are &#8220;broker non-votes&#8221;?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If
                                            you hold SciSparc ordinary shares beneficially in street name and do not provide your broker
                                            or other agent with voting instructions, your SciSparc ordinary shares may constitute &#8220;broker
                                            non-votes.&#8221; Broker non-votes occur on a matter when banks, brokers and other nominees
                                            are not permitted to vote on certain non-discretionary matters without instructions from
                                            the beneficial owner and instructions are not given. These matters are referred to as &#8220;non-discretionary&#8221;
                                            matters. Proposals Nos. 1 through 4 are non-discretionary matters. As a result, banks, brokers
                                            and other nominees will not have discretion to vote on Proposals Nos. 1 through 4.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker non-votes will
not be considered as votes cast by the holders of SciSparc ordinary shares present in person or represented by proxy at the Special Meeting,
and will therefore not have any effect with respect to Proposals Nos. 1 through 4.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">How many votes are needed to approve each
proposal?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 8%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proposal
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proposal
    Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
    Required for Approval</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    approve the consummation of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of
    SciSparc ordinary shares and the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    simple majority of shareholders present (in person or by proxy) and voting on the matter (excluding abstentions)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    approve the form of Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus,
    effective upon the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with
    all office holders of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed
    to the board of directors of SciSparc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            simple majority of all votes properly cast in person or by proxy at the Special Meeting (excluding
                                            abstentions), and the fulfillment of one of the following additional voting requirements:</span></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
                                            &#160;the majority of the Shares that are voted at the Special Meeting in favor of the Proposal,
                                            excluding abstentions, includes a majority of the votes of shareholders who are not controlling
                                            shareholders or do not have a personal interest in the approval of the Proposal; or (ii)
                                            the total number of Shares of the shareholders mentioned in clause (i) above that are voted
                                            against the Proposal does not exceed two percent (2%) of the total voting rights in the Company.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject
                                            to and contingent upon the approval of Proposal No. 1, to approve a one-time cash bonus to
                                            SciSparc&#8217;s Chief Executive Officer, Chairman and President, contingent upon the approval
                                            and closing of the Merger.</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            simple majority of all votes properly cast in person or by proxy at the Special Meeting (excluding
                                            abstentions), and the fulfillment of one of the following additional voting requirements:</span></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
                                            &#160;the majority of the Shares that are voted at the Special Meeting in favor of the Proposal,
                                            excluding abstentions, includes a majority of the votes of shareholders who are not controlling
                                            shareholders or do not have a personal interest in the approval of the Proposal; or (ii)
                                            the total number of Shares of the shareholders mentioned in clause (i) above that are voted
                                            against the Proposal does not exceed two percent (2%) of the total voting rights in the Company.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to and contingent upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board
    of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    simple majority of all votes properly cast in person or by proxy at the Special Meeting.</span></td></tr>

  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            term &#8220;controlling shareholder&#8221; means a shareholder having the ability to direct
                                            the activities of a company, other than by virtue of being an office holder. A shareholder
                                            is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting
                                            rights in a company or has the right to appoint the majority of the directors of the company
                                            or its general manager. To the knowledge of SciSparc, there is no shareholder who is a controlling
                                            shareholder. For the purpose of Proposals Nos. 2 and 3, the term controlling shareholder
                                            shall also include a person who holds 25% or more of the voting rights in the general meeting
                                            of the company if there is no other person who holds more than 50% of the voting rights in
                                            the company; for the purpose of a holding, two or more persons holding voting rights in the
                                            company each of which has a personal interest in the approval of the transaction being brought
                                            for approval of the company will be considered to be joint holders.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Under
                                            the Israeli Companies Law, 5759-1999, or the Companies Law, a &#8220;personal interest&#8221;
                                            of a shareholder in an action or transaction of a company includes a personal interest of
                                            any of the shareholder&#8217;s relatives (i.e. spouse, brother or sister, parent, grandparent,
                                            child as well as child, brother, sister or parent of such shareholder&#8217;s spouse or the
                                            spouse of any of the above) or an interest of a company with respect to which the shareholder
                                            or the shareholder&#8217;s relative (as defined above) holds 5% or more of such company&#8217;s
                                            issued shares or voting rights, in which any such person has the right to appoint a director
                                            or the chief executive officer or in which any such person serves as director or the chief
                                            executive officer, including the personal interest of a person voting pursuant to a proxy
                                            which the proxy grantor has a personal interest, whether or not the person voting pursuant
                                            to such proxy has discretion with regards to the vote; and excludes an interest arising solely
                                            from the ownership of ordinary shares of a company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Under Israeli law,
every voting shareholder is required to notify the Company whether such shareholder is an Interested Shareholder.&#160;To avoid confusion,
every shareholder voting by means of the enclosed proxy card or voting instruction form, or via telephone or internet voting, will be
deemed to confirm that such shareholder is NOT an Interested Shareholder. If you are an Interested Shareholder (in which case your vote
will only count for or against the ordinary majority, and not for or against the special tally under Proposals Nos. 2 and 3), please
notify Dr. Shachar Hadar, Adv., the Company&#8217;s legal counsel, at 16 Abba Hillel Silver Road, Ramat Gan, 5250608, Israel, Attn: Shachar
Hadar, telephone:&#160;+972-3-6103766 or email shacharh@meitar.com (in which case your vote will only count for or against the ordinary
majority, and not for or against the special majority, required for the approval Proposal Nos. 2 and 3). If your shares are held in &#8220;street
name&#8221; by your broker, bank or other nominee and you are an Interested Shareholder, you should notify your broker, bank or other
nominee of that status, and they in turn should notify the Company as described in the preceding sentence.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When and where will the Special Meeting
of SciSparc shareholders be held?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Special Meeting of
SciSparc shareholders will be held at 3:00 p.m., local time, on&#160;August 25, 2025, at the Company&#8217;s offices, at 20 Raul Wallenberg
Street, Tower A, Tel Aviv 6971916 Israel. Subject to space availability, all SciSparc shareholders as of the record date, or their duly
appointed proxies, may attend the meeting. Since seating is limited, admission to the meeting will be on a first-come, first-served basis.
Registration and seating will begin at 3:00 p.m., local time. Any such change will be announced in a Report of Foreign Private Issuer
on Form 6-K furnished to the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What happens if I do not return a proxy
card or otherwise provide proxy instructions, as applicable?</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Shareholder
of Record: Shares Registered in Your Name</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a shareholder
of record and do not vote by telephone, through the Internet, by completing the enclosed proxy card or in person at the Special Meeting,
your shares will not be voted.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">Beneficial
Owner: Shares Registered in the Name of a Broker or Bank</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Proposals
                                            Nos. 1, 2, 3 and 4 are non-discretionary matters. As a result, banks, brokers and other nominees
                                            will not have discretion to vote on Proposals Nos. 1, 2, 3 and 4.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What if I return a proxy card or otherwise
vote but do not make specific choices?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you return a signed and
dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the
approval of the consummation of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of
SciSparc ordinary shares and pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax, as contemplated
by the Merger Agreement (Proposal No. 1); &#8220;For&#8221; the approval of the form of Indemnification Agreement between SciSparc and
its directors (Proposal No.2); &#8220;For&#8221; the approval of a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman
and President (Proposal No. 3); and &#8220;For&#8221; the approval of the election of each of Tomer Levy and Yaarah Alfi and ratification
of classes, subject to approval of Proposal No. 1. (Proposal No. 4).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May I change my vote after I have submitted
a proxy or provided proxy instructions?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s shareholders
of record, may change their vote at any time before their proxy is voted at the Special Meeting in one of three ways. First, a shareholder
of record of SciSparc can send a written notice to the Chief Executive Officer of SciSparc stating that it would like to revoke its proxy.
Second, a shareholder of record of SciSparc can submit new proxy instructions either on a new proxy card or via telephone or the Internet.
Third, a shareholder of record of SciSparc can attend the Special Meeting and vote in person. Attendance alone will not revoke a proxy.
If an SciSparc shareholder of record or a shareholder who owns SciSparc shares in &#8220;street name&#8221; has instructed a broker to
vote its SciSparc ordinary shares, the shareholder must follow directions received from its broker to change those instructions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your most current proxy card
or telephone or Internet proxy is the one that is counted.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->x<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should AutoMax&#8217;s and SciSparc&#8217;s
shareholders send in their share certificates now?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No. To the extent AutoMax&#8217;s
and SciSparc&#8217;s shareholders have certificated shares, such shareholders should keep their existing share certificates at this time.
Similarly, holders of shares that are held in book-entry form should refrain from attempting to surrender their shares currently. Shareholders
should await further instructions in relation to their share certificates, if any.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Am I entitled to dissenters&#8217; rights?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No, SciSparc&#8217;s shareholders
are not entitled to dissenters&#8217; rights in connection with the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Have AutoMax&#8217;s shareholders agreed
to adopt the Merger Agreement?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Merger Agreement will
be voted on at the meeting of AutoMax&#8217;s shareholders, expected to be held on or about 35 days after the effectiveness of this proxy
statement/prospectus. Pursuant to AutoMax&#8217;s petition to the court, the court ordered that AutoMax will convene a shareholders meeting
for approval of the merger, and, in addition, will convene a separate meeting of AutoMax&#8217;s shareholders who are not controlling
shareholders or SciSparc to vote on the approval of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who is paying for this proxy solicitation?</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc will bear the cost
of soliciting proxies. In addition to these proxy materials, SciSparc&#8217;s directors and employees may also solicit proxies in person,
by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting
proxies. SciSparc and AutoMax may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to
beneficial owners.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is the quorum requirement?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A quorum of shareholders
is necessary to hold a valid meeting. The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate,
at least 15% of the voting power of SciSparc&#8217;s ordinary shares constitutes a quorum for purposes of the Special Meeting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your shares will be counted
towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if
you vote in person at the Special Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If half an
hour has elapsed from the time set for the Special Meeting and a quorum is not present, the Special Meeting will be adjourned to the
following day, at the same time and place, or to a different date, as shall be determined by the board of directors in a notice to the
shareholders. If a quorum is not present at the adjourned Special Meeting, as stated above, a minimum of one shareholder, whether present
in person or by proxy, shall be deemed as constituting a quorum.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What happens if a quorum is not present?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If half an hour has elapsed
from the time set for the Special Meeting and a quorum is not present, the Special Meeting will be adjourned to the following day, at
the same time and place.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Who can help answer my questions?</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a SciSparc shareholder
and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger and related
transactions, including the procedures for voting your shares, you should contact the Chief Executive Officer of SciSparc, at the following
address and phone number: 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup> Floor, Tel Aviv Israel, 6971916, or by calling +972-3-7175777.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<a id="m_002"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SUMMARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights
selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better
understand the Merger, and the proposals being considered at the Special Meeting, you should read this entire proxy statement/prospectus
carefully, including the Merger Agreement attached as Annex A, the form of the AutoMax Shareholder Support Agreement and form of Indemnification
Agreement attached as Annexes B and C and the other annexes to which you are referred herein. You may obtain the information incorporated
by reference into this proxy statement/prospectus without charge by following the instructions in the section entitled &#8220;Where You
Can Find More Information&#8221; beginning on page 240.</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Companies</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20 Raul Wallenberg Street</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Tower A</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Tel Aviv</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6971916 Israel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">+972-3-7175777</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">SciSparc
is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies and
assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following development programs based on
&#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptors, or CBR, agonists:
SCI-110 for the treatment of Tourette syndrome, or TS, for the treatment of obstructive sleep apnea, or OSA, and for the treatment of
Alzheimer&#8217;s disease and agitation; and SCI-210 for the treatment of Autism Spectrum Disorder, or ASD, and Status Epilepticus, or
SE. SciSparc also has a majority-owned subsidiary whose business focuses on the sale of hemp seeds oil-based products and others on Amazon
Marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-110
is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and
(2) CannAmide&#8482;, a proprietary Palmitoylethanolamide, or PEA, formulation. PEA is an endogenous fatty acid amide that belongs to
the class of nuclear factor agonists, which are molecules that regulate the expression of genes. SciSparc believes that the combination
of THC and PEA may induce a reaction known as the &#8220;sparing effect,&#8221; which has strong potential to treat various diseases
such as TS, OSA and Alzheimer&#8217;s disease&#160;and agitation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">SCI-210
is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. SciSparc believes that the combination of
CBD and PEA may also induce a sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">SciSparc
believes that modulating CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="background-color: white">&#160;</span></p>

</div><div>


</div><!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Pursuant
to the positive results obtained in a phase IIa TS study conducted at Yale School of Medicine, SciSparc is developing a regulatory dossier
to be submitted to the U.S. Food and Drug Administration, or FDA, The German Federal Institute for Drugs and Medical Devices, or BfArM,
and the Israeli Ministry of Health, or MoH, for its SCI-110 program for TS.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
was incorporated under the laws of the State of Israel on August 23, 2004. SciSparc&#8217;s ordinary shares are listed on the Nasdaq
Capital Market under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
the business of AutoMax will become the business of SciSparc as described beginning on page 175 of this proxy statement/prospectus under
the caption &#8220;<i>AutoMax Business</i>.&#8221;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Effective as of market
open on July 3, 2025, SciSparc effected a one-for-twenty-one (1-for-21) reverse share split, of its issued and outstanding ordinary shares,
no par value per share. The Reverse Split was approved by SciSparc&#8217;s shareholders at its annual meeting of shareholders held on
October 23, 2024, to be effected at the board of directors&#8217; discretion within approved parameters. Accordingly, the board of directors
approved a 1-for-21 ratio. The Reverse Split did not result in an adjustment to the authorized share capital of SciSparc under its Amended
and Restated Articles of Association, as approved by SciSparc&#8217;s shareholders on June 26, 2025, which, as of the date hereof, consists
of 2,000,000,000 ordinary shares.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Motors Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Harehavim 15,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Jerusalem,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9346213, Israel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">+972-2-622-5987</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax imports and markets
a variety of private vehicle models, from various categories such as small vehicles, crossovers, executive vehicles, premium vehicles,
work vehicles, buses manufactured by Temsa, and in addition operates in the automobile trade-in business. AutoMax&#8217;s operations
are conducted in Israel. AutoMax believes there are several primary factors that contribute to the success of vehicle importers in Israel,
including: (i) innovative vehicle models and the manner in which these are branded among customers; (ii) trade conditions, especially
the exchange rates of the foreign currencies in which the importer imports in comparison to the currency exchange rates of competitors;
(iii) the existence of good relations with the manufacturer and/or the agent which is also reflected in import prices; (iv) the technological
quality of the imported vehicles; (v) high marketing ability of the importer, which is also reflected in the adjustment of the vehicle
and the prices to market demands; (vi) the level of provided service and the reputation of the importer; (vii) good geographical layout
of purchasing agencies across the world (especially true for parallel importers, who purchase non-counterfeit product imported from different
countries to be sold on the open market); and (viii) the geopolitical situation in the countries from which the vehicles are imported.
AutoMax&#8217;s clients range from private customers to institutional customers, including companies that lease, rent, and operate vehicle
fleets, and car dealerships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax operates through
various subsidiaries, which include Dalhom AutoMax Ltd., of which it holds 50% of the voting rights, or Dalhom AutoMax; AutoMax Trade-In
Ltd., of which it holds 80% of the voting rights, or AutoMax Trade-In; AutoMax Direct Import Ltd.; and Global AutoMax Ltd., which it
wholly owns, or Global AutoMax.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Global AutoMax holds three
subsidiaries: AutoMax HaShfela Ltd., in which it holds 50% of the voting rights; AutoMax Fleet Vehicles Ltd., in which Global AutoMax
holds 100% of the voting rights; and AutoMax HaSharon Ltd., in which Global AutoMax holds 100% of the voting rights.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Industry Overview</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vehicle market in Israel
differs from most vehicle markets in the world due to the absence of open land borders for free trade in vehicles and high import duties.
The percentage of vehicle ownership in Israel is relatively low compared to various Western countries, due to, among other factors, the
relatively high price of vehicles, mainly due to high taxation, inferior road infrastructure compared to other Western countries, and
high population density. Furthermore, the vehicle market in Israel includes a relatively large number of vehicle importers, compared
to other sectors in the economy, that import vehicles that are manufactured in different countries around the world. Most vehicle importers
import several brands and products. The development of the automotive market in Israel is characterized by fluctuations resulting from
changes in the macroeconomic environment of the economy, among other factors. The main characteristics of the automotive market that
affect AutoMax&#8217;s activity and the competitors in this market are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 92%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>High
    dependence on suppliers</i>. The success of vehicle importers depends mainly on the relationship with manufacturers of the vehicles
    imported and the strategy of the manufacturers&#8217; activity in relation to the launch of new products, brand positioning in the
    world, model policy, trade conditions, price policy and marketing support. It should be noted that the dependence on the vehicle
    manufacturers is mainly relevant to the direct importers who have, in practice, exclusive franchise agreements with manufacturers
    whose products they import to Israel. AutoMax believes that it has no significant reliance on the activity of a particular vehicle
    manufacturer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

</div><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 92%"><span style="font-size: 10pt"><i>Changes in
    consumer preferences</i>. The vehicle preferences in Israel are subject to frequent changes, resulting from the preference of certain
    models by consumers, and due to a variety of factors, including but not limited to, engine type (diesel, oil, electric, hybrid or
    gasoline), the size of the vehicle, its design, technological advantages, environmental rating, fuel economy, safety standard, price
    and marketability on the resale market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Taxation of vehicles</i>.
    The importing of most private vehicles in Israel is subject to purchase taxes, Value Added Tax and customs imposed at cumulative
    rates of approximately 30%-130% (or, oftentimes, more), of the cost of the vehicles. The aforementioned tax rates are among the highest
    in the world. Changes in tax rates, including reduction in tax rates given to vehicles of a certain type, have a direct impact on
    the preferences of customers in the area of activity. In addition, changes in taxation on vehicles provided to employees as part
    of their employment conditions may affect their preference in relation to receiving vehicles from the workplace versus purchasing.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Fuel and electricity prices</i>.
    Changes in fuel and electricity prices may have an impact on consumer preferences in the long term. Vehicle model preferences vary
    depending on the type of energy used (i.e., diesel, gas, gasoline, or electricity) and each such energy price.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Regulation</i>. The automotive
    industry in Israel is characterized by vast regulation and strict regulatory requirements, including the standardization requirements,
    which may affect the Company&#8217;s expenditure and the results of its operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Infrastructure levels
    and density of the roads</i>. According to research conducted by the Bank of Israel, the roads in Israel are characterized by high
    levels of density, especially in the areas with greater population concentration. This affects the scope of vehicle purchases and
    is expected to affect it in the future as well.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Changes in currency and interest
    rates as well as the economic environment.</span></td></tr>
  </table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax operates in two highly
competitive industries: the vehicle industry in Israel as an importer and seller and in the international vehicle industry as a purchaser
of vehicles. The value chain in the automotive industry includes international vehicle manufacturers, vehicle importers, vehicle dealers
(over 8,000 authorized vehicle dealers), financing entities and end users: households, corporate firms and public organizations. According
to the Automotive Industry Review published by Dun &amp; Bradstreet in February 2024, or the Automotive Industry Review, and data retrieved
from the website &#8220;CarZone&#8221;, there are approximately 25 official import groups representing various manufacturers in Israel,
which are responsible for approximately 97% of the automotive imports to Israel. Alongside these, there are several dozen parallel importers
who are collectively responsible for approximately 3% of the imports. However, during the years 2019 to 2024, a small number of parallel
importers were responsible for approximately 75% of the total parallel import to Israel. Additionally, there are vehicle leasing and
rental companies, consisting of approximately five primary companies, alongside smaller companies.</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">According
to the Automotive Industry Review, as of year-end-2024, there were approximately 4.24 million vehicles on the roads in Israel, of which,
approximately 86% are private vehicles. According to the State of Israel Central Bureau of Statistics, despite a relatively low level
of vehicle ownership in Israel, based on the number of vehicles per 1,000 residents, the traffic density remains among the highest in
the world. Based on studies conducted in previous years, as detailed in Automotive Industry Review, the density is 3.5 times higher than
the Organization for Economic Co-operation and Development, or the OECD, average. The main contributors are the concentration of population
in central Israel, an underdeveloped public transportation system and the lack of correlation between the construction of roads and the
increase in population.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SciSparc Merger Sub Ltd.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc Merger Sub Ltd.
is a wholly-owned subsidiary of SciSparc, and was formed solely for the purposes of carrying out the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Merger (see page 88 and page 109)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
Merger Sub will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each AutoMax ordinary share outstanding immediately prior to the effective time (excluding certain AutoMax ordinary shares
that may be cancelled pursuant to the Merger Agreement) will be automatically converted into the right to receive a number of SciSparc
ordinary shares and pre-funded warrants. The Exchange Ratio has been determined pursuant to a formula described in more detail in the
Merger Agreement and later in this proxy statement/prospectus. Under the Exchange Ratio formula described in the Merger Agreement, immediately
following the Merger, AutoMax&#8217;s shareholders, and its Advisor in connection with the Merger, are expected to own approximately
49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected to own approximately 50.01% of SciSparc&#8217;s
share capital, on a fully-diluted basis, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify"><span style="-keep: true">The Exchange Ratio
is based on the number of SciSparc&#8217;s outstanding shares on a fully-diluted basis, subject to certain exceptions, divided by 0.5001,
multiplied by 0.4749, divided by the number of AutoMax&#8217;s outstanding shares, excluding dormant shares, minus SciSparc&#8217;s holdings
in AutoMax, so, that in any event, AutoMax shareholders (other than SciSparc) shall own approximately 49.99% of SciSparc&#8217;s share
capital, on a fully-diluted basis, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Merger
will occur as promptly as practicable but in no event later than the second business day after the last of the conditions to the Merger
has been satisfied or waived, other than those conditions that by their nature are to be satisfied at the closing of the Merger, but
subject to the satisfaction or waiver of each such conditions, or at such other time as SciSparc and AutoMax agree. SciSparc and AutoMax
anticipate that the consummation of the Merger will occur in SciSparc&#8217;s third quarter of 2025, the quarter ending September 30,
2025. However, because the Merger is subject to a number of conditions, neither SciSparc nor AutoMax can predict exactly when the closing
of the Merger will occur or if it will occur at all.</p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the corporate structure of SciSparc prior to and following the consummation of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the consummation
of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001a.jpg" style="width: 493px; height: 132px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the consummation
of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001b.jpg" style="height: 282px; width: 650px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; text-align: center; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reasons for the Merger (see page 94)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax believe
that the combined company will have the following potential advantages:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    range of options available to the combined company to access the public equity markets to fund future capital needs or to complete
    business development transactions, which would likely be greater than the options available to AutoMax alone as a publicly traded
    company on the TASE;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expected reaction and support of the transaction from the market, investment banks, AutoMax shareholders and SciSparc shareholders;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    the Merger will result in AutoMax shareholders, in exchange for their AutoMax shares, receiving shares in SciSparc, a publicly traded
    company on Nasdaq, which would provide AutoMax shareholders with the opportunity to obtain greater liquidity for their shares than
    on TASE;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Merger will make AutoMax more profitable and enable it to continue the process of diversifying the vehicles it imports and sells
    in Israel; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            average daily trading volume of SciSparc shares is greater than the average daily trading
                                            volume in AutoMax&#8217;s shares, and therefore the combined entity is expected to have a
                                            higher trading volume.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the boards of directors
of SciSparc and AutoMax also considered other factors for the Merger, as described herein. For example, the SciSparc board of directors
considered, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            strategic alternatives to the Merger available to SciSparc, including the discussions that
                                            SciSparc&#8217;s management and the SciSparc board of directors previously conducted with
                                            other potential merger partners;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risks associated with continuing to operate SciSparc on a stand-alone basis, including liquidity
                                            needs and cash-burn relating to, among other things, funding SciSparc&#8217;s contemplated
                                            clinical trials<span style="background-color: white">;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            management&#8217;s belief that it would be difficult to obtain sufficient equity or debt
                                            financing on acceptable terms, if at all;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            valuation report prepared by an independent valuator by E.D.B., as to the valuation of AutoMax
                                            pursuant to the Merger Agreement to SciSparc, as more fully described below in the section
                                            entitled &#8220;&#8212;<i>Valuation Report of E.D.B. Consulting and Investments Ltd</i>&#8221;;
                                            and</td>
</tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr.
                                            Weiss&#8217; dual role as both the Chairman of SciSparc&#8217;s board of directors, and as
                                            the chairman of AutoMax&#8217;s board of directors, and whether his interests in the Merger
                                            may differ from, or extend beyond, the interests of SciSparc&#8217;s shareholders generally.</td></tr>
     </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Valuation Report of E.D.B. Consulting and
Investments Ltd. (see page 99)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the March 31, 2024 meeting
of the board of directors of SciSparc, representatives of E.D.B. presented a valuation report of AutoMax, based upon and subject to the
assumptions made, procedures followed, matters considered and qualifications and limitations on the scope of the review undertaken by
E.D.B. in connection with the preparation of its valuation report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. provided its valuation
report for the information and assistance of SciSparc&#8217;s board of directors (in its capacity as such) in connection with, and for
purposes of, its consideration of the Merger and its valuation report only addresses the valuation of AutoMax. The valuation report of
E.D.B. did not address any other term or aspect of the Merger Agreement or the Merger. The valuation report does not constitute a recommendation
to the board of directors of SciSparc or any SciSparc shareholder as to how the SciSparc board of directors, such shareholder or any
other person should vote or otherwise act with respect to the Merger or any other matter.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview of the Merger Agreement (see page
109)</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merger Consideration and Exchange
Ratio (see page 109)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time, each
outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares and pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares and pre-funded warrants that AutoMax shareholders will
be entitled to receive for changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc
ordinary shares issued pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger
closes and could vary significantly from the market value of the SciSparc ordinary shares on the date of this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each AutoMax shareholder will receive SciSparc ordinary shares in exchange for its AutoMax shares in an amount equal to the
number of AutoMax shares held by such AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will receive
pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued in connection
with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary shares (after
aggregating all fractional SciSparc ordinary shares issuable to such AutoMax shareholder) will receive such amount rounded to the nearest
whole number of SciSparc ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under the Exchange Ratio formula described in the Merger Agreement,
immediately following the Merger, AutoMax&#8217;s shareholders, and its Advisor in connection with the Merger, are expected to own approximately
49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders, immediately prior to the Merger are expected to own approximately
50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions. The Exchange Ratio formula is based
on the number of SciSparc&#8217;s outstanding shares on a fully-diluted basis, subject to certain exceptions, divided by 0.5001, multiplied
by 0.4749, divided by the number of AutoMax&#8217;s outstanding shares, excluding dormant shares, minus SciSparc&#8217;s holdings in AutoMax,
so, that in any event, AutoMax shareholders (other than SciSparc) shall own approximately 49.99% of SciSparc&#8217;s share capital, on
a fully-diluted basis, subject to certain exceptions.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Treatment of AutoMax Warrants, Share
Options, Series B Bonds, and Series C Bonds</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option, and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms
of AutoMax&#8217;s Series B Bonds and the Series B Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4)
unequal annual installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that
was made on February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made
on February 28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, that was made on February
28, 2025, constituted 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February
28, 2026, will constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger, the Series
B Bonds will remain outstanding and subject to repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B
Bonds bear interest at a rate of 5.9% per annum. As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal
amount of Series B Bonds remains outstanding and will therefore become a liability of the combined company following the completion of
the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On May 19, 2025, the Series
C Bonds, were issued and began trading on the TASE. According to the terms of the Series C Bonds and the Series C Bonds Trust Deed, the
Series C Bonds are due for repayment in four (4) unequal annual installments, which will be paid annually from December 31, 2026 until
December 31, 2029, such that the first payment will constitute 5% of the principal, the second and third payments will constitute 10%
each of the principal, and the fourth payment will constitute 75% of the principal. The Series C Bonds bear fixed annual interest at
a rate of 8% per annum. The interest will be paid on each June 30 and December 31, from 2026 to 2029. As of July 3, 2025, NIS 74,353
thousand, approximately ($20,260 thousand) in principal amount of Series C Bonds remains outstanding and will therefore become a liability
of the combined company following the completion of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conditions to the Completion of the
Merger (see page 123)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations to consummate
the Merger and the other transactions contemplated by the Merger Agreement shall be subject to the satisfaction or waiver, on or prior
to the closing of the Merger, of the conditions set forth in the section entitled &#8220;<i>The Merger Agreement &#8211;&#8201;Conditions
to the Completion of the Merger</i>&#8221; below.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No Solicitation by SciSparc and AutoMax
(see page 125)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
and their representatives are prohibited by the terms of the Merger Agreement from (i) soliciting, initiating or knowingly encouraging,
inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry or
take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry; (ii) furnishing any non-public
information regarding SciSparc or AutoMax, as applicable, or any of its respective subsidiaries to any person in connection with or in
response to an acquisition proposal or acquisition inquiry; (iii) engaging in discussions or negotiations with any person with respect
to any acquisition proposal or acquisition inquiry; (iv) approving, endorsing or recommending any acquisition proposal; (v) executing
or entering into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or (vi) publicly
proposing to do any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>Share Ownership of SciSparc
Directors and Executive Officers </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
proxy statement/prospectus, SciSparc&#8217;s directors and executive officers as a group, owned and were entitled to vote 375,365 shares
of SciSparc&#8217;s ordinary shares, or 3.3% of the outstanding shares of SciSparc ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
directors and executive officers have informed us that they intend to vote all of their shares of SciSparc&#8217;s ordinary shares <b><i>&#8220;FOR&#8221;&#160;</i></b>the
approval of the consummation of the Merger and the other transactions contemplated by the Merger Agreement,&#160;<b><i>&#8220;FOR&#8221;</i></b>&#160;the
approval of the form of Indemnification Agreement for directors and officers of SciSparc, <b><i>&#8220;FOR&#8221;</i></b>&#160;the approval
of a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President, contingent upon the approval and closing
of the Merger; and <b><i>&#8220;FOR&#8221;</i></b>&#160;the approval, subject to and contingent upon the approval of the consummation
of the Merger, of the election of elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the effective
time of the Merger and the ratification of the class structure of the SciSparc board of directors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>
</div><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Termination (see page 129)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Either SciSparc or AutoMax
can terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated. In the event that
the Merger Agreement is terminated, neither party is required to pay a termination fee to the other party.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax Shareholder Support Agreement
(see page 131)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution
of the Merger Agreement, certain shareholders of AutoMax entered into the AutoMax Shareholder Support Agreement, covering approximately
55.56% of the outstanding shares of AutoMax. The AutoMax Shareholder Support Agreement provides, among other things, that the shareholders
party to the AutoMax Shareholder Support Agreement will vote all of the shares of AutoMax held by them in favor of the adoption of the
Merger Agreement, the approval of the Merger and the other transactions contemplated by the Merger Agreement.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Indemnification Agreement (see page 131)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to approval by the
shareholders in this Special Meeting, SciSparc will enter into a form of Indemnification Agreement with each of its office holders.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive Officers of SciSparc Following
the Merger (see page 123)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following the
Merger, the executive management team of SciSparc is expected to be composed as set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 18%"><b>Name</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 30%"><b>Position
    with SciSparc</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 31%"><b>Current
    Position</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 18%"><b>Age</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Oz Adler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Technology Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Technology Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors of SciSparc Following the Merger
(see page 123)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At and immediately after
the effective time of the Merger, the board of directors of SciSparc and its committees are expected to be composed of the individuals
set forth in the table below. The directors shall serve until their respective successors are duly elected or appointed and qualified
or their earlier death, resignation or removal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%"><b>Designee</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><b>Age</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 71%"><b>Position(s)</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><i>AutoMax Designees</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">Yaarah Alfi</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">37</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer of AutoMax</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">Tomer Levy</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">30</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">VP Business Development and Headquarters, director of AutoMax</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><i>SciSparc Designees</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">Amitay Weiss</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">63</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chairman of the Board of Directors of SciSparc</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">Amnon Ben Shay</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Director</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">Moshe Revach</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">49</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Director</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Liat Sidi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Director</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interests of the SciSparc and AutoMax Directors
and Executive Officers in the Merger (see page 108)</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In considering the recommendation
of SciSparc&#8217;s board of directors with respect to the issuance of SciSparc ordinary shares in connection with the Merger and the
other matters to be acted upon by SciSparc&#8217;s shareholders at the Special Meeting, SciSparc&#8217;s shareholders should be aware
that certain members of the board of directors and executive officers of SciSparc have interests in the Merger that may be different
from, or in addition to, your interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Amnon Ben Shay, Moshe
Revach and Liat Sidi will continue to be a director of the combined company after the effective time of the Merger, and, following the
closing of the Merger, will be eligible to be compensated as a non-employee director of the combined company pursuant to the compensation
policy of SciSparc. In addition, pursuant to the Merger Agreement and form of Indemnification Agreement, SciSparc&#8217;s directors and
executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss, the Chairman
of SciSparc&#8217;s board of directors, serves as the chairman of AutoMax&#8217;s board of directors. Pursuant to the terms of the Merger
Agreement, Mr. Amitay Weiss will continue to be a director of the combined company after the closing of the Merger and will receive compensation
as a director and be entitled to continued indemnification. In addition, if approved by SciSparc shareholders, Mr. Amitay Weiss will
be entitled to receive a one-time cash bonus of $150,000 as the Chairman of SciSparc subject to and upon the closing of the Merger. Each
of Mr. Oz Adler and Mr. Itschak Shrem will also be entitled to receive a one-time bonus of $315,000 and $50,000, as the Chief Executive
Officer of SciSparc and President of SciSparc, respectively. These interests may present them with actual or potential conflicts of interest,
as further described in Proposal No. 3 (see page 135), and should be aware that the directors and officers of SciSparc may have interests
in such proposal, which differ from, or extend beyond, your interests.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of July 3, 2025, all
directors and executive officers of SciSparc, together with their affiliates, beneficially owned approximately 4.51% of the outstanding
SciSparc ordinary shares.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of July 3, 2025, all
directors and executive officers of AutoMax, together with their affiliates, beneficially owned approximately 34.79% of the outstanding
AutoMax ordinary shares.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Material Israeli Income Tax Consequences
of the Merger (see page 110)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under the Israeli
Tax Ordinance [New Version], 5721-1961, the disposition of shares of an Israeli company, such as AutoMax, is deemed to be a sale of capital
assets subject to capital gains tax by both residents and non-residents of Israel, unless a specific exemption is available or unless
a treaty for the prevention of double taxation between Israel and the seller&#8217;s country of residence provides otherwise. AutoMax
has obtained the Tax Ruling (as defined herein) from the Israel Tax Authority for which AutoMax had applied, therefore, the Israeli income
tax consequences of the Merger are in accordance with the Tax Ruling (as applicable to a particular AutoMax shareholder). For more information,
please see the section entitled &#8220;<i>The Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger</i>&#8221;
of this proxy statement/prospectus.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors (see page 11)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility
that the Merger may not be completed, poses a number of risks to each company and its respective shareholders, including the following
risks:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Exchange Ratio is not adjustable based on the market price of SciSparc ordinary shares, so
                                            the Merger consideration at the closing of the Merger may have a greater or lesser value
                                            than at the time the Merger Agreement was signed;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If
                                            the conditions to the Merger are not met, the Merger will not occur;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Merger may be completed even though material adverse changes may result from the announcement
                                            of the Merger, industry-wide changes and other causes;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            market price of the combined company&#8217;s shares may decline as a result of the Merger;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            and AutoMax shareholders may not realize a benefit from the Merger commensurate with the
                                            ownership dilution they will experience in connection with the Merger; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During
                                            the pendency of the Merger, SciSparc and AutoMax will be subject to contractual limitations
                                            set forth in the Merger Agreement that restrict the parties&#8217; ability to enter into
                                            business combination transactions with another party.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These risks and other risks
are discussed in greater detail under the section entitled &#8220;<i>Risk Factors</i>&#8221; in this proxy statement/prospectus. SciSparc
and AutoMax both encourage you to read and consider all of these risks carefully.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory Approvals (see page 110)</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, SciSparc
must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance
of shares of SciSparc and the filing of this proxy statement/prospectus with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition to closing
of the Merger, the Merger Agreement sets forth that AutoMax shall obtain a court approval for the Merger, under sections 350 and 351
of the Companies Law. According to the Companies Law, the required majority at a general meeting of shareholders to approve a merger
as described is a majority of the number of voting participants, excluding abstainers, who hold at least three-quarters (3/4) of the
voting power represented at such meeting, in accordance with Section 350(9) of the Companies Law. As part of the Merger, shares of SciSparc
will be offered to AutoMax&#8217;s shareholders. As such, it is plausible to conclude that SciSparc is making an offer to the public
and is required to file a prospectus with the Israeli Securities Authority. Based on the foregoing, SciSparc and AutoMax have requested
that an Israeli court approve an exemption to the foregoing requirement given that SciSparc is a public company traded on Nasdaq and
therefore subject to the Securities Act, and as such, all relevant information is available to the Israeli public, and SciSparc shall
continue to provide information in accordance with the Securities Act. The Israeli Securities Authority has responded to AutoMax&#8217;s
petition to the court and has indicated that it will not require filing a prospectus is Israel. Pursuant to AutoMax&#8217;s petition
to the court, the court ordered that AutoMax will convene a shareholders meeting for approval of the merger, and in addition will convene
a separate meeting of AutoMax&#8217;s shareholders who are not controlling shareholders or SciSparc to vote on the approval of the Merger.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Stock Market Listing (see page 121)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to consummation of
the Merger, SciSparc intends to file a listing of additional securities application with Nasdaq, as required by Nasdaq to effect the
issuance of ordinary shares in connection with the Merger or upon exercise of AutoMax&#8217;s outstanding options that will be assumed
by SciSparc in connection with the Merger. If such application is accepted, SciSparc anticipates that its securities will be listed on
the Nasdaq Capital Market following the closing of the Merger and will trade under SciSparc&#8217;s existing name, SciSparc Ltd., and
trading symbol, &#8220;SPRC&#8221;.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anticipated Accounting Treatment (see page
122)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-weight: normal">SciSparc
and AutoMax each prepare their respective financial statements in accordance with International Financial Reporting Standards, or IFRS,
as issued by the International Accounting Standards Boards. The Merger will be accounted for using the acquisition method of accounting,
and SciSparc will be treated as the accounting acquirer.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparison of Shareholder Rights&#160;(see
page 230)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
are incorporated under the laws of Israel and, accordingly, the rights of the shareholders of each are currently, and will continue to
be, governed by Israeli law. If the Merger is completed, AutoMax shareholders will become SciSparc shareholders, and their rights will
be governed by Israeli law and the Amended and Restated Articles of Association of SciSparc attached to this proxy statement/prospectus
as Annex D, as are currently in effect, and may differ from the rights of AutoMax shareholders under AutoMax&#8217;s current amended
and restated articles of association, as more fully described under the section entitled &#8220;<i>Comparison of Shareholder Rights</i>&#8221;
in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

</div><div>
</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 6pt; width: 98%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<a id="m_003"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">MARKET
PRICE AND DIVIDEND INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc Ordinary Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s ordinary
shares are listed on the Nasdaq Capital Market under the symbol &#8220;SPRC.&#8221; AutoMax&#8217;s ordinary shares are listed on the
TASE under the symbol &#8220;AMX&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The closing price of SciSparc&#8217;s
ordinary shares on July 3, 2025, as reported on Nasdaq, was $6.60 per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming approval of Proposals
Nos. 1 through 4 and the successful application for the listing of additional securities with Nasdaq, following the consummation of the
Merger, SciSparc&#8217;s ordinary shares will be continue to be listed on Nasdaq and will trade under SciSparc&#8217;s existing name,
SciSparc Ltd., and existing trading symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of July 3, 2025, SciSparc
had 25 holders of record of its ordinary shares. As of&#160;July 3, 2025, AutoMax had&#160;35 holders of record of its ordinary shares.
For detailed information regarding the beneficial ownership of certain SciSparc shareholders upon consummation of the Merger, see the
section entitled &#8220;<i>Principal Shareholders of Combined Company</i>&#8221; in this proxy statement/prospectus.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SciSparc</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has never declared
or paid any cash dividends on its share capital, and it does not currently anticipate declaring or paying cash dividends on its share
capital in the foreseeable future. SciSparc intends to retain all future earnings, if any, to finance the operation and expansion of
SciSparc&#8217;s business. Any future determination relating to SciSparc&#8217;s dividend policy will be made at the discretion of SciSparc&#8217;s
board of directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future
prospects, contractual restrictions and covenants and other factors that SciSparc&#8217;s board of directors may deem relevant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">AutoMax has never declared
or paid any cash dividends on its share capital. In accordance with the Series B Bonds Trust Deed, until the Series B Bonds are repaid
in full, AutoMax will not distribute or pay any cash dividends. According to the terms of AutoMax&#8217;s Series B Bonds and the Series
B Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual installments, which will be paid
annually as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on February 28, 2023 constituted 10%
of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February 28, 2024, constituted 15% of the
aggregate principal amount of the Series B Bonds, the third payment, that was made on February 28, 2025, constituted 30% of the aggregate
principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute 45% of the aggregate
principal amount of the Series B Bonds. Following the closing of the Merger, the Series B Bonds will remain outstanding and subject to
repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B Bonds bear interest at a rate of 5.9% per annum.
As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal amount of Series B Bonds remains outstanding and
will therefore become a liability of the combined company following the completion of the Merger.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On May 19, 2025, the
Series C Bonds, were issued and began trading on the TASE. According to the terms of the Series C Bonds and the Series C Bonds Trust
Deed, the Series C Bonds are due for repayment in four (4) unequal annual installments, which will be paid annually from December
31, 2026 until December 31, 2029, such that the first payment will constitute 5% of the principal, the second and third payments
will constitute 10% each of the principal, and the fourth payment will constitute 75% of the principal. The Series C Bonds bear
fixed annual interest at a rate of 8% per annum. The interest will be paid on each June 30 and December 31, from 2026 to 2029. As of
July 3, 2025, NIS 74,353 thousand, approximately ($20,260 thousand) in principal amount of Series C Bonds remains outstanding and
will therefore become a liability of the combined company following the completion of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax does not anticipate
paying any cash dividends on shares of AutoMax&#8217;s share capital in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
</div><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="m_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RISK
FACTORS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The combined company will
be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control.
In addition to the other information contained in this proxy statement/prospectus, you should carefully consider the material risks described
below before deciding how to vote your shares of SciSparc. You should also read and consider the risks associated with the business of
SciSparc because these risks may also affect the combined company. You should also read and consider the other information in this proxy
statement/prospectus. Please see the section entitled &#8220;Where You Can Find More Information&#8221; on page 240 of this proxy statement/prospectus.</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors Summary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
following is a summary of some of the risks and uncertainties that could materially adversely affect SciSparc&#8217;s business, financial
condition and results of operations. You should read this summary together with the more detailed description of each risk factor contained
</span>below<span style="background-color: white">:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks related to the Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    the Exchange Ratio is fixed, AutoMax shareholders cannot be certain of the precise value of the consideration that they may receive
    in the Merger.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If
                                            the proposed merger with AutoMax is not consummated, SciSparc&#8217;s share price could decline.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Some
                                            SciSparc and AutoMax officers and directors have interests in the Merger that are different
                                            from yours and that may influence them to support or approve the Merger without regard to
                                            your interests.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            market price of the combined company&#8217;s shares may decline as a result of the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            and AutoMax shareholders may not realize a benefit from the Merger commensurate with the
                                            ownership dilution they will experience in connection with the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            and AutoMax may become involved in securities litigation or shareholder derivative litigation
                                            in connection with the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to SciSparc&#8217;s Business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            is a specialty clinical-stage pharmaceutical company and has incurred significant losses
                                            since the date of its inception, and anticipate that it will continue to incur significant
                                            losses until SciSparc is able to successfully commercialize its product candidates.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            has not generated any revenue from the sale of current product candidates and may never be
                                            profitable.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks Related to SciSparc&#8217;s Intellectual Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If
                                            SciSparc is unable to obtain and maintain effective patent rights for its product candidates,
                                            it may not be able to compete effectively in its markets.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            may not be able to identify infringements of its patents and accordingly the enforcement
                                            of its intellectual property rights may be difficult.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks Related to SciSparc&#8217;s Intended
Corporate Restructuring Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Restructuring Plan may not be completed in accordance with the expected plans or anticipated
                                            timeline, or at all, and may not achieve the expected results.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to the Ownership of SciSparc&#8217;s
Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            will need additional capital in the future.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to Israeli Law and SciSparc&#8217;s
Operations in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provisions
                                            of Israeli law may make it easy for SciSparc&#8217;s shareholders to demand that it convene
                                            a shareholders meeting and/or allow shareholders to convene a shareholder meeting without
                                            the consent of SciSparc&#8217;s management, which may disrupt its management&#8217;s ability
                                            to run its company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            results may be adversely affected by political, economic and military instability in Israel.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to AutoMax&#8217;s Business
and Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            decline in available financing may adversely affect AutoMax&#8217;s business.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Failure
                                            to renew AutoMax permits and licenses or their revocation could materially adversely affect
                                            its business, results of operations, financial condition and cash flows.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax&#8217;s
                                            ability to import and sell vehicles depends in large part on agreements with suppliers and,
                                            therefore, any disruption or deterioration in its relationship with such suppliers could
                                            impact its business.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Import
                                            product restrictions may impair AutoMax&#8217;s ability to sell vehicles or parts profitably.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax
                                            is subject to various legal proceedings, which could adversely affect its business, results
                                            of operations and financial condition.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
    business and operations face many risks inherent to international trade, and its location in Israel including the ongoing military
    conflicts, may exacerbate the import process, which is material to the success of AutoMax&#8217;s business and operations, including
    disruptions to the maritime route in the Red Sea, and Turkey&#8217;s trade embargo.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Macroeconomic
                                            factors such as fluctuation in vehicle prices, fuel prices, supply chain disruptions, and
                                            vehicle-related technology advancements could have an adverse effect on AutoMax&#8217;s revenues
                                            and operating results.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax&#8217;s
                                            operations are subject to a wide range of governmental regulations and laws. Its failure
                                            to comply with or any changes to these regulations and laws, could adversely affect AutoMax&#8217;s
                                            business, sales, results of operations and financial condition.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Risks Related to the Combined Company</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            combined company does not anticipate paying any cash dividends on the combined company&#8217;s
                                            ordinary shares in the foreseeable future.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Maintaining
                                            and improving the combined company&#8217;s financial controls and the requirements of being
                                            a public company may strain the combined company&#8217;s resources, divert management&#8217;s
                                            attention and affect its ability to attract and retain qualified board members.</td>
</tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to the Merger</b></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because the Exchange Ratio is fixed and
will not be adjusted in the event of a change in either SciSparc&#8217;s share price or AutoMax&#8217;s share price, AutoMax shareholders
cannot be certain of the precise value of the consideration that they may receive in the Merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, each outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, to be
determined in accordance with the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive to
account for changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary
shares issued pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and
could vary significantly from the market value of the SciSparc ordinary shares on the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (other than SciSparc, which
currently holds shares in AutoMax) and its Advisor are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s
shareholders are expected to own approximately 50.01% of SciSparc&#8217;s share capital on a fully-diluted basis (subject to certain
exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Exchange Ratio is
the result of the following calculation: the number of the SciSparc outstanding shares on a fully-diluted basis (subject to certain exceptions)
divided by 0.5001, multiplied by 0.4749, then divided by the number of the AutoMax outstanding shares, excluding dormant shares, less
the number of the AutoMax ordinary shares held by SciSparc; so that, in any event, immediately following the effective time, holders
of AutoMax outstanding shares (and its Advisor, but other than SciSparc), will hold together 49.99% of SciSparc&#8217;s share capital,
on a fully-diluted basis (subject to certain exceptions), immediately following the effective time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of SciSparc
ordinary shares and, as a result, the value of the consideration that AutoMax shareholders may receive pursuant to the Merger Agreement,
has been fluctuating since the date that the Merger Agreement was executed and publicly announced and may continue to fluctuate through
the date of the completion of the Merger. Accordingly, upon the completion of the Merger and the issuance of the SciSparc ordinary shares
to the AutoMax shareholders, the market price of the SciSparc ordinary shares that will be issued to the AutoMax shareholders as the
Merger consideration could be greater than, less than or the same as the market price of SciSparc ordinary shares on the date the Merger
Agreement was executed, on the date of this prospectus or on the date of the SciSparc and AutoMax shareholder meetings. Share price changes
may result from a variety of factors, including, among others, changes in SciSparc&#8217;s or AutoMax&#8217;s respective businesses operations
or prospects, risks described in the risk factors of each of SciSparc and AutoMax; legislative, regulatory and legal developments; general
market, industry and economic conditions; shareholder litigation relating to the Merger or otherwise relating to SciSparc or to AutoMax;
and market assessments of the likelihood that the Merger will be completed. Because the value of the consideration will depend on the
market price of SciSparc ordinary shares at the time the Merger is completed, AutoMax shareholders will not know or be able to determine
at the time of the AutoMax shareholders meeting the market value of the Merger consideration they may receive upon completion of the
Merger. Similarly, SciSparc shareholders will not know or be able to determine at the time of the Special Meeting of SciSparc&#8217;s
shareholders, the market value of the consideration to be paid to the AutoMax shareholders in the form of issuance of SciSparc ordinary
shares pursuant to the Merger Agreement compared to the market value of AutoMax ordinary shares that are being exchanged. You are urged
to obtain current market quotations for SciSparc ordinary shares and AutoMax ordinary shares in determining <span style="background-color: white">whether
to vote for approval of the Merger-related proposals. In addition, see the section entitled &#8220;Comparative Per Share Market Price
Information</span>&#8221; beginning on page 82.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the proposed merger with AutoMax
is not consummated, SciSparc&#8217;s share price could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consummation of the
proposed Merger with AutoMax is subject to a number of closing conditions, including the approval by SciSparc&#8217;s shareholders, approval
by Nasdaq of SciSparc&#8217;s listing of additional securities application of its ordinary shares issued in connection with the Merger,
and other customary closing conditions. SciSparc is targeting a closing of the transaction in the third quarter of 2025.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the proposed Merger is
not consummated, SciSparc may be subject to a number of material risks, and its share price could be adversely affected, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc
                                            has incurred and expects to continue to incur significant expenses related to the proposed
                                            Merger with AutoMax, even if the Merger is not consummated.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Merger Agreement contains covenants restricting SciSparc&#8217;s solicitation of competing
                                            acquisition proposals and the conduct of SciSparc&#8217;s business between the date of signing
                                            the Merger Agreement and the closing of the Merger. As a result, significant business decisions
                                            and transactions before the closing of the Merger require the consent of AutoMax. Accordingly,
                                            SciSparc may be unable to pursue business opportunities that would otherwise be in its best
                                            interest as a standalone company. SciSparc has invested significant time and resources in
                                            the transaction process and if the Merger Agreement is terminated SciSparc will have a limited
                                            ability to continue its current operations without obtaining additional financing.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            collaborators and other business partners and investors in general may view the failure to
                                            consummate the Merger as a poor reflection on its business or prospects.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Some
                                            of SciSparc&#8217;s collaborators and other business partners may seek to change or terminate
                                            their relationships with SciSparc as a result of the proposed Merger or the failure thereof.</td>
</tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            management team may be distracted from day to day operations as a result of the proposed
                                            Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; background-color: white">On
    July 16, 2024, SciSparc received a written notice, or the Notice, from Nasdaq indicating that it is not in compliance with the minimum
    bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain
    a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), SciSparc was granted a period of 180 calendar days
    to regain compliance with the minimum bid price requirement. On January 14, 2025, SciSparc received an additional written notice
    from Nasdaq indicating that it had been granted, per its request, an additional 180-day compliance period, or until July 14, 2025,
    to regain compliance with the minimum bid price requirement. No assurance can be given that SciSparc will remain eligible to be listed
    on Nasdaq. Further, because of the previous delisting of SciSparc&#8217;s American Depositary Shares, or ADSs, from Nasdaq, if SciSparc
    falls out of compliance with Nasdaq requirements in the future, its ordinary shares may be more likely to be subject to Nasdaq&#8217;s
    delisting process and no assurance can be given that SciSparc will be able to regain compliance. Any delisting could adversely affect
    SciSparc&#8217;s ability to obtain financing for the continuation of its operations and could result in the loss of confidence by
    investors, customers and employees.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">In
                                            addition, if the Merger Agreement is terminated and SciSparc&#8217;s board of directors determines
                                            to seek another business combination, it may not be able to find a third party willing to
                                            provide equivalent or more attractive consideration than the consideration to be provided
                                            by each party in the Merger. In such circumstances, SciSparc&#8217;s board of directors may
                                            elect to, among other things, divest all or a portion of SciSparc&#8217;s business, and,
                                            in such case, the consideration that SciSparc receives may be less attractive than the consideration
                                            to be received by SciSparc pursuant to the Merger Agreement.</span></td>
</tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the conditions to the Merger are
not met, the Merger will not occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if the Merger is approved
by the shareholders of SciSparc and AutoMax, specified conditions must be satisfied or waived to complete the Merger. These conditions
are set forth in the Merger Agreement and described in the section entitled &#8220;<i>The Merger Agreement &#8212; Conditions to the
Completion of the Merger</i>&#8221; in this proxy statement/prospectus. SciSparc and AutoMax cannot assure you that all of the conditions
will be satisfied. If the conditions are not satisfied or waived, the Merger will not occur or will be delayed, and SciSparc and AutoMax
each may lose some or all of the intended benefits of the Merger.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some SciSparc and AutoMax officers
and directors have interests in the Merger that are different from yours and that may influence them to support or approve the Merger
without regard to your interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain officers and directors
of SciSparc and AutoMax participate in arrangements that provide them with interests in the Merger that are different from yours, including,
among others, the continued service as an officer or director of the combined company, the continued receipt of compensation for such
service, and continued indemnification. Each of Amitay Weiss, Amnon Ben Shay, Moshe Revach and Liat Sidi will continue as directors of
the combined company after the effective time of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss is also
the Chairman of SciSparc&#8217;s board of directors and serves as the chairman of AutoMax. In addition, contingent upon the approval
and closing of the Merger, shareholders are asked to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman
and President. Furthermore, certain officers, directors and shareholders of AutoMax entered into the AutoMax Shareholder Support Agreement,
pursuant to which they agreed, solely in their capacity as shareholders, to vote their shares in AutoMax covering approximately 55.65%
of the outstanding shares of AutoMax in favor of adoption of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Yaki Baranes, a
business analyst, presented a market overview on the motor vehicle market in Israel and a company overview of AutoMax as a vehicle importer
in Israel, to SciSparc&#8217;s board of directors on February 23, 2023. Mr. Baranes was appointed on May 30, 2023, as VP Strategy and
Business Development of SciSparc. Mr. Baranes previously provided services to AutoMax. In addition, Mr. Baranes and Mr. Amitay Weiss
both serve as members of the board of Charging Robotics Inc. and Mr. Baranes provided market overview services to certain other companies
of which Mr. Amitay Weiss serves as a director.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These interests may present
them with actual or potential conflicts of interest. These interests, among others, may influence the officers and directors of SciSparc
and AutoMax to support or approve the Merger. For more information concerning the interests of SciSparc and AutoMax executive officers
and directors, see the section entitled &#8220;<i>Interests of the SciSparc and AutoMax Directors and Executive Officers in the Merger</i>&#8221;
in this proxy statement/prospectus.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SciSparc&#8217;s board of directors did
not obtain a fairness opinion&#160;in determining whether or not to proceed with the Merger.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s board of
directors did not obtain a fairness opinion&#160;in connection with its determination to approve the Merger. In analyzing the Merger,
SciSparc&#8217;s board of directors conducted due diligence on AutoMax and researched the industry in which AutoMax operates by obtaining,
for example, an independent third-party valuation report on AutoMax from E.D.B. Accordingly, investors will be relying solely on the
judgment of SciSparc&#8217;s board of directors in determining the value of the Merger and will not have assurance from an independent
source that the terms of the Merger are fair to the Company from a financial point of view. The lack of a&#160;fairness opinion&#160;may
also lead an increased number of SciSparc&#8217;s shareholders to vote against the proposed Merger, which could potentially impact SciSparc&#8217;s
ability to consummate the Merger.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger may be completed even
though material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, either party
can refuse to complete the Merger if there is a material adverse change affecting the other party following April 10, 2024, the date
of the Merger Agreement. However, some types of changes do not permit either party to refuse to complete the Merger, even if such changes
would have a material adverse effect on SciSparc or AutoMax, to the extent they resulted from the following (unless, in some cases, they
have a disproportionate effect on SciSparc or AutoMax, as the case may be):</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">changes
                                            or conditions generally affecting the industries or markets in which SciSparc and AutoMax
                                            operate, and changes in the industries in which SciSparc and AutoMax operate regardless of
                                            geographic region (including legal and regulatory changes);</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acts
                                            of war, armed hostilities or terrorism;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">changes
                                            in financial, banking or securities markets;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">any
                                            change in, or any compliance with or action taken for the purpose of complying with, any
                                            federal, state, national, foreign, material local or municipal or other law, statute, constitution,
                                            principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling
                                            or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect
                                            by or under the authority of any governmental body (including under the authority of Nasdaq
                                            or the Financial Industry Regulatory Authority), or changes in any interpretations thereof;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">any
                                            change in U.S. generally accepted accounting principles or interpretations thereof;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            announcement of the Merger Agreement or the pendency of the Merger;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            taking of any action required to be taken by the Merger Agreement;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">pandemics,
                                            including any worsening thereof, man-made disasters, natural disasters, acts of God or other
                                            force majeure event; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">changes
                                            in U.S. or non-U.S. general economic or political conditions, or in the financial, credit
                                            or securities markets in general, including any shutdown of any governmental authority.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If adverse changes occur
but SciSparc and AutoMax must still complete the Merger, the combined company&#8217;s share price may suffer.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of the combined
company&#8217;s shares may decline as a result of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of the combined
company&#8217;s shares may decline as a result of the Merger for a number of reasons, including if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            combined company does not achieve the perceived benefits of the Merger as rapidly or to the
                                            extent anticipated by financial or industry analysts;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            effect of the Merger on the combined company&#8217;s business and prospects is not consistent
                                            with the expectations of financial or industry analysts; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">investors
                                            react negatively to the effect on the combined company&#8217;s business and prospects from
                                            the Merger.</td>
</tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc and AutoMax shareholders
may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the combined company is
unable to realize the strategic and financial benefits currently anticipated from the Merger, SciSparc shareholders will have experienced
substantial dilution of their ownership interest without receiving any commensurate benefit. Significant management attention and resources
will be required to operate the two companies. Delays in this process could adversely affect the combined company&#8217;s business, financial
results, financial condition and share price following the Merger. Even if the combined company were able to operate the two businesses
operations successfully, there can be no assurance that this operation will result in the realization of the full benefits of synergies,
innovation and operational efficiencies that may be possible from this integration and that these benefits will be achieved within a
reasonable period of time.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the pendency of the Merger,
SciSparc and AutoMax will be subject to contractual limitations set forth in the Merger Agreement that restrict the parties&#8217; ability
to enter into business combination transactions with another party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Covenants in the Merger Agreement
impede the ability of SciSparc or AutoMax to make acquisitions or complete other transactions that are not in the ordinary course of
business pending completion of the Merger. As a result, if the Merger is not completed, the parties may be at a disadvantage to their
competitors. In addition, while the Merger Agreement is in effect and subject to limited exceptions, each party is prohibited from soliciting,
initiating, encouraging or taking actions designed to facilitate any inquiries or the making of any proposal or offer that could lead
to the entering into certain extraordinary transactions with any third party, such as a sale of assets, an acquisition of SciSparc&#8217;s
securities, a tender offer for SciSparc&#8217;s securities, a Merger or other business combination outside the ordinary course of business.
Any such transactions could be favorable to such party&#8217;s shareholders.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain provisions of the Merger
Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the
arrangements contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Merger Agreement
prohibit each of SciSparc and AutoMax from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover
proposals. Because the lack of a public market for AutoMax shares makes it difficult to evaluate the fairness of the Merger, the shareholders
of AutoMax may receive consideration in the Merger that is less than the fair market value of the AutoMax shares.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain shareholders could attempt
to influence changes within SciSparc that could adversely affect SciSparc&#8217;s operations, financial condition and the value of SciSparc&#8217;s
ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s shareholders
may from time to time seek to acquire a controlling stake in SciSparc, engage in proxy solicitations, advance shareholder proposals or
otherwise attempt to effect changes. Campaigns by shareholders to effect changes at publicly-traded companies are sometimes led by investors
seeking to increase short-term shareholder value through actions such as financial restructuring, increased debt, special dividends,
share repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist shareholders can
be costly and time-consuming and could disrupt SciSparc&#8217;s operations and divert the attention of the SciSparc board of directors
and senior management from the pursuit of the proposed transaction. These actions could adversely affect SciSparc operations, financial
condition, SciSparc&#8217;s ability to consummate the Merger and the value of SciSparc ordinary shares.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SciSparc and AutoMax may become involved
in securities litigation or shareholder derivative litigation in connection with the Merger, and this could divert the attention of SciSparc
and AutoMax management and harm the combined company&#8217;s business, and insurance coverage may not be sufficient to cover all related
costs and damages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities litigation or
shareholder derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale
of a business division or announcement of a business combination transaction. SciSparc and AutoMax may become involved in this type of
litigation in connection with the Merger, and the combined company may become involved in this type of litigation in the future. Litigation
often is expensive and diverts management&#8217;s attention and resources, which could adversely affect the business of SciSparc, AutoMax
and the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the events described in
AutoMax&#8217;s General Risk Factors&#8221; or &#8220;Risks Related to the Combined Company&#8221; occur, those events could cause the
potential benefits of the Merger not to be realized.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s
                                            business is expected to constitute a significant portion of the business of the combined
                                            company following the Merger. As a result, the risks described below in the sections entitled
                                            &#8220;AutoMax Business&#8221; beginning on page 175, and &#8220;Risks Related to the Combined
                                            Company&#8221; beginning on page 79 are among the most significant risks to the combined
                                            company if the Merger is completed. To the extent any of the events in the risks described
                                            in the sections referenced in the previous sentence occur, those events could cause the potential
                                            benefits of the Merger not to be realized and the market price of the combined company&#8217;s
                                            shares to decline.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks
                                            Related to SciSparc&#8217;s Business</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Financial Condition and Capital Requirements</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc is a
specialty clinical</i></b>-<b><i>stage pharmaceutical company and has incurred significant losses since the date of its inception, and
anticipate that it will continue to incur significant losses until it is able to successfully commercialize its product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has historically incurred substantial net losses; including net losses of approximately $7.5 million for the year ended December 31,
2024, $5.9 million for the year ended December 31, 2023, and $2.6 million for the year ended December 31, 2022. As of December 31, 2024,
SciSparc had an accumulated deficit of approximately $75 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has devoted substantially all of its financial resources to develop its product candidates, and more recently, to a lesser degree, SciSparc
has been searching for strategic transactions. SciSparc financed its operations primarily through the issuance of equity securities.
The amount of its future net losses will depend, in part, on completing the development of its product candidates, the demand for its
product candidates, the rate of its future expenditures and its ability to obtain funding through the issuance of its securities, strategic
collaborations or grants. Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of
risk. SciSparc is in the late stages of preclinical and at the early stages of clinical development for its product candidates, it has
not yet commenced pivotal clinical studies for any product candidate. Although SciSparc has begun early commercialization efforts for
its proprietary PEA oral tablets formulation, CannAmide&#8482;, which it expects will be marketed to pharmacies and other retail outlets
across Canada following its entering into a distribution agreement(s), it may be several years, if ever, before SciSparc completes pivotal
clinical studies and has its lead product candidate approved for commercialization. Even if SciSparc obtains regulatory approval to market
a product candidate, its future revenue will depend upon the size of the markets for which its product candidates may receive approval
and its ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors and adequate market share for
its product candidates in those markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
expects to continue to incur significant losses until it is able to commercialize its main pharmaceutical product candidates, which it
may not be successful in achieving. SciSparc anticipates that its expenses will increase substantially if and as it:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160; &#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">continues the research and
    development of its product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">expands the scope of its
    current clinical studies for its product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">seeks regulatory and marketing
    approvals for its product candidates that successfully complete clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">establishes a sales, marketing
    and distribution infrastructure to commercialize its product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">seeks to identify, assess,
    acquire, license, and/or develop other product candidates and subsequent generations of its current product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">seeks to maintain, protect,
    and expand its intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">seeks to attract and retain
    skilled personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">creates additional infrastructure
    to support its operations as a public company and its product candidate development and planned future commercialization efforts.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc has not
generated any revenue from the sale of its current pharmaceutical product candidates and may never be profitable.</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has not yet commercialized any of its pharmaceutical product candidates and have not generated any revenue from sales of its pharmaceutical
product candidates since the date of its inception. Although SciSparc has begun early commercialization efforts for its proprietary PEA
oral tablets formulation. CannAmide&#8482;, it does not currently expect the sale of CannAmide to result in material revenues, nor is
CannAmide&#8482; its lead pharmaceutical product candidate. SciSparc does not know whether or when it will become profitable. Its ability
to generate revenue and achieve profitability depends on its ability to successfully complete the development of, and to commercialize,
SciSparc&#8217;s pharmaceutical product candidates and on the demand for its pharmaceutical product candidates. SciSparc&#8217;s ability
to generate revenue and achieve profitability depends on its ability, alone or with strategic collaboration partners, to successfully
complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one or more of its pharmaceutical
product candidates. SciSparc&#8217;s ability to generate future revenue from pharmaceutical product candidate sales depends heavily on
its success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">completing
                                            research and preclinical and clinical development of its pharmaceutical product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">obtaining
                                            regulatory and marketing approvals for pharmaceutical product candidates for which SciSparc
                                            completes clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">establishing
                                            and maintaining supply and manufacturing relationships with third parties that can provide
                                            adequate (in amount and quality) pharmaceutical products to support market demand for its
                                            pharmaceutical product candidates, if approved;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">launching
                                            and commercializing pharmaceutical product candidates if and when SciSparc obtains regulatory
                                            and marketing approval, either directly or with a collaborator or distributor;</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">obtaining
                                            market acceptance of its pharmaceutical product candidates as viable treatment options;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">addressing
                                            any competing pharmaceutical or biotechnological and market developments;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">identifying,
                                            assessing, acquiring and/or developing new pharmaceutical product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">negotiating
                                            favorable terms in any collaboration, licensing or other arrangements into which SciSparc
                                            may enter;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">maintaining,
                                            protecting and expanding its portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">attracting,
                                            hiring and retaining qualified personnel.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if one or more of the pharmaceutical product candidates that SciSparc develops is approved for commercial sale, SciSparc anticipates
incurring significant costs associated with commercializing any approved pharmaceutical product candidate. Its expenses could increase
beyond expectations if it is required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or
foreign, to perform clinical, nonclinical or other types of studies in addition to those that SciSparc currently anticipates. In cases
where SciSparc is successful in obtaining regulatory approvals to market one or more of its pharmaceutical product candidates, its revenue
will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price
for the pharmaceutical product candidate, the ability to get reimbursement at an acceptable price and whether it owns the commercial
rights for that territory. If the number of its addressable patients is not as significant as SciSparc estimates, the indication approved
by regulatory authorities is narrower than it expects, or the reasonably expected population for treatment is narrowed by competition,
physician choice or treatment guidelines, SciSparc may not generate significant revenue from sales of such pharmaceutical product candidates,
even if approved. Additionally, if it is not able to generate revenue from the sale of any approved pharmaceutical product candidates,
SciSparc may be forced to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc expects
that it will need to raise substantial additional funding before it can expect to become profitable from sales of its pharmaceutical
product candidates. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital
when needed may force SciSparc to delay, limit or terminate its pharmaceutical product candidate development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of December 31, 2024, SciSparc&#8217;s cash was approximately $1.5 million, other accounts receivable was approximately $1 million, SciSparc
had working capital of approximately $6.1 million and it also had an accumulated deficit of approximately $75 million. Based upon its
currently expected level of operating expenditures, SciSparc does not expect that its existing cash will be sufficient to fund operations
for at least the next 12 months. SciSparc expects that it will require substantial additional capital to commercialize its pharmaceutical
product candidates. In addition, SciSparc&#8217;s operating plans may change as a result of many factors that may currently be unknown
to SciSparc, and may need to seek additional funds sooner than planned. SciSparc&#8217;s future funding requirements will depend on many
factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160; &#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the scope, rate of progress,
    results and cost of pharmaceutical product development, clinical studies, preclinical testing, and other related activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the cost, timing and outcomes
    of regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the cost and timing of establishing
    sales, marketing, and distribution capabilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the terms and timing of any
    collaborative, licensing, and other arrangements that SciSparc may establish.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
additional fundraising efforts may divert SciSparc&#8217;s management from their day-to-day activities, which may adversely affect its
ability to develop and commercialize its pharmaceutical product candidates. In addition, SciSparc cannot guarantee that future financing
will be available in sufficient amounts or on terms acceptable to it, if at all. Moreover, the terms of any financing may adversely affect
the holdings or the rights of holders of its securities and the issuance of additional securities, whether equity or debt, by SciSparc,
or the possibility of such issuance, may cause the market price of its ordinary shares to decline. The incurrence of indebtedness could
result in increased fixed payment obligations, and SciSparc may be required to agree to certain restrictive covenants, such as limitations
on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights and other
operating restrictions that could adversely impact its ability to conduct its business. SciSparc could also be required to seek funds
through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and SciSparc may
be required to relinquish rights to some of its technologies or pharmaceutical product candidates or otherwise agree to terms unfavorable
to it, any of which may have a material adverse effect on its business, operating results and prospects. Even if SciSparc believes that
it has sufficient funds for its current or future operating plans, it may seek additional capital if market conditions are favorable
or if it has specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more
of its research or development programs or the commercialization of any pharmaceutical product candidates or be unable to expand its
operations or otherwise capitalize on its business opportunities, as desired, which could materially affect its business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The report of
SciSparc&#8217;s independent registered public accounting firm contains an explanatory paragraph regarding substantial doubt about its
ability to continue as a going concern, which could prevent SciSparc from obtaining new financing on reasonable terms or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
report of SciSparc&#8217;s independent registered public accounting firm on its audited consolidated financial statements for the period
ended&#160;December 31,&#160;2024 contains an explanatory paragraph regarding substantial doubt about its ability to continue as a going
concern.&#160;SciSparc&#8217;s consolidated financial statements do not include any adjustments that might result from the outcome of
the uncertainty regarding its ability to continue as a going concern. This going concern opinion could materially limit its ability to
raise additional funds through the issuance of equity or debt securities or otherwise. Further reports on its consolidated financial
statements may include an explanatory paragraph with respect to its ability to continue as a going concern. Until SciSparc can generate
significant recurring revenues, it expects to satisfy its future cash needs through debt or equity financing. SciSparc cannot be certain
that additional funding will be available to it on acceptable terms, if at all. If funds are not available, SciSparc may be required
to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to its products.
This may raise substantial doubts about its ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to the
Discovery and Development of SciSparc&#8217;s Pharmaceutical Product Candidates</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc is heavily
dependent on the success of its pharmaceutical product candidates, which are in the late stages of pre-clinical development or early
stages of clinical development. SciSparc cannot give any assurance that any of its pharmaceutical product candidates will receive regulatory
approval, which is necessary before they can be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, SciSparc has invested substantially all of its efforts and financial resources to design and develop its pharmaceutical product
candidates, including conducting preclinical studies and providing general and administrative support for these operations. SciSparc&#8217;s
future success is dependent on its ability to successfully develop, obtain regulatory approval for, and then successfully commercialize
one or more pharmaceutical product candidates. SciSparc currently generates no revenue from sales of any pharmaceutical product candidate,
and it may never be able to develop or commercialize a marketable pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Each
of its pharmaceutical product candidates is in the late stages of pre-clinical development or early stages of development and will require
additional clinical development (and in some cases additional preclinical development), management of nonclinical, clinical and manufacturing
activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial organization and significant marketing
efforts before SciSparc generates any revenue from pharmaceutical product candidate sales. It may be years before a pivotal study is
initiated, if at all. Any clinical trials in the United States will require the approval of an Investigational New Drug, or IND, application
by the FDA, and SciSparc cannot assure that it will obtain such approval in a timely manner, or at all. SciSparc is not permitted to
market or promote any of its pharmaceutical product candidates before it receives regulatory approval from the FDA or comparable foreign
regulatory authorities, and it may never receive such regulatory approval for any of its pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
as a company has never submitted marketing applications to the FDA or comparable foreign regulatory authorities. SciSparc cannot be certain
that any of its pharmaceutical product candidates will be successful in clinical studies or receive regulatory approval or what regulatory
pathway the regulatory authorities shall designate for its pharmaceutical product candidates. Further, its pharmaceutical product candidates
may not receive regulatory approval even if they are successful in clinical studies. If SciSparc does not receive regulatory approvals
for its pharmaceutical product candidates, it may not be able to continue its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
generally plans to seek regulatory approval to commercialize its pharmaceutical product candidates in the United States, the European
Union and in additional foreign countries. To obtain regulatory approvals SciSparc must comply with the numerous and varying regulatory
requirements of such countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales,
pricing and distribution of its product candidates. Even if SciSparc is successful in obtaining approval in one jurisdiction, it cannot
ensure that it will obtain approval in any other jurisdictions. If SciSparc is unable to obtain approval for its pharmaceutical product
candidates in multiple jurisdictions, its revenue and results of operations would be negatively affected.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The regulatory
approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If SciSparc
is ultimately unable to obtain regulatory approval for its pharmaceutical product candidates, its business will be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following
the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations or the type and amount
of clinical data necessary to gain approval may change during the course of a pharmaceutical product candidate&#8217;s clinical development
and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. SciSparc has
not obtained regulatory approval for any pharmaceutical product candidate, and it is possible that none of its existing pharmaceutical
product candidates or any pharmaceutical product candidates it may seek to develop in the future will ever obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Applications
for its pharmaceutical product candidates could fail to receive regulatory approval for many reasons, including but not limited to the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with the design or implementation
                                            of SciSparc&#8217;s clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc
                                            may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that
                                            a pharmaceutical product candidate&#8217;s safety-benefit ratio for its proposed indication
                                            is acceptable;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with its interpretation of
                                            data from preclinical studies or clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            data collected from clinical studies of its pharmaceutical product candidates may not be
                                            sufficient to support the submission of a New Drug Application, or NDA, in the United States
                                            or elsewhere;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes,
                                            test procedures and specifications or facilities of third-party manufacturers with which
                                            SciSparc contracts for clinical and commercial supplies; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering its clinical data insufficient for approval.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in SciSparc failing to obtain
regulatory approval to market any of its pharmaceutical product candidates, which would significantly harm its business, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Inadequate funding
for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new
products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal
business functions on which the operation of our business may rely, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the FDA and other
government agencies on which our operations may rely, including those that fund research and development activities, is subject to the
political process, which is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Future
legislative and regulatory proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they have
historically operated. We cannot be sure whether additional legislative changes or executive orders will be enacted, or whether any of
the FDA&#8217;s regulations, guidance or interpretations will be changed, or what the impact of such changes on the agency and its scientific
review staff, if any, may be. In addition, disruptions at the FDA and other agencies may slow the time necessary for new products to
be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, political disputes
in the U.S. Congress may result in a shutdown of the U.S. federal government, and in such cases certain regulatory agencies, such as
the FDA, would have to furlough critical employees and stop critical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
a prolonged government shutdown occurs, or if legislative or regulatory developments or global health concerns hinder or prevent the
FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly
impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Disruptions
at the FDA and other agencies may also increase the time necessary for new drugs or medical devices to be reviewed and/or approved by
necessary government agencies or to otherwise respond to regulatory submissions, which would adversely affect our business. For example,
the&#160;Trump&#160;Administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship
with the medical device and pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription
drugs or treatments. Additionally, over the last several years, the US government has shut down multiple times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If funding
for the FDA is reduced, FDA priorities change, or a prolonged government shutdown occurs, it could significantly impact the ability of
the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Clinical drug
development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive
of future study results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical study process. The results of preclinical studies and early clinical studies of its product candidates may not be predictive
of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies
may still suffer significant setbacks in subsequent advanced clinical studies. There is a high failure rate for drugs proceeding through
clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits
despite having progressed satisfactorily through preclinical studies and initial clinical studies. A number of companies in the pharmaceutical
industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses.
SciSparc does not know whether any Phase I, Phase II, Phase III or other clinical studies it may conduct will demonstrate consistent
or adequate efficacy and safety sufficient to obtain regulatory approval to market its product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may find
it difficult to enroll patients in its clinical studies. Difficulty in enrolling patients could delay or prevent clinical studies of
its pharmaceutical product candidates.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Identifying
and qualifying patients to participate in clinical studies of its pharmaceutical product candidates is critical to its success. The timing
of its clinical studies depends in part on the speed at which SciSparc can recruit patients to participate in testing its pharmaceutical
product candidates, and it may experience delays in its clinical studies if SciSparc encounters difficulties in enrollment.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Some
of the conditions for which SciSparc plans to evaluate its current pharmaceutical product candidates are for rare diseases. Accordingly,
there is a limited patient pool from which to draw for clinical studies. Further, the eligibility criteria of its clinical studies will
further limit the pool of available study participants as SciSparc will require that patients have specific characteristics that it can
measure or to assure their disease is either severe enough or not too advanced to include them in a study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
the process of finding patients may prove costly. SciSparc also may not be able to identify, recruit and enroll a sufficient number of
patients to complete its clinical studies because of the perceived risks and benefits of the pharmaceutical product candidate under study,
the availability and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for
prospective patients and the patient referral practices of physicians. If patients are unwilling to participate in its studies for any
reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential pharmaceutical product
candidates will be delayed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc experiences delays in the completion or termination of any clinical study of its pharmaceutical product candidates, the commercial
prospects of its pharmaceutical product candidates will be harmed, and its ability to generate pharmaceutical product candidate revenue
from any of these pharmaceutical product candidates could be delayed or prevented. In addition, any delays in completing its clinical
studies will increase SciSparc&#8217;s costs, slow down its product candidate development and approval process and jeopardize its ability
to commence pharmaceutical product candidate sales and generate revenue. Any of these occurrences may harm its business, financial condition
and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
studies may also ultimately lead to the denial of regulatory approval of its pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If the FDA does
not conclude that its pharmaceutical product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway,
or if the requirements for its pharmaceutical product candidates under Section 505(b)(2) are not as SciSparc expect, the approval pathway
would likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated
and in either case may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
intends to seek FDA approval through the Section 505(b)(2) regulatory pathway for its pharmaceutical product candidate SCI-110 and potentially
for its drug candidate SCI-210. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments,
added Section 505(b)(2) to the Federal Food, Drug, and Cosmetic Act of 1938, as amended, or the FDC Act, or Section 505(b)(2). Section
505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted
by or for the applicant and for which the applicant has not obtained a right of reference.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the FDA does not allow SciSparc to pursue the Section 505(b)(2) regulatory pathway as anticipated, it may need to conduct additional
clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur,
the time and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. SciSparc may need to obtain additional funding, which could result in significant dilution to the ownership interests of its
then existing shareholders to the extent SciSparc issues equity securities or convertible debt. SciSparc cannot assure you that it would
be able to obtain such additional financing on terms acceptable to it, if at all. Moreover, inability to pursue the Section 505(b)(2)
regulatory pathway could result in new competitive pharmaceutical product candidates reaching the market faster than its pharmaceutical
product candidates, which could materially adversely impact its competitive position and prospects. Even if SciSparc is allowed to pursue
the Section 505(b)(2) regulatory pathway, it cannot assure you that its pharmaceutical product candidates will receive the requisite
approvals for commercialization.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, notwithstanding the approval of a number of pharmaceutical product candidates by the FDA under Section 505(b)(2) over the last
few years, some pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). For example,
several companies have previously petitioned the FDA regarding the constitutionality of allowing others to rely upon FDA findings that
are based on their proprietary data. If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be
required to change its 505(b)(2) policies and practices, which could require that SciSparc generates full data regarding safety and effectiveness
for previously approved active ingredients and delay or even prevent the FDA from approving any NDA that SciSparc submits under Section
505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements
designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These
requirements may give rise to patent litigation and mandatory delays in approval of its potential future NDAs for up to 30 months depending
on the outcome of any litigation. It is not uncommon for a manufacturer of an approved pharmaceutical product to file a citizen petition
with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing pharmaceutical products.
If successful, such petitions can significantly delay, or even prevent, the approval of the new pharmaceutical product. However, even
if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition.
In addition, even if SciSparc is able to utilize the Section 505(b)(2) regulatory pathway for its pharmaceutical product candidates,
there is no guarantee this would ultimately lead to faster pharmaceutical product development or earlier approval. Moreover, even if
these pharmaceutical product candidates are approved under the Section 505(b)(2) pathway, as the case may be, the approval may be subject
to limitations on the indicated uses for which the pharmaceutical products may be marketed or to other conditions of approval or may
contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the pharmaceutical products.
Its pharmaceutical product candidates are at early stages of development and are subject to uncertainty over what SciSparc must do on
its development program in order to secure approval under Section 505(b)(2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may encounter
substantial delays in its clinical studies, or it may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory
authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Before
obtaining marketing approval from regulatory authorities for the sale of its pharmaceutical product candidates, SciSparc must conduct
extensive clinical studies to demonstrate the safety and efficacy of the pharmaceutical product candidates in humans. Clinical testing
is expensive, time consuming and uncertain as to outcome. SciSparc cannot guarantee that any clinical studies will be conducted as planned
or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and its future clinical
studies may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160; &#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">inability to generate sufficient
    preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the occurrence of a pandemic
    or the spread of a virus that diverts the attention of regulatory agencies from reviewing its study design or results or which, as
    a result of such pandemic or widespread, requires SciSparc to materially modify its planned clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in reaching a consensus
    with regulatory agencies on study design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in reaching agreement
    on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be
    subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in obtaining required
    Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">imposition of a clinical
    hold by regulatory agencies, after review of an IND, application, or equivalent application, or an inspection of its clinical study
    operations or study sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in recruiting suitable
    patients to participate in its clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">difficulty collaborating
    with patient groups and investigators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure by SciSparc&#8217;s
    CROs, other third parties or it to adhere to clinical study requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure to perform in accordance
    with the FDA&#8217;s Good Clinical Practices, or GCP, requirements, or applicable regulatory guidelines in other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in having patients
    complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">patients dropping out of
    a study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">occurrence of serious adverse
    events associated with the pharmaceutical product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">changes in regulatory requirements
    and guidance that require amending or submitting new clinical protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the cost of clinical studies
    of its pharmaceutical product candidates being greater than SciSparc anticipates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">clinical studies of its pharmaceutical
    product candidates producing negative or inconclusive results, which may result in SciSparc deciding, or regulators requiring it,
    to conduct additional clinical studies or abandon pharmaceutical product candidate development programs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in manufacturing,
    testing, releasing, validating or importing/exporting sufficient stable quantities of its pharmaceutical product candidates for use
    in clinical studies or the inability to do any of the foregoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
inability to successfully complete preclinical and clinical development could result in additional costs to SciSparc or impair its ability
to generate revenue. SciSparc may also be required to conduct additional safety, efficacy and comparability studies before it will be
allowed to start clinical studies with its repurposed drugs. Clinical study delays could also shorten any periods during which its pharmaceutical
product candidates have patent protection and may allow its competitors to bring pharmaceutical product candidates to market before it
does, which could impair its ability to obtain orphan exclusivity and successfully commercialize its pharmaceutical product candidates
and may harm its business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>In respect of
its pharmaceutical product candidates targeting rare indications, orphan drug exclusivity may afford limited protection, and if another
party obtains orphan drug exclusivity for the drugs and indications SciSparc is targeting, it may be precluded from commercializing its
pharmaceutical product candidates in those indications during that period of exclusivity</i>.</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is seeking to obtain an orphan designation for some of its pharmaceutical product candidates in the United States. Under the Orphan Drug
Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part,
as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States
where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Additionally,
designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating
or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient
to justify the necessary investment in developing the drug.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States, the first NDA applicant with an orphan drug designation for a particular active moiety to treat a specific disease
or condition that receives FDA approval is entitled to a seven-year exclusive marketing period in the United States for that product
candidate, for that indication. In the European Union, orphan drug designation also entitles a party to financial incentives such as
reduction of fees or fee waivers and 10 years of market exclusivity is granted following drug approval. This period may be reduced to
six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable
not to justify maintenance of market exclusivity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2016, SciSparc submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. In a letter dated
September 29, 2016, the FDA informed SciSparc that its request could not be granted at such time, and is being held in abeyance until
and subject to SciSparc providing additional information pertaining to the overall prevalence of TS in both children and adults, and
further clinical data to support its scientific rationale for its request for orphan drug designation within 12 months. In September
2017, SciSparc responded to such FDA letter within the designated time frame, and provided the FDA with its articulated and reasoned
responses including documentation and clinical data that supports it. On December 26, 2017, SciSparc received the FDA&#8217;s response
to its response. The FDA accepted that there is adequate scientific rationale for the treatment of TS with SCI-110 mainly through the
preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide benefit in treating TS. However, the FDA stated that
it was unable to grant SciSparc&#8217;s request and indicated that SciSparc did not provide adequate prevalence estimates, and any evidence
to support its statement that only moderate to severe TS patients would require pharmacological treatment. SciSparc further responded
in January 2018 by providing additional information. On January 23, 2020, following additional correspondence with the FDA, the FDA still
did not grant us SciSparc&#8217;s request due to the fact that SciSparc has not yet provided adequate prevalence estimates. However,
the FDA did agree with SciSparc&#8217;s position that SciSparc could potentially qualify for orphan drug designation with respect to
the moderate-to-severe TS sub-group population only rather than the entire population. After SciSparc had provided additional prevalence
estimates, the FDA raised a concern in its letter, dated December 7, 2020, about SciSparc&#8217;s ability to limit the use of the pharmaceutical
product to the subset of patients SciSparc is pursuing. Due to the fact that SciSparc disagrees with this concern, it requested a clarification
call. In the clarification call conducted on February 2, 2021, SciSparc agreed with the FDA concern about its ability to limit the use
of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics population
so SciSparc suggested to amend its preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, SciSparc sent its response to the
FDA. In June 2021, SciSparc received a response from the FDA explaining that they are unable to grant SciSparc&#8217;s request until
new information becomes available to support its request for orphan drug designation. SciSparc will re-visit the application after it
obtains clinical results from its upcoming phase IIb clinical trial in TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is no assurance that SciSparc will successfully obtain orphan drug designation for TS, any future rare indications or orphan exclusivity
upon approval of any of its pharmaceutical product candidates that have already obtained designation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if SciSparc does obtain orphan exclusivity for any pharmaceutical product candidate, the exclusive marketing rights may be lost if the
FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantity of the drug. Moreover, a drug product candidate with an active moiety that is a different cannabinoid from that in its drug
candidate or, under limited circumstances, the same drug product candidate, may be approved by the FDA for the same indication during
the period of marketing exclusivity. The limited circumstances include a showing that the second drug is clinically superior to the drug
with marketing exclusivity through a demonstration of superior safety or efficacy or that it makes a major contribution to patient care.
In addition, if a competitor obtains approval and marketing exclusivity for a drug product candidate with an active moiety that is the
same as that in a pharmaceutical product candidate SciSparc is pursuing for the same indication, approval of its pharmaceutical product
candidate would be blocked during the period of marketing exclusivity unless SciSparc could demonstrate that its product candidate is
clinically superior to the approved pharmaceutical product candidate. In addition, if a competitor obtains approval and marketing exclusivity
for a drug product candidate with an active moiety that is the same as that in a pharmaceutical product candidate SciSparc is pursuing
for a different orphan indication, this may negatively impact the market opportunity for its pharmaceutical product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
have been legal challenges to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan
Drug Act, and future challenges could lead to changes that affect the protections afforded SciSparc&#8217;s pharmaceutical product candidates
in ways that are difficult to predict. In a recent successful legal challenge, a court invalidated the FDA&#8217;s denial of orphan exclusivity
to a drug on the grounds that the drug was not proven to be clinically superior to a previously approved pharmaceutical product candidate
containing the same ingredient for the same orphan use. In response to the decision, the FDA released a policy statement stating that
the court&#8217;s decision is limited just to the facts of that particular case and that the FDA will continue to require the sponsor
of a designated drug that is the &#8220;same&#8221; as a previously approved drug to demonstrate that its drug is clinically superior
to that drug upon approval in order to be eligible for orphan drug exclusivity, or in some cases, to even be eligible for marketing approval.
In the future, there is the potential for additional legal challenges to the FDA&#8217;s orphan drug regulations and policies, and it
is uncertain how such challenges might affect SciSparc&#8217;s business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>While orphan drug
product candidates are typically sold at a high price relative to other medications, the market may not be receptive to high pricing
of SciSparc&#8217;s product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
develops its product candidates to treat rare diseases, a space where medications are usually sold at high prices compared with other
medications. However, its product candidates are repurposed drugs, which means, among other things, that they contain drug substances
available in pharmacies for the purpose of treating indications that are different from the indications for which SciSparc plans to use.
Accordingly, even if regulatory authorities approve its product candidates, the market may not be receptive to, and it may be difficult
for SciSparc to achieve, a per-patient per-year price high enough to allow us to realize a return on its investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc&#8217;s
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
                                            use of dronabinol has been associated with seizures, paranoia, rapid heart rate and unusual
                                            thoughts and behaviors. Undesirable side effects caused by SciSparc&#8217;s product candidates
                                            could cause us or regulatory authorities to interrupt, delay or halt clinical studies and
                                            could result in a more restrictive marketing label or the delay or denial of regulatory approval
                                            by the FDA or other comparable foreign authorities. Potential side effects of its cannabinoid-based
                                            treatments may include: asthenia, palpitations, tachycardia, vasodilation/facial flush, abdominal
                                            pain, nausea, vomiting, amnesia, anxiety/nervousness, ataxia, confusion, depersonalization,
                                            dizziness, euphoria, hallucinations, paranoid reaction, somnolence and abnormal thinking.
                                            Results of its studies may identify unacceptable severity and prevalence of these or other
                                            side effects. In such an event, its studies could be suspended or terminated, and the FDA
                                            or comparable foreign regulatory authorities could order SciSparc to cease further development
                                            of or deny or withdraw approval of its product candidates for any or all targeted indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Drug-related
side effects could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product
candidate liability claims.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
if one or more of its product candidates receives marketing approval, and SciSparc or others later identify undesirable side effects
caused by such product candidates, a number of potentially significant negative consequences could result, including but not limited
to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">regulatory authorities may
    withdraw approvals of such product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">regulatory authorities may
    require additional warnings on the label;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc may be required
    to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining the risks of
    such side effects for distribution to patients, a communication plan for healthcare providers and/or other Elements To Assure Safe
    Use, or ETASU;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc could be sued and
    held liable for harm caused to patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">its reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
of these events could prevent SciSparc from achieving or maintaining market acceptance of the particular product candidate, if approved,
and could significantly harm its business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Even if SciSparc
obtains regulatory approval for a product candidate, its product candidates will remain subject to regulatory scrutiny.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
its product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other
post-market information, including both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#8217;
facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures
conform to current Good Manufacturing Practices, or cGMP, regulations and Quality System Regulation, or QSR. As such, SciSparc and its
contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP, QSR and adherence to commitments
made in any NDA. Accordingly, SciSparc and others with whom SciSparc works must continue to expend time, money and effort in all areas
of regulatory compliance, including manufacturing, production and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
regulatory approvals that SciSparc receives for its product candidates may also be subject to limitations on the approved indicated uses
for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. SciSparc will
also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning
advertising and promotion for its product candidates. Promotional communications with respect to prescription drugs are subject to a
variety of legal and regulatory restrictions and must be consistent with the information in the product candidate&#8217;s approved label.
As such, SciSparc may not promote its product candidates for indications or uses for which they do not have FDA approval. The holder
of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product
candidate, product candidate labeling or manufacturing process. SciSparc could also be asked to conduct post-marketing clinical studies
to verify the safety and efficacy of its product candidates in general or in specific patient subsets. If original marketing approval
were obtained via the accelerated approval pathway, SciSparc could be required to conduct a successful post-marketing clinical study
to confirm clinical benefit for its product candidates. An unsuccessful post-marketing study or failure to complete such a study could
result in the withdrawal of marketing approval. Furthermore, any new legislation addressing drug safety issues could result in delays
in product candidate development or commercialization or increased costs to assure compliance. Foreign regulatory authorities impose
similar requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
a regulatory agency discovers previously unknown problems with a product candidate, such as adverse events of unanticipated severity
or frequency, or problems with the facility where the product candidate is manufactured, or disagrees with the promotion, marketing or
labeling of a product candidate, such regulatory agency may impose restrictions on that product candidate or SciSparc, including requiring
withdrawal of the product candidate from the market. If SciSparc fails to comply with applicable regulatory requirements, a regulatory
agency or enforcement authority may, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">issue warning letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">impose civil or criminal
    penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">suspend or withdraw regulatory
    approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">suspend any of its ongoing
    clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">refuse to approve pending
    applications or supplements to approved applications submitted by SciSparc;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">impose restrictions on its
    operations, including closing its contract manufacturers&#8217; facilities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">seize or detain product candidates,
    or require a product candidate recall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
government investigation of alleged violations of law could require SciSparc to expend significant time and resources in response and
could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect
its ability to commercialize and generate revenue from SciSparc&#8217;s product candidates. If regulatory sanctions are applied or if
regulatory approval is withdrawn, the value of SciSparc and its operating results will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc is subject
to numerous complex regulations and failure to comply with these regulations, or the cost of compliance with these regulations, may harm
its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
research, testing, development, manufacturing, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising,
marketing, distribution, possession and use of its product candidates, among other things, are subject to regulation by numerous governmental
authorities in the United States and elsewhere. The FDA regulates drugs under the FDC Act and implements regulations. Noncompliance with
any applicable regulatory requirements can result in refusal to approve product candidates for marketing, warning letters, product candidate
recalls or seizure of product candidates, total or partial suspension of production, prohibitions or limitations on the commercial sale
of product candidates or refusal to allow the entering into of federal and state supply contracts, fines, civil penalties and/or criminal
prosecution. Additionally, the FDA and comparable governmental authorities have the authority to withdraw product candidate approvals
that have been previously granted. Moreover, the regulatory requirements relating to its product candidates may change from time to time
and it is impossible to predict what the impact of any such changes may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is developing product candidates that are controlled substances as defined in the Controlled Substances Act of 1970, or CSA, which establishes,
among other things, certain registration, production quotas, security, recordkeeping, reporting, import, export and other requirements
administered by the Drug Enforcement Administration, or the DEA. As a result, any product candidate that is a controlled substance (or
includes a controlled substance) cannot be marketed before such substance is rescheduled by the DEA as a Schedule II, III, IV or V substance.
The active ingredient in SciSparc&#8217;s product candidates is dronabinol, which is a Schedule III controlled substance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
manufacture, shipment, storage, sale and use, among other things, of controlled substances that are pharmaceutical product candidates
are subject to a high degree of regulation. The DEA also conducts periodic inspections of registered establishments that handle controlled
substances. Facilities that conduct research, manufacture, distribute, import or export controlled substances must be registered to perform
these activities and have the security, control and inventory mechanisms required by the DEA to prevent drug loss and diversion. Failure
to maintain compliance, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a
material adverse effect on its business, results of operations, financial condition and prospects. The DEA may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to suspend or revoke those registrations. In certain circumstances,
violations could lead to criminal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Individual
states also have controlled substances laws. Though state controlled substances laws often mirror federal law, because the states are
separate jurisdictions, they may separately schedule its product candidates as well. While some states automatically schedule a drug
when the DEA does so, other states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale
of any product candidate for which SciSparc obtains federal regulatory approval and adverse scheduling could have a material adverse
effect on the commercial attractiveness of such product candidate. SciSparc or its partners must also obtain separate state registrations,
permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale,
and failure to meet applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from
the DEA or otherwise arising under federal law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Reliance on Third Parties</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc relies
on third parties to conduct its preclinical and clinical studies and perform other tasks for it. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, SciSparc may not be able to obtain
regulatory approval for or commercialize its product candidates and its business could be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for its ongoing preclinical and clinical
programs, including Target Health, Inc., FGK Clinical Research GmbH, or FGK, and others. SciSparc relies on these parties for execution
of its preclinical and clinical studies, and control only certain aspects of their activities. Nevertheless, SciSparc is responsible
for ensuring that each of its studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards
and its reliance on the CROs does not relieve SciSparc of its regulatory responsibilities. SciSparc and its CROs and other vendors are
required to comply with current cGMP, GCP, QSR and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by
the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities
for all of its product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections
of study sponsors, principal investigators, study sites and other contractors. If SciSparc or any of its CROs or vendors fail to comply
with applicable regulations, the clinical data generated in its clinical studies may be deemed unreliable and the FDA, EMA or comparable
foreign regulatory authorities may require SciSparc to perform additional clinical studies before approving its marketing applications.
SciSparc cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of
its clinical studies comply with GCP regulations. In addition, its clinical studies must be conducted with product candidates which are
produced under cGMP regulations. SciSparc&#8217;s failure to comply with these regulations may require it to repeat clinical studies,
which would delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any of its relationships with these third-party CROs terminate, SciSparc may not be able to enter into arrangements with alternative
CROs or do so on commercially reasonable terms. In addition, its CROs are not SciSparc employees, and except for remedies available to
SciSparc under its agreements with such CROs, SciSparc cannot control whether or not they devote sufficient time and resources to its
on-going clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to SciSparc&#8217;s clinical protocols, regulatory requirements or for other reasons, its clinical studies
may be extended, delayed or terminated and SciSparc may not be able to obtain regulatory approval for or successfully commercialize its
product candidates. CROs may also generate higher costs than anticipated. As a result, its results of operations and the commercial prospects
for its product candidates would be harmed, SciSparc&#8217;s costs could increase and its ability to generate revenue could be delayed.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays may occur, which could materially impact SciSparc&#8217;s ability to meet its
desired clinical development timelines. Though SciSparc carefully manages its relationships with its CROs, there can be no assurance
that SciSparc will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material
adverse impact on its business, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc will
rely on third parties to manufacture its API and formulations. Its business could be harmed if those third parties fail to provide SciSparc
with sufficient quantities of its needed supplies, or fail to do so at acceptable quality levels or prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
does not have the infrastructure or capability internally to manufacture the API formulations, and SciSparc lacks the resources and the
capability to manufacture any of its product candidates on a clinical or commercial scale. SciSparc plans to rely on third parties for
such supplies. There are a limited number of manufacturers who have the ability to produce its API and there may be a need to identify
alternate manufacturers to prevent a possible disruption of its clinical studies. Any significant delay or discontinuity in the supply
of these components could considerably delay completion of its clinical studies, product candidate testing and potential regulatory approval
of its product candidates, which could harm its business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc and its
collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing its product candidates.
The manufacturing facilities on which SciSparc relies may not continue to meet regulatory requirements and have limited capacity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
entities involved in the preparation of therapeutics for clinical studies or commercial sale, including its existing contract manufacturers
for its product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial
sale or a product candidate used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern
manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational product candidates and products approved for sale. Poor control of production processes can
lead to the introduction of contaminants or to inadvertent changes in the properties or stability of its product candidates that may
not be detectable in final product testing. SciSparc, its collaborators or its contract manufacturers must supply all necessary documentation
in support of an NDA, or Marketing Authorization Application, or MAA, on a timely basis and must adhere to GLP and cGMP QSR regulations
enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of its contract manufacturers have
never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals
to do so. The facilities and quality systems of some or all of its collaborators and third-party contractors must pass a pre-approval
inspection for compliance with the applicable regulations as a condition of regulatory approval of SciSparc&#8217;s product candidates
or any of its other potential product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing
facility involved with the preparation of its product candidates or its other potential product candidates or the associated quality
systems for compliance with the regulations applicable to the activities being conducted. SciSparc does not control the manufacturing
process of, and are completely dependent on, its contract manufacturing partners for compliance with the regulatory requirements. If
these facilities do not pass a pre-approval plant inspection, regulatory approval of the product candidates may not be granted or may
be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
regulatory authorities also may, at any time following approval of a product candidate for sale, if ever, audit the manufacturing facilities
of its collaborators and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of its product candidate specifications or applicable regulations occurs independent of such an inspection or audit,
SciSparc or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for SciSparc or
a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales, or the
temporary or permanent closure of a facility. Any such remedial measures imposed upon SciSparc or third parties with whom SciSparc contracts
could materially harm its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc, its collaborators, or any of its third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable
regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new
drug product, withdrawal of an approval or suspension of production. As a result, its business, financial condition and results of operations
may be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or MAA
amendment, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional
studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is
likely to result in a delay in SciSparc&#8217;s desired clinical and commercial timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
factors could cause SciSparc to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions,
required approvals or commercialization of its product candidates. Furthermore, if its suppliers fail to meet contractual requirements
and SciSparc is unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, its clinical
studies may be delayed or SciSparc could lose potential revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc&#8217;s
reliance on third parties requires it to share its trade secrets, which increases the possibility that a competitor will discover them
or that its trade secrets will be misappropriated or disclosed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
SciSparc relies on third parties to develop and manufacture its product candidates, SciSparc must, at times, share trade secrets with
them. SciSparc seeks to protect its proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with its collaborators, advisors,
employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights
of the third parties to use or disclose SciSparc&#8217;s confidential information, such as trade secrets. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that
such trade secrets become known by its competitors, are inadvertently incorporated into the technology of others, or are disclosed or
used in violation of these agreements. Given that SciSparc&#8217;s proprietary position is based, in part, on its know-how and trade
secrets, a competitor&#8217;s discovery of SciSparc&#8217;s trade secrets or other unauthorized use or disclosure would impair its competitive
position and may have a material adverse effect on its business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to Commercialization
of SciSparc&#8217;s Pharmaceutical Product Candidates</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If the market
opportunities for its pharmaceutical product candidates are smaller than SciSparc believes they are, its revenue may be adversely affected,
and its business may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
projections of both the number of people who have its target diseases, as well as the subset of people with these diseases who have the
potential to benefit from treatment with its pharmaceutical product candidates, are based on SciSparc&#8217;s beliefs and estimates.
These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations
or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases.
The number of patients may turn out to be lower than expected. The effort to identify patients with diseases SciSparc seeks to treat
is in early stages, and SciSparc cannot accurately predict the number of patients for whom treatment might be possible. Additionally,
the potentially addressable patient population for each of its pharmaceutical product candidates may be limited or may not be amenable
to treatment with its pharmaceutical product candidates, and new patients may become increasingly difficult to identify or gain access
to, which would adversely affect its results of operations and its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc faces
intense competition and rapid technological change and the possibility that its competitors may discover, develop or commercialize therapies
that are similar, more advanced or more effective than that of SciSparc, which may adversely affect its financial condition and its ability
to successfully commercialize its product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
biotechnology and pharmaceutical industries are highly competitive. There are many pharmaceutical companies, biotechnology companies,
public and private universities and research organizations actively engaged in the research and development of products that may be similar
to SciSparc&#8217;s product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
first THC-based pharmaceutical, a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company
called Unimed Pharmaceuticals, with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment
for chemotherapy-related nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market,
other pharmaceuticals containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed
by SVC Pharma LP and Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole
cannabis extract administered as an oral spray. Furthermore, to the best of SciSparc&#8217;s knowledge, multiple companies that are working
in the cannabis therapeutic area and are pursuing regulatory approval for their product candidates. For example, GW Pharmaceuticals PLC,
or GW, which markets Sativex, a botanical cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis, received
FDA approval in the United States in June 2018 for Epidiolex, a liquid formulation of highly purified cannabidiol extract, as a treatment
for Dravet&#8217;s Syndrome, Lennox Gastaut Syndrome, and various childhood epilepsy syndromes. In addition, GW is developing, among
others, cannabidivarin, or CBDV, based therapy for ASD and therapy for neonatal hypoxic-ischemic encephalopathy and schizophrenia. Zynerba
Pharmaceuticals, Inc., or Zynerba, is developing a transdermal formulation of cannabidiol for Fragile X and certain refractory epilepsies
and ASD. Skye Bioscience, Inc., or Skye, is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma
and other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for their synthetic cannabinoid
for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism and solid tumors. RespireRx
Pharmaceutical Inc., or RespireRx, developing dronabinol for OSA treatment. Synendos Therapeutics AG, or Synendos, is a developer of
endocannabinoid modulators for the treatment of central nervous system, or CNS, disorders. It has developed pharmaceutical products to
restore the natural function of the brain and treat neuropsychiatric disorders. Synendos is developing small molecules as selective endocannabinoid
reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago
Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment
of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under
phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">More
established companies may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared
to SciSparc, many of its competitors may have significantly greater financial, technical and human resources. As a result of these factors,
SciSparc&#8217;s competitors may have an advantage in marketing their approved products and may obtain regulatory approval of their product
candidates before SciSparc is able to, which may limit its ability to develop or commercialize its product candidates. SciSparc&#8217;s
competitors may also develop drugs that are safer, more effective, more widely used and less expensive than those of SciSparc, and may
also be more successful than us in manufacturing and marketing their products. These advantages could materially impact SciSparc&#8217;s
ability to develop and commercialize its product candidates successfully.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
product candidates may also compete with medical and recreational marijuana, in markets where the recreational and/or medical use of
marijuana is legal. There is support in the United States for further legalization of marijuana. In markets where recreational and/or
medical marijuana is not legal, its product candidates may compete with marijuana purchased in the illegal drug market. SciSparc cannot
assess the extent to which patients may utilize marijuana obtained illegally for the treatment of the indications for which SciSparc
is developing its product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if SciSparc successfully develops its product candidates, and obtain marketing approval for them, other treatments or therapeutics may
be preferred and SciSparc may not be successful in commercializing its product candidates or in bringing them to market.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Many
of SciSparc&#8217;s competitors have substantially greater financial, technical and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in SciSparc&#8217;s competitors. As a result, these companies may obtain
regulatory approval more rapidly than SciSparc is able to and may be more effective in selling and marketing their products as well.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater
availability of capital for investment in these industries. SciSparc&#8217;s competitors may succeed in developing, acquiring or licensing
on an exclusive basis, products that are more effective or less costly than any product candidate that SciSparc may develop, or achieve
earlier patent protection, regulatory approval, product commercialization and market penetration than SciSparc does. Additionally, technologies
developed by its competitors may render its potential product candidates uneconomical or obsolete, and SciSparc may not be successful
in marketing its product candidates against competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc currently
have no marketing and sales organization. If SciSparc is unable to establish sales and marketing capabilities or enter into agreements
with third parties to market and sell its product candidates, SciSparc may be unable to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
its employees may have sold other similar products in the past while employed at other companies, SciSparc as a company have no experience
selling and marketing its product candidates and SciSparc currently has no marketing or sales organization. To successfully commercialize
any products that may result from its development programs, SciSparc will need to develop these capabilities, either on its own or with
others. If its product candidates receive regulatory approval, SciSparc intends to establish a sales and marketing organization with
technical expertise and supporting distribution capabilities to commercialize its product candidates in major markets, which will be
expensive, difficult and time consuming. Any failure or delay in the development of its internal sales, marketing and distribution capabilities
would adversely impact the commercialization of its products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
given its lack of prior experience in marketing and selling pharmaceutical products, its initial estimate of the size of the required
sales force may be materially more or less than the size of the sales force actually required to effectively commercialize its product
candidates. As such, SciSparc may be required to hire substantially more sales representatives to adequately support the commercialization
of its product candidates or SciSparc may incur excess costs as a result of hiring more sales representatives than necessary. With respect
to certain geographical markets, SciSparc may enter into collaborations with other entities to utilize their local marketing and distribution
capabilities, but SciSparc may be unable to enter into such agreements on favorable terms, if at all. If its future collaborators do
not commit sufficient resources to commercialize its future products, if any, and SciSparc is unable to develop the necessary marketing
capabilities on its own, SciSparc will be unable to generate sufficient product revenue to sustain its business. SciSparc may be competing
with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support
of a third party to perform marketing and sales functions, SciSparc may be unable to compete successfully against these more established
companies.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The commercial
success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party
payors and others in the medical community.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of SciSparc&#8217;s product
candidates will depend in part on the medical community, patients and third-party payors accepting its product candidates as medically
useful, cost-effective and safe. Any product that SciSparc brings to the market may not gain market acceptance by physicians, patients,
third-party payors and others in the medical community. The degree of market acceptance of any of its product candidates, if approved
for commercial sale, will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160; &#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the safety and efficacy of
    the product as demonstrated in clinical studies and potential advantages over competing treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the prevalence and severity
    of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the clinical indications
    for which approval is granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">relative convenience and
    ease of administration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the cost of treatment, particularly
    in relation to competing treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the willingness of the target
    patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the strength of marketing
    and distribution support and timing of market introduction of competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">publicity concerning its
    products or competing products and treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">sufficient third-party insurance
    coverage and reimbursement.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if a potential product displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the
product will not be fully known until after it is launched. Its efforts to educate the medical community and third-party payors on the
benefits of the product candidates may require significant resources and may never be successful. If its product candidates are approved
but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others in the medical community,
SciSparc will not be able to generate sufficient revenue to become or remain profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The insurance
coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement
for new or current products could limit its ability to market those products and decrease its ability to generate revenue.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
pricing, coverage and reimbursement of its product candidates, if approved, must be adequate to support SciSparc&#8217;s commercial infrastructure.
SciSparc&#8217;s per-patient prices must be sufficient to recover its development and manufacturing costs and potentially achieve profitability.
Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients
to be able to afford expensive treatments such as those of SciSparc, assuming approval. Sales of its product candidates will depend substantially,
both domestically and abroad, on the extent to which the costs of its product candidates will be paid for by health maintenance, managed
care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government authorities, private health insurers
and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, SciSparc may
not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may
not be high enough to allow SciSparc to establish or maintain pricing sufficient to realize a return on its investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services,
or CMS, an agency within the U.S. Department of Health and Human Services, or DHHS, as CMS decides whether and to what extent a new drug
will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to
a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as the SciSparc
ones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations,
and SciSparc believes the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue
to put pressure on the pricing and usage of its product candidates. In many countries, the prices of medical products are subject to
varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially
lower than in the United States. Other countries allow companies to fix their own prices for medicinal products, but monitor and control
company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that SciSparc is
able to charge for its product candidates. Accordingly, in markets outside the United States, the reimbursement for its products may
be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover
or provide adequate payment for SciSparc&#8217;s product candidates. SciSparc expects to experience pricing pressures in connection with
the sale of any of its product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs
and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the
entry of new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Healthcare legislative
reform measures may have a material adverse effect on its business and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. The following
are among the provisions established by the Patient Protection and&#160;Affordable Care Act of 2010, or ACA, of greatest importance to
the pharmaceutical and biotechnology industry:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">an annual, nondeductible fee on any entity that manufactures
    or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market
    share in some government healthcare programs;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">an increase in the statutory minimum rebates a manufacturer
    must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the Average Manufacturer Price, or AMP, for most branded and
    generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the AMP;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">extension of manufacturers&#8217; Medicaid rebate liability
    to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, or MCOs; &#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">expansion of eligibility criteria for Medicaid programs
    by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility
    categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217;
    Medicaid rebate liability;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">a Medicare Part D coverage gap discount program, in which
    manufacturers must agree to offer 50% (now 70%) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible
    beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under
    Medicare Part D; &#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">expansion of the entities eligible for discounts under
    federal 340B; &#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">a Patient-Centered Outcomes Research Institute to oversee,
    identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">establishment of a Center for Medicare Innovation at CMS
    to test innovative payment and service delivery models to lower Medicare and Medicaid spending. This center is currently focused
    on the following priorities:</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">testing new payment and service delivery models;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">evaluating results and advancing best practices; and</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">engaging a broad range of stakeholders to develop additional
    models for testing.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">implementation of the federal physician payment transparency
    requirements, or the Sunshine Act. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients
    and Communities Act, or the SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include data for
    physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse
    midwives. The amendment applies to reports submitted to CMS on or after January 1, 2022.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ACA may be modified, amended or repealed at any time and may or may not be replaced with a different law or health care payment system.
The ACA is expected to continue to have a significant impact on the health care industry. With regard to pharmaceutical product candidates,
among other things, the ACA may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the
coverage requirements under the Medicare D program. Since the enactment of the ACA, numerous regulations have been issued providing further
guidance on its requirements. The ACA continues to be implemented through regulation and government activity but is subject to possible
amendment, additional implementing regulations and interpretive guidelines. Several states have decided not to expand their Medicaid
programs and are seeking alternative reimbursement models to provide care to the uninsured. The manner in which these issues are resolved
could materially affect the extent to which and the amount at which pharmaceuticals are reimbursed by government programs such as Medicare,
Medicaid and Tricare.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program that, among other things, revised the manner in which the AMP
is calculated by manufacturers participating in the program and implemented certain amendments to the Medicaid rebate statute created
under the ACA. In addition, on December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations
in several areas, including some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit
programs sponsored by pharmaceutical manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Two
bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the
TCJA, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on
certain individuals who fail to maintain qualifying health coverage for all or part of a year, that is commonly referred to as the &#8220;individual
mandate.&#8217;&#8217; Additionally, on January 22, 2018, then President Trump signed a continuing resolution on appropriations for fiscal
year 2018 that delayed the implementation of certain ACA-mandated fees. Further, the Bipartisan Budget Act of 2018, among other things,
amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut
hole.&#8221; In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health
plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation
regarding the method CMS uses to determine this risk adjustment. On April 27, 2020, the U.S. Supreme Court reversed a Federal Circuit
decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221; funding. Congress may consider additional
legislation to repeal, or repeal and replace, other elements of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge
on procedural grounds that argued that the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress.
Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden
issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the
ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and
rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include
work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or
the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges
and the healthcare reform measures of the Biden administration will impact the ACA and its business. SciSparc continues to evaluate the
ACA and its possible repeal and replacement, as the extent to which any such changes may impact its business or financial condition remains
uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the Budget
Control Act of 2011 among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare
payments to providers of 2% per fiscal year. These reductions, known as Medicare sequestration adjustments, went into effect in 2013.
However, under the Coronavirus Aid, Relief, Economic Securities Act of 2020, and related legislation, Medicare sequestration adjustments
from May 1, 2020 through March 31, 2021 have been suspended, though sequestration has been extended through 2030. Additionally, there
has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For
example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drug products. At the federal level, including the former Administration&#8217;s
budget for fiscal year 2020, there were further drug price control measures to permit Medicare Part D plans to negotiate the price of
certain drugs under Medicare Part D, to continue to allow some states to negotiate drug prices under Medicaid through supplemental rebate
negotiations and other mechanisms, and legislation was introduced to eliminate cost sharing for generic drugs for Part D low-income patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, in November 2020, the U.S. DHHS, finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending
for prescription drugs by excluding rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors
or pharmacy benefit managers, or PBMs, acting under contract with Medicare Part D plan sponsors from the existing discount safe harbor
under the federal Anti-Kickback Statute, or the AKS. The regulation reflects the first change to the AKS Statute discount safe harbor
since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe harbors were added. One of these
new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under Medicare Part D or a MCO, for
a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided certain conditions are met.
The other protects certain fixed-fee services arrangements between manufacturers and PBMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Congress
and the executive branch have each indicated that it will continue to seek new legislative or administrative measures to control drug
costs. At the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation
from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the European Union, similar political, economic and regulatory developments may affect SciSparc&#8217;s ability to profitably commercialize
any of its product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments
at the European Union or member state level may result in significant additional requirements or obstacles that may increase its operating
costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing
and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments
and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement
of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions
on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of its product candidates,
restrict or regulate post-approval activities and affect its ability to commercialize any products for which SciSparc obtains marketing
approval. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue
after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between
low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls
or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products,
if approved in those countries. In international markets, reimbursement and healthcare payment systems vary significantly by country,
and many countries have instituted price ceilings on specific products and therapies.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
expects that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria
and lower reimbursement, and in additional downward pressure on the price that SciSparc receives for any approved product. Any reduction
in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent SciSparc from being able to generate revenue,
attain profitability or commercialize its drugs, once marketing approval is obtained. SciSparc cannot predict what healthcare reform
initiatives may be adopted in the future. However, it is possible that there will be further legislation or regulation that could harm
the business, financial condition and results of operations.</p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The COVID-19 pandemic
has resulted in delays to SciSparc&#8217;s product development and may adversely affect any potential future revenues, results of operations
and financial condition.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">COVID-19
and the various precautionary measures taken by many governmental authorities around the world to limit its spread had a severe effect
on global markets and the global economy. The extent to which the coronavirus impacts SciSparc&#8217;s business and operations will depend
on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the
severity of COVID-19 and the nature and extent of governmental actions taken to contain or treat its impact and the availability, costs,
effectiveness and public acceptance of any FDA-approved vaccines, among others. COVID-19 and official actions taken in response to it
caused a major slowdown in overall economic activity in the U.S. and elsewhere, curtailed consumer spending and made it more challenging
to adequately staff and manage SciSparc&#8217;s business and operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
COVID-19 pandemic impacted its various vendors, including CROs, and caused delays in the development of its product candidates. SciSparc
also experienced delays in the preparation toward various clinical trials, including being unable to receive prioritization to conduct
clinical trials, availability of physicians and other staff members involved in its clinical trials. At this time, SciSparc does not
anticipate that the COVID-19 pandemic and official responses would cause a material adverse effect on its results of operations and financial
condition but there can be no assurance that this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If SciSparc is
unable to obtain and maintain effective patent rights for its product candidates, SciSparc may not be able to compete effectively in
its markets. If SciSparc is unable to protect the confidentiality of its trade secrets or know-how, such proprietary information may
be used by others to compete against SciSparc.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Historically,
SciSparc has relied on trade secret protection and confidentiality agreements to protect the intellectual property related to its technologies
and product candidates. Since 2015, SciSparc has also sought patent protection for certain of its product candidates. Its success depends
in large part on its ability to obtain and maintain patent and other intellectual property protection in the United States and in other
countries with respect to its proprietary technology and new product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
seeks to protect its proprietary position by filing patent applications in the United States and in other countries, with respect to
its novel technologies and product candidates, which are important to its business. Patent prosecution is expensive and time consuming,
and SciSparc may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner. It is also possible that SciSparc will fail to identify patentable aspects of its research and development output before it is
too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Not
including patents and applications which SciSparc is in the process of being assigned, SciSparc has a portfolio of six granted patents
with the U.S. Patent and Trademark Office, or USPTO, eight patent families and three trademarks, of which four families include Patent
Cooperation Treaty, or PCT, applications, that have entered the national phase in various national entities. SciSparc cannot offer any
assurances about which, if any, patent applications will issue, the breadth of any such patent or whether any issued patents will be
found invalid and unenforceable or will be threatened by third parties. Any successful opposition to its patents after issuance could
deprive SciSparc of rights necessary for the successful commercialization of any new product candidates that SciSparc may develop and
would allow other third parties to compete with it.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has exclusively licensed one U.S. patent family from Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.,
or Yissum. SciSparc cannot assure you that it will ever enter into definitive license agreements with any third party licensor. To the
extent the licensed or future licensed patents are found to be invalid or unenforceable, SciSparc may be limited in its ability to compete
and market its product candidates. Moreover, the terms of its licenses affect its ability to control the value of any of its product
candidates. If SciSparc or any of the parties that control the enforcement of licensed patents elect not to enforce any or all of the
licensed patents it could significantly undercut the value of any of its product candidates, which would materially adversely affect
its future revenue, financial condition and results of operations. Moreover, fluctuating currency rates may create inconsistencies in
the royalty payments SciSparc is obligated to make under its licenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Also,
there is no guarantee that the patent registration applications that were submitted by SciSparc with regard to its technologies will
result in patent registration. In the event of failure to complete patent registration, its developments will not be proprietary, which
might allow other entities to manufacture its product candidates and compete with them.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
there is no assurance that all potentially relevant prior art relating to its patent applications has been found. Such prior art, to
the extent it exists, may invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do
successfully issue, and even if such patents cover SciSparc&#8217;s product candidates, third parties may challenge their validity, enforceability,
or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged,
SciSparc&#8217;s patent applications and any future patents may not adequately protect its intellectual property, provide exclusivity
for its new product candidates, or prevent others from designing around its claims. Any of these outcomes could impair its ability to
prevent competition from third parties, which may have an adverse impact on its business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Engagement
in any type of intellectual property collaboration agreement requires diligent management of intellectual property rights. Joint intellectual
property engagements may create additional administrative and financial burdens and may place us at heightened risk of disputes or litigation
regarding ownership, maintenance or enforcement of such joint intellectual property. For example, SciSparc&#8217;s collaboration with
Clearmind Medicine Inc., or Clearmind, has resulted in filings of provisional patent applications related to certain combinations of
its respective proprietary compounds. As a joint-owner of intellectual property, SciSparc is generally or would be unable to use or exploit
the intellectual property without the consent of the other joint owner. If SciSparc cannot obtain sole commercial use rights for such
jointly-owned intellectual property as a result of its collaboration, its future product development and commercialization plans may
be adversely affected. Moreover, if SciSparc cannot obtain and maintain effective patent rights for its product candidates, SciSparc
may not be able to compete effectively, and its business and results of operations may be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may not
be able to identify infringements of its patents and accordingly the enforcement of its intellectual property rights may be difficult.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug substance in some of SciSparc&#8217;s product candidates is repurposed, which means that it is available in other pharmaceutical
products for the purpose of treating indications that are different from the indications for its product candidates. It is possible that
if SciSparc receives regulatory approval to market and sell its drug candidates, some patients that receive a prescription could be sold
the same drug substance but not its product candidate. It would be difficult, if not impossible, for SciSparc to identify such instances
that may constitute an infringement of its patents. In addition, because the drug substance of some of its product candidates is repurposed,
such substance may not be eligible for patent protection or data exclusivity. Even if SciSparc identifies infringing parties, there is
no guarantee that a court will agree with its arguments and find that a third party is infringing its patents or that the court will
issue an order for an adequate remedy for that infringement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If SciSparc is unable to maintain effective proprietary rights
for its product candidates, SciSparc may not be able to compete effectively in its markets.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the protection afforded by any patents currently owned and that may be granted, historically, SciSparc has relied on trade
secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that SciSparc elects not to
patent, processes that are not easily known, knowable or easily ascertainable, and for which patent infringement is difficult to monitor
and enforce and any other elements of its product candidate discovery and development processes that involve proprietary know-how, information
or technology that is not covered by patents. However, trade secrets can be difficult to protect. SciSparc seeks to protect its proprietary
technology and processes, in part, by entering into confidentiality agreements with its employees, consultants, scientific advisors,
and contractors. SciSparc also seeks to preserve the integrity and confidentiality of its data, trade secrets and intellectual property
by maintaining physical security of its premises and physical and electronic security of its information technology systems. Agreements
or security measures may be breached, and SciSparc may not have adequate remedies for any breach. In addition, SciSparc&#8217;s trade
secrets and intellectual property may otherwise become known or be independently discovered by competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
cannot provide any assurances that its trade secrets and other confidential proprietary information will not be disclosed in violation
of its confidentiality agreements or that competitors will not otherwise gain access to its trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of its trade secrets and intellectual
property could impair its competitive position and may have a material adverse effect on its business. Additionally, if the steps taken
to maintain its trade secrets and intellectual property are deemed inadequate, SciSparc may have insufficient recourse against third
parties for misappropriating any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Intellectual property
rights of third parties could adversely affect SciSparc&#8217;s ability to commercialize its product candidates, and SciSparc might be
required to litigate or obtain licenses from third parties in order to develop or market its product candidates. Such litigation or licenses
could be costly or not available on commercially reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
is inherently difficult to conclusively assess its freedom to operate without infringing on third party rights. SciSparc&#8217;s competitive
position may be adversely affected if existing patents or patents resulting from patent applications issued to third parties or other
third party intellectual property rights are held to cover its product candidates or elements thereof, or its manufacturing or uses relevant
to its development plans. In such cases, SciSparc may not be in a position to develop or commercialize product candidates or its product
candidates unless SciSparc successfully pursue litigation to nullify or invalidate the third party intellectual property right concerned,
or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may
also be pending patent applications that if they result in issued patents, could be alleged to be infringed by its new product candidates.
If such an infringement claim should be brought and be successful, SciSparc may be required to pay substantial damages, be forced to
abandon its new product candidates or seek a license from any patent holders. No assurances can be given that a license will be available
on commercially reasonable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
is also possible that SciSparc has failed to identify relevant third-party patents or applications. For example, certain U.S. patent
applications that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United
States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering its new product candidates or platform
technology could have been filed by others without SciSparc&#8217;s knowledge. Additionally, pending patent applications which have been
published can, subject to certain limitations, be later amended in a manner that could cover its platform technologies, its new product
candidates or the use of its new product candidates. Third party intellectual property right holders may also actively bring infringement
claims against SciSparc. SciSparc cannot guarantee that it will be able to successfully settle or otherwise resolve such infringement
claims. If SciSparc is unable to successfully settle future claims on terms acceptable to it, SciSparc may be required to engage in or
continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in pursuing the
development of and/or marketing its new product candidates. If SciSparc fails in any such dispute, in addition to being forced to pay
damages, SciSparc may be temporarily or permanently prohibited from commercializing its new product candidates that are held to be infringing.
SciSparc may, if possible, also be forced to redesign its new product candidates so that SciSparc no longer infringes the third-party
intellectual property rights. Any of these events, even if SciSparc were ultimately to prevail, could require it to divert substantial
financial and management resources that SciSparc would otherwise be able to devote to its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><b><i>Third-party
claims of intellectual property infringement may prevent or delay SciSparc&#8217;s development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
commercial success depends in part on its avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S.
and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which SciSparc is
developing new product candidates. As its industries expand and more patents are issued, the risk increases that its product candidates
may be subject to claims of infringement of the patent rights of third parties.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Third
parties may assert that SciSparc is employing their proprietary technology without authorization. There may be third-party patents or
patent applications with claims to materials, designs or methods of manufacture related to the use or manufacture of its product candidates.
There may be currently pending patent applications that may later result in issued patents that its product candidates may infringe.
In addition, third parties may obtain patents in the future and claim that use of SciSparc&#8217;s technologies infringes upon these
patents.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any third-party patents were held by a court of competent jurisdiction to cover aspects of its formulations, processes for designs, or
methods of use, the holders of any such patents may be able to block its ability to develop and commercialize the applicable product
candidate unless SciSparc obtains a license or until such patent expires or is finally determined to be invalid or unenforceable. In
either case, such a license may not be available on commercially reasonable terms or at all.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Parties
making claims against SciSparc may obtain injunctive or other equitable relief, which could effectively block its ability to further
develop and commercialize one or more of its product candidates. Defense of these claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from SciSparc&#8217;s business. In the event of a successful
claim of infringement against SciSparc in the U.S. or any other relevant jurisdiction, SciSparc may have to pay substantial damages,
including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign its infringing product candidates
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Patent policy
and rule changes could increase the uncertainties and costs surrounding the prosecution of its patent applications and the enforcement
or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of any
patents that may issue from its patent applications, or narrow the scope of its patent protection. The laws of foreign countries may
not protect SciSparc&#8217;s rights to the same extent as the laws of the United States. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically
not published until 18 months after filing, or in some cases not at all. SciSparc therefore cannot be certain that SciSparc was the first
to file the invention claimed in its owned and licensed patent or pending applications, or that it or its licensor was the first to file
for patent protection of such inventions. Assuming all other requirements for patentability are met, in the United States prior to 2013,
the first to make the claimed invention without undue delay in filing, is entitled to the patent, while outside the United States, the
first to file a patent application is entitled to the patent. After 2013, the United States moved to a first to file system. Changes
in patent litigation could increase the uncertainties and costs surrounding the prosecution of its patent applications and the enforcement
or defense of any issued patents, all of which could have a material adverse effect on its business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
involved in lawsuits to protect or enforce its intellectual property, which could be expensive, time consuming, and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Competitors
may infringe SciSparc&#8217;s intellectual property. If SciSparc was to initiate legal proceedings against a third party to enforce a
patent covering one of its new product candidates, the defendant could counterclaim that the patent covering its product candidate is
invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability
are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected
with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The
validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following legal assertions of
invalidity and unenforceability is unpredictable.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Derivation
proceedings initiated by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with
respect to SciSparc&#8217;s patent or patent applications or those of its licensors. An unfavorable outcome could require SciSparc to
cease using the related technology or to attempt to license rights to it from the prevailing party. Its business could be harmed if the
prevailing party does not offer SciSparc a license on commercially reasonable terms. Its defense of litigation or interference proceedings
may fail and, even if successful, may result in substantial costs and distract its management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on its ability to raise the funds necessary to continue its clinical
trials, continue its research programs, license necessary technology from third parties, or enter into development partnerships that
would help SciSparc bring its new product candidates to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of its confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of its ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
subject to claims challenging the inventorship of its intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
may be subject to claims that former employees, collaborators or other third parties have an interest in, or right to compensation, with
respect to its current patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For
example, SciSparc may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing
its product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the
right to compensation. If SciSparc fails in defending any such claims, in addition to paying monetary damages, SciSparc may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could
have a material adverse effect on its business. Even if SciSparc is successful in defending against such claims, litigation could result
in substantial costs and be a distraction to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may not
be able to protect its intellectual property rights throughout the world.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Filing,
prosecuting, and defending patents on product candidates, as well as monitoring their infringement in all countries throughout the world
would be prohibitively expensive, and its intellectual property rights in some countries can be less extensive than those in the United
States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and
state laws in the United States.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Competitors
may use its technologies in jurisdictions where SciSparc has not obtained patent protection to develop their own products and may also
export otherwise infringing products to territories where SciSparc has patent protection, but enforcement is not as strong as that in
the United States. These products may compete with its product candidates. Future patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, which could make it difficult for SciSparc to stop the marketing of competing products in
violation of its proprietary rights generally. Proceedings to enforce its patent rights in foreign jurisdictions, whether or not successful,
could result in substantial costs and divert its efforts and attention from other aspects of its business, could put its future patents
at risk of being invalidated or interpreted narrowly and its patent applications at risk of not issuing and could provoke third parties
to assert claims against SciSparc. SciSparc may not prevail in any lawsuits that SciSparc initiates, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, SciSparc&#8217;s efforts to monitor and enforce its intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that SciSparc develops
or licenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Pharmaceutical Business Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>From
time to time, SciSparc may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation
of definitive agreements. There can be no assurance that SciSparc will enter into any such definitive agreements. Similarly, SciSparc
may strategically invest in transactions from time to time, and there can be no assurance that the value of its investment will increase
or that it will not fluctuate.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, SciSparc may sign letters of intent and/or enter into term sheets or other similar arrangements that are subject to negotiation
of definitive agreements. SciSparc may never enter into definitive agreements after signing a letter of intent and/or entering into a
term sheet or other similar arrangement for a multitude of reasons, including, but not limited to, regulatory, operational, financial
and other considerations. There may also be forces outside of SciSparc&#8217;s control that have an effect on its ability or decision
as to whether SciSparc enters into such definitive agreements. As a result, there can be no assurance that upon signing a letter of intent
and/or entering into a term sheet or similar arrangement, that SciSparc will enter into definitive documents. This could have a material
adverse effect on SciSparc&#8217;s reputation and could cause SciSparc to incur expenses if any legal claims arise as a result thereof.
For example, in November 2019, SciSparc entered into a memorandum of understanding with Heavenly Rx, Ltd., or Heavenly Rx, pursuant to
which SciSparc and Heavenly Rx agreed to pursue a business combination. In accordance with the memorandum of understanding between the
parties, any transaction between the parties remained subject to entry into definitive agreements, and to shareholder and regulatory
approvals. SciSparc never entered into definitive agreements and does not expect to do so.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Similarly,
SciSparc may strategically invest into various pharmaceutical companies. However, SciSparc can offer no assurance that the value of its
investment will increase or that it will not fluctuate because the value of its investments may be adversely affected by a number of
factors, such as negative changes in a company&#8217;s results of operations, cash flows, financial position and accounting impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">For
                                            example, on March 31, 2022, SciSparc entered into an agreement with and invested in MitoCareX
                                            Bio Ltd., or MitoCareX, a company focused on the discovery and development of potential drugs
                                            for cancers and other life-threatening conditions. Subsequent to this, on February 25, 2025,
                                            SciSparc entered into a Securities Purchase and Exchange Agreement, or the MitoCareX SPEA,
                                            as amended on May 18, 2025, relating to the sale of its entire ownership interest in MitoCareX
                                            to a N2OFF, Inc. In addition, on November 17, 2022, SciSparc invested in Clearmind, a psychedelic
                                            pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived
                                            therapeutics to solve widespread and underserved health problems. In addition, on August
                                            13, 2024, SciSparc entered into an exclusive patent license agreement with Polyrizon Ltd.,
                                            or Polyrizon, for the out-licensing of its SCI-160 program.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
potential benefits of the agreement with MitoCareX, the investment in Clearmind, the exclusive patent license agreement with Polyrizon,
or other potential investments may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse
effect on SciSparc&#8217;s results of operations, cash flows and financial position. The potential benefits of agreements with potential
ventures may not materialize or may not be realized to the full extent, in a timely fashion, or at all, which may have a material adverse
effect on its results of operations, cash flows and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc will
need to expand its organization and SciSparc may experience difficulties in recruiting needed additional employees and consultants, which
could disrupt its operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
its development and commercialization plans and strategies develop and because SciSparc is so leanly staffed, SciSparc will need additional
managerial, operational, sales, marketing, financial, legal and other resources. The competition for qualified personnel in the pharmaceutical
field is intense. Due to this intense competition, SciSparc may be unable to attract and retain qualified personnel necessary for the
development of its business or to recruit suitable replacement personnel.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial
amount of time to managing these growth activities. SciSparc may not be able to effectively manage the expansion of its operations, which
may result in weaknesses in its infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity
among remaining employees. SciSparc&#8217;s expected growth could require significant capital expenditures and may divert financial resources
from other projects, such as the development of additional pharmaceutical product candidates. If its management is unable to effectively
manage its growth, its expenses may increase more than expected, its ability to generate and/or grow revenue could be reduced and SciSparc
may not be able to implement its business strategy. Its future financial performance and its ability to commercialize pharmaceutical
product candidates and compete effectively will depend, in part, on its ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>SciSparc may not be successful in its efforts to identify, license
or discover additional pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
a substantial amount of its effort will focus on the continued clinical testing, potential approval and commercialization of its existing
pharmaceutical product candidates, the success of its business also depends in part upon its ability to identify, license or discover
additional pharmaceutical product candidates. Its research programs or licensing efforts may fail to yield additional pharmaceutical
product candidates for clinical development for a number of reasons, including but not limited to the following:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s research
    or business development methodology or search criteria and process may be unsuccessful in identifying potential pharmaceutical product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc may not be able
    or willing to assemble sufficient resources to acquire or discover additional pharmaceutical product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s pharmaceutical
    product candidates may not succeed in preclinical or clinical testing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s potential
    pharmaceutical product candidates may be shown to have harmful side effects or may have other characteristics that may make the pharmaceutical
    products unmarketable or unlikely to receive marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">competitors may develop alternatives
    that render SciSparc&#8217;s pharmaceutical product candidates obsolete or less attractive;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">pharmaceutical product candidates
    SciSparc develops may be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the market for a pharmaceutical
    product candidate may change during its program so that such a pharmaceutical product may become unreasonable to continue to develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a pharmaceutical product
    candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a pharmaceutical product
    candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any of these events occur, SciSparc may be forced to abandon its development efforts for a program or programs, or SciSparc may not be
able to identify, license or discover additional pharmaceutical product candidates, which would have a material adverse effect on its
business and could potentially cause SciSparc to cease operations. Research programs to identify new pharmaceutical product candidates
require substantial technical, financial and human resources. SciSparc may focus its efforts and resources on potential programs or pharmaceutical
product candidates that ultimately prove to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy
and security laws. If SciSparc is unable to comply, or has not fully complied, with such laws, SciSparc could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc obtains FDA approval for any of its pharmaceutical product candidates and begins commercializing those pharmaceutical products
in the United States, its operations may be directly or indirectly through its customers, subject to various federal and state fraud
and abuse laws, including, without limitation, the federal AKS, the federal False Claims Act and physician sunshine laws and regulations.
These laws may impact, among other things, its proposed sales, marketing and education programs. In addition, SciSparc may be subject
to patient privacy regulation by both the federal government and the states in which SciSparc conducts its business. The laws that may
affect its ability to operate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal AKS, which prohibits,
    among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly,
    to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program,
    such as the Medicare and Medicaid programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">federal civil and criminal
    false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting,
    or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Health Insurance Portability
    and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud
    any healthcare benefit program and making false statements relating to healthcare matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by the
    Health Information Technology and Clinical Health Act, or HITECH and its implementing regulations, which imposes certain requirements
    relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal physician sunshine
    requirements under the ACA requires manufacturers of drugs, devices and medical supplies to report annually to the U.S. DHHS information
    related to payments and other transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and
    investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing
    organizations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">state law equivalents of
    each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any
    third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical
    industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise
    restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers
    to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
    expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ
    from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of SciSparc&#8217;s
business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation
has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and
criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to
violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation
of the federal AKS constitutes a false or fraudulent claim for purposes of the False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that
apply to it, SciSparc may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation
in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of its operations,
any of which could adversely affect its ability to operate its business and its results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The use of any
of its pharmaceutical product candidates and marketed products could result in product liability or similar claims that could be expensive,
damage its reputation and harm its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
business exposes it to an inherent risk of potential pharmaceutical product liability or similar claims. The pharmaceutical and nutraceuticals
industries have historically been litigious, and SciSparc faces financial exposure to pharmaceutical product liability or similar claims
if the use of any of its pharmaceutical products were to cause or contribute to injury or death. There is also the possibility that defects
in the design or manufacture of any of its pharmaceutical products might necessitate a pharmaceutical product recall. Although SciSparc
plans to maintain pharmaceutical product liability insurance, the coverage limits of these policies may not be adequate to cover future
claims. In the future, SciSparc may be unable to maintain pharmaceutical product liability insurance on acceptable terms or at reasonable
costs and such insurance may not provide SciSparc with adequate coverage against potential liabilities. A pharmaceutical product liability
claim, regardless of merit or ultimate outcome, or any pharmaceutical product recall could result in substantial costs to it, damage
to its reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought
against SciSparc in excess of, or outside of, its insurance coverage could have a material adverse effect on its business, financial
condition and results of operations.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If SciSparc fails
to comply with environmental, health and safety laws and regulations, SciSparc could become subject to fines or penalties or incur costs
that could have a material adverse effect on the success of its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
research and development activities and its third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage,
use and disposal of hazardous materials, including the components of its pharmaceutical product candidates and other hazardous compounds.
SciSparc and its manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and
disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored
at SciSparc and its manufacturers&#8217; facilities pending their use and disposal. SciSparc cannot eliminate the risk of contamination,
which could cause an interruption of its commercialization efforts, research and development efforts, business operations and environmental
damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal
of these materials and specified waste pharmaceutical products. Although SciSparc believes that the safety procedures utilized by its
third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws
and regulations, SciSparc cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these
materials. In such an event, SciSparc may be held liable for any resulting damages and such liability could exceed its resources and
state or federal or other applicable authorities may curtail its use of certain materials and/or interrupt its business operations. Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. SciSparc cannot predict the
impact of such changes and cannot be certain of its future compliance. SciSparc does not currently carry biological or hazardous waste
insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to SciSparc&#8217;s
Intended Corporate Restructuring Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The intended Restructuring
Plan, which may involve transferring SciSparc&#8217;s pharmaceutical activities to a new wholly-owned subsidiary, may not be completed
in accordance with the expected plans or anticipated timeline, or at all, and may not achieve the expected results.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 25, 2023, SciSparc announced that its board of directors resolved to pursue a restructuring plan, or the Restructuring Plan,
which may involve transferring its pharmaceutical activities to a subsidiary, which may be listed on a stock exchange. As part of the
plan, SciSparc announced that it would examine a spin-off of certain of its assets, followed by a listing of the spun-off subsidiary,
or NewCo, on a leading stock exchange, while maintaining its controlling interest in NewCo such that SciSparc will continue to control
its current business activities. SciSparc also intends to explore other potential new opportunities, activities and investments in a
variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 22, 2023, SciSparc announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated
terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Restructuring Plan, on June 25, 2023, SciSparc entered into a securities purchase agreement with AutoMax, pursuant to which, at
the closing and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, SciSparc
invested NIS 2,500 thousand (approximately $691) in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS
0.5. Following the closing, SciSparc held approximately 5.6% of the issued and outstanding share capital of AutoMax.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 14, 2024, SciSparc entered, as a lender, into a bridge loan agreement with AutoMax, pursuant to which AutoMax received a bridge
loan in the amount of $1.4 million, or the Bridge Loan, further to the previously-announced non-binding letter of intent for SciSparc
to acquire AutoMax. On June 9, 2024, SciSparc entered, as lender, into an amendment to the Bridge Loan, or the Amended Bridge Loan, pursuant
to which AutoMax received an additional loan in the amount of $1.0 million, for an aggregate amount of $2.4 million. On September 5,
2024, SciSparc entered into a second amendment to the Bridge Loan, or the Second Amendment, pursuant to which SciSparc extended an additional
loan in the amount of $1.85 million to AutoMax under terms similar to the Amended Bridge Loan, bringing the total Loan Amount to $4.25
million. &#160;During the month of September 2024, SciSparc provided AutoMax with the loan amounts due under the Second Amendment to
the Bridge Loan, and offset any interest due until November 30, 2024 from the principal amount, such that on the closing date of the
Merger, SciSparc will be entitled to be paid the due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated),
of the Loan Amount, accruing from the period beginning on December 1, 2024 and ending on the effective date of the Merger. In consideration
for the Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned
subsidiary AutoMax Direct Import in favor of SciSparc. On February 27, 2025, SciSparc announced that it had entered into a loan agreement
with AutoMax where a $2 million loan was provided, or the Additional Loan Amount. The loan bears an 8% annual interest rate and will
be repaid in equal monthly installments of $50,000 and interest, with AutoMax retaining the option to make early repayment without penalties.
The interest on the loan will be cancelled as of the consummation of the Merger Agreement and AutoMax will continue to make monthly payments
towards the principal amount of the loan. To secure repayment of the Additional Loan Amount, AutoMax Hasharon shares held by Global AutoMax
were pledged in favor of SciSparc with a first-degree permanent lien. On May 8, 2025, SciSparc entered into a third amendment to the
Bridge Loan, or the Third Amendment, pursuant to which, in addition to the already existing subordination of the Loan Amount to AutoMax&#8217;s
Series B Bonds, the Loan Amount will also be subordinated to AutoMax&#8217;s Series C Bonds, issued and traded on the TASE. For more
information on AutoMax&#8217;s Series C Bonds, see page v.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax, as further described in this prospectus. On August 14, 2024,
November 26, 2024, March 27, 2025, and on May 8, 2025, SciSparc and AutoMax entered into the Merger Agreement Addendum, the Merger
Agreement Second Addendum, the Merger Agreement Third Addendum, and the Merger Agreement Fourth Addendum, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2024, SciSparc
signed a non-binding letter of intent, or the Spin-off LOI, for the spin-off of its advanced clinical stage pharmaceutical portfolio
to a publicly traded company on the Toronto Stock Exchange Venture in Canada, or TSXV. Pursuant to the letter of intent, SciSparc will
sell, assign, convey and transfer to Miza III Ventures Inc., or Miza, certain assets for consideration of common shares and contingent
rights of Miza, based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold a controlling interest
in Miza, the exact percentage of which is contingent on agreeing on definitive terms between the parties. The resulting entity, in which
SciSparc will hold an equity stake, will be active in both the pharmaceutical and supplement sectors. On December 16, 2024, SciSparc
entered into an amendment to the Spin-off LOI, or the First LOI Amendment, solely to extend the deadline to enter into definitive agreements
by no later than March 31, 2025, which was extended from July 31, 2024, provided that such date may be further extended by mutual written
agreement of the parties, and to close the proposed transaction by no later than April 30, 2025, which was extended from October 31,
2024. On March 28, 2025, SciSparc entered into a second amendment to the Spin-Off LOI, or the Second LOI Amendment, solely to extend
the deadline to enter into definitive agreements by no later than June 30, 2025, which was extended from March 31, 2025, provided that
such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than
July 31, 2025, which was extended from April 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Completion
of the transactions contemplated by the Merger Agreement, the Spin-off LOI or any other potential restructuring plans or transactions
in addition to the possible listing of NewCo on a stock exchange, may be subject to, among other things, market conditions, tax or other
business analyses, regulatory approvals, receipt of any necessary consents, final approvals from its board of directors and shareholders
and satisfaction of any closing conditions to effectuate such corporate restructuring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unanticipated
developments or changes, including but not limited to, changes in the general or financial market conditions, possible delays in obtaining
various regulatory and tax approvals, changes in the law, and challenges in executing the Acquisition or any other restructuring plan
could delay or prevent the completion of the Restructuring Plan and listing of NewCo, or cause the restructuring and listing of NewCo
to occur on terms or conditions that are different or less favorable than initially expected. These or other developments could cause
SciSparc not to realize some or all of the expected benefits of the Restructuring Plan and listing of NewCo or to realize them on a different
timeline than expected. If the Restructuring Plan and listing of NewCo do not occur, SciSparc could pursue other transactions involving
its pharmaceutical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The Restructuring
Plan and listing of NewCo may not achieve the anticipated benefits and may expose SciSparc to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
may not realize the anticipated strategic, financial, operational or other benefits of the Restructuring Plan and listing of NewCo. SciSparc
cannot predict with certainty when the benefits expected from these transactions will occur or the extent to which they will be achieved.
There is no assurance that following the Restructuring Plan and listing of NewCo that each separate company will be successful. Whether
or not the Restructuring Plan and listing of NewCo is completed, SciSparc may face material challenges in connection with the intended
transactions, including but not limited to, the diversion of management time on matters relating to the Restructuring Plan and listing
of NewCo, the impact of having to operate under the terms of any transition service agreements, the impact on its ability to retain talent
and potential impacts on its relationships with customers, suppliers, employees and other counterparties. In addition, SciSparc will
incur one-time costs and ongoing costs in connection with, or as a result of, the Restructuring Plan and listing of NewCo, including
costs of operating as independent, publicly-traded companies that the separate businesses will no longer be able to share. Those costs
may exceed its estimates or could negate some of the benefits SciSparc expects to realize. Further, SciSparc has not yet analyzed whether
the Restructuring Plan and listing of NewCo will be tax-free to its shareholders for Israeli tax purposes and there is no assurance that
the Restructuring Plan and listing of NewCo will qualify for this treatment. If the Restructuring Plan and listing of NewCo is ultimately
determined to be taxable, any of NewCo, its shareholders or SciSparc could incur income tax liabilities that could be significant. If
SciSparc does not realize the anticipated benefits of the Restructuring Plan and listing of NewCo it could adversely affect its business,
results of operations, cash flows and financial condition.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Following any
Restructuring Plan and listing of NewCo, the trading price of SciSparc&#8217;s ordinary shares may fluctuate significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
cannot predict whether the market value of its ordinary shares after any Restructuring Plan and listing of NewCo will be, in the aggregate,
less than, equal to or greater than the market value of its ordinary shares prior to such transactions. The trading price of its ordinary
shares may be more volatile around the time of the intended separation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to the
eCommerce&#160;Operations of SciSparc Nutraceuticals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
unable to successfully pursue, integrate, or execute upon the eCommerce operations business of SciSparc Nutraceuticals Inc., or SciSparc
Nutraceuticals.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2022, SciSparc purchased Wellution&#8482;, a business and brand which sells hemp-based products on the Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
management has limited prior experience in eCommerce business operations. There can be no assurance that SciSparc will be able to successfully
implement its new business ventures or successfully operate within this industry.&#160;The successful integration of a new business also
depends on SciSparc&#8217;s ability to manage the new business, realize forecasted synergies and full value from the combined business.
Its business, results of operations, financial condition and cash flows could be materially adversely affected if SciSparc is unable
to successfully integrate&#160;Wellution into its existing operations and any inability to do so may also hinder its ability to grow,
divert the attention of management and its key personnel, disrupt its business and impair its financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals rely on Amazon Marketplace and fulfillment by Amazon Marketplace and changes to the Amazon Marketplace,
Amazon Marketplace&#8217;s services and their terms of use may harm its business.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Wellution&#8217;s
products are sold predominantly on Amazon Marketplace and orders are fulfilled entirely by Amazon Marketplace utilizing the fulfilled
by Amazon, or FBA, model. In order to continue to utilize the Amazon Marketplace and FBA, SciSparc must comply with the applicable policies
and terms of use relating to these services. Such policies and terms of use may be altered or amended at Amazon Marketplace&#8217;s sole
discretion, including changes regarding the cost of securing these services, and changes that increase the burden of compliance with
its requirements, may cause SciSparc to significantly alter its business model or incur additional costs in order to comply, which could
negatively impact its results of operations. Non-compliance with applicable terms of use and policies can result in the removal of one
or more products from the marketplace and suspension of fulfillment services either of which could have a material adverse effect on
its business and results of its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2024, Wellution was in non-compliance with changes in Amazon&#8217;s policies concerning claims associated with vitamin and
cosmetic products. The new Amazon policy mandated that no claims, in any form, could be displayed on the product label, in the Amazon
listing, or within the product descriptions. For instance, phrases such as &#8220;Our Keto Weight Loss Gummy Bear Reduces Appetite&#8221;
were no longer permissible. Instead, it was required to describe the product using terminology such as &#8220;Keto Gummy Bears For A
Healthy Lifestyle&#8221;. Due to the extensive descriptions present on both the Amazon listing and the product label itself, it took
several weeks to achieve a comprehensive understanding of Amazon&#8217;s new requirements. Moreover, each word within the description
required prior approval from the Amazon team, with revision responses typically taking several days or longer. Often, these responses
originated from automated systems, lacking the clarity and specificity needed for effective resolution. To navigate this process efficiently,
Amazon experts were engaged to assist with the necessary adjustments. As a result, all products sold by Wellution were removed for sale
from the marketplace and product labels were updated, a process that spanned several weeks to complete and caused the sales on the Wellution
platform to dramatically decrease for such period. Since implementing these changes and resolving the issue, SciSparc has experienced
no further instances of non-compliance and remains committed to maintaining compliance. However, there is no guarantee that similar issues
will not arise in the future, which could lead to product removal from the marketplace or suspension of fulfillment services, adversely
impacting its business and operational outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals rely on other information technologies and systems to operate its business and to maintain its
competitiveness, and any failure to invest in and adapt to technological developments and industry trends could harm its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
depends on sophisticated information technologies and systems, technology and systems used for Wellution&#8217;s websites and apps, customer
service, logistics and fulfillment, supplier connectivity, communications and administration. As its operations grow in size, scope and
complexity, SciSparc will need to continuously improve and upgrade its systems and infrastructure to offer an increasing number of consumer-enhanced
services, features and functionalities, while maintaining and improving the reliability and integrity of its systems and infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
future success also depends on its ability to use A.I. tools and infrastructure, including logistics and fulfillment platform which leverages,
to meet rapidly evolving eCommerce trends and demands. The emergence of alternative platforms may require SciSparc to continue to invest
in new and costly technology. SciSparc may not be successful, or it may be less successful than its competitors, in adopting technologies
that operate effectively across multiple eCommerce platforms, which would negatively impact its business and financial performance. New
developments in other areas, such as cloud computing providers, could also make it easier for competitors to enter its markets due to
lower up-front technology costs. In addition, SciSparc may not be able to maintain its existing systems or replace its current systems
or introduce new technologies and systems as quickly or cost effectively as SciSparc would like. Failure to invest in and adapt to technological
developments and industry trends may have a material adverse effect on its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals rely on data provided by third parties, the loss of which could limit the functionality of its
platforms, cause SciSparc to invest in the wrong product or disrupt its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
uses third party software to determine market trends and what markets to enter into. Its ability to successfully use this software depends
on its ability to analyze and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google
and Amazon. Some of this data is provided to SciSparc pursuant to third-party data sharing policies and terms of use, under data sharing
agreements by third-party providers or by customer consent. The majority of this data is sourced for free or for de minimis amounts.
These sources of data allow SciSparc, along with A.I. tools, to determine trends, performance and consumer sentiment on products and
searches within eCommerce platforms. This functionality allows SciSparc to help determine which products to market, in some cases manufacture
through contract manufacturers, import and sell on eCommerce marketplaces. The connection to multiple eCommerce platforms through application
programming interfaces allow SciSparc to develop the automation of the purchase of marketing and automate the change of pricing of product
listings on those eCommerce platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the future, any of these third parties could change its data sharing policies, including making them more restrictive, charging fees
or altering its algorithms that determine the placement, display and accessibility of search results and social media updates, any of
which could result in the loss of, or significant impairment to, its ability to collect useful data. These third parties could also interpret
SciSparc, or its service providers&#8217;, data collection policies or practices as being inconsistent with their policies, which could
result in the loss of its ability to collect this data. Privacy concerns may cause end users to resist providing the personal data necessary
to allow SciSparc to determine market trends as well as its ability to effectively retain existing customers. Privacy advocacy groups
and the technology and other industries are considering various new, additional or different self-regulatory standards that may place
additional burdens on SciSparc. Any such changes could impair its ability to use data and could adversely impact select functionality
of its proprietary software, impairing its ability to use this data to anticipate customer demand and market trends, as well as adversely
affecting its business and its ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals depend on its ability to build and maintain strong product listings on eCommerce platforms. SciSparc
may not be able to maintain and enhance its product listings if SciSparc receives a substantial number of customer complaints, negative
publicity or otherwise fail to live up to customers&#8217; expectations, any of which could materially adversely affect its business,
results of operations and growth prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Maintaining
and enhancing its product listings is critical in expanding and growing its business. However, a significant portion of its perceived
performance to the customer depends on third parties outside of its control, including suppliers and logistics providers such as FedEx,
UPS, postal services and other third-party delivery agents and online retailers, mainly Amazon. Because SciSparc&#8217;s agreements with
its online retail partners are generally terminable at will, SciSparc may be unable to maintain these relationships, and its results
of operations could fluctuate significantly from period to period. Because SciSparc relies on third party logistics companies to deliver
its products, SciSparc is subject to shipping delays or disruptions caused by inclement weather, natural disasters, labor activism, health
epidemics or bioterrorism. In addition, because SciSparc relies on national, regional and local transportation companies for the delivery
of some of its other products, SciSparc is also subject to risks of breakage or other damage during delivery by any of these third parties.
If these third parties do not meet its or its customers&#8217; expectations, its brands may suffer irreparable damage. In addition, maintaining
and enhancing its current and future brands may require SciSparc to make substantial investments, and these investments may not yield
sufficient returns. If SciSparc fails to promote and maintain its brands, or if SciSparc incurs excessive expenses in this effort, its
business, operating results and financial condition may be materially adversely affected. SciSparc anticipates that, as its market becomes
increasingly competitive, maintaining and enhancing its brands may become increasingly difficult and expensive. Maintaining and enhancing
its brands will depend largely on its ability to anticipate market trends and customer demand and to provide high quality products to
its customers and a reliable, trustworthy and profitable sales channel to its suppliers, which SciSparc may not be able to do successfully.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
substantial number of customer complaints or negative publicity about its sites, products, delivery times, customer data handling and
security practices or customer support, especially on blogs, social media websites or its sites, could rapidly and severely diminish
consumer views of its products and result in harm to its brands. Customers may also make safety-related claims regarding products sold
through its online retail partners, such as Amazon, which may result in an online retail partner removing the product from its marketplace.
Such removal may materially impact its financial results depending on the product that is removed and length of time that it is removed.
SciSparc also uses and relies on other services from third parties, such as its telecommunications services, and those services may be
subject to outages and interruptions that are not within its control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations&#8217; efforts of SciSparc Nutraceuticals to acquire or retain customers, and its efforts to sell new products or increase
sales of its existing products, may not be successful, which could prevent SciSparc from maintaining or increasing its sales and achieving
profitability.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc does not successfully promote and sustain its new and/or existing product listings and brands through marketing and other tools,
SciSparc may fail to maintain or increase its sales and achieve profitability. Promoting and positioning its brands and product listings
will depend largely on the success of SciSparc&#8217;s marketing efforts, its ability to attract customers cost effectively and its ability
to consistently provide a high-quality product and maintain consumer satisfaction. SciSparc also uses promotions to drive sales, which
may not be effective and may adversely affect its gross margins. SciSparc&#8217;s investments in marketing may not effectively reach
potential customers, potential customers may decide not to buy its products or the spending of customers that purchase from SciSparc
may not yield the intended return on investment, any of which could negatively affect its financial results. The failure of its marketing
activities could also adversely affect its ability to promote its product listings and sell its products, and to develop and maintain
relationships with its customers, retailers and brands, which may have a material adverse effect on SciSparc&#8217;s business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If the eCommerce
operations of SciSparc Nutraceuticals fail to offer high-quality customer support, SciSparc&#8217;s business and reputation may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">High-quality
education and training of customer support personnel to deliver high-quality customer support are important for the successful retention
of existing customers. Providing this education, training and support requires that its support personnel has specific knowledge and
expertise of SciSparc&#8217;s products and markets, making it more difficult for SciSparc to hire experienced personnel and to scale
up its support operations. The importance of high-quality customer support will increase as SciSparc expands its business and pursue
new customers. If SciSparc does not provide effective and timely ongoing support, its ability to retain existing customers may suffer,
and its reputation with existing or potential customers may be harmed, which would have a material adverse effect on its business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations&#8217; efforts of SciSparc Nutraceuticals to expand SciSparc&#8217;s business into new brands, products, services, technologies
and geographic regions will subject SciSparc to additional business, legal, financial and competitive risks and may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Wellution&#8217;s
business success depends to some extent on SciSparc&#8217;s ability to expand its consumer offerings by launching new brands, products
and services and by expanding its existing offerings into new geographic regions. SciSparc&#8217;s strategy is to use its skills to determine
which markets to enter and optimize the mix of products and services that SciSparc offers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Launching
new brands, products and services requires significant upfront investments, including investments in marketing, namely digital marketing
and Pay Per Click (PPC), information technology and additional personnel. SciSparc operates in highly competitive industries with relatively
low barriers to entry and must compete successfully in order to grow its business. SciSparc may not be able to generate satisfactory
revenue from these efforts to offset these costs. Any lack of market acceptance of its efforts to launch new brands, products or services
or to expand its existing offerings could have a material adverse effect on its business, prospects, financial condition and results
of operations. Further, as SciSparc continues to expand its fulfillment capability or add new businesses with different requirements,
its logistics networks will become increasingly complex and operating them will become more challenging. There can be no assurance that
SciSparc will be able to operate its networks effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has also entered and may continue to enter new markets and provide product offerings in which SciSparc has limited or no experience,
which may not be successful or appealing to its customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
eCommerce consumer products goods industry is subject to evolving standards and practices, as well as changing consumer needs, requirements
and preferences. SciSparc&#8217;s ability to attract new customers and increase revenue from existing customers depends, in part, on
its ability to enhance and improve its existing tools that enable SciSparc to pinpoint new markets and introduce new products. The success
of any enhancements or new instruments depends on, in part, market-accepted pricing levels and overall market acceptance. SciSparc may
not be successful in these efforts, which could result in significant expenditures that could impact its revenue or distract management&#8217;s
attention from current offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Increased
emphasis on the sale of new products could distract SciSparc from sales of its existing products in existing markets, negatively affecting
its overall sales. SciSparc has invested and expect to continue to invest in new businesses, products, features, services and technologies.
Such endeavors may involve significant risks and uncertainties, including insufficient revenue from such investments to offset any new
liabilities assumed and expenses associated with these new investments, inadequate return of capital on its investments, distraction
of management from current operations and unidentified issues not discovered in its due diligence of such investments that could cause
SciSparc to fail to realize the anticipated benefits of such investments and incur unanticipated liabilities. Because these new strategies
and offerings are inherently risky, no assurance can be given that they will be successful. SciSparc&#8217;s new features or enhancements
could fail to attain sufficient market acceptance for many reasons, including:</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in introducing products
    in new markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure to accurately predict
    market demand or end consumer preferences;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">introduction of competing
    products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">poor financial conditions
    for SciSparc&#8217;s customers or poor general macroeconomic conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">changes in legal or regulatory
    requirements, or increased legal or regulatory scrutiny, adversely affecting SciSparc&#8217;s products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure of SciSparc&#8217;s
    brands, and products, digital promotion activities or negative publicity about the performance or effectiveness of its existing brands
    and products; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">disruptions or delays in
    the online retailers and, or in addition to, logistics providers distributing its products.</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is no assurance that SciSparc will successfully identify new opportunities or develop and bring new products to market on a timely basis,
which could materially and adversely affect its business and operating results and compromise its ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations&#8217; use of social media and email by SciSparc Nutraceuticals may adversely impact SciSparc&#8217;s reputation or subject
us to fines or other penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">SciSparc
uses social media and email as part of its digital marketing efforts. As laws and regulations rapidly evolve to govern the use of these
channels, the failure by SciSparc, its employees or third parties acting at on its behalf to abide by applicable laws and regulations
in the use of these channels could adversely affect its reputation or subject SciSparc to fines or other penalties. In addition, SciSparc&#8217;s
employees or third parties acting on its behalf may knowingly or inadvertently make use of social media in ways that could lead to the
loss or infringement of intellectual property, as well as the public disclosure of proprietary, confidential or sensitive personal information
of its business, employees, customers or others. Any such inappropriate use of social media or email could also cause reputational damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Customers
value readily available information concerning retailers and their goods and services and often act on such information without further
investigation and with no regard to its accuracy. Its customers may engage with SciSparc online through its social media platforms, including
Facebook and Instagram, by providing feedback and public commentary about all aspects of its business. Information concerning SciSparc
or its retailers and brands, whether accurate or not, may be posted on social media platforms at any time and may have a disproportionately
adverse impact on its brand, reputation or business. The harm may be immediate without affording SciSparc an opportunity for redress
or correction and could have a material adverse effect on its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>With respect to
the eCommerce operations of SciSparc Nutraceuticals, if SciSparc&#8217;s emails are not delivered and accepted or are routed by email
providers less favorably than other emails, or its sites or mobile applications are not accessible or are treated disadvantageously by
Internet service providers, its business may be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
email providers or Internet service providers, or ISPs, implement new restrictive email or content delivery or accessibility policies,
including with respect to net neutrality, or begin enforcement of existing policies, it may become more difficult to deliver emails to
SciSparc&#8217;s customers or for customers to access its sites, products and services. For example, certain email providers, including
Google, categorize SciSparc&#8217;s emails as &#8220;promotional&#8221;, and these emails are directed to an alternate, and less readily
accessible, section of a customer&#8217;s inbox. If email providers materially limit or halt the delivery of SciSparc&#8217;s emails,
or if SciSparc fails to deliver emails to customers in a manner compatible with email providers&#8217; email handling or authentication
technologies, its ability to contact customers through email could be significantly restricted. In addition, if SciSparc is placed on
&#8220;spam&#8221; lists or lists of entities that have been involved in sending unwanted, unsolicited emails, its operating results
and financial condition could be substantially harmed. Further, if ISPs prioritize or provide superior access to its competitors&#8217;
content, its business and results of operations may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals are subject to risks related to online payment methods.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals accepts payments using a variety of methods, including credit card, debit card, PayPal, Payoneer, credit accounts (including
promotional financing) and gift cards. For certain payment methods, including credit and debit cards, SciSparc Nutraceuticals pays interchange
and other fees, which may increase over time and raise its operating costs and lower profitability. In addition, its credit card and
other payment processors could impose receivable holdback or reserve requirements in the future. SciSparc Nutraceuticals relies on third
parties to provide payment processing services, including the processing of credit cards and debit cards, and it could disrupt its business
if these companies become unwilling or unable to provide these services to SciSparc Nutraceuticals. SciSparc Nutraceuticals are also
subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers, which
could change or be reinterpreted to make it difficult or impossible for SciSparc Nutraceuticals to comply. If SciSparc Nutraceuticals
fails to comply with the rules or requirements of any provider of a payment method SciSparc Nutraceuticals accepts, if the volume of
fraud in its transactions limits or terminates its rights to use payment methods SciSparc Nutraceuticals currently accept, or if a data
breach occurs relating to its payment systems, SciSparc Nutraceuticals may, among other things, be subject to fines or higher transaction
fees and may lose, or face restrictions placed upon, its ability to accept credit card or debit card payments from customers or to facilitate
other types of online payments. If any of these events were to occur, its business, financial condition and operating results could be
materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>With respect to
the eCommerce operations of SciSparc Nutraceuticals, if SciSparc Nutraceuticals is unable to manage its inventory effectively, its operating
results could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
ensure timely delivery of products, SciSparc Nutraceuticals generally enters into purchase orders in advance with manufacturers. As a
result, SciSparc Nutraceuticals is vulnerable to demand and pricing shifts and to suboptimal selection and timing of product purchases.
SciSparc Nutraceuticals relies on its procurement team to order products and SciSparc Nutraceuticals relies on its data analytics to
inform the levels of inventory SciSparc Nutraceuticals purchases, including when to reorder items that are selling well and when to write
off items that are not selling well. In these instances, SciSparc Nutraceuticals may be unable to always predict the appropriate demand
for its products by customers with accuracy, which may result in inventory shortages, inventory write offs and lower gross margins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
its sales and procurement teams do not predict demand well or if its algorithms do not help SciSparc Nutraceuticals reorder the right
products or write off the right products timely, SciSparc Nutraceuticals may not effectively manage its inventory, which could result
in inventory excess or shortages, and its operating results and financial condition could be adversely affected.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operations of SciSparc Nutraceuticals, including the costs and supply chain, are subject to risks associated with sourcing, importing
and warehousing.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals sources the products it offers from third-party vendors and, as a result, SciSparc Nutraceuticals may be subject to price
fluctuations or demand disruptions. Its operating results could be negatively impacted by increases in the prices of its products, and
SciSparc Nutraceuticals has no guarantees that prices will not rise. In addition, as SciSparc Nutraceuticals expands into new categories
and types of products, SciSparc Nutraceuticals expects that it may not have strong purchasing power in these new areas, which could lead
to higher costs than SciSparc Nutraceuticals has historically seen in its current product categories and types. SciSparc Nutraceuticals
may not be able to pass increased costs on to customers, which could adversely affect its operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, SciSparc Nutraceuticals cannot guarantee that products SciSparc Nutraceuticals receives from vendors will be of sufficient
quality or free from damage or defects, or that such merchandise will not be damaged during shipping or storage. While SciSparc Nutraceuticals
takes measures to ensure product quality and avoid damage, including evaluating vendor facilities, operations and product samples, conducting
inventory inspections and inspecting returned products, SciSparc Nutraceuticals cannot control merchandise while it is out of its possession
or prevent all damage while in its distribution centers. SciSparc Nutraceuticals may incur additional expenses and its reputation could
be harmed if or current or potential customers believe that its merchandise is not of high quality or may be damaged.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Risks associated
with the suppliers from whom SciSparc Nutraceuticals products are sourced could materially adversely affect its financial performance,
as well as its reputation and brand.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals depends on its ability to provide its customers with a wide range of products from high quality suppliers in a timely
and efficient manner. Its agreements with most of its suppliers do not provide for the long-term availability of merchandise or the continuation
of particular pricing practices, nor do they usually restrict such suppliers from selling products to other buyers or directly themselves.
There can be no assurance that its current suppliers will continue to seek to sell SciSparc Nutraceuticals products on current terms
or that it will be able to establish new or otherwise extend current supply relationships to ensure product acquisitions in a timely
and efficient manner and on acceptable commercial terms. Its ability to develop and maintain relationships with reputable suppliers and
offer high quality products to its customers is critical to its success. If SciSparc Nutraceuticals is unable to develop and maintain
relationships with suppliers that would allow it to offer a sufficient amount and variety of quality products on acceptable commercial
terms, its ability to satisfy its customers&#8217; needs, and therefore its long-term growth prospects, would be materially adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals is also unable to predict whether any of the countries in which its suppliers&#8217; products are currently manufactured
or may be manufactured in the future will be subject to trade restrictions imposed by the U.S. or foreign governments or the likelihood,
type or effect of any such restrictions. Any event causing a disruption or delay of imports from suppliers with international manufacturing
operations, including the imposition of additional import restrictions, restrictions on the transfer of funds or increased tariffs or
quotas, could increase the cost or reduce the supply of merchandise available to its customers and materially adversely affect its financial
performance as well as its reputation and brand. Its competitors may have greater existing inventory positions and other advantages that
may allow them to price more competitively relative to its products. Furthermore, some or all of its suppliers&#8217; foreign operations
may be adversely affected by political and financial instability, resulting in the disruption of trade from exporting countries, restrictions
on the transfer of funds or other trade disruptions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may not
accurately forecast revenues, profitability and appropriately plan its expenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
bases its current and future expense levels on its operating forecasts and estimates of future income and operating results. Income and
operating results are difficult to forecast because they generally depend on the volume and timing of the orders SciSparc receives, which
are uncertain. Additionally, its business is affected by general economic and business conditions around the world. A softening in income,
whether caused by changes in consumer preferences, a weakening in global economies or inflation, may result in decreased net revenue
levels, and SciSparc may be unable to adjust its spending in a timely manner to compensate for any unexpected shortfall in income. This
inability could cause its income (loss) from operations after tax in a given quarter to be lower or higher than expected. SciSparc also
makes certain assumptions when forecasting the amount of expenses it expects related to its share-based payments, which includes the
expected volatility of its share price, and the expected life of equity awards granted. These assumptions are partly based on historical
results. If actual results differ from its estimates, its operating results in a given quarter may be lower than expected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The eCommerce
operation&#8217;s operating results of SciSparc Nutraceuticals are subject to seasonal fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
eCommerce business is seasonal in nature and the fourth quarter is a significant period for SciSparc&#8217;s operating results due to
the holiday season. As a result, revenue generally declines and loss from operations generally increases in the first quarter sequentially
from the fourth quarter of the previous year. Any disruption in its ability to process and fulfill customer orders during the fourth
quarter could have a negative effect on its quarterly and annual operating results. For example, if a large number of customers purchase
SciSparc Nutraceuticals&#8217; products in a short period of time due to increased holiday demand, inefficient management of its inventory
may prevent it from efficiently fulfilling orders, which may reduce sales and harm its brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The inability
to acquire, use or maintain SciSparc&#8217;s marks and domain names for its sites could substantially harm its business and operating
results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
currently has registered trademarks for its brands in numerous jurisdictions and have registered the Internet domain names for its websites,
as well as various related domain names. However, SciSparc has not registered its trademarks or domain names in all major international
jurisdictions. Domain names generally are regulated by Internet regulatory bodies. If SciSparc does not have, or cannot obtain on reasonable
terms, the ability to use its marks in a particular country or to use or register any of its domain names, SciSparc could be forced either
to incur significant additional expenses to market its products within that country, including the development of a new brand and the
creation of new promotional materials and packaging, or to elect not to sell products in that country. Either result could materially
adversely affect its business, financial condition and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
the regulations governing domain names and laws protecting marks and similar proprietary rights could change in ways that block or interfere
with its ability to use relevant domains or its current brand names. Furthermore, SciSparc might not be able to prevent third parties
from registering, using or retaining domain names that interfere with its consumer communications or infringe or otherwise decrease the
value of its marks, domain names and other proprietary rights. Regulatory bodies also may establish additional generic or country-code
top-level domains or may allow modifications of the requirements for registering, holding or using domain names. As a result, SciSparc
may not be able to register, use or maintain the domain names that utilize the Wellution name in all of the countries in which SciSparc
currently or intends to conduct business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Any significant
disruption in service on SciSparc&#8217;s websites or apps or in its computer systems, a number of which are currently hosted or provided
by third-party providers, could materially affect its ability to operate, damage its reputation and result in a loss of customers, which
would harm its business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ability to sell and market its products relies on FBA platform whose functionality relies upon a number of third-party related services,
including those relating to cloud infrastructure, technology services, servers, open-source libraries and vendor application programming
interfaces. Any disruption or loss of any of these third-party services could have a negative effect on its business, results of operations,
financial condition and prospects. SciSparc may experience interruptions in its systems, including server failures that temporarily slow
down or interfere with the performance of its platforms and the ability to sell on eCommerce marketplaces.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Interruptions
in these systems, whether due to system failures, human input errors, computer viruses or physical or electronic break-ins, and denial-of-service
attacks on SciSparc, third-party vendors or communications infrastructure, could affect the availability of its services on its platform
and prevent or inhibit the ability of selling its products. Volume of traffic and activity on eCommerce marketplaces spikes on certain
days, such as during a Black Friday promotion, and any such interruption would be particularly problematic if it were to occur at such
a high-volume time. Problems with the reliability of its systems or third-party marketplaces could prevent SciSparc from earning revenue
and could harm its reputation. Damage to its reputation, any resulting loss of customers, eCommerce confidence and the cost of remedying
these problems could negatively affect its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ability to maintain communications, network and computer hardware in the countries in which they are used may in the future be subject
to regulatory review and licensing, and the failure to obtain any required licenses could negatively affect its business. Its systems
and infrastructure are predominately reliant on third parties. Problems faced by its third-party service providers with the telecommunications
network providers with whom they contract or with the systems by which they allocate capacity among their users, including SciSparc,
could adversely affect the experience of its customers. Its third-party service providers could decide to close their facilities without
adequate notice. Any financial difficulties, such as bankruptcy or reorganization, faced by its third-party service providers or any
of the service providers with whom they contract may have negative effects on its business, the nature and extent of which are difficult
to predict. If its third-party service providers are unable to keep up with its needs for capacity, this could have an adverse effect
on its business. Any errors, defects, disruptions or other performance problems with SciSparc&#8217;s services could harm its reputation
and may have a material adverse effect on its business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>Risks
Related to the Ownership of SciSparc&#8217;s Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc will
need additional capital in the future. Raising additional capital by issuing securities may cause dilution to existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has incurred losses every year since its inception. If SciSparc continues to use cash at its historical rates of use it will need significant
additional financing, which SciSparc may seek through a combination of private and public equity offerings, debt financings and collaborations
and strategic and licensing arrangements. To the extent that SciSparc raises additional capital through the sale of equity or convertible
debt securities, an existing shareholder&#8217;s ownership interest will be diluted, and the terms of any such offerings may include
liquidation or other preferences that may adversely affect the then existing shareholders rights. Debt financing, if available, would
result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting its ability to
take specific actions such as incurring debt or making capital expenditures. If SciSparc raises additional funds through collaboration,
strategic alliance or licensing arrangements with third parties, SciSparc may have to relinquish valuable rights to its technologies,
future revenue streams or product candidates, or grant licenses on terms that are not favorable to SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc does
not know whether a market for the ordinary shares will be sustained or what the trading price of the ordinary shares will be and as a
result it may be difficult for you to sell your ordinary shares</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
SciSparc&#8217;s ordinary shares are listed on Nasdaq, an active trading market for the ordinary shares may not be sustained. It may
be difficult for you to sell your ordinary shares without depressing the market price for the ordinary shares or at all. Further, an
inactive market may also impair SciSparc&#8217;s ability to raise capital by selling ordinary shares and may impair its ability to enter
into strategic partnerships or acquire companies, products, or services by using its equity securities as consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Sales of a substantial
number of SciSparc&#8217;s ordinary shares in the public market by its existing shareholders could cause its share price to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sales
of a substantial number of SciSparc&#8217;s ordinary shares in the public market, or the perception that these sales might occur, could
depress the market price of its ordinary shares and could impair its ability to raise capital through the sale of additional equity securities.
SciSparc is unable to predict the effect that sales may have on the prevailing market price of its ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The exercise of
outstanding warrants or conversion of outstanding convertible securities will cause significant dilution to holders of SciSparc&#8217;s
equity securities and could adversely affect the price of its ordinary shares.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
                                            of July 3, 2025, holders of warrants (including pre-funded warrants) may exercise their warrants
                                            into up to 190,161 ordinary shares. In the event that such warrants are exercised in full,
                                            the ownership interest of existing holders of SciSparc&#8217;s equity securities will be
                                            diluted and may have a negative effect on the trading price of its ordinary shares.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 25, 2025, SciSparc sold and issued Debentures (as defined below) in the aggregate principal amount of $4.2 million, which are
convertible into SciSparc ordinary shares. In the event such Debentures are converted into ordinary shares, the ownership interest of
existing holders of SciSparc&#8217;s equity securities will also be diluted and may have a negative effect on the trading price of SciSparc&#8217;s
ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>The market price
of SciSparc&#8217;s securities may be highly volatile, and you may not be able to resell your ordinary shares at or above the price you
paid.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
market price of SciSparc&#8217;s ordinary shares is volatile. The SciSparc ordinary share price is and will continue to be subject to
wide fluctuations in response to a variety of factors, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">adverse results or delays
    in preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reports of adverse events
    in its product candidates or clinical trial failures of its product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">inability to obtain additional
    funding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">any delay in filing a regulatory
    submission for any of its product or product candidates and any adverse development or perceived adverse development with respect
    to the review of that regulatory submission by the FDA or European or Asian authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure to successfully develop
    and commercialize its products or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure to enter into strategic
    collaborations or failure to successfully integrate acquisitions SciSparc has made;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure by SciSparc or strategic
    collaboration partners to prosecute, maintain or enforce its intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">changes in laws or regulations
    applicable to future products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">inability to scale up its
    manufacturing capabilities through third-party manufacturers, inability to obtain adequate product supply for its products or the
    inability to do so at acceptable prices;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">introduction of new products
    or technologies by its competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure to meet or exceed
    financial projections SciSparc may provide to the public;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failures or delays in SciSparc&#8217;s
    intended Restructuring Plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">failure to meet or exceed
    the financial expectations of the investment community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">announcements of significant
    acquisitions, strategic partnerships, joint ventures or capital commitments by its competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">disputes or other developments
    relating to proprietary rights, including patents, litigation matters and its ability to obtain patent protection for its platform
    technologies, technologies, products or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">additions or departures of
    key scientific or management personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">significant lawsuits, including
    patent or shareholder litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">changes in the market valuations
    of similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">changes in general conditions
    in the economy and the financial markets in the countries in which SciSparc operates including those related to recent unrest and
    actual or potential armed conflict in Israel and other parts of the Middle East;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">sales of SciSparc&#8217;s
    securities by SciSparc or its shareholders in the future; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">trading volumes of its securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, companies trading in the stock market have experienced extreme price and volume fluctuations that have often been unrelated
or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market
price of SciSparc&#8217;s ordinary shares, regardless of its actual operating performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Outstanding warrants
and pre-funded warrants to acquire SciSparc ordinary shares are speculative in nature. Furthermore, holders of its warrants and pre-funded
warrants will have no rights as shareholders until such holders exercise their warrants and acquire SciSparc ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Until
holders of the warrants and pre-funded warrants acquire SciSparc ordinary shares upon exercise of the warrants and pre-funded warrants,
holders of the warrants and pre-funded warrants will have no rights with respect to its ordinary shares underlying such warrants and
pre-funded warrants. Upon exercise of the warrants and pre-funded warrants, the holders thereof will be entitled to exercise the rights
of a holder of ordinary shares only as to matters for which the record date occurs after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
warrants and pre-funded warrants only represent the right to acquire ordinary shares at a fixed price, and in the case of the warrants,
for a limited period of time. Specifically, holders of the warrants and pre-funded warrants that SciSparc issued in private placements
in March 2020, March 2021, June 2022 and October 2023 and in its November 2020 and August 2023 public offerings may exercise their right
to acquire ordinary shares and pay an exercise price per ordinary shares (in the case of the pre-funded warrants, $0.021 to $0.546 per
ordinary share and in the case of other warrants, ranging from $1,435.98 to $13,377.00 per ordinary share), subject to adjustment upon
certain events, within five years from their date of issuance, with the exception of the June 2022 warrants, which will expire seven
years from the date of issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>



</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc cannot
assure you that its ordinary shares will remain listed on Nasdaq or any other securities exchange.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
July 16, 2024, SciSparc received a Notice from Nasdaq indicating that SciSparc is not in compliance with the minimum bid price requirement
for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
$1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), SciSparc was initially granted a period of 180 calendar days to regain compliance
with the minimum bid price requirement, or until January 12, 2025. On January 14, 2025, SciSparc received an additional written notice
from Nasdaq indicating that it had been granted, per its request, an additional 180-day compliance period, or until July 14, 2025, to
regain compliance with the minimum bid price requirement. The trading price of SciSparc&#8217;s ordinary shares on the Nasdaq Capital
Market as of the close of market on July 3, 2025, was $6.60.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Effective
as of market open on July 3, 2025, SciSparc effected a one-for-twenty-one (1-for-21) reverse share split, of its issued and outstanding
ordinary shares, no par value per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
addition, on June 26, 2025, SciSparc&#8217;s shareholders approved a framework for a reverse split of the issued and outstanding ordinary
shares in the range of a ratio of between 1:2 and 1:250, to be effected at the discretion of, at such ratio within the approved range
and by such number of increments, and on such dates, as may be determined by SciSparc&#8217;s board of directors within 18 months following
the date of approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
January 17, 2025, the SEC approved an amendment to Nasdaq Listing Rule 5810(c)(3)(A)(iv), according to which, if a company fails to meet
the minimum bid price requirement and the company has effected a reverse share split over the prior one-year period, the company would
not be eligible for any compliance period and the Listing Qualifications Department will issue a Delisting Determination under Rule 5810
with respect to that company&#8217;s securities. This change will apply to a company even if the company was in compliance with the bid
price requirement at the time of its prior reverse share split. In addition, if a company&#8217;s security fails to meet the bid price
requirement and the company has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250
shares or more to one, then the company is not eligible for any compliance periods and Nasdaq must issue a Delisting Determination with
respect to that security.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Accordingly,
SciSparc may be limited or not eligible to implement additional reverse splits, if required, under Nasdaq Rule 5810(c)(3)(A), which provides
that if a company&#8217;s security fails to meet the continued listing requirement for minimum bid price requirement and the company
has effected one or more reverse splits over either the prior two-year period with a cumulative ratio of 250 shares or more to one, or
the Maximum Cumulative Ratio, or if a company&#8217;s security fails to meet the minimum bid price requirement and the company has effected
a reverse split of any ratio over the prior one-year period, then the company will not be eligible for any compliance period specified
in Nasdaq Rule 5810(c)(3)(A), and the listing qualifications department will issue a delisting determination under Rule 5810 with respect
to that security. The Nasdaq rule applies to a company even if such a company was in compliance with the bid price requirement at the
time of its prior reverse split. Further, the Nasdaq rule provides that a company will not be considered to have regained compliance
with the bid price requirement if the company takes an action to achieve compliance (such as a reverse split) and that action results
in the Company&#8217;s security falling below the numeric threshold for another listing requirement. The Nasdaq rule also limit extensions
that let companies continue to trade while they appeal the delisting decision. Accordingly, if a company effects a reverse split but
its security subsequently falls out of compliance with the minimum bid requirement within a one-year period, it will be issued a delisting
determination rather than being granted a compliance period. SciSparc has effected the Reverse Splits on July 3, 2025, at a ratio of
21:1. SciSparc&#8217;s shareholders have also approved a framework for a reverse split of the issued and outstanding ordinary shares
in the range of a ratio of between 1:2 and 1:250. Accordingly, there is a risk that if until July 3, 2027 and within one year of the
Reverse Split or any other future reverse share splits effected from time to time, SciSparc&#8217;s ordinary shares trade below $1.00
per share for 30 consecutive business days, SciSparc will not be eligible for any compliance period and the Listing Qualifications Department
will issue a Delisting Determination for SciSparc&#8217;s ordinary shares by Nasdaq.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ADSs, which previously represented its ordinary shares, were listed on Nasdaq from March 2017 through July 2020. On September 21, 2020,
its ADSs were delisted from Nasdaq as a result of not meeting the shareholders equity requirements of Nasdaq. Between December 2020 and
August 2021, its ADSs were quoted on the OTCQB. In August 2021, its ADR program was terminated and its ADSs were converted to ordinary
shares on a one-for-one basis. In September 2021, its ordinary shares began to be quoted for trading on the OTCQB under the ticker &#8220;SPRCF&#8221;.
In December 2021, SciSparc&#8217;s ordinary shares were re-listed on Nasdaq and began trading under the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
assurance can be given that SciSparc will remain eligible to be listed on Nasdaq. Further, because of the previous delisting of its ADSs
from Nasdaq, if SciSparc falls out of compliance with Nasdaq requirements in the future, SciSparc&#8217;s ordinary shares may be more
likely to be subject to Nasdaq&#8217;s delisting process and no assurance can be given that SciSparc will be able to regain compliance.
Any delisting could adversely affect its ability to obtain financing for the continuation of its operations and could result in the loss
of confidence by investors, customers and employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Failure to achieve
and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect
on SciSparc&#8217;s business, results of operation or financial condition. In addition, current and potential shareholders could lose
confidence in its financial reporting, which could have a material adverse effect on the price of SciSparc&#8217;s ordinary shares.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Effective
internal controls are necessary for SciSparc to provide reliable financial reports and effectively prevent fraud. SciSparc is required
to document and test its internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which
requires annual management assessments of the effectiveness of its internal control over financial reporting. In addition, if SciSparc
fails to maintain the adequacy of its internal control, as such standards are modified, supplemented or amended from time to time, SciSparc
may not be able to ensure that SciSparc can conclude on an ongoing basis that SciSparc has effective internal control over financial
reporting in accordance with Section 404. Disclosing deficiencies or weaknesses in its internal control, failing to remediate these deficiencies
or weaknesses in a timely fashion or failing to achieve and maintain an effective internal control environment may cause investors to
lose confidence in its reported financial information, which could have a material adverse effect on the price of SciSparc&#8217;s ordinary
shares. If SciSparc cannot provide reliable financial reports or prevent fraud, its operating results could be harmed.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc
                                            has not paid, and does not intend to pay, dividends on its ordinary shares and, therefore,
                                            unless its traded securities appreciate in value, its investors may not benefit from holding
                                            its securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has not paid any cash dividends on its ordinary shares since inception. SciSparc does not anticipate paying any cash dividends its ordinary
shares in the foreseeable future. Moreover, the Companies Law imposes certain restrictions on its ability to declare and pay dividends.
As a result, investors in its ordinary shares will not be able to benefit from owning these securities unless their market price becomes
greater than the price paid by such investors and they are able to sell such securities. SciSparc cannot assure you that you will ever
be able to resell its securities at a price in excess of the price paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unfavorable outcomes in legal proceedings may harm its business
and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Regardless
                                            of whether or not there is merit to the claims underlying any legal proceedings to which
                                            SciSparc is subject, and regardless of whether or not SciSparc is found as a result of such
                                            proceedings to have violated any applicable laws, such proceedings can be expensive to defend
                                            or respond to, and could result in substantial costs and diversion of management&#8217;s
                                            attention and resources, which could harm its business, and potentially could cause substantial
                                            and irreparable harm to its public reputation. For example, on May 2, 2023, Capital Point
                                            Ltd., or Capital Point, filed a lawsuit in the Tel Aviv-Jaffa District Court against SciSparc
                                            as the sole defendant in connection with the warrant SciSparc issued to Capital Point pursuant
                                            to a joint venture transaction entered into on May 15, 2020 by and between SciSparc, Capital
                                            Point and Evero Health Ltd. one of SciSparc&#8217;s subsidiaries. The lawsuit includes allegations
                                            of breaches of contract under the Israeli Contracts Law (General Part), 1973, unjust enrichment
                                            under the Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance
                                            (New Version), 1968. The lawsuit claims damages in the amount of NIS 10,000,000 (approximately
                                            $2.75 million), which accounts for, as of the date of the filing of the lawsuit, liquidated
                                            damages according to the provisions set forth in the warrant, and seeks as well for the court
                                            to order a mandatory injunction order for SciSparc to issue a warrant to Capital Point to
                                            purchase $340,000 of its ordinary shares, the return of any unlawful profits received by
                                            SciSparc and punitive damages. As of July 3, 2025, in connection with the aforementioned
                                            litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited
                                            by Evero Health Ltd. As of the date of this prospectus, SciSparc cannot predict the likelihood
                                            of its success in the lawsuit. If SciSparc does not prevail in such lawsuit, its results
                                            of operations and reputation could be adversely affected.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc may be
a &#8220;passive foreign investment company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may
become one in any subsequent taxable year. There generally would be negative tax consequences for U.S. taxpayers that are holders of
SciSparc ordinary shares if SciSparc is or were to become a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
general, SciSparc will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75%
of its gross income is &#8220;passive income&#8221; or (2) on average at least 50% of its assets by value produce passive income or are
held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends,
interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives
rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including those
raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets
of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. If SciSparc is
a PFIC in any taxable year during which a U.S. taxpayer holds the ordinary shares, such U.S. taxpayer would be subject to certain adverse
U.S. federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing
fund,&#8221; or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and
any gain realized on the sale or other disposition of the ordinary shares by the U.S. taxpayer: (1) would be allocated ratably over the
U.S. taxpayer&#8217;s holding period for the ordinary shares; (2) the amount allocated to the current taxable year and any period prior
to the first day of the first taxable year in which SciSparc was a PFIC would be taxed as ordinary income; and (3) the amount allocated
to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer
for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable
to each such other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that SciSparc is a PFIC for
a year with respect to which SciSparc has determined that SciSparc is not a PFIC, it may be too late for a U.S. taxpayer to make a timely
QEF or mark-to-market election. U.S. taxpayers that have held the ordinary shares during a period when SciSparc was a PFIC will be subject
to the foregoing rules, even if SciSparc ceases to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a
timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election by completing the relevant portions of and filing IRS
Form 8621 in accordance with the instructions thereto. U.S. taxpayers that hold the ordinary shares are strongly urged to consult their
tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of
making a QEF or mark-to-market election with respect to the ordinary shares in the event that SciSparc is a PFIC. See &#8220;The Merger
&#8212; Material U.S. Federal Income Tax Considerations to U.S. Holders&#8221; for additional information.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Risks Related to Israeli
Law and SciSparc&#8217;s Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Conditions
in Israel, including Israel&#8217;s conflicts with Hamas and other parties in the region, as well as political and economic instability,
may adversely affect SciSparc&#8217;s operations and limit its ability to market its products, which would lead to a decrease in revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is incorporated under Israeli law, and our employees, including our Chief Executive Officer and our Chief Financial Officer, and other
senior members of SciSparc&#8217;s management team, operate from its headquarters located in Israel. In addition, all of SciSparc&#8217;s
officers and directors are residents of Israel. Accordingly, SciSparc&#8217;s business and operations are directly affected by economic,
political, geopolitical, and military conditions in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the establishment of the State of Israel in 1948 and in recent years, armed conflicts between Israel and its neighboring countries and
terrorist organizations active in the region have involved missile strikes, hostile infiltrations, terrorism against civilian targets
in various parts of Israel, and recently abduction of soldiers and citizens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the October 7th attacks by Hamas terrorists in Israel&#8217;s southern border, Israel declared war against Hamas and since then, Israel
has been involved in military conflicts with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly and
through proxies like the Houthi movement in Yemen and armed groups in Iraq and other terrorist organizations. Additionally, following
the fall of the Assad regime in Syria, Israel has conducted limited military operations targeting the Syrian army, Iranian military assets
and infrastructure linked to Hezbollah and other Iran-supported groups. Although certain ceasefire agreements have been reached with
Hamas and Lebanon (with respect to Hezbollah), these agreements failed to be upheld and military activity and hostilities continue to
exist at varying levels of intensity, and the situation remains volatile, with the potential for escalation into a broader regional conflict
involving additional terrorist organizations and possibly other countries. Also, the fall of the Assad regime in Syria may create geopolitical
instability in the region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June 13, 2025, Israel launched a strike against Iran, aimed to disrupt Iran&#8217;s capacity to coordinate or launch hostilities against
Israel. Iran has retaliated in response, firing missiles and drones at Israeli military and civilian infrastructure. As of the date of
this proxy statement/prospectus a ceasefire agreement has been reached with Iran, however there is no assurance that this agreement will
be upheld and military activity and hostilities may continue to exist at varying levels of intensity. </span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">While
SciSparc&#8217;s facilities have not been damaged during the current war, the hostilities with Hamas, Hezbollah, Iran and its proxies
and others have caused and may continue to cause damage to private and public facilities, infrastructure, utilities, and telecommunication
networks, and potentially disrupting its operations and supply chains. For example, SciSparc&#8217;s SCI-210 ASD clinical trial at Soroka
Medical Center was delayed by three months. In addition, Israeli organizations, government agencies and companies have been subject to
extensive cyber attacks. This could lead to increased costs, risks to employee safety, and challenges to business continuity, with potential
financial losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the ongoing war, several hundred thousand Israeli military reservists were drafted to perform immediate military service,
and military reservists are expected to perform long reserve duty service in the coming years. None of SciSparc&#8217;s employees have
been called to active military duty. The absence of SciSparc&#8217;s employees due to their military service in the current or future
wars or other armed conflicts may materially and adversely affect SciSparc&#8217;s ability to conduct our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli
government currently covers the reinstatement value of certain direct damages that are caused by terrorist attacks or acts of war, SciSparc
cannot assure you that such government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses
or damages incurred by SciSparc could have a material adverse effect on its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
global perception of Israel and Israeli companies, influenced by actions by international judicial bodies, may lead to increased sanctions
and other negative measures against Israel, as well as Israeli companies and academic institutions. There is also a growing movement
among countries, activists, and organizations to boycott Israeli goods, services and academic research or restrict business with Israel,
which could affect business operations. If these efforts become widespread, along with any future rulings from international tribunals
against Israel, they could significantly and negatively impact business operations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Prior
to the October 2023 war, the Israeli government pursued changes to Israel&#8217;s judicial system and has recently renewed its efforts
to effect such changes. In response to the foregoing developments, certain individuals, organizations, and institutions, both within
and outside of Israel, voiced concerns that such proposed changes, if adopted, may negatively impact the business environment in Israel.
Such proposed changes may also lead to political instability or civil unrest. If such changes to Israel&#8217;s judicial system are pursued
by the government and approved by the parliament, this may have an adverse effect on SciSparc&#8217;s business, results of operations,
and ability to raise additional funds, if deemed necessary by its management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Provisions of
Israeli law may make it easy for SciSparc shareholders to demand that SciSparc convene a shareholders meeting, and/or allow shareholders
to convene a shareholder meeting without the consent of its management, which may disrupt its management&#8217;s ability to run its company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a company listed on an exchange in the U.S., Israeli law may allow any one or more of its shareholders holding, in the aggregate, at
least 10% of its voting rights to demand that SciSparc convene a special shareholders meeting. Also, in the event that SciSparc chooses
not to convene a special shareholders meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others,
that such shareholders may independently convene a special shareholders meeting within three months (or under court&#8217;s ruling) and
require SciSparc to cover the costs, within reason, and as a result thereof, its directors might be required to repay SciSparc such costs.
If SciSparc&#8217;s shareholders decide to exercise these rights in a way inconsistent with its management&#8217;s strategic plans, its
management&#8217;s ability to run its company may be disrupted, and this process may entail significant costs to SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>SciSparc&#8217;s
operations are subject to currency and interest rate fluctuations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
incurs expenses in U.S. dollars and NIS, but its financial statements are denominated in U.S. dollars. U.S. dollars is its functional
currency and is the currency that represents the principal economic environment in which SciSparc operates. As a result, SciSparc is
affected by foreign currency exchange fluctuations through both translation risk and transaction risk. As a result, SciSparc is exposed
to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation
rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel.
In any such event, the dollar cost of its operations in Israel would increase and its dollar-denominated results of operations would
be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Provisions of
Israeli law and SciSparc&#8217;s Amended and Restated Articles of Association may delay, prevent or otherwise impede a merger with, or
an acquisition of, its company, which could prevent a change of control, even when the terms of such a transaction are favorable to SciSparc
and its shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Provisions
of Israeli law and SciSparc&#8217;s Amended and Restated Articles of Association could have the effect of delaying or preventing a change
in control and may make it more difficult for a third party to acquire SciSparc or its shareholders to elect different individuals to
its board of directors, even if doing so would be considered to be beneficial by some of its shareholders, and may limit the price that
investors may be willing to pay in the future for its ordinary shares. Among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Israeli corporate law regulates
    mergers and requires that a tender offer be effected when more than a specified percentage of shares in a company are purchased;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Israeli corporate law does
    not provide for shareholder action by written consent, thereby requiring all shareholder actions to be taken at a general meeting
    of shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s Amended
    and Restated Articles of Association divide its directors into three classes, each of which is elected once every three years;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s Amended
    and Restated Articles of Association require a vote of the holders of a majority of its outstanding ordinary shares entitled to vote
    present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited
    number of provisions, such as the provision stating that each year the term of office of only one class of directors will and dividing
    its directors into three classes, requires a vote of the holders of 65% of the voting power represented at a general meeting of its
    shareholders and voting thereon has been obtained, provided the majority constitutes more than 33.33% of the total issued and outstanding
    share capital as of the record date of such meeting. The affirmative vote of at least three-quarters (3/4) of the directors, in addition
    to the approval of its shareholders, is also required in order to amend its Amended and Restated Articles of Association;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">SciSparc&#8217;s Amended
    and Restated Articles of Association provide that director vacancies may be filled by its board of directors;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">subject to certain exceptions,
    SciSparc&#8217;s Amended and Restated Articles of Association restrict SciSparc from engaging in certain business combination transactions,
    with any shareholder who holds 15% or more of its voting power. The transactions subject to such restrictions include mergers, consolidations
    and dispositions of its assets with a market value of 10% or more of its assets or outstanding shares. Subject to certain exceptions,
    such restrictions will apply for a period of three years following each time a shareholder became the holder of 15% or more of its
    voting power; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">subject to certain exceptions,
    SciSparc&#8217;s Amended and Restated Articles of Association restrict certain transactions which may have a significant effect on
    the company&#8217;s structure, assets or business, including significant mergers and acquisitions, a disposition of all or substantially
    all of the assets of SciSparc, a voluntary dissolution and material changes to the principal business of SciSparc.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
Israeli tax considerations may make potential transactions undesirable to SciSparc or to some of its shareholders whose country of residence
does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax
law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including
a holding period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating
companies are restricted. See &#8220;The Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger&#8221; for additional
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>It may be difficult
to enforce a judgment of a United States court against SciSparc and its officers and directors and the Israeli experts named in this
prospectus in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on its officers
and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
was incorporated in Israel and its corporate headquarters are located in Israel. All of its executive officers and directors and the
Israeli experts named in this prospectus are located in Israel. All of its assets and most of the assets of these persons are located
in Israel. Service of process upon SciSparc or its non-U.S. resident directors and officers and enforcement of judgments obtained in
the United States against SciSparc or its non-U.S. directors and executive officers may be difficult to obtain within the United States.
SciSparc has been informed by its legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original
actions instituted in Israel, or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts
may refuse to hear a claim based on a violation of U.S. securities laws against SciSparc or its non-U.S. officers and directors because
Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it
may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed
by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments
rendered outside Israel, which may make it difficult to collect on judgments rendered against SciSparc or its non-U.S. officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of
judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of
the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that
was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a
court or tribunal in Israel at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Your rights and
responsibilities as a holder of SciSparc securities will be governed by Israeli law, which differs in some material respects from the
rights and responsibilities of shareholders of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is incorporated under Israeli law. The rights and responsibilities of holders of SciSparc&#8217;s ordinary shares are governed by its
Amended and Restated Articles of Association and the Companies Law. These rights and responsibilities differ in some respects from the
rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder
of an Israeli company has to act in good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations
toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things,
in voting at the general meeting of shareholders, on amendments to a company&#8217;s articles of association, increases in a company&#8217;s
authorized share capital, mergers and certain transactions requiring shareholders&#8217; approval under the Companies Law. In addition,
a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine the outcome of a
shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the company, or has other powers
toward the company has a duty of fairness toward the company. However, Israeli law does not define the substance of this duty of fairness.
There is little case law available to assist in understanding the implications of these provisions that govern shareholder behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SciSparc received Israeli government grants
for certain of its past research and development activities and programs, some of which SciSparc sold or is in the process of selling.
The terms of such grants may require SciSparc, in the future, to pay royalties and to satisfy specific conditions if and to the extent
SciSparc generates revenues from the know-how funded with these grants. SciSparc may be required to pay penalties in addition to payment
of the royalties.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
research and development efforts with respect to some of its past activities, which was focused on developing an immunotherapeutic monoclonal
antibody for the treatment of Alzheimer&#8217;s disease, which SciSparc sold in March 2015, and its Anti-CD3 technology directed toward
the treatment of inflammatory and autoimmune diseases, which in part was returned and re-assigned to Hadasit Medical Research Services&amp;
Development Ltd., or Hadasit, and in part is still in the process of being sold, were financed in part through royalty-bearing grants
from the Israeli Innovation Authority, or the IIA. As of December 31, 2024, SciSparc had received the aggregate amount of approximately
$1.1 million from the IIA for the development of its abovementioned technologies. As of December 31, 2024, its contingent liabilities
regarding IIA grants received by SciSparc were in an aggregate amount of $1.1 million including interest. With respect to such grants,
SciSparc is committed to pay royalties up to $1.1 million relating only to technologies in its possession and excluding any royalties
for technologies that SciSparc sold to third parties. SciSparc is required to comply with the requirements of the Israeli Encouragement
of Industrial Research, Development and Technological Innovation Law, 5744-1984, as amended, or the Innovation Law, and related regulations,
or the Research Law, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the
terms of these grants and the Innovation Law restrict the transfer or license of such know-how, and the transfer of manufacturing or
manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore,
the discretionary approval of an IIA committee would be required for any transfer or license to third parties inside or outside of Israel
of know how or for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects of such technologies.
SciSparc may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits
us to transfer technology or development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Innovation Law and the regulations thereunder, a recipient of IIA grants is required to return the grants by the payment of royalties
of 3% to 5% on the revenues generated from the sale of products (and related services) developed (in whole or in part) under an IIA program
up to the total amount of the grants received from IIA plus the relevant interest rate, if any. Under IIA regulations, grants received
before June 30, 2017, bear the annual interest rate that applied at the time of the approval of the applicable IIA file which will apply
to all of the funding received under such IIA approval. Grants received from the IIA after June 30, 2017, bear an annual interest rate
based on the 12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%.
Grants approved after January 1, 2024, shall bear the higher rate of (i) 12 months SOFR, plus 1%, or (ii) a fixed annual interest rate
of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
transfer or license of IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products,
technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred
or licensed technology or know-how, SciSparc&#8217;s research and development expenses, the amount of IIA support, the time of completion
of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair its ability to sell,
license or otherwise transfer SciSparc&#8217;s technology assets outside of Israel or to outsource or transfer development or manufacturing
activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to its shareholders
in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar
transaction) may be reduced by any amounts that SciSparc is required to pay to the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a &#8220;foreign private issuer&#8221; SciSparc is permitted to and follow certain home country corporate governance practices instead
of otherwise applicable SEC requirements, which may result in less protection than is accorded to investors under rules applicable to
domestic U.S. issuers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
status as a foreign private issuer also exempts it from compliance with certain SEC laws and regulations, including the proxy rules and
the short-swing profits recapture rules. In addition, SciSparc will not be required under the Exchange Act to file current reports and
financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange
Act and SciSparc will generally be exempt from filing quarterly reports with the SEC. Also, although the Companies Law requires SciSparc
to disclose the annual compensation of its five most highly compensated senior officers on an individual basis, this disclosure is not
as extensive as that required of a U.S. domestic issuer. Furthermore, as a foreign private issuer, SciSparc is also not subject to the
requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the frequency
and scope of information and protections to which you are entitled as an investor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>International
expansion of its business exposes SciSparc to business, regulatory, political, operational, financial and economic risks associated with
doing business outside of the United States or Israel.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than SciSparc&#8217;s headquarters and other operations which are located in Israel (as further described below), SciSparc currently
has limited international operations, but its business strategy incorporates potentially significant international expansion, particularly
in anticipation of approval of its product candidates. SciSparc plans to maintain sales representatives and conduct physician and patient
association outreach activities, as well as clinical trials, outside of the United States and Israel. Doing business internationally
involves a number of risks, including but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
    conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws,
    regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by SciSparc to obtain regulatory approvals for the use of its products in various countries;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    potentially relevant third-party patent rights;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    and difficulties in obtaining protection and enforcing its intellectual property;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing foreign operations;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
    in its ability to penetrate international markets;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises
    on demand and payment for its products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment
    of trade and other business restrictions;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    outbreak of a contagious disease, such as coronavirus, which may cause SciSparc, third party vendors and manufacturers and/or customers
    to temporarily suspend SciSparc or their respective operations in the affected city or country;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the
    purview of the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm SciSparc&#8217;s future international expansion and operations and, consequently, its results
of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with the FCPA could subject SciSparc to penalties and other adverse consequences.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
is subject to the FCPA, which generally prohibits companies, such as SciSparc, whose securities are listed in the United States, from
paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign government official,
political party or candidate for public office for the purpose of influencing any act or decision of such foreign person in order to
assist companies like SciSparc in obtaining or retaining business. The FCPA also obligates companies like SciSparc, whose securities
are listed in the United States, to comply with accounting provisions requiring the companies to maintain books and records that accurately
and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system
of internal accounting controls for international operations. The U.S. Department of Justice and the SEC, which have responsibility for
enforcement of the FCPA, both consider employees of government-operated health care systems to be &#8220;foreign officials&#8221; for
FCPA purposes. In addition, the U.S. Department of Justice and the SEC are both engaged in a long-running FCPA compliance review of pharmaceutical
companies. If SciSparc&#8217;s employees or agents are found to have engaged in conduct that violates the FCPA, SciSparc would be held
responsible and could suffer severe penalties and other consequences, including adverse publicity and damage to its reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity
issues, security breaches and other disruptions could compromise its information, expose SciSparc to liability and harm its reputation
and business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
business relies upon information technology systems operated by SciSparc and by its third-party service providers. These systems may
fail or experience operational disruption, experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access.
In the ordinary course of its business SciSparc collects and stores sensitive data, including intellectual property, personal information
and its proprietary business information. The secure maintenance and transmission of this information is critical to its operations and
business strategy. SciSparc relies on commercially available systems, software, tools and domestically available monitoring to provide
security for processing, transmitting and storing this sensitive data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hackers
may attempt to penetrate its computer systems, and, if successful, misappropriate personal or confidential business information. In addition,
an associate, contractor or other third-party with whom SciSparc does business may attempt to circumvent its security measures in order
to obtain such information, and may purposefully or inadvertently cause a breach involving such information. While SciSparc continues
to implement additional protective measures to reduce the risk of and detect cyber incidents, cyber-attacks are becoming more sophisticated
and frequent, and the techniques used in such attacks change rapidly. If its third-party vendors fail to protect their information technology
systems and its confidential and proprietary information, SciSparc may be vulnerable to disruptions in service and unauthorized access
to its confidential or proprietary information and SciSparc could incur liability and reputational damage and the further development
and commercialization of its product candidates could be delayed. While SciSparc has not, to its knowledge, experienced any material
IT system failures or cybersecurity attacks to date, SciSparc cannot assure you that its data protection efforts and its investment in
information technology will prevent significant breakdowns, data leakages, breaches in its systems or those of its third-party vendors
and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon its reputation, business,
operations or financial condition. If such an event were to occur and cause interruptions in its operations, it could result in a material
disruption of its development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical
data assets including trade secrets or other proprietary information. For example, the loss of clinical trial data from future clinical
trials could result in delays in its regulatory approval efforts and significantly increase its costs to recover or reproduce the data.
Such IT system failures, cybersecurity attacks or vulnerabilities to SciSparc&#8217;s or its third-party vendors&#8217; information security
programs or defenses could result in legal liability, reputational damage, business interruption, and its competitive position could
be harmed and the further development and commercialization of its products or any future products could be delayed or disrupted. Moreover,
containing and remediating any IT system failure, cybersecurity attack or vulnerability may require significant investment of resources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
information technology networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers
or breaches, employee error or malfeasance, power outages, computer viruses, telecommunication or utility failures, systems failures,
natural disasters or other catastrophic events. Furthermore, significant security breaches or disruptions of its internal information
technology systems or those of its third-party vendors and other contractors and consultants could result in the loss, misappropriation
and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets
or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business
and reputational harm to SciSparc. Any such compromise could disrupt its operations, damage its reputation and subject SciSparc to additional
costs and liabilities, any of which could adversely affect its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SciSparc
may be subject to securities litigation, which is expensive and could divert management attention.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action
litigation. SciSparc may be the target of this type of litigation in the future. Litigation of this type could result in substantial
costs and diversion of management&#8217;s attention and resources, which could seriously hurt its business. Any adverse determination
in litigation could also subject SciSparc to significant liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish or cease publishing research or reports about SciSparc, its business or its market, or
if they adversely change their recommendations or publish negative reports regarding its business or its shares, the share price and
trading volume of its securities could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for SciSparc&#8217;s ordinary shares will be influenced by the research and reports that industry or securities analysts
may publish about SciSparc, its business, its market or its competitors. SciSparc does not have any control over these analysts and SciSparc
cannot provide any assurance that analysts will cover SciSparc or provide favorable coverage. If any of the analysts who may cover SciSparc
adversely change their recommendation regarding its securities, or provide more favorable relative recommendations about its competitors,
the price of its securities would likely decline. If any analyst who may cover SciSparc were to cease coverage of its company or fail
to regularly publish reports on SciSparc, SciSparc could lose visibility in the financial markets, which in turn could cause the price
or trading volume of its securities to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to AutoMax&#8217;s Business and Operations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
decline in available financing may adversely affect AutoMax&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of AutoMax&#8217;s customers finance their vehicle purchase. As the credit markets have historically experienced volatility and disruption,
such downturns could adversely affect the credit market and affect AutoMax clients&#8217; ability to secure the required financing. A
part of AutoMax&#8217;s success is subject to the availability of affordable financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, AutoMax has
non-guaranteed credit lines from four banking corporations, which aggregated to approximately NIS 175.5 million (approximately $48.12
million) for the year ended December 31, 2024, of which it had utilized approximately NIS 170.5 million (approximately $46.75 million).
These credit lines bear interest rates that vary between prime +0.5% and prime +2.25%. If the financial market or the banking system
deteriorates, AutoMax&#8217;s ability to obtain additional financing may be affected. Such a decline in available financing could have
an adverse effect on its business, operations, and financial results.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
signed certain indemnification clauses within asset and share purchase agreements, as part of the sale of its digital media operations
between the years 2017 and 2019, and if such indemnification is sought out, AutoMax&#8217;s results of operations and financial conditions
could be adversely impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
the years 2017 and 2019, AutoMax sold its digital media and advertising operations to various third parties. As part of such sales, AutoMax
has agreed to identify the buyers in case of a breach of representations provided by AutoMax. While AutoMax estimates that there is a
low probability it will be required to indemnify any such purchasers, any such indemnification could adversely impact its financial condition
and results of operations. <b><i>&#160; </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to renew AutoMax permits and licenses or their revocation could materially adversely affect its business, results of operations, financial
condition and cash flows. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s subsidiary,
Global AutoMax, operates in accordance with and subject to the permits and licenses granted to it for the purpose and within the framework
of its activity as a parallel importer, as further detailed in this prospectus. The main licenses used for the AutoMax operations are
in accordance with the Vehicle Services Licensing Law, Licensing Regulations for Services and Professions in the Automotive Industry
(Vehicle Import and Marketing and Vehicle Trade), 5775-2016, or the Vehicle Services Licensing Law. Since its inception, Global AutoMax
was granted the required permits and licenses, and these were extended, from time to time, new permits were obtained when required. However,
failure to meet certain criteria as detailed in the Vehicle Services Licensing Law may lead to such permits and licenses being suspended
or not eligible for renewal and/or extensions. Furthermore, such permits could be suspended or revoked until the required conditions
are met. There are currently pending legal proceedings against AutoMax that could, among other things, impede on its ability to renew
or obtain new licenses. For additional information, see &#8211;<i>&#8220;Global AutoMax is subject to various legal proceedings. If the
outcomes of these proceedings are adverse to AutoMax, it could have a material adverse effect on its business, results of operations
and financial condition</i>.&#8221; Cancellation, conditioning, limitation or non-renewal of any of the AutoMax licenses, due to the
aforementioned reasons or for any other reason, may have an effect on its activities and business results.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
ability to import and sell vehicles depends in large part on agreements with suppliers and, therefore, any disruption or deterioration
in its relationship with such suppliers could impact its business. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
purchases its vehicles and components from a limited number of suppliers. Disruption or termination of these sources could occur (due
to several factors, including, but not limited to, supplier capacity limitations, bankruptcy, acts of war, terrorism, fire, earthquake).
Good relationships with such suppliers are important for AutoMax&#8217;s business prospects. If AutoMax&#8217;s relationship with its
suppliers were to deteriorate, or if its suppliers fail to supply vehicles, its business, financial condition, commercialization and
results of operations could be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, as a result of difficulties faced by major vehicle manufacturers, there has been an increase in consolidation of activities
and mergers and acquisitions in the automotive industry, as well as collaborations between vehicle manufacturers. The acquisition of
a major supplier by a larger group may lead to cancellation or non-renewal of franchise agreements, and concentration of the import of
brands to Israel under one importer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
success depends greatly on its ability to retain and/or recruit suppliers who will provide it with a vehicle inventory, in the scope
that will enable AutoMax to remain competitive in the marketing of vehicles to its customers in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
rate fluctuations between the U.S., dollar, Euro and the New Israeli Shekel currencies may negatively affect AutoMax&#8217;s earnings.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the international
nature of AutoMax&#8217;s business, it is exposed to risks associated with changes in foreign currency exchange rates. Substantially
all its cost of purchases is either in U.S. dollars or Euros while the majority of its revenues and AutoMax&#8217;s management, marketing,
sales and research and development costs are in New Israeli <span style="background-color: white">Shekels</span>. AutoMax is therefore
exposed to foreign currency risk due to fluctuations in exchange rates. This may result in gains or losses with respect to movements
in exchange rates, which may be significant and may also cause fluctuations in reported financial information that are not necessarily
related to its operating results.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increases
in interest rate could materially adversely affect AutoMax&#8217;s business, financial condition, and results of operations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
recent inflation, geopolitical issues, increase in energy costs, increases in interest rates, unstable global conditions and changes
in currency exchange rates have led to global economic instability. Furthermore, as interest rates are reaching historically high records,
it could impede AutoMax&#8217;s ability to obtain financing or comply with its existing credit lines if the banks. Such changes, and
their impact on the global macro-economic environment, can impact AutoMax&#8217;s business, operating results, and financial condition.
Furthermore, as the majority of the customers require financing to purchase vehicles, such increase in interest rates could make it less
appealing and/or more difficult to purchase vehicles and thus decrease sales, which could adversely affect AutoMax&#8217;s business,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Import
product restrictions may impair AutoMax&#8217;s ability to sell vehicles or parts profitably. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the spare or replacement parts AutoMax installs in its vehicles are manufactured outside of Israel. As a result, the AutoMax business
is sensitive to customary risks of importing merchandise, such as import duties, trade regulations and restrictions, transportation costs,
unforeseeable disasters, work stoppages, exchange rates, and general political conditions in other countries. Changes in trade policies
could limit AutoMax&#8217;s ability to import vehicles and/or its ability to purchase vehicles and/or parts at reasonable prices. Such
restrictions could additionally limit AutoMax&#8217;s ability to provide servicing for vehicles and decrease its sales and/or marketability
for customers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any inability to receive the required approvals to import its vehicles or any disputes or disagreements with officials regarding
the import duties, tariffs, or similar matters, could adversely affect AutoMax&#8217;s ability to import vehicles into Israel as well
as impact its profit margins.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
is subject to various legal proceedings. If the outcomes of these proceedings are adverse to AutoMax, it could have a material adverse
effect on its business, results of operations and financial condition. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, AutoMax or its subsidiaries may be party to legal proceedings and claims in the ordinary course of business. While the
outcomes of these matters cannot be predicted with certainty, AutoMax does not believe they will have a material effect on its consolidated
financial position, results of operations, or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are currently two pending legal proceedings against AutoMax, certain beneficial owners as well as officers of AutoMax and its subsidiaries,
which AutoMax considers material to its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 5, 2021, the Tel
Aviv District Attorney&#8217;s Office filed an indictment against Global AutoMax, Haim Levy Trade-In Ltd., and the following beneficial
owners and officers: Daniel Levy, CEO of AutoMax; Yinon Amit, Chief Business Officer of AutoMax; and Haim Levy, Trade and Procurement
Officer of AutoMax and the son of Daniel Levy, or together the Officers, together with Global AutoMax and Haim Levy Trade-In, the Defendants.
Pursuant to the indictment:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Global
                                            AutoMax was accused of committing forgery offenses according to the Penal Law, fraud under
                                            the Penal Law, smuggling according to the Customs Ordinance [new version] and money laundering
                                            offenses, according to the Money Laundering Prohibition Law.</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haim
                                            Levy Trade In was accused of committing forgery offences under the Penal Law, fraud under
                                            the Penal Law, smuggling under the Customs Ordinance, tax and customs violations under the
                                            Customs Ordinance [new version], Value Added Tax Law and the Purchase Tax Law (Goods and
                                            Services), and money laundering offenses according to the Prohibition of Money Laundering
                                            Law and the Penal Law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Officers were accused of forgery offences under the Penal Law, fraud under the Penal Law,
                                            smuggling under the Customs Ordinance, and money laundering offenses according to the Prohibition
                                            of Money Laundering Law and the Penal Law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preliminary hearings were completed, and the evidence trials began in March 2023 for each of the Defendants. AutoMax denies the claims
against Global AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc was informed that
AutoMax believes, based on the position taken by its legal counsel on this matter, that Global AutoMax has strong claims in order to
deal with the allegations in the indictment. Furthermore, based on information received from its legal counsel, in the event of a conviction
against Global AutoMax, the penal sanctions would consist of a monetary fine, and if convicted of money laundering there could be repossessions.
In addition, AutoMax could be exposed to an administrative procedure on behalf of the Israeli Ministry of Transportation and Road Safety,
or the Ministry of Transportation. Subject to Section 8 of the Vehicle Services Licensing Law, the Deputy Director General has the authority
to refuse granting a license or the renewal of a license, if the applicant has been convicted of a criminal offense that, due to its
nature, severity, or circumstance the applicant is not deemed fit to provide vehicle services or to provide services in the automotive
field for which the application was submitted. The Deputy Director General has the same authority in the event an indictment was filed,
even if a final verdict has not yet been reached. Furthermore, under Section 10(a)(7) of the Vehicle Services Licensing Law, the Deputy
Director General can revoke or suspend a license until the licensee complies with the conditions put in place.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional lawsuit was
filed on September 29, 2022, with the District Court in Tel Aviv in the form of a request for approval as a class action, or the Request,
against Global AutoMax, Union Motors Ltd., or Union, Lex Motors Ltd., or Lex, Toyota Motor Corporation, or Toyota, and Denso Corporation,
or Denso.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicant claims that
the defendants, Toyota as a manufacturer of vehicles; Danso as a manufacturer of allegedly defective fuel pumps, installed in Toyota
and Lexus vehicles, and are the subject of the Request. Union and Lex served as direct importers of Toyota and Lexus vehicles in Israel.
Global AutoMax served as a parallel importer of Toyota vehicles in Israel, and Global AutoMax imported the applicant&#8217;s vehicle
to Israel. The applicant claims that each of Lex, Union and Global AutoMax breached their obligations towards the group represented in
the class action, inter alia, producing and/or importing and/or marketing and/or selling vehicles in which a defective fuel pump was
installed, refraining from performing a service recall on all vehicles in which defective pumps were installed, avoided bearing the costs
of damages caused by the defective fuel pumps and the service recall, etc.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This,
according to the applicant, is in breach of the defendants&#8217; obligations according to the Liability for Defective Products Law,
5740-1980, the Sales Law, 5728-1968, the Contracts Law (General Part), 5733-1973, the Licensing of Services and Professions in the Automotive
Industry Law, 5776-2016 and other laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicant estimates the total damages for all members of the claim exceed an aggregate of NIS 2.5 million (approximately $691,000), and
as such that cannot be estimated by him.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, Global
AutoMax submitted a reply to the Request, in which Global AutoMax rejected all of the applicant&#8217;s claims in the Request. In February
2024, the applicant submitted a reply to the respondents&#8217; reply to the Request. A preliminary hearing is scheduled for July 2025.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
AutoMax cannot accurately predict the outcome of this proceeding, it does not believe the claims are substantial and estimate the exposure
with respect to such claim is likely immaterial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
is dependent on its management team and professional personnel, and its business could be harmed if it is unable to attract and retain
personnel necessary for its success. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
success depends highly on its ability to attract and retain skilled, professional personnel, consultants, and contractors. The departure
of highly skilled professional personnel, in particular, any particular key management personnel, could have an adverse impact on AutoMax&#8217;s
operations and ability to execute its growth plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax&#8217;s
efforts to retain and attract professional personnel may also result in significant additional expenses, which could adversely affect
its profitability. There can be no assurance that professional personnel will continue to be employed or that AutoMax will be able to
attract and retain qualified personnel in the future. Failure to retain or attract qualified personnel could have a material adverse
effect on AutoMax&#8217;s business, financial conditions and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business is sensitive to changes in the prices of new and used vehicles. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s business
is sensitive to various changes, specifically to changes in the prices of new and used vehicles. A decrease in the prices of new or used
vehicles, due to a reduction in import taxes or a reduced tax for purchasing vehicles could reduce its profit margins. For example, following
an update of the Pollution Regulations and the Procedure for Testing Pollutants in Vehicles in the European Union (WLTP) the Israeli
green taxation formula was updated. Pursuant to such updated taxation formula, the tax benefits in relation to vehicles with a low polluting
level and set tax benefit limits, are gradually decreasing, which causes an increase in the prices of the vehicles that benefited from
the purchase tax. For example, on January 1, 2023, the purchase tax on hybrid vehicles increased from 40% in 2022 to 50%, while the limit
of the tax benefit was reduced from NIS 40,000 (approximately $11,055) in 2021 to NIS 30,000. The purchase tax on electric vehicles was
doubled from 10% in 2022 to 20% in 2023, while the limit of the tax benefit was reduced from NIS 75,000 (approximately $20,730) in 2021
to NIS 60,000 (approximately $16,583) in 2022. As of the date of this proxy statement/prospectus,, the purchase tax on hybrid and plug-in
cars has increased to 83% and the tax benefit limit was cancelled, and the purchase tax on electric cars has increased to 45% and the
tax benefit limit was reduced to NIS 35,000.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax operates in Israel,
and prices AutoMax sets are denominated in New Israeli Shekel, or NIS. Any depreciation of the NIS against foreign currencies in which
AutoMax purchases vehicles from manufactures and the reduction of the price of the vehicles by the manufacturers or the importers for
other reasons may adversely affect the value of the vehicles important and marketed by AutoMax. AutoMax has a policy in place to reduce
exchange risk, which includes both financial protections and options to import the same vehicle models from different suppliers in different
currencies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors could lead to a decrease in the value of AutoMax&#8217;s inventory, and a decrease in AutoMax&#8217;s sales, which could adversely
affect AutoMax&#8217;s business, sales, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s business and operations
face many risks inherent to international trade, and its location in Israel including the ongoing military conflicts, may exacerbate
the import process, which is material to the success of AutoMax&#8217;s business and operations.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
imports, distributes and sells vehicles in Israel, and all the vehicles AutoMax sells are manufactured outside of Israel. While AutoMax
manages its inventory of vehicles and spare parts in a manner that allows AutoMax to provide a rapid response to its customers&#8217;
needs, AutoMax&#8217;s business remains sensitive to customary risks of importing merchandise, such as currency fluctuations, import
duties, trade regulations and restrictions, transportation costs, unforeseeable disasters, work stoppages, exchange rates, and general
political conditions in other countries. Changes in trade policies could limit AutoMax&#8217;s ability to import vehicles and/or its
ability to purchase vehicles and/or parts at reasonable prices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
to the maritime route in the Red Sea may adversely affect AutoMax&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Red Sea is a vital maritime route for international trade traveling to or from Israel. Following Hamas&#8217; attack on Israel and the
Israeli security cabinet&#8217;s declaration of war against Hamas, the Houthi movement, which controls parts of Yemen, launched a number
of attacks on marine vessels traversing the Red Sea, which marine vessels were thought to either be in route towards Israel or to be
partly owned by Israeli businesses or persons. As a result of such disruptions, and in order to mitigate continued economic harm, suppliers
have changed routes from Europe to the Middle East, and, as a result, AutoMax has experienced, and may continue to experience in the
future, delays in vehicle deliveries, extended lead times, and increased cost of freight, increased insurance costs, purchased materials
and manufacturing labor costs. All of these factors have had and may continue to have an effect on AutoMax, which is substantially reliant
on its ability to import and sell vehicles, and such delays and increased costs could have an impact on AutoMax&#8217;s inventory which
may prevent AutoMax from supplying vehicles in a timely fashion to purchasers and/or impede AutoMax&#8217;s ability to replenish its
inventory based on consumer trends. Such delays in supplying vehicles could result in purchasers cancelling orders, which could have
a negative effect on AutoMax&#8217;s results of operation. Furthermore, such increase in costs could impact AutoMax&#8217;s ability to
sell vehicles at competitive prices, which could materially affect its financial results and operations. Additionally, some of the main
maritime companies have announced they will no longer plan routes to Israel, until such time as it is safe, which could impede on AutoMax&#8217;s
ability to import vehicles, and as a result could have a material adverse effect on its business and financial results. The risk of ongoing
supply disruptions may further result in delayed deliveries of AutoMax&#8217;s products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Turkey&#8217;s
trade embargo on Israel may adversely affect AutoMax&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2024, the Turkish
Trade Ministry announced an embargo on trade between Turkey and Israel, which restricts the export of goods from Turkey to Israel and
the import of products from Israel to Turkey, or the Embargo. The Embargo could have a short-term impact on the supply of vehicles and
on the prices of logistics and transportation of vehicles to Israel. As a result of the Embargo, AutoMax may experience delays in vehicle
and bus deliveries, extended lead times, increased cost of freight, and increased insurance costs. All of these factors have had and
may continue to have an effect on AutoMax, which is substantially reliant on its ability to import and sell vehicles and buses, and such
delays and increased costs could have an impact on AutoMax&#8217;s inventory, which may in turn prevent AutoMax from supplying vehicles
and buses in a timely fashion to purchasers or impede AutoMax&#8217;s ability to replenish its inventory based on consumer trends. Such
delays in supplying vehicles and buses could result in purchasers cancelling orders, which could have a negative effect on AutoMax&#8217;s
results of operations. As of the date of this prospectus, the Embargo remains ongoing.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Macroeconomic
factors such as fluctuation in vehicle prices, fuel prices, supply chain disruptions, and vehicle-related technology advancements could
have an adverse effect on AutoMax&#8217;s revenues and operating results. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Macroeconomic
factors that affect oil prices and the automobile and commodity markets can have adverse effects on AutoMax&#8217;s revenues, revenue
growth rates (if any), and operating results. Significant increases in the cost of fuel could lead to a reduction in miles driven per
car and a reduction in accident rates. A material reduction in accident rates, whether due to, among other things, a reduction in miles
driven per car, vehicle-related technological advances such as accident avoidance systems and, to the extent widely adopted, the advent
of autonomous vehicles, could have a material impact on revenue growth. Similarly, a reduction in total loss frequency rates, due to
among other things, sharp increases in used car prices that make it less economical for insurance company sellers to declare a vehicle
involved in an accident a total loss, could also have a material impact on revenue growth. In addition, under the AutoMax Percentage
Incentive Program contracts, or PIP, the cost of transporting the vehicle to one of AutoMax&#8217;s facilities is included in the PIP
fee. AutoMax may incur increased fees, which it may not be able to pass on to its vehicle sellers. A material increase in transportation
rates could have a material impact on AutoMax&#8217;s operating results. Volatility in fuel, commodity, and used car prices could have
a material adverse effect on its revenues and revenue growth rates in future periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Conditions in Israel, including conflicts
in the region, may adversely affect AutoMax&#8217;s operations and limit its ability to market its products, which would lead to a decrease
in revenues.</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">AutoMax
is incorporated under the laws of the State of Israel, and its employees, including management members, operate from their headquarters
that are located in Jerusalem, Israel. In addition, all of its officers and directors are residents of Israel. Accordingly, AutoMax&#8217;s
business and operations are directly affected by economic, political, geopolitical and military conditions in Israel. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist
organizations active in the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian
targets in various parts of Israel, which have negatively affected business conditions in Israel.&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against
these terrorist organizations commenced in parallel to their continued rocket and terror attacks.&#160;Since the commencement of these
events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts
of Yemen, and most recently with Iran. As a result of the war, operations at two of AutoMax&#8217;s branch locations were closed permanently.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June 13, 2025, Israel launched a strike against Iran, aimed to disrupt Iran&#8217;s capacity to coordinate or launch hostilities against
Israel. Iran has retaliated in response, firing missiles and drones at Israeli military and civilian infrastructure. As of the date of
this proxy statement/prospectus a ceasefire agreement has been reached with Iran, however there is no assurance that this agreement will
be upheld and military activity and hostilities may continue to exist at varying levels of intensity. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">During
this escalation, all of AutoMax&#8217;s branches were closed as a result of orders of the Home Front Command, and have since reopened
as of June 25, 2025. A prolonged closure of AutoMax&#8217;s branches could lead to a decrease in sales, which in turn may materially and
adversely affect its results of operation.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications
on AutoMax&#8217;s business and operations and on Israel&#8217;s economy in general. These events may be intertwined with wider macroeconomic
indications of a deterioration of Israel&#8217;s economic standing, for instance, a downgrade in Israel&#8217;s credit rating by rating
agencies, which may have a material adverse effect on AutoMax and its ability to effectively conduct its operations.&#160;As many of
AutoMax&#8217;s customers purchase their vehicles through credit financing, an adverse material effect on Israel&#8217;s economy could
impact the ability to obtain such credit financing on favorable terms, which in turn could lead to a decrease in AutoMax sales.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
connection with the Israeli security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service. AutoMax also relies on service
providers located in Israel and has entered into certain agreements with Israeli counterparties. AutoMax&#8217;s employees and consultants
in Israel, in addition to employees of AutoMax&#8217;s service providers located in Israel, may be called for service in the current
or future wars or other armed conflicts with Hamas and others, and such persons may be absent for an extended period of time. As a result,
its operations may be disrupted by such absences, which disruption may materially and adversely affect its business and results of operations.
Additionally, the absence of employees of AutoMax&#8217;s Israeli suppliers and contract manufacturers due to their military service
in the current or future wars or other armed conflicts may disrupt their operations, which in turn may materially and adversely affect
its ability to deliver or provide products and services to customers.&#160;&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
the event that AutoMax&#8217;s facilities are damaged as a result of hostile actions, or hostilities otherwise disrupt its ongoing operations,
its ability to deliver or provide products and services in a timely manner to meet AutoMax&#8217;s contractual obligations towards customers
and vendors could be materially and adversely affected. AutoMax&#8217;s commercial insurance does not cover losses that may occur as
a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of certain
direct damages that are caused by terrorist attacks or acts of war, AutoMax cannot assure you that such government coverage will be maintained
or that it will sufficiently cover its potential damages. Any losses or damages incurred by AutoMax could have a material adverse effect
on its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
is a holding company and as a result are dependent on its operating subsidiaries to generate sufficient cash to fund its ongoing operations.
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuation of AutoMax&#8217;s activities depends on its operating subsidiaries&#8217; ability to generate sufficient cash and raise
additional financial sources in order to develop its activities. The loss of operations or not sufficient operations of its subsidiaries
could have a material adverse effect on its business, sales and results of operations. There is no certainty that AutoMax will succeed
in raising funds in the required amount, or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business is sensitive to changes in consumer preferences and global trends in the automotive industry. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
may be affected by various global trends and/or events in the environment in which it operates, on which AutoMax has no ability to influence,
which in turn may affect its operating results. The vehicle manufacturing industry has been characterized in recent years by significant
technological progress, especially in the fields of vehicles driven by alternative energy sources and autonomous vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is a noticeable increase in the cooperative economy trend and a trend of decreasing the environmental damages caused
by the use of vehicles, which are expressed, <i>inter alia</i>, by increase in demand for the use of electric and hybrid vehicles, by
the development of new models of vehicle&#8217; sharing, by short-term vehicle rentals, in a pay-as-you-go model, and by shared travels.
Alongside this, major cities in Europe are promoting processes intended to reduce and even limit completely the entrance of polluting
vehicles into the cities. This trend has recently expanded to Israel, as part of which, restrictions were imposed on the entry of polluting
vehicles into Jerusalem and Haifa, and potentially in other cities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
developments described above may create uncertainty in the long term regarding the motorization level as well as the growth rate of the
vehicle manufacturing industry in which manufacturers whose vehicles AutoMax imports are operating, as well as reducing, in the long
term, the demand for car ownership, which in turn may influence AutoMax&#8217;s activity and affect AutoMax&#8217;s business results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
may experience credit default or losses if AutoMax&#8217;s customers default from the financing it provides.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
for the date of the report, through certain subsidiaries, AutoMax provides its corporate customers with credit lines in low volumes (by
way of payment in installments). However, as is customary in the automotive industry, it is possible that according to AutoMax&#8217;s
management decision, sales made to its corporate customers will be partially made on credit. In such cases, AutoMax may be exposed to
the risk that these customers will not meet their obligations to repay the full amount of the loan made available to them for the purpose
of purchasing the vehicles. As of the day of this prospectus, these credit lines are in volumes which are immaterial to AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
operations are subject to a wide range of governmental regulations and laws. Its failure to comply with or any changes to these regulations
and laws, could adversely affect AutoMax&#8217;s business, sales, results of operations and financial condition. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
operates in a highly regulated industry, and it is subject to various local laws and regulations. Additionally, the automotive industry
in Israel is characterized by vast regulation and strict regulatory requirements, including the standardization requirements, which may
affect AutoMax&#8217;s expenditures and its operational results. Changes in regulatory arrangements that apply to the automotive industry,
such as changes in government taxation policy, changes in the policy regarding the classification of vehicles as private or commercial
for tax purposes or changes in the policy regarding the value of use of a personal vehicle provided by the employer for the use of the
employee, or changes in the standards of vehicles permitted to be imported into Israel, may, in AutoMax&#8217;s estimation, lead to changes
in demand for various types of vehicles, and affect in the long term the results of its activity. In addition, regulatory changes introduced
following the recommendations of the Committee for the Increase of Competitiveness, as well as changes in the legal provisions that will
completely remove or ease the barriers to entry into the industry, will allow the entry of additional parallel importers, increase competition
and, as a result, may cause a decrease in AutoMax&#8217;s revenues and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
operates in a highly competitive industry. Failure to develop and execute strategies to remain a preferred importer and seller of vehicles
and to adapt to the increasing use of digital and online tools to market, buy, sell, lease and finance vehicles could adversely affect
its business, sales and results of operations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The automotive imports industry
is highly competitive, including publicly and privately owned car importers, which import the same vehicle brands in a variety of models.
The value chain in the automotive industry includes international vehicle manufactures and importers. There are approximately 25 official
import groups in Israel, representing various manufactures, and responsible for approximately 97% of the automotive imports to Israel.
In addition, there are a few dozen parallel importers, who are collectively responsible for approximately 3% of the imports. AutoMax&#8217;s
competition is dynamic and changes annually based on the selection of vehicles its choses to import and hold in inventory for that year.
AutoMax&#8217;s selection of product lineup is done annually and determined by a comprehensive analysis of various factors, including
vehicle availability in the importing country, local market demand, tax advantages, currency exchange rates, and other relevant factors.
Certain of AutoMax&#8217;s competitors have access to more capital than it, which may provide them with an advantage in forging relationships
or providing customers with more competitive prices. Certain car dealers leverage relationships with vehicle manufacturers to sell used
cars as &#8220;certified pre-owned&#8221;, which could provide such competitors with an advantage over AutoMax.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
competitors are shifting more focus to online sales, as this is becoming a consumer trend. While AutoMax currently provides online sale
services, there is no guarantee it will be successful in transitioning to online tools, for buying, selling, leasing and financing vehicles
which could adversely affect its business, sales and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AutoMax&#8217;s agreement with Al Damani
is conditioned upon receiving the required regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s
strategic agreements with Al Damani New Motor Vehicles Trading LLC, or Al Damani, is contingent on obtaining necessary regulatory approvals,
which have not yet been fully secured. These approvals are crucial for importing and distributing vehicles in Israel. Delays or failures
in securing these approvals could adversely impact AutoMax&#8217;s revenues, market expansion, and competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">On March 13, 2023,
Dalhom AutoMax entered into a direct import agreement with Al Damani, a United Arab Emirates manufacturer, to import, distribute, sale
and market fully electric Al Damani vehicles in Israel. Dalhom AutoMax&#8217;s obligations under such direct importer agreement are conditional
on receiving the required regulatory approvals from the Ministry of Transportation for the import of vehicles manufacturer by Al Damani
to Israel, which have not yet been granted as of the date of this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The failure to secure these
regulatory approvals could delay or prevent the importation and sale of Al Damani vehicles in Israel, which in turn may negatively impact
AutoMax&#8217;s revenue and plans. Additionally, any changes in regulatory requirements or delays in the approval process could increase
AutoMax&#8217;s operational costs and affect its competitive position in the market, which could adversely affect its business, sales
and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>AutoMax&#8217;s agreement with Automotive
Equipment is conditioned upon receiving the required approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 8, 2025 AutoMax and
Automotive Equipment Group (2004) Ltd., or Automotive Equipment, entered into a founders&#8217; agreement, or the Automotive Equipment
Founders&#8217; Agreement, pursuant to which the parties will establish a joint company, owned by AutoMax and Automotive Equipment, or
the Joint Company, which will import and market in Israel trucks and heavy vehicles manufactured by Anhui Jianghuai Automobile Group
Corp., Ltd., or JAC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The establishment of the Joint
Company and the effectiveness of the Automotive Equipment Founders&#8217; Agreement are subject to the receipt of various regulatory
and third-party approvals, including approval from the Israel Competition Authority, the final grant of franchise by JAC to the Joint
Company, and receipt of an import license for JAC vehicles by the Joint Company. As of the date of this proxy statement/prospectus, the
Joint Company has not been established and not all required approvals have been obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the necessary approvals will be received, or that the Joint Company will be established, or that the Automotive Equipment Founders&#8217;
Agreement will become effective within any specific timeframe, or at all. If the Joint Company is not established or if the effectiveness
of the Automotive Equipment Founders&#8217; Agreement is delayed or not achieved, there could be delays to the import and marketing of
JAC trucks and heavy vehicles in Israel. Failure to establish the Joint Company or obtaining the necessary approvals would also prevent
AutoMax from pursuing the potential business opportunity of importing and marketing JAC trucks and heavy vehicles in Israel through the
Joint Company. As a result, AutoMax would not benefit from any potential future revenues or strategic advantages that may have arisen
from this collaboration.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
laws, regulations, or governmental policies in response to climate change, including fuel economy and greenhouse gas emission standards,
or changes to existing standards, could adversely impact AutoMax&#8217;s business, results of operations, financial condition, cash flow,
and prospects. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax
is subject to a variety of local laws and regulations that pertain to the environment. Its business involves the use, handling and disposal
of hazardous materials and wastes, including motor oil, gasoline, solvents, lubricants, paints and substances. AutoMax is subject to
compliance with regulations concerning, among other things, the operation of underground and above-ground gasoline storage tanks, gasoline
dispensing equipment, above-ground oil tanks and automotive paint booths. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Clean Air Law, 5768-2008, or the Clean Air Law, authorizes the Israeli Minister of Environmental Protection, or the Minister to set provisions
regarding the prevention and reduction of air pollution from mobile emission sources, in accordance with values commonly accepted in
the developed countries of the world. The Clean Air Law determines that a person shall not sell, import or market a mobile emission source,
except in accordance with the provisions set by the Minister. This law also states that it is mandatory to include the degree of air
pollution of the vehicle and data regarding the fuel consumption of the vehicle in any new vehicle&#8217; advertisement, as part of the
advertisement itself; and, in addition, said data must be displayed by any entity engaged in the business of selling and marketing new
vehicles within its premises. Similar provisions were established as part of the Clean Air Regulations (disclosure of air pollution data
from a motor vehicle in an advertisement), 5769-2009, as well. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
the best of AutoMax&#8217;s understanding, it complies with the provisions of the Clean Air Law and the regulations established by virtue
thereof and includes the required data in its publications. In addition, the Clean Air Regulations (air pollution from vehicles), 5772-2012
determines what constitutes unreasonable air pollution from a vehicle and regulates the obligation to carry out an air pollution test
for a vehicle before registering it, issuing a license, and renewing it. It should be noted that new vehicles imported to Israel undergo
inspections to verify their suitability for delivery and registration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, there is a noticeable increase in the cooperative economy trend and a trend of decreasing the environmental damages caused
by the use of vehicles, which are expressed, inter alia, by increase in demand for the use of electric and hybrid vehicles, by the development
of new models of vehicle&#8217; sharing, by short-term vehicle rentals, in a pay-as-you-go model, and by shared travels. Alongside this,
major cities in Europe are promoting processes intended to reduce and even limit completely the entrance of polluting vehicles into the
cities. This trend has recently expanded to Israel, as part of which, restrictions were imposed on the entry of polluting vehicles into
Jerusalem and Haifa, and potentially, in other cities. The developments described above may create uncertainty in the long term regarding
the motorization level as well as the growth rate of the vehicle manufacturing industry in which manufacturers whose vehicles AutoMax
imports are operating, as well as reducing, in the long term, the demand for car ownership, and thus influence AutoMax&#8217;s activity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain the security and functionality of AutoMax&#8217;s information systems, or to defend against or otherwise prevent a cybersecurity
attack or data breach, could adversely affect its business, financial position, results of operations and liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax&#8217;s
activities are linked by information systems, including telecommunications, the internet, network communications, emails and various
computer hardware and software applications. As such, it could suffer damage to the aforementioned communication systems. In the current
environment, there are numerous and evolving risks with regards to cybersecurity and privacy, including criminal hackers, hacktivists,
state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error.&#160;While AutoMax implements
various measures to minimize and even prevent these risks, including having a detailed action policy, it cannot guarantee no cyber-attack
may be carried out. Computer hackers and others routinely attempt to breach the security of technology products, services and systems,
and to fraudulently induce employees, customers, sub-contractors, agents, distributors or others to disclose information or unwittingly
provide access to systems or data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Although
AutoMax has invested in measures to reduce these risks, it can provide no assurance that its current IT systems are fully protected against
third-party intrusions, viruses, hacker attacks, information or data theft or other similar threats. The cost and operational consequences
of implementing, maintaining and enhancing further data or system protection measures could increase significantly to overcome increasingly
intense, complex, and sophisticated global cyber threats. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Despite
its best efforts, AutoMax is not fully insulated from data breaches and system disruptions and, accordingly, it has experienced and expects
to continue to experience actual or attempted cyberattacks of its IT networks. To the best of AutoMax&#8217;s knowledge, no cybersecurity
incidents were detected. Although no attempted cyberattacks has had a material adverse effect on its operations or financial condition
thus far, AutoMax cannot guarantee that any such incidents will not have a material adverse effect on AutoMax&#8217;s operations or financial
condition in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
such, its tools and servers are vulnerable to computer viruses, break-ins and similar disruptions from unauthorized tampering with the
AutoMax computer systems and tools located at its facility, at cloud services or at customer sites, or could be subject to system failures
or malfunctions for other reasons. Increased information technology security threats and more sophisticated computer crime pose a risk
to the security of AutoMax&#8217;s systems and networks and the confidentiality, availability and integrity of AutoMax&#8217;s data or
customer data. Cybersecurity attacks could also include attacks targeting the security, integrity and/or reliability of the hardware
and software installed in its products. System failures or malfunctioning could disrupt AutoMax&#8217;s operations and its ability to
timely and accurately process and report key components of its financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Environmental,
social and corporate governance, or ESG issues, including those related to climate change and sustainability, may have an adverse effect
on AutoMax&#8217;s business, financial condition and results of operations and damage AutoMax&#8217;s reputation.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Public
companies are facing increasing scrutiny related to ESG practices and disclosures from certain investors, capital providers, shareholder
advocacy groups, other market participants, and other stakeholder groups. For example, certain institutional and individual investors
have requested various ESG-related information and disclosures as they increasingly incorporate ESG criteria in making investment and
voting decisions. With this increased focus, public reporting regarding ESG practices is becoming more broadly expected. Such increased
scrutiny may result in increased costs, enhanced compliance or disclosure obligations, or other adverse impacts on AutoMax&#8217;s business,
financial condition or results of operations. If AutoMax&#8217;s ESG practices and reporting do not meet investor or other stakeholder
expectations, which continue to evolve, AutoMax may be subject to investor or regulator engagement regarding such matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
March 2024, the SEC published climate disclosure rules, subject to which SciSparc, upon consummation of the Merger, would be required
to disclose certain climate-related information such as governance of climate-related risks and relevant risk management processes, among
other things. While the final rules have yet to be implemented and are subject to ongoing litigation, AutoMax cannot predict the ultimate
scope and impact these rules will have on AutoMax&#8217;s business. If the SEC&#8217;s climate disclosure rules are implemented, they
would likely result in additional legal, accounting and financial compliance and increased general and administrative expenses. Moreover,
this could result in increased management time and attention, to ensure AutoMax is compliant with the regulations and expectations.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in local or foreign tax laws, changing interpretations of existing tax laws, or adverse determinations by tax authorities could increase
AutoMax&#8217;s tax burden or otherwise adversely affect its results of operations, and financial condition. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
certain degree of judgment is required in evaluating its tax positions and determining its provision for income taxes. In the ordinary
course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. As AutoMax operates
in numerous taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by
tax authorities of these jurisdictions. It is not uncommon for tax authorities in different countries to have conflicting views. In addition,
tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. For example,
the work being carried out by the OECD on base erosion and profit shifting as a response to increasing globalization of trade could result
in changes in tax treaties or the introduction of new legislation that could impose an additional tax on businesses. As a result of changes
to laws or interpretations, AutoMax&#8217;s tax positions could be challenged, and its income tax expenses could increase in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that its effective tax rate for the year ended December 31, 2024 will not change over time as a result <span style="background-color: white">of
changes in corporate income tax rates or other changes in the tax laws of the jurisdictions in which AutoMax operates. Any changes in
tax laws could have an adverse impact on its financial results.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
business is subject to a variety of local and international laws regarding privacy and data protection obligations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
collects, uses, maintains and otherwise processes certain data about clients, suppliers, candidates and employees. AutoMax&#8217;s ability
to collect, use, maintain or otherwise process personal data has been, and could be further, restricted by existing and new laws and
regulations relating to privacy and data collection and protection, including the Israeli Privacy Protection Law, 5741-1981, or the Privacy
Law. AutoMax implements measures for the purpose of adapting the relevant aspects of its activity to the provisions applicable subject
to the Privacy Protection Law and the regulations enacted by virtue thereof, and for this purpose it contracted with a company that manages
its information security and privacy protection aspects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax
may not be able to satisfy its debt obligations upon the occurrence of a change in control under its debt instruments or to obtain additional
financing based on existing debt. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax
intends to continue making investments to support its business growth and will likely require additional funds to respond to business
challenges and opportunities, including the need to purchase inventory of vehicles, improve AutoMax&#8217;s operating infrastructure
to support volume growth or acquire complementary businesses and technologies. Accordingly, AutoMax may need to engage in equity or debt
financing to secure additional funds if its existing sources of cash and any funds generated from operations do not provide it with sufficient
capital. If AutoMax raises additional funds through future issuances of equity or convertible debt securities, its existing stockholders
could suffer significant dilution, and any new equity securities AutoMax issues could have rights, preferences, and privileges superior
to those of holders of its other classes of shares. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Any
future debt financing that AutoMax may secure in the future could involve restrictive covenants relating to its capital raising activities
and other financial and operational matters, which may make it more difficult for AutoMax to obtain additional capital and to pursue
business opportunities, including potential acquisitions. AutoMax may not be able to obtain additional financing on terms favorable to
it, if at all. If AutoMax is unable to obtain adequate financing or financing on terms satisfactory to it when it requires it, AutoMax&#8217;s
ability to continue to support its business growth and to respond to business challenges and opportunities could be significantly impaired,
and its business may be adversely affected</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AutoMax&#8217;s
collection, use, storage, disclosure, transfer and other processing of personal information, could give rise to significant costs, liabilities
and other risks, including as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative
press about its privacy and data protection practices, which may harm AutoMax&#8217;s business, financial conditions, results of operations
and prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">AutoMax&#8217;s
operations are dependent on secure processing, transmission, storing on its computers and networks proprietary and confidential information.
AutoMax uses various third-party storage platforms which could make it more vulnerable to such cyberattacks. Furthermore, AutoMax relies
on digital technologies to process payments, both on its networks and third-party systems. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Privacy
laws are ever changing and continue to create new individual privacy rights, including regulations regarding the manner in which such
personal information should be handled. As part of its ongoing operations, AutoMax gathers certain personal information from customers,
vendors, manufactures and others. AutoMax has invested in implementing security controls and adapting its systems, amongst others, by
engaging Integrity Consulting and Risk Management (I.C.M.) Ltd., which manages information security and privacy protection within the
company. However, any misuse of such information or storing it inappropriately and not adequately protecting it could lead to inquiries,
litigation, fines, legislative and regulatory action against AutoMax. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
light of the stated, there is a certain dependence on the information security, backup and retrieval capabilities of those providers.
In this aspect, AutoMax has a system of backups, designed to create a recovery mechanism from a situation where one backup environment
cannot, for whatever reason, support the provision of services. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of Israeli law may make it easy for AutoMax&#8217;s shareholders to demand that AutoMax convenes a shareholders meeting, and/or allow
shareholders to convene a shareholder meeting without the consent of AutoMax&#8217;s management, which may disrupt AutoMax&#8217;s management&#8217;s
ability to run the company.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
law may allow any one or more of AutoMax&#8217;s shareholders holding, in the aggregate, at least 5% of <span style="background-color: white">AutoMax&#8217;s
</span>voting rights to demand that AutoMax convenes a special shareholders meeting. Also, in the event that AutoMax chooses not to convene
a special shareholders meeting pursuant to such a request, Sections 64-65 of the Companies Law provide, among others, that such shareholders
may independently convene a special shareholders meeting within three months (or under court&#8217;s ruling) and require AutoMax to cover
the costs, within reason, and as a result thereof, AutoMax&#8217;s directors might be required to repay such costs. If AutoMax&#8217;s
shareholders decide to exercise these rights in a way inconsistent with AutoMax&#8217;s management&#8217;s strategic plans, AutoMax&#8217;s
management&#8217;s ability to run the company may be disrupted, and this process may entail significant costs to AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult to enforce a judgment of a United States court against us and AutoMax&#8217;s officers and directors in Israel or the
United States, to assert United States securities laws claims in Israel or to serve process on AutoMax&#8217;s officers and directors
and these experts.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AutoMax
is incorporated in Israel and the company&#8217;s corporate headquarters are located in Israel. All of AutoMax&#8217;s executive officers
and directors are located in Israel. All of AutoMax&#8217;s assets and most of the assets of these persons are located in Israel. Service
of process upon AutoMax or the non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against
AutoMax or the non-U.S. directors and executive officers may be difficult to obtain within the United States. AutoMax has been informed
by <span style="background-color: white">AutoMax&#8217;s</span> legal counsel in Israel that it may be difficult to assert claims under
U.S. securities laws in original actions instituted in Israel, or obtain a judgment based on the civil liability provisions of U.S. federal
securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against AutoMax or AutoMax&#8217;s
non-U.S. officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli
court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to
be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain
matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described
above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered
against AutoMax or AutoMax&#8217;s non-U.S. officers and directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of
judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of
the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that
was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a
court or tribunal in Israel at the time the foreign action was brought.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to the Combined Company</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined company&#8217;s success
depends on the experience and expertise of its management team and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is a pharmaceutical
company with limited experience outside of the drug development and healthcare industries, while AutoMax is engaged in the business of
importing and distributing vehicles. These are distinct and unrelated businesses requiring different operational expertise, industry
knowledge, and strategic approaches. Following the Merger, SciSparc will become the parent company of AutoMax, and the two companies
will operate as the combined company. AutoMax is anticipated to continue to operate its current business with its own board of directors
and management; however, the management team of the combined company will be the same as SciSparc&#8217;s existing management team, and
the combined company&#8217;s board of directors will have a minority representation from AutoMax&#8217;s management. Mr. Amitay Weiss,
who is the Chairman of both SciSparc and AutoMax, will be the Chairman of the combined company after the Merger and has experience in
both industries, which may help facilitate the oversight of AutoMax&#8217;s operations. While the combined company&#8217;s management
team has experience in the pharmaceutical industry, its experience in the automotive sector is limited and may present challenges in
effectively overseeing AutoMax&#8217;s operations following the Merger. Although AutoMax is expected to retain its current management
team, which possesses automotive experience, the combined company&#8217;s overall unfamiliarity with the automotive industry may impact
its ability to effectively oversee and support AutoMax&#8217;s operations, and achieve the full extent of the expected benefits of the
Merger. This, in turn, could adversely affect the financial performance and successful operations of the combined company.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company does not anticipate paying any cash dividends on the combined company&#8217;s ordinary shares in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Neither SciSparc nor AutoMax
have ever declared or paid cash dividends on their respective ordinary shares. In accordance with the Series B Bonds Trust Deed, until
the Series B Bonds are repaid in full, AutoMax will not distribute or pay any cash dividends. According to the terms of the Series B
Bonds and the Series B Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4) unequal annual installments,
which will be paid annual as of February 28, 2023 until 2026, inclusive, such that the first payment that was made on February 28, 2023
constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made on February 28, 2024, constituted
15% of the aggregate principal amount of the Series B Bonds, the third payment, that was made on February 28, 2025, will constitute 30%
of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute
45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger, the Series B Bonds will remain outstanding
and subject to repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B Bonds bear interest at a rate of
5.9% per annum. As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal amount of Series B Bonds remains
outstanding and will therefore become a liability of the combined company following the completion of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On May 19, 2025, the Series
C Bonds, were issued and began trading on the TASE. According to the terms of the Series C Bonds and the Series C Bonds Trust Deed, the
Series C Bonds are due for repayment in four (4) unequal annual installments, which will be paid annually from December 31, 2026 until
December 31, 2029, such that the first payment will constitute 5% of the principal, the second and third payments will constitute 10%
each of the principal, and the fourth payment will constitute 75% of the principal. The Series C Bonds bear fixed annual interest at
a rate of 8% per annum. The interest will be paid on each June 30 and December 31, from 2026 to 2029. As of July 3, 2025, NIS 74,353
thousand, approximately ($20,260 thousand) in principal amount of Series C Bonds remains outstanding and will therefore become a liability
of the combined company following the completion of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither SciSparc nor AutoMax
anticipate paying any cash dividends on the combined company&#8217;s ordinary shares in the foreseeable future. It is anticipated that
the combined company will retain all available funds and any future earnings to fund the development and growth of its business. As a
result, capital appreciation, if any, of the combined company&#8217;s ordinary shares will be the combined company&#8217;s shareholders&#8217;
sole source of gain for the foreseeable future.</p><div>
</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
and improving the combined company&#8217;s financial controls and the requirements of being a public company may strain the combined
company&#8217;s resources, divert management&#8217;s attention and affect its ability to attract and retain qualified board members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, the combined company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and
Nasdaq rules. The requirements of these rules and regulations will increase the combined company&#8217;s legal and financial compliance
costs, make some activities more difficult, time-consuming or costly and place strain on its personnel, systems and resources. The Exchange
Act requires, among other things, that the combined company file annual, quarterly and current reports with respect to its business and
financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and
internal control over financial reporting. Ensuring that the combined company will have adequate internal financial and accounting controls
and procedures in place is a costly and time-consuming effort that needs to be re-evaluated frequently.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
and AutoMax do not expect that the combined company will have an internal audit group, and the combined company may need to hire additional
accounting and financial staff with appropriate public company experience and technical accounting knowledge. Implementing any appropriate
changes to the combined company&#8217;s internal controls may require specific compliance training for the combined company&#8217;s directors,
officers and employees, entail substantial costs, and take a significant period of time to complete. Such changes may not, however, be
effective in maintaining the adequacy of the combined company&#8217;s internal controls, and any failure to maintain that adequacy, or
consequent inability to produce accurate financial statements on a timely basis, could increase the combined company&#8217;s operating
costs and could materially impair its ability to operate its business. Moreover, effective internal controls are necessary for the combined
company to produce reliable financial reports and are important to help prevent fraud.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq rules, the combined company will be required to maintain a majority independent board of directors. The various
rules and regulations applicable to public companies make it more difficult and more expensive for the combined company to maintain directors&#8217;
and officers&#8217; liability insurance, and the combined company may be required to accept reduced coverage or incur substantially higher
costs to maintain coverage. If the combined company is unable to maintain adequate directors&#8217; and officers&#8217; insurance, its
ability to recruit and retain qualified officers and directors will be significantly curtailed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
and AutoMax expect that the rules and regulations applicable to public companies will result in the combined company incurring substantial
legal and financial compliance costs. These costs will decrease the combined company&#8217;s net income or increase its net loss and
may require it to reduce costs in other areas of its business.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities or industry analysts do not publish research or publish unfavorable research about the combined company&#8217;s business,
its share price and trading volume could decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for the combined company&#8217;s securities will depend in part on the research and reports that securities or industry
analysts publish about the combined company. The combined company may never obtain sufficient research coverage by securities and industry
analysts. If no sufficient securities or industry analysts commence coverage of the combined company, the trading price for the combined
company&#8217;s shares could be negatively impacted. If the combined company obtains sufficient securities or industry analyst coverage
and if one or more of the analysts who covers it downgrades the combined company&#8217;s shares or publishes inaccurate or unfavorable
research about the combined company&#8217;s business, its share price would likely decline. If one or more of these analysts ceases coverage
of the combined company or fails to publish reports regularly, demand for the combined company&#8217;s shares could decrease, which could
cause its share price and trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could
have a material adverse effect on the combined company&#8217;s share price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC require an annual management assessment of the
effectiveness of its internal control over financial reporting. AutoMax maintains disclosure controls and procedures and internal control
over financial reporting pursuant to the Israeli Securities Law in its Annual and Interim Filings, and has complied with applicable Israeli
reporting requirements. To date, AutoMax has never conducted a review of internal controls over financial reporting for the purpose of
providing the reports required by the Sarbanes-Oxley Act. During review and testing, AutoMax may identify deficiencies and be unable
to remediate them on a timely basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the combined company fails to maintain the adequacy of its internal control over financial reporting as such standards are modified,
supplemented or amended from time to time, it may not be able to ensure that it can conclude on an ongoing basis that it has effective
internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and
regulations of the SEC. If the combined company cannot in the future favorably assess the effectiveness of its internal control over
financial reporting, investor confidence in the reliability of its financial reports may be adversely affected, which could have a material
adverse effect on the combined company&#8217;s share price.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of the combined company in the public market by its existing shareholders could cause its share price
to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of the combined company in the public market or the perception that these sales might occur, could
depress the market price of its securities and could impair its ability to raise capital through the sale of additional equity securities.
Neither SciSparc nor AutoMax is able to predict the effect that sales may have on the prevailing market price of the combined company&#8217;s
securities.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company&#8217;s securities could be delisted from Nasdaq if it does not comply with Nasdaq&#8217;s listing standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Nasdaq rules, consummation of the Merger requires the combined company to submit listing of additional securities application and,
at the time of the Merger, meet all of the criteria applicable to a company initially requesting listing. While SciSparc and AutoMax
intend to obtain listing status for the combined company and maintain the same, no guarantees can be made about the combined company&#8217;s
ability to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the combined company&#8217;s security is delisted by Nasdaq, its security may be eligible to trade on the OTC Bulletin Board or another
over-the-counter market. Any such alternative would likely result in it being more difficult for the combined company to raise additional
capital through the public or private sale of equity securities and for investors to dispose of or obtain accurate quotations as to the
market value of, the combined company&#8217;s securities. In addition, there can be no assurance that the combined company&#8217;s securities
would be eligible for trading on any such alternative exchange or markets.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales and issuances of the combined company&#8217;s ordinary shares or rights to purchase ordinary shares by it, including pursuant to
its equity incentive plans, could result in additional dilution of the percentage ownership of its shareholders and could cause its share
price to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company will not be generally restricted from issuing additional ordinary shares, including any securities that are convertible
into or exchangeable for, or that represent the right to receive, ordinary shares. The market price of the combined company&#8217;s ordinary
shares could decline as a result of sales of shares or securities that are convertible into or exchangeable for, or that represent the
right to receive, shares of the combined company or the perception that such sales could occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
and AutoMax expect that significant additional capital will be needed in the future to continue the combined company&#8217;s planned
operations and costs associated with operating as a public company. To the extent the combined company raises additional capital by issuing
equity or convertible securities, its existing shareholders may experience substantial dilution. The combined company may sell ordinary
shares, convertible securities or other equity securities in one or more transactions at prices and in a manner determined from time
to time by its board of directors. If the combined company sells ordinary shares, convertible securities or other equity securities in
more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to
its existing shareholders, and new investors could gain rights superior to its existing shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the combined company may grant or provide for the grant of rights to purchase shares of its ordinary shares pursuant to the
combined company&#8217;s equity incentive plans. Increases in the number of shares available for future grant or purchase pursuant to
the combined company&#8217;s equity incentive plans may result in additional dilution, which could cause the combined company&#8217;s
share price to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPARATIVE
                                            PER SHARE DATA</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the historical comparative share information for SciSparc and AutoMax on a stand-alone basis and pro forma combined per share information
after giving effect to the business combination.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pro forma combined value
information reflects the Merger as if it had occurred on December 31, 2024, and is computed by multiplying the historical number of AutoMax
by the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pro forma combined share
information below does not purport to represent what the actual results of operations or the earnings per share would been had the companies
been combined during the periods presented, nor to project the combined company&#8217;s results of operations or earnings per share for
any future date or period. The pro forma combined shareholders&#8217; equity per share information below does not purport to represent
what the value of SciSparc and AutoMax would have been had the companies been combined during the periods presented.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma book
value information reflects the Transactions as if they had occurred on December 31, 2024. The weighted average shares outstanding and
net earnings per share information reflect the Transactions as if they had occurred on January&#160;1, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">SciSparc<br/> (Historical)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">AutoMax<br/> (Historical)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma Combined</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">As of and for the year ended December 31, 2024 for SciSparc and AutoMax</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Book
    value per share&#160;<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17.02</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average outstanding shares (basic and diluted)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,691,969</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">528,342</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average loss per share (basic and diluted)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.77</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Note:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#8211;
                                            Book value per share is calculated using the formula: total shareholders&#8217; equity from
                                            the balance sheet as of December 31, 2024 divided by shares outstanding as of December 31,
                                            2024.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>COMPARATIVE PER SHARE
MARKET PRICE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc ordinary shares
trade on Nasdaq under the symbol &#8220;SPRC&#8221; and AutoMax ordinary shares trade on the TASE under the symbol &#8220;AMX&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The table below sets forth
the closing price per SciSparc ordinary share on Nasdaq and per share of AutoMax ordinary shares on the TASE on April 10, 2024, the date
preceding public announcement of the Merger, and on July 3, 2025, the latest practicable date before the date of this prospectus, and
the equivalent price per share of AutoMax ordinary shares (as determined by multiplying the closing price per share of SciSparc ordinary
shares by the Exchange Ratio) on each such date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The table below shows
that the equivalent value of merger consideration per AutoMax ordinary share has decreased from $0.04 on April 10, 2024, to $0.034 on
July 3, 2025. This decrease is mainly due to the decrease in the share price of SciSparc ordinary shares during the same time frame.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The calculation of the
Merger consideration is based on the number of SciSparc outstanding shares (including pre-funded warrants), and the number of AutoMax
outstanding shares (excluding dormant shares and excluding AutoMax shares held by SciSparc), as of April 10, 2024 and July 3, 2025. Such
amount of SciSparc outstanding shares is divided by 0.5001 and multiplied by 0.4749. The resulting number is then divided by AutoMax
outstanding shares (excluding dormant shares and excluding AutoMax shares held by SciSparc). Such amount is then multiplied by the share
price of one SciSparc ordinary share on each applicable date, to receive the value of Merger consideration per AutoMax share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"><span style="-keep: true">Date</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc <br/> ordinary <br/> shares<br/>
    closing price per<br/> share<br/> (in $ amount)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> ordinary shares<br/>
    closing price per<br/> share <br/> (in $ amount)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Equivalent value of<br/> Merger
    consideration <br/> per<br/> AutoMax ordinary<br/> share<br/> (in $ amount)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="-keep: true">April 10, 2024</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">35.28</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.0746</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">0.04</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">July 3, 2025</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6.60</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.0494</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.034</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market prices of SciSparc
ordinary shares and AutoMax ordinary shares have fluctuated since the date of the announcement of the Merger Agreement and will continue
to fluctuate from the date of this prospectus to the date of the SciSparc general meeting and the AutoMax general meeting, and the date
the Merger is completed and thereafter. See &#8220;Risk Factors - Because the Exchange Ratio is fixed and will not be adjusted in the
event of any change in either SciSparc&#8217;s share price or AutoMax&#8217;s share price, AutoMax shareholders cannot be certain of
the precise value of the consideration that they may receive in the Merger&#8221;. We encourage you to obtain current quotes for the
SciSparc ordinary shares and AutoMax ordinary shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING
STATEMENTS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
proxy statement/prospectus and the documents incorporated by reference into this proxy statement/prospectus contain forward-looking statements.
These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could
cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions
of future events as SciSparc cannot assure you that the events or circumstances reflected in these statements will be achieved or will
occur. You can identify forward-looking statements by the use of forward-looking terminology including &#8220;believes,&#8221; &#8220;expects,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro
forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of
these words and phrases or comparable terminology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, forward-looking
statements include any statements of the plans, strategies and objectives of management for future operations, including the execution
of integration and restructuring plans and the anticipated timing of filings; any statements concerning proposed new products, services
or developments; any statements regarding future economic conditions or performance; any statements regarding the impact of the Israel-Hamas
war on its business or financial condition; statements of belief and any statement of assumptions underlying any of the foregoing. Forward
looking statements may also include any statements of the plans, strategies and objectives of management with respect to the approval
and consummation of the Merger, SciSparc&#8217;s ability to solicit a sufficient number of proxies to approve the Merger and other matters
related to the consummation of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements include, but are not limited to, statements concerning the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">likelihood
                                            of the satisfaction of certain conditions to the completion of the Merger and whether and
                                            when the Merger will be consummated;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            expected benefits of and potential value created by the proposed Merger for the shareholders
                                            of SciSparc and AutoMax;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exchange Ratio and relative ownership percentages of the SciSparc and AutoMax shareholders
                                            of the combined company;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
                                            ability to control and correctly estimate its operating expenses and its expenses associated
                                            with the Merger;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">any
                                            statements of the plans, strategies and objectives of management for future operations, including
                                            the execution of integration plans and the anticipated timing of filings</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements concerning the ability to protect and enhance the combined company&#8217;s products,
                                            product candidates and intellectual property;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements concerning proposed new products, services or developments;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements concerning the attraction and retention of highly qualified personnel;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements regarding expectations concerning AutoMax&#8217;s relationships and actions with
                                            third parties;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
                                            regulatory, judicial and legislative changes in AutoMax&#8217;s industry;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            statements regarding future economic conditions or performance;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">any
                                            statements regarding the impact of the multi-front conflict Israel faces, including Israel&#8217;s
                                            conflicts with Hamas, the effects of the hostilities with Iran, indirect effects such as
                                            the Houthi attacks in the Red Sea and the Turkish embargo, on AutoMax&#8217;s business or
                                            financial condition;;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc&#8217;s
                                            ability to achieve and maintain effective internal control over financial reporting in accordance
                                            with Section 404 of the Sarbanes-Oxley Act; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements
                                            of belief and any statement of assumptions underlying any of the foregoing.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of the factors that may cause SciSparc, AutoMax or the combined company&#8217;s actual results, performance or achievements
to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, or
for a discussion of risk associated with the ability of SciSparc and AutoMax to complete the Merger and the effect of the Merger on the
business of SciSparc, AutoMax and the combined company, see &#8220;<i>Risk Factors</i>&#8221; beginning on page 11.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in
reports filed with the SEC by SciSparc. See &#8220;<i>Where You Can Find More Information</i>&#8221; beginning on page 240.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
any of these risks or uncertainties materializes or any of these assumptions proves incorrect, the results of SciSparc, AutoMax or the
combined company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus
are current only as of the date on which the statements were made. SciSparc and AutoMax do not undertake any obligation to publicly update
any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence
of unanticipated events.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="m_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">THE
SPECIAL MEETING OF SCISPARC SHAREHOLDERS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date, Time and Place</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Special Meeting of
SciSparc shareholders will be held on&#160;August 25, 2025, commencing at&#160;3:00 p.m. local time, at the Company&#8217;s offices,
at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel. Any such change will be announced in a Report of Foreign Private Issuer
on Form 6-K furnished to the SEC. SciSparc is sending this proxy statement/prospectus to its shareholders in connection with the solicitation
of proxies by the SciSparc board of directors for use at the Special Meeting and any adjournments or postponements of the Special Meeting.
This proxy statement/prospectus is first being furnished to shareholders of SciSparc on or about&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purposes of the Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purposes of the Special
Meeting are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. To approve the consummation
of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and
the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. To approve the form of
Indemnification Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective upon
the effective time of the Merger, and to authorize the execution and delivery of such Indemnification Agreement with all office holders
of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed to the board of
directors of SciSparc;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. Subject to and contingent
upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President
contingent upon the approval and closing of the Merger; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. Subject to and contingent upon the approval of Proposal No. 1, to
elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the effective time of the Merger and to ratify
the class structure of the SciSparc board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We know of no other matters
to be submitted at the Special Meeting other than as specified herein. If any other business is properly brought before the Special Meeting,
the persons named as proxies may vote in respect thereof in accordance with their best judgment.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recommendation of the SciSparc Board of
Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors has determined and believes that the consummation of the Merger
                                            pursuant to the Merger Agreement and the issuance of SciSparc ordinary shares and pre-funded
                                            warrants at the effective time of the Merger, as contemplated by the Merger Agreement, is
                                            in the best interests of SciSparc and its shareholders and has approved such items. The SciSparc
                                            board of directors recommends that SciSparc shareholders vote &#8220;<b>FOR</b>&#8221; Proposal
                                            No. 1 to approve the consummation of the Merger, pursuant to the Merger Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors has determined and believes that it is advisable to, and in the
                                            best interests of, SciSparc and its shareholders to approve and adopt the form of Indemnification
                                            Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus,
                                            effective upon the effective time of the Merger, and to authorize the execution and delivery
                                            of such Indemnification Agreement with office holders of SciSparc to be in office immediately
                                            following the effective time of the Merger; The SciSparc board of office holders recommends
                                            that SciSparc shareholders vote <b>&#8220;FOR&#8221;</b> Proposal No. 2 to approve and adopt
                                            SciSparc&#8217;s Indemnification Agreement effective upon the effective time of the Merger.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 48px"/><td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors has determined and believes that it is advisable to, and in the
                                            best interests of, SciSparc and its shareholders to approve, subject to and contingent upon
                                            the approval of Proposal No. 1, a one-time cash bonus to SciSparc&#8217;s Chief Executive
                                            Officer, Chairman and President; The SciSparc board of directors recommends that SciSparc
                                            shareholders vote <b>&#8220;FOR&#8221; </b>Proposal No. 3 to approve a one-time cash bonus
                                            to SciSparc&#8217;s Chief Executive Officer, Chairman and President, contingent upon the
                                            approval and closing of the Merger.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The SciSparc board of directors
    has determined and believes that it is advisable to, and in the best interests of, SciSparc and its shareholders to approve, subject
    to and contingent upon the approval of Proposal No. 1, the election each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board
    of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Record Date and Voting Power</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Only holders of record
of SciSparc ordinary shares at the close of business on the record date, August 4, 2025, are entitled to notice of, and to vote at, the
Special Meeting. At the close of business on the record date, SciSparc ordinary shares were issued and outstanding. Each SciSparc ordinary
share that you own entitles the holder thereof to one vote on each matter submitted for shareholder approval. See the section entitled
&#8220;Principal Shareholders of SciSparc&#8221; in this proxy statement/prospectus for information regarding persons known to the management
of SciSparc to be the beneficial owners of more than 5% of the outstanding SciSparc ordinary shares.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Voting and Revocation of Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proxy accompanying this
proxy statement/prospectus is solicited on behalf of the board of directors of SciSparc for use at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a shareholder
of record of SciSparc as of the record date referred to above, you may vote in person at the Special Meeting or vote by proxy using the
enclosed proxy card. Whether or not you plan to attend the Special Meeting, SciSparc urges you to vote by proxy to ensure your vote is
counted. You may still attend the Special Meeting and vote in person if you have already voted by proxy. As a shareholder of record:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">to
                                            vote in person, come to the Special Meeting and SciSparc will give you a ballot when you
                                            arrive.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To
                                            vote by internet, go to www.proxyvote.com.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">to
                                            vote using the proxy card, simply mark, sign and date your proxy card and return it promptly
                                            in the postage-paid envelope provided. If you return your signed proxy card to SciSparc before
                                            the Special Meeting, SciSparc will vote your shares as you direct.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">to
                                            vote by telephone, call the toll-free telephone number 1-800-690-6903.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If
                                            your SciSparc ordinary shares are held by your broker as your nominee, that is, in &#8220;street
                                            name,&#8221; the enclosed voting instruction card is sent by the institution that holds your
                                            shares. Please follow the instructions included on that proxy card regarding how to instruct
                                            your broker to vote your SciSparc ordinary shares. If you do not give instructions to your
                                            broker, your broker can vote your SciSparc ordinary shares with respect to &#8220;discretionary&#8221;
                                            items but not with respect to &#8220;non-discretionary&#8221; items. Proposals Nos. 1, 2,
                                            3 and 4 are non-discretionary matters. As a result, banks, brokers and other nominees will
                                            not have discretion to vote on Proposals Nos. 1, 2, 3 and 4.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All properly executed proxies
that are not revoked will be voted at the Special Meeting and at any adjournments or postponements of the Special Meeting in accordance
with the instructions contained in the proxy. If a holder of SciSparc ordinary shares executes and returns a proxy and does not specify
otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; Proposal No. 1 to approve the consummation of the Merger
and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares at the effective
time of the Merger to the shareholders of AutoMax, as contemplated by the Merger Agreement; &#8220;FOR&#8221; Proposal No. 2 to approve
the form of Indemnification Agreement for directors and officers of SciSparc, attached as Annex C; &#8220;FOR&#8221; Proposal No. 3,
subject to and contingent upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&#8217;s Chief Executive Officer,
Chairman and President; and &#8220;FOR&#8221; Proposal No. 4, subject to and contingent upon the approval of Proposal No. 1, to elect
each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the effective time of the Merger and to ratify the
class structure of the SciSparc board of directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc shareholders of
record may change their vote at any time before their proxy is voted at the Special Meeting in one of three ways. First, a shareholder
of record of SciSparc can send a written notice to the Chief Executive Officer of SciSparc stating that it would like to revoke its proxy.
Second, a shareholder of record of SciSparc can submit new proxy instructions either on a new proxy card or via telephone or the Internet.
Third, a shareholder of record of SciSparc can attend the Special Meeting and vote in person. Attendance alone will not revoke a proxy.
If an owner of SciSparc ordinary shares in &#8220;street name&#8221; has instructed a broker to vote its SciSparc ordinary shares, the
shareholder must follow directions received from its broker to change those instructions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Required Vote</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The presence of two shareholders
who are present in person or by proxy, and who hold or represent at least fifteen percent (15%) of the voting rights in the Company,&#160;is
necessary to constitute a quorum at the Special Meeting. Abstentions and broker non-votes will be counted towards a quorum. If half an
hour has elapsed from the time set for the Special Meeting and a quorum is not present, the Special Meeting will be adjourned to the
following day, at the same time and place, or to a different date, as shall be determined by the board of directors in a notice to the
shareholders. If a quorum is not present at the adjourned Special Meeting, as stated above, a minimum of one shareholder, whether present
in person or by proxy, shall be deemed as constituting a quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Approval of Proposals Nos.
1 and 4, requires the affirmative vote of a simple majority of shareholders present (in person or by proxy) and voting (not including
abstentions). The approval of each of Proposals Nos. 2 and 3 requires the affirmative vote of a simple majority of votes properly cast
(not counting &#8220;abstentions&#8221; or &#8220;broker non-votes&#8221; as votes cast) plus either (i) a simple majority of shares
voted at the Special Meeting, excluding the shares of controlling shareholders, if any, and of shareholders who have a personal interest
in the approval of the resolution, or (ii) the total number of shares of non-controlling shareholders and of shareholders who do not
have a personal interest in the resolution voting against approval of the resolution does not exceed two percent of the outstanding voting
power in SciSparc.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Votes will be counted by
SciSparc, that will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Abstentions
and broker non-votes will have no effect and will not be counted towards the vote total but will be used to determine whether a quorum
is present at the Special Meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Solicitation of Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc will bear the cost
of soliciting proxies. In addition to these proxy materials, SciSparc&#8217;s directors and employees may also solicit proxies in person,
by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting
proxies. SciSparc and AutoMax may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to
beneficial owners.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement/prospectus, the SciSparc board of directors does not know of any business to be presented at the Special Meeting other than
as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Special
Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment
of the persons voting the proxies.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_007"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">THE
MERGER</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This section and the section
entitled &#8220;The Merger Agreement&#8221; in this proxy statement/prospectus describe the material aspects of the Merger, including
the Merger Agreement. Although SciSparc and AutoMax believe that this description covers the material terms of the Merger and the Merger
Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus
for a more complete understanding of the Merger and the Merger Agreement, including the Merger Agreement attached as Annex A, the form
of Voting and AutoMax Shareholder Support Agreement attached as Annex B, and the Indemnification Agreement attached as Annex C and the
other documents to which you are referred herein. See the section entitled &#8220;Where You Can Find More Information&#8221; in this
proxy statement/prospectus.</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax, entered
into the Merger Agreement, pursuant to which Merger Sub will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary
of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Merger Consideration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, ordinary shares of SciSparc, as well as pre-funded warrants exercisable into ordinary shares of SciSparc will be issued to
the AutoMax shareholders. The Exchange Ratio has been determined pursuant to a formula described in more detail in the Merger Agreement
and elsewhere in this proxy statement/prospectus. Under the Exchange Ratio, immediately following the Merger, AutoMax&#8217;s shareholders
(and its Advisor in connection with the Merger) are expected to own approximately 49.99% of SciSparc&#8217;s share capital, on a fully-diluted
basis, subject to certain exceptions, and as further defined in the Merger Agreement, and SciSparc&#8217;s shareholders are expected
to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis, subject to certain exceptions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of AutoMax Warrants, Options,
Series B Bonds, and Series C Bonds</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a result of the Merger, each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction
(in each case, whether or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled
immediately prior to the effective time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">According
                                            to the terms of AutoMax&#8217;s Series B Bonds and the Series B Bonds Trust Deed, the Series
                                            B Bonds will be due for principal repayment in four (4) unequal annual installments, which
                                            will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first
                                            payment that was made on February 28, 2023 constituted 10% of the aggregate principal amount
                                            of the Series B Bonds, the second payment, that was made on February 28, 2024, constituted
                                            15% of the aggregate principal amount of the Series B Bonds, the third payment, that was
                                            made on February 28, 2025, constituted 30% of the aggregate principal amount of the Series
                                            B Bonds, and the fourth and final payment, due on February 28, 2026, will constitute 45%
                                            of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger,
                                            the Series B Bonds will remain outstanding and subject to repayment in accordance with the
                                            terms of the Series B Bonds Trust Deed. The Series B Bonds bear interest at a rate of 5.9%
                                            per annum. As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal
                                            amount of Series B Bonds remains outstanding and will therefore become a liability of the
                                            combined company following the completion of the Merger.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On
                                            May 19, 2025, the Series C Bonds, were issued and began trading on the TASE. According to
                                            the terms of the Series C Bonds and the Series C Bonds Trust Deed, the Series C Bonds are
                                            due for repayment in four (4) unequal annual installments, which will be paid annually from
                                            December 31, 2026 until December 31, 2029, such that the first payment will constitute 5%
                                            of the principal, the second and third payments will constitute 10% each of the principal,
                                            and the fourth payment will constitute 75% of the principal. The Series C Bonds bear fixed
                                            annual interest at a rate of 8% per annum. The interest will be paid on each June 30 and
                                            December 31, from 2026 to 2029. As of July 3, 2025, NIS 74,353 thousand, approximately ($20,260
                                            thousand) in principal amount of Series C Bonds remains outstanding and will therefore become
                                            a liability of the combined company following the completion of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Background of the Merger</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The merging companies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white"><b><i>SciSparc</i></b>.
SciSparc is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies
and assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following development programs based
on &#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptors, or CBR, agonists:
SCI-110 for the treatment of Tourette syndrome, or TS, for the treatment of obstructive sleep apnea, or OSA, and for the treatment of
Alzheimer&#8217;s disease and agitation; and SCI-210 for the treatment of Autism Spectrum Disorder, or ASD, and Status Epilepticus, or
SE. SciSparc also has a majority-owned subsidiary whose business focuses on the sale of hemp seeds oil-based products and others on Amazon
Marketplace.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc was incorporated
under the laws of the State of Israel on August 23, 2004. SciSparc&#8217;s ordinary shares are listed on the Nasdaq Capital Market under
the symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>AutoMax</i></b>. AutoMax
is a company in the field of importing and marketing a variety of vehicles for personal use (including trade-in), this includes an array
of vehicle sizes such as: small; family sized; crossover, sedans, SUVs, as well as luxury vehicles and buses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initially AutoMax, under
its then corporate name Matomy Media Group Ltd., and its subsidiaries provided a variety of programmatic data-driven platforms, which
focused on two main activities of domain monetization and mobile digital advertising. These services were mainly for U.S. and Europe
based advertising agencies, app developers and domain owners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2018, AutoMax
completed a public offering of series A convertible loans, in the aggregate amount of NIS 103 million (approximately $24.5 million).
Beginning in the second half of 2017 through December 2019, AutoMax sold all its activities related to digital marketing. On January
8, 2020, following a unanimous approval of the bondholders, AutoMax repaid the full debt, approximately NIS 101 million (approximately
$27.9 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 35.9pt">On November 9,
2020, AutoMax entered into a share exchange agreement with Global AutoMax and the Advisor, or the Share Exchange Agreement. Upon the
closing, on March 24, 2021, AutoMax issued to the shareholders of Global AutoMax 120,279,312 ordinary shares representing, upon issuance,
approximately 52.53% of the issued and outstanding shares of AutoMax, with additional issuances subject to fulfilling certain milestones,
as detailed in the Share Exchange Agreement. In exchange, Global AutoMax shareholders transferred all their shares to AutoMax. On March
28, 2023, following the successful completion of such milestones, AutoMax issued an additional 168,105,258 ordinary shares to its controlling
shareholders, which constituted approximately 41% of its issued and outstanding share capital following the issuance. Following the closing
of the Share Exchange Agreement, Global AutoMax became a wholly owned subsidiary of AutoMax. In addition, some of the key officers in
Global AutoMax, who were appointed as officers in AutoMax, were issued options to purchase up to 11,851,420 ordinary shares of AutoMax
(adjusted to reflect the 5 to 1 reverse share split), subject to the terms of the company employee share incentive plan. On March 23,
2025, the said options expired. As of the date of this proxy statement/prospectus, the controlling shareholders of AutoMax collectively
hold approximately 69.45% of AutoMax's issued and outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">On
                                            June 19, 2022, AutoMax entered into a joint venture agreement, or the Agreement, with Dalhom
                                            Motors Ltd., or Dalhom, pursuant to which, AutoMax and Dalhom formed a jointly-owned subsidiary,
                                            Dalhom AutoMax, a special purpose company established for the purpose of importing and marketing
                                            of Temsa Skoda Sabanc&amp;inodot; Ula&amp;scedil;&amp;inodot;m Ara&#231;lar&amp;inodot;
                                            A.&amp;Scedil; or Temsa, buses in Israel. In addition, prior to the closing, Dalhom AutoMax
                                            entered into a franchise agreement with Temsa for a period of three years, pursuant to which
                                            Dalhom AutoMax will serve as a direct importer of Temsa buses in Israel. Furthermore, Dalhom
                                            AutoMax entered into a service and warranty agreement for a term of three years, pursuant
                                            to which it will provide maintenance and warranty services for Temsa buses, as agreed upon
                                            in the agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1pt; text-align: justify; text-indent: 0.5in">In November 2024,
AutoMax Direct Import finalized entering into agreements with JAC, a manufacturer of private and commercial vehicles, for the direct
import, distribution and service of vehicles and spare parts manufactured by JAC in Israel, or the JAC Agreements. On December 27, 2024,
AutoMax Direct Import received its first shipment of vehicles manufactured by JAC, following regulatory approvals for direct importation.
According to the JAC Agreements, AutoMax Direct Import serves as a direct importer of JAC brand in Israel, and the JAC will provide AutoMax
Direct Import with vehicles and spare parts for the vehicles for marketing and sale in Israel, in accordance with annual business plans
as agreed between the parties. The JAC Agreement includes, among others, customary provisions regarding warranty for the vehicles by
JAC, the supply of spare parts, the duty to notify about malfunctions (recalls) and compliance with other requirements required by law.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax Direct
Import will adapt its existing showrooms for the purpose of selling JAC vehicles in the standards agreed in the agreement. The JAC Agreements
are for a period of three years, subject to AutoMax Direct Import&#8217;s compliance with sales and service network expansion goals determined
in the agreements, and will enter into force only when the appropriate European regulatory approvals are received for JAC vehicles. In
addition, JAC is entitled to terminate the agreement upon the occurrence of certain events provided in the JAC Agreements, as is customary
in such agreements, such as: (a) if AutoMax Direct Import substantially violates its obligations under the JAC Agreements or encounters
special circumstances that give justifiable reasons for early termination (including AutoMax Direct Import&#8217;s failure to meet its
sales goals, service network expansion goals or market share goals); (b) in the event of change of control in AutoMax Direct Import;
and (c) in the event of bankruptcy, moratorium, receivership, liquidation, or any other similar circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1pt; text-align: justify; text-indent: 0.5in">On May 8, 2025,
AutoMax received the preliminary approval of JAC to franchise trucks and heavy vehicles manufactured by JAC, by a joint company owned
by AutoMax and Automotive Equipment. On May 8, 2025 AutoMax and Automotive Equipment entered into the Automotive Equipment Founders&#8217;
Agreement. For further details on the Automotive Equipment Founders&#8217; Agreement, please see page 74.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in"><span style="font-weight: normal">On
March 13, 2023, Dalhom AutoMax entered into a direct import agreement with Al Damani New Motor Vehicles Trading LLC, a United Arab Emirates
manufacturer, to import, distribute, sale and market fully electric Al Damani vehicles in Israel. Dalhom AutoMax&#8217;s obligations
under such direct importer agreement are conditional on receiving the required regulatory approvals from the Ministry of Transportation
for the import of vehicles manufacturer by Al Damani to Israel, which have not yet been granted as of the date of this proxy statement/prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">As of the date
of this proxy statement/prospectus, AutoMax engages in importing and marketing of vehicles in Israel (including trade-in). Within this
segment, the AutoMax engages in direct and parallel&#160;import of private vehicles and their marketing in Israel, and through joint
ventures, in the direct import buses to Israel of buses manufactured by Temsa, as well as in the purchase and sale of used vehicles (trade-in).
AutoMax holds direct and parallel&#160;importer licenses from the Ministry of Transportation, as defined in the Vehicle Services Licensing
Law, for 37 vehicle brands of various models. As of the date of this proxy statement/prospectus, AutoMax operates through nine sales
branches located in Haifa, Afula, Netanya, Ra'anana, Rishon LeZion, Ashdod, Jerusalem, Beer Sheva (which reopened) and Hedera. It additionally
operates a storage system and a system for preparing vehicles for sale. AutoMax has an international network of suppliers and manufacturers,
located in Europe and North America and China, that supply it with vehicles of different brands and models, tailored to order. AutoMax
further has an import system that consists of procurement, transportation and handling the procedure for releasing vehicles from customs,
as well as vehicle storage facilities in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0.5in; text-align: justify">AutoMax is authorized
by the Ministry of Transportation, to perform licensing inspections for the purpose of the initial registration of vehicles imported
by it. Additionally, AutoMax has been authorized by the Ministry of Transportation to import spare parts and to carry out various forms
of installations that involve changing the vehicle structure (such as installing towing hooks).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">AutoMax was formed
under the laws of the state of Israel in February 2006, as a private company, under the name Cubeeffect Ltd. In November 2009, Cubeeffect
Ltd. changed its name to Adsmarket G.M. Ltd, and in July 2011 changed to Matomy Media Group Ltd. On April 18, 2021, the company changed
its name to AutoMax Motors Ltd. AutoMax&#8217;s ordinary shares were initially listed on the London Stock Exchange in July 2014 and in
February 2016 on the TASE. From November 2020 onwards, AutoMax ordinary shares have been traded solely on TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>SciSparc&#8217;s Historical Background of the Merger </i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors and
senior management of SciSparc regularly review SciSparc&#8217;s operations, financial performance and industry conditions as they may
affect SciSparc&#8217;s strategic goals and plans, both near and long term, and consider and evaluate options for enhancing shareholder
value as an independent company (including reviewing options for raising funds) and alternatives for business combination transactions
to enhance shareholder value. As such, on June 9, 2022, following SciSparc&#8217;s board of directors meeting on May 25, 2022, SciSparc
first announced that its board of directors resolved to initiate a&#160;process to review potential strategic transactions with the goal
of maximizing shareholder value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following chronology
sets forth a summary of the material events leading up to the execution of the Merger Agreement. This chronology does not purport to
catalogue every conversation of or among the SciSparc board of directors, its committees, its representatives or other parties.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 14, 2022, as part of its efforts to expand and increase its potential market, SciSparc entered into the Wellution Acquisition
Agreement with M.R.M., and the other parties named therein, to acquire from M.R.M. its rights to purchase, the Wellution&#8482; brand,
or the Brand. In connection therewith, SciSparc incorporated a new wholly owned subsidiary,&#160;SciSparc Nutraceuticals, to hold the
new assets of the Brand. The Brand sells hemp-based products, on Amazon Marketplace. In accordance with the closing of the Wellution
Acquisition Agreement for the Brand which took place on September 30, 2022, SciSparc paid $4.59 million for the Brand and issued to M.R.M.
$15 million worth of warrants to purchase up to an aggregate amount of 82,418 of SciSparc&#8217;s ordinary shares, or the M.R.M. Warrants.
On March 26, 2024, M.R.M. agreed with us to waive all its rights under the M.R.M. Warrants and have the M.R.M. warrants cancelled for
no consideration. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 23, 2023, SciSparc&#8217;s
board of directors held a meeting in which they discussed the possibility of a corporate restructuring plan, or the Restructuring Initiative,
which would include the following steps: (i) the sale of approximately 50% of the shares held by SciSparc in SciSparc Nutraceuticals,
its then wholly owned subsidiary, to Jeffs&#8217; Brands Ltd., or Jeffs&#8217; Brands, as part of a secondary sale; (ii) the transfer
of the pharmaceutical activities and remaining stake in SciSparc Nutraceuticals, to a new wholly-owned subsidiary, which would potentially
merge with a NewCo or a Canadian-traded shell company; and (iii) the usage of the proceeds from the potential secondary sale to Jeffs&#8217;
Brands and the proceeds from future capital raises for an investment in purchasing a controlling interest in a profitable target company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, SciSparc
announced that its board of directors resolved to pursue the Restructuring Plan, the second step of the Restructuring Initiative, which
involves transferring its pharmaceutical activities to a NewCo. SciSparc also announced that it intends to explore other potential new
opportunities, activities and investments in a variety of sectors. Other than the Merger and the entry into the Spin-off LOI and the
amendments thereof, SciSparc has thus far not initiated further steps relating to the Restructuring Plan.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 23, 2023, SciSparc
entered into a stock purchase agreement, as amended on March 22, 2023, with Jeffs&#8217; Brands Holdings Inc., a wholly owned subsidiary
of Jeffs&#8217; Brands, and Jeffs&#8217; Brands, pursuant to which Jeffs&#8217; Brands Holdings Inc. acquired from SciSparc 57 shares
of common stock of SciSparc Nutraceuticals Inc., which owns Wellution<sup>TM</sup>, subject to the holdback by SciSparc of 11 shares,
representing approximately 49% of the issued and outstanding shares of common stock of SciSparc Nutraceuticals Inc., for approximately
$3.0 million in cash, of which approximately $2.5 million was paid at the closing. Following the closing of the Wellution Sale Agreement
on March 28, 2023, SciSparc completed the first step of the Restructuring Initiative. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the third step
of the Restructuring Initiative, on February 23, 2023, SciSparc&#8217;s board of directors held a meeting in which Mr.&#160;Yaki Baranes,
a business analyst, presented a market overview on the motor vehicle market in Israel, including market trends on private vehicles and
public transportation segments, and market status of electric vehicles. The market overview data was taken from various market research
reports publicly available. At the meeting, Mr.&#160;Baranes also presented a company overview of AutoMax (and solely AutoMax) as a vehicle
importer in Israel, which was solely based on available public information, and information received from AutoMax. The company overview
included AutoMax&#8217;s strategy in various sectors, including parallel import of personal-use vehicles, buses, and electric vehicles
as published by AutoMax. The market overview also included AutoMax&#8217;s competition in Israel, which includes direct and parallel
vehicle importers. SciSparc&#8217;s board of directors had the opportunity to ask Mr. Baranes questions regarding the data presented
on the automative industry and about AutoMax. The market and company overview presentation was intended to inform SciSparc&#8217;s board
of directors on the presented subjects, and did not include any recommendations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 30, 2023, SciSparc
announced that, as part of its Restructuring Initiative, it had appointed Mr. Baranes to be its VP Strategy and Business Development,
with a view to structuring business strategies and facilitating the identifying of new business opportunities. Mr. Baranes previously
provided services to AutoMax, which included market overviews of companies AutoMax was interested in collaborating with and the preparation
of investor presentations. Other than Mr. Baranes and Mr. Weiss both serving as members of the board of Charging Robotics Inc. and Mr.
Baranes providing a market overview services to certain other companies Mr. Amitay Weiss serves as a director of, there is no other connection
between Mr. Baranes and Mr. Weiss. AutoMax was first introduced to SciSparc by AutoMax&#8217;s Advisor after the board of directors announced
its Restructuring Initiative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2023, SciSparc&#8217;s
board of directors held a meeting in which it approved an investment in the aggregate amount of NIS 4 million (approximately $1.1 million)
in AutoMax. Mr. Weiss recused himself from the decision and did not participate in the discussion or voting on the matter, due to his
personal interest by virtue of serving as the Chairman of the board of directors of both SciSparc and AutoMax. The board of directors&#8217;
approval of the investment was following the recommendation of the audit committee, according to the Companies Law, due to Mr. Weiss&#8217;
personal interest in the matter. The audit committee convened on June 22, 2023, prior to the meeting of the board of directors. At its
meeting, at which AutoMax&#8217;s Advisor participated by invitation, the audit committee was presented with the terms and conditions
of the investment in AutoMax. The audit committee considered and reviewed the terms and conditions of the investment and believed that
it would be a good investment opportunity for SciSparc and a way to commence relations with AutoMax gradually. Accordingly, the audit
committee resolved that the investment in AutoMax of NIS 4 million is not deemed to be an &#8220;Extraordinary Transaction&#8221; under
the Companies Law and that it is the best interest of the SciSparc to enter into the transaction, thus recommending that the board of
directors approve. SciSparc entered into a joinder to an investment agreement with AutoMax on June 25, 2023, for an amount of NIS 2.5
million (approximately $692,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the months of June
and November 2023, Tomer Levy, VP Business Development and Headquarters of AutoMax, met with Oz Adler, Chief Executive Officer and Chief
Financial Officer of SciSparc to negotiate and discuss a potential transaction structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 30, 2023, Mr. Adler
shared with Mr. Levy an initial draft letter of intent. The draft set forth the structure of the proposed transaction, which included
a reverse triangular merger between a newly incorporated subsidiary of SciSparc and AutoMax, with AutoMax as the surviving company and
a wholly owned subsidiary of SciSparc. As a result of this proposed merger, the outstanding share capital of AutoMax would be converted
into the right to receive SciSparc ordinary shares, subject to a 9.99% ownership blocker (in which case, pre-funded warrants would be
issued in lieu), according to an exchange ratio to be determined in the definitive agreements. The ownership percentage of the pre-merger
AutoMax shareholders&#8217; and SciSparc shareholders&#8217; holdings in SciSparc post-merger were not determined in this draft. The
draft further set forth that the board of directors of SciSparc post-merger would consist of the current composition of SciSparc&#8217;s
board of directors in addition to two members designated by AutoMax. In addition to the proposed merger, the draft letter of intent also
discussed the potential spin off of SciSparc&#8217;s pharmaceutical assets to a separate legal entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 27, 2023, SciSparc&#8217;s
board of directors held a discussion with respect to the merger opportunity with AutoMax and was presented with the updated draft letter
of intent, which was received from AutoMax. This draft provided for, in addition to the previous draft, the transfer of a to be determined
amount to AutoMax upon the closing of the proposed merger and for the composition of the board of directors of SciSparc post-merger to
be agreed later in the definitive agreements. Prior to the board&#8217;s discussion and review of the letter of intent and proposed transaction,
they were informed of Mr. Weiss&#8217; personal interest in the matter, due to his service as the chairman of the board of directors
of both SciSparc and AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax continued
to negotiate the terms of the proposed transaction and on October 20, 2023, SciSparc&#8217;s counsel provided AutoMax&#8217;s counsel
with a revised draft letter of intent. The revised letter of intent provided that following the closing of the proposed merger and the
contemplated closing of a concurrent financing round, AutoMax&#8217;s pre-merger shareholders will hold approximately 80% of SciSparc&#8217;s
share capital. The revised letter of intent also included a milestone payment to AutoMax&#8217;s pre-merger shareholders of an additional
7% of SciSparc&#8217;s share capital as of immediately following the proposed merger, in the event that AutoMax secures a direct import
license pursuant to which it sells at least 100 vehicles prior to a certain end date to be determined. This draft of letter of intent
determined the amount of cash for SciSparc to transfer to AutoMax at the closing, to be $3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties continued to
negotiate the offer terms with regards to the milestone payment, with AutoMax requesting that the milestone payment be in the form of
pre-funded warrants to be issued upon the closing and exercisable in the event of the achievement of the milestone within 36 months from
the closing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 25, 2023, SciSparc&#8217;s
counsel shared an updated draft of the letter of intent, with the end date for the achievement of the milestone to be 36 months from
the closing date, to be paid in the form of ordinary shares upon such event. The parties continued to share drafts of the letter of intent,
including negotiations regarding certain non-material terms of the proposed merger, including certain tax implications and the treatment
of existing options and warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 31, 2023, the
SciSparc board of directors held a meeting to discuss the latest terms of the letter of intent. All of the then serving members of the
SciSparc board of directors were present at this meeting. The board of directors discussed the interests of SciSparc and its shareholders
in the proposed merger. The board of directors believed that the proposed merger would create the most value for SciSparc&#8217;s shareholders,
enable SciSparc to expand its activity in non-pharmaceutical spaces, and provide cash-flow positive operations to SciSparc in order to,
among other things, fund SciSparc&#8217;s pharmaceutical operations, and that SciSparc&#8217;s current cash position was sufficient to
execute the proposed merger. Therefore, the board of directors approved the execution of the letter of intent. The approval of the board
of directors followed the approval and recommendation of the audit committee, in accordance with the Companies Law, due to the personal
interest of Mr. Weiss. Mr. Weiss did not participate in the discussion or voting on the matter at the meetings of the audit committee
and the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the letter of
intent presented to the board of directors included: (i) a reverse triangular merger between a newly incorporated subsidiary of SciSparc
and AutoMax, with AutoMax as the surviving company and a wholly owned subsidiary of SciSparc; (ii) the conversion of the outstanding
share capital of AutoMax into the right to receive SciSparc ordinary shares (subject to a 9.99% ownership blocker) (iii) the equity split
of SciSparc post-merger to be 80% for AutoMax&#8217;s current shareholders and 20% for SciSparc&#8217;s current shareholders; (iv) a
milestone payment to AutoMax&#8217;s pre-merger shareholders of an additional 7% of SciSparc&#8217;s share capital as of immediately
following the proposed merger in the event that AutoMax secures a direct import license pursuant to which it sells at least 100 vehicles
within 36 months from the closing; (v) a cash transfer of $3 million by SciSparc to AutoMax at the closing of the merger; (vi) a contemplated
closing of a concurrent financing with the merger (which terms were not discussed in the letter of intent); (vii) a contemplated transfer
of SciSparc&#8217;s pharmaceutical activities, to a separate legal entity with the possible distribution of the legal entity&#8217;s
shares as a dividend in kind to SciSparc&#8217;s shareholders; and (viii) that the board of directors of the combined company post-merger
would be determined in the definitive agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 10, 2023, SciSparc&#8217;s
legal counsel distributed an initial draft of the Merger Agreement to AutoMax and its counsel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2023, SciSparc
signed the non-binding letter of intent with AutoMax, substantially as presented to the board of directors on October 31, 2023 and issued
a press release on a no-name basis announcing the event.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 7, 2023, following
comments received from AutoMax&#8217;s legal counsel and negotiations between Mr. Oz Adler and Mr. Tomer Levy, SciSparc&#8217;s legal
counsel distributed a revised draft of the Merger Agreement to AutoMax&#8217;s legal counsel. This draft, among other things, deleted
references to a separate capital raise by SciSparc concurrent with the closing of the Merger and deleted references to a transfer of
SciSparc&#8217;s pharmaceutical activities to a separate legal entity. The draft also removed the provisions relating to milestone payments
and changed the formula of the Exchange Ratio to such ratio that would result in AutoMax&#8217;s shareholders (other than SciSparc, who
currently holds shares in AutoMax) and its Advisor to own approximately 49.99% of SciSparc&#8217;s share capital as of immediately following
the Merger. On December 7, 2023, SciSparc issued a press release announcing these updated negotiated terms of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2023, SciSparc&#8217;s
board and audit committee held discussions in relation to the AutoMax Merger and a potential financing by SciSparc to AutoMax. At the
meeting of the audit committee, which was held prior to the meeting of the board of directors, the committee discussed the approval of
the Bridge Loan with AutoMax. Mr. Weiss, who participated at the meeting by invitation, recused himself from the discussions and voting
on the matter. Mr. Adler explained that the amounts provided by SciSparc under the Bridge Loan would be set-off against the financing
amount the Company is to provide AutoMax pursuant to the terms of the Merger Agreement, upon the closing of the Merger. The audit committee
considered the reasons for assuming the Bridge Loan and believed that the Bridge Loan would provide working capital to AutoMax to continue
its business and increase its share value, hence increasing the value to SciSparc shareholders from the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 16, 2024, SciSparc&#8217;s
audit committee and board of directors convened to discuss the negotiated terms of the Bridge Loan. Due to the personal interest of Mr.
Weiss in the matter, and according to the Companies Law, the audit committee examined the transaction contemplated under the Bridge Loan
and determined to classify the transaction as &#8220;Extraordinary Transaction&#8221; under the Companies Law. Accordingly, the audit
committee determined that it is in the best interest of SciSparc to assume the Bridge Loan, and thereafter approved and recommended to
the board of directors to approve the assumption and performance by SciSparc of the Bridge Loan. SciSparc&#8217;s board of directors
convened subsequently thereafter to discuss the matter and approved the Bridge Loan following the recommendation of the audit committee.
Mr. Weiss recused himself from the discussion and voting on this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, SciSparc
entered into the Bridge Loan with AutoMax in the aggregate amount of $1.4 million, with an interest rate of 7% per annum (or 9% per annum
if the Acquisition, as defined in the Bridge Loan, is not consummated prior to the repayment date), compounded annually. The Bridge Loan
was amended on June 9, 2024, in which SciSparc made available to AutoMax an additional loan in the amount of $1.0 million under similar
terms. The Second Amendment was entered into on September 5, 2024, in which SciSparc extended an additional loan in the amount of $1.85
million to AutoMax under similar terms as those of the Bridge Loan. The amendments to the Bridge Loan were duly approved on June 9, 2024
and on September 4, 2024, by the audit committee and board of directors of SciSparc, respectively. Mr. Weiss did not participate in the
voting or discussions on the matter. In the month of September 2024, SciSparc provided AutoMax with the loan amounts due under the Second
Amendment to the Bridge Loan, and offset any interest due until November 30, 2024 from the principal amount, such that on the closing
date of the Merger, SciSparc will be due interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated), of the
Loan Amount, from the period starting December 1, 2024 and ending on the effective date of the Merger. In consideration for the Loan
Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax
Direct Import in favor of SciSparc. On May 8, 2025, SciSparc entered into the Third Amendment, pursuant to which, in addition to the
already existing subordination of the Loan Amount to AutoMax&#8217;s Series B Bonds, the Loan Amount will also be subordinated to AutoMax&#8217;s
Series C Bonds, issued and traded on the TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between December 7, 2023
and March 26, 2024, SciSparc&#8217;s legal counsel and AutoMax&#8217;s legal counsel continued to exchange drafts of the Merger Agreement.
In the exchanged drafts, the parties discussed, among other issues, the following: (i) the procedure for the tax withholding ruling;
(ii) whether the issuance of pre-funded warrants would be required (due to the question if any AutoMax shareholder will hold more than
9.99% of SciSparc&#8217;s share capital immediately following the Merger); (iii) the procedure of the distribution of SciSparc ordinary
shares to AutoMax shareholders; (iv) the scope of the representations to be provided by each company; (v) the composition of the board
of directors of the combined company; and (vi) the amount of cash to be transferred by SciSparc to AutoMax at the closing of the Merger
(which would be $4,250,000, less any amount due by the Company due to the Parent Company under the Bridge Loan).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 28, 2024, and March
31, 2024, during SciSparc&#8217;s audit committee and board of directors meetings, AutoMax&#8217;s VP Business Development and Headquarters,
presented AutoMax&#8217;s business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2024, SciSparc&#8217;s
board of directors held a meeting in which the Company&#8217;s legal counsel, a representative of E.D.B., and representatives of the
management, were present. At the meeting, SciSparc&#8217;s counsel presented a detailed summary of the key provisions of the transaction
documents and reviewed the fiduciary duties of directors in connection with the proposed transaction. At this meeting, a representative
of E.D.B. discussed their valuation report of AutoMax, and then delivered to SciSparc&#8217;s board of directors its valuation report.
The SciSparc board of directors engaged E.D.B. to provide the valuation report in order to ascertain the value of AutoMax and in order
to evaluate the financial feasibility of the transaction. The valuation report, and the value ascribed to AutoMax by E.D.B. revealed
that the terms of the transaction contemplated under the Merger Agreement were favorable to SciSparc at the time of the March 31, 2024
meeting, based on the per-share consideration if the Merger was consummated on such date. If the Merger had been consummated at the time
of presentation of the E.D.B valuation report, then SciSparc would have paid approximately $4.37 million in SciSparc ordinary shares,
for a company valued $44.8 million, based on the Exchange Ratio, with 2,468,876 SciSparc shares outstanding, 103,691,969 (excluding dormant
shares) AutoMax shares outstanding, and SciSparc&#8217;s share price of $1.77, as of March 31, 2024. The valuation report was primarily
used as a data point, as part of the legal, financial and business due diligence, to evaluate whether the Merger was favorable to SciSparc&#8217;s
shareholders. After such discussion, the board of directors unanimously determined that it was advisable and fair to, and in the best
interests of SciSparc and SciSparc&#8217;s shareholders, for SciSparc to enter into the Merger Agreement, and, accordingly, the board
of directors approved the Merger Agreement and the transactions contemplated thereby. The approval of the board of directors followed
the approval and recommendation of the audit committee, in accordance with the Companies Law, due to the personal interest of Mr. Weiss.
Mr. Weiss did not participate in the discussion or voting on the matter at the meetings of the audit committee and the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>AutoMax&#8217;s historical
background for the Merger	</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the course of 2023,
AutoMax&#8217;s management assessed several potential funding and transactional opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax and SciSparc signed
a confidential disclosure agreement in November 2023, and various representatives of each party&#8217;s management, financial, legal
and scientific teams were given access to the other party&#8217;s data room in the following days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 30, 2023, SciSparc
sent AutoMax a draft of a non-binding letter of intent. AutoMax provided detailed, written comments to the draft on September 13, 2023,
and several weeks of negotiations ensued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 19 and October
23, 2023, the AutoMax&#8217;s board convened, and AutoMax&#8217;s VP Business Development and Headquarters provided an overview of the
letter of intent as sent to SciSparc and as negotiated with SciSparc. The AutoMax board considered the proposed terms, and a consensus
emerged among the board members in favor of the proposed non-binding letter of intent with SciSparc. Consequently, the board resolved
to approve the letter of intent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax
executed the non-binding letter of intent on November 21, 2023. On November 10, 2023, SciSparc provided an initial draft of the Merger
Agreement to AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In parallel to the negotiation
of the merger agreement, each of the parties conducted financial and legal due diligence. Moreover, throughout December 2023 to April
2024, each of SciSparc&#8217;s and AutoMax&#8217;s management and other employees, as well as external advisors, conducted due diligence
on the other party through access to confidential data rooms, phone calls, review of legal, financial and other diligence materials,
diligence inquiries and follow-ups and assessments of the competitive landscape.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2024, AutoMax&#8217;s
board held a meeting in which the company&#8217;s legal counsel, Lipa Meir &amp; Co., Advocated, or Lipa Meir, was present. At the meeting,
Tomer Levy, AutoMax&#8217;s VP Business Development and Headquarters and director, and Lipa Meir presented a detailed summary of the
key provisions of the transaction documents and reviewed the fiduciary duties of directors in connection with the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax conducted
final negotiations on remaining outstanding issues over the course of March and early April, 2024, including the disclosure schedule,
the AutoMax Shareholder Support Agreement and other ancillary agreements to which shareholders are a party, and the various agreements
were substantially finalized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2024, AutoMax&#8217;s
audit committee and board of directors held meetings in which the company&#8217;s legal counsel was present. At the meeting, Tomer Levy,
AutoMax&#8217;s VP Business Development and Headquarters and director, and Lipa Meir, presented a detailed summary of the key provisions
of the transaction documents, and Ziv Haft Certified Public Accountants, an Israeli partnership, is a member of BDO International Limited,
or BDO Consulting, AutoMax&#8217;s financial advisors presented a financial analysis of SciSparc. After a comprehensive discussion, AutoMax&#8217;s
audit committee and board of directors unanimously resolved entering into the Merger Agreement, and authorized and empowered Yaarah Alfi,
AutoMax&#8217;s Chief Financial Officer, and Tomer Levy, VP Business Development and Headquarters and director, to execute and deliver
all transaction documents of behalf of AutoMax. The Merger Agreement was subsequently executed on April 10, 2024.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>SciSparc&#8217;s reasons for the Merger</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
considered the following factors, among others, in reaching its conclusion to approve and adopt the Merger Agreement, the Merger, the
issuance of SciSparc ordinary shares in the Merger and the other transactions contemplated thereby and to recommend that the SciSparc
shareholders approve the Merger Agreement, the Merger, the issuance of SciSparc ordinary shares in the Merger and the other transactions
contemplated by the Merger Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As
                                            part of its reorganization strategy, the SciSparc board of directors and its advisors and
                                            valuator have undertaken a process of reviewing and analyzing potential Merger transaction
                                            candidates to identify the opportunity that would, in the SciSparc board of directors&#8217;
                                            opinion, create the most value for SciSparc&#8217;s shareholders, enable SciSparc to expand
                                            its activity in non-pharma spaces, and provide cash-flow positive operations to SciSparc
                                            in order to, among other things, fund SciSparc&#8217;s pharma operations. SciSparc believes
                                            that expanding its activities outside of the pharmaceutical world will provide maximum shareholder
                                            value. Following the Merger, SciSparc will continue to search for ways to maximize shareholder
                                            value, both within and outside of the pharmaceutical sector. SciSparc may opt to sell certain
                                            pharmaceutical assets, or participate in a spin-off, which may include its advanced clinical
                                            stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals Inc.</td></tr></table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors believes that, as a result of arm&#8217;s length negotiations
                                            with AutoMax, SciSparc and its representatives negotiated the most favorable exchange ratio
                                            for SciSparc that AutoMax was willing to agree to, and that the terms of the Merger Agreement
                                            include the most favorable terms to SciSparc in the aggregate to which AutoMax was willing
                                            to agree.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors believes, after a thorough review of strategic alternatives and
                                            discussions with SciSparc&#8217;s senior management, financial advisor and legal counsel,
                                            that the Merger is more favorable to the shareholders of SciSparc than the potential value
                                            that might have resulted from other strategic options that may have been available to SciSparc,
                                            including remaining a standalone public company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors believes, based in part on its financial, legal and commercial
                                            diligence and analysis of AutoMax&#8217;s operations, the potential market opportunity for
                                            its importation and leasing services, which was conducted over several weeks by SciSparc&#8217;s
                                            management and external consultants, and reviewed with the SciSparc board of directors, that
                                            AutoMax&#8217;s operations represent a sizeable potential market opportunity, and may thereby
                                            create value for the shareholders of the combined company and an opportunity for SciSparc&#8217;s
                                            shareholders to participate in the potential growth of the combined company. Following the
                                            Merger, each entity will continue its respective operations, with SciSparc as the parent
                                            company and AutoMax a wholly owned subsidiary.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors&#8217; consideration of the fact that while in the short term
                                            its market capitalization had responded favorably to positive announcements, SciSparc was
                                            not able to maintain this positive market capitalization in the long term.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors concluded that the Merger would provide the existing SciSparc
                                            shareholders a significant opportunity to participate in the potential growth of the combined
                                            company following the Merger given the potential ability of AutoMax to monetize its operations
                                            and contemplated strategies more quickly.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            SciSparc board of directors also considered that the combined company will be led by an experienced
                                            senior management team, including Daniel Levy, AutoMax&#8217;s chief executive officer and
                                            Tomer Levy, VP Business Development and Headquarters of AutoMax, both of whom will remain
                                            in their respective current positions.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The
                                            SciSparc board of directors considered the valuation report prepared by an independent valuator
                                            whose valuation report was delivered to the SciSparc board of directors (in its capacity
                                            as such) by a representative of E.D.B. on March 31, 2024, and based on AutoMax&#8217;s management&#8217;s
                                            estimates and assumptions as provided to E.D.B., as more fully described below in the section
                                            entitled &#8220;&#8212;<i>Valuation Report of E.D.B. Consulting and Investments Ltd.</i>&#8221;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
also reviewed the recent financial condition, results of operations and financial condition of SciSparc, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risks associated with continuing to operate SciSparc on a stand-alone basis, including liquidity
                                            needs and cash-burn relating to, among other things, funding SciSparc&#8217;s contemplated
                                            clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            consequences of current market conditions, what SciSparc believes is a low valuation of its
                                            share price, compared to its deemed peer group, continuing net operating losses, and the
                                            likelihood that the resulting circumstances for SciSparc, on a stand-alone basis, would not
                                            change for the benefit of the SciSparc shareholders in the foreseeable future;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            management&#8217;s belief that it would be difficult to obtain sufficient equity or debt
                                            financing on acceptable terms, if at all;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            results of substantial efforts made over a significant period of time by SciSparc&#8217;s
                                            senior management and financial advisor to solicit strategic alternatives for SciSparc to
                                            the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            projected liquidation value of SciSparc and the risks, costs and timing associated with liquidating
                                            compared to the value SciSparc shareholders will receive in the Merger; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            board of directors believes that the combined entity will have a more favorable positioning
                                            and positive listing on The Nasdaq Capital Market than SciSparc as a standalone company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
also reviewed the terms of the Merger and associated transactions, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exchange Ratio, which establishes the ratio of SciSparc ordinary shares and pre-funded warrants to be issued to AutoMax shareholders
    in the Merger, and sets forth, the relative percentage ownership of SciSparc shareholders and AutoMax shareholders immediately following
    the completion of the Merger is similarly fixed;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            limited number and nature of the conditions to AutoMax&#8217;s obligation to consummate the
                                            Merger and the limited risk of non-satisfaction of such conditions as well as the likelihood
                                            that the Merger will be consummated on a timely basis;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            respective rights of, and limitations on, SciSparc and AutoMax under the Merger Agreement
                                            to consider certain unsolicited acquisition proposals under certain circumstances should
                                            SciSparc or AutoMax receive a superior offer;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            AutoMax Shareholder Support Agreement, pursuant to which officers, directors and certain
                                            shareholders of AutoMax agreed, solely in their capacity as shareholders, to vote shares
                                            of their AutoMax capital stock covering approximately 55.65% of the outstanding shares of
                                            AutoMax in favor of adoption of the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            fact that AutoMax would file a request for court approval for the Merger under sections 250
                                            and 351 of the Companies Law; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            belief that the terms of the Merger Agreement, including the parties&#8217; representations,
                                            warranties and covenants, and the conditions to their respective obligations, are reasonable
                                            under the circumstances.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the course of its deliberations,
the SciSparc board of directors also considered a variety of risks and other countervailing factors related to entering into the Merger,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            substantial expenses to be incurred in connection with the Merger, including the costs associated
                                            with any related litigation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            possible volatility, at least in the short term, of the trading price of the SciSparc ordinary
                                            shares resulting from the Merger announcement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risk that the Merger might not be consummated in a timely manner or at all and the potential
                                            adverse effect of the public announcement of the Merger or on the delay or failure to complete
                                            the Merger on the reputation of SciSparc;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risk to SciSparc&#8217;s business, operations and financial results in the event that the
                                            Merger is not consummated, including the diminution of SciSparc&#8217;s cash and its likely
                                            inability to raise additional capital through the public or private sale of equity securities,
                                            in addition to the possibility that SciSparc would become a creditor of AutoMax due to the
                                            bridge loan;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            strategic direction of the continuing company following the completion of the Merger, which
                                            will be determined by a board of directors, which may be materially influenced by members
                                            designated by AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            failure to successfully manage the separate business and operations of each of AutoMax and
                                            SciSparc could disrupt SciSparc&#8217;s current business activities, including the risk of
                                            entering markets in which SciSparc has no prior experience. Even if the Merger is successfully
                                            completed, SciSparc cannot assure that it will be able to run the operations of AutoMax without
                                            encountering difficulty regarding different business strategies, corporate cultures and business
                                            sectors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the
                                            possibility of SciSparc requiring a substantial additional funding following the consummation
                                            of the Merger to fund the continuing company, which may not be available on acceptable terms,
                                            or at all, and the risks associated with failure to obtain necessary capital;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Weiss&#8217; dual role as both the Chairman of SciSparc&#8217;s board of directors, and as the chairman of AutoMax&#8217;s board
    of directors, and whether his interests in the Merger may differ from, or extend beyond, the interests of SciSparc&#8217;s shareholders
    generally. The audit committee and the board of directors of SciSparc were aware of this potential conflict of interest and considered
    it, among other matters, in reaching its decision to approve the Merger Agreement and the Merger; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">various
                                            other risks associated with the combined company and the Merger, including those described
                                            in the section entitled &#8220;Risk Factors&#8221; in this proxy statement/prospectus.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing information
and factors considered by the SciSparc board of directors are not intended to be exhaustive but are believed to include all of the material
factors considered by SciSparc board of directors. In view of the wide variety of factors considered in connection with its evaluation
of the Merger and the complexity of these matters, the SciSparc board of directors did not find it useful, and did not attempt, to quantify,
rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of SciSparc&#8217;s
board may have given different weight to different factors. SciSparc&#8217;s board conducted an overall analysis of the factors described
above, including thorough discussions with, and questioning of, the SciSparc management team and the legal and financial advisors of
SciSparc, and considered the factors overall to be favorable to, and to support, its determination.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax&#8217;s reasons for the Merger</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In approving and authorizing
AutoMax&#8217;s entry into the Merger Agreement and consummation of the Merger, AutoMax&#8217;s board of directors considered a number
of factors and alternatives. In reaching its decision, AutoMax&#8217;s board of directors consulted with AutoMax&#8217;s management with
respect to strategic and operational matters and with AutoMax&#8217;s legal counsel with respect to the Merger Agreement and the transactions
contemplated thereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among the factors considered
by the AutoMax board of directors in its decision to approve the Merger Agreement were the following potential benefits of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax
                                            was evaluating manners in which it could improve its financial situation and considered multiple
                                            avenues including strengthening its equity through capital raising, examining debt raising,
                                            and more;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as
                                            part of the Merger Agreement, SciSparc will invest in AutoMax a total of $4.25 million, of
                                            which an aggregate amount of $4.25 million was already advanced to AutoMax as a loan. The
                                            agreement as amended on June 9, 2024, and on September 5, 2024, states that the principal
                                            amount of the Bridge Loan will bear interest at a rate of 7% per annum (or 9% per annum if
                                            the Acquisition is not consummated prior to the repayment date), compounded annually. This
                                            loan was made as an advancement of the Closing Financing agreed upon in the Merger Agreement,
                                            to enable AutoMax to have sufficient cashflow to further develop its operations;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            investment will improve AutoMax&#8217;s financial situation and help it continue the process
                                            of changing the variety of vehicles its imports and sells in Israel, which could improve
                                            its profitability;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">consideration
                                            for the Merger, which was determined in the negotiations between the parties, was examined
                                            by AutoMax&#8217;s audit committee and board of directors. In the opinion of the members
                                            of the audit committee and the board of directors, it is fair, reasonable, in accordance
                                            with market conditions, and represents a fair price for AutoMax&#8217;s shareholders for
                                            their shares after considering, among other things, their familiarity with AutoMax&#8217;s
                                            business, financial situation, market situation, the feasibility and chances of completing
                                            the merger and the timetables. SciSparc&#8217;s position, based on a financial analysis of
                                            SciSparc&#8217;s financial condition was conducted by an external consultant and presented
                                            to the audit committee and the board of directors, as well as the findings of a due diligence
                                            carried out by Lipa Meir and BDO Consulting, AutoMax&#8217;s external legal advisors, all
                                            of which was considered by AutoMax&#8217;s audit committee and board of directors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            average daily trading volume in SciSparc stock is greater than the average daily trading
                                            volume of AutoMax&#8217;s shares; therefore the combined entity would have a higher trading
                                            volume;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">considering
                                            the financial situation of AutoMax and SciSparc, as well as their obligations pursuant to
                                            the merger agreement, AutoMax has no reasonable concern that it would not be able to reimburse
                                            the Bridge Loan when it becomes due;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            consideration received in SciSparc shares, pursuant to the Merger Agreement, will enable
                                            AutoMax&#8217;s shareholders to participate in a potential increase in the value of SciSparc&#8217;s
                                            securities as a result of, among other things, the potential long-term growth opportunities,
                                            or a sale or spin-off of SciSparc&#8217;s existing activities; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            fact that the Merger will result in AutoMax Shareholders, in exchange for their AutoMax shares,
                                            receiving shares in SciSparc, a U.S. publicly traded company, which would provide AutoMax&#8217;s
                                            shareholders with the opportunity to obtain liquidity for their shares in relation to the
                                            liquidity for their shares when trading on the TASE.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the AutoMax
board of directors also identified and considered the following material uncertainties and risks:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risk that the potential benefits of the Merger might not be realized;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risk of diverting AutoMax&#8217;s management&#8217;s attention from other strategic priorities
                                            to be implemented post-closing due to administrative matters related to managing any unexpected
                                            SciSparc liabilities that may arise;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            risk that the Merger may not be consummated, and that a more limited range of alternative
                                            strategic transactions would be available to AutoMax in that event;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the
                                            substantial expenses to be incurred in connection with the Merger and the related administrative
                                            challenges associated with combining the companies; and</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Amitay Weiss&#8217; dual role as both the chairman of AutoMax&#8217;s board of directors, and as the Chairman of SciSparc&#8217;s
    board of directors, and the required approvals under the Companies Law for the approval of the Merger Agreement. The audit committee
    and the board of directors of AutoMax were aware of this potential conflict of interest and considered it, among other matters, in
    reaching its decision to approve the Merger Agreement and the Merger.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AutoMax board of directors
weighed the benefits and opportunities that arise from the potential transaction against the negative factors described above and concluded
that the potential benefits significantly outweighed the potential risks of completing the merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After taking into account
these and other factors, the AutoMax board of directors approved entry into the Merger Agreement and authorized consummation of the transactions
contemplated thereby, including the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Valuation Report of E.D.B.
Consulting and Investments Ltd.</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2024, SciSparc
engaged an independent valuator to render a written valuation report, or the valuation report, to the board of directors as to the valuation,
from a financial point of view, of AutoMax. SciSparc selected E.D.B. because E.D.B. is an experienced independent valuator, with prior
knowledge of AutoMax. In exchange for the services provided, SciSparc paid E.D.B. an amount of NIS 46,800 including VAT (approximately
$12,935) as a flat rate fee, which was not contingent on the signing or closing of the Merger Agreement and the Merger, respectively.
E.D.B. has not rendered any other services to SciSparc, prior to March 4, 2024. E.D.B. was not paid by AutoMax for providing its valuation
report nor was it engaged by AutoMax in the past to provide services. E.D.B. was retained by Matomy Media Group Ltd. in the past to provide
valuation services on AutoMax, in connection with the merger between Matomy Media Group Ltd. and Global AutoMax in March 2021. In November
2024, E.D.B. was retained by SciSparc to perform a Purchase Price Allocation analysis on AutoMax in connection with the Merger, for which
SciSparc paid E.D.B. NIS 14,040 including VAT (approximately $3,900).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the presentation
of the valuation report, a representative of E.D.B. attended (via conference call) the meeting of the board of directors held on March
31, 2024, at which the board of directors evaluated the proposed Merger. At this meeting, a representative of E.D.B. reviewed the financial
aspects of AutoMax and rendered the valuation report, as of such date and subject to the procedures followed, assumptions made, matters
considered, and qualifications and limitations on the review undertaken by E.D.B. as set forth in its valuation report, as to the valuation
of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The full text of the English
translation (from the Hebrew) of the valuation report of E.D.B. dated January 4, 2024, which sets forth, among other things, the assumptions
made, matters considered and limits on the valuation undertaken, is attached as Annex E to this proxy statement/prospectus and is incorporated
herein by reference. The summary of the valuation report of E.D.B. set forth in this proxy statement is qualified in its entirety by
reference to the full text of such valuation report. SciSparc&#8217;s shareholders are urged to read the valuation report in its entirety.
The valuation report was for the information of, and was directed to, the SciSparc board of directors (in its capacity as such) in connection
with its consideration of the financial terms of the Merger. The valuation report addressed the valuation, from a financial point of
view, of AutoMax. It did not address the underlying business decision of the board of directors to engage in the Merger or enter into
the Merger Agreement. It did not constitute a recommendation to the board of directors in connection with the Merger or a recommendation
to any holder of ordinary shares as to how to vote or act in connection with the Merger or any other matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the valuation performed by E.D.B. Some of the summaries of the valuation performed by E.D.B. include information presented in tabular
format. In order to understand the valuation performed by E.D.B. more fully, you should read the tables together with the text of each
summary. The tables alone do not constitute a complete description of E.D.B.&#8217;s valuation, including the methodologies and assumptions
underlying the valuation, and if viewed in isolation could create a misleading or incomplete view of the valuation performed by E.D.B.
The data presented and the corresponding imputed ranges of values for AutoMax should be considered as a whole and in the context of the
full narrative description of the valuation set forth in the following pages, including the assumptions, and Projections (as defined
below) underlying these analyses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise noted,
the information utilized by E.D.B. in its valuation, to the extent that it was based on market data, is based on market data as it existed
on or before January 4, 2024 and is not necessarily indicative of current market conditions. The valuation described below does not purport
to be indicative of actual future results, or to reflect the prices at which any securities may trade in the public markets, which may
vary depending upon various factors, including changes in interest rates, dividend rates, market conditions, economic conditions and
other factors that influence the price of securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the valuation
report, E.D.B. reviewed, analyzed and relied upon information and material bearing upon the financial and operating condition of AutoMax,
including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax&#8217;s
                                            public information;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)
                                            audited financial statements of AutoMax for fiscal years ended December 31, 2022 and 2021,
                                            and (ii) unaudited financial statements of AutoMax for the six month period ended June 30,
                                            2023;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">financial
                                            forecasts, budget, and estimates relating to AutoMax prepared by the management of AutoMax,
                                            or the Projections;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">discussions
                                            with the senior management and advisors of AutoMax with respect to the business and prospects
                                            of AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">visitation
                                            to AutoMax&#8217;s main branch in Jerusalem;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">certain
                                            publicly available financial data for companies that E.D.B. deemed relevant in evaluating
                                            AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            public information concerning AutoMax; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            information and other factors as E.D.B. deemed appropriate.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In rendering the valuation
report, E.D.B. relied upon and assumed, without independent verification or investigation, the accuracy and completeness of all of the
financial and other information provided to or discussed with E.D.B. by AutoMax and its employees, representatives and affiliates or
otherwise reviewed by E.D.B. with respect to the Projections, E.D.B. assumed without independent verification or investigation, that
those forecasts and estimates were reasonably prepared on bases reflecting the best available information, estimates and judgments of
AutoMax&#8217;s management as to AutoMax&#8217;s future financial condition and operating results. E.D.B. did not receive any instructions
or limitations by AutoMax&#8217;s management or any affiliate of AutoMax with respect to the preparation of the valuation report. E.D.B.
also assumed that there were no material changes in the assets, liabilities, financial conditions, results of operations, business or
prospects of AutoMax since the date of the last financial statements of AutoMax that were made available to E.D.B. E.D.B. neither made
nor obtained any independent evaluations or appraisals of the assets or liabilities, contingent or otherwise, of AutoMax. For purposes
of its valuation report, E.D.B. valued AutoMax, without further verification, at $44.8 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>AutoMax
Projections</i></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Projections furnished
to E.D.B. were prepared by the management of AutoMax, which were discussed with, and approved for E.D.B.&#8217;s use by AutoMax in connection
with the valuation report. AutoMax and SciSparc do not publicly disclose internal management projections of the type provided to E.D.B.
in connection with E.D.B.&#8217;s valuation report, and such projections were not prepared with a view toward public disclosure. The
Projections were based on numerous variables and assumptions that are inherently uncertain and may be beyond the control of the managements
of AutoMax and SciSparc, including, without limitation, factors related to general economic and competitive conditions and prevailing
interest rates. Accordingly, actual results could vary significantly from those set forth in the Projections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax does not, as a matter
of course, publicly disclose forecasts or projections as to future performance, earnings or other results due to the inherent unpredictability
of projections and their underlying assumptions and estimates. However, in connection with the discussions regarding the proposed Merger,
AutoMax supplied E.D.B. and SciSparc with certain unaudited business and financial information that was not publicly available. AutoMax&#8217;s
management provided E.D.B. with certain financial forecasts for AutoMax for the calendar years 2022 through 2028. The Projections were
provided to E.D.B., for its use and reliance on in its valuation report. The Projections were prepared without giving effect to the Merger,
including the impact of negotiating or executing the Merger, the expenses that may be incurred in connection with consummating the Merger,
the impact on the combined company as a result of the Merger and the effect of any business or strategic action that would be taken as
a result of the Merger Agreement having been executed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Projections were not
prepared with a view toward public disclosure and, accordingly, do not necessarily comply with published guidelines of the SEC, or the
guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of financial forecasts
or GAAP, but, in the view of AutoMax&#8217;s management, were prepared on a reasonable basis, reflected the best available estimates
and judgments at the time of preparation and presented as of the time of preparation, to the best of AutoMax&#8217;s management&#8217;s
knowledge and belief.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Neither SciSparc&#8217;s
independent registered public accounting firm, Ernst &amp; Young Global, nor AutoMax&#8217;s independent registered public accounting
firm, Ben David Shalvi Kop &amp; Co., audited, reviewed, compiled or performed any procedures with respect to the Projections or expressed
any opinion or any form of assurance related thereto. Accordingly, neither Ernst &amp; Young Global nor Ben David Shalvi Kop &amp; Co.,
express any opinion or any form of assurance related thereto. An English translation of the summary of the Projections is included in
this proxy statement/prospectus solely to give SciSparc&#8217;s shareholders access to certain financial forecasts that were made available
to SciSparc&#8217;s board of directors, and E.D.B., and is not being included in this proxy statement/prospectus to influence any SciSparc
shareholder&#8217;s decision whether to vote for the Merger-related proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Projections, while presented
with numerical specificity, necessarily were based on numerous variables and assumptions that are inherently uncertain and many of which
are beyond the control of AutoMax&#8217;s management. Because the Projections cover multiple years, by their nature, they also become
subject to greater uncertainty with each successive year. Please consider carefully the discussion entitled &#8220;Forward-Looking Statements&#8221;
beginning on page 83. There can be no assurance that the Projections will be realized, and actual results may vary materially from those
shown.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The inclusion of the Projections
in this proxy statement/prospectus should not be regarded as an indication that AutoMax, nor SciSparc, nor any of its respective affiliates,
advisors, officers, directors or representatives considered or considers the Projections to be predictive of actual future events, and
such Projections should not be relied upon as such. Neither AutoMax nor SciSparc, nor any of their respective affiliates, advisors, officers,
directors or representatives has made or makes any representation to any of SciSparc shareholders or any other person regarding the ultimate
performance of AutoMax or SciSparc compared to the information contained in the Projections or can give any assurance that actual results
will not differ materially from the Projections, and none of them undertakes any obligation to update or otherwise revise or reconcile
any of the Projections. Neither SciSparc nor AutoMax intends to make publicly available any update or other revision to the Projections
or any of the other forecasts described herein, except as otherwise required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of the forecasted
financial information set forth herein may be considered non-GAAP financial measures. Non-GAAP financial measures should not be considered
in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as
used by AutoMax may not be comparable to similarly titled amounts used by other companies. No reconciliation of non-GAAP financial measures
in the Projections to GAAP measures was created or used in connection with preparing such forecasts or relied upon by E.D.B. for purposes
of its valuation report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the foregoing
factors and the uncertainties inherent in the Projections and the other forecasts described herein, SciSparc&#8217;s shareholders are
cautioned not to place undue, if any, reliance on such Projections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. received from AutoMax
the Projections which were prepared by its management in October 2023, in order to perform the valuation report. The statements below
are taken from the Projections and reflect AutoMax&#8217;s management&#8217;s beliefs as of October 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Projections were divided
into six chapters. The first chapter of the Projections describes AutoMax&#8217;s business and its subsidiaries. It stated that Global
AutoMax imports thousands of vehicles annually, with an operational turnover of NIS 400-450 million, which it sold through 12 sales branches
nationwide. Global AutoMax owns facilities for vehicle storage and warehouses, as well as a licensing and preparation facility for vehicle
sales. Additionally, Global AutoMax operates a vehicle transportation network, a spare parts warehouse, and holds a license for spare
parts import, along with agreements with a nationwide network of garages. In addition to Global AutoMax, AutoMax also controls AutoMax
Trade-In, which operates a used car sales branch at the Glilot Junction, and holds control over Dalhom AutoMax, which is the direct importer
of Temsa buses to Israel. The Projections state that AutoMax and its subsidiaries are growing each year, and currently employ about 120
employees. According to the Projections, AutoMax&#8217;s optimal utilization of a central headquarters (finance, logistics, human resources,
information systems, etc.) and commercial and financial strength allow the group to develop activities adjacent to the core vehicle import
business, which in turn are expected to enhance profitability. According to the Projections, AutoMax Direct Import will operate as an
independent company, which will be a subsidiary of Global AutoMax, held jointly with a group of investors. Additionally, AutoMax is actively
working to sign direct import agreements with car manufacturers from China and other countries. AutoMax is in various stages of negotiations
with car manufacturers, and if one or more of these negotiations mature into direct import activities, this activity is expected to become
the main activity of the group and significantly impact its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The second chapter of the
Projections describes Global AutoMax&#8217;s aim of importing new vehicles to Israel through parallel import. Global AutoMax is engaged
in importing and marketing a variety of private car models in Israel, holds an indirect import license for 27 vehicle products from various
models, and operates through twelve sales branches (two which as of the date of this prospectus/proxy statement have been closed). The
Projections detail which branches are operated by AutoMax, which ones are operated by joint ventures with third-parties, and which ones
are operated by authorized dealers of AutoMax. AutoMax has an international network of suppliers, mainly in Europe and North America,
providing it with vehicles of different products and models according to orders, as well as an import system that includes procurement,
transportation, handling customs clearance procedures, and vehicle storage facilities in Israel. From January to September 2023, AutoMax
delivered approximately 1,550 vehicles. The second chapter then provides that the nature of AutoMax&#8217;s business is sensitive to
external influences and macroeconomic factors. As a result of these influences, AutoMax&#8217;s financial results for 2023 were affected.
At the time of the Projections, AutoMax believed that it (and the market as a whole) will be able to adjust purchase and sale prices
to current market conditions. Therefore, AutoMax estimated that 2023 was not a representative year for its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third chapter of the
Projections focuses on Dalhom AutoMax, which is a subsidiary, established with Dalhom Motors Ltd., dedicated to the import of Temsa brand
buses. AutoMax signed an agreement with the manufacturer, under which the Dalhom AutoMax will serve as the direct importer of Temsa buses
in Israel. Temsa offers several models of buses and minibuses intended for tourism and public transportation, powered by electricity,
gas, or diesel, all suitable for marketing in Israel. At the time of the Projections, AutoMax was working on establishing a central bus
garage covering 4,000 square meters in Hod Hasharon. Dalhom AutoMax was considered one of the growth engines of AutoMax and was expected
to generate significant profitability. According to the Projections, in 2023, AutoMax intended to stabilize service systems, a central
garage, and stable sales to tourism and transport companies. Starting in 2024, the company planned to begin competing in public transportation
tenders. The Projections also included certain statistics about the public transportation market in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fourth chapter of the
Projections elaborates on the global automative industry, and includes statistics for before and after the COVID-19 pandemic. The Projections
note that most car manufacturers are organized into global groups with factories in many countries, producing different models and brands.
Further, due to the high costs associated with vehicle development, smaller car manufacturers merge to form large conglomerates, each
holding manufacturing plants in various countries and producing multiple brands while sharing platforms and components. Most car manufacturers
will have at least one luxury brand, mid-range brands, and a popular brand. The variety of models allows manufacturers to offer vehicles
for every budget and tailor their offerings to consumer preferences in different countries. Most car models are designed and styled according
to consumer tastes in various regions. The Projections then describe vehicle manufacturers&#8217; approach to parallel import/export.
According to the Projections, the vast production and employment volumes give car manufacturers significant economic and political power,
which they use to protect their interests in the countries where they operate. According to the Projections, car manufacturers design
different models for each region based on local consumer preferences, weather conditions, regulations, and purchasing power. The Projections
then stipulate reasons for such diversification. The Projections then note that fluctuations in business cycles, regulatory changes,
and changing tastes constantly create supply surpluses in different parts of the world, pressuring manufacturers to export vehicles between
regions. Arbitrage gaps are not a passing opportunistic phenomenon but an integral part of the market. As a result, the Projections state
that about 10% of global vehicle trade is conducted as &#8220;parallel&#8221; trade between brokers/traders rather than directly from
the manufacturer. The Projections review anti-trust and competition regulations in the United States and in Europe. The Projections state
that most car manufacturers impose various legal or less legal barriers on vehicle exports by agents, and explains the hurdles involved
in purchasing vehicles for parallel import. The Projections explain that AutoMax has experienced procurement systems and contractual
agreements with some of the largest official agents of car manufacturers in Europe and Canada, allowing it to order production batches
specifically for export. AutoMax purchases most of the models it imports in three or four different currency zones to reduce exposure
to currency rates or other blocking attempts and to ensure continuity of supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fifth chapter of the
Projections describes the Israeli automative industry. The Projections provide statistics about car ownership in Israel. The Projections
explain that the institutional market&#8217;s share in purchasing new vehicles is significantly higher than its share in the overall
vehicle fleet. The Projections provide statics about the average vehicle age in Israel and the level of motorization, compared to Europe
and the United States. The Projections describe the decline in the global vehicle supply due to the effects of the COVID-19 pandemic,
which also impacted delivery volumes in Israel, and increased price for new vehicles in Israel, which, in light of the increase in the
consumer price index, the Projections estimated will continue in coming years. The Projections state that AutoMax focuses mainly on the
main market segments (NIS 130,000-350,000). According to the Projections, in the last decade, there has been a clear consumer preference
in Israel (and globally) for SUV-crossover models, and AutoMax focuses on importing these models. In addition, the Projections state
that in recent years, there has been a massive influx of Chinese-made vehicles, which accounted for nearly 20% of car sales in Israel.
The Projections note that among the top ten models in 2023, there are three Chinese models and not a single European one. The Projections
further state that in recent years, there has been a significant increase in the share of electric vehicles, expected to continue at
the expense of gasoline and diesel vehicles. The Projections then describe the car import market in Israel, which it describes as concentrated,
and provides statistics to support such notion. The Projections note that the market distribution among companies and different brands
changes according to public preferences, model development by manufacturers, and currency exchange rates. Currency rates are crucial
to an importer&#8217;s competitive ability, so there is a high correlation between the currencies in which vehicles are manufactured
and the market shares of different brands. In addition to direct importers, dozens of companies operate in Israel for parallel vehicle
import. Additionally, hundreds operate in the minor import sector and personal import agencies providing consulting, logistical services,
and purchasing services for personal import. The Projections provide statistics for each type of import (direct, parallel, minor, personal),
and the market share for such import.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sixth chapter of the
Projections describes parallel import. Parallel import is a process where a consumer product is imported not through the official importer
but via competing importers who meet legal requirements and import the product themselves from the manufacturer&#8217;s agents abroad.
This process occurs in many sectors, such as food, pharmaceuticals, mobile phones, electrical goods, and also in the automotive market.
Countries, including Israel, often impose import restrictions in various fields, including vehicles, to ensure the quality and safety
of products sold to their citizens and to protect local industries. Traditionally, each manufacturer had an exclusive importer with a
license to market the manufacturer&#8217;s products in that country, responsible for complying with local regulations. To foster competition,
some regulators required manufacturers to appoint multiple official representatives in the same country. However, a widespread measure
globally has been allowing parallel import, regulated by legislation and monitored by the same regulator using uniform tools and standards
as those applied to regular importers. The import process, standards, requirements, and customs and taxation rules are identical for
both types of importers. The official importer benefits from an annual allocation of vehicles with a given model distribution, a planned
schedule, and a fixed currency, while the parallel importer can choose the manufacturer, model, import country, and currency at any time
to maximize profits and/or compete and reduce vehicle prices. Official importers in different countries may choose to sell part of their
allocation to parallel importers due to market and currency conditions in their country and to earn financial incentives for meeting
annual sales targets. The main advantage of parallel import is flexibility in choosing the mix of vehicles imported and the ability to
quickly adapt to changing market conditions. The parallel importer is not tied to a specific brand and is not obligated to a fixed model
mix or specific technology, allowing easy adaptation of the product and model offerings to changes in local demand and foreign supply.
In Israel, the Vehicle Services Licensing Law was amended in 2009 to increase competition by allowing parallel imports, enabling vehicles
to be imported from authorized agents rather than directly from manufacturers. Actual parallel imports began in 2012, with regulations
established by the Ministry of Transport. In 2016, the law was consolidated to clearly regulate parallel imports and remove barriers.
It distinguishes between four types of importers: direct, indirect (parallel), minor, and personal import brokers. The law sets conditions
for each type, including agreements, capital, and maintenance infrastructure. Direct importers must handle recalls and warranties for
all vehicles they import, even if imported by parallel importers. Indirect importers can now use secondary agents and import new vehicles
with minimal mileage, and restrictions on the number of products they can import have been lifted. The Minister of Transport can impose
conditions and restrictions on license holders to ensure compliance and competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The summary of the Projections,
as of the time of writing, notes the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales:
                                            AutoMax&#8217;s sales rely solely on the vehicles it imports, mostly sold at its branches
                                            to private buyers. Occasionally, it sells cars to large fleets and local dealers based on
                                            specific needs and demand. AutoMax offers a diverse range of vehicles appealing to a broad
                                            audience. The average vehicle price is estimated at approximately NIS 210,000, slightly above
                                            the market average. AutoMax&#8217;s pricing is 2-5% lower than regular importers for similar
                                            vehicles, with a higher gap for luxury models. AutoMax expects an average gross margin of
                                            about 11% on parallel imports. Starting in late 2024, AutoMax plans to market directly imported
                                            vehicles, which are more profitable, with an estimated margin of 17%. This activity is expected
                                            to grow to 75% of sales, increasing the average gross margin.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financing:
                                            AutoMax has credit lines from banking corporation transferred as a subordinated loan to its
                                            subsidiaries. Global AutoMax has approved credit lines from four Israeli banks, mainly for
                                            working capital and inventory financing. The time gap between purchase and sale dictates
                                            the required inventory and credit. AutoMax expects reduced credit needs, allowing increased
                                            sales cycles without significant credit growth. AutoMax is also obtaining a &#8220;bonded
                                            warehouse&#8221; approval to save on customs financing for display cars, reducing credit
                                            needs. AutoMax Trade-In and Dalhom AutoMax have separate credit lines. AutoMax Direct Import
                                            was negotiating with banks for credit approval. AutoMax has pledged all assets as collateral
                                            for bank credit. Financing costs are mainly due to exchange rate differences and foreign
                                            trade fees, influenced by currency fluctuations.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Operational,
                                            Sales, and Marketing Expenses: Operational costs, including transport, storage, sales preparation,
                                            and licensing, range from NIS 5,000-10,000 per vehicle. AutoMax has a central headquarters
                                            providing services to all subsidiaries. A significant portion of the budget is allocated
                                            to digital advertising, primarily on Google and Facebook, with an independent telemarketing
                                            center coordinating sales appointments. Marketing costs increased in 2022 and early 2023
                                            due to luxury vehicle sales but are expected to decrease as sales shift back to mainstream
                                            vehicles.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Service
                                            and Warranty: Since January 2017, official importers must cover manufacturer warranty costs
                                            for their brand&#8217;s vehicles, even if imported parallelly. AutoMax has agreements with
                                            nationwide garages and spare parts importers to provide initial parts inventory for imported
                                            vehicles. AutoMax has diagnostic equipment, technical expertise, and translated materials
                                            for imported models. Warranty costs are borne by the manufacturer, so the company does not
                                            incur significant expenses in this area.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The summary of the Projections
included a table titled &#8220;Profit and Loss Pro Forma (in thousands NIS)&#8221; and its footnotes, presented (as translated), below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; width: 26.5%; text-align: left">Year</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2023f</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2024f</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2025f</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2026f</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2027f</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.5%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5%; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">2028f****</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: center"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">453,617</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">420,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">544,340</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">598,774</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">658,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">724,517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">796,969</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">Cost of Sales</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">392,918</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">375,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">479,020</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">514,946</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">566,441</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">623,085</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">685,393</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gross Profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">65,321</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">83,824</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">92,211</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101,432</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,576</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Sales and Marketing
    Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,993</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30,442</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,964</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">General &amp;
    Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,534</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,534</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,434</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,455</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,528</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">Employee Share Options*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,451</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other Expenses
    and Losses (Profit) capital gains**</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Financing Expenses
    (Net)***</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,232</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,496</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share in Profits
    (Loss) of the Company in Associated Companies in Accordance with The Book Value Method</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(585</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">594</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Profit (Loss)
    Before Tax on Income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,999</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,175</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34,335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">41,013</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Profit (Loss)
    Before Tax, adjusted for Employee Share Options and Capital Gains</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,421</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,948</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,175</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34,335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">41,013</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left">EBITDA (Adjusted)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,646</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,536</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,357</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43,557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">56,159</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">63,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">See
                                            notes to financial statements. The share option plan ended in the first quarter of 2023.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left">**</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In
                                            2023, we recognized capital gains of NIS 4 million as a result of sale of shares in AutoMax
                                            Leasing to a third party.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left">***</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Deducting
                                            profits/losses of exchange rate from hedging foreign exchange. After June 30, 2023, there
                                            were no profits or losses.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left">****</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">f
                                            stands for forecast.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Projections were based
on the following working assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023
                                            is a transition year from a world of undersupply caused by the chip crisis during the COVID-19
                                            period (buying high and selling high) to full supply (buying low and selling low). The need
                                            to replace expensive inventory, combined with the sharp and rapid weakening of the NIS due
                                            to legal reforms and accompanying social protests, affected the company&#8217;s results.
                                            AutoMax estimates this impact is not lasting, as vehicle prices will adjust to currencies,
                                            and current purchase prices have also decreased. Therefore, 2022 was chosen as the base year
                                            for planning.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales,
                                            administration, and general expenses will grow from 2025 at a rate lower than revenue growth&#8212;5%
                                            per year.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Starting
                                            in the last quarter of 2024, AutoMax will begin marketing a directly imported Chinese electric
                                            car brand, leading to an expected increase in the gross profit margin.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            the last quarter of 2024, AutoMax will start consolidating profits from AutoMax Direct Import,
                                            and the profitability of the Dalhom AutoMax will also increase.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Starting
                                            in 2024, interest rates in the market will begin to decline, leading to a 15% annual reduction
                                            in financing expenses (equivalent to about 1.2% interest), offset by a similar increase in
                                            the financial debt volume.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Except
                                            for vehicle inventory, there will be no significant changes in fixed assets, including intangible
                                            license assets, so depreciation expenses will remain similar to their 2023 level.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Calculation of Enterprise Value of AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In calculating AutoMax&#8217;s
enterprise value, E.D.B. considered various factors, as detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. noted that AutoMax&#8217;s
market value reflected in the value of its shares on TASE is not reflective of AutoMax&#8217;s real value, and cited the following reasons:
lack of public float; the TASE not being a developed enough stock market; correlation between market trends and share price; the COVID-19
pandemic, the Israeli legal reform and the Iron Swords War preventing a reasonable value assessment based on share price; Israeli capital
market operating differently than other prominent capital markets around the world; that the stock market may self-correct in the long-term
by forecasting better years; and certain examples of volatility in the share price, which do not represent the real value of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. presented the EBITDA
multiplier and the profit multiplier, both multiplier methodologies, as two metrics commonly used to assess the value of a company. Both
metrics measure the ratio between the share price and the company&#8217;s profit, in different ways. E.D.B. explains that the multiplier
methodology is the simplest methodology for a valuation and it is primarily used to compare the value of companies; however, the profit
generally represents past results already recorded. Thus, the disadvantage of the multiplier methodology is that it is based on figures
from the past, inherently without tools to consider the potential for future profit. This disadvantage makes this method ineffective
for establishing the enterprise value of AutoMax because this methodology does not take into account the effect of AutoMax&#8217;s existing
significant growth engines which may potentially result in AutoMax generating 100% or more sales turnover and annual profit within a
few years. The results using these metrics reflect a starting point to gauge AutoMax&#8217;s enterprise value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EBITDA multiplier is
a financial metric used to assess the enterprise value of a company. It is calculated by dividing the value of the company&#8217;s operations
by its EBITDA (earnings before financing expenses, tax, depreciation and amortization). This metric determines the company&#8217;s operating
profitability prior to expenses not directly related to its operating activities. According to E.D.B., the EBITDA multiplier in the Israeli
parallel vehicle import sector ranges between 2 to 3.5, with an average multiplier of 2.5, meaning that companies in this sector are
traded based on a multiplier of 2-3.5 times their gross operating profit. Factors affecting the multiplier include: the size of the company;
its profitability; forecasted future growth; and commercial risks. In Israel, the multiplier may also vary based on: competition in the
sector; changes in government policy; changes in exchange rates; and the volatility of vehicle prices. To calculate AutoMax&#8217;s value
through the EBITDA multiple methodology, E.D.B. considered the fact that AutoMax has stable operations and is the largest player in its
sector in Israel. E.D.B. chose a multiplier of 3 as being representative for AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The profit multiplier is
a financial ratio used to assess the enterprise value of a company. It is calculated by dividing the market capitalization of the company
by its net annual profit. According to E.D.B, the profit multiplier indicates how much investors are prepared to pay for each NIS of
profit generated by a company. A higher profit multiplier means that investors expect that the company will continue to grow and increase
its profits in the future. A lower profit multiplier can be indicative of the fact that the company is not growing or that it is in a
difficult financial position. E.D.B. notes that the profit multiplier is only a single tool to assess the enterprise value of a company.
There are other factors that should be considered, including: forecasted future growth; commercial risks; competition; management. E.D.B.
notes the following limitations of the profit multiplier: that the profit multiplier does not take into account a company&#8217;s accounting;
that the profit multiplier is impacted by external factors, such as the interest in the economy; and that the profit multiplier is not
always precise. The profit multiplier in the Israeli parallel vehicle importer sector ranges between 5 to 10, with an average of 7.5.
The meaning is that companies in the sector are traded based on a multiplier of 5-10 times their net profit. Factors which affect the
profit multiplier include: the size of the company; its profitability; forecasted future growth; and commercial risks. E.D.B. chose a
multiplier of 8 as representative of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taking into account the 2022
EBITDA of NIS 24,818 thousand, and an operating profit multiplier of 3, the operating value estimate is NIS 74,454 thousand (approximately
$20,682 thousand at the time of preparation of E.D.B.&#8217;s valuation report). Taking into account an operating profit of NIS 10,431
thousand, and an operating profit multiplier of 8, the operating value estimate is NIS 83,448 thousand (approximately $22,862 thousand
at the time of writing of E.D.B.&#8217;s report). Accordingly, E.D.B. valued AutoMax&#8217;s enterprise value, according to the average
of both commonly used multiplier methodologies and with an emphasis on the fact that these methodologies do not take into account AutoMax&#8217;s
new and significant growth engines, at approximately $21.77 million (based on an exchange rate of NIS 3.65 per $1 as of the date of the
valuation report &#8211; January 4, 2024).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Next, E.D.B. assessed the
enterprise value of AutoMax through the Discounted Cash Flow, or DCF, methodology, which assesses a company&#8217;s future net cashflow
and discounts it to the present. In order to use this methodology, it is necessary to estimate the profit and loss for future years,
until the profitability plateaus at a terminal year which can be assumed to represent the permanent net annual amount. E.D.B. presented
an explanation about the calculation of the total cost of capital used to finance AutoMax&#8217;s activities and the calculation of the
discounted cashflow to assess the enterprise value. The cost of equity is the return required by a company&#8217;s shareholders. It is
established based on factors, including the risk entailed in investing in the company, as well as the possible return on alternate investments.
E.D.B. counts the various ways to assess the cost of equity, including: capital asset pricing model, or CAPM; internal rate of rate model
and average rate of return model. E.D.B. then explains that the cost of debt is the return required by a company&#8217;s lenders, which
is established based on the present interest rate of similar bonds. The cost of debt can be reduced by the tax rate since the company
is able to deduct the interest costs from its taxable revenues. E.D.B. explains that the weighting refers to the relative share of any
kind of capital, the total debt and equity of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. used the following
explanations in order to calculate the capital and interest of the discount rate for the valuation model for AutoMax: the weighted average
cost of capital, or the WACC, is the rate of return required for a company&#8217;s entire capital, including equity and debt. It is used
to discount the company&#8217;s future cashflows in order to establish its present value. CAPM is used to assess the cost of equity of
the investment. It is based on the assumption that shareholders require a higher rate of return on higher risk investments. The rate
of return required for zero risk assets is the return required for risk-free investments. It is used as the basis to assess the cost
of equity of higher risk assets. The risk parameter measures the risk entailed in investing in an asset. It is calculated by comparing
the historical return of the asset against the historical return of the market. The average market return is the average rate of return
of the assets in the market. It is used as a metric of the systemic risk entailed in investing in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. begins calculating
the WACC of AutoMax by calculating the CAPM. E.D.B. notes that it is difficult to unequivocally establish the interest rate which reflects
the risk premium prevailing in the Israeli share market, appropriate for the vehicle parallel import sector. This is because it is dependent
on multiple factors, as mentioned above. However, according to E.D.B., it can be assessed that this interest rate will be relatively
high due to the high risks entailed in operating in this sector. These factors include: fierce competition; regulatory changes; volatility
in the foreign exchange market; financing risks; size of investment requires a higher interest rate; entrepreneurial experience affects
interest rate accepted; and the issuance of collateral on loans may reduce interest rate. Based on these factors, E.D.B. assessed that
the interest rate which reflects the risk premium in the Israeli vehicle parallel import sector ranges between 10%-12%. In order to more
accurately assess the interest rate for the sector, E.D.B. calculated the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Rate
                                            of return of risk-free capital assets was based on 6%, based on data from the Bank of Israel
                                            as of January 2, 2024, the LIBOR interest rate, and other institutional interest rates.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            risk parameter was set at 1.5, based on: AutoMax&#8217;s sensitivity to changes in the vehicle
                                            market; competition; and volatility in market share. According to E.D.B., risk interest can
                                            come to a 5%-10% premium on top of the basic risk-free interest applicable in the market,
                                            and the model applied a risk parameter of 1.5%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Average
                                            market return was set at 10%, based on an examined period of time. According to E.D.B., the
                                            average market return is calculated at approximately 10% over the long-run. This is based
                                            on data from the global share markets over the preceding 100 years. The average market return
                                            may be higher or lower than 10% in the short-run, and is impacted by various factors, which
                                            include: economic growth; inflation; and base interest. The valuation model applied a conservative
                                            rate of 10% for the market return for the calculation.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to E.D.B.&#8217;s
calculations of the weight of equity, and the WACC, E.D.B, forecasted a cashflow model after having established the weighted interest
rate for the model at 10.22%. Please refer to E.D.B.&#8217;s full translated report, attached as Annex E to this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. explains the assumptions
underlying the DCF methodology as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023
                                            was a transition year, due to the shortage of supply due to the chip crisis associated with
                                            COVID-19 (buying high and selling high) to full supply (buying low and selling low), the
                                            need to replace expensive stock together with a sharp and quick decline of the NIS due to
                                            the judicial reform and associated civil unrest and the Swords of Iron war in the fourth
                                            quarter. All of these adversely impacted AutoMax&#8217;s results &#8211; AutoMax assesses
                                            that this adverse response has ended because vehicle prices adjust themselves to the currencies,
                                            and AutoMax&#8217;s current purchasing prices have also decreased. 2022 was therefore selected
                                            as the base year for the model.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Sales,
                                            management and general expenses were assumed to increase from 2025 at a lower rate of the
                                            increase in revenues - 5% annually.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            the fourth quarter of 2024, it was assumed that AutoMax will start directly importing a Chinese
                                            brand of electric vehicles and therefore the gross profitability is anticipated to increase.
                                            There will be a greater impact in 2025.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            the fourth quarter of 2024, it was assumed that AutoMax will start consolidating the earnings
                                            of AutoMax Direct Import and the profitability of the bus company will increase. There will
                                            be a greater impact in 2025.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">From
                                            2024 there it was assumed that there will be a 15% annual decline in financing costs (equivalent
                                            to interest of approximately 1.2%) which will be offset with a similar increase in the scope
                                            of the financial debt.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Apart
                                            from inventory of vehicles, it was assumed that there will be no material changes in fixed
                                            property, including intangible license assets and therefore depreciation costs will remain
                                            similar at NIS 7,888 thousand per year.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues
                                            &#8211; The basis used is the Projections that were prepared in October 2023. The plan referred
                                            to AutoMax&#8217;s new growth engines in the bus import and Chinese electric vehicle direct
                                            import segments in addition to AutoMax&#8217;s parallel vehicle import activities. The business
                                            plan also relied on 2022 as the basis and referred to a 5-year model for 2024-2028. The base
                                            assumption was a significant 20% increase in sales in 2024, with continued annual growth
                                            of 10% until stabilizing in 2028. As noted above, 2023 cannot be referred to as a representative
                                            year for the current commercial activities due to the multitude of events that occurred throughout
                                            the year which impacted activity in the economy. For similar reasons E.D.B. noted that it
                                            chose to be cautious with its working assumptions for 2024 which started in a state of war
                                            and with significant uncertainty for subsequent months. E.D.B. therefore assumed that the
                                            sales target presented in the business plan will be achieved in 2029, and that there will
                                            only be a growth rate of 6% in 2024. It was further assumed that the growth rate in 2025
                                            will increase to 16% and the growth rate will stabilize at 10% from 2026-2029, which will
                                            also serve as a terminal year for calculating the discounted revenues. E.D.B. noted that
                                            the working assumption is that the period of war will only have a short-term impact on the
                                            scope of sales. Past experience shows that vehicle demand in Israel (and around the world)
                                            is inelastic, and that vehicle demand is only adversely impacted in the short-run during
                                            periods of severe crisis but subsequently reverts. E.D.B. details various of reasons for
                                            the rapid recovery from crises in the vehicle market.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Corporate
                                            tax rate of 23%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Discount
                                            rate for the terminal year &#8211; the discount interest rate of the model, 10.22% less a
                                            permanent 2% annual increase, i.e., 8.22%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Investment
                                            in working capital &#8211; E.D.B. assumed an average rate of working capital by subtracting
                                            AutoMax&#8217;s current liabilities from its current assets based on its 2022 balance sheet
                                            and set a fixed rate of 9%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on these assumptions,
E.D.B. concluded that the enterprise value totals approximately NIS 393.6 million (or $107.8 million based on an exchange rate of NIS
3.65 per $1 as of the date of the valuation report &#8211; January 4, 2024). E.D.B. noted that enterprise value should also consider
the value of AutoMax&#8217;s net assets in the 2022 base year, which include: cash value equal to: the value of cash, less cash liabilities,
at NIS 300,848 thousand; the value of investments includes fixed property, working capital, and total other assets including intangible
assets, at NIS 94,379 thousand; changes in working capital considering the value of the difference between the working capital in the
base year (2022) and the terminal year (2029) capitalized based on the established discount interest rate &#8211; NIS 23,741 thousand;
and the total assets at NIS 230,210 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After referring to the net
asset value, E.D.B. came to an enterprise value for AutoMax totaling NIS 163.4 million, or $44.8 million, based on the DCF methodology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
valuation model is presented below (in thousands of NIS, unless specified otherwise):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Mean</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Forecast</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2027</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2028</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2029</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left">Total
    Sales</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">453,617</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">480,834</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">557,767</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">613,544</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">674,899</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">742,388</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">816,627</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Rate of Change
    (ROC)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10.30</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">6.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">16.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Cost Of Sales*</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">558,605</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">392,918</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">423,134</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">479,680</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">527,648</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">580,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">638,454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">702,300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross Profit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">89,072</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">60,699</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">57,700</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">78,087</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">85,896</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">94,486</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">103,934</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">114,328</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Rate of Profit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">13.70</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">13.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">12.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating
    Expense (OpEx)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Other</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,500</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,567</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Rate</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1.20</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.40</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">2.10</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1.30</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1.10</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">0.90</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">0.90</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sales and Advertising</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">31,582</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,993</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30,442</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,964</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36,919</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Rate</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.90</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5.70</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5.20</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.70</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.50</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.50</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">G&amp;A</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,199</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,534</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,461</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,434</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,455</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,528</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Rate</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.70</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.90</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.50</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.30</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.20</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">60,281</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">60,028</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">56,146</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">55,454</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">57,876</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">60,419</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">63,091</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">68,700</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Rate</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.50</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">13.20</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">11.70</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.90</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.40</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">8.50</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">8.40</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating
    Profit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">28,791</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">671</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,554</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">22,633</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">28,020</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">34,067</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">40,843</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">45,628</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Rate of Profit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.20</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">0.10</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">0.30</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.10</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4.60</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5.50</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5.60</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax Rate</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">23.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Working Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">58,291</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">41,703</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">43,275</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">50,199</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">55,219</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">60,741</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">66,815</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">73,496</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Working Capital
    Ratio</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net Operating
    Profit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">22,169</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">503</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,197</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">17,428</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,576</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">26,231</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">31,449</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">35,133</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Depreciation
    and Amortization</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Fixed Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-3,815</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-4,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cashflow
    for Capitalization</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">26,057</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,085</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,316</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">25,464</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">30,119</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">35,337</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">39,021</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Capitalization
    rate</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10.22</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Growth</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">2.00</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Operational Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">393,585</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Fiscal</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-300,848</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Investments</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">94,379</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Change in Capital
    Ratio</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-23,741</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-230,210</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Enterprise Value
    (EV) in NIS</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">163,375</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Enterprise Value
    (EV) in USD</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">44,760</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forecasts, projections
and estimates of AutoMax provided to E.D.B. were based on numerous variables and assumptions that are inherently uncertain, including,
without limitation, factors related to general economic and competitive conditions. Accordingly, actual results could vary significantly
from those set forth in those forecasts, Projections and estimates. E.D.B. assumed, based on discussions with AutoMax&#8217;s management,
that the projections provided a reasonable basis upon which E.D.B. could form its valuation report and E.D.B. expressed no view as to
any such information or the assumptions or bases therefor. E.D.B. relied on all such information without independent verification or
analysis and did not in any respect assume any responsibility or liability for the accuracy or completeness thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. did not express any
opinion as to AutoMax&#8217;s future performance or long-term viability of AutoMax or the price at which the combined company&#8217;s
ordinary shares would trade at any time. E.D.B. did not express any view as to, and its valuation report did not address, any terms or
other aspects or implications of the Merger or any aspect or implication of any other agreement, arrangement or understanding entered
into in connection with the Merger or otherwise. In addition, E.D.B. expressed no view as to, and its valuation report did not address,
SciSparc&#8217;s underlying business decision to proceed with or effect the Merger nor did its valuation report address the relative
merits of the Merger as compared to any alternative business strategies that might have existed for SciSparc or the effect of any other
transaction in which SciSparc might have engaged. E.D.B.&#8217;s valuation report was necessarily based on the information available
to E.D.B. and general economic, financial and stock market conditions and circumstances as they existed and could be evaluated by E.D.B.
on the date of its valuation report. It should be understood that, although subsequent developments may affect E.D.B.&#8217;s valuation
report, E.D.B. does not have any obligation to update, revise or reaffirm its valuation report. The credit, financial and stock markets
had been experiencing unusual volatility and E.D.B. expressed no opinion or view as to any potential effects of such volatility on the
AutoMax, and its opinion does not purport to address potential developments in any such markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.D.B. is not a financial,
legal, tax, regulatory or accounting advisor. In addition, E.D.B.&#8217;s valuation report did not constitute a solvency opinion or a
fair value opinion, and E.D.B. did not evaluate the solvency or fair value of AutoMax under any federal or state laws relating to bankruptcy,
insolvency, similar matters or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In performing its valuation
report, E.D.B. made numerous assumptions with respect to the industry performance, general business, economic, market and financial conditions
and other matters, which are beyond the control of AutoMax. Any estimates contained in the valuation report performed by E.D.B. are not
necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by the valuation
report. Additionally, estimates of the value of businesses or securities do not purport to be appraisals or to reflect the prices at
which such business or securities might actually be sold. Accordingly, the valuation report and estimates are inherently subject to substantial
uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the valuation report presented by E.D.B. to the SciSparc board of directors in connection with valuation report. The summary is not
a complete description of the valuation report or the presentation made by E.D.B. to the SciSparc board of directors, but summarizes
the material valuation performed and presented in connection with its valuation report. The preparation of a valuation report is a complex
process. Therefore, the valuation report is not readily susceptible to partial analysis or summary description. In arriving at its valuation
report, E.D.B. did not attribute any particular weight to any analysis or factor that it considered, but rather made qualitative judgments
as to the significance and relevance of each analysis and factor.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The valuation report&#8217;s
summary stated the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax
                                            is the largest parallel importer of cars in Israel. The vehicle market in Israel and worldwide
                                            is undergoing a reform, driven by two main forces, the first of which is the shift to usage
                                            of electric vehicle, and the second is the growing use of Chinese-produced vehicles.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax&#8217;s
                                            management has adjusted itself to the changing market by signing an agreement with a Chinese
                                            company for the sale of its cars, as a direct importer to Israel. AutoMax plans to continue
                                            its operations as a parallel importer by using its current branches and salespersons, in
                                            order to sell Chinese-produced vehicles. These operations are expected to generate growth
                                            for AutoMax.</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Another
                                            path to generating growth is AutoMax&#8217;s joint venture with Dalhom Motors Ltd. which
                                            AutoMax will use to import Temsa buses into Israel. AutoMax signed an agreement with Temsa
                                            in order to serve as a direct importer of its buses. The Temsa buses appeal to the Israeli
                                            markets, for both tourism and public transportation.</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            valuation report used two methodologies of valuation to estimate AutoMax&#8217;s value, namely
                                            the multiplier methodology and the DCF methodology, and supported such valuations using AutoMax&#8217;s
                                            business plan. The multiplier methodology is only based on past data and does not refer to
                                            future data, whereby, according to the valuation report, it cannot be used as an appropriate
                                            metric to assess the enterprise value which is anticipated to double or even more the scope
                                            of its operations in the coming years. According to E.D.B., the current valuation of AutoMax
                                            can serve as basis and be used as a comparison for a valuation based on the DCF methodology.</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.D.B.
    found AutoMax&#8217;s business plan to be realistic, given AutoMax&#8217;s trained personnel and operating branches. E.D.B. notes
    that the existing infrastructure of showrooms and trained sales personnel together with efficient management and marketing are a
    good basis for meeting the planned targets of AutoMax. E.D.B. also states that its valuation was conservative in light of the situation
    in Israel, specifically with respect to ongoing military tensions in Israel, and due to such short-term uncertainty, E.D.B. moderated
    AutoMax&#8217;s growth forecast in the model&#8217;s assumptions and chose an interest rate which incorporates risk components appropriate
    for AutoMax&#8217;s operating sector.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            valuation based on the multiplier methodology assessed the enterprise value at approximately
                                            $21.7 million and the valuation based on the DCF methodology assessed the enterprise value
                                            at approximately $44.8 million. AutoMax&#8217;s anticipated growth is expected to double
                                            its activities and also increase its profitability which AutoMax believes strengthens the
                                            reliability of the valuation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E.D.B.
                                            stated that the valuation of AutoMax is $44.8 million, as of the date of its report &#8211;
                                            January 4, 2024.</p></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The $44.8 million valuation
of AutoMax, according to the E.D.B. valuation report, was primarily used as a data point by SciSparc&#8217;s board of directors during
the due diligence process to assess the business of AutoMax and the transaction. This valuation is not recorded in the financial statements
of SciSparc or AutoMax. E.D.B.&#8217;s valuation report was used in order to ascertain the value of AutoMax and in order to evaluate
the financial feasibility of the transaction. The valuation report, and the value ascribed to AutoMax by E.D.B., revealed that the terms
of the transaction contemplated under the Merger Agreement were favorable to SciSparc at the time of the March 31, 2024 meeting, based
on the per-share consideration if the Merger was consummated on such date. If the Merger had been consummated at the time of presentation
of the E.D.B valuation report, then SciSparc would have paid approximately $4.37 million in SciSparc ordinary shares, for a company valued
$44.8 million, based on the Exchange Ratio, with 2,468,876 SciSparc ordinary shares outstanding, 103,691,969 (excluding dormant shares)
AutoMax shares outstanding, and SciSparc&#8217;s share price of $1.77 as of March 31, 2024. The actual merger consideration and Exchange
Ratio were determined based on several key factors:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negotiations
                                            between the parties: The terms of the merger consideration were heavily influenced by the
                                            negotiations between the managements of SciSparc and AutoMax, ensuring that both sides reached
                                            a mutually desirable arrangement;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217;
                                            equity in the financial statements for the year ended December 31, 2023: The shareholders&#8217;
                                            equity as reported in the financial statements for both companies during the year ended December
                                            31, 2023 was relatively equal, providing a financial basis for the transaction; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control
                                            retention by SciSparc&#8217;s board of directors: SciSparc&#8217;s board of directors was
                                            adamant about SciSparc&#8217;s current shareholders retaining control over the combined company
                                            following any strategic transaction, which influenced the structure and amount of the merger
                                            consideration.</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interests of the SciSparc and AutoMax Directors
and Executive Officers in the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In considering the recommendation
of the SciSparc board of directors with respect to issuing SciSparc ordinary shares and pre-funded warrants in the Merger and the other
matters to be acted upon by the SciSparc shareholders at the Special Meeting, the SciSparc shareholders should be aware that Amitay Weiss,
the Chairman of SciSparc&#8217;s board of directors, serves as the chairman of AutoMax&#8217;s board of directors, and as such might
have interests in the Merger that are different from, or in addition to, the interests of SciSparc&#8217;s shareholders generally, including,
among others, the continued service as an officer or director of the combined company and the continued receipt of compensation for such
service and continued indemnification. In addition, if approved by SciSparc shareholders, Mr. Amitay Weiss will be entitled to receive
a one-time cash bonus of $150,000 as the Chairman of SciSparc&#8217;s board of directors, subject to and upon the closing of the Merger.
Each of Mr. Oz Adler and Mr. Itschak Shrem will also be entitled to receive a one-time bonus of $315,000 and $50,000, as the Chief Executive
Officer of SciSparc and President of SciSparc, respectively. These interests may present them with actual or potential conflicts of interest.
See Proposal No. 3 (page 135) for more information.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Amnon Ben Shay, Moshe
Revach and Liat Sidi will be a director of the combined company after the effective time of the Merger. Furthermore, following the Merger,
and subject to the approval of the SciSparc shareholders, each of Mr. Tomer Levy, who is currently the VP Business Development and Headquarters
of AutoMax, as well as a member of the board of directors of AutoMax, and Ms. Yaarah Alfi, currently the Chief Financial Officer of AutoMax,
will be elected to serve as a director of SciSparc. Following the closing of the Merger, the directors of the combined company will be
eligible to be compensated as directors, pursuant to the compensation policy of SciSparc. In addition, pursuant to the Merger Agreement
and form of Indemnification Agreement, SciSparc&#8217;s directors and executive officers are entitled to continued indemnification, expense
advancement and insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee and the
board of directors of SciSparc were aware of these potential conflicts of interest and considered them, among other matters, in reaching
its decision to approve the Merger Agreement and the Merger, and to recommend, as applicable, that the SciSparc shareholders approve
the Proposals to be presented to the SciSparc shareholders for consideration at the Special Meeting as contemplated by this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">THE
MERGER AGREEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following is a summary
of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached as Annex A to this proxy statement/prospectus
and is incorporated by reference. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information
regarding its terms. It is not intended to provide any other factual information about SciSparc, AutoMax or Merger Sub. The following
description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to
the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Merger Agreement,
SciSparc Merger Sub Ltd., or Merger Sub, a wholly-owned subsidiary of SciSparc formed in connection with the Merger, will merge with
and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merger Consideration</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time, each
outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, in accordance with the
Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive for
changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary shares issued
pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and could vary significantly
from the market value of the SciSparc ordinary shares on the date of this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, AutoMax shareholders will receive SciSparc ordinary shares in exchange for AutoMax shares held by them in an amount equal
to the number of AutoMax shares held by each AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will
receive pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued
in connection with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary
share (after aggregating all fractional SciSparc ordinary shares issuable to such shareholder) will receive such amount rounded to the
nearest whole number of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (and its Advisor in connection
with the Merger) are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected
to own approximately 50.01% of SciSparc&#8217;s share capital, on a fully-diluted basis (subject to certain exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Exchange Ratio is
the result of the following calculation: the number of the SciSparc outstanding shares on a fully-diluted basis (subject to certain exceptions)
divided by 0.5001 multiplied by 0.4749 divided by the number of the AutoMax outstanding shares , excluding dormant shares, less the number
of the AutoMax ordinary shares held by SciSparc; so that, in any event, immediately following the effective time, holders of AutoMax
outstanding shares other than SciSparc will hold together 49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis (subject
to certain exceptions), immediately following the effective time.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of AutoMax Warrants, Options,
Series B Bonds, and Series C Bonds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms of
AutoMax&#8217;s Series B Bonds and the Series B Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4)
unequal annual installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that
was made on February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made
on February 28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, that was made on February
28, 2025, constituted 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February
28, 2026, will constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger, the Series
B Bonds will remain outstanding and subject to repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B
Bonds bear interest at a rate of 5.9% per annum. As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal
amount of Series B Bonds remains outstanding and will therefore become a liability of the combined company following the completion of
the Merger.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On May 19, 2025, AutoMax&#8217;s
Series C Bonds, or the Series C Bonds, were issued and began trading on the Tel-Aviv Stock Exchange Ltd., or TASE. According to the terms
of the Series C Bonds and the Series C Bonds trust deed, dated May 14, 2025, or the Series C Bonds Trust Deed, the Series C Bonds are
due for repayment in four (4) unequal annual installments, which will be paid annually from December 31, 2026 until December 31, 2029,
such that the first payment will constitute 5% of the principal, the second and third payments will constitute 10% each of the principal,
and the fourth payment will constitute 75% of the principal. The Series C Bonds bear fixed annual interest at a rate of 8% per annum.
The interest will be paid on each June 30 and December 31, from 2026 to 2029. As of July 3, 2025, NIS 74,353 thousand, approximately
($20,260 thousand) in principal amount of Series C Bonds remains outstanding and will therefore become a liability of the combined company
following the completion of the Merger.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective Time of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement requires
the parties to consummate the Merger after all of the conditions to the consummation of the Merger contained in the Merger Agreement
are satisfied or waived, including the adoption of the Merger Agreement by the shareholders of AutoMax and the approval of the Resolutions
by the SciSparc shareholders.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Merger
is subject to satisfaction or waiver of certain conditions including, among other things, (i)&#160;the required approvals by the parties&#8217;
shareholders, (ii) Court Approval&#160;(as defined in the Merger Agreement) in accordance with the Companies Law, including in accordance
with Sections 350 and 351 of the Companies Law and exempting, among others, the Company from the requirement to publish a prospectus
in Israel; (iii) this Registration Statement having been declared effective; (iv) the accuracy of the representations and warranties,
subject to certain materiality qualifications, (v)&#160;compliance by the parties with their respective covenants, (vi)&#160;no law or
order preventing the Merger and related transactions, (vii)&#160;the listing of the ordinary shares on Nasdaq, (viii)&#160;certain minimum
requirements of net cash (as defined in the Merger Agreement) held by SciSparc at the time of closing, and (ix) receipt of the 104H Tax
Ruling or Interim 104H Tax Ruling in Israel, which has been received. For more information, please see the section entitled &#8220;<i>The
Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement also
includes termination provisions for both SciSparc and AutoMax. Neither SciSparc nor AutoMax can predict the exact timing of the consummation
of the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory Approvals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc must comply with
applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of SciSparc ordinary
shares and pre-funded warrants and the filing of this proxy statement/prospectus with the SEC. SciSparc does not intend to seek any regulatory
approval to consummate the transactions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition to closing
of the Merger, the Merger Agreement sets forth that AutoMax shall obtain a court approval for the Merger, under sections 350 and 351
of the Companies Law. According to the Companies Law, the required majority at a general meeting of shareholders to approve a merger
as described is a majority of the number of voting participants, excluding abstainers, who hold at least three-quarters (3/4) of the
voting power represented at such meeting, in accordance with Section 350(9) of the Companies Law. As part of the Merger, shares of SciSparc
will be offered to AutoMax&#8217;s shareholders. As such, it is plausible to conclude that SciSparc is making an offer to the public
and is required to file a prospectus with the Israeli Securities Authority. Based on the foregoing, AutoMax has requested that an Israeli
court approve an exemption to the foregoing requirement given that SciSparc is a public company traded on Nasdaq and therefore subject
to the Securities Act, and as such all relevant information is available to the Israeli public, and SciSparc shall continue to provide
information in accordance with the Securities Act. The Israeli Securities Authority has responded to AutoMax&#8217;s petition to the
court and has indicated that it will not require filing a prospectus is Israel. Pursuant to AutoMax&#8217;s petition to the court, the
court ordered that AutoMax will convene a shareholders meeting for approval of the merger, and in addition will convene a separate meeting
of AutoMax&#8217;s shareholders who are not controlling shareholders or SciSparc to vote on the approval of the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain Material Israeli Income Tax Consequences
of the Merger</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli Tax Considerations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary is
a discussion of certain tax considerations in connection with the Merger to holders of AutoMax shares under Israeli tax law, as well
as general tax considerations with respect to the shareholders of SciSparc with respect to capital gain and dividend distributions. This
summary is limited to shareholders for whom disposition of their shares is treated as a capital gain within the meaning of the Israeli
Tax Ordinance [New Version], 5721-1961, or the ITO, and does not discuss all of the aspects of Israeli tax law that may be relevant to
a particular shareholder in light of his or her personal investment circumstances such as shareholders that do not hold their AutoMax
shares as a capital asset or shareholders that are subject to special tax rules. The following summary is for general information purposes
only and is based upon current Israeli tax law. No assurance can be given that new or future legislation, regulations or interpretations
will not significantly change the tax considerations described below, and any such change may apply retroactively. The following summary
should not be construed as legal or professional tax advice and does not cover all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under the ITO,
the disposition of shares of an Israeli company is deemed to be a sale of capital assets which is subject to capital gains tax, by both
residents and non-residents of Israel, unless a specific exemption is available or unless a treaty for the prevention of double taxation
between Israel and the seller&#8217;s country of residence provides otherwise. As AutoMax obtained the Withholding Tax Ruling and the
104H Tax Ruling (as defined below) from the Israel Tax Authority, or the ITA, the Israeli income tax consequences of the Merger shall
be in accordance with the Withholding Tax Ruling and the 104H Tax Ruling (if applicable to a particular AutoMax shareholder).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>Israeli
Capital Gains Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a consequence of the Merger,
holders of AutoMax shares will be treated under Israeli tax laws as having sold their AutoMax shares in the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gain tax is imposed
on the disposition of capital assets by an Israeli resident, and on the disposition of such assets by a non-Israeli resident if those
assets are, inter alia (i) located in Israel, (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent,
directly or indirectly, rights to assets located in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The capital gains tax rate
applicable to the real capital gain derived from the disposition of AutoMax shares in the Merger is generally 25% for individual shareholders
unless such shareholder claims a deduction for interest and linkage differences expenses in connection with such shares, in which case
the gain will generally be taxed at a rate of 30%. An individual holding, directly or indirectly, alone or together with such person&#8217;s
relative or another person who collaborates with such person on a permanent basis based on a contract, at least 10% of one or more of
the &#8220;means of control&#8221; in a company, or a Significant Shareholder, at the time of sale or at any time during the 12 months
preceding the sale of its securities, is subject to a 30% tax rate. &#8220;Means of control&#8221; generally include, among others, the
right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds
any of the aforesaid rights how to act, regardless of the source of such right. Individual shareholders dealing in securities in Israel
are taxed at the tax rates applicable to business income (a marginal tax rate of up to 47% for an individual in 2024 (excluding surtax
as discussed below)), unless contrary provisions in a relevant tax treaty apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional tax at a rate
of three percent (3%) on the real capital gain may be imposed upon individual shareholders (whether any such individual is an Israeli
resident or non-Israeli resident) whose annual income from all sources that is taxable in Israel exceeds a certain threshold (NIS 721,560
(approximately $199,436) for 2024, linked to the annual change in the Israeli Consumer Price Index), including, but not limited to, income
derived from dividends, interest and capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Real capital gain derived
by companies is generally subject to the ordinary corporate income tax rate (currently 23%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the ITO, non-Israeli
residents (whether individuals or a corporations) generally may be exempt from Israeli capital gains tax on any gains derived from the
sale of their shares pursuant to the Merger (subject to the receipt of a valid certificate from the ITA allowing for an exemption or
a reduced tax rate), provided that, inter alia, (i) the shares were purchased on or after January 1st 2009 (ii) the capital gain is not
derived from a fixed enterprise of such shareholders maintained in Israel; (iii) the shares were not purchased from a related party or
are subject to restrictions due to a tax free restructure under Israeli tax law (iv) the principal value of the shares does not derive,
directly or indirectly, from real property situated in Israel. Notwithstanding the foregoing, non-Israeli corporations will not be entitled
to the foregoing exemption if Israeli residents: (i) have a controlling interest of more than 25% in such non-Israeli corporation or
(ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly
or indirectly.</p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">In addition, the
sale of AutoMax shares by a non-Israeli resident may be exempt from Israeli capital gain tax under the provisions of an applicable tax
treaty between Israel and the seller&#8217;s country of residence (subject to the receipt of a valid certificate from the ITA allowing
for an exemption or a reduced tax rate). For example, under the Convention between the Government of the State of Israel and the Government
of the United States of America with Respect to Taxes on Income, as amended, or the U.S. Israel Tax Treaty, Israeli capital gains tax
generally will not apply to the disposition of securities by a resident of the United States (as defined in the U.S.-Israel Tax Treaty),
or a U.S. Treaty Resident, who holds the securities as a capital asset and is entitled to claim the benefits afforded to such person
by the treaty. However, such exemption will not apply if, among other things, (i) the capital gain arising from the disposition is attributed
to a permanent establishment of the shareholder in Israel, under certain terms (ii) the U.S. Treaty Resident holds, directly or indirectly,
securities representing 10% or more of the voting rights during any part of the 12-month period preceding the effective time of the sale,
subject to certain conditions; (iii) the U.S. Treaty Resident, if an individual, was physically present in Israel for a period or periods
aggregating to 183 days or more during the relevant taxable year;(iv) the capital gain arising from the disposition is attributed to
real estate located in Israel; or (v) the capital gain arising from the disposition is attributed to royalties. If the exemption is not
available, such disposition would be subject to Israeli capital gains tax to the extent applicable.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli Tax on Dividends</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax rate on dividend
income received by an Israeli resident shareholder, other than an Israeli corporation, is 25%. In the case of a Significant Shareholder,
determined at the time of distribution or at any time during the preceding 12 month period, the tax rate is 30%. Generally, dividends
received by Israeli corporations from another Israeli corporation are tax exempt provided the income from which such dividend is distributed
was derived or accrued within Israel (although, if such dividends are subsequently distributed to individuals or a non-Israeli company,
the aforesaid will apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax on dividends is 20%
(regardless of the holding percentage) if the distribution is from profits attributable to an &#8216;approved enterprise&#8217;, a &#8216;beneficiary
enterprise&#8217;, a &#8216;preferred enterprise&#8217;, a &#8216;preferred technology enterprise&#8217; or a &#8217;special preferred
technology enterprise&#8217; (as defined under the Law for the Encouragement of Capital Investments, 1959, or the Encouragement Law)
of the distributing company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax on dividends distributed
from profits attributable to &#8216;preferred technology enterprise&#8217; or a &#8217;special preferred technology enterprise&#8217;,
and in certain cases an &#8216;approved enterprise&#8217;, to a non-Israeli resident company that holds solely or together with other
foreign companies 90% or more in the Israeli company, under certain conditions detailed in the Encouragement Law, is at the rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends received by non-Israeli
residents from an Israeli resident company are subject to tax at a rate of 30% or 25% (or less, if a tax treaty is applicable) if the
non-Israeli resident is not a Significant Shareholder at the time of distribution or at any time during the preceding 12 month period,
or if the company is traded on a stock exchange.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli Tax Rulings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax filed an application
for and obtained a tax ruling, the Withholding Tax Ruling, of which provides, among other things, the obligation to pay capital gains
tax on the exchange of the AutoMax ordinary shares for SciSparc ordinary shares, subject to certain conditions and limitations, will
be deferred in accordance with the provisions of Section 104H of the ITO with respect to the shareholders who are not otherwise exempt
from Israeli tax on the Merger, who are eligible and elect to become a party to the Withholding Tax Ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the 104H
Ruling, and subject to certain conditions and limitations, the exchange of shares will not be deemed a sale for the shareholders eligible
and electing to be subject to that ruling, and any tax liability with respect to such exchange will be deferred until the earlier of
(i) two years after the closing of the Merger, with respect to 50% of the shares held by such shareholder, and four years after the closing
of the Merger, with respect to the other 50% of the shares held by such shareholder, and (ii) the date on which such shareholder sells
the shares of SciSparc ordinary shares it receives in the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The main conditions, limitations
and restrictions are expected to be as follows: (i) the ratio between the market value of the transferred shares and the market value
of the merged company immediately after the exchange of shares is equal to the ratio between the market value of the issued shares and
the market value of all rights in the merged company immediately after the exchange of shares; (ii) the issued shares issued to all of
the transferors grant equal rights to all of such transferors; (iii) all of the shares and all of the rights of a transferor (and of
parties associated with it) to purchase shares in the transferred company, were transferred as part of the exchange of shares, unless
the ITA approves otherwise; (iv) an application for a pre-ruling is submitted to the ITA to certify that such share exchange meets the
conditions specified in Section 104H of the ITO (such application should be submitted at least 30 days prior to the share exchange and
is subject to the ITA&#8217;s approval); (v) the issued shares must be deposited with an Israeli trustee, in order to secure the payment
of tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If SciSparc deducts any amount
from the Merger consideration payable to you in respect of Israeli withholding tax obligations, you should consult your tax advisor concerning
the possibility of obtaining a refund from the ITA of any such withheld amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are urged to consult
with your own tax advisor for a full understanding of the Israeli tax consequences of the Merger to you, including the consequences under
any applicable, state, local, foreign or other tax laws or tax treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing discussion
is for general information purposes only and is not intended to be a complete analysis or description of all potential Israeli income
tax consequences of the Merger. In addition, the discussion does not address tax consequences which may vary with, or are contingent
on, your individual circumstances. Moreover, the discussion does not address any non-income tax or any United States federal income tax
consequences, any foreign (other than Israeli), state or local tax consequences of the Merger. Accordingly, you are strongly encouraged
to consult with your own tax advisor as to the tax consequences of the Merger in your particular circumstances, including the applicability
and effect of the alternative minimum tax and any state, local or foreign and other tax laws and of changes in those laws.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>MATERIAL U.S. FEDERAL INCOME
TAX CONSIDERATIONS TO U.S. HOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion
is a summary of the material U.S. federal income tax considerations applicable to you if you are a U.S. Holder (as defined below) of
AutoMax ordinary shares, as a consequence of your shares being exchanged for SciSparc ordinary shares and SciSparc pre-funded warrants
in the Merger. With respect to the ownership and disposition of SciSparc ordinary shares and SciSparc pre-funded warrants, this discussion
is limited to SciSparc ordinary shares and SciSparc pre-funded warrants received in the Merger solely as a result of holding AutoMax
ordinary shares prior to the Merger. This discussion addresses only those U.S. Holders that hold AutoMax ordinary shares as capital assets
within the meaning of Section 1221 of the Code (generally property held for investment).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sullivan &amp; Worcester
LLP has delivered an opinion that, based upon and subject to the terms of the opinion, and subject to customary assumptions, representations
and covenants, the Merger as structured is a reverse triangular merger that meets the requirements of a &#8220;reorganization&#8221;
as in Section&#160;368(a)(1)(A) of the Code, as augmented by the provisions of Section&#160;368(a)(2)(E), which opinion has been filed
by amendment as Exhibit 8.1 to this proxy statement/prospectus.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not
address all U.S. federal income tax considerations that may be relevant to any particular investor&#8217;s particular circumstances,
including the alternative minimum tax, the Medicare tax on certain investment income and the different consequences that may apply to
investors subject to special rules under U.S. federal income tax law, such as:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">banks, financial institutions
    or financial services entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">broker-dealers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">taxpayers that are subject
    to the mark-to-market tax accounting rules;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">tax-exempt entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">governments or agencies or
    instrumentalities thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">insurance companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">pension funds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">mutual funds;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">regulated investment companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">real estate investment trusts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">persons
                                            that acquired AutoMax ordinary shares pursuant to an exercise of employee share options,
                                            in connection with employee share incentive plans or otherwise as compensation;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#8220;specified foreign
    corporations&#8221; (including controlled foreign corporations), passive foreign investment companies or corporations that accumulate
    earnings to avoid U.S. federal income tax;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">tax-exempt organizations
    (including private foundations);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">persons that hold AutoMax ordinary shares as part of a
    &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion,&#8221; &#8220;synthetic security,&#8221; &#8220;constructive ownership
    transaction,&#8221; &#8220;constructive sale,&#8221; &#8220;wash sale,&#8221; or other integrated or similar transaction for U.S.
    federal income tax purposes;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">persons that have a functional
    currency other than the U.S. dollar;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">U.S. expatriates or former
    long-term residents of the U.S.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">accrual method taxpayers
    that file applicable financial statements as described in Section&#160;451(b) of the Code;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">partnerships (or entities
    or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax purposes, including S corporations)
    and any beneficial owners of such partnerships or other pass-through entities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">persons who are not U.S.
    Holders, all of whom may be subject to tax rules that differ materially from those summarized below.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a partnership (including
an entity or arrangement treated as a partnership for U.S. federal income tax purposes) or other pass-through entity holds AutoMax ordinary
shares, the tax treatment of a partner or other member in such partnership or other pass-through entity generally will depend upon the
status of the partner or other member, the activities of the partnership or other pass-through entity and certain determinations made
at the partner or member level. If you are a partner or member of a partnership or other pass-through entity holding AutoMax ordinary
shares, you are urged to consult your tax advisor regarding the tax consequences to you of the Merger, and/or the ownership and disposition
of SciSparc ordinary shares and SciSparc pre-funded warrants by the partnership or other pass-through entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion is based
on the Code, the regulations promulgated by the U.S. Treasury Department, or Treasury Regulations, and judicial and administrative interpretations
thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect
the tax considerations described herein. The Company has not sought, and does not intend to seek, any rulings from the Internal Revenue
Service (the &#8220;IRS&#8221;) as to any U.S. federal income tax considerations described herein. Accordingly, there can be no assurance
that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained
by a court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Consequences of the Merger to U.S.
Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. federal income tax
consequences of the Merger will depend primarily upon whether such transaction qualifies as a &#8220;reorganization&#8221; within the
meaning of Section&#160;368(a) of the Code. Generally, no gain or loss is recognized by a corporation on a transfer of assets to another
corporation in exchange for stock or securities of such transferee corporation if such exchange is pursuant to a &#8220;plan of reorganization,&#8221;
as defined in section 368(a), and the transferee corporation is a party to the reorganization.&#160;Likewise, no gain or loss is recognized
by the transferee corporation on the receipt of such property in exchange for its stock.&#160; In addition to meeting the statutory definition,
a transaction must also satisfy certain other requirements to qualify as a reorganization, including the business purpose, continuity
of business enterprise, and continuity of interest requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger, AutoMax
will merge with and into SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of SciSparc, and former shareholders
of AutoMax will receive voting common shares (and in some cases pre-funded warrants to acquire SciSparc voting common shares) of SciSparc.
It is the opinion of SciSparc&#8217;s U.S. federal tax counsel that the Merger as structured is a reverse triangular merger that meets
the requirements of a &#8220;reorganization&#8221; as in Section&#160;368(a)(1)(A) of the Code, as augmented by the provisions of Section&#160;368(a)(2)(E).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company or AutoMax
is not treated as a PFIC, a U.S. Holder that exchanges its AutoMax ordinary shares in the Merger for SciSparc ordinary shares and SciSparc
pre-funded warrants should not recognize any gain or loss on such exchange, except to the extent of the value of any such pre-funded
warrants. The aggregate adjusted tax basis of the SciSparc ordinary shares received in the Merger by a U.S. Holder should be equal to
the adjusted tax basis of the AutoMax shares surrendered in exchange therefor. The holding period of the SciParc ordinary shares received
in the Merger will include the holding period of the AutoMax shares surrendered in exchange therefor. The tax basis of any SciSparc pre-funded
warrants received in the Merger will equal their value on the date of the Merger, and their holding period will commence on that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company or AutoMax
is treated as a PFIC, the tax consequences of the Merger to U.S. Holders should be similar to those described above. Under the Treasury
Regulations, if the Merger otherwise qualifies as an A Reorganization (as augmented by Section 368(a)(2)(E)), the treatment of the Company
or AutoMax as a PFIC would not adversely impact the tax consequences of the Merger to U.S. Holders, except that receipt of SciSparc pre-funded
warrants might be treated as an &#8220;excess distribution&#8221;, as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax matters described
above are very complicated and U.S. Holders are urged to consult their tax advisors regarding the potential tax consequences to them
if the Merger does not qualify as an A Reorganization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PFIC Considerations in the Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A foreign (i.e., non-U.S.)
corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i) at least 75% of its gross income in a taxable
year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares
by value, is passive income or (ii) at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and
averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at
least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends,
interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the
disposition of passive assets. Cash may be treated as a passive asset for this purpose. Pursuant to the start-up exception, a corporation
will not be a PFIC for the first taxable year the corporation has gross income (the &#8220;Start-Up Year&#8221;), if (1) no predecessor
of the corporation was a PFIC; (2) the corporation establishes to the satisfaction of the IRS that it will not be a PFIC for either of
the first two taxable years following the Start-Up Year; and (3) the corporation is not in fact a PFIC for either of those years (the
&#8220;Start-Up Exception&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Merger, the
annual PFIC income and asset tests in respect of SciSparc will be applied based on the assets and activities of the combined business.
To determine whether the PFIC asset test has been met, a calendar-year corporation generally divides the average of the values of passive
assets at the end of each quarter by the average value of all assets at the end of each quarter. Based on the projected composition of
SciSparc&#8217;s income and assets, SciSparc does not believe that it will be classified as a PFIC for its taxable year that includes
the date of the Merger and in the foreseeable future. However, because PFIC status is based on income, assets and activities for the
entire taxable year, it is not possible to determine the PFIC status of AutoMax or SciSparc for any taxable year until after the close
of the taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rules related to PFICs
discussed above are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders
are strongly urged to consult their tax advisors concerning the application of the PFIC rules to their particular circumstances, including
as a result of PFIC Elections that such U.S. Holders may have made (or may wish to make for the taxable year including the Merger).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Consequences of Ownership and Disposition
of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends and Other Distributions on SciSparc
Ordinary Shares (Pre-and Post-Merger)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the PFIC rules
discussed below under the heading &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; distributions on SciSparc ordinary
shares generally will be taxable as a dividend for U.S. federal income tax purposes to the extent paid from SciSparc&#8217;s current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of SciSparc&#8217;s
current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below
zero) the U.S. Holder&#8217;s adjusted tax basis in its SciSparc ordinary shares. Any remaining excess will be treated as gain realized
on the sale or other disposition of the SciSparc ordinary shares and will be treated as described below under the heading &#8220;&#8212;
Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of SciSparc ordinary shares and SciSparc Pre-Funded Warrants.&#8221;
SciSparc (which, as discussed above, should be a continuation of AutoMax for U.S. federal income tax purposes) may not maintain calculations
of earnings and profits under U.S. federal income tax principles for purposes of determining whether a distribution is a dividend for
U.S. federal income tax purposes. Thus, it is possible that the full amount of any distributions will be reported as dividends for U.S.
federal income tax purposes. The amount of any distribution will include any amounts withheld by SciSparc (or another applicable withholding
agent), which would include amounts expected to be payable in respect of Israeli income taxes, if any. Any amount treated as dividend
income will be treated as foreign-source dividend income. Amounts treated as dividends that SciSparc pays to a U.S. Holder that is a
taxable corporation generally will be taxed at regular rates and will not qualify for the dividends received deduction generally allowed
to domestic corporations in respect of dividends received from other domestic corporations. With respect to non-corporate U.S. Holders,
under tax laws currently in effect and subject to certain exceptions (including, but not limited to, dividends treated as investment
income for purposes of investment interest deduction limitations), dividends generally will be taxed at the lower applicable long-term
capital gains rate only if the SciSparc ordinary shares are readily tradable on an established securities market in the United States
(which should include Nasdaq) or SciSparc is eligible for benefits of the Convention between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income (the &#8220;U.S.-Israel Tax Treaty&#8221;), and SciSparc is
not treated as a PFIC with respect to such U.S. Holder at the time the dividend was paid or in the preceding taxable year and provided
certain holding period requirements are met. The amount of any dividend distribution paid in Israeli dollars will be the U.S. dollar
amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the
payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is
converted into U.S. dollars after the date of receipt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Consequences of Ownership and Disposition
of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends and Other Distributions on SciSparc
Ordinary Shares (Pre-and Post-Merger)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the PFIC rules
discussed below under the heading &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; distributions on SciSparc ordinary
shares generally will be taxable as a dividend for U.S. federal income tax purposes to the extent paid from SciSparc&#8217;s current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of SciSparc&#8217;s
current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below
zero) the U.S. Holder&#8217;s adjusted tax basis in its SciSparc ordinary shares. Any remaining excess will be treated as gain realized
on the sale or other disposition of the SciSparc ordinary shares and will be treated as described below under the heading &#8220;&#8212;
Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of SciSparc ordinary shares and SciSparc Pre-Funded Warrants.&#8221;
SciSparc (which, as discussed above, should be a continuation of AutoMax for U.S. federal income tax purposes) may not maintain calculations
of earnings and profits under U.S. federal income tax principles for purposes of determining whether a distribution is a dividend for
U.S. federal income tax purposes. Thus, it is possible that the full amount of any distributions will be reported as dividends for U.S.
federal income tax purposes. The amount of any distribution will include any amounts withheld by SciSparc (or another applicable withholding
agent), which would include amounts expected to be payable in respect of Israeli income taxes, if any. Any amount treated as dividend
income will be treated as foreign-source dividend income. Amounts treated as dividends that SciSparc pays to a U.S. Holder that is a
taxable corporation generally will be taxed at regular rates and will not qualify for the dividends received deduction generally allowed
to domestic corporations in respect of dividends received from other domestic corporations. With respect to non-corporate U.S. Holders,
under tax laws currently in effect and subject to certain exceptions (including, but not limited to, dividends treated as investment
income for purposes of investment interest deduction limitations), dividends generally will be taxed at the lower applicable long-term
capital gains rate only if the SciSparc ordinary shares are readily tradable on an established securities market in the United States
(which should include Nasdaq) or SciSparc is eligible for benefits of the Convention between the Government of the United States of America
and the Government of the State of Israel with respect to Taxes on Income (the &#8220;U.S.-Israel Tax Treaty&#8221;), and SciSparc is
not treated as a PFIC with respect to such U.S. Holder at the time the dividend was paid or in the preceding taxable year and provided
certain holding period requirements are met. The amount of any dividend distribution paid in Israeli dollars will be the U.S. dollar
amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the
payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is
converted into U.S. dollars after the date of receipt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable limitations,
Israeli income taxes withheld from dividends on the SciSparc ordinary shares at a rate not exceeding the rate provided by the U.S.-Israel
Tax Treaty generally will be eligible for credit against the U.S. treaty beneficiary&#8217;s U.S. federal income tax liability. The rules
governing foreign tax credits are complex and U.S. Holders are urged to consult their tax advisers regarding the creditability of foreign
taxes in their particular circumstances. In lieu of claiming a foreign tax credit, a U.S. Holder may deduct foreign taxes, including
any Israeli income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to
deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Gain or Loss on Sale, Taxable Exchange or
Other Taxable Disposition of SciSparc Ordinary Shares and SciSparc Pre-Funded Warrants (Pre- and Post-Merger)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the PFIC rules
discussed below under the heading &#8220;&#8212; Passive Foreign Investment Company Rules,&#8221; upon any sale, exchange or other taxable
disposition of any SciSparc Ordinary Share or SciSparc pre-funded warrant, a U.S. Holder generally will recognize gain or loss in an
amount equal to the difference between (i) the sum of (x) the amount cash and (y) the fair market value of any other property, received
in such sale, exchange or other taxable disposition and (ii) the U.S. Holder&#8217;s adjusted tax basis in such SciSparc Ordinary Share
or SciSparc Warrant, as applicable (determined as described above or below), in each case as calculated in U.S. dollars. Any such gain
or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for
such SciSparc Ordinary Share or SciSparc pre-funded warrant, as applicable, exceeds one year. Long-term capital gain realized by a non-corporate
U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This gain or loss generally
will be treated as U.S. source gain or loss. Accordingly, in the event that any Israeli tax (including withholding tax) is imposed upon
such sale, exchange or other taxable disposition, a U.S. Holder may not be able to utilize foreign tax credits unless such U.S. Holder
has foreign source income or gain in the same category from other sources. In addition, there may be other limitations on utilizing foreign
tax credits even if a U.S. Holder has foreign source income or gain in the same category from other sources. The rules governing foreign
tax credits are complex and U.S. Holders are urged to consult their tax advisers regarding the creditability of foreign taxes in their
particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If SciSparc ordinary shares
or SciSparc pre-funded warrants are sold, exchanged, or otherwise disposed of in a taxable transaction for Israeli shekels, the amount
realized generally will be the U.S. dollar value of the Israeli shekels received based on the spot rate in effect on the date of sale,
exchange, or other taxable disposition. If a U.S. Holder is a cash method taxpayer and the SciSparc ordinary shares or SciSparc pre-funded
warrants are traded on an established securities market, Israeli shekels received will be translated into U.S. dollars at the spot rate
on the settlement date of the taxable disposition. An accrual method taxpayer may elect the same treatment with respect to the taxable
disposition of SciSparc ordinary shares or SciSparc pre-funded warrants traded on an established securities market, provided that the
election is applied consistently from year to year. Such election cannot be changed without the consent of the IRS. Israeli shekels received
on the taxable disposition of a SciSparc Ordinary Share or SciSparc pre-funded warrants generally will have a tax basis equal to its
U.S. dollar value as determined pursuant to the rules above. Any gain or loss recognized by a U.S. Holder on a sale, exchange, or other
taxable disposition of the Israeli shekels will be ordinary income or loss and generally will be U.S.-source gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Exercise, Lapse or Redemption of a SciSparc
Pre-Funded Warrant</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">A U.S. Holder generally will
not recognize gain or loss upon the acquisition of a SciSparc Ordinary Share on the exercise of a SciSparc pre-funded warrant for cash.
A U.S. Holder&#8217;s tax basis in a SciSparc Ordinary Share received upon exercise of the SciSparc pre-funded warrant generally will
equal the sum of the U.S. Holder&#8217;s tax basis in such SciSparc pre-funded warrant and the exercise price. It is unclear whether
a U.S. Holder&#8217;s holding period for the SciSparc Ordinary Share received will commence on the date of exercise of the SciSparc pre-funded
warrant or the day following the date of exercise of the SciSparc pre-funded warrant; in either case, the holding period will not include
the period during which the U.S. Holder held the SciSparc Warrant. If a SciSparc pre-funded warrant is allowed to lapse unexercised,
a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the SciSparc pre-funded warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences of a
cashless exercise of a warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may not
be taxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S.
federal income tax purposes. In either situation, a U.S. Holder&#8217;s tax basis in SciSparc ordinary shares received generally should
equal the U.S. Holder&#8217;s tax basis in the SciSparc pre-funded warrants exercised therefor. If the cashless exercise was not a realization
event, it is unclear whether a U.S. Holder&#8217;s holding period for the SciSparc ordinary shares received would be treated as commencing
on the date of exercise of the SciSparc pre-funded warrants or the day following the date of exercise of the SciSparc pre-funded warrants;
in either case, the holding period will not include the period during which the U.S. Holder held the SciSparc pre-funded warrants. If
the cashless exercise were treated as a recapitalization, the holding period of the SciSparc ordinary shares received would include the
holding period of the SciSparc pre-funded warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that
a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder
could be deemed to have surrendered a number of SciSparc pre-funded warrants equal to the number of SciSparc ordinary shares having a
value equal to the exercise price for the total number of SciSparc pre-funded warrants to be exercised. In such case, subject to the
PFIC rules discussed below, the U.S. Holder would recognize capital gain or loss with respect to the SciSparc pre-funded warrants deemed
surrendered in an amount equal to the difference between the fair market value of the SciSparc ordinary shares that would have been received
in a regular exercise of the SciSparc pre-funded warrants deemed surrendered and the U.S. Holder&#8217;s tax basis in the SciSparc pre-funded
warrants deemed surrendered. In this case, a U.S. Holder&#8217;s aggregate tax basis in the SciSparc ordinary shares received would equal
the sum of the U.S. Holder&#8217;s tax basis in the SciSparc pre-funded warrants deemed exercised and the aggregate exercise price of
such SciSparc pre-funded warrants. It is unclear whether a U.S. Holder&#8217;s holding period for the SciSparc ordinary shares would
commence on the date of exercise of the SciSparc pre-funded warrants or the day following the date of exercise of the SciSparc pre-funded
warrants; in either case, the holding period will not include the period during which the U.S. Holder held the SciSparc pre-funded warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the absence of authority
on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder&#8217;s holding period would commence with
respect to SciSparc ordinary shares received, there can be no assurance regarding which, if any, of the alternative tax consequences
and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax
advisors regarding the tax consequences of a cashless exercise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Passive Foreign Investment Company Rules</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The treatment of U.S. Holders
of SciSparc ordinary shares and SciSparc pre-funded warrants could be materially different from that described above if SciSparc is treated
as a PFIC for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is not entirely clear
how various aspects of the PFIC rules apply to the warrants. Section&#160;1298(a)(4) of the Code provides that, to the extent provided
in Treasury Regulations, any person who has an option to acquire stock in a PFIC shall be considered to own such stock in the PFIC for
purposes of the PFIC rules. No final Treasury regulations are currently in effect under Section&#160;1298(a)(4) of the Code. However,
proposed Treasury Regulations under Section&#160;1298(a)(4) of the Code have been promulgated with a retroactive effective date (the
&#8220;Proposed PFIC Option Regulations&#8221;). Each U.S. Holder is urged to consult its tax advisors regarding the possible application
of the Proposed PFIC Option Regulations to an investment in the SciSparc pre-funded warrants. Solely for discussion purposes, the following
discussion assumes that the Proposed PFIC Option Regulations will apply to the SciSparc pre-funded warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the PFIC status
of SciSparc is determined annually, an initial determination that SciSparc (or, before the Merger, AutoMax) is a PFIC generally will
apply for subsequent years to a U.S. Holder who held shares or warrants in such company while such company was a PFIC, whether or not
such company meets the test for PFIC status in those subsequent years. If AutoMax is determined to be a PFIC (for any taxable year) with
respect to a U.S. Holder who exchanges AutoMax Ordinary in the Merger, and such U.S. Holder did not timely make any of the PFIC Elections
with respect to such shares or warrants, such U.S. Holder generally will be subject to special rules with respect to (i) any gain recognized
by the U.S. Holder on the sale or other disposition of its SciSparc ordinary shares and SciSparc pre-funded warrants (which may include
gain realized by reason of transfers of such shares or warrants that would otherwise qualify as nonrecognition transactions for U.S.
federal income tax purposes) and (ii) any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to
such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by
such U.S. Holder in respect of the SciSparc ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter,
the portion of such U.S. Holder&#8217;s holding period for such shares that preceded the taxable year of the distribution) (together,
the &#8220;excess distribution rules&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under these excess distribution
rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the U.S. Holder&#8217;s gain or excess distribution will
    be allocated ratably over the U.S. Holder&#8217;s holding period for the SciSparc ordinary shares and SciSparc pre-funded warrants;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the amount allocated to the
    U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period
    in the U.S. Holder&#8217;s holding period before the first day of SciSparc&#8217;s first taxable year in which SciSparc is a PFIC,
    will be taxed as ordinary income;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the amount allocated to other
    taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in
    effect for that year and applicable to the U.S. Holder without regard to the U.S. Holder&#8217;s other items of income and loss for
    such year; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an additional amount equal
    to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable
    to each such other taxable year of the U.S. Holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, if SciSparc is
determined to be a PFIC, a U.S. Holder may be able to avoid the excess distribution rules described above with respect to SciSparc ordinary
shares (but, under current law, not the SciSparc pre-funded warrants) by making (or having made) a timely and valid QEF election (if
eligible to do so) to include in income its pro rata share of SciSparc&#8217;s net capital gains (as long-term capital gain) and other
earnings and profits (as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of the U.S.
Holder in which or with which SciSparc&#8217;s taxable year ends. A U.S. Holder generally may make a separate election to defer the payment
of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S. Holder makes a
QEF election with respect to its SciSparc ordinary shares in a year after SciSparc&#8217;s first taxable year as a PFIC in which the
U.S. Holder held (or was deemed to hold) SciSparc ordinary shares, then notwithstanding such QEF election, the excess distribution rules
discussed above, adjusted to take into account the current income inclusions resulting from the QEF election, will continue to apply
with respect to such U.S. Holder&#8217;s SciSparc ordinary shares, unless the U.S. Holder makes a purging election under the PFIC rules.
Under one type of purging election, the U.S. Holder will be deemed to have sold such SciSparc ordinary shares at their fair market value
and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of such purging
election, the U.S. Holder will have additional basis (to the extent of any gain recognized on the deemed sale) and, solely for purposes
of the PFIC rules, a new holding period in the SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under current law, a U.S.
Holder may not make a QEF election with respect to its SciSparc pre-funded warrants. As a result, if a U.S. Holder sells or otherwise
disposes of such warrants (other than upon exercise of such pre-funded warrants) and SciSparc were a PFIC at any time during the U.S.
Holder&#8217;s holding period of such warrants, any gain recognized generally will be treated as an excess distribution, taxed as described
above. If a U.S. Holder that exercises such warrants properly makes and maintains a QEF election with respect to the newly acquired SciSparc
ordinary shares (or has previously made a QEF election with respect to SciSparc ordinary shares), the QEF election will apply to the
newly acquired SciSparc ordinary shares. Notwithstanding such QEF election, the excess distribution rules discussed above, adjusted to
take into account the current income inclusions resulting from the QEF election, will continue to apply with respect to such newly acquired
SciSparc ordinary shares (which, while not entirely clear, generally will be deemed to have a holding period for purposes of the PFIC
rules that includes the period the U.S. Holder held the SciSparc pre-funded warrants), unless the U.S. Holder makes a purging election
under the PFIC rules. U.S. Holders are urged to consult their tax advisors as to the application of the rules governing purging elections
to their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The QEF election is made
on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes
a QEF election by attaching a completed IRS Form&#160;8621 (Information Return by a Shareholder of a Passive Foreign Investment Company
or Qualified Electing Fund), including the information provided in a PFIC Annual Information Statement, to a timely filed United States
federal income tax return for the tax year to which the election relates. Retroactive QEF elections generally may be made only by filing
a protective statement with such return and if certain other conditions are met or with the consent of the IRS. U.S. Holders should consult
their tax advisors regarding the availability and tax consequences of a retroactive QEF election under their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply with the
requirements of a QEF election, a U.S. Holder must receive a PFIC Annual Information Statement from SciSparc. In general, if SciSparc
determines that it was a PFIC in any taxable year, SciSparc will use commercially reasonable efforts to provide the statements and information
(including a PFIC Annual Information Statement) necessary to enable U.S. Holders to make and comply with the requirements of QEF elections
or to file a protective statement. However, there is no assurance that SciSparc will timely provide such required information. There
is also no assurance that SciSparc will have timely knowledge of its status as a PFIC in the future or of such information in order for
U.S. Holders to make or maintain a QEF election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a U.S. Holder has made
a QEF election with respect to the SciSparc ordinary shares, and the excess distribution rules discussed above do not apply to such shares
(because of a timely QEF election for SciSparc&#8217;s first taxable year as a PFIC in which the U.S. Holder holds (or is deemed to hold)
such shares or a purge of the PFIC taint pursuant to a purging election, as described above), any gain recognized on the sale of SciSparc
ordinary shares generally will be taxable as capital gain and no additional interest charge will be imposed under the PFIC rules. As
discussed above, if SciSparc is a PFIC for any taxable year, a U.S. Holder of SciSparc ordinary shares that has made a QEF election will
be currently taxed on its pro rata share of SciSparc&#8217;s earnings and profits, whether or not distributed for such year. A subsequent
distribution of such earnings and profits that were previously included in income generally should not be taxable when distributed to
such U.S. Holder. The tax basis of a U.S. Holder&#8217;s shares in a QEF will be increased by amounts that are included in income, and
decreased by amounts distributed but not taxed as dividends, under the above rules. In addition, if SciSparc is not a PFIC for any taxable
year, such U.S. Holder will not be subject to the QEF inclusion regime with respect to SciSparc ordinary shares for such a taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alternatively, if a U.S.
Holder, at the close of its taxable year, owns shares in a PFIC that are treated as marketable stock, the U.S. Holder may make a mark-to-market
election with respect to such shares for such taxable year. If the U.S. Holder makes a valid mark-to-market election for the first taxable
year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) SciSparc ordinary shares and for which SciSparc is determined
to be a PFIC, such U.S. Holder generally will not be subject to the excess distribution rules described above with respect to its SciSparc
ordinary shares. Instead, in general, the U.S. Holder will include as ordinary income in each taxable year the excess, if any, of the
fair market value of its SciSparc ordinary shares at the end of its taxable year over its adjusted basis in its SciSparc ordinary shares.
These amounts of ordinary income would not be eligible for the favorable tax rates applicable to qualified dividend income or long-term
capital gains. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis in its SciSparc
ordinary shares over the fair market value of its SciSparc ordinary shares at the end of its taxable year (but only to the extent of
the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder&#8217;s basis in its SciSparc
ordinary shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable
disposition of its SciSparc ordinary shares will be treated as ordinary income. Under current law, a mark-to-market election may not
be made with respect to warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The mark-to-market election
is available only for stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange
Commission, including Nasdaq (on which the SciSparc ordinary shares are intended to be listed), or on a foreign exchange or market that
the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. If made,
a mark-to-market election would be effective for the taxable year for which the election was made and for all subsequent taxable years
unless the SciSparc ordinary shares ceased to qualify as &#8220;marketable stock&#8221; for purposes of the PFIC rules or the IRS consented
to the revocation of the election. U.S. Holders are urged to consult their own tax advisors regarding the availability and tax consequences
of a mark-to-market election with respect to SciSparc ordinary shares under their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If SciSparc is a PFIC and,
at any time, has a non-U.S. subsidiary that is classified as a PFIC, U.S. Holders generally would be deemed to own a portion of the shares
of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if SciSparc receives
a distribution from, or dispose of all or part of SciSparc&#8217;s interest in, the lower-tier PFIC or the U.S. Holders otherwise were
deemed to have disposed of an interest in the lower-tier PFIC. In general, if SciSparc determines that it was a PFIC in any taxable year,
SciSparc will use commercially reasonable efforts to cause any lower-tier PFIC to provide to a U.S. Holder the information that may be
required to make or maintain a QEF election with respect to the lower-tier PFIC. There can be no assurance that SciSparc will have timely
knowledge of the status of any such lower-tier PFIC. In addition, SciSparc may not hold a controlling interest in any such lower-tier
PFIC and thus there can be no assurance that SciSparc will be able to cause the lower-tier PFIC to provide such information. A mark-to-market
election generally would not be available with respect to such lower-tier PFIC. U.S. Holders are urged to consult their tax advisors
regarding the tax issues raised by lower-tier PFICs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder that owns (or
is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder may have to file an IRS Form&#160;8621 (whether or not
a QEF or mark-to-market election is made) and such other information as may be required by the U.S. Treasury Department. Failure to do
so, if required, will extend the statute of limitations until such required information is furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rules dealing with PFICs
and PFIC Elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders
of SciSparc ordinary shares and SciSparc pre-funded warrants should consult their own tax advisors concerning the application of the
PFIC rules to SciSparc ordinary shares and SciSparc pre-funded warrants under their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional Reporting Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders may
be required to file an IRS Form&#160;926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a transfer of property
(including cash) to SciSparc. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement,
and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event of a failure to
comply. Furthermore, certain U.S. Holders who are individuals and certain entities will be required to report information with respect
to such U.S. Holder&#8217;s investment in &#8220;specified foreign financial assets&#8221; on IRS Form&#160;8938 (Statement of Specified
Foreign Financial Assets), subject to certain exceptions. Specified foreign financial assets generally include any financial account
maintained with a non-U.S. financial institution and should also include SciSparc ordinary shares and SciSparc pre-funded warrants if
they are not held in an account maintained with a U.S. financial institution. Persons who are required to report specified foreign financial
assets and fail to do so may be subject to substantial penalties, and the period of limitations on assessment and collection of U.S.
federal income taxes may be extended in the event of a failure to comply. U.S. Holders are urged to consult their tax advisors regarding
the foreign financial asset and other reporting obligations and their application to an investment in SciSparc ordinary shares and SciSparc
pre-funded warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Treasury Regulations meant
to require the reporting of certain tax shelter transactions could be interpreted to cover transactions generally not regarded as tax
shelters, including certain foreign currency transactions. Under the applicable Treasury Regulations, certain transactions are required
to be reported to the IRS including, in certain circumstances, a sale, exchange, retirement or other taxable disposition of foreign currency,
to the extent that such sale, exchange, retirement or other taxable disposition results in a tax loss in excess of a threshold amount.
You should consult your tax advisor to determine the tax return obligations, if any, with respect to SciSparc ordinary shares, SciSparc
pre-funded warrants, and the receipt of Israeli shekels in respect thereof, including any requirement to file IRS Form&#160;8886 (Reportable
Transaction Disclosure Statement).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividend payments with respect
to SciSparc ordinary shares and proceeds from the sale or exchange of SciSparc ordinary shares or SciSparc pre-funded warrants may be
subject to information reporting to the IRS and possible United States backup withholding. Backup withholding will not apply, however,
to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise
exempt from backup withholding and establishes such exempt status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Amounts withheld as backup withholding may be credited against a U.S. Holder&#8217;s United States federal income
tax liability, and a U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely
filing the appropriate claim for refund with the IRS and furnishing any required information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Stock Market Listing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc ordinary shares
currently are listed on Nasdaq under the symbol &#8220;SPRC.&#8221; SciSparc has agreed to use its reasonable best efforts to maintain
its existing listing on Nasdaq, and to obtain approval for listing on Nasdaq of the securities of SciSparc that AutoMax shareholders
will be entitled to receive pursuant to the Merger. In addition, under the Merger Agreement, each party&#8217;s obligation to complete
the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Merger, of various conditions, including
that the existing securities of SciSparc must have been continually listed on Nasdaq, and SciSparc must have caused the securities of
SciSparc to be issued in the Merger to be approved for listing on Nasdaq as of the closing of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to consummation of
the Merger, SciSparc intends to file a listing of additional securities application with Nasdaq. If such application is accepted, SciSparc&#8217;s
additional securities will be listed on Nasdaq following the closing of the Merger under its existing trading symbol &#8220;SPRC&#8221;.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anticipated Accounting Treatment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc and AutoMax prepare
their respective financial statements in accordance with IFRS. The Merger will be accounted for using the acquisition method of accounting,
and SciSparc will be treated as the accounting acquirer. In identifying SciSparc as the acquiring entity for accounting purposes, SciSparc
and AutoMax took into account a number of factors as of the date of this proxy statement/prospectus, including the estimate of the relative
voting rights of all equity instruments in the combined company, the expected composition of senior management of the combined company
and the expected corporate governance structure of the combined company. No single factor was the sole determinant in the overall conclusion
that SciSparc is the acquirer for accounting purposes; rather, all factors were considered in arriving at such conclusion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Risk Allocation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement contains
representations and warranties that SciSparc and Merger Sub, on the one hand, and AutoMax, on the other hand, have made to one another
as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement
and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made
in the representations and warranties prove to be incorrect. In addition, the assertions made in the representations and warranties are
qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger
Agreement. While SciSparc and AutoMax do not believe that these disclosure schedules contain information required to be publicly disclosed
under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain
information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement.
Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about SciSparc,
AutoMax or Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between SciSparc
and Merger Sub on the one hand, and AutoMax on the other hand, and are modified by the disclosure schedules.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Structure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Merger Agreement,
Merger Sub will merge with and into AutoMax, with AutoMax surviving as a wholly-owned subsidiary of SciSparc.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Completion and Effectiveness of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger will be completed
as promptly as practicable after all of the conditions to completion of the Merger are satisfied or waived, including the approval of
the shareholders of each of SciSparc and AutoMax. The Merger is anticipated to occur after the Special Meeting. However, SciSparc and
AutoMax cannot predict the exact timing of the completion of the Merger because it is subject to various conditions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merger Consideration</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time, each
outstanding share of AutoMax will be converted into the right to receive a number of SciSparc ordinary shares, in accordance with the
Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement does
not provide for an adjustment to the total number of SciSparc ordinary shares that AutoMax shareholders will be entitled to receive for
changes in the market price of SciSparc ordinary shares. Accordingly, the market value of the shares of SciSparc ordinary shares issued
pursuant to the Merger will depend on the market value of the SciSparc ordinary shares at the time the Merger closes and could vary significantly
from the market value of the SciSparc ordinary shares on the date of this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the effective time of
the Merger, AutoMax shareholders will receive SciSparc ordinary shares in exchange for AutoMax shares held by them in an amount equal
to the number of AutoMax shares held by each AutoMax shareholder multiplied by the Exchange Ratio. Certain AutoMax shareholders will
receive pre-funded warrants exercisable into SciSparc&#8217;s ordinary shares. No fractional SciSparc ordinary shares will be issued
in connection with the Merger. Instead, each AutoMax shareholder who otherwise would be entitled to receive a fractional SciSparc ordinary
share (after aggregating all fractional SciSparc ordinary shares issuable to such shareholder) will receive such amount rounded to the
nearest whole number of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>


</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula described in the Merger Agreement, immediately following the Merger, AutoMax&#8217;s shareholders (and its advisor in connection
with the Merger) are expected to own approximately 49.99% of SciSparc&#8217;s share capital and SciSparc&#8217;s shareholders are expected
to own approximately 50.01% of SciSparc&#8217;s share capital, on fully-diluted basis (subject to certain exceptions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Exchange Ratio is
the result of the following calculation: SciSparc&#8217;s outstanding shares (including pre-funded warrants), divided by 0.5001, multiplied
by 0.4749, then divided by AutoMax outstanding shares, excluding dormant shares, less the number of the AutoMax ordinary shares held
by SciSparc; so that in any event, immediately following the effective time, AutoMax shareholders (other than SciSparc), together with
the Advisor in connection with the Merger, will hold together 49.99% of SciSparc&#8217;s share capital, on a fully-diluted basis (subject
to certain exceptions).</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of AutoMax Warrants, Options,
Series B Bonds, and Series C Bonds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
each AutoMax warrant, option and certain convertible rights that had resulted from a prior AutoMax transaction (in each case, whether
or not vested) that is outstanding and unexercised immediately prior to the effective time, shall be cancelled immediately prior to the
effective time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms of
AutoMax&#8217;s Series B Bonds and the Series B Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4)
unequal annual installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that
was made on February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made
on February 28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, that was made on February
28, 2025, constituted 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February
28, 2026, will constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger, the Series
B Bonds will remain outstanding and subject to repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B
Bonds bear interest at a rate of 5.9% per annum. As of July 3, 2025 NIS 20,547 thousand (approximately $5,597 thousand) in principal
amount of Series B Bonds remains outstanding and will therefore become a liability of the combined company following the completion of
the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On May 19, 2025, the Series
C Bonds, were issued and began trading on the TASE. According to the terms of the Series C Bonds and the Series C Bonds Trust Deed, the
Series C Bonds are due for repayment in four (4) unequal annual installments, which will be paid annually from December 31, 2026 until
December 31, 2029, such that the first payment will constitute 5% of the principal, the second and third payments will constitute 10%
each of the principal, and the fourth payment will constitute 75% of the principal. The Series C Bonds bear fixed annual interest at
a rate of 8% per annum. The interest will be paid on each June 30 and December 31, from 2026 to 2029. As of July 3, 2025, NIS 74,353
thousand, approximately ($20,260 thousand) in principal amount of Series C Bonds remains outstanding and will therefore become a liability
of the combined company following the completion of the Merger.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors and Officers of SciSparc Following
the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of
the Merger, Mr. Oz Adler will serve as the combined company&#8217;s Chief Executive Officer and Chief Financial Officer. Additionally,
following the closing, the board of directors of the combined company is expected to initially consist of six (6) directors and will
be comprised of two (2) members designated by AutoMax and four (4) members designated by SciSparc. The composition of the combined company&#8217;s
board of directors following the effective time of the Merger is expected to satisfy the requisite independence requirements, as well
as the sophistication and independence requirements for the required committees, pursuant to Nasdaq listing requirements. For more information
regarding the composition of board of directors following the Merger, please see the section entitled &#8220;<i>Directors and Officers
of SciSparc Following the Merger</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conditions to the Completion of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Merger
is subject to satisfaction or waiver of certain conditions including, among other things, (i)&#160;the required approvals by the parties&#8217;
shareholders, (ii) Court Approval&#160;(as defined in the Merger Agreement) in accordance with the Israeli Companies Law, including in
accordance with Sections 350 and 351 of the Companies Law and exempting, among others, SciSparc from the requirement to publish a prospectus
in Israel; (iii) this Registration Statement having been declared effective; (iv) the accuracy of the representations and warranties,
subject to certain materiality qualifications, (v)&#160;compliance by the parties with their respective covenants, (vi)&#160;no law or
order preventing the Merger and related transactions, (vii)&#160;the listing of the ordinary shares on Nasdaq, (viii)&#160;certain minimum
requirements of net cash (as defined in the Merger Agreement) held by SciSparc at the time of closing, and (ix) receipt of the 104H Tax
Ruling or Interim 104H Tax Ruling in Israel, both of which were received. For more information, please see the section entitled &#8220;<i>The
Merger &#8212; Certain Material Israeli Income Tax Consequences of the Merger</i>&#8221;.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representations and Warranties</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Merger Agreement contains customary representations and warranties of SciSparc, Merger Sub and AutoMax for a transaction of this type
relating to, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">corporate
                                            organization and power, and similar corporate matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">subsidiaries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">authority
                                            to enter into the Merger Agreement and the related agreements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">votes
                                            required for completion of the Merger and approval of the proposals that will come before
                                            the Special Meeting and that will be the subject of the AutoMax shareholder approval;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">except
                                            as otherwise specifically identified in the Merger Agreement, the fact that the consummation
                                            of the Merger would not contravene or require the consent of any third party;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">capitalization;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">financial
                                            statements and with respect to <span style="background-color: white">SciSparc</span>, documents
                                            filed with the SEC and the accuracy of information contained in those documents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            absence of material changes or events;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">liabilities
                                            and absence of undisclosed liabilities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">title
                                            to assets;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">real
                                            property and leaseholds;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">intellectual
                                            property;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">material
                                            contracts to which the parties or their subsidiaries are a party and any violation, default
                                            or breach to such contracts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">regulatory
                                            compliance, permits and restrictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">legal
                                            proceedings and orders;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">tax
                                            matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">labor,
                                            employment, and employee benefit plans;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">environmental
                                            matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">insurance;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">any
                                            brokerage or finder&#8217;s fee or other fee or commission in connection with the Merger;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">transactions
                                            with affiliates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">anti-bribery;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">with
                                            respect to <span style="background-color: white">SciSparc</span>, the valid issuance in the
                                            Merger of the <span style="background-color: white">SciSparc ordinary shares</span>;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">with
                                            respect to <span style="background-color: white">SciSparc</span>, receipt of an opinion from
                                            its financial advisor; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">an
                                            assertion that no other representations and warranties, except as set forth in the Merger
                                            Agreement, are being given to the other party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The representations and warranties
of AutoMax, <span style="background-color: white">SciSparc</span> and Merger Sub contained in the Merger Agreement or any certificate
or instrument delivered pursuant to the Merger Agreement will terminate at the effective time of the Merger, and only the covenants that
by their terms survive the effective time and certain miscellaneous provisions of the Merger Agreement will survive the effective time.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-Solicitation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both <span style="background-color: white">SciSparc
</span>and AutoMax and their representatives are prohibited by the terms of the Merger Agreement from (i) soliciting, initiating, responding
to or taking any action to or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of
any acquisition proposal or acquisition inquiry or taking any action that could reasonably be expected to lead to an acquisition proposal
or acquisition inquiry; (ii) furnishing any non-public information to any person in connection with or in response to an acquisition
proposal or acquisition inquiry; (iii) engaging in discussions or negotiations with any person with respect to any acquisition proposal
or acquisition inquiry; (iv) approving, endorsing or recommending any acquisition proposal; (v) executing or entering into any letter
of intent or any contract contemplating or otherwise relating to any acquisition transaction; or (vi) publicly proposing to do any of
the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of
the Merger Agreement, each of <span style="background-color: white">SciSparc</span> and AutoMax will immediately cease any existing discussions,
negotiations and communications with any person relating to any acquisition proposal or acquisition inquiry as of the date of the Merger
Agreement and request the destruction or return of any of such party&#8217;s (or its subsidiary&#8217;s) nonpublic information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If <span style="background-color: white">SciSparc
</span>or AutoMax, or any of their respective representatives, receives an acquisition proposal or acquisition inquiry prior to the closing
of the Merger, then such party will (within one business day of such part becoming aware of such acquisition proposal or acquisition
inquiry) advise the other party orally and in writing of such acquisition proposal or acquisition inquiry (including the identity of
the person making such acquisition proposal or acquisition inquiry, and the material terms of the acquisition proposal or acquisition
inquiry).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An acquisition proposal means,
with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made between the parties) contemplating
or otherwise relating to any acquisition transaction with such party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An acquisition inquiry means,
with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest
or request for information made between the parties) with respect to or that is reasonably likely to lead to an acquisition proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An acquisition transaction
means any transaction or series of related transactions involving:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">any
                                            merger, consolidation, amalgamation, share exchange, business combination, issuance of securities,
                                            acquisition of securities, reorganization, recapitalization, tender offer, exchange offer
                                            or other similar transaction: (i) in which a party is a constituent entity; (ii) in which
                                            a person or &#8220;group&#8221; (as defined in the Exchange Act and its rules) of persons
                                            directly or indirectly acquires beneficial or record ownership of securities representing
                                            more than 20% of the outstanding securities of any class of voting securities of a party
                                            or any of its subsidiaries; or (iii) in which a party or any of its subsidiaries issues securities
                                            representing more than 20% of the outstanding securities of any class of voting securities
                                            of such party or any of its subsidiaries; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">any
                                            sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses
                                            or assets that constitute or account for 20% or more of the consolidated book value or the
                                            fair market value of the assets of a party and its subsidiaries, taken as a whole.</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">SciSparc
</span>Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
as promptly as reasonably practicable after the filing of the definitive proxy statement, <span style="background-color: white">SciSparc
</span>will take all action necessary under applicable law to call, give notice of and hold a Special Meeting of the holders of <span style="background-color: white">SciSparc
</span>ordinary shares to vote on the Resolutions. <span style="background-color: white">SciSparc</span> will take reasonable measures
to ensure that all proxies solicited in connection with the Special Meeting are solicited in compliance with all applicable law. If,
on or before the date of the Special Meeting, <span style="background-color: white">SciSparc</span> reasonably believes that it (i) will
not receive proxies sufficient to obtain the required approvals or (ii) will not have sufficient SciSparc ordinary shares represented
to constitute a quorum necessary to conduct the business of the Special Meeting, <span style="background-color: white">SciSparc</span>
may postpone or adjourn, or make one or more successive postponements or adjournments of, the Special Meeting by up to 90 calendar days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc
</span>agreed that, subject to certain exceptions in the Merger Agreement: (i) the <span style="background-color: white">SciSparc</span>
board of directors will recommend that the holders of <span style="background-color: white">SciSparc</span> ordinary shares vote to approve
the <span style="background-color: white">Resolutions</span>; (ii) this proxy statement/prospectus would include a statement to the effect
that the <span style="background-color: white">SciSparc</span> board of directors recommends that <span style="background-color: white">SciSparc&#8217;s
</span>shareholders vote to approve the <span style="background-color: white">Resolutions</span>, or the <span style="background-color: white">SciSparc
</span>Board Recommendation; and (iii) the <span style="background-color: white">SciSparc</span> Board Recommendation would not be withheld,
amended, withdrawn or modified (and the <span style="background-color: white">SciSparc</span> board of directors would not publicly propose
to withhold, amend, withdraw or modify its recommendations without AutoMax&#8217;s prior written consent (the actions set forth in the
foregoing clause (iii), collectively, hereinafter referred to as an <span style="background-color: white">SciSparc</span> Board Recommendation
Change).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Covenants; Conduct of Business Pending the
Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax agreed that it will
conduct its business in the ordinary course in accordance with past practices and in compliance with all applicable laws, regulations
and certain contracts, and to take other agreed-upon actions. AutoMax also agreed that, subject to certain limited exceptions, without
the consent of <span style="background-color: white">SciSparc</span>, it will not, during the period prior to consummation of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">declare,
                                            accrue, set aside or pay any dividend or make any other distribution in respect of any shares
                                            of its share capital or make any other actual, constructive or deemed distribution in respect
                                            of AutoMax&#8217;s share capital, or directly or <span style="background-color: white">indirectly</span>
                                            acquire, or repurchase, redeem or otherwise reacquire any shares of its share capital or
                                            other securities (except in connection with the payment of the exercise price and/or withholding
                                            taxes incurred upon the exercise, settlement or vesting of any award granted under AutoMax&#8217;s
                                            share incentive plan in accordance with their current terms);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">sell,
                                            issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing
                                            with respect to: (i)&#160;any share capital or other security of AutoMax (except for outstanding
                                            AutoMax ordinary shares issued upon the valid exercise of AutoMax options); (ii)&#160;any
                                            option, warrant or right to acquire any share capital or any other security, other than option
                                            grants to employees and service providers; or (iii)&#160;any instrument convertible into
                                            or exchangeable for any share capital or other security of AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">except
                                            as required to give effect to anything in contemplation of the closing of the Merger, amend
                                            any of its organizational documents, or effect or be a party to any merger, consolidation,
                                            share exchange, business combination, recapitalization, <span style="background-color: white">reclassification</span>
                                            of shares, stock split, reverse stock split or similar transaction except, for the avoidance
                                            of doubt, certain transactions contemplated by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">propose
                                            to adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring,
                                            recapitalization or other reorganization of AutoMax, or elect or appoint any new directors
                                            or executive officers of AutoMax, <span style="background-color: white">except</span> for
                                            the transactions contemplated by the Merger Agreement and actions and resolutions adopted
                                            in the course of its implementation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">form
                                            any subsidiary or acquire any equity interest or other interest in any other entity or enter
                                            into a joint venture, strategic alliance or partnership with any other entity;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquire
                                            or agree to acquire (by merger, consolidation or acquisition of stock or assets or by any
                                            other manner) (i) any business or other person or (ii) any assets that are material, individually
                                            or in the aggregate, to AutoMax; or (iii)&#160;other than in the ordinary course of business,
                                            sell, lease (as lessor), license or otherwise dispose of or subject to any lien any properties
                                            or assets of AutoMax, which are material to AutoMax, except for purchases of inventory, services
                                            or supplies in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)
                                            lend money to any person (except for the advance of expenses to employees, directors and
                                            consultants in the ordinary course of business), (ii)&#160;incur or guarantee any indebtedness
                                            for borrowed money, or (iii)&#160;guarantee any debt securities of others;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">recognize
                                            any labor union, labor organization, or similar person;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter
                                            into any material transaction other than in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquire
                                            any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or
                                            properties, or grant any encumbrance with respect to such assets or properties, except in
                                            the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">sell,
                                            assign, transfer, license, sublicense or otherwise dispose of any material intellectual property
                                            (other than pursuant to non-exclusive licenses in the ordinary course of business);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">make,
                                            change or revoke any material tax election, fail to pay any income or other material tax
                                            as such tax becomes due and payable (subject to good faith disputes with respect to such
                                            taxes), file any amendment making any material change to any tax return, settle or compromise
                                            any income or other material tax liability, enter into any tax allocation, sharing, indemnification
                                            or other similar agreement or arrangement (other than customary commercial contracts entered
                                            into in the ordinary course of business the principal subject matter of which is not taxes),
                                            request or consent to any extension or waiver of any limitation period with respect to any
                                            claim or assessment for any income or other material taxes (other than pursuant to an extension
                                            of time to file any tax return granted in the ordinary course of business of not more than
                                            six months), or adopt or change any material accounting method in respect of taxes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter
                                            into, materially amend or terminate any material contract, except if such execution, amendment
                                            or termination is in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)
                                            except in the ordinary course of business, make any expenditures, incur any liabilities,
                                            settle or discharge or satisfy any claims, litigation, obligations (absolute, accrued, asserted
                                            or unasserted, contingent or otherwise) or liabilities, or (ii)&#160;cancel any material
                                            indebtedness for borrowed money (individually or in the aggregate) or waive any claims or
                                            rights with a value in excess of $250,000, or (iii)&#160;give any material discount, accommodation
                                            or other concession (other than in the ordinary course of business consistent with past practice)
                                            in order to accelerate or induce the collection of any receivable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter
                                            into, engage in or amend any transaction or contract with any interested parties (<i>Ba&#8217;alay
                                            Inyan</i>), except as required for the consummation of the closing of the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            than as required by law or IFRS, take any action to change accounting policies or procedures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">cancel
                                            or fail to in good faith seek to renew any material insurance policies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">apply
                                            for or accept (i) any government grant from the IIA or any other Israeli governmental authority,
                                            or (ii) any material government Grants from any other governmental authority;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">initiate
                                            or settle, compromise, or agree to settle any legal proceeding; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">agree,
                                            resolve or commit to do any of the foregoing.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc
</span>agreed that it will conduct its business in the ordinary course consistent with past practices and in compliance with all applicable
laws, regulations and certain contracts, and to take other agreed-upon actions. <span style="background-color: white">SciSparc</span>
also agreed that, subject to certain limited exceptions, without the consent of AutoMax, it will not, during the period prior to the
consummation of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">declare,
                                            accrue, set aside or pay any dividend or make any other distribution in respect of any of
                                            its shares or make any other actual, constructive or deemed distribution in respect of <span style="background-color: white">SciSparc&#8217;s
                                            </span>share capital, except for cash dividends made by any direct or indirect subsidiary
                                            of <span style="background-color: white">SciSparc</span> to <span style="background-color: white">SciSparc
                                            </span>or one of its subsidiaries, or directly or indirectly acquire, repurchase, redeem
                                            or otherwise reacquire any of its shares or other securities (except in connection with the
                                            payment of the exercise price and/or withholding taxes incurred upon the exercise, settlement
                                            or vesting of any award granted under <span style="background-color: white">SciSparc&#8217;s
                                            </span>share incentive plans and in accordance with their current terms);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">sell,
                                            issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing
                                            with respect to: (i)&#160;any shares or other security of <span style="background-color: white">SciSparc</span>
                                            (except for <span style="background-color: white">SciSparc</span> ordinary shares issued
                                            upon the valid exercise of outstanding <span style="background-color: white">SciSparc</span>
                                            options, restricted share units or warrants); (ii)&#160;any option, warrant or right to acquire
                                            any shares or any other security; or (iii)&#160;any instrument convertible into or exchangeable
                                            for any shares or other security of <span style="background-color: white">SciSparc</span>;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">except
                                            as required to give effect to anything in contemplation of the closing of the Merger, amend
                                            any of its or its subsidiaries&#8217; organizational documents, or effect or be a party to
                                            any merger, consolidation, share exchange, business combination, recapitalization, reclassification
                                            of shares, stock split, reverse stock split or similar transaction except, for the avoidance
                                            of doubt, the Contemplated Transactions and as permitted by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">propose
                                            to adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring,
                                            recapitalization or other reorganization of <span style="background-color: white">SciSparc</span>
                                            or any of its Subsidiaries, or elect or appoint any new directors or executive officers of
                                            <span style="background-color: white">SciSparc</span>, except for the transactions contemplated
                                            by the Merger Agreement and actions and resolutions adopted in the course of its implementation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">form
                                            any subsidiary or acquire any equity interest or other interest in any other entity or enter
                                            into a joint venture, strategic alliance or partnership with any other entity;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquire
                                            or agree to acquire (by merger, consolidation or acquisition of stock or assets or by any
                                            other manner) (i)&#160;any business or other person or (ii)&#160;any assets that are material,
                                            individually or in the aggregate, to <span style="background-color: white">SciSparc</span>
                                            and its subsidiaries, taken as a whole; or (iii)&#160;sell, lease (as lessor), license or
                                            otherwise dispose of or subject to any lien any properties or assets of <span style="background-color: white">SciSparc
                                            </span>or its subsidiaries, which are material to <span style="background-color: white">SciSparc
                                            </span>and its subsidiaries, taken as a whole;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)
                                            lend money to any person, (ii)&#160;incur or guarantee any indebtedness for borrowed money,
                                            (iii)&#160;guarantee any debt securities of others, or (iv)&#160;make any capital expenditure
                                            in excess of the budgeted capital expenditure amounts set forth in <span style="background-color: white">SciSparc&#8217;s
                                            </span>operating budget set forth in the disclosure schedules to the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            than as required by applicable law or the terms of any <span style="background-color: white">SciSparc</span>
                                            benefit plan as in effect on the date of the Merger Agreement: (i)&#160;adopt, terminate,
                                            establish or enter into any <span style="background-color: white">SciSparc</span> benefit
                                            plan; (ii)&#160;cause or permit any <span style="background-color: white">SciSparc</span>
                                            benefit plan to be amended in any material respect; (iii)&#160;pay any bonus or make any
                                            profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions,
                                            benefits or other compensation or remuneration payable to any of its directors, officers
                                            or employees; (iv)&#160;increase the severance or change of control benefits offered to any
                                            current or new employees, directors or consultants or (v)&#160;hire, terminate or give notice
                                            of termination to any officer or employee whose annual base salary is or is expected to be
                                            more than $25,000 per year;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">recognize
                                            any labor union, labor organization, or similar person;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter
                                            into any material transaction;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">acquire
                                            any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or
                                            properties, or grant any encumbrance with respect to such assets or properties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">sell,
                                            assign, transfer, license, sublicense or otherwise dispose of any material <span style="background-color: white">SciSparc
                                            </span>intellectual property;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">make,
                                            change or revoke any material tax election, fail to pay any income or other material tax
                                            as such tax becomes due and payable (subject to good faith disputes with respect to such
                                            taxes), file any amendment making any material change to any tax return, settle or compromise
                                            any income or other material tax liability, enter into any tax allocation, sharing, indemnification
                                            or other similar agreement or arrangement, request or consent to any extension or waiver
                                            of any limitation period with respect to any claim or assessment for any income or other
                                            material taxes (other than pursuant to an extension of time to file any tax return granted
                                            in the ordinary course of business of not more than six months), or adopt or change any material
                                            accounting method in respect of taxes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter
                                            into, materially amend or terminate any material contract;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)
                                            except as otherwise set forth in <span style="background-color: white">SciSparc&#8217;s</span>
                                            operating budget, make any expenditures, incur any liabilities, settle, discharge or satisfy
                                            any claims, litigation or obligations (absolute, accrued, asserted or unasserted, contingent
                                            or otherwise) or liabilities, in each case, in amounts that exceed the aggregate amount of
                                            the budget by $200,000, or (ii)&#160;cancel any material indebtedness for borrowed money
                                            (individually or in the aggregate) or waive any claims or rights with a value in excess of
                                            $200,000, or (iii)&#160;give any material discount, accommodation or other concession (other
                                            than in the ordinary course of business consistent with past practice) in order to accelerate
                                            or induce the collection of any receivable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">enter
                                            into, engage in or amend any transaction or contract with any interested parties (<i>Ba&#8217;alay
                                            Inyan</i>);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            than as required by law or IFRS, take any action to change accounting policies or procedures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">cancel
                                            or fail to in good faith seek to renew any material insurance policies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">apply
                                            for or accept (i)&#160;any government grant from the IIA or any other Israeli governmental
                                            authority, or (ii)&#160;any material government grants from any other governmental authority;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">initiate,
                                            settle, compromise, or agree to or settle any claims or legal proceeding; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">agree,
                                            resolve or commit to do any of the foregoing.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Termination</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement may
be terminated prior to the effective time of the Merger (whether before or after approval of the <span style="background-color: white">SciSparc
</span>Shareholder Matters by <span style="background-color: white">SciSparc&#8217;s</span> shareholder and whether before or after approval
of the Company Shareholder Matters (as defined therein) by AutoMax&#8217;s shareholders, unless otherwise specified below):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">at
                                            any time prior to the effective time of the Merger, by mutual written consent of SciSparc
                                            and AutoMax;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    either SciSparc or AutoMax if the Merger was not consummated by March 31, 2025, which may be extended by mutual consent of SciSparc
    and AutoMax;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">by
                                            either SciSparc or AutoMax if a court of competent jurisdiction or other governmental body
                                            shall have issued a final and non-appealable order, decree or ruling, or shall have taken
                                            any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting
                                            the Contemplated Transactions, as defined in the Merger Agreement;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">by
                                            either SciSparc or AutoMax if: (i)&#160;the shareholders&#8217; meeting of SciSparc, including
                                            any adjournments and postponements thereof shall have been held and completed and SciSparc&#8217;s
                                            shareholders shall have taken a final vote on the SciSparc Shareholder Matters and (ii)&#160;the
                                            SciSparc Shareholder Matters shall not have been approved at the such shareholders&#8217;
                                            meeting of SciSparc, or at any adjournment or postponement thereof, by the required SciSparc
                                            shareholder vote; provided, that SciSparc may not terminate the Merger Agreement if SciSparc&#8217;s
                                            breach of its obligations thereunder was the principal factor contributing to the failure
                                            to have obtained the approval of its shareholders of the SciSparc Shareholder Matters at
                                            the shareholders&#8217; meeting of SciSparc, including any adjournments and postponements
                                            thereof;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">by
                                            SciSparc (at any time prior to AutoMax&#8217;s required shareholder approval being obtained)
                                            if a Company Triggering Event (as defined in the Merger Agreement) shall have occurred;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">by
                                            AutoMax (at any time prior to AutoMax&#8217;s required shareholder approval being obtained)
                                            if a Parent Triggering Event (as defined in the Merger Agreement) shall have occurred;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">by
                                            AutoMax, upon a breach of any representation, warranty, covenant or agreement set forth in
                                            the Merger Agreement by SciSparc or Merger Sub or if any representation or warranty of SciSparc
                                            or Merger Sub shall have become inaccurate, in either case, such that certain closing conditions
                                            would not be satisfied as of the time of such breach or as of the time such representation
                                            or warranty shall have become inaccurate;&#160;<i>provided</i>&#160;that AutoMax is not then
                                            in material breach of any representation, warranty, covenant or agreement under the Merger
                                            Agreement;&#160;<i>provided</i>,&#160;<i>further</i>, that if such inaccuracy in SciSparc&#8217;s
                                            or Merger Sub&#8217;s representations and warranties or breach by SciSparc or Merger Sub
                                            is curable by the End Date (as defined in the Merger Agreement) by SciSparc or Merger Sub,
                                            then the Merger Agreement shall not terminate as a result of such particular breach or inaccuracy
                                            until the expiration of a 30 calendar day period commencing upon delivery of written notice
                                            from AutoMax to SciSparc or Merger Sub of such breach or inaccuracy and its intention to
                                            terminate (it being understood that the Merger Agreement shall not terminate as a result
                                            of such particular breach or inaccuracy if such breach by SciSparc or Merger Sub is cured
                                            prior to such termination becoming effective);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">by
                                            SciSparc, upon a breach of any representation, warranty, covenant or agreement set forth
                                            in the Merger Agreement by AutoMax or if any representation or warranty of AutoMax shall
                                            have become inaccurate, in either case, such that certain closing conditions would not be
                                            satisfied as of the time of such breach or as of the time such representation or warranty
                                            shall have become inaccurate;&#160;<i>provided</i>&#160;that SciSparc is not then in material
                                            breach of any representation, warranty, covenant or agreement under the Merger Agreement;&#160;<i>provided</i>,&#160;<i>further</i>,
                                            that if such inaccuracy in AutoMax&#8217;s representations and warranties or breach by AutoMax
                                            is curable by the End Date by AutoMax then the Merger Agreement shall not terminate as a
                                            result of such particular breach or inaccuracy until the expiration of a 30 calendar day
                                            period commencing upon delivery of written notice from SciSparc to AutoMax of such breach
                                            or inaccuracy and its intention to terminate (it being understood that the Merger Agreement
                                            shall not terminate as a result of such particular breach or inaccuracy if such breach by
                                            AutoMax is cured prior to such termination becoming effective);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">by
                                            AutoMax, if SciSparc&#8217;s net cash at the anticipated closing date of the Merger is less
                                            than $4,250,000 (less any amount owned by AutoMax to SciSparc under any loan agreement between
                                            the parties).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Merger
Agreement is terminated, neither party is required to pay a termination fee to the other party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_009"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AGREEMENTS
RELATED TO THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>AutoMax Shareholder Support
Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution
of the Merger Agreement, certain shareholders of AutoMax entered into the AutoMax Shareholder Support Agreement, covering approximately
55.56% of the outstanding shares of AutoMax. The AutoMax Shareholder Support Agreement provides, among other things, that the shareholders
party to the AutoMax Shareholder Support Agreement will vote all of the shares of AutoMax held by them in favor of the adoption of the
Merger Agreement, the approval of the Merger and the other transactions contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Indemnification Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
connection with the Merger, and subject to approval of Proposal No. 2 in the Special Meeting, to approve the form of Indemnification
Agreement for directors and officers of SciSparc, SciSparc plans to enter into Indemnification Agreements with each of the directors
and officers, following the effective time of the Merger. The Indemnification Agreements and the Amended and Restated Articles of Association
permit SciSparc to exculpate, indemnify and ensure its directors and officeholders to the fullest extent permitted by the Companies Law.
As such, the Indemnification Agreements will allow SciSparc to indemnify its directors and office holders for any obligation imposed
on them or expense spent by them as a result of their capacity as directors or executive officers of SciSparc. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
entry into the Indemnification Agreements will allow the combined company to attract and retain highly qualified directors and officers.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="background-color: white"><b>Form
of Pre-Funded Warrant</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Merger Agreement contains an ownership limitation, stating that no AutoMax shareholder may beneficially own over 9.99% of SciSparc ordinary
shares. As a result of the Exchange Ratio, certain AutoMax shareholders would be considered to hold over 9.99% of SciSparc&#8217;s share
capital following the merger. In lieu of shares, such AutoMax Shareholders will receive pre-funded warrants to purchase SciSparc&#8217;s
ordinary shares. Each SciSparc pre-funded warrant will be exercisable for $0.001 per each SciSparc ordinary share. The pre-funded warrants
will be registered in the SciSparc books and upon exercise of the pre-funded warrants, the ordinary shares underlying such exercised
pre-funded warrants will be listed for trading on any stock exchange or trading market.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Bridge
Loan, Amendment to Bridge Loan, Second Amendment to the Bridge Loan, and the Third Amendment to Bridge Loan</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
                                            January 14, 2024, SciSparc entered, as lender, into a bridge loan agreement with AutoMax,
                                            pursuant to which AutoMax received a Bridge Loan in the amount of $1.4 million. On June 9,
                                            2024, SciSparc entered, as lender, into the Amended Bridge Loan, pursuant to which AutoMax
                                            received an additional loan in the amount of $1.0 million, for an aggregate amount of $2.4
                                            million. On September 5, 2024, SciSparc entered into the Second Amendment, pursuant to which
                                            SciSparc extended an additional loan in the amount of $1.85 million bringing the total Loan
                                            Amount to $4.25 million. &#160;During the month of September 2024, SciSparc provided AutoMax
                                            with the loan amounts due under the Second Amendment to the Bridge Loan, and offset any interest
                                            due until November 30, 2024 from the principal amount, such as that on the closing date of
                                            the Merger, SciSparc will be entitled to be paid the due interest at a rate of 7% per annum
                                            (or 9% per annum if the Merger is not consummated), of the Loan Amount, accruing from the
                                            period beginning December 1, 2024 and ending on the effective date of the Merger. In consideration
                                            for the Loan Amount, AutoMax established a first ranking fixed charge security interest on
                                            AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct Import in favor of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Bridge Loan, the Amended Bridge Loan and the Second Amendment, state that the principal amount of the Bridge Loan, the Amended Bridge
Loan, and the Second Amendment, will bear interest at a rate of 7% per annum (or 9% per annum if the Merger is not consummated prior
to the repayment date), compounded annually. The Bridge Loan, the Amended Bridge Loan, and the Second Amendment, together with any accrued
interest, or the Owed Amount, may be repaid in part or in whole at the discretion of the AutoMax prior to the repayment date. The repayment
of the Owed Amount will be due at the earlier date of: (i) the closing of the Merger, in which the Owed Amount shall be deemed a part
of, and set-off against, the Closing Financing Amount SciSparc; or (ii) if the definitive agreement for the Merger is terminated, in
accordance with its terms, within three months from such termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 8, 2025, SciSparc entered into the Third Amendment, pursuant to which, in addition to the already existing subordination of the Loan
Amount to AutoMax&#8217;s Series B Bonds, the Loan Amount will also be subordinated to AutoMax&#8217;s Series C Bonds, issued and traded
on the TASE.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><b>Merger
Agreement Addendum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2024, SciSparc and AutoMax entered into the Merger Agreement Addendum, pursuant to which the right to terminate the Merger
Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Merger Agreement
Second Addendum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement Second Addendum, pursuant to which the right to terminate the
Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Merger Agreement
Third Addendum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On March 27, 2025, the parties
entered into the Merger Agreement Third Addendum, pursuant to which the right to terminate the Merger Agreement, if the Merger was not
consummated by March 31, 2025, was deferred to September 30, 2025, and the definition of &#8220;Exchange Ratio&#8221; was revised to
remove the rounding to four decimal places of the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Merger Agreement
Fourth Addendum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On
                                            May 8, 2025, the parties entered into the Merger Agreement Fourth Addendum, pursuant to which
                                            the definition of &#8220;Bondholders&#8221; was revised to include holders of AutoMax&#8217;s
                                            Series C Bonds.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Additional Loan Agreement
and Deed of Assignment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 25, 2025, SciSparc entered into a Deed of Assignment, or the Deed, with AutoMax and three investors. Pursuant to the Deed, SciSparc
assigned part of the Subscription Amount (as defined below) in the amount of $2 million to AutoMax in lieu of making the payment under
a loan agreement, or the Additional Loan Agreement, to which SciSparc entered into with AutoMax on February 24, 2025. Pursuant to the
Additional Loan Agreement, SciSparc extended to AutoMax a loan in the amount of $2 million, or the Additional Loan Amount. The Additional
Loan Amount is due and payable on a monthly basis, as follows: (i) each month subsequent to February 24, 2025, AutoMax shall pay $50,000,
or the Monthly Payment, and the interest of 8% per annum accrued on the outstanding Additional Loan Amount up to the payment date; and
(ii) upon the consummation of the Merger, the remaining interest on the Additional Loan Amount shall be cancelled and forgiven, and AutoMax
shall continue making Monthly Payments towards the remaining outstanding and due Additional Loan Amount. To secure repayment of the Additional
Loan Amount, AutoMax Hasharon shares held by Global AutoMax were pledged in favor of SciSparc with a first-degree permanent lien.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Consulting Agreement </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has entered into a consulting agreement with Pure Capital Ltd., or Pure Capital, on December 1, 2020, as amended on August 15, 2024,
for the provision of business development and strategic consulting services, including ongoing consulting to SciSparc, its management
and its chief executive officer in the following fields: M&amp;A, investment activities, and SciSparc&#8217;s position in the capital
markets, for a monthly fee of $30,000 (plus VAT), per month, and entitlement to bonus payments upon consummation of business opportunities
achieved with the assistance of Pure Capital. In addition, on February 12, 2025, SciSparc&#8217;s board of directors approved, that in
connection with and contingent upon the closing of the Merger, Pure Capital will be entitled to a cash bonus of $1,153,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="m_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">MATTERS
BEING SUBMITTED TO A VOTE OF <span style="background-color: white">SciSparc</span> SHAREHOLDERS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of the consummation of the Merger
and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and the pre-funded
warrants at the effective time of the Merger to the shareholders of AutoMax.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Special Meeting, <span style="background-color: white">SciSparc
</span>shareholders will be asked to approve the consummation of the merger of Merger Sub with and into AutoMax, with AutoMax surviving
as a wholly-owned subsidiary of <span style="background-color: white">SciSparc</span>, and ordinary shares (and pre-funded warrants)
of <span style="background-color: white">SciSparc</span> will be issued to the AutoMax shareholders at the effective time of such Merger,
as contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Exchange Ratio
formula in the Merger Agreement, at the effective time of the Merger and before accounting for the financing transaction discussed below,
the AutoMax shareholders (and its Advisor in connection with the Merger) are expected to own approximately 49.99% of the aggregate number
of SciSparc&#8217;s share capital, on a fully-diluted basis, and the shareholders of <span style="background-color: white">SciSparc</span>
immediately before the Merger are expected to own approximately 50.01% of the aggregate number of SciSparc&#8217;s share capital, on
a fully-diluted basis. The Merger has been unanimously approved by the boards of directors of both companies and is expected to close
in 2025, subject to approval of <span style="background-color: white">SciSparc&#8217;s</span> shareholders as well as other customary
conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc expects that the
combined company will take advantage of the potential benefits resulting from the combination of <span style="background-color: white">SciSparc&#8217;s
</span>U.S. public company structure with the AutoMax&#8217;s business. After consummation of the Merger, SciSparc anticipates that it
will continue to search for ways to maximize shareholder value, both within and outside of the pharmaceutical segment. SciSparc may opt
to sell, assign, convey and transfer certain pharma assets or participate in a spin-off, pursuant to the Spin-Off LOI entered into on
July 8, 2024 and amended on December 16, 2024, and March 28, 2025, including of its advanced clinical stage pharmaceutical portfolio
and its equity stake in SciSparc Nutraceuticals Inc. to Miza, a publicly traded company on the TSXV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Merger Agreement,
upon the effective time of the Merger, each of Mr. Alon Dayan, Mr. Lior Vider and Mr. Itschak Shrem, will resign from SciSparc&#8217;s
board of directors, and the designees of AutoMax, subject to each designees election at the Special Meeting, will be assigned to two
separate classes, whereby one such designee will be assigned to Class I with a term of office expiring at the annual general meeting
of SciSparc to be held in 2027 and the other such designee will be assigned to Class III with a term of office expiring at the annual
general meeting of SciSparc to be held in 2026<span style="background-color: white">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of, reasons for,
and other aspects of the Merger Agreement, the Merger and the issuance of <span style="background-color: white">SciSparc</span> ordinary
shares and pre-funded warrants in the Merger are described in detail in the other sections in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE SCISPARC BOARD OF DIRECTORS RECOMMENDS
THAT THE SCISPARC<br/>
SHAREHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 1.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 2</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of the form of Indemnification Agreement
for directors and officers of SciSparc</b></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal; background-color: white">Our
Amended and Restated Articles of Association permit us to exculpate, indemnify and ensure our directors and officeholders to the fullest
extent permitted by the Companies Law. We have entered into agreements with each of our current directors and office holders undertaking
to indemnify them for any obligation imposed on them or expense spent by them as a result of their capacity as directors or executive
officers of the Company. As part of the Merger, SciSparc shall enter into new Indemnification Agreements with each of our current directors
and office holders, and the designees of AutoMax, each, an Office Holder, and together, the Office Holders.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
light of our interest in continuing to attract and retain highly qualified directors and executive officers and due to an increasing
difficulty in obtaining a fit insurance policy for our directors and executive officers, the increasing cost of obtaining such insurance
and our current market valuation of the Company, our compensation committee and board of directors concluded that it is in our best interest
and that of our shareholders to enter into and execute with each Office Holder an Indemnification Agreement in the form attached as Annex
C to this proxy statement/prospectus.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal; background-color: white">Additionally,
our compensation committee and board of directors believe that approval of the form of Indemnification Agreement is in the best interests
of our shareholders, as it will enable the combined company to attract and retain highly qualified directors and officers. Our board
of directors has further determined that based on the ongoing and planned activity to be performed by the combined company, the events
listed in the Indemnification Agreement are reasonably anticipated, and that the amounts stated in the Indemnification Agreement are
reasonable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
light of the foregoing, our compensation committee and board of directors recommended that the shareholders approve the form of Indemnification
Agreement for directors and officers of SciSparc, attached as Annex C to this proxy statement/prospectus, effective upon the close of
the Special Meeting, and authorize the execution and delivery of such Indemnification Agreement with all office holders of SciSparc to
be in office immediately following the close of the Special Meeting or thereafter elected or appointed as an office holder of the Company.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal; background-color: white">Under
the Companies Law, the adoption of the proposed resolution requires the approval of the compensation committee, board of directors and
shareholders, in that order.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SCISPARC BOARD OF DIRECTORS RECOMMENDS
THAT <span style="background-color: white">SCISPARC</span> SHAREHOLDERS VOTE &#8220;FOR&#8221; PROPOSAL NO. 2 TO APPROVE THE FORM OF
INDEMNIFICATION AGREEMENT BETWEEN SCISPARC AND ITS OFFICE HOLDERS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 3</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of a one-time cash bonus to SciSparc&#8217;s
Chief Executive Officer, Chairman and President</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Special Meeting, shareholders
will be asked to approve a one-time bonus to SciSparc&#8217;s Chief Executive Officer, Chairman and President, which bonus shall be subject
to and contingent upon the approval of Proposal No. 1, and the closing of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under
                                            the Companies Law, the compensation of directors and officers must comply with the company&#8217;s
                                            compensation policy and requires the approval of the company&#8217;s compensation committee,
                                            the board of directors and shareholders, in that order. Our compensation policy was approved
                                            by our shareholders on June 26, 2025, or the Compensation Policy. The compensation committee
                                            and the <span style="background-color: white">board of directors</span> have reviewed, discussed
                                            and approved the proposed bonuses as detailed hereunder, in light of our Compensation Policy,
                                            and noted that Mr. Adler&#8217;s bonus is in line with the terms and conditions of SciSparc&#8217;s
                                            Compensation Policy; however, Mr. Weiss&#8217;s and Mr. Shrem&#8217;s bonuses are not in
                                            line with the terms and conditions of the Compensation Policy.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Compensation
Policy states that SciSparc may grant its Chief Executive Officer a special bonus as an award for special achievements (such as in connection
with mergers and acquisitions) or as a retention award, at the compensation committee&#8217;s and the board of directors&#8217; discretion,
subject to any additional approval as may be required by the Companies Law, or the Special Bonus. According to SciSparc&#8217;s Compensation
Policy, any such Special Bonus will not exceed 200% of the Chief Executive Officer&#8217;s annual base salary. However, SciSparc&#8217;s
Compensation Policy does not provide for the grant of special bonuses to the Chairman or the President. Therefore, and in light of the
lapse of the Compensation Policy, in considering the bonuses for the Chairman, the President, and the Chief Executive Officer, the compensation
committee and the board of directors also considered certain factors as required by the Companies Law. In addition, the compensation
committee and the board of directors considered SciSparc&#8217;s cash position, the Chairman&#8217;s, President&#8217;s, and Chief Executive
Officer&#8217;s efforts relating to the transactions contemplated under the Merger, and the fact that the bonuses will only be distributed
contingent upon the consummation of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s President,
Mr. Itschak Shrem, and Chairman of the board of directors, Mr. Amitay Weiss, both currently receive a monthly service fee of NIS 52,500
(approximately $14,500), and received a grant of options to purchase 1,196 ordinary shares and a grant of 200,000 restricted share units
under the SciSparc 2023 Share Incentive Plan. In addition, they are entitled to receive an annual bonus of up to 6 monthly fees and up
to 8 monthly fees in the event of over-achievement. Such bonuses are payable upon meeting objectives and targets that are set by our
Chief Executive Officer and compensation committee, and are subject to approval annually by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Chief Executive
Officer and Chief Financial Officer, Mr. Oz Adler, currently receives a monthly fee of NIS 55,000 (approximately $15,230), customary
social benefits, reimbursement of travel and other business expenses, and received a grant of options to purchase 1,196 ordinary shares
and a grant of 200,000 restricted shares units under the SciSparc 2023 Share Incentive Plan. Mr. Adler is also entitled to receive an
annual bonus of up to 6 monthly salaries and up to 8 monthly salaries in the event of over-achievement. Such bonus is based on pre-determined
targets as set by our board of directors, following the recommendation of our compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is proposed that in connection
with the closing of the Merger, as a reward for their individual contribution on its execution, Mr. Adler, SciSparc&#8217;s Chief Executive
Officer, will receive a one-time cash bonus of $315,000, <span style="background-color: white">Mr. Weiss, SciSparc&#8217;s Chairman of
the board of directors, </span>will receive a one-time cash bonus of $150,000, <span style="background-color: white">and Mr. Shrem, SciSparc&#8217;s
President will receive a one-time cash bonus in an amount of $50,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
and board of directors of SciSparc believe that the proposed bonuses are designed to appropriately incentivize these officers to realize
and maximize the benefits of the Restructuring Plan, including the Merger Agreement, and hold our executive officers accountable for
executing on the Restructuring Plan. As a result, SciSparc believes that the bonus structure aligns the proposed compensation with shareholder
interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE SCISPARC BOARD OF DIRECTORS RECOMMENDS
THAT <span style="background-color: white">SCISPARC</span> SHAREHOLDERS<br/>
VOTE &#8220;FOR&#8221; PROPOSAL NO. 3 TO APPROVE A ONE-TIME CASH BONUS TO SCISPARC&#8217;S CHIEF EXECUTIVE OFFICER, CHAIRMAN AND PRESIDENT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Proposal No. 4</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Approval of Election of Each of Tomer Levy
and Yaarah Alfi and Ratification of Classes, Subject to Approval of Proposal No. 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Background</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Election of Tomer Levy and Yaarah Alfi</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to Section 5.3(a)(iv)
of the Merger Agreement, SciSparc is required to seek the approval of its shareholders to elect two designees of AutoMax to its Board,
which election shall enter into effect contingent upon the closing of the Merger and upon the effective time of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has submitted the
candidacy of Mr. Tomer Levy and Ms. Yaarah Alfi as the AutoMax designees in accordance with Section 5.3(a)(iv) of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Special Meeting, shareholders
of SciSparc will be asked to elect each of Mr. Tomer Levy and Ms. Yaarah Alfi as directors of the Company, which election shall be subject
to and contingent upon the approval of Proposal No. 1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, each of Mr. Tomer Levy and Ms. Yaarah Alfi has certified to us that they meet all the requirements of the Companies Law for election
as a director of a public company, and possess the necessary qualifications and has sufficient time to fulfill their duties as a director
of SciSparc, taking into account the special needs of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biographical information
concerning Mr. Tomer Levy and Ms. Yaarah Alfi is set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Mr.
                                            Tomer Levy</i></b>, has been serving as VP Business Development and Headquarters and director
                                            of AutoMax since March 2021. Prior to that, between May 2017 and March 2021, Mr. Levy served
                                            as Global AutoMax&#8217;s VP Business Development and Headquarters. Mr. Levy has experience
                                            in a wide variety of managerial roles.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Ms.
Yaarah Alfi</i></b>, has been serving as chief financial executive of AutoMax and its subsidiaries since March 2021. Ms. Alfi previously
served as controller for Global AutoMax from January 2018 until March 2021. Between 2015 and 2018, Ms. Alfi was employed as a certified
public accountant at Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Additionally, Ms. Alfi has experience in
a wide variety of managerial, financial, tax and accounting roles. Ms. Alfi holds a B.A. in Accounting and Business management from The
College of Management, Israel and is a certified public accountant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Ratification of Classes</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the Merger Agreement
provides that such designees of AutoMax must be assigned to classes within our Board&#8217;s staggered structure such that one such designee
will be elected for a three year term and the other such designee will be elected for a two year term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board currently consists
of seven directors who are divided into three classes with staggered three-year terms as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Class&#160;I directors
    consist of Ms. Liat Sidi and Mr.&#160;Amnon Ben Shay and their terms will expire at our annual general meeting of shareholders to
    be held in 2027;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Class&#160;II directors
    consist of Mr.&#160;Lior Vider, Mr.&#160;Alon Dayan and Mr. Moshe Revach and their terms expire at our annual general meeting of
    shareholders to be held in 2028; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Class&#160;III directors
    consist of Mr.&#160;Amitay Weiss and Mr.&#160;Itschak Shrem and their terms will expire at the annual general meeting of shareholders
    to be held in 2026.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the effective time of
the Merger, each of Mr. Lior Vider, Mr. Alon Dayan and Mr. Itschak Shrem will resign as members of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply with our
Articles of Association, which requires that members of the Board be classified into three classes as nearly equal in number as practicable,
and the terms of the Merger Agreement, shareholders will be asked to reclassify the class structure of our Board in accordance with the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Class&#160;I directors
    consist of Ms. Liat Sidi and Ms. Yaarah Alfi and their terms will expire at our annual general meeting of shareholders to be held
    in 2027;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Class&#160;II directors
    consist of Mr.&#160;Amnon Ben Shay and Mr.&#160;Moshe Revach and their terms expire at our annual general meeting of shareholders
    to be held in 2028; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the Class&#160;III directors
    consist of Mr.&#160;Amitay Weiss and Mr. Tomer Levy and their terms will expire at the annual general meeting of shareholders to
    be held in 2026.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of any
doubt, SciSparc&#8217;s shareholders will be asked at the Special Meeting to vote in favor of the election of Mr. Tomer Levy, Ms. Yaarah
Alfi and the ratification of the classes of our Board in one single proposal such that each of the foregoing actions will only enter
into effect if Proposal No. 1 is approved at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>THE SCISPARC BOARD OF
DIRECTORS RECOMMENDS THAT SCISPARC SHAREHOLDERS<br/>
VOTE &#8220;FOR&#8221; PROPOSAL NO. 4 TO APPROVE THE ELECTION OF EACH OF TOMER LEVY AND YAARAH ALFI, AND RATIFICATION OF CLASSES, SUBJECT
TO APPROVAL OF PROPOSAL NO. 1.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="background-color: white">SciSparc
</span>BUSINESS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>History and Development of the Company</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s legal
and commercial name is SciSparc Ltd. SciSparc was incorporated in the State of Israel on August 23, 2004, and is subject to the Companies
Law. SciSparc&#8217;s registered office and principal place of business is located at 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup>
Floor, Tel Aviv 6971916, Israel. SciSparc&#8217;s telephone number in Israel is: +972-73-3447180.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s website
address is http://www.scisparc.com. The information contained on SciSparc&#8217;s website or available through its website is not incorporated
by reference into and should not be considered a part of this prospectus, and the reference to its website in this prospectus is an inactive
textual reference only. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the SEC. SciSparc&#8217;s filings with the SEC will also be available to
the public through the SEC&#8217;s website at www.sec.gov.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc is a foreign private
issuer as defined by the rules under the Securities Act and the Exchange Act. SciSparc&#8217;s status as a foreign private issuer also
exempts us from compliance with certain laws and regulations of the SEC, including the proxy rules and the short-swing profits recapture
rules. In addition, it will not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently
or as promptly as U.S. domestic companies registered under the Exchange Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s capital
expenditures for 2024, 2023 and 2022 amounted to $0, $0 and $9,200, respectively. These expenditures were primarily for purchases of
fixed assets. SciSparc&#8217;s purchases of fixed assets primarily include, computers, and equipment used for the development of its
products, and it financed these expenditures primarily from cash on hand<span style="background-color: white">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Overview &#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies and
assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following development programs based on
&#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptors, or CBR, agonists:
SCI-110 for the treatment of Tourette syndrome, or TS, for the treatment of obstructive sleep apnea, or OSA, and for the treatment of
Alzheimer&#8217;s disease and agitation; and SCI-210 for the treatment of Autism Spectrum Disorder, or ASD, and Status Epilepticus, or
SE. SciSparc also has a majority-owned subsidiary whose business focuses on the sale of hemp seeds oil-based products and others on Amazon
Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 13, 2024, SciSparc entered into the license agreement to out-license the SCI-160 program, which was a novel pharmaceutical preparation
containing a cannabinoid receptor type 2 agonist for the treatment of pain, to Polyrizon. Therefore, SciSparc is no longer engaged in
development of this pharmaceutical product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-110
is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and
(2) CannAmide&#8482;, a proprietary PEA, formulation. PEA is an endogenous fatty acid amide that belongs to the class of nuclear factor
agonists, which are molecules that regulate the expression of genes. SciSparc believes that the combination of THC and PEA may induce
a reaction known as the &#8220;sparing effect,&#8221; which has strong potential to treat various diseases of the central nervous system
such as TS and Alzheimer&#8217;s disease and agitation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SCI-210
is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;. SciSparc believes that the combination of
CBD and PEA may also induce a sparing effect reaction, which has strong potential to treat various diseases such as ASD and SE.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that modulating CB2 receptor activity by selective CB2 receptor agonists holds unique therapeutic potential for addressing pain
conditions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the positive results obtained in a phase IIa TS study conducted at Yale School of Medicine, SciSparc developed a regulatory dossier
that was submitted to the German Federal Institute for Drugs and Medical Devices, or BfArM, and the Israeli Ministry of Health, or MoH,
and the FDA for its SCI-110 program for TS. SciSparc plans to submit this regulatory dossier to the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2021, SciSparc announced an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical
trial to evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using its
proprietary cannabinoid-based technology. In December 2021, The Israeli Medical Center for Alzheimer&#8217;s recruited the first patient
to participate in the phase IIa clinical trial. In June 2023, SciSparc announced positive topline results from its Phase IIa clinical
trial of SCI-110 in patients with Alzheimer&#8217;s disease and agitation at the Israeli Medical Center for Alzheimer&#8217;s, suggesting
that SCI-110 is safe and tolerable while significantly improving agitation symptoms over time in the elderly population with Alzheimer&#8217;s
disease. This Phase IIa clinical trial was an open label study, which included 18 patients diagnosed with Alzheimer&#8217;s disease and
agitation, to evaluate the safety, tolerability and efficacy trends of twice daily oral administration of SCI-110.&#160;Results showed
that the clinical trial met its primary endpoints of the number of drop-out subjects due to poor tolerability and the number of clinical
trial treatment-related adverse events, with no SCI-110 related safety issues observed and no dropouts from the clinical trial due to
clinical trial medication. Specifically, SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis of
the clinical trial results showed that the clinical trial also met its secondary end point of change from baseline to end of treatment
in agitation measured by the Cohen Mansfield Agitation Inventory where out of the fifteen patients treated with SCI-110 at least two
consecutive times during the trial, thirteen of them at doses ranging between 7.5mg-12.5mg/day showed amelioration in agitation with
no need to use rescue medication to control agitation. Although not significant, in the exploratory endpoints, eleven patients reduced
food intake and showed feeding difficulties, as measured by the Edinburgh Feeding Evaluation in Dementia scale. There was not an effect
observed resulting from the treatment on cognition and sleep quality, as measured by the Mini Mental State Examination and by the Sleep
Order Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 8, 2022, SciSparc announced that it has received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct
its clinical trial for SCI-210 in patients suffering ASD. On January 9, 2023, SciSparc signed an agreement with Soroka Medical Center
to conduct the clinical trial with pediatric patients suffering from ASD. SciSparc&#8217;s regulatory request to carry out this clinical
trial was granted by the Israeli Medical Cannabis Agency, or IMCA, on July 10, 2023. This randomized, double-blind placebo-controlled
clinical trial to evaluate the potential efficacy, safety and tolerability of SCI-210 in treating patients with ASD was initiated in
July 2023.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>SciSparc&#8217;s
Pharmaceutical Drug Development Programs</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SCI-110
- TS, Alzheimer&#8217;s disease and agitation</span>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that its pharmaceutical product candidate, SCI-110, offers a safe and potentially effective solution for a variety of medical
concerns. Despite being in its early phases of clinical testing, the application of SCI-110 has extended into several treatments, including
TS and Alzheimer&#8217;s disease and agitation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>TS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">TS
is a neuropsychiatric disorder, characterized by physical (motor) tics and vocal (phonic) tics. Motor tics generally precede the development
of phonic tics in TS, and the onset of simple tics usually predates that of complex tics. TS ranges from mild symptoms to loud noises
and forceful movements that can result in self-injury (e.g. punching oneself in the face, repeating other people&#8217;s words or involuntary
swearing). Many with TS experience additional neurobehavioral problems and comorbidities including inattention, hyperactivity and impulsivity,
anger control problems, sleep difficulties, and obsessive-compulsive symptoms. Pharmacotherapy is used when symptoms are more severe
and interfere with the ability to function. Furthermore, according to the CDC, in most cases, the prevalence of tics decreases during
adolescence and early adulthood, and sometimes disappears entirely; therefore, there are a limited number of adults with TS and it is
usually manifested mainly through moderate to severe symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Market
Size</span>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
rising healthcare expenditure, favorable government initiatives, increase in use of telemedicine and increasing aging population will
drive the TS treatment market. North America was the largest region in the TS treatment market, accounting for 47.72% or $1.06 billion
of the total in 2023. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing
regions in the TS treatment market will be Asia-Pacific and Western Europe, where growth is predicted to be at CAGRs of 7.21% and 6.26%
respectively. These will be followed by North America and South America, where the markets are expected to grow at CAGRs of 5.96% and
5.14%, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
global TS treatment market size was approximately $2.23 billion in 2023 and is expected to reach $2.98 billion by 2028.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the CDC, the prevalence of moderate to severe TS is reported to be 44%, indicating a significant portion of individuals experiencing
notable symptoms of the condition. Interestingly, adolescents between the ages of 12 and 17 show a more than twofold likelihood of being
diagnosed with TS compared to children aged 6 to 11. It highlights the impact of TS on various age groups. It emphasizes the substantial
demand for effective treatments within the TS treatment market to address the diverse needs of individuals with the condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the CDC, 83% of children diagnosed with TS also have at least one additional mental, behavioral, or developmental disorder that serves
as a driver for the TS treatment market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pharmacological
intervention is considered the first line of therapy for TS, but is reserved for more severe symptoms that interfere with the individual&#8217;s
ability to function. Today, a full class of drugs that interact with dopamine and non-dopamine systems in the brain are used in the treatment
of TS symptoms. Although as of the date of this prospectus, the FDA has approved only two pharmacological treatments (for adult TS- haloperidol
and pimozide &#8211; these treatments have a &#8220;black box warning&#8221;. Many drugs approved or off-label to treat TS are limited
to the treatment of a narrow range of TS symptoms (mainly tics), and are associated with severe side effects, both of which limit their
utility. Furthermore, several of these drugs have a black box warning on their label due to their potentially lethal effect. A black
box warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence
of an association of a serious hazard with the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
medications commonly used to treat symptoms of TS can be divided into the following groups:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Antipsychotic medications:
    belong to a class of drugs primarily used to manage psychosis (including haloperidol, pimozide and fluphenazine), all of which are
    associated with severe side effects (including weight gain, sedation, akathisia (a state of agitation, distress, and restlessness),
    nausea and tardive dyskinesia (involuntary movements of the face and jaw), among others).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Alpha2 Adrenergic Agonists:
    belong to a class of drugs primarily used to manage hypertension and migraine headaches prevention (including clonidine and guanfacine),
    which have limited utility despite common application to children with Attention Deficit Hyperactivity Disorder, or ADHD. Similar
    to antipsychotic medications, these also are associated with several side effects, and some of them, such as clonidine, might even
    be lethal.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Benzodiazepines, an anticonvulsant
    or antiepileptic drug: belong to a class of drugs primarily used to manage seizures, panic disorder and movement disorders. Of these,
    Clonazepam is used off-label for the reduction of tics in TS patients, which also has associated negative side effects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
the currently used medications are managing only a small number of disease symptoms with limited efficacy and questionable safety, there
is a clear unmet medical need for the management of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-110 Solution for TS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
SCI-110 platform is a drug candidate for the treatment of TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 4, 2018, SciSparc announced topline results of its Phase IIa investigator-initiated study at Yale University of SCI-110 for the
treatment of TS. The study was a single-arm, open-label trial, in which each subject both received one daily treatment of SCI-110 via
oral administration and was followed-up for a period of 12 weeks. 16 subjects participated in the study and received SCI-110 at the Yale
University Child Study Center at Yale University. The primary endpoint of the study was to assess the performance of SCI-110 in the treatment
of adult patients suffering from symptoms of TS, as measured by the Yale Global Tic Severity Scale Total Tic Score, or YGTSS-TTS, the
customary index for assessing symptom severity. Treatment was given in a dose titration regimen with a maximum dose of SCI-110 consisting
of 10mg dronabinol and 800mg CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
topline results of the study showed that each of these 16 subjects with medication-refractory TS sustained a significant reduction of
tic symptoms (paired t-test: YGTSS-TTS mean difference (mean +/- SD) =7.9+/-8.4, t= 3.7, df=15, p=0.002) from baseline (YGTSS-TTS: 38.4
+/- 8.3) to endpoint YGTSS-TTS: 30.5 +/- 10.9). This resulted in an average tic reduction of 21% across the entire sample of 16 TS subjects.
Six of the 16 medication-refractory TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater
than 25%. Improvement over time with treatment was also observed when generalized linear models were used to analyze repeated measures
data on the YGTSS-TTS. In the study, SCI-110 demonstrated no significant effects on comorbid ADHD, anxiety, depression or obsessive-compulsive
disorder, or OCD, symptoms. The medication was generally well-tolerated by the subjects with only two subjects stopping treatment early
(one due to sedation and another due to lack of improvement in tic symptoms). 12 of the 16 subjects elected to proceed with a 24-week
extension phase of the trial, which was also completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the Phase IIa study, SciSparc announced in June 2023 BfArM approval for a Phase IIb clinical trial for SCI-110 in subjects suffering
from TS, with a view to such clinical trial being carried out in Germany at the Hannover Medical School. In August 2022, SciSparc received
MoH approval to conduct the clinical trial in Israel at Sourasky Medical Center. SciSparc also received Ethics Committee approvals in
2022 from Hannover Medical School and Sourasky Medical Center and Internal Review Board approval in 2023 at the Child Study Center at
Yale School of Medicine.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2023, SciSparc initiated the Phase IIb clinical trial at Sourasky Medical Center. The 86 patients in the clinical trial are
randomized to either oral SCI-110 or placebo at a 1:1 ratio. The overall estimated clinical trial duration is 18-24 months from the time
all clinical sites are up and running. SciSparc may also be required to conduct further preclinical studies in parallel to its clinical
plans as part of registration process with the FDA and EMA. Following these clinical trials, if successful, SciSparc intends to conduct
a Phase III, multinational, multicenter, randomized, double-blind, parallel-group, placebo controlled clinical trial to evaluate the
safety, tolerability and efficacy of up to twice daily oral SCI-110 in treating TS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2016, SciSparc submitted a request for orphan drug designation to the FDA for SCI-110 for the treatment of TS. The request is still
pending and SciSparc is in communication with FDA. SciSparc&#8217;s last communication was in December 2020 when it received a letter
from FDA raising a concern that it will be hard to limit the use of the pharmaceutical product to the subset of patients SciSparc is
pursuing. There is no assurance that SciSparc will successfully obtain orphan drug designation for TS. However, in light of the fact
that SciSparc disagrees with this concern expressed by the FDA, it requested a clarification call. In the clarification call conducted
on February 2, 2021, SciSparc agreed with the FDA concern about SciSparc&#8217;s ability to limit the use of the pharmaceutical product
to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics population so SciSparc suggested
to amend its preliminary request and asked to include only adults in the treated population. An amendment letter was discussed and the
FDA described what it would want to see in such an amendment. In March SciSparc sent its response to the FDA. In June 2021, SciSparc
received a response from the FDA, explaining that they are unable to grant its request until new information becomes available to support
its request for orphan drug designation. SciSparc will re-visit the application after it obtains clinical results from its phase IIb
clinical trial in TS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the FDA does not allow SciSparc to pursue the Section 505(b)(2) regulatory pathway as anticipated, it may need to conduct additional
clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur,
the time and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. In a pre-IND meeting SciSparc had with FDA in February 2018, the FDA did not oppose its plans to submit an NDA via the 505(b)(2)
pathway relying, in part, on clinical and nonclinical information from literature related to dronabinol and the FDA&#8217;s previous
finding of safety and efficacy for the reference listed drug (Marinol).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2024, SciSparc submitted an IND application with the FDA for its phase IIb clinical trial for SCI-110.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Alzheimer&#8217;s
disease and Agitation</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Alzheimer&#8217;s
disease is the most common type of dementia, accounting for over two-thirds of cases of dementia. Alzheimer&#8217;s disease is a neurodegenerative
disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention,
reasoning and judgment. Symptoms of Alzheimer&#8217;s disease depend on the stage of the disease. Neuropsychiatric symptoms like apathy,
social withdrawal, disinhibition, agitation, psychosis, insomnia, poor appetite and wandering are also common in the mid to late stages.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Market
Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is estimated that the
global Alzheimer&#8217;s therapeutics market is projected to reach $10.4 billion by 2035 from $4.28 billion in 2023 with a CAGR of 9.23%.
The demand for Alzheimer&#8217;s therapeutics is accelerating due to a wave of breakthrough drug approvals, increased investment in disease-modifying
therapies, and advancements in precision medicine. Researchers are focusing on transforming treatments from symptom management to targeted
interventions that slow disease progression. The integration of monoclonal antibodies, small-molecule inhibitors, and gene therapies
is expected to reshape treatment efficacy and accessibility.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
current pharmacological treatment of agitation in Alzheimer&#8217;s disease has an unsatisfactory benefit/risk ratio and often involves
using off-label drugs. Antipsychotic drugs, which are the most frequently used drugs for this purpose, are only marginally better than
placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-110 Solution for Alzheimer&#8217;s disease and Agitation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug product, SCI-110, is a unique proprietary combination of dronabinol (synthetic delta-9-tetrahydrocannabinol (&#916;&#8313;-THC),
and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2021, SciSparc signed an agreement with The Israeli Medical Center for Alzheimer&#8217;s, to conduct a phase IIa clinical trial
to evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer&#8217;s disease and agitation using its proprietary
cannabinoid-based technology. The study&#8217;s primary objective is the safety of SCI-110 and the secondary objective is the ability
of the compound to ameliorate agitation and other behavioral disturbances in patients with Alzheimer&#8217;s disease.</p><div>


</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Phase IIa clinical trial was an open label clinical trial, which included 18 patients diagnosed with AD and agitation, to evaluate the
safety, tolerability and efficacy trends of twice daily oral administration of SCI-110. Results showed that the clinical trial met its
primary endpoints of the number of drop-out subjects due to poor tolerability and the number of clinical trial treatment-related adverse
events, with no SCI-110 related safety issues observed and no dropouts from the clinical trial due to clinical trial medication. Specifically,
SCI-110 did not cause delirium, oversedation, hypotension or falls. In addition, analysis of the clinical trial results showed that the
clinical trial also met its secondary endpoint of change from baseline to end of treatment in agitation measured by the Cohen Mansfield
Agitation Inventory, or CMAI, where out of 15 patients treated with SCI-110 at least two consecutive times during the clinical trial,
thirteen of them at doses ranging between 7.5mf-12.5mg/day showed amelioration in agitation with no need to use rescue medication to
control agitation. CMAI is a standard measure for measuring agitation in people with dementia. The clinical trial showed that these subjects
had amelioration in agitation (paired t-test: CMAI mean difference (mean +/- SD) =10.6+/-14.88, t= 2.76, df=14, p=0.015) from baseline
(CMAI: 45.87 +/- 15.17) to endpoint (CMAI: 35.27 +/- 11.09). This resulted in an average reduction of 23% across the entire sample.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the exploratory endpoints, a decrease in eating and feeding difficulties was shown in 11 patients out of the 15 patients treated at least
two consecutive times during the trial as measured by the Edinburgh Feeding Evaluation in Dementia Scale, although the increase was not
significant. No effect from the treatment was observed on cognitive measurements and sleep quality, as measured by the Mini Mental State
Exam and by the and the Sleep Disorder Inventory, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SCI-210
- ASD and SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
believes that its pharmaceutical product candidate, SCI-210, offers a safe and potentially effective solution for a variety of medical
concerns. Despite being in its early phases of pre-clinical and clinical testing, the application of SCI-210 has extended into several
treatments, including ASD and SE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>ASD</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">ASD
is a neurodevelopmental disorder. The specific etiologies and neural bases of autism remain largely unknown; it has been proposed that
alterations in multiple genes in combination with environmental factors constitute the cause for the development of the autism phenotype.
ASD is characterized by early dysfunction in communication and social interactions, presenting with repetitive, restrictive, stereotyped
patterns of behavior and loss of interest in diverse activities. Additionally, ASD is frequently accompanied by impairments in adaptive
functioning, sensory processing disorder, aggression, or self-injury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2024, SciSparc announced the enrollment of the first five patients in the clinical trial of SCI-210 in children with ASD at Soroka
Medical Center in Israel. In December 2024, SciSparc announced the renewal by the Israeli Medical Cannabis Agency of the clinical trial
for SCI-210 in children with ASD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">Market
Size</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the World Health Organization, or WHO, fact sheet on epilepsy in 2024, around 50 million people have epilepsy, making it one of the
most common neurological diseases globally. The risk of premature death in people with epilepsy is up to three times higher than for
the general population.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Globally,
an estimated 5 million people are diagnosed with epilepsy each year. In high-income countries, there are estimated to be 49 per 100,000
people diagnosed with epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The epilepsy drugs market
is forecast to experience significant growth, with estimations projecting the market to reach $11.85 billion by 2033, up from $7.92 billion
in 2024. The growth is attributed to heightened global incidence of epilepsy, advancement in drug research and development, and a surge
in public and healthcare recognition of the condition. Improved healthcare spending and increased accessibility to medical treatments
further amplify market expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Strategic initiatives taken
by global health organizations and campaigns to raise awareness about epilepsy are significantly influencing the market dynamics. Governmental
health bodies are reportedly fostering an environment conducive to the approval of new epilepsy treatments, which is propelling the market
forward. These campaigns, coupled with the growing emphasis on National Epilepsy Awareness Month initiatives, improve the understanding
of epilepsy and encourage an increase in the quality and reach of treatments available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry
has seen a host of developments aimed at enhancing the treatment for epilepsy. Increased investment in research and development aspires
to produce new and improved drugs, addressing not only medical needs but also economic considerations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
cure exists for ASD. The goal of treatment is to maximize patients&#8217; ability to function by reducing ASD symptoms and supporting
development and learning. Treatment options may include: (i) behavior and communication therapies - successful programs typically include
a team of specialists and a variety of activities to improve social skills, communication and behavior; and (ii) medications - to date,
no medication can improve the core signs of ASD, specific medications can help control comorbidity symptoms. The main symptoms to be
treated in patients with ASD are: epilepsy, aggression, hyperactivity, irritability, attention deficit, sleep problems, obsessions and
anxiety. Antipsychotic drugs are sometimes used to treat severe behavioral problems and antidepressants may be prescribed for anxiety.
Among the main drugs used in the treatment of ASD are typical antipsychotics such as Haloperidol, Thioridazine, Chlorpromazine and the
atypical risperidone, Olanzapine and Clozapine, whose use is more common. These are used with the objective to treat the child&#8217;s
behavioral problems by blocking the D2 dopaminergic channels, causing a diminished reaction to stimuli known as &#8220;neuroleptic syndrome,&#8221;
observed as calm and quiet behavior in the child. In turn, some atypical antipsychotics also exhibit an antagonism of type 2A receptors
for serotonin, aside from their effect on the D2 channels. It is important to individualize the patient when these drugs are administered,
since there are no pre-established criteria for dosing and such drugs could present extrapyramidal adverse effects such as tremors, sialorrhea,
sedation, impaired liver function, etc. Serotonin reuptake inhibitors such as Fluoxetine, Paroxetine and Sertraline are given to children
with autism because they have been found to increase 25% of serotonin levels in platelets and serum. This treatment is based on suppressing
symptoms such as anxiety, depression, OCDs, and self-injurious behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unfortunately,
about 40% of children with ASD and disruptive behavior do not respond well to standard behavioral and medical treatment. Consequently,
an exceptionally high percentage of parents are seeking help through unproven methods, including the use of compounds made of the cannabis
plant.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-210 Solution for ASD</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug product SCI-210 is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 8, 2022, SciSparc announced that it received approval from the MoH and Ethics Committee of Soroka Medical Center to conduct its
clinical trial for SCI-210 in patients suffering ASD. On January 9, 2023, SciSparc signed an agreement with Soroka Medical Center to
conduct the clinical trial on pediatric patients suffering from ASD. Its regulatory request to carry out this clinical trial was granted
by the IMCA on July 10, 2023. This randomized, double-blind placebo-controlled clinical trial to evaluate the potential efficacy, safety
and tolerability of SCI-210 in treating patients with ASD was initiated in July 2023. SciSparc initiated patient enrollment for the clinical
trial in January 2024. In February 2024, SciSparc announced that it had successfully completed the manufacturing of the SCI-210 treatment
for the clinical trial. In March 2024, the first patient was enrolled in this clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>SE</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SE
is a common life-threatening medical emergency characterized by an acute, prolonged epileptic seizure. SE can represent either the exacerbation
of a pre-existing seizure or the initial manifestation of epilepsy. In order to avoid neurological sequelae, a timely treatment should
be started. When the continuous seizure does not respond to conventional drug treatment, SE can pose serious life-threatening risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
2018, GW&#8217;s Epidiolex, a plant-based, pharmaceutical grade CBD extract was approved by the FDA for the treatment of seizures associated
with two rare and severe forms of epilepsy. SciSparc&#8217;s study for SCI-210 previously met its endpoint (efficacy) when comparing
its effect to the effect of CBD alone in an in-vitro hepatocytes model of fat accumulation; the effect of CBD was enhanced by the addition
of PEA, lowering the required effective concentration of CBD. In this study, SciSparc hopes to meet the study endpoint (efficacy) when
comparing treatment using its pharmaceutical product candidate compared to the effect of CBD alone on SE and its neurological cognitive
sequelae.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="text-decoration:underline">Current
Treatment</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
first-line treatment for early SE mainly comprises the administration of benzodiazepines, the most frequently used of which include Diazepam,
Lorazepam, and Midazolam. Seizures continue and progress to established SE in about 40% of patients with Convulsive Status Epilepticus
(CSE) despite benzodiazepine administration as the first-line treatment. The second-line treatment for established SE consists of a loading
dose of antiepileptic drugs. Frequently used antiepileptic drugs include Phenytoin or Fosphenytoin, Valproate, Levetiracetam, Phenobarbital,
and Lacosamide. There is no clear evidence for the relative superiority of any of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="text-decoration:underline">SciSparc&#8217;s
SCI-210 Solution for SE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
drug product SCI-210 is a proprietary drug candidate based on two components: (1) CBD, and (2) CannAmide&#8482;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 7, 2022, SciSparc announced positive results from its pre-clinical study of SCI-210 on SE, conducted at The Sheba Fund for Health
Services and Research at Chaim Sheba Medical Center, which reaffirms the potential of its proprietary combination products to have a
positive effect while minimizing adverse side effects. SciSparc&#8217;sSCI-210 platform combines PEA with CBD. The non-clinical trial
objective was to study the potential therapeutic effects of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive
sequelae. A pilocarpine SE-induced mice (C57BL/6 male) model to study SCI-210&#8217;s effects on seizure severity and mortality was used.
After calibration, four groups of animals were studied: an effective-high dose CBD group, a sub-effective dose CBD group, a SCI-210 group
(a combination of sub-effective CBD dose and PEA) and a non-treated control group. The results indicated differences in mortality rate
as well as seizure rates over time. In the low-CBD group, a higher mortality rate (although not significant) was found and therefore
it is reasonable to believe that no significant impact on neuronal protection was achieved. In the high-CBD group, higher, although not
significant, levels of neuronal protection were found together with a decreased mortality rate when compared to control. The level of
neuronal protection in the SCI-210 treatment was significantly higher compared to the control group and no mortality was found in this
group. It was concluded that SCI-210 treatment may potentially be more effective than a CBD monotherapy. Moreover, since the concentrations
used in the combo treatment are significantly lower than those recommended for CBD monotherapy, this treatment also has the potential
to be safer.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Other Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>SciSparc&#8217;s
CannAmide&#8482; Anti-Inflammatory and Chronic Pain Solution</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">CannAmide&#8482;
is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor sensitivity and inhibiting their metabolism,
and is particularly attractive therapeutically as it appears to have a very high safety profile with low or no abuse liability. Although
numerous clinical trials have shown the favorable effect of PEA as an analgesic agent it has low solubility.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2019, SciSparc announced the issuance of a product license for its proprietary PEA oral tablet CannAmide&#8482; by Health Canada&#8217;s
Natural and NNHPD, for the recommended use as an anti-inflammatory and to help relieve chronic pain. This license was issued by the NNHPD
under the authority of the NHPR. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended
dose of one tablet three times a day. Chronic pain is estimated to affect 38% of people worldwide, and according to an analysis by the
World Health Organization, half of the most prevalent conditions responsible for living with disability is characterized by the presence
of different kinds of pain. With the NNHPD license, SciSparc is able to offer safe and beneficial non-opiate pain management products.
CannAmide&#8482;&#8217;s active compound PEA is a cannabimimetic compound that regulates endocannabinoid levels by enhancing receptor
sensitivity and inhibiting their metabolism, and is particularly attractive therapeutically as it appears to have a very high safety
profile with low or to no possibility for abuse. On February 10, 2021, SciSparc announced that it had entered into an agreement with
Procaps, a leader in contract development and manufacturing services in softgel advanced technologies for the global pharmaceutical and
nutraceutical industries, to develop and commercially manufacture both of SciSparc&#8217;s drug candidates, SCI-110 and its proprietary
PEA oral tablets CannAmide&#8482;, in softgel capsule form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Cannabinoids
have great therapeutic potential and have been used for years for medicinal purposes. For example, cannabis and cannabinoids are being
used to improve the quality of life of patients with numerous and diverse indications (oncological patients, chronic pain conditions,
etc.). SciSparc believes that the novel approaches and unique mechanism of action of SciSparc&#8217;s proprietary technology platforms,
including its drug delivery systems and unique combination and specific dosages, may be expanded to treat additional diseases and unmet
medical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the future, SciSparc may consider expanding its pipeline to include these additional indications.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Collaboration
with Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 7, 2022, SciSparc entered into a cooperation agreement, or the Cooperation Agreement, with Clearmind. The Cooperation Agreement
includes, among others, examination of the benefit of integrating the core technologies of each company to explore the development of
psychedelic-centric drug candidates and targeting mental health-related diseases. Pursuant to the terms of the Cooperation Agreement,
SciSparc conducted a joint pre-clinical study with Clearmind. Under the Cooperation Agreement, SciSparc aims to pursue, develop and commercialize
psychedelic-centric drug candidates. Its collaboration with Clearmind has resulted as of the date of this prospectus, in the filing of
thirteen patent applications. All patent applications refer to the combination of SciSparc&#8217;s CannAmide&#8482; with Clearmind&#8217;s
5-Methoxy-2-aminoindane, or MEAI, an innovative proprietary psychedelic treatment for addictions and others.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2022, SciSparc announced that its collaboration with Clearmind resulted in the filing of a provisional patent application related
to a psychedelic combination therapy treating numerous binge behaviors. The patent application referred to the combination of SciSparc&#8217;s
CannAmide&#8482; with Clearmind&#8217;s MEAI. The patent application followed successful pre-clinical studies that showed a significant
dose dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the
CannAmide&#8482; treatment at the lower sub-effective MEAI dose. Additionally, in May 2022, SciSparc announced positive safety profile
results from its joint pre-clinical trial with Clearmind. The clinical trial tested the proprietary combination of SciSparc&#8217;s CannAmide&#8482;
with Clearmind&#8217;s psychedelic molecule, MEAI, for alcohol consumption. A histopathology assessment was conducted on several organs
(heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) from all experiment groups (n=3-5 per group) to determine
the safety of the proprietary combination of MEAI and CannAmide&#8482; versus control (mice) that were not exposed to alcohol). The severity
of changes was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results
indicated a high safety profile of the combination treatment with no treatment-related changes observed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2022, SciSparc announced that its collaboration with Clearmind resulted in the filing of a provisional patent application related
to treating cocaine addiction. The patent application refers to the proprietary combination of SciSparc&#8217;s CannAmide&#8482; with
Clearmind&#8217;s MEAI, for treating cocaine addiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2022, SciSparc announced additional positive pre-clinical results of its psychedelic-based pharma collaboration for treatment
for cocaine addiction using MEAI. These pre-clinical study results added to SciSparc&#8217;s announcements regarding its collaboration
with Clearmind for their combination treatment based on SciSparc&#8217;s CannAmide&#8482; compound and Clearmind&#8217;s MEAI for various
addictions, including pre-clinical studies results, the filing of two provisional patent applications related to compositions comprised
of MEAI and n-acylethanolamines and uses thereof and treating cocaine addiction. The pre-clinical trial was led by Professor Gal Yadid
and his team from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) and was designed
to evaluate the possible reward-like effects of MEAI with connection to cocaine and its ability to abolish cocaine-induced conditioned
place preference. In the pre-clinical trial, the self-administration paradigm was utilized, which is the gold-standard model for examining
drug addiction and is based on operant conditioning. Rats were catheterized and trained to self-administer cocaine. The results identified
a statistically significant sub-group within the study, in a non-biased manner and high integrity, which dramatically responded to the
treatment, significantly decreasing the craving for cocaine as compared to non-treated control group. This sub-group, representing 60%
of animals, showed a very high response within the group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2022, SciSparc announced that Clearmind filed a provisional patent application related to metabolic syndromes including obesity,
regarding SciSparc&#8217;s collaboration with Clearmind. The patent application is the third of the collaboration, each referring to
the proprietary combination of SciSparc&#8217;s PEA and Clearmind&#8217;s MEAI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2023, SciSparc announced that announced that Clearmind filed three provisional patent applications were filed by Clearmind with
the USPTO as a part of its ongoing collaboration. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide,
psilocybin, and N,N-dimethyltryptamine and its PEA. Additionally, in February 2023, SciSparc announced that as part of its ongoing collaboration
with Clearmind, Clearmind filed three provisional patent applications with the USPTO, for unique combinations of future psychedelic-based
compounds. The patent applications refer to novel proprietary combinations of 3,4 Methylenedioxymethamphetamine, Ibogaine and Ketamine
each with SciSparc&#8217;s PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2023, SciSparc announced that together with Clearmind, it would conduct a study evaluating its combination treatment for obesity
and metabolic syndrome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2023, Clearmind filed a patent application for the treatment of dyskinesia, a combination of the pyschadelic molecule 3-Methylmethcathinone,
or 3-MMC, and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
November 2023, successful results were announced from a pre-clinical trial on rodents, testing the efficacy of the combination treatment
of PEA and MEAI on obesity, performed by Joseph Tam from the Hebrew University of Jerusalem. The results indicated that there was an
increase in the metabolic process and fat burn, a reduction in appetite and meal sizes, and reductions in ambulation with affecting voluntary
activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2024, SciSparc and Clearmind filed three patent applications under the PCT referring to novel proprietary combinations of lysergic
acid diethylamide, psilocybin, N,N-dimethyltryptamine, and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2024, SciSparc and Clearmind filed three patent applications under the PCT referring to novel proprietary compositions of MDMA,
ibogaine, and ketamine, all combined with PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
March 2024, SciSparc and Clearmind filed a patent application under the PCT referring to the composition of Clearmind&#8217;s MEAI compound
and PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2024, SciSparc and Clearmind filed a patent application under the USPTO for PEA combined with MEAI for treating metabolic syndrome
and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>



</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2024, SciSparc announced that a new article was published by Saja Baraghithy et al. on the promising results from a recent study
on MEAI using Clearmind&#8217;s innovative psychoactive molecule, MEAI, for combating obesity. The study was conducted by a team of experts
lead by Prof. Joseph Tam from the Hebrew University of Jerusalem. The study demonstrated that the treatment significantly induced weight
loss and beneficial changes in body composition in diet-induced obesity (or DIO) mice, without altering food intake, by decreasing fat
mass while preserving lean mass. There was a significant improvement in glucose metabolism, increased energy expenditure and fat utilization,
while maintaining a similar food consumption and increased activity-specific energy expenditure (without overstimulation), providing
support for its potential to impact energy balance. Furthermore, there was a decrease in fatty liver, as evidenced by lower liver triglyceride
and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation. These results further show that
the treatment was well tolerated and led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure
and fat oxidation which in turn indicates increases in the metabolic process and fat burn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
another study, evaluating the acute effect of numerous doses of MEAI on metabolic and behavioral parameters in mice, in combination with
PEA, the administered drug exhibited a remarkable degree of tolerance, leaving the animals&#8217; viability unaffected across all experimental
groups. The most favorable outcomes of the combination treatment were notably pronounced at the MEAI 20 mg/kg dose and PEA 25 mg/kg,
observed as increased energy expenditure, enhanced fat oxidation, and decreased meal sizes. These findings underscore the potential of
MEAI and PEA in modulating various aspects of metabolism, locomotor activity, and feeding behavior, warranting further investigation
of their roles in the regulation of energy homeostasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2025, SciSparc announced the publication of a European patent application submitted by Clearmind under the European Patent Office
for innovative combination therapy of MEAI and N-Acylethanolamines, to binge behavior including alcohol consumption, eating, tobacco
consumption, shopping and sexual conduct. Under this collaboration, SciSparc and Clearmind are researching innovative combination therapies
that integrate psychedelic molecules with the N-acylethanolamines family, including PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2024, SciSparc and Clearmind announced the publication of its patent application under the PCT for innovative combinations of
ketamine and N-acylethanolamines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2024, SciSparc and Clearmind announced the publication of an international patent application under the PCT for MDMA combined
with N-acylethanolamines.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2024, SciSparc and Clearmind announced the publication of a PCT patent application for ibogaine combined with and N-acylethanolamines.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2025, SciSparc announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine
(MDMA) with N-Acylethanolamines. The patent refers to SciSparc&#8217;s innovative combination therapy of N-Acylethanolamines and Clearmind&#8217;s
MEAI, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. Under this
collaboration, the two companies are researching innovative combination therapies that integrate psychedelic molecules with the N-Acylethanolamines
family, including PEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
March 2025, SciSparc announced the publication of a patent application by the South Korean Intellectual Property Office. The patent application
relates to a combination treatment using Clearmind&#8217;s MEAI and SciSparc&#8217;s PEA for the treatment of cocaine addiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
April 2025, SciSparc and Clearmind announced the filing of an International Patent Application for a proprietary treatment targeting
anorexia, bulimia and other eating disorders. The patent application, submitted initially under SciSparc and Clearmind collaboration
agreement, covers the use of 3-MMC in combination with PEA, aiming to address the complex neurobiological and psychological factors associated
with eating disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2025, SciSparc and Clearmind announced the publication of a European patent application by the European Patent Office. The patent
application relates to a combination treatment using Clearmind&#8217;s MEAI and SciSparc&#8217;s PEA for the treatment of cocaine addiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, 13 patents related to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in several other
global jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Polyrizon&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 31, 2022, SciSparc entered into a collaboration agreement with Polyrizon Ltd., or Polyrizon, a biotech company focused on the development
of innovative medical device hydrogels delivered in the form of nasal sprays, or the Polyrizon Collaboration Agreement. As part of this
collaboration, SciSparc worked together to develop a unique technology for the treatment of pain, based on its SCI-160 platform and Polyrizon&#8217;s
Trap and Target<sup>TM</sup>&#160;intranasal drug delivery technology to target the central nervous system. SciSparc agreed to pay development
fees to Polyrizon up to a total of $2,550,000 upon the completion of certain milestones, as well as royalties in the low single digits
upon sales of products under the agreement and additional royalties for sales under any sublicense by us. On August 13, 2024, SciSparc
entered into a termination agreement with Polyrizon to terminate the Polyrizon Collaboration Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 13, 2024, SciSparc entered into an exclusive patent license agreement, or the License Agreement, for the out-licensing of its
SCI-160 program with Polyrizon. Pursuant to the License Agreement, SciSparc granted Polyrizon a royalty-bearing, exclusive, sub-licensable
right and license to the SCI-160 platform, or the License. Pursuant to the License Agreement, SciSparc received 320,000 ordinary shares
of Polyrizon, pre-funded warrants to purchase 364,931 ordinary shares of Polyrizon, and common warrants to purchase 2,054,793 ordinary
shares of Polyrizon, at an exercise price of $4.38 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 30, 2024, pursuant to a share transfer agreement, SciSparc sold all of the Polyrizon ordinary shares and pre-funded warrants
held by it, as well as an aggregate of 1,541,096 Polyrizon common warrants to third parties, for aggregate consideration of $770,548.
In addition, in consideration for the License, SciSparc will receive royalties from sales related to the SCI-160 platform and income
generated from it.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 1, 2025, SciSparc entered into a securities purchase agreement with Polyrizon, pursuant to which SciSparc participated in a private
placement of Polyrizon, and invested $100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary
shares and Series A warrants to purchase ordinary shares, of Polyrizon. In addition, SciSparc entered into an exchange agreement with
Polyrizon, pursuant to which SciSparc exchanged existing ordinary share warrants of Polyrizon held by it for Series A warrants to purchase
ordinary shares of Polyrizon.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Acquisition
of Wellution&#8482;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 14, 2022, SciSparc entered into the Wellution Acquisition Agreement with the Advisor. and the other parties named therein,
to acquire from the Advisor its rights to purchase, the Wellution&#8482; brand. In connection therewith, SciSparc incorporated a new
wholly owned subsidiary,&#160;SciSparc Nutraceuticals, to hold the new assets of the Brand. The Brand sells hemp-based products, including
hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among
other beauty and hair treatment products that are all manufactured in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
accordance with the closing of the Wellution Acquisition Agreement for the Brand which took place on September 30, 2022, SciSparc paid
$4.59 million for the Brand and issued to the Advisor $15 million worth of warrants to purchase up to an aggregate amount of 82,418 SciSparc
ordinary shares, or the Advisor Warrants. The Advisor Warrants had an exercise price of $182 per share and an exercise period of five
years from the closing, until September 30, 2027.The Advisor Warrants were exercisable during the exercise period upon the earlier of
(i) an achievement of $100 million of gross sales by the Brand in the aggregate or (ii) if the price of the SciSparc ordinary shares
closes at $10.00 or above.&#160;On March 26, 2024, the Advisor agreed with SciSparc to waive all its rights under the Advisor Warrants
and have the Advisor warrants cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 23, 2023, SciSparc entered into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to
which, at the closing on March 28, 2023, Jeffs&#8217; Holdings acquired from us 57 shares of common stock of SciSparc Nutraceuticals,
equal to approximately a 49% interest in SciSparc&#8217;s wholly owned subsidiary, SciSparc Nutraceuticals, which owns the Wellution<sup>TM</sup>&#160;Brand,
for a cash consideration of $2.5 million. In addition to the cash consideration upon closing, SciSparc received from Jeffs&#8217; Brands
an additional amount accounting for certain purchase price adjustments related to inventory and working capital, which adjustments increased
the purchase price by approximately $489,330.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the closing of the Wellution Sale Agreement on March 28, 2023, including an equity conversion of the financing amounts SciSparc previously
provided to SciSparc Nutraceuticals for working capital, it holds approximately 51% of the outstanding capital stock of SciSparc Nutraceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the Wellution Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into a consulting
agreement, or the Wellution Management Agreement for the provision of services by Jeffs&#8217; Brands for the management of the Brand
for a monthly fee of $20,000, which was reduced to $10,000 in November 2023. Jeffs&#8217; Brands also received a one-time signing bonus
at the closing in the amount of $51,000. The Wellution Management Agreement is in effect for an undefined period of time and may be terminated
by either party with 30 days&#8217; advance notice.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, pursuant to the Wellution Sale Agreement, at the closing, SciSparc undertook a share exchange with Jeffs&#8217; Brands, in
which SciSparc acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 13,858 of SciSparc&#8217;s ordinary
shares, in each case having an aggregate value of $288,238, or the Share Exchange. The number of shares exchanged was calculated based
on the average closing price of the shares on the Nasdaq for the 30 consecutive trading days ending on the third trading day immediately
prior to the closing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><i>Restructuring Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 25, 2023, SciSparc announced that its board of directors resolved to pursue a Restructuring Plan which may involve transferring
its pharmaceutical activities to NewCo. As part of or independent to the Restructuring Plan, SciSparc intends to examine the possibility
of listing NewCo on a leading stock exchange, while maintaining its controlling interest in NewCo such that it will continue to control
its current business activities. SciSparc also intends to explore other potential new opportunities, activities and investments in a
variety of sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
restructuring and possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or other
business analyses, regulatory approvals, receipt of any necessary consents, final approvals from SciSparc&#8217;s board of directors
and satisfaction of any closing conditions to effectuate such corporate restructuring and listing of NewCo. There can be no assurance
regarding the ultimate timing of the intended restructuring and listing of NewCo or that they will be completed at all. Other than the
signing of the LOI with the Target Company on November 22, 2023, as of the date of this prospectus, SciSparc has not initiated the Restructuring
Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2024, SciSparc
signed the Spin-off LOI for the spin-off of advanced clinical stage pharmaceutical portfolio to a publicly traded company on the TSXV.
Pursuant to the letter of intent, SciSparc will sell, assign, convey and transfer to Miza, certain assets for consideration of common
shares and contingent rights of Miza, based on pre-determined milestones. Following the closing of such transaction, SciSparc would hold
a controlling interest in Miza, the exact percentage of which is contingent on agreeing on definitive terms between the parties. The
resulting entity, in which SciSparc will hold a stake will be active in both the pharmaceutical and supplement sectors. On December 16,
2024, SciSparc entered into the First LOI Amendment, solely to extend the deadline to enter into definitive agreements by no later than
March 31, 2025, which was extended from July 31, 2024, provided that such date may be further extended by mutual written agreement of
the parties, and to close the proposed transaction by no later than April 30, 2025, which was extended from October 31, 2024. On March
28, 2025, SciSparc entered into the Second LOI Amendment, solely to extend the deadline to enter into definitive agreements by no later
than June 30, 2025, which was extended from March 31, 2025, provided that such date may be further extended by mutual written agreement
of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Strategic
Transaction Opportunity Engagement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2023, SciSparc engaged Rosario Capital Ltd. to identify potential opportunities for a strategic transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Non-Binding
Letter of Intent with AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 22, 2023, SciSparc announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated
terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Restructuring Plan, on June 25, 2023, SciSparc entered into a securities purchase agreement with AutoMax, pursuant to which, at
the closing and upon the terms and conditions set forth in the securities purchase agreement with AutoMax, or the AutoMax SPA, SciSparc
invested NIS 2,500,000 (approximately $690,000) in cash, in exchange for ordinary shares of AutoMax based on a price per share of NIS
0.5. Following the closing, SciSparc held approximately 5.6% of the issued and outstanding share capital of AutoMax.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax, as further described in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Bridge
                                            Loan with AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
                                            January 14, 2024, SciSparc entered, as lender, into a bridge loan agreement with AutoMax,
                                            pursuant to which AutoMax received a bridge loan in the amount of $1.4 million, or the Bridge
                                            Loan, further to the previously-announced non-binding letter of intent for SciSparc to acquire
                                            AutoMax. On June 9, 2024, SciSparc entered, as lender, into the Amended Bridge Loan, pursuant
                                            to which AutoMax received an additional loan in the amount of $1.0 million, for an aggregate
                                            amount of $2.4 million. On September 5, 2024, SciSparc entered into the Second Amendment,
                                            pursuant to which SciSparc extended an additional loan in the amount of $1.85 million to
                                            AutoMax under terms similar to the Amended Bridge Loan, bringing the total bridge loan amount
                                            to $4.25 million. &#160;In consideration for the Loan Amount, AutoMax established a first
                                            ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary
                                            AutoMax Direct Import in favor of SciSparc. This subjects SciSparc to additional risk in
                                            the event of a default or partial default on payment of the bridge loan. Moreover, there
                                            can be no assurance regarding the ultimate timing of the Acquisition or any other restructuring
                                            plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
terms of the Second Amendment, which remained identical to those in the Bridge Loan and the Amended Bridge Loan, state that the principal
amount will bear interest at a rate of 7% per annum (or 9% per annum if the Acquisition is not consummated prior to the repayment date),
compounded annually. The Bridge Loan, the Amended Bridge Loan, and the Second Amendment, together with any accrued interest, or the Owed
Amount, may be repaid in part or in whole at the discretion of the AutoMax prior to the repayment date. The repayment of the Owed Amount
will be due at the earlier date of: (i) the closing of the Merger, in which the Owed Amount shall be deemed a part of, and set-off against,
the financing amount SciSparc will provide AutoMax with upon closing, or $4,250,000; or (ii) if the definitive agreement for the Merger
is terminated, in accordance with its terms, within three months from such termination date. In the month of September 2024, SciSparc
provided AutoMax with the loan amounts due under the Second Amendment to the Bridge Loan, and offset any interest due until November
30, 2024 from the principal amount, such that on the closing date of the Merger, SciSparc will be due interest at a rate of 7% per annum
(or 9% per annum if the Merger is not consummated) of the Loan Amount, from the period starting December 1, 2024 and ending on the effective
date of the Merger. In consideration for the Loan Amount, AutoMax established a first ranking fixed charge security interest on AutoMax&#8217;s
shares of its wholly-owned subsidiary AutoMax Direct Import in favor of SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 8, 2025, SciSparc entered into the Third Amendment, pursuant to which, in addition to the already existing subordination of the Loan
Amount to AutoMax&#8217;s Series B Bonds, the Loan Amount will also be subordinated to AutoMax&#8217;s Series C Bonds, issued and traded
on the TASE.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i>Additional
Loan Agreement and Deed of Assignment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 25, 2025, SciSparc entered into the Deed with AutoMax and three investors. Pursuant to the Deed, SciSparc assigned part of the
Subscription Amount in the amount of $2 million to AutoMax in lieu of making the payment under the Additional Loan Agreement to which
SciSparc entered into with AutoMax on February 24, 2025. Pursuant to the Additional Loan Agreement, SciSparc extended to AutoMax the
Additional Loan Amount. The Additional Loan Amount is due and payable on a monthly basis, as follows: (i) each month subsequent to February
24, 2025, AutoMax shall pay the Monthly Payment, and the interest of 8% per annum accrued on the outstanding Additional Loan Amount up
to the payment date; (ii) upon the consummation of the Merger, the remaining interest on the Additional Loan Amount shall be cancelled
and forgiven, and AutoMax shall continue making Monthly Payments towards the remaining outstanding and due Additional Loan Amount.&#8239;To
secure repayment of the Additional Loan Amount, AutoMax Hasharon shares held by Global AutoMax were pledged in favor of SciSparc with
a first-degree permanent lien.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
intellectual property portfolio comprises six granted U.S. patents, and pending patent applications in eight families, all of which are
in the national phase of examination. Of this portfolio, SciSparc has exclusively licensed one patent family from Yissum. SciSparc&#8217;s
intellectual property portfolio also includes an application to register the trademark CannAmide&#8482; pending in the United States.
SciSparc has also been granted a trademark registration for Wellution&#174; in Class 003 in the United States. SciSparc has also been
granted a trademark registration for Wellution&#174; in Class 005 in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Internally
                                            Developed Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
March 2013, SciSparc filed a provisional application with the USPTO for the technology of proprietary sequences of anti-CD3 antibody
and the utilization of the latter in various autoimmune diseases, as well as in hepato-pathologies. The provisional application has been
converted to a PCT and then entered a National Status in December 2014 in the U.S., with the European Patent Office, or EPO, and in China
and Canada. In the U.S. it received a grant status in June 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
April 2015, SciSparc filed a provisional application with the USPTO for combinations of cannabinoids, n-acylethanolamines, and inhibitors
of n-acylethanolamine degradation, which, in April 2016 was converted into an international PCT application that subsequently entered
national phase in the following state entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to
utilizing the potentiating effect of n-acylethanolamines on cannabinoids for any cannabinoid amenable indication, including but not limited
to analgesia and TS. The 20-year term of any patent issuing from this application would expire in April 2036. In August and September
2021, the patent was granted in Australia and Japan, respectively, and a further patent was granted in Australia in November of 2023.
A patent was granted in Israel in August of 2022, and three patents have been issued in the U.S., two in December 2021 and one in February
2022. In December 2022, SciSparc was granted a patent from the EPO. A patent was issued in Canada in April 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2015, SciSparc filed a provisional application with the USPTO for combinations of opioids, n-acylethanolamines, and inhibitors of
n-acylethanolamines degradation, which, in May 2016 was converted into an international PCT application that subsequently entered national
phase in the following state entities: U.S., EPO, Israel, Australia, Canada, China and Japan. The technology is directed to potentiating
effect of N-acylethanolamines on opioids for opioid amenable indications. The 20-year term of any patent issuing from this application
would expire in May 2036. In July 2021, the first patent was granted in Australia and a second was granted in November 2023. A patent
was issued in Japan in March 2023, and the EPO granted a patent in November 2023. A patent was issued in Canada in April 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2016, SciSparc filed a provisional application with the USPTO for the use of cannabinoids for potentiating the efficacy of antibiotics,
which in July 2017 was converted into an international PCT application that subsequently entered national phase in the following state
entities: U.S., EPO, Canada and China. The 20-year term of any patent issuing from this application would expire in July 2037. In November
2022, the USPTO issued this patent called &#8220;Compositions and Methods of Potentiating Antimicrobials&#8221;. A patent was issued
in Europe in May 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2018, SciSparc filed a provisional application with the USPTO directed to methods of treating OSA, which in January 2019 was
converted into an international PCT application that subsequently entered national phase in the following state entities: U.S., EPO,
Canada and Australia. The 20-year term of any patent issuing from this application would expire in January 2039. A patent was issued
in Australia in February 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
April 2019, SciSparc filed a provisional application with the USPTO directed to compositions and methods for potentiating derivatives
of 4-aminophenols, which in April 2020 was converted into an international PCT application. The PCT application subsequently entered
the national phase in Australia, Canada, China, EPO, Israel, India, Japan, Mexico, Russia, and the U.S. The 20-year term of any patent
issuing from this application would expire in April 2040.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2020, SciSparc filed a provisional application with the USPTO directed to methods for maintaining microvascular integrity, which
in August 2021 was converted into an international PCT application. The PCT application subsequently entered the national phase in Australia,
Canada, China, EPO, Israel, India, Japan, and the U.S. The 20-year term of any patent issuing from this application would expire in August
2041.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>In-Licensed Patents
and Patent Applications</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 29, 2018, SciSparc entered into an exclusive, worldwide, sublicensable, royalty-bearing license agreement with Yissum for a license
to make commercial use of the licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute
or sell products, or the Yissum License Agreement. According to the Yissum License Agreement, SciSparc was required to pay Yissum an
initial payment of $133,000, and shall pay Yissum royalties at the rates of 3% of net sales, subject to the royalty reductions as described
in the Yissum License Agreement. All right, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and
SciSparc shall hold and make use of the rights granted. All rights in the development results shall be solely owned by SciSparc, except
to the extent that an employee of the Yissum, including the researcher, is considered an inventor of a patentable invention arising from
the development results, in which case such invention and all patent applications and/or patents claiming such invention shall be owned
jointly by SciSparc and Yissum, as appropriate, and Yissum&#8217;s share in such joint patents shall be automatically included in the
Yissum License Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Other Intellectual
Property Protection</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to patent and trademark protection, SciSparc intends to use other means to protect its proprietary rights, including pursuing
marketing or data exclusivity periods, orphan drug status, and similar rights that are available under regulatory provisions in certain
countries, including but not limited to the United States, Europe, Canada, Japan, and China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
also relies on trade secrets, know-how, and continuing innovation to develop and maintain its competitive position. SciSparc cannot be
certain that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications
filed by it in the future, nor can it be sure that any of its existing patents or any patents granted to it in the future will be commercially
useful in protecting its technology.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
also seeks regulatory approval for its products for indications with high unmet medical need, great market potential, and where it has
a proprietary position through patents covering various aspects of its products, including but not limited to: composition, dosage, formulation,
use, and manufacturing process. Its success depends, in part, on an intellectual property portfolio that supports future revenue streams
and erects barriers to its competitors. SciSparc is maintaining and building its patent portfolio through filing new patent applications,
prosecuting existing applications, and licensing and acquiring new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Despite
these measures, any of SciSparc&#8217;s intellectual property and proprietary rights could be challenged, invalidated, circumvented,
infringed or misappropriated. Intellectual property and proprietary rights may not be sufficient to permit it to take advantage of current
market trends or otherwise to provide competitive one. For more information, see &#8220;<i>Risk Factors-Risks Related to SciSparc&#8217;s
Intellectual Property.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following table summarizes SciSparc&#8217;s portfolio of patents:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 20%; text-indent: -9pt; padding-left: 9pt; vertical-align: bottom">Country</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center">Status</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center">Filing
    Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40.5%; text-align: center">Title</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; width: 12%; text-align: center">Estimated<br/>
    Expiration&#160;Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%; text-align: center">Product<br/>
    Covered</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">19-Apr-2016</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-110<br/> THX-210</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">19-Jul-2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-110<br/> THX-210</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Pending</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">17-Oct-2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-110<br/> THX-210</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top">Canada</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">19-Apr-2016</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-110<br/> THX-210</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">United
    States of America</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">19-Apr-2016</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">May 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-110<br/> <br/></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">United
    States of America</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Abandoned</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">01-Oct-2019</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">United
    States of America</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">10-Oct-2019</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-210</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">United
    States of America</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">30-Aug-2019</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-210</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">United
    States of America</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">Published</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">27-Aug-2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April 2036</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">THX-110<br/> <br/></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Aug-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    THX-210</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Nov-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Mar-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    THX-210</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    (People&#8217;s Republic)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Jun-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    <br/>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    <br/>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Apr-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    <br/>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Mar-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-Jun-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF CANNABINOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110<br/>
    THX-210</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Jun-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19-Oct-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Aug-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    (People&#8217;s Republic)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Apr-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIODS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Apr-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Nov-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-Nov-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMBINATIONS
    OF OPIOIDS AND N-ACYLETHANOLAMINES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    2036</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jan-2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-210</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 9pt; text-indent: -9pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 40.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Aug-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-110</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Mar-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Mar-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22-Apr-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Mar-2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTER OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HUMANIZED
    ANTIBODIES TO CLUSTERS OF DIFFERENTIATION 3 (CD3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2033</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-Jun-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29-Sep-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowed</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 9pt; text-indent: -9pt; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 40.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
    Expiration&#160;Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product<br/>
    Covered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jan-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Oct-2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Oct-2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Jul-2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS OF POTENTIATING ANTIMICROBIALS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    Compositions comprising CB receptor agonists, uses thereof and methods for their preparation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    Composition comprising cb receptor agonists and uses thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THX-160</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Convention<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abandoned</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-Aug-21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7-Jun-2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    FOR MAINTAINING MICROVASCULAR INTEGRITY</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has also been granted an application to register the trademark for CannAmide&#8482; in the United States with registration pending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has also been granted a trademark registration for Wellution&#174; in Class 003 in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has also been granted a trademark registration for Wellution&#174; in Class 005 in the United States</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Validation
                                            states are not listed separately.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Sales and Transfer
of Intellectual Property Assets</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Transaction with
Former Subsidiary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2016, SciSparc entered into a share transfer agreement with its former subsidiary, Orimmune Bio Ltd., or Orimmune, and Karma Link
Ltd., or Karma Link. According to the agreement, SciSparc agreed to sell its interests in Orimmune to Karma Link, and also use its best
efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 13, 2018, an additional amendment to the transfer agreement was signed between SciSparc, Karma Link and Orimmune, under which
it was agreed that Orimmune (and Karma Link) will be assigned certain rights in IP related to the licensed technology owned by SciSparc,
subject to certain conditions precedent. In 2021, SciSparc received the approval of the IIA to complete the assignment and it is now
seeking to complete the transaction. As of the date of this prospectus, the conditions precedents have not yet been completed and the
assignment of the intellectual property rights related to the licensed technology owned by SciSparc have not yet been transferred.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>MitoCareX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 10, 2022, SciSparc entered into a founders and investment agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant
to the MitoCareX Agreement, SciSparc invested an initial amount of $700,000 in MitoCareX and agreed to invest over the next two years
an additional $1,000,000, subject to the achievement of certain pre-determined milestones as agreed upon in the MitoCareX Agreement,
for up to a 50.01% ownership in MitoCareX. MitoCareX is focused on the discovery and development of potential drugs for cancers and other
life-threatening conditions. The MitoCareX Agreement also contains customary representations, warranties, covenants and indemnification
provisions and on March 31, 2022, the closing conditions were met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 17, 2023, SciSparc announced that MitoCareX has achieved its first milestone pursuant to the MitoCareX Agreement. The first
milestone refers to the establishment of MitoCareX&#8217;s cloud-based computing infrastructure that is expected to allow its future
expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability.
As a result of MitoCareX meeting this milestone, SciSparc invested an additional $400,000 in MitoCareX and increased its share ownership
holdings in MitoCareX from 31.48% to 41.92%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 8, 2023, SciSparc announced that MitoCareX successfully developed its core algorithm for allowing the generation of reliable 3D comparative
models of human SLC25A mitochondrial carrier proteins.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 27, 2023, SciSparc announced that MitoCareX achieved positive results with the development of its laboratory capabilities by
establishing a variety of small-molecule screening platforms. With this development, MitoCareX achieved its second milestone pursuant
to the MitoCareX Agreement&#160;and as a result, on March 11, 2024 SciSparc invested an additional $600,000&#160;and increased its share
ownership holdings in MitoCareX from 41.92% to 52.73%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 26, 2024, SciSparc signed a non-binding letter of intent, or LOI, relating to the sale of its entire ownership interest in
MitoCareX, of which it owns 52.73% of the issued and outstanding share capital, to N2OFF, Inc., a Nevada corporation, or N2OFF.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 25, 2025, SciSparc entered into the MitoCareX SPEA, as amended on May 18, 2025, together with MitoCareX, Dr. Alon Silberman
and Prof. Ciro Leonardo Pierri, as the Sellers, pursuant to which the Sellers will sell their stakes in MitoCareX to N2OFF, thereby
resulting in MitoCareX becoming a wholly-owned subsidiary of N2OFF. The MitoCareX SPEA contains customary representations,
warranties and covenants by each of the parties. The closing of the MitoCareX SPEA is contingent upon, among other customary
obligations, obtaining approval of N2OFF&#8217;s stockholders by the requisite majority. On May 18, 2025, the parties amended the
MitoCareX SPEA, solely by extending the exclusivity period by an additional ninety days, such that either party may terminate the
MitoCareX SPEA in the event that the closing date has not occurred within one hundred and eighty days of February 25,
2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
the closing date of the transactions contemplated under the MitoCareX SPEA, SciSparc will transfer and sell its stake in MitoCareX to
N2OFF in consideration for a cash payment of $700,000 and shares of N2OFF common stock, par value $0.0001 per share, or the N2OFF Common
Stock, representing 16.75% of N2OFF on a fully-diluted basis. SciSparc&#8217;s sale of its stake in MitoCareX is contingent upon the
transfer of the other Sellers&#8217; stakes to N2OFF in exchange for agreed to amounts of N2OFF Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
the closing date of the MitoCareX SPEA, the Sellers may receive such number of additional shares of N2OFF Common Stock, for no additional
consideration, that reflects an aggregate amount of up to 25% of the issued and outstanding capital stock of N2OFF on a fully-diluted
basis, or the Additional N2OFF Stock, which Additional N2OFF Stock, if the respective milestones are achieved as defined in the MitoCareX
SPEA, will be duly issued in installments based on the achievement of each milestone, as set forth in the MitoCareX SPEA, and will be
allocated amongst the Sellers as follows: 50% to SciSparc, 33.33% to Mr. Silberman and 16.67% to Mr. Pierri. The Sellers&#8217; eligibility
to receive Additional N2OFF Stock will terminate on December 31, 2028, such that if a specific milestone is not achieved and therefore
the right to receive the respective number of shares of Additional N2OFF Stock issuable upon the achievement of such milestone is not
earned by December 31, 2028, the right to receive the number of shares of Additional N2OFF Stock attributable to any such non-achieved
milestone pursuant to the MitoCareX SPEA will terminate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
SciSparc started early commercialization of its proprietary PEA oral tablets CannAmide&#8482;, it intends to build a global commercial
infrastructure to effectively support the commercialization of its main pharmaceutical product candidates, if and when SciSparc believes
regulatory approval of a pharmaceutical product candidate in a particular geographic market appears imminent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
develop the appropriate commercial infrastructure, SciSparc will likely have to invest significant amounts of financial and management
resources, some of which SciSparc expects to commit prior to completing the regulatory process for its pharmaceutical product candidates.
Where appropriate, SciSparc may elect in the future to utilize strategic partners, distributors, or contract sales forces to assist in
the commercialization of its pharmaceutical products. In certain instances, SciSparc may consider building its own commercial infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2023, SciSparc entered into a license and distribution agreement with SciSparc Nutraceuticals pursuant to which it granted SciSparc
Nutraceuticals an exclusive license to sell and market its PEA oral tablets, CannAmide&#8482; on Amazon Marketplace in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Effective
as of June 7, 2024, SciSparc Nutraceuticals and SciSparc entered into an amendment to the license and distribution agreement to amend
the term of the license and distribution agreement to an indefinite term, unless terminated by either party upon 30 days advanced notice.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary products. While SciSparc believes that its scientific knowledge, technology and development experience provide it with
competitive advantages, SciSparc faces potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical
and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates
that SciSparc successfully develop and commercialize will compete with existing therapies and new therapies that may become available
in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
first THC-based pharmaceutical, a pill sold under the commercial name of Marinol (scientific name: dronabinol), was developed by a company
called Unimed Pharmaceuticals, with funding provided by the National Cancer Institute. In 1985, Marinol received FDA approval as a treatment
for chemotherapy-related nausea and vomiting. Today, Marinol is marketed by AbbVie, Inc. Since the introduction of Marinol into the market,
other pharmaceuticals containing THC have also been developed. These include generic oral capsules of dronabinol, such as those marketed
by SVC Pharma LP and Akorn Inc., Meda AB&#8217;s Cesamet (nabilone), a synthetic derivative of THC, and Sativex (nabiximols), a whole
cannabis extract administered as an oral spray. Furthermore, to the best of SciSparc&#8217;s knowledge, there are multiple companies
that are working in the cannabis therapeutic area and are pursuing regulatory approval for their product candidates. For example, GW,
which markets Sativex, a botanical cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis, received FDA approval
in the United States in June 2018 for Epidiolex, a liquid formulation of highly purified cannabidiol extract, as a treatment for Dravet&#8217;s
Syndrome, Lennox Gastaut Syndrome, and various childhood epilepsy syndromes. In addition, GW is developing, among others, CBDV based
therapy for ASD and therapy for neonatal hypoxic-ischemic encephalopathy and schizophrenia. Zynerba is developing a transdermal formulation
of cannabidiol for Fragile X and certain refractory epilepsies and ASD. Skye is focused on developing proprietary, synthetic cannabinoid-derived
molecules to treat glaucoma and other diseases with significant unmet need. Corbus Pharmaceuticals Holdings is seeking FDA approval for
their synthetic cannabinoid for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus and metabolism
and solid tumors. RespireRx is developing dronabinol for OSA treatment. Synendos is a developer of endocannabinoid modulators for the
treatment of CNS disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric
disorders. Synendos is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous
cannabinoids to treat CNS disorders caused by cannabinoid deficiency. Inversago Pharma (formerly GIcare Pharma) is focused on developing
peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance,
and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under phase-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
competitors, either alone or through their strategic partners, might have substantially greater name recognition and financial, technical,
manufacturing, marketing and human resources than it does and significantly greater experience and infrastructure in researching and
developing pharmaceutical products, obtaining FDA and other regulatory approvals of those products and commercializing those products
around the world. They may also have intellectual property portfolios that provide them with significant competitive advantages or create
substantial barriers in SciSparc&#8217;s target markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
currently contracts with third parties for the manufacturing and testing of its product candidates for preclinical trials and clinical
trials and also intend to do so in the future. SciSparc does not own or operate manufacturing facilities for the production of clinical
quantities of its product candidates. The use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient
and may eliminate the need to directly invest in manufacturing facilities and additional staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, SciSparc&#8217;s third-party manufacturers have met its manufacturing requirements. SciSparc expects third-party manufacturers
to be capable of providing sufficient quantities of its product candidates to meet anticipated full scale commercial demands. To meet
its projected needs for commercial manufacturing, third parties with whom SciSparc currently works might need to increase their scale
of production, or SciSparc will need to secure alternate suppliers. SciSparc believes that there are alternate sources of supply that
can satisfy its clinical and commercial requirements, although it cannot be certain that identifying and establishing relationships with
such sources, if necessary, would not result in significant delay or material additional costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>FDA Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States, pharmaceutical product candidates are subject to extensive regulation by the FDA. The FDC Act, and other federal and
state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion, marketing, distribution, post-approval monitoring, reporting, sampling, and import and export of pharmaceutical
drug product candidates. Failure to comply with applicable U.S. rules and regulations may subject a company to a variety of administrative
or judicial sanctions, such as FDA refusal to approve pending NDAs, warning letters, product candidate recalls, product candidate seizures,
total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pharmaceutical
drug product candidate development in the United States typically involves pre-clinical laboratory and animal testing, the submission
to the FDA of an IND Application, which must become effective before clinical testing may commence, and adequate, well-controlled clinical
trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA
pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type,
complexity and novelty of the product candidate or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Nonclinical
tests include laboratory evaluation of an API or drug substance and drug product&#8217;s candidate chemistry, formulation and toxicity,
as well as animal trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the
nonclinical toxicology studies must comply with federal regulations and requirements, including GLP. The results of nonclinical testing
are submitted to the FDA as part of an IND along with other information, including information about product candidate chemistry, manufacturing
and controls, and a proposed clinical trial protocol. Long term nonclinical tests, such as animal tests of reproductive toxicity and
carcinogenicity, may continue after the IND is submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
30-day waiting period after the submission of an original IND is required prior to the commencement of clinical testing in humans. If
the FDA has not imposed a clinical hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical
trial proposed in the IND may begin. In practice, a submitting party should contact the division after this 30 day period to ensure that
the FDA has reviewed the IND to the extent that they can assure there will be no hold placed on the IND if the FDA has not responded
to SciSparc within this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Clinical
trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of a qualified
investigator. Clinical trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP, an international
standard meant to protect the rights and health of patients to ensure the quality of the trial and to define the roles of clinical trial
sponsors, administrators and monitors. Clinical protocols and details of the objectives of the trial, the parameters to be used in monitoring
safety, and the effectiveness criteria to be evaluated. Each protocol and any amendment involving testing of U.S. study subjects within
the United States and subsequent protocol amendments must be submitted to the FDA as part of the IND.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA may order the temporary hold of a clinical trial at any time or impose other sanctions if the FDA believes that the clinical trial
either is not being conducted in accordance with FDA requirements, regulations or presents a potentially unacceptable risk to the clinical
trial subjects. The trial protocol and informed consent information for subjects in clinical trials must also be submitted to an IRB
for approval. An IRB may impose other conditions for the protocol and may also require the clinical trial at the site to be halted, either
temporarily or permanently, for failure to comply with the IRB&#8217;s requirements.<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>505(b)(2) Regulatory
Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Section
505(b)(2) of the FDC Act, or 505(b)(2), provides a regulatory pathway to FDA approval for new or improved formulations or new uses of
previously approved drug products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information required
for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference,
or use from the person by or for whom the investigations were conducted. The applicant may rely upon the FDA&#8217;s prior findings of
safety and efficacy for an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also
require 505(b)(2) applicants to perform additional studies or measurements to support any changes from the reference listed drug. The
FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved,
as well as for any new indication sought by the 505(b)(2) applicant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Orange Book Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Section
505 of the FDC Act describes three types of marketing applications that may be submitted to the FDA to request marketing authorization
for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section
505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information
required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained
a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims
cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published
in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential
competitors in support of approval of a 505(b)(2) NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
applicant who submits a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on
which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product
for which the application is submitted. This last certification is known as a Paragraph IV certification. Generally, 505(b)(2) NDA cannot
be approved until all listed patents have expired, except where 505(b)(2) NDA applicant challenges a listed patent through a Paragraph
IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented
method of use, the 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have
expired.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although
some of SciSparc&#8217;s product candidates are based on repurposed drugs, there are at present no patents or other exclusivities listed
in the Orange Book pertaining to a product containing the active ingredient dronabinol.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Three-year
exclusivity is available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed
product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability
or bioequivalence trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year
exclusivity period protects against FDA approval of 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter,
three-year exclusivity does not prohibit the FDA from approving 505(b)(2) NDAs for generic versions of the original, unmodified drug
product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting
a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled
clinical trials necessary to demonstrate safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>NDA Submission
and Review by the FDA</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Assuming
successful completion of the required clinical and nonclinical testing, among other items, the results of product development, including
chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling,
as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the
time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions
are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees,
including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced
or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing
application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
cost of preparing and submitting an NDA is substantial, mainly due to the non-clinical and clinical trial costs. Under federal law, the
submission of most NDAs is additionally subject to a substantial application user fee; the fee in the fiscal year 2024 was $4,048,695.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA has 60 or 74 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the
FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard
review drug product candidates are reviewed within 10 to 12 months, while most applications for priority review drugs are reviewed within
six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment
where no adequate therapy exists. The review process for both standard and priority review may be extended by FDA for three additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA may also refer applications for novel drug product candidates, or drug product candidates that present difficult questions of safety
or efficacy, to an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation
and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee,
but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to
assure compliance with GCP. Additionally, the FDA may inspect the facility or the facilities at which the drug substance and drug product
are manufactured. The FDA will not approve the drug product candidate unless compliance with current cGMP, or cGMP, is satisfactory and
the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction
in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or
six months depending on the type of requested information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a REMS plan to help ensure that the benefits of the drug outweigh the potential risks. REMS can
include medication guides, communication plans for health care professionals, and ETASU. An ETASU can include, but are not limited to,
special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and
the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover,
product candidate approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy.
Once granted, product candidate approvals may be withdrawn if compliance with regulatory standards is not maintained related to the manufacture,
safety or effectiveness or problems are identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Disclosure of
Clinical Trial Information</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sponsors
of clinical trials of certain FDA-regulated product candidates, including prescription drugs, are required to register and disclose certain
clinical trial information on a public website (clinicaltrials.gov) which is maintained by the U.S. National Institutes of Health. Information
related to the product candidate, patient population, phase of investigation, study sites and investigator, and other aspects of the
clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these trials after
completion. Disclosure of the results of these trials can be delayed until the product candidate drug product or new indication being
studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the design and progress
of its development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Fast Track Designation
and Accelerated Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
FDA has programs to facilitate the development, and thus expedite the review, of drugs that are intended for the treatment of a serious
or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet
medical needs for the condition. These therapies for serious conditions are approved and available to patients as soon as it can be concluded
that the therapies&#8217; benefits outweigh their risk. Under the Fast Track Program, the sponsor of a new drug candidate may request
that FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND
for the drug candidate. FDA must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the
sponsor&#8217;s request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the FDA&#8217;s accelerated approval regulations, FDA may approve a drug for a serious or life-threatening illness that provides meaningful
therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical
benefit. Accelerated approval may also be based on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality,
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, considering the severity,
rarity or prevalence of the condition and the availability or lack of alternative treatments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for
a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly
than clinical endpoints. A drug product that is approved on this basis is subject to rigorous post-marketing compliance requirements,
including the completion of confirmatory or post-approval clinical trial(s) or registries to confirm the effect on the clinical endpoint.
Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw
the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations
are subject to prior review by FDA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may
initiate review of sections of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available if
the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable
user fees. However, FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted.
Additionally, the Fast Track designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data
emerging in the clinical trial process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Patent Term Extension</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is
calculated as half of the drug&#8217;s testing phase, the time between IND submission and NDA submission, and all of the review phase-the
time between NDA submission and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant
did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension
increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval
patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for
which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been
submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Advertising and
Promotion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Once
an NDA is approved, a drug product will be subject to certain post-approval requirements. Products manufactured or distributed by us
pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling
and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional
of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences.
For instance, FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer
advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Drugs
may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of
the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities,
require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new
indication typically requires clinical data similar to that in the original application. The FDA uses the same procedures and actions
in reviewing NDA supplements as it does in reviewing NDAs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><b><i>Adverse
Event Reporting and GMP Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Adverse
event reporting and submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing
testing, known as Phase 4 testing, REMS and surveillance to monitor the effects of an approved product candidate, or the FDA may place
conditions on an approval that could restrict the distribution or use of the drug product. In addition, quality-control, drug manufacture,
packaging, and labeling procedures must continue to conform with cGMPs after approval. Drug manufacturers and certain of their subcontractors
are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to
periodic unannounced inspections by the FDA, during which the FDA inspects manufacturing facilities to assess compliance with cGMPs.
Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMPs. Regulatory authorities may withdraw product candidate approvals or request product candidate recalls if a company
fails to comply with regulatory standards, if it encounters problems following initial marketing or if previously unrecognized problems
are subsequently discovered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Pediatric Exclusivity
and Pediatric Use</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity-patent or non-patent-for
a drug if certain conditions are met. Conditions for exclusivity include a determination by the FDA that information relating to the
use of a new drug in the pediatric population may produce health benefits in that population; a written request by the FDA for pediatric
studies; and agreement by the applicant to perform the requested studies and the submission to the FDA; and the acceptance by the FDA,
of the reports of the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness
of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric
subpopulation for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from the FDA. Unless otherwise
required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted with the exception
of certain oncological indications. The required pediatric assessment must assess the safety and effectiveness of the product candidate
for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation
for which the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all
of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval
for use in adults before pediatric studies are complete or that additional safety or effectiveness data need to be collected before the
pediatric studies begin. Under PREA, the FDA must send a non-compliance letter requesting a response with 45 days to any sponsor that
fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Orphan Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition-generally a disease
or condition with a prevalence of fewer than 200,000 individuals in the United States. Orphan drug designation must be requested and
granted before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan
use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular
disease with an FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that drug
product candidate for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market
the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product candidate
with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or
condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits
for certain research and a waiver of the NDA application user fee. In addition to the potential seven years of market exclusivity after
approval, orphan drug designation status qualifies sponsors for tax credits for qualified clinical trials and exemption from user fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Special Protocol
Assessment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
company may reach an agreement with the FDA under the Special Protocol Assessment, or SPA, process as to the required design and size
of clinical trials intended to form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed to
evaluate the protocol within 45 days of the request to assess whether the proposed trial is adequate, and that evaluation may result
in discussions and a request for additional information. An SPA request must be made, and all open issues must be resolved before the
clinical trial begins. If a written agreement is reached, it will be documented and made part of the administrative record. Under the
FDC Act and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances,
such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, public
health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and FDA agree to the change in writing,
or if the study sponsor fails to follow the protocol that was agreed upon with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Controlled Substances&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
CSA and its implementing regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes
registration, security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the
oversight of the DEA. The DEA is the federal agency responsible for regulating controlled substances, and requires those individuals
or entities that manufacture, import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements
in order to prevent the diversion of controlled substances to illicit channels of commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
DEA categorizes controlled substances into one of five schedules-Schedule I, II, III, IV or V-with varying qualifications for listing
in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment
in the United States and lack accepted safety for use under medical supervision. Schedule I substances may be used only in federally
approved research programs and may not be marketed or sold for dispensing to patients in the United States. Pharmaceutical product candidates
having a currently accepted medical use that are otherwise approved for marketing may be listed as Schedule II, III, IV or V substances,
with Schedule II substances presenting the highest potential for abuse and physical or psychological dependence, and Schedule V substances
presenting the lowest relative potential for abuse and dependence. The regulatory requirements are more restrictive for Schedule II substances
than Schedule III substances. For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to
a pharmacist in most situations and cannot be refilled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Following
NDA approval of a drug containing a Schedule I controlled substance, that substance must be rescheduled as a Schedule II, III, IV or
V substance before it can be marketed. In 2015, the Improving Regulatory Transparency for New Medical Therapies Act, removed uncertainty
associated with timing of the DEA rescheduling process after NDA approval. Specifically, it requires DEA to issue an &#8220;interim final
rule,&#8221; pursuant to which a manufacturer may market its product candidate within 90 days of FDA approval. The new law also preserves
the period of orphan marketing exclusivity for the full seven years such that this period only begins after DEA scheduling. This contrasts
with the previous situation whereby the orphan &#8220;clock&#8221; began to tick upon FDA approval, even though the product candidate
could not be marketed until DEA scheduling was complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Facilities
that manufacture, distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is
specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required
for importation and manufacturing activities, and each registration authorizes which schedules of controlled substances the registrant
may handle. However, certain coincident activities are permitted without obtaining a separate DEA registration, such as distribution
of controlled substances by the manufacturer that produces them.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
DEA inspects all manufacturing facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance
registration. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances
handled. The most stringent requirements apply to manufacturers of Schedule I and Schedule II substances. Required security measures
commonly include background checks on all employees and physical control of controlled substances through storage in approved vaults,
safes and cages, and through use of alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk
manufacturer (not a dosage form manufacturer or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal
Register, and the application is open for 30 days to permit interested persons to submit comments, objections or requests for a hearing.
A copy of the notice of the Federal Register publication is forwarded by DEA to all those registered, or applicants for registration,
as bulk manufacturers of that substance. Once registered, manufacturing facilities must maintain records documenting the manufacture,
receipt and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule
I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled
substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. As with applications
for registration as a bulk manufacturer, an application for an importer registration for a Schedule I or II substance must also be published
in the Federal Register, which remains open for 30 days for comments. Imports of Schedule I and II controlled substances for commercial
purposes are generally restricted to substances not already available from domestic supplier or where there is not adequate competition
among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must obtain a permit for every
import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule
III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject to the import/export permit requirement,
if it is necessary to ensure that the United States complies with its obligations under international drug control treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
drugs manufactured in the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules
I and II that may be manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate
medical, scientific, research and industrial needs. This limited aggregate amount of cannabis that the DEA allows to be produced in the
United States each year is allocated among individual companies, which, in turn, must annually apply to the DEA for individual manufacturing
and procurement quotas. The quotas apply equally to the manufacturing of the API/drug substance and production of dosage forms. The DEA
may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during
the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Individual
states may also maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution,
and dispensing requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure
to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can
result in enforcement action that could have a material adverse effect on its business, operations and financial condition. The DEA may
seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances,
violations could lead to criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Europe/Rest of
World Government Regulation</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to regulations in the United States, SciSparc will be subject to a variety of foreign regulations governing clinical trials
and commercial sales and distribution of its products to the extent it chooses to develop or sell any products outside of the United
States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval.
The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to
country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Whether
                                            or not SciSparc obtains FDA approval for a product candidate, it must obtain the requisite
                                            approvals from regulatory authorities in non-U.S. countries prior to the commencement of
                                            clinical trials or marketing of the product candidate in those countries. Certain countries
                                            outside of the United States have a process that requires the submission of a Clinical Trial
                                            Application, or CTA, much like an IND prior to the commencement of human clinical trials.
                                            In Europe, for example, a CTA must be submitted to the competent national health authority
                                            and to independent ethics committees in each country in which a company intends to conduct
                                            clinical trials pursuant to European Clinical Trials Regulation regulations. Once the CTA
                                            is approved in accordance with a country&#8217;s requirements, clinical trial development
                                            may proceed in that country.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
requirements and process governing the conduct of clinical trials, product candidate licensing, pricing and reimbursement vary from country
to country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national
implementation of underlying European Union legislation. In all cases, the clinical trials are conducted in accordance with GCP and other
applicable regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
obtain regulatory approval of an investigational drug under the European Union. regulatory systems, SciSparc must submit a MAA. This
application is similar to the NDA in the United States, with the exception of, among other things, country-specific document requirements.
Drugs can be authorized in the European Union by using (i) the centralized authorization procedure, (ii) the Mutual Recognition Procedure,
or MRP, (iii) the decentralized procedure or (iv) national authorization procedures. The initial Sativex approvals were a consequence
of an application under the De-Centralized Procedure, or DCP, to the European Union member state of Spain acting as reference member
state.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
European Commission implemented the centralized procedure for the approval of human drugs to facilitate marketing authorizations that
are valid throughout the European Economic Area, or EEA. This procedure results in a single marketing authorization granted by the European
Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway (forming together the EEA). The centralized
procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain
a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare
human diseases) and (iv) advanced-therapy medicines, such as gene- therapy, somatic cell-therapy or tissue-engineered medicines. The
centralized procedure may at the request of the applicant also be used for human drugs which do not fall within the above mentioned categories
if the human drug (a) contains a new active substance which, on the date of entry into force of this Regulation, was not authorized in
the Community; or (b) the applicant shows that the medicinal product candidate constitutes a significant therapeutic, scientific or technical
innovation or that the granting of authorization in the centralized procedure is in the interests of patients or animal health at the
European Community level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the centralized procedure in the European Union, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days (excluding
clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee
for Medicinal Products for Human Use, or CHMP, with adoption of the actual marketing authorization by the European Commission thereafter.
Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product candidate is expected to be of a major
public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: (1) the seriousness of
the disease to be treated; (2) the absence of an appropriate alternative therapeutic approach, and (3) anticipation of exceptional high
therapeutic benefit. In this circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and
the opinion issued thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Should
any Member State refuse to recognize the marketing authorization by the reference member state in a decentralized procedure, on the grounds
of potential serious risk to public health, the issue will be referred to the Committee for the Mutual Recognition and Decentralized
Procedures human. Within a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus.
If this fails, the procedure is submitted to the CHMP for arbitration. The opinion of the CHMP is then forwarded to the Commission, for
the start of the decision making process. As in the centralized procedure, this process entails consulting various European Commission
Directorates General and the Standing Committee on Human Medicinal Product candidates or Veterinary Medicinal Product candidates, as
appropriate. Since the initial approvals of Sativex in the United Kingdom and Spain, there have been three &#8220;waves&#8221; of additional
approvals under three separate MRPs. Each of these procedures have been completed without any referral, and therefore without any delay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
other countries outside of the European Union, the requirements governing the conduct of clinical trials, product candidate licensing,
pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP
and the other applicable regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
SciSparc fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension
of clinical trials, suspension or withdrawal of regulatory approvals, product candidate recalls, seizure of product candidates, operating
restrictions and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, most countries are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic
control of narcotic substances, including cannabis extracts. Countries may interpret and implement their treaty obligations in a way
that creates a legal obstacle to SciSparc obtaining marketing approval for Sativex and its other product candidates in those countries.
These countries may not be willing or able to amend or otherwise modify their laws and regulations to permit Sativex or its other product
candidates to be marketed, or achieving such amendments to the laws and regulations may take a prolonged period of time. In that case,
SciSparc would be unable to market its product candidates in those countries in the near future or perhaps at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Expanded Access
to Investigational Drugs in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">An
investigational drug may be eligible for clinical use outside the context of a manufacturer&#8217;s clinical trial of the drug. &#8220;Expanded
access&#8221; refers to the use of an investigational drug where the primary purpose is to diagnose, monitor, or treat a patient&#8217;s
disease or condition rather than to collect information about the safety or effectiveness of a drug. Expanded access INDs are typically
sponsored by individual physicians to treat patients who fall into one of three FDA-recognized categories of expanded access: expanded
access for individual patients, including for emergency use; expanded access for intermediate-size patient populations; and expanded
access for large patient populations under a treatment IND or treatment protocol. For all types of expanded access, the FDA must determine
prior to authorizing expanded access that: (1) the patient or patients to be treated have a serious or life threatening disease or condition
and there is no comparable or satisfactory alternative therapy; (2) the potential patient benefit justifies the potential risks of use
and that the potential risks are not unreasonable in the context of the disease or condition to be treated; and (3) granting the expanded
access will not interfere with the initiation, conduct, or completion of clinical studies in support of the drug&#8217;s approval. In
addition, the sponsor of an expanded access IND must submit IND safety reports and, in the cases of protocols continuing for one year
or longer, annual reports to the FDA. Expanded access programs are not intended to yield information relevant to evaluating a drug&#8217;s
effectiveness for regulatory purposes. If a patient enrolled in one of SciSparc&#8217;s clinical trials is not eligible or able to continue
enrollment, SciSparc may be required to continue to provide its product candidate to such patient through expanded access.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Pricing and Reimbursement
in the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sales
of pharmaceutical product candidates in the United States will depend, in part, on the extent to which the costs of the product candidates
will be covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations.
These third-party payors are increasingly challenging the prices charged for medical product candidates and services. Additionally, the
containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in
this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing
cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic product
candidates. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit its net revenue and results. If these third-party payors do not consider SciSparc&#8217;s
product candidates to be cost-effective compared to other available therapies, they may not cover SciSparc&#8217;s product candidates
after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow SciSparc to sell its
product candidates on a profitable basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and
pricing of prescription drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare
Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage
of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage
as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug
plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies
which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic
category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part
D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs
of prescription drugs may increase demand for product candidates for which SciSparc receives marketing approval. However, any negotiated
prices for SciSparc&#8217;s product candidates covered by a Part D prescription drug plan will likely be lower than the prices it might
otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare
coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result
in a similar reduction in payments from non-governmental payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ACA was enacted in March 2010. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the law.
The ACA may be modified, amended or repealed at any time and may or may not be replaced with a different law or health care payment system.
The ACA is expected to continue to have a significant impact on the health care industry. With regard to pharmaceutical product candidates,
among other things, the ACA may expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the
coverage requirements under the Medicare Part D program. Since the enactment of the ACA, numerous regulations have been issued providing
further guidance on its requirements. The ACA continues to be implemented through regulation and government activity but is subject to
possible amendment, additional implementing regulations and interpretive guidelines. Several states have decided not to expand their
Medicaid programs and are seeking alternative reimbursement models to provide care to the uninsured. The manner in which these issues
are resolved could materially affect the extent to which and the amount at which pharmaceuticals are reimbursed by government programs
such as Medicare, Medicaid and Tricare. SciSparc is unable to predict the full impact of any potential modification, amendment, or repeal
of the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement
for its products, once approved, and related treatments will be available from third-party payors, such as government health administration
authorities, private health insurers and managed care organizations. Third-party payors determine which medications they will cover and
separately establish reimbursement levels. Even if SciSparc obtains coverage for a given product by a third-party payor, the third-party
payor&#8217;s reimbursement rates may not be adequate to make the product affordable to patients or profitable to SciSparc, or the third-party
payors may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their
conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with
their prescription drugs. Patients are unlikely to use SciSparc&#8217;s products unless coverage is provided, and reimbursement is adequate
to cover all or a significant portion of the cost of its products. Therefore, coverage and adequate reimbursement is critical to new
product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established
or lower cost therapeutic alternatives are already available or subsequently become available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Government
authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by
limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug
companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and
preferred drug lists to leverage greater discounts in competitive classes and are challenging the prices charged for medical products.
Further, no uniform policy for determining coverage and reimbursement for drug products exists among third-party payors in the United
States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage
determination process is often a time-consuming and costly process that will require SciSparc to provide scientific and clinical support
for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
cannot be sure that coverage and reimbursement will be available for any product that SciSparc commercializes and, if reimbursement is
available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any
product candidate for which SciSparc obtains marketing approval. If coverage and reimbursement are not available, or if reimbursement
is available only to limited levels, SciSparc may not successfully commercialize any product candidate for which it obtains marketing
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate
and report to CMS their AMP, which is used to determine rebate payments shared between the states and the federal government and, for
some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part B, to also calculate and report
their average sales price, which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final
rule regarding the Medicaid Drug Rebate Program, effective April 1, 2016, that, among other things, revised the manner in which the AMP
is calculated by manufacturers participating in the program and implemented certain amendments to the Medicaid rebate statute created
under the ACA. Drugs that are approved under an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate
and report the manufacturer&#8217;s best price for the drug and inflation penalties which can substantially increase rebate payments.
On December 21, 2020, CMS issued a final rule that made changes to the Medicaid Drug Rebate Program regulations in several areas, including
some changes to the treatment of value-based purchasing arrangements and price reporting for patient benefit programs sponsored by pharmaceutical
manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
NDA drugs, the Veterans Health Care Act of 1992 requires manufacturers to calculate and report to the Department of Veterans Affairs
a different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more
than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers
to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting
false pricing information to the government creates potential federal False Claims Act liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state
levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer
patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. SciSparc
expects that the pharmaceutical industry will continue to experience pricing pressures due to the trend toward managed healthcare, particularly
towards specialty pharmacy, the increasing influence of managed care organizations, and additional legislative proposals. For example,
CMS issued an interim final rule on November 27, 2020 designed to test whether a Most-Favored-Nation model will help control growth in
spending for Medicare Part B drugs without adversely affecting quality of care. This followed an Executive Order issued in September
2020 that directed the Secretary of DHHS to implement new payment models under the Medicare Part B and Part D programs to curb &#8220;unfair&#8221;
and high drug prices in the United States. Implementation of this interim final rule was blocked by a temporary restraining order and
preliminary injunctions through various court actions and CMS published a final rule on December 27, 2021 that rescinded the interim
final rule. Nonetheless, SciSparc expects that there will continue to be a number of U.S. federal and state proposals to implement governmental
pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs. It is unknown what form any such
changes or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or SciSparc&#8217;s business
in the future. SciSparc expects that changes or additions to the ACA, the Medicare and Medicaid programs, such as changes allowing the
federal government to directly negotiate drug prices, and changes stemming from other healthcare reform measures, especially with regard
to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the health care industry
in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">At
the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, drug price increases, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. On the federal level, the Trump Administration issued a final rule in 2020 for the safe importation
of drugs from Canada and other countries. Per this rule, the FDA authorized its first section 804 importation program, or SIP, a program
allowing the State of Florida to import certain prescription products from Canada. Section 804 (21 U.S.C. &#167; 384) of the Federal
Food, Drug, and Cosmetic Act provides a pathway for U.S. states and Indian tribes to allow importation of certain prescription drugs
from Canada. Programs under this pathway must significantly reduce the cost of these drugs to the American consumer without imposing
additional risk to public health and safety. As the first program of its kind, SciSparc has yet to see how this Program will be implemented
and what specific products will be imported. There is much opposition from the biopharmaceutical industry regarding this Program, but
if Florida can execute it as planned, it may signal a trend in the U.S. The practical implications of SIPs, and their implications for
the biopharmaceutical industry as a whole or SciSparc&#8217;s business in particular remain to be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2021, the Biden administration issued an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple
provisions aimed at increasing competition for prescription drugs. The DHHS has released a Comprehensive Plan for Addressing High Drug
Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these
principles. While no legislation or administrative actions have been finalized to implement these principles, Congress is considering
legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations
on drug price increases and allowing Medicare to negotiate pricing for certain covered drug products. The impact of these legislative,
executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on
SciSparc and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms
may prevent us from being able to generate revenue, attain profitability, or commercialize any of the product candidates for which SciSparc
receives approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
passage of the Inflation Reduction Act, or the IRA, of 2022 further affects Medicare reimbursement. The IRA has three key elements reforming
Medicare drug-pricing policy. The implementation of certain elements of the IRA are still forthcoming, as outlined below, so the specific
implications for biopharmaceutical pricing and reimbursement are yet to be determined. Likewise, SciSparc is unable to predict potential
modification, amendment, or repeal of the IRA, though some predict that challenges may be made as different provisions are enacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
the first key element, the IRA created a program for Medicare drug-price negotiation, enabling the Secretary of DHHS to negotiate the
prices of certain costly, single-source drugs or biologics within the Medicare program. Certain drugs and biologics are excluded from
this negotiation process, such as drugs that are less than 9 years, and biologics less than 13 years, from their FDA-approval or licensure
date, and drugs with an orphan designation as their only FDA-approved indication. The first set of these negotiated prices will not take
effect until 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">Second,
the IRA requires drug manufacturers to pay rebates to the federal government for price increases above the rate of inflation for single-source
drugs or biologics covered under Medicare Part B and most drugs under Medicare Part D, which already occurs under the Medicaid program.
This inflation-rebate provision for Medicare Part B took effect at the start of 2023, and such provision for Medicare Part D took effect
in 2022 as the starting point for measuring drug-price increases, with rebate payments required as of the beginning of 2023. DHHS will
start to send rebate invoices to drug manufacturers in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt; background-color: white">Third,
the IRA restructures the Medicare Part D benefit to limit patients&#8217; out-of-pocket costs and rebalance the bearing of risk for Part
D plans and manufacturers. As of 2024, Medicare Part D plan buyers will no longer have to pay out-of-pocket costs for covered drugs once
they reach the catastrophic coverage level (when the policyholder&#8217;s out-of-pocket spending reaches $7,400). Other aspects of this
provision will take effect in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
bipartisan&#160;<i>Drug-Price Transparency for Consumers Act</i>&#160;was introduced to Senate on April 20, 2023, and the House of Representatives
on October 13, 2023 (S.1250 and H.R.5958, respectively). The Act is currently in committee. This Act would require that direct-to-consumer
advertisements for drugs and biologics include a disclosure of pricing information. The Act would apply to drugs and biologicals reimbursable
under Medicare or Medicaid and for which direct-to-consumer advertisements are required to include information relating to side effects,
contraindications, and effectiveness in accordance with section 202.1(e)(1) of title 21, Code of Federal Regulations. If passed, this
Act would amend the Social Security Act to allow the Secretary of DHHS to require such advertisements to disclose the wholesale acquisition
cost, or WAC, for a 30-day supply or typical course of treatment and clearly and conspicuously present such price information. If enacted,
the Act contemplates that implementing regulations would include the visual and audio components required to communicate the WAC appropriately
for the medium of the advertisement, the reasonable amount of time to update the advertisement to reflect any changes to WAC, and the
way the manufacturer may include a statement explaining that certain consumers may pay a different amount depending on their insurance
coverage. The Act would also subject advertisers to a penalty of up to $100,000 per violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
full implications of changes such as those discussed above, and their practical impact on biopharmaceutical pricing and reimbursement,
as well as advertising requirements and related costs, on the biopharmaceutical industry as a whole and SciSparc&#8217;s business in
particular cannot yet be determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the marketability
of any products for which SciSparc receives regulatory approval for commercial sale may suffer if the government and other third-party
payers fail to provide adequate coverage and reimbursement. SciSparc expects that an increasing emphasis on cost containment measures
in the U.S. will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may
change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which SciSparc receives
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pricing and Reimbursement in Foreign Countries</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. For example, a member state of the European Union may approve a specific price for the medicinal
product candidate. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
product candidates will allow favorable reimbursement and pricing arrangements for any of SciSparc&#8217;s product candidates. Historically,
product candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly
lower.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As another example, in Canada,
for patented drugs, the Patented Medicines Prices Review Board (PMPRB) uses the median international publicly available ex-factory list
price (using prices in 11 pre-determined countries) as the maximum price the company is allowed to charge. The PMPRB is a quasi-judicial
body with a regulatory mandate to prevent pharmaceutical patentees from charging consumers excessive prices during the market exclusivity
period. This agency then monitors the prices charged by patentees for patented drugs on an ongoing basis. Under the Canadian Patent Act,
patentees are required to file price and sales information about their patented drug products at introduction and twice a year thereafter
for each strength of each dosage form of each patented drug product sold in Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Health Care Laws and Compliance Requirements</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, SciSparc&#8217;s
activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the
CMS, other divisions of the DHHS (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney
offices within the Department of Justice, and state and local governments.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal AKS prohibits,
among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or
purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable, in
whole or in part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include
anything of value, including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional
practices. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution,
but the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory
exception or regulatory safe harbor does not make the conduct per se illegal under the federal AKS. Instead, the legality of the arrangement
will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the ACA amended
the intent requirement of the federal AKS so that a person or entity no longer needs to have actual knowledge of the federal AKS, or
specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the federal AKS is grounds for
the government or whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false
or fraudulent claim for purposes of the civil False Claims Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November
2020, DHHS finalized a regulation aimed at lowering prescription drug prices and out-of-pocket spending for prescription drugs by excluding
rebates on prescription drugs paid by manufacturers to or purchased by Medicare Part D plan sponsors or PBMs acting under contract with
Medicare Part D plan sponsors from the existing discount safe harbor under the federal AKS. The regulation reflects the first change
to the AKS discount safe harbor since the Medicare Part D program was established. In addition to the rebate exclusions, two new safe
harbors were added. One of these new safe harbors protects point-of-sale reductions in price from a manufacturer to a plan sponsor under
Medicare Part D or a MCO for a prescription drug payable, in whole or in part, by a plan sponsor under Medicare Part D or a MCO, provided
certain conditions are met. The other protects certain fixed-fee services arrangements between manufacturers and PBMs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal civil and criminal
false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to avoid, decrease or conceal an obligation to pay money to the federal government.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The civil monetary penalties
statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented
a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or
is false or fraudulent.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA created additional
federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises,
any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the
payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing
a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device
a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items
or services relating to healthcare matters. The ACA amended the federal health care fraud criminal statute implemented under HIPAA so
that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated
the statute.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the federal
Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations,
require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid
or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments
or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated
on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians
and their immediate family members. The SUPPORT Act, signed into law on October 24, 2018, expanded Sunshine Act reporting to include
data for physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified
nurse midwives. The amendment applies to reports submitted to CMS on or after January 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, SciSparc may
be subject to data privacy and security regulation by both the federal government and the states in which it conducts its business. HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations,
impose requirements relating to the privacy, security and transmission of individually identifiable health information on HIPAA covered
entities and their business associates, including mandatory contractual terms and the implementation of certain safeguards of such information.
Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, independent contractors
or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of
a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions
in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.
In addition, state laws govern the privacy and security of health information in some circumstances, many of which differ from each other
in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts.&#160; Most
recently, fourteen states including California have adopted laws that regulate the privacy and security of consumer personal information,
and apply in instances where HIPAA and clinical trial laws do not. In addition, other states such as Washington, have adopted laws that
regulate the privacy and security of consumer health data which, again, apply in instances where HIPAA and clinical trial laws do not.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have also adopted
laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. SciSparc may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value
to physicians and other healthcare providers.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enforcement actions can be
brought by federal or state governments or, in some cases, as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the
name of the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal,
civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual imprisonment,
additional reporting requirements and oversight if SciSparc becomes subject to a corporate integrity agreement or similar agreement to
resolve allegations of non-compliance with these laws, exclusion from government programs, refusal to allow it to enter into supply contracts,
including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of its
operations, any of which could adversely affect its business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to distribute product
candidates commercially, SciSparc must comply with state laws that require the registration of manufacturers and wholesale distributors
of pharmaceutical product candidates in a state, including, in certain states, manufacturers and distributors who ship product candidates
into the state, even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements
on manufacturers and distributors to establish the pedigree of product candidate in the chain of distribution, including some states
that require manufacturers and others to adopt new technology capable of tracking and tracing product candidate as it moves through the
distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities
or register their sales representatives. Other legislation has been enacted in certain states prohibiting pharmacies and other health
care entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting
certain other sales and marketing practices. All of SciSparc&#8217;s activities are potentially subject to federal and state consumer
protection and unfair competition laws.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Foreign Corrupt Practices Act</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FCPA regulates part of
SciSparc&#8217;s business activities. The FCPA has two main provisions applicable to us: (a) the antibribery provisions, which prohibit
individuals and businesses from bribing foreign government officials in order to obtain or retain business; and (b) the accounting provisions,
which impose certain record keeping and internal control requirements on issuers, and prohibit individuals and companies from knowingly
falsifying an issuer&#8217;s books and records or circumventing or failing to implement an issuer&#8217;s system of internal controls.
Violations of the FCPA can lead to civil and criminal penalties, sanctions, and remedies, including fines, disgorgement, and/or imprisonment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The antibribery provisions
of the FCPA prohibits the paying, offering, promising, or authorizing payment or offering money or of anything of value, directly or
indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of such foreign
official, political party, or candidate in his or her official capacity or to secure any improper advantage in obtaining or retaining
business. Under the statute, a company is liable when its directors, officers, employees, or agents, acting within the scope of their
employment, commit FCPA violations intended, at least in part, to benefit SciSparc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accounting provisions
of the FCPA consist of two primary components. First, under the &#8220;books and records&#8221; provision, issuers must make and keep
books, records, and accounts that, in reasonable detail, accurately and fairly reflect an issuer&#8217;s transactions and dispositions
of an issuer&#8217;s assets. Second, under the &#8220;internal controls&#8221; provision, issuers must devise and maintain a system of
internal accounting controls sufficient to assure management&#8217;s control, authority, and responsibility over the company&#8217;s
assets. The accounting provisions do not apply only to bribery-related violations. Rather, the accounting provisions require that all
public companies account for all of their assets and liabilities accurately and in reasonable detail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc, its affiliates,
and its and their operations around the world are subject to the FCPA because SciSparc is an &#8216;issuer&#8217; as defined in the statute.
The U.S. Department of Justice aggressively enforces the FCPA and has, at times, focused its enforcement attention to the pharmaceutical
sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grants from the IIA</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s research
and development efforts mainly with respect to its past activities (with respect to immunotherapy programs such as the Anti-CD3)&#160;
were financed in part through royalty-bearing grants from the IIA. As of December 31, 2024, SciSparc had received the aggregate amount
of approximately $1.1 million from the IIA for the development of its abovementioned technologies. With respect to such grants, SciSparc
is committed to pay royalties of up to an aggregate amount of approximately $1.1 million relating only to technologies in its possession
and excluding any royalties for technologies that SciSparc sold to third parties. SciSparc is further required to comply with the requirements
of the Innovation Law, with respect to those past grants. In addition, any change of control and any change of ownership of SciSparc&#8217;s
securities that would make a non-Israel citizen or resident an &#8220;interested party&#8221; as defined in the Israeli Securities Law,
5728 &#8211; 1968 requires a written notice to the IIA. Non-Israeli citizens and residents are required to execute an undertaking in
favor of the IIA, in the form prescribed by the IIA. When a company develops know-how, technology or products using IIA grants, the terms
of these grants and the Innovation Law and regulations thereunder restrict the transfer or licensing of such know-how inside or outside
of Israel, and the transfer or licensing outside of Israel of manufacturing or manufacturing rights of such products, technologies or
know-how, without the prior approval of the IIA. None of its current projects in the field of cannabinoid therapeutics are supported
by the IIA, yet if eligible, SciSparc might apply for such support in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Current
Regulatory Status of SciSparc&#8217;s Pharmaceutical Products<i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>United
States</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
active ingredient in SciSparc&#8217;s pharmaceutical product candidate SCI-110 is a Schedule I controlled substance. Other drug candidates
in its portfolio are either not controlled or as yet to be scheduled.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
drug candidate SCI-110 is being developed, among others, for the treatment of TS. TS may be considered a serious condition with a potentially
disabling nature. Thus, it may be eligible for a fast-tracked submission. However, a request for eligibility may be filed by SciSparc
later in the development of this molecule. In June 2016, SciSparc submitted a request for orphan drug designation to the FDA for SCI-110
for the treatment of TS. In a letter dated September 29, 2016, the FDA informed SciSparc that its request could not be granted at such
time and is being held in abeyance until and subject to it providing additional information pertaining to the overall prevalence of TS
in both children and adults, and further clinical data to support its scientific rationale for its request for orphan drug designation
within 12 months. In September 2017, SciSparc responded to such FDA letter within the designated time frame and provided the FDA with
its articulated and reasoned responses including documentation and clinical data that supports it. On December 26, 2017, SciSparc received
the FDA&#8217;s response to SciSparc&#8217;s response. The FDA accepted that there is adequate scientific rationale for the treatment
of TS with SCI-110 mainly through the preliminary results of ongoing clinical trials, suggesting that SCI-110 may provide benefit in
treating TS. However, the FDA stated that it was unable to grant SciSparc&#8217;s request and indicated that it did not provide adequate
prevalence estimates, and any evidence to support its statement that only moderate to severe TS patients would require pharmacological
treatment. SciSparc further responded in January 2018 by providing the requested information. On January 23, 2020, following additional
correspondence with the FDA, the FDA still did not grant SciSparc&#8217;s request due to fact that it has not yet provided adequate prevalence
estimates. However, the FDA did agree with SciSparc&#8217; s position that it could potentially qualify for orphan drug designation with
respect to the moderate-to-severe TS sub-group population only rather than the entire population. After SciSparc had provided additional
prevalence estimates, the FDA raised a concern in its letter, dated December 7, 2020, about its ability to limit the use of the pharmaceutical
product to the subset of patients SciSparc is pursuing. Due to the fact that SciSparc disagrees with this concern, it requested a clarification
call. In the clarification call conducted on February 2, 2021, SciSparc agreed with the FDA concern about its ability to limit the use
of the pharmaceutical product to the subset of patients in addition to a safety concern associated with THC treatment in pediatrics population
so SciSparc suggested to amend its preliminary request and asked to include only adults in the treated population. An amendment letter
was discussed and the FDA described what it would want to see in such an amendment. In March 2021, SciSparc sent its response to the
FDA. In June 2021, SciSparc received a response from the FDA explaining that they are unable to grant the request until new information
becomes available to support the request for orphan drug designation. SciSparc will re-visit the application after it obtains clinical
results from its phase IIb clinical study in TS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Canada&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>NNHPD
Approval</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to a non-traditional class III Product License Application, CannAmide&#8482;, or TheraPEA, received Health Canada approval (NPN 80093504)
from the NNHPD on July 23, 2019. In the approval letter, the NNHPD confirmed that the application was in compliance with section 7 of
the NHPR. The dosage of 1 x 400 mg tablet 3 times daily was approved for the following use: &#8220;Studies show that PEA may be used
as an anti-inflammatory to help relieve chronic pain&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Any
labels used in the marketing of TheraPEA must reflect the information outlined on the product license and must comply with the labelling
requirements as per Part 5 of the NHPR. In addition, natural health products, such as TheraPEA, must be manufactured, packaged, labelled,
imported, distributed and stored in accordance with GMP as required by NHPR or in accordance with equivalent requirements if the natural
health product is imported. Furthermore, in accordance with Section 44 of the NHPR, each product for sale in Canada must comply with
the finished product specifications submitted to Health Canada.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the NHPR, companies are required to provide the NNHPD with the Canadian site information prior to commencing the importation and/or
sale of the natural health products in Canada.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Changes
made in respect of a licensed product require the submission of an amendment, notification or a new product license application as per
sections 11, 12 and 13 of the NHPR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Organizational
Structure</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
Nutraceuticals is SciSparc&#8217;s majority-owned subsidiary in which SciSparc has a 50.86% controlling stake and is focused on e-commerce
operations of Wellution&#8482;, a top- seller account of Amazon Marketplace, which sells hemp-based products. Brain Bright Ltd. is an
inactive wholly-owned subsidiary. SciSparc also own 100% of the issued and outstanding share capital of Evero Health Ltd., a company
focused on the development and commercialization of SCI-110 sleep technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
November 17, 2022, SciSparc invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market,
in exchange for 230,769 ordinary shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind. As of July 3,
2025, following a reverse stock split of Clearmind&#8217;s outstanding shares, SciSparc holds 7,692 ordinary shares of Clearmind, representing
less than 0.2% of the outstanding share capital of Clearmind.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
also holds 52.73% of MitoCareX, an Israeli private company<i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
holds a minority interest in AutoMax of approximately 4.82% and a minority interest of approximately 1.14% of Jeffs&#8217; Brands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Property,
Plants and Equipment </b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
offices are located at 20 Raul Wallenberg Street,&#8239;Tower A, 2nd Floor, Tel Aviv 6971916, Israel, where it currently occupies approximately
386 square meters, under a sublease agreement. The sublease ends on April 1, 2026, and may be renewed for a period of sixty additional
months. SciSparc&#8217;s current monthly rent payment is NIS 12,500 (approximately $3,600). SciSparc considers that its current office
space is sufficient to meet its anticipated needs for the foreseeable future and is suitable for the conduct of its business.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Legal
Proceedings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">In
connection with a joint venture transaction, entered on May 15, 2020, by and between SciSparc, Capital Point and Evero Health Ltd., one
of SciSparc&#8217;s subsidiaries, it issued a warrant to Capital Point to purchase $340,000 of SciSparc ordinary shares, or the Warrant
Shares, with an exercise price per ordinary share equal to the closing price of SciSparc&#8217;s ordinary shares on the trading day on
which the notice of exercise is actually received by SciSparc. Such warrant was exercisable for 12 months starting from May 15, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
November 4, 2021, SciSparc received from Capital Point a notice of exercise with respect to the Warrant Shares, which was rejected by
SciSparc. On May 2, 2023, Capital Point filed a lawsuit in the Tel Aviv-Jaffa District Court against SciSparc as the sole defendant in
connection with the Warrant Shares. The lawsuit includes allegations of breaches of contract under the Israeli Contracts Law (General
Part), 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches under the Israeli Torts Ordinance (New Version),
1968. The lawsuit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of
the filing of the lawsuit, liquidated damages according to the provisions set forth in the warrant, and seeks as well for the court to
order a mandatory injunction order for SciSparc to issue a warrant to Capital Point to purchase $340,000 of SciSparc ordinary shares
to Capital Point, the return of any unlawful profits received by us and punitive damages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
of July 3, 2025, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant
and were forfeited by Evero Health Ltd. As of the date of this <span style="background-color: white">prospectus</span>, SciSparc cannot
predict the likelihood of its success in the lawsuit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2025, SciSparc signed a settlement agreement regarding a lawsuit we filed in February 2022 with the Economic Division of the
Tel Aviv-Jaffa District Court against six of SciSparc&#8217;s former directors, or the Defendants. The lawsuit included allegations of
breaches of fiduciary duties under the Israeli Companies Law, 1999, relating to a prior acquisition of a pain clinic network through
a subsidiary of ours. As part of the settlement agreement, SciSparc will be entitled to a $411,000 cash payment from the Defendants in
exchange for our full dismissal of the lawsuit. The settlement agreement includes the termination, effective as of February 5, 2024,
of a disputed licensing agreement with Dekel Pharmaceuticals Ltd. or Dekel. As part of the Settlement, Dekel clarified, to SciSparc&#8217;s
full satisfaction, that SciSparc will retain its exclusive global rights to our extensive IP portfolio, patents, know-how and technologies
and is released from all alleged commitments, claims and royalties related or arising out of the license agreement from May 2015 with
Dekel, including those related to claimed core technologies. Dekel will assume full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related
whatsoever to SciSparc&#8217;s pipeline and development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">AUTOMAX
BUSINESS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>This
section sets forth certain information about AutoMax&#8217;s business and certain of AutoMax&#8217;s financial and operating information
appearing elsewhere in this proxy statement/prospectus. It may not contain all the information about AutoMax that may be important to
you, and we urge you to read the entire proxy statement/prospectus carefully, including the sections entitled&#160;</i>&#8220;<i>Risk
Factors,</i>&#8221; &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of AutoMax,</i>&#8221;&#160;<i>and
AutoMax&#8217;s financial statements included elsewhere in this proxy statement/prospectus. Unless otherwise noted, all references in
this subsection to &#8220;we&#8221; or the &#8220;Company&#8221; are to AutoMax.</i></b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
Overview</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax imports and markets
a variety of private vehicle models, from various categories such as small vehicles, crossovers, executive vehicles, premium vehicles,
work vehicles, buses manufactured by Temsa, and in addition operates in the automobile trade-in business. AutoMax&#8217;s operations
are conducted in Israel. AutoMax believes there are several primary factors that contribute to the success of vehicle importers in Israel,
including: (i) innovative vehicle models and the manner in which these are branded among customers; (ii) trade conditions, especially
the exchange rates of the foreign currencies in which the importer imports in comparison to the currency exchange rates of competitors;
(iii) the existence of good relations with the manufacturer and/or the agent which is also reflected in import prices; (iv) the technological
quality of the imported vehicles; (v) high marketing ability of the importer, which is also reflected in the adjustment of the vehicle
and the prices to market demands; (vi) the level of provided service and the reputation of the importer; (vii) good geographical layout
of purchasing agencies across the world (especially true for parallel importers); and (viii) the geopolitical situation in the countries
from which the vehicles are imported. AutoMax&#8217;s clients range from private customers to institutional customers, including companies
that lease, rent, and operate vehicle fleets, and car dealerships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
operates through various subsidiaries which include Dalhom AutoMax, AutoMax Trade-In, AutoMax Direct Import, and Global AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Global AutoMax holds three
subsidiaries: AutoMax HaShfela Ltd., AutoMax Fleet Vehicles Ltd., and AutoMax HaSharon Ltd.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Material
Agreements Relating to AutoMax&#8217;s Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Founders&#8217;
Agreement to establish a joint company in connection with AutoMax&#8217;s branches in Petah Tikva and Ra&#8217;anana</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 25, 2021, Global
AutoMax entered into a founders&#8217; agreement, or the HaSharon Founders&#8217; Agreement, with A.V.A. Motors Ltd., which acts as an
authorized reseller of vehicles imported by AutoMax and operated a branch in Petah Tikva, or A.V.A. Reseller. Pursuant to the HaSharon
Founders&#8217; Agreement, the parties founded a joint company, AutoMax HaSharon Ltd., or AutoMax Hasharon, which until October 2022,
engaged in operating marketing and sales centers for vehicles imported by AutoMax in the cities of Petah Tikva and Ra&#8217;anana. In
the second quarter of 2024, AutoMax closed the Petah Tikva branch. The HaSharon Founders&#8217; Agreement was cancelled on February 4,
2025. For further details on HaSharon Founders&#8217; Agreement, please see page 212.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Trade-In
Activity in Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 16, 2022, Global
AutoMax entered into a founders&#8217; agreement, as amended, with Av Yo Holdings Ltd., or the Partner, to establish a joint entity,
AutoMax Trade-In Ltd., or AutoMax Trade-In, which engages in the purchase and sale of used vehicles (trade-in), or the Trade-In Agreement.
Pursuant to the Trade-In Agreement, Global AutoMax grants AutoMax Trade-In exclusivity in the purchase of trade-in vehicles, as purchased
by Global AutoMax from its customers, according to pricing determined at Global AutoMax&#8217;s discretion, subject to fulfilment of
certain quotas as agreed in the Trade-In Agreement. Since the second quarter of 2024, AutoMax&#8217;s trade-in activity is being conducted
within AutoMax&#8217;s existing branches. For further details on the Trade-In Agreement, please see page 213.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Founders&#8217;
agreement in relation with the branches in Ashkelon and Ashdod </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On
                                            July 19, 2022, Global AutoMax entered into a founders&#8217; agreement, or the AutoMax HaShfela
                                            Founders&#8217; Agreement, with an authorized reseller, A.S Mobility Ltd., that operates
                                            AutoMax&#8217;s branch in Ashkelon pursuant to which Global AutoMax and the authorized reseller
                                            founded a joint company, AutoMax HaShfela Ltd., or AutoMax HaShfela, which operates as a
                                            vehicle distribution and sales center in Ashdod and Ashkelon. Pursuant to the AutoMax HaShfela
                                            Founders&#8217; Agreement, Global AutoMax owns half of AutoMax HaShfela and the authorized
                                            reseller holds the other half. The board of directors of AutoMax HaShfela consists of four
                                            directors, two of which were appointed by the authorized reseller and two which were appointed
                                            by Global AutoMax. In the second quarter of 2024, AutoMax closed the Ashkelon branch, while
                                            the Ashdod branch remains operational. For further details on this agreement, please see
                                            page 213.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Import
and Marketing of Buses in Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
June 19, 2022, AutoMax entered into a founders&#8217; agreement with Dalhom, which owns a franchise for importing buses of the Temsa
brand, manufactured in Turkey, pursuant to which the companies formed Dalhom AutoMax Ltd., a limited liability company formed under the
laws of the State of Israel, or Dalhom AutoMax, and the Dalhom AutoMax Founders&#8217; Agreement, respectively. The purpose of Dalhom
AutoMax is to serve as a direct importer of Temsa buses in Israel and market these. The Dalhom AutoMax Founders&#8217; Agreement closed
on November 20, 2022, following which each of AutoMax and Dalhom held 50% of Dalhom AutoMax. For further details on the Dalhom AutoMax
Founders&#8217; Agreement, please see page 214.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Agreement
for Direct Import of Electric Vehicles to Israel </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March 13, 2023, Dalhom AutoMax entered into an agreement with Al Damani, a UAE vehicle manufacturer, subject to which Dalhom AutoMax
would distribute, sell, and promote the Al Damani electric vehicles in Israel. This agreement remains subject to Dalhom AutoMax obtaining
all the regulatory approvals as required by the Ministry of Transportation to import vehicles into Israel, a condition that has not yet
been met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Import
and Marketing of Vehicles Manufactured by JAC in Israel</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, AutoMax
Direct Import finalized entering into agreements with JAC. On December 27, 2024, AutoMax Direct Import received its first shipment of
vehicles manufactured by JAC, following regulatory approvals for direct importation. AutoMax management believes the agreement with JAC
will generate growth for AutoMax. For further details on the JAC Agreements, please see page 214.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Founders&#8217; Agreement for Import and
Marketing of JAC Trucks in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2025, AutoMax
received the preliminary approval of JAC to franchise trucks and heavy vehicles manufactured by JAC, by a joint company owned by AutoMax
and Automotive Equipment. On May 8, 2025, AutoMax and Automotive Equipment entered into the Automotive Equipment Founders&#8217; Agreement.
For further details on the Automotive Equipment Founders&#8217; Agreement, please see page 74.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Marketing Channels and Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Direct Distribution and Marketing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this proxy
statement/prospectus, Global AutoMax directly operates six branches,&#160;located in Jerusalem, Haifa, Afula, Netanya, <span style="background-color: white">Ra&#8217;anana</span>,
and Rishon LeZion. The branch located in Ashdod is operated by a joint company of Global AutoMax and a third party, and the remaining
branches in Beer Sheva (which reopened) and Hedera are operated through authorized reseller, as detailed below. The Jerusalem branch
also serves as the location for AutoMax&#8217;s headquarters and includes facilities for licensing and vehicle preparation for sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax maintains an official
website and is active on social media platforms such as Facebook, Instagram, LinkedIn, and TikTok. AutoMax also utilizes paid promotion
and advertising platforms such as Taboola and Outbrain, to share updates on new products and promotions. AutoMax&#8217;s marketing efforts
extend to traditional media as well, including billboards, newspapers and flyers. AutoMax regularly assesses the need to expand its marketing
initiatives and their potential impact to enhance business operations. AutoMax&#8217;s trade-in services (through AutoMax Trade-In),
which also function as a marketing tool for selling new vehicles, are primarily conducted by AutoMax Trade-In at the existing branches,
since the closure of the Glilot branch during the second quarter of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Authorized Resellers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date this proxy
statement/prospectus, AutoMax&#8217;s branches in Hedera and Beer Sheva (which reopened) are operated through authorized Resellers under
AutoMax&#8217;s brand. The agreements with authorized resellers are typically for 3-5 years period, with some agreements automatically
renewing unless terminated as specified. The agreements with authorized resellers typically include sales targets that, if unmet, allow
AutoMax or its subsidiaries to terminate the contract. In addition, most agreements allow either party to terminate the contract&#160;for
any reason,&#160;with 90 days&#8217; prior notice. Authorized resellers are responsible for purchasing demonstration vehicles, maintaining
a minimum vehicle inventory, and running showrooms at their own expense, per AutoMax&#8217;s standards. They also conduct advertising
activities and must keep information confidential during and after the agreement period. Vehicles are sold at prices set by AutoMax,
with authorized resellers earning commissions based on the vehicle model and agreement terms. Marketing efforts are handled by authorized
resellers using AutoMax&#8217;s brand, subject to approval, to attract customers to their branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth AutoMax&#8217;s revenue share in companies held by AutoMax and third parties (not including wholly-owned subsidiaries of AutoMax),
in accordance with its holding percentages of such companies, and pursuant to its founders&#8217; agreements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 19%"><b>Company
    Name</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 11%"><b>AutoMax
    Revenue Share (directly and indirectly)</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><b>Third Party
    Name</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 11%"><b>Third Party
    Revenue Share</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><b>Agreement
    Name</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 11%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Consolidated<br/>
                                            Company (company<br/>
                                            controlled by<br/>
                                            AutoMax (as<br/>
                                            defined in <br/>
                                            IFRS 10),<br/>
                                            whose financial<br/>
                                            statements are<br/>
                                            consolidated as part<br/>
                                            of AutoMax&#8217;s<br/>
                                            financial statements)</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">AutoMax HaShfela Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">50%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">A.S Mobility Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">50%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">AutoMax HaShfela Founders&#8217; Agreement</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">No</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Dalhom AutoMax Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">50%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Dalhom Motors Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">50%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Dalhom AutoMax Founders&#8217; Agreement</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">No</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Dalhom AutoMax Service Centers Ltd.
    (subsidiary (100%) of Dalhom AutoMax)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">50%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Dalhom Motors Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">50%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Dalhom AutoMax Founders&#8217; Agreement</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">No</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">AutoMax Trade-In Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">80%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Av Yo Holdings Ltd.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">20%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Trade-In Agreement</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">Yes</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Industry
                                            Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
vehicle market in Israel differs from most vehicle markets in the world due to its geographical isolation (the absence of open land borders
for free trade in vehicles) and the existence of high import duties. The percentage of vehicle ownership in Israel is relatively low
compared to various Western countries, due to, among other things, the relatively high price of vehicles, mainly due to high taxation,
inferior road infrastructure compared to other Western countries, and high population density.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
the vehicle market in Israel includes a relatively large number of vehicle importers (compared to other sectors in the economy), who
import vehicles that are manufactured in different countries around the world. Most vehicle importers import several brands and products.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
development of the automotive market in Israel is characterized by fluctuations resulting from changes in the macroeconomic environment
of the economy, among other factors. The main characteristics of the automotive market that affect the group&#8217;s activity and the
competitors in this market are:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>High
                                            dependence on suppliers</i>. The success of vehicle importers depends mainly on the relationship
                                            with manufacturers of the vehicles imported and the strategy of the manufacturers&#8217;
                                            activity in relation to the launch of new products, brand positioning in the world, model
                                            policy, trade conditions, price policy and marketing support. It should be noted that the
                                            dependence on the vehicle manufacturers is mainly relevant to the direct importers who have,
                                            in practice, exclusive franchise agreements with manufacturers whose products they import
                                            to Israel. AutoMax believes that it has no significant reliance on the activity of a particular
                                            vehicle manufacturer.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
                                            in consumer preferences</i>. The vehicle preferences in Israel are subject to frequent changes,
                                            resulting from the preference of certain models by consumers, and due to a variety of factors,
                                            including but not limited to, engine type (diesel, oil, electric, hybrid or gasoline), the
                                            size of the vehicle, its design, technological advantages, environmental rating, fuel economy,
                                            safety standard, price and marketability on the resale market.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taxation
                                            of vehicles</i>. The importing of most private vehicles in Israel is subject to purchase
                                            taxes, Value Added Tax and customs imposed at cumulative rates of approximately 30%-130%
                                            (or, oftentimes, more), of the cost of the vehicles. The aforementioned tax rates are among
                                            the highest in the world. Changes in tax rates, or benefits given to vehicles of a certain
                                            type, have a direct impact on the preferences of customers in the area of activity. In addition,
                                            changes in taxation on vehicles provided to employees as part of their employment conditions
                                            may affect their preference in relation to receiving vehicles from the workplace versus purchasing.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fuel
                                            and electricity prices</i>. Changes in fuel and electricity prices may have an impact on
                                            consumer preferences in the long term. Vehicle model preferences vary depending on the type
                                            of energy used (i.e., diesel, gas, gasoline, or electricity) and each such energy price.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulation</i>.
                                            The automotive industry in Israel is characterized by vast regulation and strict regulatory
                                            requirements, including the standardization requirements, which may affect the Company&#8217;s
                                            expenditure and the results of its operations.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Infrastructure
                                            levels and density of the roads</i>. According to research conducted by the Bank of Israel,
                                            the roads in Israel are characterized by high levels of density, especially in the areas
                                            with greater population concentration. This affects the scope of vehicle purchases and is
                                            expected to affect it in the future as well.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in currency and interest rates as well as the economic environment.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on data provided for AutoMax, within the private vehicle market in Israel, taking into account only importers that imported 20 vehicles
or more as of June 2024, there are approximately 41 different vehicle importers, of which approximately 19 are direct importers and 22
parallel importers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
vehicle market in Israel is characterized by vast regulations, one of which is the Committee for Increasing Competitiveness in the Economy
under the Ministry of Finance of the State of Israel. In order to increase the competitiveness in the field of the automotive industry
and decrease the price of vehicles and spare parts, while increasing the existing variety in the Israeli market, one of the laws that
was adopted for this purpose was the Vehicle Services Licensing Law, which purpose was to regulate the licensing of automotive services
in the industry. The law came into effect by supervisory orders by virtue of the Supervision of Commodities and Services Law, 5717-1957,
or the Vehicle Services Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law defined three types of importers: (i) Direct importers &#8211; an importer operating according to an agreement with
the vehicle manufacturer; (ii) parallel importer &#8211; an importer operating according to an agreement with an authorized agent of
the vehicle manufacturer; and (iii) small importer &#8211; an importer who imports up to 20 vehicles per year, operating according to
an agreement with an individual in a foreign country. The Vehicle Services Law further mandates that when granting an import license,
the director of the Vehicle and Maintenance Services Department at the Ministry of Transportation, may consider, <i>inter alia</i>, aspects
related to promoting competition in the automotive industry, after consulting with the competition commissioner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><i>Competition</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
operates in two highly competitive industries, the vehicle industry in Israel as an importer and seller and in the international vehicle
industry as a purchaser of vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The value chain in the automotive
industry includes international vehicle manufacturers, vehicle importers, vehicle dealers (over 8,000 authorized vehicle dealers), financing
entities and end users: households, corporate firms and public organizations. According to the Automotive Industry Review published online
by Dun &amp; Bradstreet in February 2024, or the Automotive Industry Review, there are approximately 20 official import groups representing
various manufacturers in Israel, which are responsible for approximately 97% of the automotive imports to Israel. Alongside these, there
are several dozen parallel importers who are collectively responsible for approximately 3% of the imports. However, during the years
2019 to 2024, a small number of parallel importers were responsible for approximately 75% of the total parallel import to Israel. Additionally,
there are vehicle leasing and rental companies, consisting of approximately five primary companies, alongside smaller companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Automotive Industry Review, as of year-end-2023, there were approximately 4.1 million vehicles on the roads in Israel, of which,
approximately 86% are private vehicles. According to the State of Israel Central Bureau of Statistics, despite a relatively low level
of vehicle ownership in Israel, based on the number of vehicles per 1,000 residents, the traffic density remains among the highest in
the world. Based on studies conducted in previous years, as detailed in Automotive Industry Review, the density is 3.5 times higher than
the Organization for Economic Co-operation and Development, or the OECD, average. The main contributors are the concentration of population
in central Israel, an underdeveloped public transportation system and the lack of correlation between the construction of roads and the
increase in population.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Operating
and growth Strategy </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Automotive Industry Review, the total number of motorized vehicles in Israel consists of approximately: 3.5 million private vehicles
(representing approximately 86%), 310,000 trucks (representing approximately 8%), 169,000 motorcycles (representing approximately 4%),
and 64,000 buses and taxis in aggregate (representing approximately 2%). The Automotive Industry Review &#8211; 2023, published in Dun&amp; Bradstreet detailed that in the first part of the year 2023, the volume of automobile deliveries resembled that of the peak year
in 2021; however, commencing from June 2023 there was a slowdown in the volume of deliveries. This deceleration was a result of events
that impacted the economy in 2023, adversely affecting the purchasing power of households, high interest rates prevailing in the economy
in 2023, peaking at 4.75% in the latter half of the year, diminished both purchasing power and financing capabilities, the proposed judicial
reforms in Israel creating significant uncertainty in the economy and threatening Israel&#8217;s credit rating, also affecting the shekel-dollar
exchange rate and increasing the cost of imported goods, including automobiles; and the outbreak of Israel&#8217;s current war against
Hamas that became known as the &#8216;Iron Swords&#8217; war in Israel (for more information, see &#8220;<i>Risk Factors &#8211; Risks
Related to AutoMax&#8217;s Operations in Israel &#8211; Conditions in Israel, including the ongoing war between Israel and Hamas, and
other conflicts in the region, may adversely affect AutoMax&#8217;s operations and limit its ability to market its products, which would
lead to a decrease in revenues</i>&#8221;), which resulted in reduced demand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Israel Tax
Authority, in the year 2024, there was an aggregate of 325,943 passenger vehicles imported to Israel, compared to 283,835 in the year
2023, representing an increase of 14.8%, and compared to 306,087 in the year 2022. Passenger vehicle imports were lower in aggregate
through November 2024 compared to the corresponding period in 2023, and the annual increase was due to the massive imports in December
2024, on the eve of the reduction in the purchase tax benefit for electric vehicles, an update to the green taxation formula. Based on
AutoMax&#8217;s financial results, the import of vehicles in the first three quarters of 2023 showed an increase compared to the first
three quarters of 2022 and declined in the last quarter due to the outbreak of the &#8216;Iron Swords&#8217; war, which resulted in reduced
demand, delays, and increased transportation costs, coupled with security threats associated with transportation in the Red Sea.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the &#8216;Iron
Swords&#8217; war that began in the fourth quarter of 2023 created market uncertainties and weakened consumer sentiment. At the onset
of the war, numerous employees were put on unpaid leave or were called to serve as reservists, many businesses in the commercial sector
reduced their workforce or at least halted recruitments, reducing the inclination to acquire new cars. Due to the reduction in manpower,
the number of employed individuals in the commercial sector holding leased vehicles on behalf of the employer, who constitute major clients
of leasing services, has slowed down, and according to Automotive Industry Review, this is expected to further dampen the demand for
leasing services in the year 2025. The Israeli economy faces significant challenges due to the complex security situation and global
market conditions. Economic indicators point to mixed trends: on one hand, low unemployment and relatively moderate inflation compared
to other Western countries indicate economic resilience; on the other hand, a high deficit and rising debt-to-GDP ratio emphasize the
need for careful fiscal management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax currently operates
nine branches, six of which are operated directly by Global AutoMax, one is operated through joint company of Global AutoMax and a third
party, and two are operated by authorized representatives. AutoMax agreements with its authorized representatives are typically for a
term between three and five years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">AutoMax&#8217;s
main strategies to help enable its growth include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building
                                            and preserving an inventory of products and models in accordance with customer preferences,
                                            and technological advancements and market developments. AutoMax frequently monitors trend
                                            changes and consumer preferences, in order to expand the range of products and services it
                                            offers.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrating
                                            activity sectors in the vehicle industry synergistic to its activity and the deployment of
                                            supply sources on sales centers, while examining their contribution to its profitability.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            a leasing license and entering the leasing market.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forming
                                            partnerships and/or collaborations with representatives and manufacturers of internationally
                                            leading brands in the automotive industry as well as investment fields.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Financing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">AutoMax group companies
have non-guaranteed credit lines from five banking corporations, which are classified in its financial statements as short-term loans,
as detailed below:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Borrowing
    Company</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Credit
    Line Amount (NIS in thousands)</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Utilized
    Amount as of<br/>
    December 31, 2024 (NIS in thousands)</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lender</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Interest
                                            Rate (annual)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Collateral
    provided in favor of the lender and other essential conditions</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commitments
    to<br/>
    comply with<br/>
    financial covenants</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bank
    consent<br/>
    for the Merger</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Global
    AutoMax</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 6%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">30,000</span></p>
                                                                   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">32,500</span></p>
                                                                   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">42,500</span></p>
                                                                   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">32,500</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 7%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">25,000</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">32,500</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">42,500</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">30,000</p>

</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Bank
                                            A</span></p>
                                                                   <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Bank
                                            B<br/>
                                            Bank C<br/>
                                            Bank D<br/>
                                            &#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prime
    + 1.15%-2.15%<br/>
    Prime +1.25%-2.25%<br/>
    Prime +0.5%-1.5%<br/>
    Prime +0.75%-1.75%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 31%; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
                                            The total tangible equity of Global AutoMax will not be less than NIS 35 million (examined
                                            semi-annually, based on Global AutoMax&#8217;s financial statements); (2) Global AutoMax
                                            total tangible equity divided by Global AutoMax total tangible balance sheet will not be
                                            less than 20% from in Bank A and will not be less than 25% in Banks B, C and D (examined
                                            semi-annually, based on Global AutoMax&#8217;s financial statements) (the &#8220;<b>Equity
                                            to Balance Sheet Ratio</b>&#8221;) (3) Global AutoMax vehicle inventory in accordance with
                                            its financial statements divided by its net credit, will not be less than 115% at any time
                                            (examined monthly) (the &#8220;<b>LTC Ratio</b>&#8221;).</span></p>
                                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">As
                                            of December 31, 2024, Global AutoMax met all its financial covenants: the tangible equity
                                            of Global AutoMax was between NIS 66,374 thousand and NIS 68,072 thousand (according to the
                                            differences in the definition of tangible equity for each of the banks); the Equity to Balance
                                            Sheet Ratio was between 25.12% and 25.6% (according to the differences in the definition
                                            of the term tangible equity for each of the banks) and the LTC Ratio was 121.82%.</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Not
    yet provided as of date of this prospectus. Not yet provided as of the date of this prospectus. Not yet provided as of the date of
    this prospectus Not yet provided as of the date of this prospectus</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"/>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">AutoMax
    Trade-In</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">13,680</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bank
    C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Prime
    + 0.5% -1.5%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)
                                            The total tangible equity of AutoMax Trade-In will not be less than a total of 25% of the
                                            total tangible balance sheet of AutoMax Trade-In (examined on a semi-annual basis, according
                                            to the annual and semi-annual financial statements of AutoMax Trade-In) (the &#8220;<b>Equity
                                            to Balance Sheet Ratio</b>&#8221;); and (2) The ratio between (a) the value of AutoMax Trade-In&#8217;s
                                            vehicle inventory, and (b) its net financial debt, will not be less than 130% (examined every
                                            month as well as upon demand of the bank). As of December 31, 2024, AutoMax Trade-In did
                                            not meet all its financial covenants detailed above: the Equity to Balance Sheet Ratio was
                                            26.28 %, and the ratio detailed in section (2) was 152.98%.</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Not
    yet provided as of the date of this prospectus.</span></td></tr>

</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; width: 8%"><span style="font-family: Times New Roman, Times, Serif">Dalhom
    AutoMax</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 6%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">7,500</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,500</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 7%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7,500<br/>
                                            2,500</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif">Bank
    C<br/>
    Bank D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif">Prime
    + 0.5% -1.5%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 32%">The ratio between
    (a) the value of Dalhom AutoMax vehicle inventory plus the advance payments made to Dalhom AutoMax supplier, and (b) Dalhom AutoMax
    net financial debt, shall not be less than 1.2 (the &#8220;<b>Inventory-to-Debt Ratio</b>&#8221;). The Inventory-to-Debt Ratio is
    examined every month as well as at the request of the Banks. As of December 31, 2024, the Inventory-To-Debt Ratio is 1.29.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 20%"><span style="font-family: Times New Roman, Times, Serif">Not
    yet provided as of the date of this prospectus. Not yet provided as of the date of this prospectus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">AutoMax
    Direct Import</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">23,000</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bank
    D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Prime
    +1%-2%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    detailed below.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">(1)
    The total tangible equity of Automax Direct Import will not be less than an amount equal to 30% of the tangible balance sheet of
    Automax Direct Import (examined each quarter based on Automax Direct reports starting June 2025); (2) the ratio between AutoMax Direct
    Import vehicle inventory and AutoMax Direct Import net credit shall not be less than 130%; and (3) meeting revenue and profit targets
    according to an annual business plan (for this purpose, deviation of up to 10% will not be considered a violation of this covenant).</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;Provided.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">AutoMax
    Direct Import</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">20,000</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(extended&#160;in
                                            April 2025)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank
                                            E</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prime
                                            +1.7%-2.7%</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">As detailed below.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">(1) The total tangible equity of AutoMax
    Direct Import will not be less than an amount equal to 30% of the tangible balance sheet of AutoMax Direct Import (examined each
    quarter based on AutoMax Direct Import reports starting June 2025); (2) the ratio between AutoMax Direct Import vehicle inventory
    and AutoMax Direct Import net credit shall not be less than 130%; and (3) meeting revenue and profit targets according to an annual
    business plan (for this purpose, deviation of up to 10% will not be considered a violation of this covenant).</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;Provided.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>


</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Collateral
provided in favor of the lender and other essential conditions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to secure the repayment of the on-call credit lines provided by the Banks A-D, or the Banks, Global AutoMax provided the Banks
with the liens, collaterals and pledges, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            first-degree floating lien on all assets, funds, property and rights including the proceeds
                                            of Global AutoMax;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            first-degree permanent lien and pledge on the unassigned share capital of Global AutoMax
                                            and its goodwill;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            permanent lien and pledge of the bills of lading, certificates of ownership of goods, documentary
                                            letters of credit, or other documents indicating ownership of goods or goods which will be
                                            delivered from time to time to the Banks;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            permanent lien and pledge of all the securities, documents, bills of others which Global
                                            AutoMax has delivered or will deliver from time to time to the Banks; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
                                            commitment not to encumber shares of subsidiary Global AutoMax owns, without the prior written
                                            approval of the Banks.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, AutoMax guaranteed the full obligations of Global AutoMax to the Banks, without limitation on the amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
terms of the credit lines from Banks A-D include other customary provisions, including subordination of owner loans extended to Global
AutoMax and delivery of financial statements and other financial reports to the Banks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
secure the full repayment of the on-call credit line provided by Bank C, AutoMax Trade-in provided Bank C with a first-degree floating
lien on its plant, business, and all the assets and rights it has now and/or will have in the future. In addition, AutoMax guaranteed
AutoMax Trade-in&#8217;s obligations to Bank C, with a limitation of up to NIS 15 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the terms of AutoMax Trade-In&#8217;s credit line from Bank C include a cross-default provision in connection with the credit
extended by Bank C to Global AutoMax, and other customary provisions, including subordination of owner loans extended to AutoMax Trade-In,
and delivery of reports to Bank C.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
secure the full repayment of the on-call credit lines provided by Banks C and D, Dalhom AutoMax provided Banks C and D with first degree
floating lien on all its assets, including the rights and proceeds arising from the assets. In addition, the terms of Dalhom AutoMax&#8217;s
credit lines include a cross-default provision in connection with the credit extended by the Banks to Global AutoMax, a prohibition on
a direct change of control in Dalhom AutoMax, and other customary provisions, including subordination of owner loans extended to Dalhom
AutoMax, and delivery of reports to the Banks. Dalhom AutoMax has further undertaken that its tangible equity will increase every year
at a rate of no less than 50% of the annual net profit. AutoMax guaranteed Dalhom AutoMax&#8217;s obligations towards Banks C and D.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To secure the full repayment
of the on-call credit line provided by Banks D and E, AutoMax Direct Import provided Banks D and E (&#8216;<i>Pari-Passu&#8217;</i>)
with a first-degree permanent lien and pledge on the unassigned share capital of AutoMax Direct Import and its goodwill and a first degree
floating lien on all its assets, including the rights and proceeds arising from the assets. AutoMax guaranteed AutoMax Direct Import&#8217;s
obligations towards Bank D and Automax and one of its wholly owned subsidiaries guaranteed AutoMax Direct Import&#8217;s obligations
towards Bank E. In addition, the terms of AutoMax Direct Import&#8217;s credit lines include other customary provisions, including subordination
of owner loans extended to AutoMax Direct Import and delivery of reports to Banks D and E.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>AutoMax&#8217;s
Competitive Advantages</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Unlike
direct importers who are guaranteed a certain vehicle inventory, pursuant to agreements with manufacturers, AutoMax is required to purchase
its vehicle inventory from authorized dealers and various suppliers in various international markets, under more competitive conditions.
AutoMax is able to operate in a larger number of markets with different characteristics, with a variety of products, while aiming to
increase its geographical purchase sources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While direct importers are
bound to agreements with manufacturers, and therefore subject to such manufacturers&#8217; framework with a predetermined model cascade,
which limits the vehicle models they can import. Parallel importers, such as AutoMax, have greater flexibility with regards to the brands
and models selected for import. The number of significant parallel importers remains relatively low in Israel (during the years 2019
to 2024, a small number of parallel importers were responsible for approximately 75% of the total parallel import to Israel), reducing
AutoMax&#8217;s competition in this category. The high profit margins characterized by vehicles sold by direct importers allow AutoMax
to sell its imported vehicles at competitive prices, thus gaining consumer preference. Furthermore, its ability to find convenient procurement
sources in terms of price and transportation, distribution, and sales network provides AutoMax with a competitive advantage over other
parallel importers. In accordance with a report generated on December 30, 2024, for the period covering January 1, 2019 to December 30,
2024 from the website &#8220;CarZone&#8221;, at https://www.carzone.co.il/, a service providing statistics regarding the vehicle market
in Israel, AutoMax is currently the leading and largest company in the indirect sectors in terms of vehicle imports, importing approximately
40% of the total vehicles imported to Israel by parallel import during the years 2019 to 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Employees
and Human Capital </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the number of employees employed by AutoMax as of December 31, 2021, 2022, and 2023, by departments. None of
AutoMax&#8217;s employees are represented by a labor&#160;union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number
    of employees<br/> (including part-time positions)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Department</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,<br/>
    2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,<br/>
    2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,<br/>
    2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify">Management, headquarters and finances</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">14</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">13</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pre-delivery inspections</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">17</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">14</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sales</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">93</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">43</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">44</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">126</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">71</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">72</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
recent years, as part of the global trend, there has also been a trend in Israel aimed at reducing the environmental damage caused by
the use of vehicles. As part of this trend, the global automotive industry is investing in increasing alternative sources of propulsion,
starting with hybrid vehicles and ending with vehicles powered by gas or electricity. Similarly, governments around the world have joined
the environmental effort, by way of activating regulatory tools to encourage the development, production and purchase of vehicles with
less environmental damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
2024 in Israel, 271.7 thousand new vehicles were delivered, according to &#8220;Monthly Review December 2024&#8221;, of the Israeli Association
of Vehicle Importers, representing an increase of 0.6% compared to 2023. Of these, more environmentally friendly cars were delivered,
as the data indicates that 24.7% of all deliveries were of electric vehicles which still receive tax benefits (although reduced from
the past) as an incentive and encouragement for the green transition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the last two years,
the electric vehicle market began to develop in Israel. As of the date of this prospectus, the electric vehicle category is mainly dominated
by Chinese brands. From the data of the automobile industry for the year 2024, it is evident that electric technology was widely implemented
in the market during this year, as 67,171 electric cars were delivered, accounting for approximately 24% of all deliveries, 67,171 hybrid
vehicles were delivered, accounting for approximately 24% of all deliveries, and 6,044 hybrid plug-in vehicles were delivered, accounting
for approximately 2% of all deliveries, compared to 2023 in which approximately 270,023 electric cars were delivered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Seasonality</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
recent years, there is a seasonality in vehicle sales in Israel has manifested in an increase in vehicle sales towards the end of the
calendar year (in the fourth quarter of the year). This trend stems, to the best of AutoMax&#8217;s knowledge, from the government&#8217;s
decision to decrease</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">purchase
tax discounts for hybrid and electric vehicles starting from the beginning of the first quarter of the following year. Therefore, buyers
of this type of vehicle chose to purchase the vehicles at a lower price in the fourth quarter of that year. At the same time, importers
preferred to release from ports and bonded warehouses a large number of vehicles for inventory at a lower cost.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Governmental
Regulations </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax
operates in a highly regulated environment and is subject to many governmental regulations and laws that can impact its competitive position
and earnings. These regulations are designed to increase competition in the local market and protect consumers. AutoMax is subject to
consumer protection laws, laws regulating the import of spare parts, laws regulating services and recall obligations and regulations
by the Committee for Increasing Competitiveness in the Economy under the Ministry of Finance of the State of Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
governments across the globe, including in Israel, have started adopting new regulations aimed at environmental matters in an attempt
to slow climate change. Over the years AutoMax has seen certain tax repercussions on vehicles pursuant to these regulations, for example
the Green Tax as adopted in Israel in 2009, pursuant to which the taxation on a vehicle is set by the level of pollution for such vehicle.
This Green Tax was adopted to encourage consumers to lean towards ecofriendly vehicles. Additionally, AutoMax is subject to governmental
regulations in the countries from which it imports its vehicles. The European union has adopted the Worldwide Harmonized Light Vehicle
Test Procedure, or WLTP, which is used to measure fuel consumption and CO<sub>2</sub>&#160;emissions. All vehicles imported to Israel
are subject to the WLTP test to determine the Green Tax for such model.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
                                            order to increase the competitiveness in the field of the automotive industry and decrease
                                            the price of vehicles and spare parts, while increasing the existing variety in the Israeli
                                            market, the Vehicle Services Licensing Law was enacted to regulate the licensing of automotive
                                            services in the industry. The law came into effect by supervisory orders by virtue of the
                                            Supervision of Commodities and Services Law, 5717-1957, or the Vehicle Services Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law defined three types of importers: (i) direct importer &#8211; an importer operating according to an agreement with
the vehicle manufacturer; (ii) parallel importer &#8211; an importer operating according to an agreement with an authorized agent of
the vehicle manufacturer; and (iii) small importer &#8211; an importer who imports up to 20 vehicles per year, operating according to
an agreement with an individual in a foreign country. The Vehicle Services Law further mandates that when granting an import license,
the director of the Vehicle and Maintenance Services Department at the Ministry of Transportation may consider, inter alia, aspects related
to promoting competition in the automotive industry, after consulting with the competition commissioner.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, AutoMax is subject to various advertising, sales, employment, financing and privacy laws, all of which could affect its ability
to obtain the required licenses and permits to operate its business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a description of the Material regulatory provisions applicable to AutoMax&#8217;s activities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Certain
Material Israeli Regulatory Provisions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following summary is a discussion of material Israeli regulatory provisions applicable to AutoMax&#8217;s current activities but does
not discuss all of the aspects of Israeli or other law that may be relevant to AutoMax&#8217;s activities. The following summary is for
general information purposes only and is based upon current Israeli law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Competition
in the Automotive Industry</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the conclusions of the Committee for Increase in Economical Competition, published in 2012, the Israeli government decided to take a
series of measures in the automotive industry with the aim of increasing competition in the industry and supporting the decline in the
prices of vehicles and spare parts, while increasing the existing diversity of vehicle models in the Israeli market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of these measures, during 2016, the Vehicle Services Law was passed into law. The purpose of the Vehicle Services Law is to regulate
the licensing of vehicle services and professions in the automotive industry, most of which were regulated before the law came into force,
by supervision orders by virtue of the Supervision of Commodities and Services Law, 5718-1957. One of the goals of the Vehicle Services
Law is to establish new provisions that would promote competition in the industry and consumer rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law defines three types of importers, or Commercial Importers: direct importer &#8211; an importer acting under an agreement
with the vehicle manufacturer, or a Direct Importer; parallel importer &#8211; an importer acting under an agreement with an authorized
agent of the vehicle manufacturer, or a Parallel Importer; and small importer &#8211; an importer who imports up to 20 vehicles per year,
operating under an agreement with a person in a foreign country, or a Small Importer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">When
granting an import license, the Director of the Vehicle and Maintenance Services Division at the Ministry of Transport may consider,
inter alia, considerations of promoting competition in the automotive industry, after consulting with the Competition Commissioner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, in order to remove competitive barriers on Parallel Importers and Small Importers, the Direct Importer is obligated to provide
a manufacturer&#8217;s warranty as given in the country of origin, spare parts and treatment of serial safety malfunctions for every
vehicle manufactured by a manufacturer imported by it, even if the model of vehicle was not actually imported by the Direct Importer,
but by a Parallel Importer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law is intended to reduce regulation on the import and trade of spare part for vehicles. Such reduction in regulation
shall only apply to spare parts of vehicles certified by an Israeli, European or American standard. Accordingly, the existing complex
and cost-heavy import and trade procedures for spare parts were eliminated. In addition, the Vehicle Services Law regulated the trade
in vehicle safety equipment, while imposing various obligations on the license holder to trade in vehicle safety equipment, such as safety
requirements, providing liability for their products, handling defective products, and correctly marking traffic products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Vehicle Services Law imposes statutory obligations on Commercial Importers, including providing the buyer with safety information about
the vehicle, publicizing the level of safety equipment of the vehicle, providing information to the garage about the care and maintenance
of vehicles (except for Small Importers), securing the buyer&#8217;s financial liability by limiting the amount paid by each buyer in
advance as down payment for the purchased vehicle, unless the buyer had registered it in his or her name. If a buyer did not register
the vehicle in his or her name, the Commercial Importers must inform him or her before the purchase, of his or her entitlement to receive
a bank guarantee for the cost of the down payment for the vehicle.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Vehicle Services Law opened the market to private imports for personal or family use, which allows such importers to import
vehicles for business needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Safety
Disclosures</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Licensing Regulations for Services and Professions in the Automotive Industry (Car Importation and Marketing, Mediation In Personal Importation
and Fees), 5777-2016, were installed by virtue of the Vehicle Services Law. These regulations stipulated, among other things, provisions
regarding the regulation of serial safety malfunctions in imported vehicles (recalls), publication of safety information regarding a
vehicle in advertising and at the sale centers, provision of instructions for use of the vehicle to the buyer and reporting of damage
caused to the vehicle prior to delivery.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Direct and Parallel Importer License</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
main legal provisions governing the procedure required to obtain a Parallel Importer and Direct Importer license are included in the
Vehicle Services Law, Licensing Regulations for Services and Professions in the Automotive Industry (Car Import and Marketing and Car
Trade), 5776-2016, and Procedure No. 1/16, and Procedure 2/16, of the Vehicle and Maintenance Services Division published by the Ministry
of Transportation, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
direct importer is subject to various obligations towards the customer, including: (a) providing maintenance services; (b) supplying
transportation products; (c) warranty; (d) serial safety defects; (e) timely reporting on the termination date of the contractual engagement
with the manufacturer; (f) publication of service garages; (g) providing relevant information to the customer; and (h) compliance with
the importer's obligations according to the relevant sections of the Vehicle Services Licensing Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
provisions establish, <i>inter alia</i>, threshold requirements for obtaining a license for the parallel import of vehicles, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">entering
                                            into an agreement with an authorized agent (either a primary agent (a primary agent is an
                                            entity that has an agreement with the vehicle manufacturer according to which it is authorized
                                            to sell a vehicle made by the vehicle manufacturer) or secondary agent (a secondary agent
                                            is an entity or person connected by an agreement with a primary agent regarding the vehicle
                                            imported by a Direct Importer, according to which that entity or person is authorized to
                                            act on behalf of the primary agent and sell a vehicle manufactured by the car manufacturer
                                            with which the main agent has entered into an agreement to sell a vehicle);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            letter of commitment both from the vehicle manufacturer in a foreign country and a letter
                                            of commitment from the applicant;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">minimum
                                            equity (as specified in regulation 6 of the Import Regulations, and which varies according
                                            to the number of vehicles imported by the Commercial Importer in the year preceding the year
                                            for which the license application was submitted); and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Commercial Importer&#8217;s direct reporting obligation to the administration, and infrastructure
                                            for providing maintenance services for the vehicle.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Parallel Importer&#8217;s engagement with the authorized agent, the authorized agent is required to notify the Parallel Importer,
immediately, of any serial safety malfunction discovered in the vehicle sold to the Parallel Importer (recall). In addition, the authorized
agent must have sold more than 1,500 new vehicles in the year preceding the year of submitting the application for the Parallel Importer
license.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Parallel Importer has various obligations towards its customers, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">vehicles
                                            sold by such Parallel Importer must be new vehicles (or a vehicle registered in a foreign
                                            country that have not traveled more than 150 km);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Parallel Importer must provide maintenance services, supply spare parts to the vehicle for
                                            no less than seven years from the date of delivery of the vehicle to the consumer;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Parallel Importer has the obligation to immediately notify consumers about any serial safety
                                            fault discovered in the vehicle sold to them, as well as providing information to the consumer
                                            regarding the issue;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">timely
                                            reporting the date of termination of contractual engagement with the manufacturer;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">advertising
                                            of service garages;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">providing
                                            relevant information to customers; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">remaining
                                            in compliance with the Parallel Importer&#8217;s obligations according to the relevant sections
                                            of the Vehicle Services Law.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with the foregoing, AutoMax distribution agreements with authorized agents generally include the following provisions: (a)
the agent undertakes to sell to AutoMax, from time to time, new vehicles manufactured by a particular manufacturer (brand), in quantities
and according to prices, payment terms and supply terms as agreed between the parties, for the purpose of marketing and selling these
vehicles by AutoMax, and AutoMax is not obligated to purchase pre-determined quantities of vehicles; (b) the agreements include the agent&#8217;s
declarations and undertakings as required by the Vehicle Services Law, as a condition for granting a parallel import license, including
declarations regarding the date of manufacture of the supplied vehicles and their mileage at the time of delivery; (c) the agreement
include the agent&#8217;s undertaking to provide AutoMax with the professional booklets, manuals and instruction manuals in English;
and (d) the agreements include the Agent&#8217;s undertaking to update AutoMax as soon as possible regarding the recall of vehicles by
the manufacturer and to provide the AutoMax&#8217;s customers with any material information required in connection with such recall,
including technical instructions for correcting the malfunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Usually,
agreements are signed for a period of 6 years, where, <i>inter alia</i>, each party may bring the agreement to an end by giving the other
party written notice 90 days in advance. The agent undertakes to continue to sell to AutoMax, even after termination or expiration of
the Agreement for any reason, the spare parts for the vehicles purchased by the AutoMax, for at least seven years from the date of supply
to the customers of vehicles sold by AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the provisions of the law described above, a Parallel Importer may import and market vehicles of a certain model for which the Parallel
Importer was granted a license from the Ministry of Transportation, even not throughout the authorized agent with whom the Parallel Importer
received the license for that particular model.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Clean
Air Law, 5768-2008</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Section
38 of the Clean Air Law, 5768-2008, or Clean Air Law, requires any person who sells or markets new vehicles, to disclose in the publications
conducted and published by them in the media, the level of air pollution and fuel consumption data of the new vehicles marketed by them,
in accordance with the provisions of the Clean Air Regulations (Disclosure of Air Pollution Data from Motor Vehicles in Advertisements),
5769-2009.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2009, the &#8220;green taxation&#8221; reform in Israel, or the Green Tax, came into effect. The Green Tax is a benefit in the purchase
tax rate imposed on vehicles depending on the level of pollution of the vehicle, while setting tax incentives for the purchase of vehicles
that pollute less. According to the green index, all new vehicles are ranked according to their level of pollution, so that a vehicle
that pollutes less will receive more tax benefits. In order to implement this principle, the purchase tax on the purchase of private
vehicles was raised from 72% to 83%, and tax reductions were given at increasing rates, up to a maximum discount of about NIS 15,000,
for the least polluting vehicles. As part of the Green Tax reform, it was determined that the calculation formula for the &#8220;green
score&#8221; will be updated from time to time, in order to maintain the efficiency of the incentives and keep up with the pace of technological
changes in the world, which reduce the level of emissions from vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Green Tax reform has led to an increase in the market segment of small vehicles with small volume engines that enjoy the full tax benefit.
However, changes in fuel prices may reduce this effect. The effect of the Green Tax reform on society depends on the mix of products
proposed by vehicle manufacturers. According to a report by the Automobile Importers Association, while Green Tax regulation encourages
the entry of new, non-polluting vehicles, there is no incentive to remove old vehicles already in circulation in the Israeli market,
which boasts a high life expectancy of a vehicle and stands at 15.5 years. According to Hezi Shave and Nadav Caspi, &#8220;Multi-Year
Plan for Removing Polluting and Unsafe Vehicles 2021&#8221;, the percentage of vehicles which are 9 years old or older is 31%. Prominent
elements that delay the process of dredging vehicles in Israel are, among others, car insurance that is not affected by the age of the
vehicle, lack of monetary compensation for scrapping an old vehicle, and more.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the update of the Pollution Regulations and the Vehicle Pollution Testing Procedure in the European Union (WLTP), the Green Tax formula
was updated in Israel to reflect the change in the measurement method, or the New Green Tax Formula. The New Green Tax Formula gradually
reduces the tax benefits for vehicles with a low level of pollution and sets tax benefit ceilings, causing an increase in the prices
of vehicles that enjoyed purchase tax benefits as part of the Green Tax (such as electric and hybrid vehicles). The New Green Tax Formula
went into effect on April 1, 2019, and is updated once on January 1 of each year. The tax benefit on hybrid and plug-in vehicles was
eliminated in 2025. On January 1, 2023, the purchase tax on hybrid and plug-in cars increased from 40% in 2022 to 55% in 2023, and the
tax benefit ceiling was reduced from NIS 40,000 in 2022 to NIS 30,000 in 2023. The purchase tax on electric cars doubled from 10% in
2022 to 20% in 2023, and the tax benefit ceiling was reduced from NIS 75,000 in 2021 to NIS 60,000 in 2022. In 2025, the purchase tax
on electric vehicles was supposed to increase to 83%; however, in December 2024 the Ministry of Finance announced a halt to the increase
so that the tax rate on electric vehicles would rise from 35% to only 45% with a ceiling of up to NIS 35,000. On March 11, 2025, the
Knesset finance committee approved that the purchase tax on electric vehicles in 2025 will stand at 45% with a ceiling of up to NIS 35,000.
This update to the formula on tax rate to be paid on some of the vehicles imported by AutoMax, as well as on the vehicles of AutoMax&#8217;s
competitors, caused a moderate increase in the prices of some of the vehicles marketed in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I<span style="font-family: Times New Roman, Times, Serif">n
order to continue encouraging the import of electric vehicles, it was determined that electric vehicles will be exempted according to
pollution levels, so that the tax reduction for them under the New Green Tax Formula will remain unchanged until the end of 2027. This
exemption will allow electric vehicle buyers to continue enjoying tax benefits in 2026 and 2027, and also in 2025 it will affect the
calculation of the ceiling of the tax benefit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, it was determined
that starting from January 1, 2025, the tax benefit given to non-electric vehicles according to their air pollution level will be reduced,
as part of the New Green Tax Formula. Furthermore, it was determined that in 2025 only, an additional reduction of the New Green Tax
Formula amounting to NIS 750 will apply, so that the purchase tax reduction will decrease by NIS 750 and the tax addition will increase
by NIS 750.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2024, the finance
committee approved new regulations that for the first time equate the amount of registration fees due for electric vehicles to the registration
fees due for non-electric vehicles. The regulations increased the average cost of the fee for an electric vehicle owner by NIS 2,300
per year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Taxation
</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Changes
in the provisions relating to employee taxation and taxation of the use of an employer&#8217;s vehicle (imputation of the value of a
vehicle) may affect business entities in decisions regarding the granting of benefits to employees by way of providing a vehicle for
their use and on employees&#8217; considerations in obtaining a company vehicle as a substitute for wages. These changes may also affect
AutoMax, as employees tend to forgo receiving a car from the workplace and prefer to purchase a car privately.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Customs Tariff and Exemptions and Purchase Tax on Goods Order (Temporary Order No. 5), 5773-2013, or the Order, stipulated that the tax
on private vehicles whose consumer price exceeds NIS 300,000 will increase. According to the order, the vehicles for which the Order
applies to, in addition to the purchase tax rate applicable to the vehicle, will be tax at an additional tax rate calculated as a multiple
of 20% in the difference between the price of the vehicle to the consumer and NIS 300,000, divided by the price of the vehicle to the
consumer. On June 20, 2018, the order was updated to apply to hybrid (including plug-in) and electric vehicles. Because AutoMax imports
a variety of cars (electric, hybrid, plug-in, gas), AutoMax has the ability to change the types of vehicles imported based on the tax
policies applicable to each type of vehicle. The Order is currently in effect until the end of 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with Amendment No. 3 to the Traffic Regulations, 5728-1961, the year of manufacture of the vehicle will be determined according
to the year it went on the road, and such a vehicle will be considered new if twelve months have not yet passed from the date of manufacture,
with exceptions. This means that a vehicle that resides in the Commercial Importer&#8217;s warehouses beyond the aforementioned period
will be considered a &#8220;second-hand&#8221; vehicle, and as a result, the importer will be required to pay the purchase tax imposed
on the vehicle and sell it as a &#8220;second-hand&#8221; vehicle. Accordingly, if a year has passed since the date of manufacture of
the vehicle and the vehicle has not yet been sold, AutoMax is required to carry out a licensing procedure for the vehicle and register
it in its name, and the sale of the vehicle will be considered as a second-hand car sale. In order to avoid selling second-hand vehicles,
AutoMax updates its marketing personnel shortly before the 12-month period has passed and provides high incentives to salespeople for
selling these vehicles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
July 2013, the Ministry of Transportation published a procedure for implementing Regulation 270D of the Traffic Regulations, which deals
with the provision of tax incentives for vehicles equipped with safety systems. The purpose of the procedure is to encourage the import
and purchase of equipped and safe vehicles. In addition, from time to time the Israel Tax Authority revisions the number of points given
to the various safety systems and lowers scores for systems that have already been sufficiently implemented by the public. In accordance
with the aforementioned procedure, motor vehicles imported to Israel of type 1N and 1M (as defined in the Transportation Regulations),
weighing more than 3.5 tons, are entitled to a reduction in purchase tax according to the level of safety equipment of the vehicle, which
will be determined according to the range of safety systems installed in the vehicle and according to the scoring system set out in the
procedure. As part of the aforementioned reform, it was determined, <i>inter alia</i>, that each vehicle model will have a &#8220;level
of safety equipment&#8221;, to be specified on the vehicle license, and Commercial Importers will be required to report to the Ministry
of Transportation about the existing safety systems in the vehicle model. The more safety systems the vehicle is equipped with, the higher
the level the safety equipment will be considered. As of the date of this prospectus, the tax benefit by virtue of the safety incentive
depending on the various levels of safety equipment ranges from approximately NIS 242 to approximately 2,500 NIS, i.e. NIS 242 per credit
point. AutoMax estimates that the effect of this incentive on the prices of vehicles marketed by it is immaterial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
November 5, 2020, the Israel Tax Authority published a directive to customs agents according to which, from February 1, 2021, it is mandatory
to attach a certificate of conformity, or COC, document to the vehicle file, and for each model (determined by the Ministry of Transportation)
it is mandatory to attach at least one COC document. The directive emphasized that if at the time of creation of the vehicle file, no
COC document will be attached to one of the vehicle files of the same model (in the current file or in one of the previous vehicle files),
it will not be possible to register the vehicle. COC documents form an &#8220;identity card&#8221; of any new vehicle, which is manufactured
in Europe. The COC document includes vehicle data, including tire size, exact weights, safety accessories, technical specifications and
air pollution data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of January 1, 2017, and according to the Services and Professions in the Vehicle Industry Regulations (Vehicle Import and Marketing,
Personal Import Intermediation and Fees), 5777-2016, a Commercial Importer must publish in its show rooms or any other place where it
sells or markets vehicles, information regarding the level of safety equipment of new vehicles sold by it.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of January 1, 2018, the Traffic Regulations (Amendment No. 2), 5778-2017, came into force, according to which private and commercial
vehicles registered for the first time by a Commercial Importer will be required to install a collision warning system and lane departure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Consumer
Protection Regulations (Cancellation of a Transaction), 5771-2010</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">According
to the Consumer Protection Regulations (Cancellation of a Transaction), 5771-2010, approved by in August 2011, a consumer may cancel
an order for a new vehicle purchased from a Commercial Importer within 14 days, provided that the vehicle has not yet been delivered
to the buyer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>The
Privacy Protection Law, 5741-1981</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Certain
aspects of AutoMax activities are governed by the Privacy Protection Law, 5741-1981, or the Privacy Protection Law, and the regulations
promulgated thereunder. AutoMax acts on a regular basis to adapt the relevant aspects of its activity to the provisions applicable under
the Privacy Protection Law and the regulations promulgated thereunder, and for that purpose is updating information security policies
and procedures annually, mapping and controlling data shared with outsourcing vendors, and more.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>General
</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the above, AutoMax is subject to orders, regulations and procedures governing various restrictions and charges applicable
to vehicle importers or marketers in Israel; Traffic Ordinance [New Version]; Free Import Order, 5774-2014; Ministry of Transportation
procedures that are updated from time to time, as well as the various regulatory requirements defined and updated from time to time by
the Standardization Department of the Vehicle Division of the Ministry of Transportation, which deal mainly with vehicle safety, passenger
and pedestrian safety, and air pollution. As of the date of this prospectus, to the best of AutoMax&#8217;s knowledge, AutoMax complies
with and complies with all instructions, requirements and arrangements relevant to its operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
Property and Proprietary Rights </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">AutoMax&#8217;s
business name and brand image are critical elements to its business strategy. In Israel, Global AutoMax holds a registered tradename
&#8220;AUTOMAX&#8221; in English, and &#8220;Global AutoMax&#8221; in Hebrew, which is set to expire on November 25, 2029. AutoMax&#8217;s
business is also affected by innovation and technology which have become increasingly important. AutoMax relies on its tradename, domain
names and certain copyrights to protect its branding and differentiate it from other brands in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Global
AutoMax has a license for parallel import of thirty two vehicle types, and a direct import license for four vehicle types. AutoMax Direct
Import has a direct import license for JAC vehicles. In addition, AutoMax has a parallel import license for four vehicle types, which
are overlapping with licenses granted to its subsidiaries.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="m_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">SCISPARC
MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><i>You should read the following
discussion and analysis of SciSparc&#8217;s financial condition and results of operations together with SciSparc&#8217;s financial statements
and the related notes appearing elsewhere in this proxy statement/prospectus. In addition to historical information this discussion and
analysis contains forward-looking statements that involve risks, uncertainties and assumptions. SciSparc&#8217;s actual results may differ
materially from those results described in or implied by the forward-looking statements discussed below. Factors that could cause or
contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk
Factors &#8212; Risks Related to SciSparc&#8221; appearing elsewhere in this proxy statement/prospectus. SciSparc&#8217;s discussion
and analysis for the year ended December 31, 2023 compared to the year ended December 31, 2022 can be found in its Annual Report for
the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024.</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc
is a specialty clinical-stage pharmaceutical company. SciSparc&#8217;s focus is creating and enhancing a portfolio of technologies and
assets based on cannabinoid therapies. With this focus, SciSparc is currently engaged in the following development programs based on
&#916;9-tetrahydrocannabinol, or THC, and/or non-psychoactive cannabidiol, or CBD, and/or other cannabinoid receptors, or CBR, agonists:
SCI-110 for the treatment of Tourette syndrome, or TS, for the treatment of obstructive sleep apnea, or OSA, and for the treatment of
Alzheimer&#8217;s disease and agitation; and SCI-210 for the treatment of Autism Spectrum Disorder, or ASD, and Status Epilepticus, or
SE. SciSparc also has a majority-owned subsidiary whose business focuses on the sale of hemp seeds oil-based products and others on Amazon
Marketplace.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Operating
Results</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2024, SciSparc has generated revenues through its subsidiary SciSparc Nutraceuticals, which owns the Wellution&#8482;
brand. Total revenues recognized in the year ended December 31, 2024, amounted to $1,306 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify; background-color: white">To
date, SciSparc has not generated revenue from its drug development business from the sale of any pharmaceutical product candidates, and
does not expect to generate significant revenue in this business within the next year at least. As of December 31, 2024, SciSparc had
an accumulated deficit of approximately $75 million. SciSparc&#8217;s operating activities are described below under &#8220;Operating
Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Revenues</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">In
the year ended December 31, 2024, SciSparc has generated revenues in the amount of $1,306 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Cost
of goods sold</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
cost of goods sold comprises mainly of purchase of products and transportation costs to SciSparc&#8217;s warehouse for the SciSparc Nutraceuticals
business. In the year ended December 31, 2024, the cost of goods sold amounted to $800 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Operating
Expenses</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
current operating expenses consist of five components - research and development expenses, sales and marketing expenses, impairment of
intangible assets, general and administrative expenses, and other income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc&#8217;s
research and development expenses consist primarily of salaries and related personnel expenses, research and preclinical studies, chemistry
and formulations, regulatory, professional and other related research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
following table discloses the breakdown of research and development expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">390</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">392</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory, professional and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">681</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">719</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and preclinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Clinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">254</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">141</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,707</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,641</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">SciSparc
expects that its research and development expenses will materially increase as it plans to continue clinical trials and develop new products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Sales and Marketing Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s sales and
marketing expenses consist primarily of Amazon fees, advertising costs, depreciation costs, storage and shipping costs, and management
fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table discloses
the breakdown of sales and marketing expenses for the periods presented:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%">Advertising</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">367</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">576</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amazon fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">486</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Storage and shipping</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">120</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,515</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,484</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses consist primarily of salaries, professional service fees for accounting, legal, bookkeeping, investor relations,
Amazon Marketplace transaction fees, advertising and promotion on Amazon Marketplace, regulatory expenses and other general and administrative
expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
following table discloses the breakdown of general and administrative expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">507</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">415</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">68</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and directors&#8217; fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,594</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Business development expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">202</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office maintenance, rent and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">128</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">110</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">197</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">369</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,526</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,844</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the year ended December 31, 2024 to the year ended
December 31, 2023 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cost of goods sold</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">683</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">506</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,707</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,641</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sales and marketing</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,515</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,484</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,344</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,526</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,844</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,270</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,316</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,815</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity losses from the investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financial income, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(259</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Comprehensive loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,472</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to holders of Ordinary Shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
revenues for the year ended December 31, 2024 decreased by $1,573 thousand, or 55%, to $1,306 thousand, compared to $2,879 thousand for
the year ended December 31, 2023. The decrease is primarily due to operational difficulties which caused the Welllution<sup>TM</sup>&#160;brand
to be temporarily put offline from the Amazon Marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of Goods Sold</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s cost of
goods sold for the year ended December 31, 2024 increased by $117 thousand, or 17%, to $800, compared to $683 thousand for the year ended
December 31, 2023. This increase resulted primarily from losses resulting from the revaluation of inventory.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross Profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s gross profit
for the year ended December 31, 2024 decreased by $1,690 thousand, or 77%, to $506 thousand, compared to $2,196 thousand for the year
ended December 31, 2023. This decrease resulted primarily from the decrease in revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s research
and development expenses for the year ended December 31, 2024, amounted to $1,707 thousand, representing an increase of $66 thousand,
or 4%, compared to $1,641 thousand for the year ended December 31, 2023. The increase resulted primarily from an increase in research
and preclinical studies, that amounted to $211 thousand for the ended December 31, 2024, compared to $101 thousand for the year ended
December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s general
and administrative expenses totaled $4,526 thousand for the year ended December 31, 2024, representing an increase of $682 thousand,
or 18%, compared to $3,844 thousand for the year ended December 31, 2023. The increase resulted primarily from an increase in share-based
expenses and professional and directors&#8217; fees, that amounted to $419 thousand and $3,009 thousand, respectively, for the ended
December 31, 2024, compared to $68 thousand and $2,594 thousand, respectively, for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;Sales and marketing expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s sales and
marketing expenses totaled $1,515 thousand for the year ended December 31, 2024, representing a decrease of $969 thousand, or 39% compared
to $2,484 thousand for the year ended December 31, 2023. All sales and marketing expenses are generated by SciSparc Nutraceuticals, which
owns the Wellution&#8482; brand. The decrease resulted mainly from a decrease in Amazon fees, which were a result of the decrease in
sales of goods by SciSparc Nutraceuticals in 2024 compared to 2023. Other reasons for the decrease in sales and marketing expenses include
the decrease in management fees, advertising and depreciation costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Other income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income in the year
ended December 31, 2024, amounted to $1,270 thousand, through the sale of: (i) 320,000 ordinary shares of Polyrizon, (ii) pre-funded
warrants to purchase 364,931 ordinary shares of Polyrizon, and (iii) common warrants to purchase 1,541,096 ordinary shares of Polyrizon
to third parties, for aggregate consideration of $771 thousand. Also, SciSparc recorded a gain in the amount of $517 thousand from the
remeasurement of its remaining investment in such Polyrizon warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of intangible asset</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s impairment
of intangible assets totaled $1,344 thousand for the year ended December 31, 2024, representing an increase of $302 thousand compared
to $1,042 for the year ended December 31, 2023. The impairment in the year ended December 31, 2024, resulted from continued losses in
the Wellution&#8482; brand, similar to the loss on impairment recognized in the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s operating
loss for the year ended December 31, 2024, was $7,316 thousand, representing an increase of $501, or 7%, as compared to an operating
loss of $6,815 thousand for the year ended December 31, 2023. The increase resulted primarily from the decrease in revenues and the increase
in general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial Expense and Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expenses and income
consist of revaluations of instruments measured at fair value, exchange rate differences, bank fees, loans interest and other transactional
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc recognized financial
income in the amount of $612 thousand for the year ended December 31, 2024, as compared to financial income of $2,219 thousand for the
year ended December 31, 2023. The decrease of financial income for the year ended December 31, 2024 resulted mainly due to a decrease
in financial income from revaluation of a warrant liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc recognized financial
expenses for the year ended December 31, 2024, of $353 thousand, as compared to financial expense of $1,055 thousand for the year ended
December 31, 2023. The decrease of financial expenses for the year ended December 31, 2024 resulted mainly due to a decrease in losses
related to changes in the fair value of securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total Comprehensive Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our total comprehensive loss
for the year ended December 31, 2024, was $7,472 thousand, representing an increase of $1,589 thousand, or 27%, as compared to $5,883
thousand for the year ended December 31, 2023. The increase resulted primarily from the increase in operating loss and decrease in financial
income, net.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
SciSparc&#8217;s inception in 2004, and through December 31, 2024, SciSparc has funded its operations principally with $76 million from
the issuance of its securities in public offerings and private placements. As of December 31, 2024, SciSparc had $1.5 million in cash,
$10 thousand in trade receivables, $1,079 thousand in other accounts receivable, $113 thousand in inventory, $517 thousand in short-term
financial assets, and an additional amount of 20 thousand in short-term bank deposits. In the event that additional financing is required
from outside sources, SciSparc may not be able to raise such financing on terms acceptable to it or at all. If SciSparc is unable to
raise additional capital when desired, its business, operating results, and financial condition would be adversely affected, and there
is substantial doubt about its ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
tables below presents SciSparc&#8217;s cash flows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(5,104</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(5,887</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,094</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,193</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,483</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net increase in cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(536</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,498</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash used in operating activities was $5,104 thousand during 2024 in comparison to $5,887 thousand during 2023. The decrease resulted
primarily from a decrease in finance income related to gains from the remeasurement of a warrant liability, and a decrease in inventory
related to a revaluation of inventory, offset in part by a decrease in losses from the remeasurement of investments in financial assets.
Another reason for the decrease in cash used in operating activities is the increase in the loss on impairment of intangible assets,
which is a non-cash adjustment, as well as the increase in share-based compensation costs, which are a non-cash adjustment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Investing
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash used in investing activities was $1,625 thousand during 2024 in comparison to net cash used in investing activities of $4,094 thousand
during 2023. Net cash used by investing activities during 2024 resulted mainly from a loan granted to a related party in the amount of
$4,078, and an investment in a company accounted for using the equity method in the amount of $600 thousand, offset in part by a divestment
in short-term bank deposits in the amount of $3,000 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash used in investing activities during 2023 resulted mainly from the investment in short-term bank deposits in the amount of $3,000
thousand, investment in financial assets in the amount of $689 thousand, and an investment in a company accounted for at equity in the
amount of $400 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;<span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Financing
Activities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash provided by financing activities of $6,193 thousand in the year ended December 31, 2024, primarily consisted of proceeds from the
issuance of share capital in the amount of $6,225 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash provided by financing activities of $8,483 thousand in the year ended December 31, 2023, primarily consisted of $5,552 thousand
of net proceeds from the issuance of share capital, pre-funded warrants and warrants, and by cash generated from the sale of a minority
interest in the Wellution brand in the amount of $2,985 thousand.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Wellution
Acquisition Agreement</i></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 14, 2022, SciSparc entered into the Wellution Acquisition Agreement, pursuant to which it acquired the Wellution&#8482; brand,
or the Brand. SciSparc established SciSparc Nutraceuticals, a wholly owned subsidiary, to hold the new assets, which is also a party
to the Wellution Acquisition Agreement. On September 30, 2022, SciSparc closed the acquisition of the Brand and paid $4.59 million for
the Brand. In addition, at the closing SciSparc issued the Advisor Warrant to the Advisor, to purchase up to 3,925 of SciSparc&#8217;s
ordinary shares. On March 26, 2024, the Advisor agreed with SciSparc to waive all its rights under the Advisor Warrants and have the
Advisor warrants cancelled for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Wellution
Sales Agreement</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
February 23, 2023, SciSparc entered into the Wellution Sale Agreement with Jeffs&#8217; Holdings and Jeffs&#8217; Brands, pursuant to
which, at the closing, which occurred on March 28, 2023, Jeffs&#8217; Holdings acquired from SciSparc 57 shares of common stock of SciSparc
Nutraceuticals, which equals approximately a 49% interest in SciSparc&#8217;s wholly owned subsidiary, SciSparc Nutraceuticals, which
owns the Wellution<sup>TM</sup>&#160;brand, for a consideration of $2.5 million in cash, and additional deferred cash payments of approximately
$489 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the closing, SciSparc and Jeffs&#8217; Brands undertook a mutual share exchange in the amount of approximately $288 of
ordinary shares from each of SciSparc and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the
average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately
prior to the closing. Accordingly, SciSparc acquired 160 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 660
ordinary shares from SciSparc having an aggregate value of $288,238.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Following
the closing of the transaction, which included an equity conversion of the financing amounts of approximately $700 previously provided
by the Company to SciSparc Nutraceuticals for working capital, into shares of common stock at the price per share of the Wellution Sale
Agreement, SciSparc holds approximately 51% of SciSparc Nutraceuticals.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the Wellution Sale Agreement, at the closing, Jeffs&#8217; Brands and SciSparc Nutraceuticals entered into the Wellution
Management Agreement for management services of the Wellution<sup>TM</sup>&#160;brand by Jeffs&#8217; Brands, for a monthly fee of $20,
which was later reduced to $10 in 2024, Jeffs&#8217; Brands also received a one-time signing bonus in the amount of $51.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>At-The-Market
Issuance Sales Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
May 16, 2023, SciSparc entered into an At-the-Market Issuance Sales Agreement with Aegis Capital Corp., or the ATM Agreement, pursuant
to which it may offer and sell up to $1,729,964 of SciSparc&#8217;s ordinary shares. Between May 16, 2023 and August, 9, 2023, SciSparc
sold approximately $4,779 of ordinary shares. On August 9, 2023, the ATM Agreement was terminated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Underwritten
Public Offering</i><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2023, SciSparc closed an underwritten public offering, or the Public Offering, of 10,119 ordinary shares, at a purchase price
of $109.20 per ordinary share and pre-funded warrants to purchase up to 1,786 ordinary shares at a purchase price of $108.654 per pre-funded
warrant, for aggregate gross proceeds of approximately $1.3 million, pursuant to an underwriting agreement between SciSparc and Aegis,
or the Underwriter, on August 10, 2023. Pursuant to the terms of the Underwriting Agreement, SciSparc also granted the Underwriter a
45-day option to purchase up to an additional 1,786 ordinary shares solely to cover over-allotments, if any, at the Public Offering share
price less underwriting discounts and commissions.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $11.466 per share. Following the Public
Offering and as of July 3, 2025, SciSparc issued 57 ordinary shares in respect of the exercise of 57 pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>October
2023 Private Placement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 12, 2023, SciSparc closed a private placement transaction, or the 2023 Private Placement, pursuant to a securities purchase agreement
and a registration rights agreement with an institutional investor for aggregate gross proceeds of approximately $5 million (representing
a 30% original issue discount to the aggregate purchase price of $7,180,000), before deducting fees to Aegis, the placement agent and
other expenses payable by SciSparc in connection with the transaction. SciSparc sold units to the investors at a purchase price of $78.12
per unit, consisting of 91,910 pre-funded Ordinary Share purchase warrants to purchase up to 91,910 ordinary shares, and an additional
accompanying pre-funded warrant to purchase up to 91,910 ordinary shares.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
pre-funded warrants were exercisable immediately upon issuance and have an exercise price of $0.021 per share. Following the transaction
and as of July 3, 2025, SciSparc has issued 51,381 ordinary shares in respect of the exercise of 51,381 pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 25, 2023, SciSparc entered into a securities purchase agreement with AutoMax, pursuant to which, at the closing and upon the terms
and conditions set forth in the AutoMax SPA, it invested NIS 2,500 thousand (approximately $691) in cash, in exchange for ordinary shares
of AutoMax based on a price per share of NIS 0.5. Following the closing, SciSparc held approximately 5.6% of the issued and outstanding
share capital of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 14, 2024, SciSparc entered into the Bridge Loan with AutoMax, pursuant to which AutoMax received the Bridge Loan in the amount
of $1.4 million, further to the previously-announced non-binding letter of intent for SciSparc to acquire AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax and Merger Sub. Upon the terms and subject to the satisfaction of the
conditions described in the Merger Agreement, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a
wholly-owned subsidiary of the Company. AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of
SciSparc, equal to the Exchange Ratio set forth in the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2024, on November 26, 2024, on March 27, 2025, and on May 8, 2025, SciSparc and AutoMax entered into the Merger Agreement
Addendum, the Merger Agreement Second Addendum, the Merger Agreement Third Addendum, and the Merger Agreement Fourth Addendum, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 9, 2024, SciSparc entered, into the Amended Bridge Loan, pursuant to which AutoMax received an additional loan in the amount of
$1.0 million, for an aggregate amount of $2.4 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On September 5, 2024, SciSparc entered into the Second Amendment, pursuant to which
SciSparc extended an Additional Loan Amount to AutoMax loan in the amount of $1.85 million to AutoMax under terms similar to the Bridge
Loan Agreement, bringing the total Loan Amount to $4.25 million. During the month of September 2024, SciSparc provided AutoMax with the
loan amounts due under the Second Amendment to the Bridge Loan, and offset any interest due until November 30, 2024 from the principal
amount, such that on the closing date of the Merger, SciSparc will be entitled to be paid the due interest at a rate of 7% per annum
(or 9% per annum if the Merger is not consummated), of the Loan Amount, accruing from the period beginning on December 1, 2024 and ending
on the effective date of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Merger Agreement contemplates that at the closing, SciSparc shall deliver to AutoMax the Closing Financing Amount. In light of the Bridge
Loan and amendments thereto, no Closing Financing Amount will be transferred. In consideration for the Loan Amount, AutoMax established
a first ranking fixed charge security interest on AutoMax&#8217;s shares of its wholly-owned subsidiary AutoMax Direct Import in favor
of SciSparc. The Bridge Loan amount, together with any accrued interest, may be repaid in part or in whole prior to the repayment date,
contingent on whether the closing of the Merger Agreement occurs. The repayment date shall be at the earlier date of: (a) the Closing,
in which the Owed Amount shall be deemed set-off against, the Closing Financing Amount; or (b) if the Merger Agreement is terminated
in accordance with its terms, within three months from such termination date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 27, 2025, SciSparc announced that it had entered into the Additional Loan Agreement with AutoMax, where a $2 million loan was
provided. The Additional Loan Amount bears an 8% annual interest rate and will be repaid in equal monthly installments of $50,000 and
interest, with AutoMax retaining the option to make early repayment without penalties. The interest on the Additional Loan Amount will
be cancelled as of the consummation of the Merger Agreement and AutoMax will continue to make monthly payments towards the principal
amount of the loan. To secure repayment of the Additional Loan, Automax HaSharon shares held by Global Automax were pledged in favor
of SciSparc with a first-degree permanent lien.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
                                            May 8, 2025, SciSparc entered into the Third Amendment, pursuant to which, in addition to
                                            the already existing subordination of the Loan Amount to AutoMax&#8217;s Series B Bonds,
                                            the Loan Amount will also be subordinated to AutoMax&#8217;s Series C Bonds, issued and traded
                                            on the TASE.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>January
2024 Standby Equity Purchase Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 21, 2024, SciSparc entered into a Standby Equity Purchase Agreement, or SEPA, as amended on February 26, 2024, with YA II PN,
LTD, or YA, which provided for the sale of up to $20 million of SciSparc&#8217;s ordinary shares, or the Advance Shares. As of December
31, 2024, of the $20 million eligible to be sold pursuant to the SEPA, or the Commitment Amount, SciSparc has sold 273,466 ordinary shares
for total proceeds of $6,255,000. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share price of
97% of the market price, which is defined as the lowest daily volume weighted average price of the ordinary shares during the three consecutive
trading days commencing on the trading day immediately following the delivery of an advance notice to YA. Any sale of ordinary shares
pursuant to the SEPA is subject to certain limitations, including that YA is not permitted to purchase any shares that would result in
it owning more than 9.99% of SciSparc&#8217;s ordinary shares. SciSparc is not permitted to utilize the SEPA, until all of the Debentures
issued pursuant to the February 2025 SPAs (as defined below) have been paid off.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><i>Convertible
Debentures Securities Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">On
February 25, 2025, SciSparc entered into securities purchase agreements, or the February 2025 SPAs, with certain investors, or the Debenture
Investors, pursuant to which SciSparc agreed to sell and issue to the Debenture Investors convertible debentures, or the Debentures,
in the aggregate principal amount of $4.2 million, or the Subscription Amount, which are convertible into SciSparc&#8217;s ordinary shares,
as converted, the Conversion Shares, at a conversion rate equal to the lower of (i) $9.8301 or (ii) 95% of the lowest daily volume weighted
average price of the SciSparc ordinary shares during the twenty consecutive trading days immediately preceding the applicable conversion
date of the debenture, with a floor price of $1.7871. The issuance and sale of the Debentures is subject to certain conditions and limitations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Debentures will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding
principal balance of the Debentures at an annual rate of 8%, which will increase to an annual rate of 18% upon an Event of Default (as
defined in the Debentures) for so long as such Event of Default remains uncured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Debenture Investors will have the right to convert the Debentures into ordinary shares at the lower of (i) 110% of volume weighted average
price of the ordinary shares the trading day immediately preceding the closing or (ii) 95% of the lowest daily volume weighted average
price of the ordinary shares during the 20 consecutive trading days immediately preceding the conversion date or other date of determination,
or the Market Price; provided that the Market Price may not be lower than the floor price, which will be equal to 20% of the volume weighted
average price of the ordinary shares on the day prior to the closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
issued to the Debenture Investors 172,174 warrants which are exercisable into a number of ordinary shares equal to the Subscription Amount
applicable to the investors divided by a price equal to 130% of the volume weighted average price of the ordinary shares immediately
prior to the closing date, or $11.6172 per warrant , which shall be exercisable into Warrant Shares, for a term of five years from the
issuance date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
entered into a global guaranty agreement, or the Global Guaranty Agreement with one of the Debenture Investors, or the Lead Debenture
Investor, through certain of SciSparc&#8217;s subsidiaries, pursuant to which such subsidiaries will guaranty its obligations under the
Debenture with the Lead Debenture Investor and other instruments, agreements or other items executed or delivered pursuant to the Global
Guaranty Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
also entered into a registration rights agreement, or the Registration Rights Agreement, with the Lead Debenture Investor, pursuant to
which SciSparc has agreed to provide to the Lead Debenture Investor registration rights under the Securities Act and the rules and regulations
promulgated thereunder, and applicable state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the securities purchase agreements with the Debenture Investors, on February 25, 2025, SciSparc entered into the Deed
with AutoMax and three investors. Pursuant to the Deed, SciSparc assigned part of the Subscription Amount in the amount of $2 million
to AutoMax in lieu of making the payment under the Additional Loan Agreement to which SciSparc entered into with AutoMax on February
24, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Other Financing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2024, SciSparc
announced that it signed the Spin-off LOI to spin its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc
Nutraceuticals. The Spin-off LOI references a proposed asset and share purchase agreement, the definitive agreement of which is to be
negotiated between SciSparc and Miza. On December 16, 2024, SciSparc entered into the First LOI Amendment, solely to extend the deadline
to enter into definitive agreements by no later than March 31, 2025, which was extended from July 31, 2024, provided that such date may
be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than April 30, 2025,
which was extended from October 31, 2024. On March 28, 2025, SciSparc entered into the Second LOI Amendment, solely to the deadline to
enter into definitive agreements by no later than June 30, 2025, which was extended from March 31, 2025, provided that such date may
be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025,
which was extended from April 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 13, 2024, SciSparc entered into the License Agreement, for the out-licensing of its SCI-160 program with Polyrizon. Pursuant to
the License Agreement, SciSparc granted Polyrizon the License. Pursuant to the License Agreement, SciSparc received 320,000 ordinary
shares of Polyrizon, pre-funded warrants to purchase 364,931 ordinary shares of Polyrizon, and common warrants to purchase 2,054,793
ordinary shares of Polyrizon, at an exercise price of $4.38 per share. On December 30, 2024, pursuant to a share transfer agreement,
SciSparc sold all of the Polyrizon ordinary shares and pre-funded warrants held by it, as well as an aggregate of 1,541,096 Polyrizon
common warrants to third parties, for aggregate consideration of $770,548. In addition, in consideration for the License, SciSparc will
receive royalties from sales related to the SCI-160 platform and income generated from it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 25, 2025, SciSparc entered into the MitoCareX SPEA, as amended on May 18, 2025, together with MitoCareX, the other Sellers,
pursuant to which the Sellers will sell their stakes in MitoCareX to N2OFF, thereby resulting in MitoCareX becoming a wholly-owned subsidiary
of N2OFF. The closing of the MitoCareX SPEA is contingent upon, among other customary obligations, obtaining approval of N2OFF&#8217;s
stockholders by the requisite majority. On the closing date of the transactions contemplated under the MitoCareX SPEA, SciSparc will
transfer and sell its stake in MitoCareX to N2OFF in consideration for a cash payment of $700,000 N2OFF Common Stock, representing 16.75%
of N2OFF on a fully-diluted basis. Following the closing date of the MitoCareX SPEA, the Sellers may receive Additional N2OFF Stock,
if respective milestones are achieved as defined in the MitoCareX SPEA. On May 18, 2025, the parties amended the MitoCareX SPEA, solely
by extending the exclusivity period by an additional ninety days, such that either party may terminate the MitoCareX SPEA in the event
that the closing date has not occurred within one hundred and eighty days of February 25, 2025. For more information, see &#8220;MitoCareX&#8221;
on page 156.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Current
Outlook</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has financed its operations to date primarily through proceeds from sales of SciSparc&#8217;s securities, as well as exercises of warrants
and options to purchase ordinary shares or ADSs, as the case may be. SciSparc has incurred losses and generated negative cash flows from
operations since August 2004. Since August 2004, SciSparc has not generated any revenue from the sale of its pharmaceutical product candidates
and does not expect to generate revenues from sale of its pharmaceutical product candidates in the next few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of December 31, 2024, SciSparc&#8217;s cash, including short-term bank deposits, was $1,560 thousand.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
cash and cash equivalents position is not sufficient to fund its planned operations for at least a year beyond the date of the filing
date of these financial statements. The ability to continue as a going concern is dependent upon its obtaining the necessary financing
to meet SciSparc&#8217;s obligations and repay liabilities arising from normal business operations when they become due. While SciSparc
has successfully raised funds in the past, there is no guarantee that it will be able to do so in the future. The inability to borrow
or raise sufficient funds on commercially reasonable terms would have serious consequences on SciSparc&#8217;s financial condition and
results of operations. In addition, SciSparc started to recognize revenues from sales. However, SciSparc&#8217;s pharmaceutical operations
are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until SciSparc
is able to finance our operations through generating revenue from its products. These factors raise substantial doubt about our ability
to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2022, SciSparc purchased Wellution&#8482;, a business and brand which sells hemp-based products on Amazon Marketplace.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">On
January 25, 2023, SciSparc announced that its board of directors resolved to pursue a Restructuring Plan which may involve transferring
its pharmaceutical activities to NewCo. As part or independent of the Restructuring Plan, it intends to examine the possibility of listing
NewCo on a leading stock exchange, while maintaining its controlling interest in NewCo such that it will continue to control its current
business activities. SciSparc also intends to explore other potential new opportunities, activities and investments in a variety of sectors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Any
Restructuring Plan and possible listing of NewCo on a stock exchange may be subject to, among other things, market conditions, tax or
other business analyses, regulatory approvals, receipt of any necessary consents, final approvals from its board of directors and shareholders
and satisfaction of any closing conditions to effectuate such corporate Restructuring Plan and listing of NewCo. There can be no assurance
regarding the ultimate timing of the Restructuring Plan and listing of NewCo or that they will be completed at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2024, November 26, 2024, March 27, 2025, and on May 8, 2025, SciSparc and AutoMax entered into the Merger Agreement Addendum,
the Merger Agreement Second Addendum, the Merger Agreement Third Addendum, and the Merger Agreement Fourth Addendum, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, SciSparc&#8217;s operating plans may change as a result of many factors that may currently be unknown to it, and SciSparc may
need to seek additional financing sooner than planned. SciSparc&#8217;s efforts to commercialize its proprietary PEA oral tablets CannAmide&#8482;
may not lead to any revenue or revenue at the level at which we it is expecting. SciSparc&#8217;s future capital requirements will depend
on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            progress and costs of SciSparc&#8217;s research and development activities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the costs of manufacturing SciSparc&#8217;s product candidates;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            costs of filing, prosecuting, enforcing and defending patent claims and other intellectual
                                            property rights;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            potential costs of contracting with third parties to provide marketing and distribution services
                                            for us or for building such capacities internally; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            magnitude of SciSparc&#8217;s general and administrative expenses.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until SciSparc can generate
significant recurring revenues, it expects to satisfy its future cash needs through debt and/or equity financings. SciSparc cannot be
certain that additional funding will be available to it on acceptable terms, if at all. This raises substantial doubts about SciSparc&#8217;s
ability to continue as a going concern.&#160;If funds are not available, SciSparc may be required to delay, reduce the scope of, or eliminate
research or development plans for, or commercialization efforts with respect to SciSparc&#8217;s product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Going
Concern</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of December 31, 2024, SciSparc&#8217;s cash and cash equivalents totaled $1.5 million. In the period ended December 31, 2024, SciSparc
had an operating loss of $7.3 million and negative cash flows from operating activities of $5.1 million. SciSparc&#8217;s current cash
and cash equivalents position is not sufficient to fund our planned operations for at least a year beyond the date of the filing date
of the financial statements. The ability to continue as a going concern is dependent upon SciSparc obtaining the necessary financing
to meet its obligations and repay its liabilities arising from normal business operations when they become due. While SciSparc has successfully
raised funds in the past, there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient
funds on commercially reasonable terms, would have serious consequences on SciSparc&#8217;s financial condition and results of operations.
In addition, SciSparc has started recognizing revenues from sales. However, SciSparc&#8217;s pharmaceutical operations are dependent
on its ability to raise additional funds from existing and/or new investors. This dependency will continue until SciSparc is able to
completely finance its operations by generating revenue from its products. These above-mentioned factors raise substantial doubt about
SciSparc&#8217;s ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Intangible
Assets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Separately
acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired
in a business combination are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible
assets, excluding capitalized development costs, are recognized in profit or loss when incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">Intangible
assets with a finite useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that
the asset may be impaired. The amortization period and the amortization method for an intangible asset are reviewed at least at each
year end.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the year ended December
31, 2024, SciSparc has reviewed indications of decline to its intangible asset, and by using independent advisors, has determined there
are signs of decline in the value of the intangible asset and recognized a loss as a result of impairment in the amount of $1,344 thousand
(as of December 31, 2023 - $1,042 thousand).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Contingent
Liabilities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
evaluations of provisions and contingent liabilities are based on best professional judgment, taking into consideration the stage of
the proceedings, as well as cumulative legal experience in the various topics. Whereas the results of the lawsuits shall be determined
by the courts, these results may differ from these evaluations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Share-Based Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
employees and other service providers are entitled to benefits by way of share-based compensation settled with company options to shares.
The cost of transactions with employees settled with capital instruments is measured based on the fair value of the capital instruments
on the granting date. The fair value is determined using an accepted options pricing model. The model is based on share price, grant
date and on assumptions regarding expected volatility, expected lifespan, expected dividend, and a no risk interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
cost of the transactions settled with capital instruments is recognized in profit or loss together with a corresponding increase in the
equity over the period in which the performance and/or service takes place, and ending on the date on which the relevant employees are
entitled to the benefits, or the Vesting Period. The aggregate expense recognized for transactions settled with capital instruments at
the end of each reporting date and until the Vesting Period reflects the degree to which the Vesting Period has expired and SciSparc&#8217;s
best estimate regarding the number of options that have ultimately vested. The expense or income in profit or loss reflects the change
of the aggregate expense recognized as of the end of the reported period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
selected the Black-Scholes option-pricing model as a fair value method for its options awards. The option-pricing model requires a number
of assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Expected
dividend yield</i>&#160;- The expected dividend yield assumption is based on SciSparc&#8217;s historical experience and expectation of
no future dividend payouts. SciSparc has historically not paid cash dividends and have no foreseeable plans to pay cash dividends in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Volatility&#160;</i>-
The expected volatility is based on fluctuations in the price of SciSparc&#8217;s ordinary share prices on the Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Risk
free interest rate&#160;</i>- The risk free interest rate is based on the U.S. Treasury yield curve, in accordance with the option&#8217;s
contractual term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Contractual
term&#160;</i>- An option&#8217;s contractual term must at least include the Vesting Period and the employees&#8217; historical exercise
and post-vesting employment termination behavior for similar grants. If the amount of past exercise data is limited, that data may not
represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Share
price&#160;</i>- The share price is determined according to the last known or above closing price of SciSparc&#8217;s ordinary shares
at the grant date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair value of loan to Automax (a related party) </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc entered into a Bridge
Loan Agreement with AutoMax which is considered a related party, under which SciSparc provided a total loan amount of $4,250 thousand,
as of December 31, 2024. This loan was extended in the context of an agreement for the acquisition of AutoMax by SciSparc, serving as
an advance payment toward the transaction. The repayment terms of the loan are contingent on the completion of the Merger, with provisions
for set-off against the purchase price upon consummation of the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Evaluating the fair value
of the abovementioned loan was complex and required considerable judgment due to the significant estimates in SciSparc&#8217;s management&#8217;s
assumptions, particularly regarding the involvement of a related party. The assessment of the recoverability of the loan is complex and
subjective.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Quantitative
and Qualitative Disclosure About Market Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SciSparc
is exposed to market risks in the ordinary course of its business. Market risk represents the risk of loss that may impact its financial
position due to adverse changes in financial market prices and rates. Its current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-minus. However, a substantial majority of SciSparc&#8217;s cash is held in
current bank accounts that do not bear interest. In the future, SciSparc intends to hold most of its cash in deposits that bear interest.
Given the current low rates of interest SciSparc receives, once it begins to hold most of its cash in deposits that bear interest, it
does not expect to be adversely affected if such rates are reduced. SciSparc&#8217;s market risk exposure is primarily a result of NIS/U.S.
dollar exchange rates, which is discussed in detail in the following paragraph.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Foreign
Currency Exchange Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s results
of operations and cash flow are subject to fluctuations due to changes mainly in NIS/U.S. dollar currency exchange rates. As of December
31, 2024, the vast majority of its liquid assets are held in U.S. dollars, and the majority of its expenses are denominated in U.S. dollars.
Changes of both 5% and 10% in the U.S. Dollar/NIS exchange rate would decrease/increase SciSparc&#8217;s loss for 2024 by less than 1%,
respectively. However, these historical figures may not be indicative of future exposure, as SciSparc expects that the percentage of
its NIS denominated expenses will materially decrease in the near future, therefore reducing its exposure to exchange rate fluctuations.
Beginning October 1, 2018, SciSparc&#8217;s functional currency is the U.S. dollar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">SciSparc
does not hedge its foreign currency exchange risk. In the future, SciSparc may enter into formal currency hedging transactions to decrease
the risk of financial exposure from fluctuations in the exchange rates of its principal operating currencies. These measures, however,
may not adequately protect SciSparc from the material adverse effects of such fluctuations.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>




</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">AUTOMAX&#8217;S
MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>You
should read the following discussion and analysis of AutoMax&#8217;s financial condition and results of operations together with AutoMax&#8217;s
financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. In addition to historical information
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. AutoMax&#8217;s actual
results may differ materially from those results described in or implied by the forward-looking statements discussed below. Factors that
could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section
entitled &#8220;Risk Factors &#8212; Risks Related to AutoMax&#8221; appearing elsewhere in this proxy statement/prospectus.</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Overview</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">As
of the date of this proxy statement/prospectus, AutoMax engages in importing and marketing of vehicles in Israel (including trade-in).
Within this segment, the AutoMax engages in direct and parallel&#160;import of private vehicles and their marketing in Israel, and through
joint ventures, in the direct import to Israel of buses manufactured by Temsa, as well as in the purchase and sale of used vehicles (trade-in).
AutoMax holds direct and parallel&#160;importer licenses from the Ministry of Transportation, as defined in the Vehicle Services Licensing
Law, for 37 vehicle brands of various models. As of the date of this proxy statement/prospectus, AutoMax operates through nine branches
in Haifa, Afula, Netanya, Ra&#8217;anana, Rishon Lezion, Ashdod, Jerusalem, Beer Sheva (which reopened) and Hedera. AutoMax operates
as a holding company through its&#8217; subsidiaries, mainly Global AutoMax Ltd., a wholly owned subsidiary, Dalhom AutoMax Ltd., in
which it holds a 50% controlling interest; AutoMax Trade-In Ltd., in which it holds an 80% controlling interest; and </span>AutoMax Direct
Import, <span style="background-color: white">a wholly owned subsidiary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
main factors to the financial condition and results of operations for the year ended December 31, 2024 were the: (i)</span> receipt by
Global AutoMax of a government guaranteed loan from a bank in the amount of NIS 16 million (approximately $4.42 million)<span style="background-color: white">,
</span>on January 11, 2024<span style="background-color: white">; (ii) </span>signing of the Merger Agreement <span style="background-color: white">with
</span>SciSparc <span style="background-color: white">on April 10, 2024, and receipt of bridge loans from </span>SciSparc in a total
amount of $4.25 million<span style="background-color: white">; (iii) </span>finalizing entering into the agreements with JAC<span style="background-color: white">,
</span>November 2024; and (iv) <span style="background-color: white">receipt by </span>AutoMax Direct Import <span style="background-color: white">of
a credit line in the amount of NIS 23 million, in November 2024.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Recent Developments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 5, 2025, Global AutoMax signed an agreement for purchase of the share of the additional shareholder in AutoMax Hasharon. Following
the closing of such agreement, Global AutoMax holds 100% of AutoMax Hasharon outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 25, 2025, AutoMax received an additional loan in the amount of $2 million from SciSparc. For more information, see &#8220;Agreements
Relating to the Merger &#8211; Additional Loan Agreement and Deed of Assignment&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2025, AutoMax Direct Import received a credit line in the amount of NIS 20 million from a bank. For more information, see &#8220;AutoMax
Business &#8211; Financing&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Components
of AutoMax&#8217;s Results of Operations</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">AutoMax&#8217;s
revenues stem from the import of vehicles mainly from North America and Europe and sales in Israel in New Israeli Shekels (NIS). Therefore,
the generated revenues are dependent mainly on the exchange rate between NIS, the U.S. Dollar (USD), the Euro, and other European currencies.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
revenues for the </span>year <span style="background-color: white">ended December 31, 2024, were NIS 398,173</span> thousand <span style="background-color: white">(approximately
$107,643</span> thousand<span style="background-color: white">), a decrease of approximately 5%, compared to NIS 418,932 </span>thousand
<span style="background-color: white">(approximately $115,791</span> thousand<span style="background-color: white">) for the </span>year
<span style="background-color: white">ended December 31, 2023. There was not a material change in revenues in 2024 compared to 2023.
The revenues in 2024 were mainly derived from the sale of smaller and less expensive vehicles, following a change in the mix of vehicles
imported and sold by the AutoMax. There was an increase in the revenues in the fourth quarter of 2024 compared to the corresponding period
in 2023, which was derived from the decrease in revenues in the fourth quarter of 2023 attributed to the outbreak of the Iron Swords
War. For further details, see Note 1E to AutoMax financial statements for the year ended December 31, 2024, included elsewhere in this
proxy statement/prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Expenses &#160;</i></b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cost
of Sales</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of sales for the
period ended December 31, 2024 was NIS 347,079 thousand (approximately $93,830 thousand), a decrease of approximately 9%, compared to
NIS 381,089 thousand (approximately $105,331 thousand) for the period ended December 31, 2023. The decrease in cost of sales during 2024
compared to 2023 in relation to revenues is due to a change in the mix of vehicles imported and sold by <span style="background-color: white">AutoMax</span>,
to smaller and less expensive vehicles. <span style="background-color: white">There was an </span>increase in cost of sales in the fourth
quarter of 2024 compared to the corresponding period in 2023, mainly due to the purchase of vehicles through direct import in the fourth
quarter of 2024, as well as from a decrease in revenues (and cost of sales accordingly) in the fourth quarter of 2023 following the Iron
Swords War.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Gross
Profit</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross profit for the
year ended December 31, 2024, was NIS 51,094 thousand (approximately $13,813 thousand), an <span style="background-color: white">increase
</span>of 35%, compared to NIS 37,843 thousand (approximately $10,460 thousand) for the year ended December 31, 2023. The increase in
gross profit and gross profitability is mainly attributed to the factors detailed above, as well as to purchase and sale of vehicles
through direct import, the gross profitability of which is higher compared to parallel imports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Selling
and Marketing Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling and marketing
expenses for the year ended December 31, 2024, were NIS 21,621 thousand (approximately $5,845 thousand), a decrease of approximately
20%, compared to NIS 27,194 thousand (approximately $7,516 thousand) for the year ended December 31, 2023. The decrease in sales and
marketing expenses in 2024 compared to 2023 is derived from measures taken by AutoMax to reduce its current expenses and a change in
the nature of its marketing activities, including reduction in the number of employees engaged in marketing and sale activities, and
reduction in marketing expenses.<span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">General
and Administrative Expenses</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries, related benefits, computer systems, travel and share-based compensation expenses for personnel
in executive and administrative functions. General and administrative expenses also include professional fees for legal, consulting,
accounting and audit services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general and administrative
expenses for the year ended December 31, 2024, were NIS 17,728 thousand (approximately $4,793 thousand), an increase of approximately
4%, compared to NIS 16,965 thousand (approximately $4,686 thousand) for the year ended December&#160;31, 2023. There was no material
change in general and administrative expenses in 2024 compared to 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Granting
options to employees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
                                            expenses for granting options to employees for the year ended December 31, 2024, were NIS
                                            122 thousand (approximately $33 thousand), a <span style="background-color: white">decrease
                                            </span>of approximately 95%, compared to NIS 2,549 thousand (approximately $704 thousand)
                                            for the year ended December 31, 2023. The decrease was due to options granted to AutoMax
                                            executive officers in the framework of the merger agreement with Global AutoMax completed
                                            in March 2021, for which the recording of expenses ended in the first quarter of 2023 (except
                                            for options to an AutoMax consultant).<span style="font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other income&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other income for the
year ended December 31, 2024, was NIS 5,022 thousand (approximately $1,357 thousand), an <span style="background-color: white">increase
</span>of approximately 222%, compared to NIS 1,557 thousand (approximately $430 thousand) for the year ended December 31, 2023. The
increase was due to revenues for compensations under the <span style="background-color: white">Iron Swords War</span> fund for the months
October and November 2023, which were recorded in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Operational profit (loss)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operational profit for
the year ended December 31, 2024, was NIS 16,645 thousand (approximately $4,500 thousand), an <span style="background-color: white">increase
</span>of approximately 127%, compared to loss of NIS 7,308 thousand (approximately $2,019 thousand) for the year ended December 31,
2023. The increase was mainly due to factors set forth above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->199<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
expenses, net</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial
expenses, net consist primarily of income or expenses related to revaluation of foreign currencies and interest income on AutoMax&#8217;s
bank deposits.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Comparison of the Years Ended December&#160;31,
2024, and 2023 </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
AutoMax&#8217;s results of operations for the years ended December&#160;31, 2024, and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Results
of Operations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">NIS in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">398,173</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">418,932</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cost of goods sold</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(347,079</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(381,089</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">51,094</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37,843</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sales and marketing</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,621</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,194</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,728</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,965</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granting options to employees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,549</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating profit or loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,645</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,308</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">AutoMax&#8217;s share of losses of company accounted for at
    equity, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financial (expense) income, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14,421</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Profit or loss before tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,017</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,213</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(358</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,107</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to holders of ordinary shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,384</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Liquidity
and Capital Resources</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has generated its
revenue and funded its activities through independent financing, such as issuing bonds, financing from banks and financing entities,
credit lines provided by the suppliers to AutoMax. As of December 31, 2024, AutoMax had a total of approximately NIS 15,699 thousand
(approximately $4,304 thousand) outstanding government guaranteed loans. As of December 31, 2024, the interest rate on such loans was
prime plus 1.5%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2024, Global
AutoMax received a government guaranteed loan from a bank in the amount of NIS 16 million (approximately $4.42 million), bearing an annual
interest rate of prime plus 1.5%. The loan was granted for a period of 60 months, to be repaid in 57 equal monthly installments of principal
amount with interest, with a three months grace period. As is customary in government guaranteed loans, Global AutoMax deposited in the
bank an interest-accumulating deposit, in the aggregate amount of 5% of the loan principal, which will be encumbered by a first-class
permanent lien in favor of the bank.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>


</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->200<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash in excess of immediate
requirements is invested primarily with a view to liquidity and capital preservation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Flows</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables summarize
AutoMax&#8217;s cash flows for each of the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">NIS in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Net cash from (used in) operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(36,709</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3,142</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,537</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(353</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by financing
    activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,180</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,471</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and
    cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(66</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(682</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Activities</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December&#160;31, 2024, was NIS 36,709 thousand (approximately $10,065), and included AutoMax&#8217;s net
loss of NIS 5,107 thousand (approximately $1,380 thousand), and adjustments of non-cash amounts. Most of the non-cash amounts are due
to depreciation of import licenses and fixed assets (NIS 10,778 thousand) and tax expenses (NIS 3,619 thousand), as well as changes in
the property and liability items on the balance sheet of NIS 48,992 thousand. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash from operating activities
for the year ended December&#160;31, 2023, was NIS 3,142 thousand (approximately $868), and included AutoMax&#8217;s net loss of NIS
17,375 thousand (approximately $4,786 thousand), and adjustments of non-cash amounts. Most of the non-cash amounts are due to share-based
payments (NIS 2,549 thousand), depreciation of import licenses and fixed assets (NIS 4,642 thousand) and non-cash financing expenses
(NIS 2,939 thousand) as well as changes in the property and liability items on the balance sheet of NIS 3,800 thousand. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Investing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, net cash used in investing activities was NIS 8,537 thousand (approximately $2,340 thousand), which reflected purchases of
fixed assets. &#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, net cash used in investing activities was NIS 353 thousand (approximately $98 thousand), which reflected purchases of fixed
assets. &#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing Activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, net cash from financing activities was NIS 45,180 thousand (approximately $12,388 thousand), consisting of receipt of short-term
and long-term loans from banks of NIS 42,571 thousand (approximately $11,673 thousand), loan received from the Company of NIS 15,297
thousand (approximately $4,197 thousand), partially set off by payment of NIS 6,849 thousand (approximately $1,878 thousand) to the Series
B bondholders, and repayment of obligations for lease agreements of NIS 5,839 thousand (approximately $1,601 thousand).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 218; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->201<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2023, AutoMax
entered into a private placement agreement with certain investors, for an aggregate amount of NIS 4.0 million (approximately $1.1 million),
in exchange for the sale and issuance of 8,000,000 ordinary shares, at a purchase price of NIS 0.5 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2023, AutoMax
entered into a private placement agreement with an investor for an aggregate amount of NIS 10.0 million (approximately $2.8 million),
in exchange for the sale and issuance of 14,284,714 ordinary shares, at a price per shares of NIS 0.7 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">According to the terms of
AutoMax&#8217;s Series B Bonds and the Series B Bonds Trust Deed, the Series B Bonds will be due for principal repayment in four (4)
unequal annual installments, which will be paid annually as of February 28, 2023 until 2026, inclusive, such that the first payment that
was made on February 28, 2023 constituted 10% of the aggregate principal amount of the Series B Bonds, the second payment, that was made
on February 28, 2024, constituted 15% of the aggregate principal amount of the Series B Bonds, the third payment, that was made on February
28, 2025, constituted 30% of the aggregate principal amount of the Series B Bonds, and the fourth and final payment, due on February
28, 2026, will constitute 45% of the aggregate principal amount of the Series B Bonds. Following the closing of the Merger the Series
B Bonds will remain outstanding and subject to repayment in accordance with the terms of the Series B Bonds Trust Deed. The Series B
Bonds bear interest at a rate of 5.9% per annum. As of July 3, 2025, NIS 20,547 thousand (approximately $5,597 thousand) in principal
amount of Series B Bonds remains outstanding and will therefore become a liability of the combined company following the completion of
the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Credit Lines</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax group companies have
non-guaranteed credit lines from four banking corporations, which are classified in its financial statements as short-term loans. For
more information, see &#8220;AutoMax Business &#8211; Business &#8211; Financing&#8221; (page 180).</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funding Requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax believes that its
existing cash and cash equivalents, will enable it to fund its operating expenses and capital expenditure requirements for at least the
next 12 months. It has based these estimates on assumptions that may prove to be wrong, and it could utilize AutoMax&#8217;s available
capital resources sooner than it expects.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical Accounting Policies and Significant
Judgments and Estimates</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax&#8217;s financial
statements are prepared in accordance with the IFRS. The preparation of AutoMax&#8217;s financial statements and related disclosures
requires it to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and
the disclosure of contingent assets and liabilities in AutoMax&#8217;s financial statements. AutoMax bases its estimates on historical
experience, known trends and events and various other factors that it believes are reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other
sources. AutoMax evaluates its estimates and assumptions on an ongoing basis. AutoMax&#8217;s actual results may differ from these estimates
under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While AutoMax&#8217;s significant
accounting policies are described in more detail in Note&#160;2 to AutoMax&#8217;s financial statements, AutoMax believes that the following
accounting policy is the most critical to the judgments and estimates used in the preparation of its financial statements.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-Based Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">AutoMax&#8217;s
employees and other service providers are entitled to benefits by way of share-based compensation settled with company options to shares.
The cost of transactions with employees settled with capital instruments is measured based on the fair value of the capital instruments
on the granting date. The fair value is determined using an accepted options pricing model. The model is based on share price, grant
date and on assumptions regarding expected volatility, expected lifespan, expected dividend, and a no risk interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
cost of the transactions settled with capital instruments is recognized in profit or loss together with a corresponding increase in the
equity over the period in which the performance and/or service takes place, and ending on the date on which the relevant employees are
entitled to the benefits, or the Vesting Period. The aggregate expense recognized for transactions settled with capital instruments at
the end of each reporting date and until the Vesting Period reflects the degree to which the Vesting Period has expired and the best
estimate regarding the number of options that have ultimately vested. The expense or income in profit or loss reflects the change of
the aggregate expense recognized as of the end of the reported period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->202<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">AutoMax
                                            selected the Black-Scholes option-pricing model as a fair value method for its options awards.
                                            The option-pricing model requires a number of assumptions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Expected
dividend yield&#160;- </i>The expected dividend yield assumption is based on the historical experience and expectation of no future dividend
payouts. AutoMax has historically not paid cash dividends and have no foreseeable plans to pay cash dividends in the future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Volatility&#160;</i>-
The expected volatility is based on fluctuations in the price of AutoMax&#8217;s ordinary share prices on the TASE.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Risk
free interest rate&#160;</i>- The risk free interest rate is based on the U.S. Treasury yield curve, in accordance with the option&#8217;s
contractual term.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Contractual
term&#160;</i>- An option&#8217;s contractual term must at least include the Vesting Period and the employees&#8217; historical exercise
and post-vesting employment termination behavior for similar grants. If the amount of past exercise data is limited, that data may not
represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Share
price&#160;</i>- The share price is determined according to the last known or above closing price of SciSparc&#8217;s ordinary shares
at the grant date.</p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantitative and Qualitative Disclosures
about Market Risks</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Rate Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024,
AutoMax had cash and cash equivalents, restricted cash and long-term bank deposits of NIS 2,728 thousand (approximately $748 thousand),
which consisted of cash, restricted cash and long-term bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
AutoMax had cash and cash equivalents, restricted cash and long-term bank deposits of NIS 1,961 thousand (approximately $542 thousand),
which consisted of cash, restricted cash and long-term bank deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign Currency Exchange Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax is exposed to foreign
exchange rate risk. AutoMax is located in Israel, where the majority of its general and administrative expenses costs are incurred in
New Israeli Shekels. During each of the years ended December&#160;31, 2024, and 2023, AutoMax recognized foreign currency transaction
income NIS 1,990 thousand (approximately $538 thousand) and NIS 6,971 thousand (approximately $1,926 thousand), respectively. AutoMax&#8217;s
functional currency is NIS. These foreign currency transaction gains and losses were recorded in financial expenses, net in its statements
of comprehensive loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As
                                            AutoMax continues to grow its business, its results of operations and cash flows will be
                                            subject to fluctuations due to changes in foreign currency exchange rates, which could adversely
                                            impact AutoMax&#8217;s results of operations. AutoMax enters into hedging contracts from
                                            time to time, to mitigate AutoMax&#8217;s exposure to foreign currency exchange risk, subject
                                            to its need and according to market conditions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Off-Balance Sheet Arrangements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax did not have, during
the periods presented, and it does not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of
the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->203<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">DIRECTORS
AND OFFICERS OF SCISPARC FOLLOWING THE MERGER</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Resignations of Current Executive Officers
and Directors of SciSparc</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Merger Agreement,
two (2) of the directors of SciSparc who will not continue as member of the board following the Merger will resign effective immediately
prior to the completion of the Merger.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors of the Combined Company Following
the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SciSparc board of directors
is currently composed of seven directors. The following information sets forth the names, ages, director classes, and proposed titles
of each of the proposed directors of the combined company upon consummation of the Merger, their present principal occupation and their
recent business experience. During the last five years, neither SciSparc nor the proposed directors of the combined company have been
(i) convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or (ii) a party to any judicial or administrative
proceeding (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order
enjoining such person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding
of any violation of federal or state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><b>Designee</b>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><b>Age</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: center"><b>Position(s)</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">AutoMax Designees</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">Yaarah Alfi*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">37</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer of AutoMax</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">Tomer Levy*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">30</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">VP Business Development and Headquarters, director of AutoMax</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">SciSparc Designees</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">Amitay Weiss</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">63</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chairman of SciSparc&#8217;s board of directors</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">Amnon Ben Shay</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Director</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif">Moshe Revach</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">49</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Director</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Liat Sidi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0%"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Subject
                                            to the approval of the shareholders of SciSparc at the Special Meeting.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Mr.
Amitay Weiss</i></b><i>&#160;</i>has served on SciSparc&#8217;s board of directors since August 2020 and as its </span>Chairman <span style="background-color: white">since
January 2022. Mr. Weiss served as SciSparc&#8217;s Chief Executive Officer from August 2020 to January 2022. Mr. Weiss also currently
serves as chairman of the board of directors of AutoMax, as a director of Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR) and as an external
director of Cofix Group Ltd. (TASE: CFCS). Mr. Weiss also chairs and serves as director on the board of directors of several public and
private companies, including Clearmind Medicine Inc. (Nasdaq: CMND), Maris Tech Ltd. (Nasdaq: MTEK) and N2OFF, Inc. (Nasdaq: NITO). In
2016, Mr. Weiss founded Amitay Weiss Management Ltd. and now serves as its chief executive officer. From 2001 until 2015, Mr. Weiss served
as vice president of business marketing &amp; development and in various other positions at Bank Poalei Agudat Israel Ltd. from the First
International Bank of Israel group. Mr. Weiss holds a B.A. in economics from New England College, an M.B.A. in business administration
from Ono Academic College in Israel, an Israeli branch of University of Manchester and an LL.B. from the Ono Academic College.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt; background-color: white"><b><i>Mr.
Amnon Ben Shay</i></b></span><span style="background-color: white">&#160;<span style="font-size: 10pt">has served as a member of SciSparc&#8217;s
board of directors since January 2021 and served as an external director under the Companies Law between January 2021 and January 2022.
Mr. Ben Shay has been chief financial officer of Aerodrome Group Ltd since October 2022. Mr. Ben Shay previously served on the board
of directors of Azorim Investments and Building Development Company Ltd. (TASE: AZRM), Value Capital One Ltd. (TASE: VALU) and B.G.I.
Investments (1961) Ltd. (TASE: BGI). Mr. Ben Shay was chief financial officer of Hadar Hasharon Marketing and Distributions Ltd. from
February 2019 to October 2022. From February 2017 to January 2019, Mr. Ben Shay served as the chief financial officer of Fridenson Air&amp; Ocean Ltd. From January 2014 to January 2017, Mr. Ben Shay served as the chief financial officer of Abetrans Logistics Ltd. Prior
to that, Mr. Ben Shay served as the chief financial officer of Isline Export and Import Services Ltd. from 2010 to 2013. Prior to the
year 2009, Mr. Ben Shay served as the chief financial officer of several Israeli real estate investment groups. Mr. Ben Shay holds a
B.A. in economics and business and an M.B.A in business, both from The Hebrew University of Jerusalem, Israel, and an accounting certificate
from The College of Management Academic Studies, Israel.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt; background-color: white">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->204<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Mr.&#160;Moshe
Revach</i></b>&#160;has served as a member of SciSparc&#8217;s board of directors since September 2022. Mr. Revach also previously served
as a director since August&#160;2020 until his resignation on March&#160;13, 2022. Mr.&#160;Revach has served as vice-counselor of the
Ramat Gan municipality and has been on its financial committee since March 2024. Mr.&#160;Revach serves as a director of L.L.N IT solutions,
a wholly owned&#160;subsidiary of the Jewish Agency for Israel, RPG Economic Society, ParaZero Technologies Ltd. (Nasdaq: PRZO), Plantify
Foods Inc (CVE: PTFY), and Jeffs&#8217; Brands Ltd. (Nasdaq: JFBR). Mr.&#160;Revach previously served as a director of Biomedico Hadarim,
and Jewish Experience Company on behalf of the Jewish Agency and also served as deputy mayor of Ramat Gan, Israel from 2013 to 2023,
while also heading the sports and government relations departments in the Ramat Gan municipality. Mr.&#160;Revach holds an LL.B from
the Ono Academic College, Israel, and a B.A. in management and economics from the University of Derby.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Ms.
Liat Sidi</i></b>&#160;has served as a member of SciSparc&#8217;s board of directors since August 2020. Ms. Sidi serves as the manager
of the accounting department for Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) and has served as director for N2OFF, Inc.
(Nasdaq: NITO) since November 2023. Ms. Sidi previously served as director for Plantify Foods Inc (CVW: PTFY) from September 2023 to
January 2024. Ms. Sidi previously served as an accountant for Panaxia Labs Israel Ltd. (TASE: PNAK) from 2015 to 2020 and as an accountant
for Soho Real Estate Ltd. from 2015 to 2016. Ms. Sidi also served as an accountant for Feldman-Felco Ltd. from 2006 to 2010 and as an
accountant for Eli Abraham accounting firm from 2000 to 2006. Ms. Sidi completed tax, finance and accounting studies in Ramat Gan College
of Accounting.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Mr. Tomer Levy</i></b>
has been serving as VP Business Development and Headquarters and director of AutoMax since March 2021. Prior to that, between May 2017
and March 2021, Mr. Levy served as Global AutoMax&#8217;s VP Business Development and Headquarters. Mr. Levy has experience in a wide
variety of managerial roles.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><b><i>Ms.
Yaarah Alfi</i></b> has been serving as chief financial executive of AutoMax and its subsidiaries since March 2021. Ms. Alfi previously
served as controller for Global AutoMax from January 2018 until March 2021. Between 2015 and 2018, Ms. Alfi was employed as a certified
public accountant at Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Additionally, Ms. Alfi has experience in
a wide variety of managerial, financial, tax and accounting roles. Ms. Alfi holds a B.A. in Accounting and Business management from The
College of Management, Israel and is a certified public accountant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Composition
of </b></span><b>the <span style="background-color: white">Board of Directors</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant
                                            to the Merger Agreement, each of the directors and officers of <span style="background-color: white">SciSparc
                                            </span>who will not continue as directors or officers of <span style="background-color: white">SciSparc
                                            </span>or the combined company following the consummation of the Merger shall resign immediately
                                            prior to the effective time of the Merger. In connection with the Merger, the size of <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors will be consist of six (6) directors. Pursuant to the terms of
                                            the Merger Agreement, two (2) of such directors will be designated by AutoMax and four (4)
                                            of such directors will be designated by <span style="background-color: white">SciSparc</span>.
                                            Effective as of the effective time of the Merger, it is anticipated that Amnon Ben Shay,
                                            Moshe Revach, Liat Sidi and Amitay Weiss will remain on <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors. Subject to the approval of the SciSparc shareholders of Proposal
                                            4 at the Special Meeting and the election thereof, Tomer Levy and Yaarah Alfi will serve
                                            on <span style="background-color: white">SciSparc&#8217;s</span> board of directors as AutoMax&#8217;s
                                            designees. It is anticipated that these directors will be appointed to the three staggered
                                            director classes of the combined company&#8217;s board of directors as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Class I will consist of Ms.
Liat Sidi and Ms. Yaarah Alfi, each with a term expiring at the 2027 annual meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Class II will consist
of Mr. Amnon Ben Shay and Mr. Moshe Revach, each with a term expiring at the 2028 annual meeting of shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Class III will consist of
Mr. Amitay Weiss and Mr. Tomer Levy, with a term expiring at the 2026 annual meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The division of <span style="background-color: white">SciSparc&#8217;s
</span>board of directors into three classes with staggered three-year terms may delay or prevent a change of management or a change
of control of <span style="background-color: white">SciSparc</span>, or, following the completion of the Merger, the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The <span style="background-color: white">SciSparc
</span>board of directors has determined that all current members of the board of directors are independent, as determined in accordance
with the rules of The Nasdaq Stock Market.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The <span style="background-color: white">SciSparc
</span>board of directors has also determined that each current member of the compensation committee is independent as defined under
Nasdaq listing standards and the Companies Law, and that each current member of the audit committee is independent as defined under Nasdaq
listing standards and applicable SEC rules and Israeli laws. In making this determination, <span style="background-color: white">SciSparc&#8217;s
</span>board of directors found that none of these directors had a material or other disqualifying relationship with <span style="background-color: white">SciSparc</span>.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->205<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based
                                            upon information requested from and provided by each proposed director concerning their background,
                                            employment and affiliations, including family relationships, <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors has determined that neither of the proposed AutoMax directors is
                                            independent as defined under Nasdaq listing standards. <span style="background-color: white">SciSparc&#8217;s
                                            </span>board of directors also determined that Amnon Ben Shay, Moshe Revach and Liat Sidi,
                                            who will comprise the compensation committee, all satisfy the independence standards for
                                            such committees established by the SEC and Nasdaq listing standards, as applicable. With
                                            respect to the audit committee, <span style="background-color: white">SciSparc&#8217;s</span>
                                            board of directors has determined that Amnon Ben Shay, Moshe Revach and Liat Sidi satisfy
                                            the independence standards for such committee established by Rule&#160;10A-3&#160;under the
                                            Exchange Act, the SEC and Nasdaq listing standards, as applicable. The board of directors
                                            considered the relationships between such directors and certain of the investors of the combined
                                            company and determined that such relationships did not affect such directors&#8217; independence
                                            under the standards of Nasdaq, or, where applicable, under SEC rules.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board Committees</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The <span style="background-color: white">SciSparc
</span>board of directors has established two standing committees to assist it in fulfilling its responsibilities to <span style="background-color: white">SciSparc
</span>and its shareholders: the audit committee and the compensation committee. Each committee acts pursuant to a written charter. Each
committee reviews its charter on an annual basis. In addition to the three standing committees, the <span style="background-color: white">SciSparc
</span>board of directors may approve from time to time the creation of other committees to assist the board in carrying out its duties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately following the
consummation of the Merger, the committees of the board of directors of the combined company will operate pursuant to and apply <span style="background-color: white">SciSparc&#8217;s
</span>written charters and corporate governance policies currently in place. Thereafter, the board of directors of the combined company
intends to review the written charters and corporate governance policies of <span style="background-color: white">SciSparc</span> and,
in the discretion of the board of directors of the combined company, adopt or amend such charters and policies, as may be necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions of the audit
committee under the Companies Law include identifying and addressing flaws in the business management of <span style="background-color: white">SciSparc</span>,
reviewing and approving related party transactions, establishing whistleblower procedures, overseeing <span style="background-color: white">SciSparc&#8217;s
</span>internal audit system and the performance of its internal auditor, and assessing the scope of the work and recommending the fees
of <span style="background-color: white">SciSparc&#8217;s</span> independent accounting firm. In addition, the audit committee is required
to determine whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the
purpose of the requisite approval procedures under the Companies Law and to establish procedures for considering proposed transactions
with a controlling shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with U.S. law
and Nasdaq requirements, <span style="background-color: white">SciSparc&#8217;s</span> audit committee is also responsible for the appointment,
compensation and oversight of the work of its independent auditors and for assisting the board of directors in monitoring financial statements,
the effectiveness of internal controls and compliance with legal and regulatory requirements. The audit committee of the combined company
is expected to retain these duties and responsibilities following completion of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">SciSparc&#8217;s
</span>audit committee currently consists of Amnon Ben Shay, Alon Dayan and Lior Vider. The SciSparc board of directors has determined
that Amnon Ben Shay is an &#8220;audit committee financial expert&#8221; as defined in the SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following
                                            the consummation of the Merger, the members of the audit committee are expected to be Amnon
                                            Ben Shay, Moshe Revach and Liat Sidi. Amnon Ben Shay is expected to be the chairman of the
                                            audit committee and is a financial expert under the rules of the SEC. The SciSparc board
                                            of directors has concluded that the composition of the audit committee meets the requirements
                                            for independence under the rules and regulations of Nasdaq and SEC. SciSparc and AutoMax
                                            believe that, after completion of the Merger, the functioning of the audit committee will
                                            comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions of the compensation
committee under the Companies Law include recommending to the board of directors, for ultimate shareholder approval by a special majority,
a policy governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing
such compensation policy from time to time, and approving the actual compensation terms of directors and officers prior to approval by
the board of directors. The compensation committee of the combined company is expected to retain these duties and responsibilities following
completion of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s compensation
committee currently consists of Amnon Ben Shay, Alon Dayan and Lior Vider.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following
                                            the consummation of the Merger, the members of the compensation committee are expected to
                                            be Amnon Ben Shay, Moshe Revach and Liat Sidi. Amnon Ben Shay is expected to be the chairman
                                            of the compensation committee. The SciSparc board of directors has determined that each member
                                            of the compensation committee is independent within the meaning of the independent director
                                            guidelines of Nasdaq. SciSparc and AutoMax believe that, after the completion of the Merger,
                                            the composition of the compensation committee will meet the requirements for independence
                                            under, and the functioning of such compensation committee will comply with, any applicable
                                            requirements of the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->206<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive Officers of the Combined Company
Following the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to and effective
upon the closing of the Merger, the current executive officers of AutoMax will be the executive officers of <span style="background-color: white">SciSparc</span>.
The following information sets forth the names, ages, and proposed titles of each of the executive officers of the combined company upon
consummation of the Merger, their present principal occupation and their recent business experience. During the last five years, neither
SciSparc nor the proposed executive officers of the combined company have been (i) convicted in a criminal proceeding (excluding traffic
violations and similar misdemeanors) or (ii) a party to any judicial or administrative proceeding (except for matters that were dismissed
without sanction or settlement) that resulted in a judgment, decree or final order enjoining such person from future violations of, or
prohibiting activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><b>Name</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><b>Age</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 61%"><b>Position(s)</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Oz Adler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Dr. Adi Zuloff-Shani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Technology Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Oz Adler</i>, CPA,
was appointed to serve as SciSparc&#8217;s Chief Executive Officer in January 2022 and has served as SciSparc&#8217;s Chief Financial
Officer since April 2018 and previously held served as its VP Finance from March 2018 until April 2018 and as SciSparc&#8217;s Controller
from September 2017 to March 2018. Mr. Adler has experience in a wide variety of managerial, financial, tax and accounting roles. Mr.
Adler currently serves on the board of directors of numerous private, such as Polyrizon Ltd., and public companies, including Jeffs&#8217;
Brands Ltd. (Nasdaq: JFBR), Rail Vision Ltd. (Nasdaq: RVSN) and Clearmind (Nasdaq: CMND), (FSE: CWY), and previously served as the chief
financial officer of XYLO Technologies Ltd. (Nasdaq: XYLO) from December 2020 to April 2021. From 2012 until 2017, Mr. Adler was employed
as a certified public accountant at Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global. Mr. Adler holds a B.A. in
Accounting and Business management from The College of Management, Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Adi Zuloff-Shani</i>,
PhD, has served as SciSparc&#8217;s Chief Technologies Officer since February 2016. Dr. Zuloff-Shani has more than 20 years of experience
as a research and development executive. Prior to joining us, and from 2012 to 2016, Dr. Zuloff-Shani served as a vice president development
at Macrocure Ltd. (Nasdaq: MCUR) where besides leading all research and development activities, she interacted and was involved with
the activities of all departments including clinical, operations, quality assurance, quality control, finance, and regulatory affairs.
Dr. Zuloff-Shani currently serves as the Chief Executive Officer of Clearmind (Nasdaq: CMND), (FSE: CWY). She has served as the Chairman
of Orsus Therapeutics, Inc. since November 2022, as a member of the scientific advisory board of N2OFF, Inc. (Nasdaq: NITO) since October
2021 and as a director of MitoCareX since May 2022. Dr. Zuloff-Shani holds a Ph.D. in human biology and immunology from Bar-Ilan University,
Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DIRECTOR AND OFFICER COMPENSATION</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Director Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax currently compensates
its chairman of the board, Mr. Amitay Weiss, with monthly fee of NIS 25,000 (approximately $6,767), plus VAT for 50% position. In addition,
the chairman is entitled to annual bonus subject to fulfillment of predetermined targets. The chairman is not entitled to participation
and annual fee according to the Compensation Regulations (as defined below). AutoMax currently compensates certain of its non-executive,
non-employee directors (other than Mr. Eyal Baruch) with annual and participation fees at the rate of the maximum amount as specified
in the second and third supplements to the Companies Regulations (Rules Concerning the Compensation and Expenses of an External Director)
Regulations, 5760-2000, or the Compensation Regulations, and its external directors with annual and participation fees at the rate of
the maximum amount as specified in the fourth supplement to the Compensation Regulations, which totaled together to NIS 278,962 (approximately
$75,518) in the year 2024.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Executive Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate amounts of
salaries, consulting and director fees, pension, retirement and other similar benefits, and share-based compensation, that were payable
to AutoMax&#8217;s executive officers and directors and/or to their respective affiliates in respect of employment, consulting and directorship
agreements and arrangements (which includes other amounts described in this &#8220;<i>Director and Officer Compensation</i>&#8221; section
of this proxy statement/prospectus) during the year ended December 31, 2024 is set forth in the below table. The table does not include
any amounts that AutoMax paid to reimburse any of such persons for costs incurred in providing it with services during that period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
    thousands)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary,
    Fees and<br/>
    Related&#160;Benefits</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension,<br/>
    Retirement and<br/>
    Other Similar<br/>
    Benefits</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and senior management as a group, consisting of 12 persons<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIS
    4,986,388 (approximately $1,349,861)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIS
    796,685 (approximately $215,670)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes
                                            Emanuel Paz Puzailov who served as a director until December 31, 2024.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->207<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Merger, SciSparc
will compensate its directors and senior management team in accordance with the recommendation of its compensation committee and, generally,
subject to the approval of the SciSparc board of directors and shareholders. That compensation will generally need to be consistent with
the terms of the compensation policy, which will require periodic approval, in accordance with the requirements of the Companies Law
(as described below under &#8220;Related Party Transactions of Directors and Executive Officers of the Combined Company&#8212;Director
and Officer Compensation&#8221;). Therefore, the future compensation practices of SciSparc following the Merger may differ from the historical
practices of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Companies
Law, beginning with SciSparc&#8217;s first annual general meeting of shareholders that takes place following the Merger, the combined
company will be required to disclose the compensation paid to its five most highly compensated officers on an individual basis for the
previous fiscal year, or as otherwise required under SEC rules. Consequently, SciSparc will be required to include that information in
all annual reports on Form 20-F or Form 10-K that SciSparc files with the SEC, just as it has done until the current time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has entered into
a service agreement with Haim Levy &#8211; Trade In Ltd. for CEO services rendered by Daniel Levy, on March 24, 2021, or the CEO Agreement.
According to the CEO agreement, Daniel Levy, through Haim Levy Trade In Ltd. receives a monthly payment of NIS 50,000 (approximately
$13,535), and additional payments for expenses. The CEO Agreement contains a customary provision regarding confidentiality of information.
The CEO Agreement is in effect for three years following its signing, and terminable by either party upon 90 days&#8217; prior written
notice. On March 24, 2024, the shareholders of AutoMax voted in favor of extending the CEO Agreement for an additional period of three
years. The total amount paid under this agreement for the year ended December 31, 2024, - is NIS 702,304 (approximately $190,120).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has entered into
a service agreement with A. Ynon (2015) Ltd. for Chief Business Officer services rendered by Ynon Amit, on March 24, 2021, or the Chief
Business Officer Agreement. According to the Chief Business Officer Agreement, Ynon Amit, through A. Ynon (2015) Ltd., receives a monthly
payment of NIS 50,000 (approximately $13,535), and additional payments for expenses. The Chief Business Officer Agreement contains a
customary provision regarding confidentiality of information. The Chief Business Officer Agreement is in effect for three years following
its signing, and terminable by either party upon 90 days&#8217; prior written notice. On March 24, 2024, the shareholders of AutoMax
voted in favor of extending the Chief Business Officer Agreement for additional period of three years. The total amount paid under this
agreement for the year ended December 31, 2024, is NIS 695,867 (approximately $188,377).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has entered into
an employment agreement with Haim Levy, Trade and Procurement Officer, or the Trade and Procurement Officer Agreement. According to the
Trade and Procurement Officer Agreement, Haim Levy receives a monthly salary of NIS 45,000 (approximately $12,182) (in terms of employer
cost) including customary social benefits, and additional payments for expenses. The Trade and Procurement Officer Agreement contains
a customary provision regarding confidentiality of information. The Chief Business Officer Agreement is in effect for three years following
its signing, and terminable by either party upon 90 days&#8217; prior written notice. On December 31, 2024, the shareholders of AutoMax
voted in favor of extending the Trade and Procurement Officer Agreement for an additional period of three years. The total amount paid
under this agreement for the year ended December 31, 2024, is NIS 768,297 (approximately $207,985).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax has entered into
an employment agreement with Gal Levy, Regulation and Branch Manager Officer, or the Regulation and Branch Manager Officer Agreement.
According to the Regulation and Branch Manager Officer Agreement, Gal Levy receives a monthly salary of NIS 45,000 (approximately $12,182)
(in terms of employer cost) including customary social benefits, and additional payments for expenses. The Regulation and Branch Manager
Officer Agreement contains a customary provision regarding confidentiality of information. The Regulation and Branch Manager Officer
is in effect for three years following its signing, and terminable by either party upon 90 days&#8217; prior written notice. On December
31, 2024, the shareholders of AutoMax voted in favor of extending the Regulation and Branch Manager Officer Agreement for an additional
period of three years. The total amount paid under this agreement for the year ended December 31, 2024, (including share based compensation)
is NIS 774,808 (approximately $209,747).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax
                                            has entered into an employment agreement with Tomer Levy, Vice President Business Development
                                            Officer, or the Vice President Business Development Officer Agreement. According to the Vice
                                            President Business Development Officer Agreement, Tomer Levy receives a monthly salary of
                                            NIS 45,000 (approximately $12,182) (in terms of employer cost) including customary social
                                            benefits, and additional payments for expenses. The Vice President Business Development Officer
                                            Agreement contains a customary provision regarding confidentiality of information. The Vice
                                            President Business Development Officer is in effect for three years following its signing,
                                            and terminable by either party upon 90 days&#8217; prior written notice. On December 31,
                                            2024, the shareholders of AutoMax voted in favor of extending the Vice President Business
                                            Development Officer Agreement for an additional period of three years. The total amount paid
                                            under this agreement for the year ended December 31, 2024, (including share based compensation)
                                            is NIS 775,738 (approximately $210,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Amitay Weiss serves as
active chairman of the board of directors of AutoMax since January 1, 2022, and is entitled to the following compensation: (a) scope
of position and compensation - in his role as active chairman of the board of directors, Mr. Weiss is entitled to a fixed monthly compensation
of 25,000 NIS (approximately $6,767), plus VAT, for a 50% position, effective from January 1, 2022 (the date of his appointment as Chairman
of the Board of Directors of AutoMax). It is clarified that Mr. Weiss is not entitled to annual and participation fees under the Compensation
Regulations; (b) expense reimbursement: AutoMax will cover Mr. Weiss&#8217; expenses in Israel and abroad incurred in connection with
his role as active chairman of the board of directors, subject to prior written approval by AutoMax and in accordance with AutoMax policies
as they may be from time to time. As of date of this prospectus, no ceiling has been set for such expenses; (c) annual bonus - Mr. Weiss
is entitled to an annual bonus subject to fulfillment of predetermined targets. No bonus was paid to Mr. Weiss for the years 2023 and
2024; and (d) insurance, exemption and indemnification: Mr. Weiss is entitled to insurance, indemnification, and exemption arrangements
in accordance with AutoMax&#8217;s compensation policy. The total amount paid to Amitay Weiss for the year ended December 31, 2024, is
NIS 300,000 (approximately $81,212).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->208<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors in AutoMax are
entitled to payment as applicable under the Companies Law and its regulations. In sum, during the year ended December 31, 2024, AutoMax
paid its directors (in total) approximately NIS 278,962 (approximately $75,518). It is clarified that the board member Eyal Baruch does
not receive cash compensation for his service as a director of AutoMax. Mr. Baruch previously received equity compensation. In addition,
Mr. Weiss, active chairman of the board, is not entitled to participation and annual fee according to the Compensation Regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Share Incentive Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax maintains one incentive
plan &#8212; 2021 Share Incentive Plan, or the AutoMax Plan &#8212;which will be cancelled upon the effectiveness of the Merger. At that
time, outstanding options under the AutoMax Plan will be terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>SciSparc Executive Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation SciSparc paid to all of its directors and senior management as a group for the year ended December
31, 2024. The table does not include any amounts SciSparc paid to reimburse any of such persons for costs incurred in providing us with
services during this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
table below reflect our cost, in thousands of U.S. dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Salary/Fee</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Pension,<br/>
    Retirement<br/> and Other<br/> Similar<br/> Benefits<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Share-<br/>
    Based<br/> Compensation<sup>(2)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">All directors
    and senior management as a group, consisting of nine persons as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">675</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">90</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">157</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Represents
                                            the directors and senior management&#8217;s payment of mandatory social benefits made by
                                            SciSparc on behalf of such officer. Such benefits may include, to the extent applicable to
                                            the executive, payments, contributions and/or allocations for savings funds, education funds
                                            (referred to in Hebrew as &#8220;<i>Keren Hishtalmut</i>&#8221;), pension, severance, risk
                                            insurances (e.g., life or work disability insurance) and payments for social security.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed
    based on fair value for ordinary shares options granted and estimated using the Black-Scholes option pricing model.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
accordance with the Companies Law, the table below reflects the compensation granted to SciSparc&#8217;s five most highly compensated
officers or directors during or with respect to the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Annual Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Executive Officer</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Salary/Fee</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Pension,<br/>
    Retirement<br/> and Other<br/> Similar<br/> Benefits</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Share-<br/>
    Based<br/> Compensation<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">USD in thousands</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Oz
    Adler<br/> <i>Chief Executive Officer and Chief Financial Officer</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">374</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">453</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Dr.
    Adi Zuloff-Shani<i><br/> Chief Technologies Officer</i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">283</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">342</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Itschak
    Shrem<br/> <i>President</i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">269</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Amitay
    Weiss<br/> <i>Chairman</i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">269</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Lior
    Vider<i><br/> Director</i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Share-based
                                            compensation includes the cost of SciSparc&#8217;s non-cash share-based compensation in 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 226; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->209<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RELATED
PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS<br/>
OF THE COMBINED COMPANY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Described below are any transactions
occurring since January 1, 2021, and any currently proposed transactions to which either <span style="background-color: white">SciSparc
</span>or AutoMax was a party and in which:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            amounts involved exceeded or will exceed the lesser of&#8201;(i) $120,000 and (ii) one percent
                                            of the average of <span style="background-color: white">SciSparc&#8217;s </span>or AutoMax&#8217;s
                                            total assets at year end for the last two completed fiscal years; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            director, executive officer, holder of more than 5% of the outstanding share capital of <span style="background-color: white">SciSparc
                                            </span>or AutoMax, or any member of such person&#8217;s immediate family had or will have
                                            a direct or indirect material interest.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">SciSparc
</span>Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Employment Agreements</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has entered into written employment agreements with Oz Adler, its Chief Executive Officer and Chief Financial Officer, and Dr. Adi Zuloff-Shani,
its Chief Technologies Officer. Each of these agreements contains customary provisions regarding noncompetition, confidentiality of information
and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. These
agreements are terminable by either party upon 30 days&#8217; prior written notice. In addition, SciSparc has entered into agreements
with each executive officer and director pursuant to which it has agreed to indemnify each of them up to a certain amount and to the
extent that these liabilities are not covered by directors and officers insurance. Members of SciSparc&#8217;s senior management are
eligible for bonuses each year. The bonuses are payable upon meeting objectives and targets that are set by SciSparc&#8217;s Chief Executive
Officer and approved annually by SciSparc&#8217;s board of directors that also set the bonus targets for SciSparc&#8217;s Chief Executive
Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Options</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
SciSparc&#8217;s inception, it has granted options to purchase SciSparc&#8217;s ordinary shares, and RSUs, to its employees, officers,
service providers and certain of its directors. Such option and RSU agreements may contain acceleration provisions upon certain merger,
acquisition, or change of control transactions. SciSparc&#8217;s equity incentive plans are described above under &#8220;Director and
Officer Compensation&#8221;. If the relationship between SciSparc and an executive officer or a director is terminated, except for cause
(as defined in the various option plan agreements), options that are vested will generally remain exercisable for 90 days after such
termination.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Commercial Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Clearmind</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 7, 2022, SciSparc entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, SciSparc&#8217;s
Chief Technologies Officer, Mr. Weiss, SciSparc&#8217;s chairman of the board of directors, and Mr. Adler, SciSparc&#8217;s Chief Executive
Officer and Chief Financial Officer serve as officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 17, 2022, SciSparc invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market,
in exchange for 230,769 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind.&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Polyrizon&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 31, 2022, SciSparc entered into the Polyrizon Collaboration Agreement with Polyrizon. Mr. Adler, SciSparc&#8217;s Chief Executive
Officer and Chief Financial Officer, serves as a director in Polyrizon.</p><div>


</div><!-- Field: Page; Sequence: 227; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->210<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 13, 2024, SciSparc entered into a termination agreement with Polyrizon to terminate the Polyrizon Collaboration Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, on August 13,
2024, SciSparc entered into the License Agreement, for the out-licensing of its SCI-160 program with Polyrizon. Pursuant to the License
Agreement, SciSparc granted Polyrizon the License and received 320,000 ordinary shares of Polyrizon, pre-funded warrants to purchase
364,931 ordinary shares of Polyrizon, and common warrants to purchase 2,054,793 ordinary shares of Polyrizon, at an exercise price of
$4.38 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2024, SciSparc
entered into a share transfer agreement and sold all of the Polyrizon ordinary shares and pre-funded warrants held by it, as well as
an aggregate of 1,541,096 Polyrizon common warrants to third parties, for aggregate consideration of $770,548.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 1, 2025, SciSparc entered into a securities purchase agreement with Polyrizon, pursuant to which SciSparc participated in a private
placement of Polyrizon, and invested $100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary
shares and Series A warrants to purchase ordinary shares, of Polyrizon. In addition, SciSparc entered into an exchange agreement with
Polyrizon, pursuant to which SciSparc exchanged existing ordinary share warrants of Polyrizon held by it for Series A warrants to purchase
ordinary shares of Polyrizon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Jeffs&#8217;
Brands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 15, 2022, SciSparc entered into a letter of intent with Jeffs&#8217; Brands, to establish the Jeffs&#8217; Joint Venture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 23, 2023, SciSparc entered into the Secondary Purchase Agreement with Jeffs&#8217; Brands and Jeffs&#8217; Holdings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Mr.
Oz Adler, SciSparc&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands,
Mr. Amitay Weiss, SciSparc&#8217;s Chairman of the board of directors and Mr. Moshe Revach, a member of SciSparc&#8217;s board of directors,
are both directors in&#160;Jeffs&#8217;&#160;Brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>MitoCareX</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
                                            February 25, 2025, SciSparc entered into the MitoCareX SPEA, as amended on May 18, 2025,
                                            together with MitoCareX, the other Sellers, pursuant to which the Sellers will sell their
                                            stakes in MitoCareX to N2OFF, thereby resulting in MitoCareX becoming a wholly-owned subsidiary
                                            of N2OFF. The closing of the MitoCareX SPEA is contingent upon, among other customary obligations,
                                            obtaining approval of N2OFF&#8217;s stockholders by the requisite majority. On the closing
                                            date of the transactions contemplated under the MitoCareX SPEA, SciSparc will transfer and
                                            sell its stake in MitoCareX to N2OFF in consideration for a cash payment of $700,000 N2OFF
                                            Common Stock, representing 16.75% of N2OFF on a fully-diluted basis. Either party may terminate
                                            the MitoCareX SPEA if the closing date has not occurred within one hundred and eighty days
                                            of February 25, 2025. Following the closing date of the MitoCareX SPEA, the Sellers may receive
                                            Additional N2OFF Stock, if respective milestones are achieved as defined in the MitoCareX
                                            SPEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Each
of Amitay Weiss and Liat Sidi, board members of SciSparc, also serve as board members of N2OFF.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
more information, see &#8220;MitoCareX&#8221; on page 156.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i>AutoMax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the third step
of the Restructuring Initiative, on February 23, 2023, SciSparc&#8217;s board of directors held a meeting in which Mr. Baranes, a business
analyst presented a market overview conducted on the motor vehicles market in Israel, including market trends private vehicle ownership
and public transportation, and electronic vehicle market acceptance. Mr. Baranes then presented the market overview conducted in relation
to AutoMax, which was based on available public information, and information received from AutoMax. The market overview included AutoMax&#8217;s
strategy in various sectors, including parallel import of personal-use vehicles, buses, and electronic vehicles. The market overview
also included AutoMax&#8217;s competition, and its growth potential. On May 29, 2023, SciSparc appointed Mr. Baranes to be its VP Strategy
and Business Development. Mr. Baranes previously provided services to AutoMax, which included market overview of companies AutoMax was
interested in collaborating with, and preparation of investor presentations. Both Mr. Baranes and Mr. Amitay Weiss serve as members of
the board of Charging Robotics Inc. Mr. Baranes provided a market overview services to other companies which Mr. Weiss serves as a director
of. AutoMax was first introduced to SciSparc by AutoMax&#8217;s Advisor after the board of directors announced its restructuring initiative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the months of June
and November 2023, the management of AutoMax met with the management of SciSparc to negotiate and discuss a potential transaction structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2023, SciSparc&#8217;s
board of directors held a meeting in which it approved an investment in the aggregate amount of NIS 4 million (approximately $1.1 million)
in AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 25, 2023, SciSparc entered into the AutoMax SPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 22, 2023, SciSparc announced the signing of a non-binding letter of intent, to acquire AutoMax, with certain new negotiated
terms as announced on December 7, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 14, 2024, SciSparc entered into the Bridge Loan with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc signed the Merger Agreement with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 228; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->211<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 9, 2024, SciSparc entered into the Amended Bridge Loan with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 14, 2024, SciSparc signed the Merger Agreement Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 5, 2024, SciSparc entered into the Second Amendment with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 26, 2024, SciSparc signed the Merger Agreement Second Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
February 24, 2025, SciSparc entered into the Additional Loan Agreement with AutoMax, and on February 25, 2025, SciSparc entered into
the Deed with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 27, 2025, SciSparc signed the Merger Agreement Third Addendum with AutoMax.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 8, 2025, SciSparc entered into the Third Amendment with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 8, 2025, SciSparc entered into the Merger Agreement Fourth Addendum with AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Mr.
Amitay Weiss, SciSparc&#8217;s Chairman of the board of directors is the chairman of the board of directors of AutoMax.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related Party Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
a related party transaction in which an &#8220;office holder&#8221; has a personal interest may be approved only if it is for the benefit
of the company. An office holder is defined in the Companies Law as a director, a general manager, chief business manager, deputy general
manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of such person&#8217;s
title, and any other manager directly subordinate to the general manager. A transaction that is not an extraordinary transaction in which
an office holder has a personal interest requires the approval of the board of directors, unless the articles of association of the company
provide otherwise. If the transaction is an extraordinary transaction, it must be approved by the audit committee and the board of directors,
and, under certain circumstances, by the shareholders of the company. An &#8220;extraordinary transaction&#8221; is a transaction other
than in the ordinary course of business, other than on market terms or that is likely to have a material impact on the company&#8217;s
profitability, assets or liabilities.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, extraordinary transactions in which a controlling shareholder has a personal interest require the approval of the audit committee,
or the compensation committee if the transaction is in connection with employment or service with the company, the board of directors
and the shareholders of the company. The shareholder approval must be by a simple majority of all votes cast, provided that (i)&#160;such
majority includes a simple majority of the votes cast by non-controlling shareholders having no personal interest in the matter or (ii)
the total number of votes of shareholders mentioned in clause (i)&#160;above who voted against such transaction does not exceed 2% of
the total voting rights in the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In most cases, the Companies
Law prohibits any director who has a personal interest in a transaction from being present for the discussion or voting pertaining to
such transaction in the audit committee or board of directors. Nevertheless, a director who has a personal interest may be present at
the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest in the approval
of such transaction; in this case, however, the transaction also requires shareholder approval.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director and Officer Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
<span style="background-color: white">SciSparc</span> is required to approve, at least once every three&#160;years, a compensation policy
with respect to office holders. Following the recommendation of <span style="background-color: white">SciSparc&#8217;s</span> compensation
committee, the compensation policy must be approved by the board of directors and shareholders. The shareholder approval must be by a
simple majority of all votes cast, provided that (i)&#160;such majority includes a simple majority of the votes cast by non-controlling
shareholders having no personal interest in the matter or (ii) the total number of votes of shareholders mentioned in clause (i)&#160;above
who voted against such transaction does not exceed 2% of the total voting rights in the company. In general, the terms of compensation
of directors, the chief executive officer and any employee or service provider who is considered a controlling shareholder must be approved
separately by the compensation committee, the board of directors and the shareholders. The compensation terms of other officers who report
directly to the chief executive officer requires the approval of the compensation committee and the board of directors.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AutoMax Transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>Material Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>The Merger Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, AutoMax
signed the Merger Agreement with SciSparc, as amended on August 14, 2024, November 26, 2024, March 27, 2025, and on May 8, 2025, pursuant
to the Merger Agreement Addendum, the Merger Agreement Second Addendum, the Merger Agreement Third Addendum, and the Merger Agreement
Fourth Addendum, respectively, as further detailed in this this proxy statement/prospectus.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Founders&#8217; Agreement to establish a joint
company in connection with the Company&#8217;s branches in Petah Tikva and Ra&#8217;anana</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 25, 2021, Global
AutoMax entered into the HaSharon Founders&#8217; Agreement with A.V.A. Reseller. Pursuant to the HaSharon Founders&#8217; Agreement,
the parties founded a joint company, AutoMax HaSharon, which until October 2022, engaged in operating marketing and sales centers for
vehicles imported by AutoMax in the cities of Petah Tikva and Ra&#8217;anana. According to the HaSharon Founders&#8217; Agreement, Global
AutoMax was to hold a third of AutoMax Hasharon&#8217;s share capital, while A.V.A. held the remaining 2/3. The HaSharon Founders&#8217;
Agreement also stipulated that certain decisions would require a 100% majority of the directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 229; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->212<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HaSharon Founders&#8217;
Agreement included customary provisions that limit the possibility of transferring shares in AutoMax HaSharon, including the right of
first refusal (except in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along)
and forced sale (Bring Along).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 23, 2022, an agreement
was signed between Global AutoMax, A.V.A. and AutoMax HaSharon. Pursuant to the agreement, Global AutoMax purchased from A.V.A shares
that constitute a third of the issued share capital of AutoMax HaSharon, in addition to providing AutoMax HaSharon with an owner&#8217;s
loan in accordance with the agreement established between the parties. Following the provision of the aforementioned owner&#8217;s loan,
AutoMax HaSharon paid off an owner&#8217;s loan in the same amount provided to it by A.V.A. Simultaneously with the signing of the aforementioned
agreement, an amendment to the HaSharon Founders&#8217; Agreement was signed according to which Global AutoMax shall be entitled to appoint
two directors to AutoMax HaSharon board of directors, and A.V.A. will be entitled to appoint one director. With the completion of the
aforementioned agreement, Global AutoMax owns two thirds of the issued share capital of AutoMax HaSharon, and the A.V.A. owns the remaining
third, and two directors are appointed by Global AutoMax, and one director is appointed by A.V.A., to serve on the board of directors
of AutoMax HaSharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2022, in accordance
with the agreement between Global AutoMax and the Reseller, Global AutoMax commenced operating the branch in Petah Tikva directly, while
AutoMax HaSharon continues to operate the branch in Ra&#8217;anana. In the second quarter of 2024, AutoMax closed the Petah Tikva branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 4, 2025, Global
AutoMax and the Reseller signed an agreement, according to which Global AutoMax purchased from the Reseller its holdings in AutoMax HaSharon,
and the Reseller waived the return of the owner&#8217;s loan. Accordingly, HaSharon Founders&#8217; Agreement was cancelled, and Global
AutoMax holds 100% of the share capital of AutoMax HaSharon, and is entitled to appoint all of its board members.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Trade-In Activity in Israel
</i></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2022, Global
AutoMax signed the Trade-In Agreement with the Partner. Pursuant to the Trade-In Agreement, Global AutoMax grants AutoMax Trade-In exclusivity
in the purchase of trade-in vehicles, as purchased by Global AutoMax from its customers, according to pricing determined at Global AutoMax&#8217;s
discretion, subject to fulfilment of certain quotas as agreed in the Trade-In Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Trade-In
Agreement, Global AutoMax owns approximately 80% of the issued and paid-up capital of AutoMax Trade-In, while the remaining 20% is held
by the Partner. The Partner was given options, with a vesting schedule subject to the completion of milestones, as established in the
Trade-In Agreement, which, assuming their full exercise, may increase the holdings of the Partner in AutoMax Trade-In up to 48% of its
issued and paid-up capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the signing of the
Trade-In Agreement, Global AutoMax entered into the a lease agreement. The lease period according to the lease agreement is from February
1, 2022 to August 6, 2023, and AutoMax Trade-In was given an option to extend it for another identical period (subject to the extension
of the lease period of the main tenant). The lease agreement can be terminated with six months notice, upon request from the competent
authorities. On July 24, 2023, AutoMax Trade-In exercised its option right and extended the lease for an additional 24 months, set to
expire in August 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second quarter
of 2024, AutoMax terminated the lease agreement in respect to the lease in &#8220;Pi Glilot&#8221; complex, and its trade-in activity
is being conducted within AutoMax&#8217;s existing branches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Founders&#8217; agreement
in relation with the branches in Ashkelon and Ashdod </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On
                                            July 19, 2022, Global AutoMax entered into a founders&#8217; agreement with an authorized
                                            reseller, A.S Mobility Ltd., that operates AutoMax&#8217;s branch in Ashkelon pursuant to
                                            which Global AutoMax and the authorized reseller founded AutoMax HaShfela, which operates
                                            as a vehicle distribution and sales center in Ashdod and Ashkelon. Pursuant to the foregoing
                                            agreement, Global AutoMax owns half of the AutoMax HaShfela and the authorized reseller holds
                                            the other half. The board of directors of AutoMax HaShfela consists of four directors, two
                                            of which were appointed by the authorized reseller and two which were appointed by Global
                                            AutoMax.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties also entered
into a distribution agreement, pursuant to which, AutoMax HaShfela became the authorized reseller of vehicles imported by Global AutoMax
in the cities of Ashkelon and Ashdod, replacing the previously existing agreement between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the founders&#8217;
agreement, Global AutoMax entered into a lease agreement for a property of approximately 500 square meters in Ashdod, Israel, which was
assigned to AutoMax HaShfela and serves as a branch of Global AutoMax in Ashdod. The lease period is from September 15, 2022 for a period
of three years, with an option to extend the lease agreement for three additional periods of two years, each, in total up to September
19, 2031. The lease agreement in the name of Global AutoMax in Ashkelon was also assigned to AutoMax HaShfela.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second quarter
of 2024, AutoMax closed the Ashkelon branch, while the Ashdod branch remains operational.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 230; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->213<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Import and Marketing of
Buses in Israel </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2022, AutoMax
entered into the Dalhom AutoMax Ltd Founders&#8217; Agreement with Dalhom. The purpose of Dalhom AutoMax is to serve as a direct importer
of Temsa buses in Israel and market these. The Dalhom AutoMax Founders&#8217; Agreement closed on November 20, 2022, following which
each of AutoMax and Dalhom held 50% of Dalhom AutoMax. Pursuant to the Dalhom AutoMax Founders&#8217; Agreement, upon the closing, AutoMax
was required to lend AutoMax Dalhom an aggregate amount of NIS 10 million (approximately $2.7 million), to enable AutoMax Dalhom to fulfill
its obligations toward Dalhom, as prescribed in the Dalhom AutoMax Founders&#8217; Agreement, or the AutoMax Dalhom Loan. Under the foregoing
agreement, the AutoMax Dalhom Loan was provided at the same interest rate (back-to-back), as the loan received by AutoMax from its financing
sources, so long as it does not exceed the rate stipulated in the Dalhom AutoMax Founders&#8217; Agreement. The AutoMax Dalhom Loan is
to be repaid subject to the terms and rates defined in the agreement, and among others, will bear interest of up to 5.9% per annum, and
shall be fully repaid within six years from the closing, or exchanged into shares of Dalhom AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Dalhom AutoMax Founders&#8217;
Agreement includes provisions commonly accepted in franchise agreements, including sales goals agreed between the parties, failure to
comply with the terms set forth in the Dalhom AutoMax Founders&#8217; Agreement will grant Temsa the right to terminate the agreement,
should Dalhom AutoMax fail to be in compliance by the end of the cure period. Furthermore, Dalhom AutoMax will not import or market in
Israel products that compete with those of Temsa, during the time of the agreement, without obtaining a written approval. In addition,
Dalhom AutoMax entered into a service and warranty agreement with Temsa, for a period of 3 years, under which Dalhom AutoMax would provide
maintenance and warranty services for buses manufacture by Temsa in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Turkish Trade Ministry
has announced a trade embargo between Turkey and Israel. This trade stoppage could have a short-term impact on the supply of vehicles
and on the prices of logistics and transportation of vehicles to Israel, in particular for Dalhom&#8217;s operations. However, AutoMax
does not anticipate a significant impact on the group&#8217;s business as it holds (in Israel) a stock of Temsa buses and has taken steps
to find alternative ways to continue the regular supply of Temsa vehicles and buses to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Agreement for Direct Import
of Electric Vehicles to Israel </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2023, Dalhom
AutoMax entered into an agreement with Al Damani, a UAE vehicle manufacturer, subject to which Dalhom AutoMax would distribute, sell,
and promote the Al Damani electric vehicles in Israel. This agreement remains subject to Dalhom AutoMax obtaining all the regulatory
approvals as required by the Ministry of Transportation to import vehicles into Israel, a condition that has not yet been met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Import and Marketing of Vehicles Manufactured by JAC in Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, AutoMax
Direct Import finalized entering into agreements with JAC, a manufacturer of private and commercial vehicles, for the direct import,
distribution and service of vehicles and spare parts manufactured by JAC in Israel, or the JAC Agreements. On December 27, 2024, AutoMax
Direct Import received its first shipment of vehicles manufactured by JAC, following regulatory approvals for direct importation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the JAC Agreements,
AutoMax Direct Import serves as a direct importer of JAC brand in Israel, and the JAC will provide AutoMax Direct Import with vehicles
and spare parts for the vehicles for marketing and sale in Israel, in accordance with annual business plans as agreed between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement includes, among
others, customary provisions regarding warranty for the vehicles by JAC, the supply of spare parts, the duty to notify about malfunctions
(recall) and compliance with other requirements required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AutoMax Direct Import will
adapt its existing showrooms for the purpose of selling JAC vehicles in the standards agreed in the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 231; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->214<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The JAC Agreements are for
a period of three years, subject to AutoMax Direct Import&#8217;s compliance with sales and service network expansion goals determined
in the JAC Agreements, and will enter into force only when the appropriate European regulatory approvals are received for JAC vehicles.
In addition, JAC is entitled to terminate the agreement upon the occurrence of certain events provided in the JAC Agreements, as is customary
in such agreements, such as: (a) if AutoMax Direct Import substantially violates its obligations under the JAC Agreements or encounters
special circumstances that give justifiable reasons for early termination (including AutoMax Direct Import&#8217;s failure to meet its
sales goals, service network expansion goals or market share goals); (b) in the event of change of control in AutoMax Direct Import;
and (c) in the event of bankruptcy, moratorium, receivership, liquidation, or any other similar circumstances.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 8, 2025, AutoMax received
the preliminary approval of JAC to franchise trucks and heavy vehicles manufactured by JAC, by the Joint Company. On May 8, 2025, AutoMax
and Automotive Equipment entered into the Automotive Equipment Founders&#8217; Agreement, pursuant to which the main goal of the Joint
Company will be the import and marketing in Israel of trucks and heavy vehicles manufactured by JAC. AutoMax will own 40% of the issued
and outstanding share capital of the Joint Company, and Automative Equipment will hold 60%. The Automotive Equipment Founders&#8217;
Agreement will only become effective upon receipt of all required approvals, including, as necessary, the Israel Competition Authority,
the final grant of franchise by JAC to the Joint Company (as noted, a preliminary approval was already received), and a grant of import
license for JAC vehicles to the Joint Company. The board composition of the Joint Company will include up to five members, whereas each
20% shareholder may appoint one member, and the chairman of the board will be a member appointed by Automative Equipment as long as it
holds 50% of the issued and outstanding share capital of the Joint Company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Automative Equipment will
provide funding to the Joint Company for the first four years of its operations, via interest-carrying loans, or as a guarantor to bank
loans. In return, a floating lien will be placed on all assets of the Joint Company. From the fifth year of operations, the shareholders
will provide funding as needed, based on their pro-rated equity holding in the Joint Company. Both parties will cover the operating deficit
of the Joint Company based on their pro-rated equity holding in the Joint Company; however, AutoMax will not be required to cover more
than NIS 400,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three years after the
effectiveness of the Automotive Equipment Founders&#8217; Agreement, Automative Equipment will have the option to purchase shares from
AutoMax, such that AutoMax&#8217;s holdings in the Joint Company will be reduced to 24%, subject to payment of the exercise price, reflecting
a Joint Company fully diluted valuation of NIS 5 million, or the Exercise Price. Within five years from the effectiveness of the Automotive
Equipment Founders&#8217; Agreement, the initial Exercise Price will be adjusted as further agreed by AutoMax and Automotive Equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Three years after the
effectiveness of the Automotive Equipment Founders&#8217; Agreement, AutoMax will have the option to sell to Automotive Equipment its
shares for the Exercise Price, such that AutoMax&#8217;s holdings in the Joint Company will be reduced to 24%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Decisions on material
matters such as transactions with interested parties, change of field of activity, liquidation or merger, public offering and sale of
material assets, or amendments of the Joint Company articles of association that may impair any of AutoMax&#8217;s rights, shall require
the approval of the director on behalf of AutoMax if the decision is brought for the Joint Company&#8217;s board of directors, or the
consent of AutoMax through its vote as a shareholder at the general meeting, if such decision is brought to a vote at the general meeting
of the shareholders of the Joint Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three-year period
from the effectiveness of the Automotive Equipment Founders&#8217; Agreement, no share transfers in the Joint Company will be allowed,
and after such period, the transfer will be subject to a right of first refusal and tag-along right of the other shareholder in the Joint
Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
proxy statement/prospectus, the Joint Company has not been established and all of the approvals necessary for the effectiveness of the
Automotive Equipment Founders&#8217; Agreement have not been received.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Market Maker Agreement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 19, 2023, AutoMax
entered into a market maker agreement with I.B.I Investment House Ltd., or IBI, pursuant to which IBI will serve as a market maker for
AutoMax&#8217;s ordinary shares, effective October 22, 2023, subject to the Securities Laws. The agreement will be effective for a period
of 12 months, following which it will be automatically renewed for an additional 12 months, unless terminated by one of the parties.
The agreement is expected to terminate on April 30, 2025, with the entry into force of the Tel Aviv Stock Exchange&#8217;s 2025 Market
Making Reform 2025 in May 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 232; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->215<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><div><a id="m_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
previously disclosed, on April 10, 2024, SciSparc Ltd., or the Parent Company or SciSparc entered into an Agreement and Plan of Merger
with AutoMax Motors Ltd., an Israeli company traded on the TASE and the leading parallel importer and distributor of vehicles in Israel,
or AutoMax, and SciSparc Merger Sub Ltd., an Israeli limited company and wholly owned subsidiary of SciSparc, or the Merger Agreement.
On August 14, 2024, November 26, 2024, March 27, 2025, and on May 8, 2025, the parties entered into addendums to the Merger Agreement,
or the Merger Agreement Addendums. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement
and the Merger Agreement Addendums, SciSparc Merger Sub Ltd. will be merged with and into AutoMax, with AutoMax surviving the merger
as a wholly-owned subsidiary of the Parent Company, or the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro forma condensed combined statement of financial position is based on the individual historical balance sheet of the Parent
Company and AutoMax, prepared in accordance with IFRS as of December 31, 2024,&#160;and has been prepared to reflect the effect of the
acquisition as if it had occurred on December 31, 2024. The unaudited pro forma condensed combined statement of comprehensive loss for
the year ended December 31, 2024, gives effect to the acquisition as if it had been completed January 1, 2024, the beginning of the Parent
Company&#8217;s fiscal year. The historical condensed combined financial information has been adjusted to give effect to pro forma events
that are: 1) directly attributable to the acquisition; 2) factually supportable; and 3) with respect to the statement of comprehensive
loss, expected to have a continuing impact on the combined results. The unaudited pro forma financial statements were prepared in accordance
with Article 11 of U.S. Securities and Exchange Commission Regulation S-X. In the opinion of management, all adjustments necessary to
present fairly the unaudited pro forma condensed combined financial information have been made, as further described in the accompanying
notes.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro forma condensed combined financial information is derived from and should be read in conjunction with the Parent Company&#8217;s
historical audited financial statements for the year ended December 31, 2024 and the historical audited financial statements of AutoMax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
amounts in the historical financial statements of AutoMax are presented in NIS and in the Unaudited Pro Forma Condensed Combined Statement
of Financial Position, the amounts are presented in USD, translated using a rate of NIS 3.647 to USD 1.00, the last exchange rate published
by the Bank of Israel on December 31, 2024, the last day of the reporting period, as determined according to accepted accounting practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
amounts in the historical financial statements of AutoMax are presented in NIS and in the Unaudited Pro Forma Condensed Combined Statement
of Comprehensive Loss, the amounts are presented in USD, translated using a rate of NIS 3.699 to USD 1.00, the average exchange rate
during the reporting period as published by the Bank of Israel, as determined according to accepted accounting practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
information presented in the Unaudited Pro Forma Condensed Combined Financial Information, is presented after giving effect to the Reverse
Split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Estimated consideration
of approximately $3.33 million is based on the Parent Company&#8217;s 30 day average closing share price of $6.549 between May 21, 2025,
and July 3, 2025. The value of purchase price consideration will change based on fluctuations in the share price of the Parent Company&#8217;s
ordinary shares and the number of ordinary shares of the Parent Company&#8217;s outstanding share capital on the closing date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
allocation of the purchase price as reflected in the unaudited pro forma condensed combined financial information was based on a preliminary
valuation of the assets acquired and liabilities assumed, and the accounting is subject to revision as more detailed analyses are completed
and additional information about the fair value of assets acquired and liabilities assumed becomes available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The unaudited pro forma combined
condensed financial statements are presented for informational purposes only and are not necessarily indicative of the results of operations
that would have resulted had the transaction described above been consummated at the dates indicated, nor are they necessarily indicative
of the results of operations which may be realized in the future. Furthermore, the unaudited pro forma combined condensed financial statements
do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings
or expenses that may be associated with the integration of the two companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 233; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->216<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of December 31, 2024<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">SciSparc
    <br/> Ltd.</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">AutoMax<br/>
    Motors Ltd.</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">Transaction
    <br/> Accounting <br/>
    Adjustments</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">Pro
    Forma</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-keep: true">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Current Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="-keep: true">Cash&#8239;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true">1,540</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true">407</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true">(390</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="-keep: true">4(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true">1,557</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Restricted deposit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Short-term deposit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Trade receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">7,920</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">7,930</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Bridge loan to related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">4,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">4(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Investment in short-term financial asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">517</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">517</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Receivables and debit balances</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">18,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">18,260</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Receivable current taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Other accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">113</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">57,526</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">57,639</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Indemnity asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">274</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">274</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">7,503</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">84,394</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,614</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">87,283</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Non-current assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Long term bank deposits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">341</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">341</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Intangible asset, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,479</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">4,511</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,990</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Investments in company accounted for at equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">952</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">952</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Right-of-use assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">4,237</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">4,237</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Investment in companies handled according to the book value
    method</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,148</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,148</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Payment for credit balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,416</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Long term prepaid expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Investments in financial assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">354</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(252</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">4(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">149</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">59</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,858</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Deferred taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Non-current Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">2,844</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">15,659</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(252</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">18,251</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">10,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">100,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,866</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">105,534</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-keep: true">Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Current liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Short term loan and current portion of long-term loans</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">49,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">49,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Liability for bonds</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,940</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,940</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">4,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">4(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Trade payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">816</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">13,240</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">14,056</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Other accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">205</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">7,964</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,169</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Payable current taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">341</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">341</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,399</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">79,287</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">76,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Non-current liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,269</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Long term loans</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">3,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Loans from non-controlling shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">284</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">284</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Tax liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Liability for bonds</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">Employees</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">12,403</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">12,412</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Total Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">91,690</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">88,822</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Shareholders&#8217; Equity:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Share capital and premium</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">70,886</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">22,937</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">2,717</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">4(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">96,540</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Reserve from share-based payment transactions</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,746</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,521</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(5,521</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">4(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,746</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,190</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">506</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(506</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">4(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">5,190</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Foreign currency translation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">497</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">431</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Transactions with non-controlling interests</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">810</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">810</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Accumulated deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(74,975</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(19,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">2,720</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(92,089</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,154</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">9,064</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">16,628</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Non-controlling interests</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">785</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(701</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">84</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total Shareholders&#8217; Equity:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,363</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(590</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">17,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total Liabilities and Shareholders&#8217;
    Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">10,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">100,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(4,866</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">105,534</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 234; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->217<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF&#160;<span style="background-color: white">COMPREHENSIVE LOSS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the year ended December 31, 2024<br/>
(U.S. dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc<br/> Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> Motors Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Transaction<br/> Accounting<br/>
    Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro Forma</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Revenues</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,306</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">107,643</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 5%; text-align: center"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">108,949</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Cost of goods sold</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(93,830</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(94,630</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Gross profit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">506</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">13,813</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14,319</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Research and development expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,707</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,707</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Sales and marketing</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,515</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,845</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,360</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">General and administrative expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,526</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,793</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,058</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(d)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11,377</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Impairment of intangible asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,344</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,344</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Granting options to employees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">33</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">33</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Other incomes</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,270</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,358</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(2,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Operating loss (profit)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">7,316</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(4,500</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,058</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4,874</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">SciSparc&#8217;s share of losses of company accounted for at
    equity, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">429</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">573</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,002</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Other income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(5,035</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">4(c)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(5,035</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Finance income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(612</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(818</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1,425</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Finance expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">353</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4,716</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">252</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">4(f)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">5,321</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Loss (profit) before income taxes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,486</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(29</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,720</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,737</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Taxes on income</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,409</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,395</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total comprehensive loss (profit)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">7,472</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,380</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2,720</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,132</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Equity holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,284</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(2,720</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,564</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,188</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">380</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,568</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;Total comprehensive loss (profit)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">7,472</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,380</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(2,720</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">6,132</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average outstanding shares (basic
    and diluted)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">277,380</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">103,691,969</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">528,342</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Basic and diluted loss (profit) per ordinary
    share attributable to equity holders of SciSparc</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">26.94</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">0.01</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="-keep: true">5</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">11.61</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 235; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->218<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="m_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notes to Unaudited Pro Forma Condensed Combined
Consolidated Financial Statements</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Note 1 - Basis of presentation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro forma condensed combined statement of comprehensive loss for the year ended December 31, 2024, was derived from the audited
consolidated financial statements filed herein, and from the unaudited historical financial information of AutoMax for the same period,
and has been prepared as if the Merger had occurred on January 1, 2024. The unaudited pro forma condensed combined financial information
herein has been prepared to illustrate the effects of the Merger in accordance with IFRS.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Parent Company has accounted for the Merger under the acquisition method of accounting in accordance with the authoritative guidance
on business combinations under the provisions of IFRS 3 (&#8220;Business Combinations&#8221;). The purchase price allocation is considered
preliminary, and additional adjustments may be recorded during the measurement period in accordance with IFRS 3. The purchase price allocation
will be finalized as the Parent Company receives additional information relevant to the acquisition, including the final valuation and
reconciliation of the assets purchased, including tangible and intangible assets, liabilities assumed. Differences between these preliminary
estimates and the final purchase accounting may occur, and these differences could be material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has been determined
to be the accounting acquirer based on evaluation of the following facts and circumstances:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            existing shareholders will have the greater voting interest in the combined entity;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            directors will represent the majority of the board of directors of the combined company following
                                            the consummation of the Merger; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s
                                            senior management will be the senior management of the combined company following the consummation
                                            of the Merger.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro&#160;forma
condensed combined statement of financial position as of December 31, 2024, assumes that the Merger occurred on December 31, 2024. The
unaudited pro&#160;forma condensed combined statements of comprehensive loss for the year ended December 31, 2024, presents pro&#160;forma
effect to the Merger as if it had been completed on January&#160;1, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro&#160;forma
condensed combined statement of financial position as of December 31, 2024, has been prepared using, and should be read in conjunction
with, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s audited consolidated statement of financial
    position as of December 31, 2024, and the related notes, filed herein; and</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax&#8217;s audited consolidated financial information
    as of December 31, 2024, and the related notes, filed herein.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audited pro&#160;forma
condensed combined statement of comprehensive loss for the year ended December 31, 2024, have been prepared using, and should be read
in conjunction with, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SciSparc&#8217;s audited consolidated statement of comprehensive
    loss for the year ended December 31, 2024, and the related notes, filed herein; and</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AutoMax&#8217;s audited consolidated statement of comprehensive
    loss for the year ended December 31, 2024, and the related notes, filed herein.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 236; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->219<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information has been prepared
based on these preliminary estimates, and the final amounts recorded may differ materially from the information presented. The unaudited
pro&#160;forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax
savings, or cost savings that may be associated with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has made significant
estimates and assumptions in its determination of the pro&#160;forma adjustments. The pro&#160;forma adjustments reflecting the consummation
of the Merger are based on certain currently available information and certain assumptions and methodologies that SciSparc believes are
reasonable under the circumstances. The unaudited condensed pro&#160;forma adjustments, which are described in the accompanying notes,
may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will
differ from the pro&#160;forma adjustments and it is possible the difference may be material. SciSparc believes that these assumptions
and methodologies provide a reasonable basis for presenting all of the significant effects of the Merger based on information available
to management at the time and that the pro&#160;forma adjustments give appropriate effect to those assumptions and are properly applied
in the unaudited pro&#160;forma condensed combined financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro forma condensed combined financial information is presented solely for informational purposes and is not necessarily indicative
of the combined results of operations or financial position that might have been achieved for the periods presented, nor is it necessarily
indicative of the future results of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
unaudited pro&#160;forma condensed combined financial information does not necessarily reflect what the combined company&#8217;s financial
condition or results of operations would have been had the transactions occurred on the dates indicated. The unaudited pro&#160;forma
condensed combined financial information also may not be useful in predicting the future financial condition and results of operations
of the combined company. The actual financial position and results of operations may differ significantly from the pro&#160;forma amounts
reflected herein due to a variety of factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 2 - Adjustments to Unaudited Pro Forma
Condensed Combined Financial Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro&#160;forma
condensed combined financial information has been prepared in accordance with Article&#160;11 of Regulation&#160;S-X as amended by Release
No. 33-10786 &#8220;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#8221; Release No. 33-10786 replaces
the existing pro&#160;forma adjustment criteria with simplified requirements to depict the accounting for the transaction, or Transaction
Accounting Adjustments, and present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably
expected to occur, or Management&#8217;s Adjustments. SciSparc has elected not to present Management&#8217;s Adjustments and will only
be presenting Transaction Accounting Adjustments in the unaudited pro&#160;forma condensed combined financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma combined
provision for income taxes does not necessarily reflect the amounts that would have resulted had the combined company following consummation
of the Merger filed consolidated income tax returns during the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All pro forma pre-tax adjustments
have been considered and no tax adjustment was recorded for the income tax expense impact of the transaction adjustments, either due
to the ability to deduct such adjustments for tax purposes or the presence of significant net operating losses with a valuation allowance,
which effectively offset such expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The income tax expense impact
of the transaction adjustments will be determined by applying the expected tax treatment of the individual elements of the transaction
adjustments in the jurisdictions where they are anticipated to be incurred, using the estimated statutory tax rate applicable in those
jurisdictions. These tax adjustments may change based on the final determination of the tax treatment of the individual items and the
statutory tax rates in the relevant jurisdictions, as well as any legislative changes occurring prior to the completion of the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 3 - Estimated purchase price consideration</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 10, 2024, SciSparc entered into the Merger Agreement, as amended, by and among SciSparc, SciSparc Merger Sub Ltd. and AutoMax,
pursuant to which AutoMax agreed to convert its share capital in exchange for the right to receive a number of validly issued, fully
paid and nonassessable Parent Company ordinary shares and pre-funded warrants, equal to the Exchange Ratio (as defined in the Merger
Agreement), per each such AutoMax ordinary share and up to 47.49% of SciSparc ordinary shares immediately after to the effective time
(as defined in the Merger Agreement).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Estimated
consideration of approximately $3.33 million is based on the Parent Company&#8217;s 30 day average closing share price of $6.549 between
May 21, 2025, and July 3, 2025. The value of the purchase price consideration will change based on fluctuations in the share price of
SciSparc&#8217;s ordinary shares and the number of ordinary shares of SciSparc outstanding on the closing date.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 237; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->220<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following is a summary of the components of the estimated consideration (in thousands except per-share information and the exchange ratio)
if the acquisition of AutoMax had occurred on December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Estimated Parent Company&#8217;s ordinary shares outstanding*</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">535,197</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Exchange ratio</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">0.00514956</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Parent Company&#8217;s ordinary shares to be issued<sup>(1)</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">534,974</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">Parent Company&#8217;s share price**</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">6.549</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total estimated consideration to be paid</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">3,328,000</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            SciSparc&#8217;s outstanding shares as of July 3, 2025, including pre-funded warrants to
                                            exercise up to 628 ordinary shares.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    SciSparc&#8217;s 30-day average closing share price between May 21, 2025, and July 3, 2025.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded
    warrants to be issued in connection with the Merger are considered ordinary shares since SciSparc cannot currently calculate the
    amount of pre-funded warrants to be issued in lieu of ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated consideration
of the purchase price will depend on the market price of SciSparc&#8217;s ordinary shares when the acquisition is consummated. SciSparc
believes that a 72% fluctuation in the market price of its ordinary shares is reasonably possible based on historical volatility, and
the potential effect on estimated consideration would be:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Parent<br/> Company&#8217;s<br/>
    share price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Estimated<br/> consideration</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">As presented</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6.549</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">3,328</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">72% increase</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">11.264</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">5,725</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">72% decrease</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">1.834</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">932</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 4 - Pro Forma Adjustments</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following describes the pro forma adjustments related to the Merger, that have been made in the accompanying unaudited pro forma condensed
combined statements of comprehensive loss for the year ended December 31, 2024, giving effect to the Merger as if it had been consummated
at the beginning of the period presented, and in the accompanying unaudited pro forma condensed combined financial position as of December
31, 2024, giving effect of the Merger as if it had occurred on December 31, 2024, all of which are based on preliminary estimates that
could change significantly as additional information is obtained:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 48px">&#160;</td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the residual amount that is received, after all adjustments in the pro forma condensed combined statement of financial position are
    calculated, which include the following: (i) an offset of $390 thousand from remaining cash balance; (ii) an offset of $4,224 thousand
    from a bridge loan to a related party; (iii) an offset of $252 thousand from investments in financial assets; (iv) an offset of $4,276
    thousand in related party liabilities; (v) an offset of $5,521 thousand in reserve from share-based payment transactions; (vi) an
    offset of $506 thousand in warrant reserve; and (vii) an addition of $2,804 thousand in accumulated deficit.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    additional Merger transaction costs in the amount of $390 thousand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            the income statement impact of the difference between the estimated consideration to be paid
                                            ($3,328 thousand) as described in note 3 - Estimated purchase price consideration, as if
                                            the acquisition of AutoMax was consummated on December 31, 2024, and the total equity, net,
                                            of AutoMax ($8,363 thousand).</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 238; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->221<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Represents
                                            (i) a bonus payable to a consultant upon closing of the Merger in the amount of $1,153 thousand,
                                            (ii) bonuses payable to directors and officers upon closing of the Merger in the amount of
                                            $515 thousand, and (iii) the estimated transaction costs of approximately $390 thousand incurred
                                            by SciSparc in consummating the purchase of AutoMax. The expenses were recognized as general
                                            and administrative expenses as this is the amount attributed to legal advisors SciSparc consulted
                                            with for the consummation of the purchase.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Represents
                                            the cancellation of a short-term loan granted by SciSparc to AutoMax that as of December
                                            31, 2024, amounted to $4,224 thousand (accounted as $4,276 thousand in the financial statements
                                            of AutoMax). &#160;</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Represents
                                            the cancellation of investment of SciSparc in the shares of AutoMax, as of December 31, 2024,
                                            amounted to $252 thousand.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Note 5 - Basic and diluted profit per share</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
loss per share calculated using the historical weighted average shares outstanding after taking into account the issuance of additional
SciSparc ordinary shares in connection with the Merger, assuming such shares were outstanding since January 1, 2024. As the transactions
are being reflected as if they had occurred at the beginning of the periods presented, the calculation of weighted average shares outstanding
for basic and diluted net loss per share assumes that the shares issuable relating to the transactions have been outstanding for the
entire periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the year ended December 31, 2024<br/>
(U.S. dollars in thousands)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">SciSparc&#160;Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">AutoMax<br/> Motors Ltd.</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Transaction<br/> Accounting<br/>
    Adjustments</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro Forma</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Pro forma net loss (in thousands)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">7,472</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,380</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(2,720</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">6,132</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Weighted average outstanding shares (basic and diluted)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">277,380</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">103,691,969</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">528,342</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Basic and diluted loss per ordinary share attributable to equity
    holders of SciSparc</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">26.94</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.01</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">11.61</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 239; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->222<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of SHARE Capital</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following description
of SciSparc&#8217;s share capital and provisions of its current Amended and Restated Articles of Association are summaries and do not
purport to be complete. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Registration number and purposes of the Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s registration
number with the Israeli Registrar of Companies is 51-358165-2. SciSparc&#8217;s purpose as set forth in its Amended and Restated Articles
of Association is to engage in any lawful activity.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Type and class of securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">SciSparc&#8217;s authorized
share capital consists of 2,000,000,000 ordinary shares, of no par value, or the ordinary shares. All of its outstanding ordinary shares
have been validly issued, are fully paid and non-assessable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preemptive rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s ordinary
shares are not redeemable and are not subject to any preemptive right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer of shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s fully paid
ordinary shares are issued in registered form and may be freely transferred under its Amended and Restated Articles of Association, unless
the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are
listed for trade. The ownership or voting of its ordinary shares by non-residents of Israel is not restricted in any way by its Amended
and Restated Articles of Association or the laws of the State of Israel, except for ownership by nationals of certain countries that
are, or have been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liability to further capital calls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s board of
directors may make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to
shares held by such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon
him or her.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under SciSparc&#8217;s Amended
and Restated Articles of Association, its board of directors must consist of at least three (3) and not more than eight (8) directors,
including, if applicable, two external directors appointed as required under the Companies Law. Other than SciSparc&#8217;s external
directors (if any), its directors are divided into three classes with staggered three-year terms. Each class of directors consists, as
nearly as possible, of one third of the total number of directors constituting the entire board of directors. At each annual general
meeting of the SciSparc shareholders, the election or re-election of directors following the expiration of the term of office of the
directors of that class of directors is for a term of office that expires on the third annual general meeting following such election
or re-election, such that from 2020 and after, at each annual general meeting the term of office only one class of directors will expire.
Each director, holds office until the annual general meeting of the SciSparc shareholders for the year in which his or her term expires
and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law upon
the occurrence of certain events or unless removed from office by a vote of the holders of at least 65% of the total voting power of
the SciSparc shareholders at a general meeting of its shareholders in accordance with SciSparc&#8217;s Amended and Restated Articles
of Association.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further<span style="background-color: white">,&#160;SciSparc
</span>shareholders&#160;<span style="background-color: white">approved an approval mechanism similar to a mechanism that exists in the
Delaware Generate Corporate Law, which requires an affirmative vote of the board of directors (by 75% of the members) in addition to
the approval of its shareholders in order to amend such provisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 240; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->223<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&#8217;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the board of directors shall not
be permitted to act, other than for the purpose of convening a general meeting of the Company&#8217;s shareholders for the purpose of
appointing additional Directors. For further information on the election and removal of directors see &#8220;<span style="background-color: white">Directors,
Senior Management and Employees</span>&#8212;Board Practices&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contested election</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Amended and Restated
Articles of Association, in the event of a contested election, the board of directors in its discretion, will set the method of calculation
of the votes and the manner in which the resolutions will be presented to the SciSparc shareholders at the general meeting. In the event
that the board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a plurality
of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend and liquidation rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc may declare a dividend
to be paid to the holders of SciSparc ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend
distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s
Articles provide otherwise. The Amended and Restated Articles of Association do not require shareholder approval of a dividend distribution
and provide that dividend distributions may be determined by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to its then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or SciSparc may distribute dividends that do not meet such criteria only with
court approval; as a company listed on an exchange outside of Israel, however, court approval is not required if the proposed distribution
is in the form of an equity repurchase, provided that it notifies its creditors of the proposed equity repurchase and allow such creditors
an opportunity to initiate a court proceeding to review the repurchase. If within 30 days such creditors do not file an objection, then
it may proceed with the repurchase without obtaining court approval. In each case, SciSparc is only permitted to distribute a dividend
if its board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will
prevent it from satisfying its existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of SciSparc&#8217;s
liquidation, after satisfaction of liabilities to creditors, its assets will be distributed to the holders of SciSparc ordinary shares
in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential
dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exchange controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on SciSparc&#8217;s ordinary shares, proceeds from the sale of the shares or
interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have
been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 241; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->224<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shareholder meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
SciSparc is required to hold an annual general meeting of its shareholders once every calendar year that must be held no later than 15
months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are
referred to in the Amended and Restated Articles of Association as special general meetings. SciSparc&#8217;s board of directors may
call special general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition,
the Companies Law provides that the board of directors is required to convene a special meeting upon the written request of (i) any two
of its directors or one-quarter of the members of the board of directors or (ii) as a company listed on an exchange in the U.S., one
or more shareholders holding, in the aggregate, either (a) 10% or more of its outstanding issued shares and 1% or more of SciSparc&#8217;s
outstanding voting power or (b) 10% or more of its outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include
a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at
the general meeting. Notwithstanding the foregoing, as a company listed on an exchange outside of Israel, a matter relating to the appointment
or removal of a director may only be requested by one or more shareholders holding at least 5% of the voting rights at the general meeting
of the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and 60 days prior to the date
of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general
meeting of the shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">amendments to SciSparc&#8217;s
    Amended and Restated Articles of Association;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">appointment or termination
    of its auditors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">appointment of external directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">approval of certain related
    party transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">increases or reductions of
    its authorized share capital;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">mergers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the exercise of its board
    of directors&#8217; powers by a general meeting, if its board of directors is unable to exercise its powers and the exercise of any
    of its powers is required for its proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under SciSparc&#8217;s Amended
and Restated Articles of Association, it is not required to give notice to its registered shareholders pursuant to the Companies Law,
unless otherwise required by law. The Companies Law requires that a notice of any annual general meeting or extraordinary general meeting
be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal
of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise
required under applicable law, notice must be provided at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Voting rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All SciSparc&#8217;s ordinary shares have identical
voting and other rights in all respects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Quorum requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to SciSparc&#8217;s
Amended and Restated Articles of Association, holders of SciSparc&#8217;s ordinary shares have one vote for each ordinary share held
on all matters submitted to a vote before the shareholders at a general meeting. The quorum required for its general meetings of shareholders
consists of at least two shareholders, present in person or by proxy, holding at least fifteen percent (15%) of the voting rights of
the Company. A meeting adjourned for lack of a quorum will be adjourned for one day at the same time and place, or to such other day,
time or place if such is stated in the notice of the meeting. At the reconvened meeting, if a quorum is not present within half an hour,
any number of shareholders present in person or by proxy will constitute a lawful quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 242; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->225<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Vote requirements</i></b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association provide that all resolutions of its shareholders require a simple majority vote, unless otherwise
required by the Companies Law or by its Amended and Restated Articles of Association. Under the Companies Law, each of (i) the approval
of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling
shareholder of the company or such controlling shareholder&#8217;s relative (even if not extraordinary) requires the approval described
under &#8220;Approval of Related Party Transactions under Israeli Law&#8212;Disclosure of Personal Interests of a Controlling Shareholder&#8221;
of this prospectus. Certain transactions with respect to remuneration of the SciSparc office holders and directors require further approvals
described under &#8220;Approval of Related Party Transactions under Israeli Law&#8212; Disclosure of Personal Interests of an Office
Holder&#8221; of this prospectus. Another exception to the simple majority vote requirement is a resolution for the voluntary winding
up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires
the approval of the majority of the shareholders voting their shares, other than abstainees, holding at least 75% of the voting rights
represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Articles amendment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to amend the Articles,
in addition and prior to the approval of a general meeting of shareholders, the approval of the board of directors with the affirmative
vote of at least three-quarters (3/4) of the directors then in office and entitled to vote thereon is required in order to approve any
amendment to the Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Access to corporate records</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
shareholders are provided access to minutes of SciSparc&#8217;s general meetings, its shareholder register and principal shareholder
register, its Amended and Restated Articles of Association, its financial statements and any document that SciSparc is required by law
to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be
provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions
of the Companies Law. SciSparc may deny this request if it believes it has not been made in good faith or if such denial is necessary
to protect its interest or protect a trade secret or patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Modification of class rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law and
the Amended and Restated Articles of Association, the rights attached to any class of shares, such as voting, liquidation and dividend
rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class
meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in SciSparc&#8217;s Amended and Restated
Articles of Association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Acquisitions under Israeli law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Full tender offer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share
capital is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of
the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result
hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the
shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the
shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that
the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted
if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the
applicable class of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 243; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->226<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the
Israeli court as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a tender offer is not
accepted in accordance with the requirements set forth above, the acquirer may not acquire shares of the company that will increase its
holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who
accepted the tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Special tender offer</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already
another holder of at least 25% of the voting rights in the company. Alternatively, such an acquisition may be approved pursuant to a
private placement approved by the company&#8217;s shareholders with the purpose of approving the acquisition of 25% or more, or 45% or
more of the company&#8217;s voting rights. Similarly, the Companies Law provides that an acquisition of shares in a public company must
be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of
the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the
company, subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a special
tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall
abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the
board of directors must disclose any personal interest each member of the board of directors has in the offer or stems therefrom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding
the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or any person having a personal
interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such
person&#8217;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common
control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of
the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless
the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law permits
merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies
Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of
its shares voted on the proposed merger at a shareholders meeting. The board of directors of a merging company is required pursuant to
the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger,
the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial
status of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 244; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->227<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at
the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting
in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors
of the other party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders (as described under &#8220;Approval of Related Party
Transactions under Israeli law&#8212;Disclosure of Personal Interests of a Controlling Shareholder&#8221; of this prospectus).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the transaction would
have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes
of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting
rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to&#160;the parties to
the merger and the consideration offered to the shareholders of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the
shareholders of each party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Special Majority Board Approvals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the SciSparc Amended
and Restated Articles of Association, at least three-quarters (3/4) of its serving directors are required to vote in favor of certain
transactions which may have a significant effect on its structure, assets or business, including mergers acquisitions, consolidations
and issuance of equity securities or debt securities convertible into equity in each case that would reasonably be expected to result
in change of beneficial ownership of above than fifteen percent (15%) in SciSparc, material changes to SciSparc&#8217;s principal business
and any resolution to transfer SciSparc&#8217;s headquarters outside of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Approval of business combinations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association restrict certain business transactions with any shareholder and/or its affiliates and/or investors
for a period of three years following (i) with respect to any shareholder of the Company holding fifteen percent (15%) or more of the
voting power of the ordinary shares as of September 15, 2022, the effective date of the Amended and Restated Articles of Association,
and (ii) with respect to all SciSparc shareholders, each time as such shareholder and/or any of its affiliates and/or investors become(s)
(other than due to a buyback, redemption or cancellation of shares by SciSparc) the holder(s) (beneficially or of record) of fifteen
percent (15%) or more of the issued and outstanding voting power of the ordinary shares. The restricted business transactions include
mergers, consolidations and dispositions of assets with an aggregate market value equal to 10% or more of SciSparc&#8217;s assets or
outstanding shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 245; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->228<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Borrowing powers</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and SciSparc&#8217;s Amended and Restated Articles of Association, its board of directors may exercise all powers and take all actions
that are not required under law or under its Amended and Restated Articles of Association to be exercised or taken by a certain organ
of SciSparc, including the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association enable it to increase or reduce its share capital. Any such changes are subject to the provisions
of the Companies Law and must be approved by a resolution duly adopted by SciSparc&#8217;s shareholders at a general meeting. In addition,
transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient
retained earnings or profits, require the approval of both its board of directors and an Israeli court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forum for adjudication of disputes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Amended
and Restated Articles of Association, the federal district courts of the United States of America, shall be the exclusive forum for the
resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted
against any defendant to such complaint. The competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative
action or proceeding brought on behalf of SciSparc, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director,
officer or other employee of SciSparc to SciSparc or SciSparc&#8217;s shareholders, or (iii) any action asserting a claim arising pursuant
to any provision of the Companies Law or the Securities Law 5728-1968. SciSparc retains the ability to consent to an alternative forum
in circumstances where SciSparc determines that its interests and those of its shareholders are best served by permitting a particular
dispute to proceed in a forum other than the federal district courts or State of Israel, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer agent and registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc&#8217;s
transfer agent and registrar is Vstock Transfer LLC, or Vstock. Vstock&#8217;s address is 18 Lafayette Place, Woodmere, New York 11598
and its telephone number is (212) 828-8436.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 246; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->229<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><div><a id="m_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">COMPARISON
OF SHAREHOLDER RIGHTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Both SciSparc and AutoMax are
incorporated under the laws of Israel and, accordingly, the rights of the shareholders of each are currently, and will continue to be,
governed by Israeli law. If the Merger is completed, AutoMax shareholders will become SciSparc shareholders, and their rights will be
governed by Israeli law and the Amended and Restated Articles of Association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below summarizes
the material differences between the current rights of AutoMax shareholders under AutoMax&#8217;s current articles of association and
the rights of SciSparc&#8217;s shareholders, post-Merger, under SciSparc&#8217;s Amended and Restated Articles of Association, as in
effect immediately following the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Although SciSparc and AutoMax
believe that the summary tables cover the material differences between the rights of their respective shareholders prior to the Merger
and the rights of SciSparc shareholders following the Merger, these summary tables may not contain all of the information that is important
to you. These summaries are not intended to be a complete discussion of the respective rights of SciSparc shareholders and AutoMax shareholders
and are qualified in their entirety by reference to Israeli law and the various documents of SciSparc and AutoMax that are referred to
in the summaries. You should carefully read this entire this proxy statement/prospectus and the other documents referred to in this proxy
statement/prospectus for a more complete understanding of the differences between being an SciSparc shareholder and a AutoMax shareholder
before the Merger and being an SciSparc shareholder after the Merger. SciSparc has filed copies of its current Amended and Restated Articles
of Association with the SEC and will send copies of the documents referred to in this proxy statement/prospectus to you upon your request.
AutoMax will also send copies of its documents referred to in this proxy statement/prospectus to you upon your request. See the section
entitled&#160;<i>&#8220;Where You Can Find More Information&#8221;</i>&#160;in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify; white-space: nowrap; width: 26%"><b>Provision</b></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 37%; text-align: center"><b>AutoMax
    (Pre-Merger)</b></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 37%; text-align: center"><b>SciSparc
    (Post-Merger)</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><span style="-keep: true">Authorized
    Share Capital</span></td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify"><span style="-keep: true">The
    authorized share capital of AutoMax consists of 400,000,000 ordinary shares, par value of NIS 0.05 per share.</span></td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The
                                            authorized share capital of SciSparc consists of 2,000,000,000 ordinary shares, no par value.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">Number
    of Directors</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Under
    the AutoMax articles of association, the number of directors shall be no less than three (3) and not more than ten (10), including
    external directors, as may be amended from time to time by resolution of general meeting. &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Under
    the SciSparc Amended and Restated Articles of Association, the number of directors is not less than three (3) nor more than eight
    (8), including the external directors (if any were elected) as may be amended from time to time by resolution of the board of directors.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">Shareholder
    Nominations and Proposals &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Under
    the Companies Law, any shareholder(s) holding at least 1% of the voting rights of the company may request that the board of directors
    (i)&#160;include a matter on the agenda of a general meeting, provided that the board of directors determines that the matter is
    appropriate to be considered at a general meeting or (ii)&#160;include on the agenda of a general meeting a nomination of a person
    to be proposed for election as a director. &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Any
    shareholder(s) holding at least the required percentage under the Companies Law of the voting rights of the company may request,
    subject to the Companies Law and the conditions set forth in the Amended and Restated Articles of Association, that the board of
    directors (i)&#160;include a matter on the agenda of a general meeting, provided that the board of directors determines that the
    matter is appropriate to be considered at a general meeting or (ii)&#160;include on the agenda of a general meeting a nomination
    of a person to be proposed for election as a director.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">Classified
    Board of Directors</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">No
    equivalent provision.</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">The
    Amended and Restated Articles of Association provide that the directors (excluding the external directors if any were elected), are
    classified, with respect to the term for which they each severally hold office, into three classes, such that following the expiration
    of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general
    meeting following such election or re-election. Notwithstanding anything to the contrary, each director shall serve until his or
    her successor is elected and qualified or until such earlier time as such director&#8217;s office is vacated. &#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 247; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->230<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify; width: 26%">Removal
    of Directors and Vacancies</td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; width: 37%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Directors
                                            are appointed and removed by a resolution adopted at a general meeting or special meeting.
                                            In addition, the general meeting will have the right, from time to time: A. To dismiss any
                                            board member, provided that the director can reasonably present their position before the
                                            general assembly; and B. appoint additional director or a replacement for a director whose
                                            position was vacated for any reason.</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            board of directors may appoint a director to fill a vacancy or as an addition to the board
                                            of directors. Such appointment will be valid until the next annual meeting or until the director
                                            ceases to serve in their position in accordance with the provisions of the articles of association
                                            or any applicable law, whichever occurs first. &#160;</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">Directors,
                                            at the exception of external directors, may appoint themselves a replacement (an &#8220;alternate
                                            director&#8221;). Any such appointment will be effective from the date stated in the appointment
                                            notice but not before the notice is sent to the company.</p></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; width: 37%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            board of directors (and, if so determined by the board of directors the general meeting)
                                            may at any time and from time to time appoint any person as a director to fill a vacancy
                                            (whether such vacancy is due to a director no longer serving or due to the number of directors
                                            serving being less than the maximum number of directors set forth in the articles).</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">The
                                            SciSparc shareholders may, by vote of at least 65% of the total voting power of the SciSparc
                                            shareholders, remove any director (other than external director, if any were elected) from
                                            office.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">Special
    Meeting of the Shareholders</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Pursuant
    to the Companies Law and the AutoMax articles of association, the board of directors may whenever it deems fit convene an extraordinary
    general meeting, and, as provided in the Companies Law, it shall be obliged to do so upon the written request of (i) any two or more
    of its directors, (ii) one-quarter or more of the serving shareholders of its board of directors or (iii) one or more shareholders
    holding, in the aggregate, either 5% or more of AutoMax&#8217;s outstanding voting power. &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">The
    SciSparc board of directors may, at its discretion, convene a special general meeting at such time and place, within or outside of
    the State of Israel, as may be determined by the board of directors. &#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">Quorum
    for General Meeting</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Two
    or more shareholders present in person or by proxy, holding shares conferring in the aggregate at least one-third (1/3) of the voting
    power of the AutoMax, unless otherwise mandated by any applicable law. &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Such
    number of shareholders present in person or by proxy and holding shares conferring in the aggregate at least thirty-three and one-third
    percent (33&#8531;%) of the voting power of SciSparc, provided, however, that if (i) such general meeting was initiated by and convened
    pursuant to a resolution adopted by the SciSparc board of directors and (ii) at the time of such general meeting is qualified to
    use the forms of a &#8220;foreign private issuer&#8221; under US securities laws, then the requisite quorum shall be shareholders
    present in person or by proxy and holding shares conferring in the aggregate at least fifteen percent (15%) of the voting power of
    SciSparc.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">Voting
    Shares</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Each
    shareholder present in person, by proxy, or through a written ballot is entitled to one vote for each share held by the shareholder
    of record, on every resolution.</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify">Each
    shareholder is entitled to one vote for each share held by the shareholder of record, on every resolution.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-left: Black 1pt solid; text-align: justify">Shareholder
    Action by Written Consent &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify">Under the
    Companies Law, shareholders are not permitted to take action via written consent in lieu of a meeting. &#160;</td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify">Under the
    Companies Law, shareholders are not permitted to take action via written consent in lieu of a meeting. &#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify">Notice of Shareholder
    Meeting</td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">According
    to AutoMax articles of association, a shareholders meeting requires prior notice provided in accordance with the Companies Laws.</td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">SciSparc
    is not required to give notice of a general meeting, subject to any mandatory provision of the Companies Law.</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 248; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->231<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    Rights and Protective Provisions</span></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    equivalent provision in the AutoMax articles of association.</span></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
    derogating from any other approvals required by the applicable law, the following actions shall require the affirmative consent of
    at least three-quarters (3/4) of the directors then in office and entitled to vote thereon: (i) Any resolution to enter a merger,
    consolidation, acquisition, amalgamation, business combination, issue equity securities or debt securities convertible into equity
    or other similar transaction. (ii) Any resolution to sell directly or indirectly, assign, convey, transfer, lease or otherwise dispose,
    in one or series of related transactions, of all or substantially all of the assets of SciSparc and its subsidiaries, taken as a
    whole, to any person. (iii) Any resolution to affect any material change to the principal business of SciSparc, or otherwise materially
    change the SciSparc strategy and/or policies with respect to its main lines of business. (iv) Any resolution to transfer the headquarters
    of SciSparc outside of Israel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forum
    Selection</span></td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    equivalent provision.</span></td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Amended and Restated Articles of Association provide that unless SciSparc consents in writing to the selection of an alternative
    forum, (a)&#160;the federal district courts of the United States of America will be the exclusive forum for the resolution of any
    complaint asserting a cause of action arising under the Securities Act; and (b), the competent courts in Tel Aviv, Israel shall be
    the exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of SciSparc, (ii)&#160;any action asserting
    a claim of breach of a fiduciary duty owed by any director, officer or other employee of SciSparc to SciSparc or its shareholders,
    or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law. &#160;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 249; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->232<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; text-align: justify; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification</span></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; width: 37%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            articles of association provide that AutoMax may, subject and pursuant to the provisions
                                            of the Companies Law or any other additionally applicable law, indemnify retroactively and
                                            in advance, a director or officer of the company for certain liabilities and expenses incurred
                                            by him or her arising from or as a result of any act (or omission) carried out by him or
                                            her as a director or officer of the company and which is indemnifiable pursuant to applicable
                                            law, to the extent permitted by law. The Companies Law provides that undertakings to indemnify
                                            a director or officer for such liabilities (but not for such legal expenses) be limited to
                                            specified foreseeable events and to reasonable maximum amounts as approved by the board of
                                            directors.</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
                                            the Companies Law, indemnification of directors and officers must be approved by the compensation
                                            committee and the board of directors (and, with respect to directors and the chief executive
                                            officer, by the shareholders).</span></p></td>
    <td style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; width: 37%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Amended and Restated Articles of Association provide that SciSparc may, subject and pursuant
                                            to the provisions of the Companies Law or any other additionally applicable law, indemnify,
                                            retroactively and in advance, a director or officer of the company for certain liabilities
                                            and expenses incurred by him or her arising from or as a result of any act (or omission)
                                            carried out by him or her as a director or officer of SciSparc and which is indemnifiable
                                            pursuant to applicable law, to the fullest extent permitted by law. The Companies Law provides
                                            that undertakings to indemnify a director or officer for such liabilities (but not for such
                                            legal expenses) be limited to specified foreseeable events and to reasonable maximum amounts.</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
                                            the Companies Law, indemnification of directors and officers must be approved by the compensation
                                            committee and the board of directors (and, with respect to directors and the chief executive
                                            officer, by the shareholders).</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    Declaration and Payment of Dividends</span></td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors may, from time to time, declare, and cause, AutoMax to pay dividends as permitted by the Companies Law. The board
    of directors shall determine the time for payment of such dividends and the record date for determining the shareholders entitled
    thereto, and subject to any preferential rights held by shareholders of a particular class, if applicable, and the provisions of
    these regulations concerning a reserved fund, dividends will be distributed and paid to the shareholders recorded in the shareholders&#8217;
    register on the designated &#8220;X&#8221; day set for determining the distribution of dividends. Dividend shall not be paid on shares
    that were not paid in full.&#160;&#160;</span></td>
    <td style="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt; border-bottom: Black 1pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            board of directors may, from time to time, declare, and cause SciSparc to pay dividends as
                                            permitted by the Companies Law. The board of directors shall determine the time for payment
                                            of such dividends and the record date for determining the shareholders entitled thereto.</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            dividend paid by SciSparc shall be allocated among the shareholders entitled thereto on a
                                            pari passu basis in proportion to their respective holdings of the issued and outstanding
                                            shares in respect of which such dividends are being paid. &#160;</span></p></td></tr>
  </table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>


</div><!-- Field: Page; Sequence: 250; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->233<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_021"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PRINCIPAL
SHAREHOLDERS OF SciSparc</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table and
related notes present information on the beneficial ownership of SciSparc ordinary shares as of July 3, 2025 by:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each
                                            shareholder known by SciSparc to beneficially own more than 5% of the outstanding shares
                                            of SciSparc;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each
                                            director and named executive officer of SciSparc; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">all
                                            of SciSparc&#8217;s directors and named executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Beneficial ownership is
determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. SciSparc ordinary
shares that may be acquired by an individual or group within 60&#160;days of July 3, 2025, pursuant to the exercise of options, warrants
or restricted share units, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group,
but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The percentage of
      ownership is based on 534,569 SciSparc ordinary shares outstanding as of July 3, 2025. SciSparc does not know of any arrangements,
      including any pledge by any person of securities of SciSparc.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Except
                                            as indicated in the footnotes to this table, SciSparc believes that the shareholders named
                                            in this table have sole voting and investment power with respect to all SciSparc ordinary
                                            shares shown as beneficially owned by them, subject to community property laws where applicable.
                                            Unless otherwise noted, the address of each director and current and former executive officer
                                            of SciSparc is 20 Raul Wallenberg St., Tower A, 2<sup>nd</sup>&#160;Floor, Tel Aviv 6971916,
                                            Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders
                                            of more than 5% of SciSparc&#8217;s ordinary shares</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><b>Number of<br/> Ordinary<br/>
    Shares<br/> Beneficially<br/> Owned<sup>(1)</sup> &#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><b>Percent of<br/> Class<sup>(2)</sup>
    &#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="text-decoration:underline">Officers and Directors who are not 5% holders:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Itschak Shrem</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,835</td><td style="width: 1%; text-align: left"><sup>(3)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">*</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amitay Weiss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,820</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Oz Adler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,822</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Adi Zuloff-Shani</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,441</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amnon Ben Shay</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alon Dayan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liat Sidi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lior Vider</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Moshe Revach</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All directors and executive officers as a group (9 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.51</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less than 1%.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole
    voting and investment power with respect to all shares shown as beneficially owned by them.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The
                                            percentages shown are based on 534,569 ordinary shares issued and outstanding as of July
                                            3, 2025, plus ordinary shares relating to restricted share units, or RSUs, options and warrants
                                            currently exercisable or exercisable within 60 days of July 3, 2025, which are deemed outstanding
                                            for computing the percentage of the person holding such securities but are not deemed outstanding
                                            for computing the percentage of any other person.</span></p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 251; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->234<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 16 ordinary shares; (ii) 3,571 ordinary shares issued from vested RSUs; (iii) 1,190 RSUs vesting within 60 days; and (iv) options
to purchase 57 ordinary shares at an exercise price of $3,549 per share, and an expiration date of January 3, 2028.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 1 ordinary shares; (ii) 3,571 ordinary shares issued from vested RSUs; (iii) 1,190 RSUs vesting within 60 days; and (iv) options
to purchase 57 ordinary shares at an exercise price of $3,549 per share and an expiration date of January 3, 2028.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 3,571 ordinary shares issued from vested RSUs; (ii) 1,190 RSUs vesting within 60 days; (iii) options to purchase 57 ordinary shares
at an exercise price of $3,549 per share; and (iv) options to purchase 3 ordinary shares at an exercise price of $114,660 per share.
Mr. Adler&#8217;s options have an expiration date of January 3, 2028, to October 10, 2029, and a weighted average exercise price of $8,862.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 1,786 ordinary shares issued from vested RSUs; (ii) 595 RSUs vesting within 60 days; (iii) options to purchase 1 ordinary shares
at an exercise price of NIS 1,622,061 (approximately $438,396) per share; (iv) options to purchase 2 ordinary shares at an exercise price
of $118,440 per share; and (v) options to purchase 57 ordinary shares at an exercise price of $3,549 per share. Dr. Zuloff-Shani&#8217;s
options have an expiration date of February 16, 2026 to October 10, 2029, and a weighted average exercise price of $4,347.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 1,071 ordinary shares issued from vested RSUs; (ii) 357 RSUs vesting within 60 days; and (iii) options to purchase 10 ordinary shares
at an exercise price of $3,549 per share and an expiration date of January 3, 2028.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Includes
                                            (i) 1,071 ordinary shares issued from vested RSUs; and (ii) 357 RSUs vesting within 60 days.</span></p></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in Percentage
Ownership by Major Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
SciSparc&#8217;s knowledge, other than as disclosed in the table above and in its other filings with the SEC incorporated by reference,
there has been no significant change in the percentage ownership held by any major shareholder during the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
major shareholders listed above had or have voting rights with respect to their ordinary shares that are different from the voting rights
of other holders of SciSparc ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">As
                                            of July 3, 2025, there were 25 holders of record of SciSparc ordinary shares, 8 of which
                                            have a registered address in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
numbers are not representative of the number of beneficial holders of its shares nor is it representative of where such beneficial holders
reside, since many of these shares were held of record by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Change in Control
Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
is not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and
there are no arrangements known to SciSparc which would result in a change in control at a subsequent date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 252; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->235<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_022"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PRINCIPAL
SHAREHOLDERS OF AutoMax</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
                                            following table and related notes present information on the beneficial ownership of AutoMax
                                            ordinary shares as of July 3, 2025 by:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each
                                            shareholder known by AutoMax to beneficially own more than 5% of the outstanding shares of
                                            AutoMax;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each
                                            director and named executive officer of AutoMax; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">all
                                            of AutoMax&#8217;s directors and named executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
AutoMax&#8217;s ordinary shares that may be acquired by an individual or group within 60&#160;days of July 3, 2025, pursuant to the exercise
of options, warrants or restricted share units, are deemed to be outstanding for the purpose of computing the percentage ownership of
such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person
shown in the table.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
                                            percentage of ownership is based on 103,691,969 AutoMax ordinary shares outstanding as of
                                            July 3, 2025 (excluding dormant shares). AutoMax does not know of any arrangements, including
                                            any pledge by any person of securities of AutoMax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Except
as indicated in the footnotes to this table, AutoMax believes that the shareholders named in this table have sole voting and investment
power with respect to all AutoMax ordinary shares shown as beneficially owned by them, subject to community property laws where applicable.
Unless otherwise noted, the address of each director and current and former executive officer of AutoMax is 15 Harechavim St., Jerusalem,
Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">NAME OF BENEFICIAL OWNER</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Beneficial Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of Ordinary Shares
    Beneficially Owned (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">5% and Greater Shareholders</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Kool Car Rental Kft <sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,285,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13.78</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Belporto Investments Ltd. <sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,209,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.95</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eliyahu Baruch Ltd. <sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,209,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.95</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Emanuel Paz Puzailov <sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,449,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.93</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Directors and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Daniel Levy, Chief Executive Officer <sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,419,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.91</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Haim Levy, Procurement and Trade Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gal Levy, Regulation and Branch Manager</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ynon Amit, Chief Business Officer <sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,419,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.91</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amitay Weiss, Chairman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Eyal Baruch, Director <sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,209,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.95</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tomer Levy, Vice President Business Development, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All current executive officers and directors as a group (7 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">36,073,834</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">34.79</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Less than 1%.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The
                                            percentages shown are based on 103,691,969 ordinary shares issued and outstanding as of July
                                            3, 2025 (excluding dormant shares), plus ordinary shares relating to options and warrants
                                            currently exercisable or exercisable within 60 days of July 3, 2025, which are deemed outstanding
                                            for computing the percentage of the person holding such securities but are not deemed outstanding
                                            for computing the percentage of any other person.</span></p></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 253; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->236<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents 14,285,714 ordinary shares held by Kool Car
    Rental Kft, a company incorporated in the State of Hungary, controlled by Nikas Kostantinos.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents 7,209,614 ordinary shares held by Belporto Investments
    Ltd., a company incorporated in the State of Israel. Belporto Investments Ltd. is controlled by Ms. Esther Zochovitsky. The address
    for this entity is 8 Hamenofim St., Herzliya, Israel.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents 7,209,614 ordinary shares held by Eliyahu Baruch
    Ltd., a company incorporated in the State of Israel. Eliyahu Baruch Ltd., is controlled by Mr. Eyal Baruch, Ms. Michal Baruch Kind,
    Mr. Oded Baruch, and Ms. Sima Baruch Hakim. The address for this entity is 8 Hamenofim St., Herzliya, Israel.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(5)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents 14,449,228 ordinary shares held by Puzaylov
    Investments Ltd., a company incorporated in the State of Israel. Puzaylov Investments Ltd. is controlled by Emanuel Paz Puzailov,
    a former director of AutoMax. The address for these entities is 138 Yehuda St., Modi&#8217;in-Maccabim-Re&#8217;ut, Israel.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(6)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes 14,419,228 ordinary shares, held by Haim Levy
    &#8211; Trade In Ltd., a company incorporated in the State of Israel. Haim Levy &#8211; Trade In Ltd. is controlled by Daniel Levy.
    The address for this entity is 15 Harechavim St., Jerusalem, Israel.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(7)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes 14,419,228 ordinary shares, held by A. Ynon (2015)
    Ltd., a company incorporated in the State of Israel. A. Ynon (2015) Ltd. is controlled by Ynon Amit. The address for this entity
    is Moshe 15 Lerrer Ness Ziona, Israel.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(8)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes 7,209,614 ordinary shares held by Eliyahu Baruch
    Ltd., over which Mr. Baruch may be deemed to hold share voting and dispositive power.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 254; Options: NewSection; Value: 237 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->237<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_023"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">PRINCIPAL
SHAREHOLDERS OF Combined company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
                                            following table and the related notes present information on the beneficial ownership of
                                            the combined company&#8217;s ordinary shares immediately after the consummation of the Merger,
                                            applying an estimated exchange ratio, which may be adjusted based on the amount of SciSparc
                                            net cash and changes in the capitalization of SciSparc or AutoMax prior to the closing of
                                            the Merger, and based on beneficial ownership as of&#160;July 3, 2025 by:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each
                                            shareholder expected by AutoMax and SciSparc to become the beneficial owner of more than
                                            5% of the outstanding ordinary shares of the combined company;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each
                                            director and named executive officer of the combined company; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">all
                                            of the combined company&#8217;s directors and executive officers as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Beneficial
                                            ownership is determined in accordance with the rules of the SEC and includes voting or investment
                                            power with respect to the securities. Shares of the combined company that may be acquired
                                            by an individual or group within 60 days of July 3, 2025, pursuant to the exercise of options
                                            or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership
                                            of such individual or group, but are not deemed to be outstanding for the purpose of computing
                                            the percentage ownership of any other person shown in the table.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">The
                                            percentage ownership is based on ordinary shares of the combined company outstanding as of
                                            July 3, 2025, adjusted as required by the rules promulgated by the SEC to determine beneficial
                                            ownership. Neither AutoMax nor SciSparc know of any arrangements, including any pledge by
                                            any person of securities of the combined company.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">Immediately
                                            after the consummation of the Merger, based on the Exchange Ratio, AutoMax shareholders will
                                            own approximately 49.99% of the SciSparc ordinary shares with SciSparc shareholders holding
                                            approximately 50.01% of the SciSparc ordinary shares on a fully-diluted basis (subject to
                                            certain exceptions). The following table and the related notes assume that, at the effective
                                            time of the Merger, each share of AutoMax ordinary shares will convert into the right to
                                            receive an estimated 508,220 ordinary shares, of SciSparc and to account for the occurrence
                                            of certain events discussed elsewhere in this proxy statement/prospectus. See &#8220;<i>The
                                            Merger Agreement &#8212; Merger Consideration</i>&#8221; for more information regarding the
                                            Exchange Ratio.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Except
as indicated in footnotes to this table, AutoMax and SciSparc believe that the shareholders named in this table have sole voting and
investment power with respect to all shares of ordinary shares of the combined company shown as beneficially owned by them, based on
information provided to AutoMax and SciSparc by such shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">NAME OF BENEFICIAL OWNER</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br/>
    Beneficial<br/> Ownership<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage<br/>
    of&#160;Ordinary<br/> Shares<br/> Beneficially<br/> Owned<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">5% and Greater Shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Levy.<sup>(3)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">74,253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.94</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ynon Amit <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emanuel Paz Puzailov<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.96</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kool Car Rental Kft<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.88</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Adi Zuloff-Shani<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach<sup>(11)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tomer Levy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yaarah Alfi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All current executive officers and directors as a group (persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.54</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Less than 1%</td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 255; Value: 237 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->238<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify">Except
                                            as indicated by footnote, and subject to community property laws where applicable, the persons
                                            named in the table above have sole voting and investment power with respect to all shares
                                            shown as beneficially owned by them<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The
                                            percentages shown are based on &#160;1,069,543 ordinary shares estimated to be issued and
                                            outstanding as of immediately after the effective time of the Merger, plus ordinary shares
                                            relating to restricted share units, or RSUs, options and warrants currently exercisable or
                                            exercisable within 60 days of July 3, 2025, which are deemed outstanding for computing the
                                            percentage of the person holding such securities but are not deemed outstanding for computing
                                            the percentage of any other person.</span></p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify">Includes
                                            <span style="font-family: Times New Roman, Times, Serif">74,253 </span>ordinary shares, held
                                            by Haim Levy <span style="font-family: Times New Roman, Times, Serif">&#8211; </span>Trade
                                            In Ltd., a company incorporated in the State of Israel. Haim Levy <span style="font-family: Times New Roman, Times, Serif">&#8211;
                                            </span>Trade In Ltd. is controlled by Daniel Levy. The address for this entity is 15 Harechavim
                                            St., Jerusalem, Israel<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify">Includes
                                            <span style="font-family: Times New Roman, Times, Serif">74,253 </span>ordinary shares, held
                                            by A. Ynon (2015) Ltd., a company incorporated in the State of Israel. A. Ynon (2015) Ltd.
                                            is controlled by Ynon Amit. The address for this entity is Moshe 15 Lerrer Ness Ziona, Israel<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="text-align: justify">Represents
                                            <span style="font-family: Times New Roman, Times, Serif">74,407 </span>ordinary shares held
                                            by Puzaylov Investments Ltd., a company incorporated in the State of Israel. Puzaylov Investments
                                            Ltd<span style="font-family: Times New Roman, Times, Serif">. </span>is controlled by Emanuel
                                            Paz Puzailov, a former director of AutoMax. The address for these entities is 138 Yehuda
                                            St., Modi<span style="font-family: Times New Roman, Times, Serif">&#8217;</span>in-Maccabim-Re<span style="font-family: Times New Roman, Times, Serif">&#8217;</span>ut<span style="font-family: Times New Roman, Times, Serif">,
                                            </span>Israel<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="text-align: justify">Represents
                                            <span style="font-family: Times New Roman, Times, Serif">73,565 </span>ordinary shares held
                                            by Kool Car Rental Kft, a company incorporated in the State of Hungary, controlled by Nikas
                                            Kostantinos<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="text-align: justify">Includes
                                            (i) 134 ordinary shares; (ii) 3,571 ordinary shares issued from vested RSUs; (iii) 1,190
                                            RSUs vesting within 60 days; and (iv) options to purchase 57 ordinary shares at an exercise
                                            price of $3,549 per share and an expiration date of January 3, 2028<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td style="text-align: justify">Includes
                                            (i) 3,571 ordinary shares issued from vested RSUs; (ii) 1,190 RSUs vesting within 60 days;
                                            (iii) options to purchase 57 ordinary shares at an exercise price of $3,549 per share; and
                                            (iv) options to purchase 3 ordinary shares at an exercise price of $114,660 per share. Mr.
                                            Adler<span style="font-family: Times New Roman, Times, Serif">&#8217;</span>s options have
                                            an expiration date of January 3, 2028, to October 10, 2029, and a weighted average exercise
                                            price of $8,862<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td style="text-align: justify">Includes
                                            (i) 1,786 ordinary shares issued from vested RSUs; (ii) 595 RSUs vesting within 60 days;
                                            (iii) options to purchase 1 ordinary shares at an exercise price of NIS 1,622,061 (approximately
                                            $4<span style="font-family: Times New Roman, Times, Serif">38,396) </span>per share; (iv)
                                            options to purchase 21 ordinary shares at an exercise price of $118,440 per share; and (v)
                                            options to purchase 57 ordinary shares at an exercise price of $3,549 per share. Dr. Zuloff-Shani<span style="font-family: Times New Roman, Times, Serif">&#8217;</span>s
                                            options have an expiration date of February 16, 2026 to October 10, 2029, and a weighted
                                            average exercise price of $4,347<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(10)</span></td><td style="text-align: justify">Includes
                                            (i) 1,071 ordinary shares issued from vested RSUs; (ii) 357 RSUs vesting within 60 days;
                                            and (iii) options to purchase 10 ordinary shares at an exercise price of $3,549 per share
                                            and an expiration date of January 3, 2028.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-align: justify; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif">(11)</span></td><td style="text-align: justify">Includes
                                            (i) 1,071 ordinary shares issued from vested RSUs; (ii) 357 RSUs vesting within 60 days<span style="font-family: Times New Roman, Times, Serif">.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 256; Value: 237 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->239<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_024"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">LEGAL
MATTERS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
validity of the securities registered hereby and certain other matters of the laws of Israel will be passed upon for </span>SciSparc
<span style="background-color: white">by </span>Meitar | Law Offices, Ramat Gan, Israel<span style="background-color: white">, and certain
matters of U.S. law will be passed upon for SciSparc by </span>Sullivan &amp; Worcester LLP, New York, New York<span style="background-color: white">.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_025"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">EXPERTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
consolidated financial statements of SciSparc Ltd. at December 31, 2024 and 2023, and for each of the three years in the period ended
December 31, 2024, included in the Proxy Statement of SciSparc Ltd, which is referred to and made a part of this Prospectus and Registration
Statement have been audited by Kost Forer Gabbay &amp; Kasierer, a member of EY Global, independent registered public accounting firm,
as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing
elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
consolidated financial statements of AutoMax Motors Ltd. as of December 31, 2024 and 2023 and the years ended December 31, 2024 and 2023,
included in this prospectus have been audited by Ben David Shalvi Kop &amp; Co, independent registered public accounting firm, as set
forth in their report thereon, included herein. Such consolidated financial statements are included herein in reliance upon such report
given on the authority of such firm as experts in accounting and auditing.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><sup>&#160;</sup></b></span></p><div>

</div><div><a id="m_026"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">WHERE
YOU CAN FIND MORE INFORMATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
has filed a registration statement on Form F-4 to register the issuance of securities described elsewhere in this proxy statement/prospectus.
This proxy statement/prospectus is a part of that registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
AutoMax&#8217;s ordinary shares are traded on the&#160;TASE, AutoMax files periodic and immediate reports with, and furnish information
to, the&#160;TASE&#160;and the ISA, or the ISA, as required under Chapter Six of the Israel Securities Law, 1968 and the regulations
enacted pursuant thereof, as applicable to a public company in Israel. Copies of AutoMax&#8217;s filings with the ISA can be retrieved
electronically through the MAGNA distribution site of the ISA (www.magna.isa.gov.il) and the&#160;TASE&#160;website (www.maya.tase.co.il).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SciSparc
files reports, proxy statements and other information with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as required
by the&#160;Exchange Act, as applicable to foreign private issuers. You may access information on SciSparc at the SEC website containing
reports, proxy statements and other information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a foreign private issuer, SciSparc is exempt under the&#160;Exchange Act&#160;from, among other things, the rules prescribing the furnishing
and content of proxy statements, and its executive officers, directors and principal shareholders are exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. In addition, SciSparc will not be required under the&#160;Exchange
Act&#160;to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
are registered under the&#160;Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Information
and statements contained in this proxy statement/prospectus or any annex to this proxy statement/prospectus are qualified in all respects
by reference to the copy of the relevant contract or other annex filed as an exhibit to this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
information contained in this proxy statement/prospectus relating to SciSparc has been supplied by SciSparc, and all such information
relating to AutoMax has been supplied by AutoMax. Information provided by one another does not constitute any representation, estimate
or projection of the other.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
you would like additional copies of this proxy statement/prospectus or if you have questions about the business combination, you should
contact via phone or in writing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SciSparc Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;20 Raul Wallenberg Street,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tower A</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel Aviv 6971916 Israel Attn: Secretary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AutoMax Motors Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">C/O Mishmeret Trust Company Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">48 Derech Menachem Begin,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel Aviv 6618001, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Adv. Daniel Bar-On</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 257; Value: 237 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->240<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="m_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">HOUSEHOLDING
OF PROXY MATERIALS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for shareholder meeting
materials with respect to two or more shareholders sharing the same address by delivering a single set of shareholder meeting materials
addressed to those shareholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience
for shareholders and cost savings for companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
number of brokers with account holders who are SciSparc shareholders will be &#8220;householding&#8221; SciSparc&#8217;s proxy materials.
A single set of meeting materials will be delivered to multiple shareholders sharing an address unless contrary instructions have been
received from the affected shareholders. Once you have received notice from your broker that they will be &#8220;householding&#8221;
communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent.
If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of shareholder
meeting materials, please notify your broker or SciSparc. Direct your written request to SciSparc Ltd., 20 Raul Wallenberg St., Tower
A, 2<sup>nd</sup>&#160;Floor, Tel Aviv 6971916, Israel. Shareholders who currently receive multiple copies of the proxy statement at
their address and would like to request &#8220;householding&#8221; of their communications should contact their broker. In addition,
SciSparc will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the proxy statement
to such shareholders at a shared address to which a single copy of the documents was delivered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 258; Value: 237 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->241<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><div><a id="f-1_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>SCISPARC
LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF DECEMBER 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>U.S. DOLLARS IN THOUSANDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report
    of Independent Registered Public Accounting Firm (PCAOB ID&#160;1281)</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2
    - F-3</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Statements of Financial Position</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4
    - F-5</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Statements of Comprehensive Loss</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Statements of Changes in Equity</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Statements of Cash Flows</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-8
    - F-10</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
    to Consolidated Financial Statements</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-11
    - F-53</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; width: 33%"><img alt="" src="fin_001a.jpg" style="width: 61px; height: 72px"/></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 34%"><b>Kost Forer Gabbay &amp; Kasierer</b><br/>
    144 Menachem Begin Road, <br/>
    Tel-Aviv 6492102, Israel</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 33%">Tel: +972-3-6232525<br/>
    Fax: +972-3-5622555 <br/>
    ey.com</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of SciSparc Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024
and 2023, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in
the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company&#8217;s Ability to Continue as
a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial
statements, the Company has suffered recurring losses from operations, negative cash flows from operating activities, and has stated
that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the
events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit matters
communicated below are matters arising from the current period audit of the financial statements that were communicated or required to
be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
    of the Matter</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            discussed in Note 1 to the consolidated financial statements, the Company has incurred losses
                                            since inception, and expects to continue to incur losses for the foreseeable future. At December
                                            31, 2024, the Company&#8217;s cash and cash equivalents position is not sufficient to fund
                                            the Company&#8217;s planned operations for at least a year beyond the date of the issuance
                                            of the consolidated financial statements. Those factors raise substantial doubt about the
                                            Company&#8217;s ability to continue as a going concern.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We determined the Company&#8217;s ability
    to continue as a going concern is a critical audit matter due to the estimation and execution uncertainty regarding the Company&#8217;s
    future cash flows and the risk of bias in management&#8217;s judgments and assumptions in estimating these cash flows to conclude
    the Company would have sufficient liquidity to sustain itself for at least a year beyond the date of the issuance of the consolidated
    financial statements. This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting
    the liquidity conclusions.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
    We Addressed the Matter in Our Audit</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Addressing
                                            the matter involved performing procedures and evaluating audit evidence in connection with
                                            our overall opinion on the consolidated financial statements.&#160;Our audit procedures included
                                            testing the reasonableness of the forecasted revenue, operating expenses, and uses and sources
                                            of cash used in management&#8217;s assessment of whether the Company has sufficient liquidity
                                            to fund operations for at least one year from the consolidated financial statement issuance
                                            date. This testing included inquiries with management, consideration of positive and negative
                                            evidence impacting management&#8217;s forecasts, the Company&#8217;s financing arrangements
                                            in place as of the report date, market and industry factors, we evaluated management&#8217;s
                                            analysis of their impact on the forecasted cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assessed the adequacy of the Company&#8217;s
    going concern disclosures included in Note 1 to the consolidated financial statements.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fair value of loan to Automax (a related party) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 23%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><i>Description
                                            of the Matter</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><i>&#160;</i></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 76%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            discussed in Note 24 to the consolidated financial statements, the Company entered into a
                                            Bridge Loan Agreement with AutoMax Motors Ltd. (&#8220;AutoMax&#8221;), which is considered
                                            a related party, under which the Company provided a total loan amount of $4,250 (the &#8220;Loan&#8221;)
                                            as of December 31, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evaluating
                                            the fair value of the Loan was complex and required considerable judgment due to the significant
                                            estimates in management&#8217;s assumptions, particularly regarding the involvement of a
                                            related party. The Company determined that the fair value of the Loan is a critical audit
                                            matter due to its materiality and the complexity involved in assessing the fair value of
                                            the Loan under the unique terms of the agreement.</p></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 23%"><i>How
    We Addressed the Matter in Our Audit</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 76%">Our audit procedures related to the valuation
    of Loan to AutoMax at fair value included the following, among others, engaging specialists with expertise in evaluating the assumptions
    used by management in determining the fair value, assessing the methodology used in the valuation of the Loan, testing independent
    sourcing of key inputs and assumptions, and developing independent estimates. The significant assumptions used to estimate the fair
    value of the Loan included estimates of payment dates, credit spreads, volatility, share price, risk-free rate as of the valuation
    date, and loan cost were based on an analysis of AutoMax&#8217;s credit portfolio and the trading data of its Series B bonds listed
    on the Tel Aviv Stock Exchange. This analysis was conducted in order to derive an appropriate economic interest rate for the bridge
    loan. We examined the reasonableness and adequacy of the disclosures related to the transaction within the financial statements.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    KOST FORER GABBAY &amp; KASIERER</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 20%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel
    Aviv, Israel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    24, 2025, except for note 1(d), as to which the date is July 8, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-indent: -118.05pt">A Member of EY Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2007.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Note</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD in
    thousands</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">ASSETS</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">CURRENT ASSETS:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; padding-left: 9pt">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">4</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85115">1,540</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85116">2,076</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Restricted deposit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85117">20</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85118">65</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Short-term deposit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-85119">3,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-85120">10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTradeReceivables" scale="3" unitRef="usd" id="ixv-85121">22</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Other accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-85122">1,079</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-85123">540</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Investments in short-term financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">24g</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85124">517</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Bridge loan to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">24a</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-85125">4,224</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-85126">113</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-85127">742</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-85128">7,503</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-85129">6,445</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">NON-CURRENT ASSETS:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85130">1,479</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85131">3,189</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Investments in company accounted for at
    equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85132">952</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85133">781</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,
    24d</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85134">354</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85135">659</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Property and equipment,
    net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85136">59</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85137">108</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-85138">2,844</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-85139">4,737</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-85140">10,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="3" unitRef="usd" id="ixv-85141">11,182</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Note</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD in
    thousands</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">LIABILITIES AND EQUITY</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">CURRENT LIABILITIES:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left">Trade payables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-85142">816</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-85143">802</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-85144">205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-85145">185</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:CurrentWarrantLiability" scale="3" unitRef="usd">191</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(*)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other short-term liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">17e</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-85147">341</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:OtherCurrentLiabilities" scale="3" unitRef="usd">341</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(*)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-85149">37</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-85150">52</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-85151">1,399</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-85152">1,571</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">NON-CURRENT LIABILITIES:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-85153">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" unitRef="usd" id="ixv-85154">24</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share capital and premium</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-85155">70,886</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="3" unitRef="usd" id="ixv-85156">64,526</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reserve from share-based payment transactions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-85157">5,746</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="3" unitRef="usd" id="ixv-85158">5,282</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-85159">5,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WarrantLiability" scale="3" unitRef="usd" id="ixv-85160">5,190</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign currency translation reserve</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2d</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-85161">497</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-85162">497</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Transactions with non-controlling interests</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-85163">810</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="3" unitRef="usd" id="ixv-85164">810</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-85165">74,975</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-85166">68,691</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-85167">8,154</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="3" unitRef="usd" id="ixv-85168">7,614</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Non-controlling interests</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-85169">785</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncontrollingInterests" scale="3" unitRef="usd" id="ixv-85170">1,973</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85171">8,939</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85172">9,587</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-85173">10,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="3" unitRef="usd" id="ixv-85174">11,182</ix:nonFraction></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">Year
    ended December&#160;31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">Note</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">USD
    in thousands (except per share data)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 53%"><span style="-keep: true">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="-keep: true">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85176">1,306</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85177">2,879</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85178">1,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Cost of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85179">800</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85180">683</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85181">322</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Gross profit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-85182">506</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-85183">2,196</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-85184">1,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Research and development expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">21a</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85185">1,707</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85186">1,641</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85187">2,803</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Sales and marketing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">21b</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85188">1,515</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">2,484</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">*</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">1,082</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Impairment of intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85191">1,344</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85192">1,042</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5"><span style="-keep: true">-</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">General and administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">21c</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85193">4,526</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,844</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">*</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">5,427</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">21d</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="3" unitRef="usd" id="ixv-85196">1,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6"><span style="-keep: true">-</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7"><span style="-keep: true">-</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85197">7,316</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85198">6,815</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85199">8,287</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Equity losses from the investment in MitoCareX</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-85200">429</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-85201">210</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-85202">109</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Finance income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">21e</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85203">612</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85204">2,219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85205">7,832</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Finance expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">21f</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85206">353</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85207">1,055</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85208">2,014</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Loss before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-85209">7,486</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-85210">5,861</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-85211">2,578</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Taxes on income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-85212">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-85213">22</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-85214">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total comprehensive loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85215">7,472</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85216">5,883</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85217">2,592</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Attributable to:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">Equity holders of the Company</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-85218">6,284</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-85219">5,122</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="3" sign="-" unitRef="usd" id="ixv-85220">2,592</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Non-controlling interests</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-85221">1,188</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="3" sign="-" unitRef="usd" id="ixv-85222">761</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8"><span style="-keep: true">-</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85223">7,472</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85224">5,883</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85225">2,592</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per ordinary share attributable to equity
    holders of the Company</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-85226">26.94</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-85227">303.03</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-85228">311.22</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per ordinary share attributable to
    equity holders of the Company</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-85229">26.94</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-85230">303.03</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" unitRef="usdPershares" id="ixv-85231">311.22</ix:nonFraction></span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Attributable
    to equity holders of the Company</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Share<br/>
    capital<br/> and<br/> premium</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Reserve<br/>
    from&#160;share-<br/> based<br/> payment<br/> transactions</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Transactions<br/>
    with non-<br/> controlling<br/> interests</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Foreign<br/>
    currency<br/> translation<br/> reserve</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated<br/>
    deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-<br/>
    controlling<br/> interests</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total<br/>
    equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="34" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD
    in thousands</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 32.5%; padding-bottom: 2.5pt">Balance
    at January 1, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85233">58,541</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85234">4,331</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85235">5,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85236">559</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85237">497</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-85238">60,977</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85239">8,141</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85240">8,141</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85241">2,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85242">2,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85243">2,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Exercise of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-85244">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-85245">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" unitRef="usd" id="ixv-85246">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost
    of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85247">48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85248">849</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85249">897</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85250">897</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balance
    at December&#160;31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85251">58,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85252">5,180</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85253">5,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85254">559</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85255">497</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-85256">63,569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85257">6,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85258">6,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85259">5,122</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85260">5,122</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85261">761</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85262">5,883</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of minority
    interest in subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-85263">251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-85264">251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-85265">2,734</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" scale="3" unitRef="usd" id="ixv-85266">2,985</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of
    share capital in respect of investment in affiliate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-85267">288</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-85268">288</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="3" unitRef="usd" id="ixv-85269">288</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of
    share capital, net of issue expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-85270">5,552</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-85271">5,552</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-85272">5,552</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost
    of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85273">94</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85274">102</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85275">196</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85276">196</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balance
    at December&#160;31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85277">64,526</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85278">5,282</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85279">5,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85280">810</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85281">497</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-85282">68,691</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85283">7,614</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85284">1,973</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85285">9,587</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">Loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85286">6,284</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85287">6,284</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85288">1,188</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85289">7,472</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of
    share capital, net of issue expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-85290">6,255</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#160;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-85291">6,255</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" scale="3" unitRef="usd" id="ixv-85292">6,255</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cost
    of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85293">105</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85294">464</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85295">569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85296">569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balance
    at December&#160;31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85297">70,886</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85298">5,746</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85299">5,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85300">810</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85301">497</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" sign="-" unitRef="usd" id="ixv-85302">74,975</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85303">8,154</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85304">785</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="3" unitRef="usd" id="ixv-85305">8,939</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD
    in thousands</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">Loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85306">7,472</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85307">5,883</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85308">2,592</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Adjustments to reconcile loss to net cash
    used&#160;in operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Adjustments to the profit or loss items:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-85309">482</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-85310">538</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" unitRef="usd" id="ixv-85311">187</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-85312">1,344</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-85313">1,042</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Cost of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85314">569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85315">196</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85316">897</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Finance income, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-85317">897</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-85318">2,205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-85319">6,585</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Group&#8217;s share of losses of company
    accounted for at equity, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-85320">429</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-85321">210</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-85322">109</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Losses from remeasurement of investment
    in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-85323">305</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-85324">1,048</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" scale="3" unitRef="usd" id="ixv-85325">770</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-85326">2,232</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" unitRef="usd" id="ixv-85327">829</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForReconcileProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85328">4,622</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Working capital adjustments:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Decrease (increase) in other accounts
    receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-85329">535</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-85330">409</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" unitRef="usd" id="ixv-85331">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Increase (decrease) in trade payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" unitRef="usd" id="ixv-85332">25</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="3" sign="-" unitRef="usd" id="ixv-85333">397</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Increase (decrease) in other accounts
    payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-85334">20</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" sign="-" unitRef="usd" id="ixv-85335">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" unitRef="usd" id="ixv-85336">39</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Increase in related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdjustmentsForIncreaseInRelatedParties" scale="3" unitRef="usd" id="ixv-85337">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Decrease (increase) in trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-85338">12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" unitRef="usd" id="ixv-85339">55</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" sign="-" unitRef="usd" id="ixv-85340">77</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Decrease (increase)
    in inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" unitRef="usd" id="ixv-85341">629</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-85342">74</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-85343">668</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" unitRef="usd" id="ixv-85344">136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-85345">833</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" scale="3" sign="-" unitRef="usd" id="ixv-85346">703</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85347">5,104</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85348">5,887</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85349">7,917</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD
    in thousands</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from investing activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 27pt">Withdrawal
    of (investment in) restricted bank deposits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85350">45</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-85351">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-85352">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Withdrawal of (investment
    in) short-term bank deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" unitRef="usd" id="ixv-85353">3,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" sign="-" unitRef="usd" id="ixv-85354">3,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Sale (purchase) of
    property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:SalepurchaseOfPropertyAndEquipment" scale="3" sign="-" unitRef="usd" id="ixv-85355">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:SalepurchaseOfPropertyAndEquipment" scale="3" unitRef="usd" id="ixv-85356">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Investment in a company
    accounted for at equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85357">600</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85358">400</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85359">700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Bridge loan to related
    parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" scale="3" unitRef="usd" id="ixv-85360">4,078</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Investments in financial
    assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85361">689</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85362">1,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Purchase
    of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" unitRef="usd" id="ixv-85363">4,861</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net
    cash provided by (used in) investing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85364">1,625</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85365">4,094</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85366">7,084</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash
    flows from financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Proceeds from issue
    of share capital (net of issuance expenses)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-85367">6,255</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-85368">5,552</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-85369">9,005</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Sale of minority interest
    in subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" scale="3" unitRef="usd">2,985</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">*</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 27pt">Exercise of warrants (a)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" unitRef="usd" id="ixv-85371">2,770</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of issuance
    expenses related to previous period</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" scale="3" unitRef="usd" id="ixv-85372">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 27pt">Interest paid on lease
    liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-85373">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-85374">7</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-85375">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Repayment
    of lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-85376">54</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-85377">47</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-85378">70</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net
    cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-85379">6,193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-85380">8,483</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-85381">11,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease in cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-85382">536</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-85383">1,498</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-85384">3,301</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash
    at the beginning of the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85385">2,076</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85386">3,574</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85387">6,875</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Cash
    at the end of the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85388">1,540</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85389">2,076</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85390">3,574</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">Reclassified</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">USD
    in thousands</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
    <span style="text-decoration:underline">Significant non-cash transactions</span>:</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt">Right-of-use asset recognized
    with corresponding lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-85392">75</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" scale="3" unitRef="usd" id="ixv-85393">102</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Investment in financial asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-85394">288</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="ixv-34912"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    1:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;),
    a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc
    and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s
    own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing
    on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in
    development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment
    of Tourette syndrome, Alzheimer&#8217;s disease and agitation, autism spectrum disorder and Status Epilepticus. The headquarters
    of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated
under the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1,
which became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2024, the Group had an accumulated deficit of approximately $<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="3" sign="-" unitRef="usd" id="ixv-85395">74,975</ix:nonFraction> as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
cash and cash equivalents totaled $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85396">1,540</ix:nonFraction>. In the period ended December 31, 2024, the Company had an operating loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85397">7,316</ix:nonFraction> and negative
cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-85398">5,104</ix:nonFraction>. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its
liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past,
there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially
reasonable terms, would have serious consequences on our financial condition and results of operations. In addition, the Group has started
recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing
and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue
from its products. These above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions
    and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
    that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts
    are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221;
    and is not a Subsidiary.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Parties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
    Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
    Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"/><td style="width: 48px; text-align: left">d.</td><td style="text-align: justify">On July 3, 2025, the Company effected a twenty one-for-one
reverse share split of its ordinary shares. All share and per share information has been retroactively adjusted to reflect the reverse
share split for all periods presented.</td>
</tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-35078"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies
have been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_1" escape="true" name="sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" id="ixv-35090"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_2" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_3" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_4" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory" id="ixv-35111"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="sprcy:OperatingTerm" id="ixv-85399">one year</ix:nonNumeric>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" id="ixv-35123"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_3" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-35141"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c0_cont_1" escape="true" name="sprcy:DescriptionOfAcquisitionOfASingleAssetCompany" id="ixv-35153"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" id="ixv-35202"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" id="ixv-35214"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    ventures:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    operations:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" id="ixv-35254"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-35319"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory" id="ixv-35331"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Mainly
    %</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-85400">6</ix:nonFraction>-<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-85401">50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-85402">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Computers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-85403">33</ix:nonFraction>-<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-85404">50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-85405">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-85406">7</ix:nonFraction>-<ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRatePropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-85407">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" scale="-2" unitRef="pure" id="ixv-85408">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c74" name="ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" id="ixv-85409">see below</ix:nonNumeric></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="ixv-35384"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="ixv-35399"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-35448"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual cash flow terms of the financial asset.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    instruments are measured at amortized cost when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    instruments and other financial assets held for trading:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_15"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
    of financial assets:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized
only when:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_17"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_18"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the
    financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred
    control of the asset; or</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_19"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation
    to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_20"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify">3.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment
                                            of financial assets:</p>
</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company evaluates at the end of
each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss.
The Company distinguishes between two types of loss allowances:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_22"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 168px"/><td style="font: 10pt Times New Roman, Times, Serif; width: 48px">a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Debt
                                            instruments whose credit risk has not increased significantly since initial recognition,
                                            or whose credit risk is low - the loss allowance recognized in respect of this debt instrument
                                            is measured at an amount equal to the expected credit losses within 12 months from the reporting
                                            date (12-month ECLs); or</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_23"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 168px"/><td style="font: 10pt Times New Roman, Times, Serif; width: 48px">b)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Debt
                                            instruments whose credit risk has increased significantly since initial recognition, and
                                            whose credit risk is not low - the loss allowance recognized is measured at an amount equal
                                            to the expected credit losses over the instrument&#8217;s remaining term (lifetime ECLs).</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has short-term financial
assets in respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to
the lifetime expected credit losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company considers a financial
asset in default when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial
asset to be in default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual
amounts in full.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_26"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_28" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_27"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities measured at amortized cost:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_29" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_30" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_31" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_30"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities measured at fair value through profit or loss:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_32" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_33" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_34" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_33"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
    of financial liabilities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_35" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    instruments: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_36" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_35"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting
    financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_37" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_36"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.</p></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_38" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_37"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound
    financial instruments:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_39" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_38"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_40" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_39"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    of a unit of securities:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-35787"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="ixv-35802"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-35814"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value measurement: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="ixv-35922"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    taxes:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-36012"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and
other service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-36043"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-36099"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    employee benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment
    benefits:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-36138"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-36161"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:
    (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company as a lessee:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    extension and termination options:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    modifications:</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="ixv-36317"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForMeasuringInventories-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="ixv-36330"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">The
Company&#8217;s Brand sells products directly to customers mainly through the Brand&#8217;s online Amazon stores.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3" id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForRecognitionOfRevenue-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" id="ixv-36351"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_2" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" id="ixv-36394"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    3:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount
    rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental
borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar
security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there
are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk,
the lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
    the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable options pricing model (&#8220;OPM&#8221;). The inputs to the model
include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest
and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
    and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on
its management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are
based, among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best
professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the
outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    3:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
    and assumptions: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial
assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value
is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken
from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models
are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    of new standards in the period prior to their adoption:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18, &#8220;Presentation and Disclosure
in Financial Statements&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In April 2024, the International Accounting
Standards Board (&#8220;the IASB&#8221;) issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS
18&#8221;) which replaces IAS 1, &#8220;Presentation of Financial Statements&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is aimed at improving comparability
and transparency of communication in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 retains certain existing requirements
of IAS 1 and introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals.
It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation
of financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 does not modify the recognition
and measurement provisions of items in the financial statements. However, since items within the statement of profit or loss must be
classified into one of five categories (operating, investing, financing, taxes on income and discontinued operations), it may change
the entity&#8217;s operating profit. Moreover, the publication of IFRS 18 resulted in consequential narrow scope amendments to other
accounting standards, including IAS 7, &#8220;Statement of Cash Flows&#8221; and IAS 34, &#8220;Interim Financial Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is effective for annual reporting
periods beginning on or after January 1, 2027, and is to be applied retrospectively. Early adoption is permitted commencing from January
1, 2025, subject to disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is evaluating the effects
of IFRS 18, including the effects of the consequential amendments to other accounting standards, on its consolidated financial statements.</p></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-36571"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    4:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock" id="ixv-36581"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85410">1,383</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85411">1,866</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in
    NIS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85412">157</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85413">210</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85414">1,540</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85415">2,076</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="ixv-36639"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    5:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInventorieExplanatory" id="ixv-36649"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Goods in transit</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-85416">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInventoriesInTransit" scale="3" unitRef="usd" id="ixv-85417">73</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-85418">104</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="3" unitRef="usd" id="ixv-85419">669</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-85420">113</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="3" unitRef="usd" id="ixv-85421">742</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-36707"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    6:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
    ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclourseOfAccountsReceivablesTableTextBlock" id="ixv-36717"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Government authorities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:Governmentauthoritiescurrent" scale="3" unitRef="usd" id="ixv-85422">78</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:Governmentauthoritiescurrent" scale="3" unitRef="usd" id="ixv-85423">62</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-85424">449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-85425">203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-85426">350</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" unitRef="usd" id="ixv-85427">275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables in respect of downpayment on merger</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ReceivablesInRespectOfDownpaymentOnMerger" scale="3" unitRef="usd" id="ixv-85428">187</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Related party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-85429">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-85430">1,079</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="3" unitRef="usd" id="ixv-85431">540</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="ixv-36807"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    7:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT
    IN ASSOCIATES AND JOINT VENTURES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitoCareX
    - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $<ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-85432">700</ix:nonFraction>, and agreed to invest over the next two years, an additional $<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-85433">1,000</ix:nonFraction>, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a <ix:nonFraction contextRef="c81" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-85434">50.01</ix:nonFraction>% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InitialInvestment" scale="3" unitRef="usd" id="ixv-85435">700</ix:nonFraction> to MitoCareX. As of December 31, 2022, the Company owns
<ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingSharesPercentage" scale="-2" unitRef="pure" id="ixv-85436">31.48</ix:nonFraction>% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-85437">400</ix:nonFraction> in MitoCareX and increase its share ownership in MitoCareX Bio from <ix:nonFraction contextRef="c85" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-85438">31.48</ix:nonFraction>% to <ix:nonFraction contextRef="c86" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-85439">41.92</ix:nonFraction>%.</p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    7:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT
    IN ASSOCIATES AND JOINT VENTURES (CONT.)</b></span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitoCareX
    - Joint Venture Transaction (Cont.)</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSignificantInvestmentsInAssociatesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInvestment" scale="3" unitRef="usd" id="ixv-85440">600</ix:nonFraction> in MitoCareX and increased its share ownership in MitoCareX from <ix:nonFraction contextRef="c88" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-85441">41.92</ix:nonFraction>% to <ix:nonFraction contextRef="c89" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-85442">52.73</ix:nonFraction>%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $<ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalInstallment" scale="3" unitRef="usd" id="ixv-85443">600</ix:nonFraction> installment to be deferred to March 25, 2024, and the $<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentPaid" scale="3" unitRef="usd" id="ixv-85444">600</ix:nonFraction> installment was paid on March
11, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 26, 2024, the Company
signed a non-binding letter of intent relating to the sale of its entire ownership interest in MitoCareX to N2OFF, Inc. (&#8220;N2OFF&#8221;)
a publicly-traded company in the United States which is a related party (the &#8220;Purchaser&#8221;). Pursuant to the terms of the letter
of intent, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute
<ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" unitRef="pure" id="ixv-85445">27</ix:nonFraction>% of SciSparc&#8217;s ownership in MitoCareX, SciSparc will receive cash consideration of $<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashConsideration" scale="3" unitRef="usd" id="ixv-85446">700</ix:nonFraction>. Subsequent to this first phase, SciSparc
will transfer to the Purchaser the remaining <ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchaserRemainingOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-85447">73</ix:nonFraction>% of its ownership stake in MitoCareX in exchange for a certain number of shares based
on the valuation of the Purchaser equal to $<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RemainingPurchaserAmount" scale="3" unitRef="usd" id="ixv-85448">8,000</ix:nonFraction> and a valuation of MitoCareX equal to $<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RemainingPurchaserAmount" scale="3" unitRef="usd" id="ixv-85449">5,000</ix:nonFraction> (the latter of which includes the $<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CashConsideration" scale="3" unitRef="usd" id="ixv-85450">700</ix:nonFraction>,
in cash consideration for SciSparc&#8217;s shares described above). The letter of intent also includes provisions for additional milestones
that, upon achievement, may increase the consideration paid by the Purchaser to SciSparc from $<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85451">5,000</ix:nonFraction> to $<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85452">7,000</ix:nonFraction>. The details of the full
terms of this transaction are subject to negotiation and execution of definitive agreements.&#160;As of December 31, 2024, the Company
and the Purchaser have not closed the sale of the ownership of MitoCareX and the Company still holds <ix:nonFraction contextRef="c94" decimals="4" format="ixt:num-dot-decimal" name="sprcy:IssuedAndOutstandingSharePercentage" scale="-2" unitRef="pure" id="ixv-85453">52.73</ix:nonFraction>% of the issued and outstanding
share capital of MitoCareX. See also Note 25(d).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company recorded equity losses from the investment in MitoCareX in the amount of $<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85454">429</ix:nonFraction> (for the year ended December 31, 2023
- $<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85455">210</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="ixv-36882"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%">Investment date March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentsDate" scale="3" unitRef="usd" id="ixv-85456">700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-85457">109</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85458">591</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment following achievement of first milestone</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAchievementOfFirstMilestone" scale="3" unitRef="usd" id="ixv-85459">400</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-85460">210</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85461">781</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment following achievement of second milestone</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InvestmentAchievementOfSecondMilestone" scale="3" unitRef="usd" id="ixv-85462">600</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="3" sign="-" unitRef="usd" id="ixv-85463">429</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" unitRef="usd" id="ixv-85464">952</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory" id="ixv-36968"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    8:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT
    IN FINANCIAL ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Clearmind</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-85465">1,500</ix:nonFraction> in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85466">230,769</ix:nonFraction> common shares of Clearmind, resulting in the Company holding <ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-85467">9.33</ix:nonFraction>% of share capital of Clearmind. Shares of Clearmind are listed for trading on Nasdaq Capital Market and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, <ix:nonFraction contextRef="c102" decimals="0" format="ixt:fixed-zero" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-85468">no</ix:nonFraction> par value, at a ratio of <ix:nonNumeric contextRef="c103" name="sprcy:ReverseShareSplitRatio" id="ixv-85469">1-for-30</ix:nonNumeric>. As a result, the Company holdings in Clearmind decreased from <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85470">230,769</ix:nonFraction> common shares to <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85471">7,692</ix:nonFraction>. As of December 31, 2024, the listed share price of Clearmind on Nasdaq was $<ix:nonFraction contextRef="c0" decimals="-1" format="ixt:num-dot-decimal" name="sprcy:SharePricePerShare" scale="3" unitRef="usdPershares" id="ixv-85472">1.38</ix:nonFraction> and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2024 of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85473">11</ix:nonFraction> on its investment (for the year ended December 31, 2023 - $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85474">727</ix:nonFraction>). &#160;</p></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-37014"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    9:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 1, 2024, the Company entered
into a two-year lease agreement with for a total area of approximately <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AreaOfLease" scale="0" unitRef="sqm" id="ixv-85475">240</ix:nonFraction> square meters, whereby the Company occupies approximately
<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AreaOfLease" scale="0" unitRef="sqm" id="ixv-85476">120</ix:nonFraction> square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional
<ix:nonNumeric contextRef="c108" format="ixt-sec:durwordsen" name="sprcy:OptionToExtendLeaseTerm" id="ixv-85477">three-year</ix:nonNumeric> term. The monthly lease fee was set at approximately $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MonthlyLeaseFee" scale="3" unitRef="usd" id="ixv-85478">3</ix:nonFraction>, linked to the NIS.</p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="ixv-37028"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    10:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY
    AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-37038"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Computers</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Office<br/>
    furniture<br/> and<br/> equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Right
    of use asses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif">Cost:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Balance at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85479">11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85480">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85481">181</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85482">225</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85483">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85484">75</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85485">77</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Disposals</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85486">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85487">21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85488">181</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85489">203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85490">12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85491">12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85492">75</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85493">99</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Accumulated depreciation:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January&#160;1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85494">6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85495">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85496">106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85497">117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85498">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85499">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85500">28</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85501">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Disposals</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85502">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85503">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85504">106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85505">111</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85506">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85507">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85508">28</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85509">40</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Depreciated cost at December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85510">3</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85511">9</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85512">47</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85513">59</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85514">11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85515">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85516">78</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85517">122</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85518">103</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85519">103</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85520">11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85521">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85522">181</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85523">225</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Accumulated depreciation:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January&#160;1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85524">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85525">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85526">59</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85527">65</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85528">3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c149" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85529">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85530">47</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85531">52</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85532">6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85533">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85534">106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85535">117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Depreciated cost at December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85536">5</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85537">28</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85538">75</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-85539">108</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2024, 2023 and 2022 amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-85540">37</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-85541">52</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="3" unitRef="usd" id="ixv-85542">43</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="ixv-37565"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    11:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE
    ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the
Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-85543">4,540</ix:nonFraction> and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PaymentsOfAdditionalDeferredCash" scale="3" unitRef="usd" id="ixv-85544">1,120</ix:nonFraction> during the 12-month period following the closing of the Acquisition.
The Company paid an additional $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:PurchaseCostsValue" scale="3" unitRef="usd" id="ixv-85545">321</ix:nonFraction> as purchase costs.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    11:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE
    ASSET (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfIntangibleAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85546">4,861</ix:nonFraction> as an intangible asset, to be amortized over a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" id="ixv-85547">10</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline
in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-85548">1,344</ix:nonFraction> (as of December 31, 2023
- $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" unitRef="usd" id="ixv-85549">1,042</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="ixv-85550">7.8</ix:nonNumeric>
years (2023 &#8211; <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="ixv-85551">8.7</ix:nonNumeric>), commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections
were determined based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s
expectations that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter
of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-85552">27.8</ix:nonFraction>% (2023 &#8211; <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="sprcy:GrowthRatePercentage" scale="-2" unitRef="pure" id="ixv-85553">13.8</ix:nonFraction>%) and a declining growth rate for the long term, reaching <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-85554">2</ix:nonFraction>% (2023 &#8211; <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="sprcy:LongTermPercentage" scale="-2" unitRef="pure" id="ixv-85555">2</ix:nonFraction>%) at the terminal year. Theoretical
royalties arising from the brand were capitalized at a discount rate of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="sprcy:DiscountRatePercentage" scale="-2" unitRef="pure" id="ixv-85556">21.9</ix:nonFraction>% (2023 &#8211; <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="sprcy:DiscountRatePercentage" scale="-2" unitRef="pure" id="ixv-85557">20.6</ix:nonFraction>%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="ixv-37624"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85558">4,717</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85559">1,042</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85560">486</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85561">3,189</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85562">1,344</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Depreciation of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85563">366</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" unitRef="usd" id="ixv-85564">1,479</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2024, the Company recognized depreciation expenses in respect to intangible asset in the amount of $<ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-85565">366</ix:nonFraction> (for the year ended December
31, 2023 - $<ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" unitRef="usd" id="ixv-85566">486</ix:nonFraction>).&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-37693"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    12:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE
    PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfTradePayablesExplanatory" id="ixv-37703"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-85567">608</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-85568">538</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NetDebt" scale="3" unitRef="usd" id="ixv-85569">208</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NetDebt" scale="3" unitRef="usd" id="ixv-85570">264</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-85571">816</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="3" unitRef="usd" id="ixv-85572">802</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfOtherAccountsPayableTextBlock" id="ixv-37785"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    13:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
    ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="ixv-37795"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees
    and payroll accruals</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-85573">75</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="3" unitRef="usd" id="ixv-85574">48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-85575">130</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Accruals" scale="3" unitRef="usd" id="ixv-85576">104</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other
    payables</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="3" unitRef="usd" id="ixv-85577">33</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-85578">205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" unitRef="usd" id="ixv-85579">185</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-37864"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    14:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
    INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" id="ixv-37882"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">Financial assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash and restricted deposits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85580">1,560</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85581">2,141</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" unitRef="usd" id="ixv-85582">3,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-85583">449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherReceivables" scale="3" unitRef="usd" id="ixv-85584">203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" scale="3" unitRef="usd" id="ixv-85585">4,239</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financial assets at amortized
    cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-85586">6,248</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtAmortisedCost" scale="3" unitRef="usd" id="ixv-85587">5,344</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Investments in financial assets at
    fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" unitRef="usd" id="ixv-85588">871</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" unitRef="usd" id="ixv-85589">659</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Financial liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit from others</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-85590">75</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CreditFromOthers" scale="3" unitRef="usd" id="ixv-85591">48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-85592">191</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-85593">48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="3" unitRef="usd" id="ixv-85594">76</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financial and lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-85595">123</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="3" unitRef="usd" id="ixv-85596">315</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    14:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
    INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    of financial assets and financial liabilities: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="ixv-38119"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison
between the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2024, and 2023, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Investments in short-term financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85597">354</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85598">354</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85599">517</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85600">517</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85601">659</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#160;&#160;&#160;&#160;-&#8239;</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="3" unitRef="usd" id="ixv-85602">659</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-85603">191</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-&#8239;</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:WarrantsLiability" scale="3" unitRef="usd" id="ixv-85604">191</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Management believes that the carrying
amount of cash, short-term deposits, trade receivables, trade payables, overdrafts and other current liabilities approximate their fair
value due to the short-term maturities of these instruments.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    14:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
    INSTRUMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
    risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
    risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2024, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-38376"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    15:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE
    BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. <ix:nonNumeric contextRef="c0" continuedAt="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c0_cont_1" escape="true" name="sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" id="ixv-85605">These contributions and contributions for compensation represent defined contribution plans.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt">Expenses in respect of
    defined contribution plans</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-85606">106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-85607">105</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="usd" id="ixv-85608">115</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-38435"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    16:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES
    ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were <ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" unitRef="pure" id="ixv-85609"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" unitRef="pure" id="ixv-85610"><ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" unitRef="pure" id="ixv-85611">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2024, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward
    tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
net carryforward tax losses are estimated to be approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:OperatingLossCarryforwardsTaxAmount" scale="3" unitRef="usd" id="ixv-85612">62,000</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-38502"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    17:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT
    LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments
include: <ix:nonNumeric contextRef="c0" name="sprcy:DekelLicenseAgreementDescription" id="ixv-85613">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to
the Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention
to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect
the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for
a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined
under the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AnnualInvestment" scale="3" unitRef="usd" id="ixv-85614">350</ix:nonFraction>. The Amendment
also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive
Chairman of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $<ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AdditionalMilestoneAmount" scale="3" unitRef="usd" id="ixv-85615">75</ix:nonFraction>, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 5, 2024, SciSparc received
written notice from Dekel for the termination of the Dekel License Agreement, effective immediately, based on SciSparc allegedly breaching
its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the licensed products under
the Dekel License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 16, 2025, the Dekel License
Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc&#8217;s former directors, effective as of February
5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents,
know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License
Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    17:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT
    LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2" id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $<ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:InstallmentAmount" scale="3" unitRef="usd" id="ixv-85616">122</ix:nonFraction> out of a total estimated amount
of approximately $<ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-85617">776</ix:nonFraction>. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of
the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under
a new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $<ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-85618">1,385</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $<ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EstimatedAmount" scale="3" unitRef="usd" id="ixv-85619">370</ix:nonFraction>.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    17:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT
    LIABILITIES, COMMITMENTS, CLAIMS AND LIENS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="3" unitRef="usd" id="ixv-85620">16</ix:nonFraction> of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="0" unitRef="ils" id="ixv-85621">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c2" decimals="-4" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="6" unitRef="usd" id="ixv-85622">2.75</ix:nonFraction> million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December 31, 2024, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-38660"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    18:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-38676"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DisclosureOfClassesOfShareCapitalExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Issued and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Issued and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="-keep: true">Ordinary shares</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-85623">75,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-85624">515,631</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" unitRef="shares" id="ixv-85625">75,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-85626">33,652</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    18:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
    (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    of share capital: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to <ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85627">75,000,000</ix:nonFraction> ordinary shares with <span style="-sec-ix-hidden: hidden-fact-110">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, <i>inter alia</i>, a reverse split of the Company&#8217;s share
capital up to a ratio of <ix:nonNumeric contextRef="c172" name="sprcy:CapitalRatio" id="ixv-85628">30:1</ix:nonNumeric> (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85629">75,000,000</ix:nonFraction> ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-111">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be <ix:nonNumeric contextRef="c172" name="sprcy:ReverseSplitRatio" id="ixv-85630">26:1</ix:nonNumeric>, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfIssuedAndOutstandingShareCapital" id="ixv-38838"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> ordinary shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-keep: true">Balance at January 1, 2024</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85631">33,652</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-85632">175,110</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:ShareIssuedToAConsultants" scale="0" unitRef="shares" id="ixv-85633">30,770</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfShareCapitalInRespectSEPA" scale="0" unitRef="shares" id="ixv-85634">276,099</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85635">515,631</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    18:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
    (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
    attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders
meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    issuances of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">On August 2, 2022, the Company
issued a consultant <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85636">44</ix:nonFraction> ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">On November 1, 2022, the Company
issued a consultant <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85637">68</ix:nonFraction> ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">On March 22, 2023, the Company
issued <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85638">660</ix:nonFraction> ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered
into by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also Note 25a).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">During the year ended December
31, 2024, the Company issued <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85639">30,770</ix:nonFraction> ordinary shares to consultants in respect of services rendered in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-85640">105</ix:nonFraction></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $<ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-85641">10,210</ix:nonFraction> (the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of <ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="sprcy:IssuanceOfAggregateShares" scale="0" unitRef="shares" id="ixv-85642">6,495</ix:nonFraction> units and pre-funded units, as follows: (a) <ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-85643">614</ix:nonFraction> units at a price of $<ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-85644">1,542.48</ix:nonFraction> per unit, each consisting of (i)
one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateUnits" scale="0" unitRef="shares" id="ixv-85645">5,881</ix:nonFraction> pre-funded units at a price of $<ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="sprcy:AggregateUnitsPerShare" scale="0" unitRef="usdPershares" id="ixv-85646">1,539.09</ix:nonFraction> per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">The June 2022 Warrants have an
exercise price of&#160;$<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85647">1,435.98</ix:nonFraction>&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire <ix:nonNumeric contextRef="c181" format="ixt-sec:durwordsen" name="sprcy:IssuanceExpireTerm" id="ixv-85648">seven
years</ix:nonNumeric> from the date of issuance.&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    18:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
    (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    2022 Financing Round (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_4" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="ixv-39108"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85649">0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85650">0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85651">72</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85652">72</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85653">4.38</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85654">3.872</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    share price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85655">7.56</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85656">102.48</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85657">1,435.98</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85658">1,435.98</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    fair value ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd">192</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">Less than $1 thousand</ix:footnote></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">During the year ended December
31, 2022, the Company issued <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85661">5,881</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-85662">5,881</ix:nonFraction> pre-funded warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.25in; text-indent: 0in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">On August 14, 2023, the Company
closed an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85663">10,119</ix:nonFraction> ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-85664">109.20</ix:nonFraction>
per ordinary share and pre-funded warrants to purchase up to <ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85665">1,786</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-85666">108.654</ix:nonFraction> per pre-funded warrant,
for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateGrossProceeds" scale="3" unitRef="usd" id="ixv-85667">1,300</ix:nonFraction>, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85668">1,786</ix:nonFraction> ordinary shares solely to cover
over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $<ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" unitRef="usd" id="ixv-85669">5,026</ix:nonFraction>, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">In connection with the private
placement, the Company issued an aggregate of <ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85670">91,910</ix:nonFraction> units, each unit consisting of two pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;).
The Pre-Funded Warrants have an exercise price of $<ix:nonFraction contextRef="c189" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85671">0.021</ix:nonFraction>, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">During the year ended December
31, 2024, the Company issued <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85672">175,110</ix:nonFraction> ordinary shares in respect of the exercise of <ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="sprcy:WarrantsAndExercise" scale="0" unitRef="shares" id="ixv-85673">175,110</ix:nonFraction> Pre-Funded Warrants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    18:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
    (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2024 Standby Equity Purchase Agreement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">On January 21, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $<ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SaleOrIssueOfTreasuryShares" scale="3" unitRef="usd" id="ixv-85674">20,000</ix:nonFraction> of the Company&#8217;s ordinary shares (the &#8220;Advance Shares&#8221;). As of December
31, 2024, of the $<ix:nonFraction contextRef="c192" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CommitmentAmount" scale="3" unitRef="usd" id="ixv-85675">20,000</ix:nonFraction> eligible to be sold pursuant to the SEPA (the &#8220;Commitment Amount&#8221;), the Company has sold <ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="sprcy:SaleOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-85676">273,466</ix:nonFraction>
ordinary shares for total proceeds of $<ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="3" unitRef="usd" id="ixv-85677">6,255</ix:nonFraction>. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share
price of <ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="sprcy:SharePriceRate" scale="-2" unitRef="pure" id="ixv-85678">97</ix:nonFraction>% of the market price, which is defined as the lowest daily volume weighted average price of the Company&#8217;s ordinary
shares during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice
to YA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $<ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CommitmentAmount" scale="3" unitRef="usd" id="ixv-85679">5,000</ix:nonFraction> (each a &#8220;Pre-Paid Advance&#8221;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#8220;Promissory Note&#8221;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of <ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestRate" scale="-2" unitRef="pure" id="ixv-85680">5</ix:nonFraction>% per annum, increasing to
<ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestRate" scale="-2" unitRef="pure" id="ixv-85681">18</ix:nonFraction>% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InstallmentPayment" scale="-2" unitRef="pure" id="ixv-85682">10</ix:nonFraction>% of the original principal amount of the Promissory Note and accrued
interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such
notice against an equal amount of the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash,
the installment amount shall also include a payment premium in the amount of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PaymentForPremiumPercentage" scale="-2" unitRef="pure" id="ixv-85683">5</ix:nonFraction>% of the principal amount of the installment payment. The
Promissory Note contains the Company&#8217;s customary representations and warranties and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-keep: true">In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AggregateIssuedAmount" scale="0" unitRef="shares" id="ixv-85684">2,633</ix:nonFraction> of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-85685">200</ix:nonFraction>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-39341"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    19:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED
    PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" id="ixv-39359"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85686">45</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85687">34</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85688">264</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85689">524</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85690">162</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85691">633</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85692">569</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85693">196</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85694">897</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED
    PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    cost of share-based payment recognized in the financial statements: (Cont.)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2005 and 2015 ESOP and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="background-color: white">The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity-based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="-keep: true">On December 28, 2023, the Board
approved to reserve for <span style="background-color: white">issuance under the 2023 Plan <ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85695">47,619</ix:nonFraction> Ordinary Shares. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="-keep: true">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-keep: true">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-85696">326</ix:nonFraction> Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" unitRef="usdPershares" id="ixv-85697">3,549</ix:nonFraction> per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" id="ixv-39536"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February&#160;10,<br/>
    2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
    3,<br/>
    2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    ordinary share price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85698">2,724.54</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85699">3,674.58</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85700">0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85701">0</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85702">133</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85703">134</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85704">2.00</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85705">1.46</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life of Share Options (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-85706">6</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" unitRef="pure" id="ixv-85707">6</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="-keep: true">The fair value of the Share Options
granted on January 3, 2022, was set at $<ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-85708">3,325.14</ix:nonFraction> per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $<ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="sprcy:FairValueOfShareOptionsGranted" scale="0" unitRef="usdPershares" id="ixv-85709">2,407.86</ix:nonFraction> per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end
at April 21, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">During the year ended December 31,
2024, share-based compensation in respect of Share Options of $<ix:nonFraction contextRef="c202" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85710">7</ix:nonFraction> was charged to the consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="-keep: true">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-keep: true">During the year ended December 31, 2024, the Company issued consultants <ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85711">30,770</ix:nonFraction> ordinary shares in respect of services rendered. The shares were granted at a discount rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="sprcy:OrdinarySharesGrantedDiscountRate" scale="-2" unitRef="pure" id="ixv-85712">25</ix:nonFraction>% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $<ix:nonFraction contextRef="c204" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" unitRef="usd" id="ixv-85713">105</ix:nonFraction>.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED
    PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement
    during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-39721"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of<br/> Share<br/> Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> average<br/> exercise<br/>
    price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">2024:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options outstanding
    at the beginning of the year</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-85714">334</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85715">3,491.88</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options outstanding at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-85716">324</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85717">7,354.83</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options exercisable at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-85718">324</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85719">7,354.83</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">2023:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options outstanding at the beginning of the year</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-85720">336</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85721">3,488.94</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options cancelled during the year</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-85722">2</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85723">3,035.55</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options outstanding at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-85724">334</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85725">3,491.88</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Share Options exercisable at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-85726">279</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-85727">3,477.18</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-85728">2.99</ix:nonNumeric> years and <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-85729">4.03</ix:nonNumeric> years as of December 31, 2024, and 2023, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="-keep: true">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-keep: true">The range of exercise prices of Share Options outstanding at the end of the year was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:NumberOfOptionsOutstanding" scale="3" unitRef="usd" id="ixv-85730">3,549</ix:nonFraction> - $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:NumberOfOptionsOutstanding" scale="3" unitRef="usd" id="ixv-85731">444,759</ix:nonFraction> (inclusive) as of December 31, 2024, and 2023, respectively.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;19:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED
    PAYMENT TRANSACTIONS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted
                                            Share Units:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 1.25in"><span style="-keep: true">&#160;</span></td> <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 20, 2024, the Company granted <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-85732">25,238</ix:nonFraction> Restricted Share Units (&#8220;RSUs&#8221;) to directors and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s discretion and taking into account personal tax implications and convert into <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConvertIntoOrdinaryShares" scale="0" unitRef="shares" id="ixv-85733">25,238</ix:nonFraction> ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of <ix:nonNumeric contextRef="c205" format="ixt-sec:durwordsen" name="sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" id="ixv-85734">two years</ix:nonNumeric>, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on June 20, 2024, which was $<ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85735">18.753</ix:nonFraction>.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 1.25in"><span style="-keep: true">&#160;</span></td> <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2024, the Company granted <span style="-sec-ix-hidden: hidden-fact-117">25,238</span> RSUs to directors and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s discretion and taking into account personal tax implications and convert into <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ConvertIntoOrdinaryShares" scale="0" unitRef="shares" id="ixv-85736">25,238</ix:nonFraction> ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of <ix:nonNumeric contextRef="c206" format="ixt-sec:durwordsen" name="sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" id="ixv-85737">two years</ix:nonNumeric>, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August 8, 2024, which was $<ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85738">6.636</ix:nonFraction>.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="ixv-40110"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Balance, January 1, 2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left"><span style="-keep: true">RSUs granted</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" unitRef="pure" id="ixv-85739">50,476</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Expiry of RSUs</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Exercise of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">Balance, December 31, 2024</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-85740">50,476</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-keep: true">Total exercisable RSUs as of December
31, 2024, are <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-85741">12,619</ix:nonFraction>. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $<ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" unitRef="usd" id="ixv-85742">456</ix:nonFraction> was charged to the
Consolidated Statements of Comprehensive Loss.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="ixv-40211"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES
    AND COST OF REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s Brand sells products
directly to customers mainly through the Brand&#8217;s online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue
based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant
revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it
expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates
of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2024,
the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right
of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company
evaluates the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining
the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis
based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible
for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other
factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore,
sales are recorded on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" id="ixv-40227"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Cost of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Purchased goods</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c214" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85743">798</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85744">672</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85745">301</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Freight</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85746">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85747">11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c219" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85748">21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85749">800</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85750">683</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="3" unitRef="usd" id="ixv-85751">322</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAdditionalInformationExplanatory" id="ixv-40341"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:-
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL
    INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="ixv-40351"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">a.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Research and development expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85752">390</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85753">392</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85754">436</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85755">45</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85756">34</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85757">264</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory, professional and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85758">681</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85759">719</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85760">750</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and preclinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85761">211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85762">101</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85763">703</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Clinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85764">276</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85765">254</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85766">369</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85767">104</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85768">141</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85769">281</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85770">1,707</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85771">1,641</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-85772">2,803</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">b.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Sales and marketing expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Advertising</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85773">367</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c239" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85774">576</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c240" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85775">363</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amazon fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c241" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85776">495</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">1,042</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c243" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">454</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">*</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c244" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85779">366</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85780">486</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85781">144</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Storage and shipping</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85782">167</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c248" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">145</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd">91</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">*</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c250" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85785">120</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c251" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85786">235</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c252" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85787">30</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85788">1,515</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85789">2,484</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" unitRef="usd" id="ixv-85790">1,082</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">c.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">General and administrative
    expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85791">507</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85792">415</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c222" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85793">437</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85794">419</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85795">68</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85796">633</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and directors&#8217; fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c253" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85797">3,009</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c254" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85798">2,594</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c255" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85799">2,468</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Business development expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c256" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85800">108</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c257" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85801">86</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c258" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85802">161</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c259" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85803">158</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85804">202</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c261" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85805">162</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office maintenance, rent and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c262" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85806">128</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c263" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85807">110</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c264" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85808">80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c265" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85809">197</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c266" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85810">369</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c267" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85811">1,486</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85812">4,526</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,844</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-85814">5,427</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">d.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Other expenses (income):</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from sale of property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c268" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="3" sign="-" unitRef="usd" id="ixv-85815">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on sale of patent license, net
    (net of Polyrizon Ltd. holdings sold) (See also Note 25b)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c271" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-85816">1,287</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="3" unitRef="usd" id="ixv-85817">1,270</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">e.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Finance income:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in fair value of financial liabilities designated
    at fair value through profit or loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c274" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85818">191</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85819">2,205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c276" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85820">7,832</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest from loans to related parties and deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85821">421</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Exchange rate differences, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c281" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85822">14</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85823">612</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85824">2,219</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="3" unitRef="usd" id="ixv-85825">7,832</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">f.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Finance expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance expenses related to warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85826">1,204</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exchange rate differences, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c280" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85827">18</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c282" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85828">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Losses from remeasurement of investment in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c286" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85829">305</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c287" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85830">1,046</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85831">770</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense in respect of leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c289" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85832">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c290" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85833">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c291" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85834">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finance expenses from interest and
    commissions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c292" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85835">22</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85836">21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85837">353</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85838">1,055</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="3" unitRef="usd" id="ixv-85839">2,014</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-41156"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    22:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS
    PER SHARE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:EarningsPerShareExplanatory" id="ixv-41172"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_EarningsPerShareExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amounts used in the computation of basic and diluted&#160;loss</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left"><span style="-keep: true">Continuing operations:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="-keep: true">Basic loss per share</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-85840">277,380</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-85841">7,472</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-85842">19,413</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-85843">5,883</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-85844">8,379</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-85845">2,592</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Effect of potential dilutive ordinary shares</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Diluted loss per share</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-85846">277,380</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-85847">7,472</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-85848">19,413</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-85849">5,883</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-85850">8,379</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" scale="3" sign="-" unitRef="usd" id="ixv-85851">2,592</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the
    loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable
    warrants to investors.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-41704"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING
    SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Segment performance (segment income
(loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items
that are allocated directly to the segments and items that can be allocated on a reasonable basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried
out according to the results of the segment&#8217;s performance. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="ixv-41722"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drug
    <br/>
    Development</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Online
    <br/>
    Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">External</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-85852">1,306</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-85853">1,306</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85854">1,306</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85855">1,306</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Segment
    loss (gain)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85856">4,873</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85857">2,443</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85858">7,316</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity losses from the investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EquityLossesFromTheInvestment" scale="3" unitRef="usd" id="ixv-85859">429</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense (income), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-85860">259</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-85861">14</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85862">7,472</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drug
    <br/>
    Development</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Online
    <br/>
    Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">External</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-85863">2,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-85864">2,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85865">2,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85866">2,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Segment
    loss (gain)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85867">5,359</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85868">1,456</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85869">6,815</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Company&#8217;s share of losses of company accounted for at
    equity, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-85870">210</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense (income), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-85871">1,164</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-85872">22</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85873">5,883</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Drug Development Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the year ended December 31, 2024, the Company
recognized other income in the amount of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIntangibleAssets" scale="3" unitRef="usd" id="ixv-85874">1,288</ix:nonFraction> as a result of a sale of an intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Online Sales Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2023, and 2024,
the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of
the Brand and recognized a loss as a result of impairment to its intangible asset of $<ix:nonFraction contextRef="c295" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIntangibleAssets" scale="3" unitRef="usd" id="ixv-85875">1,344</ix:nonFraction> (as of December 31, 2023 - $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherIntangibleAssets" scale="3" unitRef="usd" id="ixv-85876">1,042</ix:nonFraction>).</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING
    SEGMENTS (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1"><ix:continuation id="_DisclosureOfEntitysReportableSegmentsExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Year
    ended December&#160;31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenues</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-size: 10pt">External</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-85877">1,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ExternalRevenues" scale="3" unitRef="usd" id="ixv-85878">1,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85879">1,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="3" unitRef="usd" id="ixv-85880">1,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c300" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85881">8,405</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" sign="-" unitRef="usd" id="ixv-85882">118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome" scale="3" unitRef="usd" id="ixv-85883">8,287</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Company&#8217;s share of losses
    of company accounted for at equity, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" scale="3" unitRef="usd" id="ixv-85884">109</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Finance expense (income), net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InterestRevenueExpense" scale="3" sign="-" unitRef="usd" id="ixv-85885">5,818</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" unitRef="usd" id="ixv-85886">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-85887">2,592</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85888">8,407</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85889">1,764</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85890">10,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-85891">1,194</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-85892">226</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-85893">1,420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85894">7,069</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85895">4,113</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85896">11,182</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-85897">1,441</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-85898">154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="3" unitRef="usd" id="ixv-85899">1,595</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="ixv-42667"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS
    AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="sprcy_RelatedPartyBalancetextBlock-c0_cont_1" escape="true" name="sprcy:RelatedPartyBalancetextBlock" id="ixv-42683"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="sprcy_RelatedPartyBalancetextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Key<br/>
    management<br/> personnel</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Other<br/>
    related<br/> parties</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Key<br/>
    management<br/> personnel</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Other<br/>
    related<br/> parties</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CurrentAsset" scale="3" unitRef="usd" id="ixv-85900">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CurrentAsset" scale="3" unitRef="usd" id="ixv-85901">121</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="3" unitRef="usd" id="ixv-85902">4,224</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="3" unitRef="usd" id="ixv-85903">108</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c329" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-85904">55</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-85905">245</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c331" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="3" unitRef="usd" id="ixv-85906">95</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="ixv-42806"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research
    and development expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-85907">63</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-85908">40</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" scale="3" unitRef="usd" id="ixv-85909">208</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale
    of minority interest in subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:SaleOfMinorityInterestInSubsidiary" scale="3" unitRef="usd" id="ixv-85910">2,985</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-42864"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term
    benefits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-85911">765</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-85912">1,204</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="3" unitRef="usd" id="ixv-85913">1,940</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management
    fees (see also note 25a)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-85914">120</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:KeyManagementPersonnelCompensationManagementFees" scale="3" unitRef="usd" id="ixv-85915">220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost
    of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-85916">157</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-85917">84</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" unitRef="usd" id="ixv-85918">779</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a <ix:nonFraction contextRef="c306" decimals="2" format="ixt:num-dot-decimal" name="sprcy:InterestPercentage" scale="-2" unitRef="pure" id="ixv-85919">49</ix:nonFraction>% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution, for $<ix:nonFraction contextRef="c307" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-85920">2,500</ix:nonFraction> in cash, and additional deferred cash payments of approximately $<ix:nonFraction contextRef="c307" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:DeferredCashPayment" scale="3" unitRef="usd" id="ixv-85921">489</ix:nonFraction> accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately <ix:nonFraction contextRef="c308" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-85922">51</ix:nonFraction>% of the share capital of SciSparc US.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, at the closing of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands provides management services to SciSparc US for the Wellution brand for a monthly fee of $<ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-85923">20</ix:nonFraction> and Jeffs&#8217; Brands received a one-time signing bonus in the amount of $<ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:BonusAmountReceived" scale="3" unitRef="usd" id="ixv-85924">51</ix:nonFraction>. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice. On November 2023 the monthly fee reduced to $<ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherFeeAndCommissionExpense" scale="3" unitRef="usd" id="ixv-85925">10</ix:nonFraction> thousand. For the year ended December 31, 2024, the Company has recorded management services expenses in the amount of $<ix:nonFraction contextRef="c310" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-85926">120</ix:nonFraction> (for the year ended December 31, 2023 - $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ServicesExpense" scale="3" unitRef="usd" id="ixv-85927">220</ix:nonFraction>).</p></td></tr>
</table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS
    AND BALANCES WITH RELATED PARTIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfRelatedPartyExplanatory-c0_cont_2" id="_DisclosureOfRelatedPartyExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-keep: true">In addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" unitRef="usd" id="ixv-85928">288</ix:nonFraction> of ordinary shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AcquiredOrdinaryShares" scale="0" unitRef="shares" id="ixv-85929">35,345</ix:nonFraction> ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired <ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="sprcy:AcquiredOrdinaryShares" scale="0" unitRef="shares" id="ixv-85930">660</ix:nonFraction> ordinary shares of the Company having an aggregate value of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValues" scale="3" unitRef="usd" id="ixv-85931">288</ix:nonFraction> which was adjusted from $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateValueAdjusted" scale="3" unitRef="usd" id="ixv-85932">300</ix:nonFraction> according to the <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-85933">4.99</ix:nonFraction>% ownership limit included in the definitive agreements. As of December 31, 2024, the listed share price of Jeff&#8217;s Brands on Nasdaq was $ <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ListedSharePrice" scale="0" unitRef="usdPershares" id="ixv-85934">2.57</ix:nonFraction>, and the Company has recorded a loss in its statements of comprehensive loss of $<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLossOnInvestment" scale="3" unitRef="usd" id="ixv-85935">17</ix:nonFraction> on its investment (for the year ended December 31, 2023 -$<ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:ComprehensiveLossOnInvestment" scale="3" unitRef="usd" id="ixv-85936">180</ix:nonFraction>).<br/> <br/> Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company&#8217;s Chief Technologies Officer, Mr. Weiss, the Company&#8217;s President, and Mr. Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2024 and 2023, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementAmount" scale="3" unitRef="usd" id="ixv-85937">63</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:CooperationAgreementAmount" scale="3" unitRef="usd" id="ixv-85938">40</ix:nonFraction>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $<ix:nonFraction contextRef="c314" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="6" unitRef="usd" id="ixv-85939">1.5</ix:nonFraction> million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="sprcy:ExchangeOfCommonShares" scale="0" unitRef="shares" id="ixv-85940">7,692</ix:nonFraction> common shares of Clearmind, representing <ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="sprcy:OutstandingShareCapital" scale="-2" unitRef="pure" id="ixv-85941">9.33</ix:nonFraction>% of the outstanding share capital of Clearmind (see also Note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Amitai Weiss, the Company&#8217;s chairman of the Board, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 13, 2024, the Company entered into the license agreement (the &#8220;License Agreement&#8221;) of the out-licensing of its SCI-160 program (the &#8220;Assets&#8221;), with Polyrizon Ltd. (the &#8220;Licensee&#8221; or &#8220;Polyrizon&#8221;). According to the License Agreement, the Company granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the &#8220;License&#8221;). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $<ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:LicenseeIssuePrice" scale="3" unitRef="usd" id="ixv-85942">805</ix:nonFraction>, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones relating to the Assets. <br/> <br/> Pursuant to the terms of the License Agreement, the Company is entitled to up to $<ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:MilestonesAmount" scale="3" unitRef="usd" id="ixv-85943">3,320</ix:nonFraction> based on the achievement of certain milestones, including <ix:nonNumeric contextRef="c315" name="sprcy:LicenseAgreementDescription" id="ixv-85944">(i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.</ix:nonNumeric> Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of <ix:nonFraction contextRef="c315" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfAggregateNetSales" scale="-2" unitRef="pure" id="ixv-85945">5</ix:nonFraction>%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country. <br/> <br/> On October 31, 2024, following an initial public offering of the Licensee, the Company received <ix:nonFraction contextRef="c316" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfUnitsReceived" scale="0" unitRef="shares" id="ixv-85946">684,931</ix:nonFraction> units, of which (i) <ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfUnitsReceived" scale="0" unitRef="shares" id="ixv-85947">320,000</ix:nonFraction> units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c318" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-85948">4.38</ix:nonFraction> (<ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85949">960,000</ix:nonFraction> warrants in total); and (ii) <ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfUnitsReceived" scale="0" unitRef="shares" id="ixv-85950">364,931</ix:nonFraction> units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c321" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-85951">4.38</ix:nonFraction> (<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85952">1,094,793</ix:nonFraction> warrants in total). Altogether, the Company received <ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85953">320,000</ix:nonFraction> ordinary shares, <ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85954">364,931</ix:nonFraction> pre-funded warrants to purchase one ordinary share of the Licensee, and <ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-85955">2,054,793</ix:nonFraction> warrants to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-85956">4.38</ix:nonFraction>. &#160; <br/> <br/> On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of <ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-85957">1,541,096</ix:nonFraction> Licensee common warrants to third parties, for aggregate consideration of $<ix:nonFraction contextRef="c325" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-85958">771</ix:nonFraction>. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. &#160; <br/> <br/> As of December 31, 2024, the Company holds <ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfWarrantsHolds" scale="0" unitRef="shares" id="ixv-85959">513,698</ix:nonFraction> warrants to purchase one additional ordinary share of the Licensee at a purchase price of $<ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-85960">4.38</ix:nonFraction>. The warrants expire on <ix:nonNumeric contextRef="c326" format="ixt:date-monthname-day-year-en" name="sprcy:WarrantsExpireDate" id="ixv-85961">October 31, 2029</ix:nonNumeric>. The value of the warrants on December 31, 2024, is $<ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" unitRef="usd" id="ixv-85962">517</ix:nonFraction>.<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Oz Adler, the Company&#8217;s Chief Executive Officer, is a director
of the Licensee.</p>
</td></tr>
</table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS
    AND BALANCES WITH RELATED PARTIES (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfRelatedPartyExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i> &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="ixv-43097"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    <br/> 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">October&#160;31,
    <br/> 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Dividend yield (%)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85963">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85964">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility (%)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85965">72</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85966">72</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c326" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85967">2.17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c323" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-85968">4.15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Underlying Share Price of Polyrizon Ltd. ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85969">0.36</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85970">4.38</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85971">4.38</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="usdPershares" id="ixv-85972">4.38</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants fair value ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c327" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" unitRef="usd" id="ixv-85973">517</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c333" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" unitRef="usd" id="ixv-85974">1,399</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2024, the Company entered into an Agreement and plan of merger, as amended (the &#8220;Merger Agreement&#8221;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#8217;s shareholders and AutoMax&#8217;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2024, SciSparc and AutoMax entered into the Merger Agreement addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024. On November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement second addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025. On March 27, 2025, SciSparc and AutoMax entered into the Merger Agreement third addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the effective time of the Merger (the &#8220;Effective Time&#8221;, as further defined in the Merger Agreement): (a)&#160;each outstanding share of AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of the Company, equal to the exchange ratio set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;). Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders immediately before the Merger (other than the Company) are expected to hold together approximately <ix:nonFraction contextRef="c328" decimals="4" format="ixt:num-dot-decimal" name="sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage" scale="-2" unitRef="pure" id="ixv-85975">49.99</ix:nonFraction>% (minus the Finder Fee, as defined in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of the Company on a fully diluted basis (subject to certain exceptions). The shareholders of the Company, together with the holders of the Company&#8217;s convertible securities, immediately before the Merger are expected to hold together approximately <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage" scale="-2" unitRef="pure" id="ixv-85976">50.01</ix:nonFraction>% of the aggregate number of the outstanding ordinary shares of the Company on fully diluted basis (subject to certain exceptions); (b) subject to the consummation of the Merger (as defined in the Merger Agreement, the &#8220;Closing&#8221;), and immediately after the Effective Time, AutoMax shall have the right to (i) designate two members to the Board if the Board is comprised of five or six directors; or (ii) designate three members if the Board is comprised of seven directors. At least one such designee shall be an independent director, as defined under the Nasdaq Stock Market listing rules. (See also Note 26b).</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" id="ixv-43209"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    25:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    EVENTS DURING THE REPORTING PERIOD</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"/> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2024, the Company announced that it signed a non-binding letter of intent with Miza III Ventures Inc. (&#8220;Miza&#8221;), a publicly traded company on the Toronto Stock Exchange Venture in Canada, which references a proposed asset and share purchase agreement, to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals. (collectively, the &#8220;Target Assets&#8221;)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement is based on the approximate total $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:EnterpriseValue" scale="3" unitRef="usd" id="ixv-85977">3,300</ix:nonFraction> (CAD <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="sprcy:EnterpriseValue" scale="6" unitRef="cad" id="ixv-85978">4.5</ix:nonFraction> million) enterprise value of Miza, when including its $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="3" unitRef="usd" id="ixv-85979">1,000</ix:nonFraction> cash position, and an approximate $<ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="3" unitRef="usd" id="ixv-85980">11,600</ix:nonFraction> (CAD <ix:nonFraction contextRef="c334" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="6" unitRef="cad" id="ixv-85981">15.8</ix:nonFraction> million) value of the Company&#8217;s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LOI, the Company will sell, assign, convey and transfer to Miza the Target Assets in consideration for <ix:nonFraction contextRef="c335" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-85982">63,300,000</ix:nonFraction> common shares of Miza and up to <ix:nonFraction contextRef="c336" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ConsiderationPaidReceived" scale="3" unitRef="usd" id="ixv-85983">48,000,000</ix:nonFraction> Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, the Company would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately <ix:nonFraction contextRef="c336" decimals="2" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-85984">75</ix:nonFraction>% to a maximum of <ix:nonFraction contextRef="c335" decimals="4" format="ixt:num-dot-decimal" name="sprcy:ShareCapitalPercentage" scale="-2" unitRef="pure" id="ixv-85985">84.53</ix:nonFraction>%, will be active in both the pharmaceutical and supplement sectors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 28, 2025, the Company entered into a second amendment (the &#8220;Miza Amendment&#8221;) to the non-binding letter of intent, as amended by the first amendment on December 16, 2024, with Miza. According to the Miza Amendment, the deadline to enter into definitive agreements was extended from March 31, 2025 to June 30, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.</p></td></tr>
</table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-43258"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS
    AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2025, the Company announced that it has reached a settlement agreement (the &#8220;Settlement&#8221;) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against six of the Company&#8217;s former directors (the &#8220;Defendants&#8221;) case number 34426-02-22 (the &#8220;Suit&#8221;). The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior acquisition of a pain clinic network through a subsidiary of the Company (See Note 17a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Settlement, which was facilitated through mediation and approved by the court, SciSparc will be entitled to a $<ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="3" unitRef="usd" id="ixv-85986">411</ix:nonFraction> cash payment from the Defendants, in exchange for the full dismissal by SciSparc of the alleged claims brought against the Defendants in the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Settlement also includes the termination, effective as of February 5, 2024 of a disputed licensing agreement with Dekel, entered into on May 21, 2015 and amended from time to time (the &#8220;License Agreement&#8221;). As part of the Settlement, Dekel clarified, to SciSparc&#8217;s full satisfaction, that SciSparc will retain its exclusive global rights to its extensive intellectual property portfolio, patents, know-how and technologies and is released from all alleged commitments, claims and royalties related or arising out of the License Agreement, including those related to claimed core technologies, ensuring a continued focus on SciSparc&#8217;s core development programs. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related whatsoever to the Company&#8217;s pipeline and development program.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2025, the Company announced that it has entered into a loan agreement with AutoMax to provide a $<ix:nonFraction contextRef="c338" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="3" unitRef="usd" id="ixv-85987">2,000</ix:nonFraction> loan (the &#8220;New Loan&#8221;). The funding will support AutoMax&#8217;s business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $<ix:nonFraction contextRef="c339" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateLoanAmount" scale="3" unitRef="usd" id="ixv-85988">4,250</ix:nonFraction> (the &#8220;Previous Loans&#8221;). The Previous Loans were provided in lieu of SciSparc&#8217;s obligation to provide a $<ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:AggregateLoanAmount" scale="3" unitRef="usd" id="ixv-85989">4,250</ix:nonFraction> closing financing, in accordance with the merger agreement signed between the parties. On March 27, 2025, SciSparc and AutoMax entered into a third addendum to the Merger Agreement, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan, bearing an <ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-85990">8</ix:nonFraction>% annual interest rate, will be repaid in equal monthly installments of $<ix:nonFraction contextRef="c342" decimals="-3" format="ixt:num-dot-decimal" name="sprcy:RepaidOfMonthlyInstallments" scale="3" unitRef="usd" id="ixv-85991">50</ix:nonFraction> and interest, commencing on March 24, 2025,with AutoMax retaining the option for early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the merger agreement, and thereafter AutoMax shall continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax has pledged a first-ranking fixed charge on its subsidiary&#8217;s shares.</p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company entered into securities purchase agreements (the &#8220;Securities Purchase Agreements&#8221;) with certain investors, pursuant to which the Company agreed to sell and issue to the investors convertible debentures (the &#8220;Debentures&#8221;) in the aggregate principal amount of $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NotionalAmount" scale="3" unitRef="usd" id="ixv-85992">4,200</ix:nonFraction> (the &#8220;Subscription Amount&#8221;), which are convertible into the Company&#8217;s ordinary shares, no par value per share (the &#8220;Ordinary Shares&#8221; and, as converted, the &#8220;Conversion Shares&#8221;), at a purchase price equal to <ix:nonFraction contextRef="c344" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PurchasePricePercentage" scale="-2" unitRef="pure" id="ixv-85993">95</ix:nonFraction>% of the Subscription Amount. The issuance and sale of the Debentures is subject to certain conditions and limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Debentures, when issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding principal balance of the Debentures at an annual rate of <ix:nonFraction contextRef="c345" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-85994">8</ix:nonFraction>%, which will increase to an annual rate of <ix:nonFraction contextRef="c346" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" unitRef="pure" id="ixv-85995">18</ix:nonFraction>% upon an Event of Default (as defined in the Debentures) for so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at the lower of (i) <ix:nonFraction contextRef="c344" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" scale="-2" unitRef="pure" id="ixv-85996">110</ix:nonFraction>% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii) <ix:nonFraction contextRef="c344" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" scale="-2" unitRef="pure" id="ixv-85997">95</ix:nonFraction>% of the lowest daily volume weighted average price of the Ordinary Shares during the twenty (<ix:nonNumeric contextRef="c344" format="ixt-sec:durday" name="sprcy:ConsecutiveTradingDays" id="ixv-85998">20</ix:nonNumeric>) consecutive trading days immediately preceding the conversion date or other date of determination (the &#8220;Market Price&#8221;); provided that the Market Price may not be lower than the floor price, which will be equal to <ix:nonFraction contextRef="c344" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" scale="-2" unitRef="pure" id="ixv-85999">20</ix:nonFraction>% of the volume weighted average price of the Ordinary Shares on the day prior to the closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the closing of the transaction, the Company issued to the investors <ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="sprcy:NumberOfWarrantsIssued" scale="0" unitRef="shares" id="ixv-86000">172,174</ix:nonFraction> warrants which are exercisable into a number of Ordinary Shares equal to the Subscription Amount applicable to the investors divided by a price equal to <ix:nonFraction contextRef="c348" decimals="2" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" scale="-2" unitRef="pure" id="ixv-86001">130</ix:nonFraction>% of the volume weighted average price of the Ordinary Shares immediately prior to the closing date, or $<ix:nonFraction contextRef="c347" decimals="4" format="ixt:num-dot-decimal" name="sprcy:VolumeWeightedAveragePricePerWarrant" scale="0" unitRef="usdPershares" id="ixv-86002">11.6172</ix:nonFraction> per warrant. The warrants are exercisable for a term of <ix:nonNumeric contextRef="c344" format="ixt-sec:durwordsen" name="sprcy:WarrantExercisableTerm" id="ixv-86003">five years</ix:nonNumeric> from the issuance date.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">On April 1, 2025, we entered into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement of Polyrizon and invested $<ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-86004">100,000</ix:nonFraction> (out of an aggregate investment of approximately $<ix:nonFraction contextRef="c349" decimals="-6" format="ixt:num-dot-decimal" name="sprcy:AggregateInvestment" scale="6" unitRef="usd" id="ixv-86005">17</ix:nonFraction> million), in exchange for ordinary shares and Series A warrants to purchase ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant to which we exchanged existing ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.</span></td></tr>
</table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>SCISPARC LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>USD in thousands (except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS
    AFTER THE REPORTING DATE (CONT.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfEventsAfterReportingPeriodExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company entered into a global guaranty agreement (the &#8220;Global Guaranty Agreement&#8221;) with one of the investors (the &#8220;Investor&#8221;) through certain of the Company&#8217;s subsidiaries, pursuant to which such subsidiaries will guaranty the Company&#8217;s obligations under the Debenture with the Investor and other instruments, agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.<br/> <br/> The Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the Company subsidiaries, pursuant to which the Company has agreed to provide to the Investor registration rights under the Securities Act of 1933, as amended (the &#8220;Act&#8221;) and the rules and regulations promulgated thereunder, and applicable state securities laws.<br/> <br/> In connection with the transaction, on February 25, 2025, the Company entered into a Deed of Assignment (the &#8220;Deed&#8221;) with AutoMax, and three of the investors. Pursuant to the Deed, the Company assigned part of the Subscription Amount in the amount of $<ix:nonFraction contextRef="c350" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:LoansReceived" scale="3" unitRef="usd" id="ixv-86006">2,000</ix:nonFraction> to AutoMax in lieu of making the payment under the Loan Agreement (the &#8220;Loan Agreement&#8221;) to which the Company entered into with AutoMax on February 24, 2025.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company announced it has signed a definitive agreement to sell its entire ownership interest in MitoCareX to N2Off, Inc., a publicly-traded company in the United States (Nasdaq: NITO) (&#8220;N2OFF&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which the Company and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX to N2OFF. As part of the agreement, the Company will sell <ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-86007">4,961</ix:nonFraction> shares of MitoCareX to N2OFF for $<ix:nonFraction contextRef="c352" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="3" unitRef="shares" id="ixv-86008">700</ix:nonFraction> and exchange its remaining shares for common stock in N2OFF. In total, the Company and the other sellers will receive N2OFF common stock equivalent to <ix:nonFraction contextRef="c344" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfFullyDilutedCapitalStock" scale="-2" unitRef="pure" id="ixv-86009">40</ix:nonFraction>% of the company&#8217;s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF&#8217;s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF&#8217;s control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company and the other sellers will be entitled to receive additional N2OFF stock based on milestone achievements, representing up to <ix:nonFraction contextRef="c353" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfFullyDilutedCapitalStock" scale="-2" unitRef="pure" id="ixv-86010">25</ix:nonFraction>% of N2OFF&#8217;s fully diluted capital stock. As part of the financial terms, the Company, along with the other sellers, will collectively receive <ix:nonFraction contextRef="c344" decimals="2" format="ixt:num-dot-decimal" name="sprcy:PercentageOfFinancingProceeds" scale="-2" unitRef="pure" id="ixv-86011">30</ix:nonFraction>% of N2OFF&#8217;s financing proceeds over five years, up to a maximum of $<ix:nonFraction contextRef="c344" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="3" unitRef="usd" id="ixv-86012">1,600</ix:nonFraction>. N2OFF has also committed to investing $<ix:nonFraction contextRef="c354" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InvestmentIncome" scale="3" unitRef="usd" id="ixv-86013">1,000</ix:nonFraction> in MitoCareX post-closing. Dr. Silberman will continue as CEO of N2OFF under a revised employment agreement, which includes a restricted stock grant of <ix:nonFraction contextRef="c343" decimals="2" format="ixt:num-dot-decimal" name="sprcy:RestrictedStockGrantPercentage" scale="-2" unitRef="pure" id="ixv-86014">5</ix:nonFraction>% of N2OFF&#8217;s capital stock, vesting over <ix:nonNumeric contextRef="c344" format="ixt-sec:durwordsen" name="sprcy:VestingPeriod" id="ixv-86015">three years</ix:nonNumeric>. The agreement contains customary representations, warranties, and provisions for termination if the closing does not occur within 30 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Amitay Weiss, who serves as the chairman of the Board, also serves as the chairman of the board of directors of N2OFF. In addition, Ms. Liat Sidi, who also serves as a member of the Board, also serves as a member of the board of directors of N2OFF.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - - - - - - - - - - -
- -</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div><a id="au_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="fin_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">AutoMax
Motors Ltd.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Consolidated
Financial Statements for</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">December
31, 2024</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="fin_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated Financial Statements for</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">December 31, 2024</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Table of Contents</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 418.9pt 0pt 0; text-align: right; text-indent: -390.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; vertical-align: top; width: 90%; text-align: center; direction: ltr; unicode-bidi: embed; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 1.5pt; vertical-align: top; width: 1%; text-align: center; direction: ltr; unicode-bidi: embed; text-indent: 0pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; width: 9%; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_001"><span style="font-family: Times New Roman, Times, Serif">Auditor&#8217;s
    report to the shareholders</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-56&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: right; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_002"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    statements of financial position</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-58&#8239;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: right; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_003"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    statements of profit and loss</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-60&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: right; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_004"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    statements of comprehensive income</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-61&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: right; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_005"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    statements of changes in shareholders&#8217; equity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-62&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: right; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_006"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    statements of cash flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-63&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: right; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-left: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-right: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: left; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><a href="#mm_007"><span style="font-family: Times New Roman, Times, Serif">Notes
    to the consolidated financial statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; vertical-align: top; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; text-align: center; direction: ltr; unicode-bidi: embed; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">F-66&#8239;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="fin_003.jpg" style="width: 850px; height: 130px"/>&#160;</b></p><div>

</div><div><a id="mm_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Auditors&#8217; Report</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">To the shareholders of </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance sheets
of AutoMax Motors Ltd. (hereafter: &#8220;the Company&#8221;) as of December 31, 2024 and 2023, and the related statements of profit
and loss, statements of changes in equity and statements of cash flow for the years then ended. These financial statements are the responsibility
of the Company&#8217;s Board of Directors and Management. Our responsibility is to express an opinion on these financial statements based
on our audits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the AICPA. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the board
of directors and management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the financial statements referred
to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023 and the results
of its operations, the changes in equity and cash flow for those years ended, in conformity with International Financial Reporting Standards
(IFRS) and the provisions of the Securities Regulations (Annual Financial Statements), 2010.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without qualifying our above opinion, we refer
to note 21(a) to the financial statements regarding the indictment that was filed against the company Global AutoMax Ltd. along with
its officers, for suspicions of committing offenses as detailed in the note, and also to what is stated in note 1(d) regarding the company&#8217;s
financial situation, the company&#8217;s losses and regarding the steps the company is taking in order to meet its obligations. The company
estimates that its financial strength, together with its financial sources and taking the actions detailed in the note, will allow it
to continue to finance its activities and meet its obligations in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Key matters in the audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Key matters in the audit are matters that were
communicated, or were required to be communicated, to the company&#8217;s board of directors and which, according to our professional
judgment, were most significant in the audit of the consolidated financial statements for the current period. These matters include,
among other things, any matter which: (1) relates, or may relate, to material sections or disclosures in the financial statements and
(2) our judgment regarding it was particularly challenging, subjective or complex. These matters are answered as part of our audit and
formation of our opinion on the consolidated financial statements as a whole. The communication of these matters below does not change
our opinion on the consolidated financial statements as a whole and we do not use it to give a separate opinion on these matters or on
the sections or disclosures to which they refer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="fin_004.jpg" style="width: 850px; height: 117px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="fin_003.jpg" style="width: 850px; height: 130px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vehicle inventory</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in note 8 to the consolidated financial
statements, as of December 31, 2024, the balance of the vehicle inventory amounts to approximately 209,798 thousand NIS and constitutes
approximately 57% of the total assets in the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, as described in note 2(9), the company&#8217;s
management measures the inventory according to the lower of cost or net realizable value. The inventory cost includes the expenses for
purchasing the inventory and bringing it to its current location and condition. Net realizable value is the estimate of the sale price
in the normal course of business minus the estimate of costs for completion and costs necessary to carry out the sale. Vehicle inventory
cost is determined based on a specific cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the materiality of the vehicle inventory
balance in the consolidated financial statements and due to the fact that the audit of the inventory is an essential part of the audit
work, we determined, according to our professional judgment, that the examination of the existence and evaluation of the inventory as
of December 31, 2024 is a key matter in the audit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The audit procedures carried out in response
to the key matter in the audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit procedures we performed, related to
this key matter, included, among others, the following procedures: understanding the internal control environment regarding the vehicle
inventory registration process; Attending the company&#8217;s inventory counts and sampling inventory details for the purpose of checking
their existence; receiving direct counting approvals from external websites; checking vehicle inventory costs and their book value; Assessing
the adequacy of the disclosure in the consolidated financial statements; Checking that inventory items are shown according to the lower
of cost or net realizable value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Examining the decline in value of the company&#8217;s
assets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a continuation of Notes 2(13) and 2(15), the
company identified signs of asset impairment and performed an asset impairment assessment, in accordance with the requirements of International
Accounting Standard IAS 36, through a comparison between the book value of the cash-generating unit and its recoverable amount. We identified
the examination of the decline in value of the company&#8217;s assets, as of December 31, 2024, as a key matter in the audit. Determining
the recoverable amount for the aforementioned cash-generating units involved a great deal of subjective judgment, since changes in the
assumptions can have a material effect on the result of the examination of the decline in value of the cash-generating units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The audit procedures carried out in response
to the key matter in the audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit procedures we performed, related to
this key matter, included, among others, the following procedures: understanding of processes and the control environment, regarding
the examination of impairment by the company; Examining the adequacy of the identification of the cash generating units; Examining the
methodology used in determining the refundable amount; assessment of the skills, experience and independence of the valuer on behalf
of the Company&#8217;s Management; Assessing the plausibility of the significant assumptions underlying the works to examine impairment;
Performing a sensitivity analysis regarding the Management&#8217;s significant assumptions used in the valuation; due diligence of the
book value and value in use of the cash-generating units; Examination of the adequacy of the disclosures in the financial statements
related to the examination of the decrease in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sincerely,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><img alt="" src="fin_005.jpg" style="width: 200px; height: 78px"/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 28%"><b>Ben David Shalvi, Kop &amp; Co.</b></td>
  <td style="width: 34%">&#160;</td>
  <td style="width: 38%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><b>Certified Public Accountants, (Isr.)</b></td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td><b>Jerusalem,</b></td>
  <td/>
  <td style="text-align: right">Jerusalem, March 27, 2025</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="fin_004.jpg" style="width: 850px; height: 117px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="mm_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">AutoMax
Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of financial position</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Note</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="text-decoration:underline">Current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,486</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,552</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Customers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">6</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,552</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables and debit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">66,593</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34,801</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivable current taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,023</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vehicle inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">209,798</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">183,647</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Indemnity asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">307,786</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">249,575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Non-current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment in companies handled according to the book value
    method</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">9</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,482</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,489</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right-of-use assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fixed assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">11</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,561</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,871</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,453</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,119</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term deposits in banking corporations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">13</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,242</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payment for credit balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financial asset stated at fair value through profit and loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">172</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">172</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">24</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,005</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Long-term prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">582</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">57,110</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">55,741</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">364,896</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">305,316</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of financial position</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Note</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="text-decoration:underline">Current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Short term credit from banking corporations and
    financing bodies</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">14</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">175,683</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">141,430</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current maturities of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,775</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Suppliers and service providers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">15</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29,045</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,169</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and credit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">16</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48,286</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loan given as an advance on the merger transaction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">21B (16)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,593</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payable current taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,183</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Liability for bonds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,371</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,849</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">289,162</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">216,043</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Non-current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term credit from banking corporations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">17</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,241</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,807</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term liabilities with respect to lease</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,919</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,329</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loans from non-controlling shareholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">18</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,037</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">985</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liability for bonds</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">19</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,344</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34,598</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities for employee benefits, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">20</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">57</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Deferred taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">24</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">635</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,233</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,859</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Total equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Total equity attributed to Company
    shareholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">22</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share premium</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78,467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78,467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,845</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,845</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Capital reserve funds</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(240</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,136</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,014</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Retained loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(72,336</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(68,636</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total equity attributable to company
    shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,056</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">36,562</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Non-controlling rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,148</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30,501</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,414</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">364,896</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">305,316</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; width: 25%; text-align: center; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">27.03.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; width: 1%; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center; direction: ltr; unicode-bidi: embed; width: 24%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; width: 1%; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center; direction: ltr; unicode-bidi: embed; width: 24%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: top; width: 1%; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; vertical-align: bottom; text-align: center; direction: ltr; unicode-bidi: embed; width: 24%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date
                                            of approval</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of financial statements</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Daniel
                                            Levy</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CEO</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amitay
                                            Weiss</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chairman of the Board</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; direction: ltr; unicode-bidi: embed">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ya&#8217;ara
                                            Alfie</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CFO&#160;</p></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="mm_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of profit and loss</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the
    year ended on December 31,</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Note</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Revenues</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center; text-indent: 0pt; padding-left: 0pt">25</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">398,173</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">418,932</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">453,617</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cost of sales</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">26</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(347,079</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(381,089</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(392,918</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross profit</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">51,094</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37,843</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,699</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sales and marketing expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">27</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,621</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,194</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,612</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">28</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,728</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,965</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,849</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Granting options to employees</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,549</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,976</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other incomes</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">29</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,022</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,557</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">226</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operational profit (loss)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,645</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,308</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,488</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing expenses</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">30</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,446</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,831</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,935</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Financing incomes</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 0pt">30</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,025</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,722</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,703</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing expenses, net</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14,421</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,109</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,232</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Company&#8217;s share in losses of companies handled according
    to the book value method</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,118</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(600</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(585</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Profit (loss) before taxes on income</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">106</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,017</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">671</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(Taxes on income) tax benefit</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,213</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(358</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,931</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Profit (loss) for the year</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,107</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,375</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,260</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual profit (loss) allocation:</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">For company shareholders</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,700</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,384</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-controlling shareholders</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,407</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(991</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(156</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(5,107</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(17,375</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,260</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>Profit (loss)
    per share attributable to the Company&#8217;s shareholders&#160;number of shares</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">103,691,970</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">77,377,503</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">47,785,204</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Profit (loss) per share in ILS</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt; padding-left: 0pt">31</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.21</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Profit (loss) for the year</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; text-indent: 0pt; padding-left: 0pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,700</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">16,384</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,104</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="mm_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of comprehensive
income</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                            31st</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Loss for the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(5,107</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(17,376</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(1,260</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other comprehensive income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Items not reclassified as profit or loss:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Recalculation of net liability with
    respect to employment termination</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">118</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">98</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other comprehensive annual
    income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">118</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">98</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total annual comprehensive income (loss)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,035</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">17,258</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,162</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total annual comprehensive income (loss):</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">For Company shareholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,628</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,266</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,006</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">For non-controlling shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,407</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(991</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(156</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,035</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,258</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,162</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>


</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="mm_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated statements of changes in shareholders&#8217;
equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Share
    capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares
    premium</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option
    warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital
    reserve funds</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Share-based
    payment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Retained
    loss</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total
    equity attributed to Company shareholders</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-controlling
    interest rights</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 19%">Balance
    as of Jan. 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">5,184</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">78,467</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">1,845</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(312</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">20,014</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(68,636</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">36,562</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(1,148</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">35,414</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based
    payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other total
    income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss
    for the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,700</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,700</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,407</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,107</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance
    as of December&#160;31,&#160;2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,184</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">78,467</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,845</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(240</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,136</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(72,336</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">33,056</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(2,555</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">30,501</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Share
    Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares
    premium</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option
    warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital
    reserve funds</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Share-based
    payment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Retained
    loss</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total
    equity attributed to Company shareholders</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-controlling
    interest rights</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 19%">Balance
    as of Jan. 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">2,389</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">67,382</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">1,457</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(430</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">17,465</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(52,252</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">36,011</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(156</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">35,855</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of
    shares and allocation of options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">388</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">388</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">388</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of
    shares via private offer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,114</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,766</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,880</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,880</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of
    shares according to milestones</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,681</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,681</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based
    payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,549</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,549</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,549</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other total
    income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss
    for the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,384</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,384</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(992</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,376</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance
    as of December&#160;31,&#160;2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,184</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">78,467</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,845</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(312</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,014</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(68,636</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">36,562</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,148</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">35,414</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: center; padding-bottom: 1.5pt; width: 19%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Share
    Capital</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Shares
    premium</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Option
    warrants</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Capital
    reserve funds</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Share-based
    payment</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Retained
    loss</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Total
    equity attributed to Company shareholders</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Non-controlling
    interest rights</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><b>Total</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balance as for
    Jan. 1, 2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,389</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">67,382</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,457</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(413</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,488</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(51,148</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,155</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,155</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based
    payment</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,977</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,977</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,977</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other total
    income</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">98</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">98</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">98</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Allocation of
    rights to shares</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(115</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(115</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(115</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss
    for the period</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(156</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,260</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance
    as for December&#160;31,&#160;2022</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,389</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">67,382</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,457</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(430</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">17,465</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(52,252</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">36,011</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(156</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">35,855</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>

</div><div><a id="mm_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated Statements of Cash Flows</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                            31,</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="text-decoration:underline">Cash flow from current operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Loss for the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(5,107</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(17,375</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(1,260</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Adjustments that are required to present
    net cash flows from operating activities (Appendix A)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(31,602</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,516</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(96,782</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash generated by (used for) operating
    activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,709</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,141</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(98,042</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Cash flows from investment
    activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Purchase of fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,049</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,951</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,810</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Entry into Consolidation (Appendix C)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">465</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Withdrawal (investment) in affiliated companies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(521</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,268</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14,534</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment in financial asset calculated at fair value through
    profit and loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(172</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Withdrawing (depositing) a long-term deposit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment in intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(854</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,416</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(923</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Consideration for realization of fixed assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">115</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,703</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">460</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Acquisition of leased assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Payment for credit balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,164</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash used for investing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,537</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(353</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,453</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Cash flows from financing
    activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loan given as an advance on the merger transaction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,880</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receipt (repayment) of short-term credit from banking corporations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,749</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(391</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77,874</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Repayment of liabilities for lease agreements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,839</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,272</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,785</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receipt (repayment) of long-term loans from banking corporations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,822</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,969</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,446</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Assignment of minority rights</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(151</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(767</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">(Repayment) issuance of bonds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,849</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,567</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,015</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash generated by (used for) financing
    activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,180</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,470</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">115,891</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Decrease in cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(66</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(604</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents as for the
    beginning of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,552</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,234</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,838</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents for year
    end</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,486</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,552</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,234</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated Statements of Cash Flows</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Appendix A - Adjustments required for the
presentation of net cash flows from operating activities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on December 31,</b></p>

</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="text-decoration:underline">Incomes and expenses that do not involve cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Depreciation and amortizations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">10,778</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">10,392</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">8,182</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">293</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">421</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other incomes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(31</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(104</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,549</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">The Group&#8217;s share in the results of companies handled
    according to the book value method, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">585</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net financing expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">790</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,939</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,662</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,396</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,668</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Changes in assets and liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase in vehicles inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,551</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(97,082</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Decrease (increase) in accounts receivable and debit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(31,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,806</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,238</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase in trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10,021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,733</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,253</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase (decrease) in suppliers and service providers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,876</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,949</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,403</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and credit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,634</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,743</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase in long-term prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(391</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase in employee&#8217; benefits and employee related
    provisions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Increase (decrease) in current payable
    taxes to receive (to pay)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,180</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,355</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,332</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(48,998</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,848</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(118,382</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(31,602</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">20,516</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(96,782</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes constitute an integral
part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Consolidated Statements of Cash Flows</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Appendix B - Non-cash transactions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                            31,</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt">Increase in right-of-use
    assets against lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">570</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6,188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,202</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Payment for credit balance	</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,690</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration:underline">Appendix C - Entry into Consolidation</span></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Working capital not including cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">167</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">613</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fixed assets and intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">938</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balances with respect to lease, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loan from related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,780</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Goodwill</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">764</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">465</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes
constitute an integral part of the financial statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><div><a id="mm_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>A. <span style="text-decoration:underline">Company description</span>:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated in 2006 and until
December 2019, it offered and supplied, together with its subsidiaries, a variety of proprietary programmatic data-driven platforms that
focused on two main activities of domain monetization and mobile digital advertising for advertisers, advertising agencies, application
developers, and domain owners, mainly in the US and in European countries. Its ordinary shares were traded on the London Stock Exchange
(&#8220;LSE&#8221;) and on the Tel Aviv Stock Exchange Ltd. (&#8220;TASE&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 23, 2020, trading in the Company&#8217;s
shares was suspended on the LSE and TASE exchanges. On November 25, 2020, trading resumed on the TASE as part of the list for limited
trading (retention list) and on January 12, 2021, the Company&#8217;s shares returned to general trading on the main list of TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 23, 2020, the Company&#8217;s shares
were delisted from trading on the LSE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period between the middle of 2017
and up to December 2019, the Company sold all of its activities in the field of digital advertising.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of the completion of the merger
transaction with Global Automax (as detailed in Note 1(c) hereunder), the Company is engaged, through Global Automax Ltd, a fully controlled
subsidiary, in the import to Israel and in the marketing of a variety of private and commercial vehicles models. In addition, the Company
is also engaged in the direct import and marketing in Israel of private vehicles by Anhui Jianghuai Automobile Group Corp. LTD (&#8220;JAC
Motors&#8221;) (through Automax Direct Import Ltd. (for further details, see Note 21B(21) below), in the direct import and marketing
in Israel of TEMSA SKODA SABANCI ULASIM ARACLARI A.S. (&#8220;Temsa&#8221;) buses (through Dalhom Automax (as defined below), and the
purchase and sale of used vehicles (trade-in) (through Automax Trade In (as defined below). Regarding the merger with Global Automax
Ltd., see Note 1(c) hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021, the Company changed its name
from Matomy Media Group Ltd. to AutoMax Motors Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following are details of companies held by the
Company as of the reporting date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Global
                                            Automax Ltd. - holding 100% of the issued and paid-up capital, a private company incorporated
                                            and registered in Israel (hereinafter: &#8220;Global Automax&#8221;) in 2014.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Automax
                                            Trade In Ltd. (hereinafter: &#8220;Automax Trade In&#8221;) - holding 80% of the issued and
                                            paid-up capital, a private company incorporated and registered in Israel in 2022.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dalhom
                                            Automax Ltd. (hereinafter: &#8220;Dalhom Automax&#8221;) - holding 50% of the issued and
                                            paid-up capital, a private company incorporated and registered in Israel in 2022.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Automax
                                            Leasing Ltd. - holding 100% of the issued and paid-up capital, a private company incorporated
                                            and registered in Israel in 2022.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Description of Global Automax Ltd.:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Global Automax was incorporated in Israel in
2014 as a private company in accordance with the provisions of the Companies Law, 1999 (hereinafter: &#8220;the Companies Law&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The head offices of Global Automax are situated
in Jerusalem. As of the day of its incorporation, Global Automax has been engaged in importing into Israel and marketing a variety of
private vehicle models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Global Automax has an indirect and direct importer
license, as defined in Paragraph 42 of the Services and Professions Licensing in the Automotive Industry Law, 5766-2016 (hereunder: &#8220;Automotive
Services Licensing Law&#8221;) for 37 vehicle in a variety of models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of signing the financial statements,
Global Automax operates through eight car sales centers located in Jerusalem, Rishon Le-Zion, Afula, Haifa, Ra&#8217;anana, Acre, Netanya,
and Ashdod, and operates a storage complex and a vehicle preparation - pre-delivery inspection (PDI) system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the financial statements period, the Company
closed its branches in Ashkelon and Petah Tikva (which were closed since the outbreak of the Iron Swords War), in Beer Sheva <span style="font-size: 10pt">&#160;&#160;&#160;</span>(due
to the end of an agreement with an authorized distributor who operated this branch), and also after the financial statements period,
the branch in Galilot, which served as a trade-in center and for the sale of new vehicles. It should be clarified that as of the closure
of the branch in Galilot, trade-in operations are not being conducted within the framework of the existing Company&#8217;s branches.
The Company estimates that the closing of these branches has no significant impact on the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following are details of companies held by Global
Automax as of the reporting date:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Automax
                                            Fleets Ltd. (formerly IDV Vehicle Importers Ltd.) - 100% ownership of the issued and paid-up
                                            capital, a private company incorporated and registered in Israel in 2019.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Automax
                                            HaSharon (2021) Ltd. (hereinafter: &#8220;Automax HaSharon&#8221;) - holding of 67% of the
                                            issued and paid-up capital. A private company incorporated and registered in Israel in 2021.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Automax
                                            HaShfela Ltd. - holding 50% of the issued and paid-up capital, a private company incorporated
                                            and registered in Israel in 2022.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Automax
                                            Leasing and Car Rental Ltd. - holding 100% of the issued and paid-up capital, a private company
                                            incorporated and registered in Israel in 2023.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Merger with Global Automax</span>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2021, the merger transaction was
completed, under which the Company allocated shares to the controlling shareholders of the Company (former shareholders of Global Automax),
in exchange for the transfer to the Company of 100% of the share capital of Global Automax - ordinary shares which immediately after
their allocation constituted 52.53% of the Company&#8217;s issued and paid-up share capital, as well as rights to the allocation of additional
shares upon the fulfillment of milestones set in the merger agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 28, 2023, in light of the Company&#8217;s
fulfilment of milestones number 2 and 3, stipulated in the merger agreement, the Company allocated additional ordinary shares of the
Company to the controlling shareholders, which together constituted approximately 41% of the issued and paid-up capital of the Company
after the allocation. As of the date of signing the financial statements, the controlling shareholders of the Company collectively hold
approximately 55.65% of the issued and paid-up share capital of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2025, the options granted to the
Company&#8217;s officers in connection with the merger transaction with Global Automax expired. For further details, see Note 33c (events
after the balance sheet date).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Effect of changes in the business environment
on the Group&#8217;s activities and the Group&#8217;s business condition</span>:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company imports its inventory of vehicles
from various suppliers, from Europe and North America. Its revenues are derived from the sale of vehicles in Israel in ILS. Therefore,
the Company is exposed to depreciation in the exchange rate of the shekel (ILS) against foreign currencies, from which vehicles are imported.
In light of the trend of decline in the exchange rate of the shekel against foreign currencies that the Company is exposed to since the
beginning of 2023, the Company has changed the mix of vehicles it imports and the purchase currencies (in accordance with the changes
in the market). In addition, the Company implements a currency risk management policy which is designed to reduce these exposures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From the second quarter of 2022 and until the
second quarter of 2023, inter alia due to the emergence of a number of economic and geopolitical events that affected price levels worldwide,
there was a sharp increase in inflation (during the 12-months period between March 2023 and March 2024, the consumer price index in Israel
rose by 5%). The increase in the consumer price index in Israel in 2024 amounted to 3.2% compared to 3% in 2023. According to the Bank
of Israel forecast, inflation is projected to be 2.6% in 2025, and 2.3% in 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In response to the increase in prices and subsequently
to the interest rate increases by the central banks in Europe and the USA, starting in April 2022, the Bank of Israel decided to raise
the Bank of Israel&#8217;s interest rate, and it increased the rate several times from a rate close to zero (which prevailed for about
7 years) to a rate of 4.75% per year. In January 2024, the Bank of Israel decided to lower the annual interest rate by 0.25% to a level
of 4.5%, which also applies at the time of the statement&#8217;s publication. According to the Bank of Israel forecast, the Bank of Israel
interest rate is expected to average 4.0/4.25% in the fourth quarter of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The credit lines provided by banking corporations
to the companies within the Group bear interest at the rate of the prime interest rate (which is the Bank of Israel&#8217;s interest
plus 1.5%. At the time of the publication of the financial statements, the prime interest rate is 6%), plus a specific rate, as agreed
during deliberations with the banking corporations upon actual takeout of the credit. This rate is influenced, inter alia, by the market
interest rate, the credit volume, and the bank&#8217;s familiarity with the Company. Therefore, the increase in the Israeli interest
rate has led to a rise in the Group&#8217;s financing costs, which may affect the financial results of the Group and its profitability.
However, the Company does not expect that a higher interest rate environment will pose a practical obstacle in obtaining credit from
banks or other financing entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, the high interest rate environment and
the effects of the Iron Swords War, especially if the war continues or expands, are expected to slow down the growth rate of the market
in general and the Company in particular, as well as cause a decline in private consumption. In a forecast published in January 2025
by the Research Department of the Bank of Israel, the Israeli growth rate in 2024 is expected to be 0.6% (a decrease of 0.1% compared
to the forecast published in October 2024), and the rate of growth in private consumption is expected to increase from a negative rate
of 0.9% in 2023, to 4% in 2024, and to 7.5% in 2025. (A decrease of 1% and 0.5%, respectively, compared to the forecast published in
October 2024). High inflation and interest rates may negatively affect the Company&#8217;s sales pace and consequently its profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the first quarter of 2023, the new government
began promoting a plan to make fundamental changes to the legal system in Israel, culminating in the Knesset&#8217;s approval of the
Basic Law: The Judiciary (Amendment No. 3) (constricting the reasonableness standard), without agreement with the opposition, in a manner
that provoked public criticism and widespread protests, and its annulment on January 1, 2024 by the Supreme Court. The proposed changes
aroused widespread controversies and criticisms, which may, according to various publications by international credit rating companies
(such as Moody&#8217;s), financial bodies, senior economists in the market, heads of academia and experts in the fields of law, economics
and society in Israel, influence the stability of the economy and the market in Israel. These changes, along with other factors detailed
below, have led to a downgrading of Israel&#8217;s credit rating by international rating agencies, as well as downgrading of rating forecasts
by these agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such changes may have a negative impact on the
economic environment in which the Company operates, on the cost of financing sources, on the credit rating of the Israeli market, and
more. However, since these are changes, most of which have not yet been enacted or entered into force, the extent of their impact on
the Israeli economy and the automotive industry in general and the Company in particular, are unknown and cannot be assessed at this
stage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the second quarter of 2023, the Company
is working to reduce the cost of vehicle inventory per vehicle it owns by increasing the supply of vehicles of the intermediate and lower
category, that are marketed by the Company, with the aim of adjusting the Company&#8217;s vehicle inventory to the increased demand for
vehicles of the intermediate and lower category, as a result of the economic and financial situation in the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is exploring expanding and diversifying
its sources of supply for imported vehicles, including brands manufactured in China that have been in demand in the Israeli automotive
market, and during the months of September-November 2024, Automax Direct Import, a wholly owned subsidiary of the Company, finalized
an agreement with Anhui Jianghuai Automobile Group Corp., Ltd., incorporated in China (hereinafter: &#8220;the Manufacturer&#8221;),
which manufactures private and commercial vehicles, among others under the JAC Motors brand, under agreements for direct import, distribution
and service of vehicles and spare parts manufactured by the Manufacturer in Israel. For additional details, see Note 21b here below.
According to the Company&#8217;s assessment, the implementation of this step will have a positive impact on its revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company bases its cash flows for the forthcoming
periods on the consolidated cash flow, taking into account the individual cash flows of the companies it holds, in order to conservatively
serve all of the Company&#8217;s obligations towards bondholders (series B) and the fully/partially owned companies towards various banking
corporations and third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To this end, the Group has taken and continues
to take the following steps:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Changing
                                            the mix of imported and sold vehicles in the Company&#8217;s branches according to the current
                                            demand of its customers. The changes in the business environment as mentioned above, caused
                                            a demand for vehicles in the intermediate and small vehicle categories. During the reporting
                                            period, the Company primarily sold vehicles from the intermediate category, which corresponds
                                            with the Company&#8217;s plans to change its vehicle mix to vehicles in the intermediate
                                            and small category, and contributed to an increase in sales compared to the same period last
                                            year.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Group has flexibility regarding the financing of advances to suppliers and discount policies
                                            to customers according to conditions in the market, interest rates and exchange rates and
                                            the needs of the Company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            financing that the Company provides to the companies within the Group is subject to the Company&#8217;s
                                            amortization schedule towards the bondholders (series B).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Strengthening
                                            the Company&#8217;s equity capital through the raising of capital (including the Merger Transaction
                                            (insofar as it is completed) with SciSparc Ltd., (hereinafter: &#8220;SciSparc&#8221;) as
                                            detailed in Note 21(b) below.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.65pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be clarified that the Company&#8217;s
assumption regarding the repayment of loans provided to held companies, which have been granted credit facilities by banking corporations,
is based on the fact that on the repayment date as mentioned, the held companies will comply with the financial criteria and other terms
that they have undertaken towards those banking corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company raised funds from the public via
bonds (series B), as detailed in Note 19 below. As part of the shelf offering report and trust deed, the Company undertook to comply
with a number of financial criteria, detailed in note 21c hereunder. The Company&#8217;s policy and operations are aimed at meeting the
principal and interest payments to bondholders (series B) as well as the financial criteria at any point in time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has various tools for implementing
this policy, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Selecting
                                            the mix of imported vehicles, the import currencies, the amount of advances to suppliers
                                            and the selling prices in Israel, as detailed above.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory
                                            management policy - the Group can increase or decrease the amount of vehicles as well as
                                            inventory value according to its operational plans and to the seasonality in the automotive
                                            industry.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of the publication of this report,
the Company is unable to assess the full future effects, to the extent that they may be, of all of the factors mentioned above on the
automotive industry in Israel in general and on the Company&#8217;s activities in particular. However, the Company estimates that its
financial stability, along with its financial sources and the actions detailed above, will enable it to continue and finance its operations
and meet its obligations in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Effects of the Iron Swords War:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2023, the terrorist organization
Hamas launched a murderous attack on the State of Israel, which included firing rockets and the infiltration of thousands of terrorists
into its territory. The attack claimed many victims, including Israeli and foreign citizens who were abducted to the territory of the
Gaza Strip. Following the attack, the Israeli government declared war, named the Iron Swords war, and mobilized approximately 300,000
reservists and launched an attack on the Gaza Strip (hereinafter: &#8220;the war&#8221;). At the same time, a conflict is underway in
the northern part of the country against the terrorist organization Hezbollah, and attacks have also been carried out from other arenas
aimed at the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The immediate impact of the outbreak of the war
on Israel&#8217;s economy was evident, and was reflected, inter alia, in the devaluation of the shekel against foreign currencies, declines
in stock exchange rates, the closing of many businesses due to the directives of the Home Front Command and the extensive mobilization
of reservists, a trend that was moderated in the first quarter of 2024, with the release of reserve forces, appreciation of the shekel
against foreign currencies, increases in exchange rates and a return to a certain routine in the shadow of the war.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The macroeconomic forecast published by the Bank
of Israel in January 2025, as detailed in Note 1d above, assumes that the direct economic impact of the war will continue until the end
of the first quarter of 2025. According to the forecast, this assumption embodies a moderate level of intensity of the fighting even
in early 2025. The downside risk to the growth forecast has decreased in light of geopolitical developments in the fourth quarter of
2024, and in particular the relative calm on the Lebanese front, so that the probability attributed to security scenarios with more serious
economic consequences has decreased. However, this risk is still at a very high level compared to normal. Therefore, the level of uncertainty
surrounding growth, inflation, interest rate, and government deficit forecasts is still high.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the outbreak of the war, the Company worked
to reduce its ongoing expenses, as much as possible under the circumstances, including reducing advertising and marketing expenses, reducing
other ongoing expenses, and reducing personnel expenses. In addition, the Company also worked to reduce its fixed expenses, as much as
possible under the circumstances, including partial or no payment of rent in some of its branches, as well as the closing of three branches,
as detailed in note 1b above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the outbreak of the war, the Houthis, an
Islamic political and military organization in Yemen, declared war on Israel, and began to launch missiles at targets in Israel as a
supportive action for the terrorist organizations in the Gaza Strip and Hezbollah, to launch drones at Israel, and to attack ships that
they claim have a connection to Israel. As a result of these attacks on ships, several shipping companies have announced the suspension
of sailing through the Red Sea. The situation developed into an international crisis that led to the formation of an international coalition
to ensure freedom of navigation and the declaration by the United States and its allies of the launch of Operation Prosperity Guardian
against the Houthis in order to stop attacks against vessels. With the declaration of a ceasefire between Israel and Hamas, as detailed
below, the Houthis stopped attacks against Israel as well as attacks on vessels, but most shipping companies did not return to sailing
in the Red Sea region. After the reporting period, the United States launched a military operation in Yemen, which at this stage includes
air strikes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company imports its inventory of vehicles
from various suppliers situated in Europe and North America. The vehicles that the Company imports from China are directly affected by
delays in delivery times and increases in logistics and transportation prices resulting from Houthi attacks in the Red Sea region, but
the Company has taken into account the effects of the above disruptions and price increases in its work plans. However, the changes and
disruptions in the shipping routes as mentioned above have caused significant delays in delivery dates and an increase in logistics and
transportation prices within Europe and from Europe to Israel. The delays in delivery dates and the increase in logistics and transportation
prices, both from China as well as from within Europe and from Europe to Israel, have had a negative impact on the Company&#8217;s financial
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be noted that with the outbreak of
the war and its continuation, a number of government decisions have been made that may have a positive impact on the Group&#8217;s activities.
This includes providing compensation for the decrease in transaction volumes of businesses, some of which are included in the standards
established for this matter (a request for compensation has been submitted), compensation for the full damage caused to businesses in
frontier settlements (which is relevant to the Company&#8217;s branches in Ashkelon, Ashdod, and Beer Sheva) (a request for compensation
has been submitted), and receiving a state-guaranteed loan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company regularly examines its eligibility
and works to receive the benefits in accordance with government decisions as stated. In addition, in January 2024 the Company received
a state-guaranteed loan from a banking corporation in the amount of ILS 16 million (for additional details, see Note 21(1) following).
In addition, for the months of November and December 2023, the Group companies are entitled to receive compensation from the state in
the amount of approximately 5.3 million ILS (that were recognized in the financial reports).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In light of the outbreak of the war, the Company
took action to raise capital by way of a private offering in the amount of ILS 10 million which was completed on December 31, 2023 and
strengthened the Company&#8217;s equity and liquidity. Furthermore, on April 10, 2024, the Company entered into a binding merger agreement
with Scisparc, a company incorporated in Israel and whose securities are traded on the Nasdaq. In accordance with the provisions of the
merger agreement with SciSparc, upon completion of the merger agreement (if completed), SciSparc will invest a total of approximately
$4,250,000 million in the Company. During 2024, SciSparc provided the company with a loan in several installments, in an aggregate amount
equal to the amount it committed to invest in the company as part of the merger transaction, which will be converted into equity on the
date of completion of the merger transaction. For additional details, see Note 21b here below. It should be emphasized that upon completion
of the merger transaction with SciSparc (to the extent that it is completed), the Company&#8217;s equity is expected to increase by an
additional 15 million ILS. In addition, the Company entered an agreement to receive an additional loan from Scisparc, in the amount of
$2 million, as detailed in Note 33b below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Towards the end of the third quarter of 2024,
the international credit rating company Moody&#8217;s downgraded Israel&#8217;s credit rating, for the second time in 2024, from A2 to
Baa1, which is a double downgrade of the rating, with a negative outlook. In the report, the rating agency estimated that the broad implications
of the current conflict with Hamas, both during and after its conclusion, significantly increase the political risks in the State of
Israel, weaken the legislative and executive authorities, and significantly impact Israel&#8217;s budgetary stability in the foreseeable
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2024, S&amp;P 500 also announced the
downgrading of Israel&#8217;s rating from AA- to A+, and maintained the rating outlook as &#8220;negative&#8221;, mainly due to the escalation
of tensions between Israel and Iran, as detailed below, and the geopolitical risks that Israel has been dealing with since the outbreak
of the war.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2024, Iran attacked Israel for the first
time in history, using the launch of hundreds of ballistic missiles, cruise missiles, and drones, an attack that was thwarted by air
defense systems, in cooperation with other countries, including the United States. In October 2024, and for the second time in that year,
Iran attacked Israel by launching approximately two hundred ballistic missiles. Israel responded to the attack by striking military targets
in Iran. The escalation with Iran, as also noted by the rating agency S&amp;P 500, may have a significant impact on Israel, the Middle
East, and other involved countries. As of the date of publication of the report, an escalation in the region with Iran cannot be ruled
out, which may result, among other things, from an attack on Iran&#8217;s nuclear facilities. As mentioned, escalation can have a significant
impact on the State of Israel as well as on other involved countries in the Middle East region and globally, and may cause a substantial
negative effect on the economic situation in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 27, 2024, a ceasefire agreement between
Israel and Lebanon came into effect. As part of the agreement, fighting on the northern front ceased. However, from time to time Israel
carries out attacks on Lebanese territory due to violations of the ceasefire agreement by Hezbollah. Therefore, as of the date of publication
of the report, a return to all-out fighting on the northern front against Hezbollah, which could have a significant impact on the State
of Israel and the Israeli economy, cannot be ruled out.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 19, 2025, a ceasefire agreement between
Israel and the terrorist organization Hamas came into effect, under which fighting in the Gaza Strip stopped and the Israeli Defense
Forces (&#8220;IDF&#8221;) carried out certain withdrawals from the Gaza Strip. Hamas released Israeli hostages who had been abducted
to the Gaza Strip, and in return, Israel released Palestinian security prisoners. On March 18, 2025, the ceasefire ended with extensive
airstrikes carried out by the IDF in the Gaza Strip.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the reporting period, Turkish trade officials
announced the suspension of trade between Turkey and Israel. The company Dalhom Automax imports and markets buses manufactured by Temsa
in Turkey in Israel. Furthermore, Global Automax imports and markets vehicles that it purchases in Turkey. The cessation of trade, as
mentioned, has a negative impact on the supply of vehicles and on the prices of logistics and transportation of vehicles to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the date of completion of this report, the
Company is not capable of assessing or estimating the duration of the period in which the trade suspension with Turkey will remain in
effect, and therefore the impact of the above on the long-term results of the Group&#8217;s operations. However, the Company does not
expect a significant impact on the Group&#8217;s business since it has (in Israel) an inventory of Temsa buses and has worked to find
ways of operation and alternatives for the continued regular supply of Temsa vehicles and buses to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 1 - General (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 20, 2024, the Prosecutor of the International
Criminal Court in the Hague announced that he has filed an application with the Court to issue arrest warrants for war crimes and crimes
against humanity allegedly committed by Israeli Prime Minister Benjamin Netanyahu, Defense Minister Yoav Galant, and Hamas leaders. In
September 2024, Israel responded to the request for arrest warrants. On November 21, 2024, the International Criminal Court approved
the issuance of arrest warrants against Benjamin Netanyahu, Prime Minister of Israel, and Yoav Galant, former Minister of Defense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, on May 24, 2024, following South
Africa&#8217;s appeal to the International Court of Justice (ICJ) in the Hague, alleging that Israel is allegedly violating its obligations
under the resolution regarding the prevention and punishment of the crime of genocide in the Iron Sword War, the court decided to issue
orders for a ceasefire in Rafah, Gaza and to submit a status report within a month. On July 19, 2024, at the request of the United Nations,
an advisory opinion was given by the ICJ, according to which the ongoing occupation of Israel in the Palestinian territories (including
the Gaza Strip and East Jerusalem), as well as the establishment of settlements and exploitation of natural resources, apparently violate
international law. As mentioned, these developments may undermine Israel&#8217;s international standing and lead to the imposition of
sanctions on Israel, which could have a negative impact on its economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of the publication of this report,
and since the war is a dynamic occurrence characterized by significant uncertainty, the Company is unable to assess the full future effects,
if any, of the war and/or the expansion of its scope on the automotive industry in Israel in general and on the Company&#8217;s activities
in particular. The Company estimates that its financial stability, along with its financial sources and taking the actions detailed above
(including those covered in Note 1d above), will allow it to continue to finance its activities and meet its obligations in the foreseeable
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>f. <span style="text-decoration:underline">Separate financial
information:</span></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not attach separate financial
information in these financial statements due to the insignificance of the additional information. The Company fully owns Global Automax,
and as of the date of the report on the financial condition, most of the Group&#8217;s business activity is carried out in Global Automax,
which is fully reflected in the Group&#8217;s consolidated report. As of the date of the report on the financial condition, the company
has no business activity and therefore the publication of separate financial statements will not constitute additional material information
for the reasonable investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>g. <span style="text-decoration:underline">Definitions</span>:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">The
    Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">Automax
    Motors Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">The
    Group</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">The
    Company and its affiliates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">Consolidated
    companies/ <br/>
    subsidiary companies</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">Companies
    over which the Company has control (as defined in IFRS 10 - Consolidated Financial Statements), and whose reports are consolidated
    with the Company&#8217;s reports.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">Related
    parties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">As
    defined in IAS 24 - Related Party Disclosures.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">Interested
    parties and <br/>
    controlling parties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">As
    defined in the Securities Regulations (Annual Financial Statements), 5771-2010.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting policies detailed below have been
consistently implemented by the Company during the preparation of the financial reports for all presented periods, unless indicated otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>a.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Statement
                                            regarding implementation of International Financial Reporting Standards (IFRS):</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The consolidated financial statements
of the Group have been prepared in accordance with the International Financial Reporting Standards (hereunder: &#8220;IFRS&#8221;) and
their interpretations as published by the International Accounting Standards Board (IASB).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>b.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Application
                                            of securities regulations:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The financial statements have been
prepared in accordance with Securities Regulations (Annual Financial Statements), 5770-2010 (hereunder: &#8220;Financial Statement Regulations&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>c.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Operational
                                            turnover period:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The operational turnover period of
the Company is 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>d.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Format
                                            of the analysis of expenses recognized in profit or loss:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company elected to present profit
or loss items and other comprehensive income using the &#8220;activity characteristics&#8221; method. The Group estimates that due to
the organizational structure of the Group, the classification of expenses in such a manner provides more reliable and relevant information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>e.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Basis
                                            for preparation of financial statements:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The financial statements of the Company
have been prepared on a cost basis, with the exception of financial instruments calculated at fair value through profit or loss. The
Company elected to present its statement of comprehensive income based on the activity characteristics method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><span style="text-decoration:underline">Note 2 - Principles of
accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>f.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Consolidated
                                            Financial Statements</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>(1)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>General:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consolidated financial statements
of the Group include the financial reports of the Company and of entities controlled by the Company, whether directly or indirectly.
An investing company controls an investee when it is exposed, or has rights, to variable returns from its holding in the investee, and
when it has the ability to affect those returns through the exercise of power over the investee. In determining whether control exists,
the Company considers potential voting rights that could be exercised or converted to shares in the held company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Potential voting rights shall be considered
de-facto rights in the event that the Group has practical ability to realize such rights. When de-facto potential voting rights exist,
such as: convertible instruments, options and future contracts of the investee held by the Company or other investing parties, whose
realization shall increase the number of voting rights in the investee - the Group considers whether the existence of said potential
voting rights, together with other existing voting rights, amount to control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The results of the operations of any
subsidiaries acquired or sold during the reported periods are included in the Company&#8217;s consolidated statements of profit and loss,
as of the date that control was attained or the date it ceased to exists, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial statements of subsidiaries
that were not prepared in accordance with the accounting policies of the Group have been adjusted, prior to consolidation, in compliance
with the accounting policy implemented by the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For the purpose of consolidation, all
inter-company transactions, balances, incomes and expenses are fully cancelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>(2)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Business
                                            combinations:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The consideration transferred includes
the fair value of assets transferred to the previous owners of the purchased, liabilities incurred by the buyer vis-&#224;-vis the
previous owners of the purchased, and capital rights issued by the Group. In a business combination achieved in stages, the difference
between the fair value at the time of the acquisition of capital rights in the purchased that were previously held by the Group and their
book value at that time, is recognized in the statement of profit and loss under other income or expenses. In addition, the transferred
consideration includes the acquisition-date fair value of the contingent consideration. Subsequently to the acquisition date, the Group
recognizes changes in the fair value of contingent consideration classified as a financial liability in the profit and loss statement,
while contingent consideration classified as an equity instrument is not calculated once again.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>(3)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Subsidiaries:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subsidiaries are entities controlled
by the Company. The financial statements of subsidiaries are included in the consolidated financial statements from the day control is
obtained until the day control is lost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accounting policy of subsidiaries
has been changed, if necessary, in order to adjust it to the accounting policy adopted by the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>(4)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Non-controlling
                                            interest rights:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The share of non-controlling interest
rights in the net assets (excluding goodwill) of combined subsidiaries is presented separately within the Group&#8217;s equity. Non-controlling
interest rights include the balance of said rights on the date of business combination and the share of non-controlling interest rights
in any changes in the combined company&#8217;s equity as of the date of business combination. Any losses of combined companies attributable
to non-controlling interest rights, that exceed the non-controlling interest rights in the equity of the combined company, shall be assigned
to non-controlling interest rights which do not confer control while disregarding their undertakings and the ability of said shareholders
to make additional investments in the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For transactions with non-controlling
rights shareholders with respect to acquiring additional shares in the combined company, following establishment of control, the excessive
costs of acquisition, which exceed the book value of said non-controlling interest rights as of the date of acquisition, shall be recognized
as part of equity attributable to the parent company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The results of any transactions with
non-controlling rights shareholders involving the sale of the Group&#8217;s investment in a combined company, while maintaining control,
shall be recognized as part of equity attributable to the parent company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>(5)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Investment
                                            in consolidated companies and joint ventures:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Consolidated companies are entities
in which the Group has a significant influence over the financial and operational policies, yet no control or joint control has been
attained. There is an assumption which can be refuted according to which holdings of 20% to 50% confer essential influence. In examining
the existence of essential influence, potential voting rights that can be exercised or converted immediately into shares of the held
company are taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Joint ventures are joint arrangements
in which the Group has rights to the net assets of the arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Investment in consolidated companies
and joint ventures are handled according to the equity method and are initially recognized at cost. The investment cost includes transaction
costs. Transaction costs directly related to the expected acquisition of a consolidated company or a joint venture are recognized as
an asset. The deferred expenses item with respect of an expected acquisition of a consolidated company or a joint transaction is recognized
as an asset in the deferred expenses item of the statement of financial position. These costs are added to the investment cost at the
time of acquisition. When a company first obtains essential influence or joint control in an investment treated as a financial asset
calculated at fair value through other comprehensive income until the date of obtaining the essential influence or joint control, other
comprehensive income accumulated in respect of the investment will be credited to the retained earnings balance at that time. The consolidated
financial statements include the Group&#8217;s share of the income and expenses in the profit or loss and of other comprehensive income
of held companies that are handled according to the equity method, after adjustments required to adapt the accounting policy to that
of the Group, from the day on which the essential influence or joint control exists and until the day on which the essential influence
or joint control ceases to exist.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>(6)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Transactions
                                            eliminated during consolidation:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mutual balances within the Group and
unrealized income and expenses, arising from inter-company transactions, were eliminated as part of the preparation of the consolidated
financial statements. Unrealized profits arising from transactions with consolidated companies and joint transactions were eliminated
against the investment, according to the Group&#8217;s rights in these investments. Unrealized losses were eliminated similarly to the
way in which unrealized gains were eliminated, as long as there were no indications of impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>g. Functional currency, presentation currency
and foreign currency</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>(1)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Functional
                                            currency and presentation currency:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The financial statements of each of
the companies within the Group are prepared in the currency of the primary economic environment in which they operate (hereunder: &#8220;functional
currency&#8221;). For the purpose of consolidation of the financial statements, the results and the financial position of each of the
companies within the Group are converted into New Israeli Shekels, which constitutes the functional currency of the Company. The consolidated
financial statements of the Group are presented in New Israeli Shekels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.75pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in"><b>(2)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Conversion
                                            of transactions that are not in the functional currency:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the preparation of the financial
statements of each of the companies within the Group, any transactions carried out in currencies which do not constitute the functional
currency of said company (hereunder: &#8220;foreign currency&#8221;) are documented in accordance with the official exchange rates at
the time they occur. At the end of each reporting period, monetary items denominated in foreign currency are translated in accordance
with the official exchange rates at the time they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in"><b>(3)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Recording
                                            exchange rate differences:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Exchange rate differences are recognized
in profit and loss during the period in which they occurred, except in the event that such exchange differences arise from receivable
or payable monetary items originating in foreign operations whose settlement is not planned or expected to happen, which therefore constitute
a part of net investment in foreign operations, in which case they are recognized under other comprehensive income as part of the adjustments
deriving from translation of financial statements of foreign operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>h.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Cash
                                            and cash equivalents</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and cash equivalents are considered
highly liquid investments. This includes short-term deposits in banking corporations that are non-restricted by liens, with original
maturities that do not exceed three months as of the date of investment, or that exceed three months and yet can be withdrawn immediately
without fines, and constitute a part of the Group&#8217;s cash flow management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>i.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Inventory</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Inventory is calculated based on the
lower of cost and net realizable value. Inventory cost comprises all costs of inventory purchase and any other costs incurred in bringing
the inventory to its present location and condition. Net realizable value constitutes the estimated selling price that would be established
in a regular transaction, deducted of any completion costs and costs required in order to finalize the sale. The Company reviews the
state and the age of its inventory on a periodical basis, and performs corresponding slow inventory allowances. For details regarding
considerations taken into account during the review of net realizable value of the new vehicle inventory, see Note 3b1 below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Inventory cost is determined as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Vehicle inventory &#8211; based on
specific cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Accessories &#8211; based on average
cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>j.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Income
                                            Recognition</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Accounting policies implemented
since January 1, 2018 with respect to income recognition are as follows:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income deriving from contracts with
customers are recognized in profit or loss upon the transition of control over the asset or the service to the customer. The price of
the transaction equals the expected consideration amount as per the contract terms, with the deduction of any amounts collected in favor
of third parties (e.g. taxes).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Following are the specific income
recognition criteria to be fulfilled prior to income recognition:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income from sales of new vehicles</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income from sales of new vehicles
and spare parts is recognized upon transfer of control over the new vehicle or the spare parts to the customer. Usually, control is transferred
when the vehicle is delivered to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income from sales of used vehicles</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income from sales of used vehicles
is recognized upon transfer of control over sold used vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Credit transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company elected to use the relief
provided by the standard, based on which it would not be required to separate the credit component in transactions with credit terms
of less than 12 months and would recognize income in accordance with the consideration amounts as set within the contract, even in the
event the customer pays before or after the date the product or service are delivered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>k.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Income
                                            Tax</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The taxes on income that are included
in the statement of profit and loss include current taxes, taxes with respect to previous years and deferred taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Tax expenses comprising current or
deferred tax expenses are recognized in profit or loss, except in the event said taxes derive from items recognized in other comprehensive
income or in equity. In such case, the tax amount is recognized in the corresponding item within equity as well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Current taxes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The current tax liability is determined
using tax rates that have been enacted or substantively enacted by the reporting date, as well as any adjustments required with respect
to tax liabilities from previous years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Deferred taxes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Deferred taxes are calculated on temporary
differences between the amounts as presented in the financial statements and amounts adjusted for tax purposes. Deferred tax balances
are calculated using the expected tax rates that would apply upon the realization of the asset or the removal of the liability, based
on tax laws that have been enacted or substantively enacted by the reporting date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On every reporting date, deferred
tax assets are reviewed according to their expected usage. Losses carried forward and temporary differences can be deducted for which
deferred tax assets have not been recognized are reviewed at each reporting date and an appropriate deferred tax asset is recognized
for them if it is expected that they will be utilized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In calculating deferred tax amounts
the Company does not take into consideration any taxes that would apply in the event of the realization of investments in held entities,
as long as the sale of the held entities is not expected in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>l.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Government
                                            grants</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Government grants are recognized when
there is reasonable assurance that the grants will be received and the company will meet all conditions for receiving the grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>m.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Leases</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Initial implementation of IFRS 16
&#8211; Leases (hereunder: the &#8220;Standard&#8221;) &#8211; the Company elected to implement the provisions of the Standard using
the modified retrospective manner (without restatement of comparative figures). The Company adopted the following accounting policy as
of January 1, 2018 with respect to leases:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company treats the contract as
a lease when, in accordance with the terms of the contract, the right to control an identified asset is transferred for a period of time
in exchange for consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(1)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">The
                                            Group as a lessee</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For transactions in which the Company
is the lessee, it recognizes, at the lease start date, a lease of a right-of-use asset against a lease liability, with the exception
of lease transactions for a period of up to 12 months and lease transactions in which the underlying asset is of low value, in which
the Company has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease period.
As part of the calculation of the liability for a lease, the Company chose to apply the relief afforded by the Standard and did not separate
the lease components and non-lease components, such as: management services, maintenance services and more that were included in the
same transaction on the date the liability for the lease commenced. This includes all lease payments not yet paid, capitalized with the
interest rate included in the lease when it can be easily determined, or with the Company&#8217;s additional interest rate. After this
date, the Company calculates the lease liability using the effective interest method. The right-of-use asset on the formation date is
recognized at the amount of the lease liability plus lease payments paid on or before that date plus any transaction costs incurred.
The right-of-use asset is calculated by the cost model and depreciated over its useful life or over the lease term, whichever is shorter.
Below are data regarding the number of years of depreciation of the relevant right-of-use assets according to Groups of right-of-use
assets:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Number of years</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Primarily</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: justify">Land and office buildings</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">1-6</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When indicators of impairment exist,
the Company reviews whether there is a need to recognize any right-of-use asset impairment subject to the provisions of IAS 36.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -14.2pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in"><b>(2)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">CPI-linked
                                            lease payments </span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the time the lease is created,
the Company uses the index rate existing at that time for the purpose of calculating future lease payments. For transactions in which
the Company constitutes the lessee, any changes in future lease payments originating in index variations are capitalized (without amending
the capitalization rate used for lease liability calculations) to the balance of the right-of-use asset and are credited as an adjustment
to the balance of the lease obligation. Only when there is a change in the cash flows resulting from a change in the index (that is,
at the time when the coordination of the lease payments takes effect).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in"><b>(3)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Options
                                            for extending and canceling a lease period </span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The lease period that cannot be canceled
includes both periods covered by an option to extend the lease when it is reasonably certain that the option to extend will be exercised,
and periods covered by an option to cancel the lease when it is reasonably certain that the option to cancel will not be exercised. In
the event that there is a change in the expectation for exercising an extension option or for not exercising a cancellation option, the
Company recalculates the remaining liability for the lease in accordance with the updated lease period, according to the updated capitalization
rate on the day of the change in expectation, with the total change credited to the balance of the right-of-use asset until it is reset,
and beyond that to profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in"><b>(4)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Lease
                                            amendments </span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company amends the terms
of a lease, and said amendment does not reduce the scope of the lease and is not handled as a separate lease transaction, the Company
re-calculates the balance of its lease liability in accordance with the new lease terms, using the capitalization rate applicable on
the modification date, and credits the change in the liability balance for the lease to the balance of the right to use asset. When an
amendment is made to the terms of the lease that results in a reduction in the scope of the lease, the Company recognizes the profit
or loss resulting from the partial or full write-off of the balance of the right-of-use asset and the liability for the lease. Subsequently,
the Company re-calculates the balance of the lease liability in accordance with the new lease terms, using the capitalization rate applicable
on the modification date, and credits the change in the liability balance for the lease to the balance of the right to use asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>n.</b></td><td style="text-align: justify"><b>Fixed assets</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(1)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Fixed
                                            asset items are calculated at cost with deduction of accrued depreciation and accrued impairment
                                            losses</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The cost of fixed assets includes
expenses directly attributable to the purchase of the asset. The cost of self-constructed assets includes the cost of materials and direct
labor, as well as any additional cost that can be directly attributed to bringing the asset to the location and condition necessary for
it to be able to operate in the manner intended by the management, an estimate of the costs of dismantling and removing the items and
restoring the site where the item is located, as well as credit costs that have been used. The cost of purchased software, which is an
integral part of the operation of the related equipment, is recognized as part of the cost of this equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The spare parts, auxiliary equipment
and backup equipment are classified as fixed assets when they meet the definition of fixed assets according to IAS-16 - Property, Plant
and Equipment, and otherwise they are classified as inventory. A fixed asset item purchased in exchange for another non-monetary item
as part of a commercial transaction is recognized at fair value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When significant fixed asset parts
have different life spans, they are treated as separate items (significant components) of the fixed asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Changes in the obligation to dismantle
and remove items and restore the site where they are located, except for changes resulting from the passage of time, are added to or
subtracted from the cost of the property in the period in which they occur. The amount deducted from the cost of the asset shall not
exceed its book value. The balance, if any, is immediately recognized in profit and loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Profit or loss arising from deducting
a fixed asset item is determined by comparing the net proceeds from deducting the asset to its book value, and recognized net in the
other income or other expenses items, as the case may be, in the profit and loss statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in"><b>(2)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Depreciation</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Depreciation is a systematic allocation
of the depreciable amount of an asset over its useful life. A depreciable amount is the cost of the asset, or another amount that replaces
the cost deducted of its residual value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">An asset is depreciated when it is
available for use, that is, when it has reached the location and condition necessary for it to be able to operate in the manner intended
by management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Depreciation is recognized in the
profit and loss statement using the straight-line method over the estimated useful life of each component of the fixed asset items, since
this method reflects the predicted consumption pattern of the future economic benefits inherent in the asset in the best way. Assets
leased under financing leases are depreciated over the shorter of the lease term and the useful life of the assets, unless it is reasonably
expected that the Group will receive ownership of the asset at the end of the lease term. Owned lands are not depreciated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The estimated useful life for the
current period and the comparison period is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>%</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">8.5-10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: justify">Throughout the leasing period, including extension
    option</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Computers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">15-33</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mainly 33%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Office equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">6-33</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mainly 25%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">15-20</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mainly 15%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leasehold improvements are depreciated
using the straight-line method over the lease period (including the Group&#8217;s lease term extension option which it is planning to
exercise) or over the useful life of the improvement, whichever is shorter. The Company reviews the useful life period, the depreciation
method and the residual value of each asset at least annually. Any adjustments are implemented as a change in an accounting estimate,
in a prospective manner. Depreciation of assets is terminated as soon as possible between the date on which the asset is classified as
held for sale and the date on which the asset is written off.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The estimates regarding the depreciation
method, the useful life and the residual value are re-examined at least at the end of each reporting year and adjusted when necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>o.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Intangible
                                            assets</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Intangible assets that are acquired
separately are calculated upon initial recognition at cost plus direct acquisition costs. Intangible assets purchased as part of business
combinations are included based on their fair value on the date of acquisition. Costs related to internally developed intangible assets,
excluding capitalized development costs, are recognized in the profit or loss as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The intangible assets of the Group
have a defined useful life. The assets are amortized over their economic useful life, while the need for impairment is reviewed whenever
impairment indicators exist. The amortization period and method are reviewed at least annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Goodwill</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Goodwill arising from an acquisition
of a business is calculated by the excess of the acquisition cost, plus the fair value of the rights that do not confer control, including
the net fair value of the identified assets, liabilities and contingent liabilities of the consolidated company recognized at the time
of acquisition. The method of calculating goodwill, in accordance with the alternatives listed above, is determined individually in each
business combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Goodwill is recognized for the first
time as an asset at cost, and is calculated in subsequent periods at cost deducted of accumulated impairment losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For the purpose of examining impairment,
goodwill is allocated to each of the Group&#8217;s cash-generating units that are expected to benefit from the synergy of the business
combination. Cash-generating units to which goodwill has been allocated are reviewed annually or more frequently insofar as indicators
attesting to a possible decrease in value of said unit exist. When the recoverable amount of a cash-generating unit is less than the
book value of that unit, the impairment loss is allocated first to reduce the book value of any goodwill attributed to the cash-generating
unit. After that, the remaining impairment loss, if any, is allocated to other assets of the cash-generating unit, in proportion to their
book value. An impairment loss of goodwill is not eliminated in subsequent periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon disposal of a consolidated company,
the amount of the related goodwill is included in determining the profit or loss from the disposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Website </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company operates an official website
and official Facebook and Instagram pages, where it publishes product updates and promotions. In addition, the Company also operates
a LinkedIn page.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Licenses </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The capitalized costs for the license
are the costs of purchasing the license and costs that can be directly attributed and which are needed to obtain the license and include,
among others, legal costs and consultants, travel costs abroad and salary costs that can be directly attributed to the license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The capitalization of the costs for
the license begins in the development phase and ends when the license is achieved, that is, when the property is in the necessary condition
in order to be able to operate in the way management intended. Initial costs incurred during the research phase, meaning amounts used
for obtaining knowledge and for searching for dealers and sub-agents, cannot be capitalized and shall therefore be recognized as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The useful life of a license shall
not exceed the term of its contractual rights, yet the useful life might be shorter, according to the period the Company expects to use
the license. In the event the contractual rights are provided for a renewable limited period, the useful life of the license shall include
the renewal period only insofar as evidence exists supporting the Company&#8217;s intent of such renewal without incurring material costs.
In the opinion of the Company, the requirements for including the renewal period as part of the useful life of the license have not been
fulfilled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><span style="text-decoration:underline">Depreciation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Depreciation is a systematic allocation
of the depreciable amount of an intangible asset over its useful life. A depreciable amount is the cost of the asset, deducted of its
residual value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The depreciation is recognized in
profit and loss using the straight-line method, over the estimated useful life of the intangible assets as of the date when the assets
are available for use, since these methods reflect the predicted consumption pattern of the future economic benefits inherent in each
asset in the best way. Goodwill and intangible assets with an indefinite lifespan are not systematically depreciated, but are tested
at least once a year for impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Intangible assets that are formed
in the Group are not systematically depreciated as long as they are not available for use, that is, they are not in the location and
condition required for them to be able to operate in the way management intended. Therefore, these intangible assets, such as development
costs, are tested for impairment at least once a year, until the time they become available for use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The estimated useful life for the
current period and the comparative periods is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>%</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 79%; text-align: justify">Website</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">33</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Licenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Throughout the license validity period</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The estimates regarding the useful
life and the residual value are re-examined at least at the end of each reporting year and adjusted when necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Group reviews the estimated useful
life of an intangible asset that is not amortized at least annually in order to determine whether the events and circumstances continue
to support the determination that the intangible asset has an indefinite life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>p.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Impairment
                                            of non-financial assets</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company reviews the need for impairment
of non-financial assets whenever indicators resulting from events or changes in circumstances show that the carrying amounts as stated
in the financial reports may not be recoverable. In cases where the balance in the financial statements of non-financial assets exceeds
their recoverable amount, the assets are written down to their recoverable amount. The recoverable amount of an asset is determined as
the higher of fair value deducted by cost of disposal, and its value of use. In assessing the value of use, the expected cash flows are
capitalized according to a pre-tax discount rate that reflects the specific risks for each asset. For assets which do not generate individual
cash flows, the recoverable amount is determined for the cash-generating unit to which they can be attributed. Any impairment losses
are recognized in profit and loss. An impairment loss on an asset, other than goodwill, is reversed only when there have been changes
in the estimates used to determine the asset&#8217;s recoverable amount since the date the impairment loss was last recognized. Such
impairment reversal is limited to the lower of previously recognized impairment (deducted of depreciation or amortization) and the recoverable
amount of the asset. As for assets calculated at cost, said impairment reversal shall be recognized in profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>q.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Financial
                                            instruments</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On January 1, 2018, the Company implemented
the provisions of IFRS 9 &#8211; Financial Instruments (hereunder: the &#8220;Standard&#8221;) for the first time. The Company elected
to implement the provisions of the Standard using the modified retrospective manner, without restatement of comparative figures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accounting policy implemented
for financial instruments as of January 1, 2018, is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(1) <span style="text-decoration:underline">Financial assets</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial assets are initially calculated
at fair value, plus any transaction related costs directly attributable to the acquisition of the financial asset, excluding financial
assets calculated at fair value through profit or loss, for which transaction related costs are recognized in profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company classifies and measures
debt instruments in its financial statements based on the following criteria:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            Company&#8217;s business model for managing financial assets, and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            contractual cash flow characteristics of the financial asset.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">The
                                            Company measures debt instruments at amortized cost when:</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&#8217;s business model is
holding the financial assets in order to collect contractual cash flows, and the contractual terms of the financial assets provide entitlement
at specified times to cash flows that are only principal and interest payments for the principal amount that has not yet been repaid.
After initial recognition, debt instruments in this Group are calculated according to their terms at amortized cost using the effective
interest method and deducting an allowance for impairment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify; text-indent: -63.85pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify; text-indent: -63.85pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify; text-indent: -63.85pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify; text-indent: -63.85pt"><b><span style="text-decoration:underline">Note
2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 0; text-align: justify; text-indent: -63.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">At the time of first recognition, a company
can designate, without the possibility of changing this designation, a debt instrument as calculated at fair value through profit or
loss, if this designation eliminates or significantly reduces inconsistencies in calculation or recognition, for example in the case
where the related financial liability is also calculated at fair value through profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">The
                                            Company calculates debt instruments at fair value through other comprehensive income when:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&#8217;s business model is
holding the financial assets in order to collect contractual cash flows, and the contractual terms of the financial assets provide entitlement
at specified times to cash flows that are only principal and interest payments for the principal amount that has not yet been repaid.
Following initial recognition, all instruments within this Group are calculated at fair value. Any profits or losses arising from fair
value adjustments, except interest and exchange rate differences, are recognized through other comprehensive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">The
                                            Company calculates debt instruments at fair value through profit or loss when:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A financial asset that is a debt instrument
does not meet the criteria for measuring it at amortized cost or at fair value through other comprehensive income. After initial recognition,
the financial asset is calculated at fair value and gains or losses as a result of fair value adjustments are credited to profit or loss.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.9pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Equity
                                            instruments and other financial assets held for trading</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Investments in capital instruments that
do not meet the aforementioned criteria and are therefore calculated at fair value through profit or loss. Other financial instruments
held for trading, such as derivatives, including embedded derivatives separated from their host contracts, are calculated at fair value
through profit or loss, unless designated to serve as effective hedging instruments. With respect to certain equity instruments not held
for trading, upon initial recognition the Company may irrevocably elect to present as part of other comprehensive income any subsequent
fair value changes which otherwise would have been calculated at fair value through profit or loss. These changes will not be attributed
to profit or loss in the future, not even when the investment is withdrawn.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.9pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Dividend incomes deriving from investments
in equity instruments are recognized on the effective date for dividend eligibility, in the statement of profit and loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(2)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Impairment
                                            of financial assets</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Group examines, on each reporting
date, the provision for loss for financial debt instruments that are not calculated at fair value through profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(3)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Financial
                                            liabilities</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Financial liabilities calculated
at amortized cost</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon initial recognition, the Company
calculates financial liabilities at fair value, deducted of any transaction related costs directly attributable to issuance of the financial
liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Following the initial recognition,
the Company calculates all of its financial liabilities at amortized cost, while using the effective interest rate method, excluding:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial liabilities at fair value
through profit or loss, such as derivatives;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Financial
                                            liabilities that arise when the transfer of a financial asset does not qualify for amortization
                                            or when the continuing involvement approach applies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Financial
                                            guarantee contracts;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Obligations
                                            to provide a loan at an interest rate lower than the market interest rate;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingent
                                            consideration recognized by a purchaser in a business combination to which IFRS 3 applies.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(4)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Warrants
                                            for the purchase of shares of the Company and/or a consolidated company</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Receipts for the issuance of warrants
to purchase the shares of the Company and/or a consolidated company, which give the holder the right to purchase a fixed number of ordinary
shares in exchange for a fixed amount of cash, are presented within the capital in the item &#8220;Share-based payment&#8221;. In this
context, for an exercise amount that changes according to the exercise date, the exercise price can be determined for any possible exercise
date on the issuance date, and therefore it is considered a fixed amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(5)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Derivative
                                            financial instruments for hedging (protection) purposes</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At times, the Company enters into
engagements involving derivative financial instruments, such as foreign currency forwards, in order to mitigate risks arising from the
fluctuation of foreign currency exchange rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Group does not implement accounting
hedging. Profits or losses deriving from changes in fair value of derivatives that are not held for hedging purposes, are immediately
recognized in profit or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.2475in; text-align: left"><b>(6)</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Offsetting
                                            financial instruments</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial assets and financial liabilities
are offset against each other. The net amount is presented as part of the statement of financial position, in the event the Company has
a legally enforceable right to offset any amounts recognized, and insofar as the Company intends to clear the asset or the liability
on a net basis, or realize the asset while clearing the liability, in parallel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>r.</b></td><td style="text-align: justify"><b>Fair value calculation</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fair value is the price that would
have been received for the sale of an asset or the price that would have been paid to transfer a liability in a normal transaction between
market participants at the time of calculation. Fair value calculation is based on the assumption that the transaction is made in the
active market of the asset or the liability, or in absence of active markets, the most advantageous market. The fair value of the asset
or the liability is calculated by using the following assumptions: that it would be used by market participants for quoting the price
of the asset or liability, and that market participants act with the purpose of achieving their economic interests. Fair value calculation
for a non-financial asset takes into account the ability of a market participant to generate economic benefits by using the asset in
its best use or by selling it to another market participant who will use the asset in its best use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Group uses valuation techniques
that are appropriate to the circumstances and for which there is sufficient obtainable data to calculate fair value, while maximizing
the use of relevant data. All assets and liabilities calculated or presented at fair value are categorized into different fair value
levels based on the lowest data level that is significant for the fair value calculation as a whole:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1: Quoted prices (not adjusted)
in active markets for identical assets and liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2: Data other than quoted prices
included in level 1 which can be directly or indirectly observed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3: Data not based on observable
market data (valuation techniques without the use of observable market data).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>s.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Provisions</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A provision is recognized when the
Group has a current, legal or implied obligation, as a result of an event that occurred in the past, that can be reliably calculated,
and when it is expected that a negative flow of economic benefits will be required to settle the obligation. Provisions are determined
by capitalizing future cash flows using the pre-tax interest rate which reflects current market assessments with respect to the time-value
of the cash and the specific risks of the liability without taking the Company&#8217;s credit risk into consideration. The book value
of the provision is adjusted in each period in order to reflect the passage of time. The amount of the adjustment is recognized as financing
expenses. The Group recognizes indemnification assets if and only if it is virtually certain that the indemnification amount would be
received insofar as the liability is settled. The recognized amount with respect to the indemnification shall not exceed the value of
the provision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Legal Claims</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A provision for claims is recognized
when the Group has a legal obligation at present or an implied obligation as a result of a past event, when it is more likely than not
that the Group will require its financial resources to settle the obligation and when it can be reliably estimated. When the effect of
the time value is material, the provision is calculated according to its present value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>t.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Share-based
                                            payment:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Share-based payments to employees
and others who provide similar services that are settled in the Company&#8217;s capital instruments are calculated at their fair value
at the time of granting. The Company calculates at the time of granting the fair value of the capital instruments granted by using the
Black-Scholes model. When the capital instruments that are granted do not mature until those employees complete a specified period of
service during which the employees may also be required to meet certain performance conditions, the Company recognizes the share-based
payment arrangements in the financial statements over the vesting period against capital growth, under the item &#8220;Capital fund for
share-based payment&#8221;. At the end of each reporting period, the Company estimates the number of capital instruments expected to
mature. A change in estimate compared to previous periods is recognized in profit or loss over the remainder of the vesting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>u.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Annual
                                            profit (loss)</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Profit per share is calculated by
dividing net profit attributable to Company shareholders by the weighted number of actual ordinary shares, as exist for the period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Potential ordinary shares are included
in the calculation of diluted profit per share in the event their effect dilutes the profit per share that arises from ongoing operations.
Potential ordinary shares converted during the period shall be included as part of the diluted profit per share, only until the date
they are converted. As of said date, potential ordinary shares shall be included in the basic profit per share. The Company&#8217;s share
in profits of subsidiaries is calculated based on the Company&#8217;s portion in the profit-per-share of the subsidiaries, multiplied
by the number of shares held by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>v.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Accounting
                                            aspects of Global Automax merger transaction</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As
                                            part of the transaction described in note 1 (b) above, the Company issued shares for the
                                            purpose of purchasing all of Global Automax&#8217;s shares. The Company constitutes the legal
                                            buyer of the transferred operation. However, since as of the date the transaction was finalized
                                            Global Automax&#8217; shareholders became the Company&#8217;s controlling shareholders with
                                            the power to determine its financial and operational policies, the Company constitutes the
                                            accounting acquiree in the transaction. Therefore, the transaction is treated in the financial
                                            statements as a reverse purchase in which the net assets of the Company are considered as
                                            assets purchased by Global Automax (the accounting purchaser). In addition, since at the
                                            time of the transaction the Company was without any business activity, then it is not a &#8220;business&#8221;
                                            as defined by IFRS 3 and therefore the transaction was treated as a share issue. The financial
                                            statements prepared after the completion of the transaction as stated above were described
                                            as a continuation of the financial statements of Global Automax and the comparative information
                                            presented in these reports will be for Global Automax only, excluding the activity previously
                                            reported as part of the Company&#8217;s financial statements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.7pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Below
                                            are the principles that were applied in the context of the accounting treatment of the purchase
                                            of the Company by Global Automax, which was handled in the way of a &#8220;reverse purchase&#8221;.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.7pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            assets and liabilities of the accounting purchaser and accounting acquiree were recognized
                                            in the consolidated financial statements according to their book value immediately before
                                            the transaction.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 78pt 0pt 0; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Surpluses
                                            and the other capital items of the consolidated entity after the merger transaction are those
                                            of the accounting purchaser Global Automax, which is the legal subsidiary (shortly before
                                            the business combination). The structure of the legal capital, i.e. the type and number of
                                            remaining shares of the Company (the legal parent company).</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 78pt 0pt 0; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            accounting acquiree was a shelf corporation as of the date of the transaction. As a result
                                            of the transaction, no original differences or goodwill were created. The difference between
                                            the consideration for the value of the capital instruments of the Company (the accounting
                                            acquiree) on the day of completion of the transaction and the balance sheet value of the
                                            net assets of the accounting acquiree on the day of completion of the transaction is credited
                                            as one-time expenses for the registration for trading.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Comparative
                                            information presented in the consolidated financial statements for the periods preceding
                                            the date of the transaction is that of the accounting purchaser. </span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 2 - Principles of accounting policy (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>w.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Implementation
                                            of new financial reporting standards and amendments to existing accounting standards for
                                            the first time</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">1. <span style="text-decoration:underline">Amendment to IAS 1, Presentation
of Financial Statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0in; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In January 2020, the IASB published
an amendment to IAS 1 - Presentation of Financial Statements regarding the requirements for the presentation of current or non-current
liabilities (&#8220;the original amendment&#8221;). In October 2022, the IASB published an amendment to the aforementioned amendment
(&#8220;the follow-up amendment&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">The subsequent
amendment determined that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Only
                                            financial criteria that an entity must meet at the end of the reporting period or earlier,
                                            affect the classification of that obligation as current or non-current.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
                                            commitments that the compliance with financial covenants is tested within the following 12
                                            months from the reporting date, disclosure should be provided in a manner that allows users
                                            of the financial statements to assess the risks associated with that commitment. According
                                            to the following amendment, disclosure should be made regarding the value in the books of
                                            the obligation, information on financial covenant units, as well as facts and circumstances
                                            at the end of the reporting period that may lead to the conclusion that the entity has difficulty
                                            in complying with the financial covenant units.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.85pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The original amendment determined
that the right of conversion of an obligation will affect the classification of the entire obligation as either a current or non-current
obligation, except in cases where the conversion component is monetary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The original amendment and the subsequent
amendment will be applied for settlement starting from annual periods beginning on January 1, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The above amendment did not have a
material impact on the Company&#8217;s interim consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">2. <span style="text-decoration:underline">Amendment
to IFRS 16, Leases </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In September 2022, the IASB published
an amendment to IFRS 16, Leases (hereinafter: the &#8220;Amendment&#8221;) aimed at providing accounting treatment in the financial statements
of the seller-lessee in sale and leaseback transactions when the lease payments are variable lease payments that do not depend on an
index or exchange rate. As part of the amendment, the seller-lessee is required to adopt one of two approaches to measuring a liability
for the lease at the date of initial recognition of such transactions. The chosen approach constitutes an accounting policy that must
be applied consistently.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The standard will be applied for annual
periods beginning on January 1, 2024 or later. The amendment was applied retroactively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The above amendment did not have a
material impact on the Company&#8217;s consolidated financial statements<span style="font-size: 10pt">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt">3. <span style="text-decoration:underline">Amendments
to International Accounting Standard 7, Statement of Cash Flows, and International Financial Reporting Standard 7, Financial Instruments:
Disclosures</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In May 2023, the IASB issued amendments
to IAS 7, Statement of Cash Flows, and International Financial Reporting Standard 7, Financial Instruments: Disclosures (hereinafter:
the &#8220;Amendments&#8221;), to clarify the characteristics of supplier financing arrangements and require additional disclosure for
these arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The disclosure requirements in the
amendments are intended to assist and enable users of financial statements to assess the effects of supplier financing arrangements on
the entity&#8217;s liabilities as well as on the entity&#8217;s cash flows and exposure to liquidity risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The standard will come into effect
for annual reporting periods beginning on January 1, 2024 or later.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The above amendment did not have a
material impact on the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 3 - The main considerations, estimates
and assumptions in preparing the financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing the financial statements in accordance
with the IFRS, the Company&#8217;s management is required to use discretion in assessments, estimates and assumptions that affect the
implementation of the accounting policy and the amounts of assets and liabilities, income and expenses. It is hereby clarified that the
actual results may differ from said estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the formulation of accounting estimates
used in the preparation of the Group&#8217;s financial statements, the Company&#8217;s management was required to make assumptions regarding
circumstances and events involving significant uncertainty. At its discretion in formulating the estimates, the Company&#8217;s management
bases the estimates on past experience, various facts, external factors and reasonable assumptions according to the circumstances appropriate
to each estimate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimates and assumptions based on which
changes in recognized accounting estimates are regularly reviewed are recognized in the period in which the estimates were revised and
in any affected future period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding assumptions made by the
Group regarding the future and other main factors of uncertainty in connection with estimates where there is a significant risk that
their result will be a substantial adjustment to the book values of assets and liabilities during the next financial year is included
in the following notes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>a.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>The
                                            considerations</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Capitalization rate of a liability
for a lease </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company cannot easily determine
the interest rate inherent in leases, and therefore for the purpose of calculating the liabilities for a lease, it uses the additional
interest rate of the Company. The additional interest rate determined by the Company constitutes the interest rate that the Company had
to pay on a loan for a period similar to the lease period and with similar security, in order to obtain an asset of similar value to
the right-of-use asset resulting from the lease, and all in a similar economic environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>b.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Estimates
                                            and assumptions </b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In preparing the financial statements,
management is required to use estimates, evaluations and assumptions that affect the implementation of the accounting policies and the
amounts reported for assets, liabilities, income and expenses. Actual results may differ from management&#8217;s estimates. The changes
in the accounting estimates are credited in the period in which the change in the estimate is made. Below are the main assumptions made
in the financial statements in connection with the uncertainty for the reporting date and critical estimates calculated by the Group,
where a material change in the estimates and assumptions may change the value of assets and liabilities in the financial statements in
the following reporting periods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 14.2pt"><b>1.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Determining
                                            the net disposal value of the new vehicle inventory</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company regularly examines the
realizable value of its inventory, and in particular the inventory of new vehicles. As part of the considerations used to determine the
realization value of the new vehicle inventory, the Company estimates the expected sales prices of the inventory and the total additional
costs that it is expected to incur in order to complete the sale, including agent commission payments and costs for preparing the vehicle
for sale.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 3 - The main considerations, estimates
and assumptions in preparing the financial statements (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 14.2pt"><b>2.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Legal
                                            Claims </span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In assessing the chances of the results
of the lawsuits filed against the Company and its held companies, the companies relied on the opinions of their legal advisors. These
evaluations of the legal advisors are based on their best professional judgment, taking into account the stage of the proceedings as
well as the legal experience gained in the various issues. Since the results of the legal claims will be determined by the courts, these
results may differ from the estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 14.2pt"><b>3.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Pension
                                            benefits and other benefits after employment is terminated </span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The liability for post-employment
benefit plans is determined using actuarial valuation techniques. Calculating the liability involves determining assumptions regarding
discount rates, expected rates of return on assets, the wage increase rate and employee turnover rates, among other assumptions. The
balance of the obligation may be significantly affected by changes in these estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 14.2pt"><b>4.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Lease
                                            transactions that include extension and cancellation options </span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">For the purpose of assessing whether
it is reasonably certain that the Company will exercise an option to extend a lease period or to cancel a lease period, the Company takes
into account all the relevant facts and circumstances that create an economic incentive for the Company to exercise or not exercise the
option, such as: significant amounts invested for improvements to the leased property, the importance of the underlying asset and the
uniqueness inherent in it for the purpose of the Company&#8217;s activity, the Company&#8217;s past experience in similar lease transactions
and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">After the start date, the Company
re-evaluates whether it is reasonably certain that it will or will not exercise an option when a significant event or a significant change
in circumstances occurs that has the potential to influence the Company&#8217;s decisions regarding the exercise of the option, such
as: significant improvements made to the leased property that were not foreseen at the start date, entering into a lease of a sub-asset
of the base asset for a period that exceeds the end of the previously determined lease period and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 63.45pt 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 4 - New standards and interpretations
that have not yet been adopted</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Standard/interpretation/
    correction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Publication expenses</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Start
    &amp; transition instructions</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: justify; text-indent: 1.3pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3pt"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Expected effects</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">International
                                            Financial Reporting Standard 18 &#8220;Revenue Recognition&#8221; (&#8220;IFRS 18&#8221;)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            April 9, 2024, IFRS 18 was published, replacing IAS 1 &#8220;Presentation of Financial Statements&#8221;
                                            (IAS 1). The purpose of the standard is to improve the manner of information presentation
                                            by entities to users in their financial reports.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The standard focuses on the following areas:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Profit or Loss Statement Structure - Presentation
    of defined interim summaries and categorization into profit or loss statement categories.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Requirements regarding the improvement
    of cooperation and the dissemination of information in financial reports and explanations.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Presentation of information regarding
    performance measures defined by management (&#8220;MPM&#8221;) that are not based on Generally Accepted Accounting Principles (NON-GAAP)
    in the explanations to the financial reports. In addition, amendments to other IFRS standards, including International Accounting
    Standard 7 &#8220;Statement of Cash Flows,&#8221; will come into effect with the implementation of IFRS 18, aimed at improving comparability
    between entities. The changes mainly include: use of a sub-summary of operating profit as a single starting point in the implementation
    of the indirect method for reporting cash flows from current operations as well as the cancellation of the alternatives for choosing
    an accounting policy regarding the presentation of interest and dividends. In light of this, except for certain cases, interest and
    dividends received will be included within the framework of cash flows from investment activities, while interest paid and dividends
    paid will be included within the framework of financing activities.</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            standard will come into effect for annual reporting periods beginning on January 1, 2027
                                            or later. The standard is applied retroactively, with specific transition instructions. Early
                                            adoption is possible.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 1.3pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3pt">The
                                            Company is examining the impact of IFRS 18, including the impact of amendments to other IFRS
                                            standards as a result of its application, on the financial statements.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 1.3pt">&#160;</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 4 - New standards and interpretations
that have not yet been adopted (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; padding-right: 0pt; padding-left: 0pt; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>Standard/interpretation/
    correction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Publication expenses</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center; width: 22%"><span style="font-family: Times New Roman, Times, Serif"><b>Start
    &amp; transition instructions</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.3pt"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Expected effects</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Amendments
                                            to IFRS 9 &#8220;Financial Instruments&#8221; and IFRS 7 &#8220;Financial Instruments: Disclosures&#8221;
                                            (regarding classification and calculation of financial instruments and adding disclosure
                                            requirements)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Main
                                            amendments to IFRS 9:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Adding the option to write off a financial
    obligation that was settled via an electronic payment system transfer before the settlement date, provided the following criteria
    are met:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* The entity has no practical ability to
    withdraw, stop or cancel the payment order;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* The entity does not have the practical
    ability to access the cash that would be used for settlement as a result of the payment instruction; and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* The clearance risk associated with the
    electronic payment system is not significant.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An entity that chooses this option is required
    to apply it to all liabilities settled in the same electronic payment system.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Adding implementation guidance and examples
    for assessing whether contractual cash flows of a financial asset constitute only payments of principal and interest on the principal
    amount outstanding for the purpose of classifying the financial asset.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. The amendment clarifies that a financial
    asset has the characteristics of a non-recourse asset if the entity&#8217;s ultimate right to receive cash flows is contractually
    limited to cash flows generated from specified assets.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The amendments clarify the characteristics
    of contractually linked instruments that distinguish them from other transactions.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -19.65pt"><span style="text-decoration:underline">Main
    amendments to IFRS 7:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Updating the disclosure requirements regarding
    investments in equity instruments designated at fair value through other comprehensive income.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Adding disclosure requirements for contractual
    terms that may change the timing or amount of the contractual cash flows of financial instruments upon the occurrence (or non-occurrence)
    of a contingent event (for example, achieving greenhouse gas emission reduction targets) that does not directly relate to changes
    in the risks and costs of underlying loan agreements (such as the time value of money or credit risk).</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The
                                            standard will come into effect for annual reporting periods beginning on January 1, 2026
                                            or later. Early application is possible provided that all amendments are applied simultaneously
                                            or only the amendments related to the classification of financial assets are applied.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An entity is required to apply the amendments
    retrospectively. The entity is not required to restate previous periods at the date of initial application but may do so if, and
    only if, it can be done without the use of hindsight.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4pt">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">The
    Group is examining the consequences of the amendment on the financial statements without the intention of early implementation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 4 - New standards and interpretations
that have not yet been adopted (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; padding-right: 0pt; padding-left: 0pt; text-align: left; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif"><b>Standard/interpretation
    /correction</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 33%; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Publication expenses</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; text-align: center; width: 22%"><span style="font-family: Times New Roman, Times, Serif"><b>Start
    &amp; transition instructions</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 22%; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Expected effects</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt">Annual Improvements to IFRS Accounting
    Standards (Volume 11):<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As
                                            part of the annual improvements process, in July 2024, a number of amendments to IFRS standards
                                            were published, including:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#160;Drafting amendments are limited in
    scope to IFRS 1 &#8220;First-time Adoption of International Financial Reporting Standards&#8221;, IFRS 10 &#8220;Consolidated Financial
    Statements&#8221; and IAS 7 &#8220;Statement of Cash Flows&#8221;.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#160;Amendments to IFRS 9 &#8220;Financial
    Instruments&#8221; clarifying that when it is determined that a lease liability has been extinguished in accordance with the provisions
    of IFRS 9, the lessee is required to apply the provisions of section 3.3.3 of IFRS 9 so that the gain or loss arising from the derecognition
    is recognized in profit or loss. It was also clarified that the balance of customers will be calculated at the date of initial recognition
    in accordance with the amount determined in the application of IFRS 15 and not in accordance with the transaction price.</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">The
    standard will come into effect for annual reporting periods beginning on January 1, 2026 or later. Earlier implementation is possible.
    The amendment to IFRS 9 regarding de-recognition of lease liabilities will be applied to lease liabilities that were extinguished
    at the beginning of the annual reporting period in which the amendment is first applied.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; text-align: justify; direction: ltr; unicode-bidi: embed"><span style="font-family: Times New Roman, Times, Serif">The
    Group is examining the consequences of the amendment on the financial statements without the intention of early implementation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 5 - Cash and cash equivalents</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash in banking corporations in Israeli currency</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,463</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,475</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash in banking corporations in Israeli
    currency</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total cash and cash equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,486</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,552</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 6 - Customers</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">a. The composition:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Open debts</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">8,837</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">17,709</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Checks for collection and credit cards</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,168</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,965</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29,005</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,674</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less - provision for doubtful debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total net customers</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">28,883</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">26,552</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 7.05pt">Customer debts do not bear
interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 7.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>b.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Information
                                            regarding the Company&#8217;s exposure to credit risk due to customer balances:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Customers whose repayment date has not yet
    arrived</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Customers
    whose due date has passed and the delay in<br/>
    their collection is:</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(w/out
    collection arrears)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Up to
    60<br/>
    days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">60-90
    days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">More
    than 90 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of
    December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; width: 40%; text-align: left; padding-left: 0.125in">Customer
    balance before provision Doubtful debts</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,687</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,128</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">8,837</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Balance of provision
    for doubtful debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,687</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,006</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,715</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 6 - Customers (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 7.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Customers whose repayment date has not yet
    arrived<br/>
(w/out</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Customers
    whose due date has passed and the delay in their collection is:</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> collection arrears)</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Up to
    60 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">60-90
    days</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">More
    than 90 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of
    December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 0pt">Customer balance before provision</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,143</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3,123</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5,704</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,739</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">17,409</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt">Doubtful debts</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Balance of provision
    for doubtful debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,143</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,123</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,704</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,617</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,587</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 7 - Receivables and debit balances</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Advanced payments to suppliers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">53,277</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">17,286</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,328</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,166</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,308</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,601</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Value Added Tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,386</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">369</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables and other debit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,048</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,386</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">245</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,979</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax assessing officer - company</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">66,593</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">34,801</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>


</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 8 - Vehicles inventory</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">a. The composition:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">New cars</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">196,087</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">170,009</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Used cars</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,024</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,033</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accessories</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,687</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,605</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">209,798</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">183,647</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">b. As
stated in Note 2i above, the Group calculates its inventory according to the lower of the cost base and the net realizable value. The
Group regularly examines the realizable value of the inventory, taking into account a number of factors and characteristics, and in particular
the age and condition of the inventory. About the considerations taken into account regarding the examination of realizable value in
respect of the new car inventory, see also Note 3b1. As of December 31, 2024 and 2023, the inventory of new cars is without reduction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 9 - Investment in stocks of held companies</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further to what was covered in Notes 1 (c) and
2 (u) regarding the merger and reverse acquisition: Matomy is the legal purchaser of Global Automax and both own subsidiaries as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>a. Additional information regarding subsidiaries
whose reports are consolidated in the Company&#8217;s reports:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Country of incorporation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>The Company&#8217;s
    rights in capital and voting rights </b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>%</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amounts
    advanced by the Company to the consolidated company</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">The scope
    of investment in the apital of the consolidated company</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="text-decoration:underline">December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Automax Hasharon (1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">Israel</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">67</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">504</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,504</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Automax &#8220;Trade In&#8221; Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Israel</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,430</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,430</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Automax Direct Import Ltd. (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Israel</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,008</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,008</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Automax car fleets Ltd:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Israel</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">291</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">291</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,233</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,233</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">As for December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Automax Hasharon (1)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Israel</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">67</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">270</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,899</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,169</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Automax &#8220;Trade In&#8221; Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Israel</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,128</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,128</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Automax Direct Import Ltd. (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Israel</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Automax Netanya Ltd. (4)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Israel</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">682</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">682</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,157</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,899</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,056</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">See
                                            Note 33a below.</td></tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">See
                                            Note 21b below.</td></tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During
                                            November 2024, the subsidiary Global Automax acquired the remaining 50% of the shares of
                                            Automax Fleets. See Note 21b below.</td></tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Automax
                                            Netanya Ltd.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 9 - Investment in stocks of held companies
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -83.7pt"><b>B. Details
regarding affiliated companies held by the Company:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -83.7pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>Investment
in affiliated companies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Number of</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Nominal</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>Company&#8217;s rights<br/>
    in capital and<br/>
    voting rights</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>for December 31st</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>shares</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Type</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>value</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>%</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>2024</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>2023</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Dalhom Automax Ltd. (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%; padding-left: 5.4pt">Ordinary</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">0.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,256</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">0.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Management</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">0.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Automax Shefela Ltd. (2)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Ordinary</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,148</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Automax car fleets Ltd:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Management</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">171,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Ordinary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,482</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,489</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
    Dalhom Automax Ltd.: </b>&#160; &#160; &#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Share capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-(*)</td><td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Debits and credits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">770</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">684</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Loan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,566</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,156</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Investment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,607</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,662</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,125</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(246</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">10,818</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">11,256</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            lower than 1 thousand ILS.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 21b(c) below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 9 - Investment in stocks of held companies
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0.25in; margin-bottom: 0pt; text-align: left"><b>2.
Automax HaShfela Ltd.:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-(*)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-(*)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">HaShfela Debits and credits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,664</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,249</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity losses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,470</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Loan</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">470</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">664</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,148</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: right"></p><div>





</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
                                            lower than 1 thousand ILS.</span></td>
</tr></table><div>
                                                                                </div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, see Note 21b(e) below.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>3. Automax car fleets
Ltd:</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Debits and credits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">102</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity losses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Share capital</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">85</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">See
Note 21b(g) below.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for lease
agreements&#160;</span></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 1, 2018, the Company applies standard
IFRS 16 as detailed in Note 2 p.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>a. Assets composition due to lease agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">for December
    31st</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cost:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Opening balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">36,409</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">28,044</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,392</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,897</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,532</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Closing Balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,554</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Accrued depreciation and amortization:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Opening balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,923</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes during the year:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,951</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,774</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,073</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Closing Balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,924</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>b. Composition of liabilities for the lease agreements:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of
    December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Opening balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">22,104</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">18,032</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes during the year:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,127</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,807</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Changes during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(509</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Payments and changes due to leases</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,804</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,226</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,920</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities with respect to lease agreements &#8211; current
    maturities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,775</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Long-term lease related liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,919</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,329</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,920</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>c.
Amounts recognized in profit and loss:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the
    year ended on</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Depreciation expenses with respect to right-of-use
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5,951</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5,750</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing expenses with respect to liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for lease
agreements (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.05pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>d.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>The
                                            lease agreements include the following breakdown:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.05pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement for a land plot and a building in which the Global Automax Jerusalem branch is
                                            based</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global Automax has a Lease Agreement
with a third party for the lease of an asset in Jerusalem. The Lease Agreement is valid until March 31, 2025, after exercising the extension
option. Also, Global Automax was granted with additional options to extend it until March 31, 2027. Global Automax is entitled to notify
the lessor on a determined date of every year, about its decision to shorten and/or to terminate the lease agreement by submitting a
written notice of 6 months in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The current monthly lease fees amount
to approximately 117 thousand ILS, plus VAT and linkage differentials. On April 1, 2020, and every two years thereafter, the lease fees
shall increase by 3% when compared to the monthly fees paid on the previous month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the undertakings
of Global Automax subject to the lease agreement, the lessor was provided with various collaterals, as follows: (a) personal guarantees
provided by Messrs. Daniel Levi, Yinon Amit, Emanuel Paz Puzailov and Eyal Baruch (hereunder: the <b>&#8220;Guarantors&#8221;</b>); (b)
a promissory note by the subsidiary at the amount of 500 thousand ILS, personally guaranteed by the Guarantors; and (c) a deposit in
the amount of the monthly fees, provided by Global Automax and held by the lessor as collateral to secure the undertakings of Global
Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In accordance with the approval
of the general meeting of the company&#8217;s shareholders, Global Automax intends to replace the personal guarantees given by the Guarantors
as mentioned above, with other acceptable collaterals to be provided by Global Automax in the amount of up to 5 months of lease fees.
As of the reporting date, said guarantees have not yet been replaced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">This property houses the Global
Automax building in Jerusalem, which includes an exhibition center, a parking lot for vehicles imported by the subsidiary, the Company&#8217;s
headquarters as well as a facility for preparing vehicles for sale (PDI).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -15.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 4.3%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 14.2pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for lease
agreements (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement in connection with a plot of land in Rishon Lezion and a building in which the
                                            Global Automax branch is based</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global Automax has a lease agreement
with a third party, according to which it leases a 2,000 square meters plot of land in Rishon Lezion on which a building of approximately
566 square meters is built. The lease agreement is valid until May 2031. Global Automax is entitled to shorten the lease term by submitting
a written notice to the lessor 6 months in advance. In addition, the lessor may shorten the lease period by submitting a written notice
five months in advance, if it wishes to build on the property, provided that it presents Global Automax with a signed and valid building
permit from the Rishon LeZion Planning and Construction Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The monthly lease fees vary between
approximately 82 to approximately 100 thousand ILS, plus VAT and linkage differencials from May 2015 (predefined annual increases for
each lease year).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">To secure its undertakings as detailed
in the lease agreement, the Company provided the lessor with various sureties, including a bank guarantee on behalf of the Global Automax,
promissory notes by the Company, as well as a Company guarantee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A Global Automax branch is located
in this property, which includes a presentation center comprised of a showroom for the sale of vehicles imported by Global Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 3.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement for a land plot with a storage lot of Global Automax in Jerusalem</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global Automax has a lease agreement
with a third party according to which it leases a plot of land of 1,776 square meters in Jerusalem. The lease agreement is valid until
July 2024 (after Global Automax exercised options granted to it to extend the lease period). Global Automax is entitled to shorten the
lease period, provided that it notifies the lessor accordingly by submitting a written notice 60 days in advance. The lessor is entitled
to cancel the agreement with a written notice of 6 months in advance, in cases of development and/or planning and/or sale of the leased
property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 7.1pt">	</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The current rent is 44.1 thousand
ILS, plus VAT and linkage differentials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 7.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 24, 2024, the general meeting
of the Company&#8217;s shareholders approved the extension of the lease agreement for a period of up to 5 additional years, at a monthly
lease not exceeding ILS 44,100, plus VAT and linkage differentials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Approximately 47% of the leased
property rights are held by an affiliated party of one of the Company&#8217;s Directors, who is also a shareholder of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee its undertakings
in acordance with the lease agreement, Global Automax provided the lessor with a sum equivalent to 3 months lease fees (120 thousand
ILS) plus VAT as required by law, as payment for the last three months of the lease term. In addition, Global Automax provided an additional
CPI-linked promissory note in the amount of 100 thousand ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">This property contained the logistic
warehouse of Global Automax, where it stores its imported vehicles after they are released by the Customs Authorities and prior to their
transportation to the PDI center of Global Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 3.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The lease agreement ended at the
end of June 2024 after Global Automax decided not to renew it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><span style="text-decoration:underline">Note
10 - Assets and liabilities for lease agreements (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>




</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement of a land plot with a building in which the Haifa branch of Global Automax operates</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global Automax has a lease agreement
with a third party, according to which it leases a plot of land in Haifa, with an area of 510 square meters, on which a building with
an area of approximatively 363 square meters is built. After having been extended for an additional period, the lease agreement is in
effect until May 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The monthly lease fees total 42.5
thousand ILS, plus VAT and linkage differentials, and the lease fees for the additional period total 44 thousand ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A deposit equal to three months&#8217;
rent plus VAT was paid to the lessor when receiving possession of the property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A Global Automax branch is located
in this property, which includes a presentation center comprised of a showroom for sale of vehicles imported by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">5.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement for a land plot with a building in which the Global Automax Raanana branch operates</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Automax Hasharon has a lease agreement
with a third party according to which it leases a 1,550 square meter lot in the city of Raanana, on which a building of approximately
1,550 square meters is built. The lease agreement is in effect for the period from May 1, 2021 to April 30, 2026, and Automax Hasharon
was granted options to extend it until April 30, 2031. Automax Hasharon is entitled to notify the lessor on a determined date of every
year of the shortening and/or termination of the lease agreement by submitting a written notice 3 months in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The monthly lease fees were set
at the amount of 55,000 ILS, plus VAT and linkage differentials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A Global Automax branch is located
in this property, which includes a presentation center comprised of a showroom for sale of vehicles imported by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 9%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">6.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement for a land plot with a building in which the Global Automax Rishon Lezion branch
                                            operates</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Automax Hasharon has a lease agreement
with a third party according to which it leases a 4,095 square meter lot in the city of Petach Tikva, on which a building of approximately
4,095 square meters is built. The lease agreement is valid until December 2024, and the Company was granted options to extend it until
December 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The monthly lease fees total 27,500
ILS, plus VAT and linkage differentials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A Global Automax branch is located
in this property, which includes a presentation center comprised of a showroom for sale of vehicles imported by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 17%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In accordance with the agreement
with the landlord, the lease agreement ended in March 2024 and Global Automax closed this branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">7.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement for a land plot in Glilot with a building on which the Global Automax branch operates</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Automax Trade-in has a lease agreement
with a third party, according to which it leases a 1,100 square meter lot in Glilot, on which a building of approximately 1,100 square
meters is built. The lease agreement is valid until August 2024 (after exercising an option for its extension).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The monthly lease fees were set
at the amount of 37,500 ILS, with the addition of VAT and linkage differentials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global Automax branch is located
in this property including a presentation center for sale of new and used vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 1.7% and at 7.2% during the option period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The lease agreement ended at the
end of August 2024, after Automax Trade-In decided not to renew it and closed the branch in Glilot.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 10 - Assets and liabilities for lease
agreements (continued)&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">8.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Lease
                                            agreement of a plot of land with a building where Global Automax Afula branch operates </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">Global Automax has a lease agreement
with a third party according to which it rents a plot of land with an area of 545 square meters, on which a building with an area of
approximatively 545 square meters operates in Afula. The lease agreement is for the period from December 1, 2021 to December 1, 2024,
and Global Automax is granted options to extend it until December 1, 2030. Global Automax is entitled to notify the lessor on a determined
date of every year about its decision to shorten and/or to terminate the lease agreement by submitting a written notice 3 months in advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The monthly lease fees were set
at the amount of 27,250 ILS, plus VAT and linkage differentials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">A Global Automax branch is located
in this property, which includes a presentation center comprised of a showroom for sale of vehicles imported by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
lease is estimated at 2.9%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">9.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Vehicles
                                            under operational lease</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">As of December 31, 2024 and 2023,
the Company has 23 and 19 (respectively) operating lease agreements for vehicles, for periods of 3 years. The aforementioned vehicles
are presented on the basis of cost plus one-time setup costs transaction, after deduction of accrued depreciation. The vehicles are amortized
based on individual calculations for each vehicle over the lease period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The inherent interest rate of this
leases is estimated between 4.53% and 7.15%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 11 - Fixed Assets, net</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="22" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Vehicles</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Computers</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Office
    equipment and furniture</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Leasehold
    improvements</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Electronic
    equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balance
    as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,828</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,159</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,059</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">7,940</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">468</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">14,454</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additions during
    the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">554</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">138</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">119</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,048</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Subtractions
    during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(857</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(959</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance
    as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,525</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,362</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,058</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,078</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">520</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,543</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Accumulated
    depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balance as of
    January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,603</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">974</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,583</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additions during
    the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">280</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">329</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">137</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">796</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">73</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,615</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Subtractions
    during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(195</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(216</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance
    as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(420</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,932</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,107</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,395</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(128</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,982</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Fixed
    assets, net, as of December&#160;31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,105</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">430</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">951</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,683</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">392</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">6,561</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 11 - Fixed Assets, net</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="22" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Vehicles</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Computers</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Office
    equipment and furniture</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Leasehold
    improvements</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Electronic
    equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,365</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,834</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,893</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">7,235</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">260</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">12,587</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">341</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">924</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">346</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,951</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Subtractions during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,680</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(138</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,084</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance
    as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,829</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,159</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,059</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,939</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">468</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,454</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">208</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,269</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">817</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,838</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,157</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">355</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">337</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">771</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Write-offs during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(229</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(249</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Balance
    as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(334</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,604</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(974</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(70</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Fixed
    assets, net, as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,495</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">555</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,085</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,339</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">365</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,871</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 12 - Intangible assets, net</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Import
    licenses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Goodwill</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Website</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cost</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">19,664</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">764</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,817</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">22,245</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,544</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,544</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,208</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">764</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,817</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30,789</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Cumulative reduction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(11,126</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,955</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(255</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,210</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,834</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,502</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,336</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Reduced cost, net, as of December
    31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">15,374</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">764</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">315</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">16,453</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Import
    licenses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Goodwill</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Website</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">17,020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">764</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,045</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">18,829</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,644</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">772</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,416</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,664</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">764</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,817</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22,245</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Cumulative reduction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,114</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,045</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,159</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Additions during the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,765</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(202</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,967</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,879</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,247</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,126</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Reduced cost, net, as of December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">9,785</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">764</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">570</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">11,119</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 13 - Long-term deposits in banking corporations</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-term deposits in banking corporations, as
of December 31, 2024 are presented at the amount of 1.242 thousand ILS. As of December 31, 2023, said deposits amounted to 409 thousand
ILS. The deposits comply with some of the terms of state-guaranteed loans. as well as an additional deposit deposited by Automax Hasharon
with respect to a guarantee provided in relation with the lease agreement of the Raanana branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 14 - Short-term credit from banking corporations
and financing bodies</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Interest rate</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Bank - overdraft</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">13</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">8</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current maturities of long-term loans (see Note 17)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,628</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,004</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Short-term loans</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6.75-8.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">171,042</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">139,418</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">175,683</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">141,430</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has unsecured credit lines that amounted
to a total of approximately 175.5 million ILS as of December 31, 2024 and to approx. 150 million ILS as of December 31, 2023. Out of
these credit lines the Group utilized approx. 170.5 million ILS as of December 31, 2024 (and approx. 143 million ILS as of December 31,
2023). The Group does not pay for unused credit lines, which as mentioned above, are unsecured.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For details regarding financial benchmarks, see
Note 21c below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 15 - Suppliers and services providers&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Open debts</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">28,534</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">14,117</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Checks for collection and credit cards</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">511</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,052</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">29,045</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">16,169</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 16 - Accounts payable and credit balances</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>a.
The composition:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Advances from customers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">33,352</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">22,407</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Contingent liability in respect of former shareholders of
    a subsidiary (b)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,836</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,777</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Employees and related institutions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,531</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">819</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Value Added Tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,898</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expenses payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">442</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,725</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitment to previous shareholders of Global Automax (c)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Provision for sick leave and vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">277</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">262</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liability for future transactions (Forward)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">151</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">320</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Liability towards the stakeholders
    of the Company</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">48,286</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">45,820</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>B.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingent
                                            liability in respect of the subsidiary&#8217;s former shareholders and an indemnifying asset
                                            for it &#8211;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On November 13, 2015, Matomy USA
(the Company&#8217;s wholly-owned subsidiary, incorporated in accordance with the laws of Delaware, USA), acquired the entire holdings
(100%) in Optimatic Media Inc. (&#8220;Optimatic&#8221;) by means of a reverse triangular merger (&#8220;The Transaction&#8221;). In
accordance with the transaction documents, since Optimatic had a large number of shareholders, including inactive companies, and after
the company took all reasonable measures to locate those shareholders, the company transferred the full transaction proceeds to a trustee,
who was responsible for locating the shareholders and making the payment to the located shareholders. In accordance with the provisions
of the Trust agreement signed with the Trustee, one year from the date of completion of the transaction, the Trustee transferred to Matomy
USA the balance of the proceeds of those shareholders who had not yet been located until that date, in the amount of $2,971 thousand
(the &#8220;Liability Amount&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On October 29, 2019, Matomy USA
was dissolved in accordance with Delaware law, and as part of its liquidation the company undertook to bear the claims filed against
Matomy USA. To the best of the Company&#8217;s knowledge, according to the law applicable in Delaware, lawsuits can be filed against
Matomy USA for a period of up to 3 years from the dissolution date as stated, and the Company&#8217;s obligation to bear claims filed
against Matomy USA is valid for a period of up to 10 years from the date of dissolution. As part of the merger transaction between the
Company and the shareholders of the former Global Automax, and as a condition precedent to its completion, an agreement was signed with
M.R.M Merhavit Holdings and Management Ltd. (the initiator of the transaction) and L.I.A. Pure Capital Ltd. (hereafter collectively:
&#8220;the Indemnifiers&#8221;), according to which in return for a payment of 1 million ILS plus VAT, to be paid to the Indemnifiers
by the Company, the Indemnifiers will indemnify the Company for any amount paid to any of Optimatic&#8217;s undocumented shareholders
as specified above, up to the liability amount. This liability was settled in an agreement signed on March 18, 2021 between the Company
and the Indemnifiers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">It should be noted that the aforementioned
understanding was approved by the Company&#8217;s Board of Directors at meetings held prior to the approval of the merger transaction
by the Company&#8217;s shareholders, and that it was brought to the Company&#8217;s shareholders for approval as part of the merger transaction,
which was approved by them on February 28, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 16 - Accounts payable and credit balances
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>C</b>.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In
                                            an immediate report published by the Company on March 24, 2021 in connection with the merger
                                            transaction completion, it was clarified that according to the merger agreement the cash
                                            amount in the Company&#8217;s treasury should amount to approximately 22 million ILS. On
                                            the deadline set for a settlement of accounts according to the aforementioned report, the
                                            cash amount in the Company&#8217;s treasury amounted to about 21.6 million ILS. In accordance
                                            with the aforementioned report, the indemnification provision set forth in item 1.1.10.5
                                            of the meeting summons report dated February 22, 2021, whose agenda was the approval of the
                                            merger transaction (&#8220;the Meeting Summons Report&#8221;), applies to the entire amount
                                            of the difference (about ILS 495 thousand) (&#8220;the Difference Amount&#8221;), according
                                            to which the amount difference will be paid by way of allocating the indemnification shares
                                            (as defined in the merger agreement) against the capital raising to be carried out by the
                                            Company (and everything as specified in item 1.1.10.5 of the Meeting Summons Report), without
                                            applying the absorption of 150,000 ILS stipulated in item 1.1.10.2 of the Meeting Summons
                                            Report. It should be clarified that as of the date of publication of this report, to the
                                            best of the Company&#8217;s knowledge, the former shareholders of the subsidiary postponed
                                            the execution date of the aforementioned mechanism in accordance with the right granted to
                                            them to postpone it until after the date of the third milestone, but no later than 72 months
                                            from the date of completion of the transaction. It should be noted that if the Company fails
                                            to raise capital, the liability will be repaid in cash. As of December 31, 2024, the amount
                                            of the difference was recorded as capital fund in the Company&#8217;s books.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 17 - Long-term credit from banking corporations</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">In ILS, non-linked (*)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">15,869</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3,811</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">With deduction of current maturities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,628</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,004</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">11,241</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,807</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Loans
                                            were provided in ILS, and beared a Prime+1.5% interest rate during 2024 and 2023. The loans
                                            are not CPI linked.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For details regarding financial benchmarks, see
Note 21c below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 18 - Non-granting control Loans from
Right Holders</span></b>&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Automax Motors</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,037</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">985</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 19 - Liability for bonds</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: left"><b>A. Composition as of December 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Capital
    amount</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Nominal
    interest</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Effective
    interest</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Balance</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Balance
    with deduction of current maturities</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Unlinked bonds (series A)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">34,245</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5.9</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">6.9</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">34,715</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">20,344</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>B. Additional
information regarding bond issuance (series B)</b>	</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">On March 1, 2022, the Company issued
a total of ILS 45,660 thousand face value bonds (series B) of the Company, worth ILS 1 each, in accordance with the shelf offer report
published by the Company on February 27, 2022, based on the Company&#8217;s shelf prospectus dated November 30, 2021 (hereinafter: &#8220;The
Shelf Offer Report&#8221;). The total gross consideration received by the Company for the bonds (series B) allocated according to the
shelf offer report, amounted to a total of ILS 45,660 thousand. The Company incurred issuance costs of approximately ILS 889 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Terms of the bonds (series B)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The bonds (series B) bear a fixed,
non-linked annual interest rate of 5.9% and will be paid twice a year, on February 28 and August 31 of each of the years 2023 to 2025
(inclusive) and on February 28, 2026, all for the interest period that ended on the last day before the payment date (hereinafter: the
&#8220;Interest period&#8221;). The interest rate that will be paid for a certain interest period (except for the first interest period,
as detailed below), will be calculated as the annual interest rate divided by two. The first interest payment date will be on February
28, 2023 for the period that begins on the first trading day after the tender day according to the first shelf offer report, and ends
on February 27, 2023 (hereinafter: &#8220;the first interest period&#8221;), and the last payment will be made on February 28, 2026,
together with the final repayment of the bond fund, and against handing over the bond certificates to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">The bonds (series B) will be settled
for repayment of the principal in 4 unequal annual payments, to be paid on February 28 of each of the years 2023 to 2026 (inclusive),
in such a way that the first payment (on February 28, 2023) will be 10% of the principal nominal value of the bonds, the second payment
(on February 28, 2024) will be 15% of the total nominal value of the bonds, the third payment (on February 28, 2025) will be 30% of the
total nominal value of the bonds, the fourth and final payment (on February 28, 2026) will constitute 45% of the total nominal value
of the bonds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 19 - Liability for bonds (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Securing the bonds</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In order to guarantee the complete
fulfillment of all the Company&#8217;s obligations according to the terms of the bonds (series B) and to guarantee the full and accurate
repayment of all the principal and interest payments the Company must pay to the bonds (series B) holders, the Company undertook to create
and/or register the guarantees listed below for the trustee&#8217;s benefit:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As
                                            a condition for providing owner loans to the controlled companies, the Company undertook
                                            to pledge, with a floating lien, the full rights of the Company by virtue of the owner loans
                                            provide from time to time to the controlled companies, and this is to ensure the full and
                                            exact fulfillment of all the Company&#8217;s obligations according to the bonds (series B)
                                            and the deed of trust.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Company has committed that as long as the bonds (series B) have not been paid in full, in
                                            a final settlement, the Company will not create general current liens on all of its assets
                                            and all of its rights, existing or future, for the benefit of any third party, to secure
                                            any debt or obligation, unless:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(A)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prior
                                            approval will be obtained from the bonds holders (series B), to create the lien in favor
                                            of a third party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(B)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Company established - for the benefit of the holders of the bonds (series B) to secure the
                                            undisputed balance of debt towards the holders, at the same time as the creation of the ongoing
                                            lien in favor of the third party - an ongoing lien of the same level pari passu according
                                            to the ratio of the Company&#8217;s debts to the third party and to the holders of the bonds
                                            as will change from time to time, and this lien will be in effect as long as the bonds (series
                                            B) have not been paid in full, or until the cancellation of the lien given in favor of the
                                            aforementioned third party, whichever comes first.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">In addition, the Company undertook
that as long as the bonds (series B) were not paid in full, it will not create and will not undertake to create, for the benefit of any
person and/or entity, liens of any kind and type on the shares of Global Automax, which it owns.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Company undertook that as long as the bonds (series B) were not paid in full, it would refrain
                                            from making a distribution (as the term is defined in the Companies Law, 5759-1999 (hereinafter:
                                            &#8220;The Companies Law&#8221;)), including that it would not declare, pay or distribute
                                            dividends (as defined in the Companies Law). Notwithstanding the above and subject to any
                                            law, the Company will be entitled to make a distribution by way of a dividends in kind of
                                            shares that are held by it in the controlled companies and are listed for trading on the
                                            stock exchange, provided that the equity of the Company, after making the distribution, does
                                            not amount to less than ILS 60 million.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59.35pt; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify">For details regarding financial
benchmarks, see Note 21c below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 20 - Liabilities for employee benefits,
net</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Post-employment benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Israeli Labor Law and Severance Pay Law require
the Company to pay severance payments to its employees upon termination or retirement. Therefore, the Company handles the corresponding
liability as a post-employment benefit. The calculation of the company&#8217;s liability for employee benefits is done in accordance
with valid employment contracts, and it is based on employees&#8217; salaries and employment period, the basis that entitles them to
receive severance pay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 0.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Defined deposit plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Group&#8217;s severance payments
to its employees in Israel is subject to the provisions of section 14 of the Severance Pay Law, 5723-1963. According to this paragraph,
current contributions to pension funds and/or insurance policies with insurance companies exempt the Group from recognizing any further
liabilities toward those employees for whom said amounts were deposited. Said contributions, as well as deposits in respect of remunerations,
constitute defined deposit plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 0.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Defined benefit plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The portion of severance pay not covered by contributions
to defined deposit plans, as detailed above, is handled by the Group as a defined benefit plan according to which the Group recognizes
the liability towards an employee&#8217; benefits for which the Group is contributing amounts in corresponding insurance policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 86.1pt 0pt 0; text-align: justify; text-indent: -0.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. The composition of employee benefits liability
presented in the Balance Sheet:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: -28.35pt">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Benefits after termination of employment by departments:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">PDI department</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">20</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sales department</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Management</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">57</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">140</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements,
encumbrances and guarantees</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Claims and legal decisions in the field</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">The Group may be exposed to legal
proceedings and claims from time to time as part of its current business operations. Regardless of the outcome of said actions, litigations
may have negative impacts over the Company as a result of the costs arising from settlements and the need to receive legal defense and
settlements, the reassignment of management resources and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During
                                            2015, an investigation was initiated against a subsidiary, Haim Levy Trade In Ltd. (hereunder:
                                            &#8220;<b>Haim Levy Trade In</b>&#8221;), one of the Company&#8217;s controlling shareholders,
                                            and against Company&#8217; position holders &#8211; Daniel Levy, CEO; Yinon Amit, Chief Business
                                            Officer and Director; Haim Levy, Trade Manager and the son of Daniel Levy; and, Gal Levy,
                                            VP of Regulations and Branch network and the son of Daniel Levy, under the suspicion of fraud,
                                            forgery and money laundering. In addition, said position holders (excluding Messrs. Daniel
                                            and Gal Levy) were interrogated on the suspicion of having committed tax fraud and regulatory
                                            breaches with respect to Company activities as a parallel importer of vehicles subject to
                                            the provisions of the Product and Services Supervision Order (Vehicle Import and Provision
                                            of Automotive Services), 5739-1978 (hereunder: the &#8220;Order&#8221;).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At the end of the investigation, Global
Automax, Haim Levy Trade In and the aforementioned position holders (with the exception of Mr. Gal Levy) (hereinafter: the &#8220;<b>Position
holders</b>&#8221;) received summons to a hearing, according to which the attorney&#8217;s office is considering prosecuting them for
having committed the aforementioned offenses. On August 5, 2021, the parties involved received a notice from the Tel Aviv District Attorney&#8217;s
Office (Taxation and Economy), according to which, after a hearing procedure that was held for Global Automax and the office holders
(excluding Gal Levy) and Haim Levy Trade In, it was decided to reject their claims and file an indictment against them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 25, 2021, a notice of indictment
was received against Global Automax, Haim Levy Trade In and the position holders. The offenses attributed to the accused in the indictment,
were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Global
                                            Automax is accused of committing forgery offenses under the Penal Law, 5733-1977 (hereinafter:
                                            the &#8220;Penal Law&#8221;), fraud under the Penal Law, smuggling under the Customs Ordinance
                                            [New Version] (hereinafter: the &#8220;Customs Ordinance&#8221;) and money laundering offenses,
                                            according to the Money Laundering Prohibition Law of 5760-2000 (hereinafter: the &#8220;Money
                                            Laundering Prohibition Law&#8221;) and the Penal Law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Haim
                                            Levy Trade In is accused of conducting forgery acts under the Penal Law, fraud subject to
                                            the Penal Law, contraband under the Customs Ordinance, tax and customs offenses (subject
                                            to the Customs Ordinance [New Version], the Value Added Tax Law, 5736-1975 and Acquisitions
                                            Tax Law (Goods and Services), 5712-1952) and money laundering offenses under the Anti-Money
                                            Laundering Law and the Penal Law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            position holders are accused of forgery according to the Penal Law, fraud according to the
                                            Penal Law, smuggling according to the Customs Ordinance and money laundering offenses according
                                            to the Law on the Prohibition of Money Laundering and the Penal Law.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">With
                                            regard to events related to Albar&#8217;s Group activity, Haim Levy Trade In and the office
                                            holders are accused of conducting acts of forgery under the Penal Law, fraud under the Penal
                                            Law, contraband under the Customs Ordinance, tax and customs offenses (subject to the Customs
                                            Ordinance [New Version], the Value Added Tax Law, 5736-1975 and Acquisitions Tax Law (Goods
                                            and Services), 5712-1952) and money laundering subject to the Anti-Money Laundering Law and
                                            the Penal Law; In addition, Yinon Amit is accused in the aforementioned case with impeachment
                                            of the investigation, conspiracy to commit a crime and misdemeanor, and obstruction of justice
                                            according to the Penal Code.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements,
encumbrances and guarantees</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the financial statements signing
date, the preliminary hearings regarding the indictment were completed, and hearings on the substantial evidence began in March 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global Automax rejects the charges
against the subject of the indictment, among other things in light of the fact that as of 2016 the Order was replaced by the Vehicle
Services Licensing Law, which allows the importer to purchase vehicles from any source. Since then, and despite Global Automax being
under investigation and later even being summoned to a hearing - which was well known to the Ministry of Transportation as the regulator
entrusted with licensing and supervision of the field in which Global Automax operates - the Ministry of Transportation renewed and extended
Global Automax&#8217;s import licenses in accordance with the Vehicle Services Licensing Law, and even issued additional import licenses
and permits to Global Automax. It should be emphasized that the vehicles subject to the indictment were not released from customs at
all, and no import documents, registrations or invoices were submitted to the Customs Authority. In addition, Global Automax did not
continue to operate according to the import license subject of the indictment, which expired in 2015. In fact, this is a single incident,
originating from the beginning of Global Automax&#8217;s operations; Global Automax has learned lessons regarding the required manner
of conduct and control with its suppliers, and it operates under internal procedures with regard to the company&#8217;s contracts with
suppliers from which it purchases vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global Automax believes, relying on
the position of its legal advisors, that it holds good arguments to handle the charges which are the subject of the indictment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to legal advice received
by Global Automax, in the event of a conviction, as part of a sentence, the punitive sanction as far as Global Automax is concerned could
result in a financial fine, while for the aforementioned party, in case of a conviction for money laundering offenses, confiscation may
be also possible as part of the verdict. In addition, besides the aforementioned, there is exposure to an administrative procedure by
the Ministry of Transportation as detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to section 8 of the Vehicle
Services Licensing Law, an employee of the Ministry of Transportation serving as the Deputy Director General for Traffic (in this section
&#8220;<b>the Director</b>&#8221;) has the authority to refuse granting or renewing a license &#8220;if the license applicant has been
convicted of a criminal offense which, due to its nature, seriousness, or circumstances, makes him unfit to engage in providing vehicle
service, or in a profession in the automotive industry for which he requested the license, or if an indictment was filed against him
for a criminal offense as mentioned and a final judgment has not yet been given in his case.&#8221; Also, according to Section 10(a)(7)
of the Vehicle Services Licensing Law, the Director may revoke a license, suspend it until ordered conditions are fulfilled, limit it
or refuse to renew it, after giving the license holder an opportunity to assert his claims, if the license holder &#8220;has been convicted
of a criminal or a disciplinary offense, which due to its nature, seriousness or circumstances, makes him unfit to engage in providing
car service, or in a profession, or if an indictment was filed against him for a criminal offense as mentioned and a final judgment was
not yet given in his case.&#8221; In the opinion of the Company&#8217;s Management and Global Automax, based on its legal advisors&#8217;
opinions, the filing of an indictment against Global Automax, or the fact that it may be convicted with respect to the offences in the
indictment, is insufficient to cause the Director to refuse to grant it import licenses, renew its indirect importer license, revoke,
restrict, or refuse to renew any licenses granted to Global Automax, due to the following reasons, cumulatively, or to any of them:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            offenses which constitute the subject of the indictment, do not lead the Director due to
                                            their nature, severity and circumstances, as described above, to the conclusion that Global
                                            Automax is not the suitable body to engage in the importation and sale of vehicles.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Ministry of Transportation is aware of the criminal investigation and of the filing of the
                                            indictment against Global Automax. However, this did not prevent it from granting the Company
                                            an indirect importer&#8217;s license, from extending it on an ongoing basis to additional
                                            vehicle products (while most indirect importer licenses for vehicle products were received,
                                            or renewed, after having received the summons for the hearing) and from granting the Company
                                            import permits for various types of vehicles since it began its operations. The management
                                            of the Company concludes from the above that the Ministry of Transportation does not see
                                            the investigation opened and the indictment filed against Global Automax, and their possible
                                            results, as possibly leading to the conclusion that Global Automax is not suitable to engage
                                            in the business of importation of vehicles.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">According
                                            to the management&#8217;s estimate, the policy of the Ministry of Transportation is to increase
                                            competition in the industry including the promotion of the Company and of its lines of business.
                                            Thus, based on its goal of realizing the purpose of the Vehicle Services Licensing Law, to
                                            open up the vehicle import market in Israel to competition, and to lower the entry barriers
                                            for commercial imports in the vehicle industry. The Company is a leading party in the competition
                                            in the industry and it has brought about a real revolution in it. Therefore, the understanding
                                            of the Company&#8217;s management is that a refusal to grant Global Automax licenses or to
                                            renew its licenses, would be against the competition that the Ministry of Transportation
                                            aims to promote.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To
                                            the best of Global Automax&#8217;s knowledge, since the enactment of the Vehicle Services
                                            Licensing Law, the Director has not exercised his authority not to grant or renew a license,
                                            and in the opinion of the Company&#8217;s management, the use of such authority will be done
                                            sparingly and very cautiously.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify; text-indent: -28.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Furthermore, Global Automax believes,
relying on the position of its legal advisors, that if such administrative proceedings were taken against it, it would be possible to
establish a substantial argument against it, including the possibility of achieving a delay in execution (and this is based, among other
things, on parallel administrative proceedings that are underway today, for example the proceedings of the Commissioner on the Capital
Market, Insurance and Savings Authority vis-&#224;-vis credit services providers).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">It should also be noted that the Company
and Global Automax have a broad and solid managerial and professional structure, a good management system and excellent trade relations,
which the Company and Global Automax expect to be able to successfully deal with all the challenges that will arise, to the extent that
they arise, following the filing of the indictment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In light of the above, Global Automax
assesses, relying on the position of its legal advisors, that the filing of the indictment does not cause cancellation or non-renewal
or refusal to grant licenses to Global Automax by the Director, or to harm the operations of the Company and of Global Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
                                            September 29, 2022, a lawsuit was filed with the District Court in Tel Aviv and an application
                                            for its approval as a class action against Global Automax, a company fully owned by the Company,
                                            and against Union Motors Ltd. (hereinafter: &#8220;Union&#8221;), Lex Motors Ltd. (hereinafter:
                                            &#8220;Lex&#8221;), Toyota Motor Corporation (hereinafter: &#8220;Toyota&#8221;), and Denso
                                            Corporation (hereinafter: &#8220;Denso&#8221;).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The subject of the application is the
applicants&#8217; claim that the defendants (Toyota as a manufacturer of vehicles; Denso as a manufacturer of allegedly defective fuel
pumps which are installed in vehicles made by Toyota and Lexus and are the subject of the request; Union and Lex as direct importers
of vehicles made by Toyota and Lexus to Israel; and Global Automax as an indirect importer of vehicles manufactured by Toyota to Israel,
as well as the company that imported the applicant&#8217;s vehicle to Israel) breached their obligations towards the members of the Group
by, inter alia, producing and/or importing and/or marketing and/or selling vehicles in which a defective fuel pump is installed, refrained
from performing a service call for all vehicles in which defective pumps are installed, refrained from bearing the costs caused by the
damaged fuel pumps and the service call, and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This, according to the applicants,
was in breach of the respondents&#8217; obligations according to the Liability for Defective Products Law, 5740-1980, the Sales Law,
5728-1968, the Contracts Law (General Part), 5733-1973, the Licensing of Services and Professions in the Automotive Industry Law, 5776-2016
and other laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities,
engagements, encumbrances and guarantees (continued)</span></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group which the applicants wish
to represent as part of the class action (if approved) is all the owners (at any time), or holders of vehicles made by Toyota or Lexus,
in which a fuel pump made by Denso was installed and of the type for which the service call was made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The respondents estimate the total
damage allegedly caused to all the members of the alleged Group, in the amount of more than 2.5 million ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On November 14, 2023, Global Automax
submitted a response to the approval application, in which it rejected all the claims raised in the approval application. In particular,
Global Automax rejected the claims specifically directed at it, and this in view of its being an indirect importer, for which most of
the alleged obligations on which the request for approval purports to be based - do not apply to it at all, and in view of the fact that
with regard to the service calls, the object of the request for approval, it fully complied with all obligations (that are limited in
any case) that apply to it in this context. On February 25, 2024, the applicants submitted a response on their behalf, in response to
the respondents&#8217; answers to the approval request. In their response, the applicants repeated their main claims. The pre-trial hearing
is set for September 10, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At this proceedings preliminary stage,
the Company&#8217;s legal advisors are unable to assess the chances of an approval request being accepted, but according to the information
and data provided to them by Global Automax, the Company&#8217;s legal advisors estimate that the exposure of the Company pertaining
to this procedure is not material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0%"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><b>B.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Engagements</span></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.25pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            January 6, 2022, the Company contracted with an attorney for the purpose of joint legal representation
                                            of Global Automax, and of the position holders who are accused together in the indictment
                                            filed against them and others in August 2021, as detailed in Note 21A above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.55pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            March 16, 2022, the Company signed an agreement with third parties (hereinafter: the &#8220;Partners&#8221;),
                                            according to which the parties will work to establish and register a joint company that shall
                                            engage in the purchase and sale of used vehicles (trade-in) (hereinafter in this sub-item:
                                            the &#8220;Agreement&#8221; and the &#8220;Joint Company&#8221;, as the case may be).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company will grant the Joint Company
exclusivity in the purchase of trade-in vehicles (to be purchased from the Company&#8217;s customers), according to pricing to be determined
at the Company&#8217;s discretion, subject to meeting the goals set forth in the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the agreement, at the
time of the Joint Company&#8217;s establishment, the Company will own 80% of its issued and paid-up capital, while the Partners will
jointly own the remaining 20%. The Partners were given options (which will be exercisable subject to meeting the objectives of the joint
company as stipulated in the agreement) (hereinafter: &#8220;the option subject to meeting the objectives&#8221;), as well as the Company
meeting the milestones established in the merger agreement between the Company and the subsidiary), which, assuming their full exercise,
may increase the holdings of the partners in the joint company up to 48% of the issued and paid-up capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the option subjected to
meeting the objectives, if in a certain period after the signing of the agreement the net profit of the Joint Company will be higher
than a set threshold, and also the Joint Company will purchase a minimum amount of vehicles from the subsidiary as stipulated in the
agreement, the Partners will be entitled to purchase ordinary shares of the Joint Company at a rate of 20% from the issued and repaid
capital, according to a company value of ILS 30 million pre-money.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Close to the establishment of the joint
company, the Company will provide financing to the Joint Company, in the form of an owner&#8217;s loan in the amount of ILS 3 million,
for its current activities (hereinafter: &#8220;the Owner&#8217;s Loan&#8221;). The Owner&#8217;s Loan will bear interest according to
Item 3(j) of the Income Tax Ordinance [new version] (hereinafter: &#8220;the Ordinance&#8221;), to be repaid in 30 equal monthly payments
starting on January 1, 2025. Should the Joint Company require additional financing for the needs of its current activities in addition
to the Owner&#8217;s Loan, the parties will provide the joint company with such financing, in the form of owner loans, based on the relative
share of each of them in the Company&#8217;s issued share capital (hereinafter: &#8220;Additional owner loans&#8221;). The additional
owner loans, if any issued, will bear interest according to item 3(j) of the Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Prior to signing the agreement, the
Company entered into a sublease agreement in connection with offices with an area of approximately 100 square meters as well as land
with an area of approximately 1,000 square meters in the &#8220;Pi Gillot&#8221; complex, which will be assigned to the joint venture
company from the date of its establishment and will be used for its operations (hereinafter: the &#8220;Lease Agreement&#8221;). The
lease period according to the Lease Agreement is from February 1, 2022 to August 6, 2023, and the Company was given an option to extend
for another identical period (subject to the extension of the lease period of the main tenant). The agreement can be terminated with
a 6 months notice, upon request from the competent authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the fourth quarter of 2024,
the Company closed the branch in Glilot, which served as a trade-in activity center and for the sale of new vehicles. It should be clarified
that as of the closure of the branch in Glilot, trade-in operations are being conducted within the framework of the existing Company
branches. The Company estimates that the closing of these branches has no significant impact on the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            April 27, 2022, following the Company&#8217;s signing on April 27, 2022 of a non-binding
                                            memorandum of understanding with Dalhom Motors Ltd. (hereinafter: &#8220;<b>Dalhom</b>&#8221;),
                                            a franchise holder for the import of Temsa brand buses (hereinafter: &#8220;the <b>Franchise</b>&#8221;),
                                            to establish a joint venture, on June 19, 2022, a detailed agreement was signed between the
                                            Company, Dalhom and Dalhom Automax Ltd., a dedicated company established to operate the abovementioned
                                            joint venture (hereinafter: &#8220;the <b>Agreement</b> &#8221; and &#8220;the <b>Joint company</b>&#8221;,
                                            and the transaction subject to the agreement &#8220;<b>the Transaction</b>&#8221;), that
                                            will engage, among other things, with the import of Temsa brand buses to Israel and with
                                            their marketing in the country.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The main points of the agreement are
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Each
                                            party&#8217;s holdings, appointment of directors, and management of the Joint Company</span></b>:
                                            upon the agreement&#8217;s completion, each party will hold 50% of the Joint Company&#8217;s
                                            ordinary shares, and the Company will be entitled to appoint more than half of the board
                                            of directors members. When the Company&#8217;s loans (as defined below) are repaid to the
                                            Company in full, the rights of the Company and of Dalhom to appoint directors to the Joint
                                            Company&#8217;s board of directors will be equal. In the articles of association of the Joint
                                            Company it is stipulated that decisions on certain matters in connection with the management
                                            of the Joint Company will require the approval of Dalhom.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Company
                                            loans</span></b>: As of the date of completion, the Company will provide the joint venture with
                                            owner loans in a total amount of 10 million ILS (above and below: &#8220;<b>company loans</b>&#8221;)
                                            and at times that will allow the joint venture to meet its obligations to Dalhom as detailed
                                            in section 4 below. The Company&#8217;s loans will be offered at the same interest rate (back-to-back),
                                            as the rate for which the Company will raise the said amount from its financing sources.
                                            However, loans will not exceed the rate stipulated in the agreement in any case. The Company&#8217;s
                                            loans, plus interest, will be repaid to the Company or converted to the joint company&#8217;s
                                            unredeemable capital, all in the manner and at the times stipulated in the agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Initial
                                            repayment to the Company</span></b>: The Company will be entitled to be the first to receive
                                            the profits made by the joint company or from its other sources, equivalent to the actually
                                            advanced Company&#8217;s loans, plus interest accrued on the Company&#8217;s loans.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Payments
                                            to Dalhom</span></b>: Subject to the completion of the agreement, the joint company will transfer
                                            to Dalhom an aggregate amount equal to the total of the Company&#8217;s loans, according
                                            to the details and under the following conditions and dates:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">A.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            inventory: at the completion date, Dalhom will sell to the joint company, the entire Temsa
                                            spare parts inventory that it will possess at that time, based on the cost of the inventory
                                            in Dalhom&#8217;s books (hereinafter: &#8220;<b>Inventory</b>&#8221; and &#8221; <b>Amount
                                            of Inventory Value</b> &#8220;).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">B.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Contingent
                                            advance: at the time of completion, the joint company will pay Dalhom an additional amount,
                                            as a conditional advance for the transfer of the franchise to the joint company (hereinafter:
                                            &#8220;<b>the Conditional Advance for the Concession</b>&#8221;). The agreement sets a mechanism
                                            according to which the conditional advance in respect of the concession will gradually become
                                            a payment for the franchise to Dalhom, depending on the number of years the franchise will
                                            be in effect from the date of completion.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">C.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dalhom
                                            loan: As of the date of completion, the joint company will transfer to Dalhom an interest-bearing
                                            loan to Dalhom (hereinafter: the <b>&#8220;Dalhom Loan&#8221;</b>), as a loan at the expense
                                            of Dalhom&#8217;s share in future profits of the joint company which will be repaid in the
                                            manner and at the times stipulated in the agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">5.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Collaterals</span></b>:
                                            To secure repayment of the Company&#8217;s loans, at the time of completion the joint company
                                            will pledge to the Company its rights towards Dalhom for the repayment of the Dalhom loan,
                                            and Dalhom will pledge to the Company its shares in the joint company as a first-class lien.
                                            The liens will be removed upon full repayment of the Dalhom loan and the Company&#8217;s
                                            loans in accordance with the provisions of the agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">6.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Liability
                                            and maintenance</span></b>: Dalhom will remain a party to bus maintenance agreements it entered
                                            into until the date of the agreement, and will bear its obligations according to these agreements.
                                            The joint company and/or the Company will not have any liability or obligation in connection
                                            with these maintenance services. The parties reached understandings on the manner and conditions
                                            of supplying spare parts to Dalhom by the joint company, for the purpose of providing the
                                            aforementioned services.</td></tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">7.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Financing
                                            the joint company&#8217;s activity:</span></b> In addition to the Company&#8217;s loans as mentioned
                                            above, after the agreement completion, the Company will provide the joint company with a
                                            credit line, or arrange a credit line to be provided by financing entities, to the extent
                                            stipulated in the agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">8.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Suspending
                                            conditions</span></b>: The parties agreed that the completion of the agreement will be subject
                                            to the existence of a number of suspending conditions, including: (a) receiving Temsa&#8217;s
                                            consent to transfer the franchise to the joint company, and signing a concession agreement
                                            between Temsa and the joint company, with substantially similar wording to the existing concession
                                            agreement wording and to the satisfaction of the agreement parties, for a period of at least
                                            3 years; and (b) receiving the approval of the Israel Competition Authority (received at
                                            the time of publication of the financial statements).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On November 20, 2022, the transaction
was completed after all the conditions agreed for the agreement&#8217;s completion were met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Prior to completing the transaction,
the joint company signed a concession agreement with Temsa for a period of three years, under which the joint company would serve as
a direct importer to Israel of buses manufactured by Temsa (hereinafter: &#8220;<b>The Concession Agreement</b>&#8221;). The Concession
Agreement includes the provisions customary in agreements of this kind, including sales objectives agreed between the parties, failure
to comply with which will give Temsa the right to cancel the concession agreement at the end of an agreed recovery period. Moreover,
the joint company has committed that without Temsa&#8217;s prior written approval, it will not import and market in Israel during the
period of the agreement products competing with those of Temsa.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The concession agreement includes additional
conditions as is customary in the industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, the joint company signed
a service and warranty agreement with Temsa for a period of three years. According to this agreement, the joint company would provide
maintenance and warranty services in Israel for buses manufactured by Temsa based on the commercial terms established between the parties
(hereinafter: &#8220;<b>The Service and Warranty Agreement</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            April 27, 2022, following the Company&#8217;s signing on April 27, 2022 of a non-binding
                                            On July 24, 2022, the Company entered an agreement with a third party, under which it shall
                                            serve as an authorized distributor of the Company (hereunder: the &#8220;Distribution Agreement&#8221;
                                            and the &#8220;Distributor&#8221;, as applicable).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Simultaneously with signing the Distribution
Agreement, the Distributor entered an agreement to rent a display center in the city of Acre, in which the Distributor intends to operate
a Company&#8217;s branch, in accordance with the provisions of the Distribution Agreement (hereunder: the &#8220;Lease Agreement&#8221;).
The Company committed towards the lessor in the lease agreement that insofar as the distributor shall terminate the lease agreement (or
shall not comply with the provisions of the lease agreement), then it will step in in its place and sign a lease agreement with the lessor
under identical terms. The Lease Agreement was signed for a period of 3 years starting August 1, 2022, and the Distributor is given an
option to extend it for an additional period of 3 years. The Distribution Agreement is in effect for a period of 5 years, and includes
the occurrence of certain events, after which each party will be entitled to cancel the Distribution Agreement immediately. In addition,
each party will be entitled to cancel the Distribution Agreement for any reason by giving 3 months&#8217; written notice to the other
party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Distribution Agreement stipulates
that the Distributor will purchase demonstration vehicles from the Company for the purpose of demonstration drives, and that the Company
will loan an inventory of vehicles to the distributor for displaying them in the showroom, subject to the purchase of an insurance policy
by the Distributor and other mutually agreed commercial matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Distribution Agreement,
the vehicles sold by the Distributor to end customers will be priced in accordance with the price list set forth by the Company, and
each vehicle sale by the Distributor will earn the Distributor a commission at a certain rate determined in the Distribution Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            August 5, 2022, Global Automax entered a Founders&#8217; Agreement with a third party that
                                            acts as an authorized distributor of vehicles imported by the Company, and operates the Company&#8217;s
                                            branch in the city of Ashkelon (hereunder: &#8220;<b>the Distributor</b>&#8221; and &#8220;<b>the
                                            Founders&#8217; Agreement</b>&#8221;, as applicable).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Founder&#8217;s Agreement,
the parties founded a joint company, Automax HaShfela Ltd., which, inter alia, operates vehicle&#8217; distribution and sales centers
in the cities of Ashdod, Ashkelon and other locations to be decided by the parties (hereunder: the &#8220;<b>Joint Company</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the Founder&#8217;s Agreement,
Global Automax holds half of the joint company&#8217;s issued share capital, while the distributor holds the remaining half. The parties
undertook to provide the joint company with an initial amount as an owner&#8217;s loan for the purpose of financing its activities, divided
between them according to the relative share of each party in the joint company&#8217;s share capital. Distribution of profits in the
joint company will be made subject to any law, according to the relative share of each party in the joint company&#8217;s share capital.
The joint company&#8217;s Board of Directors will appoint four members, of whom two will be appointed by the Distributor and two by Global
Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Founder&#8217;s Agreement includes
customary provisions limiting the possibility of transferring shares in the joint company, including the right of first refusal (except
in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along) and a forced sale
provision (Bring Along).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Prior to the signing of the Founder&#8217;s
Agreement, Global Automax entered into an agreement for the lease of a showroom of approximately 500 sqm. in the city of Ashdod, which
has been assigned to the joint company and will be used as a branch of Global Automax in the city (hereunder: the &#8220;Lease Agreement&#8221;).
The lease period is three years starting on September 15, 2022, and Global Automax is granted an option to extend the Lease Agreement
for three additional periods of two years each, and in total until September 19, 2031. The Lease Agreements of the properties in Ashdod
and Ashkelon were assigned to the joint company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the last quarter of 2022, the
parties signed a vehicle Distribution Agreement between the joint company and Global Automax, according to which the joint company shall
be the authorized distributor of the vehicles imported by the Company in the cities of Ashkelon and Ashdod. The aforementioned agreement
shall replace the existing agreement between the Company and the Distributor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the second quarter of 2024,
the Company closed the branch in Ashkelon (which had been closed since the outbreak of the Iron Swords War), and it estimates the impact
resulting from the closure of this branch as immaterial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">f.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            March 13, 2023, Dalhom entered into a conditional agreement for the distribution, sale, and
                                            marketing in Israel of private electric vehicles manufactured by Al Damani, a manufacturer
                                            from the United Arab Emirates (hereinafter: &#8220;the Distribution Agreement&#8221;, &#8220;the
                                            Vehicles&#8221; and &#8220;the Manufacturer&#8221;, respectively).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with the Distribution
Agreement, the vehicles will be sold to Dalhom according to the orders it will place from time to time, while the appointment of Dalhom
as a distributor of the Vehicles in Israel is subject to its meeting order goals within a certain period from the date of signing the
Distribution Agreement. The parties will agree on prices and additional commercial terms until the date on which Dalhom&#8217;s obligations
under the Distribution Agreement will come into effect. The manufacturer will provide Dalhom with warranty services for the Vehicles,
for the period stipulated in the Distribution Agreement, and will also provide it with spare parts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Distribution Agreement is valid
for several years, and subject to Dalhom meeting order goals, its validity will be automatically extended for several additional years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The law applicable to the Distribution
Agreement is the law of the Dubai International Financial Center (hereinafter: &#8220;DIFC&#8221;), and the place of jurisdiction pertaining
to any dispute between the parties regarding the Distribution Agreement will be Dubai, in accordance with DIFC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">It should be emphasized that all Dalhom
obligations according to the Distribution Agreement are subject to receiving all the required regulatory approvals from the Ministry
of Transportation for the import of vehicles to Israel, which have not yet been granted as of the date of the financial reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The information presented above in
connection with the import and distribution of vehicles in Israel is considered forward-looking information as defined in the Securities
Law, 5728-1968, which at this stage there is no certainty of its realization, <i>inter alia</i>, due to factors that are not under the
control of the Company or are not under its full control. The realization of the aforementioned information depends, <i>inter alia</i>,
on the authorizations of the Ministry of Transportation and other institutions, which, as mentioned, have not yet been granted at the
present stage and there is no certainty that they shall be obtained in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements,
encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">g.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            lease agreement that is used as a service center for buses that are manufactured by Temsa</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February 2023, Dalhom Automax signed
a lease agreement with third parties (hereinafter: &#8220;the Lease Agreement&#8221; and the Lessors&#8221;, as applicable, according
to which Dalhom will rent from the Lessors an asset of approx. 4,000 square meters in the city of Hod Hasharon, for the purpose of establishing
and operating a vehicles&#8217; repair shop, which will be used as a service center for buses manufactured by Temsa.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The initial lease period according
to the agreement is 5 years starting on March 15, 2023, and ending on March 14, 2028 (&#8220;the First Lease Period&#8221;). Dalhom will
have the option to extend the initial lease period for an additional period of 5 years, subject to its compliance with the provisions
stipulated in the Lease Agreement (&#8220;the Additional Lease Period&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the first year of the lease
period, Dalhom will pay a monthly rental fee of 120 thousand ILS, plus VAT. Starting from the beginning of the second year of the First
Leasing Period (i.e., starting from the 13th month of the rental period), Dalhom will pay a monthly rental fee of 130 thousand ILS plus
VAT. The rental fees during the Additional Leasing Period will increase by 5% compared to the last rent that was paid prior to the beginning
of the Additional Lease Period. Rental fees shall be linked to the consumer price index.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In order to guarantee Dalhom&#8217;s
undertakings according to the Lease Agreement, the Lessors were provided with the following securities: (a) a Compay&#8217; guarantee,
jointly and severally with Dalhom Motors and for an unlimited amount, for all the undertakings of Dalhom according to the Lease Agreement;
(b) an autonomous bank guarantee in an amount equal to the rental fees for a 4 months period plus VAT, whereby the guarantee sum is linked
to the consumer price index. Instead of providing a bank guarantee, Dalhom may pay the Lessors an amount of 561,600 ILS which shall be
used as a deposit to be held by the Lessors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalhom has undertaken to indemnify
the Lessors and/or anyone on their behalf for any amount they will be required to pay in connection with a lawsuit of a certain third
party, insofar as it is filed, for the failure of Dalhom and the aforementioned third party to rent the property jointly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The service center was opened to customers
during January 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 38.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">h.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Given
                                            that the Company met milestones no. 2 and 3 that were set in the merger agreement between
                                            the Company, Global Automax and its shareholders at the time (the current stakeholders in
                                            the Company), and between M.R.M Merchavit Holdings and Management Ltd. (the initiator of
                                            the transaction), on March 28,2023, the company allocated to the stakeholders in the Company
                                            an additional 168,105,258 ordinary shares of the Company, which constituted about 41% of
                                            the Company&#8217;s issued and paid-up share capital after the allocation. After this allocation,
                                            the stakeholders of the Company held together about 70.9% of the issued and paid-up share
                                            capital of the Company, and as of the day of signature of the financial statements, they
                                            hold together about 55.65% of the Company&#8217;s issued and paid-up share capital.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.1pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">i.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval of the general meeting of the Company&#8217;s shareholders, which took place
                                            on May 8,2023, on May 21,2023 the Company&#8217;s registered share capital, and its issued
                                            and paid-up share capital were consolidated at a ratio of 1:5, in such a way that every five
                                            (5) ordinary shares in the Company&#8217;s registered share capital and in its issued and
                                            paid-up share capital, that the nominal value of each one of them is 0.01 ILS, were consolidated
                                            into one (1) share whose nominal value is 0.05 ILS. The articles of association of the Company
                                            were amended accordingly.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.1pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">j.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval of the Company&#8217;s Board of Directors, on June 28, 2023 8,000,000 ordinary
                                            shares of the Company of a nominal value of 0.05 ILS each were allocated to 3 investors in
                                            exchange for a total investment of ILS 4,000,000 at a price of 50 Agorot per share by way
                                            of a private offer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.35pt 0pt 0; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">k.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            July 30, 2023, an agreement was signed between E.V Drive and Global Automax and Automax Vehicle
                                            Fleets (which until the signing of the aforementioned agreement was a non-active company,
                                            fully owned (100%) by Global Automax). According to this agreement, shares which represent
                                            50% of the issued and paid-up capital of Automax Vehicle Fleets were transferred to EV Drive,
                                            without consideration, and it was decided that Automax Vehicle Fleets will engage in the
                                            field of leasing, or in the brokerage of leasing transactions (hereinafter in this sub-article:
                                            &#8220;the <b>Agreement</b>&#8221;). The Agreement specifies the management of Automax Vehicle
                                            Fleets and states, among other things, that Global Automax will provide to Automax Vehicle
                                            Fleets an initial amount as an owner&#8217;s loan for the purpose of financing its operations,
                                            which will be repaid from the profits of Automax Vehicle Fleets in 24 payments, starting
                                            at the end of 36 months from the signing of the agreement. The distribution of profits in
                                            the joint company will be done subject to any law,</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.35pt 0pt 0; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">according to the proportional share
of each party in the joint company&#8217;s share capital. The Board of Directors of the joint company will appoint two members, and each
party will appoint one director. The Founders&#8217; Agreement also stipulates that certain decisions will require a majority of 100%
of the directors, including a change in the joint company&#8217;s incorporation documents, and inter alia, a change in the rights attached
to the joint company&#8217;s shares, the provision of loans and/or guarantees and/or other financing for the joint company&#8217;s activities
that deviate from its regular course of business or the provision of loans to stakeholders in the joint company, as well as the approval
of transactions in which an office holder, director, shareholder and/or stakeholders in the Company have a personal interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.8pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Founders&#8217; Agreement includes
customary provisions that limit the possibility of transferring shares in the joint company, including the right of first refusal (except
in the circumstances stipulated in the Founders&#8217; Agreement), the right to join the sale of shares (Tag Along) and a forced sale
(Bring Along).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.1pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 1, 2024, an agreement was
signed between the parties to transfer shares of Automax Fleet held by EV Drive to the Global Automax subsidiary, which brought the subsidiary
to full ownership of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.1pt 0pt 0; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">l.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            September 18, 2023, following the approval by the Company&#8217;s Board of Directors from
                                            August 15, 2023 and August 24, 2023, new credit limits were provided to Dalhom Automax from
                                            two banking corporations (which also provided credit limits to Global Automax) at a sum of
                                            ILS 7.5 million each (hereinafter: the &#8220;<b>Credit Limits</b>&#8221;). The credit which
                                            was provided out of the Credit Limits, carries an annual interest that ranges between prime
                                            + 1.5%-0.5%. The Company guarantees the undertakings of Dalhom Automax towards each of the
                                            banking corporations in connection with the Credit Limits. The Credit Limits include a commitment
                                            of Dalhom Automax to comply with financial benchmarks, as detailed in Note 21c below.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">m.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            October 19, 2023, the Company entered into a market making agreement (the &#8221; <b>Agreement</b>&#8221;)
                                            with Israel Brokerage and Investments - IBI Ltd. (&#8220;the <b>Market Maker</b>&#8221;),
                                            according to which the Market Maker will act as a market maker of the Company&#8217;s ordinary
                                            shares (the &#8220;Securities&#8221;) which are listed on the Tel Aviv Stock Exchange Ltd.
                                            (&#8220;the <b>Stock Exchange</b>&#8221;) effective from October 22, 2023. Such market making
                                            will be done according to the rules set forth in Chapter IX of Part III of the Stock Exchange&#8217;s
                                            bylaws, and the instructions pursuant thereto, in exchange for an amount which was set forth
                                            in the agreement, that is immaterial for the Company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The agreement is signed for a period
of one year starting from the day it came into effect, and it will be extended automatically for additional periods of 12 months each,
as long as it is not cancelled in accordance with its provisions. The agreement is expected to end on April 29, 2025, with the entry
into force of the Stock Exchange&#8217;s 2025 Market Making Reform.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">n.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval of the Company&#8217;s Board of Directors, on December 31, 2023 14,285,714 ordinary
                                            shares of the Company with a nominal value of 0.05 ILS each were allocated by way of a private
                                            offer at a price of 70 Agorot per share, in exchange for an offset of a current credit of
                                            suppliers in the sum of 10,000,000 ILS related to an inventory of about 90 vehicles that
                                            the Company purchased and received.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 38.9pt 0pt 0; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">o.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            January 11, 2024, Global Automax received a state-guaranteed loan in the amount of 16 million
                                            ILS from a banking corporation. The loan carries an annual interest of prime + 1.5%, and
                                            is not linked to any linkage base. The loan was granted for a period of 60 months, and it
                                            will be repaid in 57 equal monthly payments of principal and interest, with the first 3 months
                                            of the loan constituting a grace period during which no payments of principal and interest
                                            will be made. Against the loan acceptance, and as customary in state-guaranteed loans, Global
                                            Automax deposited an interest-accruing deposit at the banking corporation, in the amount
                                            of 5% of the loan principal, which will be encumbered with a first-degree permanent lien
                                            in favor of the banking corporation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">p.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            April 10, 2024, after approval by the Audit Committee and the Board of Directors , the Company
                                            entered with Scisparc Ltd into a binding merger agreement hereinafter: &#8220;the Merger
                                            Agreement,&#8221; or &#8220;the Agreement,&#8221; or &#8220;the Merger,&#8221; respectively,
                                            and the transaction carried out under the Merger Agreement, &#8220;the Transaction.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with the Merger Agreement,
and subject to the compliance with the suspending conditions set forth therein, a triangular merger will be carried out as part of an
arrangement in accordance with the provisions of sections 350 and 351 of the Companies Law 5759-1999, (hereinafter, respectively: &#8220;the
<b>Arrangement</b>&#8221; and &#8220;the <b>Companies Law</b>&#8221;), whereby a wholly-owned subsidiary of Scisparc (established in
Israel for the purposes of the merger) (hereinafter: &#8220;the <b>Target Company&#8221;</b>) will merge into and with the Company, so
that the Company will become a wholly-owned subsidiary of Scisparc and the Target Company will cease to exist.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon completion of the transaction,
the current shareholders of the Company (excluding Scisparc) will hold, as a Group, about 47.49% of the issued and paid-up capital of
Scisparc in full dilution at the time of completion of the merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">After the completion of the Merger
(subject to the conditions set forth below), the Company will become a private company that is a bond company, its shares will be delisted
from trading on the Exchange, but its bonds (Series B) will continue to be traded on the Exchange until their full repayment. All assets,
rights, business operations, authorities, licenses, obligations, and liabilities of the Company will continue to be transferred to it,
and it will continue to engage in the field of importing vehicles and marketing them in Israel (or in other areas, as may be decided
from time to time). The Company will continue to hold its subsidiaries (including Global Automax) and affiliated companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Following the completion of the Merger,
all business operations, assets, rights, authorities, licenses, obligations, and liabilities of Scisparc will continue to be allocated
to it (including its existing operations in the pharmaceutical field), and its stocks will continue to be listed on the Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon completion of the merger, Scisparc
will hold in its coffers no less than $4,250,000 (less sums that the Company owes to Scisparc in accordance with the loan agreements
between the parties), net cash (meaning after deduction of all the liabilities of Scisparc at the time of completion, and after deduction
all fees and payments in connection with the merger transaction, as stipulated in the Merger Agreement). On the date of the Merger, Scisparc
will invest a total of $4,250,000 in cash as equity into the Company (net of amounts owed by the Company to Scisparc under the loan agreements
between the parties), which will be used by the Company for its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The liabilities of the parties to complete
the transaction will be subject to the fulfillment, or waiver in writing, by the relevant party of the conditions detailed in the agreement,
which include, among others, the following main conditions: (a) obtaining court approval for the settlement, including an exemption from
publishing a prospectus for Scisparc in Israel (a request to issue a warrant to hold a meeting of shareholders of the Company to approve
the settlement, in accordance with the provisions of the Merger Agreement, was submitted by the Company on May 30, 2024).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On August 8, 2024, and a decision was
issued by the Court ordering the convening of a meeting of shareholders for the purpose of approving the settlement); (b) Approval of
the transaction at the general meeting of the Company&#8217;s shareholders, by a majority of at least 75% of the participants in the
meeting and its approval in a separate specific type of shareholders meeting, who are not stakeholders in the Company; (c) Approval of
the transaction at the general meeting of the shareholders of Scisparc, by a simple majority, as well as approval of the appointment
of the candidates on behalf of the Company as directors of Scisparc; (d) The Securities and Exchange Commission will approve the registration
document that Scisparc will submit for the purpose of registering for trading the shares that will be allocated to AutoMax shareholders,
so that no restriction will apply to their tradeability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">From time to time, the parties signed
addendums to the Merger Agreement, pursuant to which the deadline for completing the merger transaction was extended. The last addendum,
pursuant to which the deadline for completing the merger transaction was postponed from March 31, 2025, to September 30, 2025, was signed
on March 27, 2025. Apart from the aforementioned, there have been no changes to the Merger Agreement&#8217;s provisions and both parties
continue to be obligated by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For the avoidance of doubt, it should
be emphasized that there is no certainty that the conditions to the transaction will be met, in whole or in part, and accordingly, there
is no certainty that the transaction will be implemented. It is impossible to estimate, at this stage, whether and when the transaction
will be completed as aforementioned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In January, June and September 2024,
SciSparc provided the Company with a loan in the amount of US$4,250,000, which constitutes the full amount that SciSparc undertook to
invest in the Company under the Merger Agreement between the parties (if completed). The loan carries an annual interest of 7% from the
date of making any payment of the loan, and it is not linked to any linkage base. 2% will be added to the annual interest if the Merger
Agreement is canceled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To secure repayment of the loan, the
Company pledged to SciSparc, under a first-degree permanent lien, its shares in Automax Direct Import Ltd., a wholly owned (100%) subsidiary
of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.9pt 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The loan will be repaid at the earliest
date of the following: (a) if the Merger Agreement is canceled in accordance with its terms - within 3 months from the date of its cancellation;
(b) on the date of completion of the Merger Agreement, by way of converting the loan and the interest that was accrued thereon into equity
at the expense of the amount that Scisparc Ltd. undertook to invest in the Company on the date the merger is completed ($4,250,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">q.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            February 28, 2024, the Company made the second payment of principal and interest for the
                                            bonds (series B), in a total amount of approximately 8 million ILS. After the mentioned payment,
                                            the company repaid 25% of the principal of the bonds (series B).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify; text-indent: -14.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">r.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval by the Company&#8217;s audit and balance committee, the compensation committee
                                            and the Company&#8217;s Board of Directors, on March 24, 2024 the general meeting of the
                                            Company&#8217;s shareholders approved, as follows: (a) the extension of the service agreement
                                            between the company and Haim Levy - Trade In Ltd., a company owned by Mr. Daniel Levy, regarding
                                            the provision of CEO services for an additional three years period; (b) the extension of
                                            the service agreement between the Company and A. Yinon (2015) Ltd., a company that is owned
                                            by Mr. Yinon Amit, regarding the provision of the services of a CFO for an additional three
                                            years period; (c) the extension of the indemnification and exemption letters to the officers
                                            and directors who are amongst the stakeholders, their relatives, or those serving on behalf
                                            of the stakeholders, or which the stakeholders have a personal interest in the provision
                                            of these letters; (d) the Company&#8217;s updated compensation policy; and (e) the extension
                                            of a lease agreement with third parties pertaining to a land plot in Jerusalem used as a
                                            logistics warehouse.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">s.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During
                                            the reporting period, the Company invested a total of approximately ILS 12 million in obtaining
                                            new licenses for the import of vehicles.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">t.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            August 14, 2024, the Company, Scisparc, and the target company signed an addendum to the
                                            merger agreement, according to which the final date for completing the Merger Transaction
                                            would be postponed from August 30, 2024, to November 30, 2024. On November 26, 2024, the
                                            Company, Scisparc, and the target company signed an addendum to the Merger Agreement, according
                                            to which the final date for completing the merger transaction would be postponed from November
                                            30, 2024, to March 31, 2025. &#160;On March 27, 2025, the Company, Scisparc, and the target
                                            company signed an addendum to the Merger Agreement, according to which the final date for
                                            completing the merger transaction would be postponed from March 31, 2025, to September 30,
                                            2025. Apart from the aforementioned, there have been no changes to the Merger Agreement&#8217;s
                                            provisions and both parties continue to be obligated by it.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">u.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During
                                            the months of September-November 2024, Automax Direct Import, a wholly owned subsidiary of
                                            the Company, completed an agreement with Anhui Jianghuai Automobile Group Corp., Ltd. a corporation
                                            incorporated in China (hereinafter: &#8220;the <b>Manufacturer</b>&#8221;), that manufactures
                                            private and commercial vehicles, inter alia under the JAC Motors brand, under agreements
                                            for the direct import, distribution and service of vehicles and spare parts manufactured
                                            by the Manufacturer in Israel (hereinafter: &#8220;the <b>Agreement</b>&#8221; and &#8220;the
                                            <b>Vehicles</b>&#8221;, respectively), following Automax Direct Import&#8217;s application
                                            to the Ministry of Transportation to receive a direct import license for vehicles manufactured
                                            by the Manufacturer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">According to the agreement, a subsidiary
will become the official marketer of the JAC Motors brand in Israel, and the manufacturer will supply the subsidiary with vehicles and
spare parts for the vehicles for marketing and sales in Israel, in accordance with annual business plans to be agreed upon between the
parties (with the business plan for 2025 was already agreed upon between the parties).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The agreement set forth accepted conditions
regarding the manufacturer&#8217;s warranty for the vehicles, the supply of spare parts, the obligation to notify of malfunctions (recall),
and other accepted conditions required to comply with the requirements of Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As part of the agreement, a subsidiary
undertook to market the vehicles and to adapt the Group&#8217;s existing showrooms for the purpose of selling the vehicles at the standard
determined in the agreement. The Company estimates that the expenses for adapting the showrooms are immaterial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The term of the agreement is three
years from the date of its signing, subject to the subsidiary meeting minimum sales targets determined in the agreement. These targets
will come into effect only when appropriate European regulatory approvals are received for the vehicles produced by the manufacturer.
In addition, the manufacturer will be entitled to terminate the agreement early upon the occurrence of certain events stipulated in the
agreement, as is customary in such agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the date of signing the financial
statements, Automax Direct Import received a license from the Ministry of Transportation to import to Israel vehicles manufactured by
the manufacturer. Accordingly, Automax Direct Import started the importation and marketing operations of vehicles manufactured by the
Manufacturer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">v.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            November 21, 2024, following approval by the Company&#8217;s Board of Directors , Automax
                                            Direct Import, a wholly owned subsidiary of the Company which engages in the direct importation
                                            to Israel and marketing of vehicles manufactured by JAC Motors, was granted a credit line
                                            in the amount of ILS 23 million from a banking corporation (hereinafter: &#8220;the <b>Banking
                                            Corporation</b>&#8221;, &#8220;the <b>Credit Line</b>&#8221; and &#8220;<b>Automax Direct
                                            Import</b>&#8221;, as applicable). The Company will guarantee Automax Trade In&#8217;s liabilities
                                            towards the banking corporation in connection with the credit limit.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aforementioned credit line was
fully utilized at the time it was provided, with an annual interest ranging between prime + 1%-2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.35pt 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The credit limit includes Automax Trade
In&#8217;s liabilities to meet financial benchmarks in accordance with the letter of commitment signed between Automax Direct Import
and the banking corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To secure the full repayment of the
amounts which were provided to the Company by virtue of its credit lines Automax Direct Import will pledge in favor of the banking corporation
a first-degree floating lien over its plant, its business operations, and all the assets and rights it holds at present and/or will hold
in future times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">w.</td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At
                                            a special general meeting of the Company&#8217;s shareholders which took place on December
                                            31, 2024, the general meeting of the Company&#8217;s shareholders confirmed, as follows:
                                            (a) the reappointment of the accounting firm Ben David Shalvi Kop (BDSK) as the Company&#8217;s
                                            auditor, and made a decision about its remuneration; (b) the reappointment of the Company
                                            directors who are not external directors; and (c) the extension of the employment terms of
                                            Mr. Tomer Levy, VP of Business Development and Administration and director, of Mr. Haim Levy,
                                            VP of Trade and Procurement, and of Mr. Gal Levy, VP of Standardization and Manager of the
                                            Company&#8217;s Branch Network. Additionally, the meeting discussed the Company&#8217;s periodic
                                            report for the year 2023.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, engagements,
encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>C.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><span style="text-decoration:underline">Liens
                                            and financial benchmarks</span></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.25pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Banking Corporations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Global
                                            Automax</span></b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Global Automax has non-guaranteed On-Call
credit lines from four banking corporations, which amounted to 137.5 million ILS as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company guarantees Global Automax&#8217;s
undertakings towards the banking corporations in connection with the credit limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In order to guarantee the full repayment
of the amounts that will be provided to Global Automax according to the credit limits from the banking corporations, Global Automax mortgaged
in favor of the banking corporations certain assets and rights that were agreed upon, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            floating lien in the first degree on the entire plant, the equipment, the assets, the funds,
                                            the property and rights of Global Automax, including their fruits;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.55pt 0pt 0; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            permanent lien in the first degree and pledge on Global Automax&#8217;s unallocated share
                                            capital and its reputation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.55pt 0pt 0; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            permanent lien and pledge on the bills of lading, certificates of ownership of goods, documentary
                                            letters of credit, or other documents that indicate an ownership of goods or chattel which
                                            will be delivered from time to time to the banking corporation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.55pt 0pt 0; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A
                                            permanent lien and pledge on all the securities, documents, and bills of others that Automax
                                            has delivered or will deliver from time to time to the banking corporation.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Also, as part of Global Automax&#8217;s
undertakings to the banking corporations, it must meet financial benchmarks. Following is a specification of the maximum and cumulative
financial covenants that Global Automax undertook towards the banking corporations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            tangible equity in the Company&#8217;s financial statements shall be no less than 35 million
                                            ILS. This standard will be examined according to Global Automax&#8217;s consolidated financial
                                            statements for June 30th and December 31st of every year.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            tangible equity will constitute no less than 25% of Global Automax&#8217;s tangible balance
                                            sheet. This standard will be reviewed according to Global Automax&#8217;s consolidated financial
                                            statements for June 30th and December 31st of every year.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            ratio between the inventory and net credit (LTC) will be no less than 115% at all times.
                                            This standard shall be reviewed once a month.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.65in 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aforementioned financial benchmarks
will be examined pertaining to the consolidated financial statements of Global Automax Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, agreements, liens and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In the letters of commitments that
Global Automax gave the banking corporations, it undertook, amongst other things, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">No
                                            dividend will be distributed if the equity in the financial statements of Global Automax
                                            is less than 35 million ILS, and its ratio in relation to the total balance sheet is not
                                            less than 25%.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loans
                                            and promissory notes that were issued in favor of Global Automax&#8217;s shareholders will
                                            be inferior to the credit of Global Automax, which was received from the banks.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Hereunder
are the results of financial stipulations as of December 31, 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Bank
    A</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Bank
    B</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Bank
    C</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Bank
    D</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Tangible equity</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">66,374</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">68,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">68,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">68,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tangible Equity compared to the Balance Sheet</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">LTC ratio to net credit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">121.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">121.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">121.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">121.82</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As specified above, on December 31,
2024 Global Automax met all the financial stipulations, which are detailed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Automax
                                            Trade In</span></b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify; text-indent: -28.4pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 25, 2023, Automax Trade
In Ltd. was granted a credit limit of 15 million ILS by a banking corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company guarantees Automax Trade
In&#8217;s obligations towards the banking corporation in connection with the credit limit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The credit limit includes Automax Trade
In&#8217;s obligations to meet financial covenants in accordance with the letter of commitment signed between Automax Trade In and the
banking corporation, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            amount of Automax Trade In&#8217;s tangible equity shall be no less than 25% of Automax Trade
                                            In&#8217;s tangible balance sheet.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Compliance with this standard will
be assessed based on semi-annual and annual reports of Automax Trade In.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 49.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 49.7pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2024, the said ratio
is 26.28%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 49.7pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, agreements, liens and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            ratio between (a) the value of Automax Trade-in&#8217;s vehicles, and (b) the net financial
                                            debt, will not be less than 130%. The value of the vehicles is according to Yad 2&#8217;s
                                            price list, or according to another price list that will be approved by the banking corporation
                                            as was known at the time of the relevant calculation.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.45pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Compliance with this benchmark will
be reviewed on a monthly basis and also at the request of the banking corporation. As of the date of the financial statements, the ratio
of this standard was 152.98%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.2pt 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, the letter of commitment
includes a provision of a cross-commitment regarding the credit that was provided by the banking corporation to Global Automax, as well
as subordination and discounting of the owner&#8217;s loans that were given to Automax Trade In.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.2pt 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As was specified above, as of December
31, 2024, Global Automax met all the financial stipulations specified above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.2pt 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Dalhom
                                            Automax</span></b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.2pt 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On September 28, 2023, new credit limits
at a sum of 7.5 million ILS each were provided to Dalhom Automax by two banking corporations. The Company guarantees the undertakings
of Dalhom Automax towards each of the banking corporations in connection with the credit limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The credit limit includes Dalhom Automax&#8217;s
undertakings to meet a financial benchmark in accordance with the letters of commitment that were signed between Dalhom Automax and the
banking corporations, which specifies as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            ratio between (a) the value of the inventory of vehicles of Dalhom Automax together with
                                            the remainder of the advance payment to the supplier, and (b) the net financial debt, shall
                                            be no less than 1.2. As of December 31, 2024, the ratio of this standard was 1.29.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Compliance with this standard will
be reviewed on a monthly basis and also at the request of the banking corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 50.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the date of the financial statements,
Dalhom Automax was in compliance with the financial criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.4pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the letters of commitment that Dalhom
Automax submitted to the banking corporations, Dalhom Automax undertook, amongst other things, that its tangible equity will increase
every year at a rate that will be no less than 50% of the annual net profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, the letters of commitment
include a cross default provision regarding the credit that is provided by the banking corporations to Global Automax, a prohibition
on directly changing the control at Dalhom Automax and other acceptable instructions, including a subjection and subordination of the
owners&#8217; loans that were given to Dalhom Automax, the provision of statements and reports to the banking corporations, etc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, agreements, liens and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In order to secure the full repayment
of the amounts that will be provided to Dalhom Automax according to the credit limits, Dalhom Automax mortgaged in favor of the banking
corporations in a floating lien (a general current lien) all its assets, including the rights and fruits that derive from the assets,.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">It should be noted that at the Company&#8217;s
request, part of the credit limits for Dalhom Automax were diverted from an existing credit limit of another company in the Group, so
that after the credit limits were provided to Dalhom Automax, the total amount of credit for the Group (including Dalhom Automax) actually
increased by 7.5 million ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2024, ILS 2.5 million from
Dalhom Automax&#8217;s credit line were diverted from Banking Corporation A to Global Automax, and an additional ILS 2.5 million from
Dalhom Automax&#8217;s credit line with the same banking corporation were diverted from short-term loans to a long-term loan, to be repaid
in 24 equal installments of principal and interest, bearing annual interest at a rate between 6.9%-7.9%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 28.35pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Automax
                                            Direct Import</span></b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.2pt 0pt 0; text-align: justify; text-indent: 0.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On November 21, 2024, a new credit
limit of 23 million ILS was granted to Automax Direct Import by a banking corporation. The Company guarantees the liabilities of Automax
Direct Import towards the banking corporation with respect to the credit limit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The credit limit includes Automax Direct
Import&#8217;s obligations to meet financial covenants in accordance with the letter of commitment signed between Automax Trade In and
the banking corporation, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            total tangible equity of Automax Direct Import shall amount to no less than a total of 30%
                                            of the tangible assets of Automax Direcdt Import. This benchmark will be reviewed on a quarterly
                                            basis starting with the first half of 2025 reports.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            ratio between the inventory and LTC will be no less than 130% at all times. This standard
                                            shall be reviewed once a month. As of the date of the financial statements, the ratio of
                                            this benchmark was 160.20%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.4pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Meeting
                                            revenue and profit targets according to an annual business plan. This benchmark will be reviewed
                                            on a quarterly basis starting with the reports for the first quarter of 2025.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 50.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of the date of the financial statements,
Automax Direct Import was in compliance with the financial criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 50.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To ensure the full repayment of the
amounts that have been provided by virtue of Automax Direct Import credit lines, Automax Direct Import pledged in favor of the banking
corporation a first-degree floating lien over its plant, its business operations, and all the assets and rights held at present and/or
in future times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Note 21 - Contingent liabilities, agreements,
liens and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="text-decoration:underline">Bonds</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On March 1, 2022, the Company issued
bonds to the public (series B) (see Note 19 below). As part of the issuance of these bonds, the Company undertook to meet (until the
date of the final and full repayment of the bonds (series B)) certain financial benchmarks, as detailed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.9pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            ratio between the Company&#8217;s equity and its total balance sheet, according to the Company&#8217;s
                                            consolidated financial statements, will be no less than 11%. In order to calculate the equity
                                            ratio, the liabilities due to lease agreements and the current liabilities due to lease agreements
                                            will be deducted from the total balance sheet. As of December 31, 2024, the ratio is 11.88%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#8220;Equity&#8221; means the equity
(including minority rights) that is presented in the company&#8217;s consolidated financial statements, in accordance with the valid
regulation and accounting standardization at the time of their issuance, and without taking into account regulatory changes. When calculating
the equity, the Company&#8217;s liability to the former shareholders of Optimatic Media, Inc. will be taken into account as part of that
equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Regulatory changes mean changes in
the relevant legislation and/or accounting standardization, including changes in the direct or indirect tax regime, which applies to
the fleet of vehicles of the Company and of its subsidiaries, and/or to their operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">2.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Company&#8217;s equity shall not be less than 25 million ILS according to the company&#8217;s
                                            consolidated financial statements (The &#8220;minimal equity&#8221;). As of December 31,
                                            2024, the Equity as defined above was 41,337 thousand ILS.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            total assets of the Company according to its consolidated financial statements, which are
                                            not encumbered with a specific lien, will not be less than the principal of the bonds that
                                            has not been repaid yet, together with the interest that has accrued thereon up to that date
                                            and has not yet been paid. As of December 31, 2024, the sum of the Company&#8217;s assets
                                            (which is calculated in the manner that is specified below) is 326,747 thousand ILS, and
                                            the sum of the principal of the bonds that has not yet been repaid, together with the interest
                                            that accumulated until that date, amounts to 34,413 thousand ILS.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">According to the deed of trust, the
assets due to the lease agreements, intangible assets and deferred taxes will be neutralized in the manner that is specified in the Company&#8217;s
consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.6pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            quotient obtained from dividing (a) the value of vehicles owned by the company by (b) the
                                            net credit, shall be no less than 110% (&#8220;the minimum vehicle value&#8221;). As of December
                                            31, 2024, the ratio is approximately 114%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The aforementioned benchmarks are
reviewed on a quarterly basis, based on the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">If during two or more consecutive
reporting periods, the equity ratio (as defined above) shall be lower than 11% and/or the Equity (as defined above) will fall below 20
million ILS, and/or the minimal sum of the assets shall be lower than the principal of bonds that has not yet been repaid, plus the interest
that it accrued up to that date and has not yet been paid, and/or the Minimal Value of a Vehicle shall be less than 110%, this will be
grounds for an immediate repayment of the bonds (series B). The aforementioned will not apply if the Company does notify up to the date
of signature of the financial statements for the second consecutive reporting period, from which it derives that it has not met the undertakings
regarding the Equity and/or the Minimum Equity and/or the Minimum Sum of Assets and/or of the Minimum Value of Vehicles, that it had
amended the violation after the date of the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.3pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><b><span style="text-decoration:underline">Note
21 - Contingent liabilities, engagements, encumbrances and guarantees (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As mentioned above, The Company had
met all the financial conditions of the bonds (Series B) as of the date of the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><b>d. Guarantees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company guarantees the obligations
of Global Automax, Automax Trade In, of Automax Direct Import and of Dalhom Automax with respect to loans they received from banking
corporations, including state-guaranteed loans, and also Global Automax&#8217;s obligations under the rental agreements for the Rishon
Le-Zion branch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.25pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The additional shareholder at Dalhom
Automax undertook to indemnify the Company for the guarantee the latter gave with respect to Dalhom Automax undertakings to banking corporations
for the credit limits they submitted to it at a sum of half (50%) of the expenses the Company expended in connection with the exercise
of any of the guarantees by any of the banking corporations , and it also undertook to pay to the Company every month a sum of 25,000
ILS plus VAT, as long as the shareholder is not a guarantor towards the banking corporations in accordance with their requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.25pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, some of the Company&#8217;s
stakeholders guarantee, either directly or through companies controlled by them, the undertakings of the subsidiary according to the
rent agreement regarding the Global Automax branch in Jerusalem. For additional details, see Note 10d 1 below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21.25pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A consolidated company provided a
bank guarantee in the amount of approx. 1,315 thousand ILS to the customs authorities, and a bank guarantee to a third party at an amount
of approx. 50 thousand ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 22 &#8211; Share capital and premium
on the shares</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A.
                                            Registered, issued and paid up share capital:&#160;</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number
    of shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Registered</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Issued
    and Paid up (*)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Ordinary shares, 0.05 ILS nominal value each (**)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">400,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">103,691,969</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number
    of shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">As of
    December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Registered</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Issued
    and <br/>
    Paid up (*)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Ordinary shares, 0.05 ILS nominal value each</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">400,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">103,691,969</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(*)</span></td><td style="text-align: justify">Including
                                            <span style="font-family: Times New Roman, Times, Serif">dormant shares at a nominal value
                                            of 1,951,775.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(**)&#160;</td><td style="text-align: justify">On May
                                            21, 2023, the Company&#8217;s registered share capital and issued and paid-up share capital
                                            were consolidated at a ratio of 1:5.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.05pt">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>B.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Rights
                                            attached to shares:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The ordinary shares entitle their
holders with the right to participate in the Company&#8217;s general assemblies and to vote in them. All the ordinary shares entitle
their holders with a right to receive dividends and distributions of the surpluses of the Company&#8217;s property in the event of a
liquidation, or to any other form of capital return, based on their nominal value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Management shares confer their owners
all the rights granted to ordinary shares, and in addition they grant the right to appoint a director to the Company&#8217;s Board of
Directors, as detailed in the Company&#8217;s articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 93.5pt 0pt 0; text-align: justify; text-indent: -0.7pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>C.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Capital
                                            note conversion:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">According to the provisions of the
Merger Agreement with Matomy, the capital note that was issued to the former shareholders of the subsidiary, based on their proportional
share in its equity, at a total amount of approx. 15.6 million ILS, was converted into premium on the issued share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56.7pt 0pt 0; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>D.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Option
                                            warrants and rights to shares:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On February 28, 2021, the merger agreement
with Matomy was approved by the general meeting of the Company&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 22 - Share capital and premium on the
shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
                                            March 24, 2021, the merger transaction was completed, in which securities were allocated
                                            as follows (prior to the capital consolidation being carried out at a ratio of 1:5): the
                                            entrepeneur received 7,900,947 ordinary shares of the Company in exchange for the transaction
                                            without any financial consideration on its part.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">59,257,103
                                            warrants of the Company were allocated to candidates for positions as officers of the Company,
                                            and an additional 3,394,549 option warrants of the Company were allocated to a candidate
                                            for the position of active chairman of the Board of Directors of the Company.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Below
                                            is a breakdown of the allocations:</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">Name</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Position</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Rights
    to shares<br/> that were<br/> converted into<br/> ordinary shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option
    warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Rights
    to shares<br/> (the indemnity) (1)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: left">Haim Levy &#8211; Trade In
    Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">42,026,314</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3,460,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">A. Yinon 2015 Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,026,314</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,460,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Pozilov Investments Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,026,315</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,460,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Eliyahu Baruch Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,013,158</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,730,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Belporto Investments Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,013,157</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,730,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Daniel Levy</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">CEO</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,888,565</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Yinon Amit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Business Officer</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,888,565</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Emanuel Pozilov</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shareholder and Director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,888,565</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Eyal Baruch</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Shareholder and Director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,888,565</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Haim Levy &#8211; Trade In Ltd.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vice President of Trade and Procurement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,900,948</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Gal Levy</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vice President of Standardization and Manager of Chain of
    Branches</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,900,948</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Tomer Levy</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vice President of Business Development and Headquarters and
    Director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,900,947</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Doron Shorer</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Chairman of the Board, retired (2)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,132,917</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">168,105,258</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">69,390,020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">13,840,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This
                                            includes the indemnification shares for the undertaking to the stakeholders, see Note 16c.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax
                                            Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 22 - Share capital and premium on the
shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 42.6pt 0pt 0; text-align: justify; text-indent: -14.2pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            December 29, 2021, Doron Shorer ceased to serve as chairman of the board, and as a result
                                            2,545,912 options from series B1, 2,799,014 options from series B2 and 3,939,354 options
                                            from series B3 expired. On March 16, 2022, the Company&#8217;s Board of Directors approved
                                            an allocation of 9,284,280 non-tradable option warrants (series B) to Mr. Shorer, instead
                                            of the option warrants that expired.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The allocation of options and rights
to shares is in accordance with the terms, and in compliance with the milestones stipulated in the Merger Agreement. Furthermore, the
Merger Agreement included employment agreements for the designated officers, as approved in the merger transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Hereinafter
                                            is a table that includes the number of stock options and the changes made in the employee
                                            option plans. Following the capital consolidation detailed in Note 22F below, the amount
                                            of shares that will result from the exercise of the options will be one fifth of the amount
                                            of options that is shown below:</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">For
    the year ended <br/>
    December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">The number
    of<br/>
    option warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">Option warrants to shares for the beginning of
    the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">69,390,020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Option warrants to shares awarded during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Option warrants that expired during the year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Option warrants to shares for the end
    of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">69,390,020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679; Hereinafter is data used when determining the fair
    value of the option:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Series A</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">Stock price (in ILS)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0.589</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Standard deviation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Series A</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">Stock price (in ILS)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0.589</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;2.25-5
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;0.4%-0.13%
                                            </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Series B for allocation given
    in March 2022 (*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left">Stock price (in ILS)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0.427</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.7065</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2-4
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As
                                            stated above following the expiration of the options to Mr. Schorer, and re-granting in March
                                            2023.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>E.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            March 28, 2023, given that the Company met milestones no. 2 and 3 of the Merger Agreement
                                            between the Company, Global Automax and its shareholders at the time (the current shareholders
                                            in the Company), and M.R.M Merchavit Holdings and Management Ltd. (the initiator of the transaction),
                                            the Company allocated an additional 168,105,258 ordinary shares of the Company to the stakeholders
                                            in the Company, which constituted approximately 41% of the Company&#8217;s issued and paid-up
                                            share capital after the allocation. As of the date of signing the financial statements, the
                                            stakeholders of the Company collectively hold approximately 55.65% of the issued and paid-up
                                            share capital of the Company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>F.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval of the general meeting of the Company&#8217;s shareholders, on May 8,2023, on
                                            May 21,2023, the Company&#8217;s registered share capital and its issued and paid-up share
                                            capital were consolidated at a ratio of 1:5, in such a way that every five (5) ordinary shares
                                            of the Company&#8217;s registered share capital and of its issued and paid-up share capital,
                                            whose nominal value is 0.01 ILS each, were consolidated into one (1) share with a nominal
                                            value 0.05 ILS each. The articles of association were amended accordingly.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify; text-indent: -35.5pt"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify; text-indent: -35.5pt"><b><span style="text-decoration:underline">Note 22
- Share capital and premium on the shares (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>G.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval of the Company&#8217;s Board of Directors, on June 28, 2023 8,000,000 ordinary
                                            shares of the Company of a nominal value of 0.05 ILS each were allocated to 3 investors in
                                            exchange for a total investment of ILS 4,000,000 at a price of 50 Agorot per share by way
                                            of a private offer.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: right; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>h.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            July 26, 2023, the Company allocated 733,592 (non-tradable) option warrants, which can be
                                            exercised into up to 733,592 ordinary shares of the Company, to Leumi Partners Ltd., as part
                                            of the consideration for the distribution services they provided to the Company in connection
                                            with the Company&#8217;s bond offering (series B). The option warrants can be exercised in
                                            full on the date of their allocation and for a period of 48 months thereafter, at an exercise
                                            price of 3 ILS per share.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>I.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Following
                                            the approval by the Company&#8217;s Board of Directors, on December 31, 2023 14,285,714 ordinary
                                            shares of the Company were allocated by way of a private offer at a price of 70 Agorot per
                                            share, in exchange of an offset of a current credit of suppliers in the sum of 10,000,000
                                            ILS related to an inventory of about 90 vehicles that the Company purchased and received.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.5pt 0pt 0; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>J.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expenses
                                            with respect to awarding of options in the amount of 122 thousand ILS were recognized during
                                            2024 in profit or loss. Expenses with respect to an award of options in the amount of 2,549
                                            thousand ILS were recognized during 2023 in profit or loss.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; text-align: justify; text-indent: -35.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 23 - Financial instruments</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Financial
risk factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Group&#8217;s operations expose
it to various financial risks, such as a market risk (foreign exchange risk, consumer price index risk, interest rate risk), credit risk
and liquidity risk. The Group uses derivative financial instruments in order to reduce certain exposures to risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 87.2pt 0pt 0; text-align: justify; text-indent: -0.7pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">1.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration:underline">Foreign
                                            currency risk</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group imports vehicles from suppliers
abroad, and is exposed to an exchange rate risk which derives from the exposure to various currencies, mainly to the euro and to the
Polish zloty. An exchange rate risk derives from future commercial transactions, recognized assets and recognized liabilities that are
quoted in a currency, which isn&#8217;t the Group&#8217;s measurement currency, including transactions in foreign currency derivative
instruments. Furthermore, the Group&#8217;s exposure to foreign currency also derives from the fact that sales price of the vehicles
cannot be linked fully to changes in the exchange rates of the foreign currencies. In addition, a change in the prices of new vehicles,
which are affected by changes in foreign currency exchange rates, may also affect the value of the Group&#8217;s vehicle inventory.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Hereinafter
is a segmentation of the balances disclosed in the financial statement:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For
    December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-linked
    ILS</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Canadian
    dollar</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">US dollar</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">European
    euro</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Pound<br/>
    sterling</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Polish
    zloty</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hungarian
    forint</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left">Cash
    and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1,466</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1,486</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term
    deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,242</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,242</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">41,671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">41,691</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Overdraft</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Credit from
    banking corporations and financing institutions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(186,911</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(186,911</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Suppliers and
    service providers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,232</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,035</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(20,841</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(936</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(29,045</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other accounts
    payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,947</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10,974</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(26</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(14,934</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Liability
    for bonds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">34,715</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(34,715</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(231,818</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(31,815</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(962</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(265,690</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(190,147</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(31,809</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(955</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(223,926</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For
    December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-linked
    ILS</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Canadian<br/>
    dollar</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">US dollar</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">European
    euro</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Pound<br/>
    sterling</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Polish<br/>
    zloty</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Hungarian<br/>
    forint</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left">Cash
    and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1,480</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1,552</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,552</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,552</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,296</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,296</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term
    deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">409</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">409</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,737</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,809</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Overdraft</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Credit from
    banking corporations and financing institutions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(143,229</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(143,229</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Suppliers and
    service providers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,205</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,941</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,215</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,809</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,169</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other accounts
    payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,698</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(11,097</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(23,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Liabilities
    with respect to bonds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(41,447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(41,447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(200,587</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,941</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,809</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(224,648</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(157,850</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,936</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,264</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,792</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(181,839</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">AutoMax Motors Ltd.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table hereinafter demonstrates the sensitivity
test to a possible and reasonable change to the various exchange rates when all other variables remain unchanged. The impact on the Company&#8217;s
pre-tax profit is due to the changes in the fair value of financial assets and liabilities, including foreign currency derivatives. The
Company&#8217;s exposure to foreign currency risk, based on nominal values, is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Note</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Decrease</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Change in the exchange rate of:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left">Canadian Dollar by 5%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">51</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">51</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">US Dollar by 5%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,590</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,590</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Euro by 5%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Polish zloty by 5%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Pound Sterling by 5%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Hungarian forint by 5%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31, 2023</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Increase</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Decrease</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; text-align: left">Canadian Dollar by 5%</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(147</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">147</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">US Dollar by 5%</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(554</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">554</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Euro by 5%</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(52</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Polish zloty by 5%</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(109</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Pound Sterling by 5%</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">86</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(86</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            sensitivity mainly derives from supplier balances denominated in a foreign currency.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            sensitivity mainly derives from receivable balances denominated in a foreign currency.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            sensitivity mainly derives from receivable balances denominated in a foreign currency.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Below is data regarding major exchange rates:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the
    year ended on</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"/>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">% change</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Spot
    rate at the time of<br/>
    the report</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt">Canadian Dollar exchange
    rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(8.03</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5.20</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2.5354</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2.739</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">US Dollar exchange rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.55</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2.98</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.647</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.627</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Euro exchange rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5.67</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6.45</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.7964</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4.012</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Polish zloty exchange rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2.32</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12.39</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.89193</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.913</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Pound Sterling exchange rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8.29</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4.5743</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4.620</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Canadian Dollar exchange rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(11.54</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9.28</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0093</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <span style="text-decoration:underline">Credit risk </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Credit risk is the risk that the counter
party shall not meet its obligations as a customer, or its obligations that arise from a financial instrument, resulting in a loss for
the Group. The Group&#8217;s incomes derive mainly from customers in Israel. In addition, the Group regularly monitors customer debts
and the terms of the credit it grants, and the financial statements include allocations for doubtful debts that adequately reflect, in
the opinion of the Company&#8217;s management, the inherent loss of any doubtful debts. The Group is exposed to credit risk because of
its operational activity (mainly because of customer balances) and its financial activity, including loans that the Group has provided,
transactions in a foreign currency and other financial instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Hereunder is information regarding
the maximum exposure to credit risks (book value):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 117.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For December
    31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Thousands of ILS</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,486</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,552</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,552</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables and debit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,296</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,242</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">409</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,691</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">42,809</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note
                                            23 - Financial instruments (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <span style="text-decoration:underline">Liquidity risk</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s goal regarding
the liquidity risk is to maintain the extent of cash balances and other liquid assets in a way that will allow for the preservation of
a level of liquidity, which is sufficient for meeting all its financial obligations - both under regular conditions and in extreme scenarios,
and without the occurrence of unwanted losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The table below shows the repayment
dates of the Group&#8217;s financial liabilities according to the contractual terms, in uncapitalized amounts (including interest payments):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Book
                                            value</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Projected
    <br/>
    cash flow</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">First
    year</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Second
                                            year</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Third
    to <br/>
    fifth year</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Suppliers and service providers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">29,045</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">29,045</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">29,045</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and credit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,006</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,006</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,006</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt">Credit
    and loans from banking and other corporations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">221,626</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">227,235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">193,693</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,410</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,132</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">265,677</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">271,286</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">237,744</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">25,410</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,132</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Suppliers and service providers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,169</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,169</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,169</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and credit balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt">Credit
    and loans from banking and other corporations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">199,707</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">204,140</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">165,908</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,872</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,360</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">239,671</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">244,104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">205,872</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,872</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">21,360</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <span style="text-decoration:underline">Interest rate risk</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in; text-align: justify">The Group is exposed to risk due
to changes in the market interest rate that arises from loans, which carry a variable interest. Loans that carry fixed interest rates
expose the Group to an interest rate risk because of the fair value. The Company only accepts credit limits and prime-linked loans. As
of December 31, 2024, the balances of variable interest liabilities amounted to 186,740 thousand ILS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in; text-align: justify"><span style="text-decoration:underline">Interest rate sensitivity analysis</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in; text-align: justify">The sensitivity analysis is determined
based on the exposure to interest rates of derivative and non-derivative financial instruments during the period of the report. The sensitivity
analysis regarding liabilities that carry a variable interest was prepared under the assumption that the sum of the liabilities at the
end of the period of the report remained the same throughout the entire year of the report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in; text-align: justify">A 1% change in the interest rates
at the end of the reporting period would increase (decrease) the capital and the profit and loss in the amounts shown below (after taxes).
This analysis was done under the assumption that the other variables, and especially the foreign exchange rates, remained constant. The
analysis regarding 2023 was prepared according to the same basis.&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Effect of a 1% change in the interest
    rate</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: center">1,867</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 48%; text-align: center">1,583</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 24 - Income Tax</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>A.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Tax
                                            rates applicable to the Group</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in; text-align: justify">The applicable corporate tax rate
in Israel for 2022 - 2024 is 23%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0.22in 0.25in; text-align: justify">An assembly of people is liable
for tax on real capital gain at the corporate tax rate, which is applicable in the year of sale.</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>C.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Income
                                            tax assessments</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The companies within the Group
have not yet been assessed by the Income Tax Authorities from the day they were incorporated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>D.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Carried
                                            forward losses</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The companies of the Group have business
losses for tax purposes, which are carried forward to the following years. As of December 31, 2024, these losses amounted to approx.
16 million ILS, and as of December 31, 2023 they amounted to approx. 7 million ILS. As a result of these losses, deferred taxes in the
amounts of approx. 0.3 million ILS and 0.3 million ILS respectively were recognized in the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.8pt 0pt 0; text-align: justify; text-indent: -1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">According to a tax ruling from December
10, 2020, given with respect to the Merger Transaction with Matomy (hereinafter: the &#8220;<b>Ruling</b>&#8221;), every kind of loss
of the Company for tax purposes, including losses that would be decided as a result of any tax assessments prior to the finalization
of the merger transaction, and including any losses incurred by the Company during or as a result of the dissolution of subsidiaries,
shall be deleted and would no longer be available in any way for a direct or indirect carrying forward, and/or offseting and/or for deduction
and/or for capitalization. In addition, according to the Ruling, the Company and/or a party close to it (as this term is defined in section
88 of the Ordinance) will not be left in any way with a balance of advance payments on the expense of its excess expenses, which can
be transferred and utilized in the following tax years, nor will the Company and/or the party close to it be left with any kind of credit
balance due to foreign taxes and/or with any kind of tax balance, which was deducted and not yet used and is associated to it, and which
can be transferred and credited and/or deducted in any way starting from the date of completion of the Merger Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>


</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax
                                            Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 24 - Income Tax (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>E.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Deferred
                                            taxes</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 83.7pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><b>Deferred taxes
&#8211; composition and movements:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>&#160;</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Intangible
                                            <br/>
                                            assets</b></p> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Carried
                                            <br/>
                                            forward <br/>
                                            losses</b></p> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Employee
    <br/>
    and <br/>
    others&#8217;<br/>
    benefits</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Other
                                            <br/>
                                            differences</b></p> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total</b></p> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Balance
    as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">265</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">323</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">201</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,544</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3,333</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes that
    were attributed to the income statement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">89</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(123</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,704</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(363</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Changes
    that were attributed to the income statement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance
    as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">354</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,698</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">113</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">840</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,005</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes that
    were attributed to the income statement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">414</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,698</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">212</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,590</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,662</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Changes
    that were attributed to the income statement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance
    as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">768</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">347</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,750</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(635</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For
    December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Profit
    (loss) before taxes on income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(17,017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">671</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Company&#8217;s
    share in losses of companies handled according to the book value method</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,118</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(577</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(585</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Profit (loss)
    when the Company&#8217;s share in the losses of companies that are handled according to the method of the balance sheet value is
    deducted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,224</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,256</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Statutory
    tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax expenses
    (incomes) according to the statutory tax rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">512</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">289</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase
    (decrease) of income tax amounts due to:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible
    expenses and exempted incomes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">260</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">154</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">213</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Temporary differences
    and losses for tax purposes in respect of which no deferred taxes were attributed</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,445</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,027</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,136</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Carried forward
    losses leading to deferred taxes being created for the first time</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(81</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Differences
    in the basis of the measurement and other differences</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">996</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,958</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">374</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Tax
    expenses (incomes) in the income statement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,213</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,931</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 25 - Income</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                            31,</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Revenues from the sale of new vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">352,900</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">346,922</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">434,786</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Income from the sale of used vehicles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">39,745</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">64,012</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,094</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Income from accessories</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,971</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,052</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other Income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,534</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,027</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,685</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">398,173</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">418,932</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">453,617</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 26 - Cost of sales</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on December 31</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Inventory at the beginning of the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">183,647</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">176,864</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">79,168</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cost of vehicles</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">361,724</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">378,710</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">482,474</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation and amortizations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,372</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,719</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,611</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fuel, spare parts, repairs and vehicle fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,556</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,084</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,345</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,480</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,297</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,112</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Miscellaneous</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">62</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">71</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less inventory at the end of the year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(207,759</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(183,647</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(176,863</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">347,079</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">381,089</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">392,918</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 27 - Sales and marketing expenses</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on December 31</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Salaries of sales agents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">8,939</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">12,090</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">10,483</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Advertisement and sales promotion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,147</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,184</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation and amortizations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,447</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit cards commissions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">324</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">420</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">305</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Miscellaneous</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">77</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,621</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">27,194</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">27,612</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 28 - General and administrative expenses</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on December 31,</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Salaries and salary related payments</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5,348</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3,979</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,483</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,149</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,518</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office maintenance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,353</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,488</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation and amortizations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,936</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Miscellaneous</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,910</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,935</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,387</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Taxes and fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,352</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,267</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Travel abroad</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">899</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,083</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,266</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Consultancy</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,430</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Bad debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">114</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">17,728</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">16,965</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">16,849</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 29 - Other income</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The majority of other income in 2024 and 2023
derived from grants submitted by the Group&#8217;s companies to the Tax Authority as part of Iron Swords war compensation.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax
                                            Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 30 &#8211; Financing expenses, net</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
                                            the year ended on December 31</b></p> </div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Financing expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Interest paid to banking corporations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">12,722</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">11,768</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,347</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Bond interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,340</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,808</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,483</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest for commitment to lease agreements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">951</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fees to banking corporations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,132</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income to institutions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Miscellaneous</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Exchange rate differentials</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,446</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,831</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,935</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Financing revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exchange rate differentials</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,990</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,971</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,511</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Financing income from related companies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,034</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">188</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Income of interest from related companies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income from deposit interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,025</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,722</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,703</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Financing expenses, net</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(14,421</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(9,109</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(5,232</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 31 - Profit (loss) per share</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>A.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Profit
                                            (loss) per share:</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic loss per share is calculated
by dividing the loss that is attributable to the holders of the Company&#8217; ordinary shares, by the weighted average number of issued
ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For
    the year ended on December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Profit (loss) attributable to Company owners</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(3,700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(16,384</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(1,104</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">The weighted average of the number
    of issued ordinary shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">103,691,970</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">77,377,503</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">47,785,204</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic profit (loss) per share (ILS)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The number of shares that was used
for calculating the loss per share in the periods that preceded the date of the reverse purchase, has been retroactively adjusted according
to the exchange rate that was decided in the merger agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><b>B.</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Diluted
                                            loss per share</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The diluted loss per share is calculated
by adjusting the weighted average of the number of ordinary shares by including all potential ordinary shares with dilutive impacts.
The diluted loss per share as for the reported periods equals the basic loss per share, since the impact is anti-dilutive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 32 - Concentration of balances and transactions
with related parties</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Balances
                                            with related parties:</b></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For 31
    December</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-bottom: 2.5pt">Receivables and debit balances
    (*)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">8,441</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">5,031</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,894</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,144</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,144</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Investment in companies handled according
    to the book value method</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,470</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,536</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Suppliers</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">157</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,589</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Accounts payable and credit balances</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">167</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">167</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Commitment to previous shareholders
    of Global Automax</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The
                                            Company periodically purchases vehicles from companies controlled by Mr. Nikas Konstantinos,
                                            who is a stakeholder in the Company and holds, as of the reporting date, 13.78% of the Company&#8217;s
                                            issued and paid-up capital. The aforementioned transactions were made in the ordinary course
                                            of the Company&#8217;s business and on market terms.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 32 - Concentration of balances and transactions
with related parties (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transactions with related and interested parties
&#8211; General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Some of the Company&#8217;s employees
and its service providers are parties related to the Company. According to their identity at any given time, some of them might be parties
who are related to the Company&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.2pt 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s key people as
of December 31, 2024 are the Company&#8217;s CEO, Chief Business Officer, CFO, VP of Trade, Chief of Technology, the Company&#8217;s
Manager of Regulation and Chain of Branches, and the Manager of HQ and Business Development. No personnel changes took place amongst
the Company&#8217;s management level key people during the reporting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="15" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>C.
                                            Below are the total expenses that were paid or received by the Company to/from related parties
                                            during the reporting period:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For
    the year ended December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">The
    nature of the expense</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2024</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 52%; text-align: left">Company shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">Management fees</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Granting of options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">701</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,688</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Key people in the Company who are
    related parties:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Vice President of Trade</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Salary</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">768</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">616</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Vice President of Technology, Standardization
    and Branches Manager</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Salary</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">775</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">615</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">VP of HQ and Business Development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Salary</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">775</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">616</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Directors wages</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Consultancy</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">518</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">753</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">686</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Payments to suppliers that are related
    parties and stakeholders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,768</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">782</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">872</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Automax HaShfela (an associate company)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,975</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Materials procurement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">339</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Commissions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">731</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Interests</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Automax Netanya (a consolidated
    company that was included last year)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Commissions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">47</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Interests</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Dalhom Automax (an associate company)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,320</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,920</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Materials procurement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,612</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Interests</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,607</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(678</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(192</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">Dalhom Automax Service Centers,
    a subsidiary of Dalhom Automax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Interests</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AutoMax Motors Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">Notes to the consolidated financial statements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands of ILS)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><span style="text-decoration:underline">Note 33 - Material events after the reporting
period</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            February 4, 2025, Global Automax, a company that held 1/3 of the issued and paid-up share
                                            capital of Automax Hasharon (hereinafter: the &#8220;<b>Additional Shareholder</b>&#8221;),
                                            and Automax Hasharon signed an agreement, pursuant to which Global Automax purchased from
                                            the Additional Shareholder shares held by it constituting 1/3 of the issued share capital
                                            of Automax Hasharon, the Additional Shareholder would forgive the owner&#8217;s loan that
                                            it had provided to Automax Hasharon in the past, and the founders&#8217; agreement between
                                            Global Automax and the Additional Shareholder regarding the management of Automax Hasharon
                                            would be terminated. After the completion of the aforementioned agreement, Global Automax
                                            holds 100% of the issued and paid-up capital of Automax Hasharon, and is entitled to appoint
                                            all of its directors.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: right">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            February 25, 2025, SciSparc provided the Company with an additional loan in the amount of
                                            US$2 million for a period of 40 months from the date of granting the loan, which will be
                                            repaid in 40 equal monthly installments of principal and interest.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The loan bears annual interest at
a rate of 8% from the date it is granted until the date the merger transaction between the parties is completed. The loan will not bear
interest from the date the merger is completed. The loan will not be linked to any linkage basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">To secure repayment of the loan, the
Automax Hasharon shares held by Global Automax were pledged in favor of SciSparc with a first-degree permanent lien.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            February 28, 2025, the Company made the third payment of principal and interest for the bonds
                                            (series B) in a total amount of approximately 14.7 million ILS. After the mentioned payment,
                                            the Company repaid 55% of the principal of the bonds (series B).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On
                                            March 23, 2025, 59,257,103 option warrants exercisable for 11,851,420 ordinary shares of
                                            the Company, which were granted to a number of officers of the Company as part of the merger
                                            transaction with Global Automax, expired.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --> </p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="B_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ANNEX A</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><p style="text-align: right"><i>Execution
                                            Copy</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>AGREEMENT AND PLAN OF MERGER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">among</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt"><b>SCISPARC
LTD.</b>,</span><br/>
an Israeli limited company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt"><b>SCISPARC
MERGER SUB LTD.</b>,</span><br/>
an Israeli limited company; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt"><b>AUTOMAX
MOTORS LTD.</b>,</span><br/>
an Israeli limited company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Dated as of April 10, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0in; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 149 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 28.35pt">TABLE OF CONTENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>



</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>1.</td>
    <td colspan="2"><b>DESCRIPTION OF TRANSACTION</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0pt">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%">1.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; width: 80%"><b>The Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 6%">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Effects of the Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Closing; Effective Time</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Articles of Association; Directors and Officers</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Conversion of Shares</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Calculation of Parent Net Cash</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Closing of the Company&#8217;s Transfer Books</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Payment of Aggregate Merger Consideration</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>1.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Further Action</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>1.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Withholding; Tax Rulings</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>2.</td>
    <td colspan="2"><b>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Due Organization; Subsidiaries</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">11</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Organizational Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Authority; Binding Nature of Agreement</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Vote Required</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Non-Contravention; Consents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Capitalization</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">13</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>TASE Filings, Financial Statements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Changes</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">16</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Undisclosed Liabilities</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Title to Assets</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Real Property; Leasehold</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Intellectual Property</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Agreements, Contracts and Commitments</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.14</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Compliance; Permits</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.15</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Legal Proceedings; Orders</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.16</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.17</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Employee and Labor Matters; Benefit Plan</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">24</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.18</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Environmental Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">27</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.19</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Insurance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.20</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Financial Advisors</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.21</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Transactions with Affiliates</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">28</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>2.22</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Anti-Bribery</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>2.23</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Disclaimer of Other Representations or Warranties</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>3.</td>
    <td colspan="2"><b>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Due Organization; Subsidiaries</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">29</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Organizational Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Authority; Binding Nature of Agreement</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">30</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Vote Required</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Non-Contravention; Consents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">31</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Capitalization</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>SEC Filings; Financial Statements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Changes</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Absence of Undisclosed Liabilities</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">36</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 150; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%">3.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; width: 80%"><b>Real Property; Leasehold</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 6%">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Intellectual Property</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Agreements, Contracts and Commitments</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Compliance; Permits</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.14</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Legal Proceedings; Orders</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.15</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.16</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Transactions with Affiliates</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.17</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Insurance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.18</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Financial Advisors</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.19</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Anti-Bribery</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.20</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Valid Issuance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>3.21</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Opinion of Financial Advisor</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>3.22</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Disclaimer of Other Representations or Warranties</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>4.</td>
    <td colspan="2"><b>CERTAIN COVENANTS OF THE PARTIES</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Operation of Parent&#8217;s Business</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>4.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Operation of the Company&#8217;s Business</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">50</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Access and Investigation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>4.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Parent Non-Solicitation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Non-Solicitation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>4.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Notification of Certain Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>4.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Post-Closing Financing</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>5.</td>
    <td colspan="2"><b>ADDITIONAL AGREEMENTS OF THE PARTIES</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Court Approval, Registration Statement and Transaction Report</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Meetings</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Parent Shareholders&#8217; Meeting; Merger Sub Approval</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Regulatory Approvals</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Certificate of Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Options</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Warrants</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>TASE De-Listing of Company Ordinary Shares</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Additional Agreements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Disclosure</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Listing</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Matters</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Directors and Officers</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.14</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Termination of Certain Agreements and Rights</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.15</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Cooperation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.16</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Allocation Certificates; Ownership Certificate</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.17</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Company Financial Statements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>5.18</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Shareholder Litigation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>5.19</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Certain Adjustments</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6.</td>
    <td colspan="2"><b>CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Restraints</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>6.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Shareholder Approval</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Court Approval</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>6.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Tax Rulings</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Certificate of Merger</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>6.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Legal Prohibition</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>6.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Bonds Trustee</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">65</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 151 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>7.</td>
    <td colspan="2"><b>ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 7%">&#160;</td>
    <td style="width: 7%">7.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; width: 80%"><b>Accuracy of Representations</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 6%">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>7.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Performance of Covenants</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>7.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>7.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Company Material Adverse Effect</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>7.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Termination of Investor Agreements</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>8.</td>
    <td colspan="2"><b>ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Accuracy of Representations</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>8.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Performance of Covenants</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Documents</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>8.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Parent Material Adverse Effect</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Parent Net Cash</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>8.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Listing</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>8.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Directors and Officers</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>9.</td>
    <td colspan="2"><b>TERMINATION</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2"/>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>9.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Termination</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>9.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Notice of Termination; Effect of Termination</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>9.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Expenses</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>10.</td>
    <td colspan="2"><b>MISCELLANEOUS PROVISIONS</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.1</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Non-Survival of Representations and Warranties</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.2</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Amendment</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.3</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Waiver</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">71</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.4</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.5</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Applicable Law; Jurisdiction</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.6</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Attorneys&#8217; Fee</b>.</td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.7</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Assignability</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.8</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Notices</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.9</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Cooperation</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.10</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Severability</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.11</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Other Remedies; Specific Performance</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>10.12</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>No Third Party Beneficiaries</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">75</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>10.13</td>
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in"><b>Construction</b></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">75</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 152 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Exhibits:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 10%; text-align: justify">Exhibit A</td>
    <td style="vertical-align: bottom; width: 90%; text-align: justify">Definitions</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">Exhibit B</td>
    <td style="vertical-align: bottom; text-align: justify">Company Shareholder Support Agreements</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">Exhibit C</td>
    <td style="vertical-align: bottom; text-align: justify">Form of Restated Company Articles</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">Exhibit D</td>
    <td style="vertical-align: bottom; text-align: justify">Form of Pre-Funded Warrant (to be agreed prior to the Closing)</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify">Exhibit E</td>
    <td style="vertical-align: bottom; text-align: justify">Company Allocation Schedule (to be agreed prior to the Closing)</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify">Exhibit F</td>
    <td style="vertical-align: bottom; text-align: justify">Form of Indemnification Agreement</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 153 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>AGREEMENT AND PLAN OF MERGER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THIS AGREEMENT AND PLAN
OF MERGER</b> (together with its exhibits and schedules, this &#8220;<b><i>Agreement</i></b>&#8221;) is made and entered into as of April
10, 2024, by and among SciSparc Ltd., an Israeli limited company (&#8220;<b><i>Parent</i></b>&#8221;), SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of Parent (&#8220;<b><i>Merger Sub</i></b>&#8221;), and AutoMax Motors Ltd., an Israeli limited
company (the &#8220;<b><i>Company</i></b>&#8221;). Certain capitalized terms used in this Agreement are defined in <b><span style="text-decoration:underline">Exhibit A</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>RECITALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. &#160;Parent and the Company
intend to effect a merger of Merger Sub with and into the Company (the &#8220;<b><i>Merger</i></b>&#8221;) in accordance with this Agreement
and by way of a court approved arrangement between the Company and its shareholders and, if applicable, its Bondholders and creditors,
in accordance with the provisions of Sections 350 and 351 of the Companies Law. Upon consummation of the Merger, Merger Sub will cease
to exist, and the Company will become a wholly-owned subsidiary of Parent, on the terms and subject to the conditions set forth in this
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B. &#160;The Parent Board
has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its shareholders,
(ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the authorization and issuance of ordinary
shares, with no par value, of Parent (&#8220;<b><i>Parent Ordinary Shares</i></b>&#8221;), listed and traded on Nasdaq, to the shareholders
of the Company pursuant to the terms of this Agreement and (iii) determined to recommend, upon the terms and subject to the conditions
set forth in this Agreement, that the shareholders of Parent vote to approve the Parent Shareholder Matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C. &#160;The Merger Sub Board
has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Merger Sub and its sole shareholder,
(ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms
and subject to the conditions set forth in this Agreement, that the sole shareholder of Merger Sub votes to adopt this Agreement and
thereby approve the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D. &#160;The Company Board
has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its shareholders,
(ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms
and subject to the conditions set forth in this Agreement, that the shareholders and, if applicable, the creditors of the Company, vote
to approve the Company Approval Matters and if required, pursuant to the Companies Law or the Applicable Court, that the Bondholders
of the Company vote to approve the Company Approval Matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E. &#160;Concurrently with
the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement,
(a) the shareholders of the Company listed in Section A-1 of the Company Disclosure Schedule (the &#8220;<b><i>Company Signatories</i></b>&#8221;)
(solely in their capacity as shareholders of the Company) are executing support agreements in favor of Parent in substantially the form
attached hereto as <b><span style="text-decoration:underline">Exhibit B</span></b> pursuant to which such Company Signatories are agreeing to take specified actions in furtherance
of the Merger, including actions relating to the approval of the Merger and adoption of this Agreement by the Company&#8217;s shareholders
(the &#8220;<b><i>Company Shareholder Support Agreements</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 154; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>AGREEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties, intending to
be legally bound, agree as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">1.
<b><span style="text-decoration:underline">DESCRIPTION OF TRANSACTION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1 &#160;<b><span style="text-decoration:underline">The Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the terms and subject
to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company, and the separate
existence of Merger Sub shall cease. The Company will continue as the surviving company in the Merger (the &#8220;<b><i>Surviving Company</i></b>&#8221;)
and shall (a) become a private debenture company (<i>Chevrat Igrot Hov</i>) within the meaning of the Companies Law and a wholly-owned,
direct subsidiary of Parent, (b) continue to be governed by the Laws of the State of Israel, (c) maintain a registered office in the
State of Israel, and (d) succeed to and assume all of the rights, properties and obligation of Merger Sub in accordance with the Companies
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 &#160;<b><span style="text-decoration:underline">Effects of
the Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger shall have the
effects set forth in this Agreement. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time (as
defined below), by virtue of, and simultaneously with, the Merger and without any further action on the part of Parent, Merger Sub, the
Company or any Company Shareholder, (a) Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger
Sub shall cease and the Company shall continue as the Surviving Company; (b) all the properties, rights, privileges, powers and franchises
of the Company and Merger Sub shall vest in the Surviving Company; (c) all debts, liabilities and duties of the Company and Merger Sub
shall become the debts, liabilities and duties of the Surviving Company; and (d) all the rights, privileges, immunities, powers and franchises
of the Company (as the Surviving Company) shall continue unaffected by the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3 &#160;<b><span style="text-decoration:underline">Closing;
Effective Time</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless this Agreement is
earlier terminated pursuant to the provisions of <span style="text-decoration:underline">Section &#8206;9.1&#8206;</span>, and subject to the satisfaction or, to the extent permitted
by Law, waiver by such party entitled to waive such condition of the conditions set forth in <span style="text-decoration:underline">Sections &#8206;6</span>&#8206;, <span style="text-decoration:underline">&#8206;7</span>
and <span style="text-decoration:underline">&#8206;&#8206;8</span>, the consummation of the Merger (the &#8220;<b><i>Closing</i></b>&#8221;) shall take place remotely as promptly
as practicable (but in no event later than the second Business Day following the satisfaction or waiver by such party entitled to waive
such condition of the last to be satisfied or waived of the conditions set forth in in <span style="text-decoration:underline">Sections &#8206;6&#8206;</span>,<span style="text-decoration:underline">&#8206;7</span> &#8206;and
<span style="text-decoration:underline">&#8206;&#8206;8</span>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction
or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing.
The date on which the Closing actually takes place is referred to as the &#8220;<b><i>Closing Date</i></b>.&#8221; As soon as practicable
after the determination of the Closing Date in accordance with this <span style="text-decoration:underline">Section &#8206;&#8206;1.3</span>, each of the Company and Merger Sub
shall (and Parent shall cause Merger Sub to), in coordination with each other, deliver to the Registrar of Companies of the State of
Israel (the &#8220;<b><i>Companies Registrar</i></b>&#8221;), a notice of the proposed date of the Closing, in which notice the parties
shall request that the Companies Registrar issue a certificate evidencing the Merger (the &#8220;<b><i>Certificate of Merger</i></b>&#8221;)
on the date that the Parties shall provide further notice to the Companies Registrar that the Closing has occurred, and the Parties shall
deliver such further notice to the Companies Registrar on the Closing Date. The Merger shall become effective upon the issuance by the
Companies Registrar of the Certificate of Merger (the time at which the Merger becomes effective is referred to herein as the &#8220;<b><i>Effective
Time</i></b>&#8221;). For the avoidance of doubt, and notwithstanding any provision of this Agreement to the contrary, it is the intention
of the Parties that the Merger being declared effective and that the issuance by the Companies Registrar of the Certificate of Merger
shall both occur on the Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4 &#160;<b><span style="text-decoration:underline">Articles
of Association; Directors and Officers</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">At the Effective
Time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;the articles of association
of the Surviving Company shall be amended and restated, as reflected in the form of amended and restated articles of association attached
hereto as <b><span style="text-decoration:underline">Exhibit C</span></b> (the &#8220;<b><i>Restated Company Articles</i></b>&#8221;), until thereafter amended as provided by
the Companies Law and such articles of association;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;unless otherwise
agreed upon by the Parent and the Company, the articles of association of Parent shall be amended in order to change the name of Parent
to such name as to be reasonably agreed upon by the Parties, and as may be approved by the Company and the Israeli Companies Registrar
(the &#8220;<b><i>Restated Parent Articles</i></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;the directors and
officers of Parent, each to hold office in accordance with the amended and restated articles of association of Parent, shall be as designated
by the Parent and the Company prior to Closing after giving effect to the provisions of <span style="text-decoration:underline">Section <b>&#8206;</b>5.13</span>, or such other
persons as shall be mutually agreed upon by Parent and the Company, until the earlier of their resignation or removal or until their
respective successors are duly elected or appointed and qualified, as the case may be; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;the directors and
officers of the Surviving Company, each to hold office in accordance with the articles of association of the Surviving Company, shall
be the directors and officers of the Company as in office immediately prior to the Effective Time, until the earlier of their resignation
or removal or until their respective successors are duly elected or appointed and qualified, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5 &#160;<b><span style="text-decoration:underline">Conversion
of Shares</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) At the Effective Time,
by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any shareholder of the Company
or shareholder of Parent, the following shall occur:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">(i) &#160;any Company Ordinary
Shares held in the treasury of the Company or held or owned by the Company or Merger Sub immediately prior to the Effective Time shall
be canceled and retired without any conversion and shall cease to exist, and no consideration shall be delivered in exchange therefor;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 113.4pt">(ii) &#160;subject to <span style="text-decoration:underline">Section
<b><i>&#8206;</i></b>1.5(d)</span> each Company Ordinary Share outstanding immediately prior to the Effective Time (excluding shares to be
canceled pursuant to <span style="text-decoration:underline">Section <b><i>&#8206;&#8206;</i></b>1.5(a)(i)</span> and excluding Company Ordinary Shares held by the Parent immediately
prior to the Effective Time) shall be automatically converted solely into the right to receive a number of validly issued, fully paid
and nonassessable Parent Ordinary Shares, equal to the Exchange Ratio, per each such Company Ordinary Share (the &#8220;<b><i>Merger
Consideration</i></b>&#8221;) in accordance with <span style="text-decoration:underline">Section <b><i>&#8206;&#8206;</i></b>1.8(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;Notwithstanding any
other provision of this Agreement, under no circumstances shall the Parent issue Parent Ordinary Shares to any Company Shareholder pursuant
to the terms of this Agreement, to the extent that after giving effect to such issuance, the Company Shareholder, together with any affiliate
thereof, would beneficially own (as determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder)
in excess of 9.99% of the number of Parent Ordinary Shares outstanding immediately after giving effect to such issuance (the &#8220;<b><i>Ownership
Limitation</i></b>&#8221;). If the Parent cannot issue Parent Ordinary Shares due to be issued pursuant to this Agreement, the Parent
shall (i) issue all such Parent Ordinary Shares that may be issued without causing a Company Shareholder to exceed the Ownership Limitation,
and (ii) issue to the Company Shareholder, pre-funded warrants to purchase Parent Ordinary Shares, in substantially the form attached
hereto as <b><span style="text-decoration:underline">Exhibit D</span></b> (the &#8220;<b><i>Parent Pre-Funded Warrant</i></b>&#8221;), in lieu of Parent Ordinary Shares not
so provided to such holder. Each Parent Pre-Funded Warrant shall be exercised for $0.001 per each Parent Ordinary Share. The Pre-Funded
Warrants will be registered in the Parent&#8217;s books and will not be listed for trading on any stock exchange or trading market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;If any Company Ordinary
Shares outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture
under any applicable restricted share purchase agreement or other similar agreement with the Company, then the Parent Ordinary Shares
issued in exchange for such Company Ordinary Shares will to the same extent be unvested and subject to the same repurchase option or
risk of forfeiture, and the certificates representing such Parent Ordinary Shares shall accordingly be marked with appropriate legends.
The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, Parent is entitled to exercise
any such repurchase option or other right set forth in any such restricted share purchase agreement or other agreement in accordance
with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;No fractional Parent
Ordinary Shares shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued.
Any holder of Company Ordinary Shares who would otherwise be entitled to receive a fraction of a Parent Ordinary Share shall not receive
such fraction, and shall instead receive such amount rounded to the nearest whole number of Parent Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;All Company Options
outstanding immediately prior to the Effective Time under the Company Share Plans shall be treated in accordance with <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.6(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) &#160;All Company Warrants
outstanding if any, immediately prior to the Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.7(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) &#160;Each ordinary share,
with no par value, of Merger Sub issued and outstanding immediately prior to the Effective Time shall automatically and without further
action be converted into and exchanged for one validly issued, fully paid and nonassessable ordinary share, NIS 0.05 par value per share,
of the Surviving Company. Each share certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time,
evidence ownership of such ordinary shares of the Surviving Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) &#160;If, between the time
of calculating the Exchange Ratio and the Effective Time, the outstanding Company Ordinary Shares or Parent Ordinary Shares shall have
been changed into, or exchanged for, a different number of shares or a different class, by reason of any share dividend, subdivision,
reclassification, recapitalization, split, combination or exchange of shares or other like change, the Exchange Ratio shall be equitably
adjusted to reflect such change to the extent necessary to provide the holders of Company Ordinary Shares, Parent Ordinary Shares, Company
Options with the same economic effect as contemplated by this Agreement prior to such share dividend, subdivision, reclassification,
recapitalization, split, combination or exchange of shares or other like change; <i>provided, however</i>, that nothing herein will be
construed to permit the Company or Parent to take any action with respect to Company Ordinary Shares or Parent Ordinary Shares, respectively,
that is prohibited or not expressly permitted by the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6 &#160;<b><span style="text-decoration:underline">Calculation
of Parent Net Cash</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;For the purposes
of this Agreement, the &#8220;<b><i>Anticipated Closing Date</i></b>&#8221; shall be the date, as agreed upon by Parent and the Company,
to be the anticipated date for Closing. At least fifteen (15) calendar days prior to the Anticipated Closing Date, Parent shall deliver
to the Company a schedule (the &#8220;<b><i>Net Cash Schedule</i></b>&#8221;) setting forth, in reasonable detail, Parent&#8217;s good
faith, estimated calculation of the Parent Net Cash (the &#8220;<b><i>Net Cash Calculation</i></b>&#8221;) as of the Anticipated Closing
Date, prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer, the principal accounting
officer). <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(a)</span> of the Parent Disclosure Schedule is an illustrative Net Cash Schedule containing an
illustrative Net Cash Calculation. Parent shall make available the work papers and back-up materials used or useful in preparing the
Net Cash Schedule, as reasonably requested by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;Within five (5) calendar
days after delivery of the Net Cash Schedule (the &#8220;<b><i>Response Date</i></b>&#8221;), the Company will have the right to dispute
any part of the Net Cash Schedule by delivering a written notice to that effect to Parent (a &#8220;<b><i>Dispute Notice</i></b>&#8221;).
Any Dispute Notice shall identify in reasonable detail any information available and known to the Company at such time related to the
nature of any proposed revisions to the Net Cash Calculation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;If on or prior to
the Response Date, the Company: (i) notifies Parent in writing that it has no objections to the Net Cash Calculation or (ii) fails to
deliver a Dispute Notice as provided in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(b)</span>, then the Net Cash Calculation as set forth in the Net
Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent Parent Net Cash at the
Anticipated Closing Date for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;If the Company delivers
a Dispute Notice on or prior to the Response Date, then Representatives of both Parties shall promptly meet and attempt in good faith
to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon Parent Net Cash amount
shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash, at the Anticipated
Closing Date for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;(x) If Representatives
of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash at the Anticipated Closing Date pursuant
to <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(d)</span> within three (3) calendar days after delivery of the Dispute Notice (or such other period as
Parent and the Company may mutually agree upon), then the Chief Executive Officer of Parent and the Chief Executive Officer of the Company
shall promptly meet and agree on the amount of Parent Net Cash. (y) If the Chief Executive Officer of Parent and the Chief Executive
Officer of the Company are unable to negotiate an agreed-upon determination of Parent Net Cash at the Anticipated Closing Date within
three (3) calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon),
then Parent and the Company shall jointly approach (or either party may approach) one of the &#8220;big four&#8221; accounting firms
(other than EY) (the &#8220;<b><i>Accounting Firm</i></b>&#8221;) to resolve any remaining disagreements as to the Net Cash Calculation
within seven (7) calendar days; <i>provided</i> that the Accounting Firm shall be authorized and empowered by the parties solely as a
neutral expert and not as an arbitrator to resolve accounting issues, and shall not be authorized to resolve any disputes related to
the interpretation of this Agreement or any other legal disputes between the parties. Parent shall promptly deliver to the Accounting
Firm the work papers and back-up materials used in preparing the Net Cash Schedule, and Parent and the Company shall use commercially
reasonable efforts to cause the Accounting Firm to make its determination within seven (7) calendar days of approaching the Accounting
Firm. The Company and Parent shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved
disputes and to discuss the issues with the Accounting Firm; <i>provided, however</i>, that no such presentation or discussion shall
occur without the presence of a Representative of each of the Company and Parent. The determination of the Accounting Firm shall be limited
to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash made by the Accounting Firm
shall be deemed to have been determined for purposes of this Agreement and to represent Parent Net Cash at the Anticipated Closing Date
for purposes of this Agreement, and the Parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>1.6(e). </span>The fees and expenses of the Accounting Firm shall be allocated between Parent and Company in the same proportion
that the disputed amount of Parent Net Cash that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm)
bears to the total disputed amount of Parent Net Cash (and, for the avoidance of doubt, the fees and expenses to be paid by Parent shall
reduce Parent Net Cash). If this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(e)</span> applies as to the determination of Parent Net Cash, at the Anticipated
Closing Date described in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.6(a)</span> upon resolution of the matter in accordance with this <span style="text-decoration:underline">Section <b>&#8206;</b>1.6(e)
</span>(the &#8220;<b><i>Resolution Number</i></b>&#8221;), the Parties shall not be required to determine Parent Net Cash again, even though
the Closing Date may occur later than the Anticipated Closing Date, except that either Party may request a re-determination of Parent
Net Cash if the Closing Date occurs later than (10) ten Business Days after the Anticipated Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7 &#160;<b><span style="text-decoration:underline">Closing of
the Company&#8217;s Transfer Books</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Effective Time: (a)
all Company Ordinary Shares outstanding immediately prior to the Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section &#8206;&#8206;1.5(a)</span>,
and all holders of Company Ordinary Shares that were outstanding immediately prior to the Effective Time shall cease to have any rights
as shareholders of the Company; and (b) the share transfer books of the Company shall be closed with respect to all Company Ordinary
Shares outstanding immediately prior to the Effective Time. No further transfer of any such Company Ordinary Shares shall be made on
such share transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any Company
Ordinary Shares outstanding immediately prior to the Effective Time (a &#8220;<b><i>Company Share Certificate</i></b>&#8221;) is presented
to the Parent, such Company Share Certificate shall be canceled and shall be exchanged as provided in&#160;<span style="text-decoration:underline">Sections&#160;&#8206; &#8206;1.5</span>&#160;and&#160;<span style="text-decoration:underline">&#8206;Section
&#8206;1.8(b)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.8 &#160;<b><span style="text-decoration:underline">Payment of
Aggregate Merger Consideration</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;<i>Payment Procedures
with Respect to Company Ordinary Shares.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Effective Time
(but in no event later than five (5) Business Days prior to the anticipated Effective Time), the Parent shall select a bank or trust
company in Israel that is a TASE member and reasonably acceptable to the Company, to act as the paying agent for the Merger (the &#8220;<b><i>Paying
Agent</i></b>&#8221;) and, in connection therewith, shall enter into an agreement with the Paying Agent in form reasonably satisfactory
to the Company and Parent (the &#8220;<b><i>Paying Agent Agreement</i></b>&#8221;). No later than the Effective Time, the Parent shall
deliver to the Transfer Agent an irrevocable letter instructions, instructing the Transfer Agent to deposit, via The Depository Trust
Company Deposit or Withdrawal at Custodian system (&#8220;<b><i>DWAC</i></b>&#8221;), with the account of the Paying Agent, in trust
for the benefit of the Persons who were holders of Company Ordinary Shares (excluding Company Certified Shares), that were converted
into the right to receive the Merger Consideration, such number of whole Parent Ordinary Shares and, if applicable, Parent Pre-Funded
Warrants, representing the Merger Consideration to which the holders thereof are entitled to receive pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(a)</span>.
Immediately following the execution of this Agreement and prior to the Effective Time, the Parties will jointly discuss with the TASE
all procedures relating to the transfer of the Company Ordinary Shares to the Parent as of the Effective Time and the delivery of the
relevant portion of the Merger Consideration to the holders of Company Ordinary Shares, including the delivery of any information required
by the Paying Agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;<i>Payment Procedures
with Respect to Company Certified Shares</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Effective Time, the
Company will deliver to Parent a true, complete and accurate listing of all record holders of Company Certified Shares at the Effective
Time, including the number and class of Company Certified Shares held by such record holder, and the number of Parent Ordinary Shares
such holder is entitled to receive pursuant to <span style="text-decoration:underline">Section &#8206;1.5</span>, in the form attached hereto as <b><span style="text-decoration:underline">Exhibit E</span></b> (the &#8220;<b><i>Company
Allocation Schedule</i></b>&#8221;). Promptly after Parent&#8217;s receipt of the Company Allocation Schedule (and in no event later
than five (5) Business Days after the date of such receipt), the Parties shall cause to be mailed to the record holders of Company Certified
Shares that were converted into the right to receive the Merger Consideration: (A) a letter of transmittal in such form as the Company
and Parent may reasonably agree (a &#8220;<b><i>Letter of Transmittal</i></b>&#8221;), which shall specify that delivery shall be effected,
and risk of loss and title to such Company Ordinary Shares shall pass, only upon delivery of the Company Share Certificates (or affidavits
of loss in lieu thereof as provided below) to the Parent; and (B) instructions for use in effecting the surrender of the Company Share
Certificates into the right to receive the Merger Consideration payable in respect thereof pursuant to the Company Allocation Schedule.
Upon, surrender of Company Share Certificates (or affidavit of loss in lieu thereof as provided below) for cancellation to the Parent,
the Parent shall deliver to the Transfer Agent an irrevocable letter instructions, instructing the Transfer Agent to deposit, via DWAC,
with the account of the record holders of Company Certified Shares, that were converted into the right to receive the Merger Consideration,
such number of whole Parent Ordinary Shares representing the Merger Consideration to which the holders thereof are entitled to receive
pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(a)</span>. Until surrendered as contemplated by this <span style="text-decoration:underline">Section&#8206;1.8(b)</span>&#8206;, each Company Share
Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive book-entry Parent Ordinary Shares
representing the Merger Consideration. If any Company Share Certificate shall have been lost, stolen or destroyed, Parent may, in its
discretion and as a condition precedent to the delivery of any Parent Ordinary Shares, require the owner of such lost, stolen or destroyed
Company Share Certificate to provide an applicable affidavit with respect to such Company Share Certificate and post a bond (in reasonable
amount), as indemnity against any claim suffered by Parent with respect to such lost, stolen or destroyed Company Share Certificate as
Parent may reasonably request. In the event of a transfer of ownership of a Company Share Certificate that is not registered in the transfer
records of the Company, payment of the Merger Consideration may be made to a Person other than the Person in whose name such Company
Share Certificate so surrendered is registered if such Company Share Certificate shall be properly endorsed or otherwise be in proper
form for transfer and the Person requesting such payment shall pay any transfer or other Taxes required by reason of the transfer or
establish to the reasonable satisfaction of Parent that such Taxes have been paid or are not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;The Merger Consideration
and any dividends or other distributions shall be deemed to have been in full satisfaction of all rights pertaining to Company Ordinary
Shares. Notwithstanding the above, any Merger Consideration payable in respect of Company Ordinary Shares subject to the Withholding
Tax Ruling or the 104H Ruling shall be transferred by the Paying Agent on the Closing Date to the Withholding Agent or the 104H Trustee,
respectively, to the extent required by the Withholding Tax Ruling or the 104H Ruling for the benefit of the beneficial owners thereof,
and shall be held and released (or otherwise treated) by said trustee to the beneficial holders of such Company Ordinary Shares in accordance
with the requirements of the Withholding Tax Ruling, the 104H Ruling and the Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;No party to this
Agreement shall be liable to any holder of Company Ordinary Shares or to any other Person with respect to any Parent Ordinary Shares
(or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable
abandoned property Law, escheat Law or similar Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.9 &#160;<b><span style="text-decoration:underline">Further Action</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at any time after the
Effective Time, any further action is determined by the Surviving Company to be necessary or desirable to carry out the purposes of this
Agreement or to vest the Surviving Company with full right, title and possession of and to all rights and property of the Company, then
the officers and directors of the Surviving Company shall be fully authorized, and shall use their and its commercially reasonable efforts
(in the name of the Company, in the name of Merger Sub, in the name of the Surviving Company and otherwise) to take such action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.10 &#160;<b><span style="text-decoration:underline">Withholding;
Tax Rulings</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;Notwithstanding anything
to the contrary hereunder, Parent, the Surviving Company, the 102 Trustee, the Transfer Agent, the Withholding Agent, the 104H Trustee,
the Paying Agent, the Hevra Le&#8217;Rishumim, and the TASE members and any of their respective agents (each, a &#8220;<b><i>Payor</i></b>&#8221;)
shall be entitled to deduct and withhold from any payment or consideration made pursuant to this Agreement (including the Merger Consideration)
such amounts as may be required to be deducted and withheld with respect to the making of such payment under the Code, the Ordinance,
or under any provision of applicable U.S. federal, state, local, Israeli, or other Tax Law, including the Withholding Tax Ruling and
the 104H Ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;The parties herby
acknowledge that they and the Withholding Agent shall act in accordance with Income Tax Circular 19/2018 (Transaction for Sale of Rights
in a Corporation that includes consideration that will be transferred to the Seller at Future Dates) (the &#8220;<b><i>Circular</i></b>&#8221;)
and the Withholding Agent shall provide the Company, prior to the Closing Date, with an undertaking as required under Section 6.2.4.3(c)
of the Circular.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;Notwithstanding the
provisions of <span style="text-decoration:underline">Section<b>&#8206;</b>1.10(a)</span> above, with respect to withholding of Israeli Tax, subject to the provisions of the Withholding
Tax Ruling or the 104H Ruling, as applicable, no tax shall be deducted or withheld from any payment pursuant to this Agreement, except
as set forth in the Withholding Tax Ruling and the 104H Ruling, if obtained. The Merger Consideration payable or otherwise deliverable
hereunder to any holder of Company Ordinary Shares (each, a &#8220;<b><i>Payee</i></b>&#8221;) shall (notwithstanding <span style="text-decoration:underline">Section <b>&#8206;</b>1.10(a)
</span>above) be paid or delivered to, and retained by, the respective Payor for the benefit of such Payee until the earlier of: (x) (A)
with respect to a Payee which holds 5% or more of the Company share capital on the date which is ten (10) days prior to the Closing Date,
unless a different date for such calculations is specified by the ITA, in which case such date shall be as specified by the ITA (a &#8220;<b><i>5%
Payee</i></b>&#8221;), and the 104H Ruling has been obtained, the date on which the 104H Ruling has been obtained or (B) if such Payee
is a Less Than 5% Payee and the Withholding Tax Ruling has been obtained, the date on which the Withholding Tax Ruling has been obtained,
or (C) with respect to a Payee that is not included in the application for the Withholding Tax Ruling nor the 104H ruling, the date on
which such Payee delivers to the Withholding Agent a Valid Tax Certificate, and (y) the date that is 180 days following the Closing Date,
as may be further extended (with respect to all or some of the Payees) by mutual agreement of the Company, Parent and the Withholding
Agent (the &#8220;<b><i>Withholding Drop Date</i></b>&#8221;), during which time (unless a request is submitted by the Payee to Payor
to release its portion of the consideration prior to the Withholding Drop Date) no Payor shall withhold any Israeli Tax from such Merger
Consideration pursuant to this Agreement to such holder<b>&#8206;</b>, except as provided below, and if during which time such recipient
provides the Payor with a Valid Tax Certificate issued by the ITA regarding the withholding (or exemption from withholding) of Israeli
Tax from the consideration payable in respect thereof in accordance with this Agreement, or other treatment with respect to Israeli Tax,
at least three (3) Business Days prior to the Withholding Drop Date, then the deduction and withholding of any amounts under the Ordinance
or any other provision of Israeli Law or requirement, if any, from the Merger Consideration payable to such holder of record of Company
Ordinary Shares shall be made in accordance with the provisions of such Valid Tax Certificate, subject to any deduction and withholding
as may be required to be deducted and withheld under any applicable Law. If any holder of record of Company Ordinary Shares (A) does
not provide the Payor with a Valid Tax Certificate no later than three (3) Business Days prior to the Withholding Drop Date, or (B) submits
a written request to the Payor to release his or her portion of the Merger Consideration prior to the Withholding Drop Date and fails
to submit a Valid Tax Certificate at or before such time, then the amount to be withheld from the payment to such holder shall be calculated
based on the applicable withholding rate on the actual payment date in accordance with applicable Law as determined by the Parent or
its Israeli advisors at their reasonable discretion, and such amount will be calculated in NIS based on the USD-NIS exchange rate known
on the date the payment is actually made to such Payee and shall be delivered to the ITA by the Payor, and the Payor shall deliver to
such holder the balance of the portion of the Merger Consideration due to such holder that is not so withheld (if any).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;To the extent that
amounts are so withheld pursuant to this <span style="text-decoration:underline">Section <b>&#8206; &#8206;</b>1.10</span>, they shall be paid over to the appropriate Governmental
Body prior to the last day on which such payment is required to be paid to such Governmental Body, and such withheld amounts shall be
treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;For the avoidance
of doubt, to the extent that the Payor is obliged to withhold Israeli Taxes at the rate prescribed under the Ordinance and/or the Withholding
Tax Ruling and/or 104H Ruling (the &#8220;<b><i>Withheld Amounts</i></b>&#8221;), each Person in respect of which such withholding is
required to be made shall provide the Payor a cash payment equal to the Withheld Amounts within seven (7) Business Days from receipt
of a request from the Payor to make such payment, and in any event prior to the release of the Merger Consideration deliverable to such
Person. In the event that such Person fails to provide the Payor with the Withheld Amounts within such timeframe, the Payor will be authorized
to sell on the open market, subject to any lock-up or transfer restrictions applicable at such time to the consideration or a portion
thereof, any number of Parent Ordinary Shares required to cover any amount required to be deducted or withheld under this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>1.10</span> and such amounts shall be treated for all purposes of this Agreement as having been delivered and paid to such
Payee. Notwithstanding anything else to the contrary in this Agreement, and unless instructed otherwise by the ITA in writing, for Israeli
withholding Tax purposes, the value of the consideration shall be determined based on the closing price of a Parent Ordinary Share on
the Closing Date. Any currency conversion commissions will be borne by the applicable payment recipient and deducted from payments to
be made to such payment recipient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) &#160;Notwithstanding anything
to the contrary herein, any payments made to holders of any Company Options, if any, will be subject to deduction or withholding of Israeli
Tax under the Ordinance on the sixteenth (16<sup>th</sup>) day of the calendar month following the month during which the Closing Date
occurs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) &#160;Without derogating
from the foregoing, as soon as reasonably practicable, but in no event more than five (5) Business Days after the date hereof, the Company,
in full coordination with Parent and its Israeli counsel, will cause its Israeli counsel, advisors or accountants to prepare and file
with the ITA an application for a Withholding Tax Ruling and 104H Ruling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) &#160;Without limiting
the generality of this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>1.10</span>, each of the Company and Parent shall cause their respective Israeli counsel,
advisors and accountants to coordinate all material activities and to cooperate with each other with respect to the preparation and filing
of such applications for rulings and in the preparation of any written or oral submissions that may be necessary, proper or advisable
to obtain the Withholding Tax Ruling and 104H Ruling. In any event, the final text of the Withholding Tax Ruling and the 104H Ruling
shall be subject to the prior written confirmation of Parent, which consent shall not be unreasonably withheld, conditioned or delayed.
The Company shall keep Parent informed, on a prompt basis (and, in any event, within two Business Days) of its receipt of any notice
or information in connection with any of the above rulings or approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) &#160;Each party hereto
is relying solely on the advice of its own Tax advisors with respect to the Tax consequences of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">2.
<b><span style="text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>References in this Section
2 to the &#8220;Company&#8221; shall mean the Company and each of its Subsidiaries unless the nature of the context provides otherwise<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <span style="text-decoration:underline">Section &#8206;&#8206;10.13(h)</span>,
except: (i) as set forth in the disclosure schedule delivered by the Company to Parent (the &#8220;<b><i>Company Disclosure Schedule</i></b>&#8221;)
or (ii) as disclosed in the Company TASE Documents filed with the ISA or the TASE prior to the date hereof and publicly available (but:
(x) without giving effect to any amendment thereof filed with, or furnished to the ISA or the TASE on or after the date hereof and (y)
excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking
statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking
in nature), the Company represents and warrants to Parent and Merger Sub as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 &#160;<b><span style="text-decoration:underline">Due Organization;
Subsidiaries</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;The Company is a
public company, listed and traded on TASE, duly organized and validly existing under the Laws of the State of Israel, is not a &#8220;breaching
company&#8221; under the Companies Law, and has all necessary corporate power and authority: (i) to conduct its business in the manner
in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property
and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except
where the failure to have such power or authority would not reasonably be expected to prevent or materially delay the ability of the
Company to consummate the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;The Company is duly
licensed and qualified to do business and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all
jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure
to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;The Company has no
Subsidiaries except for the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;</b>2.1(c)</span> of the Company Disclosure Schedule; and neither
the Company nor any of the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.1(c)</span> of the Company Disclosure Schedule owns any
share capital of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other
Entity other than the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.1(c)</span> of the Company Disclosure Schedule. Each of the Company&#8217;s
Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws
of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner
in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property
and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected
to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;Except as set forth
in Section <b>&#8206;</b>2.1(d) of the Company Disclosure Schedule, the Company is not and since March 24, 2021 has not been, directly
or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not
agreed or is obligated to make or is bound by any Contract under which it may become obligated to make, any future investment in or capital
contribution to any other Entity. The Company is not and has never been a general partner of or has otherwise been liable for any of
the debts or other obligations of, any general partnership, limited partnership or other Entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;The Company is not
subject to any delisting proceedings by TASE, nor does the Company foresee any reason for delisting proceedings to commence following
the Effective Date contemplated hereby, nor is the Company subject to any enforcement action by the ISA, or equivalent enforcement entities,
nor does the Company foresee any reason for the commencement of enforcement actions against the Company, or its Affiliates, following
the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2 &#160;<b><span style="text-decoration:underline">Organizational
Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has made available
to Parent accurate and complete copies of the Organizational Documents of the Company in effect as of the date of this Agreement. The
Company is not in material breach or violation of its Organizational Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3 &#160;<b><span style="text-decoration:underline">Authority;
Binding Nature of Agreement</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has all necessary
corporate power and authority to enter into and to perform its obligations under this Agreement and, subject to receipt of the Required
Company Approval, and the filing and recordation of appropriate merger documents as required by the Companies Law, to consummate the
Contemplated Transactions. The Company Board (at meetings duly called and held) has: (i) determined that the Contemplated Transactions
are fair to, advisable and in the best interests of the Company and its shareholders; (ii) authorized, approved and declared advisable
this Agreement and the Contemplated Transactions in accordance with the requirements of the Companies Law; and (iii) determined to recommend,
upon the terms and subject to the conditions set forth in this Agreement, that the shareholders of the Company vote to approve this Agreement
and the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization,
execution and delivery by Parent and Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, subject to the Enforceability Exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4 &#160;<b><span style="text-decoration:underline">Vote Required</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Section 350 Vote (the
&#8220;<b><i>Required Company Approval</i></b>&#8221;) is the only vote of the holders of any class or series of Company share capital,
creditors or holders of any notes or bonds, necessary to adopt and approve this Agreement and to approve the Contemplated Transactions.
Unless otherwise required by the Applicable Court and assuming the fulfilment of Section &#8206;6.7 below, no approval or vote of the Bondholders
is necessary to adopt and approve this Agreement and to consummate the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5 &#160;<b><span style="text-decoration:underline">Non-Contravention;
Consents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to obtaining the
Required Company Approval, the filings with the TASE, the ISA and the Companies Registrar of all notices or filings required under the
Companies Law or the Israeli Securities Law, including with respect to the consummation of the Merger and the issuance of the Certificate
of Merger by the Companies Registrar or any filings with the Applicable Court, neither: (i) the execution, delivery or performance of
this Agreement by the Company, nor (ii) the consummation of the Contemplated Transactions, will directly or indirectly (with or without
notice or lapse of time):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;contravene, conflict
with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;contravene, conflict
with or result in a violation of, or give any Governmental Body the right to challenge the Contemplated Transactions or to exercise any
remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which the Company, or any of the assets
owned or used by the Company, is subject, except as would not reasonably be expected to be material to the Company or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;contravene, conflict
with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend,
cancel, terminate or modify, any Governmental Authorization that is held by the Company, except as would not reasonably be expected to
be material to the Company or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;subject to obtaining
the requisite approvals and consents in respect of the Contracts set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.5(d)</span> of the Company Disclosure
Schedule, contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company
Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Company Material Contract;
(ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (iii) accelerate
the maturity or performance of any Company Material Contract; or (iv) cancel, terminate or modify any term of any Company Material Contract,
except in the case of any non-material breach, default, penalty or modification; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;result in the imposition
or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for: (i) the filings
with the Companies Registrar and all such other notices or filings with respect to the consummation of the Merger and the issuance of
the Certificate of Merger by the Companies Registrar, (ii) or any filings with the Applicable Court and (iii) such consents, waivers,
approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable securities Laws, the Company
is not and will not be required to make any filing with or give any notice to, or to obtain any Consent from, any Governmental Body in
connection with (x) the execution, delivery or performance of this Agreement, or (y) the consummation of the Contemplated Transactions,
which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the
ability of the Company to consummate the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6 &#160;<b><span style="text-decoration:underline">Capitalization</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;The authorized share
capital of the Company is 400,000,00 Company Ordinary Shares, of which 105,643,744 Company Ordinary Shares have been issued and are outstanding
as of the close of business on the Business Day immediately preceding the date of this Agreement. Except as set forth in Section 2.6(a)
of the Company Disclosure Schedule, the Company does not hold any of its share capital in its treasury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;All of the outstanding
Company Ordinary Shares have been duly authorized and validly issued, and are fully paid and nonassessable. None of the outstanding Company
Ordinary Shares is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and
none of the outstanding Company Ordinary Shares is subject to any right of first refusal in favor of Company. Except as contemplated
herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging
or otherwise disposing of (or granting any option or similar right with respect to), any Company Ordinary Shares. Company is not under
any obligation, nor is it bound by any Company Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise
acquire any outstanding Company Ordinary Shares or other securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &#160;Except for the Company
Share Plans, the Company does not have any share option plan or any other plan, program, agreement or arrangement providing for any equity-based
compensation for any Person. As of the date of this Agreement, Company has reserved 14,611,596 Company Ordinary Shares for issuance under
the Company Share Plans, of which 70,123,612 options are issued and are currently outstanding, with a weighted average exercise price
of NIS 1.77 (collectively, the &#8220;<b><i>Company Options</i></b>&#8221;), and 0 shares remain available for future issuance pursuant
to the Company Share Plans. <span style="text-decoration:underline">Section &#8206;(c)</span> of the Company Disclosure Schedule sets forth the following information with respect
to each Company Option outstanding as of the date of this Agreement: (i) the name of the optionee; (ii) the number of Company Ordinary
Shares subject to such Company Option at the time of grant; (iii) the number of Company Ordinary Shares subject to such Company Option
as of the date of this Agreement; (iv) the exercise price of such Company Option; (v) the date on which such Company Option was granted;
(vi) the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration
provisions; (vii) the date on which such Company Option expires; and (viii) (A) the Tax route under which such Company Option was granted
and is currently intended to qualify (pursuant to Section 102 or Section 3(i) of the Ordinance), and (B) for Company 102 Options, the
date of the applicable corporate approval and the date of deposit of the respective award agreement with the 102 Trustee. The Company
has made available to Parent an accurate and complete copy of the Company Share Plans and all share option agreements evidencing outstanding
options granted thereunder. Except as set forth in <span style="text-decoration:underline">Section &#8206;&#8206;1.1(c)</span> of the Company Disclosure Schedule, no vesting of
Company Options will accelerate in connection with the closing of the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &#160;All Company Options
granted under Section 102 of the Ordinance were granted under an employee option plan deemed approved, or not rejected within 30 days
from filing, by the ITA under the capital gains route of Section 102 of the Ordinance and comply in all respects with the requirements
of Section 102 of the Ordinance and qualify for treatment under the capital gain route thereunder, and were duly and timely deposited
in accordance with the provisions of Section 102 of the Ordinance with the 102 Trustee and no action has been threatened against the
Company (nor is the Company aware of a reasonable basis for an action against the Company) with respect to the failure of the Company
to comply with such requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &#160;No unexercised Company
Options shall be outstanding immediately prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) &#160;<span style="text-decoration:underline">Section &#8206;1.1(f)
</span>of the Company Disclosure Schedule lists, as of the date of this Agreement: (i) each holder of issued and outstanding Company Warrants,
(ii) the number and type of shares subject to each Company Warrant, (iii) the exercise price of each Company Warrant and (iv) the termination
date of each Company Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) &#160;Except for the Company
Warrants, the Company Share Plans, including the Company Options, and as otherwise set forth on <span style="text-decoration:underline">Section &#8206;&#8206;1.1(g)</span> of the
Company Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable)
to acquire shares or other securities of Company or any of its Subsidiaries; (ii) outstanding security, instrument or obligation that
is or may become convertible into or exchangeable for any shares or other securities of Company or any of its Subsidiaries; or (iii)
condition or circumstance that is reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to
the effect that such Person is entitled to acquire or receive any shares or other securities of Company or any of its Subsidiaries. There
are no outstanding or authorized share appreciation, phantom shares, profit participation or other similar rights with respect to Company
or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) &#160;All outstanding Company
Ordinary Shares, Company Options, Company Warrants and other securities of Company have been issued and granted in material compliance
with: (i) all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) &#160;Except as set forth
in Section 2.6(h) of the Company Disclosure Schedule, all of the issued and outstanding Company Ordinary Shares are registered and held
through the Hevra Le&#8217;Rishumim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7 &#160;<b><span style="text-decoration:underline">TASE Filings,
Financial Statements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#160;The Company has delivered
or made available to the Parent accurate and complete copies of all prospectuses, proxy statements and other statements, reports, schedules,
forms and other documents filed by the Company with the ISA or the TASE since March 24, 2021 (the &#8220;<b><i>Company TASE Documents</i></b>&#8221;),
other than such documents that can be obtained on the ISA&#8217;s or the TASE&#8217;s websites. All material statements, reports, schedules,
forms and other documents required to have been filed by the Company or its officers with the ISA or the TASE have been filed on a timely
basis. As of the time it was filed with the ISA or the TASE (or, if amended or superseded by a filing prior to the date of this Agreement,
then on the date of such filing), each of the Company TASE Documents complied in all material respects with the applicable requirements
of the Israeli Securities Law and, as of the time they were filed, none of the Company TASE Documents contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. The Company has made available to the Parent true and complete
copies of all, but transmittal, correspondences, between the ISA and the Company and all material correspondences between the TASE and
the Company, since March 24, 2021, including all ISA or TASE comment letters and responses to such comment letters by or on behalf of
the Company other than such documents that can be obtained on the ISA&#8217;s or the TASE&#8217;s website. Except as set forth in <span style="text-decoration:underline">Section
<b>&#8206;</b>2.7(a)</span> of the Company Disclosure Schedule, as of the date of this Agreement, there are no outstanding or unresolved comments
in comment letters received from the ISA or the TASE with respect to the Company TASE Documents. To the Knowledge of the Company, none
of the Company TASE Documents is the subject of ongoing ISA or TASE review and there are no inquiries or investigations by the ISA or
TASE or internal investigations pending or threatened, including with regard to any accounting practices of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &#160;The financial statements
(including any related notes) contained or incorporated by reference in the Company TASE Documents: (i) complied as to form in all material
respects with the published rules and regulations of the Israeli Securities Law; (ii) were prepared in accordance with IFRS (except as
may be indicated in the notes to such financial statements, and except that the unaudited financial statements may not contain footnotes
and are subject to normal and recurring year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout
the periods indicated; and (iii) fairly present, in all material respects, the financial position of the Company as of the respective
dates thereof and the results of operations and cash flows of the Company for the periods covered thereby. Other than as expressly disclosed
in the Company TASE Documents filed prior to the date hereof, there has been no material change in Company&#8217;s accounting methods
or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><!-- Field: Split-Segment; Name: 001 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(c)&#160;The Company is in compliance
in all material respects with the applicable current listing and governance rules and regulations of the TASE. Except as set forth in
<span style="text-decoration:underline">Section &#8206;<b>&#8206;</b>2.7(c)</span> of the Company Disclosure Schedule and the Company TASE Documents, from March 24, 2021 through
the date hereof, Company has not received any correspondence from TASE or the staff thereof relating to the delisting or maintenance
of listing of the Company Ordinary Shares on the TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;The Company maintains
disclosure controls and procedures. Such disclosure controls and procedures are designed to provide reasonable assurance that all material
information concerning the Company (including its Subsidiaries) required to be disclosed by the Company in the Company TASE Documents
is made known on a timely basis to the individuals responsible for the preparation of the Company TASE Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;The Company maintains
a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&#160;transactions are executed in accordance
with management&#8217;s general or specific authorizations; and (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;During the twelve
(12) month period prior to the date hereof, to the Company&#8217;s Knowledge, the Company&#8217;s principal executive officer and its
principal financial officer have disclosed to the Company&#8217;s auditors and the audit committee of the Company Board (i)&#160;those
significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting that are reasonably
likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information of the Company
and its Subsidiaries on a consolidated basis that are known to them and (ii)&#160;any fraud known by such individuals, whether or not
material, that involves management or other employees who have a significant role in the Company&#8217;s and in the Company Subsidiaries&#8217;
internal controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">2.8&#160;<b><span style="text-decoration:underline">Absence of Changes</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;2.8</span> of the Company Disclosure Schedule, between the date of the Company Balance Sheet, together with the statements of income,
shareholders&#8217; equity and cash flows of the Company for the period reflected in the Company Balance Sheet (collectively, the &#8220;<b><i>Company
Financials</i></b>&#8221;) and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business
(except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there
has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required the consent of Parent
pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;4.2(b)</span> had such action, event or occurrence taken place after the execution and delivery of this
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.9&#160;<b><span style="text-decoration:underline">Absence of
Undisclosed Liabilities</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, the
Company has no liability, indebtedness, obligation or expense of any kind and is not subject to any claim, whether accrued, absolute,
contingent, matured or unmatured (whether or not required to be reflected in the financial statements in accordance with IFRS) or any
involvement in any special purpose vehicles (each a &#8220;<b><i>Liability</i></b>&#8221;), individually or in the aggregate, of a type
required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under IFRS except for: (a) Liabilities
disclosed, reflected or reserved against in the Company Balance Sheet; (b) Liabilities that have been incurred by the Company since the
date of the Company Balance Sheet in the Ordinary Course of Business; (c) Liabilities for performance of obligations of the Company under
any Contract to which it is party; (d) Liabilities incurred in connection with the Contemplated Transactions; (e) Liabilities which would
not, individually or in the aggregate, reasonably be expected to be material to the Company; and (f) Liabilities described in <span style="text-decoration:underline">Section
&#8206;&#8206;2.9</span> of the Company Disclosure Schedule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.10&#160;<b><span style="text-decoration:underline">Title to
Assets</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company owns, and has
good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible
assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets
reflected on the Company Balance Sheet and (b) all other tangible assets reflected in the books and records of the Company as being owned
by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances,
other than Permitted Encumbrances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.11&#160;<b><span style="text-decoration:underline">Real Property;
Leasehold</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in Section
&#8206;2.11 of the Company Disclosure Schedule, the Company does not own and since March 24, 2021 has not owned any real property. The
Company has made available to Parent: (i) an accurate and complete list of all real properties with respect to which the Company directly
or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company
and (ii) copies of all leases under which any such real property is possessed (the &#8220;<b><i>Company Real Estate Leases</i></b>&#8221;),
each of which is in full force and effect, with no existing material default thereunder. The Company&#8217;s use and operation of each
such leased property conforms to all applicable Laws in all material respects, and the Company has exclusive possession of each such
leased property and has not granted any occupancy rights to tenants or licensees with respect to such leased property. In addition, each
such leased property is free and clear of all Encumbrances other than Permitted Encumbrances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.12&#160;<b><span style="text-decoration:underline">Intellectual
Property</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except for the trademarks
set forth on <span style="text-decoration:underline">Section <b>&#8206;</b>2.12(a)</span> of the Company Disclosure Schedule, the Company does not own, license or otherwise have
any right, title or interest in any material Intellectual Property Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;To the Knowledge of
the Company the operation of the businesses of the Company as currently conducted does not infringe any valid and enforceable Registered
IP or misappropriate or otherwise violate any Intellectual Property Right owned by any other Person. As of the date of this Agreement,
no Legal Proceeding is pending (or, to the Knowledge of the Company, is threatened in writing) against the Company alleging that the
operation of the businesses of the Company infringes or constitutes the misappropriation or other violation of any Intellectual Property
Rights of another Person. Since March 24, 2021, the Company has not received any written notice or other written communication alleging
that the operation of the business of the Company infringes or constitutes the misappropriation or other violation of any Intellectual
Property Right of another Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;To the Knowledge of
the Company, the Company and the operation of the Company&#8217;s business are in substantial compliance with all Laws pertaining to
data privacy and data security of any personally identifiable information and sensitive business information (collectively, &#8220;<b><i>Sensitive
Data</i></b>&#8221;) except to the extent that such noncompliance has not and would not reasonably be expected to have a Company Material
Adverse Effect. To the Knowledge of the Company, since March 24, 2021, there have been: (i) no material losses or thefts of data or security
breaches relating to Sensitive Data used in the business of the Company, (ii) no violations of any security policy of the Company regarding
any such Sensitive Data, (iii) no unauthorized access or unauthorized use of any Sensitive Data used in the business of the Company or
(iv) no unintended or improper disclosure of any personally identifiable information in the possession, custody or control of the Company,
or a contractor or agent acting on behalf of the Company, in each case of (i) through (iv), except as would not reasonably be expected
to, individually or in the aggregate, have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.13&#160;<b><span style="text-decoration:underline">Agreements,
Contracts and Commitments</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.13(a)
</span>of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this Agreement other than any
Company Benefit Plans (each, a &#8220;<b><i>Company Material Contract</i></b>&#8221; and collectively, the &#8220;<b><i>Company Material
Contracts</i></b>&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;each Company Contract
relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;each Company Contract
containing: (A) any covenant limiting the freedom of the Company or the Surviving Company to engage in any line of business or compete
with any Person, (B) any most-favored pricing arrangement, (C) any exclusivity provision, or (D) any non-solicitation provision;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;each Company Contract
relating to capital expenditures and requiring payments after the date of this Agreement in excess of $200,000 pursuant to its express
terms and not cancelable without penalty;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;each Company Contract
relating to the disposition or acquisition of material assets or any ownership interest in any entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;each Company Contract
relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating
to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets of the Company or any
loans or debt obligations with officers or directors of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;each Company Contract
requiring payment by or to the Company after the date of this Agreement in excess of $200,000 pursuant to its express terms relating
to: (A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any dealer, distributor, joint marketing,
alliance, joint venture, cooperation or other agreement currently in force under which the Company has continuing obligations to market
any product, technology or service; or (C) any Contract to license any third party to manufacture or produce any product, service or
technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case,
except for Company Contracts entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;each Company Contract
with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the
Company in connection with the Contemplated Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;each Company
Real Estate Lease;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;each Company Contract
with any Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;each Company Contract
containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;any other Company
Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment or receipt by the
Company after the date of this Agreement under any such agreement, contract or commitment of more than $200,000 in the aggregate, or
obligations after the date of this Agreement in excess of $200,000 in the aggregate, or (B) that is material to the business or operations
of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The Company has delivered
or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. Except
as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.13(b)</span> of the Company Disclosure Schedule, there are no Company Material Contracts that
are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party
to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under,
any of the terms or conditions of any Company Material Contract in such manner as would permit any other party to cancel or terminate
any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to be material
to the Company or its business. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding,
enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant
to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material
Contract or any other material term or provision of any Company Material Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.14&#160;<b><span style="text-decoration:underline">Compliance;
Permits</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;The Company is in
compliance in all material respects with all applicable U.S., Israeli and other Laws, including the rules and regulations of the Israeli
Ministry of Transport and Road Safety, except for any noncompliance, either individually or in the aggregate, which would not be material
to the Company. No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Knowledge
of the Company, threatened against the Company. There is no agreement, judgment, injunction, order or decree binding upon the Company
which: (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the
Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii) is
reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under
this Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with
the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The Company holds
all required Governmental Authorizations necessary for the operation of the business of the Company as currently conducted (the &#8220;<b><i>Company
Permits</i></b>&#8221;). <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.14(b)</span> of the Company Disclosure Schedule identifies each Company Permit. The
Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company,
threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit. All of the Governmental Authorizations are
valid and in full force and effect, except where the invalidity of such Governmental Authorizations or the failure of such Governmental
Authorizations to be in full force and effect would not have a Company Material Adverse Effect; and the Company has not received any
notice of proceedings relating to the revocation or modification of any such Governmental Authorizations which, singly or in the aggregate,
would reasonably be expected to result in a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.15&#160;<b><span style="text-decoration:underline">Legal Proceedings;
Orders</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As of the date of
this Agreement, there is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence
any Legal Proceeding: (i) that involves (A) the Company, (B) any Company Associate (in his or her capacity as such) or (C) any of the
material assets owned or used by the Company; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal
or otherwise interfering with, the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except as set forth
in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.15(b)</span> of the Company Disclosure Schedule, since March 24, 2021, no Legal Proceeding has been pending
against the Company that had or would reasonably be expected to have resulted in material liability to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There is no order,
writ, injunction, judgment or decree to which the Company, or any of the material assets owned or used by the Company, is subject. To
the Knowledge of the Company, no officer of the Company is subject to any order, writ, injunction, judgment or decree that prohibits
such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or
to any material assets owned or used by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.16&#160;<b><span style="text-decoration:underline">Tax Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;Each Tax Return
required to be filed with any Governmental Body by the Company has been filed when due (taking into account extensions in the ordinary
course of business) in accordance with applicable Law, each of which is true, accurate and complete;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;the Company has
timely paid, collected or withheld, to the appropriate Governmental Body all Taxes due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;the Company has
complied with all applicable Law relating to the payment and withholding of any Tax and has, within the time and in the manner prescribed
by Law, withheld and paid over to the proper Governmental Body all amounts required to be so withheld and paid over;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;the Company has
established adequate accruals or reserves, in accordance with IFRS, for all Taxes for taxable periods beginning on or after the date
of the most recent Company Financials;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;Except as set forth
in Section <b><i>&#8206;</i></b>2.16<b><i>&#8206;</i></b>(a)<b><i>&#8206;</i></b>(v) of the Company Disclosure Schedule, there is no Legal
Proceeding against or with respect to the Company in respect of any Tax or any Tax Return and there is no investigation against or with
respect to the Company, pending or threatened or otherwise in respect of any Tax or any Tax Return. All deficiencies asserted or assessments
made against the Company as a result of any examinations by any Governmental Body have been fully paid;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;the Company has
not consented or requested to extend the time, or is the recipient of any extension of time, in which any Tax may be assessed or collected
by any Governmental Authority and the Company has not waived any statute of limitations;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;no Governmental
Authority in a jurisdiction where no Tax Return has been filed or no Tax has been paid has made or threatened to make a claim for the
payment of any Tax or the filing of any Tax Return;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;the Company is
a Tax resident only in its jurisdiction of formation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>2.16(a)(ix)</span> of the Company Disclosure Schedule, no power of attorney granted by or with
respect to the Company for Taxes is currently in force, no ruling with respect to Taxes has been requested by or on behalf of the Company;
and no closing agreement pursuant to Section 7121 of the Code (or any predecessor provision) or any similar provision of any state, local
or non-U.S. Law has been entered into or requested by or with respect to the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;the Company has
provided or made available to Parent prior to the date hereof true, correct and complete copies of all material Tax Returns, examination
reports, and statements of deficiencies filed, assessed against, or agreed to by the Company with respect to Taxes and all material written
correspondence with any Governmental Authority regarding Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>2.16(a)(xi)</span> of the Company Disclosure Schedule, the Company is neither a controlled foreign
corporation (as defined in Section 957 of the Code or any similar provision of any state, local or non-U.S. Law) nor a passive foreign
investment company (as defined in Section 1297 of the Code). The Company does not own any interest in any controlled foreign corporation
(as defined in Section 957 of the Code or any similar provision of any state, local or non-U.S. Law), or passive foreign investment company
(as defined in Section 1297 of the Code) or other entity the income of which is or could be required to be included in the income of
the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)&#160;the Company is
not and has never been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the
applicable period specified in Section 897(c)(1)(A)(ii) of the Code;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)&#160;the Company will
not be required to include any item of income in, or exclude any item of deduction from, taxable income for (A) any Tax period (or portion
thereof), as a result of any deferred foreign income within the meaning of Section 965 of the Code, including, but not limited to, as
the result of an election under Section 965(h) of the Code, or (B) any Tax period (or portion thereof) ending after the Closing Date,
as a result of any (1) deferred intercompany gain or any excess loss account described in Treasury Regulations under Section 1502 of
the Code (or any corresponding provision of state, local or non-U.S. Tax Law); (2) installment sale or other open transaction disposition
made on or prior to the Closing Date; (3) prepaid amount, refund or credit received on or prior to the Closing Date; (4) change in accounting
method for a taxable period ending on or prior to the Closing Date; (5) use of an improper method of accounting for a taxable period
ending on or prior to the Closing Date; or (6) &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding
or similar provision of state, local or non-U.S. Tax Law) executed on or prior to the Closing Date;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)&#160;all material records
which the Company is required to keep for Tax purposes or which would be needed to substantiate any claim made or position taken in relation
to Taxes by the Company have been duly kept and are available for inspection at the premises of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)&#160;the Company is
in compliance in all respects with all terms and conditions of any Tax exemption, Tax holiday or other Tax reduction agreement or order
of a Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)&#160;all of the Company&#8217;s
property that is subject to property Tax has been properly listed and described on the property Tax rolls of the appropriate Tax jurisdiction
and no portion of any the Company&#8217;s property constitutes omitted property for property Tax purposes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)&#160;there are no
Liens for Taxes on any of the assets of the Company other than for any Taxes not yet due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section </span><b><i>&#8206;</i></b>2.16<b><i>&#8206;</i></b>(a)<b><i>&#8206;</i></b>(xviii) of the Company Disclosure Schedule,
the Company does not and has never participated or engaged in any transaction listed in Section 131(g) of the Ordinance and the Israeli
Income Tax Regulations (Reportable Tax Planning), 5767-2006, promulgated thereunder; the Company does not and has never taken a tax position
that is subject to reporting under Section 131E of the Ordinance; the Company has never obtained a legal or tax opinion that is subject
to reporting under Section 131D of the Ordinance; and the Company does not and has never performed and was not part of any action or
transaction that is classified as a &#8220;reportable opinion&#8221; under Section 67C of the Israeli VAT Law or a &#8220;reportable
position&#8221; under Section 67D of the Israeli VAT Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix)&#160;the Company is
duly registered for the purposes of Israeli value added tax and has complied in all respects with all requirements concerning VAT. The
Company (i) has not made any exempt transactions (as defined in the Israeli Value Added Tax Law, 5736-1975) and there are no circumstances
by reason of which there might not be an entitlement to full credit of all VAT chargeable or paid on inputs, supplies, and other transactions
and imports made by it, (ii) has collected and remitted in a timely manner to the ITA all output VAT which it is required to collect
and remit under any applicable Law and (iii) has not received a refund for input VAT for which it is not entitled under any applicable
Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xx)&#160;each of the Company
Share Plans that is intended to qualify as a capital gains route plan under Section 102 of the Ordinance has received a favorable determination
or approval letter from, or is otherwise approved by or deemed approved by passage of time without objection by, the ITA. All Company
102 Options have been granted and issued, as applicable, in compliance with the applicable requirements of Section 102 and the written
requirements and guidance of the ITA, including the filing of the necessary documents with the ITA, the appointment of an authorized
trustee, the grant of Company 102 Options only following the lapse of the required 30 day period from the filing of each of the Company
Share Plans that is intended to qualify as a capital gains route plan under Section 102 of the Ordinance with the ITA, the receipt of
the required written consents from the option holders and the due deposit of such securities with the 102 Trustee pursuant to the terms
of Section 102 of the Ordinance and the guidance published by the ITA on July 24, 2012, and clarification dated November 6, 2012;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxi)&#160;the Company is
not and has never been a real property corporation (<i>Igud Mekarke&#8217;in</i>) within the meaning of this term under Section 1 of
the Israeli Land Taxation Law (Appreciation and Acquisition), 5723-1963;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxii)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section </span><b><i>&#8206;</i></b>2.16<b><i>&#8206;</i></b>(a)<b><i>&#8206;</i></b>(xxii) of the Company Disclosure Schedule,
neither the Company nor any holder of Company securities is subject to any restrictions or limitations pursuant to Part E2 of the Ordinance
or pursuant to any Tax ruling made with reference to the provisions of Part E2;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiii)&#160;no independent
contractor was, or to the Knowledge of the Company will be, entitled to be considered to be an employee of the Company by any applicable
Tax authority; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiv)&#160;the Company did
not apply for any tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except as provided
in <span style="text-decoration:underline">Section </span><b>&#8206;</b>2.16<b>&#8206;</b>(b), the Company is in compliance in all respects with all applicable transfer pricing
laws and regulations, and the prices for any property or services provided by or to it are arm&#8217;s length prices for purposes of
the applicable laws, including Section 85A to the Ordinance and the Income Tax Regulations (Determination of Market Terms) 2006 and including
to the extent required, the execution and maintenance of contemporaneous documentation substantiating the transfer pricing practices
and methodology of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;The Company does not
have any (A) place of management, (B) branch, (C) office (or any other place of business), (D) operations or employees, (E) agent with
binding authority, or (F) other activities, in each case that gives rise to a permanent establishment or taxable presence which has subjected
it to any Tax obligation or to a requirement to file any Tax return in any country other than the country where the Company was organized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b>&#8206;</b>2.16<b>&#8206;</b>(d)</span> of the Company Disclosure Schedule, the Company is not, nor at any time has
it been, engaged in the conduct of a trade or business within the United States within the meaning of Section 864(b) or Section 882(a)
of the Code, or considered to be so engaged under Section 882(d) or Section 897 of the Code or, if applicable, considered to have a U.S.
permanent establishment as defined under any applicable or relevant bilateral income tax treaty or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;(i) The Company is
not nor has it ever been, a party to any Tax Sharing Agreement pursuant to which it will have any obligation to make any payments for
Taxes after the Closing Date, (ii) the Company is not and has never been a member of a group filing a consolidated, combined or unitary
Tax Return, and (iii) the Company has no liability for the payment of any Tax imposed on any Person (other than the Company) as a transferee
or successor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;The Company has never
taken a position that could give rise to substantial understatement of income tax within the meaning of Section 6662 of the Code (or
any corresponding provision of state, local or non-U.S. Tax Law) or has ever been a beneficiary or otherwise participated in any &#8220;reportable
transaction&#8221; as defined in Code Section 6707A(c)(1)) and Treasury Regulation Section 1.6011-4(b)(1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;With the exception
of Israeli VAT, the Company is not, nor is it required to be, registered as a taxable person for purpose of value added Taxes or any
similar indirect Tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this <span style="text-decoration:underline">Section
&#8206;&#8206;2.16</span>, each reference to the Company shall be deemed to include any Person that was liquidated into, merged with, or is
otherwise a predecessor to, the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.17&#160;<b><span style="text-decoration:underline">Employee
and Labor Matters; Benefit Plans</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(a)
</span>of the Company Disclosure Schedule is a list of all material Company Benefit Plans, including, without limitation, each Company Benefit
Plan that provides for change in control, stay or retention, deferred compensation, incentive compensation, pension and severance benefits.
&#8220;<b><i>Company Benefit Plan</i></b>&#8221; means each pension, profit sharing, bonus, incentive, equity or equity-based, phantom
equity, employment (other than at-will employment offer letters or employment agreement on the Company&#8217;s standard form as may be
amended from time to time and other than individual Company Options or other compensatory equity award agreements made pursuant to the
Company&#8217;s standard forms, in which case only representative standard forms of such agreements shall be scheduled) and fringe benefit
plan, program, agreement (including collective bargaining agreement and extension order), policy or arrangement (whether written or unwritten,
but excluding statutory benefits or benefits mentioned in the Company&#8217;s standard form of employment agreement) for the benefit
of any current or former employee, director, officer or independent contractor of the Company or any of its Subsidiaries or under which
the Company or any of its Subsidiaries has any actual or contingent liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;As applicable with
respect to each material Company Benefit Plan, the Company has made available to Parent true and complete copies of each material Company
Benefit Plan, including all amendments thereto, and in the case of an unwritten material Company Benefit Plan, a written description
thereof, and all material correspondence to or from any Governmental Body with respect to each Company Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Each Company Benefit
Plan has been established, maintained, operated and administered in compliance in all material respects with its terms and all applicable
Laws. Each Company Benefit Plan required to be funded is fully funded, and with respect to Company Share Plans that are not required
by applicable Law to be so fully funded, adequate reserves therefor have been established on the Company Financials (except for severance
pay that is fully funded, and full Section 14 Arrangements apply to all of the Company&#8217;s employees). No material liability or obligation
of the Company or any of its Affiliates exists with respect to any Company Benefit Plan that has not been disclosed in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(c)
</span>of the Company Disclosure Schedule. The Company does not have, and except as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(c)</span>
of the Company Disclosure Schedule has never had, any employees in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;To the Knowledge of
the Company, there are no pending audits or investigations by any Governmental Body involving any Company Benefit Plan, and no pending
or, to the Knowledge of the Company, threatened claims (except for individual claims for benefits payable in the normal operation of
the Company Benefit Plans), suits or proceedings involving any Company Benefit Plan in any case except as would not be reasonably expected
to result in material liability to the Company. The Company does not have any Company Benefit Plan that is maintained in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Neither the execution
of, nor the performance of the Contemplated Transactions will either alone or in connection with any other event(s): (i) result in any
material payment becoming due to any current or former employee, director, officer, or independent contractor of the Company, (ii) increase
any material amount of compensation or benefits otherwise payable under any Company Benefit Plan, (iii) result in the acceleration of
the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv) require any material contribution or payment
to fund any obligation under any Company Benefit Plan or (v) limit the right to merge, amend or terminate any Company Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(f)
</span>of the Company Disclosure Schedule sets forth the policy of the Company with respect to accrued vacation, accrued sick time and earned
time off and the amount of such liabilities, including regarding bonuses to employees and independent contractors for the last two years,
as of the date of this Agreement (in the case of accrued vacation, per employee for those who have more than 44 accrued days). The Company
does not have and has not had a policy regarding the payment of bonuses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;The Company is not
a party to, is not bound by, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a
labor union, labor organization, or similar Person representing any of its employees, and to the Knowledge of the Company, there is no
labor union, labor organization, or similar Person representing or purporting to represent or seeking to represent any employees of the
Company. There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of,
any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or,
to the Knowledge of the Company, any union organizing activity, against the Company. No event has occurred, and no condition or circumstance
exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown,
work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the
Company, any union organizing activity. The Company has paid all required payments, if any, that the Company has been requested to pay
to any employers&#8217; association or organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(h)
</span>of the Company Disclosure Schedule contains a list of all employees of the Company and its Subsidiaries along with the position,
the monthly rate of salary of each such employee, whether such employee is full time or part time, is exempt or non-exempt from the Hours
of Work and Rest Law, is on leave and if so, the type of leave and expected date of return, visa status (as applicable), date of hire,
any incentive payment paid or payable in calendar year 2023 (and whether such incentive is cash or, if not, what other property is due),
short-term or temporary basis, vacation entitlement and accrued vacation or paid time-off balance, car entitlement, sick leave entitlement
and accrual (if any), and recuperation pay entitlement and accrual, pension entitlements and provident funds (including manager&#8217;s
insurance, pension fund, education fund and health fund), their respective contribution rates for each component (<i>e.g.,</i> severance
component, pension savings and disability insurance) and the salary basis for such contributions, severance entitlements (including whether
such employee, to the extent employed in the State of Israel, is subject to a Section 14 arrangement under the Severance Pay Law, 5723-1963
(the &#8220;<b><i>Israeli Severance Pay Law</i></b>&#8221; and &#8220;<b><i>Section 14 Arrangement</i></b>&#8221;), and, to the extent
such employee is subject to such a Section 14 Arrangement, an indication of whether such arrangement (or other applicable pension arrangement)
has been applied to such person from the commencement date of their employment and on the basis of their entire salary including other
compensation (e.g., commission), main work location, notice period entitlement, and any other material compensation payable to such employee.
Neither the Company nor its Subsidiaries is delinquent in payments to any employees for wages, salaries, commissions or bonuses for services
performed as of the date hereof or amounts required by applicable Law to be reimbursed to such employees. The consummation of the Contemplated
Transactions will not give rise to any liability of the Company or any of its Subsidiaries for payments related to severance, termination,
bonus, accrued vacation or personal time, accrued days of sick pay or any similar payment. No current employee of the Company or any
of its Affiliates is or was, during the period of such employment or other service, based in or resident of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(i)
</span>of the Company Disclosure Schedule contains a list of each individual who currently renders services to Company as an independent
contractor or consultant (collectively, the &#8220;<b><i>Company Contractors</i></b>&#8221;) and the Company has made available to Parent
true and complete copies of each Company Contractors agreement and the last 3 months invoices. The Company has accurately classified
each such Company Contractor or former Company Contractor as an independent contractor under all applicable Laws (including for purposes
of Taxes and Tax reporting and under the Company Benefit Plans). Except as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.17(i)</span> of the
Company Disclosure Schedule, each Company Contractor can be terminated on notice of thirty days or less to the Company Contractor. According
to the Company Contractors&#8217; agreements with the Company, no Company Contractor is entitled to any rights under the applicable labor
laws. All current and former Company Contractors have received all their rights to which they are and were entitled according to any
applicable Law or Contract with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;The Company is not
delinquent in payments to any employees for wages, salaries, commissions or bonuses for services performed as of the date hereof or amounts
required by applicable Law to be reimbursed to such employees. The employment seniority for each employee for any employment purposes
began as of the date of hire and prior to such date no employment relations existed between any employee and the Company for any matter
or purpose. The Company has withheld, paid and reported all amounts required by the Ordinance, the National Insurance Law [Consolidated
Version], 5755-1995, and the National Health Insurance Law, 5754-1994 regarding its current and former employees and Company Contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;The Company is, and
since March 24, 2021 has been, in material compliance with all applicable Laws and agreements (including collective bargaining agreements
and extension orders) respecting labor (including consultants), employment, employment practices, and terms and conditions of employment,
including proper classification of independent contractors as not being employees. There are no actions, suits, claims, charges, lawsuits,
investigations, audits or administrative matters pending or, to the Knowledge of the Company, threatened or reasonably anticipated against
the Company relating to any employee, applicant for employment, consultant, employment agreement or Company Benefit Plan (other than
routine claims for benefits).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;There is not and has
not been in the past three years, nor is there or has there been in the past three years any threat of, any material claim, charge, grievance
or Legal Proceeding against the Company brought by or on behalf of any current or former applicant, employee, independent contractor,
subcontractor, leased employee, volunteer, or temporary employee of the Company, alleging violation of any applicable employment Law,
agreement or any other claim arising out of such Person&#8217;s employment, application for employment or termination of employment,
consulting or other relationship with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#160;At all times since
March 24, 2021, the Company has not engaged any employees whose employment would require special licenses or permits by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#160;The Company&#8217;s
obligations to provide statutory severance pay to its Israeli employees pursuant to the Israeli Severance Pay Law are fully funded in
accordance with Section 14 Arrangements and it is and was implemented properly, from the commencement date of each employee&#8217;s employment
and on the basis of 8.33% of the employee&#8217;s entire salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#160;The Company has not
been and is not subject to, and none of its employees or consultants benefits from, any collective agreement, extension order (<i>tzavei
harchave</i>) or any general contract or arrangement with respect to employment or termination of employment, except those extension
orders that apply to all Israeli companies generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#160;Each officer of the
Company is a party to a confidentiality agreement with the Company; copies of such agreements have previously been delivered, or made
available, to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&#160;No group of employees
has notified the Company of its intent, or, to the Knowledge of the Company, has any plans, to terminate employment with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&#160;The Company does not
have unsatisfied obligations of any nature to any of its former employees or consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.18&#160;<b><span style="text-decoration:underline">Environmental
Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is, and since
March 24, 2021 has been, in compliance with all applicable Environmental Laws, which compliance includes the possession by the Company
of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected
to be material to the Company or its business. The Company has not received since March 24, 2021 (or prior to that time, which to the
Knowledge of the Company is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from
a Governmental Body or other Person, that alleges that the Company is not in compliance with or has liability pursuant to any Environmental
Law and, to the Knowledge of the Company, there are no circumstances that would reasonably be expected to prevent or interfere with the
Company&#8217;s compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably
be expected to be material to the Company or its business. No current or (during the time a prior property was leased or controlled by
the Company) prior property leased or controlled by the Company has had a release of or exposure to Hazardous Materials in material violation
of or as would reasonably be expected to result in any material liability of the Company pursuant to Environmental Law. No consent, approval
or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection
with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions. Prior to the date hereof, the
Company has provided or otherwise made available to Parent true and correct copies of all material environmental reports, assessments,
studies and audits in the possession or control of the Company with respect to any property leased or controlled by the Company or any
business operated by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.19&#160;<b><span style="text-decoration:underline">Insurance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has delivered
or made available to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs
and arrangements relating to the business, assets, liabilities and operations of the Company. Each such insurance policy is in full force
and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications
from insurance carriers, since March 24, 2021, the Company has not received any notice or other communication regarding any actual or
possible: (i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights
or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance
carrier(s) of each Legal Proceeding that is currently pending against the Company for which the Company has insurance coverage, and no
such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding or informed the Company
of its intent to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.20&#160;<b><span style="text-decoration:underline">No Financial
Advisors</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;2.20</span> of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s
fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon
arrangements made by or on behalf of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.21&#160;<b><span style="text-decoration:underline">Transactions
with Affiliates</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>2.21(a)
</span>of the Company Disclosure Schedule describes any material transactions or relationships, since March 24, 2021, between, on one hand,
the Company and, on the other hand, any: (i) executive officer or director of the Company or, to the Knowledge of the Company, any of
such executive officer&#8217;s or director&#8217;s immediate family members, (ii) owner of more than 5% of the voting power of the outstanding
Company Ordinary Shares or (iii) to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item 404 of
Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of sub-limb
(i), (ii) or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>2.21(b)
</span>of the Company Disclosure Schedule lists each shareholders&#8217; agreement, voting agreement, co-sale agreement or other similar
Contract between the Company and any holders of Company Ordinary Shares, including any such Contract granting any Person investor rights,
rights of first refusal, rights of first offer, director designation rights or similar rights (collectively, the &#8220;<b><i>Investor
Agreements</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.22&#160;<b><span style="text-decoration:underline">Anti-Bribery</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither of the Company nor
any of its directors, officers, employees or, to the Company&#8217;s Knowledge, agents or any other Person acting on their behalf has
directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions,
or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices
Act of 1977, the UK Bribery Act of 2010, Sections 291 and 291A of the Israeli Penal Law, 5737-1977 or any other anti-bribery or anti-corruption
Law (collectively, the &#8220;<b><i>Anti-Bribery Laws</i></b>&#8221;). The Company is not and since March 24, 2021 has not been the subject
of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.23&#160;<b><span style="text-decoration:underline">Disclaimer
of Other Representations or Warranties</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in this
<span style="text-decoration:underline">Section &#8206;2</span> or in any certificate delivered by the Company to Parent and/or Merger Sub pursuant to this Agreement, the Company
makes no representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities or
operations, and any such other representations or warranties are hereby expressly disclaimed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">3.
<b><span style="text-decoration:underline">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <span style="text-decoration:underline">Section &#8206;&#8206;10.13(h)</span>,
except: (i) as set forth in the disclosure schedule delivered by Parent to the Company (the &#8220;<b><i>Parent Disclosure Schedule</i></b>&#8221;)
or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s
Electronic Data Gathering Analysis and Retrieval system (but: (x) without giving effect to any amendment thereof filed with, or furnished
to the SEC on or after the date hereof and (y) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any
disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are
forward-looking statements or cautionary, predictive or forward-looking in nature), Parent and Merger Sub represent and warrant to the
Company as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&#160;<b><span style="text-decoration:underline">Due Organization;
Subsidiaries</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Parent is a public
company duly organized and validly existing under the Laws of the State of Israel and Merger Sub is a company duly organized and validly
existing under the laws of the State of Israel, and neither Parent nor Merger Sub is a &#8220;breaching company&#8221; under the Companies
Law, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently
being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned
or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such
power or authority would not reasonably be expected to prevent or materially delay the ability of Parent and Merger Sub to consummate
the Contemplated Transactions to which it is a party. Since the date of its incorporation, Merger Sub has not engaged in any activities
other than activities incident to its formation or in connection with or as contemplated by this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Parent is duly licensed
and qualified to do business and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions
where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified
individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;The Parent has no
Subsidiaries, except for the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.1(c)</span> of the Parent Disclosure Schedule; and neither
the Parent nor any of the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.1(c)</span> of the Company Disclosure Schedule owns any share
capital of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity
other than the Entities identified in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.1(c)</span> of the Parent Disclosure Schedule. Each of the Parent&#8217;s
Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws
of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner
in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property
and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected
to have a Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;The Parent is not
and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar
business entity. The Parent has not agreed and is not obligated to make, or is bound by any Contract under which it may become obligated
to make, any future investment in or capital contribution to any other Entity. The Parent has not any time, been a general partner of,
or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#160;<b><span style="text-decoration:underline">Organizational
Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent has made available
to the Company accurate and complete copies of Parent&#8217;s and Merger Sub&#8217;s Organizational Documents in effect as of the date
of this Agreement. Neither Parent nor Merger Sub is in material breach or violation of its respective Organizational Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&#160;<b><span style="text-decoration:underline">Authority;
Binding Nature of Agreement</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of Parent and Merger
Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and, subject, with
respect to Parent, to receipt of the Required Parent Shareholder Vote and, with respect to Merger Sub, the adoption of this Agreement
by Parent in its capacity as sole shareholder of Merger Sub, to perform its obligations hereunder and to consummate the Contemplated
Transactions to which it is a party. The Parent Board (at meetings duly called and held) has: (i) determined that the Contemplated Transactions
to which it is a party are fair to, advisable and in the best interests of Parent and its shareholders; (ii) authorized, approved and
declared advisable this Agreement and the Contemplated Transactions to which it is a party, including the issuance of Parent Ordinary
Shares to the shareholders of the Company pursuant to the terms of this Agreement and the treatment of the Company Options and Company
Warrants pursuant to this Agreement; and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the shareholders of Parent vote to approve this Agreement and the Contemplated Transactions, including the issuance of
Parent Ordinary Shares to the shareholders of the Company pursuant to the terms of this Agreement. The Merger Sub Board (by unanimous
written consent) has: (x) determined that the Contemplated Transactions to which it is a party are fair to, advisable and in the best
interests of Merger Sub and its sole shareholder; (y) deemed advisable and approved this Agreement and the Contemplated Transactions
to which it is a party; and (z) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that
the sole shareholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions to which it is a party.
This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery
by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Sub, enforceable against each of Parent and
Merger Sub in accordance with its terms, subject to the Enforceability Exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&#160;<b><span style="text-decoration:underline">Vote Required</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The affirmative vote of a
majority of the votes cast by the holders of the outstanding Parent Ordinary Shares is the only vote of the holders of any class or series
of Parent&#8217;s outstanding share capital necessary to approve the proposals in <span style="text-decoration:underline">Section &#8206;5.3(a)&#8206;</span> (the &#8220;<b><i>Required
Parent Shareholder Vote</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5&#160;<b><span style="text-decoration:underline">Non-Contravention;
Consents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to obtaining the
Required Parent Shareholder Vote and the filings with the Companies Registrar or all other notices or filings required under the Companies
Law with respect to the consummation of the Merger and the issuance of the Certificate of Merger by the Companies Registrar or any filings
with the Applicable Court, neither: (i) the execution, delivery or performance of this Agreement by Parent or Merger Sub, nor (ii) the
consummation of the Contemplated Transactions to which it is a party, will directly or indirectly (with or without notice or lapse of
time):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;contravene, conflict
with or result in a violation of any of the provisions of the Organizational Documents of Parent or Merger Sub;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;contravene, conflict
with or result in a violation of, or give any Governmental Body the right to challenge the Contemplated Transactions to which it is a
party or to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which Parent
or Merger Sub, or any of the assets owned or used by Parent or Merger Sub, is subject, except as would not reasonably be expected to
be material to Parent or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;contravene, conflict
with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend,
cancel, terminate or modify, any Governmental Authorization that is held by Parent, except as would not reasonably be expected to be
material to Parent or its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;subject to obtaining
the requisite approvals and consents in respect of the Contracts set forth in <span style="text-decoration:underline">Section <b>&#8206;</b></span><b>&#8206;</b>3.5<b>&#8206;</b>(d)
of the Parent Disclosure Schedule, contravene, conflict with or result in a violation or breach of, or result in a default under, any
provision of any Parent Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Parent
Material Contract; (ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract;
(iii) accelerate the maturity or performance of any Parent Material Contract; or (iv) cancel, terminate or modify any term of any Parent
Material Contract, except in the case of any non-material breach, default, penalty or modification; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;result in the imposition
or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or Merger Sub (except for Permitted Encumbrances).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for: (i) the filing
with the Companies Registrar and all such other notices or filings with respect to the consummation of the Merger and the issuance of
the Certificate of Merger by the Companies Registrar, (ii) the filing of the Nasdaq Notification and receiving the requisite approval
from Nasdaq, (iii) or any filings with the Applicable Court and (iv) such consents, waivers, approvals, orders, authorizations, registrations,
declarations and filings as may be required under applicable federal and state securities Laws, neither the Parent nor Merger Sub is
or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Governmental Body in connection
with (y) the execution, delivery or performance of this Agreement, or (z) the consummation of the Contemplated Transactions to which
it is a party, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially
delay the ability of Parent and Merger Sub to consummate the Contemplated Transactions. No takeover statute or regulation is applicable
to this Agreement, the Merger or any of the other Contemplated Transactions to which it is a party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6&#160;<b><span style="text-decoration:underline">Capitalization</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;The authorized Parent
Share Capital is 75,000,000 Parent Ordinary Shares, of which 2,703,674 Parent Ordinary Shares have been issued and are outstanding as
of the close of business on the Business Day immediately preceding the date of this Agreement. Parent does not hold any of its share
capital in its treasury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;All of the outstanding
Parent Ordinary Shares have been duly authorized and validly issued and are fully paid and nonassessable. None of the outstanding Parent
Ordinary Shares is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and
none of the outstanding Parent Ordinary Shares is subject to any right of first refusal in favor of Parent. Except as contemplated herein,
there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or
otherwise disposing of (or granting any option or similar right with respect to), any Parent Ordinary Shares. Parent is not under any
obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any
outstanding Parent Ordinary Shares or other securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Except for the Parent
Share Plans, Parent does not have any share option plan or any other plan, program, agreement or arrangement providing for any equity-based
compensation for any Person. As of the date of this Agreement, Parent has reserved 1,020,800 Parent Ordinary Shares for issuance under
the Parent Share Plans, of which 7,013 Parent Options are issued and are currently outstanding, with a weighted average exercise price
of $166.28, no Parent Ordinary Shares are issuable upon the vesting or settlement of outstanding Parent RSUs, and 1,013,787 Parent Ordinary
Shares remain available for future issuance pursuant to the Parent Share Plans. <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.6(c)</span> of the Parent
Disclosure Schedule sets forth the following information with respect to each Parent Equity Award outstanding as of the date of this
Agreement: (i) the name of the grantee; (ii) the number of Parent Ordinary Shares subject to such Parent Equity Award at the time of
grant; (iii) the number of Parent Ordinary Shares subject to such Parent Equity Award as of the date of this Agreement; (iv) the exercise
price (if applicable) of such Parent Equity Award; (v) the date on which such Parent Equity Award was granted; (vi) the applicable vesting
schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii)
the date on which such Parent Equity Award expires; and (viii) (A) the Tax route under which such Parent Equity Award was granted and
is currently intended to qualify (pursuant to Section 102 or Section 3(i) of the Ordinance), and (B) for Parent 102 Equity Awards, the
date of the applicable corporate approval and the date of deposit of the respective award agreement with the 102 Trustee. The Parent
has made available to the Company an accurate and complete copy of the Parent Plans and all share award agreements evidencing outstanding
awards granted thereunder. Except as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.6(c)</span> of the Parent Disclosure Schedule, no vesting
of Parent Equity Awards will accelerate in connection with the closing of the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;All Parent Equity
Awards granted under Section 102 of the Ordinance were granted under an employee option plan deemed approved, or not rejected within
30 days from filing, by the ITA under the capital gains route of Section 102 of the Ordinance and comply in all respects with the requirements
of Section 102 of the Ordinance and qualify for treatment under the capital gain route thereunder, and were duly and timely deposited
in accordance with the provisions of Section 102 of the Ordinance with the 102 Trustee and no action has been threatened against Parent
(nor is Parent aware of a reasonable basis for an action against Parent) with respect to the failure of Parent to comply with such requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.6(e)
</span>of the Parent Disclosure Schedule lists, as of the date of this Agreement: (i) each holder of issued and outstanding Parent Warrants,
(ii) the number and type of shares subject to each Parent Warrant, (iii) the exercise price of each Parent Warrant and (iv) the termination
date of each Parent Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Except for the Parent
Warrants, the Parent Share Plans, including the Parent Equity Awards, and as otherwise set forth on <span style="text-decoration:underline">Section <b>&#8206;</b>3.6(f)<b>&#8206;
</b></span>of the Parent Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not
currently exercisable) to acquire shares or other securities of Parent; (ii) outstanding security, instrument or obligation that is or
may become convertible into or exchangeable for any shares or other securities of Parent; or (iii) condition or circumstance that is
reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled
to acquire or receive any shares or other securities of Parent. There are no outstanding or authorized share appreciation, phantom shares,
profit participation or other similar rights with respect to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;All outstanding Parent
Ordinary Shares, Parent Equity Awards, Parent Warrants and other securities of Parent have been issued and granted in material compliance
with: (i) all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;The Parent Pre-Funded
Warrants legally bind the Parent and are enforceable against the Parent in accordance with their terms. The Parent Pre-Funded Warrants
and the transactions contemplated thereby were duly approved by all required corporate approvals of the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7&#160;<b><span style="text-decoration:underline">SEC Filings;
Financial Statements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Parent has delivered
or made available to the Company accurate and complete copies of all registration statements, proxy statements, Certifications (as defined
below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC since January 1, 2021 (the &#8220;<b><i>Parent
SEC Documents</i></b>&#8221;), other than such documents that can be obtained on the SEC&#8217;s website at <span style="text-decoration:underline">www.sec.gov</span>. All material
statements, reports, schedules, forms and other documents required to have been filed by Parent or its officers with the SEC have been
filed on a timely basis. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this
Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements
of the Securities Act or the Exchange Act (as the case may be) and, as of the time they were filed, none of the Parent SEC Documents
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements
required by: (i) Rule 13a-14 under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section 906 of the Sarbanes-Oxley Act) relating to
the Parent SEC Documents (collectively, the &#8220;<b><i>Certifications</i></b>&#8221;) are accurate and complete and comply as to form
and content with all applicable Laws. As used in this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.7</span>, the term &#8220;file&#8221; and variations
thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made
available to the SEC. Parent has made available to the Company true and complete copies of all correspondences, other than transmittal
correspondences, between the SEC, on the one hand, and Parent, on the other, since January 1, 2021, including all SEC comment letters
and responses to such comment letters by or on behalf of Parent other than such documents that can be obtained on the SEC&#8217;s website
at <i><span style="text-decoration:underline">www.sec.gov</span></i>. As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received
from the SEC or Nasdaq with respect to the Parent SEC Documents. To the Knowledge of Parent, none of the Parent SEC Documents is the
subject of ongoing SEC review and there are no inquiries or investigations by the SEC or internal investigations pending or threatened,
including with regard to any accounting practices of Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The financial statements
(including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material
respects with the published rules and regulations of the SEC applicable thereto; (ii) were prepared in accordance with IFRS(except as
may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by
Form 6-K of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring
year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods indicated; and (iii) fairly
present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations
and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to
the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed
in Parent&#8217;s financial statements in accordance with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Parent&#8217;s auditor
has at all times since its retention by Parent been: (i) to the Knowledge of Parent, a registered public accounting firm (as defined
in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within
the meaning of Regulation S-X under the Exchange Act; and (iii) to the Knowledge of Parent, in compliance with subsections (g) through
(l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight
Board thereunder with respect to services provided to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Parent is in compliance
in all material respects with the applicable current listing and governance rules and regulations of Nasdaq. Except as set forth in <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>3.7(d)</span> of the Parent Disclosure Schedule and the Parent SEC Documents, from January 1, 2021 through the date hereof,
Parent has not received any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the
Parent Ordinary Shares on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Since January 1, 2021,
there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with,
reviewed by or initiated at the direction of the chief executive officer or chief financial officer of Parent, the Parent Board or any
committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by
the Sarbanes-Oxley Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Parent maintains a
system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with IFRS and to provide reasonable assurance: (i) that transactions are recorded as necessary to permit preparation
of financial statements in accordance with IFRS, (ii) that receipts and expenditures are made only in accordance with authorizations
of management and the Parent Board and (iii) regarding prevention or timely detection of the unauthorized acquisition, use or disposition
of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness
of Parent&#8217;s internal control over financial reporting as of September 30, 2023, and, to the extent required by applicable Law,
presented in any applicable Parent SEC Document that is a report on Form 20-F or Form 6-K (or any amendment thereto) its conclusions
about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment
based on such evaluation. Parent has disclosed, based on its most recent evaluation of internal control over financial reporting, to
Parent&#8217;s auditors and audit committee (and made available to the Company a summary of the significant aspects of such disclosure):
(A) all significant deficiencies, if any, in the design or operation of internal control over financial reporting that are reasonably
likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any known fraud
that involves management or other employees who have a significant role in Parent&#8217;s internal control over financial reporting.
Parent has not identified, based on its most recent evaluation of internal control over financial reporting, any material weaknesses
in the design or operation of Parent&#8217;s internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;Parent maintains &#8220;disclosure
controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure
that information required to be disclosed by Parent in the periodic reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the required time periods, and that all such information is accumulated and communicated to
Parent&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to make the Certifications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8&#160;<b><span style="text-decoration:underline">Absence of
Changes</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;&#8206;3.8</span> of the Parent Disclosure Schedule, between the date of the Parent Balance Sheet and the date of this Agreement, Parent
has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the
discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action,
event or occurrence that would have required the consent of the Company pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;4.1(b)</span> had such action,
event or occurrence taken place after the execution and delivery of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9&#160;<b><span style="text-decoration:underline">Absence of
Undisclosed Liabilities</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, neither
the Parent nor Merger Sub has any Liability, individually or in the aggregate, whether or not of a type required to be recorded or reflected
on a balance sheet or disclosed in the footnotes thereto under IFRS except for: (a) Liabilities disclosed, reflected or reserved against
in the Parent Balance Sheet; (b) Liabilities that have been incurred by Parent since the date of the Parent Balance Sheet in the Ordinary
Course of Business; (c) Liabilities for performance of obligations of Parent under Parent Contracts; (d) Liabilities incurred in connection
with the Contemplated Transactions; (e) Liabilities which would not, individually or in the aggregate, reasonably be expected to be material
to Parent; and (f) Liabilities described in <span style="text-decoration:underline">Section &#8206;&#8206;3.9</span> of the Parent Disclosure Schedule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10&#160;<b><span style="text-decoration:underline">Real Property;
Leasehold</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in Section
&#8206;3.10 of the Parent Disclosure Schedule, the Parent does not own and since January 1, 2021 has not owned any real property. The Parent
has made available to Company: (i) an accurate and complete list of all real properties with respect to which the Parent directly or
indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Parent and
(ii) copies of all leases under which any such real property is possessed (the &#8221; <b><i>Parent Real Estate Leases</i></b>&#8221;),
each of which is in full force and effect, with no existing material default thereunder. The Parent&#8217;s use and operation of each
such leased property conforms to all applicable Laws in all material respects, and the Parent has exclusive possession of each such leased
property and has not granted any occupancy rights to tenants or licensees with respect to such leased property. In addition, each such
leased property is free and clear of all Encumbrances other than Permitted Encumbrances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.11&#160;<b><span style="text-decoration:underline">Intellectual
Property</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except as set forth
on <span style="text-decoration:underline">Section <b>&#8206;</b>2.12(a)</span> of the Parent Disclosure Schedule, the Parent does not own, license or otherwise have any right,
title or interest in any material Intellectual Property Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;To the Knowledge of
the Parent the operation of the businesses of the Company as currently conducted does not infringe any valid and enforceable Registered
IP or misappropriate or otherwise violate any Intellectual Property Right owned by any other Person. As of the date of this Agreement,
no Legal Proceeding is pending (or, to the Knowledge of the Parent, is threatened in writing) against the Parent alleging that the operation
of the businesses of the Parent infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights
of another Person. The Parent has not received any written notice or other written communication alleging that the operation of the business
of the Parent infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;To the Knowledge of
the Parent, the Parent and the operation of the Parent&#8217;s business are in substantial compliance with all Laws pertaining to data
privacy and data security of any personally identifiable information and sensitive business information (collectively, &#8220;<b><i>Sensitive
Data</i></b>&#8221;) except to the extent that such noncompliance has not and would not reasonably be expected to have a Company Material
Adverse Effect. To the Knowledge of the Parent, since January 1, 2021, there have been: (i) no material losses or thefts of data or security
breaches relating to Sensitive Data used in the business of the Parent, (ii) no violations of any security policy of the Parent regarding
any such Sensitive Data, (iii) no unauthorized access or unauthorized use of any Sensitive Data used in the business of the Parent or
(iv) no unintended or improper disclosure of any personally identifiable information in the possession, custody or control of the Parent,
or a contractor or agent acting on behalf of the Parent, in each case of (i) through (iv), except as would not reasonably be expected
to, individually or in the aggregate, have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.12&#160;<b><span style="text-decoration:underline">Agreements,
Contracts and Commitments</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.12
</span>of the Parent Disclosure Schedule lists the following Parent Contracts in effect as of the date of this Agreement (each, a &#8220;<b><i>Parent
Material Contract</i></b>&#8221; and collectively, the &#8220;<b><i>Parent Material Contracts</i></b>&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;each Parent Contract
relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;each Parent Contract
containing: (A) any covenant limiting the freedom of the Parent to engage in any line of business or compete with any Person, (B) any
most-favored pricing arrangement, (C) any exclusivity provision, or (D) any non-solicitation provision;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;each Parent Contract
relating to capital expenditures and requiring payments after the date of this Agreement in excess of $200,000 pursuant to its express
terms and not cancelable without penalty;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;each Parent Contract
relating to the disposition or acquisition of material assets or any ownership interest in any entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;each Parent Contract
relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating
to the borrowing of money or extension of credit or creating any material Encumbrances with respect to any assets of the Parent or any
loans or debt obligations with officers or directors of the Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;each Parent Contract
requiring payment by or to the Parent after the date of this Agreement in excess of $200,000 pursuant to its express terms relating to:
(A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any dealer, distributor, joint marketing, alliance,
joint venture, cooperation or other agreement currently in force under which the Parent has continuing obligations to market any product,
technology or service; or (C) any Contract to license any third party to manufacture or produce any product, service or technology of
the Parent or any Contract to sell, distribute or commercialize any products or service of the Parent, in each case, except for Parent
Contracts entered into in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;each Parent Contract
with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the
Parent in connection with the Contemplated Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;each Parent Real
Estate Lease;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;each Parent Contract
with any Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;each Parent Contract
containing any royalty, dividend or similar arrangement based on the revenues or profits of the Parent; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;any other Parent
Contract that is not terminable at will (with no penalty or payment) by the Parent, and (A) which involves payment or receipt by the
Parent after the date of this Agreement under any such agreement, contract or commitment of more than $200,000 in the aggregate, or obligations
after the date of this Agreement in excess of $200,000 in the aggregate, or (B) that is material to the business or operations of the
Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The Parent has delivered
or made available to Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are
no Parent Material Contracts that are not in written form. The Parent has not, nor to the Parent&#8217;s Knowledge, as of the date of
this Agreement has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached,
violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such manner as would permit any other
party to cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably
be expected to be material to the Parent or its business. As to the Parent, as of the date of this Agreement, each Parent Material Contract
is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or
has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to the Parent under
any Parent Material Contract or any other material term or provision of any Parent Material Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.13&#160;<b><span style="text-decoration:underline">Compliance;
Permits</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Parent is in compliance
in all material respects with all U.S., Israeli and other applicable Laws, including the FDA regulations adopted thereunder, and any
other similar Law administered or promulgated by the FDA or other Drug Regulatory Agency, except for any noncompliance, either individually
or in the aggregate, which would not be material to Parent. No investigation, claim, suit, proceeding, audit or other action by any Governmental
Body is pending or, to the Knowledge of Parent, threatened against Parent. There is no agreement, judgment, injunction, order or decree
binding upon Parent which: (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business
practice of Parent, any acquisition of material property by Parent or the conduct of business by Parent as currently conducted, (ii)
is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this
Agreement, or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the
Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Parent holds all required
Governmental Authorizations which are material to the operation of the business of Parent as currently conducted (the &#8220;<b><i>Parent
Permits</i></b>&#8221;). <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>3.13(b)</span> of the Parent Disclosure Schedule identifies each Parent Permit. Parent
is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened,
which seeks to revoke, limit, suspend, or materially modify any Parent Permit. All of the Governmental Authorizations are valid and in
full force and effect, except where the invalidity of such Governmental Authorizations or the failure of such Governmental Authorizations
to be in full force and effect would not have a Parent Material Adverse Effect; and Parent has not received any notice of proceedings
relating to the revocation or modification of any such Governmental Authorizations which, singly or in the aggregate, would reasonably
be expected to result in a Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.14&#160;<b><span style="text-decoration:underline">Legal Proceedings;
Orders</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As of the date of
this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to
commence any Legal Proceeding: (i) that involves (A) Parent, (B) any Parent Associate (in his or her capacity as such) or (C) any of
the material assets owned or used by Parent; or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal
or otherwise interfering with, the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except as set forth
in <span style="text-decoration:underline">Section <b>&#8206;</b>3.14(b)</span><b>&#8206;</b> of the Parent Disclosure Schedule, since January 1, 2021, no Legal Proceeding has been
pending against Parent that resulted in material liability to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There is no order,
writ, injunction, judgment or decree to which Parent, or any of the material assets owned or used by Parent is subject. To the Knowledge
of Parent, no officer of Parent is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee
from engaging in or continuing any conduct, activity or practice relating to the business of Parent or to any material assets owned or
used by Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.15&#160;<b><span style="text-decoration:underline">Tax Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;Each Tax Return
required to be filed with any Governmental Body by Parent has been filed when due (taking into account extensions in the ordinary course
of business) in accordance with applicable Law, each of which is true, accurate and complete;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;Parent has timely
paid to the appropriate Governmental Body all Taxes due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;Parent has complied
with all applicable Law relating to the payment and withholding of any Tax and has, within the time and in the manner prescribed by Law,
withheld and paid over to the proper Governmental Body all amounts required to be so withheld and paid over;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;Parent has established
adequate accruals or reserves, in accordance with IFRS, for all Taxes for taxable periods beginning on or after the date of the most
recent Parent financial statements;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#160;there is no Legal
Proceeding against or with respect to Parent in respect of any Tax or any Tax Return and there is no investigation against or with respect
to Parent, pending or threatened or otherwise in respect of any Tax or any Tax Return. All deficiencies asserted or assessments made
against Parent as a result of any examinations by any Governmental Body have been fully paid;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#160;Parent has not
consented or requested to extend the time, or is the recipient of any extension of time, in which any Tax may be assessed or collected
by any Governmental Authority and Parent has not waived any statute of limitations;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#160;no Governmental
Authority in a jurisdiction where no Tax Return has been filed or no Tax has been paid has made or threatened to make a claim for the
payment of any Tax or the filing of any Tax Return;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#160;Except as otherwise
provided in <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>3.15(a)(viii)</span> of the Parent Disclosure Schedule, no power of attorney granted by or with
respect to Parent for Taxes is currently in force, no ruling with respect to Taxes has been requested by or on behalf of Parent; and
no closing agreement pursuant to Section 7121 of the Code (or any predecessor provision) or any similar provision of any state, local
or non-U.S. Law has been entered into or requested by or with respect to Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#160;Parent has provided
or made available to the Company prior to the date hereof true, correct and complete copies of all material Tax Returns, examination
reports, and statements of deficiencies filed, assessed against, or agreed to by Parent with respect to Taxes and all material written
correspondence with any Governmental Authority regarding Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)&#160;[Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi)&#160;Parent is not and
has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable
period specified in Section 897(c)(1)(A)(ii) of the Code;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii)&#160;Parent will not
be required to include any item of income in, or exclude any item of deduction from, taxable income for (A) any Tax period (or portion
thereof), as a result of any deferred foreign income within the meaning of Section 965 of the Code, including, but not limited to, as
the result of an election under Section 965(h) of the Code, or (B) any Tax period (or portion thereof) ending after the Closing Date,
as a result of any (1) deferred intercompany gain or any excess loss account described in Treasury Regulations under Section 1502 of
the Code (or any corresponding provision of state, local or non-U.S. Tax Law); (2) installment sale or other open transaction disposition
made on or prior to the Closing Date; (3) prepaid amount, refund or credit received on or prior to the Closing Date; (4) change in accounting
method for a taxable period ending on or prior to the Closing Date; (5) use of an improper method of accounting for a taxable period
ending on or prior to the Closing Date; or (6) &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding
or similar provision of state, local or non-U.S. Tax Law) executed on or prior to the Closing Date;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii)&#160;all material
records which Parent is required to keep for Tax purposes or which would be needed to substantiate any claim made or position taken in
relation to Taxes by Parent, have been duly kept and are available for inspection at the premises of Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv)&#160;Parent is in compliance
in all material respects with all terms and conditions of any Tax exemption, Tax holiday or other Tax reduction agreement or order of
a Governmental Body;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv)&#160;all of Parent&#8217;s
property that is subject to property Tax has been properly listed and described on the property Tax rolls of the appropriate Tax jurisdiction
and no portion of any Parent&#8217;s property constitutes omitted property for property Tax purposes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi)&#160;there are no Liens
for Taxes on any of the assets of Parent other than for any Taxes not yet due and payable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii)&#160;Parent has not
ever (A) participated or engaged in any transaction listed in Section 131(g) of the Ordinance and the Israeli Income Tax Regulations
(Reportable Tax Planning), 5767-2006, promulgated thereunder; (B) taken a tax position that is subject to reporting under Section 131E
of the Ordinance; (C) obtained a legal or tax opinion that is subject to reporting under Section 131D of the Ordinance; or (D) performed
or been part of any action or transaction that is classified as a &#8220;reportable opinion&#8221; under Section 67C of the Israeli VAT
Law or a &#8220;reportable position&#8221; under Section 67D of the Israeli VAT Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii)&#160;Parent is duly
registered for the purposes of Israeli value added tax and has complied in all respects with all requirements concerning VAT. Parent
(i) has not made any exempt transactions (as defined in the Israeli Value Added Tax Law, 5736-1975) and there are no circumstances by
reason of which there might not be an entitlement to full credit of all VAT chargeable or paid on inputs, supplies, and other transactions
and imports made by it, (ii) has collected and remitted in a timely manner to the ITA all output VAT which it is required to collect
and remit under any applicable Law and (iii) has not received a refund for input VAT for which it is not entitled under any applicable
Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix)&#160;each of the Parent
Share Plans that is intended to qualify as a capital gains route plan under Section 102 of the Ordinance has received a favorable determination
or approval letter from or is otherwise approved by or deemed approved by passage of time without objection by, the ITA. All Parent 102
Equity Awards and Parent 102 Shares have been granted and issued, as applicable, in compliance with the applicable requirements of Section
102 of the Ordinance and the written requirements and guidance of the ITA, including the filing of the necessary documents with the ITA,
the appointment of an authorized trustee, and the due deposit of such securities with the 102 Trustee pursuant to the terms of Section
102 of the Ordinance and the guidance published by the ITA on July 24, 2012, and clarification dated November 6, 2012;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xx)&#160;409A. The Parent
believes in good faith that any &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section 409A(d)(1)
of the Code and the guidance thereunder) under which the Parent makes, is obligated to make or promises to make, payments (each, a &#8220;409A
Plan&#8221;) complies in all material respects, in both form and operation, with the requirements of Section 409A of the Code and the
guidance thereunder. To the knowledge of the Company, no payment to be made under any 409A Plan is, or will be, subject to the penalties
of Section 409A(a)(1) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxi)&#160;Parent is not
and has never been a real property corporation (Igud Mekarke&#8217;in) within the meaning of this term under Section 1 of the Israeli
Land Taxation Law (Appreciation and Acquisition), 5723-1963;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxii)&#160;neither Parent
nor any holder of Parent securities is subject to any restrictions or limitations pursuant to Part E2 of the Ordinance or pursuant to
any Tax ruling made with reference to the provisions of Part E2;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xxiii)&#160;no independent
contractor was, or to the Knowledge of Parent will be, entitled to be considered to be an employee of Parent by any applicable Tax authority;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Parent has not (nor
has it ever had) any (A) place of management, (B) branch, (C) office (or any other place of business), (D) operations or employees, (E)
agent with binding authority, or (F) other activities, in each case that gives rise to a permanent establishment or taxable presence
which has subjected it to any Tax obligation or to a requirement to file any Tax return in any country other than the country where Parent
was organized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Parent is not, nor
at any time has been, engaged in the conduct of a trade or business within the United States within the meaning of Section 864(b) or
Section 882(a) of the Code, or considered to be so engaged under Section 882(d) or Section 897 of the Code or, if applicable, considered
to have a U.S. permanent establishment as defined under any applicable or relevant bilateral income tax treaty or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;(i) Parent is not,
nor has been, a party to any Tax Sharing Agreement (other than an agreement exclusively between or among Parent and its Subsidiaries)
pursuant to which it will have any obligation to make any payments for Taxes after the Closing Date, (ii) Parent has never been a member
of a group filing a consolidated, combined or unitary Tax Return (other than a group the common parent of which is or was Parent or any
of its Subsidiaries), and (iii) Parent has no liability for the payment of any Tax imposed on any Person (other than Parent) as a transferee
or successor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Parent has never taken
a position that could give rise to substantial understatement of income tax within the meaning of Section 6662 of the Code (or any corresponding
provision of state, local or non-U.S. Tax Law) or has ever been a beneficiary or otherwise participated in any &#8220;reportable transaction&#8221;
as defined in Code Section 6707A(c)(1)) and Treasury Regulation Section 1.6011-4(b)(1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;With the exception
of Israeli VAT, Parent is not, nor is required to be, registered as a taxable person for purpose of value added Taxes or any similar
indirect Tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For purposes of this <span style="text-decoration:underline">Section
<b>&#8206;</b>3.15</span>, each reference to Parent shall be deemed to include any Person that was liquidated into, merged with, or is otherwise
a predecessor to, Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.16&#160;<b><span style="text-decoration:underline">Transactions
with Affiliates</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except as set forth
in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed in
2023 with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.16(b)
</span>of the Parent Disclosure Schedule describes any material transactions or relationships, since January 1, 2021, between, on one hand,
the Parent on the other hand, any: (i) executive officer or director of the Parent or, to the Knowledge of the Parent or any of such
executive officer&#8217;s or director&#8217;s immediate family members, (ii) owner of more than 5% of the voting power of the outstanding
Parent Share Capital or (iii) to the Knowledge of the Parent, any &#8220;related person&#8221; (within the meaning of Item 404 of Regulation
S-K under the Securities Act) of any such officer, director or owner (other than the Parent) in the case of each of sub-limb (i), (ii)
or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There is no Investor
Agreement between the Parent and any holders of Parent Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.17&#160;<b><span style="text-decoration:underline">Employee
and Labor Matters; Benefit Plans</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.17(a)
</span>of the Parent Disclosure Schedule is a list of all material Parent Benefit Plans, including, without limitation, each Parent Benefit
Plan that provides for change in control, stay or retention, deferred compensation, incentive compensation, pension and severance benefits.
&#8220;<b><i>Parent Benefit Plan</i></b>&#8221; means each pension, profit sharing, bonus, incentive, equity or equity-based, phantom
equity, employment (other than at-will employment offer letters or employment agreement on the Parent&#8217;s standard form as may be
amended from time to time and other than individual Parent Options or other compensatory equity award agreements made pursuant to the
Parent&#8217;s standard forms, in which case only representative standard forms of such agreements shall be scheduled) and fringe benefit
plan, program, agreement (including collective bargaining agreement and extension order), policy or arrangement (whether written or unwritten,
but excluding statutory benefits or benefits mentioned in the Parent&#8217;s standard form of employment agreement) for the benefit of
any current or former employee, director, officer or independent contractor of the Parent or any of its Subsidiaries or under which the
Parent or any of its Subsidiaries has any actual or contingent liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;As applicable with
respect to each material Parent Benefit Plan, the Parent has made available to Company true and complete copies of each material Parent
Benefit Plan, including all amendments thereto, and in the case of an unwritten material Parent Benefit Plan, a written description thereof,
and all material correspondence to or from any Governmental Body with respect to each Parent Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Each Parent Benefit
Plan has been established, maintained, operated and administered in compliance in all material respects with its terms and all applicable
Laws. Each Parent Benefit Plan required to be funded is fully funded, and with respect to Parent Share Plans that are not required by
applicable Law to be so fully funded, adequate reserves therefor have been established on the Parent Financials (except for severance
pay that is fully funded, and full Section 14 Arrangements apply to all of the Parent&#8217;s employees). No material liability or obligation
of the Company or any of its Affiliates exists with respect to any Parent Benefit Plan that has not been disclosed in <span style="text-decoration:underline">Section <b>&#8206;</b>3.17<b>&#8206;</b>(c)
</span>of the Parent Disclosure Schedule. The Parent does not have, and has never had, any employees in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;To the Knowledge of
the Parent, there are no pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and no pending
or, to the Knowledge of the Parent, threatened claims (except for individual claims for benefits payable in the normal operation of the
Parent Benefit Plans), suits or proceedings involving any Parent Benefit Plan in any case except as would not be reasonably expected
to result in material liability to the Parent. The Parent does not have any Company Benefit Plan that is maintained in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Neither the execution
of, nor the performance of the Contemplated Transactions will either alone or in connection with any other event(s): (i) result in any
material payment becoming due to any current or former employee, director, officer, or independent contractor of the Parent, (ii) increase
any material amount of compensation or benefits otherwise payable under any Parent Benefit Plan, (iii) result in the acceleration of
the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv) require any material contribution or payment
to fund any obligation under any Parent Benefit Plan or (v) limit the right to merge, amend or terminate any Parent Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Section <b>&#8206;&#8206;&#8206;&#8206;</b>3.17(f)
</span>of the Parent Disclosure Schedule sets forth the policy of the Parent with respect to accrued vacation, accrued sick time and earned
time off and the amount of such liabilities, including regarding bonuses to employees and independent contractors for the last two years,
as of the date of this Agreement (in the case of accrued vacation, per employee for those who have more than 44 accrued days). The Parent
does not have and has not had a policy regarding the payment of bonuses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;The Parent is not
a party to, is not bound by, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a
labor union, labor organization, or similar Person representing any of its employees, and to the Knowledge of the Parent, there is no
labor union, labor organization, or similar Person representing or purporting to represent or seeking to represent any employees of the
Parent. There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of,
any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or,
to the Knowledge of the Parent, any union organizing activity, against the Parent. No event has occurred, and no condition or circumstance
exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown,
work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the
Parent, any union organizing activity. The Parent has paid all required payments, if any, that the Parent has been requested to pay to
any employers&#8217; association or organization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="text-decoration:underline">Section <b>&#8206;</b>3.17<b>&#8206;</b>(h)
</span>of the Parent Disclosure Schedule contains a list of all employees of the Parent and its Subsidiaries along with the position, the
monthly rate of salary of each such employee, whether such employee is full time or part time, is exempt or non-exempt from the Hours
of Work and Rest Law, is on leave and if so, the type of leave and expected date of return, visa status (as applicable), date of hire,
any incentive payment paid or payable in calendar year 2023 (and whether such incentive is cash or, if not, what other property is due),
short-term or temporary basis, vacation entitlement and accrued vacation or paid time-off balance, car entitlement, sick leave entitlement
and accrual (if any), and recuperation pay entitlement and accrual, pension entitlements and provident funds (including manager&#8217;s
insurance, pension fund, education fund and health fund), their respective contribution rates for each component (<i>e.g.,</i> severance
component, pension savings and disability insurance) and the salary basis for such contributions, severance entitlements (including whether
such employee, to the extent employed in the State of Israel, is subject to a Section 14 arrangement under the Severance Pay Law, 5723-1963
(the &#8220;<b><i>Israeli Severance Pay Law</i></b>&#8221; and &#8220;<b><i>Section 14 Arrangement</i></b>&#8221;), and, to the extent
such employee is subject to such a Section 14 Arrangement, an indication of whether such arrangement (or other applicable pension arrangement)
has been applied to such person from the commencement date of their employment and on the basis of their entire salary including other
compensation (e.g., commission), main work location, notice period entitlement, and any other material compensation payable to such employee.
Neither the Parent nor its Subsidiaries is delinquent in payments to any employees for wages, salaries, commissions or bonuses for services
performed as of the date hereof or amounts required by applicable Law to be reimbursed to such employees. The consummation of the Contemplated
Transactions will not give rise to any liability of the Parent or any of its Subsidiaries for payments related to severance, termination,
bonus, accrued vacation or personal time, accrued days of sick pay or any similar payment. No current employee of the Parent or any of
its Affiliates is or was, during the period of such employment or other service, based in or resident of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Section </span><b>&#8206;</b>3.17<b>&#8206;</b>(i)
of the Parent Disclosure Schedule contains a list of each individual who currently renders services to Parent as an independent contractor
or consultant (collectively, the &#8220;<b><i>Parent Contractors</i></b>&#8221;) and the Parent has made available to Company true and
complete copies of each Parent Contractors agreement and the last 3 months invoices. The Parent has accurately classified each such Parent
Contractor or former Parent Contractor as an independent contractor under all applicable Laws (including for purposes of Taxes and Tax
reporting and under the Company Benefit Plans). Except as set forth in <span style="text-decoration:underline">Section <b>&#8206;</b></span><b>&#8206;</b>3.17<b>&#8206;</b>(i) of
the Parent Disclosure Schedule, each Parent Contractor can be terminated on notice of thirty days or less to the Parent Contractor. According
to the Parent Contractors&#8217; agreements with the Parent, no Parent Contractor is entitled to any rights under the applicable labor
laws. All current and former Parent Contractors have received all their rights to which they are and were entitled according to any applicable
Law or Contract with the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;The Parent is not
delinquent in payments to any employees for wages, salaries, commissions or bonuses for services performed as of the date hereof or amounts
required by applicable Law to be reimbursed to such employees. The employment seniority for each employee for any employment purposes
began as of the date of hire and prior to such date no employment relations existed between any employee and the Parent for any matter
or purpose. The Parent has withheld, paid and reported all amounts required by the Ordinance, the National Insurance Law [Consolidated
Version], 5755-1995, and the National Health Insurance Law, 5754-1994 regarding its current and former employees and Parent Contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;The Parent is, and
since January 1, 2021 has been, in material compliance with all applicable Laws and agreements (including collective bargaining agreements
and extension orders) respecting labor (including consultants), employment, employment practices, and terms and conditions of employment,
including proper classification of independent contractors as not being employees. There are no actions, suits, claims, charges, lawsuits,
investigations, audits or administrative matters pending or, to the Knowledge of the Parent, threatened or reasonably anticipated against
the Parent relating to any employee, applicant for employment, consultant, employment agreement or Parent Benefit Plan (other than routine
claims for benefits).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;There is not and has
not been in the past three years, nor is there or has there been in the past three years any threat of, any material claim, charge, grievance
or Legal Proceeding against the Parent brought by or on behalf of any current or former applicant, employee, independent contractor,
subcontractor, leased employee, volunteer, or temporary employee of the Parent, alleging violation of any applicable employment Law,
agreement or any other claim arising out of such Person&#8217;s employment, application for employment or termination of employment,
consulting or other relationship with the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: 002 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m) At all times, the Parent
has not engaged any employees whose employment would require special licenses or permits by the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n) The Parent&#8217;s obligations
to provide statutory severance pay to its Israeli employees pursuant to the Israeli Severance Pay Law are fully funded in accordance
with Section 14 Arrangements and it is and was implemented properly, from the commencement date of each employee&#8217;s employment and
on the basis of 8.33% of the employee&#8217;s entire salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o) The Parent has not been
and is not subject to, and none of its employees or consultants benefits from, any collective agreement, extension order (<i>tzavei harchave</i>)
or any general contract or arrangement with respect to employment or termination of employment, except those extension orders that apply
to all Israeli companies generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p) Each employee of the Parent
is a party to a confidentiality, non-competition and protection of intellectual property agreement with the Parent; copies of such agreements
have previously been delivered, or made available, to Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q) No group of employees has
notified the Parent of its intent, or, to the Knowledge of the Parent, has any plans, to terminate employment with the Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r) The Parent does not have
unsatisfied obligations of any nature to any of its former employees or consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.18 <b><span style="text-decoration:underline">Environmental
Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is, and since
January 1, 2021 has been, in compliance with all applicable Environmental Laws, which compliance includes the possession by the Parent
of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected
to be material to the Parent or its business. The Parent has not received since January 1, 2021 (or prior to that time, which to the
Knowledge of the Parent is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from
a Governmental Body or other Person, that alleges that the Parent is not in compliance with or has liability pursuant to any Environmental
Law and, to the Knowledge of the Parent, there are no circumstances that would reasonably be expected to prevent or interfere with the
Parent&#8217;s compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably
be expected to be material to the Parent or its business. No current or (during the time a prior property was leased or controlled by
the Parent) prior property leased or controlled by the Parent has had a release of or exposure to Hazardous Materials in material violation
of or as would reasonably be expected to result in any material liability of the Parent pursuant to Environmental Law. No consent, approval
or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection
with the execution and delivery of this Agreement or the consummation of the Contemplated Transactions. Prior to the date hereof, the
Parent has provided or otherwise made available to Company true and correct copies of all material environmental reports, assessments,
studies and audits in the possession or control of the Parent with respect to any property leased or controlled by the Parent or any
business operated by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.19 <b><span style="text-decoration:underline">Insurance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent has delivered or made
available to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and
arrangements relating to the business, assets, liabilities and operations of Parent. Each of such insurance policy is in full force and
effect and Parent is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications
from insurance carriers, since January 1, 2021, Parent has not received any notice or other communication regarding any actual or possible:
(i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights or rejection
of any material claim under any insurance policy. Parent has provided timely written notice to the appropriate insurance carrier(s) of
each Legal Proceeding that is currently pending against Parent for which Parent has insurance coverage, and no such carrier has issued
a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent of its intent to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.20 <b><span style="text-decoration:underline">No Financial Advisors</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth on <span style="text-decoration:underline">Section
&#8206;&#8206;3.20</span> of the Parent Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s
fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions to which it
is a party based upon arrangements made by or on behalf of Parent or Merger Sub.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.21 <b><span style="text-decoration:underline">Anti-Bribery</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither Parent nor any of
its directors, officers, employees or, to Parent&#8217;s Knowledge, agents or any other Person acting on their behalf has directly or
indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other
payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of Anti-Bribery Laws. Parent is not nor has
ever been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.22 <b><span style="text-decoration:underline">Valid Issuance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Ordinary Shares
to be issued in the Merger (including the Parent Ordinary Shares issuable upon exercise of the Parent Pre-Funded Warrants) will, when
issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.23 <b><span style="text-decoration:underline">Valuation Report
of Financial Advisor</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Board has received
the valuation report prepared by E.D.B. Consulting and Investments Ltd., and has determined based on the value of the Company estimated
therein, that, as of the date of this Agreement and subject to the assumptions, qualifications, limitations and other matters set forth
therein, the Exchange Ratio is fair, from a financial point of view to the holders of Parent Ordinary Shares. It is agreed and understood
that such valuation report is for the benefit of the Parent Board and may not be relied upon by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.24 <b><span style="text-decoration:underline">Disclaimer of
Other Representations or Warranties</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in this
<span style="text-decoration:underline">Section &#8206;3</span> or in any certificate delivered by Parent or Merger Sub to the Company pursuant to this Agreement, neither Parent
nor Merger Sub makes any representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets,
liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">4.
<b><span style="text-decoration:underline">CERTAIN COVENANTS OF THE PARTIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1 <b><span style="text-decoration:underline">Operation of Parent&#8217;s
Business</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Except as set forth in
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.1(a)</span> of the Parent Disclosure Schedule, as expressly permitted by this Agreement (including the consummation
of a Closing Financing), as required by applicable Law or unless the Company shall otherwise consent in writing (which consent shall
not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until
the earlier to occur of the termination of this Agreement pursuant to <span style="text-decoration:underline">Section <b>&#8206;</b>9</span> and the Effective Time (the &#8220;<b><i>Pre-Closing
Period</i></b>&#8221;): (i) Parent shall conduct its business and operations in the Ordinary Course of Business subject to and without
derogating from any of the Parent&#8217;s covenants set forth in <span style="text-decoration:underline">Section &#8206;<b>&#8206;</b>4.1(b)</span>; (ii) Parent shall conduct its
business and operations in compliance in all material respects with all applicable Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Except: (i) as expressly
permitted by this Agreement, (ii) as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.1(b)</span> of the Parent Disclosure Schedule, (iii) for
entering into and consummating the Closing Financing, (iv) as required by applicable Law, or (v) with the prior written consent of the
Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent
shall not do any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) declare, accrue, set
aside or pay any dividend or make any other distribution in respect of any of its shares or make any other actual, constructive or deemed
distribution in respect of the Parent Share Capital, or directly or indirectly acquire, repurchase, redeem or otherwise reacquire any
of its shares or other securities (except in connection with the payment of the exercise price and/or withholding Taxes incurred upon
the exercise, settlement or vesting of any award granted under the Parent Share Plans and in accordance with their current terms);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) sell, issue, grant,
pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any shares or other security of Parent
(except for Parent Ordinary Shares issued upon the valid exercise of outstanding Parent Equity Awards or Parent Warrants); (B) any option,
warrant or right to acquire any shares or any other security; or (C) any instrument convertible into or exchangeable for any shares or
other security of Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) except as required
to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any
merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, share split, reverse share
split, or similar transaction except, for the avoidance of doubt, the Contemplated Transactions and as permitted by this Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) propose to adopt a plan
of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the
Parent, or elect or appoint any new directors or executive officers of the Parent, except for the transactions contemplated by this Agreement
and actions and resolutions adopted in the course of its implementation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v) form any Subsidiary or
acquire any equity interest or other interest in any other Entity or enter into a joint venture, strategic alliance or partnership with
any other Entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi) acquire or agree to
acquire (by merger, consolidation or acquisition of s or assets or by any other manner) (1) any business or other Person, or (2) any
assets that are material, individually or in the aggregate, to the Parent, or (3) sell, lease (as lessor), license or otherwise dispose
of or subject to any Lien any properties or assets of the Parent, which are material to the Parent;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii) (A) lend money to any
Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, or (D) make any capital
expenditure in excess of the budgeted capital expenditure amounts set forth in Parent operating budget set forth in Section <b><i>&#8206;</i></b>4.1(b)(vii)of
the Parent Disclosure Schedule (the &#8220;<b><i>Parent Budget</i></b>&#8221;); other than as required by applicable Law or the terms
of any Parent Benefit Plan as in effect on the date of this Agreement: (i) adopt, terminate, establish or enter into any Parent Benefit
Plan; (ii) cause or permit any Parent Benefit Plan to be amended in any material respect; (iii) pay any bonus or make any profit-sharing
or similar payment to, or increase the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable
to any of its directors, officers or employees except for the payment of annual bonuses according to the targets predetermined for the
year end 2023 (including any discretionary component); (iv) increase the severance or change of control benefits offered to any current
or new employees, directors or consultants or (v) hire, terminate or give notice of termination to any (x) officer or (y) employee whose
annual base salary is or is expected to be more than $25,000 per year;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii) recognize any labor
union, labor organization, or similar Person;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix) enter into any material
transaction;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x) acquire any material
asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such
assets or properties;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi) sell, assign, transfer,
license, sublicense or otherwise dispose of any material Parent IP;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii) make, change or revoke
any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable (subject to good faith disputes
with respect to such Taxes), file any amendment making any material change to any Tax Return, settle or compromise any income or other
material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement, request or
consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material
Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than
six months), or adopt or change any material accounting method in respect of Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii) (A) except as otherwise
set forth in the Parent Budget, make any expenditures, incur any Liabilities, settle, discharge or satisfy any claims, litigation or
obligations (absolute, accrued, asserted or unasserted, contingent or otherwise) or Liabilities, in each case, in amounts that exceed
the aggregate amount of the Parent Budget by $200,000, except for any amounts related to claims, litigations, obligations, or Liabilities
that are outstanding as of the date of this Agreement, or (B) cancel any material indebtedness for borrowed money (individually or in
the aggregate) or waive any claims or rights with a value in excess of $200,000, or (C) give any material discount, accommodation or
other concession (other than in the ordinary course of business consistent with past practice) in order to accelerate or induce the collection
of any receivable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv) enter into, engage
in or amend any transaction or Contract with any interested parties (Ba&#8217;alay Inyan);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv) other than as required
by Law or IFRS, take any action to change accounting policies or procedures;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi) cancel or fail to in
good faith seek to renew any material insurance policies;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii) apply for or accept
(x) any Government Grant from the IIA or any other Israeli Governmental Authority, or (y) any material Government Grants from any other
Governmental Authority; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii) agree, resolve or
commit to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing contained in this
Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective
Time. Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral
control and supervision over its business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 <b><span style="text-decoration:underline">Operation of the
Company&#8217;s Business</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Except as set forth in
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.2(a)</span> of the Company Disclosure Schedule, as expressly permitted by this Agreement (including a Closing
Financing), as required by applicable Law or unless Parent shall otherwise consent in writing (which consent shall not be unreasonably
withheld, delayed or conditioned), during the Pre-Closing Period, the Company shall conduct its business and operations: (i) in the Ordinary
Course of Business subject to and without derogating from any of the Company&#8217;s covenants set forth in <span style="text-decoration:underline">Section<b>&#8206;</b> 4.2(b)
</span>&#8206;; and (ii) in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute
Company Material Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Except: (i) as expressly
permitted by this Agreement, (ii) as set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>4.2(b)</span> of the Company Disclosure Schedule, (iii) as
required by applicable Law or (iv) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed
or conditioned), at all times during the Pre-Closing Period, the Company shall not do any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) declare, accrue, set
aside or pay any dividend or make any other distribution in respect of any shares of its share capital or make any other actual, constructive
or deemed distribution in respect of Company Ordinary Shares, or directly or indirectly acquire, or repurchase, redeem or otherwise reacquire
any shares of its share capital or other securities (except in connection with the payment of the exercise price and/or withholding Taxes
incurred upon the exercise, settlement or vesting of any award granted under the Company Share Plans in accordance with their current
terms);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) sell, issue, grant,
pledge or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any share capital or other security
of the Company (except for outstanding Company Ordinary Shares issued upon the valid exercise of Company Options); (B) any option, warrant
or right to acquire any share capital or any other security, other than award grants to employees and service providers; or (C) any instrument
convertible into or exchangeable for any share capital or other security of the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) except as required
to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any
merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, share split, reverse share
split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv) propose to adopt a plan
of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the
Company, or elect or appoint any new directors or executive officers of the Company, except for the transactions contemplated by this
Agreement and actions and resolutions adopted in the course of its implementation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v) form any Subsidiary or
acquire any equity interest or other interest in any other Entity or enter into a joint venture, strategic alliance or partnership with
any other Entity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi) acquire or agree to
acquire (by merger, consolidation or acquisition of shares or assets or by any other manner) (1) any business or other Person or (2)
any assets that are material, individually or in the aggregate, to the Company; or (3) other than in the Ordinary Course of Business,
sell, lease (as lessor), license or otherwise dispose of or subject to any Lien any properties or assets of the Company, which are material
to the Company, except for purchases of inventory, services or supplies in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii) (A) lend money to any
Person (except for the advance of expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or
guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii) recognize any labor
union, labor organization, or similar Person;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix) enter into any material
transaction other than in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x) acquire any material
asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such
assets or properties, except in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xi) make, change or revoke
any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable (subject to good faith disputes
with respect to such Taxes), file any amendment making any material change to any Tax Return, settle or compromise any income or other
material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than
customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request
or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material
Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than
six months), or adopt or change any material accounting method in respect of Taxes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xii) enter into, materially
amend or terminate any Company Material Contract, except if such execution, amendment or termination is in the Ordinary Course of Business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiii) (A) except in the
Ordinary Course of Business, make any expenditures, incur any Liabilities, settle or discharge or satisfy any claims, litigation, obligations
(absolute, accrued, asserted or unasserted, contingent or otherwise) or Liabilities, or (B) cancel any material indebtedness for borrowed
money (individually or in the aggregate) or waive any claims or rights with a value in excess of $200,000, or (C) give any material discount,
accommodation or other concession (other than in the Ordinary Course of Business consistent with past practice) in order to accelerate
or induce the collection of any receivable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xiv) enter into, engage
in or amend any transaction or Contract with any interested parties (Ba&#8217;alay Inyan), except as required for the consummation of
the Closing ;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xv) other than as required
by Law or IFRS, take any action to change accounting policies or procedures;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvi) cancel or fail to in
good faith seek to renew any material insurance policies;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xvii) apply for or accept
(x) any Government Grant from the IIA or any other Israeli Governmental Authority, or (y) any material Government Grants from any other
Governmental Authority;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xviii) initiate or settle,
compromise, or agree to settle any Legal Proceeding; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(xix) agree, resolve or commit
to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing contained in this
Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective
Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral
control and supervision over its business operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 <b><span style="text-decoration:underline">Access and Investigation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing
Period, upon not less than three (3) Business Days&#8217; notice, Parent, on the one hand, and the Company, on the other hand, shall
and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a) provide the other Party and such other
Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property
and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and
its Subsidiaries; (b) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records,
Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such
additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably
request; (c) permit the other Party&#8217;s officers and other employees to hold discussions, upon reasonable notice and during normal
business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial
statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary or appropriate and;
(d) make available to the other Party copies of unaudited financial statements, material operating and financial reports prepared for
senior management or the board of directors of such Party, and any material notice, report or other document filed with or sent to or
received from any Governmental Body in connection with the Contemplated Transactions. Any investigation conducted by either Parent or
the Company pursuant to this <span style="text-decoration:underline">Section &#8206;4.3</span> shall be conducted in such manner as not to interfere unreasonably with the conduct
of the business of the other Party. Each Party shall provide the other Party with unaudited cash balances promptly after such cash balances
are available to such Party, and with a statement of accounts payable of such Party as of the end of each calendar month, promptly after
such Party prepares such a statement, all to the extent prepared by and available to such Party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
any Party may restrict the foregoing access to the extent that any Law applicable to such Party requires such Party to restrict or prohibit
access to any such properties or information or as may be necessary to preserve the attorney-client privilege under any circumstances
in which such privilege may be jeopardized by such disclosure or access.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 <b><span style="text-decoration:underline">Parent Non-Solicitation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Parent agrees that during
the Pre-Closing Period it shall not, nor shall it authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit,
initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal
or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;
(ii)&#160;furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal
or Acquisition Inquiry; (iii)&#160;engage in discussions (other than to inform any Person of the existence of the provisions in this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.4</span>)
or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&#160;approve, endorse or recommend
any Acquisition Proposal (subject to&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>5.3</span>); (v)&#160;execute or enter into any letter of intent
or any Contract contemplating or otherwise relating to any Acquisition Transaction; or (vi)&#160;publicly propose to do any of the foregoing.
Without limiting the generality of the foregoing, Parent acknowledges and agrees that, in the event any Representative of Parent (whether
or not such Representative is purporting to act on behalf of Parent) takes any action that, if taken by Parent, would constitute a breach
of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.4</span>, the taking of such action by such Representative shall be deemed to constitute
a breach of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.4</span> by Parent for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If Parent or any Representative
of Parent receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then Parent shall promptly
(and in no event later than one Business Day after Parent becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the
Company orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting
such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof). Parent shall keep the Company reasonably informed
with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or
proposed material modification thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Parent shall immediately
cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition
Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or
return of any nonpublic information of Parent provided to such Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Section &#8206;4.4
shall be deemed to restrict Parent and its Representatives from communications, negotiations and entering into agreements to the extent
reasonably necessary for purposes of pursuing and completing for transactions that are specifically authorized by this Agreement, including
transactions related to the Closing Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 <b><span style="text-decoration:underline">Company Non-Solicitation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company agrees that,
during the Pre-Closing Period, the Company shall not, nor shall it authorize any of its Representatives to, directly or indirectly: (i)&#160;solicit,
initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal
or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;
(ii)&#160;furnish any non-public information regarding the Company to any Person in connection with or in response to an Acquisition
Proposal or Acquisition Inquiry; (iii)&#160;engage in discussions (other than to inform any Person of the existence of the provisions
in this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.5</span>) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition
Inquiry; (iv)&#160;approve, endorse or recommend any Acquisition Proposal; (v)&#160;execute or enter into any letter of intent or any
Contract contemplating or otherwise relating to any Acquisition Transaction; or (vi)&#160;publicly propose to do any of the foregoing.
Without limiting the generality of the foregoing, the Company acknowledges and agrees that, in the event any Representative of the Company
(whether or not such Representative is purporting to act on behalf of the Company) takes any action that, if taken by the Company, would
constitute a breach of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.5</span>, the taking of such action by such Representative shall be
deemed to constitute a breach of this&#160;<span style="text-decoration:underline">Section&#160;<b>&#8206;&#8206;</b>4.5</span>&#160;by the Company for purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If the Company or any Representative
of the Company receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then the Company shall
promptly (and in no event later than one Business Day after the Company becomes aware of such Acquisition Proposal or Acquisition Inquiry)
advise Parent orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making
or submitting such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof). The Company shall keep Parent reasonably
informed with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification
or proposed material modification thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company shall immediately
cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition
Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or
return of any nonpublic information of the Company provided to such Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Section &#8206;4.5
shall be deemed to restrict Company and its Representatives from communications, negotiations and entering into agreements to the extent
reasonably necessary for purposes of pursuing and completing for transactions that are specifically authorized by this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 <b><span style="text-decoration:underline">Notification of
Certain Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) During the Pre-Closing
Period, the Company shall promptly notify Parent (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice
or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with
any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting the Company is commenced,
or, to the Knowledge of the Company, threatened against the Company or, to the Knowledge of the Company, any director or officer of the
Company; (iii) the Company becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the
failure of the Company to comply with any covenant or obligation of the Company; in the case of sub-limbs (iii) and (iv) that could reasonably
be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6 or <b>&#8206;</b></span>7
<b><span style="text-decoration:underline">&#8206;</span></b>, as applicable, impossible or materially less likely. No notification given to Parent pursuant to this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>4.6(a)</span> shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations
of the Company contained in this Agreement or the Company Disclosure Schedule for purposes of <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6 or <b>&#8206;</b></span>7,
as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) During the Pre-Closing
Period, Parent shall promptly notify the Company (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice
or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with
any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting Parent is commenced, or,
to the Knowledge of Parent, threatened against Parent or, to the Knowledge of Parent, any director or officer of Parent; (iii) Parent
becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the failure of Parent to comply
with any covenant or obligation of Parent or Merger Sub; in the case of sub-limbs (iii) and (iv) that could reasonably be expected to
make the timely satisfaction of any of the conditions set forth in <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6</span> or <b>&#8206;</b><span style="text-decoration:underline">8</span>, as applicable,
impossible or materially less likely. No notification given to the Company pursuant to this <span style="text-decoration:underline">Section <b>&#8206;</b>4.6(b)</span> shall change,
limit or otherwise affect any of the representations, warranties, covenants or obligations of Parent contained in this Agreement or the
Parent Disclosure Schedule for purposes of <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>6</span> and <b>&#8206;</b><span style="text-decoration:underline">8</span>, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 <b><span style="text-decoration:underline">Post-Closing Financing</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the Closing, the Parent
shall deliver to the Company an amount of $4,250,000 (less any amount due by the Company to the Parent under any loan agreement between
the parties), by wire transfer of immediately available funds to an account, the details of which shall be provided by the Company, for
the Company&#8217;s ongoing capital requirements and operational expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">5.
<b><span style="text-decoration:underline">ADDITIONAL AGREEMENTS OF THE PARTIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <b><span style="text-decoration:underline">Court Approval,
Registration Statement and Transaction Report</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) As promptly as practicable
after the execution and delivery of this Agreement and in accordance with Sections 350 and 351 of the Companies Law, the Company shall
submit to the district court of Tel Aviv-Jaffa (the &#8220;<b><i>Applicable Court</i></b>&#8221;) a first motion to convene, in the manner
set forth in the Companies Law and the regulations promulgated pursuant to Sections 350 and 351 of the Companies Law and as shall otherwise
be ordered by the Applicable Court (the &#8220;<b><i>First Motion Approval</i></b>&#8221;), a shareholders meeting (the &#8220;<b><i>Company
Shareholders&#8217; Meeting</i></b>&#8221;) and, if required by the Applicable Court, a Bondholder or creditors meeting (collectively,
the &#8220;<b><i>Company Meetings</i></b>&#8221;) for the approval of the terms and conditions of an arrangement between the Company
and its shareholders, Bondholders and/or creditors, including the Merger, by a majority representing at least 75% of the votes cast at
the Company Meetings (the &#8220;<b><i>Section 350 Vote</i></b>&#8221;), together with a request to exempt from the need to publish a
prospectus by reason of Section 15A(a)(3) of the Israeli Securities Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) As promptly as practicable
after the execution of this Agreement, the Parties shall prepare and the Parent shall cause to be filed with the SEC, the Registration
Statement. Parent hereby covenants and agrees that the Registration Statement, including any pro forma financial statements included
therein (and the letter to shareholders, notice of meeting and form of proxy included therewith), will not, at the time that the Registration
Statement or any amendments or supplements thereto is filed with the SEC or declared effective by the SEC, contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made
therein not misleading. The Company hereby covenants and agrees that the information provided by the Company to Parent for inclusion
in the Registration Statement (including the Company Financials) will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make such information not misleading. Notwithstanding
the foregoing, Parent makes no covenant, representation or warranty with respect to statements made in the Registration Statement, if
any, based on information provided by the Company or any of their Representatives specifically for inclusion therein. The Company and
its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments
and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration
Statement, prior to the filing thereof with the SEC. Parent shall use commercially reasonable efforts to cause the Registration Statement
to comply with the applicable rules and regulations promulgated by the SEC and to respond promptly to any comments of the SEC or its
staff. Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s shareholders in accordance
with the applicable rules and regulations promulgated by the SEC. Each Party shall promptly furnish to the other Party all information
concerning such Party and such Party&#8217;s Affiliates and such Party&#8217;s shareholders that may be required or reasonably requested
in connection with any action contemplated by this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.1</span>. If Parent, Merger Sub or the Company become aware
of any event or information that, pursuant to the Exchange Act, should be disclosed in an amendment or supplement to the Registration
Statement, then such Party shall promptly inform the other Parties thereof and shall cooperate with such other Parties in filing such
amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to Parent&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) As promptly as practicable
after the execution of this Agreement, the Parties shall prepare, and as soon as practicable after the First Motion Approval, the Company
shall cause to be filed with the ISA such notice of the Company Meetings to call, give notice of and hold the Company Meetings, which
shall include a transaction report as well as a proxy card (<i>Ktav Hatzbaa</i>) (such notice, transaction report and proxy card, collectively,
shall be referred to herein as the &#8220;<b><i>Transaction Report</i></b>&#8221;), in order to obtain the Required Company Approval,
in each case for purposes of adopting and approving this Agreement and the Contemplated Transactions, including the Section 350 Vote
and the approval of the Restated Company Articles, (collectively, the &#8220;<b><i>Company Approval Matters</i></b>&#8221;). The Company
covenants and agrees that the Transaction Report, including any pro forma financial statements included therein (and the letter to shareholders,
notice of meeting and form of proxy included therewith), will not, at the time that the Transaction Report or any amendments or supplements
thereto is filed with the ISA contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
The Parent covenants and agrees that the information provided by the Parent to the Company for inclusion in the Transaction Report will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in
order to make such information not misleading. Notwithstanding the foregoing, Company makes no covenant, representation or warranty with
respect to statements made in the Proxy Transaction Report (and the letter to shareholders, notice of meeting and form of proxy included
therewith), if any, based on information provided by the Parent or any of their Representatives specifically for inclusion therein. The
Parent and its legal counsel shall be given reasonable opportunity to review and comment on the Transaction Report, including all amendments
and supplements thereto, prior to the filing thereof with the ISA, and on the response to any comments of the ISA or the TASE on the
Transaction Report, prior to the filing thereof with the ISA. Company shall use commercially reasonable efforts to cause the Transaction
Report to comply with the applicable rules and regulations promulgated by the ISA and the TASE and to respond promptly to any comments
of the ISA, the TASE or its staff. Company covenants and agrees that the Transaction Report will comply in all respects with the requirements
of Israeli law. Each Party shall promptly furnish to the other Party all information concerning such Party and such Party&#8217;s Affiliates
and such Party&#8217;s shareholders that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section
&#8206;<b>&#8206;</b>5.1</span>. If Parent, Merger Sub or the Company become aware of any event or information that, should be disclosed in
an amendment or supplement to the Transaction Report, then such Party shall promptly inform the other Parties thereof and shall cooperate
with such other Parties in filing such amendment or supplement with the ISA and, if appropriate, in mailing such amendment or supplement
to the Company&#8217;s shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) The Parties shall reasonably
cooperate with each other and provide, and require their respective Representatives to provide, the other Party and its Representatives,
with all true, correct and complete information regarding such Party or its Subsidiaries that is required by Law to be included in the
Registration Statement and/or the Transaction Report or reasonably requested by the other Party to be included in the Registration Statement
and or/the Transaction Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <b><span style="text-decoration:underline">Company Meetings</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company agrees that:(i)
the Company Board shall recommend that the Company&#8217;s shareholders and if applicable, the Company&#8217;s Bondholders and/or creditors
vote to approve the Company Approval Matters and shall use reasonable best efforts to solicit such approval (the recommendation of the
Company Board that the Company&#8217;s shareholders, creditors or Bondholders (as applicable) vote to adopt and approve this Agreement
being referred to as the &#8220;<b><i>Company Board Recommendation</i></b>&#8221;); and (ii) the Company Board Recommendation shall not
be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in
a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation
in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition
Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a &#8220;<b><i>Company Board
Adverse Recommendation Change</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) As part of the notice of
the Company Meetings, the Company will deliver to each of its shareholders, and if applicable, creditors and Bondholders, a notice of
the meetings, the order of the court to convene the meetings, the application for the approval of the proposed Merger submitted to the
court and a proxy card for the vote (the &#8220;<b><i>Proxy Materials</i></b>&#8221;). The Proxy Materials will include a description
of the rights of a shareholder to object to the Merger, information on the hearing scheduled before the Applicable Court and the Company
Board Recommendation. Following the approval of the Merger by the shareholders and if applicable, creditors and Bondholders, as set forth
above, the Company will submit to the Applicable Court a second motion for the approval of the arrangement and the Merger and the order
of all actions to be taken in accordance with the Merger, including the exemption from the need to publish a prospectus by reason of
Section 15A(a)(3) of the Israeli Securities Law (these approvals when obtained shall be collectively referred to as the &#8220;<b><i>Court
Approval</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company&#8217;s obligation
to solicit the Required Company Approval in accordance with <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.2(a)</span> and <span style="text-decoration:underline">Section <b>&#8206;</b>5.2(b)<b>&#8206;
</b></span>shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any other Acquisition
Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <b><span style="text-decoration:underline">Parent Shareholders&#8217;
Meeting; Merger Sub Approval</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Promptly as practicable
following the date the Registration Statement is declared effective by the SEC under the Securities Act, or later, in case the Parent
Board determines, after consultation with its outside counsel that it is likely that there are required changes/amendments to the Registration
Statement, Parent shall take all action necessary under applicable Law to call, give notice of and hold the Parent Shareholders&#8217;
Meeting for the purpose of seeking approval of (i) this Agreement and the Contemplated Transactions; (ii) to the extent applicable, the
adoption of the Restated Parent Articles (which shall include the change of the Parent&#8217;s company name); (iii) adoption of the form
of Indemnification Agreement, (iv) if not so appointed by the Parent Board, election to the post-Closing Parent Board of the candidates
designated by the Company to serve thereon in accordance with Section <b>&#8206;</b>5.13 below (provided that (i) if, in accordance with
Section <b>&#8206;</b>5.13 below, the Company designates two candidates to the post-Closing Parent Board, than one of them shall be appointed
or elected for three year term and another for two year term, and (ii) if, in accordance with Section <b>&#8206;</b>5.13 below, the Company
designates three candidates to the post-Closing Parent Board, than each to be classified to a different class of the Parent Board) and
(v) compensation to the directors and officers of the Parent (as of the Pre-Closing Period), all effective upon the Merger (the matters
contemplated by this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>5.3(a)</span> are referred to as the &#8220;<b><i>Parent Shareholder Matters</i></b>&#8221;
and such meeting, the &#8220;<b><i>Parent Shareholders&#8217; Meeting</i></b>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Parent shall take reasonable
measures to ensure that all proxies solicited in connection with the Parent Shareholders&#8217; Meeting are solicited in compliance with
all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Shareholders&#8217; Meeting,
or a date preceding the date on which the Parent Shareholders&#8217; Meeting is scheduled, Parent reasonably believes that: (i) it will
not receive proxies sufficient to obtain the Required Parent Shareholder Vote, whether or not a quorum would be present, or (ii) it will
not have sufficient Parent Ordinary Shares to constitute a quorum necessary to conduct the business of the Parent Shareholders&#8217;
Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Shareholders&#8217;
Meeting as long as the date of the Parent Shareholders&#8217; Meeting is not postponed or adjourned more than an aggregate of 90 calendar
days in connection with any postponements or adjournments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Parent agrees that: (i)
the Parent Board shall recommend that Parent&#8217;s shareholders vote to approve the Parent Shareholder Matters, (ii) the Registration
Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s shareholders vote to approve the
Parent Shareholder Matters (the recommendation of the Parent Board with respect to the Parent Shareholder Matters being referred to as
the &#8220;<b><i>Parent Board Recommendation</i></b>&#8221;); and (iii) the Parent Board Recommendation shall not be withheld, amended,
withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation)
without the Company&#8217;s prior written consent (the actions set forth in the foregoing clause (iii), collectively, a &#8220;<b><i>Parent
Board Adverse Recommendation Change</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) Nothing contained in this
Agreement shall prohibit Parent or Parent Board from making any disclosure to the Parent shareholders if the Parent Board determines
in good faith, after consultation with its outside legal counsel, that such disclosure is required for the Parent Board to comply with
its fiduciary duties to the Parent shareholders under applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) Without derogating from
the above, nothing contained in this Agreement shall prohibit Parent or the Parent Board from: (i) complying with Rule 14d-9 promulgated
under the Exchange Act, or (ii) issuing a &#8220;stop, look and listen&#8221; communication or similar communication of the type contemplated
by Section 14d-9(f) under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) Promptly after the execution
of this Agreement, and in any event within 2 Business Days, Parent, as the sole shareholder of Merger Sub, shall deliver to the Company
a unanimous written consent in lieu of a meeting that adopted and approved this Agreement and the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) Parent as the sole shareholder
of Merger Sub shall not take any action to rescind the unanimous written consent in lieu of a meeting that adopted and approved this
Agreement and the Contemplated Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <b><span style="text-decoration:underline">Regulatory Approvals</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Each Party shall use reasonable
best efforts to file or otherwise submit, as soon as practicable after the execution of this Agreement, all applications, notices, reports,
filings and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental
Body with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental
Body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) No Party hereto shall take
any action that could reasonably be expected to adversely affect or materially delay the approval of any Governmental Body, or the expiration
or termination of any waiting period under any antitrust, competition or trade regulation Laws that are designed or intended to prohibit,
restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening competition through merger
or acquisition, including by agreeing to merge with or acquire any other person or acquire a substantial portion of the assets of or
equity in any other person. The parties hereto further covenant and agree, with respect to a threatened or pending preliminary or permanent
injunction or other order, decree or ruling or statute, rule, regulation or executive order that would adversely affect the ability of
the parties to consummate the Contemplated Transactions, to use reasonable best efforts to prevent or lift the entry, enactment or promulgation
thereof, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <b><span style="text-decoration:underline">Certificate of
Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required under the Companies
Law, the Company and Merger Sub shall (and the Parent shall cause Merger Sub to) file any required filings with the Companies Registrar.
On the Closing Date and subject to the terms and conditions hereof, the Parties shall cause the Merger to be consummated by obtaining
a certificate of merger (the &#8220;<b><i>Merger Certificate</i></b>&#8221;) issued by the Companies Registrar. The Merger shall become
effective at such time as the Merger Certificate is issued and delivered by the Companies Registrar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <b><span style="text-decoration:underline">Company Options</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Each Company Option that
is outstanding and unexercised immediately prior to the Effective Time under the Company Share Plans, whether or not vested (taking into
account any acceleration of vesting as a result of the consummation of the Merger), shall be cancelled immediately prior to the Effective
Time for no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Prior to the Effective
Time, the Company shall take all actions that may be necessary (under the Company Share Plans and otherwise) to effectuate the provisions
of this <span style="text-decoration:underline">Section <b>&#8206;</b>5.6</span> and to ensure that, from and after the Effective Time, holders of Company Options have no rights
with respect thereto other than those specifically provided in this <span style="text-decoration:underline">Section <b>&#8206;</b>5.6</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7 <b><span style="text-decoration:underline">Company Warrants</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Each Company Warrant that
is outstanding and unexercised immediately prior to the Effective Time, shall be cancelled immediately prior to the Effective Time for
no consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Prior to the Effective
Time, the Company shall take all actions that may be necessary to effectuate the provisions of this <span style="text-decoration:underline">Section <b>&#8206;</b>5.7</span> and
to ensure that, from and after the Effective Time, holders of Company Warrants have no rights with respect thereto other than those specifically
provided in this <span style="text-decoration:underline">Section 5.7.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company shall use its
reasonable best efforts to maintain the effectiveness of the Registration Statement under the Securities Act, including if necessary
the filing with and seeking effectiveness from the SEC of a replacement registration statement on an appropriate form, as long as the
Pre-Funded Warrants are outstanding following the Closing, for the purpose of registering the issuance of Parent Ordinary Shares upon
the exercise of any Parent Pre-Funded Warrants issued, pursuant to the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8 <b><span style="text-decoration:underline">TASE De-Listing
of Company Ordinary Shares</span></b><span style="text-decoration:underline">.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Effective Time,
the Company shall cooperate with Parent and use commercially reasonable best efforts to take, or cause to be taken, all actions, and
do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Law and rules and policies
of the TASE to enable the de-listing of the Company Ordinary Shares from the TASE under the Israeli Securities Law effective as of the
Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <b><span style="text-decoration:underline">Additional Agreements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties shall (a) use
commercially reasonable efforts to cause to be taken all actions necessary to consummate the Contemplated Transactions and (b) reasonably
cooperate with the other Parties and provide the other Parties with such assistance as may be reasonably requested for the purpose of
facilitating the performance by each Party of its respective obligations under this Agreement and to enable the Surviving Company to
continue to meet its obligations under this Agreement following the Closing. Without limiting the generality of the foregoing, each Party
to this Agreement: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given
by such Party in connection with the Contemplated Transactions; (ii) shall use reasonable best efforts to obtain each Consent (if any)
reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated
Transactions or for such Contract (with respect to Contracts set forth in <span style="text-decoration:underline">Section &#8206;2.5(d)</span> of the Company Disclosure Schedule)
to remain in full force and effect; (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other
legal bar to, the Contemplated Transactions; and (iv) shall use commercially reasonable efforts to satisfy the conditions precedent to
the consummation of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10 <b><span style="text-decoration:underline">Disclosure</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The initial press release
relating to this Agreement shall be a joint press release issued by the Company and Parent and thereafter Parent and the Company shall
consult with each other before issuing any further press release(s) or otherwise making any public statement or making any announcement
to Parent Associates or Company Associates (to the extent not previously issued or made in accordance with this Agreement) with respect
to the Contemplated Transactions and shall not issue any such press release, public statement or announcement to Parent Associates or
Company Associates without the other Party&#8217;s written consent (which shall not be unreasonably withheld, conditioned or delayed).
Notwithstanding the foregoing: (a) each Party may, without such consultation or consent, make any public statement in response to questions
from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures
in Parent SEC Documents and/or Company TASE Documents, so long as such statements are consistent with previous press releases, public
disclosures or public statements made jointly by the parties (or individually, if approved by the other Party); (b) a Party may, without
the prior consent of the other Party hereto but subject to giving advance notice to the other Party, issue any such press release or
make any such public announcement or statement as may be required by any Law; and (c) a Party need not consult with the other Party in
connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;5.3(e)
</span>or with respect to any Acquisition Proposal or Board Adverse Recommendation Change, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11 <b><span style="text-decoration:underline">Listing</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent shall use its commercially
reasonable efforts, to the extent required by the rules and regulations of Nasdaq (including pursuant to any applicable discretion afforded
to Nasdaq under such rules and regulations), to prepare and submit to Nasdaq a notification form for the listing of the Parent Ordinary
Shares to be issued in connection with the Contemplated Transactions (including the Parent Ordinary Shares issuable upon the exercise
of the Parent Pre-Funded Warrants) (the &#8220;<b><i>Nasdaq Notification</i></b>&#8221;). The Parties will use commercially reasonable
efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Company will cooperate with Parent as reasonably
requested by Parent with respect to the Nasdaq Notification, and promptly furnish to Parent all information concerning the Company and
its shareholders that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section &#8206;&#8206;5.11</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12 <b><span style="text-decoration:underline">Tax Matters</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties will cooperate
in preparing and filing all Tax Returns of the Company that are required to be filed for any taxable periods ending on or before the
Closing Date. All such Tax Returns will be prepared by treating items on such Tax Returns in a manner consistent with the past practices
of the Company with respect to such items, except as required by applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <b><span style="text-decoration:underline">Directors and
Officers</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parties shall take all
necessary action so that immediately after the Effective Time, (a)&#160;the post-Closing Parent Board shall be comprised of at least
five and not more than seven directors; whereby (b) the Company shall have the right to designate two members to the post-Closing Parent
Board, if the post-Closing Parent Board is comprised of five or six directors, or three members, if the post-Closing Parent Board is
comprised of seven directors; provided that at least one shall be an independent director (as defined under the Nasdaq listing rules)
and if so required (based on the advice of counsel) in order to meet such condition, such director shall be acceptable by the Company
but appointed by the Parent Board; (c) one designated member shall be mutually agreed between the Company and the Parent (initially being
Mr. Amitai Weiss); (d) the Parent shall designate the remaining directors (the &#8220;<b><i>Company Designees</i></b> and the &#8220;<b><i>Parent
Designee</i></b>s&#8221;, respectively) and (e) the Persons designed by the Parent Board shall be appointed to the positions of officers
of Parent, as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and
qualified in accordance with applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14 <b><span style="text-decoration:underline">Termination of
Certain Agreements and Rights</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall cause any
Investor Agreements (excluding the Company Shareholder Support Agreements) to be terminated immediately prior to the Effective Time,
without any liability being imposed on the part of Company, Parent or the Surviving Company, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15 <b><span style="text-decoration:underline">Cooperation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Party shall cooperate
reasonably with the other Party and shall provide the other Party with such assistance as may be reasonably requested for the purpose
of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the combined entity to
continue to meet its obligations following the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16 <b><span style="text-decoration:underline">Allocation Certificates;
Ownership Certificate</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company will prepare
and deliver to Parent at least ten Business Days prior to the Closing Date a certificate signed by the chief financial officer of the
Company in a form reasonably acceptable to Parent setting forth (as of immediately prior to the Effective Time): (i) each record holder
of Company Ordinary Shares, Company Options or Company Warrants, (ii) such record holder&#8217;s name and address, (iii) the number of
Company Ordinary Shares held and/or underlying the Company Options or Company Warrants as of the Effective Time for such holder (the
&#8220;<b><i>Company Outstanding Shares Certificate</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Parent will prepare and
deliver to the Company at least ten Business Days prior to the Closing Date a certificate signed by the chief financial officer of Parent
in a form reasonably acceptable to the Company, setting forth, as of immediately prior to the Effective Time: (i) each record holder
of Parent Ordinary Shares, Parent Equity Awards or Parent Warrants, (ii) such record holder&#8217;s name and address, (iii) the number
of Parent Ordinary Shares held and/or underlying the Parent Equity Awards or Parent Warrants as of the Effective Time for such holder
(the &#8220;<b><i>Parent Outstanding Shares Certificate</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Parent will deliver to
the Company at least ten Business Days prior to the Closing Date either (i) an ownership certificate, issued by a TASE member, confirming
Parent&#8217;s ownership of the Company Ordinary Shares on the date of issuance thereof, together with a confirmation of the chief financial
officer of Parent that no changes in Parent&#8217;s ownership of the Company Ordinary Shares were made since such ownership certificate
was issued, or (ii) a certificate signed by the chief financial officer of Parent confirming that on the date of issuance thereof Parent
does not own any Company Ordinary Shares, all in a form reasonably acceptable to the Company (a certificate provided under this Section
<b>&#8206;</b>5.16<b>&#8206;</b>(c) &#8211; the &#8220;<b><i>Parent Ownership Certificate</i></b>&#8221;). Following the issuance of the
Parent Ownership Certificate and up to the Closing Date, the Parent shall not dispose of or acquire Company Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17 <b><span style="text-decoration:underline">Company Financial
Statements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) As promptly as reasonably
practicable following the date of this Agreement: (i) the Company will furnish to Parent audited financial statements for the fiscal
years ended 2022 and 2021, and to the extent necessary to be included in the Registration Statement, for the fiscal year ended 2023,
translated into English for inclusion in the Registration Statement (the &#8220;<b><i>Company Audited Financial Statements</i></b>&#8221;);
(ii) the Company will furnish to Parent unaudited interim financial statements, translated into English for each interim period completed
prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing
if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;<b><i>Company
Interim Financial Statements</i></b>&#8221;); and (iii) the Company will furnish to Parent any such additional information or documents
reasonably required by Parent, after consulting with its independent auditors, for compliance with Regulation S-X. The Company hereby
covenants that each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion
in the Registration Statement and prepared as applied on a consistent basis during the periods involved (except in each case as described
in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations,
changes in shareholders&#8217; equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company
Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Following the Closing,
the financial statements shall be audited in accordance with the auditing standards of the U.S. Public Company Accounting Oversight Board
(&#8220;<b><i>PCAOB</i></b>&#8221;) by a PCAOB qualified auditor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18 <b><span style="text-decoration:underline">Shareholder Litigation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Closing, Parent
shall conduct and control the settlement and defense of any shareholder litigation against Parent or any of its directors relating to
this Agreement or the Contemplated Transactions; <i>provided</i> that (i) Parent shall keep the Company reasonably apprised of any material
developments in connection with any such shareholder litigation, (ii) Parent shall consult with the Company in connection with the defense
and settlement of any such shareholder litigation and (iii) any settlement or other resolution of any such shareholder litigation shall
be subject to the approval of the Company, which approval shall not be unreasonably withheld, delayed or conditioned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19 <b><span style="text-decoration:underline">Certain Adjustments</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and the Company shall
discuss and agree the terms of any reverse split of the Parent Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">6.
<b><span style="text-decoration:underline">CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of each Party
to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction
or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior to the Closing, of each of the
following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1 <b><span style="text-decoration:underline">No Restraints</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No temporary restraining
order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been
issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall
not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2 <b><span style="text-decoration:underline">Shareholder Approval</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Parent shall have obtained
the Required Parent Shareholder Vote and (b) the Company shall have obtained the Required Company Approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3 <b><span style="text-decoration:underline">Court Approval</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Court Approval shall
have been obtained in accordance with the Companies Law, including after obtaining the Required Company Approval, in accordance with
Sections 350 and 351 of the Companies Law and exempting among others, the Parent from the requirement to publish a prospectus in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4 <b><span style="text-decoration:underline">Tax Rulings</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall have received
the Withholding Tax Ruling and the 104H Ruling, in the forms reasonably acceptable on the Parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5 <b><span style="text-decoration:underline">Certificate of
Merger</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and Merger Sub
shall have received the Merger Certificate from the Companies Registrar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6 <b><span style="text-decoration:underline">No Legal Prohibition</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Governmental Authority
of competent jurisdiction shall have (i) enacted, issued or promulgated any Law that is in effect and has the effect of making the Merger
illegal or which has the effect of prohibiting or otherwise preventing the consummation of the Merger, or (ii) issued or granted any
order that has the effect of making the Merger illegal or which has the effect of prohibiting or otherwise preventing the consummation
of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7 <b><span style="text-decoration:underline">Bonds&#8217; Trustee</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not less than seven (7) Business
Days prior to the Closing, the Company and the Parent shall provide the Bonds&#8217; Trustee, to the extent not reported by the Company
on an immediate report filed with the TASE, with (a) a written confirmation that no reasonable concern exists that due to the Merger
the Company and the Parent as the absorbing company, will be unable to perform all and any obligations to the Bond holders under the
terms of the Series B Bonds and the Bonds Trust Deed, and (b) a written confirmation that as a result of the Merger, no pledges that
are inconsistent with the Company&#8217;s obligations under the Bonds Trust Deed regarding the creation of certain pledges, will be assigned
to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8 <b><span style="text-decoration:underline">Registration Statement</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registration Statement
will have been declared effective and continue to be effective under the Securities Act. No stop order suspending the effectiveness of
the Registration Statement will be in effect, and no proceedings for purposes of suspending the effectiveness of the Registration Statement
will have been initiated or be threatened by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 218; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">7.
<b><span style="text-decoration:underline">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of Parent
and Merger Sub to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction
or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1 <b><span style="text-decoration:underline">Accuracy of Representations</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company Fundamental Representations
shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made
as of a particular date, in which case such representations and warranties shall be true and correct as of such date) other than, with
respect to the representations and warranties set forth in <span style="text-decoration:underline">Section &#8206;&#8206;2.6</span>, for inaccuracies that are <i>de minimis </i>in
nature and amount as of such date. The representations and warranties of the Company contained in this Agreement (other than the Company
Fundamental Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as
of the Closing Date with the same force and effect as if made on the Closing Date except: (i) in each case, or in the aggregate, where
the failure to be true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect
to any references therein to any Company Material Adverse Effect or other materiality qualifications), and (ii) for those representations
and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to
the qualifications as set forth in the preceding clause (i), as of such particular date) (it being understood that, for purposes of determining
the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Schedule made or purported
to have been made after the date of this Agreement shall be disregarded).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2 <b><span style="text-decoration:underline">Performance of
Covenants</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall have performed
or complied in all material respects with all agreements and covenants required to be performed or complied with by it under this Agreement
at or prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3 <b><span style="text-decoration:underline">Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent shall have received
the following documents, each of which shall be in full force and effect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) a certificate executed
by the chief executive officer or chief financial officer of the Company certifying: (i) that the conditions set forth in <span style="text-decoration:underline">Sections
<b>&#8206;&#8206;</b>7.1</span>, <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">7.2</span>, <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">7.4</span> and <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">7.5</span> have been duly
satisfied and (ii) that the information set forth in the Company Allocation Schedule and the Company Outstanding Shares Certificate delivered
by the Company in accordance with <span style="text-decoration:underline">Section <b>&#8206;</b>1.8(b)</span> and <span style="text-decoration:underline">Section <b>&#8206;</b>5.16(a)</span> is true and accurate in all
respects as of the Closing Date; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) the Company Allocation
Schedule and the Company Outstanding Shares Certificate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4 <b><span style="text-decoration:underline">No Company Material
Adverse Effect</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the date of this Agreement,
there shall not have occurred any Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5 <b><span style="text-decoration:underline">Termination of
Investor Agreements</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investor Agreements shall
have been terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">8.
<b><span style="text-decoration:underline">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of the Company
to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the
written waiver by the Company, at or prior to the Closing, of each of the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1 <b><span style="text-decoration:underline">Accuracy of Representations</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Fundamental Representations
shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made
as of a particular date, in which case such representations and warranties shall be true and correct as of such date) other than, with
respect to the representations and warranties set forth in <span style="text-decoration:underline">Section &#8206;&#8206;3.6</span>, which shall be true and correct as of the Closing
Date except for inaccuracies that are <i>de minimis</i> in nature and amount as of such date. The representations and warranties of Parent
and Merger Sub contained in this Agreement (other than the Parent Fundamental Representations) shall have been true and correct as of
the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the
Closing Date except (a) in each case, or in the aggregate, where the failure to be true and correct would not reasonably be expected
to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other
materiality qualifications), and (b) for those representations and warranties which address matters only as of a particular date (which
representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such
particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update
of or modification to the Parent Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2 <b><span style="text-decoration:underline">Performance of
Covenants</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and Merger Sub shall
have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with
by each of them under this Agreement at or prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3 <b><span style="text-decoration:underline">Documents</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall have received
the following documents, each of which shall be in full force and effect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) a certificate executed
by the chief financial officer of Parent certifying that the conditions set forth in <span style="text-decoration:underline">Sections <b>&#8206;&#8206;</b>8.1</span>, <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">8.2
</span>and <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">8.4</span> have been duly satisfied; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) the Parent Outstanding
Shares Certificate; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) the Parent Ownership Certificate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4 <b><span style="text-decoration:underline">No Parent Material
Adverse Effect</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the date of this Agreement,
there shall not have occurred any Parent Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5 <b><span style="text-decoration:underline">Parent Net Cash</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent and the Company have
agreed in writing upon the calculation of the Parent Net Cash, or the Accounting Firm has delivered its determination with respect to
the calculation of the Parent Net Cash, in each case pursuant to <span style="text-decoration:underline">Section &#8206;&#8206;1.6</span>, and the Parent Net Cash shall be no less
than $4,250,000 (less any amount owned by the Company to the Parent under any loan agreement between the parties) and the sum of $4,250,000
(less any amount owned by the Company to the Parent under any loan agreement between the parties), in accordance with Section &#8206;4.7
shall have been transferred and cleared to the Company&#8217;s designated bank account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6 <b><span style="text-decoration:underline">Listing</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Parent Ordinary Shares
shall remain listed on Nasdaq and shall not be subject to a delisting notice from Nasdaq that will not be cured by the Contemplated Transactions.
The Nasdaq Notification shall have been accepted and approved (subject to official notice of issuance).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7 <b><span style="text-decoration:underline">Directors and Officers</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) The Parent shall have
appointed, effective as of the Effective Time in accordance with <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>5.13</span>, to the Parent Board all Persons
designated by the Company to the Parent Board and all such Persons shall receive an executed Indemnification Agreement with Parent in
the form of <b><span style="text-decoration:underline">Exhibit F</span></b>, and (ii) Parent shall have appointed the Persons designated by the Company to the positions of officers
of Parent, as set forth therein, to serve in such positions effective as of the Effective Time in accordance with <span style="text-decoration:underline">Section <b><i>&#8206;</i></b>5.13</span>;
all until successors are duly appointed and qualified in accordance with applicable Law and Restated Parent Articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">9.
<b><span style="text-decoration:underline">TERMINATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1 <b><span style="text-decoration:underline">Termination</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be terminated
prior to the Effective Time (whether before or after approval of the Company Approval Matters and whether before or after approval of
the Parent Shareholder Matters by Parent&#8217;s shareholders, unless otherwise specified below):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) at any time prior to the
Effective Time, by mutual written consent of Parent and the Company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) by either Parent or the
Company if the Contemplated Transactions shall not have been consummated by August 30, 2024, which can be extended by mutual consent
of the Parent and the Company by additional periods (subject in either case to possible extension by agreement between the Parties, the
&#8220;<b><i>End Date</i></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) by either Parent or the
Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and non-appealable order, decree or
ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated
Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) by either Parent or the
Company if: (i) the Parent Shareholders&#8217; Meeting (including any adjournments and postponements thereof) and/or the Company Meetings
shall have been held and completed and the Parent&#8217;s and/or the Company&#8217;s shareholders and/or the Company&#8217;s Bondholders
or creditors (if applicable), shall have taken a final vote on the Parent Shareholder Matters or the Company Approval Matters, as applicable
and (ii) the Parent Shareholder Matters or the Company Approval Matters, as applicable, shall not have been approved at the Parent Shareholders&#8217;
Meeting or the Company Meetings, as applicable (or at any adjournment or postponement thereof), by the Required Parent Shareholder Vote
or the Required Company Approval, as applicable; provided, that Parent or the Company may not terminate this Agreement pursuant to this
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(d)</span> if its breach of its obligations under this Agreement was the principal factor contributing to
the failure to have obtained the approval of the Parent Shareholder Matters at the Parent Shareholders&#8217; Meeting or of the Company
Approval Matters at the Company Meetings, as applicable (including any adjournments and postponements thereof), <i>provided, however</i>,
that Parent shall not be deemed in breach of its obligations under this Agreement in the event that a request for additional information
has been made by any Governmental Body, or in the event that the SEC has not declared effective under the Securities Act the Registration
Statement or otherwise delayed such declaration and as a result Parent did not have sufficient time to solicit votes;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) by the Company (at any
time prior to the approval of the Parent Shareholder Matters by the Required Parent Shareholder Vote) if a Parent Triggering Event shall
have occurred;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) by Parent (at any time
prior to the Required Company Approval being obtained) if a Company Triggering Event shall have occurred;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) by the Company, upon a
breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub or if any representation
or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>8.1</span>or
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>8.2</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty
shall have become inaccurate; <i>provided</i> that the Company is not then in material breach of any representation, warranty, covenant
or agreement under this Agreement; <i>provided</i>, <i>further</i>, that if such inaccuracy in Parent&#8217;s or Merger Sub&#8217;s representations
and warranties or breach by Parent or Merger Sub is curable by the End Date by Parent or Merger Sub, then this Agreement shall not terminate
pursuant to this <span style="text-decoration:underline">Section <b>&#8206;</b>9.1(g)<b>&#8206;</b></span> as a result of such particular breach or inaccuracy until the expiration
of a 30 calendar day period commencing upon delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy
and its intention to terminate pursuant to this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(g)</span> (it being understood that this Agreement shall
not terminate pursuant to this <span style="text-decoration:underline">Section <b>&#8206;</b>9.1(g)</span> as a result of such particular breach or inaccuracy if such breach by
Parent or Merger Sub is cured prior to such termination becoming effective);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) by Parent, upon a breach
of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty
of the Company shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section <b>&#8206;</b>7.1</span><b>&#8206;
</b>or <span style="text-decoration:underline">Section <b>&#8206;</b>7.2<b>&#8206;</b></span> would not be satisfied as of the time of such breach or as of the time such representation
or warranty shall have become inaccurate; <i>provided</i> that Parent is not then in material breach of any representation, warranty,
covenant or agreement under this Agreement; <i>provided</i>, <i>further</i>, that if such inaccuracy in the Company&#8217;s representations
and warranties or breach by the Company is curable by the End Date by the Company then this Agreement shall not terminate pursuant to
this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(h)</span> as a result of such particular breach or inaccuracy until the expiration of a 30 calendar
day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate
pursuant to this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(h)</span> (it being understood that this Agreement shall not terminate pursuant to this
<span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.1(h)</span> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior
to such termination becoming effective); or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) by Company, if the Parent
Net Cash is less than $4,250,000 (less any amount owned by the Company to the Parent under any loan agreement between the parties), by
the End Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j) by Parent, if the Company
Audited Financial Statements have not been provided by the Company to Parent within 45 calendar days immediately following the date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2 <b><span style="text-decoration:underline">Notice of Termination;
Effect of Termination</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any proper and valid termination
of this Agreement pursuant to <span style="text-decoration:underline">Section &#8206;9.1</span> shall be effective immediately upon the delivery of written notice of the terminating
party to the other party or parties hereto, as applicable. In the event of the termination of this Agreement as provided in <span style="text-decoration:underline">Section
&#8206;9.1</span>, this Agreement shall be of no further force or effect; <i>provided</i>, <i>however</i>, that (a) this <span style="text-decoration:underline">Section &#8206;&#8206;9.1</span>,
<span style="text-decoration:underline">Section &#8206;&#8206;5.10</span>, <span style="text-decoration:underline">Section &#8206;9.3&#8206;</span>, <span style="text-decoration:underline">Section &#8206;10</span> and the definitions of the defined terms in such
Sections shall survive the termination of this Agreement and shall remain in full force and effect, and (b) the termination of this Agreement
and the provisions of <span style="text-decoration:underline">Section &#8206;9.3</span> shall not relieve any Party of any liability for fraud or for any willful and material
breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. For purposes of this Agreement,
&#8220;willful breach&#8221; shall mean any act or failure to act by any person with the actual knowledge that the taking of such act
or the failure to take such act would cause a breach of this Agreement. In addition to the foregoing, no termination of this Agreement
shall affect the obligations of the Parties set forth in the Confidentiality Agreement, all of which obligations shall survive termination
of this Agreement in accordance with their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3 <b><span style="text-decoration:underline">Expenses</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Except as set forth in
this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.3(a)</span>, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions
shall be paid by the Party incurring such expenses, whether or not the Merger is consummated (including any attorney&#8217;s, accountant&#8217;s,
financial advisor&#8217;s or finder&#8217;s fees); <i>provided that</i> (i) Parent shall pay all fees and expenses incurred in relation
to the drafting, printing and filing with the SEC of the Registration Statement and any amendments and supplements thereto and paid to
a financial printer or the SEC, and (ii) drafting, printing and filing with the ISA of the Transaction Report and any amendments and
supplements thereto. It is understood and agreed that all fees and expenses incurred or to be incurred by the Company in connection with
the Contemplated Transactions and preparing, negotiating and entering into this Agreement and the performance of its obligations under
this Agreement shall be paid by the Company and that it is understood and agreed that all fees and expenses incurred or to be incurred
by Parent in connection with the Contemplated Transactions and preparing, negotiating and entering into this Agreement and the performance
of its obligations under this Agreement shall be paid by Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Each of the Parties acknowledges
that: (i) the agreements contained in this <span style="text-decoration:underline">Section <b>&#8206;&#8206;</b>9.3</span> are an integral part of the Contemplated Transactions,
(ii) without these agreements, the Parties would not enter into this Agreement and (iii) any amount payable pursuant to this <span style="text-decoration:underline">Section
<b>&#8206;&#8206;</b>9.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Company in
the circumstances in which such amount is payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -0.5in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">10.
<b><span style="text-decoration:underline">MISCELLANEOUS PROVISIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1 <b><span style="text-decoration:underline">Non-Survival of
Representations and Warranties</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The representations and warranties
of the Company, Parent and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement
shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this <span style="text-decoration:underline">Section &#8206;10
</span>shall survive the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2 <b><span style="text-decoration:underline">Amendment</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be amended
with the approval of the respective boards of directors of the Company, Merger Sub and Parent at any time (whether before or after obtaining
the Required Company Approval or before or after obtaining the Required Parent Shareholder Vote); <i>provided</i>, <i>however</i>, that
after any such approval of this Agreement by a Party&#8217;s shareholders, no amendment shall be made which by Law requires further approval
of such shareholders without the further approval of such shareholders. This Agreement may not be amended except by an instrument in
writing signed on behalf of each of the Company, Merger Sub and Parent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3 <b><span style="text-decoration:underline">Waiver</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) No failure on the part
of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising
any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and
no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of
any other power, right, privilege or remedy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) No Party shall be deemed
to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver
of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf
of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.4 <b><span style="text-decoration:underline">Entire Agreement;
Counterparts; Exchanges by Electronic Transmission</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement, the Company
Disclosure Schedule, the Parent Disclosure Schedule and the other agreements referred to in this Agreement constitute the entire agreement
and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the
subject matter hereof and thereof; <i>provided</i>, <i>however</i>, that the Confidentiality Agreement shall not be superseded and shall
remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall
be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts
or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions
of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5 <b><span style="text-decoration:underline">Applicable Law;
Jurisdiction</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) This Agreement shall
be governed by, and construed in accordance with, the Laws of the State of Israel, regardless of the Laws that might otherwise govern
under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to
this Agreement or any of the Contemplated Transactions, each of the Parties irrevocably and unconditionally consents and submits to the
exclusive jurisdiction and venue of the courts located in Tel Aviv, Israel; and (b) agrees that all claims in respect of such action
or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <span style="text-decoration:underline">Section &#8206;&#8206;10.5</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6 <b><span style="text-decoration:underline">Attorneys&#8217;
Fees</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In any action at law or suit
in equity to enforce this Agreement or the rights of any of the Parties, the prevailing Party in such action or suit (as determined by
a court of competent jurisdiction) shall be entitled to recover its reasonable out-of-pocket attorneys&#8217; fees and all other reasonable
costs and expenses incurred in such action or suit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.7 <b><span style="text-decoration:underline">Assignability</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall be binding
upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns;
<i>provided</i>, <i>however</i>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned
or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement
or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.8 <b><span style="text-decoration:underline">Notices</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices and other communications
hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a) one Business Day after being
sent for next Business Day delivery, fees prepaid, via a reputable overnight courier service, (b) upon delivery in the case of delivery
by hand, or (c) on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery)
prior to 5:00 p.m. Israel time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if to Parent or Merger Sub:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">SciSparc Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">20 Raul Wallenberg
Street, Tower A</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel Aviv, Israel,
6971916</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Oz Adler</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: oz@scisparc.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">with a copy to (which shall
not constitute notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Meitar | Law Offices</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">16 Abba Hillel
Rd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Ramat Gan 5250608,
Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel: (+972) (3)
610-3100</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Dr.
Shachar Hadar</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: shacharh@meitar.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">And</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Sullivan &amp;
Worcester LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">1633 Broadway</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">New York, NY 10019</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel: (212) 660-3000</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Oded
Har-Even, Esq., Howard E. Berkenblit, Esq</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: ohareven@sullivanlaw.com,
hberkenblit@sullivanlaw.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if to the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">AutoMax Motors
Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">15 HaRechavim St.,
Jerusalem</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Tomer
Levy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: tomer@automax.co.il</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">with a copy to
(which shall not constitute notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Lipa Meir &amp;
Co. Law Office</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">2 Weizmann ST.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel -Aviv 6423902,
Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Tel: +973 (3) 6070600</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: Gregory
Irgo, Adv.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: gregory@lipameir.co.il</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">And</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Greenberg Traurig,
P.A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">One Azrieli Center</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Round Tower, 30th
floor</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">132 Menachem Begin
Rd, Tel Aviv 6701101, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Attention: David
A. Huberman</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">Email: David.Huberman@gtlaw.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 226; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.9 <b><span style="text-decoration:underline">Cooperation</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Party agrees to cooperate
fully with the other Parties and to execute and deliver such further documents, certificates, agreements and instruments and to take
such other actions as may be reasonably requested by the other Parties to evidence or reflect the Contemplated Transactions and to carry
out the intent and purposes of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.10 <b><span style="text-decoration:underline">Severability</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any term or provision of
this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision
of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit
such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid
and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement
shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence,
the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will
achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.11 <b><span style="text-decoration:underline">Other Remedies;
Specific Performance</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy
conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of
any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy,
would occur in the event that any Party does not perform the provisions of this Agreement (including failing to take such actions as
are required of it hereunder to consummate this Agreement) in accordance with its specified terms or otherwise breaches such provisions.
Accordingly, the Parties acknowledge and agree that the Parties shall be entitled to an injunction, specific performance and other equitable
relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy
to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific
performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance
is not an appropriate remedy for any reason at law or in equity. Any Party seeking an injunction or injunctions to prevent breaches of
this Agreement shall not be required to provide any bond or other security in connection with any such order or injunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 227; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.12 <b><span style="text-decoration:underline">No Third Party
Beneficiaries</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Agreement,
express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by
reason of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.13 <b><span style="text-decoration:underline">Construction</span></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) References to &#8220;cash,&#8221;
&#8220;dollars&#8221; or &#8220;$&#8221; are to U.S. dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) For purposes of this Agreement,
whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine
and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine
and feminine genders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Parties have participated
jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the effect that ambiguities are
to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) As used in this Agreement,
the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but
rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; The word &#8220;or&#8221; shall not be exclusive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) Except as otherwise indicated,
all references in this Agreement to &#8220;Sections,&#8221; &#8220;Exhibits&#8221; and &#8220;Schedules&#8221; are intended to refer
to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) Any reference to legislation
or to any provision of any legislation shall include any modification, amendment, re-enactment thereof, any legislative provision substituted
therefor and all rules, regulations, and statutory instruments issued or related to such legislations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) The bold-faced headings
and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) The Parties agree that
each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding
to the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the
Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) Each of &#8220;delivered&#8221;
or &#8220;made available&#8221; means, with respect to any documentation, that prior to 11:59 p.m. (Israel time) on the date that is
two calendar days prior to the date of this Agreement: (i) a copy of such material has been posted to and made available by a Party to
the other Party and its Representatives in the electronic data room maintained by such disclosing Party or (ii) such material is disclosed
in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data
Gathering Analysis and Retrieval system and/or disclosed in the Company TASE Documents filed with the ISA prior to the date hereof and
publicly made available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j) Whenever the last day for
the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Friday, Saturday, or any date on which banks in
Tel Aviv, Israel are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege
or discharge such duty on the next succeeding day which is a regular Business Day.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<i>Remainder of page intentionally
left blank</i>)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 228; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>IN WITNESS WHEREOF, </b>the
Parties have caused this Agreement to be executed as of the date first above written.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt"><b>SCISPARC LTD.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; width: 35%; text-align: justify; font-size: 10pt">/s/ Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Chief Executive Officer</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>SCISPARC MERGER SUB LTD.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:</td>
    <td style="text-align: justify; font-size: 10pt">Oz Adler</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>AUTOMAX MOTORS LTD.</b> &#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:</td>
    <td style="text-align: justify; font-size: 10pt">Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Director</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Yaarah Alfi</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Name:</td>
    <td style="text-align: justify; font-size: 10pt">Yaarah Alfi</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt">Title:</td>
    <td style="text-align: justify; font-size: 10pt">Chief Financial Officer</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE PAGE TO MERGER
AGREEMENT]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 229; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Exhibit
A</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Certain
Definitions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
purposes of this Agreement (including this Exhibit A):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>104H
Ruling</i></b>&#8221; means a ruling </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuant to Section
104H of the Ordinance, (i) exempting from or deferring any applicable Israeli Tax with respect to any consideration payable to 5% Payee,
pursuant to this Agreement, until the date set forth in Section 104H of the Ordinance or (ii) instructing the Payor and its agents on
how such withholding is to be executed from the payment of such consideration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>104H
Trustee</i></b>&#8221; means </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trustee appointed for
the purpose of 104H Ruling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>102
Trustee</i></b>&#8221; means the trustee appointed by the Company from time to time in accordance with the provisions of the Ordinance,
and approved by the Israel Tax Authority, with respect to the Company 102 Options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Acquisition
Inquiry</i></b>&#8221; means, with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry,
indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to
the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Acquisition
Proposal</i></b>&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal
made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its
Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Acquisition
Transaction</i></b>&#8221; means any transaction or series of related transactions involving:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(i)
</b>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities,
reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Party is a constituent entity;
(ii) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly
or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class
of voting securities of a Party or any of its Subsidiaries; or (iii) in which a Party or any of its Subsidiaries issues securities representing
more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; <i>provided</i>,
that in the case of Company, the Closing Financing shall not be an &#8220;Acquisition Transaction&#8221;; or</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>(ii)
</b>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute
or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken
as a whole.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 230; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Affiliate</i></b>&#8221;
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. The term &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under
common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Applicable
Court</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;5.1(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Bondholders</i></b>&#8221;
means holders of the Company&#8217;s Series B Bonds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Bonds&#8217;
Trustee</i></b>&#8221; means Mishmeret Trust Company Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Bonds
Trust Deed</i></b>&#8221; means the trust deed dated February 23, 2022, by and between the Company and the Bonds&#8217; Trustee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Business
Day</i></b>&#8221; means any day other than a Friday, Saturday or other day on which banks in Tel Aviv, Israel are authorized or obligated
by Law to be closed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Cash
and Cash Equivalents</i></b>&#8221; means all (a) cash (not including restricted cash) and cash equivalents (not including restricted
cash); (b) deposits; (c) marketable securities and (d) short term receivables, in each case determined in accordance with IFRS, consistently
applied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Closing</i></b>&#8221;
shall have the meaning ascribed thereto in Section &#8206;1.3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Closing
Date</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;1.3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Closing
Financing</i></b>&#8221; means any offering, issuance and sale by Parent, by means of a public offering, a registered direct offering,
a private placement offering or such other offering that the officers of Parent shall determine to be advisable, of securities of the
Parent to investors, which may be consummated prior to or concurrently with the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Code</i></b>&#8221;
means the Internal Revenue Code of 1986, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Companies
Law</i></b>&#8221; means the Israeli Companies Law, 5759-1999, and all rules and regulations thereunder, all as amended from time to
time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
102 Options</i></b>&#8221; means Company Options that are granted and subject to Section 102(b)(2) and Section 102(b)(3) of the Ordinance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Approval Matters</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;5.1(c).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Affiliate</i></b>&#8221; means any Person that is (or at any relevant time was) under common control with the Company within the meaning
of Sections 414(b), (c), (m) and (o) of the Code, and the regulations issued thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 231; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Associate</i></b>&#8221; means any current or former employee, independent contractor, officer or director of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Board</i></b>&#8221; means the board of directors of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Ordinary Shares</i></b>&#8221; means the ordinary shares, par value NIS 0.05 per share, of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Certified Shares</i></b>&#8221; means Company Ordinary Shares represented by Company Share Certificates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Contract</i></b>&#8221; means any Contract: (a) to which the Company is a Party; (b) by which the Company or any asset of the Company
is or may become bound or under which the Company has, or may become subject to, any obligation; or (c) under which the Company has or
may acquire any right or interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Fundamental Representations</i></b>&#8221; means the representations and warranties of the Company set forth in <span style="text-decoration:underline">Sections &#8206;&#8206;2.1
</span>(Due Organization; Subsidiaries), <span style="text-decoration:underline">&#8206;&#8206;2.3</span> (Authority; Binding Nature of Agreement), <span style="text-decoration:underline">&#8206;&#8206;2.4</span> (Vote Required),
&#8206;2.6 (Capitalization) and <span style="text-decoration:underline">&#8206;&#8206;2.20</span> (No Financial Advisors).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Material Adverse Effect</i></b>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to
the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material
adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of the Company; <i>provided</i>,
<i>however</i>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has
been a Company Material Adverse Effect: (a) changes or conditions generally affecting the industries or markets in which the Company
operates, and changes in the industries in which the Company operates regardless of geographic region (including legal and regulatory
changes), (b) acts of war, armed hostilities or terrorism, including the current ongoing war declared by Israel against Hamas, (c) changes
in financial, banking or securities markets, (d) any change in, or any compliance with or action taken for the purpose of complying with,
any Law or IFRS (or interpretations of any Law or IFRS), (e) resulting from the announcement of this Agreement or the pendency of the
Contemplated Transactions, (f) resulting from the taking of any action required to be taken by this Agreement or (g) changes in U.S.
or non-U.S. general economic or political conditions, or in the financial, credit or securities markets in general, including any shutdown
of any Governmental Authority; except in each case with respect to clauses (a) through (c), to the extent disproportionately affecting
the Company, relative to other companies in the industries in which the Company operates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Meetings</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;5.1(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Options</i></b>&#8221; means options or other rights granted by the Company to purchase Company Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 232; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Shareholder</i></b>&#8221; means a holder of Company Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Share Plans</i></b>&#8221; means Company&#8217;s 2021 Equity Incentive Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Triggering Event</i></b>&#8221; shall be deemed to have occurred if: (a) the Company shall have made a Company Board Adverse Recommendation
Change; (b) the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal
(or shall have not publicly recommended against any Acquisition Proposal that is a tender offer or exchange offer within five Business
Days after the commencement thereof); or (c) the Company shall have entered into any letter of intent or any Contract contemplating or
otherwise relating to any Acquisition Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
TASE Documents</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;2.7(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Balance Sheet</i></b>&#8221; means the audited balance sheet of the Company for the period ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Warrant</i></b>&#8221; means the warrants to purchase Company Ordinary Shares listed in <span style="text-decoration:underline">Section &#8206;&#8206;1.1(f)</span> of the Company
Disclosure Schedule.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Confidentiality
Agreement</i></b>&#8221; means the non-disclosure agreement, dated as of November 28, 2023, between the Company and Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Consent</i></b>&#8221;
means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Contemplated
Transactions</i></b>&#8221; means the Merger and the other transactions and actions contemplated by this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Contract</i></b>&#8221;
means, with respect to any Person, any agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license,
sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or
any of its assets are bound or affected under applicable Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Effect</i></b>&#8221;
means any effect, change, event, circumstance, or development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Effective
Time</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;1.3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Encumbrance</i></b>&#8221;
means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude,
adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction
or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security
or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any
restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 233; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;<i>Enforceability
Exceptions</i>&#8221;</b> means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors; and
(b) rules of law governing specific performance, injunctive relief and other equitable remedies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Entity</i></b>&#8221;
means any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or
limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company
or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Environmental
Law</i></b>&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment
(including ambient air, surface water, ground water, land surface or subsurface strata), including any Law or regulation relating to
emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Exchange
Act</i></b>&#8221; means the Securities Exchange Act of 1934.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Exchange
Ratio</i></b>&#8221; means, subject to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(h)</span>, the result of the following calculation (rounded to four decimal
places): the number of the Parent Outstanding Shares divided by 0.5001 multiplied by 0.4749 divided by (the number of the Company Outstanding
Shares less the number of the Company Ordinary Shares set forth in the Parent Ownership Certificate); so that, in any event, immediately
following the Effective Time, holders of Company Outstanding Shares (other than the Parent) and Parent Pre-Funded Warrants issued hereunder
will hold together 49.99%, <i>minus</i> the Finder Fee, of the Parent Outstanding Shares, immediately following the Effective Time, all
which shall be calculated in accordance with the example of the calculation set forth in <span style="text-decoration:underline">Section &#8206;&#8206;1.6(a)</span> of the Parent
Disclosure Schedule.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Company
Outstanding Shares</i></b>&#8221; means subject to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(h)</span>, the total number of Company Ordinary Shares outstanding
immediately prior to the Effective Time expressed on a fully-diluted basis, but assuming, without limitation or duplication, Company
Warrants, and other outstanding options, warrants or rights to receive such shares, in each case, outstanding as of immediately prior
to the Effective Time, whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or
associated with the consummation of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Outstanding Shares</i></b>&#8221; means, subject to <span style="text-decoration:underline">Section &#8206;&#8206;1.5(h)</span>, the total number of Parent Ordinary Shares outstanding
immediately prior to the Effective Time expressed on a fully-diluted basis, including any shares or warrants issued in relation with
the Closing Financing(s) (solely to the extent consummated) and assuming, without limitation or duplication, the issuance of Parent Ordinary
Shares in respect of all Parent Equity Awards, Parent Warrants (but excluding Parent Warrants with an exercise price per Parent Ordinary
Share ranging between $68.38 to $637), and other outstanding options, warrants or rights to receive such shares, in each case, outstanding
as of immediately prior to the Effective Time, whether conditional or unconditional and including any outstanding options, warrants or
rights triggered by or associated with the consummation of the Merger.</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>"<b>Parent
Ownership Certificate</b></i>" shall have the meaning ascribed thereto in Section 5.16(c).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 234; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<b>Finder
Fee</b>&#8221;</i> means such amount: (i) of Parent Ordinary Shares equal to 2.5% of the Parent Outstanding Shares immediately following
the Effective Time, to be issued at the Effective Time to Merhavit M.R.M Holding and Management Ltd. by the Parent, on account of the
Company and (ii) VAT applicable thereto to be paid by the Company, all against appropriate tax invoice to be issued by Merhavit M.R.M
Holding and Management Ltd. to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<b>First
Motion Approval</b>&#8221;</i> shall have the meaning ascribed thereto in Section &#8206;5.1(a).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>GAAP</i></b>&#8221;
means generally accepted accounting principles and practices in effect from time to time within the United States applied consistently
throughout the period involved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Governmental
Authorization</i></b>&#8221; means any: (a) permit, license, certificate, franchise, permission, variance, exception, order, clearance,
registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental
Body or pursuant to any Law; or (b) right under any Contract with any Governmental Body.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Governmental
Body</i></b>&#8221; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of
any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation,
center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority); or
(d) self-regulatory organization (including Nasdaq).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Governmental
Grant</i></b>&#8221; means any grant, incentive, subsidy, award, participation, cost sharing arrangement, reimbursement arrangement,
including any application therefor, whether pending, approved, provided or made available by or on behalf of or under the authority of
the IIA, the Israeli Investment Center, the State of Israel, the BIRD Foundation, the European Union, the Fund for Encouragement of Marketing
Activities of the Israeli Government or any other Governmental Body.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Hazardous
Materials</i></b>&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable
or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject
to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and
petroleum products or by-products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Hevra
Le&#8217;Rishumim</i></b>&#8221; means Mizrahi Tefahot nominee company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>IFRS</i></b>&#8221;
means the international financial reporting standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>IIA</i></b>&#8221;
means the Israel Innovation Authority, formerly known as the Office of the Chief Scientist of the Ministry of Economy of the State of
Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Indemnification
Agreement</i></b>&#8221; means the agreement between the Parent and the members of Parent&#8217;s Board, in the form attached hereto
as <b><span style="text-decoration:underline">Exhibit G</span></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 235; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Innovation
Law</i></b>&#8221; means the Israeli Encouragement of Research, Development and Technological Innovation in the Industry Law, 5744-1984
(formerly known as the Israeli Encouragement of Research and Development in Industry Law, 5744-1984), and all rules and regulations thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Intellectual
Property Rights</i></b>&#8221; means and includes all past, present, and future rights of the following types, which may exist or be
created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation
rights, copyrights, moral rights, software, databases, and mask works; (b) trademarks, service marks, trade dress, logos, trade names
and other source identifiers, domain names and URLs and similar rights and any goodwill associated therewith; (c) rights associated with
trade secrets, know how, inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms
of technology; (d) patents and industrial property rights; and (e) other similar proprietary rights in intellectual property of every
kind and nature; (f) rights of privacy and publicity; and (g) all registrations, renewals, extensions, statutory invention registrations,
non-provisionals, continuations, continuations-in-part, provisionals, divisions, or reissues of, and applications for, any of the rights
referred to in clauses &#8220;(a)&#8221; through &#8220;(f)&#8221; above (whether or not in tangible form and including all tangible
embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same
through administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights
to sue or seek other remedies arising from or relating to the foregoing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>IRS</i></b>&#8221;
means the United States Internal Revenue Service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>ISA</i></b>&#8221;
means the Israel Securities Authority.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Israeli
Securities Law</i></b>&#8221; means the Israeli Securities Law, 5728-1968, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>ITA</i></b>&#8221;
means the Israel Tax Authority.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Knowledge</i></b>&#8221;
means, with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably
be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment or officer/director responsibilities.
Any Person that is an Entity shall have Knowledge if any officer or director of such Person as of the date such knowledge is imputed
has Knowledge of such fact or other matter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Law</i></b>&#8221;
means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law,
resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of Nasdaq or the Financial
Industry Regulatory Authority).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Legal
Proceeding</i></b>&#8221; means any action, suit, claim, litigation, arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard
by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Merger
Sub Board</i></b>&#8221; means the board of directors of Merger Sub.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 236; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Nasdaq</i></b>&#8221;
means the Nasdaq Stock Market, including the Nasdaq Capital Market or such other Nasdaq market on which Parent Ordinary Shares are then
listed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Ordinance</i></b>&#8221;
means the Israeli Income Tax Ordinance [New Version], 1961, and all rules and regulations promulgated thereunder, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Ordinary
Course of Business</i></b>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of
its normal operations and consistent with its past practices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Organizational
Documents</i></b>&#8221; means, with respect to any Person (other than an individual), (a) the articles of association or certificate
of incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company,
operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization
of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such
Person, in each case, as amended or supplemented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Associate</i></b>&#8221; means any current or former employee, independent contractor, officer or director of Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Balance Sheet</i></b>&#8221; means the audited balance sheet of Parent as of December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Board</i></b>&#8221; means the board of directors of Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Closing Price</i></b>&#8221; means the volume weighted average closing trading price of a Parent Ordinary Shares on Nasdaq for the five
consecutive trading days ending five trading days immediately prior to the date upon which the Merger becomes effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Contract</i></b>&#8221; means any Contract: (a) to which Parent is a party; (b) by which Parent or any Parent IP or any other asset of
Parent is or may become bound or under which Parent has, or may become subject to, any obligation; or (c) under which Parent has or may
acquire any right or interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Equity Awards</i></b>&#8221; means the Parent RSUs and the Parent Options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
102 Equity Awards</i></b>&#8221; means Parent Equity Awards that are granted and subject to Section 102(b)(2) and Section 102(b)(3) of
the Ordinance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Fundamental Representations</i></b>&#8221; means the representations and warranties of Parent and Merger Sub set forth in <span style="text-decoration:underline">Sections
&#8206;&#8206;3.1</span> (Due Organization; Subsidiaries), <span style="text-decoration:underline">&#8206;&#8206;3.3</span> (Authority; Binding Nature of Agreement), <span style="text-decoration:underline">&#8206;&#8206;3.4</span>
(Vote Required), &#8206;<span style="text-decoration:underline">3.6</span> (Capitalization) and <span style="text-decoration:underline">&#8206;&#8206;3.20</span> (No Financial Advisors).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
IP</i></b>&#8221; means all Intellectual Property Rights that are owned or purported to be owned by Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 237; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Material Adverse Effect</i></b>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to
the date of determination of the occurrence of a Parent Material Adverse Effect, has or would reasonably be expected to have a material
adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent, regardless
of whether or not such change constitutes a breach of the representations and warranties made by the Parent or Merger Sub in this Agreement;
<i>provided</i>, <i>however</i>, that Effects arising or resulting from the following shall not be taken into account in determining
whether there has been a Parent Material Adverse Effect: (a) changes or conditions generally affecting the industries or markets in which
Parent operates, and changes in the industries in which Parent operates regardless of geographic region (including legal and regulatory
changes), (b) acts of war, armed hostilities or terrorism, including the current ongoing war declared by Israel against Hamas, (c) changes
in financial, banking or securities markets, (d) any change in, or any compliance with or action taken for the purpose of complying with,
any Law or IFRS (or interpretations of any Law or IFRS), (e) resulting from the announcement of this Agreement or the pendency of the
Contemplated Transactions, (f) resulting from the taking of any action required to be taken by this Agreement, or (g) pandemics, including
any worsening thereof, man-made disasters, natural disasters, acts of God or other force majeure event, or (h) changes in U.S. or non-U.S.
general economic or political conditions, or in the financial, credit or securities markets in general, including any shutdown of any
Governmental Authority; except in each case with respect to clauses (a) through (c) and (h), to the extent disproportionately affecting
Parent, relative to other similarly situated companies in the industries in which Parent operates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Net Cash</i></b>&#8221; means, without duplication and including after taking into account the proceeds of the Closing Financing, a dollar
amount which may be greater than or lower than zero, equal to (a) the sum of Parent&#8217;s Cash and Cash Equivalents, in each case as
of the Anticipated Closing Date, <i><span style="text-decoration:underline">minus</span></i> (b) the sum of Parent&#8217;s short and long term liability or obligations accrued
at Closing (as reasonably and in good faith estimated by the Company) and <i><span style="text-decoration:underline">minus </span></i>(c) all fees and expenses incurred in connection
with this Agreement and the Contemplated Transactions (including but not limited to any investment bankers, financial advisors, attorneys,
accountants or other advisors, agents or representatives retained by Parent or any of its Subsidiaries) outstanding and not paid as of
the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Options</i></b>&#8221; means options or other rights granted by Parent to purchase Parent Ordinary Shares pursuant to the Parent Share
Plans or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Pre-Funded Warrant</i></b>&#8221; shall have the meaning ascribed thereto in Section <b><i>&#8206;</i></b>1.5(b).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8220;<b>Parent
RSUs</b></i>&#8221; means any restricted share unit award granted pursuant to the Parent Share Plans or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Share Capital</i></b>&#8221; means the Parent Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Share Plans</i></b>&#8221; means Parent&#8217;s (a) 2023 Share Incentive Plan, (b) Israeli Share Option Plan (2015), and (c) Israeli
Share Option Plan (2005).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Triggering Event</i></b>&#8221; shall be deemed to have occurred if: (a) Parent shall have failed to include in the Proxy Statement,
the Parent Board Recommendation or shall have made a Parent Board Adverse Recommendation Change; (b) the Parent Board or any committee
thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal (or shall have not publicly recommended against
any Acquisition Proposal that is a tender offer or exchange offer within five Business Days after the commencement thereof); or (c) Parent
shall have entered into any letter of intent or Contract or similar document contemplating or otherwise relating to any Acquisition Proposal
(other than a confidentiality agreement permitted pursuant to <span style="text-decoration:underline">Section &#8206;4.4</span>).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 238; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Parent
Warrants</i></b>&#8221; means all the warrants to purchase Parent Ordinary Shares outstanding immediately prior to the Effective Time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Party</i></b>&#8221;
or &#8220;<b><i>Parties</i></b>&#8221; means the Company, Merger Sub and Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Permitted
Encumbrance</i></b>&#8221; means: (a) any liens for current Taxes not yet due and payable or for Taxes that are being contested in good
faith and for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Balance Sheet, as applicable;
(b) minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract
from the value of the assets or properties subject thereto or materially impair the operations of the Company or Parent, as applicable;
(c) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements; (d) deposits or pledges
made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by
Law; (e) non-exclusive licenses of Intellectual Property Rights granted by the Company or Parent, as applicable, in the Ordinary Course
of Business and that do not (in any case or in the aggregate) materially detract from the value of the Intellectual Property Rights subject
thereto; (f) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or
supplies and (g) any restrictions imposed pursuant to the rules and regulations of the Securities Act, the Nasdaq, or applicable law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Person</i></b>&#8221;
means any individual, Entity or Governmental Body.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Proxy
Statement</i></b>&#8221; means the proxy statements to be sent to Parent&#8217;s shareholders in connection with the Parent Shareholders&#8217;
Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Registered
IP</i></b>&#8221; means all Intellectual Property Rights that are registered or issued under the authority of any Governmental Body,
including all patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, registered
domain names, and all applications for any of the foregoing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Registration
Statement</i></b>&#8221; means the Registration Statement on Form F-4 for the registration of the Parent Ordinary Shares, including the
Parent Ordinary Shares issuable upon exercise of Parent Pre-Funded Warrants, to be issued in connection with the Contemplated Transactions,
including the Proxy Statement contained therein and any and all amendments and supplements to such registration statement, in each case
including a prospectus contained therein, all exhibits thereto and any document incorporated by reference therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Representatives</i></b>&#8221;
means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 239; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Required
Company Approval</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;2.4.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Required
Parent Shareholder Vote</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;3.4.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Sarbanes-Oxley
Act</i></b>&#8221; means the Sarbanes-Oxley Act of 2002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>SEC</i></b>&#8221;
means the United States Securities and Exchange Commission.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Securities
Act</i></b>&#8221; means the Securities Act of 1933, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
entity shall be deemed to be a &#8220;<b><i>Subsidiary</i></b>&#8221; of a Person if such Person directly or indirectly owns or purports
to own, beneficially or of record, (a) an amount of voting securities or other interests in such entity that is sufficient to enable
such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body, or (b) at
least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Series
B Bonds</i></b>&#8221; means the Series B bonds of the Company, par value NIS 1.00 each.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Surviving
Company</i></b>&#8221; shall have the meaning ascribed thereto in Section &#8206;1.1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>TASE</i></b>&#8221;
means the Tel Aviv Stock Exchange Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Tax</i></b>&#8221;
or &#8220;<b><i>Taxes</i></b>&#8221; means: (a) any federal, state, local, foreign or other tax, including any income, capital gain,
gross receipts, share capital, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty,
ad valorem, occupancy, occupation, alternative, add-on, windfall profits, value added, severance, property, business, production, sales,
use, license, excise, franchise, employment, payroll, social security, disability, unemployment, workers&#8217; compensation, national
health insurance, withholding or other taxes, duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof of
any kind whatsoever, however denominated, and including any fine, penalty, addition to tax or interest imposed by a Governmental Body
with respect thereto (b) any liability for the payment of any amounts of the type described in clause (a) as a result of being a member
of an affiliated, consolidated, combined, unitary or similar group (including any arrangement for group or consortium relief or similar
arrangement) for any period, and (c) any liability for the payment of any amounts of the type described in clauses (a) or (b) as a result
of any express or implied obligation to indemnify any other Person or as a result of any obligation under any agreement or arrangement
with any other Person with respect to such amounts and including any liability for taxes of a predecessor or transferor or otherwise
by operation of Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 240; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Tax
Return</i></b>&#8221; means any return (including any information return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document, and any amendment or supplement to any of the foregoing, filed with or submitted
to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection
or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating
to any Tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Transfer
Agent</i></b>&#8221; means Computershare Inc. the current transfer agent of the Purchaser, with a mailing address of 480 Washington Blvd,
Jersey City, NJ 07310, email Brian.Cossin@computershare.com, and any successor transfer agent of the Parent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Treasury
Regulations</i></b>&#8221; means the United States Treasury regulations promulgated under the Code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Valid
Tax Certificate</i></b>&#8221; means a valid certificate, ruling or any other written instructions regarding Tax withholding, issued
by the ITA in form and substance reasonably satisfactory to Parent, that is applicable to the payments to be made to any holder of securities
of the Company pursuant to this Agreement stating that no withholding, or reduced withholding, of Tax is required under Israeli law with
respect to such payment or providing other instructions regarding such payment or withholding. For purposes hereof, the Withholding Tax
Ruling and the 104H Ruling will be considered a Valid Tax Certificate, provided they include such instructions, and further provided
that if the applicable ruling requires the affirmative consent of the relevant holder, such holder consented in writing to join any such
applicable ruling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>VAT</i></b>&#8221;
means Value Added Tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Withholding
Agent</i></b>&#8221; means a bank or trust company in Israel appointed, if necessary, by the Parent reasonably acceptable to the Company
to act as Parent&#8217;s withholding agent for Israeli tax withholding purposes and taking such other actions with respect to, Israeli
Tax, as stipulated in <span style="text-decoration:underline">Section </span>1.10.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#8220;<b><i>Withholding
Tax Ruling</i></b>&#8221; means a ruling (i) </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exempting
from or deferring Israeli Tax on any consideration payable to each Payee which holds less than 5% in the Company share capital on a date
which is ten (10) days prior to the Closing Date (a &#8220;<b><i>Less Than 5% Payee</i></b>&#8221;), pursuant to this Agreement, to such
time as determined in the Withholding Tax Ruling, or (ii) instructing the Payor and its agents on how such withholding is to be executed
from the payment of such consideration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 241; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><div><a id="sc_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">addendum
no. 1<br/>
<i>to<br/>
</i><span style="text-decoration:underline">AGREEMENT AND PLAN OF MERGER</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">This addendum, dated August
14, 2024 (the &#8220;<b>Effective Date</b>&#8221;) constitutes addendum no. 1 (the &#8220;<b>Addendum</b>&#8221;) to that certain Agreement
and Plan Of Merger dated April 10, 2024 (hereinafter together, the &#8220;<b>Agreement</b>&#8221;), by and between, SciSparc Ltd., an
Israeli limited company (the &#8220;<b><i>Parent</i></b>&#8221;), SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned
subsidiary of Parent (&#8220;<b><i>Merger Sub</i></b>&#8221;), and AutoMax Motors Ltd., an Israeli limited company (the &#8220;<b><i>Company</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>WHEREAS</b>
the Parties wish to modify and amend certain provisions set forth in the Agreement, all as further stipulated herein.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>NOW
THEREFORE,</b> the parties hereto agree to amend the Agreement as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">1.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">Amendment
                                            of End Date</span>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 0.25in; text-align: justify; text-indent: 0in">Notwithstanding
Section 9.1(b) of the Agreement, the End Date shall be extended from August 30, 2024, to November 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 21.3pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">2.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">General</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 28.35pt">2.1.</td><td style="text-align: justify; padding-right: 4.25pt">Any
                                            and all provisions, terms and/or conditions contained in the Agreement shall continue in
                                            full force and effect, unless and to the extent otherwise expressly provided herein which
                                            provisions will supersede any such provisions of the Agreement. In the event of a conflict
                                            or inconsistency between the terms of the Agreement, previous addendums/amendments (if any),
                                            and the terms of this Addendum, the terms of the latter shall govern and prevail.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 28.35pt">2.2.</td><td style="text-align: justify; padding-right: 4.25pt">This
                                            Addendum shall be deemed for all intents and purposes an integral part of the Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 28.35pt">2.3.</td><td style="text-align: justify; padding-right: 4.25pt">Terms
                                            used but not defined herein shall have the meanings assigned to such terms in the Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>[Signature page to follow]</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 242; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF,</b> the undersigned have
caused this Addendum to be executed as of the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>SCISPARC
    LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>SCISPARC MERGER
    SUB LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>AUTOMAX MOTORS
    LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">/s/ Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:
    </span></td>
    <td style="text-align: justify">Tomer Levy</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yaarah Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:
    </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaarah Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 243; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="sc_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">addendum
no. 2<br/>
<i>to<br/>
</i><span style="text-decoration:underline">AGREEMENT AND PLAN OF MERGER</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">This addendum, dated November
26, 2024 (the &#8220;<b>Effective Date</b>&#8221;) constitutes addendum no. 2 (the &#8220;<b>Addendum</b>&#8221;) to that certain Agreement
and Plan Of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024 (hereinafter together, the &#8220;<b>Agreement</b>&#8221;),
by and between, SciSparc Ltd., an Israeli limited company (the &#8220;<b><i>Parent</i></b>&#8221;), SciSparc Merger Sub Ltd., an Israeli
limited company and wholly-owned subsidiary of Parent (&#8220;<b><i>Merger Sub</i></b>&#8221;), and AutoMax Motors Ltd., an Israeli limited
company (the &#8220;<b><i>Company</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -63.8pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>WHEREAS</b> the Parties
wish to modify and amend certain provisions set forth in the Agreement, all as further stipulated herein.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -63.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOW THEREFORE,</b> the parties hereto agree
to amend the Agreement as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0in"/><td style="text-align: justify; width: 0.25in">1.</td><td style="text-align: justify"><span style="text-decoration:underline">Amendment
                                            of End Date</span>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in">Notwithstanding
Section 9.1(b) of the Agreement, the End Date shall be extended from November 30, 2024, to March 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0%"/><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify"><span style="text-decoration:underline">General</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">2.1.</td><td style="text-align: justify">Any
                                            and all provisions, terms and/or conditions contained in the Agreement shall continue in
                                            full force and effect, unless and to the extent otherwise expressly provided herein which
                                            provisions will supersede any such provisions of the Agreement. In the event of a conflict
                                            or inconsistency between the terms of the Agreement, previous addendums/amendments (if any),
                                            and the terms of this Addendum, the terms of the latter shall govern and prevail.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">2.2.</td><td style="text-align: justify">This
                                            Addendum shall be deemed for all intents and purposes an integral part of the Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">2.3.</td><td style="text-align: justify">Terms
                                            used but not defined herein shall have the meanings assigned to such terms in the Agreement.
                                            	</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>[Signature page to follow]</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 244; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF,</b> the undersigned have
caused this Addendum to be executed as of the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>SCISPARC
    LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 60%"/>
    <td style="text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>SCISPARC
    MERGER SUB LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>AUTOMAX
    MOTORS LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"/>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Tomer Levi</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tomer Levi</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"/>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yaara Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yaara Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Chief
    Financial Officer</span></td></tr>
  </table><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 245; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="sc_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">addendum
no. 3<br/>
<i>to<br/>
</i><span style="text-decoration:underline">AGREEMENT AND PLAN OF MERGER</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">This addendum, dated March
27, 2025 (the &#8220;<b>Effective Date</b>&#8221;) constitutes addendum no. 3 (the &#8220;<b>Addendum</b>&#8221;) to that certain Agreement
and Plan Of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024, and Addendum No. 2 dated November 26, 2024
(hereinafter together, the &#8220;<b>Agreement</b>&#8221;), by and between, SciSparc Ltd., an Israeli limited company (the &#8220;<b><i>Parent</i></b>&#8221;),
SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of Parent (&#8220;<b><i>Merger Sub</i></b>&#8221;),
and AutoMax Motors Ltd., an Israeli limited company (the &#8220;<b><i>Company</i></b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 63.8pt"><b>WHEREAS</b></td><td style="text-align: justify">the Parties wish to modify
                                            and amend certain provisions set forth in the Agreement, all as further stipulated herein.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOW THEREFORE,</b> the parties hereto agree
to amend the Agreement as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">1.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">Amendment
                                            of End Date</span>:</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 21.3pt; text-align: justify; text-indent: 0in">Notwithstanding
Section 9.1(b) of the Agreement, the End Date shall be extended from March 31, 2025, to September 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.3pt 0pt 21.3pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">2.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">Amendment
                                            of Exhibit A &#8211; Certain Definitions:</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The definition of &#8220;Exchange
Ratio&#8221; shall revised as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#8220;<b><i>Exchange Ratio</i></b>&#8221;
means, subject to Section <span style="font-family: Times New Roman, Times, Serif">&#8206;&#8206;</span>1.5(h), the result of the following
calculation <span style="text-decoration:line-through">(rounded to four decimal places)</span>: the number of the Parent Outstanding Shares divided by 0.5001 multiplied
by 0.4749 divided by (the number of the Company Outstanding Shares less the number of the Company Ordinary Shares set forth in the Parent
Ownership Certificate); so that, in any event, immediately following the Effective Time, holders of Company Outstanding Shares (other
than the Parent) and Parent Pre-Funded Warrants issued hereunder will hold together 49.99%, minus the Finder Fee, of the Parent Outstanding
Shares, immediately following the Effective Time, all which shall be calculated in accordance with the example of the calculation set
forth in Section <span style="font-family: Times New Roman, Times, Serif">&#8206;&#8206;</span>1.6(a) of the Parent Disclosure Schedule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">3.</td><td style="text-align: justify; padding-right: 35.4pt"><span style="text-decoration:underline">General</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.1.</td><td style="text-align: justify">Any and all
                                            provisions, terms and/or conditions contained in the Agreement shall continue in full force
                                            and effect, unless and to the extent otherwise expressly provided herein which provisions
                                            will supersede any such provisions of the Agreement. In the event of a conflict or inconsistency
                                            between the terms of the Agreement, previous addendums/amendments (if any), and the terms
                                            of this Addendum, the terms of the latter shall govern and prevail.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.2.</td><td style="text-align: justify; padding-right: 4.25pt">This
                                            Addendum shall be deemed for all intents and purposes an integral part of the Agreement.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.3.</td><td style="text-align: justify; padding-right: 4.25pt">Terms
                                            used but not defined herein shall have the meanings assigned to such terms in the Agreement.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>[Signature page to follow]</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 246; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF,</b> the undersigned have
caused this Addendum to be executed as of the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white"><b>SCISPARC LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; width: 35%; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white"><b>SCISPARC
    MERGER SUB LTD.</b></span></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white"><b>AUTOMAX
    MOTORS LTD.</b></span></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Tomer Levi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name: </span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Tomer Levi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Yaara Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name: </span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Yaara Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 247; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><div><a id="sc_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">addendum
no. 4<br/>
<i>to<br/>
</i><span style="text-decoration:underline">AGREEMENT AND PLAN OF MERGER</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">This addendum, dated May
8, 2025 (the &#8220;<b>Effective Date</b>&#8221;) constitutes Addendum No. 4 (the &#8220;<b>Addendum</b>&#8221;) to that certain Agreement
and Plan of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024, Addendum No. 2 dated November 26, 2024,
and Addendum No. 3 dated March 27, 2025 (together with Addendums, the &#8220;<b>Agreement</b>&#8221;), by and between, SciSparc Ltd.,
an Israeli limited company (the &#8220;<b>Parent</b>&#8221;), SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary
of Parent (&#8220;<b>Merger Sub</b>&#8221;), and AutoMax Motors Ltd., an Israeli limited company (the &#8220;<b>Company</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -63.8pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>WHEREAS</b>
the Parties wish to modify and amend certain provisions set forth in the Agreement, all as further stipulated herein.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -63.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"><b>NOW THEREFORE,</b> the
parties hereto agree to amend the Agreement as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify"><span style="text-decoration:underline">Amendment of
                                            Exhibit A &#8211; Certain Definitions:</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 21.3pt; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.75in; text-align: justify; text-indent: -35.4pt">The definition
of &#8220;Bondholders&#8221; in Exhibit A to the Agreement shall be amended to read as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#8220;<b><i>Bondholders</i></b>&#8221;
means holders of the Company&#8217;s Series B Bonds, and holders of the Company&#8217;s contemplated Series C bonds, which upon their
issuance (when and if so issued) shall be traded on TASE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify"><span style="text-decoration:underline">General</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.1.</td><td style="text-align: justify">Any and all
                                            provisions, terms and/or conditions contained in the Agreement shall continue in full force
                                            and effect, unless and to the extent otherwise expressly provided herein which provisions
                                            will supersede any such provisions of the Agreement. In the event of a conflict or inconsistency
                                            between the terms of the Agreement, previous addendums/amendments (if any), and the terms
                                            of this Addendum, the terms of the latter shall govern and prevail.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 49.6pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.2.</td><td style="text-align: justify">This Addendum
                                            shall be deemed for all intents and purposes an integral part of the Agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 49.6pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.3.</td><td style="text-align: justify">Terms used
                                            but not defined herein shall have the meanings assigned to such terms in the Agreement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 49.6pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>[Signature page to
follow]</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 248; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF,</b> the undersigned have
caused this Addendum to be executed as of the Effective Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white"><b>SCISPARC LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; width: 35%; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name:&#160;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="background-color: white"><b>SCISPARC MERGER SUB LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="background-color: white"><b>AUTOMAX MOTORS LTD.</b></span> &#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt">/s/ Tomer Levi</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name: </span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Tomer Levi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td>Director &#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: justify; font-size: 10pt"><span style="font-size: 10pt">/s/
    Yaara Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Name: </span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Yaara Alfi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt; background-color: white">Title:</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 249; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><div><a id="B_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ANNEX
B</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: normal"><i>Execution
Copy</i></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SHAREHOLDER SUPPORT AGREEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Shareholder Support
Agreement, dated as of April 10, 2024 (this &#8220;<b>Agreement</b>&#8221;), is entered into by and among SciSparc Ltd., an Israeli limited
company (the &#8220;<b>Parent</b>&#8221;) and each of the shareholders of AutoMax Motors Ltd. (the &#8220;<b>Company</b>&#8221;) listed
on <span style="text-decoration:underline">Schedule I</span> hereto (the &#8220;<b>Shareholders</b>&#8221;).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">W I T N E S S E T H:</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, Parent, SciSparc
Merger Sub Ltd., a company organized under the laws of the State of Israel and a wholly-owned subsidiary of Parent (&#8220;<b>Merger
Sub</b>&#8221;), and the Company are concurrently with this Agreement entering into that certain Agreement and Plan of Merger a copy
of which was provided to the Shareholders (the &#8220;<b>Merger Agreement</b>&#8221;), pursuant to which, among other things, at the
Effective Time, Merger Sub will merge with and into the Company, with the Company continuing as the Surviving Company and a wholly owned
subsidiary of Parent on the terms and conditions set forth in the Merger Agreement (the &#8220;<b>Merger</b>&#8221;) on the terms and
subject to the conditions set forth in the Merger Agreement and by way of a court approved arrangement between the Company and its shareholders
and, if applicable, its creditors and bondholders, in accordance with the provisions of Sections 350 and 351 of the Companies Law 5759-1999
of the State of Israel (together with the rules and regulations promulgated thereunder, the &#8220;<b>Companies Law</b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, each Shareholder,
as of the date hereof, holds or Beneficially Owns its Existing Shares; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, as a condition
and material inducement to the Parent&#8217;s willingness to enter into the Merger Agreement and to consummate the transactions contemplated
thereby, including the Merger, the Shareholders have agreed to enter into this Agreement, pursuant to which the Shareholders are agreeing,
among other things, to vote all of their Covered Shares in accordance with the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the mutual representations, warranties, covenants and agreements contained herein, and intending to be legally bound
hereby, the parties hereto hereby agree as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE I<span style="font-size: 10pt"><br/>
<br/>
GENERAL</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Defined
Terms</span>. Each of the following capitalized terms, as used in this Agreement, shall have the meaning set forth below next to such term.
Each capitalized term used but not otherwise defined in this Agreement shall have the meaning ascribed thereto in the Merger Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Beneficial
Ownership</span>&#8221; the ownership of Company Shares, including Company Shares of which a Shareholder directly or indirectly, through
any contract, arrangement, understanding, relationship, or otherwise has or shares the power to vote or direct the voting of, or the
power to dispose or to direct the disposition of, such Company Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Company
Shares</span>&#8221; means ordinary shares, par value NIS 0.05 per share, of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Covered
Shares</span>&#8221; means each Shareholder&#8217;s Existing Shares, together with any Company Shares or other voting share capital of Company
issuable upon the conversion, exercise or exchange of securities that are, as of the relevant date, convertible into or exercisable or
exchangeable for Company Shares or other voting share capital of Company, and any other Company Shares or other voting share capital
of Company, in each case that such Shareholder has or acquires Beneficial Ownership of on or after the date hereof and prior to the termination
of this Agreement (including by means of purchase, dividend or distribution, or upon the exercise of any stock options, warrants or other
rights).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 250; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Existing
Shares</span>&#8221; means the Company Shares Beneficially Owned by such Shareholder as of the date hereof. Each Shareholder represents
and warrants that all of the Existing Shares owned by such Shareholder are as set forth in <span style="text-decoration:underline">Exhibit B</span> hereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Expiration
Date</span>&#8221; means any date upon which the Merger Agreement is validly terminated (for any reason) in accordance with its terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Permitted
Transfer</span>&#8221; means a Transfer of Covered Shares by any Shareholder to a Permitted Transferee, <i>provided</i> that (i) the transferee
remains a Permitted Transferee of such Shareholder at all times following such Transfer until the termination of this Agreement in accordance
with Section 5.1 hereof; <i>provided further</i>, that prior to the effectiveness of such Transfer (A) written notice of such Transfer
is delivered to Parent in accordance with <b>&#8206;</b><span style="text-decoration:underline">Section 5.4</span>, and (B) such transferee executes and delivers to the Parent
a joinder to this Agreement in the form attached hereto as <span style="text-decoration:underline">Exhibit A</span>, pursuant to which such transferee agrees to assume all of
such Shareholder&#8217;s obligations hereunder in respect of the securities subject to such Transfer and to be bound by the terms of
this Agreement, with respect to the securities subject to such Transfer, to the same extent as such Shareholder is bound hereunder and
to make each of the representations and warranties in respect of the securities Transferred as such Shareholder shall have made hereunder
(the &#8220;<span style="text-decoration:underline">Joinder Agreement</span>&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Permitted
Transferee</span>&#8221; means transfers of a Shareholder&#8217;s Covered Shares as <i>bona fide </i>charitable contributions, gifts or
donations, (ii) transfers or dispositions of a Shareholder&#8217;s Covered Shares to an immediate family member of such Shareholder or
to any trust for the direct or indirect benefit of the Shareholder or the immediate family of such Shareholder, (iii) transfers or dispositions
of a Shareholder&#8217;s Covered Shares by will, other testamentary document or intestate succession to the legal representative, heir,
beneficiary or a member of the immediate family of such Shareholder, (iv) if a Shareholder is a partnership, limited liability company,
corporation or other entity, transfers of such Shareholder&#8217;s Covered Shares to the shareholders, partners (general or limited),
members, managers, other equity holders or affiliates of such Shareholder, as applicable, or to the estates of any such shareholders,
partners, members, managers, other equity holders or affiliates, or to another corporation, partnership, limited liability company or
other entity that controls, is controlled by or is under common control with such Shareholder or with any of such Shareholder&#8217;s
partners, members, managers or other equity holders or affiliates (v) transfers that occur by operation of law pursuant to a qualified
domestic relations order or in connection with a divorce settlement, (vi) transfers or dispositions not involving a change in beneficial
ownership, and (vii) if a Shareholder is a trust, transfers or dispositions to any beneficiary of such Shareholder or the estate of any
such beneficiary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="font-size: 10pt">&#8220;<span style="text-decoration:underline">Transfer</span>&#8221;
means, directly or indirectly, to sell, transfer, assign, pledge, encumber, hypothecate, convey any legal or beneficial interest in,
or otherwise dispose of (by merger (including by conversion into securities or other consideration), by tendering into any tender or
exchange offer, by testamentary disposition, by operation of Law or otherwise), either voluntarily or involuntarily, or to enter into
any Contract or other arrangement or understanding with respect to the voting of or sale, transfer, assignment, pledge, encumbrance,
hypothecation, conveyance of any direct or indirect legal or beneficial interest in, or other disposition of (by merger, by tendering
into any tender or exchange offer, by testamentary disposition, by operation of Law or otherwise) the Covered Shares.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 251 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE II<span style="font-size: 10pt"><br/>
<br/>
VOTING</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Agreement
to Vote</span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">Each
Shareholder hereby irrevocably and unconditionally agrees that during the period beginning on the date hereof and ending upon the termination
of this Agreement in accordance with its terms, at any meeting of the Company&#8217;s Shareholders, however called, including any adjournment
or postponement thereof, such Shareholder shall, in each case, to the fullest extent that such matters are submitted for the vote of
the Company Shareholders and that the Covered Shares are entitled to vote thereon or consent thereto:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">appear
at each such meeting or otherwise cause all of its Covered Shares to be counted as present for purposes of calculating a quorum; and
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">vote
(or cause to be voted), in person or by a proxy covering all of its Covered Shares (A) in favor of (1) the approval of the Merger and
the other transactions contemplated by the Merger Agreement; (2) any action in connection with the Merger and the Contemplated Transactions;
or (3) any proposal to adjourn or postpone to a later date any meeting of the Company&#8217;s Shareholders at which any of the foregoing
matters of this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.1(a)(ii)</span> are submitted for consideration and vote of the Company Shareholders if
there are not sufficient votes for approval of any such matters on the date on which the meeting is held, and (B) against (1)&#160;any
Acquisition Proposal or Acquisition Inquiry; (2)&#160;any other action, proposal, transaction or agreement involving Company that is
intended or would reasonably be expected to have the effect of frustrating the purposes of the Merger or preventing, impeding, interfering
with, delaying, postponing or impairing the ability of the Company, Parent or Merger Sub to consummate the Merger or any other transaction
contemplated by the Merger Agreement; or (3)&#160;any action or Contract that would be expected to result in any condition to the consummation
of the Merger set forth in Sections 6, 7 or 8 of the Merger Agreement not being fulfilled on or prior to the End Date. No Shareholder
shall enter into any Contract with any Person prior to the termination of this Agreement to vote in any manner inconsistent herewith.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt">Any
vote required to be cast or consent required to be executed pursuant to this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.1</span> shall be cast (or
consent shall be given if legally valid) by such Shareholder in accordance with such procedures relating thereto so as to ensure that
it is duly counted, including for purposes of determining whether a quorum is present.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt">Except
as explicitly set forth in this <span style="text-decoration:underline">Section 2.1</span>, nothing in this Agreement shall limit the right of each Shareholder to vote in favor
of, against or abstain with respect to any other matters presented to the Company Shareholders. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="font-size: 10pt">The
obligations of each Shareholder specified in this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.1</span> shall not be affected by the commencement, public
proposal, public disclosure or communication to Company of any Acquisition Proposal, Acquisition Inquiry or by any Company Board Adverse
Recommendation Change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 252 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Grant
of Irrevocable Proxy; Appointment of Proxy.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">From
and after the date hereof until the Expiration Date, each Shareholder hereby irrevocably and unconditionally grants to, and appoints,
the Parent as such Shareholder&#8217;s proxy and attorney-in-fact (with full power of substitution) in accordance with the Companies
Law, for and in the name, place and stead of such Shareholder, to attend any and all meetings of the Company&#8217;s Shareholders and
to vote or cause to be voted (including by proxy) the Covered Shares in accordance with this Agreement; <span style="text-decoration:underline">provided</span> that each Shareholder&#8217;s
grant of the proxy contemplated by this <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.2</span> shall be effective if, and only if, such Shareholder has
failed to act in accordance with such Shareholder&#8217;s obligations as to voting pursuant to <span style="text-decoration:underline">Section 2.1</span> of this Agreement by
delivering to Company at least 5 business days prior to the meeting at which any of the matters described in <b>&#8206;</b><span style="text-decoration:underline">Section 2.1
</span>are to be considered, a duly executed irrevocable proxy card directing that the Covered Shares of such Shareholder be voted in accordance
with this Agreement. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">Each
Shareholder hereby represents that any proxies heretofore given in respect of the Covered Shares, if any, are revocable, and hereby revokes
all such proxies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">Each
Shareholder hereby affirms that the irrevocable proxy set forth in <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 2.2</span>, if it becomes effective, is
given in connection with the execution of the Merger Agreement, and that such irrevocable proxy is given to secure the performance of
the duties of such Shareholder under this Agreement. The parties hereby further affirm that the irrevocable proxy, if it becomes effective,
is coupled with an interest and is intended to be irrevocable until the Expiration Date, at which time it will terminate automatically,
at which time any underlying appointment shall automatically be revoked and rescinded and of no force and effect, in each case without
further action by any party. The proxy granted by the Shareholders herein shall survive the dissolution, bankruptcy, death or incapacity
of any Shareholder. If for any reason any proxy granted herein is not irrevocable after it becomes effective, then the Shareholder granting
such proxy agrees, until the Expiration Date, to vote, or to cause the holder of record on any applicable record date to vote, the Covered
Shares in accordance with this Agreement. The parties agree that the foregoing is a voting agreement.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE III<span style="font-size: 10pt"><br/>
<br/>
REPRESENTATIONS AND WARRANTIES </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Representations
and Warranties of Each Shareholder</span>. Each Shareholder hereby represents and warrants to Parent and the Company, as of the date hereof,
and at all times during the term of this Agreement, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Authorization</span>.
Such Shareholder has the power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby. The execution and delivery by such Shareholder of this Agreement, the performance by it of its
obligations hereunder and the consummation by it of the transactions contemplated hereby have been duly and validly authorized by all
necessary action on the part of such Shareholder and no other actions or proceedings on the part of such Shareholder are necessary to
authorize the execution and delivery by it of this Agreement, the performance by it of its obligations hereunder or the consummation
by it of the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by such Shareholder and,
assuming this Agreement constitutes a valid and binding obligation of Parent, constitutes a legal, valid and binding obligation of such
Shareholder, enforceable against it in accordance with its terms (except to the extent that enforceability may be limited by the Enforceability
Exceptions).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 253 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Ownership</span>.
Such Shareholder&#8217;s Existing Shares are, and all Covered Shares of such Shareholder from the date hereof through and on the Closing
Date will be, Beneficially Owned and owned of record by such Shareholder or by a Permitted Transferee. Except as set forth in Schedule<b>&#8206;&#8206;&#8206;
</b>3.1(b), such Shareholder has good and valid title to such Shareholder&#8217;s Existing Shares, free and clear of any Encumbrances
(except for transfer restrictions arising under securities Laws). Except as set forth in Schedule<b>&#8206;&#8206;&#8206;</b> 3.1(b1), other
than the Existing Shares, as of the date hereof such Shareholder does not Beneficially Own or own of record: (i)&#160;any securities
of Company convertible into or exchangeable or exercisable for shares of the share capital or other voting securities or equity interests
of Company; (ii)&#160;any warrants, calls, options or other rights to acquire from Company any share capital, voting securities, equity
interests or securities convertible into or exchangeable or exercisable for share capital or voting securities of Company, or any stock
appreciation rights; (iii)&#160;&#8220;phantom&#8221; stock rights, performance units or other rights to receive Company Shares (or cash
or other economic benefit in respect thereof) on a deferred basis; or (iv) other rights that are linked to the value of Company Shares.
As of the date hereof, such Shareholder&#8217;s Existing Shares constitute all of the Company Shares that are Beneficially Owned or owned
of record by such Shareholder. Such Shareholder has and will have at all times through the Effective Time sole voting power (including
the right to control such vote as contemplated herein), sole power of disposition, sole power to issue instructions with respect to the
matters set forth in <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">ARTICLE II</span> and sole power to agree to all of the matters set forth in this Agreement,
in each case with respect to all of such Shareholder&#8217;s Existing Shares and with respect to all of the Covered Shares owned by such
Shareholder at all times through the Effective Time. Each Shareholder hereby represents that all proxies, powers of attorney, instructions
or other requests given by such Shareholder prior to the execution of this Agreement in respect of the voting of such Shareholder&#8217;s
Covered Shares, if any, are revocable by such Shareholder at any time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">No
Violation</span>. The execution, delivery and performance of this Agreement by such Shareholder does not and will not, and the consummation
of the transactions contemplated hereby and the compliance with the provisions hereof do not and will not (in each case, whether with
or without notice or lapse of time, or both):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any provision of the Organizational Documents of such Shareholder (to the extent such Shareholder
is not a natural Person);</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any of the terms or conditions of, result in any (or the right to make any) modification of
or the cancellation or loss of a benefit under, require any notice, consent or action under, or otherwise give any Person the right to
terminate, accelerate obligations under or receive payment or additional rights under, or constitute a default under, any Contract to
which such Shareholder is a party or by which it is bound; </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;<span style="font-size: 10pt">require
any consent of, approval, authorization or permit of, filing with or license from or registration, declaration or notification to any
Governmental Body (except for filings, if any, under the Israeli Securities Law, 5728-1968 or the Companies Law); or </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;<span style="font-size: 10pt">violate
or conflict with any Law applicable to such Shareholder or by which any of such Shareholder&#8217;s assets or properties is bound.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except under the Organizational Documents of
Company and as set forth by such Shareholder&#8217;s name in <span style="text-decoration:underline">Exhibit B</span>, such Shareholder&#8217;s Existing Shares are not, with
respect to the voting or Transfer thereof, subject to any other Contract (other than a Contract for Transfer of Existing Shares to a
Permitted Transferee), including any voting agreement, shareholders agreement, irrevocable proxy or voting trust.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Absence
of Litigation</span>. There is no Legal Proceeding pending or, to the knowledge of such Shareholder, threatened by, against, involving or
affecting such Shareholder or the Covered Shares, that would reasonably be expected to impair the ability of such Shareholder to perform
its obligations hereunder or to consummate the transactions contemplated hereby on a timely basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Reliance
by the Parent</span>. Such Shareholder understands and acknowledges that the Parent is entering into the Merger Agreement in reliance upon
the execution and delivery of this Agreement by such Shareholder and the representations, warranties, covenants and agreements of such
Shareholder contained herein and that the same are a material inducement thereto. Such Shareholder understands and acknowledges that
the Merger Agreement governs the terms of the Merger and the other transactions contemplated by the Merger Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 254 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="font-size: 10pt; background-color: white">&#160;</span><span style="font-size: 10pt"><span style="text-decoration:underline">Independent
Advice</span><span style="background-color: white">. </span>Such Shareholder has carefully reviewed the Merger Agreement, the other documentation
relating to the Merger and other transactions contemplated in the Merger Agreement referred to therein and this Agreement and has had
an opportunity to discuss the Merger Agreement, such other documentation and this Agreement with an attorney of his, her or its own choosing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Representations
and Warranties of the Parent</span>. The Parent hereby represents and warrants to the Shareholders, as of the date hereof, and at all times
during the term of this Agreement, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Authorization</span>.
The Parent has the power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby. The execution and delivery by the Parent of this Agreement, the performance by the Parent of its
obligations hereunder and the consummation by the Parent of the transactions contemplated hereby have been duly and validly authorized
by all necessary action on the part of the Parent and no other actions or proceedings on the part of the Parent are necessary to authorize
the execution and delivery by the Parent of this Agreement, the performance by the Parent of its obligations hereunder or the consummation
by the Parent of the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Parent
and, assuming this Agreement constitutes a valid and binding obligation of the other parties hereto, constitutes a legal, valid and binding
obligation of the Parent, enforceable against the Parent in accordance with its terms (except to the extent that enforceability may be
limited by the Enforceability Exceptions).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">No
Violation</span>. The execution, delivery and performance of this Agreement by the Parent does not and will not, and the consummation of
the transactions contemplated hereby and the compliance with the provisions hereof do not and will not (in each case, whether with or
without notice or lapse of time, or both):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any provision of the Organizational Documents of the Parent;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#160;<span style="font-size: 10pt">violate,
conflict with or result in the breach of any of the terms or conditions of, result in any (or the right to make any) modification of
or the cancellation or loss of a benefit under, require any notice, consent or action under, or otherwise give any Person the right to
terminate, accelerate obligations under or receive payment or additional rights under, or constitute a default under, any Contract to
which the Parent is a party or by which the Parent is bound; </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#160;<span style="font-size: 10pt">require
any consent of, approval, authorization or permit of, filing with or license from or registration, declaration or notification to any
Governmental Entity (except for filings, if any, under the Exchange Act, the Israeli Securities Law, 5728-1968 or the Companies Law);
or </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#160;<span style="font-size: 10pt">violate
or conflict with any Law applicable to the Parent or by which any of the Parent&#8217;s assets or properties is bound.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt"><span style="text-decoration:underline">Absence
of Litigation</span>. There is no Legal Proceeding pending or, to the knowledge of the Parent, threatened by, against, involving or affecting
the Parent that would reasonably be expected to impair the ability of the Parent to perform its obligations hereunder or to consummate
the transactions contemplated hereby on a timely basis.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 255 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE IV<span style="font-size: 10pt"><br/>
<br/>
OTHER COVENANTS</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">No
Solicitation</span>. Each Shareholder shall not (a)&#160;engage or participate in, or knowingly facilitate, any discussions or negotiations
regarding any Acquisition Proposal of the Company, (b)&#160;furnish to any Person other than the Company or Parent any non-public information
that could reasonably be expected to be used for the purposes of formulating any Acquisition Proposal of the Company, or (c)&#160;enter
into any letter of intent, agreement in principle or other similar type of agreement relating to any Acquisition Proposal of Company.
If prior to the Expiration Date, any Shareholder receives an Acquisition Proposal, then such Shareholder will promptly notify the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Prohibition
on Transfers; Other Actions</span>. During the term of this Agreement, each Shareholder hereby agrees not to (a) Transfer any of the Covered
Shares, Beneficial Ownership thereof or any other interest therein (including by tendering into a tender or exchange offer), unless such
Transfer is a Permitted Transfer; (b) grant any proxy, consent or power of attorney with respect to any of the Covered Shares or deposit
any of the Covered Shares into a voting trust or enter into a voting agreement, voting trust or arrangement with respect to any such
Covered Shares; (c) take any other action that would or would reasonably be expected to make any representation or warranty contained
in this Agreement untrue or incorrect or that would or would reasonably be expected to restrict or otherwise adversely affect the performance
of or have the effect of preventing or disabling such Shareholder from performing any of its obligations under this Agreement; or (d)
commit or agree (whether or not in writing) to take any of the actions prohibited by the foregoing clause (a), (b) or (c). Any Transfer
or other action in violation of this provision shall be void <i>ab initio. </i>It is hereby clarified that if any involuntary Transfer
of any of the Covered Shares shall occur (such as in the case of appointment of a receiver to Shareholder&#8217;s assets as part of bankruptcy
proceedings), the transferee (which term, as used herein, shall include the initial transferee and any and all subsequent transferees
of the initial transferee) shall take and hold such Covered Shares subject to all of the restrictions, liabilities and rights under this
Agreement, which shall continue in full force and effect until the valid termination of this Agreement. During the term of the Agreement,
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent (if relevant) with respect to any sale,
pledge, or transfer, except upon the conditions specified in this Agreement. A transferring Shareholder will cause any proposed transferee
of the Covered Shares pursuant to a Permitted Transfer to agree to take and hold such securities subject to the provisions and upon the
conditions specified in this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.3 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Share
Dividends, etc</span>. In the event of a share split, share dividend or distribution (including any dividend or distribution of securities
convertible into Company Shares), or any change in the Company Shares by reason of any split-up, reverse share split, recapitalization,
reorganization, combination, reclassificat<span style="text-decoration:underline">i</span>on, reincorporation, exchange of shares or the like, the terms &#8220;Existing Shares&#8221;
and &#8220;Covered Shares&#8221; shall be deemed to refer to and include such shares as well as all such share dividends and distributions
and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.4 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Public
Announcements</span>. Except as required by applicable Law (in which case the Shareholders shall use reasonable best efforts to allow the
Parent reasonable time to comment on such announcement and shall consider in good faith any comments provided by the Parent), no public
announcements by the Shareholders regarding this Agreement, the transactions contemplated hereby, the Merger Agreement or the transactions
contemplated thereby are permitted. Each Shareholder (a) to the extent such consent or authorization of such Shareholder is required,
consents to and authorizes the publication and disclosure by Parent, the Company and their respective affiliates of such Shareholder&#8217;s
identity and holding of the Covered Shares and the nature of its commitments and obligations under this Agreement in any announcement
or disclosure required (in the opinion of the Parent&#8217;s counsel) by the SEC, the Israel Securities Authority or any other Governmental
Body or the rules or regulations of any applicable securities exchange (including Nasdaq and TASE); (b) agrees as promptly as practicable
to give to Parent and the Company any information that it may reasonably require for the preparation of any such announcement or disclosure
documents; and (c) agrees to promptly notify Parent and the Company of any required corrections with respect to any written information
supplied by it specifically for use in any such disclosure document, if any, to the extent that any shall be or have become false or
misleading, in any material respect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 256 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.5 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Further
Assurances</span>. Each Shareholder agrees, from time to time, at the request of the Parent and without further consideration, to execute
and deliver such additional documents and take all such further action as may be reasonably required to consummate and make effective,
in the most expeditious manner practicable, the transactions contemplated by this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 4.6 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Acquisition
of Covered Shares</span>. Each Shareholder agrees that any additional Covered Shares acquired by such Shareholder after the date of this
Agreement and prior to the Expiration Date (including through the exercise of any Company options or otherwise) shall automatically be
subject to the terms of this Agreement as though owned by such Shareholder on the date hereof. Each Shareholder hereby agrees to notify
the Company in writing as promptly as practicable (and in any event within one Business Day of receipt following such acquisition by
such Shareholder) of the number of any additional Covered Shares or other securities of Company of which the Shareholder acquires Beneficial
Ownership on or after the date hereof.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE V<span style="font-size: 10pt"><br/>
<br/>
MISCELLANEOUS </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.1 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Termination</span>.
This Agreement shall remain in effect until the earliest to occur of (a) the Expiration Date and (b) the Effective Time; <i>provided,
however,</i> that the provisions of this <b><i><span style="text-decoration:underline">&#8206;</span></i></b><span style="text-decoration:underline">ARTICLE V</span> shall survive any termination of this Agreement.
Neither the provisions of this <b><i>&#8206;</i></b><span style="text-decoration:underline">Section 5.1</span> nor the termination of this Agreement shall relieve any party hereto
from any liability of such party to any other party arising out of or in connection with a breach of this Agreement incurred prior to
such termination or expiration. For the avoidance of doubt, in the event this Agreement is terminated prior to the Effective Time, any
consent or other document executed pursuant hereto shall be deemed null and void and shall have no further effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.2 </b><span style="font-size: 10pt"><span style="text-decoration:underline">No
Ownership Interest</span>. Nothing contained in this Agreement shall be deemed to vest in the Parent or any other Person any direct or indirect
ownership or incidence of ownership of or with respect to any Covered Shares. All rights, ownership and economic benefits of and relating
to the Covered Shares shall remain vested in and belong to each respective Shareholder, and neither the Parent nor any other Person shall
have any authority to direct such Shareholder in the voting or disposition of any of the Covered Shares, except as otherwise expressly
provided herein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.3 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Expenses</span>.
All costs and expenses incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be paid by
the party incurring such costs and expenses, whether or not the Merger is consummated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 257 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.4 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Notices</span>.
All notices, consents and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly
given upon receipt) by hand delivery, by prepaid overnight courier (providing written proof of delivery) or by confirmed electronic mail,
addressed as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Parent, to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">SciSparc Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">20 Raul Wallenberg
Street, Tower A </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Tel Aviv, Israel,
6971916</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Attention: Oz Adler</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Email: </span>oz@scisparc.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">with a copy to (which shall not constitute notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Meitar | Law Offices</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">16 Abba Hillel Rd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Ramat Gan 5250608,
Israel</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Tel: (+972) (3) 610-3100</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Attention: Dr. Shachar
Hadar</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Email: shacharh@meitar.com</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">And</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Sullivan &amp; Worcester
LLP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">1633 Broadway</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">New York, NY 10019</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Tel: (212) 660-3000</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Attention: Oded Har-Even,
Esq., Howard E. Berkenblit, Esq</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><span style="background-color: white">Email: ohareven@sullivanlaw.com,
hberkenblit@sullivanlaw.com </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Shareholders, to the address set forth in the signature
page hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any notice received at the
addressee&#8217;s location on any Business Day after 5:00 p.m., addressee&#8217;s local time, or on any day that is not a Business Day
will be deemed to have been received at 9:00 a.m., addressee&#8217;s local time, on the next Business Day. From time to time, any party
hereto may provide notice to the other parties of a change in its address through a notice given in accordance with this &#8206;<span style="text-decoration:underline">Section
5.4</span>, except that notice of any change to the address or any of the other details specified in or pursuant to this &#8206;<span style="text-decoration:underline">Section
5.4</span> will not be deemed to have been received until, and will be deemed to have been received upon, the later of the date that is
(a) specified in such notice; or (b) five Business Days after such notice would otherwise be deemed to have been received pursuant to
this &#8206;<span style="text-decoration:underline">Section 5.4</span>. The inability to deliver because of changed address of which no notice is given will be deemed to be receipt
of the notice as of the date of such inability to deliver.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.5 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Interpretation.
</span>The words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;hereunder&#8221; and &#8220;herewith&#8221; and
words of similar import shall refer to this Agreement as a whole and not to any particular provision of this Agreement. References to
articles, sections, paragraphs, exhibits, annexes and schedules are to the articles, sections and paragraphs of, and exhibits, annexes
and schedules to, this Agreement, unless otherwise specified, and the headings in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221;
or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the phrase &#8220;without limitation.&#8221;
Words describing the singular number shall be deemed to include the plural and vice versa, words denoting any gender shall be deemed
to include all genders, words denoting natural persons shall be deemed to include business entities and vice versa and references to
a Person are also to its permitted successors and assigns. The term &#8220;or&#8221; is not exclusive. The word &#8220;extent&#8221;
in the phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other thing extends, and such phrase shall not
mean simply &#8220;if.&#8221; Any Law or agreement defined or referred to herein or in any agreement or instrument that is referred to
herein shall mean such Law or agreement as from time to time amended, modified or supplemented, including (in the case of statutes) by
succession of comparable successor Laws (provided that for purposes of any representations and warranties contained in this Agreement
that are made as of a specific date or dates, references to any statute or agreement shall be deemed to refer to such statute or agreement,
as amended, and to any rules or regulations promulgated thereunder, in each case, as of such date).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 258 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.6 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Counterparts</span>.
This Agreement and any amendments hereto may be executed in one or more identical counterparts, all of which will be considered one and
the same agreement and will become effective when one or more counterparts have been signed by each party hereto and delivered to the
other parties, it being understood that all parties need not sign the same counterpart. Any such counterpart, to the extent delivered
electronically will be treated in all manners and respects as an original executed counterpart and will be considered to have the same
binding legal effect as if it were the original signed version thereof delivered in person. No party hereto may raise the use of electronic
delivery to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated through the
use of electronic delivery, as a defense to the formation of a contract, and each party forever waives any such defense, except to the
extent such defense relates to lack of authenticity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.7 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Entire
Agreement</span>. This Agreement and the documents and instruments and other agreements among the parties as contemplated by or referred
to herein or therein constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof and thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Section 5.8 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Governing
Law; Consent to Jurisdiction</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="font-size: 10pt">This
Agreement and any dispute, controversy or claim arising out of, relating to or in connection with this Agreement, the negotiation, execution,
existence, validity, enforceability or performance of this Agreement, or for the breach or alleged breach hereof (whether in contract,
in tort or otherwise) shall be governed by and construed and enforced solely in accordance with the Laws of the State of Israel, without
giving effect to any choice of Law or conflict of Law provision or rule (whether of the State of Israel or otherwise) that would cause
the application of the Laws of any jurisdiction other than the State of Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="font-size: 10pt">Each
of the parties (i) irrevocably consents to the service of statement of claim and any other process in any action or proceeding relating
to the transactions contemplated by this Agreement, for and on behalf of itself or any of its properties or assets, in accordance with
<b>&#8206;</b><span style="text-decoration:underline">Section 5.4</span> or in such other manner as may be permitted by Applicable Law, and nothing in this <b>&#8206;</b><span style="text-decoration:underline">Section
5.8</span> shall affect the right of any party to serve legal process in any other manner permitted by Applicable Law, (ii) irrevocably
and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any court located in Tel Aviv-Jaffa, Israel,
in any action or proceeding arising out of or relating to this Agreement or the agreements delivered in connection herewith or the transactions
contemplated hereby or thereby or for recognition or enforcement of any judgment relating thereto, and (iii)&#160;irrevocably and unconditionally
(A) agrees not to commence any such action or proceeding except in any competent court located in Tel Aviv-Jaffa, Israel, (B)&#160;agrees
that any claim in respect of any such action or proceeding may be heard and determined in any competent court located in Tel Aviv-Jaffa,
Israel, (C)&#160;waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have
to the laying of venue of any such action or proceeding in such courts, and (D) waives, to the fullest extent permitted by Law, and agrees
not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient
forum. Each of the parties agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 259 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="font-size: 10pt">Each
party hereto irrevocably consents to the service of process in any Legal Proceeding with respect to this Agreement and the transactions
contemplated by this Agreement or for recognition and enforcement of any judgment in respect hereof brought by any other party hereto
made by mailing copies thereof by registered mail, postage prepaid, return receipt requested, to its address as specified in or pursuant
to <b><span style="text-decoration:underline">&#8206;</span></b><span style="text-decoration:underline">Section 5.4</span> and such service of process shall be sufficient to confer personal jurisdiction over such party
in such Legal Proceeding and shall otherwise constitute effective and binding service in every respect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.9 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Specific
Performance</span>. The Shareholders hereby acknowledge and agree that the Parent will suffer irreparable damage in the event that any of
the obligations of the Shareholders in this Agreement are not performed in accordance with its specific terms or if the Agreement is
otherwise breached by the Shareholders and that money damages, even if available, would not be an adequate remedy therefor. Accordingly,
each Shareholder agrees that the Parent shall be entitled to specific performance, an injunction, restraining order and/or such other
equitable relief, in addition to any other rights and remedies existing in its favor at law or in equity, as a court of competent jurisdiction
may deem necessary or appropriate to enforce its rights and such Shareholder&#8217;s obligations hereunder (without posting of bond or
other security). The Shareholders agree not to raise any objection or legal or equitable defense to the availability of any equitable
remedy that the Parent may have in respect of this Agreement. These injunctive remedies are cumulative and in addition to any other rights
and remedies the Parent may have at law or in equity. In the event the Parent seeks an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement, the Parent shall not be required to provide
any bond or other security in connection with any such order or injunction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.10 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Amendment;
Waiver</span>. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except
by an instrument in writing signed by each of the parties. Any party hereto may, to the extent permitted by Law, waive compliance with
any of the agreements or conditions for the benefit of such party contained herein if such waiver is set forth in an instrument in writing
signed on behalf of such party. Any delay in exercising any right under this Agreement shall not constitute a waiver of such right.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.11 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Severability</span>.
In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of competent jurisdiction
to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such
provision to other Persons or circumstances will be interpreted so as reasonably to effect the intent of the parties. The parties further
agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to
the extent possible, the economic, business and other purposes of such void or unenforceable provision.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.12 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Assignment;
Successors; No Third Party Beneficiaries</span>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall
be assigned by any of the parties hereto (whether by operation of Law or otherwise) without the prior written consent of the other parties
hereto. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by and against
the parties and their respective permitted successors and assigns. Any attempted assignment in violation of this <b><i>&#8206;</i></b><span style="text-decoration:underline">Section
5.12</span> shall be null and void <i>ab initio</i>. Nothing in this Agreement, express or implied, is intended to or shall confer upon
any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy
of any nature under or by reason of this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.13 </b><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholder
Capacity</span>. The parties acknowledge that this Agreement is entered into by each Shareholder solely in his or its capacity as the record
or Beneficial Owner of such Shareholder&#8217;s Company Shares and nothing in this Agreement restricts or limits any action taken by
such Shareholder in his capacity as a director or officer of Company. The taking of any action (or failure to act) by any Shareholder
in his capacity as an officer or director of Company will not be deemed to constitute a breach of this Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>The remainder of this page is intentionally
left blank</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 260 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.3in; text-indent: -0.3in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.3in; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt"><b>THE PARENT:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt"><b>SCISPARC LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/s/ Oz Adler</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Oz Adler </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title:</span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">CFO </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>[Signature Page to Shareholder Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 261 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">Haim Levy Trade-In Ltd.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in">/S/ Daniel Levy</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name: </span></td>
    <td style="text-indent: 0in; width: 31%">Daniel Levy</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title: </span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[SHAREHOLDERS]<br/>
[&#160;&#160;&#160;]<br/>
[&#160;&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#160;&#160;&#160; ]<br/>
Email: [&#160;&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#160;&#160;&#160;]<br/>
[&#160;&#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#160;&#160;&#160;]<br/>
Email: [&#160;&#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 262 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt">A. Yinon (2015) Ltd. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Yinon Amit</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name: </span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Yinon Amit</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title: </span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[SHAREHOLDERS]<br/>
[ &#160;&#160;&#160;]<br/>
[ &#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [ &#160;&#160;]<br/>
Email: [ &#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#160;&#160; ]<br/>
[&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [ &#160;&#160;]<br/>
Email: [&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 263 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt">Puzailov Investments Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Emanuel Paz Puzailov</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name: </span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Emanuel Paz Puzailov</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title: </span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director </span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><b>Emanuel Paz Puzailov</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">/S/ Emanuel Paz Puzailov</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[SHAREHOLDERS]<br/>
[&#160;&#160; ]<br/>
[&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [&#160;&#160; ]<br/>
Email: [ &#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[ &#160;&#160;]<br/>
[&#160;&#160; ]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: [ &#160;&#160;]<br/>
Email: [ &#160;&#160;]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 264 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the parties
have caused to be executed and delivered or executed and delivered this Shareholder Support Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>SHAREHOLDERS:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><span style="font-size: 10pt"><b>Eliyahu Baruch Ltd.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Eyal Baruch</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name:</span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Eyal Baruch</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title:</span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director</span></td></tr>

<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in"><b>Belporto Investments Ltd.</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td colspan="3" style="text-indent: 0in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">By: </span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-size: 10pt">/S/ Eyal Baruch</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in; width: 60%">&#160;</td>
    <td style="text-indent: 0in; width: 4%">&#160;</td>
    <td style="text-indent: 0in; width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="text-indent: 0in; width: 31%"><span style="font-size: 10pt">Eyal Baruch</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in">&#160;</td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Title:</span></td>
    <td style="text-indent: 0in"><span style="font-size: 10pt">Director</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for notices:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 20%">&#160;</td>
    <td style="width: 80%"><span style="font-size: 10pt">[SHAREHOLDERS]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">[&#160;&#160;&#160;] </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">[&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attention: [&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Email: [&#160;&#160;&#160;]</span>&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>with copies (which shall not constitute notice) to:</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 20%">&#160;</td>
    <td style="width: 80%"><span style="font-size: 10pt">[&#160;&#160;&#160;] </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">[&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attention: [&#160;&#160;&#160;]</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Email: [&#160;&#160;&#160;]</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>[Signature Page to Shareholder
Support Agreement]</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></p><div>

</div><!-- Field: Page; Sequence: 265 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&#160;</p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SCHEDULE I</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration: none">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Haim Levy Trade-In Ltd.,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Yinon (2015) Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eliyahu Baruch Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Belporto Investments Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Puzailov Investments Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emanuel Paz Puzailov</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 266 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration:underline">EXHIBIT A</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-size: 10pt">FORM
OF JOINDER AGREEMENT</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned is executing
and delivering this Joinder Agreement pursuant to that certain Shareholder Support Agreement, dated as of April 10, 2024 (as amended,
restated, supplemented or otherwise modified in accordance with the terms thereof, the &#8220;<b>Shareholder Support Agreement</b>&#8221;)
by and between SciSparc Ltd., an Israeli limited company, and each of the shareholders of AutoMax Motors Ltd., an Israeli limited company
(the &#8220;<b>Company</b>&#8221;), listed on Schedule I thereto (the &#8220;<b>Shareholders</b>&#8221;). Each capitalized term used
but not defined in this Joinder Agreement shall have the respective meaning ascribed to such term in the Shareholder Support Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By executing and delivering
this Joinder Agreement to the Shareholder Support Agreement, the undersigned hereby (i) adopts and approves the Shareholder Support Agreement,
(ii) assumes and agrees to comply with all of the Shareholder&#8217;s obligations under the Shareholder Support Agreement in respect
of the securities subject to the applicable Transfer and (iii) agrees, effective commencing on the date hereof and as a condition to
the Transfer, to become a party to, and to be bound by and comply with the provisions of, the Shareholder Support Agreement applicable
to the Shareholders, in the same manner as if the undersigned were an original signatory to the Shareholder Support Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby (i)
represents and warrants that, pursuant to this Joinder Agreement and the Shareholder Support Agreement, it is a Permitted Transferee
under the Shareholder Support Agreement and (ii) makes all of the representations and warranties set forth in Article 3 of the Shareholder
Support Agreement, <i>mutatis mutandis</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges
and agrees that the provisions of &#8206;<span style="text-decoration:underline">ARTICLE V</span> of the Shareholder Support Agreement are incorporated herein by reference, <i>mutatis
mutandis</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>Remainder of page intentionally left blank</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 267 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, the undersigned have executed and
delivered this Joinder Agreement as of the _____ day of _______, _______.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.3in; text-indent: -0.3in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; &#160;</span></td>
    <td style="width: 40%; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PERMITTED TRANSFEREE</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Notice Information</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>


</div><!-- Field: Page; Sequence: 268 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="B_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ANNEX
C</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="text-decoration:underline">FORM OF indemnification
agreement</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS INDEMNIFICATION AGREEMENT (the &#8220;<b>Agreement</b>&#8221;),
dated as of __________, 2024, is entered into by and between SciSparc Ltd., an Israeli company whose address is 20 Raul Wallenberg St.,
Tower A, 2nd Floor, Tel Aviv 6971916, Israel (the &#8220;<b>Company</b>&#8221;), and the undersigned Director or Officer of the Company
whose name appears on the signature page hereto officer (the &#8220;<b>Indemnitee</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">Indemnitee
                                            is an Office Holder (&#8220;<i>Nosse Misra</i>&#8221;), as such term is defined in the Companies
                                            Law, 5759&#8211;1999, as amended (the &#8220;</span>Office Holder<span style="font-weight: normal">&#8221;
                                            and the &#8220;</span>Companies Law<span style="font-weight: normal">&#8221;, respectively),
                                            of the Company; </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.9pt">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">both
                                            the Company and Indemnitee recognize the increased risk of litigation and other claims being
                                            asserted against Office Holders of companies and that highly competent persons have become
                                            more reluctant to serve corporations as directors and officers or in other capacities unless
                                            they are provided with adequate protection through insurance or adequate indemnification
                                            against inordinate risks of claims and actions against them arising out of their service
                                            to, and activities on behalf of, companies; </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.85pt">WHEREAS<span style="font-weight: normal">,</span></td><td style="text-align: justify"><span style="font-weight: normal">the
                                            Articles of Association of the Company authorize the Company to indemnify and advance expenses
                                            to its Office Holders and provide for insurance and exculpation to its Office Holders, in
                                            each case, to the fullest extent permitted by applicable law; </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.85pt">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">the
                                            Company has determined that (i) the increased difficulty in attracting and retaining competent
                                            persons is detrimental to the best interests of the Company&#8217;s shareholders and that
                                            the Company should act to assure such persons that there will be increased certainty of such
                                            protection in the future, and (ii) it is reasonable, prudent and necessary for the Company
                                            contractually to obligate itself to indemnify, and to advance expenses on behalf of, such
                                            persons to the fullest extent permitted by applicable law, so that they will serve or continue
                                            to serve the Company free from undue concern that they will not be so indemnified; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 70.85pt">WHEREAS,</td><td style="text-align: justify"><span style="font-weight: normal">in
                                            recognition of Indemnitee&#8217;s need for substantial protection against personal liability
                                            in order to assure Indemnitee&#8217;s continued service to the Company in an effective manner
                                            and, in part, in order to provide Indemnitee with specific contractual assurance that the
                                            indemnification, insurance and exculpation afforded by the Articles of Association will be
                                            available to Indemnitee, the Company wishes to undertake in this Agreement for the indemnification
                                            of and the advancing of expenses to Indemnitee to the fullest extent permitted by applicable
                                            law and as set forth in this Agreement and provide for insurance and exculpation of Indemnitee
                                            as set forth in this Agreement.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOW, THEREFORE</b>, the parties hereto agree
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">1.</td><td style="text-align: justify"><b>INDEMNIFICATION AND INSURANCE.</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.1.</td><td style="text-align: justify">The Company hereby undertakes
                                            to indemnify Indemnitee to the fullest extent permitted by applicable law for any liability
                                            and expense specified in Sections &#8206;1.1.1 through &#8206;1.1.4 below, imposed on Indemnitee
                                            due to or in connection with an act performed by such Indemnitee, either prior to or after
                                            the date hereof, in Indemnitee&#8217;s capacity as an Office Holder, including, without limitation,
                                            as a director, officer, employee, agent or fiduciary of the Company, any subsidiary thereof
                                            or any other corporation, collaboration, partnership, joint venture, trust or other enterprise,
                                            in which Indemnitee serves at any time at the request of the Company (the &#8220;<b>Corporate
                                            Capacity</b>&#8221;). The term &#8220;act performed in Indemnitee&#8217;s capacity as an
                                            Office Holder&#8221; shall include, without limitation, any act, omission or failure to act
                                            and any other circumstances relating to or arising from Indemnitee&#8217;s service in a Corporate
                                            Capacity. Notwithstanding the foregoing, in the event that the Office Holder is the beneficiary
                                            of an indemnification undertaking provided by a subsidiary of the Company or any other entity,
                                            with respect to his or her Corporate Capacity with such subsidiary or entity, then the indemnification
                                            obligations of the Company hereunder with respect to such Corporate Capacity shall only apply
                                            to the extent that the indemnification by such subsidiary or other entity does not actually
                                            fully cover the indemnifiable liabilities and expenses relating thereto. The following shall
                                            be hereinafter referred to as &#8220;<b>Indemnifiable Events</b>&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 269; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.1.</td><td style="text-align: justify">Financial liability imposed
                                            on Indemnitee in favor of any person pursuant to a judgment, including a judgment rendered
                                            in the context of a settlement or an arbitrator&#8217;s award approved by a court. For purposes
                                            of Section &#8206;1 of this Agreement, the term &#8220;<b>person</b>&#8221; shall include,
                                            without limitation, a natural person, firm, partnership, joint venture, trust, company, corporation,
                                            limited liability entity, unincorporated organization, estate, government, municipality,
                                            or any political, governmental, regulatory or similar agency or body;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.2.</td><td style="text-align: justify">Reasonable Expenses (as defined
                                            below) expended by Indemnitee as a result of an investigation or any proceeding instituted
                                            against the Indemnitee by an authority that is authorized to conduct such investigation or
                                            proceeding, and that was concluded without filing an indictment against the Indemnitee and
                                            without imposing on the Indemnitee a financial liability in lieu of a criminal proceeding,
                                            or that was concluded without filing an indictment against the Indemnitee but imposing a
                                            financial liability in lieu of a criminal proceeding in an offence that does not require
                                            proof of <i>mens rea</i>, or in connection with a financial sanction. In this section &#8220;conclusion
                                            of a proceeding without filing an indictment in a matter in which a criminal investigation
                                            has been instigated&#8221; and &#8220;financial liability in lieu of a criminal proceeding&#8221;
                                            shall have the meaning assigned to such terms under the Companies Law, and the term &#8220;financial
                                            sanction&#8221; shall mean such term as referred to in Section 260(a)(1a) of the Companies
                                            Law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.3.</td><td style="text-align: justify">Reasonable Expenses expended
                                            by or imposed on Indemnitee by a court, in a proceeding instituted against Indemnitee by
                                            the Company or on its behalf or by another person, or in a criminal charge from which Indemnitee
                                            was acquitted or in which Indemnitee convicted of an offence that does not require proof
                                            of <i>mens rea</i>; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 63.8pt"/><td style="width: 42.5pt">1.1.4.</td><td style="text-align: justify">Any other event, occurrence,
                                            matter or circumstances under any law with respect to which the Company may, or will be able
                                            to, indemnify an Office Holder (including, without limitation, in accordance with Section
                                            56h(b)(1) of the Israeli Securities Law 5728-1968 (the &#8220;<b>Israeli Securities Law</b>&#8221;),
                                            if applicable, and Section 50P(b)(2) of the Israeli Economic Competition Law, 5758-1988 (the
                                            &#8220;<b>Economic Competition Law</b>&#8221;)).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">For the purpose of this Agreement,
&#8220;<b>Expenses</b>&#8221; shall include, without limitation, legal fees and all other costs, expenses and obligations paid or incurred
by Indemnitee in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing
to defend, be a witness in or participate in any claim, action, suit, proceeding, alternative dispute resolution mechanism, hearing,
inquiry or investigation relating to any matter for which indemnification hereunder may be provided. Expenses shall be considered paid
or incurred by Indemnitee at such time as Indemnitee is required to pay or incur such cost or expenses, including upon receipt of an
invoice or payment demand. The Company shall pay the Expenses in accordance with the provisions of Section&#8206;1.3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 270 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 28.4pt">&#160;</td>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything herein to the contrary, the Company&#8217;s undertaking to indemnify the Indemnitee under Section &#8206;1.1.1 shall only
    be with respect to events described in <b><span style="text-decoration:underline">Exhibit A</span></b> hereto. The Board of Directors of the Company (the &#8220;<b>Board</b>&#8221;)
    has determined that the categories of events listed in Exhibit A are foreseeable in light of the operations of the Company. The maximum
    amount of indemnification payable by the Company to the Indemnitee under Section &#8206;1.1.1 and other indemnitees under similar indemnification
    agreements with the Company (the &#8220;<b>Indemnifiable Persons</b>&#8221;) shall be as set forth in <span style="text-decoration:underline">Exhibit A</span> hereto (the
    &#8220;<b>Limit Amount</b>&#8221;) for each five year period commencing as of [DATE OF APPROVAL], and for every subsequent five year
    period thereafter, and shall apply to all Indemnifiable Persons, in the aggregate. If the Limit Amount is insufficient to cover all
    the indemnity amounts payable with respect to all Indemnifiable Persons during the relevant five year period, then such amount shall
    be allocated to such Indemnifiable Persons pro rata according to the percentage of their culpability, as finally determined by a
    court in the relevant claim, or, absent such determination or in the event such persons are parties to different claims, based on
    an equal pro rata allocation among such Indemnifiable Persons. The Limit Amount payable by the Company as described in <span style="text-decoration:underline">Exhibit
    A</span> is deemed by the Company to be reasonable in light of the circumstances. The indemnification provided under Section &#8206;1.1.1
    herein shall not be subject to the limitations imposed by this Section &#8206;1.2 and Exhibit&#160;A if and to the extent such limits
    do not or are no longer required by the Companies Law.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.3.</td><td style="text-align: justify">If so requested by Indemnitee
                                            in writing, and subject to the Company&#8217;s repayment and reimbursements rights set forth
                                            in Sections &#8206;3 and &#8206;5 below, the Company shall pay amounts to cover Indemnitee&#8217;s
                                            Expenses with respect to which Indemnitee is entitled to be indemnified under Section &#8206;1.1
                                            above, as and when incurred. The payments of such amounts shall be made by the Company directly
                                            to the Indemnitee&#8217;s legal and other advisors, as soon as practicable, but in any event
                                            no later than fifteen (15) days after written demand by such Indemnitee therefor to the Company,
                                            and any such payment shall be deemed to constitute indemnification hereunder. As part of
                                            the aforementioned undertaking, the Company will make available to Indemnitee any security
                                            or guarantee that Indemnitee may be required to post in accordance with an interim decision
                                            given by a court, governmental or administrative body, or an arbitrator, including for the
                                            purpose of substituting liens imposed on Indemnitee&#8217;s assets.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.4.</td><td style="text-align: justify">The Company&#8217;s obligation
                                            to indemnify Indemnitee and advance Expenses in accordance with this Agreement shall be for
                                            such period (the &#8220;<b>Indemnification Period</b>&#8221;) as Indemnitee shall be subject
                                            to any actual, possible or threatened claim, action, suit, demand or proceeding or any inquiry
                                            or investigation, whether civil, criminal or investigative, arising out of the Indemnitee&#8217;s
                                            service in the Corporate Capacity as described in Section &#8206;1.1 above, whether or not
                                            Indemnitee is still serving in such position.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.5.</td><td style="text-align: justify">The Company undertakes that,
                                            subject to the mandatory limitations under applicable law, as long as it may be obligated
                                            to provide indemnification and advance Expenses under this Agreement, the Company will purchase
                                            and maintain in effect directors and officers liability insurance, which will include coverage
                                            for the benefit of the Indemnitee, providing coverage in amounts as reasonably determined
                                            by the Board; provided that, the Company shall have no obligation to obtain or maintain directors
                                            and officers insurance policy if the Company determines in good faith that such insurance
                                            is not reasonably available, the premium costs for such insurance are disproportionate to
                                            the amount of coverage provided, or the coverage provided by such insurance is so limited
                                            by exclusions that it provides an insufficient benefit. The Company hereby undertakes to
                                            notify the Indemnitee 30 days prior to the expiration or termination of the directors and
                                            officers liability insurance.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">1.6.</td><td style="text-align: justify">The Company undertakes to give
                                            prompt written notice of the commencement of any claim hereunder to the insurers in accordance
                                            with the procedures set forth in each of the policies. The Company shall thereafter diligently
                                            take all actions reasonably necessary under the circumstances to cause such insurers to pay,
                                            on behalf of Indemnitee, all amounts payable as a result of such action, suit, proceeding,
                                            inquiry or investigation in accordance with the terms of such policies. The above shall not
                                            derogate from Company&#8217;s authority to freely negotiate or reach any compromise with
                                            the insurer which is reasonable at the Company&#8217;s sole discretion provided that the
                                            Company shall act in good faith and in a diligent manner.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 271 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">2.</td><td style="text-align: justify"><b>SPECIFIC LIMITATIONS ON INDEMNIFICATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Notwithstanding anything to the contrary
in this Agreement, the Company shall not indemnify or advance Expenses to Indemnitee with respect to (i) any act, event or circumstance
with respect to which it is prohibited to do so under applicable law, or (ii) a counter claim made by the Company or in its name in connection
with a claim against the Company filed by the Indemnitee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">3.</td><td style="text-align: justify"><b>REPAYMENT OF EXPENSES</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">3.1.</td><td style="text-align: justify">In the event that the Company
                                            provides or is required to provide indemnification with respect to Expenses hereunder and
                                            at any time thereafter the Company determines, based on advice from its legal counsel, that
                                            the Indemnitee was not entitled to such payments, the amounts so indemnified by the Company
                                            will be promptly repaid by Indemnitee, unless the Indemnitee disputes the Company&#8217;s
                                            determination, in which case the Indemnitee&#8217;s obligation to repay to the Company shall
                                            be postponed until such dispute is resolved.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">3.2.</td><td style="text-align: justify">Indemnitee&#8217;s obligation
                                            to repay to the Company for any Expenses or other sums paid hereunder shall be deemed as
                                            a loan given to Indemnitee by the Company subject to the minimum interest rate prescribed
                                            by Section 3(9) of the Income Tax Ordinance [New Version], 1961, or any other legislation
                                            replacing it, which is not considered a taxable benefit.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">4.</td><td style="text-align: justify"><b>SUBROGATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">4.1.</td><td style="text-align: justify">In the event of payment under
                                            this Agreement, the Company shall be subrogated to the extent of such payment to all of the
                                            rights of recovery of Indemnitee, who shall execute all documents required and shall do everything
                                            that may be necessary to secure such rights, including the execution of such documents necessary
                                            to enable the Company effectively to bring suit to enforce such rights.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">5.</td><td style="text-align: justify"><b>REIMBURSEMENT</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company shall not be liable under
this Agreement to make any payment in connection with any Indemnifiable Event to the extent Indemnitee has otherwise actually received
payment under any insurance policy or otherwise (without any obligation of Indemnitee to repay any such amount) of the amounts otherwise
indemnifiable hereunder. Any amounts paid to Indemnitee under such insurance policy or otherwise after the Company has indemnified Indemnitee
for such liability or Expense shall be repaid to the Company promptly upon receipt by Indemnitee, in accordance with the terms set forth
in Section &#8206;3.2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">6.</td><td style="text-align: justify"><b>EFFECTIVENESS</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement shall be valid, binding
and enforceable in accordance with its terms and shall be in full force and effect immediately upon its approval by the Company&#8217;s
general meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">7.</td><td style="text-align: justify"><b>NOTIFICATION AND DEFENSE OF CLAIM</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Indemnitee shall notify the Company
of the commencement of any action, suit or proceeding, and of the receipt of any notice or threat that any such legal proceeding has
been or shall or may be initiated against Indemnitee (including any proceedings by or against the Company and any subsidiary thereof),
promptly upon Indemnitee first becoming so aware; but the omission so to notify the Company will not relieve the Company from any liability
which it may have to Indemnitee under this Agreement unless and to the extent that such failure to provide notice prejudices the Company&#8217;s
ability to defend such action. Notice to the Company shall be directed to the Chief Executive Officer or Chief Financial Officer of the
Company at the address shown in the preamble to this Agreement (or such other address as the Company shall designate in writing to Indemnitee).
With respect to any such action, suit or proceeding as to which Indemnitee notifies the Company of the commencement thereof and without
derogating from Sections &#8206;1.1 and &#8206;2:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.1.</td><td style="text-align: justify">The Company will be entitled
                                            to participate therein at its own expense.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 272 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.2.</td><td style="text-align: justify">Except as otherwise provided
                                            below, the Company, alone or jointly with any other indemnifying party similarly notified,
                                            will be entitled to assume the defense thereof, with counsel selected by the Company. Indemnitee
                                            shall have the right to employ his or her own counsel in such action, suit or proceeding,
                                            but the fees and expenses of such counsel incurred after notice from the Company of its assumption
                                            of the defense thereof shall be at the expense of Indemnitee, unless: (i)&#160;the employment
                                            of counsel by Indemnitee has been authorized in writing by the Company; (ii) the Company,
                                            in good faith, reasonably concluded that there may be a conflict of interest between the
                                            Company and Indemnitee in the conduct of the defense of such action; or (iii)&#160;the Company
                                            has not in fact employed counsel to assume the defense of such action within reasonable time,
                                            in which cases the reasonable fees and expenses of Indemnitee&#8217;s counsel shall be at
                                            the expense of the Company. The Company shall not be entitled to assume the defense of any
                                            action, suit or proceeding brought by or on behalf of the Company or as to which Indemnitee
                                            and the Company shall have reached the conclusion specified in (ii) above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.3.</td><td style="text-align: justify">The Company shall not be liable
                                            to indemnify Indemnitee under this Agreement for any amounts or expenses paid in connection
                                            with a settlement of any action, claim or otherwise, effected without the Company&#8217;s
                                            prior written consent.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.4.</td><td style="text-align: justify">The Company shall have the right
                                            to conduct the defense as it sees fit in its sole discretion (provided that the Company shall
                                            conduct the defense in good faith and in a diligent manner), including the right to settle
                                            or compromise any claim or to consent to the entry of any judgment against Indemnitee without
                                            the consent of the Indemnitee, provided that, the amount of such settlement, compromise or
                                            judgment does not exceed the Limit Amount (if applicable) and is fully indemnifiable pursuant
                                            to this Agreement (subject to Section &#8206;1.2 of this Agreement) and/or applicable law,
                                            and any such settlement, compromise or judgment does not impose any penalty or limitation
                                            on Indemnitee without the Indemnitee&#8217;s prior written consent. The Indemnitee&#8217;s
                                            consent shall not be required if the settlement includes a complete release of Indemnitee,
                                            does not contain any admission of wrong-doing by Indemnitee, and includes monetary sanctions
                                            only as provided above. In the case of criminal proceedings, the Company and/or its legal
                                            counsel will not have the right to plead guilty or agree to a plea-bargain in the Indemnitee&#8217;s
                                            name without the Indemnitee&#8217;s prior written consent. Neither the Company nor Indemnitee
                                            will unreasonably withhold or delay their consent to any proposed settlement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 28.4pt"/><td style="width: 0.5in">7.5.</td><td style="text-align: justify">Indemnitee shall fully cooperate
                                            with the Company and shall give the Company all information and access to documents, files
                                            and to his or her advisors and representatives as shall be within Indemnitee&#8217;s power,
                                            in every reasonable way as may be required by the Company with respect to any claim which
                                            is the subject matter of this Agreement and in the defense of other claims asserted against
                                            the Company (other than claims asserted by Indemnitee), provided that the Company shall cover
                                            all expenses, costs and fees incidental thereto such that the Indemnitee will not be required
                                            to pay or bear such expenses, costs and fees.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 273 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">8.</td><td style="text-align: justify"><b>EXCULPATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Subject to the provisions of the
Companies Law, the Company hereby releases, in advance, the Office Holder from liability to the Company for any damage that arises from
the breach of the Office Holder&#8217;s duty of care to the Company (within the meaning of such terms under Sections 252 and 253 of the
Companies Law), other than breach of the duty of care towards the Company in a distribution (as such term is defined in the Companies
Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">9.</td><td style="text-align: justify"><b>NON-EXCLUSIVITY</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The rights of the Indemnitee hereunder
shall not be deemed exclusive of any other rights Indemnitee may have under the Articles of Association, applicable law or otherwise<b><i>,
</i></b>and to the extent that during the Indemnification Period the indemnification rights of the then serving directors and officers
are more favorable to such directors or officers than the indemnification rights provided under this Agreement to Indemnitee, Indemnitee
shall be entitled to the full benefits of such more favorable indemnification rights to the extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">10.</td><td style="text-align: justify"><b>PARTIAL INDEMNIFICATION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">If Indemnitee is entitled under any
provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually
or reasonably incurred by Indemnitee in connection with any proceedings, but not, however, for the total amount thereof, the Company
shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled
under any provision of this Agreement. Subject to the provisions of Section &#8206;5 above, any amount received by Indemnitee (under any
insurance policy or otherwise) shall not reduce the Limit Amount hereunder and shall not derogate from the Company&#8217;s obligation
to indemnify the Indemnitee in accordance with the provisions of this Agreement up to the Limit Amount, as set forth in Section &#8206;1.2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">11.</td><td style="text-align: justify"><b>BINDING EFFECT</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement shall be binding upon
and inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns. In the event
of a merger or consolidation of the Company or a transfer or disposition of all or substantially all of the business or assets of the
Company, the Indemnitee shall be entitled to the same indemnification and insurance provisions as the most favorable indemnification
and insurance provisions afforded to the then-serving Office Holders of the Company. In the event that in connection with such transaction
the Company purchases a directors and officers&#8217; &#8220;tail&#8221; or &#8220;run-off&#8221; policy for the benefit of its then
serving Office Holders, then such policy shall cover Indemnitee and such coverage shall be deemed to be in satisfaction of the insurance
requirements under this Agreement. This Agreement shall continue in effect during the Indemnification Period regardless of whether Indemnitee
continues to serve in a Corporate Capacity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any amendment to the Companies Law,
the Israeli Securities Law, the Economic Competition Law or other applicable law adversely affecting the right of the Indemnitee to be
indemnified, insured or released pursuant hereto shall be prospective in effect, and shall not affect the Company&#8217;s obligation
or ability to indemnify or insure the Indemnitee for any act or omission occurring prior to such amendment, unless otherwise provided
by applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">12.</td><td style="text-align: justify"><b>SEVERABILITY</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The provisions of this Agreement
shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of
the other provisions hereof. If any provision of this Agreement, or the application thereof or any circumstance, is invalid or unenforceable,
(a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the
intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision
or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the
validity or enforceability of such provision, or the application thereof, in any other jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 274 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">13.</td><td style="text-align: justify"><b>NOTICE</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">All notices and other communications
pursuant to this Agreement shall be in writing and shall be deemed provided if delivered personally, telecopied, sent by electronic facsimile,
email, reputable overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid, to the parties
at the addresses shown in the preamble to this Agreement, or to such other address as the party to whom notice is to be given may have
furnished to the other party hereto in writing in accordance herewith. Any such notice or communication shall be deemed to have been
delivered and received (i) in the case of personal delivery, on the date of such delivery, (ii) in the case of telecopier or an electronic
facsimile or email, one business day after the date of transmission if confirmation of receipt is received, (iii) in the case of a reputable
overnight courier, three business days after deposit with such reputable overnight courier service, and (iv) in the case of mailing,
on the seventh business day following that on which the mail containing such communication is posted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">14.</td><td style="text-align: justify"><b>GOVERNING LAW; JURISDICTION</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement shall be governed
by and construed and enforced in accordance with the laws of the State of Israel, without giving effect to the conflicts of law provisions
of those laws. The Company and Indemnitee each hereby irrevocably consent to the exclusive jurisdiction and venue of the courts of Tel
Aviv, Israel for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">15.</td><td style="text-align: justify"><b>ENTIRE AGREEMENT</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement represents the entire
agreement between the parties and supersedes any other agreements, contracts or understandings between the parties, whether written or
oral, with respect to the subject matter of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">16.</td><td style="text-align: justify"><b>NO MODIFICATION AND NO WAIVER</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">No supplement, modification or amendment,
termination or cancellation of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of
any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar)
nor shall such waiver constitute a continuing waiver. Any waiver shall be in writing. The Company hereby undertakes not to amend its
Articles of Association in a manner which will adversely affect the provisions of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">17.</td><td style="text-align: justify"><b>ASSIGNMENTS; NO THIRD PARTY RIGHTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Neither party hereto may assign any
of its rights or obligations hereunder except with the express prior written consent of the other party. Nothing herein shall be deemed
to create or imply an obligation for the benefit of a third party. Without limitation of the foregoing, nothing herein shall be deemed
to create any right of any insurer that provides directors and officers&#8217; liability insurance, to claim, on behalf of Indemnitee,
any rights hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">18.</td><td style="text-align: justify"><b>INTERPRETATION; DEFINITIONS</b>.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">Unless the context
shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding
masculine, feminine and neuter forms; the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed
to be followed by the phrase &#8220;without limitation&#8221;; the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;
and words of similar import refer to this Agreement in its entirety and not to any part hereof; all references herein to Sections or
clauses shall be deemed references to Sections or clauses of this Agreement; any references to any agreement or other instrument or law,
statute or regulation are to it as amended, supplemented or restated, from time to time (and, in the case of any law, to any successor
provisions or re-enactment or modification thereof being in force at the time); any reference to &#8220;law&#8221; shall include any
supranational, national, federal, state, local, or foreign statute or law and all rules and regulations promulgated thereunder; any reference
to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without any explicit reference otherwise, such as to business days) shall be
interpreted as a reference to a calendar day or number of calendar days; reference to month or year means according to the Gregorian
calendar; reference to a &#8220;company&#8221;, &#8220;corporate body&#8221; or &#8220;entity&#8221; shall include a, partnership, firm,
company, corporation, limited liability company, association, joint venture, trust, unincorporated organization, estate, or a government
municipality or any political, governmental, regulatory or similar agency or body, and reference to a &#8220;person&#8221; shall mean
any of the foregoing or a natural person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 28.35pt">19.</td><td style="text-align: justify"><b>COUNTERPARTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">This Agreement may be executed in
any number of counterparts, each of which shall be deemed an original and enforceable against the parties actually executing such counterpart,
and all of which together shall constitute one and the same instrument; it being understood that parties need not sign the same counterpart.
The exchange of an executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery in pdf format shall be sufficient
to bind the parties to the terms and conditions of this Agreement, as an original.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>[SIGNATURE PAGE TO FOLLOW]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 275 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 28.35pt; text-align: justify"><b>IN WITNESS
WHEREOF</b>, the parties, each acting under due and proper authority, have executed this Indemnification Agreement as of the date first
mentioned above, in one or more counterparts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="3" style="font-size: 10pt; text-align: left"><span style="font-size: 10pt"><b>SciSparc Ltd.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 13%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 27%; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 60%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Name and title:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: left"><span style="font-size: 10pt"><b>Indemnitee:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 13%; text-align: left"><span style="font-size: 10pt">Name:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 27%; text-align: left">&#160;</td>
    <td style="width: 60%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-size: 10pt">Signature:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-size: 10pt">Address:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 276 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b><span style="text-decoration:underline">EXHIBIT
A*</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="width: 95%; text-align: center"><span style="font-size: 10pt"><b>CATEGORY OF INDEMNIFIABLE EVENT</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">1. </span></td>
    <td style="text-indent: 0in; padding-left: -0.125in; text-align: justify"><span style="font-size: 10pt">Matters, events, occurrences
    or circumstances in connection or associated with employment relationships with employees or consultants or any employee union or
    similar or comparable organization. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">2. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Matters, events, occurrences or circumstances in connection or associated
    with business relations of any kind between the Company and its employees, independent contractors, customers, suppliers, partners,
    distributors, agents, resellers, representatives, licensors, licensees, service providers and other business associates.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">3. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Negotiations, execution, delivery and performance of agreements of
    any kind or nature and any decisions or deliberations relating to actions or omissions relating to the foregoing; any acts, omissions
    or circumstances that do or may constitute or are alleged to constitute anti-competitive acts, acts of commercial wrongdoing, or
    failure to meet any standard of conduct which is or may be applicable to such acts, omissions or circumstances.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">4. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Approval of and recommendation or information provided to shareholders
    with respect to any and all corporate actions, including the approval of the acts of the Company&#8217;s management, their guidance
    and their supervision, matters relating to the approval of transactions with Office Holders (including, without limitation, all compensation
    related matters) or shareholders, including controlling persons and claims and allegations of failure to exercise business judgment,
    reasonable level of proficiency, expertise, care or any other applicable standard, with respect to the foregoing or otherwise with
    respect to the Company&#8217;s business, strategy, operations and prospective outlook, and any discussions, deliberations, reviews
    or other preparatory or preliminary phases relating to any of the foregoing.&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">5. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Violation, infringement, misappropriation, dilution and other misuse
    of copyrights, patents, designs, trade secrets, confidential information, proprietary information and any intellectual property rights,
    acts in connection with the registration, assertion or protection of rights to intellectual property and the defense of claims related
    to intellectual property, breach of confidentiality obligations, acts in regard of invasion of privacy or any violation of privacy
    or privacy related right or regulation, including with respect to databases or handling, collection or use of private information,
    acts in connection with slander and defamation, and claims in connection with publishing or providing any information, including
    any filings with any governmental authorities, whether or not required under any applicable laws.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">6. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Violations of or failure to comply with securities laws, and any regulations
    or other rules promulgated thereunder, of any jurisdiction, including without limitation, claims under the U.S. Securities Act of
    1933 or the U.S. Exchange Act of 1934 or under the Israeli Securities Law, fraudulent disclosure claims, failure to comply with any
    securities authority or any stock exchange disclosure or other rules and any other claims relating to relationships with investors,
    debt holders, shareholders, optionholders, holders of any other equity or debt instrument of the Company, and otherwise with the
    investment community (including without limitation any such claims relating to a merger, acquisition, change in control transaction,
    issuance of securities, restructuring, spin out, spin off, divestiture, recapitalization or any other transaction relating to the
    corporate structure or organization of the Company); claims relating to or arising out of financing arrangements, any breach of financial
    covenants or other obligations towards investors, lenders or debt holders, class actions, violations of laws requiring the Company
    to obtain regulatory and governmental licenses, permits and authorizations in any jurisdiction, including in connection with disclosure,
    offering or other transaction related documents; actions taken in connection with the issuance, purchase, holding or disposition
    of any type of securities of Company, including, without limitation, the grant of options, warrants or other rights to purchase any
    of the same or any offering of the Company&#8217;s securities (whether on behalf of the Company or on behalf of any holders of securities
    of the Company) to private investors, underwriters, resellers or to the public, and listing of such securities, or the offer by the
    Company to purchase securities from the public or from private investors or other holders, and any undertakings, representations,
    warranties and other obligations related to any of the foregoing or to the Company&#8217;s status as a public company or as an issuer
    of securities.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 277 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 5%"><span style="font-size: 10pt">7. </span></td>
    <td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Liabilities arising in connection with any products or
    services developed, distributed, rendered, sold, provided, licensed or marketed by the Company or any Affiliate thereof, and any
    actions or omissions in connection with the distribution, provision, sale, marketing, license or use of such products or services,
    including without limitation in connection with professional liability and product liability claims or regulatory or reputational
    matters.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">8. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The offering of securities by the Company (whether on behalf of itself
    or on behalf of any holder of securities and any other person) to the public and/or to offerees or the offer by the Company to purchase
    securities from the public and/or from private investors or other holders pursuant to a prospectus, offering documents, agreements,
    notices, reports, tenders and/or other processes.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">9. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Events, facts or circumstances in connection with change in ownership
    or in the structure of the Company, its reorganization, dissolution, winding up, any other arrangements concerning creditors rights,
    merger, change in control, issuances of securities, restructuring, spin out, spin off, divestiture, recapitalization or any other
    transaction relating to the corporate structure or organization of the Company, and the approval of failure to approve of any corporate
    actions and any matters relating to corporate governance, capital structure, articles of association or other charter or governance
    documents, appointment or dismissal of office holders or compensation thereof and appointment or dismissal of auditors, internal
    auditor or any other person performing any services for the Company.&#160;&#160;&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">10. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand made in connection with any transaction not in
    the ordinary course of business of the Company, as well as the sale, lease, purchase or acquisition of, or the receipt or grant of
    any rights with respect to, any assets or business.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">11. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand made by any third party suffering any personal
    injury and/or bodily injury or damage to business or personal property or any other type of damage through any act or omission attributed
    to the Company, or its employees, agents or other persons acting or allegedly acting on its behalf, including, without limitation,
    failure to make proper safety arrangements for the Company or its employees and liabilities arising from any accidental or continuous
    damage or harm to the Company&#8217;s employees, its contractors, its guests and visitors as a result of an accidental or continuous
    event, or employment conditions, permanent or temporary, in the Company&#8217;s offices.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">12. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand made directly or indirectly in connection with
    complete or partial failure, by the Company or its directors, officers and employees, to pay, report, keep applicable records or
    otherwise, of any local or foreign federal, state, county, municipal or city taxes or other taxes or compulsory payments of any nature
    whatsoever, including, without limitation, income, sales, use, transfer, excise, value added, registration, severance, stamp, occupation,
    customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll or employee
    withholding or other withholding, including any interest, penalty or addition thereto, whether disputed or not.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 278 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 5%"><span style="font-size: 10pt">13. </span></td>
    <td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Any administrative, regulatory, judicial or civil actions
    orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance
    or violation by any governmental entity or other person alleging potential responsibility or liability (including potential responsibility
    or liability for costs of enforcement investigation, cleanup, governmental response, removal or remediation, for natural resources
    damages, property damage, personal injuries or penalties or for contribution,&#160;&#160;indemnification, cost recovery, compensation
    or injunctive relief) arising out of, based on or related to (a) the presence of, release, spill, emission, leaning, dumping, pouring,
    deposit, disposal, discharge, leaching or migration into the environment (each a &#8220;<b>Release</b>&#8221;) or threatened Release
    of, or exposure to, any hazardous, toxic, explosive or radioactive substances, wastes or other pollutants, including petroleum or
    petroleum distillates, asbestos or asbestos-containing material, polychlorinated biphenyls (&#8220;<b>PCBs</b>&#8221;) or PCB-containing
    materials or equipment, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant
    to any environmental law, at any location, whether or not owned, operated, leased or managed by the Company or any of its subsidiaries,
    or (b) circumstances forming the basis of any violation of any environmental law or environmental permit, license, registration or
    other authorization required under applicable environmental law.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">14. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any administrative, regulatory or judicial actions, orders, decrees,
    suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance or violation by
    any governmental or regulatory entity or authority or any other person alleging the failure to comply with any statute, law, ordinance,
    rule, regulation, order or decree of any governmental entity applicable to the Company or any of its businesses, assets or operations,
    or the terms and conditions of any operating certificate or licensing agreement, and without derogating from the generality of the
    above, including the Israel Innovation Authority or the Investment Center at the Ministry of Industry and Trade, the Antitrust Authority
    and/or the Securities Authority in Israel and/or the U.S.A. and/or in any other country and/or location, the Ministry of Health and/or
    any competent food and drug administrations in Israel, the U.S.A.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">15. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Participation and/or non-participation at Company Board meetings, expression
    of opinion or view and/or voting and/or abstention from voting at Company Board meetings, including, in each case, any committee
    thereof, as well as expression of opinion publicly in connection with the service as an Office Holder.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">16. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Review and approval of the Company&#8217;s financial statements and
    any specific items or matters within, including any action, consent or approval related to or arising from the foregoing, including,
    without limitations, engagement of or execution of certificates for the benefit of third parties related to the financial statements.&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">17. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Violation of laws, rules or regulations requiring the Company to obtain
    regulatory and governmental licenses, permits and authorizations (including without limitation relating to export, import, encryption,
    antitrust or competition authorities) or laws related to any governmental grants in any jurisdiction. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">18. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Resolutions and/or actions relating to investments in the Company and/or
    its subsidiaries and/or affiliated companies and/or investment in corporate or other entities and/or investments in other traded
    or non-traded securities and/or any other form of investment.&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">19. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Liabilities arising out of advertising, including misrepresentations
    regarding the Company&#8217;s products or services and unlawful distribution of emails.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">20. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Management of the Company&#8217;s bank accounts, including money management,
    foreign currency deposits, securities, loans and credit facilities, credit cards, bank guarantees, letters of credit, consultation
    agreements concerning investments including with portfolio managers, hedging transactions, options, futures, and the like.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">21. </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">All actions, consents and approvals, including any prior discussions,
    reviews and deliberations, relating to a distribution of dividends, in cash or otherwise, or to any other &#8220;distribution&#8221;
    as such term is defined under the Companies Law.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 279 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 5%"><span style="font-size: 10pt">22. </span></td>
    <td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Any administrative, regulatory, judicial, civil or criminal,
    actions orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices of noncompliance,
    violation or breaches alleging potential responsibility, liability, loss or damage (including potential responsibility or liability
    for costs of enforcement, investigation, cleanup, governmental response, removal or remediation, property damage or penalties, or
    for contribution,&#160;&#160;indemnification, cost recovery, compensation or injunctive relief), whether alleged or claimed by customers,
    consumers, regulators, shareholders or others, arising out of, based on or related to: (a) cyber security, cyber attacks, data loss
    or breaches, unauthorized access to information, data, or databases (including but not limited to any personally identifiable information
    or private health information) and use or disclosure of information contained therein, not preventing or detecting the breach or
    failing to otherwise disclose or respond to the breach; (b) circumstances forming the basis of any violation of any law, permit,
    license, registration or other authorization required under applicable law governing data security, data protection, network security,
    information systems, privacy or any cyber environment (including, users, networks, devices, software, processes, information systems,
    databases, information in storage or transit, applications, services, and systems that can be connected directly or indirectly to
    networks); (c) failure to implement a reporting system or control, or failure to monitor or oversee the operation of such a system;
    (d) data destruction, extortion, theft, hacking, and denial of service attacks; losses or liabilities to others caused by errors
    and omissions, failure to safeguard data or defamation; or (e) security-audit, post-incident public relations and investigative expenses,
    criminal reward funds, data breach/privacy crisis management (including, management of an incident, investigation, remediation, data
    subject notification, call management, credit checking for data subjects, legal costs, court attendance and regulatory fines), extortion
    liability (including, losses due to a threat of extortion, professional fees related to dealing with the extortion), or network security
    liability (including, losses as a result of denial of access, costs related to data on third-parties and costs related to the theft
    of data on third-party systems).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">23.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any claim or demand instituted in connection with the acts of the Company
    and/or its subsidiaries and/or affiliates, as shall exist from time to time, concerning the Company&#8217;s field of activities and
    operations, as shall be conducted from time to time, and including in connection with the research, development, manufacture, commercialization,
    marketing and/or sale of pharmaceuticals and/or medical instruments and/or any act directly and/or indirectly associated with the
    execution of the aforesaid acts, including and without derogating from the generality of the above, in connection with clinical and
    preclinical trials, as well as in connection with actions associated with the promotion, marketing and/or support of products, solutions
    and technologies in the Company&#8217;s field of activity.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Limit Amount
        for all Indemnifiable Persons during each relevant period referred to in Section 1.2 of the Indemnification Agreement for all
        events described in this <span style="text-decoration:underline">Exhibit A</span> (in Sections 1-23 (inclusive) above), shall be the greater of:</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">(a)&#160;twenty-five
    percent (25%)&#160;of the Company&#8217;s total shareholders&#8217; equity according to the Company&#8217;s most recent financial
    statements as of the time of the actual payment of indemnification;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">(b)&#160;US$
    7.5 million;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">(c)
    ten percent (10%) of the Company&#8217;s Total Market Cap (which shall mean the average closing price of the Company&#8217;s ordinary
    shares over the 30 trading days prior to the actual payment of indemnification multiplied by the total number of issued and outstanding
    shares of the Company as of the date of actual payment); and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">(d)&#160;in
    connection with or arising out of a public offering of the Company&#8217;s securities, the aggregate amount of proceeds from the
    sale by the Company and/or any shareholder of Company&#8217;s securities in such offering.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Any reference in
                                            this <span style="text-decoration:underline">Exhibit A</span> to the Company shall include the Company and any entity in which the
                                            Indemnitee serves in a Corporate Capacity.</td>
</tr></table><div>
</div><p style="margin: 0">&#160;</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>


</div><!-- Field: Page; Sequence: 280 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><div><a id="B_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ANNEX
D</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE COMPANIES LAW, 1999</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A LIMITED LIABILITY COMPANY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AMENDED AND RESTATED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ARTICLES OF ASSOCIATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SCISPARC LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">As Adopted on June 26, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Preliminary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Definitions;
    Interpretation</span></b>. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In these
    Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless
    the subject or context requires otherwise.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 180px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Affiliate&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect to any specified
    person, shall mean, any other person who or which, directly or indirectly, controls, is controlled by, or is under common control
    with such specified person.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Articles&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean these Amended
    and Restated Articles of Association, as amended from time to time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Board of Directors&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Board of
    Directors of the Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Chairperson&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Chairperson
    of the Board of Directors, or the Chairperson of the General Meeting, as the context implies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#8220;Companies
    Law&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Israeli
    Companies Law, 5759-1999 and the regulations promulgated thereunder.&#160;The Companies Law shall include reference to the Companies
    Ordinance (New Version), 5743-1983, of the State of Israel, to the extent in effect according to the provisions thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Company&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean SciSparc Ltd.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Director(s)&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the member(s)
    of the Board of Directors holding office at a given time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Economic Competition
    Law&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Israeli
    Economic Competition Law, 5758-1988 and the regulations promulgated thereunder.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Effective Time&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the effective
    time of these Articles.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;External Director(s)&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning
    provided for such term in the Companies Law.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;General Meeting&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean an Annual General
    Meeting or Special General Meeting of the Shareholders (each as defined in Article 23 of these Articles), as the case may be.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NIS&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean New Israeli
    Shekels.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Office&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the registered
    office of the Company at any given time.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 180px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Office
    Holder&#8221; or &#8220;Officer&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning
    provided for such term in the Companies Law.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Ordinary Resolution&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a resolution adopted
    at the (Annual or Special) General Meeting by a majority of those voting and without counting the abstaining votes.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities Law&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Israeli
    Securities Law, 5728-1968, and the regulations promulgated thereunder. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Shareholder(s)&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the shareholder(s)
    of the Company, at any given time.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Stock Exchange&#8221;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall mean the Nasdaq Stock
    Market or on any other stock exchange on which the Company&#8217;s ordinary shares are then listed for trading.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 281; Options: NewSection --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless the context shall
    otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding
    masculine, feminine and neuter forms; the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be
    deemed to be followed by the phrase &#8220;without limitation&#8221;; the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;
    and words of similar import refer to these Articles in their entirety and not to any part hereof; all references herein to Articles
    or clauses shall be deemed references to Articles or clauses of these Articles; any references to any agreement or other instrument
    or law, statute or regulation are to it as amended, supplemented or restated, from time to time (and, in the case of any law, to
    any successor provisions or re-enactment or modification thereof being in force at the time); any reference to &#8220;law&#8221;
    shall include any law (&#8217;<i>din</i>&#8217;) as defined in the Interpretation Law, 5741-1981 and any applicable supranational,
    national, federal, state, local, or foreign statute or law and shall be deemed also to refer to all rules and regulations promulgated
    thereunder; any reference to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without any explicit reference otherwise, such
    as to business days) shall be interpreted as a reference to a calendar day or number of calendar days; any reference to a business
    day shall mean each calendar day other than any calendar day on which commercial banks in New York, New York or Tel-Aviv, Israel
    are authorized or required by applicable law to close; reference to a month or year means according to the Gregorian calendar; any
    reference to a &#8220;person&#8221; shall mean any individual, partnership, corporation, limited liability company, association,
    estate, any political, governmental, regulatory or similar agency or body, or other legal entity; and reference to &#8220;written&#8221;
    or &#8220;in writing&#8221; shall include written, printed, photocopied, typed, any electronic communication (including email, facsimile,
    signed electronically (in Adobe PDF, DocuSign or any other format)) or produced by any visible substitute for writing, or partly
    one and partly another, and signed shall be construed accordingly.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The captions in these Articles
    are for convenience only and shall not be deemed a part hereof or affect the construction or interpretation of any provision hereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The specific provisions
    of these Articles shall supersede the provisions of the Companies Law to the extent permitted thereunder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Limited
Liability</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a limited
    liability company and each Shareholder&#8217;s liability for the Company&#8217;s debt is therefore limited (in addition to any liabilities
    under any contract) to the payment of the full amount (par value (if any) and premium) such Shareholder was required to pay the Company
    for such Shareholder&#8217;s Shares (as defined below) and which amount has not yet been paid by such Shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Company&#8217;s
Objectives</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Objectives</span></b>.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company&#8217;s objectives are
to carry on any business, and do any act, which is not prohibited by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Donations</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Company may donate a reasonable
amount of money (in cash or in kind, including the Company&#8217;s securities) to worthy purposes such as the Board of Directors may
determine in its discretion, even if such donations are not made on the basis or within the scope of business considerations of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Share
Capital</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Authorized
    Share Capital</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The authorized share capital
                                    of the Company shall consist of 2,000,000,000 Ordinary Shares without par value (the &#8220;<b>Shares</b>&#8221;).</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Shares shall rank <i>pari
    passu</i> in all respects. The Shares may be redeemable to the extent set forth in Article 18.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 282 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Increase
    of Authorized Share Capital</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time
    to time, by a Shareholders&#8217; resolution, whether or not all of the Shares then authorized have been issued, and whether or not
    all of the Shares theretofore issued have been called up for payment, increase its authorized share capital by increasing the number
    of Shares it is authorized to issue by such amount, and such additional Shares shall confer such rights and preferences, and shall
    be subject to such restrictions, as such resolution shall provide.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent otherwise
    provided in such resolution, any new Shares included in the authorized share capital increase as aforesaid shall be subject to all
    of the provisions of these Articles that are applicable to Shares that are included in the existing share capital.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Special
    or Class Rights; Modification of Rights</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time
    to time, by a Shareholders&#8217; resolution, provide for shares with such preferred or deferred rights or other special rights and/or
    such restrictions, whether in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such
    resolution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If at any time the share
    capital of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by
    these Articles, may be modified or cancelled by the Company by a resolution of the General Meeting of the holders of all shares as
    one class, without any required separate resolution of any class of shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of these
    Articles relating to General Meetings shall apply, <i>mutatis mutandis</i>, to any separate General Meeting of the holders of the
    shares of a particular class, it being clarified that the requisite quorum at any such separate General Meeting shall be Shareholders
    present in person or by proxy and holding not less than thirty-three and one-third percent (33&#8531;%) of the issued shares of
    such class, <i>provided</i>, <i>however</i>, that if (i) such separate General Meeting of the holders of the particular class was
    initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of such meeting the Company
    is qualified to use the forms of a &#8220;foreign private issuer&#8221; under US securities laws, then the requisite quorum at any
    such separate General Meeting shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present
    in person or by proxy and holding not less than fifteen percent (15%) of the issued shares of such class.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise provided
    by these Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized
    share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital,
    shall not be deemed, for purposes of this Article 7, to modify or derogate or cancel the rights attached to previously issued shares
    of such class or of any other class.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Consolidation,
    Division, Cancellation and Reduction of Share Capital</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time
    to time, by or pursuant to an authorization of a Shareholders&#8217; resolution, and subject to applicable law:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">consolidate
                                            all or any part of its issued or unissued authorized share capital;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">divide
                                            or sub-divide its Shares (issued or unissued) or any of them and the resolution whereby any
                                            Share is divided may determine that, as among the holders of the Shares resulting from such
                                            subdivision, one or more of the Shares may, in contrast to others, have any such preferred
                                            or deferred rights or rights of redemption or other special rights, or be subject to any
                                            such restrictions, as the Company may attach to unissued or new shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="padding-bottom: 0; width: 1in; text-align: right"/><td style="padding-bottom: 0; width: 0.25in">(iii)</td><td style="padding-bottom: 0; text-align: justify">cancel
                                            any authorized Shares which, at the date of the adoption of such resolution, have not been
                                            issued to any person nor has the Company made any commitment, including a conditional commitment,
                                            to issue such Shares, and reduce the amount of its share capital by the amount of the Shares
                                            so canceled; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="padding-bottom: 0; width: 1in; text-align: right"/><td style="padding-bottom: 0; width: 0.25in">(iv)</td><td style="padding-bottom: 0; text-align: justify">reduce
                                            its share capital in any manner.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 0; width: 47px">&#160;</td>
    <td style="padding-bottom: 0; width: 32px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="padding-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    respect to any consolidation of issued Shares and with respect to any other action which may result in fractional Shares, the Board
    of Directors may settle any difficulty which may arise with regard thereto, as it deems fit, and, in connection with any such consolidation
    or other action which could result in fractional shares, may, without limiting its aforesaid power:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="padding-bottom: 0; width: 1in; text-align: right"/><td style="padding-bottom: 0; width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">determine,
                                            as to the holder of Shares so consolidated, which issued Shares shall be consolidated;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">issue,
                                            in contemplation of or subsequent to such consolidation or other action, Shares sufficient
                                            to preclude or remove fractional share holdings;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="text-align: justify">redeem such
                                            Shares or fractional shares sufficient to preclude or remove fractional Share holdings;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 283 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="text-align: justify">round up, round
                                            down or round to the nearest whole number, any fractional Shares resulting from the consolidation
                                            or from any other action which may result in fractional Shares; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(v)</td><td style="text-align: justify">cause the transfer
                                            of fractional Shares by certain Shareholders of the Company to other Shareholders thereof
                                            so as to most expediently preclude or remove any fractional Share holdings, and cause the
                                            transferees of such fractional Shares to pay the transferors thereof the fair value thereof,
                                            and the Board of Directors is hereby authorized to act in connection with such transfer,
                                            as agent for the transferors and transferees of any such fractional Shares, with full power
                                            of substitution, for the purposes of implementing the provisions of this sub-Article&#160;8(b)(v).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Issuance
    of Share Certificates, Replacement of Lost Certificates</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that the
    Board of Directors determines that all Shares shall be certificated or, if the Board of Directors does not so determine, to the extent
    that any Shareholder requests a share certificate or the Company&#8217;s transfer agent so requires, share certificates shall be
    issued under the corporate seal of the Company or its written, typed or stamped name and shall bear the signature of one Director,
    the Company&#8217;s Chief Executive Officer, or any person or persons authorized therefor by the Board of Directors. Signatures may
    be affixed in any mechanical or electronic form, as the Board of Directors may prescribe.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the provisions
    of Article 9(a), each Shareholder shall be entitled to one numbered certificate for all of the Shares of any class registered in
    his or her name. Each certificate shall specify the serial numbers of the Shares represented thereby and may also specify the amount
    paid up thereon. The Company (as determined by an officer of the Company to be designated by the Chief Executive Officer) shall not
    refuse a request by a Shareholder to obtain several certificates in place of one certificate, unless such request is, in the opinion
    of such officer, unreasonable. Where a Shareholder has sold or transferred a portion of such Shareholder&#8217;s Shares, such Shareholder
    shall be entitled to receive a certificate in respect of such Shareholder&#8217;s remaining Shares, <i>provided</i> that the previous
    certificate is delivered to the Company before the issuance of a new certificate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A share certificate registered
    in the names of two or more persons shall be delivered to the person first named in the Register of Shareholders in respect of such
    co-ownership.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A share certificate which
    has been defaced, lost or destroyed, may be replaced, and the Company shall issue a new certificate to replace such defaced, lost
    or destroyed certificate upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the
    Board of Directors in its discretion deems fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Registered
    Holder</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Except as otherwise provided in these
Articles or the Companies Law, the Company shall be entitled to treat the registered holder of each Share as the absolute owner thereof,
and accordingly, shall not, except as ordered by a court of competent jurisdiction, or as required by the Companies Law, be obligated
to recognize any equitable or other claim to, or interest in, such Share on the part of any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Issuance
    and Repurchase of Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unissued Shares from
    time to time shall be under the control of the Board of Directors (and, to the extent permitted by applicable law, any Committee
    thereof), which shall have the power to issue or otherwise dispose of Shares and of securities convertible or exercisable into or
    other rights to acquire from the Company to such persons, on such terms and conditions (including, inter alia, price, with or without
    premium, discount or commission, and terms relating to calls set forth in Article 13(f) hereof), and at such times, as the Board
    of Directors (or the Committee, as the case may be) deems fit, and the power to give to any person the option to acquire from the
    Company any Shares or securities convertible or exercisable into or other rights to acquire from the Company on such terms and conditions
    (including, inter alia, price, with or without premium, discount or commission), during such time as the Board of Directors (or the
    Committee, as the case may be) deems fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may at any
    time and from time to time, subject to applicable law, repurchase or finance the purchase of any Shares or other securities issued
    by the Company, in such manner and under such terms as the Board of Directors shall determine, whether from any one or more Shareholders.
    Such purchase shall not be deemed as payment of dividends and as such, no Shareholder will have the right to require the Company
    to purchase his or her Shares or offer to purchase shares from any other Shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 284 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Payment
    in Installment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If pursuant to the terms of issuance
of any Share, all or any portion of the price thereof shall be payable in installments, every such installment shall be paid to the Company
on the due date thereof by the then registered holder(s) of the Share or the person(s) then entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Calls
    on Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors
    may, from time to time, as it, in its discretion, deems fit, make calls for payment upon Shareholders in respect of any sum (including
    premium) which has not been paid up in respect of Shares held by such Shareholders and which is not, pursuant to the terms of issuance
    of such Shares or otherwise, payable at a fixed time, and each Shareholder shall pay the amount of every call so made upon him or
    her (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated
    by the Board of Directors, as any such times may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise
    stipulated in the resolution of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call
    shall be deemed to constitute a pro rata payment on account of all the Shares in respect of which such call was made.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of any call for
    payment by a Shareholder shall be given in writing to such Shareholder not less than fourteen (14) days prior to the time of payment
    fixed in such notice, and shall specify the time and place of payment, and the person to whom such payment is to be made. Prior to
    the time for any such payment fixed in a notice of a call given to a Shareholder, the Board of Directors may in its absolute discretion,
    by notice in writing to such Shareholder, revoke such call in whole or in part, extend the time fixed for payment thereof, or designate
    a different place of payment or person to whom payment is to be made. In the event of a call payable in installments, only one notice
    thereof need be given.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If pursuant to the terms
    of issuance of a share or otherwise, an amount is made payable at a fixed time, such amount shall be payable at such time as if it
    were payable by virtue of a call made by the Board of Directors and for which notice was given in accordance with paragraphs (a)
    and (b) of this Article 13, and the provision of these Articles with regard to calls (and the non-payment thereof) shall be applicable
    to such amount or such installment (and the non-payment thereof).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint holders of a Share
    shall be jointly and severally liable to pay all calls for payment in respect of such Share and all interest payable thereon.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any amount called for payment
    which is not paid when due shall bear interest from the date fixed for payment until actual payment thereof, at such rate (not exceeding
    the then prevailing debitory rate charged by leading commercial banks in Israel), and payable at such time(s) as the Board of Directors
    may prescribe.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the issuance of Shares,
    the Board of Directors may provide for differences among the holders of such Shares as to the amounts and times for payment of calls
    for payment in respect of such Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Prepayment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">With the approval of the Board of Directors,
any Shareholder may pay to the Company any amount not yet payable in respect of his or her Shares, and the Board of Directors may approve
the payment by the Company of interest on any such amount until the same would be payable if it had not been paid in advance, at such
rate and time(s) as may be approved by the Board of Directors. The Board of Directors may at any time cause the Company to repay all
or any part of the money so advanced, without premium or penalty. Nothing in this Article 14 shall derogate from the right of the Board
of Directors to make any call for payment before or after receipt by the Company of any such advance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Forfeiture
    and Surrender</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any Shareholder fails
    to pay an amount payable by virtue of a call, installment or interest thereon as provided for in accordance herewith, on or before
    the day fixed for payment of the same, the Board of Directors may at any time after the day fixed for such payment, so long as such
    amount (or any portion thereof) or interest thereon (or any portion thereof) remains unpaid, forfeit all or any of the Shares in
    respect of which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest
    thereon, including, without limitation, attorneys&#8217; fees and costs of legal proceedings, shall be added to, and shall, for all
    purposes (including the accrual of interest thereon) constitute a part of, the amount payable to the Company in respect of such call.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 285 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the adoption of a
    resolution as to the forfeiture of a Shareholder&#8217;s Share, the Board of Directors shall cause notice thereof to be given to
    such Shareholder, which notice shall state that, in the event of the failure to pay the entire amount so payable by a date specified
    in the notice (which date shall be not less than fourteen (14) days after the date such notice is given and which may be extended
    by the Board of Directors), such Shares shall be ipso facto forfeited, <i>provided</i>, <i>however</i>, that, prior to such date,
    the Board of Directors may cancel such resolution of forfeiture, but no such cancellation shall stop the Board of Directors from
    adopting a further resolution of forfeiture in respect of the non-payment of the same amount.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without derogating from
    Articles 51 and 55 hereof, whenever Shares are forfeited as herein provided, all dividends, if any, theretofore declared in respect
    thereof and not actually paid shall be deemed to have been forfeited at the same time.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, by resolution
    of the Board of Directors, may accept the voluntary surrender of any Share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Share forfeited or
    surrendered as provided herein, shall become the property of the Company as a dormant Share, and the same, subject to the provisions
    of these Articles, may be sold, re-issued or otherwise disposed of as the Board of Directors deems fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any person whose Shares
    have been forfeited or surrendered shall cease to be a Shareholder in respect of the forfeited or surrendered Shares, but shall,
    notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect
    of such Shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until
    actual payment, at the rate prescribed in Article 13(e) above, and the Board of Directors, in its discretion, may, but shall not
    be obligated to, enforce or collect the payment of such amounts, or any part thereof, as it shall deem fit. In the event of such
    forfeiture or surrender, the Company, by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all
    amounts then owing to the Company by the person in question (but not yet due) in respect of all Shares owned by such Shareholder,
    solely or jointly with another.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors
    may at any time, before any Share so forfeited or surrendered shall have been sold, re-issued or otherwise disposed of, nullify the
    forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the Board of Directors from re-exercising
    its powers of forfeiture pursuant to this Article 15.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Lien</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent the
    same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the Shares registered in
    the name of each Shareholder (without regard to any equitable or other claim or interest in such Shares on the part of any other
    person), and upon the proceeds of the sale thereof, for his or her debts, liabilities and engagements to the Company arising from
    any amount payable by such Shareholder in respect of any unpaid or partly paid Share, whether or not such debt, liability or engagement
    has matured. Such lien shall extend to all dividends from time to time declared or paid in respect of such Share. Unless otherwise
    provided, the registration by the Company of a transfer of Shares shall be deemed to be a waiver on the part of the Company of the
    lien (if any) existing on such Shares immediately prior to such transfer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 286 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors
    may cause the Company to sell a Share subject to such a lien when the debt, liability or engagement giving rise to such lien has
    matured, in such manner as the Board of Directors deems fit, but no such sale shall be made unless such debt, liability or engagement
    has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served on such Shareholder,
    his or her executors or administrators.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net proceeds of any
    such sale, after payment of the costs and expenses thereof or ancillary thereto, shall be applied in or toward satisfaction of the
    debts, liabilities or engagements of such Shareholder in respect of such Share (whether or not the same have matured), and the remaining
    proceeds (if any) shall be paid to the Shareholder, his or her executors, administrators or assigns.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Sale
    After Forfeiture or Surrender or For Enforcement of Lien</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon any sale of a share after forfeiture
or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute an instrument of transfer of the Share
so sold and cause the purchaser&#8217;s name to be entered in the Register of Shareholders in respect of such Share. The purchaser shall
be registered as the Shareholder and shall not be bound to see to the regularity of the sale proceedings, or to the application of the
proceeds of such sale, and after his or her name has been entered in the Register of Shareholders in respect of such Share, the validity
of the sale shall not be impeached by any person, and the remedy of any person aggrieved by the sale shall be in damages only and against
the Company exclusively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Redeemable
    Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may, subject to applicable
law, issue redeemable shares or other securities and redeem the same upon terms and conditions to be set forth in a written agreement
between the Company and the holder of such shares or in their terms of issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Transfer
of Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Registration
    of Transfer</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.05pt">No transfer of
Shares shall be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to
the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer) has been submitted to the Company
(or its transfer agent), together with any share certificate(s) and such other evidence of title as the Board of Directors or an officer
of the Company to be designated by the Chief Executive Officer may require. Notwithstanding anything to the contrary herein, Shares registered
in the name of The Depository Trust Company or its nominee shall be transferrable in accordance with the policies and procedures of The
Depository Trust Company. Until the transferee has been registered in the Register of Shareholders in respect of the Shares so transferred,
the Company may continue to regard the transferor as the owner thereof. The Board of Directors, may, from time to time, prescribe a fee
for the registration of a transfer, and may approve other methods of recognizing the transfer of Shares in order to facilitate the trading
of the Company&#8217;s shares on the Stock Exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.05pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Suspension
    of Registration</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Board of Directors may, in its
discretion to the extent it deems necessary, close the Register of Shareholders of registration of transfers of Shares for a period determined
by the Board of Directors, and no registrations of transfers of Shares shall be made by the Company during any such period during which
the Register of Shareholders is so closed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Transmission
of Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Decedents&#8217;
    Shares</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Upon the death of a Shareholder,
the Company shall recognize the custodian or administrator of the estate or executor of the will, and in the absence of such, the lawful
heirs of the Shareholder, as the only holders of the right for the Shares of the deceased Shareholder, after receipt of evidence to the
entitlement thereto, as determined by the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Receivers
    and Liquidators</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may recognize
    any receiver, liquidator or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder, and a
    trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or
    similar proceeding with respect to a Shareholder or its properties, as being entitled to the Shares registered in the name of such
    Shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 287 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such receiver, liquidator
    or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder and such trustee, manager, receiver,
    liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceedings with respect
    to a Shareholder or its properties, upon producing such evidence as the Board of Directors (or an officer of the Company to be designated
    by the Chief Executive Officer) may deem sufficient as to his or her authority to act in such capacity or under this Article, shall
    with the consent of the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer (which the
    Board of Directors or such officer may grant or refuse in its absolute discretion), be registered as a Shareholder in respect of
    such Shares, or may, subject to the regulations as to transfer herein contained, transfer such Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center"><span style="font-variant: small-caps"><b>General
Meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">General
    Meetings</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual General Meeting
    (&#8220;<b>Annual General Meeting</b>&#8221;) shall be held at such time and at such place, either within or outside of the State
    of Israel, as may be determined by the Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All General Meetings other
    than Annual General Meetings shall be called &#8220;<b>Special General Meetings</b>&#8221;. The Board of Directors may, at its discretion,
    convene a Special General Meeting at such time and place, within or outside of the State of Israel, as may be determined by the Board
    of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If so determined by the
    Board of Directors, an Annual General Meeting or a Special General Meeting may be held through the use of any means of communication
    approved by the Board of Directors, provided all of the participating Shareholders can hear each other simultaneously. A resolution
    approved by use of means of communications as aforesaid, shall be deemed to be a resolution lawfully adopted at such general meeting
    and a Shareholder shall be deemed present in person at such general meeting if attending such meeting through the means of communication
    used at such meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Record
    Date for General Meeting</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">Notwithstanding any provision of these
Articles to the contrary, and to allow the Company to determine the Shareholders entitled to notice of or to vote at any General Meeting
or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or grant of any rights, or entitled
to exercise any rights in respect of or to take or be the subject of any other action, the Board of Directors may fix a record date for
the General Meeting, which shall not be more than the maximum period and not less than the minimum period permitted by law. A determination
of Shareholders of record entitled to notice of or to vote at a General Meeting shall apply to any adjournment of the meeting; <span style="text-decoration:underline">provided</span>,
<span style="text-decoration:underline">however</span>, that the Board of Directors may fix a new record date for the adjourned meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Shareholder
    Proposal Request</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Shareholder
    or Shareholders of the Company holding at least the required percentage under the Companies Law of the voting rights of the Company
    which entitles such Shareholder(s) to require the Company to include a matter on the agenda of a General Meeting (the &#8220;<b>Proposing
    Shareholder(s)</b>&#8221;) may request, subject to the Companies Law, that the Board of Directors include a matter on the agenda
    of a General Meeting to be held in the future, provided that the Board of Directors determines that the matter is appropriate to
    be considered at a General Meeting (a &#8220;<b>Proposal Request</b>&#8221;). In order for the Board of Directors to consider a Proposal
    Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must
    be timely delivered in accordance with applicable law, and the Proposal Request must comply with the requirements of these Articles
    (including this Article 25) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing,
    signed by all of the Proposing Shareholder(s) making such request, delivered, either in person or by registered mail, postage prepaid,
    and received by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company). To be considered timely,
    a Proposal Request must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement
    of a General Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described
    above. In addition to any information required to be included in accordance with applicable law, a Proposal Request must include
    the following: (i) the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing
    Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number
    of Shares held by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation
    of how they are held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder,
    accompanied by evidence satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the
    date of the Proposal Request; (iii) the matter requested to be included on the agenda of a General Meeting, all information related
    to such matter, the reason that such matter is proposed to be brought before the General Meeting, the complete text of the resolution
    that the Proposing Shareholder proposes to be voted upon at the General Meeting, and a representation that the Proposing Shareholder(s)
    intend to appear in person or by proxy at the meeting; (iv) a description of all arrangements or understandings between the Proposing
    Shareholders and any other person(s) (naming such person or persons) in connection with the matter that is requested to be included
    on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a personal interest in the matter
    and, if so, a description in reasonable detail of such personal interest; (v) a description of all Derivative Transactions (as defined
    below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of the transactions and
    the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions; and (vi)
    a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange
    rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The
    Board of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional
    information necessary so as to include a matter in the agenda of a General Meeting, as the Board of Directors may reasonably require.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 288 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A &#8220;<b>Derivative Transaction</b>&#8221;
means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder
or any of its Affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the
value of any class or series of shares or other securities of the Company, (2) which otherwise provides any direct or indirect opportunity
to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to
mitigate loss, manage risk or benefit of security value or price changes, or (4) which provides the right to vote or increase or decrease
the voting power of, such Proposing Shareholder, or any of its Affiliates or associates, with respect to any Shares or other securities
of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position,
note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting
agreement, performance-related fee or arrangement to borrow or lend Shares (whether or not subject to payment, settlement, exercise or
conversion in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company
held by any general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly,
a general partner or managing member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information
    required pursuant to this Article shall be updated as of (i) the record date of the General Meeting, (ii) five business days before
    the General Meeting, and (iii) as of the General Meeting, and any adjournment or postponement thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions
    of Articles 25(a) and 25(b) shall apply, <i>mutatis mutandis,</i> to any matter to be included on the agenda of a Special General
    Meeting which is convened pursuant to a request of a Shareholder duly delivered to the Company in accordance with the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Notice
    of General Meetings; Omission to Give Notice</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
    is not required to give notice of a General Meeting, subject to any mandatory provision of the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accidental
    omission to give notice of a General Meeting to any Shareholder, or the non-receipt of notice sent to such Shareholder, shall not
    invalidate the proceedings at such meeting or any resolution adopted thereat.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Shareholder
    present, in person or by proxy, at any time during a General Meeting shall be entitled to seek the cancellation or invalidation of
    any proceedings or resolutions adopted at such General Meeting on account of any defect in the notice of such meeting relating to
    the time or the place thereof, or any item acted upon at such meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition
    to any places at which the Company may make available for review by Shareholders the full text of the proposed resolutions to be
    adopted at a General Meeting, as required by the Companies Law, the Company may add additional places for Shareholders to review
    such proposed resolutions, including an internet site.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 289 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Proceedings
at General Meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Quorum</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No business
    shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles for such
    General Meeting or such adjourned meeting, as the case may be, is present when the meeting proceeds to business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the
    absence of contrary provisions in these Articles, the requisite quorum for any General Meeting shall be Shareholders (not in default
    in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate
    at least thirty-three and one-third percent (33&#8531;%) of the voting power of the Company, provided, however, that if (i) such
    General Meeting was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of
    such General Meeting the Company is qualified to use the forms of a &#8220;foreign private issuer&#8221; under US securities laws,
    then the requisite quorum shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in
    person or by proxy and holding Shares conferring in the aggregate at least fifteen percent (15%) of the voting power of the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If within
    half an hour from the time appointed for the meeting a quorum is not present, then without any further notice the meeting shall be
    adjourned either (i) to the same day in the next week, at the same time and place, (ii) to such day and at such time and place as
    indicated in the notice of such meeting, or (iii) to such day and at such time and place as the Chairperson of the General Meeting
    shall determine (which may be earlier or later than the date pursuant to clause (i) above). No business shall be transacted at any
    adjourned meeting except business which might lawfully have been transacted at the meeting as originally called. At such adjourned
    meeting, if the original meeting was convened by a Shareholder pursuant to a request under Section 63 of the Companies Law, such
    Shareholder in addition to at least one or more Shareholder, present in person or by proxy, and holding the higher of ten percent
    (10%) of the voting power of the Company or the number of Shares required for making such request, shall constitute a quorum, but
    in any other case any Shareholder (not in default as aforesaid) present in person or by proxy, shall constitute a quorum.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Chairperson
    of General Meeting</span></b>. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Chairperson of the Board of Directors
shall preside as Chairperson of every General Meeting of the Company. If at any meeting the Chairperson is not present within fifteen
(15) minutes after the time fixed for holding the meeting or is unwilling or unable to act as Chairperson, any of the following may preside
as Chairperson of the meeting (and in the following order): a Director designated by the Board of Directors, the Chief Executive Officer,
the Chief Financial Officer, the General Counsel, the Secretary or any person designated by any of the foregoing. If at any such meeting
none of the foregoing persons is present or all are unwilling or unable to act as Chairperson, the Shareholders present (in person or
by proxy) shall choose a Shareholder or its proxy present at the meeting to be Chairperson. The office of Chairperson shall not, by itself,
entitle the holder thereof to vote at any General Meeting nor shall it entitle such holder to a second or casting vote (without derogating,
however, from the rights of such Chairperson to vote as a Shareholder or proxy of a Shareholder if, in fact, the Chairperson is also
a Shareholder or such proxy).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Adoption
    of Resolutions at General Meetings</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
    as required by the Companies Law or these Articles, including, without limitation, Article 39 below, a resolution of the Shareholders
    shall be adopted if approved by the holders of a simple majority of the voting power represented at the General Meeting in person
    or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.
    Without limiting the generality of the foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes
    a higher majority or pursuant to which a provision requiring a higher majority would have been deemed to have been incorporated into
    these Articles, but for which the Companies Law allows these Articles to provide otherwise (including, Sections 327 and 24 of the
    Companies Law), shall be adopted by a simple majority of the voting power represented at the General Meeting in person or by proxy
    and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
    question submitted to a General Meeting shall be decided by a show of hands, but the Chairperson of the General Meeting may determine
    that a resolution shall be decided by a written ballot. A written ballot may be implemented before the proposed resolution is voted
    upon or immediately after the declaration by the Chairperson of the results of the vote by a show of hands. If a vote by written
    ballot is taken after such declaration, the results of the vote by a show of hands shall be of no effect, and the proposed resolution
    shall be decided by such written ballot.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A defect
    in convening or conducting a General Meeting, including a defect resulting from the non-fulfillment of any provision or condition
    set forth in the Companies Law or these Articles, including with regard to the manner of convening or conducting the General Meeting,
    shall not disqualify any resolution passed at the General Meeting and shall not affect the discussions or decisions which took place
    thereat.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A declaration
    by the Chairperson of the General Meeting that a resolution has been carried unanimously, or carried by a particular majority, or
    rejected, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without proof
    of the number or proportion of the votes recorded in favor of or against such resolution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 290 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Power
    to Adjourn</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A General Meeting, the consideration
of any matter on its agenda, or the resolution on any matter on its agenda, may be postponed or adjourned, from time to time and from
place to place: (i) by the Chairperson of a General Meeting at which a quorum is present (and he shall do so if directed by the General
Meeting, with the consent of the holders of a majority of the voting power represented in person or by proxy and voting on the question
of adjournment), but no business shall be transacted at any such adjourned meeting except business which might lawfully have been transacted
at the meeting as originally called, or a matter on its agenda with respect to which no resolution was adopted at the meeting originally
called; or (ii) by the Board of Directors (whether prior to or at a General Meeting).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Voting
    Power</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of Article
32(a) and to any provision hereof conferring special rights as to voting, or restricting the right to vote, every Shareholder shall have
one vote for each Share held by the Shareholder of record, on every resolution, without regard to whether the vote thereon is conducted
by a show of hands, by written ballot, or by any other means.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Voting
    Rights.</span></b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Shareholder
    shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all calls then payable by
    him or her in respect of his or her Shares in the Company have been paid.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A company
    or other corporate body being a Shareholder of the Company may duly authorize any person to be its representative at any meeting
    of the Company or to execute or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise on behalf of
    such Shareholder all the power, which the Shareholder could have exercised if it were an individual. Upon the request of the Chairperson
    of the General Meeting, written evidence of such authorization (in form acceptable to the Chairperson) shall be delivered to him
    or her.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Shareholder
    entitled to vote may vote either in person or by proxy (who need not be a Shareholder of the Company), or, if the Shareholder is
    a company or other corporate body, by representative authorized pursuant to Article (b) above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If two
    or more persons are registered as joint holders of any Share, the vote of the senior who tenders a vote, in person or by proxy, shall
    be accepted to the exclusion of the vote(s) of the other joint holder(s). For the purpose of this Article 32(d), seniority shall
    be determined by the order of registration of the joint holders in the Register of Shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a Shareholder
    is a minor, under protection, bankrupt or legally incompetent, or in the case of a corporation, is in receivership or liquidation,
    it may, subject to all other provisions of these Articles and any documents or records required to be provided under these Articles,
    vote through his, her or its trustees, receiver, liquidator, natural guardian or another legal guardian, as the case may be, and
    the persons listed above may vote in person or by proxy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 291 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Proxies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Instrument
    of Appointment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px">&#160;</td>
    <td style="width: 32px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An instrument
    appointing a proxy shall be in writing and shall be substantially in the following form:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 13%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;I</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: justify">&#160;</td>
    <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 39%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name of Shareholder)</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address of Shareholder)</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Being a shareholder
    of SciSparc Ltd. hereby appoints</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name of Proxy)</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address of Proxy)</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as my proxy
    to vote for me and on my behalf at the General Meeting of the Company to be held on the ___ day of _______, _______ and at any adjournment(s)
    thereof.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed this
    ____ day of ___________, ______.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&#160;</td>
    <td colspan="4" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of
    Appointor)&#8221;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">or in any usual or common form or in
such other form as may be approved by the Board of Directors. Such proxy shall be duly signed by the appointor of such person&#8217;s
duly authorized attorney, or, if such appointor is company or other corporate body, in the manner in which it signs documents which binds
it together with a certificate of an attorney with regard to the authority of the signatories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the Companies Law, the original instrument appointing a proxy or a copy thereof certified by an attorney (and the power of attorney
    or other authority, if any, under which such instrument has been signed) shall be delivered to the Company (at its Office, at its
    principal place of business, or at the offices of its registrar or transfer agent, or at such place as notice of the meeting may
    specify) not less than forty eight (48) hours (or such shorter period as the notice shall specify) before the time fixed for such
    meeting. Notwithstanding the above, the Chairperson shall have the right to waive the time requirement provided above with respect
    to all instruments of proxies and to accept instruments of proxy until the beginning of a General Meeting. A document appointing
    a proxy shall be valid for every adjourned meeting of the General Meeting to which the document relates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 292 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Effect
    of Death of Appointer of Transfer of Share and or Revocation of Appointment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A vote
    cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the prior death or bankruptcy of the appointing
    Shareholder (or of his or her attorney-in-fact, if any, who signed such instrument), or the transfer of the Share in respect of which
    the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairperson of such meeting
    prior to such vote being cast.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairperson,
    subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the
    Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed)
    or of an instrument appointing a different proxy (and such other documents, if any, required under Article 33(b) for such new appointment),
    provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time
    for delivery of the instrument revoked thereby as referred to in Article 33(b) hereof, or (ii) if the appointing Shareholder is present
    in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairperson of such meeting of written
    notice from such Shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote
    cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation
    of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless
    such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 34(b) at or prior to
    the time such vote was cast.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Board
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Powers
    of the Board of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may exercise all such powers and do all such acts and things as the Board of Directors is authorized by law or as the
    Company is authorized to exercise and do and are not hereby or by law required to be exercised or done by the General Meeting. The
    authority conferred on the Board of Directors by this Article 35 shall be subject to the provisions of the Companies Law, these Articles
    and any regulation or resolution consistent with these Articles adopted from time to time at a General Meeting, provided, however,
    that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of Directors
    which would have been valid if such regulation or resolution had not been adopted.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
    limiting the generality of the foregoing, the Board of Directors may, from time to time, set aside any amount(s) out of the profits
    of the Company as a reserve or reserves for any purpose(s) which the Board of Directors, in its absolute discretion, shall deem fit,
    including without limitation, capitalization and distribution of bonus Shares, and may invest any sum so set aside in any manner
    and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or
    any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and
    may subdivide or re-designate any reserve or cancel the same or apply the funds therein for another purpose, all as the Board of
    Directors may from time to time think fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 293 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Exercise
    of Powers of the Board of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A meeting
    of the Board of Directors at which a quorum is present in accordance with Article 45 shall be competent to exercise all the authorities,
    powers and discretion vested in or exercisable by the Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A resolution
    proposed at any meeting of the Board of Directors shall be deemed adopted if approved by a majority of the Directors present, entitled
    to vote and voting thereon when such resolution is put to a vote.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may adopt resolutions, without convening a meeting of the Board of Directors, in writing or in any other manner permitted
    by the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary herein, including under Articles 36(a) and 36(b), and without derogating from any other approvals required
    pursuant to these Articles or applicable law, the following actions shall require the affirmative consent of at least three-quarters
    (3/4) of the Directors then in office and entitled to vote thereon:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.4pt 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">Any resolution
                                            to enter into a merger, consolidation, acquisition, amalgamation, business combination, issue
                                            equity securities or debt securities convertible into equity or other similar transaction
                                            (collectively, a &#8220;<b>Transaction</b>&#8221;), in each case that would reasonably be
                                            expected to result (A) in any person (together with its Affiliates) becoming, as a result
                                            of such Transaction, a beneficial owner (as determined in&#160;accordance with&#160;Rule&#160;13d-3
                                            under the Securities Exchange Act of 1934, as amended) of fifteen percent (15%) or more of
                                            the Ordinary Shares issued and outstanding immediately following the consummation of such
                                            Transaction or (B) in the increase in the beneficial ownership of Ordinary Shares of any
                                            person (together with its Affiliates) who immediately prior to the consummation of such Transaction
                                            holds fifteen percent (15%) or more of the then issued and outstanding Ordinary Shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">Any resolution
                                            to directly or indirectly sell, assign, convey, transfer, lease or otherwise dispose, in
                                            one or series of related transactions, of all or substantially all of the assets of the Company
                                            and its subsidiaries, taken as a whole, to any person;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="text-align: justify">Any resolution
                                            to effect any material change to the principal business of the Company, enter into new lines
                                            of business that are materially different from the Company&#8217;s then current line of business,
                                            or exit the then current line of business of the Company, or otherwise materially change
                                            the Company&#8217;s strategy and/or policies with respect to its main lines of business;
                                            or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="text-align: justify">Any resolution
                                            to transfer the headquarters of the Company outside of Israel.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 294 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Delegation
    of Powers</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees (in these Articles
    referred to as a &#8220;<b>Committee of the Board of Directors</b>&#8221;, or &#8220;<b>Committee</b>&#8221;), each consisting of
    one or more persons (who may or may not be Directors), and it may from time to time revoke such delegation or alter the composition
    of any such Committee. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any regulations imposed
    on it by the Board of Directors, subject to applicable law. No regulation imposed by the Board of Directors on any Committee and
    no resolution of the Board of Directors shall invalidate any prior act done or pursuant to a resolution by the Committee which would
    have been valid if such regulation or resolution of the Board of Directors had not been adopted. The meetings and proceedings of
    any such Committee of the Board of Directors shall, mutatis mutandis, be governed by the provisions herein contained for regulating
    the meetings of the Board of Directors, to the extent not superseded by any regulations adopted by the Board of Directors. Unless
    otherwise expressly prohibited by the Board of Directors, in delegating powers to a Committee of the Board of Directors, such Committee
    shall be empowered to further delegate such powers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may from time to time appoint a Secretary to the Company, as well as Officers, agents, employees and independent contractors,
    as the Board of Directors deems fit, and may terminate the service of any such person. The Board of Directors may, subject to the
    provisions of the Companies Law, determine the powers and duties, as well as the salaries and compensation, of all such persons.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of persons to be
    the attorney or attorneys of the Company at law or in fact for such purposes(s) and with such powers, authorities and discretions,
    and for such period and subject to such conditions, as it deems fit, and any such power of attorney or other appointment may contain
    such provisions for the protection and convenience of persons dealing with any such attorney as the Board of Directors deems fit,
    and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in him or her.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Number
    of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors shall consist of such number of Directors (not less than three (3) nor more than eight (8), including the External Directors,
    if any were elected) as may be fixed from time to time by resolution of the Board of Directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Election
    and Removal of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Directors
    of the Company shall be appointed or re-appointed by Ordinary Resolution at the Annual General Meeting (other than External Directors,
    if any) following the expiration of the term of office of the Directors of that class of Directors will be for a term of office that
    expires on the third annual general meeting following such election or re-election, such that from the Annual General Meeting of
    2021 and thereafter, each year the term of office of only one class of Directors will expire, unless their office is vacated pursuant
    to any law or as stipulated in these Articles.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">This Section 39 (a) shall not be amended
unless an affirmative vote of 65% of the voting power represented at a general meeting of shareholders and voting thereon has been obtained,
provided that such majority constitutes more than 33.33% of the Company&#8217;s total issued and outstanding share capital at the record
date for such general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 295 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with the provisions of Section 39 (a) above, the Directors (excluding the External Directors if any were elected), shall be classified,
    with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable,
    hereby designated as Class I, Class II and Class III (each, a &#8220;<b>Class</b>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with the provisions of Section 39 (a) above, at each Annual General Meeting, each Nominee or Alternate Nominee (each as defined below)
    elected at such Annual General Meeting to serve as a Director in a Class whose term shall have expired at such Annual General Meeting
    shall be elected to hold office until the third Annual General Meeting next succeeding his or her election and until his or her respective
    successor shall have been elected and qualified. Notwithstanding anything to the contrary, each Director shall serve until his or
    her successor is elected and qualified or until such earlier time as such Director&#8217;s office is vacated.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the
    number of Directors (excluding External Directors, if any were elected) that comprises the Board of Directors is hereafter changed
    by the Board of Directors, any newly created directorships or decrease in directorships shall be so apportioned by the Board of Directors
    among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of
    Directors constituting the Board of Directors shall shorten the term of any incumbent Director.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to every General Meeting of the Company at which Directors are to be elected, and subject to clauses(a), (b) and (h) of this Article,
    the Board of Directors (or a Committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or
    such Committee), a number of persons to be proposed to the Shareholders for election as Directors at such General Meeting (the &#8220;<b>Nominees</b>&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Proposing
    Shareholder requesting to include on the agenda of a General Meeting a nomination of a person to be proposed to the Shareholders
    for election as Director (such person, an &#8220;<b>Alternate Nominee</b>&#8221;), may so request provided that it complies with
    this Article 39(f), Article 25 and applicable law. Unless otherwise determined by the Board of Directors, a Proposal Request relating
    to an Alternate Nominee is deemed to be a matter that is appropriate to be considered only at an Annual General Meeting. In addition
    to any information required to be included in accordance with applicable law, such a Proposal Request shall include information required
    pursuant to Article 25, and shall also set forth: (i) the name, address, telephone number, fax number and email address of the Alternate
    Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements, relations or understandings
    during the past three (3) years, and any other material relationships, between the Proposing Shareholder(s) or any of its Affiliates
    and each Alternate Nominee; (iii) a declaration signed by the Alternate Nominee that he or she consents to be named in the Company&#8217;s
    notices and proxy materials and on the Company&#8217;s proxy card relating to the General Meeting, if provided or published, and
    that he or she, if elected, consents to serve on the Board of Directors and to be named in the Company&#8217;s disclosures and filings;
    (iv)&#160;a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock
    exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that
    is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment
    has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable
    disclosure requirements under Form 20-F (or Form 10-K, if applicable) or any other applicable form prescribed by the U.S. Securities
    and Exchange Commission (the&#160;&#8220;<b>SEC</b>&#8221;)); (v) a declaration made by the Alternate Nominee of whether he or she
    meets the criteria for an independent director and, if applicable, External Director of the Company under the Companies Law and/or
    under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information
    required at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the
    Proposing Shareholder(s) and each Alternate Nominee shall promptly provide any other information reasonably requested by the Company,
    including a duly completed director and officer questionnaire, in such form as may be provided by the Company, with respect to each
    Alternate Nominee. The Board of Directors may refuse to acknowledge the nomination of any person not made in compliance with the
    foregoing. The Company shall be entitled to publish any information provided by a Proposing Shareholder or Alternate Nominee pursuant
    to this Article 39(f) and Article 25, and the Proposing Shareholder and Alternate Nominee shall be responsible for the accuracy and
    completeness thereof.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 296 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nominees
    or Alternate Nominees shall be elected by a resolution adopted at the General Meeting at which they are subject to election. Notwithstanding
    Articles 25(a) and 25(c), in the event of a Contested Election, the method of calculation of the votes and the manner in which the
    resolutions will be presented to the General Meeting shall be determined by the Board of Directors in its discretion. In the event
    that the Board of Directors does not or is unable to make a determination on such matter, then the method described in clause (ii)
    below shall apply. The Board of Directors may consider, among other things, the following methods: (i) election of competing slates
    of Director nominees (determined in a manner approved by the Board of Directors) by a majority of the voting power represented at
    the General Meeting in person or by proxy and voting on such competing slates, (ii) election of individual Directors by a plurality
    of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors (which shall
    mean that the nominees receiving the largest number of &#8220;for&#8221; votes will be elected in such Contested Election), (iii)
    election of each nominee by a majority of the voting power represented at the General Meeting in person or by proxy and voting on
    the election of Directors, provided that if the number of such nominees exceeds the number of Directors to be elected, then as among
    such nominees the election shall be by plurality of the voting power as described above, and (iv) such other method of voting as
    the Board of Directors deems appropriate, including use of a &#8220;universal proxy card&#8221; listing all Nominees and Alternate
    Nominees by the Company. For the purposes of these Articles, election of Directors at a General Meeting shall be considered a &#8220;Contested
    Election&#8221; if the aggregate number of Nominees and Alternate Nominees at such meeting exceeds the total number of Directors
    to be elected at such meeting, with the determination thereof being made by the Secretary (or, in the absence thereof, by the Chief
    Executive Officer of the Company) as of the close of the applicable notice of nomination period under Article 25 or under applicable
    law, based on whether one or more notice(s) of nomination were timely filed in accordance with Article 25, this Article 39 and applicable
    law; <span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that the determination that an election is a Contested Election shall not be determinative
    as to the validity of any such notice of nomination; and provided, further, that, if, prior to the time the Company mails its initial
    proxy statement in connection with such election of Directors, one or more notices of nomination of an Alternate Nominee are withdrawn
    such that the number of candidates for election as Director no longer exceeds the number of Directors to be elected, the election
    shall not be considered a Contested Election. Shareholders shall not be entitled to cumulative voting in the election of Directors,
    except to the extent specifically set forth in this clause (g).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary in these Articles, the election, qualification, removal or dismissal of External Directors, if so elected,
    shall be only in accordance with the applicable provisions set forth in the Companies Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Commencement
    of Directorship</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Without derogating from Article 39,
the term of office of a Director shall commence as of the date of his or her appointment or election, or on a later date if so specified
in his or her appointment or election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Continuing
    Directors in the Event of Vacancies</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors (and, if so
determined by the Board of Directors, the General Meeting) may at any time and from time to time appoint any person as a Director to
fill a vacancy (whether such vacancy is due to a Director no longer serving or due to the number of Directors serving being less than
the maximum number stated in Article 38 hereof). In the event of one or more such vacancies in the Board of Directors, the continuing
Directors may continue to act in every matter, provided, however, that if the number of Directors serving is less than the minimum number
provided for pursuant to Article 38 hereof, they may only act in an emergency or to fill the office of a Director which has become vacant
up to a number equal to the minimum number provided for pursuant to Article 38 hereof, or in order to call a General Meeting of the Company
for the purpose of electing Directors to fill any or all vacancies. The office of a Director that was appointed by the Board of Directors
to fill any vacancy shall only be for the remaining period of time during which the Director whose service has ended was filled would
have held office, or in case of a vacancy due to the number of Directors serving being less than the maximum number stated in Article
38 hereof the Board of Directors shall determine at the time of appointment the class pursuant to Article 39 to which the additional
Director shall be assigned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Vacation
    of Office</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The office of a Director shall be
vacated and he shall be dismissed or removed:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ipso facto,
    upon his or her death;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if he
    or she is prevented by applicable law from serving as a Director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the
    Board of Directors determines that due to his or her mental or physical state he or she is unable to serve as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 297 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if his
    or her directorship expires pursuant to these Articles and/or applicable law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by a resolution
    adopted at an Annual General Meeting by a majority of at least 65% of the total voting power of the Shares (with such removal becoming
    effective on the date fixed in such resolution);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by his
    or her written resignation, such resignation becoming effective on the date fixed therein, or upon the delivery thereof to the Company,
    whichever is later; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect
    to an External Director, if so elected, and notwithstanding anything to the contrary herein, only pursuant to applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Conflict
    of Interests; Approval of Related Party Transactions</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of applicable law and these Articles, no Director shall be disqualified by virtue of his or her office from holding
    any office or place of profit in the Company or in any company in which the Company shall be a Shareholder or otherwise interested,
    or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement
    entered into by or on behalf of the Company in which any Director shall be in any way interested, be avoided, nor, other than as
    required under the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office
    or place of profit or realized by any such contract or arrangement by reason only of such Director&#8217;s holding that office or
    of the fiduciary relations thereby established, but the nature of his or her interest, as well as any material fact or document,
    must be disclosed by him or her at the meeting of the Board of Directors at which the contract or arrangement is first considered,
    if his or her interest then exists, or, in any other case, at no later than the first meeting of the Board of Directors after the
    acquisition of his or her interest.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the Companies Law&#160;and these Articles, a transaction between the Company and an Office Holder, and a transaction between the
    Company and another entity in which an Office Holder of the Company has a personal interest, in each case, which is not an Extraordinary
    Transaction (as defined by the Companies Law), shall require only approval by the Board of Directors or a Committee of the Board
    of Directors. Such authorization, as well as the actual approval, may be for a particular transaction or more generally for specific
    type of transactions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary in these Articles, the Company shall not engage in any Business Combination (as defined below) with any
    Shareholder and/or any of its Affiliates and/or investors for a period of three years following (i) with respect to any Shareholder
    holding as of the Effective Time fifteen percent (15%) or more of the voting power of the Shares, the Effective Time and (ii) with
    respect to all Shareholders, each time as such Shareholder and/or any of its Affiliates and/or investors become(s) (other than due
    to a buyback, redemption or cancellation of shares by the Company) the holder(s) (beneficially or of record) of fifteen percent (15%)
    or more of the issued and outstanding voting power of the Shares (the &#8220;<b>Threshold</b>&#8221; and such shareholder, an &#8220;<b>Interested
    Shareholder</b>&#8221;), except if the Board of Directors approves either the Business Combination or the transaction which resulted
    in such Shareholder and/or any of its Affiliates and/or investors becoming an Interested Shareholder prior to consummation of a Business
    Combination. As used in this Article 43 only, &#8220;<b>Business Combination</b>&#8221; means (i) a merger or consolidation of the
    Company in which the holders of a majority of the Ordinary Shares issued and outstanding immediately prior to the consummation of
    such transaction hold immediately following the consummation of such transaction less than 50% of the issued and outstanding share
    capital of the surviving, acquiring or resulting company (or if the surviving, acquiring or resulting company is a wholly owned subsidiary
    of another company immediately following the consummation of such transaction, the parent company of such surviving, acquiring or
    resulting company) or (ii) a disposition of assets of the Company with an aggregate market value equal to 10% or more of the Company&#8217;s
    assets or of its outstanding shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 298 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Proceedings
of the Board of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Meetings</span></b>.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Board of Directors thinks
    fit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A meeting
    of the Board of Directors shall be convened by the Secretary upon instruction of the Chairperson or upon a request of at least two
    (2) Directors which is submitted to the Chairperson or in any event that such meeting is required by the provisions of the Companies
    Law. In the event that the Chairperson does not instruct the Secretary to convene a meeting upon a request of at least two (2) Directors
    within seven (7) days of such request, then such two (2) Directors may convene a meeting of the Board of Directors. Any meeting of
    the Board of Directors shall be convened upon not less than two (2) days&#8217; notice, unless such notice is waived in writing by
    all of the Directors as to a particular meeting or by their attendance at such meeting or unless the matters to be discussed at such
    meeting are of such urgency and importance that notice is reasonably determined by the Chairperson as ought to be waived or shortened
    under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
    of any such meeting shall be given orally, by telephone, in writing or by mail, facsimile, email or such other means of delivery
    of notices as the Company may apply, from time to time.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary herein, failure to deliver notice to a Director of any such meeting in the manner required hereby may be
    waived by such Director, and a meeting shall be deemed to have been duly convened notwithstanding such defective notice if such failure
    or defect is waived prior to action being taken at such meeting, by all Directors entitled to participate at such meeting to whom
    notice was not duly given as aforesaid. Without derogating from the foregoing, no Director present at any time during a meeting of
    the Board of Directors shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted at such
    meeting on account of any defect in the notice of such meeting relating to the date, time or the place thereof or the convening of
    the meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Quorum</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Until otherwise unanimously decided
by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted by the presence in person or by any means
of communication of a majority of the Directors then in office who are lawfully entitled to participate and vote in the meeting. No business
shall be transacted at a meeting of the Board of Directors unless the requisite quorum is present (in person or by any means of communication
on the condition that all participating Directors can hear each other simultaneously) when the meeting proceeds to business. If within
thirty (30) minutes from the time appointed for a meeting of the Board of Directors a quorum is not present, the meeting shall stand
adjourned at the same place and time forty-eight (48) hours thereafter unless the Chairperson has determined that there is such urgency
and importance that a shorter period is required under the circumstances. If an adjourned meeting is convened in accordance with the
foregoing and a quorum is not present within thirty (30) minutes of the announced time, the requisite quorum at such adjourned meeting
shall be, any two (2) Directors, if the number of Directors then serving is up to five (5), and any three (3) Directors, if the number
of Directors then serving is more than five (5), in each case who are lawfully entitled to participate in the meeting and who are present
at such adjourned meeting. At an adjourned meeting of the Board of Directors the only matters to be considered shall be those matters
which might have been lawfully considered at the meeting of the Board of Directors originally called if a requisite quorum had been present,
and the only resolutions to be adopted are such types of resolutions which could have been adopted at the meeting of the Board of Directors
originally called.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 299 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Chairperson
    of the Board of Directors</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors shall, from
time to time, elect one of its members to be the Chairperson of the Board of Directors, remove such Chairperson from office and appoint
in his or her place. The Chairperson of the Board of Directors shall preside at every meeting of the Board of Directors, but if there
is no such Chairperson, or if at any meeting he is not present within fifteen (15) minutes of the time fixed for the meeting or if he
is unwilling to take the chair, the Directors present shall choose one of the Directors present at the meeting to be the Chairperson
of such meeting. The office of Chairperson of the Board of Directors shall not, by itself, entitle the holder to a second or casting
vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Validity
    of Acts Despite Defects</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">All acts done or transacted at any
meeting of the Board of Directors, or of a Committee of the Board of Directors, or by any person(s) acting as Director(s), shall, notwithstanding
that it may afterwards be discovered that there was some defect in the appointment of the participants in such meeting or any of them
or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid as if there were no such defect or disqualification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Chief
Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Chief
    Executive Officer</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Board of Directors shall from time
to time appoint one or more persons, whether or not Directors, as Chief Executive Officer of the Company who shall have the powers and
authorities set forth in the Companies Law, and may confer upon such person(s), and from time to time modify or revoke, such titles and
such duties and authorities of the Board of Directors as the Board of Directors may deem fit, subject to such limitations and restrictions
as the Board of Directors may from time to time prescribe. Such appointment(s) may be either for a fixed term or without any limitation
of time, and the Board of Directors may from time to time (subject to any additional approvals required under, and the provisions of,
the Companies Law and of any contract between any such person and the Company) fix their salaries and compensation, remove or dismiss
them from office and appoint another or others in his, her or their place or places.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Minutes</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">49.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Minutes</span></b><span style="text-decoration:underline">.
    </span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any minutes of the General Meeting
or the Board of Directors or any Committee thereof, if purporting to be signed by the Chairperson of the General Meeting, the Board of
Directors or a Committee thereof, as the case may be, or by the Chairperson of the next succeeding General Meeting, meeting of the Board
of Directors or meeting of a Committee, as the case may be, shall constitute prima facie evidence of the matters recorded therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Dividends</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Declaration
    of Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors may, from
time to time, declare, and cause the Company to pay dividends as permitted by the Companies Law. The Board of Directors shall determine
the time for payment of such dividends and the record date for determining the shareholders entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Amount
    Payable by Way of Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of these
Articles and subject to the rights or conditions attached at that time to any Share in the capital of the Company granting preferential,
special or deferred rights or not granting any rights with respect to dividends, any dividend paid by the Company shall be allocated
among the Shareholders (not in default in payment of any sum referred to in Article 13 hereof) entitled thereto on a <i>pari passu</i>
basis in proportion to their respective holdings of the issued and outstanding Shares in respect of which such dividends are being paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 300 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Interest</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">No dividend shall carry interest
as against the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Payment
    in Specie</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">If so declared by the Board of Directors,
a dividend declared in accordance with Article 50 may be paid, in whole or in part, by the distribution of specific assets of the Company
or by distribution of paid up Shares, debentures or other securities of the Company or of any other companies, or in any combination
thereof, in each case, the fair value of which shall be determined by the Board of Directors in good faith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Implementation
    of Powers</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors may settle,
as it deems fit, any difficulty arising with regard to the distribution of dividends, bonus shares or otherwise, and in particular, to
issue certificates for fractions of shares and sell such fractions of shares in order to pay their consideration to those entitled thereto,
or to set the value for the distribution of certain assets and to determine that cash payments shall be paid to the Shareholders on the
basis of such value, or that fractions whose value is less than NIS 0.01 shall not be taken into account. The Board of Directors may
instruct to pay cash or convey these certain assets to a trustee in favor of those people who are entitled to a dividend, as the Board
of Directors shall deem appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Deductions
    from Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">The Board of Directors may deduct
from any dividend or other moneys payable to any Shareholder in respect of a Share any and all sums of money then payable by him or her
to the Company on account of calls or otherwise in respect of Shares of the Company and/or on account of any other matter of transaction
whatsoever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">56.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Retention
    of Dividends</span></b><span style="text-decoration:underline">. </span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may retain any dividend or other moneys payable or property distributable in respect of a Share on which the Company
    has a lien, and may apply the same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien
    exists.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board
    of Directors may retain any dividend or other moneys payable or property distributable in respect of a Share in respect of which
    any person is, under Articles 21 or 22, entitled to become a Shareholder, or which any person is, under said Articles, entitled to
    transfer, until such person shall become a Shareholder in respect of such Share or shall transfer the same.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Unclaimed
    Dividends</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">All unclaimed dividends or other
moneys payable in respect of a Share may be invested or otherwise made use of by the Board of Directors for the benefit of the Company
until claimed. The payment of any unclaimed dividend or such other moneys into a separate account shall not constitute the Company a
trustee in respect thereof, and any dividend unclaimed after a period of one (1) year (or such other period determined by the Board of
Directors) from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the date the same
were payable, shall be forfeited and shall revert to the Company, <i><span style="text-decoration:underline">provided</span></i>, <i><span style="text-decoration:underline">however</span></i>, that the Board of Directors
may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who would have
been entitled thereto had the same not reverted to the Company. The principal (and only the principal) of any unclaimed dividend of such
other moneys shall be if claimed, paid to a person entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 301 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Mechanics
    of Payment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Any dividend or other moneys payable
in cash in respect of a Share, less the tax required to be withheld pursuant to applicable law, may, as determined by the Board of Directors
in its sole discretion, be paid by check or warrant sent through the post to, or left at, the registered address of the person entitled
thereto or by transfer to a bank account specified by such person (or, if two (2) or more persons are registered as joint holders of
such Share or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to any one of such persons
or his or her bank account or the person who the Company may then recognize as the owner thereof or entitled thereto under Article 21
or 22 hereof, as applicable, or such person&#8217;s bank account), or to such person and at such other address as the person entitled
thereto may by writing direct, or in any other manner the Board of Directors deems appropriate. Every such check or warrant or other
method of payment shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled thereto
as aforesaid may direct, and payment of the check or warrant by the banker upon whom it is drawn shall be a good discharge to the Company.
Every such check shall be sent at the risk of the person entitled to the money represented thereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Accounts</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Books
    of Account</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Company&#8217;s books of account
shall be kept at the Office of the Company, or at such other place or places as the Board of Directors may think fit, and they shall
always be open to inspection by all Directors. No shareholder, not being a Director, shall have any right to inspect any account or book
or other similar document of the Company, except as explicitly conferred by law or authorized by the Board of Directors. The Company
shall make copies of its annual financial statements available for inspection by the Shareholders at the principal offices of the Company.
The Company shall not be required to send copies of its annual financial statements to the Shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Auditors</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The appointment, authorities, rights
and duties of the auditor(s) of the Company, shall be regulated by applicable law, provided, however, that in exercising its authority
to fix the remuneration of the auditor(s), the Shareholders in General Meeting may act (and in the absence of any action in connection
therewith shall be deemed to have so acted) to authorize the Board of Directors (with right of delegation to a Committee thereof or to
management) to fix such remuneration subject to such criteria or standards, and if no such criteria or standards are so provided, such
remuneration shall be fixed in an amount commensurate with the volume and nature of the services rendered by such auditor(s). The General
Meeting may, if so recommended by the Board of Directors, appoint the auditors for a period that may extend until the third Annual General
Meeting after the Annual General Meeting in which the auditors were appointed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Fiscal
    Year</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The fiscal year of the Company shall
be the 12 months period ending on December 31 of each calendar year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Supplementary
Registers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Supplementary
    Registers</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to and in accordance with
the provisions of Sections 138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any place outside
Israel as the Board of Directors may think fit, and, subject to all applicable requirements of law, the Board of Directors may from time
to time adopt such rules and procedures as it may think fit in connection with the keeping of such branch registers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 302 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Exemption,
Indemnity and Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">63.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Insurance</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of the
Companies Law with regard to such matters, the Company may enter into a contract for the insurance of the liability, in whole or in part,
of any of its Office Holders imposed on such Office Holder due to an act performed by or an omission of the Office Holder in the Office
Holder&#8217;s capacity as an Office Holder of the Company arising from any matter permitted by law, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach
    of duty of care to the Company or to any other person;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach
    of his or her duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to assume
    that act that resulted in such breach would not prejudice the interests of the Company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial
    liability imposed on such Office Holder in favor of any other person; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other
    event, occurrence, matters or circumstances under any law with respect to which the Company may, or will be able to, insure an Office
    Holder, and to the extent such law requires the inclusion of a provision permitting such insurance in these Articles, then such provision
    is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section 56h(b)(1)
    of the Securities Law, if and to the extent applicable, and Section 50P of the Economic Competition Law).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Indemnity</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of the Companies Law, the Company may retroactively indemnify an Office Holder of the Company to the maximum extent
    permitted under applicable law, including with respect to the following liabilities and expenses, provided that such liabilities
    or expenses were imposed on such Office Holder or incurred by such Office Holder due to an act performed by or an omission of the
    Office Holder in such Office Holder&#8217;s capacity as an Office Holder of the Company:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">a
                                            financial liability imposed on an Office Holder in favor of another person by any court judgment,
                                            including a judgment given as a result of a settlement or an arbitrator&#8217;s award which
                                            has been confirmed by a court;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">reasonable
                                            litigation expenses, including legal fees, expended by the Office Holder (A) as a result
                                            of an investigation or proceeding instituted against him or her by an authority authorized
                                            to conduct such investigation or proceeding, provided that (1) no indictment (as defined
                                            in the Companies Law) was filed against such Office Holder as a result of such investigation
                                            or proceeding; and (2) no financial liability in lieu of a criminal proceeding (as defined
                                            in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding
                                            or if such financial liability was imposed, it was imposed with respect to an offense that
                                            does not require proof of criminal intent or (B) in connection with a financial sanction;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="padding-bottom: 0; text-align: justify">reasonable
                                            litigation costs, including legal fees, expended by an Office Holder or which were imposed
                                            on an Office Holder by a court in proceedings filed against the Office Holder by the Company
                                            or in its name or by any other person or in a criminal charge in respect of which the Office
                                            Holder was acquitted or in a criminal charge in respect of which the Office Holder was convicted
                                            for an offence which did not require proof of criminal intent; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="padding-bottom: 0; text-align: justify">any
                                            other event, occurrence, matter or circumstance under any law with respect to which the Company
                                            may, or will be able to, indemnify an Office Holder, and to the extent such law requires
                                            the inclusion of a provision permitting such indemnity in these Articles, then such provision
                                            is deemed to be included and incorporated herein by reference (including, without limitation,
                                            in accordance with Section 56h(b)(1) of the Israeli Securities Law, if and to the extent
                                            applicable, and Section 50P(b)(2) of the RTP Law).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 303 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder, in advance, with respect to those
    liabilities and expenses described in the following Articles:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">Sub-Article 64(a)(i)(a)(ii)
                                            to 64(a)(iv); and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">Sub-Article
                                            64(a)(i), provided that:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in; text-align: right"/><td style="width: 0.25in">(1)</td><td style="padding-bottom: 0; text-align: justify">the
                                            undertaking to indemnify is limited to such events which the Directors shall deem to be foreseeable
                                            in light of the operations of the Company at the time that the undertaking to indemnify is
                                            made and for such amounts or criterion which the Directors may, at the time of the giving
                                            of such undertaking to indemnify, deem to be reasonable under the circumstances; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.25in; text-align: right"/><td style="width: 0.25in">(2)</td><td style="padding-bottom: 0; text-align: justify">the
                                            undertaking to indemnify shall set forth such events which the Directors shall deem to be
                                            foreseeable in light of the operations of the Company at the time that the undertaking to
                                            indemnify is made, and the amounts and/or criterion which the Directors may, at the time
                                            of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.35pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Exemption</span></b>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of the
Companies Law, the Company may, to the maximum extent permitted by law, exempt and release, in advance, any Office Holder from any liability
for damages arising out of a breach of a duty of care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">General</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any amendment
    to the Companies Law or any other applicable law adversely affecting the right of any Office Holder to be indemnified, insured or
    exempt pursuant to Articles 63 to 65 and any amendments to Articles 63 to 65 shall be prospective in effect, and shall not affect
    the Company&#8217;s obligation or ability to indemnify, insure or exempt an Office Holder for any act or omission occurring prior
    to such amendment, unless otherwise provided by applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions
    of Articles 63 to 65 (i) shall apply to the maximum extent permitted by law (including, the Companies Law, the Securities Law and
    the Economic Competition Law); and (ii) are not intended, and shall not be interpreted so as to restrict the Company, in any manner,
    in respect of the procurement of insurance and/or in respect of indemnification (whether in advance or retroactively) and/or exemption,
    in favor of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor
    of the Company who is not an Office Holder; and/or any Office Holder to the extent that such insurance and/or indemnification is
    not specifically prohibited under law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Winding
Up</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Winding
    Up</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">If the Company is wound up, then,
subject to applicable law and to the rights of the holders of Shares with special rights upon winding up, the assets of the Company available
for distribution among the Shareholders shall be distributed to them in proportion to the number of issued and outstanding Shares held
by each Shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Notices</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Notices</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any written
    notice or other document may be served by the Company upon any Shareholder either personally, by facsimile, email or other electronic
    transmission, or by sending it by prepaid mail (airmail if sent internationally) addressed to such Shareholder at his or her address
    as described in the Register of Shareholders or such other address as the Shareholder may have designated in writing for the receipt
    of notices and other documents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt"></p><div>

</div><!-- Field: Page; Sequence: 304 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any written
    notice or other document may be served by any Shareholder upon the Company by tendering the same in person to the Secretary or the
    Chief Executive Officer of the Company at the principal office of the Company, by facsimile transmission, email or other electronic
    submission, or by sending it by prepaid registered mail (airmail if posted outside Israel) to the Company at its Office.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any such
    notice or other document shall be deemed to have been served:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of mailing, forty-eight (48) hours after it has been posted, or when actually received
                                            by the addressee if sooner than forty-eight hours after it has been posted, or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of overnight air courier, on the next business day following the day sent, with
                                            receipt confirmed by the courier, or when actually received by the addressee if sooner than
                                            three business days after it has been sent;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iii)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of personal delivery, when actually tendered in person, to such addressee;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(iv)</td><td style="padding-bottom: 0; text-align: justify">in
                                            the case of facsimile, email or other electronic transmission, on the first business day
                                            (during normal business hours in place of addressee) on which the sender receives automatic
                                            electronic confirmation by the addressee&#8217;s facsimile machine that such notice was received
                                            by the addressee or delivery confirmation from the addressee&#8217;s email or other communication
                                            server.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a notice
    is, in fact, received by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively
    addressed or failed, in some other respect, to comply with the provisions of this Article 68.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All notices
    to be given to the Shareholders shall, with respect to any Share to which persons are jointly entitled, be given to whichever of
    such persons is named first in the Register of Shareholders, and any notice so given shall be sufficient notice to the holders of
    such Share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Shareholder
    whose address is not described in the Register of Shareholders, and who shall not have designated in writing an address for the receipt
    of notices, shall not be entitled to receive any notice from the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    anything to the contrary contained herein, notice by the Company of a General Meeting, containing the information required by applicable
    law and these Articles to be set forth therein, which is published, within the time otherwise required for giving notice of such
    meeting, in either or several of the following manners (as applicable) shall be deemed to be notice of such meeting duly given, for
    the purposes of these Articles, to any Shareholder whose address as registered in the Register of Shareholders (or as designated
    in writing for the receipt of notices and other documents) is located either inside or outside the State of Israel:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(i)</td><td style="padding-bottom: 0; text-align: justify">if
                                            the Company&#8217;s Shares are then listed for trading on a national securities exchange
                                            in the United States or quoted in an over-the-counter market in the United States, publication
                                            of notice of a General Meeting pursuant to a report or a schedule filed with, or furnished
                                            to, the SEC pursuant to the Securities Exchange Act of 1934, as amended; and/or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in; text-align: right"/><td style="width: 0.25in">(ii)</td><td style="padding-bottom: 0; text-align: justify">on
                                            the Company&#8217;s internet site.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The mailing
    or publication date and the record date and/or date of the meeting (as applicable) shall be counted among the days comprising any
    notice period under the Companies Law and the regulations thereunder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Amendment</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">Any amendment of these Articles shall
require, in addition and prior to the approval of the General Meeting of Shareholders in accordance with these Articles, also the approval
of the Board of Directors with the affirmative vote of at least three-quarters (3/4) of the Directors then in office and entitled to
vote thereon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 305 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b>Forum
for Adjudication of Disputes</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70.</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b><span style="text-decoration:underline">Forum
    for Adjudication of Disputes</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify; text-indent: -35.4pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America,
    shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the U.S. Securities
    Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt,
    this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters to any offering
    giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that
    person or entity and who has prepared or certified any part of the documents underlying the offering. The foregoing provisions of
    this Article 70 shall not apply to causes of action arising under the U.S. Securities Exchange Act of 1934, as amended.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the Company consents in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive
    forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of
    breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s shareholders,
    or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any person
    or entity purchasing or otherwise acquiring&#160;or holding&#160;any interest in&#160;shares of the Company shall be deemed to have
    notice of and consented to the provisions of this Article 70.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;*</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 306 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><div><a id="B_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ANNEX
E</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>OPINION OF E.D.B. CONSULTING
AND INVESTMENTS LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">&#8220;Automax Motors Ltd&#8221;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Company Valuation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_002.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drafted on January 4, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This valuation of &#8220;Automax Motors Ltd&#8221;
(hereinafter - Automax or the Group) was commissioned by Mr. Oz Adler, CEO of &#8220;SCISPARC Ltd&#8221;. This valuation is a commercial
document solely intended to convey information to the organs of SCISPARC, to Automax, its advisors and anyone the Company&#8217;s management
determines it should be presented to. This document includes data, assessments, forecasts and plans of Automax regarding its operations
which constitute forward looking information, as such term is defined in the Israel Securities Law, 1968 (hereinafter: the &#8220;Securities
Law&#8221;), the manifestation of which is uncertain and not exclusively within Automax&#8217;s control. Forward looking information
is based on assessments made by Automax&#8217;s management, which, <i>inter alia</i>, are based on the information known by the management
at the time this document was prepared. Only partial information and details are included in this document, they are presented in a condensed
format solely for convenience purposes, and they should be read jointly with the details, descriptions, clarifications, assumptions,
qualifications, assessments and overview of the risk factors included in the Company&#8217;s periodic and annual reports published on
the Israel Securities Authority distribution website (&#8220;MAYA&#8221;). There is no certainty that the data and/or assessments and/or
forecasts and/or plans will be achieved, in whole or in part, and they may manifest differently than as presented in the document, <i>inter
alia</i>, due to them being dependent on external factors not within Automax&#8217;s control, including: Changes in the competitive and
commercial environment and the manifestation of any of the risk factors applicable to Automax. Additionally, the document may include
data taken from external sources not independently verified by Automax, and Automax should therefore not be held responsible for their
accuracy. The document may also include information not presented in the Company&#8217;s financial statements and immediate reports and/or
information which may be presented or applied differently. It should be clarified that the document is no substitute to the Company&#8217;s
public reports, and in any event of any inconsistency between the data presented in this document and the public reports, the data in
the aforementioned public reports should prevail. The forecasts and assessments in this document are based on the information held by
the Company at the time the document was being prepared, and the Company is not subject to any obligation to update and/or change said
forecasts and/or assessments, in order to reflect events and/or developments which may occur after the document has been drafted. All
calculated assessments applied in this valuation were done on the basis of my professional assessments which are based on more than 35
years of experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 307; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Preface</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to perform this valuation I received
the Company&#8217;s audited balance sheets for the 2020-2022 annual periods, an unaudited balance sheet as of June 30, 2023, and a budget
and business plan prepared by the Company&#8217;s management for the 2024-2028 5-year period, quantitative data about the Company&#8217;s
sales, progress about the bus marketing project and the direct import of the electric vehicle from China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I also met with the Company&#8217;s managers,
including the VP and Director of Business Development as well as with current and former officers and advisors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I visited the Company&#8217;s head branch in
Jerusalem and I examined public materials regarding competitors and about the vehicle import market in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on my study of the materials in recent
weeks I am presenting the valuation document containing six chapters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter A</b> - Which will include an exhaustive
overview of the Company and its activities in the parallel import segment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter B</b> - Which will include an overview
of both the Israeli and global sector in which it operates and competes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter C</b> - Which will include an overview
of the Company&#8217;s planned activities for the sale of TEMSA buses in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter D</b> - Which will include an overview
of the Company&#8217;s planned activities for the sale of HYCAN electric vehicles in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter E</b> - Which will propose a valuation
of the Company&#8217;s enterprise value based on multiplier methodologies and the net DCF methodology which, unlike the multiplier methodology,
is forward looking.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chapter F</b> - In which I will summarize
my work and in which I will argue an enterprise value of USD 44.8 million, based on the independent valuation I presented in the previous
chapter, which is a cautious and conservative assessment of the Company&#8217;s activities which I rely upon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">65-66 Bareket Street, Mevasseret
Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160; Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 308; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter A - The &#8220;Group&#8221; - A
general and historic overview of the Group and of the parallel import industry</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax Motors Ltd (hereinafter: &#8220;Automax&#8221;
or the &#8220;Group&#8221;) is a public company which has been listed on the Tel Aviv Stock Exchange since 2021 and which owns multiple
companies, primarily &#8220;Global Automax Ltd&#8221; - an indirect (parallel) importer of vehicles to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2021, &#8220;Global Automax Ltd&#8221;
(&#8220;Global Automax&#8221;) merged via a share swap transaction into the public shell company &#8220;Matomy Media Group&#8221; which
changed its name to &#8220;Automax Motors&#8221; and which holds Global Automax&#8217;s entire issued share capital as of the merger
date (see the description in the Group&#8217;s financial statements and in the prospectus).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Global Automax&#8221; is the largest indirect
parallel importer in Israel, and imports thousands of vehicles, with annual sales turnover of ILS 400-450 million, which it sells via
12 showrooms throughout Israel. It owns facilities to store vehicles, a PDI (pre-delivery inspection) licensing site and facility. The
Company also operates a vehicle transport network, a replacement part storage facility, and it is licensed to import replacement parts
and has agreements with a national service center network.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to Global Automax, the Group also
owns a controlling stake in &#8220;Automax Trade-In&#8221; which operates a used vehicle sales branch at Glilot Junction, and it also
owns a controlling stake in &#8220;Dalhom Automax&#8221; which is the direct importer of TEMSA-Skoda buses to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has equity totaling tens of millions
of shekels, and it is consistently growing on an annual basis. The Group has approximately 120 employees. The optimal utilization of
central headquarters (finance, logistics, HR, IT, etc.) and its strong commercial and financial position, allow the Group to launch new
activities at the core of vehicle importing which in turn are expected to bolster profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax Leasing (under formation) is one of these
operating segments and it will operate as an independent company, jointly owned by &#8220;Global Automax&#8221; (30%) and a group of
investors. The company has also entered into an agreement with a Chinese vehicle manufacturer - HYCAN - for direct import activities.
This operating segment is expected to become the Group&#8217;s primary operating segment and materially impact its activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_003.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 309; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are the Group&#8217;s operating
results (on a consolidated basis) for the 2022 annual period in ILS 000&#8217;s:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: normal 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-style: normal; vertical-align: bottom; font-weight: normal">
    <td style="font-style: normal; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>&#160;</b></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-style: normal; font-weight: normal; text-align: center"><b>For the<br/>
    period&#160;ended<br/> December 31, <br/> 2022</b></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"><b>&#160;</b></td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; width: 88%; font-weight: normal; text-align: justify">Revenues</td><td style="font-style: normal; width: 1%; font-weight: normal">&#160;</td>
    <td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; width: 9%; font-weight: normal; text-align: right">453,617</td><td style="font-style: normal; width: 1%; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Cost of sales</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(392,918</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>Gross profit</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">60,699</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Sales and
    marketing expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(27,612</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Issuance related
    expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">-</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Administrative
    and general expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(16,849</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Granting options
    to employees</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(9,976</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Other incomes</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">226</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Operating
    profit (loss)</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">6,488</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Net financing
    expenses</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(5,232</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: left"><b>Profit (loss)
    when the Company&#8217;s share in the losses of companies that are handled according to the method of the balance sheet value is
    neutralized</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">1,256</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">Company&#8217;s
    share in losses of&#160;&#160;companies handled according to&#160;&#160;the book value method</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(585</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>Profit
    (loss) before taxes on&#160;&#160;income</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">671</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify">(Taxes on
    income) tax benefit</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(1,931</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: justify"><b>Total profit
    (loss) for the year</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">(1,260</td><td style="font-style: normal; font-weight: normal; text-align: left">)</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: left">Adjusted profit
    (loss) before tax deducted by options granted to employees, non-cash-flow rate differences with respect to the Optimatic transaction
    and expenses related to the merger transaction</td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">10,421</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <td style="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; text-align: left"><b>EBITDA, adjusted
    for options granted to employees, issuance related expenses relating to the merger transaction</b></td><td style="font-style: normal; font-weight: normal">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td><td style="font-style: normal; font-weight: normal; text-align: right">24,352</td><td style="font-style: normal; font-weight: normal; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#8220;Global Automax&#8221;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Global Automax Ltd&#8221; (hereinafter:
&#8220;Automax&#8221; or the &#8220;Company&#8221;) was established in 2015 with the stated objective of importing new vehicles to Israel
via indirect (parallel) imports. The Company is engaged in importing and marketing a range of private vehicle models to and in Israel.
The Company holds an indirect importer license, as defined under Section 42 of the Vehicle Industry Services and Professions Licensing
Law, 2016 (hereinafter: the &#8220;Vehicle Services Licensing Law&#8221;), with respect to a wide range of models produced by 27 vehicle
manufacturers. The Company operates 12 showrooms - Jerusalem, Rishon Letzion, Petah Tikva, Raanana, Beer Sheva, Haifa, Afula, Akko, Netanya,
Glilot, Ashkelon and Ashdod, and it is licensed to import an unrestricted number of new vehicles to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 310; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_004.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s branches in Jerusalem, Haifa,
Afula, Petah Tikva and Rishon Letzion are directly operated by the Group; the Company&#8217;s branches in Netanya, Raanana, Ashdod, Ashkelon
and Glilot are operated by companies jointly owned by a subsidiary and third-parties, and the two remaining branches, in Akko and Beer
Sheva, are operated by the Company&#8217;s authorized retailers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a map of the Company&#8217;s
branches in Israel:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_005.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an international network of suppliers,
primarily in Europe and in North America, which supply it with various brand and model vehicles, subject to orders, and an import structure
which includes procurement, shipping, vehicle customs release handling, and vehicle storage facilities in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indirect (parallel) importing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indirect (parallel) importing is a process under
which a particular consumer product is imported not through the direct importer (the official importer), but rather through indirect
competing importers, which comply with statutory requirements and which personally import the product from a manufacturer&#8217;s overseas
direct agents. This process exists in many industries including the food, pharmaceutical, cellular, and electric product markets, and
now also in the vehicle market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Countries around the world, including Israel,
often apply import restrictions to various sectors, including the vehicle market, in order to ensure the quality and safety of the products
sold to their citizens and/or to protect local industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 311; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It was previously common practice for each manufacturer
to have a sole importer licensed to market that manufacturer&#8217;s products in their country, and which would be responsible <i>vis-a-vis
</i>the government authorities to comply with regulatory rules. This arrangement, convenient for all parties (apart from consumers),
resulted in uncompetitive and over-priced markets. In order to generate competition, some of the regulators required manufacturers to
appoint multiple official representatives in their country; however, the most significant measure which has succeeded and become commonplace
around the world is to allow for parallel importing regulated by law and overseen by the same regulator with identical tools and metrics
used with respect to the direct importer. The importing process, the standards and requirements and the customs and tax rules are identical
to both kinds of importers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The direct importer benefits from an annual allocation
of vehicles broken down into various models, with a set schedule, and in a set currency; while the parallel importer is able to choose
the manufacturer, model, country of origin and currency at any time and to maximize its profits and/or compete and lower vehicle prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Direct importers in different countries choose
to sell some of their allocated vehicles to parallel importers depending on market and currency conditions in their home countries and
in order to become eligible for financial incentives for meeting annual sales targets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The big advantage of parallel importing is flexibility
with choosing the mix of vehicles the parallel importer can import and the ability to quickly respond to changing market conditions.
The parallel importer is not limited to a specific brand and is not committed to a fixed mix of models or a particular technology and
it is able to easily adjust the supply of products and models imported by it in response to changes in local demand and international
supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Vehicle and Transportation Services Licensing
Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2009 the Israeli government adopted a formal
resolution to increase competition in the Israeli vehicle market by opening the vehicle sector up to parallel imports, the law was subsequently
amended to allow vehicles purchased from a manufacturer&#8217;s authorized agent (a &#8220;dealer&#8221;) to be imported to Israel, and
not just vehicles directly purchased from the manufacturer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The parallel import of vehicles to Israel only
actually started in 2012 (by Ayalon Motors importing Ford vehicles), which led to operating and control procedures being established
by the Ministry of Transport.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until 2016 the parallel import of vehicles to
Israel was subject to the &#8220;Products and Services Control Order - Vehicle Import&#8221;. The order defined the conditions the parallel
importer is required to meet in order to receive a license, but it did not explicitly specify how the vehicles are to be purchased abroad.
This ambiguity created an opening for various interpretations between the relevant regulators (the Ministry of Transport and the Tax
Authority) and it created an opening for various arguments against the parallel importers operating at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2016 the &#8220;Vehicle and Transportation
Services Licensing Law&#8221; which consolidated all the orders, regulations and procedures in the sector into a single law, which clearly
and more conveniently clarifies various issues including the parallel import of vehicles to Israel was approved by the Knesset (Israeli
parliament) at its third reading. The law removes various barriers in the field.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law includes the following primary matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">1.</td><td style="text-align: justify">The law makes a distinction between
                                            four kinds of importers:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Direct importer - being the &#8220;original&#8221;
                                            importer which is party to an agreement with the vehicle manufacturer. i.e., the direct importer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 312; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Indirect importer - an importer
                                            which is party to an agreement with one of the vehicle manufacturer&#8217;s international
                                            authorized agents. i.e., a parallel importer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Small importer - an importer which
                                            is party to an agreement with the vehicle manufacturer or authorized agent or with an international
                                            party established by the Minister of Transport, and restricted to importing up to 20 vehicles
                                            annually.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Personal import agent - someone
                                            who provides brokerage and consulting services for importing a vehicle but is not personally
                                            an importer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law establishes the conditions for all importers,
the requirements for agreements with manufacturers/agents, the scope of equity, the existence of maintenance service infrastructure,
etc., for each importer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The law subjects the direct importers
                                            to an obligation to issue service bulletins (recalls) and to be liable for all the vehicles
                                            manufactured by the make imported by them (even if imported by a parallel importer) from
                                            January 1, 2017.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">3.</td><td style="text-align: justify">The parallel importer, who until then
                                            could have imported a vehicle via an authorized agent, is now able to import via a secondary
                                            agent (a retailer).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">4.</td><td style="text-align: justify">The indirect importer is permitted
                                            to import new vehicles (up to 150km) even if the vehicle is already registered abroad.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">5.</td><td style="text-align: justify">The restriction on the number of products
                                            an indirect importer is able to import was cancelled. Products not formally imported to Israel
                                            were also permitted to be indirectly imported.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">6.</td><td style="text-align: justify">As a first, the new law gives the Minister
                                            of Transport the ability to establish conditions and restrictions applicable to the licensee
                                            - i.e., licensed vehicle importers - including to not issue or renew an import license if
                                            the licensee fails to meet established conditions, including adversely impacting competition.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently dozens of companies in Israel
engaged in parallel importing vehicles, the largest being Automax which imports approximately 2,500 vehicles annually (on average) and
Ayalon Motors which imports approximately 1,300 vehicles annually (on average).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are also hundreds of companies which operate
in the small import segment (up to 20 vehicles per company annually) and personal import agencies which provide advisement, logistics
and purchasing services for personal import. Approximately 2,000 vehicles are personally imported to Israel annually, almost entirely
in the luxury segment. This kind of import has significant disadvantages relative to direct or parallel import - difficulties with implementing
the vehicle warranty, various restrictions on selling the vehicle, and others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market segment for parallel (and small) import
is relatively negligible and totals approximately 3.5% of the market compared with approximately 10% on average in Europe. (There is
a big difference between Eastern European countries such as Poland with 30% and Italy with only 2%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 313; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a breakdown of the parallel
import market in 2023 (based on the quantity of vehicles, excluding small imports, by importer):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Based on a five-year calculation, the market
segment of each of the first three importers is identical.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax is the leading company in the parallel
vehicle import segment and it is intending to also maintain its status in the future unrelated to it expanding to other fields.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Vehicle manufacturers&#8217; response to parallel
import (and export)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scale of manufacturing and employment give
the vehicle manufacturers significant financial and political clout which they use to entrench and protect their interests in the countries
they operate in.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, vehicle manufacturers designate various
models to each region based on general preferences in that region, weather restrictions, the applicable standards and purchasing power,
and they try to prevent models from &#8220;leaking&#8221; between regions due to engineering and &#8220;anti-competitive&#8221; reasons
- in order to maintain their ability to implement price discrimination between regions/continents based on exchange rates, tax rates
and the competitive standing of the manufacturer in that region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, volatility with business cycles, regulatory
changes and changing preferences constantly create excess supply in some parts of the world and pressure the manufacturers to export
vehicles between regions. Arbitrage differentials are not a passing opportunistic phenomenon but an inherent part of the market (similar
to a certain extent to the &#8220;zero km&#8221; phenomenon in Israel). As a result, approximately 10% of global vehicle trade is performed
as &#8220;parallel&#8221; trade between brokers/merchants and not directly <i>vis-a-vis</i> the manufacturer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">US antitrust law prohibits vehicle manufacturers
from preventing vehicle exports from the US by dealers, and prohibits the manufacturer from owning the dealerships which retail its products
(these dealerships form alliances and act as a counterforce against the manufacturer&#8217;s power).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unlike the US, in Europe there is no legal prohibition
against manufacturers owning retail agencies (dealerships) and therefore some of the largest distributors are wholly or partially owned
by the manufacturers. However, European antitrust laws prohibit manufacturers from preventing exports between European countries, and
even impose significant financial sanctions for associated breaches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In practice, most vehicle manufacturers subject
agents exporting vehicles to more or less legal barriers, including prohibiting agents from selling to companies suspected of engaging
in parallel export, agreements preventing shipping companies from transporting vehicles the subject of parallel import or which require
them to report such to the manufacturer, and the like.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 314; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, most parallel importers try to operate
&#8220;under the radar&#8221;, and typically need to purchase the vehicles from the agent in the territory permitted to it via local
companies, to pay taxes and VAT in the country of origin and to personally export them. This activity requires an extensive logistical
basis and significant interim financing capabilities (for the taxes and VAT).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the manufacturer identifies that a company
is purchasing and exporting the vehicles it includes them on a &#8220;black list&#8221; of companies which cannot be sold to, and the
parallel importer needs to engage new retail companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of the other common barriers in the field,
primarily in Europe, is the manufacturer refusing to issue original manufacturing certificates - these certificates are required where
Israeli customs authorities request the European customs house to validate the original certificate which gives the vehicle preferential
customs treatment, and without which the parallel importer is required to pay additional customs tax (7% of the total value including
taxes) even if the vehicle is manufactured in a country with a preferential status. The Israeli Customs Tariff Order was recently amended
(in September 2023) to exempt a parallel importer from presenting the original certificate of models imported by direct importers and
which requires customs to rely on the original certificate furnished by the direct importer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As aforementioned, Automax has established and
experienced purchasing networks and contractual agreements with some of the largest vehicle manufacturer agents in Europe and Canada,
which allow it to purchase from production batches especially manufactured for export with almost no restriction. The Company purchases
most of the models it imports in three or four different currency regions, in order to mitigate the exposure to exchange rates or other
blockage attempts, and to enable it to have consistent supply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company&#8217;s sales:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See details about the new vehicles sold by the
Group as of December 31, 2022 and December 31, 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the period ended<br/>
    December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For a Period ended on<br/>
    December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate for <br/>
    Institutional <br/>
    Customers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate for<br/>
    Institutional <br/>
    Customers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 23%; text-align: right">2,048</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">35.84</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">2,462</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">26.69</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 315; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See sales of vehicles imported by the Group,
split by make:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Product</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the period ended<br/>
    December 31,<br/>
    2022</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For a Period ended on<br/>
    December 31,<br/>
    2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quantity</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quantity</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Sales Rate</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Toyota</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">497</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">24.27</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">669</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.17</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Honda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">471</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jeep</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.41</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hyundai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.96</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BMW</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.88</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ford</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.74</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.57</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Volkswagen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.81</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mercedes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.44</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Skoda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.42</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.52</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Seat</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.03</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mazda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.83</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Volvo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.66</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mini</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Land Rover</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.39</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fiat</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.81</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.63</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over January-September 2023, Automax delivered
approximately 1,550 vehicles based on the following breakdown (according to licensing data):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_007.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 316; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of macro-economic factors on the Company
in 2023: </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operating segment is inherently sensitive
to external and macro-economic factors: The Company&#8217;s financial results in 2023 were adversely impacted as a result of these factors
and, in my view, it (and the entire market) knew how to adjust the price level for sales and purchasing and to adapt to the current market
conditions, therefore, I assess that 2023 was not a representative year for its operating activities. Presented below is an overview
of the relevant trends and their impact on the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trend</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Local
    Influence (Seller-Side)</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Global
    Influence (Buyer-Side)</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    of the Automotive Industry from the &#8220;Global Chip Shortage&#8221; of 2020-2023<br/>
    (= increase in vehicle inventory).</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
    market competition creates pricing pressure.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    pressure and buying opportunities; Return of the supply of low-priced cars that last year were almost unattainable.</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rising
    in local and global interest rate.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in household disposable income causes decrease in demand of cars, especially amongst luxury vehicle market segment.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in bargaining power of the Company vis-a-vis its suppliers.</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Civil
    protests due to the Israeli legal reform proposal.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in Consumer confidence index (CCI) moderates demand; NIS depreciation vis-&#224;-vis main foreign currencies used for purchasing
    stock, causing an increase in the cost of sales.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massive
    market penetration of Chinese brands to the Israeli market.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion
    in new brands&#8217; market segment at the expense of the market segment that is relevant to Company&#8217;s brands.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chinese
    manufacturers that did not consider investing in Israeli&#160;&#160;market penetration, increasingly start to show interest. </span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Swords
    of Iron&#8221; War<br/>
    (October 7, 2023 War)</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in Consumer confidence index (CCI) moderates demand; Increase in maritime transportation costs and supply delays due to the &#8220;The
    Houthi Crisis in the Red Sea&#8221;, causing an increase in the cost of sales.</span></td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter B &#8211; The Israeli vehicle market</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are approximately 3.4 million private vehicles
on Israel&#8217;s roads. These include approximately 3.1 million vehicles which are privately owned by individuals and approximately
300,000 vehicles owned by corporations and institutional entities (primarily leasing companies). Approximately 260,000-290,000 new vehicles
are sold annually (and another approximately 500,000 used cars are sold), and approximately 200,000 cars are written off (wear and tear,
scrap metal, accidents and thefts). The institutional market&#8217;s share of new vehicle purchases is significantly greater than its
general share of the vehicle market and is estimated at approximately 40% of total purchases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 317; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average vehicle age in Israel is approximately
6.9 years - slightly below the European average. The vehicle penetration level in Israel (the number of vehicles per 1,000 people) is
relatively low for the Western World and is consistently growing - approximately 380 vehicles per thousand people vs. approximately 600-650
vehicles per thousand people in Western Europe and approximately 700-900 in the US.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a graph of vehicle deliveries
in Israel over time (in 000&#8217;s):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_008.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over 2020-2022 there was a decline in the global
vehicle supply associated with the COVID-19 crisis which also impacted the volume of deliveries in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is an overview of monthly vehicle
deliveries in the first nine months of the year compared with the previous year:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_009.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 318; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average price of a new vehicle in Israel
has consistently risen over time and it is currently ILS 193,000:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_010.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This increase is consistent with rises in the
CPI. In recent years, as a corollary of the COVID-19 crisis and the associated short-supply, there was also an increase in used vehicle
prices - this phenomenon (for used vehicles) is expected to reverse in coming years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index of new and used vehicle prices, years
2008-2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_011.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Source: Israeli Central Bureau
of Statistics, Ministry of Transportation&#8217;s data, processed by the Israeli Tax Authority</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 319; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a breakdown of new vehicle
sales in 2023 by price (importer&#8217;s pricelist):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_012.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax mainly focuses on the primary market
segments (ILS 130,000-350,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Over
                                            the last decade Israeli consumers (and consumers generally around the world) started to have
                                            a clear preference for Crossover SUV models and therefore Automax is focused on importing
                                            these models - presented below is the scope of sales in recent years according to vehicle
                                            structure:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_013.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 320; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">In
                                            recent years Chinese vehicles have started to penetrate the market <i>en masse </i>and they
                                            are almost at 20% of Israeli vehicle sales (!). The top ten models in 2023 include 3 Chinese
                                            models, and not a single European model. Presented below is a graph of vehicle sales in Israel
                                            in recent years based on country of manufacture:</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_014.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another trend apparent in recent years which
is anticipated to continue is a significant increase in the market share of electric vehicles on account of the market share of gasoline
and diesel motor vehicles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline"><img alt="" src="image_015.jpg"/></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli vehicle importers - Direct import</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Israeli vehicle market is a concentrated
market - the 12 largest vehicle import groups, which import approximately 55 different brands of private vehicles and buses, trucks and
motorcycles have almost 100% of the vehicle market share in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 321; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The five leading vehicle brands generally comprise
approximately 50% of vehicle deliveries, while the five leading importers are responsible for approximately 70% of the total vehicle
deliveries in Israel. Presented below is a breakdown of the market in 2023 by importer:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_016.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is a breakdown of the market
by vehicle brand: As aforementioned, the share of western brands has been declining over time in favor of Korean, Japanese and Chinese
brands:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_017.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The breakdown of the market between companies
and the different brands changes according to public preferences, the development of models by the manufacturers and exchange rates.
Exchange rates play a critical role in the importer&#8217;s competitiveness, there is accordingly a high correlation between the exchange
rate of the currencies relevant to the production of the vehicles and the market segments of the various brands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As aforementioned, the scope of vehicles imported
from China to Israel has consistently been increasing which also directly correlates with the increase in the number of electric vehicles
being imported to Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 322; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is data about the scope and range
of electric vehicles imported from China to Israel over January-September 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Group</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Manufacturer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Model</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deliveries<br/>
    until September<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Import<br/>
    Price in<br/>
    NIS&#160;<br/>
    (Entry&#160;Model)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Volume<br/>
    of Money in<br/>
    NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Importer</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 14%; text-align: center; padding-left: 5.4pt">Leapmotor</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-left: 5.4pt">Leapmotor</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-left: 5.4pt">T03</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">424</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">99,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">42,395,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: center; padding-left: 5.4pt">Metro</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Small Ant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">GWM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Ora</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Funky Cat</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">792</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,216,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Colmobil</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Dolphine</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,197,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">JAC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">JAC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">S4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,720,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Automotive Equipment (AEV)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,937,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">DFSK</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SERES</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">E3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,884,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Talcar Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">FX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,973,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geometry C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">987,881,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Union Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Tiggo 7 Pro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,343,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">EVeasy</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Eveasy</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Limo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,156,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">ZS SUV</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,917,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Atto 3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,148,630,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,104,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Chery</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Tiggo 8 Pro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">994,293,180</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">e Deliver 3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,376,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Dongfeng</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Forthing</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Friday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,439,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">UMI</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">U5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,118,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Blilious Group</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">HS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490,384,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">V80</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">W5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">795,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Automotive Equipment (AEV)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">ETP-3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">MG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Marvel R</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,946,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Lubinski</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SKYWELL</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SKYWELL</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">ET 5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,643,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Caduri</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Aiways</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">U6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,314,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Blilious Group</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Seal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">689,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">P7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Lynk &amp; Co.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">231,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,997,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Mayer</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">EUNIQ 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,997,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">DFSK</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SERES</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,926,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Talcar Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">SAIC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Maxus</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">EUNIQ 5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,046,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">China Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">GWM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WEY</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Coffee 02</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,919,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Samelet</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Polestar</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Polestar2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,672,525</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Mayer</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">GWM</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">WEY</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Coffee 01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,843,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Samelet</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Tang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,297,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">XPENG</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">G9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Carasso Motors</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">BYD Auto</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Han</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,990</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,188,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Shlomo Sixt</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">eT5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Delek</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Geely</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">LEVC</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">TX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Automotive Equipment (AEV)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Dongfeng</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Voyah</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Free</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,586,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Metro</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Honggi</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">Honggi</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">E-HS9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,592,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Samelet</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">eS8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Delek</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">NIO</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">eT7</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">499,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Delek</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; font-weight: bold; text-align: center; padding-left: 5.4pt">Total</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,661</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,752,495,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; font-weight: bold; text-align: center; padding-left: 5.4pt">Mean</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 323; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we examine the sales data of all vehicles
in Israel over January-September 2023 we can easily see the revolution in the market with the 10 leading models. There are three Chinese
manufactured models and not a single European model. It can cautiously be said that the &#8220;Western&#8221; brands are slowly disappearing
from the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The data are presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Manufacturer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Model</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jan-Sep<br/>
    2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jan-Sep<br/>
    2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jan-Sept<br/>
    2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%; text-align: left">BYD Auto</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%">Atto 3</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,913</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kia</td><td>&#160;</td>
    <td>Niro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,885</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Hyundai</td><td>&#160;</td>
    <td>Elantra</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,673</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Toyota</td><td>&#160;</td>
    <td style="text-align: left">Yaris Cross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Geely</td><td>&#160;</td>
    <td style="text-align: left">Geometry C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Kia</td><td>&#160;</td>
    <td>Picanto</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,360</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Chery</td><td>&#160;</td>
    <td style="text-align: left">Tiggo 8 Pro</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Hyundai</td><td>&#160;</td>
    <td>Tucson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,835</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Mazda</td><td>&#160;</td>
    <td style="text-align: left">2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Mitsubishi</td><td>&#160;</td>
    <td>Outlander</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,740</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter C - &#8220;Dalhom Automax&#8221;
(direct import of &#8220;TEMSA-Skoda&#8221; brand buses)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the Company, jointly with Dalhom
Motors Ltd. (hereinafter: &#8220;Dalhom&#8221;), established a SPV to import TEMSA brand buses. The Company signed an agreement with
the manufacturer under which the common company will serve as the direct importer of TEMSA brand buses to Israel. TEMSA has multiple
electric, gasoline or diesel engine model buses and minibuses designed to serve tourism and public transportation, all of which are suitable
to be marketed in Israel.<br/>
The Company is currently completing the establishment of a central bus service center with a total area of 4,000 sqm in Hod Hasharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company is one of the Group&#8217;s growth
engines, and is anticipated to generate significant profits under the plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 324; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E.D.B Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div style="border: Black 1pt solid; padding: 1pt 4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TEMSA
                                            Skoda</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Temsa Skoda is a leader in production of buses
and minibuses worldwide:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* A manufacturing plan of 500,000 sqm in Turkey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Leading in electric buses</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Production capabilities of 10,000 vehicles,
including Motor Coach, Midibus, Light Trucks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Selling in 66 countries worldwide</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is an overview of the specifications
of the central service center and garage:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><img alt="" src="image_018.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Area of 4,000 sqm.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Bus service center of 2,000
                                            sqm.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Offices - Located at the
                                            entrance and split over 2 floors: First floor: Service center, office reception and waiting
                                            area. Second floor: Offices + employee rest area.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Work stations (Diagnostics
                                            + mechanics + electric + HVAC)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">6 work stations (including
                                            one station with a &#8220;safety line&#8221; for working on the top part of the bus roof)
                                            + another work station (with a pit jack) - 7 stations in total.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Metal work area:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">5 work stations + one area
                                            for preparing the bus before paint + painting area.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Between the general work
                                            stations and the metal work area there is a dividing wall separating the areas.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Parking areas:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Officially - 8 parking spaces,
                                            16 parking spaces in reality.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 325; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The company is currently
                                            negotiating leasing another 1,000 sqm on the site next to the new service center, which is
                                            meant to add another 30 parking spaces.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is planning to apply for tenders
issued by public transportation companies starting in 2024.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_019.jpg" style="width: 650px; height: 368px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Israeli commuter transportation market:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Approximately
                                            2,500 buses are sold annually in Israel, half of which are sold for public transportation
                                            purposes (to large companies which win operating tenders) and half of which are sold to tour
                                            and commuter companies (small and medium companies and authorized dealers).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">933
                                            commuter companies are registered in Israel, 532 of which are actively operating (hold a
                                            valid license to operate a commuter service).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Approximately
                                            400 commuter companies operate full-size buses (more than 44 seats).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            commuter sector operates approximately 11,000 buses (more than 19 seats), and approximately
                                            16,000 minibuses (up to 19 seats).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Average
                                            fleet size of a commuter company: 5-80 buses.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            average age in the sector is 6 years, and the maximum age is 12 years.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            annual mileage of a bus is 50,000-80,000km. The average daily mileage in the industry is
                                            approximately 220km.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            daily cost of operating a bus is approximately ILS 1,300.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
                                            commuter sector is extremely competitive and diverse, and is subject to geopolitical changes
                                            and business cycles.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 326; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Division of bus fleets by year of production,
type, as of year-end 2019</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt; font-weight: bold; text-align: left">Vehicle Type
    /<br/>
    Year of<br/>
    Manufacture</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2016</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2013</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2012</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2011</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2010</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2009</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Until 2008</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; width: 15.5%">Public
    Bus for Special Transportation</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">8,598</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">530</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">914</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">960</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">847</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">823</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">777</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">605</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">370</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">481</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">458</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">401</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 0.5%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 5%; font-weight: bold; text-align: right">1,432</td><td style="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Bus for
    Tour</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,592</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">70</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">110</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">112</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">110</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">141</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">73</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">133</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">156</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">86</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">460</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Minibus</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5,330</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">158</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">274</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">512</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">707</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">510</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">390</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">456</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">457</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">485</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">445</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">310</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">626</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Minibus
    for Tour</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">38</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">8</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Public Minibus
    for Special Transportation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3,214</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">239</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">715</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">614</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">454</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">260</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">248</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">212</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">140</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">138</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">88</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">42</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">64</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Private Bus</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">709</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">15</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">42</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">48</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">47</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">64</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">24</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">38</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">51</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">52</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">48</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">239</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Private Minibus</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">6,852</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">34</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">93</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">108</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">128</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">125</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">165</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">261</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">365</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">429</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">536</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">490</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,118</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Touring Car</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">215</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">41</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">51</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">28</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">26,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,064</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,173</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,388</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,353</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,846</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,794</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,679</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,461</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,722</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,742</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,380</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,946</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sales of buses and public transport brands</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Make</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">H1 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Volvo</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">220</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">366</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">372</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">285</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Golden Dragon</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">HIGER</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">58</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">438</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">197</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Mercedes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">191</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">396</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">151</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">OTOKAR</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">BYD Auto</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Isuzu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">TEMSA</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">79</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">43</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Zhongtong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Irizar</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold">OTHER</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">453</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,276</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,534</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,279</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 327; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>
</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">According to the
Company&#8217;s business plan, presented below is a proforma profit and loss statement for the garage activities and an operating budget
for the bus sales activities:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Profit &amp; Loss Forcast (in NIS)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Hod Hasharon Garage</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">Section / Period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Incomes from mechanical work</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">7,393,350</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">8,502,353</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">8,927,470</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from spare parts (mechanics)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3,696,675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,251,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,463,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from works outsourcing mechanical works</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,232,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,417,059</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,487,912</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">PDI for new buses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">124,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total income from mechanical work</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12,447,050</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14,170,588</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14,879,117</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from metal works (&#8216;body work&#8217;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9,556,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,990,210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">11,539,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from metal works spare parts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9,556,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,990,210</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">11,539,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from outsourcing metal working</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,123,712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,442,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,564,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Income from metal working</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,237,120</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">24,422,688</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">25,643,822</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income from mobile vehicles</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,112,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,428,800</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,550,240</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">35,796,170</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41,022,076</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">43,073,179</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost of Sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Mechanics</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">11,575,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,178,646</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,837,579</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Metal works</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,804,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15,874,747</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16,668,485</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Cost of Sales</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">25,379,885</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">29,053,394</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">30,506,063</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">70.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">70.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">70.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10,416,286</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">11,968,682</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12,567,116</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold; text-align: left">Sales General &amp; Administrative (G&amp;A) Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and Payroll Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3,948,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,046,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4,147,868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Rent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,440,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,596,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,599,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rates (Tax)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">288,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">295,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">302,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advertising &amp; Marketing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Car Maintenance and Travel Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">312,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">312,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">312,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional Services (Fees)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Maintenance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office Supplies (Electricity, Water, Gas)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">54,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">59,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">59,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Phone &amp; Communication Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office Supplies &amp; IT Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Towing/Transportation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">189,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mobile Units Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">189,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Food &amp; Drink (Refreshments)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unexpected Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">103,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">150,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total Sales and G&amp;A Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,933,048</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,801,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,944,048</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">19.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,929,166</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,166,982</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,634,069</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Financing Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">600,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">320,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Earning Before Tax (EBT)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,329,166</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3,566,982</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,314,069</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income Tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,181,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,077,181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,181,836</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Income/Loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,793,457</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,489,801</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2,132,232</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>% of Income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 328; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Dalhom Automax - Budget in NIS</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Incomes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Incomes from Sale of Buses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">105,954</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from Sale of Commercial Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Incomes from Sale of Used Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3,219</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Incomes from Sale of Spare Parts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Income</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">110,303</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of Sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Direct Cost of Buses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">95,546</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Direct Cost of Commercial Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">389</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Direct Cost of&#160;&#160;Used Vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,744</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Spare Parts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Llicensing, Tests &amp; PDI</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,076</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Transportation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">139</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Direct Cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">100,109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10,194</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9.24</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating Cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Salaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,568</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketing, Advertising &amp; Sales Promotion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lot/Warehouse Rent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Translation &amp; Editing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mobile Unit Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Towing Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Garage Services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Insurances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Car Maintenance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Hospitality</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unexpected Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total General &amp; Administrative (G&amp;A) Expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,172</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Operating Cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>G&amp;A</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bookkeeping, Accountancy &amp; Audit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Legal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">96</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rates (Tax)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unexpected Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total General &amp; Administrative (G&amp;A) Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">420</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5,602</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing cost (FC)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">1,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4,162</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.77</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 329; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As stated above, Automax owns 50% of &#8220;Dalhom
Automax&#8221; and the company still does not have a multi-year business plan for selling the buses. The 2024 budget has a forecasted
net profit of approximately ILS 4 million and a similar anticipated profit under the three-year business plan for the service center
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no doubt that Automax entering the bus
import and maintenance sector is likely to be profitable and will be one of the central factors of growth for the Company, if not the
central factor for growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter D - &#8220;HYCAN Automax&#8221;
(direct import of &#8220;HYCAN&#8221; brand electric vehicles (from China))</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax has entered into a commercial agreement
with the Chinese electric vehicle manufacturer HYCAN.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HYCAN is a leading and innovative vehicle manufacturer
which specializes in manufacturing electric and high-tech vehicles for the global market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company was established in 2018 under the
name &#8220;GAC-NIO&#8221; - a reference to the joint venture by its investors - GAC - the state-owned vehicle manufacturer, and NIO
- the US electric vehicle manufacturer. HYCAN benefits from the expertise and resources of its parent companies, GAC and NIO, both of
which are well established in the Chinese and global electric vehicle market. The brand was officially launched in 2020 and focuses on
manufacturing exceptional electric vehicles. HYCAN also established a global R&amp;D center in Silicon Valley, California. The center
focuses on developing advanced technologies for electric vehicles, including autonomous driving and smart mobility solutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By establishing a R&amp;D center in Silicon Valley,
HYCAN will be able to take advantage of the rich skill-set and innovative culture in the area and to collaborate with leading tech companies
and research institutes. This allows HYCAN to be at the forefront of electric vehicle technologies and to develop advanced technologies
which improve the driving experience and which reduce the environmental impact of its vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021 HYCAN announced that they are planning
to expand their business globally and to sell their electric vehicles in selected markets in Europe, the Middle East and in South-East
Asia. The brand is therefore expected to expand its global reach in coming years with a wide range of new EV model vehicles. The company
plans to gradually enter these markets and is focusing on specific regions and countries with high demand for electric vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It should be noted that HYCAN will have to deal
with difficult competition from other companies established in the global electric vehicle market. However, the company&#8217;s focus
on technology, sustainability and premium designs can be a differentiating factor which attracts customers in new markets. All in all,
HYCAN&#8217;s plans for international sales demonstrate their aspirations to become a global player in the electric vehicle market. As
the demand for electric vehicles continues to grow around the world, companies such as HYCAN will have significant opportunities to expand
their business activity and to offer innovative solutions to customers in different regions and markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 330; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%">&#160;<img alt="" src="image_020.jpg"/></td>
  <td style="text-align: center; width: 50%"><img alt="" src="image_021.jpg"/></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of HYCAN&#8217;s efforts to become independent
and enter global markets, in 2022 the Chinese investment company Pearl River invested in HYCAN and it currently controls the company
with a 65.5% ownership stake. The GAC group owns 25% and NIO owns the remaining minority stake comprising just 4.5%. Pearl River Investments
is a Chinese investment company which focuses on the vehicle industry. The Company also invests in various industrial sectors, including
electric vehicles, autonomous driving and smart mobility solutions. Pearl River aspires to identify and invest in innovative companies
in the vehicle industry which are able to generate value for their customers and stakeholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HYCAN is committed to creating innovative, reliable,
sustainable and high performance electric vehicles which offer a unique driving experience. The vehicles are designed with advanced technology,
premium design and features which aspire to provide exceptional performance, safety and reliability. The product basket includes a range
of electric vehicles, including Sedans, SUVs, MPVs and Crossovers, all with advanced electric engine systems, innovative battery technology
and smart communication systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The HYCAN vehicle activities will be performed
by a subsidiary of Global Automax/Automax Motors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company will operate in addition to and not
instead of Automax&#8217;s parallel import activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company will operate through Automax&#8217;s
existing infrastructure (showrooms, sales channels, PDI system, head-office and the like), and no independent infrastructure will be
set up for it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales will be performed at all Automax showrooms,
one of which will be converted into a flagship showroom for the brand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One central service center will be established
for the brand, in addition to the network of external service centers currently with an arrangement with Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brand will have a significant launch campaign
over 2024-2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The transition to electric
                                            vehicle gives the Chinese vehicle industry a relative advantage over its global competitors
                                            and allows it to more easily meet the relevant standards requirements.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Israel is considered to be
                                            a &#8220;gateway&#8221; to Europe for many Chinese manufacturers and is the subject of significant
                                            interest for the Chinese vehicle industry.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Approximately 41,103 of the
                                            vehicles sold over January-September this year were manufactured in China (16.6%) compared
                                            with only 12,736 vehicles in the same period the previous year.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Automax&#8217;s business plan, the
Company will commence selling HYCAN model vehicles already in Q4 2024 and its sales target is approximately 400 vehicles, while the sales
target forecasts annual vehicle sales totaling approximately 2,400 vehicles within 4 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 331; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is the basis of the plan:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td><td style="font-weight: bold; font-style: normal; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal; text-align: center">Representive
    Year</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: normal; font-style: normal; text-align: left">Sales
    (Quantity of Vehicles)</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">400</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">800</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">1,600</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">2,400</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Vehicle&#8217;s
    CIF Average Cost (in Thousand NIS)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">After-Tax &amp;
    Tariff Cost (Average Tax for an Electric Vehicle 40%, Tariff 7%)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">127.33</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Average Selling Price (ASP)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">151.58</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">151.58</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">155.28</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">155.28</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Gross</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">16</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">16</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">18</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">18</td><td style="font-weight: normal; font-style: normal; text-align: left">%</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="font-weight: normal; font-style: normal; text-align: center"><b>Pro Forma Balance Sheet (in Thousand NIS)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: normal; font-style: normal; text-align: left">Vehicles
    Inventory</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">8,500</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">17,000</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">34,000</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">51,000</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Spare Parts Inventory</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">255</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">510</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,020</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,530</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Fixed Assets
    (Garage, Showroom)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">500</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">4,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Demo Cars</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">255</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">425</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">850</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">850</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Total Assets</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">95,510</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">20,935</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">38,870</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">57,380</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="font-weight: normal; font-style: normal; text-align: center"><b>Statements of Income Pro Forma (in Thousand
    NIS)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: normal; font-style: normal; text-align: left">Income
    from Sales of Vehicles</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">60,633</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">121,267</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">248,449</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 1%; font-weight: normal; font-style: normal">&#160;</td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="width: 9%; font-weight: normal; font-style: normal; text-align: right">372,673</td><td style="width: 1%; font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Cost of Sales</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">50,932</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">101,864</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">203,728</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">305,592</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Net Revenue from
    Sales of Spare Parts and Garage Services</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,819</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">4,244</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">9,938</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">18,634</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Gross profit</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">11,520</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">23,647</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">54,659</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">85,715</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: center">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Marketing &amp;
    Advertising</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">6,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,000</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Designated HQ</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,200</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,440</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,728</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">2,074</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Rent &amp; Rent
    Bills (Garage and Showroom)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Travel and Living
    Expenses Abroad</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">800</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Depreciation
    and Amortization</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">144.29</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">562.14</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">695.71</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">911.43</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Financing</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">665.7</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">1,465.45</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">2,720.90</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">4,016.60</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Total Expenses</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">7,610</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">12,068</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">10,745</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">12,602</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: center">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal; text-align: left">Pre-tax Profit</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">3,910</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">11,579</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">43,914</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">73,113</td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 332; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is apparent that the Company&#8217;s target
is to achieve annual sales totaling approximately 2,400 HYCAN vehicles a year within 4 years by primarily using the Company&#8217;s existing
platform (showrooms, sales personnel, etc.), which is meant to achieve a pretax annual profit of approximately ILS 73 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Granted, the Israeli vehicle import market is
becoming more and more competitive primarily in the electric vehicle segments, and each month we are seeing new models and companies
(the vast majority of which are Chinese) enter the Israeli market, primarily through the large vehicle importers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, despite the significant competition
and considering the fact that Automax is already operating in the market, it appears that the sales target the Company has set for itself
is realistic (in reality it involves approximately 0.8% of the total annual vehicle imports to Israel) and it is certainly achievable
through proper marketing work.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter E - Calculation of the Enterprise
Value</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, I will refer to the simple valuation method
relevant to public companies listed on the TASE and the simple argument that the Company&#8217;s market value reflected in the value
of its shares on TASE is the Company&#8217;s real value and I will explain why I did not find it correct to refer to this valuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reasons are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">There
                                            is little &#8220;public float&#8221;, 5-7 shareholders of the Company&#8217;s controlling
                                            group own the majority of shares (approximately 80%). The trading volume in the market is
                                            extremely low.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            Israeli stock exchange on which the Company&#8217;s remaining shares are traded is not developed.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">In
                                            the last two years there has generally been correlation between market trends and the direction
                                            of the share.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">In
                                            recent years there have been multiple events which prevent reasonable value assessments (COVID-19,
                                            the legal reform and the war).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            Israeli capital market operates differently than any other prominent capital market around
                                            the world.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            stock market is self-correcting in the long-run and good years are therefore being forecasted.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Just
                                            as on January 21, 2021, the Company&#8217;s value on the Tel Aviv Stock Exchange came to
                                            approximately ILS 278 million (based on a share price of ILS 310), reflecting a value of
                                            approximately USD 84.7 million (based on an exchange rate of 3.28), and in January 2022 the
                                            Company&#8217;s value on the Tel Aviv Stock Exchange came to approximately ILS 197 million
                                            (based on a share price of ILS 220), reflecting a value of approximately USD 63.5 million
                                            (based on an average exchange rate of 3.1) - being high values which do not reflect the Company&#8217;s
                                            real value; so too, the Company&#8217;s low value on January 1, 2024 on the Tel Aviv Stock
                                            Exchange coming to approximately ILS 36 million (based on a share price of ILS 40), reflecting
                                            a value of approximately USD 9.9 million (based on an exchange rate of 3.65), is also not
                                            representative of its real value.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 333; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I will now present the calculations of the valuations
based on two alternative methodologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The representative profit multiplier methodology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier and the profit multiplier
are two metrics commonly used to assess the value of a company. Both metrics measure the ratio between the share price and the company&#8217;s
profit, but do so in different ways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier measures the ratio between
the share price and the company&#8217;s gross operating profit. The gross operating profit is the company&#8217;s profit before financing
expenses, taxes and depreciation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier measures the ratio between
the share price to the company&#8217;s net profit. The net profit is the company&#8217;s profit after financing expenses, taxes and depreciation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Theoretically, this multiplier methodology is
the simplest methodology for a valuation and it is primarily used to compare the value of companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profit data, whether it is EBITDA, operating
profit or net cashflow, are consistently announced and the relevant profit multiplier can be calculated for each company by dividing
the company&#8217;s market cap by the relevant profit line-item. This can also be done by taking a reported profit figure and by multiplying
it by the relevant multiplier and to assess the enterprise value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit generally represents past results
already recorded. Thus, the disadvantage of the multiplier methodology is that it is based on figures from the past, inherently without
tools to consider the potential for future profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This disadvantage makes this method ineffective
for establishing the enterprise value. This is because this methodology does not take into account the effect of the Company&#8217;s
existing significant growth engines, and which are meant to result in the Company doubling or more its sales turnover and annual profit
within a few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding, I have decided to present the
results of this metric to reflect a kind of starting point to gauge the Company&#8217;s enterprise value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I chose to take the average of the two common
multiplier methodologies, the EBITDA and profit multipliers, which I assess are appropriate for the Company&#8217;s characteristics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As I already noted above, the 2023 annual period
cannot be used as a representative year due to the multitude of macro events which impacted the commercial results of many companies
in the economy including Automax. The 2022 annual period was therefore chosen as the representative year for the assessments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>EBITDA multiplier</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier is a financial metric used
to assess the enterprise value of a company. It is calculated by dividing the value of the company&#8217;s operations by its gross operating
profit (EBITDA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Formula: EBITDA multiplier = enterprise value
/ EBITDA</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EBITDA is the earnings before financing expenses,
tax, depreciation and amortization. This metric determines the company&#8217;s operating profitability prior to expenses not directly
related to its operating activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier is a popular metric for
valuing companies since it allows for a comparison to be made between companies with different capital structures. Financing expenses,
taxes, depreciation and amortization can significantly change between companies, and therefore the use of net income to value a company
can result in an imprecise comparison.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 334; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The EBITDA multiplier in the Israeli parallel
vehicle import sector ranges between 2 to 3.5. The meaning is that companies in the sector are traded based on a multiplier of 2-3.5
times their gross operating profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average multiplier in the parallel vehicle
import sector is approximately 2.5. However, there are companies which are traded at higher or lower multipliers, based on different
factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The size of the company, its profitability, forecasted
future growth, commercial risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are some examples of EBITDA multipliers
of companies in the Israeli parallel vehicle import sector:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Union Motors is traded at a multiplier of 2.8</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eldan is traded at a multiplier of 2.3</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Semel is traded at a multiplier of 3.2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are various factors which may
impact the EBITDA multiplier in the Israeli parallel vehicle import sector:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition in the sector, changes in government
policy, changes in exchange rates, volatility with vehicle prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To calculate Automax&#8217;s value through the
EBITDA multiplier methodology and considering the fact that the Company has stable operations and is the largest player in its sector
in Israel I have chosen a multiplier of 3 as being representative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The profit multiplier</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier is a financial ratio used
to assess the enterprise value of a company. It is calculated by dividing the market cap of the company by its net annual profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Formula: Profit multiplier = Market cap / Net
profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier provides us with an indication
of how much investors are prepared to pay for each shekel of profit generated by the company. A higher profit multiplier means that investors
expect that the company will continue to grow and increase its profits in the future. A lower profit multiplier can be indicative of
the fact that the company is not growing or that it is in a difficult financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, it is important to emphasize that the
profit multiplier is only a single tool to assess the enterprise value of a company. There are other factors that should be considered,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forecasted future growth, commercial risks, competition,
management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Limitations of the profit multiplier:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier does not take into account
the company&#8217;s accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier is impacted by external
factors, such as the interest in the economy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier is not always precise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit multiplier in the Israeli parallel
vehicle import sector ranges between 5 to 10. The meaning is that companies in the sector are traded based on a multiplier of 5-10 times
their net profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 335; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average multiplier in the sector is approximately
7.5. However, there are companies which are traded at higher or lower multipliers, based on different factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The size of the company, its profitability, forecasted
future growth, commercial risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below are some examples of profit multipliers
of companies in the Israeli parallel vehicle import sector:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Union Motors is traded at a multiplier of 8.2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eldan is traded at a multiplier of 6.8</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Semel is traded at a multiplier of 9.1</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I have chosen a multiplier of 8 as being representative
for Automax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the assumptions presented above, presented
below is an assessment of the enterprise value based on the EBITDA methodology and the representative profit multiplier methodology:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold">EBITDA 2022</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">24,818</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Profit Multiplier</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">74,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of Dollars</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Profit Multiplier</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of NIS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">83,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Value Estimate in Thousands of Dollars</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">22,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Average Operating Value Estimate in Thousands of Dollars</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">21,772</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">i.e., Automax&#8217;s enterprise value, according
to the average of both commonly used multiplier methodologies and with an emphasis on the fact that this methodology does not take into
account the Company&#8217;s new and significant growth engines, is approximately USD 21.77 million (based on an exchange rate of ILS
3.65 per USD 1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As stated above, the objective of this valuation
was solely to establish a starting point and comparison tool prior to performing a more comprehensive valuation which takes into account
the Company&#8217;s business plan which includes significant growth engines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below I shall present a valuation based on the
future cashflow forecast</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Assessing enterprise value through a DCF methodology
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under this methodology we assess the company&#8217;s
future net cashflow and discount it to the present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is therefore necessary to estimate the profit
and loss for future years, typically for just a few years, until the profitability plateaus at a terminal year which we assume represents
the permanent net annual amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presented below is an explanation about the calculation
of the total cost of capital used to finance the company&#8217;s activities (WACC) and the calculation of the discounted cashflow to
assess the enterprise value:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The WACC (weighted average cost of capital) of
a company is the total cost of the capital used to finance the company&#8217;s activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">WACC is assessed by calculating the relative
weights of the company&#8217;s debt and equity, and calculating the cost of each kind of capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 336; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Cost of equity</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of equity is the return required by
the company&#8217;s shareholders. It is established based on factors, including the risk entailed in investing in the company, as well
as the possible return on alternate investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are various ways to assess the cost of
equity, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Capital
                                            asset pricing model (CAPM)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Internal
                                            rate of rate model (IRR)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Average
                                            rate of rate model (ARR)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cost of debt</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of debt is the return required by the
company&#8217;s lenders. It is established based on the present interest rate of similar bonds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of debt can be reduced by the tax rate,
since the company is able to deduct the interest costs from its taxable revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Weighting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighting refers to the relative share of
any kind of capital, the total debt and equity of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, if the company has equity totaling
ILS 100 million and debt totaling ILS 50 million, its weighting would be 0.67 and 0.33, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculating the WACC to determine the present
value of the company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WACC, or the weighted average cost of capital,
is the rate of return required for a company&#8217;s entire capital, including equity and debt. It is used to discount the company&#8217;s
future cashflows in order to establish its present value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following formula is used to calculate the
WACC:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WACC = (E / (E + D)) * RE + (D / (E + D)) * RD
* (1 - T)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>E
                                            </b>is the company&#8217;s equity</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>D
                                            </b>is the company&#8217;s debt</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>RE
                                            </b>is the cost of the equity</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>RD
                                            </b>is the cost of the debt</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>T
                                            </b>is the tax rate</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 337; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Capital asset pricing model (CAPM) </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Is used to assess the cost of equity of the investment.
It is based on the assumption that shareholders require a higher rate of return on higher risk investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is the formula for calculating
a company&#8217;s cost of equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RE = Rf + &#946; * (Rm - Rf)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>RE
                                            </b>is the cost of the equity</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Rf
                                            </b>is the rate of return required for risk-free assets, such as government bonds</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>&#946;
                                            </b>is the risk parameter of the asset</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Rm
                                            </b>is the average rate of return in the market</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Rate of return required for risk-free assets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rate of return required for zero risk assets
is the return required for risk-free investments. It is used as the basis to assess the cost of equity of higher risk assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk parameter</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk parameter measures the risk entailed
in investing in an asset. It is calculated by comparing the historical return of the asset against the historical return of the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Average market return</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return is the average rate
of return of the assets in the market. It is used as a metric of the systemic risk entailed in investing in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Example</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let&#8217;s assume that the rate of return required
for risk-free assets is 5%, the parameter of risk of a particular asset is 1.2, and the average market return is 10%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the formula, the cost of equity of the
asset is 11.2%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RE = 5% + 1.2 * (10% - 5%) = 11.2%</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I calculated the capital and interest for the
discount rate for the valuation model for Automax based on these explanations. Presented below is the calculation methodology:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculating the WACC for the Company </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculating the cost of equity (CAPM)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is difficult to unequivocally establish the
interest rate which reflects the risk premium prevailing in the Israeli share market, appropriate for the vehicle parallel import sector.
This is because it is dependent on multiple factors, as mentioned earlier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, it can be assessed that this interest
rate will be relatively high due to the high risks entailed in operating in this sector. These factors include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fierce competition: The Israeli vehicle import
market is extremely competitive, and parallel importers are forced to compete with official importers and local manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 338; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory changes: The Israeli vehicle market
is subject to strict regulation, and regulatory changes are liable to significantly impact the activities of parallel importers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Volatility in the foreign exchange market: The
USD exchange rate impacts the cost of purchasing vehicles abroad, and exchange rate volatility is liable to cause losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financing risks: Parallel importers require significant
equity and bank financing for their activities, a fact which increases the financial risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Size of investment: Large investments generally
require a higher interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Entrepreneurial experience: Entrepreneurs with
proven experience in the sector are likely to accept a lower interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collateral: Issuing collateral for a loan may
reduce the risk for the lender and may make it possible to receive a lower interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on these factors, it can be assessed that
the interest rate which reflects the risk premium in the Israeli vehicle parallel import sector ranges between 10%-12%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to perform a more accurate assessment,
I performed the following calculation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; width: 35%; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Rate
    of return of risk-free capital assets</span></td>
    <td style="border-top: black 1pt solid; width: 19%; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">6.00%</span></td>
    <td style="border-top: black 1pt solid; width: 4%; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border: black 1pt solid; width: 42%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">See
    Appendix 1 - Data from the Bank of Israel and others</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Risk
    parameter</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">1.5</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">See
    Appendix 2</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Average
    market return</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">10.00%</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">See
    Appendix 3</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculation of the weight of the equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; width: 24%; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-top: black 1pt solid; width: 27%; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">ILS
    millions</span></td>
    <td style="border-top: black 1pt solid; width: 24%; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">%
    of total</span></td>
    <td style="border: black 1pt solid; width: 25%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Equity</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Share
    capital</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">2,389</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Share
    premium</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">67,382</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Options</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">1,457</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Share-based
    payments</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">17,466</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">88,694</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">30%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Debt</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Bonds</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">42,543</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Lease
    liabilities</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">13,855</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Long-term
    credit</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">3,675</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Short-term
    credit</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">141,392</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Current
    maturities</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">4,177</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">205,642</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">70%</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Total
    general</span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">294,336</span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Calculation of the weighted average cost of
capital (WACC): </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border: Black 1pt solid; width: 56%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-top: Black 1pt solid; width: 44%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">12.00%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Cost
    of equity</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">7.90%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Cost
    of debt&#160;</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">23.00%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Tax
    rate</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">70%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Weight
    of equity&#160;</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">30%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">Weight
    of debt</span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt">WACC</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>10.22%</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify"><span style="font-size: 10pt"><b>Weighted
    cost of capital </b></span></td></tr>
  <tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I am able to present the forecasted cashflow
model after having established the weighted interest rate for the model at 10.22%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 339; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation model is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mean</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Forecast</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2029</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 12%; font-weight: bold; text-align: left">Total Sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">816,627</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">742,388</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">674,899</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">613,544</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">557,767</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">480,834</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 8%; font-weight: bold; text-align: right">453,617</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Rate of Change (ROC)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">16.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">6.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cost Of Sales*</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">558,605</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">702,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">638,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">580,413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">527,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">479,680</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">423,134</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">392,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">89,072</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">114,328</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">103,934</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">94,486</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">85,896</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">78,087</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">57,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,699</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Rate of Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">13.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">14.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">12.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">13.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Operating
    Expense (OpEx)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Other</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">7,500</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">15,567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Sales and Advertising</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">31,582</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">36,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">33,563</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,964</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">30,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">28,993</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">G&amp;A</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">24,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">22,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">21,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20,434</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">19,461</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">18,534</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16,849</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">3.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,281</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">68,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">63,091</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,419</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">57,876</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">55,454</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">56,146</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,028</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">8.4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">8.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">11.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">13.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Operating Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">28,791</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">45,628</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">40,843</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">34,067</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">28,020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">22,633</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,554</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">671</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Rate of Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.6</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.5</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.6</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">4.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tax Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Working Capital</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">58,291</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">73,496</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">66,815</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">60,741</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">55,219</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">50,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">43,275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">41,703</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Working Capital Ratio</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">9.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net Operating Profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">22,169</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">35,133</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">31,449</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">26,231</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,576</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">17,428</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">1,197</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">503</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Depreciation and Amortization</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Fixed Capital</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-4,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-3,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cashflow for Capitalization</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">26,057</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">39,021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">35,337</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">30,119</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">25,464</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">21,316</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">5,085</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Capitalization rate Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">10.22</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Growth</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">2.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Operational Value</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">393,585</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Fiscal</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-300,848</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Investments</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">94,379</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Change in Capital Ratio</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-23,741</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">-230,210</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 7pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Enterprise Value (EV) in NIS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">163,375</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Enterprise Value (EV) in USD</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">44,760</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">See
                                            Appendix 4</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 340; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various short explanations for the assumptions
underlying the cashflow model are presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"/>
    <td style="width: 0.25in">1.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify">2023 was a transition year from there being a shortage of supply due to the chip crisis associated
    with COVID-19 (buying high and selling high) to full supply (buying low and selling low), the need to replace expensive stock together
    with a sharp and quick decline of the Shekel due to the judicial reform and associated civil unrest and the Swords of Iron war in
    Q4 adversely impacted the Company&#8217;s results - the Company assesses that this adverse response has ended because vehicle prices
    adjust themselves to the currencies, and the Company&#8217;s current purchasing prices have also decreased - 2022 was therefore selected
    as the base year for the model.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>2.</td>
    <td style="text-align: justify">Sales, management and general expenses will increase from 2025 at a lower rate of the increase in
    revenues - 5% annually.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>3.</td>
    <td style="text-align: justify">From Q4 2024 the Company will start directly importing a Chinese brand of electric vehicles and therefore
    the gross profitability is anticipated to increase. There will be a greater impact in 2025.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>4.</td>
    <td style="text-align: justify">From Q4 2024 the Company will start consolidating the earnings of &#8220;Automax Leasing&#8221; and
    the profitability of the bus company will increase. There will be a greater impact in 2025.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>5.</td>
    <td style="text-align: justify">From 2024 there will be a 15% annual decline in financing costs (equivalent to interest of approximately
    1.2%) which will be offset with a similar increase in the scope of the financial debt.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>6.</td>
    <td style="text-align: justify">Apart from inventory of vehicles, there will be no material changes in fixed property, including
    intangible license asset and therefore depreciation costs will remain similar at ILS 7,888 thousands per year).</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>7.</td>
    <td style="text-align: justify">Revenues - The point of departure is the Company&#8217;s business plan prepared in September 2023.
    The plan referred to the Company&#8217;s new growth engines in the bus import and Chinese electric vehicle direct import segments
    in addition to the Company&#8217;s parallel vehicle import activities. The business plan also relied on 2022 as the basis and referred
    to a 5-year model for 2024-2028. The base assumption was a significant 20% increase in sales in 2024, with continued annual growth
    of 10% until stabilizing in 2028. As noted above, 2023 cannot be referred to as a representative year for the current commercial
    activities due to the multitude of events that occurred throughout the year which impacted activity in the economy. For similar reasons
    I chose to be extra cautious with my working assumptions also for 2024 which started in a state of war and with significant uncertainty
    for subsequent months. I therefore assumed that the sales target presented in the business plan will be achieved in 2029, and that
    there will only be a growth rate of 6% in 2024, the growth rate in 2025 will increase to 16% and the growth rate will stabilize at
    10% from 2026-2029, which will also serve as a terminal year for calculating the discounted revenues.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 341; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">stabilizing in 2028. As noted above,
2023 cannot be referred to as a representative year for the current commercial activities due to the multitude of events that occurred
throughout the year which impacted activity in the economy. For similar reasons I chose to be extra cautious with my working assumptions
also for 2024 which started in a state of war and with significant uncertainty for subsequent months. I therefore assumed that the sales
target presented in the business plan will be achieved in 2029, and that there will only be a growth rate of 6% in 2024, the growth rate
in 2025 will increase to 16% and the growth rate will stabilize at 10% from 2026-2029, which will also serve as a terminal year for calculating
the discounted revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As aforementioned, the working assumption
is that the period of war we anticipate for the coming months will only have a short-term impact on the scope of sales. Past experience
shows that vehicle demand in Israel (and around the world) is inelastic, and that vehicle demand is only adversely impacted in the short-run
during periods of severe crisis but subsequently reverts. The main reasons for this include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- Vehicle demand has &#8220;cumulative&#8221;
features - a person who typically replaces their vehicle once every 4 years and who experiences an external crisis at the planned replacement
time, will slightly postpone the replacement but will not skip it - unlike, for example, the consumption of tourism or recreational services
- where someone who &#8220;misses&#8221; a meal at a restaurant will not return twice the next day.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- Vehicles are also a sensitive purchase
and people tend to &#8220;treat&#8221; themselves after tense periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- 90% of the demand is intended to
address an increased population (new drivers in the market) and vehicle write-offs (thefts, accidents, old vehicle operating faults or
vehicles not worth repairing) - this component of demand is relatively inelastic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Presented below is a diagram which
presents the annual scope of sales of vehicles in Israel over 1997-2023 while highlighting crisis periods. We can clearly see that vehicle
demand is inelastic and self-correcting after crisis periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><b>Rapid recovery from crises</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">The exchanges of private vehicles in
Israel over time</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_022.jpg" style="width: 650px; height: 259px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in">8.</td>
    <td>Corporate tax rate - 23%.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>9.</td>
    <td style="text-align: justify">Discount rate for the terminal year - the discount interest rate of the model, 10.22% less a permanent
    2% annual increase, i.e., 8.22%.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 342; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#160;</td><td style="width: 0.25in; text-align: left">10.</td><td style="text-align: justify">Investment
                                            in working capital - I assumed an average rate of working capital by subtracting the Company&#8217;s
                                            current liabilities from its current assets based on its 2022 balance sheet and set a fixed
                                            rate of 9%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Based on these assumptions I came to
an enterprise value totaling approximately ILS 393.6 million or USD 107.8 million based on an exchange rate of ILS 3.65 per USD 1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Enterprise
                                            value should also consider the value of the Company&#8217;s net assets in the 2022 base year.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Cash
                                            value is equal to the value of cash, less cash liabilities - ILS 300,848 thousands.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">The
                                            value of investments includes fixed property, working capital, and total other assets including
                                            intangible assets - ILS 94,379 thousands.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Change
                                            in working capital considers the value of the difference between the working capital in the
                                            base year (2022) and the terminal year (2029) capitalized based on the established discount
                                            interest rate - ILS 23,741.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: justify">Total
                                            assets - ILS 230,210 thousands.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>After referring to the net asset value I came
to an enterprise value for the Company totaling ILS 163.4 million, or USD 44.8 million.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Considering that the valuation is based on working
assumptions which take into account future forecasts, I found it correct to examine the sensitivity of the result of the valuation to
changes with two of the model&#8217;s primary variables, the discount interest rate and the growth in the Company&#8217;s sales after
stabilizing from 2026 through 2029 - the terminal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A sensitivity table is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sensitivity of company valuation in thousands
of $ to discount rate and profit growth rate from 2026</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 12%; font-weight: bold; text-align: left">Growth Rate</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">9.0%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">9.5%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">10.0%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 10%; font-weight: bold; text-align: center">10.22%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">10.5%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">11.0%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">11.5%</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">8.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">52,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,178</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34,303</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">30,998</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">20,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">9.0%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">56,471</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">48,070</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,356</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,744</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">28,575</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">23,471</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">9.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">60,758</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">52,002</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">45,539</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,632</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,670</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">26,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">10.0%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">65,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">55,980</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">49,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">34,804</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">29,265</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">10.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">69,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">60,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">53,898</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">48,336</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">37,988</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">32,218</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">11.0%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">73,918</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">64,058</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">58,078</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51,958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">47,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">41,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">35,208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">11.5%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">78,472</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">68,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">62,258</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">55,627</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51,421</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">44,451</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">38,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 343; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: none"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B
                                            Consulting and Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Chapter F - Summary and conclusions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax is the largest parallel importer of vehicles
in Israel. The vehicle market in Israel, just like in most of the world, is currently in the midst of a revolution led by two trends:
first - a transition to electric vehicles; second - an increasing number of Chinese manufactured vehicles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Automax&#8217;s management has adjusted itself
to the market trends and entered into an agreement with the Chinese company HYCAN to sell its vehicles in Israel as a direct importer.
Automax plans on continuing to operate as the leading company in Israel in the parallel import sector and to also use the existing platform
of showrooms and sales personnel to sell HYCAN vehicles. This activity is anticipated to commence at the end of 2024 and will become
the Company&#8217;s primary growth engine in the coming years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another growth engine is the joint establishment
of a company with Dalhom Motors Ltd. to import TEMSA brand buses. The Company signed an agreement with the manufacturer under which the
joint company will serve as the direct importer of TEMSA brand buses to Israel. TEMSA has multiple electric, gasoline and diesel engine
model buses and minibuses designed to serve tourism and public transportation, all of which are suitable to be marketed in Israel. The
Company is currently completing the establishment of a central bus service center with a total area of 4,000 sqm in Hod Hasharon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this document I presented calculations to
value Automax under two methodologies. The multiplier methodology and the DCF (discounted cashflow) methodology. I also explained why
the enterprise value apparent from the Company&#8217;s share price on the Tel Aviv Stock Exchange should not be relied upon as the representative
value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As emphasized, the multiplier methodology is
only based on past data and does not refer to future data, whereby it cannot be used as an appropriate metric to assess the enterprise
value which is anticipated to double or even more the scope of its operations in the coming years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, a current valuation of the Company can
certainly serve as a point of departure and be used as a comparison for a valuation based on the DCF methodology - as it refers to forecasted
future activities and indeed appears to be so. The valuation based on the multiplier methodology assessed the enterprise value at approximately
USD 21.7 million and the valuation based on the DCF methodology assessed the enterprise value at approximately USD 44.8 million. The
Company&#8217;s anticipated growth is meant to double its activities and also increase its profitability which certainly strengthens
the reliability of the valuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fact should also be emphasized that the working
assumptions applied to the Company&#8217;s business plan were examined in-depth by me and were found to be completely realistic. The
existing infrastructure of showrooms and trained sales personnel together with efficient management and marketing are a good basis for
meeting the planned targets. Furthermore, I was exceptionally conservative considering the prevailing situation in Israel and the short-term
uncertainty and I moderated the Company&#8217;s growth forecast in the model&#8217;s assumptions and chose an interest rate which incorporates
risk components appropriate for the Company&#8217;s operating sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Based on that stated above, I determine
that the current value of Automax is approximately USD 44.8 million. </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sources for establishing the risk-free interest
rate for the period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate calculated for the
model is 6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This rate was taken from the Bank of Israel banking
interest rate data records, returns on shares, government bonds and more.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current Bank of Israel data 2/1/2024 (Original
- Bank of Israel)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LIBOR interest rate</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telbond - corporate interest rate spreads</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stated Bank of Israel interest</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Bank of Israel overnight interest rate (for
banks)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 344; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>E.D.B Consulting and
Investments Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Co. no. 514752195</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 2</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk interest for the sector</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk interest for the sector depends on various
market factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will be sensitive to changes in the
vehicle market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market competition: Companies compete for the
same target market; the Company is therefore expected to be adversely impacted by the operations of other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The volatility in the share market, the value
of the Company&#8217;s shares is liable to be extremely volatile. This is attributable to these companies being dependent on the vehicle
market and due to volatility in the general share market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk interest can come to a 5%-10% premium on
top of the basic risk-free interest applicable in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The model applied a risk parameter of 1.5%, i.e.,
risk interest of 6%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 3</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Average market return</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return changes based on the
examined period of time. The average market return is calculated at approximately 10% over the long-run. This is based on data from the
global share markets over the preceding 100 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return may be higher or lower
than 10% in the short-run. For example, in the 10 years prior to 2016, the average market return of the US S&amp;P 500 index was approximately
14%. However, in the 5 years prior to 2016, the average market return of this index was approximately 9%. In recent years (2011-2023)
this index had a significantly higher average return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">S&amp;P index return - (28% total average) 2011-2023</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The average market return is impacted by various
factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Economic growth: Strong economic growth causes
an increase in market returns, since it leads to an increase in corporate earnings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation: High inflation causes a decline in
market returns as it is responsible for a decline in the value of money.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Base interest: An increase in the base interest
rate causes a decline in market returns as it is responsible for an increase in loan costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation model applied a conservative rate
of 10% for the market return for the calculation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Appendix 4</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comments regarding the data for the valuation
taken from the Company&#8217;s financial statements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grant of employee options - see the note in the
financial statements. The options plan ended in Q1 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other capital expenses and losses (profits) -
In 2023 there was a capital gain of ILS 4 million due to the sale of shares in Automax Leasing to a third-party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net financing costs - Less exchange rate gains/losses
from currency hedging transactions. No profits or losses were seen from hedging activities after Q1 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">65-66 Bareket Street, Mevasseret Zion 9078750&#160;&#160;&#160;&#160;&#160;&#160;
Tel: 02-5333857</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Email: <span style="text-decoration: none">ebrik10@gmail.com</span>&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Cell: 052-3817124</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 345; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>INFORMATION NOT REQUIRED
IN PROXY STATEMENT/PROSPECTUS</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">Item
20. Indemnification of Directors and Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, 5759-1999, or the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty.
An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to
the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles
of association. SciSparc&#8217;s Amended and Restated Articles of Association include such a provision. An Israeli company may not exculpate
a director from liability arising out of a prohibited dividend or distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed as an office
holder, either in advance of an event or following an event, provided a provision authorizing such indemnification is contained in its
articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a
                                            financial liability imposed on him or her in favor of another person pursuant to a judgment,
                                            including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking
                                            to indemnify an office holder with respect to such liability is provided in advance, then
                                            such an undertaking must be limited to events which, in the opinion of the board of directors,
                                            can be foreseen based on the company&#8217;s activities when the undertaking to indemnify
                                            is given, and to an amount or according to criteria determined by the board of directors
                                            as reasonable under the circumstances, and such undertaking shall detail the abovementioned
                                            events and amount or criteria;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reasonable
                                            litigation expenses, including legal fees, incurred by the office holder (1)&#160;as a result
                                            of an investigation or proceeding instituted against him or her by an authority authorized
                                            to conduct such investigation or proceeding, provided that (i)&#160;no indictment was filed
                                            against such office holder as a result of such investigation or proceeding; and (ii)&#160;no
                                            financial liability, such as a criminal penalty, was imposed upon him or her as a substitute
                                            for the criminal proceeding as a result of such investigation or proceeding or, if such financial
                                            liability was imposed, it was imposed with respect to an offense that does not require proof
                                            of criminal intent; and (2)&#160;in connection with a monetary sanction;</span></td>
</tr></table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">reasonable litigation expenses,
    including legal fees, incurred by the office holder or imposed by a court (i) in proceedings instituted against him or her by the
    company, on its behalf or by a third-party, or (ii) in connection with criminal proceedings in which the office holder was acquitted,
    or (iii) as a result of a conviction for an offense that does not require proof of criminal intent; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">expenses, including reasonable
    litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such
    office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding,
    pursuant to certain provisions of the Israeli Securities Law, 1968, or the Israeli Securities Law.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company may insure
an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the
company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a breach of the duty of loyalty
    to the company, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would
    not prejudice the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a breach of the duty of care
    to the company or to a third-party, including a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 346; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a financial liability imposed
    on the office holder in favor of a third-party;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a financial liability imposed
    on the office holder in favor of a third-party harmed by a breach in an administrative proceeding; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">expenses, including reasonable
    litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against
    him or her, pursuant to certain provisions of the Israeli Securities Law.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Israeli company may not
indemnify or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a breach of the duty of loyalty,
    except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice
    the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a breach of the duty of care
    committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an act or omission committed
    with intent to derive illegal personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a fine or forfeit levied
    against the office holder.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law,
exculpation, indemnification and insurance of office holders must be approved by the compensation committee, the board of directors and,
with respect to directors and the chief executive officer, by the shareholders. However, under regulations promulgated under the Companies
Law, the insurance of office holders shall not require shareholder approval and may be approved by only the compensation committee, if
the engagement terms are determined in accordance with the company&#8217;s compensation policy, and that policy was approved by the shareholders
by the same special majority required to approve a compensation policy, provided that the insurance policy is on market terms and the
insurance policy is not likely to materially impact the company&#8217;s profitability, assets or obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc&#8217;s Amended
and Restated Articles of Association allow SciSparc to exculpate, indemnify and insure its office holders for any liability imposed on
them as a consequence of an act (including any omission) which was performed by virtue of being an office holder. SciSparc&#8217;s office
holders are currently covered by a directors and officers liability insurance policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has entered into
agreements with each of its directors and executive officers exculpating them in advance, to the fullest extent permitted by law, from
liability to SciSparc for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest
extent permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on its activities,
and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The maximum indemnification
amount set forth in such agreements is limited to an amount equal to 25% of SciSparc&#8217;s total shareholders&#8217; equity as reflected
in SciSparc&#8217;s most recent consolidated financial statements prior to the date on which the indemnity payment is made. The maximum
amount set forth in such agreements is in addition to any amount paid (if paid) under insurance and/or by a&#160;third-party&#160;pursuant
to an indemnification arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the opinion of the Securities
and Exchange Commission, or the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities
Act, however, is against public policy and therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SciSparc has purchased and
currently intends to maintain insurance on behalf of each and every person who is or was a director or officer of the company against
any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 347; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 21. Exhibits And Financial Statements
Schedules</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Exhibits</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed as part of this Registration Statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Document</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#B_001">Agreement and Plan of Merger, dated as of April 10, 2024, by and among SciSparc Ltd., SciSparc Merger Sub Ltd., and AutoMax Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sc_001">Addendum to the Agreement and Plan of Merger, dated August 14, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sc_002">Second Addendum to the Agreement and Plan of Merger, dated November 26, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sc_003">Third Addendum to the Agreement and Plan of Merger, dated March 27, 2025, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sc_004">Fourth Addendum to the Agreement and Plan of Merger, dated May 8, 2025, by and between SciSparc Ltd. with AutoMax Motors Ltd., and SciSparc Merger Sub Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#B_002">Form of AutoMax Shareholder Support Agreement, dated April 10, 2024, by and between SciSparc Ltd. and each of the parties named in each agreement thereof (included as Annex B to the proxy statement/prospectus forming a part of this Registration Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#B_006">SciSparc
    Ltd. Amended and Restated Articles of Association (included as Annex D to the proxy statement/prospectus forming a part of this Registration
    Statement)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex4-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. Form of Pre-Funded Warrant</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2+</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390025058382/ea024713301ex99-2_scisparc.htm">Compensation
    Policy for Executive Officers and Directors (Incorporated by reference to Exhibit 99.2 to the Report of Foreign Private Issuer on
    Form 6-K, furnished to the Commission on June 26, 2025)</a></span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 90%"><a href="ea024813801ex5-1_scisparc.htm">Opinion of Meitar | Law Offices</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025013463/ea023082101ex8-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sullivan &amp; Worcester LLP as to certain U.S. Federal Tax Matters</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex10-7_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    2023 Share Incentive Plan (Incorporated by reference to Exhibit 10.7 to the Registration Statement on Form F-1 (File No. 333-277394),
    filed with the Commission on February 27, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-2_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    Agreement, dated January 14, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-3_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Loan Agreement, dated June 9, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-4_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amendment to Loan Agreement, dated September 5, 2024, by and between SciSparc Ltd. with AutoMax Motors Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390025043282/ea024168101ex10-5_scisparc.htm">Third
    Amendment to Loan Agreement, dated May 8, 2025, by and between SciSparc Ltd. with AutoMax Motors Ltd.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex10-5_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement of SciSparc Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025013463/ea023082101ex10-6_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
    Agreement by and between AutoMax Leasing Ltd. and Anhui Jianghuai Automobile Group Corp., Ltd., dated September 15, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025013463/ea023082101ex10-7_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founders&#8217;
    Agreement by and between AutoMax Motors Ltd. and Dalhom Motors Ltd., dated June 16, 2022. (translated from Hebrew)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025022367/ea023356101ex10-8_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    Agreement, dated February 24, 2025, by and between SciSparc Ltd. with AutoMax Motors Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024017526/ea0200391ex21-1_scisparcltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries (Incorporated by reference to Exhibit 21.1 to the Registration Statement on Form F-1 (File No. 333-277394), filed
    with the Commission on February 27, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="ea024813801ex23-1_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Kost, Forer, Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, independent registered accounting firm for SciSparc
    Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390025057781/ea024580401ex23-2_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ben David Shalvi Kop &amp; Co., independent registered accounting firm for AutoMax Motors Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea024813801ex5-1_scisparc.htm">Consent of Meitar | Law Offices (contained in Exhibit 5.1).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span>*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390025022367/ea0233561-f4a3_scisparc.htm#POA_001">Power of Attorney (included on signature page herein)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea024813801ex99-1_scisparc.htm">Form of Proxy Card for Special Meeting of Shareholders of SciSparc Ltd.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex99-2_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of E.D.B. Consulting and Investments Ltd, relating to valuation report for SciSparc Ltd.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex99-3_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Yaarah Alfi as director nominee</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1611746/000121390024082318/ea021390801ex99-4_scisparc.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Tomer Levy as director nominee</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1611746/000121390025057781/ea024580401ex-fee_scisparc.htm">Filing Fee Table</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Previously filed.</td>
</tr></table><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">To be filed by amendment.</td>
</tr></table><div>



</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A
                                            copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
                                            identified information contained in this document, marked by brackets, was omitted because
                                            it is both (i) not material and (ii) is the type that the Company treats as private or confidential.
                                            &#8220;[***]&#8221; indicates where the information has been omitted from this exhibit.</span></td>
</tr></table><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensatory
                                            arrangement</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 64.3pt 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 348; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The financial statements filed
with this Registration Statement on Form&#160;F-4&#160;are set forth on the Financial Statement Index and is incorporated herein by reference.</p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Item 22. Undertakings.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The undersigned registrant
hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b)&#160;if,
    in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth
    in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act, each such&#160;post-effective&#160;amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial&#160;<i>bona fide</i>&#160;offering thereof.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form&#160;20-F&#160;at
    the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by
    Section&#160;10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective
    amendment, financial statements required pursuant to this paragraph (1)(d) and other information necessary to ensure that all other
    information in the prospectus is at least as current as the date of those financial statements.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">That, for
the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160; &#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 349; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The undersigned
registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a
prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning
of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration
form with respect to re-offerings by persons who may be deemed underwriters, in addition to the information called for by the other items
of the applicable form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The registrant
undertakes that every prospectus: (a)&#160;that is filed pursuant to the immediately preceding paragraph, or (b)&#160;that purports to
meet the requirements of Section&#160;10(a)(3) of the Act and is used in connection with an offering of securities subject to Rule 415,
will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that,
for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">Insofar as
indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication
of such issue.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The undersigned
registrant hereby undertakes (i)&#160;to respond to requests for information that is incorporated by reference into the prospectus pursuant
to Items 4, 10(b), 11, or 13 of this Form, within one business day of receipt of such request, and to send the incorporated documents
by first class mail or other equally prompt means; and (ii)&#160;to arrange or provide for a facility in the U.S. for the purpose of
responding to such requests. The undertaking in subparagraph (i)&#160;above includes information contained in documents filed subsequent
to the effective date of the registration statement through the date of responding to the request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white">The undersigned
registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company
being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.1pt; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 350; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&#160;</p><div>

</div><div><a id="POA_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURES</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Tel Aviv, State of Israel, on the 8<sup>th</sup> day of July, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-top: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCISPARC LTD. &#160;</b></span></td></tr>
  <tr>
    <td style="padding-top: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="3" style="padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr>
    <td style="padding-top: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="padding-top: 0pt; vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</span></td></tr>
  <tr>
    <td style="padding-top: 0pt; vertical-align: top; width: 60%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: bottom; width: 4%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: bottom; width: 5%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="padding-top: 0pt; vertical-align: bottom; width: 31%; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td></tr>
  <tr>
    <td style="padding-top: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&#8239;</span></td>
    <td style="padding-top: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by each of the following persons in the capacities
and on the dates indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Oz Adler&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Chief Financial Officer</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
    Officer, <br/>
    Principal Financial Officer and Principal Accounting Officer)</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board
    of Directors</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitay Weiss</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amnon Ben Shay</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Dayan</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe Revach</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itschak Shrem</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liat Sidi</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Vider</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 40%">*By Attorney-in-Fact</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">&#160;</td>
</tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">/s/ Oz Adler</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Oz Adler</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 351; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pursuant to the Securities
Act of 1933, as amended, the undersigned, Puglisi &amp; Associates duly authorized representative in the United States of SciSparc Ltd.,
has signed this registration statement on July 8, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-size: 10pt; text-transform: uppercase"><b>PUGLISI
    &amp; ASSOCIATES</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">/s/ Donald J.
    Puglisi&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Donald J. Puglisi</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Managing Director</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-7</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">F-4/A</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ifrs-full:OtherCurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="ifrs-full:CurrentWarrantLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="ifrs-full:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="ifrs-full:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-9" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-10" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-11" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-12" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-13" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-14" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-15" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-16" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-17" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-19" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-20" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-21" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-22" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-24" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-25" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-26" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-27" name="ifrs-full:Equity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-28" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-29" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-30" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-31" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-32" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-33" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-34" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-35" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-36" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-37" name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-38" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-39" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-40" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-41" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-42" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-43" name="ifrs-full:ShareIssueRelatedCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-44" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-45" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-46" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-47" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-48" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-49" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-50" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-51" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-52" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-53" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-54" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-55" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-56" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-57" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-58" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-59" name="ifrs-full:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-60" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-61" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-62" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-63" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-64" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-65" name="sprcy:IssueOfShareCapitalNetOfIssueExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-66" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-67" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-68" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-69" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-70" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-71" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-72" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-73" name="sprcy:AdjustmentsForIncreaseInRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-74" name="sprcy:AdjustmentsForIncreaseInRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-75" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-76" name="sprcy:SalepurchaseOfPropertyAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-77" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-78" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-79" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-80" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-82" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-83" name="ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-84" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-85" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-87" name="sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-88" name="sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-89" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-90" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-91" name="sprcy:LeaseholdImprovementsMainlyRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-92" name="sprcy:ReceivablesInRespectOfDownpaymentOnMerger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-93" name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-94" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-95" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-96" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-97" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-98" name="ifrs-full:OtherPayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-99" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-100" name="ifrs-full:NoncurrentReceivablesDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-101" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-102" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c159" id="hidden-fact-103" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c158" id="hidden-fact-104" name="ifrs-full:OtherCurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c159" id="hidden-fact-105" name="ifrs-full:OtherCurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-106" name="ifrs-full:OtherNoncurrentFinancialAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-107" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c161" id="hidden-fact-108" name="sprcy:WarrantsLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-109" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-110" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-111" name="ifrs-full:ParValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-112" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-114" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-115" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-116" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" decimals="0" id="hidden-fact-117" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="pure">530000</ix:nonFraction>
<ix:nonFraction contextRef="c269" id="hidden-fact-118" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c270" id="hidden-fact-119" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c272" id="hidden-fact-120" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c273" id="hidden-fact-121" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-122" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-123" name="ifrs-full:OtherFinanceIncomeCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c278" id="hidden-fact-124" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c279" id="hidden-fact-125" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c280" id="hidden-fact-126" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c282" id="hidden-fact-127" name="ifrs-full:FinanceIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c283" id="hidden-fact-128" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c284" id="hidden-fact-129" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c281" id="hidden-fact-130" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c293" id="hidden-fact-131" name="ifrs-full:FinanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-132" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-133" name="sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-134" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-135" name="sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-136" name="ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-137" name="sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c296" id="hidden-fact-138" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c296" id="hidden-fact-139" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c298" id="hidden-fact-140" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c298" id="hidden-fact-141" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c300" id="hidden-fact-142" name="sprcy:ExternalRevenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c300" id="hidden-fact-143" name="ifrs-full:Revenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c329" id="hidden-fact-144" name="sprcy:CurrentAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c331" id="hidden-fact-145" name="sprcy:CurrentAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c329" id="hidden-fact-146" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c331" id="hidden-fact-147" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c332" id="hidden-fact-148" name="ifrs-full:CurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c329" id="hidden-fact-149" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c330" id="hidden-fact-150" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c331" id="hidden-fact-151" name="ifrs-full:NoncurrentAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c332" id="hidden-fact-152" name="ifrs-full:CurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-153" name="sprcy:SaleOfMinorityInterestInSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-154" name="sprcy:SaleOfMinorityInterestInSubsidiary" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-155" name="sprcy:KeyManagementPersonnelCompensationManagementFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-86174">0001611746</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-86175">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="sprcy-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact ix_4_fact ix_5_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-109 ix_7_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact" toRefs="ix_4_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-10</xbrli:startDate>
    <xbrli:endDate>2022-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-17</xbrli:startDate>
    <xbrli:endDate>2023-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-25</xbrli:startDate>
    <xbrli:endDate>2023-11-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-11</xbrli:startDate>
    <xbrli:endDate>2024-03-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-26</xbrli:startDate>
    <xbrli:endDate>2024-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-17</xbrli:startDate>
    <xbrli:endDate>2022-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-21</xbrli:startDate>
    <xbrli:endDate>2023-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-11-13</xbrli:startDate>
    <xbrli:endDate>2019-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-04-11</xbrli:startDate>
    <xbrli:endDate>2017-04-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-02</xbrli:startDate>
    <xbrli:endDate>2021-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-27</xbrli:startDate>
    <xbrli:endDate>2022-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-15</xbrli:startDate>
    <xbrli:endDate>2022-09-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPH1ELcI9xyt3K1DchISeFlf0gxWybNUtM0z5SubuERPcsyFjjcRvlY0woC4Gu3fMsvVXVWKV7wODmQlScdq8DcGYwOT7maUpClVnfueBWSE6BHhwo0f0EXUnILvWj74PXyhBesuwkl8ZeR5liO5Mn8yKD2cBi2EPNR6RNqIweR9mA==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-18</xbrli:startDate>
    <xbrli:endDate>2023-08-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-02</xbrli:startDate>
    <xbrli:endDate>2022-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-22</xbrli:startDate>
    <xbrli:endDate>2023-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PreFundedUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-30</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-14</xbrli:startDate>
    <xbrli:endDate>2023-08-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-21</xbrli:startDate>
    <xbrli:endDate>2024-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-21</xbrli:startDate>
    <xbrli:endDate>2024-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-03</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-02-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-20</xbrli:startDate>
    <xbrli:endDate>2024-06-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-08</xbrli:startDate>
    <xbrli:endDate>2024-08-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-02-10</xbrli:startDate>
    <xbrli:endDate>2022-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-03</xbrli:startDate>
    <xbrli:endDate>2022-01-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-23</xbrli:startDate>
    <xbrli:endDate>2023-02-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-31</xbrli:startDate>
    <xbrli:endDate>2024-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-01</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-13</xbrli:startDate>
    <xbrli:endDate>2024-08-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="sprcy:SaleOfStockAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-31</xbrli:startDate>
    <xbrli:endDate>2024-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-30</xbrli:startDate>
    <xbrli:endDate>2024-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-24</xbrli:startDate>
    <xbrli:endDate>2025-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-24</xbrli:startDate>
    <xbrli:endDate>2025-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-24</xbrli:startDate>
    <xbrli:endDate>2025-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611746</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-25</xbrli:startDate>
    <xbrli:endDate>2025-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea024813801ex5-1_scisparc.htm
<DESCRIPTION>OPINION OF MEITAR | LAW OFFICES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">July 8, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: right; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SciSparc Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">20 Raul Wallenberg Street, Tower A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tel Aviv, Israel, 6971916 &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Re:&nbsp;<B><U>SciSparc Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
have acted as Israeli counsel to SciSparc Ltd., a company organized under the laws of the State of Israel (the &ldquo;<B>Company</B>&rdquo;),
in connection with the filing by the Company of a registration statement on Form F-4 (the &ldquo;<B>Registration Statement</B>&rdquo;)
registering the issuance by the Company of up to 5,373,648 ordinary shares of the Company, no par value (&ldquo;<B>Ordinary Shares</B>&rdquo;)
and/or pre-funded warrants (&ldquo;<B>Pre-Funded Warrants</B>&rdquo;) to purchase one Ordinary Share per Pre-Funded Warrant (the Ordinary
Shares underlying the Pre-Funded Warrants, the &ldquo;<B>Warrant Shares</B>&rdquo;), in each case to be issued pursuant to the merger
(the &ldquo;<B>Merger</B>&rdquo;) contemplated by the Agreement and Plan of Merger, dated as of April 10, 2024 and as amended on August
14, 2024, November 26, 2024, March 27, 2025, and May 8, 2025, by and among the Company,&nbsp;<FONT STYLE="background-color: white">SciSparc
Merger Sub Ltd., a limited company organized under the laws of the State of Israel and a wholly owned subsidiary of the Company, and AutoMax
Motors Ltd., a limited company organized under the laws of the State of Israel (&ldquo;<B>AutoMax</B>&rdquo;)&nbsp;</FONT>(the &ldquo;<B>Merger
Agreement</B>&rdquo;). This opinion is rendered pursuant to Item 21(a) of Form F-4 promulgated under the United States Securities Act
of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;) and Items 601(b)(5) and (b)(23) of Regulation S-K promulgated by the United
States Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction,
of: (i) the Registration Statement, as amended, filed by the Company with the SEC and to which this opinion is attached as an exhibit;
(ii) the amended and restated articles of association of the Company, as currently in effect (the &ldquo;<B>Articles</B>&rdquo;); (iii)
resolutions of the board of directors (the &ldquo;<B>Board</B>&rdquo;) of the Company which have heretofore been approved and relate to
the Registration Statement and to the consummation of the transactions contemplated by the Merger Agreement and other actions to be taken
in connection therewith; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates or
comparable documents of public officials and of officers of the Company as we have deemed relevant and necessary as a basis for the opinions
hereafter set forth. We have also made inquiries of such officers as we have deemed relevant and necessary as a basis for the opinions
hereafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all
documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed
as photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to the opinion
set forth below that have not been independently established, we have relied upon certificates or comparable documents of officers and
representatives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
have further assumed that at the time of issuance and to the extent any such issuance would exceed the maximum share capital of the Company
currently authorized, the number of Ordinary Shares that the Company is authorized to issue shall have been increased in accordance with
the Company&rsquo;s Articles such that a sufficient number of Ordinary Shares are authorized and available for issuance under the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B><IMG SRC="ex5-1_002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
the basis of the foregoing, and in reliance thereon, we are of the opinion that, subject to and effective upon the Merger, and upon receipt
by the Company of the consideration for the issuance of the Ordinary Shares or Warrant Shares, as applicable, contemplated under the Merger
Agreement, the Ordinary Shares and the Warrant Shares being registered under the Registration Statement, when issued pursuant to the Merger,
will be duly authorized, validly issued, fully paid and non-assessable, and the Pre-Funded Warrants, if and when issued and paid for in
accordance with the terms of the Merger, will be valid and binding obligations of the Company enforceable against the Company in accordance
with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Members
of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction.
This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the
caption &ldquo;Legal Matters&rdquo; in the prospectus forming part of the Registration Statement. In giving this consent, we do not thereby
admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations
of the SEC promulgated thereunder or Item 509 of the SEC&rsquo;s Regulation S-K promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">This
opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments
that may be brought to our attention after the date of the Registration Statement that may alter, affect or modify the opinions expressed
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/S/ Meitar | Law Offices</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Meitar | Law Offices</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea024813801ex23-1_scisparc.htm
<DESCRIPTION>CONSENT OF KOST, FORER, GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR SCISPARC LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm under the caption &ldquo;Experts&rdquo; in Amendment No. 9 to the Registration Statement on Form
F-4/A and the related Prospectus of SciSparc Ltd. and to the use of our report dated April 24, 2025 (except for Note 1(d), as to which
the date is July 8, 2025), with respect to the consolidated financial statements of SciSparc Ltd. included therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left; direction: ltr; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">/s/ Kost Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">July 8, 2025</P></TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-size: 10pt">Member firm of EY Global</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea024813801ex99-1_scisparc.htm
<DESCRIPTION>FORM OF PROXY CARD FOR SPECIAL MEETING OF SHAREHOLDERS OF SCISPARC LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; width: 50%"><BR>
<BR>
<BR>
<BR>
<I>SCISPARC LTD.</I> <I><BR>
20 Raul Wallenberg Street, Tower A<BR>
</I> <I>Tel Aviv 6971916 Israel.</I></TD>
    <TD STYLE="text-align: justify; width: 50%"><B>VOTE BY INTERNET - <U>www.proxyvote.com<BR>
</U></B> Use the Internet to transmit your voting instructions and
    for electronic delivery of information up until 11:59 p.m. Eastern Time, August 24, 2025. Have your proxy card in hand when you access the
    web site and follow the instructions to obtain your records and to create an electronic voting instruction form.<BR>
<BR>
<B>ELECTRONIC
    DELIVERY OF FUTURE PROXY MATERIALS<BR>
</B> If you would like to reduce the costs incurred by our company in mailing proxy materials, you
    can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To
    sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that
    you agree to receive or access proxy materials electronically in future years. <BR>
<BR>
<B>VOTE BY PHONE - 1-800-690-6903</B> <BR>
Use any
    touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time, August 24, 2025. Have your proxy card in hand
    when you call and then follow the instructions. <BR>
<BR>
<B>VOTE BY MAIL</B><BR>
 Mark, sign and date your proxy card and return it in the
    postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 60%; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 40%">KEEP THIS PORTION FOR YOUR RECORDS</TD></TR>
  </TABLE>





<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="text-align: left; font-size: 10pt; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt; width: 40%">D<FONT STYLE="font-size: 10pt">ETACH
AND RETURN THIS PORTION ONLY</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND
DATED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt"><B>SCISPARC LTD.</B></FONT></TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt"><B>The Board of Directors recommends you vote FOR the following proposals:</B>&nbsp;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-size: 10pt"><B>For&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-size: 10pt"><B>Against</B></FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-size: 10pt"><B>Abstain</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: left;  "><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 75%; text-align: justify;  "><FONT STYLE="font-size: 10pt">To approve the consummation of the Merger and the other transactions contemplated by the Merger Agreement, including the issuance of SciSparc ordinary shares and the pre-funded warrants at the effective time of the Merger to the shareholders of AutoMax.</FONT></TD>
    <TD STYLE="width: 7%; text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 7%; text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 7%; text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt">To approve the form of indemnification agreement for directors and
officers of SciSparc, effective upon the effective time of the Merger, and to authorize the execution of such indemnification agreement
with all office holders of SciSparc to be in office immediately following the effective time of the Merger or thereafter elected or appointed.</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt">Subject to and contingent upon the approval of Proposal No. 1, to approve a one-time cash bonus to SciSparc&rsquo;s Chief Executive Officer, chairman of the board of directors, or Chairman, and President, contingent upon the approval and the closing of the Merger.</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  ">&nbsp;</TD>
    <TD STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt">Subject to and contingent upon the approval of Proposal No. 1, to elect each of Tomer Levy and Yaarah Alfi to serve on the SciSparc board of directors upon the effective time of the Merger and to ratify the class structure of the SciSparc board of directors.</FONT></TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  ">&nbsp;</TD>
    <TD STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt"><B>Nominees:</B></FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-size: 10pt"><B>For</B></FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-size: 10pt"><B>Against</B></FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-size: 10pt"><B>Abstain</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  ">&nbsp;</TD>
    <TD STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt">4.a.</FONT></TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt">Tomer Levy.</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  ">&nbsp;</TD>
    <TD STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt">4.b.</FONT></TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt">Yaarah Alfi.</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  ">&nbsp;</TD>
    <TD STYLE="text-align: justify;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD>
    <TD STYLE="text-align: center;  ">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;  "><FONT STYLE="font-size: 10pt">4.c.</FONT></TD>
    <TD STYLE="text-align: justify;  "><FONT STYLE="font-size: 10pt">To ratify the class structure of the SciSparc board of directors.</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: center;  "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Please sign exactly as
your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such.
Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership
name by authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 2%; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="width: 25%; border: black 1.5pt solid; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="width: 10%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="width: 25%; border: black 1.5pt solid; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="width: 10%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: left;  ">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 2pt; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; text-align: left;  "><FONT STYLE="font-size: 10pt">Signature [PLEASE SIGN WITHIN BOX]</FONT></TD>
    <TD STYLE="padding-right: 2pt; text-align: left;  "><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="padding-right: 2pt; text-align: left;  ">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; text-align: left;  "><FONT STYLE="font-size: 10pt">Signature (Joint Owners)</FONT></TD>
    <TD STYLE="padding-right: 2pt; text-align: left;  "><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="padding-right: 2pt; text-align: left;  ">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Important Notice Regarding the Availability
of Proxy Materials for the Special General Meeting:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Proxy Statement is available at www.proxyvote.com.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCISPARC LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Special General Meeting of Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>To be held August 25, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>This proxy is solicited by the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned shareholder(s) hereby
appoint(s) Ronen Fatal as proxy and attorney-in-fact, with the power to appoint (his/her) substitute or successive substitutes, and
hereby authorize(s) him to represent and to vote, as designated on the reverse side of this ballot, all of the ordinary shares of
SciSparc Ltd. that the shareholder(s) is/are entitled to vote at the Special General Meeting of Shareholders to be held at 3:00 PM
(Israel time) on August 25, 2025, at 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel, and in his discretion, according
to his best judgment and the recommendation of the board of directors, to vote upon such other business as may properly come
before the meeting, any adjournment(s) or postponement(s) thereof. The undersigned shareholder(s) also acknowledge(s) receipt of the
Notice of Special General Meeting of Shareholders and the Company&rsquo;s Proxy Statement, dated July&nbsp;&nbsp;&nbsp;, 2025, for such meeting
(including either a physical copy or by way of electronic access).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>IMPORTANT NOTE</U>: By voting, whether
by means of the enclosed proxy card, via telephone or internet voting, you will be deemed to confirm to the Company that you do not have
a personal interest in Proposals Nos. 2 and 3, and that you are not a controlling shareholder under the Israeli Companies Law, 5759-1999</B>,
<B>(an &ldquo;Interested Shareholder&rdquo;). If you are an Interested Shareholder, please notify Dr. Shachar Hadar, Adv., the Company&rsquo;s
legal counsel, at 16 Abba Hillel Silver Road, Ramat Gan, 5250608, Israel, Attn: Shachar Hadar, telephone:&nbsp;+972-3-6103766 or email
shacharh@meitar.com (in which case your vote will only count for or against the ordinary majority, and not for or against the special
majority, required for the approval Proposal Nos. 2 and 3). Please see the Company&rsquo;s Proxy Statement for the definition of &ldquo;Interested
Shareholder&rdquo; and a further explanation as to who may be considered a controlling shareholder or may have a personal interest in
the vote.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy also delegates, to
the extent permitted by applicable law, discretionary authority to vote with respect to any other business which may properly come before
the annual general meeting or any adjournment(s) or postponement(s) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING,
PLEASE COMPLETE, DATE AND SIGN THIS FORM OF PROXY AND MAIL THE ENTIRE PROXY PROMPTLY, ALONG WITH PROOF OF IDENTITY IN ACCORDANCE WITH
THE COMPANY&rsquo;S PROXY STATEMENT, IN THE ENCLOSED ENVELOPE IN ORDER TO ASSURE REPRESENTATION OF THESE SHARES. NO POSTAGE NEED BE AFFIXED
IF THE PROXY IS MAILED IN THE UNITED STATES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This proxy, when properly executed, will be
voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors&rsquo;
recommendations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Continued and to be signed on reverse side</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M/:I--<QA+)KYA,\<;16[?95,P65U9E(*@[AGX/\ ^"TG_!SG\+/^"<OQ$O\
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MW?QC\%=1^)VN1[7N-<^(&N33"23^+%K T5MM)SPT;''!8]:_-7]COXE^!O\
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MYU4OL?=$X*# S].GGBOP9_X.F?\ @E3XW^%7C6S_ ."RW[%,=]H^N:-=0/\
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M=8U3PSKUU;VUKXG\3317%]I"S2>7#J$6H1$KJ-D7RLI=I'0!BK!HVB;]A/\
M@J3_ ,$Z?A5_P5!_8_\ $'[-'Q'2.SOIE^W>#_$GD[Y-$U:-6\BY7N4^9HY%
M'WHI'4$$AA^+_P#P0'_:(\(?LX?M7:M_P1)_X*P? OPAJ&H:3XBN++X:WGCK
MP_:7W]D:HSEWTR.6XC8?9KO=Y]LRD!I),+O^T(%_HB\/^'/#_A31[?P_X7T2
MST_3[.,1VMCI]ND,,*#HJ(@"J/8 "M"BBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBC(SBOD;_@L9_P2:^%'_!6_P#9E7X.^,-9_L#Q1H-T^H>!?&$=MYK:7=LF
MUTD3(,EO*H59$!!.U&!W(M?C%X=_X)4?\'9/[._AYOV._@C\5?$D?P]MV-MI
M^I^'/BS90Z;!;DX_T=YYH[VUB[^6B)C)PO//UQ_P2Y_X-+/A9\$?%MK^T)_P
M4K\:67Q8\9?:OMD?@^U\V;0X+DMN,MW),!)J3[N2KJD1.X.DP((_933M/L=(
ML(=+TRSBM[6VB6*WMX(PD<4:C"JJ@ *H P . !7X1_\ !ZOK7PY\56_[/?P2
M\.:=#J7Q,O-:U.YT^ULP'NHM/F$$"QE1\V)[D((_[S6\F.AK]POA+H&O>&?A
M5X;\+^*KTW&J:?X?L[74K@MGS;B.!$D?/?+ FOSO_P""YW_!O];_ /!43XC^
M ?V@_@#\0M.^'OQ*T+4K>P\2>)IXI?\ 3-'5BZS 0@,]Y;. 83N3>KE&D4)&
M5_13X7^&/$/@GX=:#X.\6>-[WQ-JFD:/:V>I>)-2MXXKC59XH522ZD2)5C5Y
M&!<A %!8@ "N@HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKYV_;2^*_\ P4#^
M&_Q2^#^F_L;_ +-7AOQYX5USQD++XLZAK?B'[%-H>FOL5;B$=2%W22,ZI,1Y
M2H(CYF]/H43Q[MA==V,[=W^?4?G4@.>E<Q\5OC)\(?@5X1D^('QO^*WAOP;H
M,,R0RZYXJURWTZS21SA$,UPZ(&8]!G)[5^<?_!0G_@ZN_P""<W[)_A+4M$_9
MQ\:0_&CQ\J/%8Z7X59_[(@FP-LEQJ)7RGBYSBV,S,5VG9G>/G+_@BM_P2X_:
M[_;X_;)C_P""WO\ P5CLKR.^DO(]2^%_@W4[,P-)(G_'K>&V?FULK<8:VB/S
MR.%F8[0&G_= # Q1111111111111111111111111111111111101G@U\B_\
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444444444444444444444445__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "\ L # 2(  A$! Q$!_\0
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MY_\ UJ-S_P#/1_S_ /K5C_Q+QX5_] L__"K$_P#S01_Q$GBK_G]_7W'[V?\
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M ,]'_/\ ^M1_Q+QX5_\ 0+/_ ,*L3_\ - ?\1)XJ_P"?W]?<?O9_P_J^,_\
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M_$U=_B?OOO?;=Y_::ZRZ_B%%%%6 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVR644!,UP)9T%@]U<+OC:.,S.<[XVDD &XEES@BG6[Q1Q%D-Y+:@V ;3(=S
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M ":/XB_[+!XL_P#3+X6K^2)>H^H_G7];O_!#C_DT?Q%_V6#Q9_Z9?"U?S?\
M2@_Y('AO_L8Q_P#2<:?IOA-_R.I>LOS9^TL/W!]34M10_<'U-2U_!;W?J_S/
MZD>[]7^84444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#A:>#_ /Y=T?\ #IG]O#_HD%G_ .%IX/\ _EW5_P#$6_"G_HNL+_X#1_\
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M %Z"N>S=C]WT.?7_ #[=_P!(O^'3/[>'_1(+/_PM/!__ ,NZ/^'37[> P/\
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M];6VUOT/U"_9=V_\,]?!W/4_#_PWSGI_Q+XL9KWD9.%].<'^N.>]?CE\#?\
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MQ^.7_AA/B3_\I*:X=S)[93C?_!$_\@_MC*O^@W+EZXJ"_P#;3],-A]%_-O\
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M  \/^ O_ $!_C/\ ^&6\?_\ RII_V1FG_0OQG_@B8?6Z'_/R/WH^[:*^$O\
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MF4$B++8. <@8.1Z<5:^UVYY#0X/(_> <'_@)KI;Q:_YC,S3ZWB_NM[-/OO\
M<<?L\%_U)_)^WI-/5]?K'X',#P3X,YSX/\,'T_XI[2?_ )$%+_PA/@O_ *$[
MPS_X3VD__(E=-]K@_O0_]_!_\31]K@_O0_\ ?P?_ !-+FQ?_ $&9E_Y.ORB/
MDP7?*/\ P?2_^:#F?^$)\%_]"=X9_P#">TG_ .1*/^$)\%_]"=X9_P#">TG_
M .1*Z;[7!_>A_P"_@_\ B:/M<']Z'_OX/_B:.;%_]!F9?^3_ /R(<F"[Y1_X
M/I__ #0<S_PA/@O_ *$[PS_X3VD__(E'_"$^"_\ H3O#/_A/:3_\B5TWVN#^
M]#_W\'_Q-'VN#^]#_P!_!_\ $T<V+_Z#,R_\G_\ D0Y,%WRC_P 'T_\ YH.3
ME\$>"&(C_P"$.\*EI.74>']*#B,8.XG['C.X 8SW'IFOA7X;>']%3_@H#^T?
M:V^CZ7:Z8GP<^!<D-I%I&GI MW(_CW[6P1;<*LGRQ[V&%; P6Q7Z$/=6OFR(
M9T+W#A%6.0"2(*G(!'.&QNS@=<8[U\8^ _#OB"P_;B^/'C*ZTK6(_"FN_"?X
M-Z-H^K7'G+I=QJ&@-XU_M2)69/)DG07UKN82;OG7(YKT,-+%1C4_VK,'S496
MNY*[?(O?O%I0DVHMKE:=O?3=GSXJ>3KV:J5X*2<$U2E%P4DKM0DFUR;V?-9I
M;[,^PAX<T(<G2-*XXS_95@/Q_P"/<]<^U/\ ^$?T/_H#Z5_X*K+_ .1ZU!>1
M$?\ +,?B/YC_ .L?84?;(?6+\Q7GU)8N4W;&9A%K=07N_)NE*^NN[-J=3)U!
M6JP:\YJ^WE,R_P#A'M#_ .@/I7_@JLO_ )'H_P"$>T/_ * ^E?\ @JLO_D>M
M3[9#_>B_[Z%'VR'^]%_WT*BV,_Z#<R_\E_\ E)7MLH_Y^0_\"_\ MC+_ .$>
MT/\ Z ^E?^"JR_\ D>C_ (1[0_\ H#Z5_P""JR_^1ZU/MD/]Z+_OH4?;(?[T
M7_?0HMC/^@W,O_)?_E(>VRC_ )^0_P# O_MC+_X1[0_^@/I1]CI5C@^QS;X_
M.G#P_H61_P 231QS_P! K3__ (S6E]MA]8C[;@,T"]A)P1&/^!J>>/1:N-/&
MM.7U[,;+=-QOWT7LTW]S*CCLLI-4X.,G/722>NW7F,XZ!X?!YTG25X)Q_9-A
MT! _Y]CW(XSGFG+X>T!R0NDZ22"5Q_9-@#D $XS;#. 1DC(&:GDN[>29(C.L
M1<;$5)PKRL>=JJ #NXX// .*O6[&2?+HORJ6A)&)8U<8(93D@L%P3D9Z8]<?
MK=6G4C3J5\QDYNR]I3G[.6MKR?L8KD;T<N9)=[Z'8E1K0<J<=&GK9:>NWY?,
MS?\ A&M$_P"@-I7_ (*=/_\ D:C_ (1K1/\ H#:5_P""G3__ )&KHZ*Z?:S_
M )G][,O8KO\ F<O-X=T&-0SZ/I(&X#)TJPQD\ <6W<D5"V@>'U&6TC1Q\VS_
M )!5@?FYXXMSZ&M_4)4CC0.H.]CAV3?''L7>6?/"CC@GO6='>6S!2QB9C^^W
MQE0&"="< \?-^.<5G*IB;MPQ&/A'1<M!7I)VOH^25F]W=[F,WEU.7+B*D8U=
M+IR:T:O'3F73R*/_  CN@_\ 0$TG_P %.G__ !BC_A'="'31-)_\%5@/Y6YK
M8^VP>L?_ 'VO^%!O8>QB_%@?Z"HYL9+3ZYF:OU:7_P K(=7*?^?M/Y37Z3N9
M \/:'G_D":2/?^RK'C_R7IW_  CVA_\ 0'TK_P %5E_\CUJ?;(?[T7_?0H^V
M0_WHO^^A3MC/^@W,O_)?_E(>URC_ )^P_P# O_MS+_X1[0_^@/I7_@JLO_D>
MC_A'M#_Z ^E?^"JR_P#D>M3[9#_>B_[Z%'VR'^]%_P!]"BV,_P"@W,O_ "7_
M .4A[;*/^?D/_ O_ +8R_P#A'M#_ .@/I7_@JLO_ )'JN?#NC;WC72M*VE))
M)4CT^U8E77";TDA$0)*D!4!'4,!WW/MD/]Z+_OH54-[;AFA\T,\KR2$POLD1
M54$1@KDXZ@9QDYZ&MJ'UY3=J^+KJSYHXCX(I:\RY80][IJVK/:^I,Z^41B_W
MT(WT5I)W?SD_P5SX3_9:M;>V_:=_;8ALHUM[/_A/O 16U2VAMDMY%^&7A165
M$A1(P'.Z3C.2Q8C)K]!0ZICYOSS[\9[^O_ZJ^'?V>]#\0Z+^T=^V'XAUC2=6
ML=&\8^.O NH^&KZ^$T=E?V6F_#;POI%VUGYB+&[)?6LZ,T;L,H^><BOM87,4
MG5X@/4L.W]/ZBNK'4\6Y+VD5&?LJ6CN_=<$X;7UY7=W?5=U>,'BLJYO<KQ^*
M6\DKN[O;5==/D7\*>0W!Z<&C"_WO_'35'[7$.-Z\<=<]/Q%'VR+^\O\ G\:X
MO9XW^6/W2-_KF5_]!%/_ ,"_^V+V%_O?^.FC"_WO_'35'[9%_>7_ #^-'VR+
M^\O^?QH]GC?Y8_=,/KF5_P#013_\"_\ MB]A?[W_ (Z:"!V;/M@BJ/VR+^\O
M^?QI&O(\'#*3]0/ZG^5'L\:].6/W3!X[*XKF5>FW'WDN;=K5+?K8NT50%VK$
M?,!Z?./U ']*B2YC>9XS<>6P;<(XIPTDO Y\L %0/[O.0.>IHE3Q<;_NXS45
M=\J:TOJW?:U_(TI9AA\0U[*2[:6?Z=C^(O\ X*">-?&6D_MH?'[3-,\7>*=/
MT[2/']W::9967B+6+6UL[>.*UDCBAAAO$CV*[LPW*Q.[!)&!7QW_ ,+'^(8+
M8\>^-!EW8_\ %4Z[]YF)8_\ ']W))/IV%?3_ /P4/#2_MP?M(+&-W_%R+Y&<
M?=#"WL\H3V)W#  ZU\6;E:62/>JR0I)-<QL<-:P)((C<7''R1&1D16!;)D08
MYX_TRX#X:X5J\&\&SQ^3Y+7Q6+P6&G6Q&)RS 5:]:4Z%"3=6K5PDZE5N[;<Y
MR;U?<_DKB+%YQ1S'BJ5#'X^-/#XJJJ$*>+Q,(4DJM1<M*,*RC32222@HKI;1
M'9GXD?$,Y!\>^-/_  J=<_3_ $__ #S2?\+&^(7_ $/GC3_PJM=_^3ZXU\"%
MYXR+B*+8)F@^?RGG)%K'(#MVR7C*Z6R\B1HW!*@9(X:%5>Y5K2)Y?(CEN!LC
MDF\C[08T*EB6$><Y P01T&:^QAP3PC2J8J/]BY%)?6JKC_PE9:U&+]G:*O@]
M$K.R225]%J?/?V]F\J.$;Q>/<GA*/-)XK$N4I?O+N3]M=MZ7;N]-=CLO^%C?
M$+_H?/&G_A5:[_\ )]'_  L;XA?]#YXT_P#"JUW_ .3ZXDRQ NID0%(UE89Z
M1L-ROTZ$<CZT^0B)X(YOW4ET8Q:1OP]UYC[/W"C.X)]Y\E<(,C/2M'PAP?37
M,\DR&RTURC+;7E[JO_L?>2^=B?[>S6/O/%XZR_ZB<1Z=:WF=G_PL;XA?]#YX
MT_\ "IUW_P"3Z/\ A8WQ"_Z'SQI_X56N_P#R?7%NPC0O*?) FD@828#+)&[(
M0P^; ;:60C)91G /%1-<1!G5&\YU%N42(;GF^TR-&GD@[=^PKF7D!%*GG.*F
MIP?PAE4%4Q.29#)8C6GSY5ELDK[<O-@W;=;6L-9WFU7X<9CNFV*Q'_RU'='X
MC?$(E3_PG?C+*-O0GQ1K9*L!@')OLGCUX]J8/B'\0 )/^*Z\8DRSFY=CXGUL
MOYQ8L65S?%T!9B2B%8SQE2 ,<B8W!.$9QM)C9!E9V5=SQPGC?)'AU=> K(XR
M=O,"RHWV4;MCW4<TJQM@211P;/->=>?+5?,7)!;OZ4I<-\/RI0CA<@R%12:C
M..4Y:G*+;=FU@D[.[6[OLR99SFR]UXO'-IZMXG$/S6];S^7<[C_A8_Q#_P"A
M\\9_^%1KG_R=1_PL?XA\?\5YXS_\*C7..#_T_5QXBE^19(I(9I!NAMY0%GGC
MSM$T2 E6B+ @,64DJPQQ385,[*D.99&F:W6-%9F:5"RRJ"%V#R74I)EAM?@9
M&2%_JSPTXT88K(L@I?OX7J+*<MC.3M/W&U@DVI=FW>R=KHM9WG,UR+&YA9>]
M;ZWB>731/E]M;KVT.R_X6/\ $/\ Z'SQG_X5&N?_ "=1_P +'^(?_0^>,_\
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M]NYN]5C,=9Z_[SB-M_\ G]INCL/^%C_$/_H?/&?_ (5&N?\ R=1_PL?XA_\
M0^>,_P#PJ-<_^3JX]HI(VF613&\4\=NBN"&NI)0YC^R@9,JN(R0?E)!7CGAK
M;8Y'MYY$M[N-I4DLYRT=TC0PB9E:,J<$H1M!;DG!QR1UT.%N%*V.ITJ>39';
MZAF<I0659=:4XT:#IR<5@[2E!N3@VKQ<FTU=D5<SSJO!SCF&8TO8ZODQN+A=
M2V;Y:R>G+\CU?P;\2OB(GBWPN?\ A._&#;?$>BL!)XDUB1"6U"WB8,DEXR,&
M1V4JP*D'D9 (_P! W1+>)K/3&*$M!9PB)BSDJ'B4/DECN+ =7W'T(K_.\\';
MSXJ\*N4=%?Q#HI <88C^U+7!QD\'@^O(K_1)T0XL;(>MI;_F8A_B:_BCZ2F6
MX+)L?PK3P.$PN"A7P692JK"8>CAHU9+&RA&554*5)3DH/D3DI-1]U.VA^^^$
MV.QN,P]7ZSB\3B'%+^/B*U9K27_/RI/L;M%%%?S*?M!2U"-);.>*0;DD0QNN
M2,H_RL,J01D$C(((Z@@U_ U^T3\0/'EO^T'\9HK?QMXMMXM/^*OCNQLH8/$>
ML0PVUI9^*-8MK:"*&*\2)4A@CCB3Y,A5&23S7]]%[_Q[R?A_,5_GT_M'?\G#
M?'+_ ++!\1/_ %+M;K^H/HR8# YCFW%M+,,%A,=2I9+AZM*GC,-0Q5.G5]OC
M(^UIPQ%*K&%3EBH\\8QE9)7LDE^/>+%:MA\#2J4*M6A4Y;>THU)TIVOMSPE&
M5M>YQ*_$7XA* J^._&8 Z#_A*=</\[[-+_PL?XA_]#YXS_\ "HUS_P"3JXRB
MO[+?#'#7M,L7^KN16G@7*:_L?+??E:C[TO\ 8O>EJ]7=ZO74_ :6:9FX8=O,
M<>VY:MXS$MO26_[[7YG9_P#"Q_B'_P!#YXS_ /"HUS_Y.IK?$;XD*T^SQWXR
M(6Y\Z>2;Q/KK6Z6<ELD"1:<L-\)Y9!<_OOF$O[PL"-@*KQU3VMQ+!+IE]%&;
MJ/3V;$[()K-)-TA2*X@?,9)>0 95CDH0#Q7!B<@X=HX+&RCPYD;E&%1QE_8^
M6WBU%VY7]2NG?M8UHYIF;KI/,,>U=*SQ>(<?N=9K\/O/L72O@%^V)K?A#3O&
MEK>^*K?1-5T\:GI(N_B;9V6NW^DI%&ZZI!X=O?$D.N7Z7,4L4ZQ6&G22D2J!
M'D@5\UO\0OB1%.8'\9^.(97 =+:Y\6:M%<Q01RO'/+.K:@@,C^7*L4<:[HW4
M/,HC()_2_P ,^+?AO^V-+\)?#_\ PD_C?X,_M4>$O#UCX/\ A]<6:2R?#[Q5
M<Z7965AHUA+>G5+!_#UWJ=M813M]AT2],ACF9F8QJ6Y[^QK/]E3]F^Q\>Z3X
M+\&^/_BOXW^*/BCPQKWB3XB>&=)^(UAHMAH&G:'J+VEII_B>SOK?29IWOKP7
M$EJ(W,,\9/F%54?A&7\2X# 8O%X'%<+9%B\5#%*E0PU3*<MH14*T\0Z;EBZ^
M%Q,*U+EI3E'$*E%\R]@Z$91YE]=2P>.Q4(8A9KCH1J0YG;&8EI.-HM**JQL[
MK6-^O-=GQ)X;;XU>)/#?B?Q;IOC;Q$^D^%BLOB".]^(XLKZSMBRK;R:/9W.N
MP7.K-*KP_:8;*&^F6220*B;"%]D\+_ W]K_QCX/TWXA>'I/%']C:TD-WH2ZS
M\3[+0[W4XIPKQSZ+H6L>)['7[FUE#Q[(VLY9I\A( T@85[YX,/@KXE_LW?M=
M_$5OAGX0\,:KH^E>%KG0IHM$TXIX?UV2VT675-5T2,V$(LK+4;LWLT5A;""V
M@2\6./*Q+NN>$_&OPI_:O\,_!?X?^,?$_CKX)_'[PCI5MX=^&WBK2XY;[P?X
MO>*.T@\.B[FEU;2F\,W,EX@^SSZ?IVHRVQG+PDM$N>G.<URYU'7I\/Y/AL/3
MQ-!5W2R3 U_94YX>-5P]GAXT)5(RJN<*E91O0IQ56-"M!2Y>BCEF-YGS9KCW
M>G.U\=B8INZ2WJM+1:+[3=KIGYQ3^,OB/I=U=Z;<>+?'L,VFRWEI+%<>,;Z2
M\AU1)YDO3++%J)7%L#/)"-WV81I&CAI]V:3?$KXC6=O)--X\\826UK#:)!-)
MXKUF6:^$D;L+N?[-J!1/M 02%HUC49X"C@?I+\/- L?@O\!/CGXE\6^ /!7Q
M-^)?PZ^+ATVV\1:W96EY9Z=->:-IRW$FIP76F7B>);&2SU":^DL=55+=KN;[
M0P,L:.;6M> +3]H'P3^S-\7/#?PI\'7_ (Q\:^,=<\$>(?"'A/2['P%X3\2:
M;X;U#2]/TG6OL/A_3/LVEV"V\LSW9MM-F607:%O,V GU*?&_"F&E3PU;A3)9
MT7STEBYX#*:GOPI>VA^X>!=2-&4%5O4G4ING."BZ,E44UYKR3,J=1U?[9S"]
M[\GUS%VLW9Z^WM=:623O>]^A^:;?$7XC02&"X^('B\!D5H7C\4:VS3SS?*((
M'%\8BL8*O\P+ D@DG@*GQ,^(\D1G_P"$Q\:0/'NMKJ&3Q1KDRQM"_DQM'%!J
M#3I>7BH;I'E!MO+\WY1F,5^L?Q$\):=XO_9?^,LGBNZ_99U+Q'\/]7\)2^'[
MCX%:;HH\1>&[BX\2Z/I]WI.O2V7A7P]-M^R[XI)WN)I))II-\8SN8_::U3P[
MX7N_@5\#_#'PM^'7A?3OBW\+OAS+XZ\81>#?#U[XQ-S=>&_#ES)J&GZM-IT-
M_IM[>^?+)]OM;]+@+,X#D2-GDP7'N19C5]A1\/.&I-5*T%.V&I)PH*G*52\L
MDI7<J5124:5*4.=<BJ).,SJK9%CJ4%6>;8Z7.HU-<9B7?GNU_P OVM]]?EI8
M_*$_$?XA(S1GQ]XND:T,HN%B\5:T9&CVCR'?&H$0RROO53+L3*@[0 :8/B1\
M0B 1X[\:#/.#XIULD9[$K?8)'0D<$].*_0#]I[XP>'?AO\4OBA\"?#_P7^%L
MGP\\-Z9?>$K2&'P/X?L?',]Q96EVMKXIU'Q_!I#>([VY26=)[J"XFDCA6VWK
M<R&:3;^9F5;E$$:'E(PQ<1J>50.0"X484,0"P&2 3BOTGA3#Y'G^'GBJ_!F0
M9="=&A7H1C1P./E4I8A<].4XSRRBJ$^247.FO:.,VX>TFH\S^?Q\\;@I1C',
M<9.[E%OZSB%9Q2NM:KNKMV?5:V6QV?\ PL?XA_\ 0^>,_P#PJ-<_^3J/^%C_
M !#_ .A\\9_^%1KG_P G5QE%?7+AGANZ_P",>R/=?\RC+>Z_Z@CSO[0Q_P#T
M'8S_ ,*:_P#\M.S_ .%C_$/_ *'SQG_X5&N?_)U>R?L\?$;X@2?'OX)P2^./
M%L\-S\6?A[97$,_B+5YXI[6^\6Z3;7<$L<UVZ/'/!(\;JRGY6.,$YKYHKV3]
MG7_DO_P-_P"RQ?#+_P!3/1J^4XUX=X?I<'<;XBED634J^&P>,EAZ]/*LOA6H
M2C0Q3C*C5AA(SI.+BFG3E!II-/16]#(LQS#^W,-3^O8SV;JP3I_6L1R-76CC
M[7E:^1_H'VT,2F!PN&2!(5.YCB+"G;R2#RH.X@MQUY-:>Q?3]3_C5&WZ0_[J
M?^@BM"O\P)MMZMO?=O\ FEYG]C89+ZM0=E=THMNRNW9:O35^8W8OI^I_QK&\
M06L%UI%]!,F^*2WF61=[H2OE/P&1E=3G!RK C'!K;K,U@ Z==#(!,,H&?4Q/
M_P#7IT7)5:;C*46IQ:E%M--23333NFGJFMK7Z&>.BI8/$QY5*]&:LTFG=+1I
MJS^9_GQ^,OB-\0/^$V\6S?\ "<^,5?\ X2#78?D\3:U&@B%W/$J)&EZL:*(P
M$&Q%P!QR,US ^(WQ"  'CSQF   !_P )1KG0<#_E^K.\87$+>+_%3EPH?Q1K
MZ!&X8E;ZX8D#NOOGMT'6N8>X@C\L-(OF/%)(8ADR1E)5C2*5<?+-<*WGVZ9(
MD@#/N4C;7^JG#/#G"F<Y=P[2_LG)'766PGB9O+,O=2M-0J-RK3>$YJDFUK*;
MD[]3^/LWQ68T\ZQ=*GB<5"G&4K4X8BM&$=/LQC445\DCN?\ A8_Q#_Z'SQG_
M .%1KG_R=1_PL?XA_P#0^>,__"HUS_Y.KCYHY(&=)4977&%QDN&^X4 /S!SE
M4Z98$'%1AD;!CD25<$NT9++&PY:.0X&V1%!9E&<*I.3BO5CP?P_%U(TLBR*I
M"-:O!2>59=)ODK5(M7>";]UQY4NB21XLLUS6#<?K6+=F]?K%=]7_ -/#M/\
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M?[$VG**2;6K2L[I(_&Z&>YH\+33Q6-E)I7D\37;=NO,ZM]?,[/\ X6/\0_\
MH?/&?_A4:Y_\G4?\+'^(?_0^>,__  J-<_\ DZN/*-D%2)(F?RXKA#N@F88
M$3\%MV1MRHSGZTUQ+&D;R0RQB:;RH@RX9\!B95 )_<KA@S]BIX.,UY\.&N$G
M7:>49$U?;^R\NMHWT^IV_KU#^V\V_P"@K&^?^TU]O_!VC\]_O.R_X6/\0_\
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M /J,:G7^>D?OR?\ ;;/4_P ?MS^5?Z%_QT&?@[\4/;X=^-S_ .6QJ=?YZ/\
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M[-M-VU2=D_F#X=_'S]HKXI1^&+;2/@I\/_C5XT^'UC!:^'O$6J?#&\\<^/\
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M$OB;7?[+D\.76MZOJNG6MSJFIZEIEQ+=3V4VI3%IOLMQ/++$=Z-)(06'QY\
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M^N;J=@Q,LC>8V6"J =TA.",D@\<&O1/V=,G]H#X(,22S?&+X:$Y&.3XST8$
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M-/;EHP&4MR[$;L.6!D:-60''G7#QEFN&.""$(=-G4LV[<,8/WU^SWI=UX]^
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M:Z^/V;;7X3ZMI_AB?QQK/QJ'C6_^P>(IK GP<_A>"X(@N6T+^T9;(7S1L'=
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MNZIHZ3ZA>7EPB12SRS%P6=DC09()X].*YT_\$_/V+LX?]G'X92D #?+H2,Q
M "@D2 $* % QT %?@_!7TF,BP&19+A*W#F<5)99E&&RR,Z57+E&JJ6'PM*51
MJ==23;PR:2MI+571^F9_X>_6<SGCOKW+.HY24++E2DVU_P NW*]GWW/X8<_Y
MP?Y=?\^U&1[_ )'_  K^YX_\$_/V+3_S;;\+O_! H_E+2?\ #OS]BS_HV[X7
M_P#@A7_X]7T-#Z3W#]&FJ<>&\Z:A[J<JV67:6FMJZ1X$_#-\S:S!>]:6L>K_
M .X9_#%D>_Y'_"C.?7\B/YBO[G?^'?G[%G_1MWPO_P#!"O\ \>H_X=^?L6?]
M&W?"_P#\$*__ !ZJJ?2?R"K#DEPWG27-"6E;+;_NZE.HEK7V;II/R;MK8E>&
MDD[_ -H+_P !?_RL_ABR.  <?0C^E&?K^1_PK^YW_AWY^Q9_T;=\+_\ P0K_
M /'J/^'?G[%G_1MWPO\ _!"O_P >I5OI/9!66:K_ %<SNG_:K@ZG)6RS]QR*
MJE["]=[^U=^>_P ,?,O_ (AM+_H/C_X"_P#Y6?PQ9'O^1_PHR/?\C_A7]SO_
M  [\_8L_Z-N^%_\ X(5_^/4?\._/V+/^C;OA?_X(5_\ CU:U/I29'4;D^'<[
M3:BM*^6_9A""WK]5!-^;?2Q:\.9))?7*;\W%W?\ Y3/X8LCW_(_X49^OY'_"
MO[G?^'?G[%G_ $;=\+__  0K_P#'J/\ AWY^Q9_T;=\+_P#P0K_\>K%?2>R)
M._\ J_GK\G6RNW_IX/\ B'3T_P!KI:._PR_^5G\,61[_ )'_  HR/?\ (_X5
M_<[_ ,._/V+/^C;OA?\ ^"%?_CU'_#OS]BS_ *-N^%__ ((5_P#CU:OZ4.0-
M6?#6<OS]MEM__3Y57P]J58<GUZG!;>[&5_Q@S^&+(]_R/^%&1[_D?\*_N=_X
M=^?L6?\ 1MWPO_\ !"O_ ,>H_P"'?G[%G_1MWPO_ /!"O_QZA?2BR%)+_5K.
M=-/XV6]/^XYS?\0SE_T,%_X"_P#Y6?PQ9'O^1_PI,\YYP0.Q]S_45_<]_P .
M_/V+/^C;OA?_ ."%?_CU,7_@G_\ L7$@?\,V_"W'MH"CI_VUJ*WTGLAK4I4O
M]6\Y5Y0G?VN77O3<G%?Q]FY:];; _#><4X?7XM3LF[.ZM?;]W;KU/XB/"#*O
MBGPXQ.!'X@T-W.#\J#5;52QXS@,P&1ZU_HDZ0RM8V 4@D6]OG!!_@4_RKXVM
M/V!OV-+.^M[BU_9R^&$%PA5HYX]!598VBD6:-D;S>"DL:.#@X*BOL31K:W@A
M$5M!%:Q13O"B0 HHCB"! 02V< X)[BOYW\9_$W#>(&99?FRR[$8!82A]3A2E
M*C+GC4J0Y9S<:L[--6:CH]UV/U;@#AV60PJ4Z>(C6YOB<T]+;\O+&*>^ESHJ
M***_(#],*E\P6VD+$ 949/J6 'YDU_GR_M%S12?M"?'5T<,J?%_XD%CR,"+Q
MEK<<AY )".0IQGD\9'-?Z"FJN8[&5@ 3F,889!!D4$$ CL?6OC;6/V#_ -C_
M ,2ZGJ'B#7OV??ASJFNZS>WNJ:GJ]WHJ27]Y?ZI=/?7US+-O&Z2XNI7E<[>6
M8YS7ZMX1^*6!\.,ZS98O+,9F+S;+J&'?U:>&A[*FJ^(DY7KU(7G^\DDM8W2O
MI<^"XWX=_P!8,,J+K^PC3A=M+WG?FM:\9+H?PH!@>1G\C_A6YH7B3Q!X:NWN
M?#NO:KH%Q=P2V=S/I=]=6)N;2129+6[>UFB>2V<A24;S$+A&*' (_N";_@G[
M^Q>22_[./PQE;/S/)H2L[GIEB)0"3WX ]J0_\$_/V+#_ ,VV_"[_ ,$"C^4M
M?T=7^DUPU6CAX3X8SJI"E0^K2IU*N5N-2-Z;?,E7=]:4?+R/R*'AQ*"BJ>8.
M+I/FA*VM]5K:FN[V/X=9=?U^31;?P\=:UAM @U-KJ+0&U;4O[-%U(RF2_>'S
M3'\Q569_+9B >_%79?%/BJ\NM N+[Q+K-Y<>#[61/"%]/K6J?;/#D1DN)OLV
MFSF9IH2+FXN)HTB>-1YQZ9-?V^_\._/V+/\ HV[X7_\ @A7_ ./4?\._/V+/
M^C;OA?\ ^"%?_CU85/I'\'U8>S?!F8):ZJ66-KF3C)J]5V<DVI6MS)V=TVGM
M_J'C/^AJ_/XM>R?N=.A_%#J_Q6^)WB&^TR\UOXE?$+7KC1?(U71[_7/%WB&6
MZT/6(D!>?2 ^I7 CE,DDA4J\!PH&17(ZMJ&I:Y?:CJNKW\FL:QJEQ!=MJNKW
MEU=W=Y.743OK4L_GRO(8D !9[@G Z=O[C/\ AWY^Q9_T;=\+_P#P0K_\>H_X
M=^?L6?\ 1MWPO_\ !"O_ ,>KEPOTB^%L%4<L-PGF=.'U.M@HTXRRFG"%*M.K
M4FXJG.%GSU9-))0;LVG)N3R_XA]B74=269<TFTVY<VME9?8OLDM]DC^0?XA_
M'/1?'GPI^"^F2R>*+3XG_"--9TFUU1)G&G-IMYJ5]>6CV5VM\+B(VRM:0V[K
M;1M' I1"J_*?$-<^*OQ2\4Z7_8_B[XB>/_$]G<BRFNM+UGQSXHUC0/MUNS.9
MQINHZC/9Q",LIA1+4+QC"@9K^V?_ (=^?L6?]&W?"_\ \$*__'J/^'?G[%G_
M $;=\+__  0K_P#':X\O\>^#<#2PU"7"&9XJGA7C)T7B)914E&KC:L:U6I&3
MG*4)*<6XNG*&DFGHHI=,N",;*"A',E3UB^:#FFU%647[J33TO=/8_B4\/?$3
MXB>$K"ZTKPIX[\7^%M/O;DS:A8>'?%>OZ-INH++;BUDDN;+3;NUMKB58<)Y<
MT3J5C5MV0 ,V/Q3XKM;;6-*L/$NO6>GZ^QM=1_L[Q/KNBQZI&1(KW/B&STVX
MBM]:,@<LS:B+IG\R7<?WCY_M]_X=^?L6?]&W?"__ ,$*_P#QZC_AWY^Q9_T;
M=\+_ /P0K_\ 'JZO^)@^#54G4APAF=.4Y1E/D_L>TY0:<)3O*\Y0:7+*;E*-
MERRC96SJ\"8RM!0GFK:2:O[S=G>ZUC9;ZVWZG\4&E?%WXLZ%HJ^'O#WQ(\>Z
M1H2NLXT/2_&OB?PSIEN(RC!;6+1-0BC0R/'F6V6*.&16+/EI)!61I7C?QKH-
M]=ZKX?\ &7B[1];U=IGU35=(\4:]X=OIA<3">6UN-5T>]AO]0AGEVSW4UV[2
M23QJ[!R2P_MV_P"'?G[%G_1MWPO_ /!"O_QZC_AWY^Q9_P!&W?"__P $*_\
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MM8G"_P#"S]+CR> '>QU JI)X!8*2,X''6O[L+9E8@J00%QP0>U?(/A+]BO\
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M9^OY'_"C(]_R/^%?W._\._/V+/\ HV[X7_\ @A7_ ./4?\._/V+/^C;OA?\
M^"%?_CU*/TH,AA2C2APYG<5&;G=5LLN[IKE?[^UM;Z).Y<_#B<XI/'Q5G>Z4
MNUK?!8_ABR/?\C_A1D>_Y'_"O[G?^'?G[%G_ $;=\+__  0K_P#'J/\ AWY^
MQ9_T;=\+_P#P0K_\>K3_ (FDR&UGPUG+\W6RV_\ Z?"/AO)6_P!N@VNKB_\
MY _ABR/?\C_A1D>_Y'_"O[G?^'?G[%G_ $;=\+__  0K_P#'J/\ AWY^Q9_T
M;=\+_P#P0K_\>J?^)HLB_P"B<SK_ ,'9;_\ +P_XAQ+_ *#H?=+_ .0/X8LC
MOG\C_A1D>_Y'_"O[G?\ AWY^Q9_T;=\+_P#P0K_\=H_X=^?L6?\ 1MWPO_\
M!"O_ ,>K&K])_)9N+CP]G:2337M\L2=VG_S^OT\@_P"(<RLU]=IN_5J5UZ?N
MV?PQ9'O^1_PHR/?\C_A7]SO_  [\_8L_Z-N^%_\ X(5_^/4A_P""?O[%H!(_
M9N^%W'KH*G_VM51^E%DJE"7^K6;^[)/^/EW1I]*]W]YFO#:I!J2S!>[K9IVT
MU_Y]_D?PQYY/7DL1P>A)([>G;K7Z8?\ !(N6,?MT_"<%P"VG>/T&>!N3P7J[
MLI)X!"D'!(]!SQ7]-:_\$_OV+6SG]FWX7<>F@+W_ .VOM78^ /V/OV8?A?XB
MC\7_  _^"'@'PGXFTI;N2PUK1]'%M?6[7MLUG=;)1(V!/;2/#( !E&*YQQ7Q
M_&_C_EO$O"F<<.87(\?AH9G&I*>(Q$\)*=)RL_<C2KM-)Q6DE=I[GM\/<!O
69I0QKQO/*-134$O=?*[V?[M27WG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #J F # 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_P F^O\
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MCJC_ .HN9G]O5%%%?QX?Z"!1110 4444 %%%% !1110 4444 %%%% !1110
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M_P )^(O_ )C#^T<!_P!%EEW_ (5<(_\ S>9W_#3/QJ_Z1X?MA_\ A;?L ?\
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M^)&?!_\ ^;&C_AO?]A;_ */1_9-_\2,^#_\ \V-<7U+%_P#1-8W_ ,)^(O\
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M["W_ $>C^R;_ .)&?!__ .;&C_AO?]A;_H]']DW_ ,2,^#__ ,V-=WU+%_\
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M +"W_1Z/[)O_ (D9\'__ )L:/J6+_P"B:QO_ (3\1?\ S&']HX#_ *+++O\
MPJX1_P#F\SO^&F?C5_TCP_;#_P#"V_8 _P#HY:/^&F?C5_TCP_;#_P#"V_8
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MOZUI,[P&?3M4OK22&XD]1K\NOV0_VN/V1/A=^SO\/? OCK]KO]DW0_%6A_\
M"6?VII?_  TW\#-3^R_VGXX\3:Q8_P"G:/X^U#3I_/T[4+.Y_P!&O)O+\[R9
MO+GCEB3Z3_X;W_86_P"CT?V3?_$C/@__ /-C66*RC,(8G$0HY9F;HPKU8TFL
MOS*:=)5)*FU/^SO?7+:TOM+7=LWP.?Y55P6$J8G.LFCB*F&H3Q$7FV3TG&M*
ME!U4Z?\ :W[MJ?->'V&W%:)'UE17R;_PWO\ L+?]'H_LF_\ B1GP?_\ FQH_
MX;W_ &%O^CT?V3?_ !(SX/\ _P V-8?V5FO_ $*\T_\ #9F7_P [SJ_MS(_^
MAWDO_AYR?_Y['UE17R;_ ,-[_L+?]'H_LF_^)&?!_P#^;&O;OAI\7OA/\:-#
MO/$_P=^)WP]^+'AK3]5FT&_\1_#7QGX<\=:#9:[;6=EJ%SHEUK/A?4M4TV#5
M[:PU/3+ZYTR6Y6]@LM2T^ZF@2"^M9)<JV QV'@ZF(P..P]--1=2O@L90IJ4F
MU&+J5\)1IJ4FFHQ<U*3345)II;8?,\LQ=14<+F>6XJLXRDJ.%S'+\36<8).<
ME2PV/Q%5Q@FG*2I.,4TY2BFF_1****Y3N"BBB@ HHHH **** "BBB@ HHHH
M*_ST_P#@N1_RE)_:@_[HI_ZSO\)*_P!"RO\ /3_X+D?\I2?VH/\ NBG_ *SO
M\)*_6O!O_DI\=_V(\3_ZG9>?@_TA?^2,RS_LI<'_ .JW-3\FZ*^\_P!D3]G?
MX*_&GP]JT_Q1\2^)-#\0ZI\5? GPH\ 66A^*X_#AUC7?''AKQQJ%A96-G/\
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MF=_]CK.?_5QFP5[#K?P%^)_AWX>Z=\3]8TC0[3PIJFEZ+KMK&OCSP!=>+H]
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M)KX'HK[F\._L+>*_$7PW\-^,H?B;\/[3Q/XRU_X56?AOP+<VOC-I)/#/Q/\
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MMII'_"06&CII/C;0_A[HVD<!X\_9A\/6WP M9_!WPREU[Q:^H?"72/AU\7/
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MI;/$L2!>PD_:2_:*FO[+59?CY\:9=3TW5+O7-.U&3XI^.7O[#6M0\/-X2O\
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M2I5F\ESV\ZM2=2;MA<':\ZDZDW:[M>;M=VM=W_H6HHHK^7#^V0HHHH ****
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M0U75]5U"XN+[4M2O[BXO;Z\GFNKJ:6>5Y&R?^&"/V%O^C+OV3?\ Q'/X/_\
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M_P#5P? BO[>J\/\ AK^S)^S;\&-=NO%/P>_9\^"'PG\37VDSZ#?>(OAI\*/
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M<_@__P#,=7Z'_P 1JRK_ *$.:?\ A;EO_P @?DO_ !+CGG_14Y+_ .&[./\
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M\1S^#_\ \QU>A?#7]F3]FWX,:[=>*?@]^SY\$/A/XFOM)GT&^\1?#3X4> _
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MT_\ "W+?_D _XEQSS_HJ<E_\-V<?_+#_ #(:_MZ_X-J_^3%OBO\ ]G9>.O\
MU3_P(K]9/^&"/V%O^C+OV3?_ !'/X/\ _P QU>W_  T^$7PH^"^A7?A?X/?#
M'X>_"?PS?ZM/KU]X=^&O@OPWX%T&]UVZL['3KG6KO1_"^FZ5I]QJ]SI^EZ98
MW&I36[WLUGIMA:RS-!9VT<7RO&?B3@>*,CJ93A\JQV$J3Q>"Q*K5\3@ZM-1P
MM2K.4'"A%5.::J)1:?*FGS:-'W'AWX/9GP5Q-2S[%9YEN/HT\!F.#>&PN$S"
MC6<L;1H4X353$SE24:;HMR37-)22CJF>AT445^1'[X%%%% !1110 45\F?MR
M_M0G]C#]EOXG_M*CP./B0/AL?!6[P4?$I\'G6QXQ^(?A/P#@>)/[ \4?V8=.
M;Q4NKY.@Z@+P6!T_%J;L7UK_ #U?\10O_5CG_FR__P"3_7TV3<'\1<086IC,
MHR_ZWAJ=>6&G4^M8.ARUH0IU)0Y,17I3=H5:<N91<7S63NFE\;Q#X@<)<*8V
MEE^?9M]1QE;#0QE.C]2S#$\V'J5*M&%3GPF%KTU>I0JQY)34URW<5%Q;_K(H
MK^3?_B*%_P"K'/\ S9?_ /)_H_XBA?\ JQS_ ,V7_P#R?Z];_B&7&W_0E_\
M,AEG_P V'@_\1F\-O^BC_P#,5G7_ ,[S^LBBOY-_^(H7_JQS_P V7_\ R?Z/
M^(H7_JQS_P V7_\ R?Z/^(9<;?\ 0E_\R&6?_-@?\1F\-O\ HH__ #%9U_\
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M@S_Z"2C_ (9M^,O_ $D"_:Z_\(S]@S_Z"2OY\?\ B*%_ZL<_\V7_ /R?Z/\
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M]!)7\^/_ !%"_P#5CG_FR_\ ^3_7]-WP"^*!^.'P*^"_QI;0QX9/Q?\ A/\
M#KXH_P#"-#4CK(\.CX@>$-'\6+H7]L&PTK^USI"ZL-/.J?V7I@U$VYO!IU@)
MOLD/B9WDO%/#M+#U\XP5#!TL55G1H2]CD-?GJTZ:K3C;#8.K*-J;4KS48O9-
MO0^CX<XBX(XMKXK#</YCBL?6P5"GB,3#ZQQ1AO94:M9X>G/FQ>84(SYJJ<.6
M#E)6YFE'4^5O '[!_B'X7:K\2];\"_MP_M=:'JGQ@\?77Q0^(MU_87[%&I_\
M)%XYO=!T'PS<ZYY.L?L;ZA;Z1YNA^&-#L?[,T*+3-'3[#]ICT]+NYO+BX])_
MX9M^,O\ TD"_:Z_\(S]@S_Z"2OKJOR:_X*A?\%0C_P $VS\#O^+'#XSK\9Q\
M2\#_ (66?AT?#1^'1\ ;B6_X0#QV-9&LCQVN!MTDZ:=)))O_ +>!8^?E[SS/
M<PHX'!1I8S'XE25*$\-E,)5%A\/S-.KB,!""5/#X=**E->Y3A".T8GK9K#AK
MAC*L1F>8RKY?E6#<'7J4\9GU2%)XO%<B:H87-*E23JXO%-S<*<FZE:=2?Q3D
M?5?_  S;\9?^D@7[77_A&?L&?_024?\ #-OQE_Z2!?M=?^$9^P9_]!)7\^/_
M !%"_P#5CG_FR_\ ^3_1_P 10O\ U8Y_YLO_ /D_U]7_ *A^(/\ T)Z'W\,_
M_*#X;_B)_A1_T4&*^[C/_P":3^@[_AFWXR_]) OVNO\ PC/V#/\ Z"2C_AFW
MXR_]) OVNO\ PC/V#/\ Z"2OY\?^(H7_ *L<_P#-E_\ \G^C_B*%_P"K'/\
MS9?_ /)_H_U#\0?^A/0^_AG_ .4!_P 1/\*/^B@Q7W<9_P#S2?LU\>/AW^T'
M\+]/^%UWH'[>_P"U'>2>-OCI\)_ACJJZQX$_88N$M]!\=^)H=&U>[T\67[&F
MGM%J]M:R&33;BY:[LH;@![K3[R/,1]T_X9M^,O\ TD"_:Z_\(S]@S_Z"2OYJ
M_B1_P<;Z#\4+;P?::_\ L4:O9Q^"?B-X*^)VE-H_[3]E;O<:]X$U=-9TBTU
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M_P 10O\ U8Y_YLO_ /D_T?\ $4+_ -6.?^;+_P#Y/]'^H?B#_P!">A]_#/\
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M?AYHMG<S:C:ZI:OHUUJEO%9PWT]IJ-E^,O\ Q%"_]6.?^;+_ /Y/]><^,_\
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MDT^S\0/^"?\ X?\ "7B/XKW&D^,OB!_PBWP]^(?Q*T?38_&?PTAT_2;;P_\
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M+QK5*$JF+I8R<*,U1R^4%"D\+!4%*NY1S&,*DJN,Q+IRE1=2G3=*I]&>&O\
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M\.M-TH?$C5-8L?&NE>.+-?C-!KWB[Q'XD^+/Q1E\;Z/K&F^*M3E\ Z?HMMX
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ME3A4O4I4YSIQ3]I3GB(4[5517)S?=MU^S-HFF_M9?M#_ +/?AKPS\1?'-OX
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M.(<+4I4E:U*E4R[%3I4E;2U.G.G3TT]S31(*_P ]/_@N1_RE)_:@_P"Z*?\
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MXAJ_VZ?^BK_LF_\ A=?&#_YQ%'_$-7^W3_T5?]DW_P +KXP?_.(K^WJBL/\
MB+7&7_/_ "O_ ,--#_YI.K_B _AY_P! N=?^'W%?_,9_$+_Q#5_MT_\ 15_V
M3?\ PNOC!_\ .(K^IO\ X)Q?LU>.OV0/V,O@W^SK\2]5\)ZWXV^'?_"P_P"V
MM4\#7^L:GX6N_P#A+?BKXX\<Z<=*O=?T+PSJ\WD:3XFL+:^^V:'8F/4H;R*
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MXAJ_VZ?^BK_LF_\ A=?&#_YQ%'_$-7^W3_T5?]DW_P +KXP?_.(K^WJBMO\
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MHYQ2I4H2J5*E3/\ $QA3A%7E.<G@K1C%:MN^ZT;:3_C&_P"(:O\ ;I_Z*O\
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M&#E:#YHIQ=E)M?R?_P#$-7^W3_T5?]DW_P +KXP?_.(H_P"(:O\ ;I_Z*O\
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M*>#JK/<QC*NL9@,1B,6Y3EE+C45'$TH4HN$(*"<H3<Y^]'^3_P#XAJ_VZ?\
MHJ_[)O\ X77Q@_\ G$4?\0U?[=/_ $5?]DW_ ,+KXP?_ #B*_K _X;;^#7_0
MF?M=?^*_?V\__H;:/^&V_@U_T)G[77_BOW]O/_Z&VN+_ (B1XA?\^L'_ .&?
M"?\ SR/2_P"(0>$W_/\ S#_Q(,?_ /.8_D__ .(:O]NG_HJ_[)O_ (77Q@_^
M<11_Q#5_MT_]%7_9-_\ "Z^,'_SB*_K _P"&V_@U_P!"9^UU_P"*_?V\_P#Z
M&VC_ (;;^#7_ $)G[77_ (K]_;S_ /H;:/\ B)'B%_SZP?\ X9\)_P#/(/\
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M_0VUW?\ $2/$+_GU@_\ PSX3_P">1YG_ !"#PF_Y_P"8?^)!C_\ YS'\G_\
MQ#5_MT_]%7_9-_\ "Z^,'_SB*/\ B&K_ &Z?^BK_ +)O_A=?&#_YQ%?U@?\
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MQ_\ $6N,O^?^5_\ AIH?_-)Z'_$!_#S_ *!<Z_\ #[BO_F,_B%_XAJ_VZ?\
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M+%8E8S&U,;)UJ-!X:FX3J4J+IQ5*33BE)2E[S:>@5_+'_P %'?\ @B!^U?\
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M]NG_ **O^R;_ .%U\8/_ )Q%?V]44?\ $6N,O^?^5_\ AIH?_-(?\0'\//\
MH%SK_P /N*_^8S^(7_B&K_;I_P"BK_LF_P#A=?&#_P"<17M_[,O_  ;[?MF?
M!?\ :1_9]^,7BCXE_LR:AX9^$_QO^%'Q+\16&@>,_BI=:]>Z%X$\>:!XHU>T
MT2VU'X,:5I]QJ]SI^E7$.FP7^J:;937CPQW5_9P,]Q'_ &%T5E7\5.+\10K8
M>I7RUT\11K4*BCE5",G3KT:M"HHR6);C)TZTU&23<9-22;BD]L-X'< 83$X?
M%4<-G*K87$8?%47+/,3.*K8:O0Q-)R@\&E.*JX>DY1;2E%2BVE)M(2 0"0"Q
MPH) +'!; ]3M5FP.< GH#2U^3?\ P7(_Y1;?M0?]T4_]:(^$E?Y]6@>']>\5
MZWI7AKPMHFK^)?$>NWUMI>B>'] TV]UG6]9U.\E6&TT[2M*TZ&YO]0OKJ9EB
MMK2T@FN)Y66.*-F(!TX.\/5Q7E6(S.6<++HX?&U<)*G+!+$1<:6'H5W6E5EC
M,-&$;5FFI*T5!R<TF^7+Q!\6)<"YYA,EAP_+-Y8O+J&/C5AF,L+)2KXK$X6.
M'C0C@,7*I+FPZ<91DY3=50C3<DN?_5YHK_*?\;_#SQ_\,]8B\/?$CP-XP^'V
MOSZ=:ZO!H?C?PSK7A36)M)OC*+'4XM,UZRL+V33KPP3BUO4@-M<&&40RN8WQ
M5OO!?C'2]"M/%&I^$_$VG>&;^2PBL?$5]H.J6FA7DNJP:A=:9'::O<6L>GW$
MFI6NDZI<V"0W#M>0:;J$UN)([.Y:/ZI>#%*482CQ52E&K_"E'+:<HU;WM[*4
M<UE&I>SM[.52]G:]G;X>7TBJ\)583X(K0G1O[:$\XK0G1M9/VT)9'&=&SE&_
MM84K<T;VNK_ZM59>N1R3:+K$42/+++I>H1QQQJSR22/:3*B(B@L[NQ"JJ@LS
M$  DU_E!T5JO!2S3_P!9-FG_ ,BGLT_^ACY&,OI'\T91_P!3[<R:O_;W=-?]
M"GS/]0']CG0];\,?LB_LK^&O$NCZIX>\1^'OV</@?H>OZ!KFGW>DZWH>MZ3\
M,O#%AJNCZQI5_#;WVF:IIE];SV6H:?>P07=E=P36US#'-&Z+]'U_E':IX3\4
MZ'H_AKQ#K7AKQ!H^@>,[/4-0\'ZYJFC:CI^C^*[#2=4NM#U6^\-:G=VT-EKM
MGIFM65YH^H7.ESW4-EJEI=:?<O'=P2PI@5=;P:6)K5\0N)8?O\1B*LE#*U.,
M9U,17J3@I+,I7]G.I.FTWS)P:FHS4HK/#_2'>"PV%PCX.J?[-A,)0BZN=NG.
M=.CA<-1I590>3QM[6E1IU4XIPDJBE3E.FX3E_K(45_E.Z=\/_'FKVOA:^TGP
M3XNU2R\<>)+GP;X*N].\-ZS>VOC#Q?9-HZWGA7PM<6UE+%X@\26C>(= 6YT/
M27N]3@;7-'$MJAU.R$_-WUC>Z9>WFFZE9W6GZCI]U<6-_87UO+:7MC>VDKV]
MU9WEK<)'/;75M/')#<6\T:2PRH\<B*ZLHQ7@M"3<8\40E)7O&.5PE)<LN25X
MQS.4ERS]R5TN6?N.T_=.B7TC*D(J4^"JD8RY>64LZJ1C+FA[2/+*62QB^:FU
M4C:3YJ;52/-!\Y_K#4@()(!!*G# $$J<!L'T.UE;!YP0>A%?Y.%?Z%G_  0W
M_P"46W[+_P#W6O\ ]:(^+=?*<9>'?^J664,Q_M?Z_P"VQU/!>Q^H_5N7VE#$
M5O:>T^M5[V]AR\G(K\U^9<MG]SX>>+7^OF=8G*/[!_LOZOEE;,?K']I_7>?V
M6)PN']C[+ZCAN7F^L\_M/:.W)R\CYKQ_62BBBOS0_9 HHHH **** "BBB@ H
MHHH **** "BBB@!,C(7(W$$A<C)"D!B!U(!903T!89ZBEK^>G_@Y4_Y,6^%'
M_9V7@7_U3_QWK^(6OU/A+PU_UIR:GF_]L_4>?%8O#?5_[/\ K-OJM2E#G]K]
M<HWY_:7Y?9KEM:\KW7XCQYXQ_P"I/$57(?\ 5W^TO9X+ 8SZU_:OU2_UVE6J
M>S]C]0Q%O9>QY>?VKY^:_+&UG_K(45_DWT5]+_Q!/_JI?_,1_P#A$^-_XF0_
MZH[_ ,SW_P""3_60KY<_:_\ #^O>)OA/X2TWPWHFK^(-1MOVH_V'?$%Q8:)I
MM[JU[;Z#X2_;5_9_\5>*M;FM;"&XGBTCPSX7T;6/$GB#4I(ULM&T'2=2UC4I
MK;3[&ZN(O\Q*BML/X,O#UZ5>/$:DZ4U-1EE+2DU&I&S:S&Z7[QO371=V<^+^
MD1'%X6OA9<(RA&O3=.4XYZG**<J4KI2RGE;O12L]/>?9'^LA17^3?16/_$$_
M^JE_\Q'_ .$3H_XF0_ZH[_S/?_@D_P!9"BO\F^BC_B"?_52_^8C_ /"(?\3(
M?]4=_P"9[_\ !)_K(4@(894@C)&001E258<=U8%2.H((/(K_ "<*_P!-[]@C
M_DQ;]B[_ +--_9S_ /5/^#J^+XUX"_U/PN Q/]J_VA]>Q5;#<GU+ZK[+V.&C
MB.?F^LU^?FYN3EM&UN:[V/T;PX\4?^(@8[-,%_8G]D_V;@L/C/:?VC]=]M]8
MQDL)[/D^I87V?)R^TYN:?-?EY5;F/K*DR,E<C< "5R,@,2%)'4 E6 /0E3CH
M:6OY-_\ @Z%_YL<_[N8_]]_KYGAG)/\ 6/.\%DWUGZG]<^L?[1['V_L_886M
MB?X7M*7/S>RY/XD>7FYM;6?V7&?$G^J/#>8\0_4_[0_L_P"J?[)]8^J^U^M8
MW#X/^/[&OR<GM_:?PI\W+R^[S<R_K(HK_)OHK]:_X@G_ -5+_P"8C_\ ")^#
M_P#$R'_5'?\ F>__  2?ZR%%?Y-]%'_$$_\ JI?_ #$?_A$/^)D/^J._\SW_
M ."3_3M_:X\/Z]XD^'OP\LO#NB:OK]Y9?M1_L?\ B"]M-%TV]U6ZM-!\,_M0
M?"?Q!XDUNZM[&&>6WTCP_H.FZCK>N:E*B66DZ187NI7\UO9VL\T?U'7^3?16
MT_!ESH4*#XC25"6(DI+*7>3Q$Z,Y)IYC9<KHI1MNI.^J1ST_I$1IXG$XE<(R
M<L3#"0E!YZN6"PE/$4XN+64\S<UB).7-HG&/+HV?ZR%%?Y-]%8_\03_ZJ7_S
M$?\ X1.C_B9#_JCO_,]_^"3_ %D**_R;Z*/^()_]5+_YB/\ \(A_Q,A_U1W_
M )GO_P $G^L>"& 92&5@"K @@@C(((X((Y!'!%+117X.?U (""2 02IPP!!*
MG ;!]#M96P><$'H12U_$+_P<J?\ )]/PH_[--\"_^K@^.]?STU^Q9#X3_P!M
MY-EN;_V]]6_M#"QQ/U?^S?;>QYJE>')[7Z]3Y[>QOS>SA\5K:7?\^\4>.O\
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M%'_$$_\ JI?_ #$?_A$/^)D/^J._\SW_ ."3_6/)"@LQ"JH)9B0  !DDD\
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M/#;V0_:<^#7VM?$$^D076JPZ(T'F#5I=,MKC4([ W#V4$UR(HV_E2\2_"_\
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MM&FVWS.2WA!Q<W=\NLF^7WS_ %4J***_AD_TS/XA?^#E3_D^GX4?]FF^!?\
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MIQY*:4H\U_,:***]P^:"O]"S_@AO_P HMOV7_P#NM?\ ZT1\6Z_STZ_T+/\
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M:'_P42U6VTVW@\0^!_%FK>)KKPYX;T3Q'\4-)^+USH?Q:N]4\/?"GQ=\+O\
MA-?#OCR^\#^(M0\/>,[VQ\1V43Z[?0>);B+PMI^I>#_WL.LPZMI'YKT5_3[X
M>R=N3^I03E.=23C4JQ?-4J.K/:7PNH^=P:E!M1YH34(I?Q3'BOB"*@O[1J-0
MITJ45.G1FE"A25"EI*/Q1HKV:J+DJJ,I\M2DYS;_ $N^$'_!0^?X/KJTVD>"
M/'FJ>(=1U[QS?K\1=:^*7@GQ)\3I-$\8>+?#GB]M(UKQ+XZ^ OC/2=;O]0O=
M$GC\>:X_ABS;QFTFD7EEIWA2\T1I=3\0^+/[5LWQ8^ G@;X+ZEX4U>SN_ WB
M9=<TG5U\96D/@K1M.DG\=7NHZ+X4^%WA[P9X8TG2&U?4/&<=Y>:UKVM>+]6M
M1I'V#19])TO4KFQC^0**UIY)EE+$+%0PR6(C5IUU5]I4<E4I0J4X-:I**A5J
M1]G&,*=I-*$4W&657B/.:V%E@JF,<L+*A6PSH^RI*+I5ZM*M53:3DYRJ4*4G
M5E*=6\(MU)R49Q_0+3/VU?#/AZV^(TOASX8^/[+5?BO\+_A=X \<V=]\;=/O
M/ >MW_PF;X<-H5]>^#+#X0Z/<ZAX3UZ#P)J6B>,O!6K^)=3FUGPOXSUS0K/Q
M1I*27%U?<%^T?^T]X>_:'$$VK>%?BR-3T>3QGJ'AC5O&_P <['XBWVF:IXU\
M6Z)KMU::C<7/PF\/W&H^#]$T6PU/0?#GAC3Y]!N--N+_ $_5)->NK32KC0]7
M^.J*JED^7T:\,33HSC7A;EJ^WJN2M!4DKN[<522I)-_P_<;E%)1FMQ!FN(PU
M3!UJ].6%J)J=%8:A&#;J.LY)1:2DZTG6<DK^U;J)0FY.?TCHWQ=T?1?!7[.[
M*MS?^(?@A\7?%?BRY\,227%G9:SH6J:E\/O$VFW=GJHM;VUL;VZU+PYK.BZM
MOMY9K>WCT.\AMK]#<QV_M?A[]N"V\-Z9K&L67PLN9_BW::I\4X/AMXUN_B"9
M?"'@WP3\7_&UCXV\3^'];^'8\&I=>+]>L;MO%%EX?\36WC?PIIMI%XMO;G5?
M"6M7>FZ3):_ =%55RK UTU6I.HG.I.SJ5(JU6O+$5*35.4.:E.I.?/"5U4A)
MTYR<$DLZ&=YEAK?5ZT:5J=*&E*E-\U'#0PE*M%U8U.2O3HTZ?LZL+.E5@JU.
M,:C;?WA>_MMW&C>)_"]]\+O 5YX1\&^%M&^*(A\'>+?%VD?$234_&'Q,UGQA
MKS^(]2U>;X?>&K(Z=X>O/$MEINGZ-9>';+5;SPK9^(?#&H^*Y]/\<>(C+E_&
MK]J+1?C#\*]6T>30[S1/%FM^(?AD+JREU"#6D-AX!A^,6J:CJSZM;^'?#4<&
MFW.J?%>ST#P3X9GCU_5?#WAWPY=6VK^)=2SIT]S\1T5$<FR^G4HUH4'&K0E&
M4*OM*DJDG"<ZG[V4I-U;SFY2E-<[:C[UHI+2?$&:U:6)H5,2IT,5"<)T?94H
MTH*=.G2;H0A&*H<M.FH1C3?LTG+W;RDY?ZR%%%%?Q&?Z3'\0O_!RI_R?3\*/
M^S3? O\ ZN#X[U_/37]"W_!RI_R?3\*/^S3? O\ ZN#X[U_/37]A\!_\D;PW
M_P!BNG_Z?QQ_GWXH?\G#XP_['5;_ -1<L"ONGX9?M>^&?AM;>"]0T_P'\4[/
MQMX<^!/CS]G_ %CQ'X/^.^G^#-/UGPGXVC^(4BZMINDP?![5M7T/Q#H>I^-M
M/U>PGNO%6OZ:U]X9M9QID%Q<P7&F_"U%?1XK!X?&P5/$PE."YO=4YP34XQA.
M,N6ZG&2C&\9)J\8O=:_(8',<7EM25;!U(TZDE#WI4H5'%TYRJ0E#G:=.<93G
M:<)1E:<XW:D[?;OQB_:U\/?&GP/HW@KQ'X#^(EM9:3_96HV>GP?&BQNO"'A?
M7/#WPM?P!H.G_#/PC?\ PIN(O /PVMM82T\1WO@.+4]:O+K3H)?#MGXMTNZF
MB\26N+\-?VAM&^'_ ('^%D/VGXB1:]X#U+XV:/=VOPU^)7B/X0>+[;0OB9I/
M@ZXTGQ1X2^(.C:9K]AI^I0ZQHVJZ1XGT77O#GB#2]9\.K:V3:6UQ>QZOH'QY
M17.LIP,:"PT*<XT%5E6]FJLI+GG"I"I;GC.RG&H^:RDY.,&W-J3J]4L]S*>*
M>-G5A/%.C"A[9T81ER4IT:E*_LYPNZ<J,>2\HJ*E.,53BX1H_?\ XN_;E'B2
M+XA:UIWPVU#PU\1O$UOX^\/^#O&&F?$)$L?"'A+XA>+O"'C#5Y=7T2#P3::G
MXL^) U'P_K=TWQ!M?%?A2WNM7\5W>M3>$OM.G6D3=AX$_;W2YU'P?IGQ#\*I
M9:)X:U3X2:A%J^A2:);QP0_##5O!'BK5YI_"NE>"+2'4]?UW5/ \^E?#Q](U
M3P9I7PZTKQ5/X>N_[:\.:?:O9_FA16,LARN5+V7U:RLU"2JU74I_NE12ISE.
M3C&,+\L/>@I3J3Y>:I)G1#B?.X5E6^N<TKIS@Z-!4JW[]XANK3A""G.51KFJ
M+DJ.$*4.;EI01:OKIKV]O+UD$;7=U<73(I)5&N)7E* G!(4O@$@$@9-5:**]
MA)))+9))>B22_!(\!MMMO5MMM]VVV_Q;/K+]@C_D^G]B[_L[+]G/_P!7!X.K
M_3>K_,A_8(_Y/I_8N_[.R_9S_P#5P>#J_P!-ZOYX\:O^1KD/_8KQO_JR@?UI
M]''_ )$?%/\ V.LN_P#5/4"BBBOQ8_HP**** "BBB@ HHHH **** "BBB@#R
M;XY? WX6_M)?"WQ1\%OC3X7_ .$S^&?C/^Q/^$E\-?VWXB\._P!I_P#".^(M
M)\5Z,#K/A35M"\06?V/Q!H6E:A_Q+]5M#<&T^RW1GL9[FVF_/3_AQO\ \$MO
M^C7_ /S-?[1'_P ]NOUDHKT\%G6<9=2E0R_-<QP-&51U94L'C<3AJ4JLHQBZ
MDH4:D(N;C"$7)KF<8Q3=DCQLQX<X?S>M'$YKD>49GB(4HT85\?EV$QE:%&,I
MSC2C4Q%*I.-.,ZDYJ":BI3E)*\FW^3?_  XW_P""6W_1K_\ YFO]HC_Y[='_
M  XW_P""6W_1K_\ YFO]HC_Y[=?K)177_K3Q/_T46>?^'7'?_+C@_P!2.#/^
MB2X:_P##'EO_ ,S'Y-_\.-_^"6W_ $:__P"9K_:(_P#GMT?\.-_^"6W_ $:_
M_P"9K_:(_P#GMU^LE%'^M/$__119Y_X=<=_\N#_4C@S_ *)+AK_PQY;_ /,Q
M^3?_  XW_P""6W_1K_\ YFO]HC_Y[='_  XW_P""6W_1K_\ YFO]HC_Y[=?K
M)11_K3Q/_P!%%GG_ (=<=_\ +@_U(X,_Z)+AK_PQY;_\S'Y-_P##C?\ X);?
M]&O_ /F:_P!HC_Y[='_#C?\ X);?]&O_ /F:_P!HC_Y[=?K)11_K3Q/_ -%%
MGG_AUQW_ ,N#_4C@S_HDN&O_  QY;_\ ,Q^3?_#C?_@EM_T:_P#^9K_:(_\
MGMU^A?P-^!OPM_9M^%OA?X+?!;PO_P (9\,_!G]M_P#"->&O[;\1>(O[,_X2
M+Q%JWBO60-9\5ZMKOB"\^V>(-=U74/\ B8:K=FW-V;6U,%C!;6T/K-%<F-SK
M.,QI1H9AFN8XZC&HJL:6,QN)Q-*-6,9152,*U2<5-1G.*DES*,I).S9WY=PY
MP_E%:6)RK(\HRS$3I2HSKX#+L)@ZTZ,I0G*E*IAZ5.<J<ITX3<&W%RA&35XI
MHHHHKS#V0HHHH **** "BBB@ HHHH **** "BBB@#YY_:5_94^ G[7_@72?A
MK^T5X#_X6'X)T/Q98^.=+T3_ (2CQGX2%MXITW1]=T"QU7^TO WB+PSJ\_D:
M3XFURT^PW%_+ILOVXSS6<EU;6<UO\0_\.-_^"6W_ $:__P"9K_:(_P#GMU^L
ME%>KA,]SK+Z*PV!S?,\%AU.<U0PN.Q.'HJ=1IU)JG2J1@I3<8N<K7DTFV[(\
M/'\,\.9KB'C,SR#)LQQ<H4Z4L3CLLP>*Q#ITE*-*FZU>C.HX4XRDH1<N6"E)
M1239^3?_  XW_P""6W_1K_\ YFO]HC_Y[='_  XW_P""6W_1K_\ YFO]HC_Y
M[=?K)173_K3Q/_T46>?^'7'?_+CC_P!2.#/^B2X:_P##'EO_ ,S'Y-_\.-_^
M"6W_ $:__P"9K_:(_P#GMT?\.-_^"6W_ $:__P"9K_:(_P#GMU^LE%'^M/$_
M_119Y_X=<=_\N#_4C@S_ *)+AK_PQY;_ /,Q^3?_  XW_P""6W_1K_\ YFO]
MHC_Y[='_  XW_P""6W_1K_\ YFO]HC_Y[=?K)11_K3Q/_P!%%GG_ (=<=_\
M+@_U(X,_Z)+AK_PQY;_\S'Y-_P##C?\ X);?]&O_ /F:_P!HC_Y[='_#C?\
MX);?]&O_ /F:_P!HC_Y[=?K)11_K3Q/_ -%%GG_AUQW_ ,N#_4C@S_HDN&O_
M  QY;_\ ,Q^3?_#C?_@EM_T:_P#^9K_:(_\ GMU^F_@'P-X6^%_@7P7\-/ V
ME_V)X)^'GA/P[X&\'Z*;W4=3_L?PMX3T>ST#P]I7]HZO=W^K:A_9VD:?9V8O
MM4O[[4KL0^??7EU=22SR=;17%C<WS;,H4Z>8YGF&/A2G*=*&,QF(Q,:<Y1Y)
M3IQK5)J$I02A*44FXKE;MH>CEN09%D]2K5RC)LJRNK7A&E7J9?E^%P<ZU.$W
M4A3JRP]*G*I"-1N<8R;C&;<DD]0KY-_:A_8;_9;_ &SSX'_X:5^%_P#PLG_A
M6_\ PDW_  A0_P"$U^(G@X:+_P )A_PC_P#PD9_XH'Q;X6.H_P!I?\(MH.?[
M6-^+/[ /L M?M5[]I^LJ*YL+BL5@J\,3@\37PF)I<WL\1AJLZ%:GSQE"?)5I
MRC./-"4H2Y9*\9.+T;1VXW X+,L-4P6883#8[!UN3VV%QE"EB</5]G.-2'M*
M-:,Z<^2I"%2'-%\LXQDK22:_)O\ X<;_ /!+;_HU_P#\S7^T1_\ /;H_X<;_
M /!+;_HU_P#\S7^T1_\ /;K]9**];_6GB?\ Z*+//_#KCO\ Y<>#_J1P9_T2
M7#7_ (8\M_\ F8_)O_AQO_P2V_Z-?_\ ,U_M$?\ SVZ/^'&__!+;_HU__P S
M7^T1_P#/;K]9**/]:>)_^BBSS_PZX[_Y<'^I'!G_ $27#7_ACRW_ .9C\F_^
M'&__  2V_P"C7_\ S-?[1'_SVZ/^'&__  2V_P"C7_\ S-?[1'_SVZ_62BC_
M %IXG_Z*+//_  ZX[_Y<'^I'!G_1)<-?^&/+?_F8_)O_ (<;_P#!+;_HU_\
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HI.--N$923DH-Q3MH%%%%<1Z04444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L B4# 2(  A$! Q$!_\0
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MV,L.L^/I$N/#VFW*RO/'_P (UX&M1'X<T&VMY7VVDBVAO5C5#-<R2;F;YO\
M&_\ P4"^,OB@-9Z+>P^%]+\LQ0V&DJEG%%$,A42*S6! JJ  "S<#KBOML'P'
MB)I/%5+=[S]C#TC"$*^*FMUS3>&3W4$K'QN)XUBW;"8=I-VBZD>>=M=97G2H
MTWL^5>WDMG)NZ/VJU_\ :"UC0\O)\$OB0MOMW";4]4^&^C$X.#N@N?'$DZ\9
M8#8S8&"%8X'"I^UY+)NQ\'/%@VG!!\7?#@'V./\ A*,X/.*_G\UCXQ?$7Q%(
M\^J>)=2NI'9BS/<L02W)ZLW7/([GDUC1>-/$Y_YBUZ6VCYO-/!7/7&,_F,?E
M7T=/@?(H02KTZ]2?64,5B(1?I%J4OFVO1'DOBW.92DU4H0C]E?5J+:5^KYM7
M;R1_1.O[64S*&/PA\4J#Z^+OAUP>XR/$QR1WVY_/BE/[6,P.%^$'BMOIXK^'
MG3\?$PS7\]$?B_Q3GYM7O&!' \XC!..>A_2K2>+_ !-YA+:O>_. I/FG&1DC
M SQ[GGIUS3EP7P];W:.)O_V&5_U@-<59W+:KA_GA:*6GFYI?B?T)#]JRX8 C
MX1>*#G''_"6_#LD9[$#Q,2#[>O%)_P -6762!\'O%38.,CQ;\.B#R1D'_A)O
M;ZU_/LOB_P 3[AC5;WKU,P(XYZ9[C]:V[7Q5XGD!SJMY\V/^6F<=L'USV&!6
M3X.X>2NZ6)M_V&5U_P"V&\.)LZ:M*KAW*[LEAJ3TLND9OS\S]\4_:INW8+_P
MJ#Q0I./O>+OAUW]AXF)X[\5/_P -0WQ&5^$/B9N,\>+_ (='^7B8G],>]?A1
M:ZWXK9LC4[P>F)#D'L>,=?\ ZW&:UHM7\5' ;5[U<\?>/J><^WU[=*B7"7#:
MWAB%?;_:Z[Z_X#9<09Y+15,.K[/ZM3=NNOO6^\_<5?VGKYQD?"'Q0O/&[Q9\
M/1_[LA JPO[2U^P!'PE\2<COXM^'XQ[?\C'_ /6K\0%U#Q/(2AU>^)8$'$A_
M$@YXXXQ^N*VK>[\2F,?\32]X/_/0GICJ"/;_ #BL)<+\.IV5+$6NTG]<KN_G
M;E5OG]Q<<^SM\R<Z+:5DUAJ25[;VYK?(_:E?VDM08@#X3^(LD9 /B[X?_P!/
M$1YJ1?VC=3;/_%I/$O'?_A*_ )!^A'B(YK\8/MOB5%#?VE> @$@[\9XSQ@C]
M!FJ,WB'Q/#PVJWJ9!X,AX/4]^G^1CI6<^&N'HVM2Q&KM_O5=_DBEG>=V5ZU"
M_P#V"4K;^4NQ^V"_M%:FS!1\)O$F3Z>*_ )_EXB-75^/NJL,CX6:Z/8^+? 6
M?T\0>GY5^%W_  EOBF+*+J]X2"/F,IQ@#D8R3Z?E[\/7QIXJ  _M>\YY_P!8
M?IC.<<8]?\*I\*9'+6$*R7_816EMOU&\]SB.KK4&NRPU)/7SYC]TA\>-7(R/
MA9KO_A6^!/\ Y?\ 2GK\==88 CX6ZX1GDCQ;X$.,G&3_ ,3^OPQ3QMXI7[VK
MWG(W<2$C''7G_/KQ5R/QMXH&#_:MY\Q!&)"/S(/ .>_%1+A/)HK:K\Z];\/>
M14>(,T>CG2OT_<4_\S]Q#\<]7&<?"[6S@ _\C9X%!Y],Z]_GM2I\<M8=0Q^%
MVMIGG#>+/ H(Z_\ 4>(SZU^'G_":^*$PSZM>D$D#$I'(/XYXZ^]6$\;^)1D)
MJ]Z#W+2DC''&/7IS63X6RB\4HU+?:;KUM/\ R;^O,T6>YG9WJ44^C]A3=O-Z
MZG[?_P#"[M8_Z)CK)^GB[P)_\OJ4?&W63_S3'6!]?%W@3GZ?\3ZOQ%7QUXH
M .L7G'?S#G^=*OCGQ2I9_P"V+W&0<"0Y[\#.<9[]>]"X5RB[34[+9^VK7?\
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MI[_^!'[8?\+MUG!(^%^M'&.GBWP*>X';7CTSFG#XV:T>1\+]:QG!/_"6>!\
M^A_XGO\ C7XH?\)GXD"A1K%\" !GS3VXSC_Z],_X37Q-&K8UB].[&29#G(.<
M]?PH?".4=JK_ .XM;_Y,7^L&;6OSTK+?]Q2_^2/VT/QJUG /_"L=8YSD?\);
MX%!!!P,YUT=>U(_QJUI!_P DPU@\9X\7>!??CG71SQ_AGI7XH-XZ\2^4Q;5[
MPY!QAP.<\#\^:B7QGXH8$G5[W<>!B4?=Z]"2#G\#[5FN%LHYFG"HE>UW6J]]
M[>UNO.Z*_MW-K)JI1E?I["DK?^3:W_0_:YOCCK"L5_X5AK)(ZX\7^!/_ )?4
MT_'/6 ,_\*NUH^P\7>!"?R_MZOQ*D\8^*2QSJ]]SR=TV3QQZ]..A[YJNWC7Q
M4N5_M>[&<@9DS[#OQUKIAPADTDFE4>E_XU;I_P!OF;XBS6+<7.BFM_\ 9Z?Y
M\UG\C]NO^%ZZS_T2O7L>O_"6>!,'_P K](?COK _YI5KQ]AXK\"?UU\#]:_$
M(^,_%&T :O>;P!N)E." .P&.3Q^M1'QGXK?"_P!KWBX!)82DC&0<=L]#Q[^E
M6N#LF?V:OI[>LG_Z61+B/-K>[4HWOUH4]OO/W$3XZZP[!!\+=<!.>OBSP+Q@
M9.<:\?3Z>]2CXX:N21_PK#6>/7Q;X$^F?^0]QR".>>,U^'$?C7Q5YD8_MB]X
M89_>=B,9Y],]^<YS6N/%OBE(U!UF\8L.OFXVY]<<=?KW H?!V37MRU5IUK5O
MSYT0^(\YT:JT-TG'ZM2;:OJ[N6ED?MDWQNUE3@_##63]/%O@0_\ N>I5^-VL
M,<#X8ZSG&<'Q;X&''_@]Q^M?BFWC/Q.PYU>\W( 1^\_B ..1@\YYS^=5_P#A
M,_$Q/.K7I?\ B_?$<>W7VI+@W*'HE4O_ -?:WY>TU-GQ%FJM>I1U_P"G%/\
MS/VW'QIULD#_ (5AK7/_ %-G@8_RUVG#XT:V<G_A6&L@ X)_X2SP-^?_ "'>
M>W^>OXIKXS\4@ G6+SH#GS6.,^GS GKC_.*E3QQXH&0=7NSD#&9#VYYR3]/Q
M_-_ZF93VJ?\ @RO_ /+3)\29NW)*5&*6BDZ%)W\TKO;=WL?M8/C'KA&?^%9:
MP >03XL\#C/T_P")Y2/\8]<0;C\,=8QQS_PEG@?IG!/_ "'>@[U^+4?C3Q1(
M!OU:\7Y0>)C\O4'([XQVQ3;CQYXFR NKWH525SYIY'TXXZ]_SZU*X-RF]O??
ME[2O?[_;6'_K)FR5O:4936_^STTK>5M.W4_:,?&?6BVW_A6.L]^?^$K\$=AG
M_H.4O_"Y];_Z)AK7_A5^!_\ Y>U^*H\;^)\_-K%X1[2'/ZYI6\<>*"<C6+OI
M_P ]#[^]5_J9E/\ +4_\&U__ ):'^LF;_P ]#_P13L?M2?C-K@_YIAK7/0'Q
M9X&7/TSKO/\ 3CUJ+_A=FM98?\*NULE?O8\6>!CC_P KU?BXGC;Q.#N_M>\X
MY(\T\]<_0GG].M59?''B7>P.K7O/(VRE<9]?[WX\=1T-'^IF4?RU/_!M?_Y:
MQ/B3-U=N="RZ^PIG[5GXW:R "?A?K?/_ %-G@4'OV.O#TIG_  O'6/\ HEVN
M?^%9X%_^7U?B<WC?Q02<:S> <8!D]OI31XU\4L-PU:\ZX.Z;/MW7_/I3_P!3
M,G_EJ_\ @ZO_ /+!/B;-DE>I05U=?N*;T^_S\S]L_P#A>.L?]$NUS_PJ_ O_
M ,OJ8WQTUA2 ?A;KG)P/^*M\"#^>O>]?B=_PG'B4==6O@P[B;I[8 P>]1'QM
MXF));5[TG.4_>GCG//Z=.N*?^IF3_P E7_P=7_\ E@_]8\X_GH?^"*?^9^V;
M?'?6%.#\+-=Y. ?^$M\!X/\ Y7\_I2?\+XU?=M_X59KN<$Y_X2WP'C@$_P#0
MP9['M7XBR>-?$Y9MVL7IXX E/#8&"*JGQOXH7DZS?<\<2G/ZT?ZFY/\ R5?_
M  ?7_P#DR7Q-FR=G5P]_^O%/_,_<%OCWJJX)^%NN\@G_ )&WP'QCUSK_ #T/
M3(]ZA/[06IC/_%J_$!QW'BOP&03Z CQ!U[X]/J*_#E_&WB8[D_MB^8\C_7=?
MQ/IWYY-0CQIXH ?_ (F][CG.9%X/(],GZU2X,R3K"LG_ -?Z_P#\DS*?$^=7
M]RIAVK?] ]'?KO-/\#]RO^&A-3/3X5:^3G&T^+/ 0;)Z<'Q!W['WJ-OVB-33
MAOA3X@!SC'_"6^ ,@^__ !4-?A>_C/Q1NW+K%Z01C E (_D.?SJO)XT\4 %C
MK-[D#E3("!Z=.#^GIFM%P9D+<4H5VNO^T8C_ .2(?%&>)-NKATO^P>A^7.W^
M!^ZA_:,U$#/_  JGQ!CW\7>  ?R_X2&HC^TEJ !/_"I_$/'_ %-_P^'\_$0K
M\(G\:>*=I UB]R1T:8CKWZ<CVXY[U#_PF?B0@#^U[[DC),QQGOCT^GI6W^I&
M0VNZ=9^F*KK\+W_K0C_6S.?^?M#_ ,):7_R1^Y5]^UOIVC.%UOX6^.;0%L>9
M9ZEX&U.(KW93!XI1V('.T)D\XSCG6T7]LGX$ZK<"TO\ Q#J?A>Y*JQ3Q)H5_
M:P)N.,2ZCIZ:GI<)7(WM+?(B#+,P4$C\$KCQ5K]PNV?4+F10>K2;L8Z>A.>_
MKWQ6'/JE_,7$ES(^[&2S,W  XPS$?CU';%9U>!<AG#]W+&T)/:4,3[37NZ=:
ME)6\G)>O4J'%^<PE[T<)6CII*A[-O_MZE537KROT[_U*:!XE\.^*M/BU;PSK
MND>(-,F56BO]%U&TU.T8,,C]_9S31AN#E&8,I#*R@J0-NOY8O"_Q#\:> ]53
M7/"/B/5M!U2+RR+K3;VYM7E6(%4@N#!*GVFVPS!K6<O;R E7B9>*_3/X!?\
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M=I'?9@8Y'>N(OO\ @NE^S!;([^&O@[\6]?,>Y&>_G\+:"@89QD&^U%U#'[I
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M#N';'/H3[$=[_ED<+P.Q(XQGD#K[@"IX;9UVD $!MN#@_>R>]7Q;DH%;@,<
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M$CV/S?X_S_PI^2RDQC.[ 8=6/)QC@$C[M:QJ:*R>RZBLNR^Y?Y&8;5=O"DG
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MOG'!&3SZ].*B>!R<&,9'1LG/./;M6[Y6<\].N!D'_=X_+/\ 0T;!@K@ @?Q
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M%7(.1ZYY[?4_YS4ZVV02R $8SU.<]^V,^GK^-:JV^W@$'(/)'^>?3Z&IXX6
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MLDG>U^:3C9]E;=;ZLYY8:I&VVJNKW_0Y&2%N HV@]5/&2.AYYS^%5_)<A@P
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M],U+7UL_",+)>-J!#6 6[M;5IE2-%9@$/]X<6IM&@6';$H4*!"J1[1V "*H
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M,;F%YK6_U6.TM)8IXK.> &1H"JI)*F.7=T4<_P E%CKYDF:1B[;Y <KA%9@
M""><$*1N4$9)XY-?H1\&/$G_  3^L-$\#ZI^T5;?'F]^+6FO#]F7X?>(/"]G
MX6708M?O+_2KB'2=8T*\NI/$$5PLL-Q:27<MGJ%I,KL+9XE#_/9_64:%.K2B
MY\U1+W8N3TC-7=MEI:_H=>#C&IS1J-<D;74IN"?[ZG%V?6Z;T>Y_:7J?[2'@
M?QGHT&F>$?&=GH?B>\U3P\J66J07MK</:S:O8C4+6.<%8V+V37"2F.0.8=_D
M?.T9KNO"OQ_\'>-OBUX@^$WAG6],U3Q#X'LK]_&%@CO'>6E[:SVUJ\<<#DRA
M+2:51<RNC(QN80C$A]OX"67_  4V_9-F>R?3?A1^T39:^?LQT:^A'AV18/$E
MCJ4/]EE'N/"K0M:):6WF3RSH)'NY3:S01V@:X'@_A[_@H]^PMH/Q+\>?%3PM
MX>_:0MO%7C+7_$$VLW]U\0/"\<<EM<()[#RUL] #K,_B-#>:I;/<3P1VD:6=
MHTD>0ORF"Q5>=*H\9AJT)IOV2H?O8-NW*ISYVXW=U;ELWHG<[\9AL%3J4X83
M%TITIZ5:F(_=3BW>_)%PU4='=2NM[6/V\_X*67/C$>!/!'_"#V]G+XH6^UEM
M+BN3#-;.2VDK=&47+00?+:&;;OD&) IX( /Y9ZO=?%U/AC<W&CV6E-\4D%HD
M6GWCZ:ED,ZFJW4D@%P=/4II.]XL3[9)@N#OR!O\ B3_@J;\*OC;I-C?2_!G]
MH_QMI7ARPTF^N-1T."UU"W>WL_LFD^,!976F^!;BSCDNM0-M=V4VFR+=^='-
M97L"VYD=/F'4?^"EO[+6BWUSHFL?"SXX6^OVUKON-/U35;32-3-W;7KW6GM=
M:=/X.CU&"UU3P_((]5 A62RN8EN](,EO-(5PJ2JN<I1HMMVNI1YI7V:27STZ
M?*QU4(TJ=!4WB8>ZVJ<X5+0G%ROS*2VUT?-9O=:,]LT2_P#BF_B'PBGB;3],
MB\-W&GWHU^\DETY;Z+Q%]IN(M+M;>PMGF:2WFLRKO+!,8T+;7W2!JYOQB_Q\
M@\9(_@W1].G\-2ZK9V\MY?:CX:A6#03- ]S-#:W).HS3HYN!+$6BD9540MA%
M4\GH/[?O[+WC:VTZ]\._!/XZ^)K4>)X]-TM;#Q+87^IB\M;0:LY;3M*\&7KM
M?6ZSI:S2M FE1:6ZW,DJ:H>*WB?]O7X3^&;!-3\0_ 7XO^&+2XL+AQ>:]JM_
MI%C]OM-5^T:R+:?5OAW DMOIV@(UGHELS-=W=^9;_4?/BB5:YIU9Q:YJ$^;6
MT84V[M6^)=.FC\T=<L-3<8+ZW&]XMRC7U2W>K>C^]::GN/C_ /X6*+ASX(BT
M][&/PKXGD-O?/8PM-XI%M+_PC*O)=9FBMI+D(LKJ#; ,6NAY8!K@_!%W\??^
M%5^(7\::/X9L/BW!IFJQ^&-/LM2LKS1Y9(X(%T234=0M8([*'S[DR?:D,;K
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M2LWW/]/V+_5K^/\ Z$:*(O\ 5K^/_H1HKU#P#A/B1_R+5]_UPE_] :OX&/\
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M^&KCP^^L:+8QZMX=BM?'KW;O';:LGB#1H=4U*TAN;&.X;5-/D6TEAC^S[O\
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MKWN_>E>[:T_AWT^\]2K6P-2I&I]<DO9J24%2CU6S:GOIU3W..^'OPR^"NO\
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MAVLS$ K&S=Y&F58=\M>/^'?V)_$GCR*S\;V_Q#%KIFIR:NU[HOB?PQK?AKQ
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M/ITP^T[HT$*744+VLBDSQDSF;8H# 2?(U8/CCPS/IP\<^)_%>AZ7JOBNUNO
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M)G[0@N]2'A3P=K>MZ39RSS3:K>3:3"UV6=Y));>T34 XMU);RQ/NEE'S>6G
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M LDI_>JR_='Q0U_2]3M/'L=S),VWX6:=;R2PWDT"*B64:?)&KJD3K]YI0-Q
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M"?7&\0Z:IPI<M)7C"4*,^25:<M.6;;;2UU<>Q_>%%_JU_'_T(T41?ZM?Q_\
M0C17TA\><)\2/^1:OO\ KA+_ .@-7^;]_P '!T3ZA^UYX"L;J\NETRU^&-EJ
M1L8'EE$LR^)?%<,LD=GM> SB,Q$2F.21A&J*HV\_Z0/Q(_Y%J^_ZX2_^@-7\
M6W_!0F7X+?#+]K[1/V@?$?AZ3QK\9O#?P_3PSX#T/6DAOO"'A_3[C5->NY?%
M;Z7=1/8R:]'<7%Q:VU_=I=R6T"A;.VBE9K@>'Q%AY8G+94H:R>)PLHKE4N9Q
MJ3]V[34%+F:=2WN;]3T<JP^'Q.-I4L4XQH*-2I-RV_=0YUU5WO9+5O1=3\HO
MV"_V7M.T+2K7XN>)?AC^R_\ &;6+:]GM-+^$?[2'Q#T?X=:CX$LWL#-:ZMX_
M\%ZGXA\/ZE?G4;>Z%]H"7MPEH]A'+?W-I*]Q"(OW:\0^%O'>K_"+X5^*OA5\
M+_V!?V4= \0CQ]#\8?'OPFN-.\:7LVEV3:?8>$]&\%7_ ("U?4;O4=9U:$ZS
MJ-Q%%XITG3M,$-M'<R+(QB;^3CXK_P#!1KX@Q?&'Q+JUQ\ M=\0Z?)K-R=06
MZ\)6EW:>)8]J1DE(O+NK6U"I(EL9+JY:6%RTB*#Y:];K_P"V'^T%^TGX3T#P
M+X7\/ZS^R[\-M$M-0TF^T/PIY.CW/B.RU\VTOB!],TFVG\KPWJ-Q-86<::YY
M']IVMK+J4>F7-J=0FSEA<EP6$PE&G%4I3E%5<0Y4H3FIU5S3HPGSRDXP=HMW
MC9W=MT=E3&3J5JWU=5Z$(U(+!0IR4*:ITYS<JE7DH4Y/ZQ&TI/F;Y?=O:/O?
M6/Q8\6>!/$7C+Q*_PP\2^*/$?P[TO5KO03K_ (EL[:R\0>(O$'AZX?1_$]]!
M'9W=[&VAW&OVEZ^BW$MPUQ-IIMS<#SRV?.KJ[@DL[>.&"41;@!"6"!\@[8Q#
MN9F4Y5GGE&XD,(T3 +<CX+TNS\(>%M%\(Z9!,MEID)@M;:6XENKRZ'F-,;C4
M[N>22>>1Y9&F=7E8>:[RLTDS-)7HMA;); WEUAYV4?NPFY(RPZ*!R" "  ,$
M$G/)S[4>2E2ARQ248)QOLK);O3IU26G1&$W4K3G*3<GS>]*+<DKO[-^G\M]T
ME<IZ9I4DLT=Q>QE8AM$5LG"%AG"(A + Y^^26(Y; YK[A_9I^ =W\3O$*:OK
M<$D'AG1&@N+U%:*&66+S52.RL/-#))=W3'9&$1FB1)KJ0&*%L^2_!_X:ZS\2
M_$UCI]E#+L3-S*RQL%L[*&/SKFZF)&R.&WA1I+B5BH5  ""5%?JE\2?$^D?L
MW_L_>*M9\%PV][-X1TNVN=&>]L_WM]?ZGJ.F:5<:E?QP36I:6<7;M;P3WD=M
M:6L:)/(J-<-7SF:YI4IRCA<.X.O7G&G=.W)&:LWS;J?2.EKO5KI]5DN54H4J
MN98Y2^J8=2G)RBKUITX.JH*]KPARJ51K1V4+ZNWN\]I!I5FEC9+9:7H^DZ</
M.CBB"0V=AI]N2$41E-\-M;PL\DVWS)G$DKAY)#GX,_:.\>7&KV$>C:/J;V6H
M^+]_AKP_!9PWMN'\+6UW>27GC43S,8H3J>C:N;-V@BQ)9^8SRC:L:]3X>_:&
MDUSX/W_C#Q%%9Z+JHUKQ,^LK:W,4^G2>!-%U_P 0^%[CRKQ+R\M-0:_32WD^
MW:5/<V,SW$#6,Q@97/P9XM\>W/B.5M1TDKJMWXST2+PQH5JES)*_AWX:Q6<$
M?F6ES.SQ6-]=6T(6XNDMFD,P#-O7"C\FXKQL\.O[,IN*K.JHUY*HVK1<9JG)
M).[DVY2NW[O*^K2_2<GKX2E06<5Z\7&5.$L/3=)JHZ4Y*$)4Z<7=NJU##TW%
M6IJ=:J[*C=U_"GBN9O%^BV?@CP8_B74-"6_\+_![PVLEP]B^L1[-.UCQ]JT
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M[(\9^ ?V>O&EA-%&MZGB#X)^%D-ZQD8%9SH3Z3%.60#<I@ VCD$X%?1W@_\
MX*X?%R+P2GPYTWX$_ VT\#>$KB#QV-!\*MXT\ V2W^DZE;WT-S&ND>,K9[O[
M1J*PK)HS>=#?PJ\$UI/;AHCMBY5<2HQ<Z;LYMQ<+<\I1<;2<%9*[3;;NM;')
MA,)@*-";D\34QLZU*$(RJ+ZNL+>3K+D]G*<JTW%*+YH0C!/6[NOUP^)O[2_A
MKQU^V[\.?AYXG\5R7NM>!Y=3^.7Q0N;^"ZOM"^%^@Z5%%!X=;Q#JR+/::+>>
M(&U:<Z;%<-'=SW<D >)5N@[_ (:_M#_%G_@KUI?QO^,OAGP+XD^/_A_Q#=^-
M-9^+WAC5?A-\<-?UW3- ^!FH^([WP[X4\->&]*\)^(I_#\/A.745MIDAL[%;
MYM0MWCFLT&\UU'P__P""J7PO\-^&?BUX//[&?A2)OC=XEG\3?%+Q9I'Q@\>0
M^-/%.KF6*19;CQ-J]OK.I0Z=:"!8=-T=+C^S-/M]\-O;QH[ \-:_MQ?LSW'Q
MKU3XLZ[^SQ\1+/3[OX?:)X&TWPMX?^,-BTFFZEHOB*^\0W/B?^W=8\(7$L\E
MRMW#96FGI:P+9F)[D7;M*$5X.+PLY.HHU-*-FXJ:<XINIZ1YI<L;:N,4VVVS
M3&2=;#PAAJWLI>TKJ48+EBJ<I0ITXWD[RERQE.4HVC>5EL?H]^P'=_\ !1[X
MO>$OCY\-O^"G/QF^+VG?LU_$_P"&>@^'?A_K?QW\0VWB6TTSXL1>.?#VL>&[
MKP]X+U:=?%6L:K<V-MJ5N;6UMTM&5A]ORH3;^EWBS7_ WAG]I?\ 9F^ ^FZ8
M=+\,_##0/B%<>#_"BS6,-_>Z7X=\/QZ)J/BB^%O.MO)J&IZ_XF.HZM.!L%Y?
MW,:D)9F,?A)<?\%'OV/-3N/"]WJ'P>_:BTY_#>OZ9XGT];/XJ_#N_BFO-+G%
MQ';71U'P>CO:2RJ!<+$;>=D&U)T5I ?2OA=_P4>_8S\/?$#QM\4]9\!?M,^+
MO'/BS1-0\)V7B3Q=KOPUU/4/!'A;4];U7Q#?Z%X6>S2U,-C>:QJWVB\,Q,\\
M6F:7;F810*IRS%5<5552C3BDXN+C=4[-P<;I/2R3;?6_J;X"&'PU&C"K.I5Q
M$I5'7J5)P=.$(U83HQIM7FW*G&?/SMI5%3C%*+=]K_@IO_P4B_;=^$/[9?CW
MX1_LX?$KXZ>#/A+X!TOPOX4TO3?AM_PD,/AO7?$9T:#4_%6O6U[H^G"+4;F\
MU;4GL6NH+J=-FG1K"X"D"/\ 88_;2_X*Q?%GXN_#;7;CXB?M.?$7X)>%/BAX
M!T[XQ13ZEXIU?PS;>$/%.OV^B:K:>*I)TFB73[NQOKB.Z6[<QQ1HTC&-49D\
MG^(/[;O[)FD?#?Q#H/PK'Q[C\;7+!]#'B2S\.:/H$-[+>QWT]]<:]X4\4KXD
MM9K)A]HL8;();2W2I#<@6C2HWV1\8?\ @OQX7^-?PK\(?"GQ%\/6M])T+P[9
M6?BK7_#MG)\/]4\:ZK!;".\&HV'A>ZGLY-)65;>1$N9)YYKJ)[T?9S,T"^D\
M6Z5&EAJ%.-O8QIU*DHPDTE'EFX7][F<4N5WLI7L>)##8J>)Q%6KB>2"KRJJG
MI-U(3E.4.22]SG245);1;O+2QZA\&?AAX?\ AC^T_P"'?!7AKQ1/XSU/PG\0
M/VG8+FX_M"&;PS-H*^(?&>C:)>:3:@R10O<6^C0J]U%<SR3>6Q$FRX9!\P?\
M%M/BAI_AK5OA%\#;Z'49-6\8^"+WQJMOHET+Z..Z_MJ(:1]MT1;2:?4&D?3[
MK[(ME+9362)+<2RW$+10GC/"W[2Z?LZ:'\)?C!XA^%%G9>']8G\96RW%V][:
MZ[K%[XOTC3O&>C/I5M!?7[-X0T;PWXPT\:?-<"SOAJ=_?QWL *(TGSI^UM^V
M-^SM^T_XZL_C#XH\"^-K'Q]H'@2W\$>'M6TOQ=JEIH.@:78^7 !:^'1IHN5O
MKZVN+H'5X=:MI;&=A,C?O"K>53C4CF6'KI2="BYSF^?DDVHP]FDXVFVW?GY=
MDFMG(]B,\/'*,=2A3E+%5E"G2YOX4.>$55JRM[LI0BN51UO-N^B1^:WA_P 9
M:'/IMBWB'Q1'8W-W=W4%[9V2C4+R*RLWMD67[*R020QWT4\C6'VE'1Y8)1(Y
MQ\W]2O\ P1B\>_#^7X(?$KPQX;FU=[+P?KGA."S_ .$DET]]:N4U72[N>6X2
M.P::RCMVNVN%CMI(X;RUB6..\C5EX_G>L-)_X)M:?KMQXA7QQ^UQ<7%PSSQ:
M8G@'X6RV%BT[/,]E!?WOC!;S4+>U>1K>WNKZ%)IDC6:6&-W:-?T>_9=_X*:_
ML<_LI?\ "QKG0O"'[1_Q5U7XA?V MW=^+K/X.>#[/2+?PYI]Q806ND:9X1MH
M;)3=K<?:+JYGAENI9T#S32NTCM[.;XIXS#>SI.3DIQDZ<HQ4'[\5=5)?!R)M
MK9NS?1GD</87^S\17JXK"4U*M1A"CBGB(Q5%1FYU6L/"$G.5>*A3<9N#A&/N
MOF;M^YOQJ^.>F?!S]I/]F#1]09++6/B/HWQ(UWPSKVIVMN/"!;P['8"]\*ZS
M?S-%;'4?$]B-1TR'2D#1W<3!&WF=5/YI?'OX2?![]NG4=:_:73P;XZ_9B\:S
M2GPAXA\.-JD/C?PXOAOX9V@\,Z(VD:5K7A[1[K191HEE:QLFF37&FK/!(MM'
M<G>\GSI^TC_P5I_8X_:7LOA3;^./V:_C@UY\'/%">+O!M]I7Q2\+:,?MZW#W
M/V'4X3H&IV\^F2SE'F$4$5TXCBB\_P I%0,\7_\ !</P;J7ANT\-6_[.?C+7
M="TNS2QT:Q\7?&6SN!IEG:L\T-MI\NF^ TN["V26629H+2XC1I)&9M[,6KAR
MFI/"44\0YJLG6A/V34TXRG-0<'M+W%3;MIJ^Q[.;?5\6L12IX>C4IUOJ=2EB
MI2E&5)TX7KT?8I\TE4FY<TW[]E".S9]K?LN_LZS?LQ:5H_Q1_9T^%OB3X\_%
MSQ;<Z!X&\0>-?&$=[JVA^#/A?X\U.UMO'&MZ-X8T:#0-,\,,=&M[;=KWB3^T
MCI,JAPH60!F?\%AO&7Q#^$OP1^ 7C3X36EKJ/B2?XS7=V=-O;."_>Y7PGX/\
M2:WK-HEP8B]E\EM"LNH6@@G2QGQOCC>0M^86J_\ !<GXB7-M;>'/#OP#\':3
MH2KE=-UGXE?$O5K0F#'D&ZL-(U+PS97C8SYGVB$H1D%2'8-Y'\;?^"N_QT^-
MC^!1XH^'/P.@L/ASXFUKQ;HVDQ>&/$-_I-YK'B+PEJ'@G4?[=L=2\47,>JV3
M:)J-THL"T%HTY26YCG51&<\?3EBL9A,5"KRTJ,E[:G56M6*OHN7523Y7!OW5
MROFW1&%G0PV5U\%"E2IUGSU*&)I0DJCJ3K49/VZE-JI3C"#@H\B?(W9W3/WQ
M_9Z_X*@GQ1\ [S4?@3\/M#\7^-M-?P=XHUOPU\2+JYTW1HI?$.A7-KK^G:9K
MMG'<SV.M^&I8M5T%M4BB\R)U1GAECO"I_.6^_97_ &1;KP5<>(O&G[*OC:\\
M;:OK5U'9V'@[X^>,?%5E9'4'>[;56CCT6S+RPW37$2VS0W%NRBVWJV]D'YP^
M'/\ @IW^T;X1T\Z3\/(/@G\+]-F\V62'P!\"/AKHS/++)YFYY9]#U":1GD+.
MSRR.Q8%@0=QK%\2?\%)OVV=7LI+?_AHWX@:18[G5K;PJ^D^$+8I)DE47PSI>
MD&(%OF81N"W?G!K7$5ZCI5/JF(Q.&Q4X2C'$4U1J*E+[%;ZO6A*%:I'5.%27
MLI1:YHNP0KTIT8X;%X#*L73^L4Z\J\L+6IX[EIWOAJ6-I5(U:.&JMWJ0A3;;
M2DI<R37]!'[/_P"S'I7P^\4>#HOV=_@AI'P2\,^.O#TOA7XNZGKWA/Q;XP^)
M/CGPAK\L<_B3P[J/Q-\57?V3PAI-U;16,0&@:;IUS;SP&>"[28(4_)O5O^"8
M/Q0^ GQI^*'@(Z3-XZ^!/BRX;QEX9OK'X^^!/ 4$-I;7.H74G@/Q9J'B;44U
M%M3O9WTZVGU);/[$)+*+4;EVWK-;_F)XG_:*^/'C9B/%_P 9_BMXG,F]F&M?
M$+Q=J,#Y4_*T%UJTL10GHNPJ.,#!K&\+>)+BUU'5-6O7GOY7\+:_;[[EC?/)
M+>V1M5,INV<IB:X#K(@9UD5",$EAFZK?/5=2;G*G"-5U6FYU(6M4CS:4G\2Y
M*=H+FLE91M$JM.M'!T)TZ-&& ]K3P[PF'H8:3HU9U:DZ=>5&$)8B3G)?OL0Y
MUU&$(\UDS]2/VFO@]\%(O#[?$_4G^"47QAT;2_!V@V^A#]H?4/B9XSL;*SNK
M#1WT^UL_!MW%X/O5TRRNK[[;J,UM<?:;7SIH0D@C*^L_"3XB?L,^ /#6D7_B
M;7/A_P#\(/JN@Z_J^J^#-;^#VF_$_P ?>$/%]AK.E:)IW@CP9IGBO^T/#5SH
M,< N/$EOXFFM;:ZU'3(8'C (OK.#\5O LMG?ZQHFGWEM=6UE?:A<).+&V\RZ
MN#:Q;[6"-6(^_)A#)R(BYD,4@!C:3Q_IPBUZ:QTB/4/L$$+Q1)>J3>0K'?7J
M*DSM!:/,\!_<^=]GA\]T:01(KJJS*?-AI.I.;]]VE[64;1TT5M%%;JVB=[GG
MRJ+^U_:N$JU6O1J2K2JW;J.;G4<I6U;J5)*4KZ/2S=S]:M!_;0_9P\ _%.X^
M)/\ ;OQU^,.IV\>I6VA6^G>!/A-\$M*L-!N-';0[7P_)!HSZS<?8=,MEM)X5
ML[:TMWN;:*1[)F576]XN_P""M,M]%%:^%/@MYWDMF.Y^(?Q,\2:\TL>,K#+I
M_AR'PQ:&(C >(2 $C  '7\7TL;R, !TCN6!5 S*DTF-A;9$6W# (9B 0!S[U
MUNA:"LERD5S.@)96E*YD<9))]1]X<C'09)QD5E*M#E49/:*Y5%J[26C:6C3T
MN[ZMZZL].C&,;N"5YN[E>[<WK);][WBE[MK+1'Z+ZS_P5E_:]6PFT;PAJO@7
MX8:8'E^RQ^!_ >BI=P"7)91JWB%=?U*1F) ,KW!?))SQD?,WC;]M7]K/XFB9
MO&W[0'Q7UJVDB9)[0>+]4TW3_)5<&'[!HDVG6'E\\(MN!@%<8)%8.G_#)]7A
M*Z=I>HZE*TJ*D%M#([2DOUCB16D(8\?*"-S#L17T7X!_8'_:>^(]N4\'_ ?Q
MG/;W(C$>HZAH>H:;IC?:?]66U+48+:R10H)WBX/*\]1CAGCH4]:LJ-*/>;A2
M=WMJFM'LN]O(ZE2Q%2S3JRF]%&E>46N]ES)O7>^G8^$IYO$'B)DO]1NK_4;B
MYC9FN-2N;FZN&#,2I,UR\LK 8+?.QP#WS@:MKX6N7C9KF58@&099L;R8SGKC
M  .,@8]^*_</X7?\$3/VF-<O8K?XGZ[X1^&.F0V4$RSSWPU=YRTW[VQA@T@W
M4GVV*!3))YKPP*K*$F:0[%_37X<_\$-?V;_#AMKWQ;XU\:?%*^,*S26=G)8^
M$=*B"A X,H_M*\>,EC\QN89@@V'):O.J9U@J<91IUY5^;5PP\/:/F3VUE&-U
MOK)>ZKZ]?1HY+CZOQX?V4+)\V(E[.+O9W=H3E9Z:J+?,[/2[7\EUKX20/LL8
MK_4[MEW16NFVL\[RJ JJB!4"N=W&-Y!XSS7T'\+_ -ES]H3Q,O\ PEOASX2^
M/-.T33KFP*>(;S3;C3K0WEQ?+'8JL]XD$#0W;^=!%.DD@+$HCA]M?VX?!?\
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MP[%\2_#?PST^?6-*MM26UMO$[:?=-=77V58C<BS>\D,=M"%WJ%5"KDUWDO\
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M-"MQJ/EZ#IULP:36O$6N:7HVD1V\I)+3ZCKMU96T,8W 9,F%P!@<$_-/CO\
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MEA<'E>+I*2KXV=&;IX?!QE6J<S5U)NG&<V^6[?NQY7<]G^'?@[PM>^'KR_\
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M5:E1I*5/!X2$FZ6&HN5VDW;VE:HTI5ZSBG4DDHJ%*%.FBBBBO3/GPHHHH "
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MNGC_ .+;10(8P)/%^F.90VWYIV_X1<-*XVC#$]SQ7]#OD0_\\T_[Y%'D0_\
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M/\/?AU*T4%M$D$,?G2^#GGD"QHH9I97DD.YY'=V9C^P/D0_\\T_[Y%'D0_\
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5MMO=MN[;?5MMON%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "5 5H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#RK82O6H2?LZ^-<7.A7IUH*3C>,XS<9-/FE^A_\ PZG_ &!_^B#?^91^,_\
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M#9V7CH3BZ$P\8VMMJ,<'B<3"^O1+_;<=]Y@O+H/D7$V_[.\&_LH^ _$?P?\
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MV%4HX!5L7C:6$PE2OC*CKY?1QF"KP6"I5,1&AA\TRW$577QN*C5IU:T'AO\
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M*XLET_4TT5/V?8EUSXPIX/U'0K]+GP_\3[S7M,T_75DL=1D\.:-::G8P3C_
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M(4Y-[2%7^V>)75IQKPA4>/PCJ1CBG5EB8J;P$I6Q$J]9UKRDZKK5'-OGE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 6$# 2(  A$! Q$!_\0
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M=-10!S/_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\
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M3V'BWP6VKJ=5L-(UW0?%.DW4FAZK-<ZGHM[]IM+FXE0P2. ?65%%% !1110
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M2Q@N+N8Y8$K##(RKN=@$5F&#X*_Y$WPE_P!BSH/_ *:K2NFH YG_ (2W2O\
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M]/$W_A%>,O\ Y0UTU% ',_\ "6Z5_P ^GB;_ ,(KQE_\H:/^$MTK_GT\3?\
MA%>,O_E#7344 4K"_@U* W%O'>QQB1H]M_INHZ5/N4*21:ZI:V=R8R&&V41&
M)R&".Q5@+M%% 'YGT444 ?H5X*_Y$WPE_P!BSH/_ *:K2NFKF?!7_(F^$O\
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M ")OA+_L6=!_]-5I734 <S_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\
MP0Z5_P#(E=-10!S/_"%>#?\ H4O#/_@ATK_Y$H_X0KP;_P!"EX9_\$.E?_(E
M=-10!S/_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\
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M-$\):;I,FDZ;K?AW09[>WGT'QQXEO'U%[SQ+8210R6$5LUM%=N]W'+'##/\
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MJ%I:WUI-_P +.\ZUO+>*ZMI?+^#GQ"EC\R"='B?9*B2)N4[9$5UPR@C^P?\
MX0KP;_T*7AG_ ,$.E?\ R)7\@/\ P2G_ .3^/@-_W5'_ -4Q\1*_LDK^0?'_
M /Y+'+?^R<PG_JQS0_I;P;_Y)C'?]CS$_P#J#EYS/_"%>#?^A2\,_P#@ATK_
M .1*/^$*\&_]"EX9_P#!#I7_ ,B5TU%?AI^M',_\(5X-_P"A2\,_^"'2O_D2
MC_A"O!O_ $*7AG_P0Z5_\B5TU% ',_\ "%>#?^A2\,_^"'2O_D2C_A"O!O\
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MW_LG,)_ZL<T/Z6\&_P#DF,=_V/,3_P"H.7G345S/V3QE_P!![PS_ .$EJO\
M\VM'V3QE_P!![PS_ .$EJO\ \VM?AI^M'345S/V3QE_T'O#/_A):K_\ -K1]
MD\9?]![PS_X26J__ #:T =-17,_9/&7_ $'O#/\ X26J_P#S:T?9/&7_ $'O
M#/\ X26J_P#S:T =-17,_9/&7_0>\,_^$EJO_P VM'V3QE_T'O#/_A):K_\
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M_P UM=-10!S/]O:K_P!"5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6UTU%
M',_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;7344 <S_;VJ_\
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M_P#U&QA_4OA+_P D;0_[&F;?^G\,<S_;VJ_]"5XF_P# OP;_ /-;1_;VJ_\
M0E>)O_ OP;_\UM=-17Y ?I9S/]O:K_T)7B;_ ,"_!O\ \UM']O:K_P!"5XF_
M\"_!O_S6UTU% ',_V]JO_0E>)O\ P+\&_P#S6U_/U_P75O[J^_X9:^TZ+J>C
M^5_PN[9_:,NC2_:-_P#PJ+=Y/]D:MJFWR=B^9]H\C/FIY7FXE\O^BNOYY_\
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M_P#5,?$2O[)*_C;_ ."4_P#R?Q\!O^ZH_P#JF/B)7]DE?R#X_P#_ "6.6_\
M9.83_P!6.:']+>#?_),8[_L>8G_U!R\****_#3]:"BBB@ HHHH **** "BBB
M@ HHHH **** /S/HHHH _0KP5_R)OA+_ +%G0?\ TU6E;UW9VE_;RVE]:V][
M:3 +-:W<$5Q;S*K!U66&97CD =58!U(#*&'(!K!\%?\ (F^$O^Q9T'_TU6E=
M-0!S/_"%>#?^A2\,_P#@ATK_ .1*/^$*\&_]"EX9_P#!#I7_ ,B5TU% ',_\
M(5X-_P"A2\,_^"'2O_D2C_A"O!O_ $*7AG_P0Z5_\B5TU?R@?\%+?VB_V@_
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MX9_\$.E?_(E'_"%>#?\ H4O#/_@ATK_Y$KIJ*_(#]+.9_P"$*\&_]"EX9_\
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M6T>XA(8,6B6^M;VT)8 H?.M9EVLQ50^UE +%%<S_ &#JO_0Z^)O_  $\&_\
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M<9!C.)L@JY5@:F&I8B>,P.(4\5.I"CR8:K6G43E2I5I\S52/(N1IM.[6C?\
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M$?P)_9+M/A5\7-0^(*6-KX9\+>$O#/BCX<_!OX?Z=\5_C%\6+#P_X3\3>(-
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3OS/HH _3"BOS/HH **T** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "M *<# 2(  A$! Q$!_\0
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M:WF"-)$S"*>*0/#))&R.I#;MRKU]?DKX"^+?C#X>1W-MH=^PL;MS+-8S+!-
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MG_@J:FMD^#[S]H-=),-B]N/$.N>"9;RVOF@C-[#=301V]M/;07>]$F6W5'@
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M;W3S)'?8LCE4WL6V*68MM4':NXD[0,DG)K\J_P!H;]@'QO\ &']HF3XRVOQ
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MOCIXD^-O_"=S+)XIC6;4?"6O^'[?6M-BU2.WLX8+JVOC=1W!L(9+&"==,:%
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.::UUZ]?D9_UM_P $_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' ?<# 2(  A$! Q$!_\0
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M10!6ELH[C3I;*=Y)(Y49'9F^9@>O/;KVJC;Z L,\<\NH7MS-#$T4$DQCS$&
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M ,5^//O7I5E?6NHVJ7-I,LL3=&4_H?0UX#6GHNNWNA7@GM7^4_ZR)ONN/?\
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MEQQO>W*0+(XC0OT)/]/?H*M2.L4;2.P5%!9F/0 =Z\0\4Z^_B#6'G!(MH\I
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M*%JK@]&8OQ&UK[%I2:;"V)KO[^.T8Z_F>/P->45M^+=3.K>)+N<-F)&\J/\
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MX;KSST]NE>[[7R_K3_,\SV7F:U%9IOKDA$CC1I,.6/;Y3CN1_.I%N;ES*1Y
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MHHH **** "BBB@ HHHH **** "BBB@"*V_X]8?\ <'\J*+;_ (]8?]P?RHH
M)_\ 5C_?3_T(5+44_P#JQ_OI_P"A"I: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LCQ-#YV@SX&2FUQ^!Y_3-:]17,*W-K+ WW9$*G\
M145(\T''N)['E=%.D1HY&C<89201[BL.WU<R:S<0B5)8MC>7$A&\,AP?SR<9
M]*^9C!RO;H8V-JBLV+68YEA9+6Y(EC,@PH) SC! .<Y_SP<1'4GEOK389(8S
M))'-%(%ZJN>HS^AI^REU"QKT5E'7H!"TIM[@)Y1F0E5_>(.I7GWS@X.*MVM\
MMU)+&(I8WC"DB0#D'H1@GT^M)TY)7:%8M445)!"]S<1P1C+R,%'XU*5W9 :M
MA.NB:'?:[(!O5?*MU/\ $Y_^O^@->9N[2.SNQ9V.69CDD^IKL?'VH(MQ:Z';
M,?(L4!D_VI"/Z _^/&N,KUU'DBH+I^9];EF']E1YGO(****#TPHHHH ****
M"BBB@ KW?PM;?9/"^FQ$8/D*Y'NWS'^=>):99-J.IVMFF<SRJF1V!/)_ 5]!
MJJHBHHPJC 'H*ZL.MV>)FT](P^8M%%%=1X04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!%;?\ 'K#_ +@_E11;?\>L/^X/Y44 $_\ JQ_O
MI_Z$*EJ*?_5C_?3_ -"%2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H0J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0RD?PCV]3^'T]@1%CC6-%"HH 55&  .PK:C3^TSS\QQB2=&&_7_(=11176>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH BMO\ CUA_W!_*BBV_X]8?]P?RHH 696>/"XR&!Y..A!I-
MT_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#S
MSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *
M** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X
M_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_
MPHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_
M //./_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_
M  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\
MSSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[
M^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #
M=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#O
MX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3
M_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //.
M/_OX?\*-T_\ SSC_ ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HH
MH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_
M ._A_P *** #=/\ \\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"
MC=/_ ,\X_P#OX?\ "BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** #=/\
M\\X_^_A_PHW3_P#/./\ [^'_  HHH -T_P#SSC_[^'_"C=/_ ,\X_P#OX?\
M"BB@ W3_ //./_OX?\*-T_\ SSC_ ._A_P *** '0H8X8T.,JH!Q1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &S 8H# 2(  A$! Q$!_\0
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MCXW?])Q/^"E?_A:3?_-90!_4[17\L7_$-Q\;O^DXG_!2O_PM)O\ YK*^_?\
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M&W_!=S]L_2O@%\/?B'X>^'7P-L?'5WX@_P""E/ASQEHWB_X3_%V:+6?^&/\
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M@)_P44\9_MR>%/'/PD^).KZ7^S]_;_[*\FAOIGQ.N?"O@KX=> /!GC'Q_?\
M[9OA?XE?"RWU6QN/B=XH^/O@/5/"'ACX7^);31?$5SX%U33XM2M=8^']UI*:
MU?\ B'[._P"PG_P4#^&O[1?A75_BM\?/B[\4OV=-"G_:5\(ZIX>U?]J?XLZG
MXKUKP9X&^,UO\2_V,/'EW+=>,[*+4/B7XX\(^)?$/PH^,\-V]MIDGA+P-X-A
MU.[=S?2:I_0'10!_)?\ !G]DS_@NSX8^ OQ$\(ZYXZ^+B_$+5_A3^R7#?W?Q
M)_:RTWXES^+/%O@']J3XH^)?VE_#_P /?$EI\2XO$'P^U/XC?LS^*?AQX)TG
MQ!8^(OAS_:EUX&U+3KOQEX:U6XTOQ>_Z(?LQ?LD?MLZ9^USX-\4_M$?&?]IS
MQ'\#OA[^R-\!=/TK5;O]H"S\.Z7X_P#VGO OQ&^)%[XMU#XI_!SX?^/_ !'I
M6I7>I_"OQ+X"\+^*)8;C5_!GC/4_"&IW^N:CXGU?^S/$E_\ N!10!_*7^WGJ
M_P 9?V<?BQ^TK/?ZU\8]"\1_'K_@J+_P3T^)GA#7/A7XU\3_  SUCXK_ +'\
M_@CX<_![XC_#.P^(F@ZKH=EI6@>#-0T+QUX;\=:/KVNZ5I/A6+Q-H_CS4Y]%
MMO%&G>)53X\_L<?\%L+_ .!_@F#X7?$;XQW_ ,1+_P""7[9/@1-!TC]L6?PK
MX@^%^M^*OVK_  /\4_V-+[Q_XSO/&FF:/\2/&'PP^ ]AXM^&GB/X@Z/-XCUN
M[>]B\+ZQJ?BGP_+/X@N_ZM:* /Y[?B+^R?\ \%+/$7_#RWXC?#WXA_'+PE\0
M?%WQ@\)ZW^Q-\/\ 7OVKKN#X;WGP.U?PQ\'H?CGX TC1](\3^)=&^$OC7Q=?
M>$/B?8>!/%>IVMLOPSU7QMHWB'P1/X:D&N7<?@WQ\_8B_P""AS?M9?!_X^_L
MS^"/C[X:L_!/P%_96^&R^(?&?[8/@SQ%\1!9^#_V[O$?QT^.7P^^+6MZQ\0[
MG4/BSH5S\!?$NJ^"]&L-=U;QCX=O+B\71Y;O49=/T[Q!:_U%T4 ?S=:A^SK_
M ,%7?%'QZ_;9U!W^.WPH^!GQ5\"ZGI_P9MO"7[76B?%'7]+^)/A']J%_%GA_
MQIH&F>.?B/X8M?!GAGXG_!.Z;1]9^'?@Z?X+VF@>$$G^%$?B/3-9TO2/BAJ-
MJS_9D_X*_:I\3O$_B?QG\1?%NA>!Q^QWH'A;X>?#+X5_'"?5O#EI\2I_V4/B
M#\._&WPT\8^-_'7Q/T+QG:^,5_:-NO!'QD\+_'FV\/\ Q \;7%Y:6&C7GQGT
M'PWH^L6?B/\ H[HH ^'_ /@G?\%OBY\$_P!E+X0:+^T-XR^+7C/]HC6/AS\-
M[_X^W?Q9^,.H_&>YM/C!I7P^\,^&/'B^$_$%QJ>IZ1IWA74]>T.\UNTT[PXU
MMI=Q=:E=:O<6RZOJ6I/)]P444 9.OJS:%K2JK,S:3J*JJ@LS,;.8!54 EF)X
M  ))X )KA?@E87NE_!SX6:;J5I/8ZA8_#[PA:7ME=1-#<VEU!H-C'/;W$+@/
M%-#(K1RQN \;JRL P(KO=:T^35]&U;2HKZYTR74],O\ 3X]2LF"WFGR7MK+;
M)?6C$@+<VC2B>!B0!+&AS7\NB_\ !MO\;@ /^'XO_!2LX')_X32?D]SSXM8\
MGU8GU)ZUTK$M8.>#Y%RSQ=/%N=WS*5/#5<,H<MK6:JN;=[W225KLR=).O&OS
M.\:$J/+96M*M"JY7WNG!12VLV]S^IZBOY8O^(;CXW?\ 2<3_ (*5_P#A:3?_
M #64?\0W'QN_Z3B?\%*__"TF_P#FLKF-2K_P6$!_X?O?\&]IP<'Q_P#'X XX
M)%AX1) /0D!@2.V1GJ*_JGK_ #]OBI^P7XY_8$_X+\?\$6? 7C+]M#]HS]LA
M?''BGQEXMTW6/VA=:DU>]\#&U75=(N],\,;]6U-;>TUDP6]WJ0'DM)/9VQ8R
M!5$?^@30!\J:S_R?!\.?^S5/C3_ZMWX!U]5U\J:S_P GP?#G_LU3XT_^K=^
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MC\'AY-=W3I4:[CZ.I+U/]>M)(Y5#Q.DB'(#(RNI(Z@,I(X[\T^O\B/0_CO\
M'7PQ(DOAKXW?&+P_)&XDC;1_B=XVT_8ZG(91;ZVBA@><XSFON7X0?\%EO^"F
M7P5FL/\ A&_VL?'_ (HTW3B@CT'XI)I7Q-TF:%.#;3GQ78WVJB%U)5C;ZI;S
M+D-',CJK#/$>%^80BWALSP=:2O:%6CB*%^RYTZT4WMK&W4UP7TBLAJS4<?P_
MFN$@VDZN'Q.#QBC=V;=.4<+4:BM?=DY.UDKV/]/>BOXPOV9_^#J/Q1:7>EZ'
M^UU^SOI>IZ:?)M[_ .(7P-U&YLM1@RRK)?W7P_\ %5W=V]YA2SR0Z9XHLS@
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MT%%U<//VD%/F<'+EE&TE"<)2C:;O'F2DG*,DX3G&7Z+>&/VI?A/\./A%X+\
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M[GXT?$*PO]/\/ZI9VUY<O'(/A_H<>N>/[A8D58;G1])4[3<QAOVE_P""=_\
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MQ(G@[QD8GNKOP-<W+F0V%_&@:;4O E_,Q:_TU=\^B32/JND!?]*M+G\Y\1>
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M^(_AK4O"?BK2G*W&FZE"46XAW%8[_2[M0;;5=+N0N^UU"QDFMYD(.Y7W(O\
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MT5/$]U+XE^&DUPX5+#XBVEIY=[X?CD; BM_'^C6PT]8\JC^(=/T>0_/,Q/\
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M +-4^-/_ *MWX!U]5U^7'[<J>*I/B#JR>"4U]_%3?L>?%3^QT\+"^.OF8?M
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M2PTJ+1+/6/$%E-<WEOI,-Q/=Q6$;QW$2BW2YN;B95VD[Y7.><5K?"?\ 9J^
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MZ1=7.HVFB7UYH6C0:_K#>']$?7-6@1K?31JFLK]@M/.SNF93)Y<;!Z\0UO\
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M'3R]Y+F^)RVC'&YG6JY)6QN8TZN#GA,N]C&AFT:.68>JE3A-RFZL7S4,2_\
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M/A-_\T='E?\ !,__ *+S^RQ_X>#X3?\ S1U^:G_$*A_P3'_Z$#3?_ #Q7_\
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M_P#-'7YJ?\0J'_!,?_H0--_\ /%?_P \2C_B%0_X)C_]"!IO_@!XK_\ GB4
M?I7Y7_!,_P#Z+S^RQ_X>#X3?_-'1Y7_!,_\ Z+S^RQ_X>#X3?_-'7YJ?\0J'
M_!,?_H0--_\  #Q7_P#/$H_XA4/^"8__ $(&F_\ @!XK_P#GB4 ?I7Y7_!,_
M_HO/[+'_ (>#X3?_ #1T>5_P3/\ ^B\_LL?^'@^$W_S1U^:G_$*A_P $Q_\
MH0--_P# #Q7_ //$H_XA4/\ @F/_ -"!IO\ X >*_P#YXE 'Z5^5_P $S_\
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M;_YHZ/*_X)G_ /1>?V6/_#P?";_YHZ^-/^(7C_@BY_T:S>?^'0^(W_S14?\
M$+Q_P1<_Z-9O/_#H?$;_ .:*@#[+\K_@F?\ ]%Y_98_\/!\)O_FCH\K_ ()G
M_P#1>?V6/_#P?";_ .:.OC3_ (A>/^"+G_1K-Y_X=#XC?_-%1_Q"\?\ !%S_
M *-9O/\ PZ'Q&_\ FBH ^R_*_P""9_\ T7G]EC_P\'PF_P#FCH\K_@F?_P!%
MY_98_P##P?";_P":.OC3_B%X_P""+G_1K-Y_X=#XC?\ S14?\0O'_!%S_HUF
M\_\ #H?$;_YHJ /LORO^"9__ $7G]EC_ ,/!\)O_ )HZ/*_X)G_]%Y_98_\
M#P?";_YHZ^-/^(7C_@BY_P!&LWG_ (=#XC?_ #14?\0O'_!%S_HUF\_\.A\1
MO_FBH ^R_*_X)G_]%Y_98_\ #P?";_YHZ/*_X)G_ /1>?V6/_#P?";_YHZ^-
M/^(7C_@BY_T:S>?^'0^(W_S14?\ $+Q_P1<_Z-9O/_#H?$;_ .:*@#[+\K_@
MF?\ ]%Y_98_\/!\)O_FCH\K_ ()G_P#1>?V6/_#P?";_ .:.OC3_ (A>/^"+
MG_1K-Y_X=#XC?_-%1_Q"\?\ !%S_ *-9O/\ PZ'Q&_\ FBH ^R_*_P""9_\
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MDE9[34=.NK:^LKA8[FTN(;B*.1?S=\+?\$M?V<_@3I<&O?LE:!8_"+XV>#/
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M+:P^7\6/#<X,S@LHD,%U((4P"3-,8X5Z-("10!^E]%?FQ_P^,_X)7?\ 1_\
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M:QJ*:9:;-/T^35=;U75-9U&+3+6SM[W5]1OM3N8I;ZZGG?U^@ HHHH ****
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MSL]%^8\<^,?AUX=N5'B;B/"TLR4%..29?&>:YU)-7AS9?@95)X6,U;DGCZV
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MY4%NMUX>O)BOS,CV%GYC])4R2?W _9F_X*+?LP_M1O:Z-X/\9CPMX]GC0O\
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M):PW'Q>UG3K@K<"&Y EL? T,\+[HA<P[;SQ"%(D\A[?3VV>9<!OP>
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MV;R6FH6,T4T,F2Z)_1MUZUY]\<O@;X5_:E\!6'@?Q'J&G^&OBAX3MYH?@O\
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M/C@ZU>OBI5L2HXI5(Q<*5"G1PM)>U]E=?O>6.D>Y_HBT445_"1_405_G+?\
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M[NROK2=$N+6[M+B.2"YMYHUEAE1XW0,I%0NH5V4,KA690RY*M@D9&0IP<<9
M/J!7\JJI!S4$[RE3]JK1DXN',H<RFHNGK*2M'VG.XOG4'"\U_.#PU94)8B4%
M&E#$K"3<JE&-2.(=&>(Y'AW66*Y52IS<JRPKP\9KV,\1'$2CAY-HHHJS ***
M* "NJ\">.O$'PO\ '/@OXE^$[N:P\3_#WQ7X?\:Z#=P2-%+#JGAK5+;5K4K(
MA#*)'M?)<#[T<CH058@\K2$ @@\@C!'J#4SC&<)0DE*,XRA*+5U*,HRC)-:W
M3C)IJVJ;1I1JSH5:5:G*4*E&I3JTYQ;C*,Z<X5(2C):J490BTULTGT/]=3X
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MY..*_1-_^"'7_!2V-&ED^"'AI8E8J9C\7/ASY&X=0)QKAA;'?:Y [D5ES_\
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MCAZM5LH4>.O GQ9R%4W*R2Q&)P69YUA()-VG*%:<59M-Q5S]0?\ @WD_9_\
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M$95JLJE;DI>S@L16DU3BI3K3:](_9]^'C^(]?7Q;J4!_L3P].&LA(OR7^LH
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MC/X>N/LNM0:)J$=S<:?)YTUNKS0$),;:2>VN(8KR-'M)I8)HXIW>-PO\B_\
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MIC%S=6VB?$OX&:E-;VYE98A/-';-'$9&5 [*6(7)K\\/^']GP+^S&Y_X4?\
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M/'$8^A6>'Q,88V,HTYT<O<,3A(>UH^VE6A2QF-K+#574IT\+6ISUOAOXNO\
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M>M^ -<T[5_$_B?7?&_PLTG5/B/X(^'?@IM;\=:#XQL]0^$\'A6^L;JZU6-=
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M>!;UO--2_8U^)OQ;^)?[1MU<V?@'P!X9U?X_>-O&WA_QIJ/A753\4O$$FH?
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M=<NK&ZECL(;%I;E+>2%1/JT4T4)2*T<Y MM)>0QWDBDW+W#Q*ZI$-TGY%?\
M#W_P&;6WLS_P2_\ ^"KK6MK.;J"%OV(M898[AOOS#=XL+,[X D9BWF !7W
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M]9I%<VW[ W_!9'4+O2%TB#PE&W[$26Y\.0Z/X@N-?L7W2>)!#K+P2W,EK/\
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MJ]S-/9I8RW=E&P<3%Q_:I0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I :D# 2(  A$! Q$!_\0
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M_P""^#_XFC_A7?@7_H4]"_\ !?!_\376[V]?T'^%&]O7]!_A0!R7_"N_ O\
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M (T;SZ#]?\: +/F>WZ__ %J/,]OU_P#K56WGT'Z_XT;SZ#]?\: +/F>WZ_\
MUJ/,]OU_^M5;>?0?K_C1O/H/U_QH L^9[?K_ /6H\SV_7_ZU5MY]!^O^-&\^
M@_7_ !H L^9[?K_]:CS/;]?_ *U5MY]!^O\ C1O/H/U_QH L^9[?K_\ 6H\S
MV_7_ .M5;>?0?K_C1O/H/U_QH L^9[?K_P#6H\SV_7_ZU5MY]!^O^-&\^@_7
M_&@"SYGM^O\ ]:CS/;]?_K56WGT'Z_XT;SZ#]?\ &@"SYGM^O_UJ/,]OU_\
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M*H^;_M?I_P#6H\W_ &OT_P#K4 7MZ^OZ'_"C>OK^A_PJCYO^U^G_ -:CS?\
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M>OK^A_PJCYO^U^G_ -:CS?\ :_3_ .M0!>WKZ_H?\*-Z^OZ'_"J/F_[7Z?\
MUJ/-_P!K]/\ ZU %[>OK^A_PI5.XA5!9CT"JQ)P,G  ).!S]*H>;_M?I_P#6
MKX*_X*>^)/$'A?\ 84^/6O>%M?UOPSK]A8>"FT_7/#FJW^A:U8//\1_"-M.U
MCJNESVE_:--;336\S6]Q&9;>:6&0M%(Z-ZN0Y5//<\R;)*=>&&J9QFN7Y7#$
M5(3J4\//,,71PD:TZ=.4:E2%)UE.4(2C.48N,9)M,XLRQL<MR['YA*G*M' 8
M+%8R5*,HPE5CAJ$ZSIQG).,934.52DG%-IM-:'Z$>7+_ ,\I?^_4G_Q-'ER_
M\\I?^_4G_P 37^?E_P -"_M!_P#1??CA_P"'<^(/_P T5'_#0O[0?_1??CA_
MX=SX@_\ S15_3W_$J&<_]%MD_P#X9,V_^;3\>_XC7@/^B>QW_APP7_S.?Z!O
MER_\\I?^_4G_ ,31Y<O_ #RE_P"_4G_Q-?Y^7_#0O[0?_1??CA_X=SX@_P#S
M14?\-"_M!_\ 1??CA_X=SX@__-%1_P 2H9S_ -%MD_\ X9,V_P#FT/\ B->
M_P"B>QW_ (<,%_\ ,Y_H&^7+_P \I?\ OU)_\3365D&71T&<99'49ZXR0!G
M/'M7^?I_PT+^T'_T7WXX?^'<^(/_ ,T5?M-_P1"^*'Q-\<?';XX:?XY^)7Q!
M\;:?8?!W1[ZQL?&/C7Q-XILK&]?QSI]L]Y9VNN:G?P6MT]N[0/<01QS-"QB9
MRA*GYKC'Z.F9\'\,9SQ-7XKRS'TLFPL<5/!T<JS*A5Q"EBL)AN2%:MBJE*G)
M/%QGS3A)6@XVO*+7KY#XJX//<XP&44\EQ>&GCZSHQKU,;A:D*35&O6YI0IT8
MSDK4'&T9)WDGLF?TQ;U]?T/^%&]?7]#_ (51\W_:_3_ZU'F_[7Z?_6K^<3]7
M+V]?7]#_ (4;U]?T/^%4?-_VOT_^M1YO^U^G_P!:@"]O7U_0_P"%&]?7]#_A
M5'S?]K]/_K4>;_M?I_\ 6H O;U]?T/\ A1O7U_0_X51\W_:_3_ZU'F_[7Z?_
M %J +V]?7]#_ (4;U]?T/^%4?-_VOT_^M1YO^U^G_P!:@"_N7^\GXLH/Y$@B
MC<O]]/\ OM?\:_AQ_P""B>H:E'^W3^U+'%JFJPQ1_%.Y6.*'4[^&*-1X?T A
M8XHKA(XUR2=J*HR2<9)KXS_M/5O^@QK/_@WU+_Y*K^K\F^B]4S?)\IS9<;4\
M.LURO+LS5!\/5*KH+,,#A,:J/M5G$%4]E]:]G[10@I\G/R1YN5?BF/\ &*.!
MQV-P3X>E5>#QF*PGM%FD8>T^K8BMA_:<GU&7)S^QY^7FER\W+S.UW_HM;E_O
MI_WVO^-&Y?[Z?]]K_C7^=+_:>K?]!C6?_!OJ7_R51_:>K?\ 08UG_P &^I?_
M "57I?\ $IU3_HO*?_B-5/\ Y]')_P 1LA_T3<__  [1_P#F _T6MR_WT_[[
M7_&C<O\ ?3_OM?\ &O\ .E_M/5O^@QK/_@WU+_Y*IK:IJP (UC6?O)_S%]2_
MOK_T]4?\2G5/^B\I_P#B-5/_ )]!_P 1LA_T3<__  [1_P#F _T6]R^O\Z-Z
M^OZ'_"L/2I<:1HWS?\P71SR"22=-M2221DDGDD]35[S?]K]/_K5_'\ERRE&]
M^64HWVORRE&]NE^6]NE[=#]U3ND]KI.W:Z3M\KDUVR_8[SG_ )<[OL?^?>3V
MK\Z:_0FZE_T2[^;_ )=+KM_T[R>U?GM2&?;/@J4KX0\,CGC1K+L/[E=-YQ]_
MR%<-X/EQX4\.#CC2+/L?[AKH_.'M^1H UO./O^0H\X^_Y"LV&56FB!VD&1 0
M0V""P!!]B.*_C5_:$_;6_:_\/?'[XY^'] _:9^,NC:#H/QA^)>C:)H^G>,+N
MWT_2=(TOQCK%EINFV%NJ$06=C9PPVUM""1'#$B X6OTGPV\,\S\3,;FN!RS,
M\NRRIE.#PN-K3S&ECJL*T,5BZF$C"DL#"<HSA.FYR=1*+@TH^]<^2XMXOP?"
M&'P6(QF#Q6,CCL16P\(X6>'A*G*C0C7E*;Q$DG&49J*4->9-O2Q_9YYQ]_R%
M'G'W_(5_#+_PW=^VM_T=7\<?_"VO/_C='_#=W[:W_1U?QQ_\+:\_^-U^M_\
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MC<PP.6T/K.8XS#8'#\\*7M\76A0I>TJ<W)3YZGN\\^27+'=\LK;,^X?./O\
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M_ 9WD^:3J4LMS3+\PJ4H*I5IX/%4L1.G3E+D4YQIZQ@Y^XI/1RTW/0_./O\
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MUBVU"T6WENM5M/,R/GNR_;"UOPM\.?%/@3X4_!SX.?!K6/B%8^"].^)7Q)\
M:?XK3Q;XVL_ FHV^L:/')8:YXFU;PKX9:[UBT@U+6G\+Z)IG]I7!N-ZQBY<K
MN_%O]N/Q;\8=%U?0=9^$?PC\.V/C_P")'A7XK?'4^$X/&.G7'QZ\7>$=/CT[
M3W\:SW'B>ZDT'2KB'[3-=Z;X';P]$;Z\FOH7CN@)&_O^AE7B+',X5)X[&O*_
M[;K8FE3GG>72Q%#+98G 5*]#&4_JE>&-H5L!2S+!930I8I3PN/Q>&S/%4\#2
MI?5,/_,M3%<*O!RC'#4/KG]GTZ,YQR_%*E4Q2HXF-.I0G[:G+#U*>*GA,1C:
MDJ/+6PU"KA*4\3.?MJO/?MC_  8^&_P/\6_":S^%MWXSN/"OQ(_9_P#AM\8&
M_P"$]O\ 2-0\06E]XWM]0NI[6:71-.TW3H8(8;: BUABN%MYFF1;VYC"/7LU
MW^QOX'\*_L9>._B_XVUOQ?!^T/H&A?";XEP>!K&6P@\*^$_A?\8?&Z>%_!4?
MC"UETR?4YO&'B'1=/UCQ@EG#J-E'H^B7WA^6ZAD:YD0YFL?MF?"WXJ^,/"WB
MSXS?LQ?#)+;X4?!+Q'\-/A]X7\*-XTU[2?%,EOX7N/#7PM\-^-E\<>,M6M=/
M\,> KO4KOQ2FO:9977BB[O[&VM+B>Z\^.XM//=*_;[_:CM?@Y\1?@GKWQ.\1
M^-_#'Q#T7PGX<^V>+-9U"_O_  ?X?\,73276B>%X8Y8;)-*\6::4\.^);348
M+Q;G0XUM;9K=\R'IA0\0*^69!@J2JX+'95F668C/\5F&:8:=7.L'+-L;5J83
M#8[ X3$T:]/#Y2Z3S:-3#X.>+JO!X/"UX5:6*E5QD^&*>,S/$3<:^'QN$Q='
M+:.&P=6,,OKK!8>$:]7#8BM1G3G5QJFL%*-6O&C#V^(K4Y0G14/J[XR?L+_"
M70O%OPT\.?#[0_B5I/PQ\9_%GX7?#W5/VLM7^.'PA^)?PJTZW\9V.FRZTFH>
M"?".B:=KG@K5XM1U-M-T-_&?B"QLKBYT\JRW$5_!)'^P'_!.[]C?P?\  #Q=
M\5_B;X4\*?&[X<O=2>(/@M?>$OC;J7A36]1\4:?X:\4Z9KGASXK>%;_POI>C
MQV/AWQ590W(AT>[M[XQ9AFM=5O(099/YO]<_:S-S\/9_A3X+_9_^!WPK^'GB
M3Q[X4^(OQ3\+>"+3QPVG_%K6O!LB2Z-IWB,Z_P"+]7G\/^&8Y1,YT'P9-H=O
M%YY6UD@6-0W[,?\ !(;]I/5OBG\1_B1\+M$^'G@#X/?"GP+\,)/%NC?#_P"'
MW_"4WUG>>,_$OCG0;+6?%FO^(?&NO^)?%&MZK)IMI;:98)>:H;32M/1[6R@C
M21L?E/BIE/B!0\.,WEC<SQ4L#@\+6CFBQ>987$5,=ERS3*90KXZ%"I7A/,\9
M5J4Z%+"8)RRO X7"T\9AZV!Q>)Q>#?VG!N,X8J<58%8?!T8XFO6IO!NAA*U*
M.'Q3P>-4J6&E4C2E'!T(QE5G7Q%L9B:U:="K#$4*-&NOW^\X^_Y"JU[?I8V5
M]?RAWBL+&]OY4C">8\5C:RW<J1[B%\QXX66/<RJ7(W,HR12\X>WY&LGQ!,/^
M$=\2=/\ D6_$/8_] :^K^(:<5*I3B]I5*<6KVTG5I0>O32;UZ;]#^AI-J,FM
MU";7JH3:_%(_'E/^"[O[,SJKCX0?'O# ,/\ 1?AZ>",C./&6,XZ^]._X?M_L
MS_\ 1(/CW_X"?#W_ .;*OY<+'2]5NM-N-1M-)U>\TW38T_M+4K/2M0N]-TT,
MF]3J.H6UM+9V *?.#=S0@IE_NC-:R^$_%SV*ZI'X/\7R:4\!NUU6/PKX@DTI
MK0(93=KJ2:<UBUH(E:4W0G-N(E:0R! 6'^A4OHZ^$L&U+"9K!J?):?%6*BU.
MR:@U.$'SN+4E!I5'%J2@XM2?\N+Q4XWDKJO@I>[S>[DU&2Y4[.5XRDN5--<U
M^5--.2::7]//_#]O]F?_ *)!\>__  $^'O\ \V5'_#]O]F?_ *)!\>__  $^
M'O\ \V5?S#7?A3Q=86;:CJ'A#Q?I^FI&DKZEJ'A7Q!8Z;'%(5$<LE_=:=#9Q
MQ2%T6.1YE1V=%5B74&A8Z5J^J17D^EZ-K.JV^G1B;4;C2](U+4H-.A96<3:A
M/8VL\5C$421Q)=/"A2.1PVU&(2^CMX2RBYQPN:R@FHN<>*L5*"DVDHN<82@I
M-M)1E.,FVDHMM)C\5.-TU%U\&I-747DM%2:LW=1;4FK)NZBU9-WLFU_41_P_
M;_9G_P"B0?'O_P !/A[_ /-E7JWP,_X*^_ 7X^_%_P"'_P &/"_PS^,>C>(O
MB+KC:!I&J^(;?P4FB6-TNFW^IF;4FT[Q1?7PMS#I\T8^RVD\GFO'\FS<R_R/
MV>F:KJ-M>7VG:1J^HV.FH)-2O].TK4+ZQTV,H9!)J-[:6TUK81F,&0/=RPIY
M8:3.P$C[C_X)S>&_$UM^V]^RYK%UX7\3VNC'XC"4:S=>'-;M]',4_A3Q&()5
MU6:P33VBG,D8@E%R4F,D8B9RZY\7B?P#\+LIX<XAS'"X;,Z>-RW(\YQN$]KQ
M-B9QCC,'E6.QF&4Z%2$/:VJT*4W0DE*K3NN7DGS'H91XF<98W-<KPM:MA)8?
M%YA@</6Y,HHQ;H5\;AZ%5QJ1<N3W:DXJHFU"6M^:/*?VK^<??\A1YQ]_R%9/
MG#V_(T></;\C7\&G]*G\D'QXTCX9>)/^"FO[5&B?$_0_!&NZ;>^/;\Z/%\3/
MCC=?L_\ @&SU&'3_  B+R[U_QMINDZIJ]W.FDR7@T30-,?3Y;[4@DUS<S6EM
M+:R]_P#%K]E/]F;]G_Q%^TO\1=>^&/Q ^(/PN\ _%3]G_P"&/PP^'FJ?$35O
M"T-W:?%S0UU_Q+X]@\<^'DN=:\5>&;2"WO;;X=3F6--9+1/K.Y@RQ>!?MA?%
M?5OA1^W[^U_?Z?X0^%WCJSU[XA7&DZMX:^+?P^T?XB^%[J"WTSPY?6MS'I>J
MF&6QU&TNH5DAOM.O;29XVDMKG[1:R/ ?-++]OO\ :*C\6^//%>NW/PW\=P_$
M23P1-KG@CQ_\-/#WB7X;:=<?#-T;X<W'A;P6XM+#PW-X(5!'H!T^55B1G:^2
M^F;SA_HYE^2<78W*.$\9D^-K4LJEP/PA1Q6!7$-;+?K[IX'AW$5J>#=##UYY
M3BJF&IXC#SQ\U"/LY-4:M2IBZRPO\IXC'Y'A\;G-#'X>G/&KB'.ZE+$O+*>+
M^K<V(S2E3EB%5JTXXVC&M.E5CAHN3YHIU(1C1@ZWWI\//V+?V6;?]JKXT?LR
M>+M)T_Q/:^%_&.N6F@ZWK/[1$W@CXTMH6I?#VR\9>"/#OPH^#NGZ1;V7Q*\4
MV5[=S:5KFI>(=56RU">*W2&QLWBNH[CX"_9=^$'@+Q;K7[2?BCXKZ!XA\1>%
M_P!F;X.^,_B5?_#6'6;GP;K7BKQ#I/B+3_"VA^%_$NMZ:DNI^&;2VO;^6[\2
M2:6GV^(V$EM:L%+$U_#'[<?QR\+^)->\>+8_"/Q-\3M:\8>(_'EG\5_&WPE\
M*^)OB7X0\4^*;9;35-0\%>*;J**;1(HH(XH](L9[;4;'0TB2/2;>TB,D<FI:
M_MH>*/!=I\,+7X6>%_#>G2>&_A5XW\ ?%^Z^('AKP]XQ7]H34OBKXGNO%?Q%
MG^)]DMO:KXD\-27S:?:^%K'4[J35M+M[&2=[Y'O);=?2H9+Q_A:68X:IC:^/
MJYGEN0X18QY][*GAL=E5+"U\]QU"7U9U,MAQ!3HXC*L/*E1CC,/C<6L=*C0P
M>&EB:G+4QW#%:IA*T,/3PT,'B\RKN@LN4Y5L/C9UJ>78:K'VRABWE<ZE+&55
M4J2H5:%#ZNJE2O55&/V)X[_97_9A^%OPR\0?M97WP[\6^,OAEK'PH_9A\7^$
MO@)<_$KQ!HG_  C'B?X\:MXBL/$T>J_$/3X/^$LU;0_#=KX7N+GPLDZ)=:A=
M:E#'JLLD$25VGCK]B3]ESX >+;%/&OA'QU\6O#'QB_:N\'? CX>V(\?ZKX.U
M+X6>"_%7P[\'^-[K7+RZT&V>3QCXTTK4/&EOIFGV6LI'I-QI^D-<7L#75Q+G
MX"M_V]_V@U\5^,?$FJ?\*P\4:/XX\.^!/"FL?"WQ7\,]#UKX.6?A_P"%\XN?
MAOIWA_X>R20V&AQ^"+DS7&@O9W7FQ3W5U+=O>/-E;/AW_@H1^TQH&M>+?$%_
MJ_@/QWJ7B_XF6_QC#_$KX=Z#XSM_!OQ2M]-30;'QQ\/+2]$-OX/UG3-$BM-)
MTT6:36%I8Z?80I9$VY=_+?"WB8H-3SRI6BH-5:4.*<7AYXK#3IS6 R^GB8Y;
MS8'%9)7=.MC,ZBG5XCITI4:T;57%]G]K\(W]W+H0?,G"<LHP]6-&LIIXK%3I
M/%VQ%',*:E3H9>WR95*:J4W[G,O[=Q$M@L=A&[O'8116,3N%+O%9Q);1,Y4*
MI=HXE+E54%B2 !@ \X^_Y"N?L+R6YT_3KJ>3S;BZT[3[JXE8?-+/<V<$\TA
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M+)<-]7K83#X[%_D5*GP7&%!U9QE?!5OK$(U\7.K2Q*]K.3A44**Q%64W2PF
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MNU?P[XAUW2I)F^%_B_5+R^TK^QK[3K2\_L^R2ZM([>.[CC@UK']OCX+:S?\
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MC]*UWS+@;1+_ (3>(-O^QEE9^_\ @I_N?$>EO]LRO37_ *!,9W-#[0??]?\
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M;V]?T'^%&]O7]!_A5;S#_>'Z4>8?[P_2O[4YE_3C_F?S[R^<OO99WMZ_H/\
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MXN*_"2_['&6]$^F.[GYF;QZ']/\ &C>/0_I_C5?>/0_I_C1O'H?T_P :_O\
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M%[^WTJ7S/;]?_K5_KXVKOU?YL_AA)66BV71=O0MY'J/S%&1ZC\Q53S/;]?\
MZU'F>WZ__6I77]?\.%EV7W+_ "+>1ZC\Q7V-_P $]G"_MN?LU$'I\1&Z8/\
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M^DB_^-88E?\ 50\.?^I.8'Z5X3+_ (S"EJW_ ,)>:]O^?6%[(_6CS?=OS_\
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M^G^-?LK_ ,$5)!_PO#XWX./^+/:1UQ_T/>F?X?SK\7][>OZ#_"OV5_X(J/\
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MD2LO7?\ D >(/^Q?UW_TTWE6F=4^\0/\C_'O6-KMS#_8'B#YQ_R+^N]Q_P!
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MQ_PQ_P#2(%FJ]%%046%3*@[0<@>E+Y9_NC]*T(808HSCJBG^'N,U+Y _N_\
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MS_PKXO\ ^"AOQ(BUW]CCXSZ4#S=V?A%1_P!L_'GAF;T_Z9U_&O G_);\'?\
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MF1G'O7\T?2<=^&N%ME;B+&;:?\R.1^N>$'_(VSG_ +%=#_U8Q/1OL9]OS/\
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MDG*$8":3>/D]>/EZG'-?YUTOXU'_ *_4?_3U$_JF?P3_ .O=3_TW4/XJ8O\
M5)_NBI*AA8&*,Y'* ]1Z5+D>H_,5_K YRN]MWT\V?Q0MEZ+\D+129'J/S%&1
MZC\Q2YY>7W#%KZ._9!7?^T[\%4_O>,&'_E#UFOG#(]1^8KZ6_8W42?M2_!!,
MCYO&3CC!/_(!UH].]?-\93;X/XMV_P"27XBZ?]23-#ULA_Y'N2?]CC*O_5A@
MS^BK[&?;\S_C0+)CP "?09_QKL+?1I;APL:,V3V0?KZ?SKU;PI\+[[5)(V:!
MPA()_=\X],=/<_\ ZS7^8!_81_*#^UM&8OVF_C=$1@IXYN%/U_LS3#W^M?/%
M?6/[>.FC0_VS/VD='(V_V=\2KJVVXZ;=%T5B,<XY<\=J^3-Z^OZ'_"O]0.$)
M-<(\*6;_ .28X=_]4>5'\=Y[_P CS.O^QQFG_JQQHZBF[U]?T/\ A1O7U_0_
MX5]%S2[O^OD>6.I#T_%?YBDWKZ_H?\*0NN.O=>Q]1[4<TN[![']7%C9M]@T\
M\<Z?8'J>]I"?6OT)_9]LS_PJ[2NG_(5U_N?^@C)[U\0:9IC2V&FA S9TW3L8
MC!S_ *%;]/S'M7Z*? /2'MOACI,4BLK?VEKCE2HSA]0=E/.#@@Y'\Z_R@J?Q
M*G_7RI_Z<JG]K1^&/^&/_I$#LGLSL?..$<]?12?6O/\ >/0_I_C7M\E@1%*>
M>(I#]P=D;WKPNH*/I/PW9;_#^C/M?Y].MFR,X.4[?*:VOL _NO\ K_\ $UH>
M$+,R>%/#K[0=VD6C9QURAKHOL!_NC\C_ (T <C%8A98FPPQ+&<G( PZ\DE0
M!UR>*_@U_:>^ _QUU#]I7]H?4M/^"'QDO],U#XY?%>^T[4K+X6^.KO3]0L;O
MQUKD]I>V-[;Z#+;7EG=V\D<]M=6\LD%Q"Z312/&ZL?[^/L!_NC\C_C4XBNP
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MU(^H/AX4W_A0/Q[_ .B%_&C_ ,-3X^_^9^O]'7R[S_GO/_W^E_\ BZ/+O/\
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M/<WT]W/(]M%;6[& @'GWB[]NGXTZ!XU\;?%&"T^'4'[,?PW_ &W?#7[$VO\
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M$_3_  SH?BWQ;$&F\4>/+SPEJ>H:Q=)!;SP#1H5TN@#A? W_  4'\1>-M?\
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M ?IA]LLO^?VS_P# F+_XJC[99?\ /[9_^!,7_P 57YGT4 ?IA]LLO^?VS_\
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7\V]C_P!UO^^3_A0GWU_WE_F*Z:@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $_ BH# 2(  A$! Q$!_\0
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M\/\ [1OC[X\:I::9^S?I?@FVL--^'G@CQYXS\5?%%-=O-/TO4OB+IDVK^&/
M.G:-X8O-/O+G7(--MYM1\1:M)J'V#2H'L;:&TO;F]!A]J^ ?Q;N_B_X-U+4]
M;\/IX5\8^#_&'B7X=^//#T%[_:5AI_B[PC>BRU)](U QPR7NBZC$]KJFDSSP
M0W'V*]BBN(_/BD9@#K_^$]?_ *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00
M?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH
MX#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/
M'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#
M_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?
M\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\
M\$$'_P L:[^B@#@/^$]?_H2/'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:
M[^B@#@/^$]?_ *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_
M (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ_
M_P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/'_\ X((/_EC1
M_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#_P"6-'_">O\
M]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\
MP00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B
M@#@/^$]?_H2/'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_
M *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_
M /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\
M)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/'_\ X((/_EC1_P )Z_\ T)'C
M_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#_P"6-'_">O\ ]"1X_P#_  00
M?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?\)Z__0D>/_\ P00?_+&N_HH
MX#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\ \$$'_P L:[^B@#@/^$]?_H2/
M'_\ X((/_EC1_P )Z_\ T)'C_P#\$$'_ ,L:[^B@#@/^$]?_ *$CQ_\ ^""#
M_P"6-'_">O\ ]"1X_P#_  00?_+&N_HH X#_ (3U_P#H2/'_ /X((/\ Y8T?
M\)Z__0D>/_\ P00?_+&N_HH X#_A/7_Z$CQ__P"""#_Y8T?\)Z__ $)'C_\
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M9B H!)( K\^_AG^UYXJ\9?&SXHQ:SHV@:5^SSHWP7U3XL_#/7X(M0D\9^)M
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M/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\
MH)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@
MU7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z
M*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$
M:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB
M_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_
M .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:
MMO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(
MO_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y
M)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=
M_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^
M@GXB_P#"@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"
M@U7_ .2:/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:
M/^$:MO\ H)^(O_"@U7_Y)H Z*BN=_P"$:MO^@GXB_P#"@U7_ .2:/^$:MO\
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MU?9>'G_)=\'_ /90Y9_Z?F?(\??\D1Q9_P!B#,O_ $S _F*N/^/>?_KC+_Z
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M.IZ=8^+?"-XMGJ$VCW[Q037>B:I#+:ZKI,MS!%<K97L4-RIGAD=@#W"BBB@
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M?_KC+_Z U?L)_P %#O\ DG7[&7_9(8O_ %'/!M:_M)O^3"Q_['>$7_E_DO\
MD>A^S6_Y2"I?]B7,/_59G1\Z_L*P_:/VL/A%!YT]OYE]KP,MM(89U \/:B2$
MD )4-C#8'*DCO7]-_P#PC0_Z#WB7_P &I_\ C-?S+?L&?\G;_!__ *_M?_\
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M)UMK#3M/^(6AWE]>W#AF6"UM;>XDGN)F56*QQ([D*2!@&O0O^$:'_0>\2_\
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M27O>SA&.R05\2_\ !1?_ ),U^-?_ &!]%_\ 4HT2OMJOB7_@HO\ \F:_&O\
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MBM##8?$8FHI.GAJ%?$5%!)S<,/1K5YJ*;BG)PHS44VDY.*;2;:]&HK^6R/\
MX*<?MEM'&S?$3PV2R(2?^%=>$ADE02<?8>,GM7] W[-?Q1U'QO\ LZ?!SXB_
M$GQ!I"^)?&?@W2]4UC4KC^SM M+_ %6Y262<VUHK6]I 2B;_ +/;*%15+!0
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M/%TH4<!AL+)5XXW#45)U*+YI1]G4FN1^[=J6Z1]F4445_.9_004444 %%%%
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MK^&/H?\ _)O>(?\ LL<1I_W1<J_KY']O_32_Y.1PW_V1.%U_[KN<'2U\ ?\
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MU(2((BD( RH Q8[8TYSFO2_:5?\ */,/^ROR/_T]$U_9I?\ *1T?^R/XA_\
M4:9YA^R-_P G1? 3_LI&E?\ I%J5?U@5_)U^R;&TW[3GP)B2:6V:3XBZ6JSP
M%!-"39ZB=\9D5T#@ @;E888\9P1_5"= O"2?^$EUT9/3?8<>W_'C7\#_ $./
M^2,XQ_[*S"_^L]AC^[_IL?\ );\$_P#9'XO_ -:7%'245S7]@7G_ $,VN_\
M?=A_\@UQWQ U_0?A=X-U_P ?^./'.O:-X4\,6:W^MZF+9;\V=HUQ#:B7['IV
MDW=[/F>XB39;V\KC=N*[58C^PZ-&MB*U+#X>E4KUZ]2G1H4:4)5*M:M5G&G2
MI4J<4Y3J5*DXPA"*<I2E&*3;2/XKK5J6'I5:]>I3HT*%.=:M6JSC3I4J5*$J
ME2K4G)J,*=.$93G.348QC*3:2;/5J\1^+O[1GP;^!$^@VWQ5\9VWA2;Q-%J$
MVB)/IVKWQOH]+:U2^93I=A>B+R&O;8$3&,MYHV!MK;?F#_AX-^R%_P!' Z__
M .$9XO\ _F+KX4_X*7>*_#WCW2/V:?'?A'Q'?>*/"WBWP[XYUC0=4O;:6S-S
M83W'AGRIX[2YL=/O;?S<8>*[MXY5\M<HISGXGQPS#C+PH\.LWXR7#N(PN)P6
M)RO#8-<0Y9F-#+Z]3&YEAL+6IOEEA*E2K##5:E6$*=>+3BIR4H)I_?\ @1D_
M!WBWXE9-P55X@I8C!X_#9OB<9+A[,LNK9C0IX#*\5BZ-2//#&4J=*>)HTZ52
M52A).,G"+C-J2_4+PW^W1^RSXM\0Z'X5\/?%2QU'7O$>JV6BZ-8)H?B>)[W4
M]0F6WL[59;C1HH(VFF=4#S2QQJ3EW4<U];5_(Y^SFC2?M ?!.-)9(&D^*'@U
M%FBVB6(MK-L/,C+!E#KG*EE8 X)!K^K\Z#>$DCQ+KH!)( >PP 3T'^@]!TK\
MU\ O%//_ !4R?B/,.(,'E&#K91F^"P&&AE%'&4:<Z.)RR6-G.LL7B\7*5158
MJ,7"4(J&CBW[Q^F?2(\)>'?"3.^&<MX=QN<XZAG.38[,<5/.:V"K5:=;"YK#
M TX4'@L'@XQINC)RFIQG)U-5)1]TZ2OE_P#;4_Y-1^//_9.]:_\ 08J][_L"
M\_Z&;7?^^[#_ .0:^:/VRM'N;;]ECX[32:]J]TJ?#S628)WLS$^!"=KA+1&*
ML 5.&!P3CG%?TQPQ_P E+P[_ -C_ "7_ -6V7'\O<2?\D[Q!_P!B/./_ %5X
M\_DJG_X\I_\ KTF_]$/7["_MT?\ )O'[#O\ V3F[_P#48\#U^/4_%G/W_P!$
MFX/3_4-7Z]?MP6TD'[/G[$DCWMW=+-\.[MEBN#$8X/\ BF_!38A$<2,!M=8R
M'9_EBCYSN)^H_:/?\H^XK_L<87_U-R0\S]F__P I$Y;_ -BG'?\ JNSO7^NY
M\/\ P-_Y+=\&?^RK_#S_ -2S2:_KWK^0;X(J7^-?P=19'B9_BI\/T66/;YD1
M;Q7I2B2/<&7S$)W)N5EW 94CBOZU3H-X22/$NN@$D@![# !/0?Z#T'2O\[OH
M:?\ )/\ 'O\ V/\ (_\ U1XL_P!#?IN_\E#X>?\ 9/Y__P"K[!'25X)^U/\
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MC>A;Q'IH#ID%=R$[EW C(&01D5_7FV@WA)(\2ZX,]@]A@?3_ $&O\V?H9_\
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M$3_L*X8[_P#0+G7J?Z;_ $X&WBO#6_\ T"<5_P#J7D1TE?,7[:/_ ":A\?\
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M"7AFU\67L;0WGBBWT'2H/$5W"R)&T5SK<5HNI3QM'%&C)+<NI2-%(*HH'&>
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M),P_]5N='SW^P9_R=O\ !_\ Z_M?_P#4<U*OZCJ_EQ_8,_Y.W^#_ /U_:_\
M^HYJ5?U'5_#'T/\ _DWW$/\ V6%?_P!4N5']O_32_P"3D<-_]D3A?_5YG 5\
M ?\ !3G_ ),]^(/_ &%?!_\ ZDEA7W_7P!_P4Y_Y,]^(/_85\'_^I)85_;W
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M &1_$/\ ZCS/*OV1O^3HO@)_V4C2O_2+4J_K K^3_P#9&_Y.B^ G_92-*_\
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MQ/FW_JKS(_CM7_4#_KD/_0*_7G]K3_DRG]A;_L78O_4-LJ_(9?\ 4#_KD/\
MT"OUY_:T_P"3*?V%O^Q=B_\ 4-LJ^Z_:*_\ */&;?]C'#?\ J3E)\U^SI_Y2
M.R'_ + <5_ZA9R?G]\-O^2D?#G_L?_!?_J2:97]BM?QU?#;_ )*1\.?^Q_\
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M\:_^P/HO_J4:)7VU7Q+_ ,%%_P#DS7XU_P#8'T7_ -2C1*_M[@G_ )++A/\
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M/^4<,;_V5&1?^I5 XOV;?_*2N6_]DOQ%_P"H&)/"/V;O^3A?@?\ ]E3\%_\
MIZM:_K?K^2#]F[_DX7X'_P#94_!?_IZM:_K?K_/#Z&W_ "3'''_91Y5_ZH:A
M_H-]-O\ Y*O@+_LF,W_]:&F%?+_[:G_)J/QY_P"R=ZU_Z#%7U!7R_P#MJ?\
M)J/QY_[)WK7_ *#%7]R<,?\ )2\._P#8_P E_P#5KEQ_!G$G_).<0?\ 8CSC
M_P!5>//Y#I_^/*?_ *])O_1#U^PO[='_ ";Q^P[_ -DYN_\ U&/ ]?CU/_QY
M3_\ 7I-_Z(>OV%_;H_Y-X_8=_P"R<W?_ *C'@>OJ/VCW_*/N*_['&%_]3<D/
M,_9O_P#*1.6_]BG'?^J[.SX4^!O_ "6[X,_]E7^'G_J6:37]>]?R$? W_DMW
MP9_[*O\ #S_U+-)K^O>O\[?H:?\ )/\ 'O\ V/LC_P#5'BS_ $.^F[_R4/AY
M_P!D_G__ *OL$%>"?M3_ /)M7QZ_[))X^_\ 4:U&O>Z\$_:G_P"3:OCU_P!D
MD\??^HUJ-?W)D'_(^R/_ +'>3_\ JVRP_@K//^1)G7_8GS;_ -5>9'\=J_Z@
M?]<A_P"@5^O/[6G_ "93^PM_V+L7_J&V5?D,O^H'_7(?^@5^O/[6G_)E/["W
M_8NQ?^H;95]U^T5_Y1XS;_L8X;_U)RD^:_9T_P#*1V0_]@.*_P#4+.3\_OAM
M_P E(^'/_8_^"_\ U)-,K^Q6OXZOAM_R4CX<_P#8_P#@O_U)-,K^Q6O\V?H9
M_P#(K\0?^QIP[_ZK,S/](_IO?\C7PX_[%7$W_JURH*\?_:$_Y(+\:O\ LE/Q
M!_\ 44U6O8*\?_:$_P"2"_&K_LE/Q!_]135:_N?)_P#D;Y1_V-LK_P#5GEQ_
M N;?\BK-?^Q7F7_JNQY_&G#_ *J+_KFG_H(K]>OVC?\ E'A^Q'_O:=_ZA_B"
MOR%A_P!5%_US3_T$5^O7[1O_ "CP_8C_ -[3O_4/\05^F_M"O^4<^(/^PNG_
M .E98?$_L\_^4D>%_P#KS5_],9N?G!X>_P"1B\._]C#H7_IVLZ_LQK^,[P]_
MR,7AW_L8="_].UG7]F-?YB?0R_W7Q#_["N&/_47.C_3?Z;_^]>&O_8+Q7_ZE
M9$%?,7[:/_)J'Q__ .R9>)?_ $D-?3M?,7[:/_)J'Q__ .R9>)?_ $D-?WSP
MS_R4O#O_ &/\D_\ 5MEI_GIQ)_R3N?\ _8CSC_U5Y@?R)KT'T'\J_6OXP?\
M*,W]E'_L;F_EXRK\E%Z#Z#^5?K7\8/\ E&;^RC_V-S?R\95^F_M /^4;^*?^
MOD/_ $G"'P_[/_\ Y25X.]9_ECCXE^!W_);?@W_V53P#_P"I/IM?U\5_(/\
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M=4@_98^.TD^OW5U$OP\UDM ]E8QJX A)4M'&K@, 5.#G!)'.*^O*^7_VU/\
MDU'X\_\ 9.]:_P#08J_N3AC_ )*7AW_L?Y+_ .K;+C^#.)/^2=X@_P"Q'G'_
M *J\P/Y#I_\ CSGR,_Z)-QZ_N&XK]>OVX(+B+]GW]B1YKV2YCE^'=V8HGAAC
M6W'_  C?@IL*T:AG^5DC^<GY8E8?,S9_(6?_ (\I_P#KTF_]$/7["_MT?\F\
M?L._]DYN_P#U&/ ]?4?M'O\ E'W%?]C?"_\ J;DAYO[-_P#Y2(RW_L58Y_\
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M\C%X=_[&'0O_ $[6=?V8U_F)]#+_ '7Q#_["N&/_ %%SH_TW^F__ +UX:_\
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M5Z%0!P'CW[_@C_L?] _]$:C7?UP'CW[_ ((_['_0/_1&HUW] !1110 4444
M%%%% !1110 4444 %?G-_P %4/\ DT/Q%_V._P /?_4DMJ_1FOSF_P""J'_)
MH?B+_L=_A[_ZDEM7V7AY_P EWP?_ -E#EG_I^9\CQ]_R1'%G_8@S+_TS _F*
MN/\ CWG_ .N,O_H#5^PG_!0[_DG7[&7_ &2&+_U'/!M?CW<?\>\__7&7_P!
M:OV$_P""AW_).OV,O^R0Q?\ J.>#:T_:3?\ )A8_]CO"?^IV3'H?LUO^4@J7
M_8DS#_U6YT?/?[!G_)V_P?\ ^O[7_P#U'-2K^HZOY<?V#/\ D[?X/_\ 7]K_
M /ZCFI5_4=7\,?0__P"3?<0_]EA7_P#5+E1_;_TTO^3D<-_]D3A?_5YG 5\
M?\%.?^3/?B#_ -A7P?\ ^I)85]_U\ ?\%.?^3/?B#_V%?!__ *DEA7]O<!?\
MEOPC_P!E%E/_ *EQ/X4XY_Y(SBK_ +)_-?\ U$D?RWW7_'K=?]>UQ_Z)>OV.
M_;P_Y-R_86_[)Y=?^H9\/:_'&Z_X];K_ *]KC_T2]?L=^WA_R;E^PM_V3RZ_
M]0SX>UZ_[1W_ )1^Q7_8UP__ *FY"3^S@_Y2)RW_ +%F-_\ 5=GY\M_L3?\
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M $&*O[DX8_Y*7AW_ +'^2_\ JURX_@SB3_DG.(/^Q'G'_JKQY_(=/_QY3_\
M7I-_Z(>OV%_;H_Y-X_8=_P"R<W?_ *C'@>OQZG_X\I_^O2;_ -$/7["_MT?\
MF\?L._\ 9.;O_P!1CP/7U'[1[_E'W%?]CC"_^IN2'F?LW_\ E(G+?^Q3CO\
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M1_3>_P"1KX<?]BKB;_U:Y4%>/_M"?\D%^-7_ &2GX@_^HIJM>P5X_P#M"?\
M)!?C5_V2GX@_^HIJM?W/D_\ R-\H_P"QME?_ *L\N/X%S;_D59K_ -BO,O\
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MZW3S/,,7+V=%XO%\]+V.)I6J>TC>?-'D]WF?1U\ ?\%.?^3/?B#_ -A7P?\
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M:O0?0?RK]:_C!_RC-_91_P"QN;^7C*OLP?\ !(W]G4 #_A*/B9P,?\AK3/\
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MQ%/DC:ISQYI7CRV?]N_25\6^$?%;&\(8CA-YNZ>28+.</CO[6RQY;+VF/QN
MKX?V$7C<9[:/L\/4]I*]/DERQM+FNNBHK.T^WU* 2_VAJ,>H%BOE&.Q2R\H#
M.X';//YF[@\[=N.,YK1K^D#^8CSWP/\ \A7XA?\ 8Z3_ /IGTBO0J\]\#_\
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MLK074(FC:,RVTZ_-#/'NWPRK\T<BJXY K^=;]C*]^,L'Q'^,?Q#^)GC;]O\
M\1?"G]GC]I+]M>V;XP>)OVE_!/B_X+Z_\/\ ]GOXA>,]#\.?##6?@W#+>>-=
M4N5\*6,FG7.M^(_#GA22]U_PY#JEAXFU&6_ACD /Z,**_F6_:,_;[^.O[5'[
M.EAXITO]FC]HG]G&U\+?M+_\$\?BK\#_ !(_C?Q3\-=%_:/\'?$S]IKP)H2?
M#3Q)>Z[X4\ WH6?2-7TV;QSHMG%XQ^%M]::UIMYIWC;Q+#ILEG=_M]^RM^T5
MXB^/6G_%O1?'WP[L/AC\4/@5\6]<^#_Q$\.:!XR_X6'X-N=7TW1]#\2Z7X@\
M%^-9?#G@[4-9T#7/#OB32;U8M;\(^&==TJ^:\TS4M(B>VCGN0#ZKHHHH **_
M&K_@HE\1?C5^RW^T5^SG^UCX$^)_Q&N/@3X"T+QC??MB_ 9]275/AQJWP A\
M5?"WP%K7QAT+PV=.DO=(\:_!&?XH'XEZK?Z9J=NNN^%_#VH:??VTR0QD9>L?
M'+XM>,/^"D]_KFA^/_%U]^SS\.?V'OCK\4OA7\'?#OCSP_X&^'7QC^('PJ^)
M?@3PAJ?CSQIXIU+&D7>AZY>^,M<\'^&K_P 1:G;>#="LO#-AX]$UQ::G]IA
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MNE7MW<2^'95\27OA;P;/>7.I: =-U2]@.@6J:==WDVG1SWR6JWUP >MT444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD5Z%0!P'CW[_ ((_['_0/_1&HUW]<!X]^_X(_P"Q_P! _P#1&HUW] !1110
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MWXO_ #T+_P"7%'_"::U_T3OQ?^>A?_+BOR!_XAP_^",O_1G<_P#XD=^UE_\
M/VH_XAP_^",O_1G<_P#XD=^UE_\ /VH _7[_ (336O\ HG?B_P#/0O\ Y<4?
M\)IK7_1._%_YZ%_\N*_('_B'#_X(R_\ 1G<__B1W[67_ ,_:C_B'#_X(R_\
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M]J /U^_X336O^B=^+_ST+_Y<4?\ "::U_P!$[\7_ )Z%_P#+BOR!_P"(</\
MX(R_]&=S_P#B1W[67_S]J/\ B'#_ .",O_1G<_\ XD=^UE_\_:@#]?O^$TUK
M_HG?B_\ /0O_ )<4?\)IK7_1._%_YZ%_\N*_('_B'#_X(R_]&=S_ /B1W[67
M_P _:C_B'#_X(R_]&=S_ /B1W[67_P _:@#]?O\ A--:_P"B=^+_ ,]"_P#E
MQ1_PFFM?]$[\7_GH7_RXK\@?^(</_@C+_P!&=S_^)'?M9?\ S]J/^(</_@C+
M_P!&=S_^)'?M9?\ S]J /U^_X336O^B=^+_ST+_Y<4?\)IK7_1._%_YZ%_\
M+BOR!_XAP_\ @C+_ -&=S_\ B1W[67_S]J/^(</_ ((R_P#1G<__ (D=^UE_
M\_:@#]?O^$TUK_HG?B_\]"_^7%'_  FFM?\ 1._%_P">A?\ RXK\@?\ B'#_
M .",O_1G<_\ XD=^UE_\_:C_ (AP_P#@C+_T9W/_ .)'?M9?_/VH _7[_A--
M:_Z)WXO_ #T+_P"7%'_"::U_T3OQ?^>A?_+BOR!_XAP_^",O_1G<_P#XD=^U
ME_\ /VH_XAP_^",O_1G<_P#XD=^UE_\ /VH _7[_ (336O\ HG?B_P#/0O\
MY<4?\)IK7_1._%_YZ%_\N*_('_B'#_X(R_\ 1G<__B1W[67_ ,_:C_B'#_X(
MR_\ 1G<__B1W[67_ ,_:@#]?O^$TUK_HG?B_\]"_^7%'_"::U_T3OQ?^>A?_
M "XK\@?^(</_ ((R_P#1G<__ (D=^UE_\_:C_B'#_P"",O\ T9W/_P")'?M9
M?_/VH _7[_A--:_Z)WXO_/0O_EQ1_P )IK7_ $3OQ?\ GH7_ ,N*_('_ (AP
M_P#@C+_T9W/_ .)'?M9?_/VH_P"(</\ X(R_]&=S_P#B1W[67_S]J /U^_X3
M36O^B=^+_P ]"_\ EQ1_PFFM?]$[\7_GH7_RXK\@?^(</_@C+_T9W/\ ^)'?
MM9?_ #]J/^(</_@C+_T9W/\ ^)'?M9?_ #]J /U^_P"$TUK_ *)WXO\ ST+_
M .7%'_"::U_T3OQ?^>A?_+BOR!_XAP_^",O_ $9W/_XD=^UE_P#/VH_XAP_^
M",O_ $9W/_XD=^UE_P#/VH _7[_A--:_Z)WXO_/0O_EQ1_PFFM?]$[\7_GH7
M_P N*_('_B'#_P"",O\ T9W/_P")'?M9?_/VH_XAP_\ @C+_ -&=S_\ B1W[
M67_S]J /U^\!V^I*_BS4-2TJ\T<ZSXEEU&UM+\VYN1;-ING6X=_LL]Q$,RP2
M* )#]VO0:^3OV0?V'/V7/V#/ 7B/X8_LH_#%_A9X'\6>+Y_'GB#1'\<?$;QX
M;_Q7<Z-H_A^?5!J?Q+\7^,M8M ^D:!I-I]@L=0MM,7[)]H2S6ZN+J>;ZQH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #O BH# 2(  A$! Q$!_\0
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M?75T4N9?R0_\G_\ DQ\K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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M7UU=%',OY(?^3_\ R8<K_GG_ .2?_('*?VEXM_Z%>R_\*"+_ .5]']I>+?\
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MQ7=^'=&\66^BW[75K!#-<R^'?$.C:HLEC+=6P@OXD:83K+%& >@T4A( ))
M!)).  .223P !R2>E>3> ?C[\"OBMX;\2^,?A=\:?A-\2?"/@RYOK+QAXI\
M_$;P?XP\.>%+S3+)=3U*T\2ZWX>UC4=-T*ZT[3F74+ZWU2YM9K2R9;JX2. B
M2@#UJBOE1?V[OV'WM-&U!/VR?V5'L/$6IW.B>'KY?VAOA&UGKVLV;V\=WI&B
MW(\7F'5-4M9+RT2YL+%Y[N![JV66%&GB#>I:M\>_@7H'CM?A=KOQH^$^B_$Q
M]/AU=?AUJWQ%\'Z=XZ;2KD(UOJ:^$KS6(=?.GW"NC07@T_[/*'4QR,"#0!ZS
M11UZ44 %%%% !115>YFD@B,D5M)=.&4>5$T2.03@L#,\:87J1NSCH#0!8HK'
M_M*^_P"@)??]_K'_ .2J/[2OO^@)??\ ?ZQ_^2JKE?E_X%'_ #%=>?W/_(V*
M*Q_[2OO^@)??]_K'_P"2J/[2OO\ H"7W_?ZQ_P#DJCE?E_X%'_,+KS^Y_P"1
ML45C_P!I7W_0$OO^_P!8_P#R51_:5]_T!+[_ +_6/_R51ROR_P# H_YA=>?W
M/_(V**Q_[2OO^@)??]_K'_Y*H_M*^_Z E]_W^L?_ )*HY7Y?^!1_S"Z\_N?^
M1L45C_VE??\ 0$OO^_UC_P#)5']I7W_0$OO^_P!8_P#R51ROR_\  H_YA=>?
MW/\ R-BBOS4^(_QF_:)\'?\ !0S]F;X3R>+/#T?P.^,_A+XQZC+X!LO"-@NO
M0W'P_P#"^F7EI?ZSXSO;^\NY;I]5OI;E+/1K?3K*.Q6""47<[RN/@73_ /@H
MQ\?[3]I_0]'\1_%+P[9:CJO[:9_9IU?]B.\^%J:9XF\/_"+6-1NM#\)?&-/B
M5-%_:UQJVJS)9Z];F>[_ .$<U.UNUL;"!@CNG?2RS$5HJ4)46GAUB5:<F^5S
MKPY6E!VDI8>HI3E:C#W5*JG.-^2>.HTW:<:BM6='6*2YE&E)R5Y*ZM5A:*O4
ME[S4&HRM_1+17XD?"K]K+]H*W_X*):5^SWXC^,4OC_P-K^F?%@>+_"/C_P"
M)_9_L_#'B'PA/#_PC&D_ #Q=KOV?4/C:GEFX&O75O?:S;MI5NVLPW""18X/H
MK_@I%\:?VB?@=\(_"OQ*^#/BC0? ]A9_%+X8>%_%=GJ_A'3_ !7KWB.R\:>.
M=%T"6QTJ[OM1.DZ':)8W-V+J[;3KW49)IK<6DEJJ22-+RZM'$8?#N='FQ,(5
M*<G*2A:IS\J=X<RE>#6D6G>,N91>C6,INE6K<M3EH3E"<;1<KPY;M6ERVM)/
M5IJS5FUK^EM%?DO_ ,%+_C'^U'\"O#?A?XC_  ,^,&A>&-<U#Q=X%\!_#/\
M9XG^&7A_QIKGQ\\=^(O$*P:OH=QK5YJ4NN:?I]MH+&Z67PM96C:/!;7NHZO?
M>2T'E]7^T7\;/VFOAO\ M*_L,Z)9^(_"_ASX9_'/XD+X#\=_#RT\*V6JZ]=7
M]IX#U+Q'K33^-M0O[@6EE!J<<-KI<.B6%G.T%K/->WLS2QQ*H8"I4A1G&I1M
M6CB)13G)23PU-U*D6G#5N*:C*#E3YTX2G&49).6+A&52+A5O3E13:BFFJ\N2
M$D^;1)N[4E&?+:2BXM-_HE=?\CII'_8 UC_TLTRNKKBOM$UQXRTHS6<UF5T'
M5PJS/ Y<&\TS)7R9),;<<[B,Y&,X-=K7)/3D_P"O:\_M3[&\/M_XW^43D]3_
M .1N\+?]>/B+_P!%Z=765R>I_P#(W>%O^O'Q%_Z+TZNLHGM3_P '_M\PCO/_
M !_^VQ/ /"/[+OP-\!>+KSQSX-\&7'AWQ'J/B76?&.HSZ;XO\<1:9J/BCQ"T
MCZWKFH>'6\2OX<OM0U)Y6:YFN])FW,(V4*88BDV@_LP_ +PSJ_B36]&^%WAN
MWO/%EAXBTK6;>X2]U+13I?B^=[GQ7IFE>'-3O+SP]X=T_P 37$CRZ_9>'M+T
MNVUAW8ZA%<9-;/AWX^_"'Q;\5/&?P5\->.-*UKXE?#S0[+Q%XU\.V"W<W_"/
M:;?WCV$!OM4%N-(^V)=1F*[TZ&_EO[!BOVZVM]ZYXOP]^UY^SYXFU+4M/L/'
M]O;0Z?H?B3Q/:Z]K.E:UH7A7Q'X<\&OY?BO7/!_BG5M/L]!\6Z9X>.'U.ZT"
M_OXX8"+I3):D3UO_ +;+FO\ 66^2FY:U;NG*TJ;>S<792AO=*\?=5S/_ &96
M_@)<TU'^';G6D[;I-:J6VNCUT,/7?V.?A!-\._$/PS\%Z0/ N@>-M4\''QW=
MVEQJVOZ]XB\*>$-5LM1@\&Q:]XAUB^U;2=(EALAIMC!:7AL=$L[N_.F:=%+=
MRNWHUO\ LZ_!2T^(K_%>V^'VCP^.GU)M<.JI-J8L5\0OIJ:/)XFC\.?;CX8B
M\52Z7&MC+XHCT9/$$MON234FWN6E^%WQ]^&/QAOM9TGP7K&H-K>@V6EZMJ.@
M>(?#OB#PEKRZ%K@F.B^(K;2/$NFZ7?7WA_56MKF*RUBSAGL9)[>:W>9)T,=9
M+?M,_!E/B)%\,6\4S#Q%-XG/@:*^_L/73X1D\>"T-\? J^-AIQ\*'QB+<'_B
MG?[6&I?:%:Q\C[<IM@-XQN<&\1S1C*51>_S<LTN9SL[RBXP25W)<L6HJRD"6
M&2C)*E9M1@_=MS1;LHZ633D]DG=ZO6):T3]FOX%>'?&&L>.](^&OA^V\2:Z/
M$'V^>47M[I2OXL4)XJGTWPU?7ESX:T2Z\3QAH_$5WHND:?=:Y%-<Q:I-=1W5
MRLNE\+_@)\(O@S+J<_PT\$V'AFXU:ULM/N[F.\U;5+I-)TUIGTW0M/N=;U#4
MI](\.Z<\\SZ?X=TF2RT.R>1FM=/B8YKF-/\ VJO@5J/C&X\$Q>-XK?48IO$U
MK::QJ.E:SIO@W6;[P5;S7?B_3O#_ (WOK"W\*ZYJ'AJVM;V?5[33-6N9K:'3
M]1DVLEA=M#L?"_\ :(^%'Q@U;4-!\$Z]?3ZS8Z-9>)H],UOP[X@\,7FK^$]2
MN)+73O%WA^#Q%INFOK_A:^N(VAM]<TD7=@TC0J\R&> 2*:QG++G^L<G+!SYW
M4Y>1?!S7=G%=+IVZI#B\/S1Y?8\W-+EY5#FYG\5K*]WUMOTN>W4445S&P444
M4 %%%% !1110 4444 %%%% !7Y0_\%&M;M?V@/LO[ 7ASX9:Q^T#'\2_".H>
M-_VG/A=X!^+7@/X7>-].^ $+S:-H,#:WXSUS1(;&#QU\1Y-%MIX;6Y:]U'PM
MX=\4V!MC9ZDUU#^KU><VOP>^$EE\2M1^,UE\+?AS:?&#5]&C\.:M\5K7P1X9
MM_B5J?AZ);1(M"U'QU%IB>*+W1HTL+!(]+N=4EL46RM%6 "VA" 'X(?L^_$/
M]J/]K7_@F%\>?V3O#GQN\<_ W_@IQ^P??ZU\%?%=WX-\8^"+KX@:[XM^$MLN
MM_!C4_$FH0V/BCP_JGAG]HCX7-X9L/$?B*PL7LAXLU'Q->Z//%=:!&HS_'G[
M:GQ$UW]E+P]^W;\(?BO\0?!'P>^//BW]E?\ 9H(^.OCNY\&>!O@?I,U[/X:^
M/?Q<\1^*HOAKXQOOAWXE/Q-:/X$:_P#%"]\-:SI?AWQ-H^M>-+?2K>UNK#4H
MOWH\%?L_? ;X;>,/$OQ"^'7P2^$7@'Q_XT^T'QCXX\%?#;P;X5\8>+#>7HU&
M[/B7Q-H6BV&M:[]JU "_N/[4O;KS[T"ZEW3_ +RNQU#P%X%U;PCJ'P_U7P7X
M3U/P%J]A?:5JO@G4/#FCWOA'4],U-Y9=2T[4/#=S9R:->V&H27$\E]9W-E+;
MW;S2O/'(TCE@#^=L?$[]J?P_H7[(/PH\=?M]>$[RS^,W_!0OXC_!#2OB5\"O
MB3X<^(NK7?P+\5_LX_$7QIX9^&.M?&'QY\+O!UG\2?BC\.O&NGZ;%I?C[PYX
M,MV::\\,Z7K<.H^(K.^M)<ZX_:=^-'P[_;+^#-OH7[6'Q"^)'PLT7_@H/IO[
M!OQ5N_BWXC^&_@WPUK-I:_LZ>(-4U/P9IWP<T?1GU77_ !KX>\;^&M/\5^(/
MVB]2U;X=Q^)->\3IH/A;P7K'AQHW@_>N^_9;_9EU/2OAYH6I?LZ? G4-$^$<
MPN?A1HU]\(OA_=Z5\,;@7<%^)_AYI\_AZ2T\%S"^MK:]$OAN'37%W;P7&[SH
MHW7=NO@)\"[WQ+J7C2\^"_PFN_&.L>)/#OC+5_%ES\.?!]QXFU3QAX0MY+/P
MGXKU'79=&?5+[Q+X7M)I;7P[KMU=2ZIHEO+)!IMU;1.RD _G9^%/QB_:5^.O
M[<OA'0X_VL_B%?:Q\)?VIOVLX?VA_AMX ^-?P@\.?L]^.?@_\.'\>:%^SY\+
M/AKX#"S_ !;/Q%TWQCHO@[1/B+H]SI6GW^I3Z?\ $;4_%.JZGX=NO#4TWL/_
M  3)_:$_:D_:(^,'PE^-'B?]JGX(>+/ GQ6^''Q*@^.?[,FE_%K7OB'\1_!'
MQ3T"_LWTQ](^$D_P3\!7/[,DWPIU*#4?A_\ $/PQKWC7Q;IOB"75-(N/MM_K
MKZ?JNI?5'PI_X)8Z=X7^(>D^+/BUXB_9_P#C'-X6^)</Q7\/?%Z7]DCP'X*_
M;!UGQ78>,9?'&DW'Q#_:1T7Q-<OXAGMM8E$>IZOX>\!^#]9\0:?$;'4+Q;>[
MO4G_ $T\+_"/X4>!_%/C'QSX+^&/P]\(>-OB)=0WWQ \8>%_!?AOP_XI\<WM
MN"+>\\8^(-)TVTU;Q-=0 D0W&M7=]-$"0CKDT ?C;^VSXW^)=W^V=\:?@Y#^
MW!\1/V6O .F?\$V[S]H_PB?"FI_#31AX?^*'@CXL^)M%G\802>+O"FMZAKWA
M^STFPTW_ (3;PVS7%EJNGW4=I*UD)K9SP?['7QB_:1_:O_:5\(:+\8?VH?'?
MPEUW0OV ?^">_P"U=XY^ _P__P"%>>'+.#XJ?$6S^):_%_2O$&@^(/#FN^*[
M#P)XG.DZ-+K'AZ:YL[W2);JP:#5=/>.T1OO3QE^P8_Q._;XA_:[^*^J_ OXG
M_#72?@AH_P &O"GP3\=_L[6?BKQ!X2GT/Q9?_$&Q^(6A?$_Q#X^U73[#Q?\
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M_P# I?YF/]@U/_H.W'_@#IW_ ,CT?8-3_P"@[<?^ .G?_(];%%',_+_P&/\
MD'*O/_P*7^9C_8-3_P"@[<?^ .G?_(]'V#4_^@[<?^ .G?\ R/6Q11S/R_\
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MT4RL#D\'J>M?)G_!1/X=CXB?LG?$JWCM_M%_X4M['QOIRJGF2"7P[=+->"(
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MD:-I-CIUA:Q#$<%M;06J1QHHY.!N=BSNS.S,3P%X(\/?#;P9X9\!^%+)-/\
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MX&V__P <K1V)_=7_ +Y'^%&Q/[J_]\C_  H]WM+[X_Y!KY?<_P#,SO[:T?\
MZ"NG?^!MO_\ '*/[:T?_ *"NG?\ @;;_ /QRM'8G]U?^^1_A1L3^ZO\ WR/\
M*/=[2^^/^0:^7W/_ #,[^VM'_P"@KIW_ (&V_P#\<H_MK1_^@KIW_@;;_P#Q
MRM'8G]U?^^1_A1L3^ZO_ 'R/\*/=[2^^/^0:^7W/_,SO[:T?_H*Z=_X&V_\
M\<H_MK1_^@KIW_@;;_\ QRM'8G]U?^^1_A1L3^ZO_?(_PH]WM+[X_P"0:^7W
M/_,SQK.D,0JZIIY). !>6Y)/L/,H.M:0"0=4TX$'!!O+<$$=01YG!%?F=_P4
MM_:.UWX:>#?#?P=^&.IZE9?%'XIWD*B7PZTJZ]IOAB*Z6V==.>V'VF#4?$&I
M&+2K!K<BX,27IB*D*XZS_@G!^T7J/QK^$5WX0\;ZG/J7Q,^%EXNAZW<ZF^[5
MM8T*9I/[#U>\,F)IKN$13Z1J4SKO^U6*23GS;GG[6? F<4^"Z7&\E#^SZF-]
MA]4M+ZY'!2J2PM/-I+EY/J-7'PG@XRY4^>*JN;IR2/CH<;Y34XPJ<&1<_K]/
M!^W^M7C]4EC(TXXFIE<7?G^NT\#.&+E'F:Y9.FHJI%L_03^VM'_Z"NG?^!MO
M_P#'*KW?B30+&TNKVYUC3H[:SMY[NXD-Y;D1P6\3S3.0).B1HS'V%;.Q/[J_
M]\C_  KX]_;S^)J_"C]EKXH:W;S"VU;7M*3P3H;KA7_M'Q9)_9;M&1AE>'3I
M+^X5UYC:$/P%)'S>39;4SG-\LRG#J3KYGF&#P-.UGRO%8BE2E-I1O:G3E5JR
M_NTF?09OF-/*,JS+-:[C['+L#B\;4O=<RPU"K5C"]]ZE2-*DO.JNI\#?\$]F
MA^,'[4G[2'[3?B">V6 W]_H?AB6[GC01MXBU!I(Q:M*RG9:>%])L;?9CY8M2
MVG[M<-\1=77_ ()\?MKS_$S0[:>_^!_QBL-5U#5=#T&6WE -T[W.L:99PM/#
M:K?Z'XB:+5M)AGFB4Z=J4\(D5 ^/OO\ X)K?#!?AS^RKX,NKJV$6K>/[K4/'
M>H,Z 3&#595M]'C=OO%(](L[22(, 4$[+7U]X]^%OPZ^*-CINF_$3P7X=\96
M.D:E#K&F6NOZ;;W\5CJ4 (CNK<2J2C%3LE0'RITPD\<B@ ?K><\<8#+N/N)<
M-B<)5S+A"IERX)Q654*U.FZN59-AJ6!P=;"3J)TJ6*PN8X6KBJ%>UXRG6E%\
MSCS?E>4<%XW,.!>'<1A\52R[BN&8/C+"YG6I5*BI9IG&)J8W%TL5"#52KAL3
M@,52PU>C=J484HRCRI\OXZR_MI?MP?M%:K=:I^S/\*;'PIX%T-GG2[UZWTV]
MFUQ8R1';S:QX@FT[3+FYF4Y&G:#$YC^437FY=S3)^WY^VS\,66#XO_LSPZI#
M"ZF[U#3-)US3RL2 EV2[T:;Q!HT;2#D--($R!@#E:_;:SL+'3K2VT_3[*TL+
M"SB2"TLK.VAM;2U@C&V.&VMH$2&")% 5(XD5%'"J!5O QC QZ=ORKP9<=\+M
M_55X8<+SRFFE##4YXK-H9Q&"T=3$9S1Q,:F)Q%1^_*4L.J<)>[3A[-)/W8\$
M\2I?67XD\2PS2H^?$3AALKGE,IMIJ&'RBMAY0P]"FO<C&.(=2<?>J2<W=?SA
M?M1?MKWW[9_AWX:_ KPAX%UWP)JOB#Q_IC>(+'5-1MK^/49RPL=$@M)(;>TF
M:WLKF\N-4O3<6\2QFSMQE@&9?WV^'&A>$_AKX"\'^ =&U'2XM,\(>'=*T"U$
M=W;JKC3K2."6?!DSNN9EDN)"?F9Y6+$DFNA?P7X.EUJW\22>$_#,GB*T9WM=
M??0=+?6K9Y$,<C6^JM:F^A9T9D=HYU+(Q5B02*Z38G]U?^^1_A7E<4\697G&
M59+D60Y)6X?R;*JV88^>"J9B\QEB,SS*=)5<0\34HTJLJ=+#T88>@JZE4A!R
M7,HJ*?I\,\+YEE.9YQG>>9S2SW-\SI8# T\9# ++XX?+<OA4=+#K#PJU*49U
M<15E7KNBXTYR479R;:\ZU#PG\*M6\9:-\0]3T7P=?>.?#MG<Z?H?BNZATV;7
M-+LKL.+BWL[]R9X8W$D@&ULH)91&4$LF[M/[:T?_ *"NG?\ @;;_ /QRM'8G
M]U?^^1_A1L3^ZO\ WR/\*^*J5ZE:-*-6K7JQH4U1H1JUI5(T**E.:HT8U)35
M*DIU*DU3I*G34YSDH*4I2E]C3HTZ3JRI4J-*5>HZU:5.E"G*M5<8P=6JX1@Z
MM5PA"#J5'.;C"$7/EC%+E?$:^'?$WA_7?#=]J6FR66OZ/J6BW:&\MCOMM4LI
MK*9>9#R8YVP<'!P:_EG\/_%SXC_##X:_&+]CKPM:7DFL>//BS%H*W5I.5>*Q
M@FE\/ZSHMFH/F>9XFELM#ADN8V6)--BOBQ8W&X?UA;$_NK_WR/\ "OC+0OV(
M?AAHG[3NN_M.M?ZGJ.NZJ\VIZ?X4O+>S.AZ'XIO+6.SOO$EI,JBYFN9;=)#:
MVTJB.QN;B6ZBD>7R]GZ=X<<8Y+PSAN(L/GN%ECL/6I9=G&48.5.56E6XCR/$
MU:N61JN%HT:;>(4ZE6HG34<,XR4I.E&7YOXA<)9QQ'B,@KY)B8X*O1JYAE.:
MXN-2-*K2X?SK#TJ68NDIZUJB6'<(4J;4W+$*47&*JR76_LI_!OPG^S?\&/#'
MP\M=2TB77!%_;'C/4X[JU5]5\5ZBD<FIS%A)N:WLRL>G6*DD)9VD.T*685]'
M_P!M:/\ ]!73O_ VW_\ CE:.Q/[J_P#?(_PHV)_=7_OD?X5^<YCF&)S;'XS,
M\?5J5\;C\36Q>*K2<;SK5YRG-I6?+"-XPIP7NTZ5.E3BE&"1^@9?@,-E>!PF
M78&E"A@\#AZ.%PU**=H4J,(PBF].:3LYSF_>G4J5)R;E-LSCK6C$$'5=.(/!
M!O;;!'H?WE?-OP@_9I^ /P/\=^/?B+X!MX;/Q)\0KJ:?4I;[6X+VUTBWNKQ]
M1O--\.6[A/[*TZ\OW-W<0*\K.Z11B011+'7U'L3^ZO\ WR/\*-B?W5_[Y'^%
M/#9ECL'A\=A,)C,7AL+F=*E0S'#T:[IT<;1HU57I4L3"*M5A3K152,7:TE9N
M46X,Q&7X+%XC!8O%83"XC$Y;5J5\!7K454JX.M6I.A5J8><G>E.=)NG*2O[N
MJY9)36=_;6C_ /05T[_P-M__ (Y1_;6C_P#05T[_ ,#;?_XY6CL3^ZO_ 'R/
M\*-B?W5_[Y'^%<7N]I??'_([-?+[G_F9W]M:/_T%=._\#;?_ ..4?VUH_P#T
M%=._\#;?_P".5H[$_NK_ -\C_"C8G]U?^^1_A1[O:7WQ_P @U\ON?^9G?VUH
M_P#T%=._\#;?_P".4?VUH_\ T%=._P# VW_^.5H[$_NK_P!\C_"C8G]U?^^1
M_A1[O:7WQ_R#7R^Y_P"9QK7EI>>,]*-I=6]R$T'5PYMYHY@A:\TPJ&\MFVD@
M'&<9P<=#7:5R=R /&>D8 '_$@UCH /\ E\TSTKK*<[>Y:]O9K?\ Q3[$P^W_
M (W_ .DQ.3U/_D;O"W_7CXB_]%Z=765R>I_\C=X6_P"O'Q%_Z+TZNLHGM3_P
M?^WS".\_\?\ [;$:70,4+J'"[RI8;@F<;RN<[<\;L8SQG-4[;5-,O)#%::C8
MW4H!)BMKNWGD '4E(I&8 8.21QBO@+P9X/\ #?A+_@HQ\2;G3M4UC4+_ ,?_
M ++^D:_XC&O^+-3U\2:C%\5]3TVTT_2]-U&^GL]"TO3--B6TLM(TFSM((HC+
M)(DLDSR'Y+^/?AGPC8^*_P!J3XI? WPEX?\ AYH_[+OPMC^%4OB7P!H]GX;N
M+WXD?%?5O#=]\7=7_M'0;6*6:Y^&?PIN8;7[1-F30]7\0:A=Q>7<6@FAZZ>#
MC4G&'M9+GH4:L9NFE%2K24(TY)SYM:KY(N-W))RY5L83Q$H0<N2+Y:E6#BIW
M;5).;E%J-M(+FDG:S:5WN?MQ;W5M=HTEK<07*)(\3O;S1S(LJ8WQLT;,%D3(
MWH2&7(R!FC[5;?:/LGVB#[7Y7G?9?.C^T>3NV^;Y.[S/*W?+YFW;NXSFOSP^
M'&G_  Z^$?[7MUX;^$\GAWPK\)]2_96TSQ;\0+'1-2MH/!EKXGLOB!9Z)X#\
M5ZG(+G^R[3Q)X@\/7.NV<FJRR+?^)+'3X;F]>Z:SBN*^6YY+6Y^%VF_'*S\B
M?]K _MU3^$HM6ANY'\:R^7\:+WP<_P +Y%!CU ^"_P#A4L*^9X4>-=%31E&O
M?9_,Q?,1P:E+2<E&4:+@Y0M)2KJORJHN:T(Q]A+GDI.RG!I;@\3RK6,>9.IS
M)3T:I^RNX.UY.7M8\J:5W&2;V/VS6ZMGN)+5+B![J%%DFMEFC:XB1\%'DA#&
M1$<$%690&R,$YHAN;:Y\W[/<07'D2M!-Y,L<ODS)]^&78S>7*F1NC?#KW K^
M>3XO^(;_ ,'?LC_!3]H3X1W;+^UIXP^(/Q)L_'7B/1;R>Z\=^(-,OM*^* ^+
M&G>)XX=^H7FF> ;+1M/O].LM0MOLO@^[\/:++IL-E(L?G?>?PAT#P-\/_P!J
M;X,Z)\#$T^W\'^.OV4=:\3?$V#P[<_:],UZ;3-=\&+\//'WB1H9)(;OQ3K4N
MK^*+9?$]\TFKZ_ ]ZES<7*6NZ*ZF Y*<I^U;M]9BDZ?*N;"<OM>9\WNPGS+V
M$K7FTU)(F&*<IJ/(DFJ+;Y[Z5^;DLK*\H\K]JOLW5KGZ7T457N99XH]UO;&Z
MDW >4)HX?E.<MOD^7CCCJ<UYV^G_  /Q9V%BBL?[;JO_ $!&_P#!C:4?;=5_
MZ C?^#&TJN5]X_\ @<?\R>9>?_@,O\C8HK'^VZK_ - 1O_!C:4?;=5_Z C?^
M#&THY7WC_P"!Q_S#F7G_ . R_P C8HK'^VZK_P! 1O\ P8VE'VW5?^@(W_@Q
MM*.5]X_^!Q_S#F7G_P" R_R-BBL?[;JO_0$;_P &-I1]MU7_ * C?^#&THY7
MWC_X''_,.9>?_@,O\C8HK'^VZK_T!&_\&-I1]MU7_H"-_P"#&THY7WC_ .!Q
M_P PYEY_^ R_R-BBL?[;JO\ T!&_\&-I1]MU7_H"-_X,;2CE?>/_ (''_,.9
M>?\ X#+_ "-BBL?[;JO_ $!&_P#!C:4?;=5_Z C?^#&THY7WC_X''_,.9>?_
M (#+_(V**Q_MNJ_] 1O_  8VE?EA\>/^"I'ACX6_%[3?A_X1\*V'C3P[H.J)
M8_$WQ+'JY<6C>;'%?6/A![(O::A>:*ID?4;FZ,EG+/&UA;+O1[D>]P]PMGO%
M6+JX+(L!/'5Z&&JXJNHU*=.E2HTHR=ZE:I*-*$ZTXJCAJ4I*IB*\HTJ46W*=
M/P\^XFR3AC"TL9G>.A@J%?$4\+1<H5*E2K6J2BK4Z-.,JLX4H-UL14C!PP]"
M,JM627+"I^L]%<EH7BI/$^BZ5XC\/VD.K:'KFGVFJZ3J5IJEE);WNGWT"7-K
M<Q,I8%9(9%;&25.5;# BLCQYXUNO!'@CQAXQO]+6WM/"WAG7-?FEEU"T,8&E
M:;<WJJ^"#B1X5CX.<L  3@5X\,+7GB(86--_6)UX8949>[4]O.M'#JE*#M.-
M15IJG*#BI1DI1<4XM+UYXFA"A/%2J1^KPH3Q+K1]ZG["%&6(=6,U>,H.C%U(
MR4G&46FI-23?\V_Q^^/FJZ1^WWXF^-VD//<VGPQ^).C:%'-''(8G\/\ A54T
M'5=-EDC!4)J,(UR%(@Z_:@X W?,1_3UHVKV&OZ1I6NZ5.EUIFLZ=9:KI]S&P
M9+BRU"VCN[69&4E2LD$J.""1@]:_G5_9Q^ &I?&W]C?]JCQO<Z1)J/BOQ=XI
M7Q-X7OYGC$XU+P*EQXCU"& R#S)?[1;5=1T^18]PDF91@O&F/T>_X)I_&:]^
M)'[-6A^'Y;=M1USX77DW@J_,EY!%/_9<2_;/#LLB3'S JZ9.MA'\BHJV 12S
M(^/W[Q8RW+\7DF%>5PC]8\.<9@."<V<7']YA<1E&7XO!XIVLXTXYI',,-[UU
M&I4FKWG8_"_"[,,=A<YQ2S*<E0\0<+CN,LK4E)<F)H9KCL+B\,F_BJ2RR6 Q
M&GQ4Z<';W+GZ/45C_;=5_P"@(W_@QM*/MNJ_] 1O_!C:5_/?*^\?_ X_YG[S
MS+S_ / 9?Y&Q16/]MU7_ * C?^#&TH^VZK_T!&_\&-I1ROO'_P #C_F',O/_
M ,!E_D;%%8_VW5?^@(W_ (,;2C[;JO\ T!&_\&-I1ROO'_P./^8<R\__  &7
M^1L45Y[XY\=-X"\%^*_&VLZ4(-+\*>'M6U^]DDU&T"F'2[*:[,?5?FF,0B0
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MYEY_^ R_R-BBL?[;JO\ T!&_\&-I1]MU7_H"-_X,;2CE?>/_ (''_,.9>?\
MX#+_ "-BBL?[;JO_ $!&_P#!C:4?;=5_Z C?^#&THY7WC_X''_,.9>?_ (#+
M_(V**Q_MNJ_] 1O_  8VE'VW5?\ H"-_X,;2CE?>/_@<?\PYEY_^ R_R-BBL
M?[;JO_0$;_P8VE'VW5?^@(W_ (,;2CE?>/\ X''_ ##F7G_X#+_(V**Q_MNJ
M_P#0$;_P8VE'VW5?^@(W_@QM*.5]X_\ @<?\PYEY_P#@,O\ (V**Q_MNJ_\
M0$;_ ,&-I1]MU7_H"-_X,;2CE?>/_@<?\PYEY_\ @,O\C8HK'^VZK_T!&_\
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MT:-.G1HT80I4J5*$:=*E3IQ4(4Z=.$8PA"$(QC&$8QC&*22204445F6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
MI=?\CII'_8 UC_TLTRNKKE+K_D=-(_[ &L?^EFF5U=7/:G_U[7_I4R([S_QO
M_P!)B<GJ?_(W>%O^O'Q%_P"B].KK*Y/4_P#D;O"W_7CXB_\ 1>G5UE$]J?\
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MUC#23SR)&J\DCY2_;J_8^L_VC?!L?BGP=%%I?QI\#V[7?A/5HG^R/KUK;/\
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MS_X[1_8MO_S]:I_X,[S_ ..UL44<TN_Y?Y!RQ[?G_F8_]BV__/UJG_@SO/\
MX[1_8MO_ ,_6J?\ @SO/_CM;%%'-+O\ E_D'+'M^?^9C_P!BV_\ S]:I_P"#
M.\_^.T?V+;_\_6J?^#.\_P#CM;%%'-+O^7^0<L>WY_YF/_8MO_S]:I_X,[S_
M ..T?V+;_P#/UJG_ (,[S_X[6Q11S2[_ )?Y!RQ[?G_F8_\ 8MO_ ,_6J?\
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M*<X0C>SE-J*6C:UE))O3;<^D?[=TK_GZ/_@/=?\ QFC^W=*_Y^C_ . ]U_\
M&:X_X7_%[X9_&GPXWBSX5^-="\;Z!#?W.E7=[HMUYKZ;JUGM^V:1J]C,D.H:
M/JUIO0W.F:I:VE] '1I;=5=2?1ZF2Y).,H3C*+M*,FXR3[-.*:?DU^EZ3YDI
M1E&46KIQU37=-2:?R9CKX@TAAE;P, 64E8+E@&4E64D0D;E8%6'56!4@$$4O
M]NZ5_P _1_\  >Z_^,U\I^,?VYOV2OA3XJN? 'B_XTZ%:^)X->U'2KRPT_2_
M$GB".RUXR2ZC>Z#=W_AS1M6TV#6=-MY7FO\ 2GNQJ-E;123WEK B.5^F/!'C
MKP;\2O"VC^-_A_XGT3QEX0\06WVS1?$?AW4;;5=(U*W#O$[VUY:221.T4T<D
M$\182V\\<D$Z1S1NBZ3HU*<8SG1K0IS^"<XSC&5U=<LI4TG=:JSU6J36I$*L
M)MQC4IRG&_-&,HRE&SL[I2;5GH]-'H]34.O:4 2;H@ $DFWNL #DDGR> !R3
MVI%U_264,MWN5@&5E@N65E/1E80D,#V()![&M28H(93(ZQQB*0R2.0J1H$.Y
MV9B%547+,20  22!S7Q<_P#P4 _8XT.X.B2_'/P_=0Z4TNGWGB+3](\4ZIX.
MMIM.>2VO6N?&NEZ%>>$88K.:WECO;DZT;6T=&6XGC*MA4Z4ZM_94:M1QMS*G
M&4[)WLWRP=KM62>KULG8<ZD:;7M*E."=[.<E&[5KI<TE>R>KV75H^OO[=TK_
M )^C_P" ]U_\9I#KVDJ"S7>U5!+,T%R H R2280   222  ,GBI=%UK2/$>D
M:9K_ (?U2PUO0]:L;75-(U?2KN"_TW4].OH4N+.^L+VV>2WNK2Z@D2:">&1X
MY8W5T8@@U/J+6Z:??/>7,5G:)9W+75W<21Q06MNL+F>YFEE9(HHH(@TLDDCI
M&B*S.RJ"1G[M[.,D[V:OJM;-6Y;W6JM:]U:U]"M;733TNM-'I=:WM;SVMJ4Q
MKVDD B[R" 01!<D$$9!!$)!!!R".".12_P!NZ5_S]'_P'NO_ (S7Q^G_  4*
M_8SM)H]//QU\/2V-L%MF\41:3XIF\#@0CR6N'\=PZ%)X.6T61"DE]_;AL8W!
M5[D8)'V;8WUEJEE9ZEIMY:ZAIVH6L%[87]E/%=6=[9W42SVUW:7,#/#<6UQ"
MZ2P3Q.\4L3JZ,RL"=*E&=*WM*-:FI7Y74C*'-;MS06MFFUNKJZ1,*D*E^2I3
MG:UU!J5K][2>G9[/HV46\0:0BEGO BC&6>&Y51D@#+-" ,D@#)Y) ')%+_;N
ME?\ /T?_  'NO_C-9GC?7O#7A?PEKWB3QEXATKPIX6T'3Y=6U[Q'KE[;:=I&
MCZ;8%;FXO=0OKR6"VMK>)8_GDEE0<@#+%5/S/H/[??[(GB/7=-\/:?\ &C1+
M:\UG4+/2M&O=<T?Q5X:\/ZQJ.HW$=KIMGIGBCQ%H6E^&[V;4IY8H]-6#57^W
MM(@M#-O7+A1G4BY4Z-:HHMJ3A&4E&ROJXP:O:[MJTE>UM12J1A)1G4IP<DN5
M2DHMZVT3DG:]E?17=KWT/JO^W=*_Y^C_ . ]U_\ &:C&N:+$3BY2(RR9.+>=
M#+*P_P"N \R1@ON[!>^*VZ\Y^*7Q$^'GPJ\+-XY^*'C30O GA31]1L?/UOQ!
M>Q65I)>W4AM;#3;?>WG7>H7]Q*L-E8645S?7<N([>WE;(J(I2DH1C-N3248M
MRE)ZV2BHMR;>R2;UNBY/E3DW%**NW*R275MN225MW='7_P!NZ5_S]'_P'NO_
M (S1_;NE?\_1_P# >Z_^,U\W_#W]M?\ 9@^*/BO3/ _A'XK:7)XMUR66WT#0
M?$&C^)O!M_XAN(();J:V\/)XPT70TUR[CMH9;A[32WNKD0HTGD[!NKZGIU*<
MJ34:M*I3DU=*:<&UM=<T%=7TNKJ^E[Z"A.-17A.$U>UXM25^SM)V?D[::[:F
M.?$&D*5#7@4N2J!H+D%V +%5!A!9@H+$+DA06Q@$TO\ ;NE?\_1_\![K_P",
MU8O(X&FL9YKF.#[)/).HD9%$NZVFMRNYV7 43AR0#R " &S4RWMF[*B7=L[L
M<*BSQ,S$] JAR2?8 FH]VRLI>>NVO^'MJ/775?=_]L4?[=TK_GZ/_@/=?_&:
M;_PD&D;@GVP;RI8)Y%SO*J0&8+Y.XJI906 P"R@D$C.S6?.MM'?0W<UU%"T-
MI<6XBD>--RW,UO)YF7<$;3:[5 4AMS<Y7%"Y>TMGUOKT^R#YNZW[6T^\@_MW
M2O\ GZ/_ (#W7_QFC^W=*_Y^C_X#W7_QFK\=W:RL$BN;>5R"0D<T;L0.20JL
M3@#D\<58H]W^67_@7_VH]>Z^[_@F.-?T@L4%X"ZA2RB&Y+*&SM+*(<J&P=I(
M ;!QG!I?[=TK_GZ/_@/=?_&:E_T2VOKJYEO($>>*VA:*22*,Q^1YK Y9PQ+B
M;."!@ $9SFKD5S;SDB&>&8J,L(I4D('3)",2!GC)H?+T4K677K;7[/1]1*_>
M.[_X'4SO[=TK_GZ/_@/=?_&:0:_I!+*+P%DP'40W)9"PW*'40Y7<OS+N W#D
M9%;%9B&SM+J]F>]@5[N2%GBDEB0Q-!!'#MY?)RJACD C=CD8-"Y==)>6N^O^
M'L#YM-5YZ>7KW(_[=TK_ )^C_P" ]U_\9H_MW2O^?H_^ ]U_\9K1BN+>?/DS
MPS;<;O*E23;GIG8QQGMGK4U'N_RO_P "_P#M1Z]U]W_!,=?$&D-DK>!@K%&*
MPW+;74X96Q"<,IX93@@]0*7^W=*_Y^C_ . ]U_\ &:\8T?\ :0_9]G^*.J_!
M*P^,/@:]^*MKJ]W;7W@F/6[7^V+;6)(%U";0"N[[-)KUO9NMU-H<=PVL16S"
M>6Q2([J]-\+?$'P5XVU'QEI/A/Q)I>O:E\/?$K^#O&UGIT_G3^&O%$>F:?K+
MZ'JB[5\B_72]6TV^:'+8M[V!\_/BKE3E#65*K%<L9IRC**Y)M*,M::7+)NT9
M;2>B;;L1&:EM.FW=QM%J7O1NY1TF]4E=K=:W2L;7]NZ5_P _1_\  >Z_^,TB
M^(-(=0R7@=6&598+EE89QE6$)!&1U!(K6? 5BQ"J%.YB0 HP<DD\  <DG@5X
M'\*_VD/V??BAKNI^ /AC\8? _CGQ3X8^W0ZGH^A:U;75\!I=X]CJ<UFBL(]5
MM]-OE:RU&ZTF2^MK&Z7[/=2Q2_)2C!RC.4:=22A9S<5*48IW5YR4&HJ^BYFD
M_D-RY91BY03E=13:3DUTBG).3MJ[)V/9_P"W=*_Y^C_X#W7_ ,9H_M[2ADFZ
M( !))M[D  <DDF'  '))X K&\"_$#P7\3?#T?BOP!XDTOQ7X<EU+6M'CUC1Y
M_M%D^I^'=7O-!URR$NU<SZ9K&GWNG7:8_=W-M*F3MR>JN6B2WN'GE2"!(96F
MGE=8XX8EC8R2R.Y5$2- 7=W8*J@EB ":32C)QE"49)V:;:DGIHTXIIJ^S2?D
M--M74HM-736J:[IJ5K>=S-77])90RW>Y6 966"Y964C(96$)!!!R""01R#BE
M_MW2O^?H_P#@/=?_ !FO&_A+^TG^S]\7[C4O#WPH^+_@CQ_J?A6S)U2T\/ZS
M;W=RME82'3[C5+:(%?[1TN*[A>UEU32S>Z;'= VS7?G80^G>!/'G@[XG>$]&
M\=^ /$6F^+/!_B&&>XT3Q#H\WVC3=2AM;RYT^XDM9BJ^8L5[:7-LYVC$L,B]
MLU4Z<J;DITJL.5I/G4H-<R;A=2IQLY13DD[72=KV=IC.,TG&=.5TVN5J2=K*
M5FI.ZBVDVMFU>UU?4;Q!I"*7>\"(HRSO#<JJCN69H0 !W)(%._MW2O\ GZ/_
M (#W7_QFJ/C+6O#WASPIXAU_Q9KNF>&/#.C:1?:EKOB'6;NWL-*T;2[2!YKS
M4;^\NY(;:VM;6%&DEEFE1%5>3T%>6^#OVGOV??B!X%\7?$SP9\6_!GB'P-X"
MTV]UGQIXAL-45K;POI%AI\VK7&J:U;RI%?6&G_V7;SZC;WD]JMO>V43W-G)<
M0@O0J<I1YXTJLHJ2@Y14G%2E;DBY*FUS2;LHMW>ED[J[<U&7+*<(MQ<DFTFX
MQOS.SDGRQ2NW:RUNU9V]@_MW2O\ GZ/_ (#W7_QFD;7](7!:\"@L%!:&Y7+,
M<*HS",LQX51DD\ &IM&UC3/$.D:5K^B7L&I:-KFFV.L:1J-JV^VU#3-3M8KV
MPO;=\#?!=6L\4\+8&Z.13@9KE/B7XY\!_#7PC?>./B5XQ\/^ O!WAV:SOM6\
M3>)]3M-)T>R"W")!'<7M[+#"CW,[I!#&&:661U2*-W(%2HIR4%";DWR\JNY.
M5VN514')RNK62;OI:XV[1<G**25VWI%+>[;DDE;6[=K=3IO[=TK_ )^C_P"
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MEN9/VOK\0/C+:_ ']I3XS?#2?PC\0?B?^S%XW\:?%[X0^(/%7A?XN? 7XA>
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M+WX=.*2=%J2IN+G34O:6<8KG7O).4>:47RN,5).5VDI/W9:'PH^'?[!7PO\
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M5^?/[5<_PT^%_P"T!^SE^T+KGQ4OO!_Q!T/3_'OPSTWX:Z1\/]9^*OB+XT^
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M?AGX\\3?LQ?LE_MK_ Z3P_'\1_B(/"_@GXL?!SQ=XAU?PUXTUGQ!JWB_QMX
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M;>S76M1TJ_GN5<?0G[%?B_6]6^.W[1WA'3_B)#^T5\+_  AHOPQ;PM^TA?\
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MX^U<H2I>U;A3UTJ2HQ=J=+E<%.]3])Z_ _\ :Q_:D^*L?BC]J3PQ)^T1X_\
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M?%KP=96'B72/ 7PVD^!GQ@\;>'+[7-&L9-%^,7Q_\.VBP^"/@EKGC/5$DLO
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M_P"1N\+?]>/B+_T7IU=97-/:G_@_]OF;1WG_ (__ &V(4445!84444 %%%%
M!7A?QU\%_#OQKHVBVGC_ .(>L_#?['?W<^AZSHGQ!'@.YGNI;)X+RUF6ZN5T
MCQ%:&T8O/I.LZ=JMB !.UJK /7NE?#O[?7A3]ESQC\&]-T;]J"YT[3[";QEH
M<GPNU&+PPWC/QQ:_$^VE-YH*?#WPM::-X@U/Q!KEVEK/:WNBVVCWUEJ6CRWM
MMK$(TYI9(]\,KXBDDZL;S2YJ,%4JJZ=W&F])V6K3^RI/H95W:E4=H.T;VJ2<
M(.S6DIK6/DU]KE[F3\,]#UOX<^,-$L? 7[2?[/\ \1/#>LZQIFGZQH/B;PC\
M/_#_ ,2+K1RY6XAT'Q=\)]1\/6>NZX1MEM+?7_!%\U]<AC<:A$S-*?OBOS%^
M$'B#_@GM=_$KP+X?TGX :'\'?BWJ&I"?X:S?$W]EW5O@IK7B/Q#H]K+?SS>!
M]:\2^"=%TZ?7;2*":[BT_3M3CU4@,;"UF6.0I^G5:8Q-3AS0JQ;@VY5:5*G*
M:YFE).C*4)I6<>9.Z:<6KJRC#M.,K2@TI62ISJ34=+V?M(QE%ZWM:UM5IJ_
M_CAX/\ >*%\-W/BWXL>)?A'K.D/JDOAKQ!X7^)O_  KV_=KF"&+44EMKJZ_L
M;Q%;1QK TEKJVF:E!;[@RK#YSE_+_A_JGQ(T3QEX<T2R_:O^$'QL\(W^HK:Z
MAHOB[2_#&F_%.+3H[*X*CPWX@^'6NV.BZ]J2S10226^K^!HY;BW%U+)JBRJ"
MW*?M^^$_V4O%O@'P)9?M+/8P:W;^/=+U#X*3Z?X*?XB?$.7Q]I3+JLVE^!_!
M5GH?B/4?$\6L:/976F>*=&;1[O1;O0[N5=8^SXL[J#D/@AX@_P""?VH_%7PI
MH7@SX"Z!\%_C--_:6K_#RR^(/[->K?!3Q=K)TJS?^UKWP-J?BCP;H<>I7=A8
MW$OVRVTC4GU..T>>4VIM4FD7:G!O"*7)B*BM6NOJV'G2@H[3A5FU6<;MNI*G
M?V4HOF5FC.<K8CEYJ,'>G9^VK1J2OO&4(IT^;2T5.W.FK=3])J^4_CU\-/A9
MXSUNVO\ Q1\:-7^%?BJ#1;>UMX;7Q]H%CH][IT5_<7-E=:O\//&T6L>#M<1+
MUKB-+Z\\/M<2H'LVO&BC$2_5E?FK^VUX8_8PU3XI? _Q!\<= 3Q3\;O"SZMK
M'@GPAX3^$]W\9?B!XX^',:M8>,/#&L>#-(\,^)KNX\!3W&H6]S_:>I6]C%I&
MNV\-UH>HPZC]IBGY\(G*NDG6B^6;O0IPJ3TBY:QG[O(VDIR;2@FI-V3-<0[4
MF[4W[T4U5G*$;.23M*'O<R3;BDFY-.*U:/:?@-#XK\,>)U\(VWQM^ 'Q4\#2
M:?JNH-!X2\*>'O _Q-MM1CDLULI[G3_ .O77@K6]-6%IHM2O8/#'AJX@;[&4
M6<.RK]@U\&_LR:W^Q#K7Q U:P^!_PH\+?"3XS:'X::_U7PMK7P/O?@K\4K;P
M;JM[':MJ46E^(?"_AW5M1\-WM]:P0W%WI<E]8QW*6L5\T$TENC_>5&*355WA
M4A+EBVJE.G3E)N[YN6E*4&I*UI1=I)>0Z#3IJTH25Y).$YSBK6]V]11FFNL6
MERWMU/BCXR?";X3>(_%VL:[)^T+=_#3QG//92ZCHNJ^,? WBOPE%>06$=O!)
M=?"[XI6OB+P[8RW%B(6F_LRQT>6Z7;=.[3,)Z]!_9]N?&%I_;/AC6?BA\#/B
M?X:T.QT[_A']2^%.A0>$M?M9IYKK[8OBOPSH_B3Q)X8MHYPL4EG>Z(VDQ7%Q
M]K#:5 JH:^-_VC?#O[!MK^U4/&_CCX>S_%/XYV/@&+2/B?\ #KP!\ M3^.=_
MK'A759(YO!&O_$6RT'P?XB_X1S5-$FLKI?#6J7%]IVLW^E7DUE+%>Z2MMY'T
M_P#LJ:M^R)KP\;7?[,_@KP;X"\0:3=:7HOQ.\+Z=\,Y?A1X\T&]-N^H:1IWC
M;PIJF@^'O$%J&M[B:XTR:[LY+"Y#7#6%U,8Y]G35C)82+<<3.+I4Y*53#T53
MI2;LK5%)5E!I6IU'%QFI)7O<PIM/$22="+4YJT*U5SFDKZP<73<E>\X*5XM-
MVM8^OZ^&/BS\(OA+K?BW7==M/VD)OASXON=3DNM2T+Q#XK^'_C[P?::HUK%#
M.K_#;XK6OB+2]':2)())[71!H1W*LZ>5,RS#[GK\C_C;X>_8 TS]JWQ=XW\1
M?#*X^+WQB?P=IOA_XT?#WX>?L[:M\<X3/<26^I^"?%OCI_#_ (+U^'PQXRL]
M-2]L+6;^U+35=7T+484U>RGM[72[B/'!)NI.SKIJFY+V%.E4NU*-HU%5:A&#
MO;GDTE+EBW[QKB6E"-U2:<TOWLYPM=/6'LTY2DK?"D_=N[:'W3^S_>^,!I^N
M:#XB^(_P2^)>CZ!_95MX:UCX0Z/_ ,(S=06\L%PU[#XM\,V?B3Q/H.F73S)'
M+I\FAWMI:W2-=,=-LPB(?H>OE+]E75?V4==T3Q?J/[+WA?P5X/6UURVT3XD^
M'?#_ ,/V^&7BG1/$VGV0FM=)\=^$;_1/#^O:=J=K97I:R_M73Q%-;RR2Z=/<
M6Y:0_5M8XA6K37).#NKQG3C3FGRIMRA!N*O?F]UM--27Q&E'6G%\T9*SM*,I
M3BU=V2E)*32M;575FNA\(:IX(\,^&-0U"^^$O[:^K_#>\N+_ %*[F\,>+_'?
M@OXM>!XKNZOGN;RU3P[X]O)M<TFV2\,\;VNA^*-(>T5W@MGM@@0?2_P;UKQC
MKGA.XN?&WB_X7>.M4M]<U"RM?$OPE2_M_#E_I<$=JUH;[3[_ %OQ&VE^(%:6
M;^TM/MM<U*TB0VLD-Q^]:-/RUDT3_@FSX1^-7QQUW1?@M>?&AO$_BZ/_ (61
MIO@#]E;7OC%\/O 'Q2T99[3QC=6WC#P_X!U6QTW6-:22TN/%^B:=J]]I]OJM
MA->&WL]4GU&)_P!*?V;]0_9ZUCX7Z?K?[,5GX&L?A=K&J:O=06_@'0(/"VF)
MX@@N1INO1:IX>33])O-(\16MU8+9ZQ8:QIMEJ]M+;1Q7MO&405UXJ'+2BW#$
M2O[)JK6PV'IV<H*3@ZE-JK?I%5(VJ12G%V9ST)7J-<U%6Y_<IUJT[VDTI*,U
MR6ZOD?N-N+V/9M:M]/N]'U:TU6<VVEW.FWUOJ5R+V733;V$UK+'=SC489K>:
MP,5NTD@O8IX);4KY\<T;('7\\+KX2>!/#6HVVL?"W]KKP;;75H]I<6VE?&Q?
MA;\<=.86H/V:)/$FM7>A?$ZS@\L1*DUIX^\X>5%(6E=%(_1/58]+ETO4HM;2
MPDT62PO(]7CU5;=M,?2WMY%U!-16[!M6L&M#*MXMR#;FW,@F'EEJ_$3X96W_
M  2U^&^D>)QX>^"-]\2_A+>>+_$WBK2/B5'^Q_XP\;?"[P1HVH7)N-9T30_B
M38?#6[CU;P/H&JQ:E<6%\;G5K?3[6Y:TL-0N=+MK/8L$I.-9Q^L-ITUR4:-&
MK"?-S)J;K2BHR25X13YIIRY4W$>):4J=_8JZE[U2I4A*+5FG%4U)N/\ -)JT
M7:[29^R?PWU/Q#K/@CP]J7BO5?!.N>(;JSD?4]8^',][<^"M1F2ZN(DNO#\F
MH7%Y>"UE@CB,L4]W=FWN_M$"W,\<:ROK^++'1=4\,:_IWB*]?3M!OM(O[76-
M0CU>XT"2RTZ>VDCN[J/6[6YL[G27@A9Y$U""[MI;1E$T<T;(&'.?"9OAC)\-
MO!EQ\%X_"<?PKO="M-1\"CP-!86OA)M U(-?VLNAV^F1Q64%I.UQ),8H8HRD
MTDJRQI,)%'1^+(?"]QX7\1P^-XM%F\&R:'JB^*HO$B6;^'W\._8IO[9&MIJ
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MBF66S?RPR^OV\5O!;P0VJ116L,,45M% JK!';QHJ0I"J818DC"K&J *$ "\
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M'M[/1Q:YG9P<Y1Z:)U%&;MM[R36VR3?)ZG_R-WA;_KQ\1?\ HO3JZRN3U/\
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M/K&GIJD,,[6MS?W,<4!3Z3_9D_9_3]GGP1XDT.]\8:AX_P#&/Q#^)'C+XO\
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M ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM7_P06/\ \?HY8_\ /R'W3_\
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M?\D__)/_ ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM7_P06/\ \?HY8_\
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M=/\ ^0#F?\D__)/_ ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM7_P06/\
M\?HY8_\ /R'W3_\ D YG_)/_ ,D_^3.JHKE?[)\4?]#:O_@@L?\ X_1_9/BC
M_H;5_P#!!8__ !^CEC_S\A]T_P#Y .9_R3_\D_\ DSJJ*Y7^R?%'_0VK_P""
M"Q_^/T?V3XH_Z&U?_!!8_P#Q^CEC_P _(?=/_P"0#F?\D_\ R3_Y,ZJBN5_L
MGQ1_T-J_^""Q_P#C]']D^*/^AM7_ ,$%C_\ 'Z.6/_/R'W3_ /D YG_)/_R3
M_P"3.JHKE?[)\4?]#:O_ ((+'_X_1_9/BC_H;5_\$%C_ /'Z.6/_ #\A]T__
M ) .9_R3_P#)/_DSJJ*Y7^R?%'_0VK_X(+'_ ./T?V3XH_Z&U?\ P06/_P ?
MHY8_\_(?=/\ ^0#F?\D__)/_ ),ZJBN5_LGQ1_T-J_\ @@L?_C]']D^*/^AM
M7_P06/\ \?HY8_\ /R'W3_\ D YG_)/_ ,D_^3.JHKE?[)\4?]#:O_@@L?\
MX_1_9/BC_H;5_P#!!8__ !^CEC_S\A]T_P#Y .9_R3_\D_\ DSJJ*Y7^R?%'
M_0VK_P"""Q_^/T?V3XH_Z&U?_!!8_P#Q^CEC_P _(?=/_P"0#F?\D_\ R3_Y
M,ZJBN5_LGQ1_T-J_^""Q_P#C]']D^*/^AM7_ ,$%C_\ 'Z.6/_/R'W3_ /D
MYG_)/_R3_P"3.JHKE?[)\4?]#:O_ ((+'_X_1_9/BC_H;5_\$%C_ /'Z.6/_
M #\A]T__ ) .9_R3_P#)/_DSJJ*Y7^R?%'_0VK_X(+'_ ./T?V3XH_Z&U?\
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:7M>\GU2?5=!QO[S::O)M)VO:T5T;71]3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %K BH# 2(  A$! Q$!_\0
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MIXY_\+/P)_\ +*ODI4SP.!G_ #]?_KBK21@=OP]?K_A]>.: /J[_ (;RU?\
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MP^_^6-/'[5/Q&)P/V9/&/_AP/A]_\L:S53/; _S^9]ZG1,\ 8'KC.?\ '^E
M%X?M2_$@G'_#,GC#G_JH7P\_^65/'[4'Q+/(_9D\7_\ APOAY_\ +*H4C"]@
M3^?K^?XU85,]?P'^- !_PT_\3#T_9C\8'_NH7P\_^65.'[3OQ-;./V8_&''K
M\0OA[_\ +&IE3ID?0?Y_E5E(R>HX]/3ZXZ4 4A^TS\4#G;^S%XN..N?B)\/1
M_P"Y'FGC]I7XID _\,Q>+>?7XB_#P'_TX5J*F. .<?Y^@_\ K585.G<^OI_G
MUZ_RH QA^TE\5#S_ ,,P^+/_  XWP\_^6%.'[1_Q6(S_ ,,P^+!]?B-\//\
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M\//_ )85UI.>3_\ J_\ K5"7)R!T]>__ -:@#EC^T;\6!_S;!XL_\.-\//\
MY84G_#1WQ8_Z-?\ %O\ X<;X=_\ RQKIZC9^H'Y_X4 <Y_PT=\5^_P"S#XL'
MU^(_P\_^6%'_  T=\5O^C8O%?_AQ_AY_\L*WZC9^H'Y_X4 89_:0^*HZ_LQ>
M*_\ PX_P\_\ EA3?^&DOBK_T;#XL_P##C?#O_P"6-;). 2:B9BWL/2@#)/[2
MGQ3_ .C8O%G_ (<;X>?_ "P_EQ1_PTI\4_\ HV+Q9_X<;X>?_+"M0G )]*B9
MR>!P/U_S_G- &<?VE_BB/^;8O%A^GQ&^'G_RPI/^&E_BE_T;%XM_\.-\//\
MY8U?J-G[#\_7_"@#5^'_ .TCJ_BKXEZ-\,O%?PB\1_#[4_$7A_7?$&C:C?\
MB3POK]A=0^'GLEO[:1=#O)I[:?%]&\32Q^6X1QN! S]3U\ Z,?\ C*_X->O_
M  K?XJY_[[\.]?\ Z]??U 'RQ^VUS^RM\:/^Q8M__3YI-?EY:1EK:V[#[/!P
M!C'[I>O&!Z]\_6OU$_;9_P"35_C-_P!BS;?^GW2:_,JUC_T:VXP/LT''?_4H
M>^>IY_I0 JH!T&3].G^'UJPJ>V3_ "_SZU*L?X#]?\_7FK"19Z=.ON??G@?Y
MXYH B1.?4_H/?I^M6$B)Y/\ ];_Z_P"GO7/>,?%.C> /"FO>,M?749-(\.Z=
M<:E?1:1IMWK&J7$<"%EM]/TRPCDNKR[G8".&%%"[VW2/'&&<>/\ AO\ :0T3
MQK\$?"OQX\%> /'WB3PMXJTW6=972/LNEZ/KV@:5X?EU"+5;GQ'%J%\+;3Y8
M6TRY2*U669II=D1DBR7 !]&(GIP.Y_S_ /J_.IT3T_$G_/Z?K7QJO[<WP:NM
M'A\5:-IWC37/ UEHWP[UWQKXTLM(ABTCX>6/Q1>)?"8\30SW"WIF,,]O?:RE
MG&ZZ5IEQ;WS/<1S!1[)\4?CMX<^%^M:-X6_X1WQ3XY\6ZUX2\0>/X/#7@VVM
M;F^MO OA;"ZWXFNY+R>&%+6*7-M8VR;KC4+M3!%Y?WR >W(G. /J>_\ GT%6
MDB Y/_U__K?SKF? /C+PW\2/!GACQ_X/OCJ/ACQ=H]KK>BWK1-#)+9W0/R3P
M-EH;JWE26VNH6),5Q#*F2!D]HL)ZX].20 /\Y]R* (E3UX'IC!_^M5A4_ >G
M?_ZW^>*D6/GC!/;++_B*M)#T)(_!AUS_ )Z_E0!"D9/ &!_/\_YGK5I8P.V3
MZ8X_^O\ 6IDB^@'^\N3^M6$B^@'KN7)_7_/:@"%4QCN?\_G_ )XJPJ>O)]!_
M6I4B],8[DL,GZ<_TQQ5A(L],=<9W+GZ#G_/X4 0JG3/X ?Y_2K*Q$]?_ -7U
M.#_GO4Z0XZX)/^TOY?\ ZOS]+(B/? ]@R_XXH A1,< ?CZ?X"K")^?<^G^']
M:E6(]\ =@&7_ !JRD)([ ?4<?4Y/Y4 0JG/')]?3_"K*1=S_ "^G3_']*G2$
M# &..?O#\^N?YU86+Z$_[RX_G_.@")4].!_G\_K5A$X]!^I_SZU*L7T)_P!Y
M<?S_ )U92 G&<>_S#GZ=_P >E $")G@#\<9/_P!>K21 >Y].OY^OT''US4R1
M>F,>NY>GH.?Z?X582+TQ]25_3G_/Y4 1*G3/Y?X_X?K4ZIZ\#TZ?G4R1'J!^
M)([_ (^HJVEN1R0>1QR/\\T 5TC+=L#TZ?GZ?SJVB < <^O3'^'^?6IEA; X
MP.P!%6%A;'3 [8(S_7_&@"!4YXY/^>?;ZYJPJ?B?Y?Y]34Z0,>@XZ]1D^_/
M_P \<U:2 C QD_48_IV% %>.+N?\\]L_SQQS5I4[#@=S_GJ>:F6%N.,GTR,?
MS_GQ[5.(6[CGT!'Y?_JH B5/0<>I_P \U.D?I^)]?8?X582W8@9&/Q&/I_\
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MQC^=  S]AQ[^O^'\ZC+ ?X?Y_G2$MV'YD?X_XU&58\D?J/\ &@!"Q/7\J:6
M_P /\_SI"6[#\21_+/\ /\JC*L>2/U'^-  6)^GI3"0.30VX< 9/U&/YU$P;
MJ>WN/\: !F)]A_/ZU&S >Y_SU_PZTAWGH,?B,_SIA5AR1^H_QH 0DGK3&8#Z
M^G^-(=QZ#'XC/\^*9M;N/U'^- "$D]::6 ^OI2$MV'XDC^6?Y_E43;AR1DGW
M'^/2@!68GKP/\]ZB9^PY]_3_ !_E2$.>V!Z9'^-,*D#)'ZC_ !H 0G/)IC.!
MP.3_ "H.\]!C\1G\\_X5&5(ZC]1_C0 $D\FF,P'U]/\ &D)<YP,#ZC/\ZB;<
M.V3]1^O- "DYY)_I43/V'Y_YZ4UBV<'C';TJ,L![GT_Q]* .'T/_ ).O^#?_
M &3?XJ?^C/#M?H%7Y]:"Q;]K#X-^G_"MOBK_ .C/#M?H+0!\L?MM?\FK?&;_
M +%JU_\ 3]I%?FM:Q_Z/;9Y/V:W^G^IC_P Y/%?I5^VSS^RO\91Z^&[3_P!/
MVD5^<EH@%M:X&3]FMSZ_\L(SGZT *D1ZG'^?3_'_ .O5E4..,?CW/KWJ14]>
M3Z?YZ_RJPJ>HY[#K_G_/X &!XBAUV7P_K$/AA--?7KC3KRUTP:P\L6F_:+JW
MEMPUW+ #,L2"0L3&I.5QWKXK\"_LT_%3P[^S1X4^ 7BO3?@O\08M$N_%*:Q'
MK4WBRST?4K+7M2U?5["[M'TVXM[F*[T^\U7RKNUN'>&ZMH3L7>]??B1DG)]^
MV?\ ZV?;\:M*GH,^I_+_ #CF@#\N/#7[ _Q$\,^"O'/PH?XIZ#XE\!?&C3?A
M':?%36-7TJZ@\5Z5_P *UL]/T74-/\%16X6RDT_6/#6CZ5I&DOJ $VF202W-
MP) RU[[XW^!GQMUWXCZ1\7/#OB/X::?XKTSX:?$/X'C1[VRUQ]"D^'/BG5/[
M2\,Z\T@9KK_A,=#D9_[6MEQIVH#8EMLYK[15/3D^I[?X?SJPB>G)[F@#S#X,
M?#'3_@W\*O ?PMTR\EU"R\$^'[?1QJ$R".2_N3+/>W]YY0SY4=Q?W=S)#$26
MBA,<;?,I->D?L_?![P!XB_:0U'0]:T6:_P!(O_A%XA\3W.G7&IZDUJ^NP^-_
M"UE'J(B^T@1RI:W]Y @CVH$G8 <"M!(N<G/\O3IU_/\ "O0OV:1C]J>3C _X
M4'XEQ_X<'P5_^N@#Z[_X99^!7_0BVG_@=J?_ ,F4?\,M? S_ *$>V_\  _4O
M_DNOH.B@#Y\_X9:^!G_0CVW_ ('ZE_\ )=+_ ,,M_ W_ *$BW_\  _4__DNO
MH*B@#Y^_X9<^!_\ T)4'_@PU/_Y,H_X9=^!__0E0?^##5/\ Y,KZ!HH ^?\
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M_P"$ Z>&)1_W&=9_^3J]SHH \,_X9P^$'_0LR_\ @YUG_P"3J/\ AG#X0_\
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MK'_R=7NM% 'A/_#-?P<_Z%5O_!OK'_R=1_PS7\'/^A5;_P &^L?_ "=7NU%
M'A/_  S7\'/^A5;_ ,&^L?\ R=0/V;/@X#G_ (14GG.#J^L8/UQ? ^W6O=J*
M /SP^%K%/!=I;[YI%M-4\0V4#3S//(EK::Y?6]M$992TCB&&-(U+L6VJ,DXK
MO_K7GGPQ.WPDN>/^)]XJ^O'B+4>W^1FN]9B?IZ4 <;X>(/[6'P<P>GPV^*G_
M *,\.U^A%?GIX<_Y.P^#O_9-OBI_Z,\.U^A= 'RS^VS_ ,FL?&7_ +%NT_\
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M[JNMZ!X>ABN?$7B#P_X>MYYO(M[GQ#KNDZ#;3W& ?(MY]7O+*&>< @F&)WE
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M*)\)O_"0UG_Y+H ^E:*^:O\ A'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\
MHHGPF_\ "0UG_P"2Z /I6BOFK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)
MO_"0UG_Y+H ^E:*^:O\ A'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGP
MF_\ "0UG_P"2Z /I6BOFK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0
MUG_Y+H ^E:*^:O\ A'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\
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M6BOFK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\
MA'OVK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\ "0UG_P"2Z /I6BOF
MK_A'OVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\ A'OV
MK/\ HHGPF_\ "0UG_P"2Z/\ A'OVK/\ HHGPF_\ "0UG_P"2Z /I6BOFK_A'
MOVK/^BB?";_PD-9_^2Z/^$>_:L_Z*)\)O_"0UG_Y+H ^E:*^:O\ A'OVK/\
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M5GX,+M_:MM>,#_AG[Q7C_P .%X&_&@#]#:*** "BBB@ HHHH **** "BBB@
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MLZ=.*<I1BG*<4W**3O))IM)7;22W;:27JVTOQ/"_^&C$_P"B'_M%?^&KOO\
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M\ JJ      , 8IW_  T8G_1#_P!HK_PU=]_\GU]'45]Z=9\X_P##1B?]$/\
MVBO_  U=]_\ )]'_  T8G_1#_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK
M_P -7??_ "?1_P -&)_T0_\ :*_\-7??_)]?1U% 'SC_ ,-&)_T0_P#:*_\
M#5WW_P GT?\ #1B?]$/_ &BO_#5WW_R?7T=10!\X_P##1B?]$/\ VBO_  U=
M]_\ )]'_  T8G_1#_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK_P -7??_
M "?1_P -&)_T0_\ :*_\-7??_)]?1U% 'SC_ ,-&)_T0_P#:*_\ #5WW_P G
MT?\ #1B?]$/_ &BO_#5WW_R?7T=10!\X_P##1B?]$/\ VBO_  U=]_\ )]'_
M  T8G_1#_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK_P -7??_ "?1_P -
M&)_T0_\ :*_\-7??_)]?1U% 'SC_ ,-&)_T0_P#:*_\ #5WW_P GT?\ #1B?
M]$/_ &BO_#5WW_R?7T=10!\X_P##1B?]$/\ VBO_  U=]_\ )]'_  T8G_1#
M_P!HK_PU=]_\GU]'44 ?./\ PT8G_1#_ -HK_P -7??_ "?1_P -&)_T0_\
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M44 ?./\ PT8G_1#_ -HK_P -7??_ "?1_P -&)_T0_\ :*_\-7??_)]?1U%
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M-"C37-.I4G+11BK;*4I-QC&,YRC&4SG&$93G)1C%-RE)V22W;9ZE17P#IO\
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MI8M[PB^N88R(Y+6%X+:WP\]T1(Q4ZTN 4N>MB^+^"L/@J,)UZN)H9[3S"O\
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M5#&,7FP_+^BGG1?\]8_^^U_QI&G@17=IHE2-6=W:1 J(@+,[L2 JJH)9B0
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MUC_[[7_&@"2BH_.B_P">L?\ WVO^-'G1?\]8_P#OM?\ &@"2BH_.B_YZQ_\
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MRE\)OBI^T(GA+4M.U+2(=5^#7C#Q7)?6.L:G>R_\)$OCGPC9K?M;ZU>:E;"
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M\U]?1]% 'SA_PR5\ O\ H3-3_P##@?$C_P":^C_ADKX!?]"9J?\ X<#XD?\
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MA_PR5\ O^A,U/_PX'Q(_^:^C_ADKX!?]"9J?_AP/B1_\U]?1]% 'SA_PR5\
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MK*Q^N<^@_P#U?RH C5.PX'<G_/6IT3T_$_Y_E_C4BQ],]?0>GIT_E5I(L]>
M,?3Z?_J_/F@"%$[#KCDG_/\ *N(\&J5_:ST3/?\ 9Z\9?7_DHG@/J.W^%>C)
M'S\OZ]!^0Z_XUP'A10O[6FA<YS^SSXSS^'Q$\!B@#[0IKHDJ/'(JO'(K(Z.
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M%EMH/A#0-+\.:3$WPRU3>MAI%G%96QEV>*T0S/'"KS,JJ'D+/C+&NI_X1?\
M:E_Z*O\ "O\ \-EJ_P#\UM>_E>"CEV PF#BES4:%.-6:WJ5VN>O5E+><JE>I
M6FY2;;<K]3\JXVXEK\7<59[Q!6E4]GF.9XJK@J$FU#!Y;"?U;+,'1I<WLZ%'
M"Y9A<OP].C2A"%.-/E4=#Z0HKYO_ .$7_:E_Z*O\*_\ PV6K_P#S6T?\(O\
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M3O.DAT_Q-80Q>,I/-T75&BD%O(<21,%2=4:2,-Y>0YC1>7Y;A,5B*<<?RXG
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MXRO;#87#QK0Q$<#@*:C)4HU81C!U<37<Z^(E!)RY:4&[02/J.-N(,AH9%D7
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M *E6@UT5BG^A6.!_RXV?)_Z]8>_]!7._MC_\FU?%/_L&Z)_ZE6@UT]HP%E9
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M](LK6_\ B!HGB_5_!NH1:#K_ (;\+>/- \;Z7'<GPO>B:W-P_P!#_P##Q?\
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M7?#.[TNZU'X?7TR^&-=U%O$5AK%C8?6M !1110 4444 %%%% !1110 4444
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M]SWK]K* /F7]L?\ Y-J^*?\ V#=$_P#4JT&M.T)-G9?]>-G^'^BQ5F?MD?\
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M? #QC;2.^HV:+'<?\+"\#,;>1FF 6?;&[>2V)-J.VW"D@ ^[Z*PO^$H\-?\
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MF^$_@O\ %SPGXF\(Z+#H>O1W6J_\)7XJ9/#4K:4\<5KJ-P&D742_F:>'4@D
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MZ'J\=W,OF6^H:+;V^G7,($L$"*6K%\6_LU^+/&FJ>/O%.F_M4_M'_#^WU1/
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M ELBV@&&)=BWW/O%Y)&ZY+2.V<NQ-9[6R;K96F JJ,V\/"H"J ?)P$4D*.<
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MO_&>@?"6]N(M'N-3UK45FT'3M2CN?[#OH(7U.Q:6(HY/AY^U!^V=^T1KN@_
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M8Q:KJNJ6NCQ7,\6E0VB2," <Q\*/B-^U!\5?'_[7WPH\9Z]X'^#_ (G\!R>
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MO0=$U+P))X=M/#?AVU@L]*\#:0=6\#:CKND^#HK6W6%](LM8B$A:29Y3,V\
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M2Y/3@?K_ /6_SS3*0L!U_+O4+,3UP /RH >S]A^?^'^-1,V.3U_G3"_I^?\
MA_\ 7J.@!2Q/7\NU-) ZTTN!TY_E_G]*C)).30 K,3[#_/6FTQG Z8)_2HRQ
M/7\NU "LQ/3@?S^M-IK.!P.3_GK43,3UX'Z4 .9L\#IZ^O\ ]:HR0!_(>M,+
M^GY_X?\ UQ49/<G\30 I8GK^7:FDX&:87]!^)_P__53"23DT *6)_P /\]Z:
M2!UIC/CIR?TJ)F[D_P"?04 .9B?8>E1LV/<_R^M,+D]./Y__ %O\\TPG')-
M"DDG)IC,![GT_P ?2F%SR!T]>_\ ]:F?6@!223DTTL!]?2F%_3]:B+ =3D_F
M?\_6@!Y8GZ=A43-C@8^OIU_7_.*:SD\=!^OXU&2!U- "TQGQP.3_ "II<G([
M?KBF$@=: %))ZTQF ]SZ?X^E,+GD#IZ]_P#ZU1,P&><G\^??^O>@!Y.>2?\
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MO^?J?>HFE)X&/?KST]ZK/(!DYR?\_G_(4 2,^>3T_G_B:JR2X'\^?Y^OT_\
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M:5Y_T1GX_P#_ (;&[_\ EC36^*-\>!\&?C\!_P!DQO,_C_Q,*_1^B@#\W?\
MA9U]_P!$9^/W_AL;S_Y84QOB=J!Z?!GX_8_[)E=\_P#E0_2OTEHH _-?_A9E
M_P#]$8^/W_ALKO\ ^6%(?B9J)Z?!GX_#W_X5E=__ "P_6OTIHH _-+_A9.H_
M]$8^/O\ X;*[_P#EA4;?$C4V_P":,?'T#T_X5G=__+"OTQHH _,S_A8VI_\
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M ?QK.>O_ !1+Y_6^JNWPY^-+$Y^ ?QK//_0E,/\ V_\ _P!5?TBT4 ?S:/\
M#;XUD''P#^-(/_8E-C_TO_\ K>U5F^&/QN;_ )H'\:>_7P6W3M_R_P#UX'%?
MTJ44 ?S2-\+OC@?N_ +XT?\ A%L,^^?M_'TJNWPI^.)R?^%!?&<GM_Q1;#_V
M_P"G^<U_3'10!_,J_P )OCJ<X^ /QG]O^*-(^O\ R_\ '_ZN2<U6;X0_'<Y/
M_"@?C,>X'_"&G_Y/_6OZ<Z* /YA'^#_QZ;I\ /C+]3X.('Y?;SS]?\*A;X-_
M'OM^S_\ &4GU/@\__)^>F.O\J_J!HH _#/\ 81^%?Q<\/?M,Z9XE\6_"CX@^
M#O#]G\//&%A/K?BC0AI>G?;KZYT<VEFDQNIBT\ZPRLD83D1N<@"OW,HHH __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #5 <@# 2(  A$! Q$!_\0
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M_P HJ/MOB?\ Z &E_P#A13?_ "BKHJ* .=^V^)_^@!I?_A13?_**C[;XG_Z
M&E_^%%-_\HJZ*B@#G?MOB?\ Z &E_P#A13?_ "BH^V^)_P#H :7_ .%%-_\
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M;6/B;4?#EFFJ?#&:WN[3PA'I,NOR3WJ?$$V]FUJFN::88[AE>[\Z00!C!)@
M];^V^)_^@!I?_A13?_**C[;XG_Z &E_^%%-_\HJ\GN_C??6'BS3/ ]Y\)?B!
M!XHUNPDU/1M/&I_#26*_LK5;][^7[?%X_>TM6LDL2TD5Y+ \_P!HA%H+AA.(
M?/?BS^TC\0O!EIXG\-^"?V=_''BWXNQ?!_XC_%'P'X1U+Q-\.=,T#Q1<> X]
M*M8= U'7M*\8Z]J6ERZQKOB#0M-A>Q\/ZQ=K#=W%U!97+VIMY #Z:^V^)_\
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M?MOB?_H :7_X44W_ ,HJ/MOB?_H :7_X44W_ ,HJZ*B@#G?MOB?_ * &E_\
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MU5MKZ2^1H)9IH%+N]C9!&+PMM5?,) 8L$ 4N55B_Y'"]_P"Q<T[_ -.6I44
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M!\0ZMK.I?'?P%X]M/A[\2&\-^&_"^L:9JMV_A*ZBFCO-6AUN.TCM[.29;RZ
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M9] _[!?B+_T=H5=%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?!SP68QP>/P7Y0_%SX,_P#"1:[XA;X=^#O'\>O:#\.==^,/Q:^&H\3:I/\
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M0.IYZ8'. >,9P"F#NH!)]<DXZ9Z@=0O.#P3C&< IM.[/U;Z[?U_7X'R_;?\
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MY'FB'_1KV+.^&]MYXS@ %KWP1!/C"XYS_P 22\'0CK-;?7)/ XZC..E?K?\
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M#%<4Y>U_A6$XNC&*\E"R['ITO&3Q/HI*/&.9S2Z5J66U_O=7*VW]YZVGQ2(
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M^"[VVU"+P;I]S;VR:;]NF9+VQ_M@^(H],?3KM'&DVL\+"7]3+W1=8TUWCO\
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MS6IN*Y7&<<MA.,;5ZZ]Z/UAQ=\/AY+FNXUZL52C"%;V7X2_ [0=,/@W3=/\
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M['*\^F>&?$>M17=Q;:3XJT2*'1QX8OM3T-9-3U=]1GGMP#\[KC/<@X8]B/\
M%?Y'T[UAW&0,8Z#!X .<,#P3M7_<.=HP%)(&-GQ3]I\&>*]4\!>.=/U#P-XY
MT._N-.U7PAXPM)=!UVWN[5D68007HCM]5ME,D>S4=&N-1TV<2QM;WD@D&<:Y
MW* -I& 5P<@CKV(VI@'.TDX^ZI+;30!AF]O;"3S+.\NK.1<D/;3/;L"7+<['
M&T'CY1DM]\_>8#MO#W[0'QA\$NO_  COC[Q#8QP$.(EU"X9 ,Y(!W'R\GJ<8
M&!@EOEK@+O.2/0$8! P"S'E2,+UZ Y.2PZD#F[PG+\]%_O$]\]0/D_X%E!V^
M:@#[1TG_ (*%?';3AY&M:C!XCM1Y68M4M+&]+*HRX9[RUD)+;ODP^5!)4$9
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MX7T36?$_B'46,6G>'_#>F7^NZW?2#DK9Z3I=M=W]P4'S2&*!A$@,DA1 6'[
M_LL?\$.OVV_VA[S2=3\7>#K;X(>$+C6H]/O+7XCW\^A?$K4(;74/[.UV/1_
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B_L&GV5CYF/,^QVD%MYFW.W?Y,:;]N3C=G&3CJ:*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #4 BH# 2(  A$! Q$!_\0
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M;_\ "FOO_F<KLJ* .-^W>//^A=\-_P#A37W_ ,SE'V[QY_T+OAO_ ,*:^_\
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M?;O'G_0N^&__  IK[_YG*[*H;BYM[6)IKJ>&VA4@-+<2I#$I8X4-)(RH"Q(
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MN\>?]"[X;_\ "FOO_F<KJ+6^L;X.;*\M;P1[0YM;B&X"%@2H<Q.X7< 2N<9
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MXO\ @S5/%/@/Q'J^DK#':>*]*GT.ZBU&QU:;8]U=1-$FV]DO98KUK?5+FSC
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-\3?\ (:\"?]C)=?\
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M_4:UVNRH XSQ?_Q\>#/^QST__P!->LUV=<9XO_X^/!G_ &.>G_\ IKUFNSH
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M4&HRG/GKQ<&J;@ESS@=N7T,)BL;A\/C\PAE6#JS<:^83P>,S".%@H3DJCP6
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MA\8:Y9Q7^D>'7UNP&J:C:3VT][;36EOYV91=65K<WMHBGS+JTMYKJW22"-Y
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M-8NA?\>EU_V&-;_].UY6U0 4444 %%%% !1110 4444 %%%% !1110 4444
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M &,EU_ZC6NUV5 '&>+_^/CP9_P!CGI__ *:]9KLZXSQ?_P ?'@S_ +'/3_\
MTUZS79T 8=G_ ,A[7/\ KUT;_P!!U"MRL.S_ .0]KG_7KHW_ *#J%;E !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+H7_'I=?]AC6_\
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MN$N&$^:60955E_-B<)'&2TZN6.K8YM^;;?F?/>D?LF_LR:"Z2:7\!OA5;S(
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M0O\ CTNO^PQK?_IVO*VJQM#4K:W61C.KZV1[C^UKSG]*V:[#C"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *P_$O_(#U'_KBO\ Z-CK<K#\2_\
M(#U'_KBO_HV.@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K&U/_ (_O#_\ V%9__3+JU;-8VI_\?WA__L*S_P#IEU:@#9KXZ@_;5^&_
MV[Q2NH>'_%FGZ'X?TOXAZE9:VJZ!J4NL2?#'Q3IO@KQ'I4WAS3=<N?$OA76+
M_P 3ZOI^F^$K'QCI>A-XG,_G63HBD'[%K\V(?^"?GGZGXWO[_P ?Z59:EXLT
MSQG!JOCCP]X0EL?B#\1]8U[Q/IOBOP=K?QLU&[UZ\T?QU+\,M2T?3T\,V]II
M6C%H(FA@N=*M));.4 ]IE_:XL8]>USX?K\)OB%<?&#PI97OB'Q7\*K2\\#7.
MMZ+X(LM*TK6%\:+KD?BO_A%-3TG48M:L-,TBTT_6YM6O_$(O]'%C&^FWD\4%
M]^VS\++/3%\:KIGB>X^#]I/X6T[Q)\7TM]+B\+>%M;\9>'].\2:#I6JZ;/J<
M?BB3-IK6A6.JZA8:)=V&CZSK5CIEY,LJ7[67+/\ LK?$U/B?XG^/]A\3?!=A
M\:_'WA*Y^&GC"=? 6KW'@&'X>"PTB'1;7PWH4_C,ZY:>(M"UC29?$2:GJ?B'
M4;'4KC6M1TRZTV.Q@L&M^9U']@:RO? &N_ -/'VW]GSQA?\ A#7_ !5H4N@E
M_B'<:[X0\-^'M%2+3/%J:FFCVNCZWJGA+P_XEU..X\,W5_#=QZEIMC=0V%_%
M]B /J'X6_'/3_B3KVH^%KWP=XK\ ^);;PIX<^(.EZ/XL&AO<:[X!\6SZA::'
MXDLY-!UC6(+:3[;I=Y8ZOHFHR6FL:+=B".\M=ES#(WN=?./PB^"_BKPAXMNO
M'_Q$\9:1XP\6P_#CPI\)-%F\.^'+GPOI5OX/\)W^IZLNHZC97FM:[-=>)_$&
MJZH]WJLUO<VNE6<5I:VFF6$2>?++]'4 <;XF_P"0UX$_[&2Z_P#4:UVNRKC?
M$W_(:\"?]C)=?^HUKM=E0!QGB_\ X^/!G_8YZ?\ ^FO6:[.N,\7_ /'QX,_[
M'/3_ /TUZS79T 8=G_R'M<_Z]=&_]!U"MRL.S_Y#VN?]>NC?^@ZA6Y0 4444
M %%%% !1110 5!<VUM>02VMY;P75K.ACGMKF*.>":-N&CEAE5HY$8=4=64]Q
M4]%)I23C)*49)J49)2C)---2C)----IIIIIM---IM-Q:E%N,HM2C*+<91DFF
MI1E%QE%II-.,DTTFFFDUS:>#?"$3QR1>%?#<<D3I)%(FAZ8CQR(P9'C=;4,C
MHP#(RD,K $$$"NDHHK.E0H4%)4:%&BI-.2HT:-%2:NDY*C2I*32;2<E)I-I-
M7=]*M>O7<77KUZ[BFHNO7K5G%-W:BZU:LXIM)M1<4VDVFTFBBBBM3(**** *
M5WING7XVWUA97HZ8N[6"Y&..,31N.P_(>E<?J7PJ^&&L*5U;X<^!-2#?>%]X
M2T"ZSTSDSZ>Y.<#//.!Z5WM%<N(P.!Q::Q6!P6*3T:Q6#P>)3]5B,)B$_FF=
M>'S#'X-J6$Q^.PDHZQ>$QV-PK3[IX;&89KY-'SYJG[)_[-&L@C4/@9\,9 PP
M?(\):38G'UL;>V(Z=B,5QMQ^PO\ LL2KMM/A38Z)@85O#NO>*M!*^Z?V7KEJ
M$([%0,=N:^M:*^?Q' G!&*;EB.#>%*TGO.7#F21GW_B4LKP]1?*I$^CPWB!Q
MYA(J&&XVXOHP6JIPXGSYT^W\.KFV)I/336G(^)=*_8C^#XMIFT3Q#\9_"ABU
M'5;>,^'?C+X[M?+2WU&XABV"ZU6]4%4C3YF5F9AN=G8DG4'[(M]IZ[?#7[3?
M[3NAX&$^T?$2T\0JO3&1KFA7?F $#(D+ XP<Y.?JS0O^/2Z_[#&M_P#IVO*V
MJX_^(<\#QUH<.8/!/H\MQ6<Y6X_X5EG$6!C'_MVFK=+';_Q$WCV7\?B;&XY7
MNUFF$R/-E)_WWFO#682G_P!O5'^I\<)^SO\ 'K31C0_VS/B7E0?+_P"$H\"?
M#[Q-SQM\T_V?I9DQ@;ON[OFY&[A&^&?[9^F+MTO]IKX?:_MSM/BGX)6EFTF!
M\OFG0/$<!7<0-_EXQN?:.%Q]D44?Z@9%!6PN,XLP%MOJ7'/&%)1](8C.LSIZ
M=+PE\^I_Q$7/YN^*P/!V87=W]>X!X*JN7^*>&R+*ZNO6U2/?1[?'"6/[>FE*
M"NN_LQ^+64=+O2?B)X9:4@#EOLEQJBQ%B.0K2!=YQNV %O\ PFW[<FF?\?OP
M.^"7B8J/F_X1OXKZQHWFD=?+_P"$A\.OLWX.WS/N[UW'Y6K[)HH_U+JTU;"<
M;>(&&MLI\0X3,HKUCFW#&+<O^WZLK]0_UXHU&WB^!/#G%7=Y.'#>,RR3\E+)
M^*L&H_\ ;E*-NEM#XW?XZ?M.Z4A.N?L<ZU>,JY8^$?B[X$UD' ^;RTO$TQG/
MRML5BA.4SC<=J)^U7XVL1N\2?LC_ +1^EJN#*VCZ#X9\5A,<OL.D^(_WNW#[
M0G+X7:,.M?9-%'^K7$])_P"S>(V>M)64<PX=X+S%>LY1RW*:D_/WH7\MT_\
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M&'0AT+( RD,N00:^7Q\+/VQX/DM_VI_!]Q&?F9]0^!FC/,K\ JAM_$$*>7@
M@,I;<3SCBOY_OVO=.\0Z;^TA\4;#XB>(-!\6^,[74='36O$6F:'#X=L=28^&
M]'>TD@T5[J^:P$-BUM;RQB[G22>*6X1@LP4?FOBCXV9IX=9'@<WEX?9S&6,S
M6GEO_&08W*L!@??PF)Q3]CB<DS;/*]3$6PZY:<\)1H.G[63KJI"-.I^H^$W@
M3E/B7GV/R>/B/DDHX+**F9_\8Y@,WS''^YC<+A%[;#9[D^08>EAKXA\]6GC*
MU>-3V4%AW3G.K3_JVTO5])UNU^W:+JFG:O9>8\/VS2[VVU"U\V/'F1?:+266
M+S(]R[TW[DR-P&16C7YG?\$H_)'[,>K"#RO+'Q;\9X$.W8#_ &9X8R $^4'/
M) [G)ZU^F-?JO O$L^,>#>&N*JF$IX"IG^4X;,YX*E7GB:6&E7GBH.C3Q%2G
M2G6C'ZM=3G3A)\[3C[MW^1^('"]/@GC;BCA&EC*F84^'<YQ.50QU:A#"U<5'
M#PPDU6J8>G4JTZ,Y?6FG3A5G%<B:D^:R****^K/CPHHHH **** "L;4_^/[P
M_P#]A6?_ -,NK5LUC:G_ ,?WA_\ ["L__IEU:@#9HHJG;ZCI]W->6UK?V5S<
M:>ZQW\%O=0336,CABD=Y%'(SVSL$<JLRHS!6(!"G !<HK*_MW1/L<.H_VSI7
M]GW$ZVT%_P#VC:?8Y[EI&B6WANO.\B2=I4>-8D=I#(K(%W*0+3W]C'>1:<][
M:)J$\+W$%@]S"MY-;QDK)/%:EQ/)#&00\J(44@AF!H MT54M+^QOUF>PO;2]
M2WN);2=[2XAN5@NH2!-;3-"[B.XB+*)87*R1DC>HR*MT <;XF_Y#7@3_ +&2
MZ_\ 4:UVNRKC?$W_ "&O G_8R77_ *C6NUV5 '&>+_\ CX\&?]CGI_\ Z:]9
MKLZXSQ?_ ,?'@S_L<]/_ /37K-=G0!AV?_(>US_KUT;_ -!U"MRL.S_Y#VN?
M]>NC?^@ZA6Y0 4444 %%%% !1110 5EZYK6F^'-'U37]8N4L]*T>QNM2U"ZD
M^Y!:6D+S3R$=20B':HY=L*H)(%:E8GB6UM[[P_K-I=:%!XH@GTZZ23P[<K9O
M!K7[IF7391J'^A;+MPL1:ZS"F[>X(7!Y<=5GA\#C:].:IU*&"QE>G4EA,3CX
MTZE'"8JM"I+ 8)K&XZ,)TH3E@L&UB\8HO"81K%8G#-:T8J=:C"2YHSK4H2BJ
MM.@Y1G5IQE%5ZW[FBW&32K5?W5)M5:O[NG4/Q^^#?[8'QH\2?&OQWI^@Z/I/
MB./XDZ^C^&/#?C37[W0=+\*+I<4UEI.FV=]':WJ6EUJNGQ6\4]F;=5OM642J
MXD=M_P!W?\)E^V%_T17X3_\ AT;_ /\ E!7GT'[)<$7B[1_%]Y:)92Z]J9U+
M7-.\"75GH'_" ZP";C2-0\/W5S;RMJ=AI2HMC=%1;Z@MRZZAIJ+;EK2+W7_A
M0T'_ $53XR?^%Q+_ /(5?SYPKXF>.F=+-Y9E]']8'ZGC<'AL%2K^)/#W#];$
MX.KD^ QBS-T.(,BQ]:5/-,1B,1BJ&"IXF>+X=HJ/#G$3EQ/EV;U*OW69<.\%
MX1X58?CGVWM:-6I6E#A[,,?&G6CBZ])X93P&-H04L-"%.E.M*FJ6/G?,,!;+
M<1A8QXO_ (3+]L+_ *(K\)__  Z-_P#_ "@H_P"$R_;"_P"B*_"?_P .C?\
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M(\017R<<?4=_*R7GT?(?\)]^UK_T;]X$_P##N6G_ ,IZ/^$^_:U_Z-^\"?\
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MI3^:YFD^Z3:3O9M:G(_\++_:E_Z-FT/_ ,/-X;_^5='_  LO]J7_ *-FT/\
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MG4Q&#5/V&*E/$QJR?(?\+H_: _Z-.\1?^'1\#?X4?\+H_: _Z-.\1?\ AT?
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M46_6+X7;7H[M&!_PT'\5?^C3_B[_ .#;P3_\NJ/^&@_BK_T:?\7?_!MX)_\
MEU7:?\(Y^T5_T4OP!_X0EW_\N:1O#W[1R8,?Q%^',Q/!6X\$:C&JCU4PZQN+
M9XPW&"3UQ1_Q%?.E\7@?XW)=6L@X'FU_VY#Q6<Y>D5?KLF/_ %7P;VXTX-OY
MX[.HKYREPO9?,XS_ (:#^*O_ $:?\7?_  ;>"?\ Y=4?\-!_%7_HT_XN_P#@
MV\$__+JNQ_L/]I/_ *'WX7_^$;K7_P N*7^R?VEE^4>+OA-*!_RT?PUXBB=L
M\\QIJ#HN.@ 8Y R3DX!+Q:S.&L_!/QTL]/W?"'"U=W\XTO%7F2_O/2^F[0?Z
MK8;IQEP4WV_M7,X_C/AA+Y;G&G]H7XI(-TG[)_QA\M>7\K4O!4LNT=?+B_MQ
M#(^/NH&7<>,BH_\ AI+X@?\ 1I_Q[_\  ;P7_P#-37;?V;^TNOS#Q/\ ".7;
MSY;:#XFC63'.PNMXS(&Z;@K%<YP<8H^S_M,_]!#X.?\ @)XL_P#BZ2\7\6OX
MG@SX\TWT7_$/\HK775WPWB?5C&STM)J3W2:U#_56D_AXNX)EW;SW%0M\JG#D
M6_5)KI>YQ/\ PTE\0/\ HT_X]_\ @-X+_P#FIH_X:2^('_1I_P >_P#P&\%_
M_-37<!?VF8A_K/@U=ENS+XOMMF/38LF_=GOC&.^>%\S]IG_GU^"__@3XQ_\
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MY(W;$OMW^MCQC+XSG'7/T-=I6-XACDFT:_CB1Y)'B4*B*7=CYL9PJJ"2< G
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M_P"'T7_!)3_I([^QO_X?SX>__+NC_A]%_P $E/\ I([^QO\ ^'\^'O\ \NZ
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MZ9H&FZG;PV>KW6KW6H<?_P /HO\ @DI_TD=_8W_\/Y\/?_EW1_P^B_X)*?\
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M /\ $4 ?JS17Y3?\/K?^"8/_ $?W^P]_XE-\/_\ XBC_ (?6_P#!,'_H_O\
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MOTD      !@ <  = !V K\IO^'UO_!,'_H_O]A[_ ,2F^'__ ,11_P /K?\
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M8_\ !!I7_P B444 '_"$^#/^A1\,?^"#2O\ Y$H_X0GP9_T*/AC_ ,$&E?\
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(D&MNBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I BH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^\K5]6UQ=
M<M=$T.VTF2232KC59Y]5GO(D5(KR"T2*%;2"9B[-,79GP JX')IN_P ?_P#/
MOX/_ / S6O\ Y!H?_D?[?_L3[S_T]6-=A0!Q^_Q__P ^_@__ ,#-:_\ D&C?
MX_\ ^??P?_X&:U_\@UU^Y1U('0=1U/0?CVHW+TW#/3&1U]* .0W^/_\ GW\'
M_P#@9K7_ ,@T;_'_ /S[^#__  ,UK_Y!KK]R_P!Y>F>HZ>OTHW+_ 'AV[COT
M_/MZT <AO\?_ //OX/\ _ S6O_D&C?X__P"??P?_ .!FM?\ R#77[E_O#J1U
M'4=1]1W]*-R_WATSU'3.,_3/&?6@#D-_C_\ Y]_!_P#X&:U_\@T;_'__ #[^
M#_\ P,UK_P"0:Z[<O]Y>W<=^1W[CD4NY?4=<=1U'4?4>E '(;_'_ /S[^#__
M  ,UK_Y!HW^/_P#GW\'_ /@9K7_R#77[E_O+TSU'0=3]*-R\_,.,9Y'&>F?K
MV]: .0W^/_\ GW\'_P#@9K7_ ,@T;_'_ /S[^#__  ,UK_Y!KK]R^HZXZCKZ
M?7VHW+_>7IGJ.GK]* .0W^/_ /GW\'_^!FM?_(-&_P ?_P#/OX/_ / S6O\
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M )!HW^/_ /GW\'_^!FM?_(-=?N7^\.N.HZ^GU]J3<O\ >7\QVZ]Z .1W^/\
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M::7N95%<7");K&I>]BFAB>XM4BN9V2]O+2%XS+?:=>*2FMV4A%SX4;]_:DH
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M);"SNH?,AL7O0GF'1[BX(ETKQ<I%REV1IEVI0$&=DF:8NAG>1[EY]P6&"_\
M[1M;=(&F:(Q^1'XMM(PZ0V>?[)\0:>&N) TI7$_F( '0H(_(EN5DMX':(6$\
M^VXN8K5P6?2KAP8]<T%_]*TN<M>62A0IH JNB/=7,>PN6^R0%'5(KMKNQEEE
M1"JAH8_$-@@$D=H/^);XDMPG(9R0MN$5O,VH GF:BLJP9"%FE2]U%+5E'VB&
M3*IXB\.$B;0)238,1MS%$ACN)(Y%38MKIEBT;OOM/*;[0VGV372*)GT,RLK^
M'?$BXOK:[/DZ@QBCV5:E#R$!?/:0W4C(6"QW?]I68"/) I!AB\5V2J5@5_\
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M4CW-E%*TRK;S2Q6]V55A9W,L5M=^3/*D; #O'W_(HZS_ -<[7_TOM:["N/\
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MHX0W.F3-&#XL\*[O/TV8[X@OREC_ %CP<_XW!_"%2_6E@L[P3U[?4^*4D_\
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M/X;<B*ZD7+**-[?:=92L=0\06%E+]KB9EU35M"L+\W<$"1#SYY9(XXO%-M"
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M . H^'S^PAX(U-HSXC_:!_;/\7-F\F/]J_M$>,-.NKB.1HS?3I#I%MHGDZM
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MZ)#<,RLJ_8]2:9$ DEA#JD>G>)U21DN]+;]UX@TT/=1H3,=H!6>&65)%-R[
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MXCB\R[^?<09G BC:9/)PD,UQN02/9+;2D_:IY()\&Y\+R.Q&J:: ;WP]/O\
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M;HPO;@3VJV=S+(+87U\I-S-H4SJ#X7U>(F_L-0_<WFV$.*L^6_S@B[,KR(C
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M(@) ("EW*YWV\OF^8L126]DL[\SJ"MM%++'"L=KXA6(YTO7@0FMV 6RG<R.
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M]6\-?&$_M9^#+[5-7NM \#^(-+UK2X? -M'X;NYY-!\&>7,9;'P<?#]M8_\
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M =8[77XX\2V/B7 AUJP4:;(&=U<RK)&<;)49MUQ)$UK;[6:4@)?3VVFGG[5
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M^'?C?Q=8>3'+$B65QK,NF6&FWUE=7";])U:34([[1Y&2VB+V\9!]7\*_L_\
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MSQ# 9)/+N&*B/T#PV8SI%N8FMVC,MX4>UB:"W<&\G)>*%P&A#MEFB8#RW+H
M%50 #R?XK_&^U^&/BSX=>#?["@U;5/B,?$+Z?<ZEXM\-^#M)LX_#DWAZ"Y@:
M_P#$=U NH:M?2>([0:7HVG17%[>+;WC!4$0+>:>,?VQ/"?@G5;J/5?!OBJ;P
MS<>/M8^#WA/Q7:3:(]OXP^,>C3_87\ Z?I<VHPZC8MJ&KQ:AHFF:_J26^D3Z
MII.HQW$EI:):WEWZU\:/A'-\9/#TGA"[\777A_PKK&G:KHGBW3+;PYX:UFYU
MK1M9@CM+M-,U/7=/O;KPSJ\=H;N"SUK30\UHUV;J*#[;:65S!XMXH_8M\)>*
MI)[&]\<>+[?PEIWCJ^^+7@/PQ;1Z0W_"!_%R]>.ZC\;V.M7-E<:GK2Z;JIO]
M8T[0==>\TU+_ %C4_MOVZU>RMK$ O77[7%I;-XDT5?AAXMN_'WP^MO%FL_$_
MP/:ZOX7:\\'>%?!MGX=U/4?$5MJTVJ0Z9XE35=+\6:)>>&--TN1;_5R^HVT\
M>FSZ9.AZ;X8_M0^%/BGKO@^VT30-:M_!_P 4=*\7:Q\(_'MQ<:7+I7C^R\"W
M=I:>))8=,MKN36=!4B[&H:$=9M(/[;TFWN;U!:NB6TG+W7[(UK<W>N^(D^*'
MBRT\=^/K+Q9H7Q5\7VFD^&UE\<>%O&5KX<T[4-"MM)GL)]/\*MI&F>$]&L?"
M^J:0&OM)4:C/=-JEQJ,LJ])\*?V6_"WPFU?PC)H_B'6K_P (?"[3_%^D_![P
M1>6^FQ:?\/--\=WEO>^(K2/5+:VCU?Q$D:VR:;H#ZU<32:+HTD]ENO9I!>(
M>W^/O^11UG_KG:_^E]K785Q_C[_D4=9_ZYVO_I?:UV% ''O_ ,C_ &__ &)]
MY_Z>K&NO;H?H>^.WKV^O:N0?_D?[?_L3[S_T]6-=>WW6Z=#UZ=.^.WK0!Y)!
M<.RVY@R&;S)8YK&)XF::#$=Q?6-K,Y-M>V43&'5](G4CQ' 1=:?'(0RF0+!&
M@DC^SP1I;L4\J%KNPAL;B1?M,<5L$^T77AK4)D#7UON-_H6HGDI;A L36V_<
M7FN'D+6B2"X:TLIC*BF33X+J<6I^S7L)Q+X;UP.8W118SO'( 2R-;QYT;[=J
M4DOGSSK*D$-E<O=QI&DUW!:/;A;+5;>)GAO_  XQQXA@+:I S?,I +!<R;DF
MA*J'MX9H;JY# R(D4]EIM[>"20/>V[%9]"\41'[)*HATZ[F,ZN2XLT1!C:8R
M//+*SK$J7$UY"!'<ZGL585M=>MXB5US1F M]<M@3I\3/(4-4P+$B&WN?*"VG
MEH]O!;7,,>G3S[)E@M([0/=^'+LG;<6A'G>&KO?</$88]P(X9I WGW%T^&LH
MW2XGM]JL@$FGV<]T]JWG7$$H27P_XQ7,5W-Y=I,T;Q\@$X\N90Y$4:?97*+L
M+VHTZY8+<F*-EFE;POJA11?Z<S'4?#LI5B$C5=KGD:-F01M)@PPF*60I+N5!
M<:?I<EY')'&)HR?-\.>*U*VT<2K9W\_VAV9JTB7$3!K>\OD=KBYN"\4,"RM?
MQA1->_9X[91#KUL'D&I^'R<>)T:26W=\,"Y+96CRT[>5]EF!+I;7%L=.EG9;
MO]V;3=+X<O&"+J6E$&?P[<[28FAC#  M)'ND$BR3&8W4LRRP11P7;ZC$AMYK
M^.WDB(C\2VUL3%J6FO\ Z+K6GAKFRC<G88EG!'R)%'%]G,I9(Y9+-;*X+_:)
M_LK2/+-X>U.5/+N]$VMJ7AZX\RZ=8XBDBU7CN-SJUS>X;[- T<UQ"C,J0F:R
ML);];<@!)L7.B^-!^ZD?;I,FR;FK/D.)#)'<W?GBZGE29(K2"\-^BJD]Q#;K
M:*(_$-O;EH]3TW<(_$-D1);R2>8RT /9$A5RL?RD6T#V[RJZ21*"^G:9/=QB
M,PPQ%V;PMXF$@CC4^5J$AD1MPK-.5),^\W$KQ2(JI=OJ$&^%[RRAE$J6OB2P
MC+17EK,HL_$<0DNK1)5?!IQ)(RG-W,8A:S,6,,+6RVEP\@O)C9O:YO-&OF .
MJZ"%,_A60'*,K*P?+ \:R!)YTWK;P7$;36^9HUC+V%E?7L-H#! &59-!\6@,
MEM&$LYC'(0* "&5((I1$;=(%:ZF58K6:>QMK6:1OM4T$*^7+J6AWTZ;=5T8B
M74-+OY7N45884:.R8T<2>;#U6V@N+:ZN4<B%6$MAIVI7ZAUE@CFE,_AOQ!!+
ML2Y"6=[("KJ_RS>?'[QM;^+_ !1X7T?]G[XX>*Y?#OB;4K"+Q+::?H^BZ3JU
M_:Q'R]5T:;6H+>"UN&M6:"46LES#K-HTUR0S3[#Y)XF_:$_:UBD2#PK^RU>>
M'+ VDDEKJ'B2\U+Q5;6D3F4:J%T7PCI=M]NTRX0(9='6X(TN9#/M0F-D]&AE
ME>M55&K6P. ;A"ISYGCJ&!IN$XJ<)J4HXJ4E*$HR7)3<FFK1N^4\^OF5"C2=
M6G2QN.2E*'+EN"K8V?/"3A*+C&6&47&47%N<U%-/WK*Y^@/FR^8%5KEY&N&"
MRI&+?4)[V ^5+<I&66&PU_380/[0@DC2S\46V18I,<1AR18C2:#8JI#/+$UO
M:/<6<5O<.&OI;6R$7VFZT749U5=>TAF-_I5X1) %3:X_,G_A8_Q^U>&4^/OB
M[X\^&]O)8V3WECX&_9/UB::&!)Q)8VLOBSQ5+KLTIMF63^PO$,5HQAE1G&-Q
M9UDT_P#9]UV5A\4OVB?VIO&DJ2K)>V?BO5/B'X$T^=[N.)%?^Q?"WA7P]866
MI6$#20?9TFV:S'(#%<+@(?1_LG)Z/^^<4X"36]/*<LSC-I^BK5:.2X-ZZ7]K
M*.SO9G!_:N;UO]TX9QT4]JF:YCE.5P\FZ5.MG&+2ZV]E&72R>A^A/B+QUX'\
M*Q2?\)?XK\(>&K7$<$UMXG\5Z380>6HCEM=+OKFXU!)+M/G:[T'7;5&:P"K8
M7I$D<J/X;J7[97[-]A-);:3\2G\=:CY\<S6'PZ\/>(/&^K7MV76TBU"*3POI
M%Q8V_B&R$:QWD<=R]EK-C&4CC9Y=J>1>&-#_ .">7AR1;G1Q\'5U2%XY'U?Q
M3I\_B;4XYPLD:WWE^-K&]NKNWND.R_TYVCNM/G+7*/,FUF^E?#WQ/^!L,/V'
MP[\1_AA86^8K(:9IWB?PC8VT7DB&2WTN?R(K9;J%)&\_1_$\4(-I<NMI,B-#
M(S'-PE0VI<29I)=:E;)\DH2_[=H4L[QBB_\ KXI)>8<O%-?>KP]EL7TIT<VS
MFM'_ +>KU<GPC:_Z]N+?2QYLW[2OBC7]O_"OOV8/CSXIC6&ZDMM2U_0M"^&N
M@F-F2.]GLF\8ZQ_: T'5@"-6T9K![S345I+=%8K('OXE_;*UUY(=,^%WP,^&
M=D42V@;QS\0?$7CW4;:VE0OI5G<6_@K2M(TZZMC/*C:-K*ZFHTMD$5S=*#(S
M_0,'BWPS>['TOQSHUZ)IS/NLM?\ #\MQ<7D!1?M+"VD*VFO6$)'VF!-UOXGM
MR(5FQ(0-RV$-S#')%J"3Q^1<2)+";"[MS;7#$7]Q#:K;NRZ/>E5_M[PV<3:4
MVR:-)EB5J7]LY;1TP7"^3P:VJ9EB,WSJKY-PQ./R[!M]6OJCCTY;:,_L?,:W
M^^<2YO-/>GEU#*LGI^:4\/@LPQ:79_6E+^]?4^8E^$?[37B9T;QG^U)_8(DO
M()9]-^$?PK\->'KN34+:(PW$#:[XIGUV_36X80ZV\PBM_P"UM/"_9WF*@-67
M]D+X?:QL?XA>/_CA\5F:W>25_&'Q0\4KI,]L97N;C4AX<\,W'AZS^P7%R6M-
M5\/FW.K6"EYXP8&68?54EM>#=&);SR1%#;F%W22'[.42>VL&U".T*R:?)*6G
MTCQ: 1HLN-.F6.3?5E[6029,M\9&OMX+"TM[QM1B3REDW_9=D/B6ULP(PP;[
M/XDTP!8YCOV!_P"M>>4],'B<-E:Z+)\LRG*I)=E6P>6O&?/Z_P W7FOJ'^K&
M33UQ>'Q&9/J\VS+-,SBWOK1Q>8K"?)8+EZ<MM#PWPS^S7^SYX+O9YO#_ ,&?
MAW:7"K:2M<WOAZPUZXD^UR.B6\VM:K#>WLMA=LJ2:+XE6=9M/N0L6IR>6C1-
M[;9Q0P(MK:VHLX?/\I+>TAM[%Q>V^Y8Q D0^RV_B;28T2.&X=%TKQ+ %\CS5
MP$IPQS-<NS7=R5-GYWF)#"4*2_:?MMX-.>V)-E<R+MUOPBZ_:-(??>(LC,IJ
MQ+;M$CB.>5$\BW@DC62WDC>R.&L[*XNH[0%-&F9G;0_$P#'0F9HITB*D'R,7
MF&/S"?M,?C\=CI_SXW&XO%R7H\5B<1RKLHJ"71*RMZF%P&!P$.3 X'!8*'\F
M#PF%PL7ZK#8:A?S<G)OJW=WL&7R5#(XV^7=7*.EO)-! K%GOM1@@7RY;JRNI
M6*>(_##![V&Y9[BT4)$)*4QQOO$\,040Q02P74ZRQ+9-(3;:=>WJK+Y^B322
M"YT?5[=_.TF\,=K>NJ))&8HH9I'!ENK^5C>@J7^RPW+7T(>.+RTDMBMCXAL[
M<>7;7AQ;>*;-6E60+. ("DL2IY%]/%$L=S/"UI91W%M&95E%]>VMDMJIN8IW
M7R]:\)%4FLI2^IHKA$8\AUEPS2^=Y;"[N)&G\HDXM-1FO(4;:#)O2ULO$.FP
MH&&H,BZ=XCL<6L1EE*JJ+Y:JLR.H95NKJ*XM[8O'$SDR:C?6>GM&)I8;ML1^
M*?#[YNK=E,]DJDB2H6M5,4B2R,L8MK:)X[BYM;J 69DWV=K<ZA]D;[5H[S,\
MFB:T@+:-?,\,R1 -356[:XV/=:G(6NX\HQ@MKN6Z@8QP*;AK8PV&M6$&!:W[
M'[/XQM\(D@4X !,65UDAEBA6 11PS1SO)-8I92N!;6%_<!Y/M>C7GF-/I&J0
MJTOAR3_0[]H@KQ-*P=&.1=3RS72K*DCPV][<WT,)\@372B*#3?$6GPP(+&^9
MQI^NZ<JQ?O9YD*5C"Z(DD-W<(Z)>36\UK9V\AB\S<^HW=CI@M5DN8Y9U7_A(
M_#!V3+=#[7#YN$8L6%F26.>=S;K;QP-#//!=6,5DSPO#:W5P;1AJ6CSR222V
M&NQ*S:!<O]@E1!#+0!:1Q*D;EAP)[BTF@MBN 5 O=1TNRF$CPP7(>6#Q#X;G
M5;N.,37UG&I(=VNZP*L02-HHX;>)8V9Y+6"RE=8[?3_M,;1F_P!#O&P=&U6,
M&;P[<[&OW2(%1'+#.KLJW%_ODNX_/3=;0W,U["I$/VZZ2VV:;KUG$D+6NH;F
M@\36L4-B)095"LCA=XXFDNYW.VZFBE^S6_)D1?[0N[2PDM#):QR\CQ'X3?;+
M#&3/$LC)D@$DD7FS6S.EP]P;U1*&F@AO&OH;:46@NI71HAXBTR-"-'OT;^S]
M=MPPD:5BF'K<,2NTL3MN+F*YMK:2,@JJ?;-4@L9'S'$7=K?Q#X7=/M-U(#J%
MA%L4R-EW,<B26D7VEQ"%$"0LT<MI'I\D)>.SBO$MMMUHUVQ+6>NA3_PB+X@F
MC0LV--K5F<^;-=O,UW!O$TME;W;7T2;;99KO[*P@\06MNJ#2]6W?9]=T]5MS
M*K,HH >8X84 5;=(X[:&!5P;JS33I9/+BL"419)_#-W*QFT_45)NM#U!C'=N
MEO&T0-SS,5E64OY\",)9 DS7T"^9;V\EPS2Q+XDTWRXWTS71C3=>C,5LTLDN
M"M2$7,CJ3?7TC$7%PDD5K# YE>$&]U"*REM?W3NV8];\%MB4@/J<0=V&72VQ
MC3$=PR1BT@@ C-M-;+I<DH6"UWI:!I?#-P7<:?JGW_"\SRM/$L<;4 6&?R0&
MC=B<W5T)4MR=DRG=?ZM%;KY3-<$R,OB?PL1YUX=TNG1C:6<*12JRRQPH@MQ"
MR3.9;=-+N)"BVDT^V5I_"U^VR:WN(R;WP[=M%!=;(E:)88X9I7(FN+V5_M5N
MF)9+9)C=0F1+2W\V2V*PZU9HD8T?Q$&%MXBB54:9=Z5&RSQ[##>W: -=W,<E
MM:1,J7)0F\U&"T6V5I+T.TB:YX-(66^=Y=0A,AC)(!<>63S61H[F:9IDA;S7
M6UO9KF.)IK:TEN1)';V^M6"*)=-\0X6PU6R"Z?)))<L&**%#":.0^8'N;F.Y
MMK<+(+I01?ZE;6$D6_[?(A,/B7P^^&GMQ]KT] Y)-<VJ,A6:8!%M1$R3RVMW
M:)ISS_)#)=?8V:[\.7$G-O.H,OAV_(22-8@2&;+MYS')=:A(YGMXF262&VG>
M:$.;2WEOS 8;;4;,!9=+\2%C!XDB"Z=YBMB@"PLB.DD;1PI!]G"N6,DFG1V-
MS(R+#<*S227?AS4R2]J(E:]\*S,ZW8CC.RI&!CWD1RO,\D44D<DT<=Q=3Q1&
M2QM+F]3RH[#5;%(T_P"$?UX2+97]D!%=2/<,CK 874B:*ZN5G1KVXAGAMK9;
MI+K:6OKVTL!:!I+_ '#;XC\-$JVHL/M,!E+"HHHF=)(Y;AVMUM6C9)?)FL(M
M/FG4-'<%K0G4_#]Z9'8R1JTGA*=FM9(O+5B !T[>=!OWMO$YFMIXK<PNUPDT
M45WJ>FV4X=K?4(UEE@UO0)PG]IHLU[8QLKGS9RT<";$6W2&."-5&R2>RMK&X
MD>,01^64DU/P[J$B 0A ][X;OG,]UY=NH"4[^"98IA]HO?-DNK!+E'EMDGGG
MB96L[?4+U+?;8ZC;K'#)H_B4LT&I01V]D[([H!/'%++LD:[O))C-=3PS);6T
M4[7/E*+N\L;"2UW6-\L;RIKGAM]IO[8RW4!E=V! +'E[RYE23S6DMDG2::);
MIYH<3:?:7][AX_[4L&&[PYKD4OV/4\"VNI&D(>D$\A9/+:8R&2>5+F& P7$D
M\+)'>:I!92,JVM];K(T6OZ#+$#KHW7>FPD!@U)XW1!&EU)';);*D:HL4VGPZ
M?/.J-%"PM =1T"^X3S HD\&2A99H_+Z6#:L^\RS7#3-+9K*MQ<6<<YN(HRUA
M#=:B+5MNI0;4D\/^(PYBOX5%K-)'(4P 2!8(HP\8MH8TMB%\N(W5E#I]PX$T
M,< C%Q=>&-0F423H&-_H6HL5<I;JJH;_ #@T<T+C]Y!!-'<W (::-$GL]/O+
MK=*K:I:,$FT3Q/&18WB""PN)C,&8UX1=O*C?;M1DF,UQ.LD=O#9W+W2QQ+/?
M06LEN!:ZE%&SPZGX68@ZU$7U2$OEE9&@$<2M!<^4$M!&C016L\$>FS2[7BAM
MTLU>[\,W1)4QX\[PS<M)/)%Y4(:@"TS-%@QM+YCRSS,ZP[)GNX<"\U01*(A;
MZU#&[+X@T!P(M9A!.G0EW97;B.5 S"*./[+(@5E,ELNF7+E9U4,LLLGA35#&
MANK3=_:'AN8IO6.-0D<$44TH83W%V[![.-UGFMP5EBR]A9S7#VK%[RV=(Y-
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M'<RR1 !>W'Q$_:^NT62+]F_X?7!>XNWCEM_CKI[2?VK8X6WEBD'ALP)KT:*
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M1,CRW+>=J$%K(B7<4BW%TEAJ$=O);0W;E1XB\.D>6)#YMHX=%S:'[0/P,W"
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M!N!F5[_*,KEYW-Q*DBV[V^H27MJ@BO9TM\_9K37K5/EU/36QI_B"#,ML"2:
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M;!&A@\4VH,P.D#_0/%,!EF8Y.!WWAPHVDP-'Y)1I;ME-O&886#7<[%HX2 8
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MCN&'F^$OA[;N'*2+<^)/$$MP=2C01VCS7<=A&(_$?DA4M-5!VZI9E+43W 8
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M$6NY+)I%9JX77?V=?C3XWOY;GXD_&"?Q9H#;0_@Z.^USPMX&?3!-YNGBXM/
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M:ZU"-+'Q';J=:G5V75M*,:P:UF2:"T7/'H(\._%FW5,?%+3S'Y%TIW?#733
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MC7,$?R2>&?$L)"Q78AM;V1S$\9$)@'#3$R7$EP#$@2Z:Z@7;<W,XB1X[;Q;
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M%M>LBQR@@ ["W$>QH ACED1E5C 82PBN9=.MW#EO#[ D>(]#DQ)H0WW-M&6
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MPR%P+3.\3B[+F=$99)5M=1-RD<?DQW-Q&$&E^*4BF)TZXC;[/X@TP1K/(7G
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M'BV:*PO)2VEF74O$&M647]F,@5]-U3[-,FF;H[6X5&5U65O@3\6-4N$?Q/\
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MZ07_ .$C\X:L#IAA%\/(KVD2Q%(Y!+&4EV&)PZE)!(,QF-@</O'*;2=PY7-
M'/'PGHY;>1J&XSM<[AJVI@^>X DDXNP!YP'[]0-EQ_RW60T@\):,%"!=0VB*
M6 *=6U-AY$S^9+!AKL@P,_SB _NHV ,:)@8Z))H9"HCEB<LK,H216+*K;&9=
MI.55_E8C@-\I.>*:+BW,(N1/";=E#K.)4,+(V-KB4-L*MD88-@Y&#S0!S[>$
M=&?.X:DQ*1(6.LZMN(A_U+;Q>!_.B'RI<;O/5/D$FSY:>?"ND%]Y_M#?Y[7(
M8:MJ:D7#KLDF&VZ&'E7Y9L<3CB8/6\EQ!(P2.:)W*&0(DB,QC#F,R!58DH)
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M[9Q_KX\>7,?FD1FYJ,>$-$52H2_VF)[=E.KZH5:!W\PPNIO")(U<!HE<,(,
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MC@$8U'D0Y/\ ;&JDEK;_ %$I)O"3/%_#<Y^T8 #2L   ^$]')W$:AGSGN/\
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M[1962%&W:QJK,PMO^/<LYO"[20=(9BQFC'"R 5T:.LB*Z'*NJNIP1E6 (."
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M:K)*$^4.S;>,5T5% !1110!Q_C[_ )%'6?\ KG:_^E]K785Q_C[_ )%'6?\
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M?@1^U+XS^,WQJT2W\7^(M&TW58WD^$7C2;X0Z)K&EZ=I-IXBTJUN?!;V6D^
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MEG>64MS>:GHOB;PEH<.F7*3^5'83P>(M2LKB>6:+_2%EMDDA5!L=@^ ?//\
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M)'B#_P #/#7_ ,O*/^$BUK_H2/$'_@9X:_\ EY7744 <C_PD6M?]"1X@_P#
MSPU_\O*/^$BUK_H2/$'_ (&>&O\ Y>5UU% '(_\ "1:U_P!"1X@_\#/#7_R\
MH_X2+6O^A(\0?^!GAK_Y>5UU% '(_P#"1:U_T)'B#_P,\-?_ "\H_P"$BUK_
M *$CQ!_X&>&O_EY7744 <C_PD6M?]"1X@_\  SPU_P#+RC_A(M:_Z$CQ!_X&
M>&O_ )>5UU% '(_\)%K7_0D>(/\ P,\-?_+RC_A(M:_Z$CQ!_P"!GAK_ .7E
M==10!R/_  D6M?\ 0D>(/_ SPU_\O*/^$BUK_H2/$'_@9X:_^7E==10!R/\
MPD6M?]"1X@_\#/#7_P O*/\ A(M:_P"A(\0?^!GAK_Y>5UU% '(_\)%K7_0D
M>(/_  ,\-?\ R\H_X2+6O^A(\0?^!GAK_P"7E==10!R/_"1:U_T)'B#_ ,#/
M#7_R\H_X2+6O^A(\0?\ @9X:_P#EY7744 <C_P )%K7_ $)'B#_P,\-?_+RC
M_A(M:_Z$CQ!_X&>&O_EY7744 <C_ ,)%K7_0D>(/_ SPU_\ +RC_ (2+6O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "" BH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBN$^)L>M3> O$T?AW0M3\3ZV^GXTWP]H_B6+P??ZQ<?:("+%/
M$TUYIZZ/;SH&6^NH[VVN?L'VF*TE6ZDASK1I^VK4://&G[6K3I\\W&,(>TG&
M'/.4YTX1C'FYI2G4IPBDW*<8J4EG6J>RHU:JA*HZ5.I44(*4ISY(2GR1C"%2
M<I2Y>6*A3G)MI1A*347W=%?&.D> _CAX5U7P+KNE7OB?Q;&;'PO#XS\/^,_$
MVGV<-K=1M+I=S);+IWB+6(Y8=!LGO]3,3:MJ\EQ)>Z8]U<>*+Z&X-DSQ@G[3
M?B+QEXN'@UKVRT#PUXW9]!&K_P#"/:-I&HZ?8^%?#=UI,6A/#LUS6;>?6=0\
M3P>)9/$X?1KB5=*ATEB-.NC#[BR*E.MR4LZRIT51E4GB*M9T(PE'$2PWLI4Y
M.I54YS4)P?O1G0FJL?=C+E\5YW4A2YZF49FJKJQIQP]*BJTIQEAXXAU8U(JG
M3<(P<X37NRA6@Z4K2E%2^T:*^+-,\5_M+7'Q5T[1;W3;O2M.U&Y\2:G'9ZAH
MNE:CX,T3P?\ 9_$LFBV_BO7=$MS=7'C!-1C\/VL*^&?$D^G"VD\B\CN9VN+N
M3T?X5:+\=M+UV";X@:Q9W/A^2'Q':S:):MI$MKIZ1#PU/X9O[.ZAM1K,]Y=W
M<OB^/41>:E=0):C34%O"8HG.6)R1X6E*I5S/*G)8:GB:=&EBO:U*T:CJ+V=+
MV<)Q=2+IR6LXP;32T=.=77#YRL35C3IY=F:B\1/#U*M7"^RIT904'[2ISSC)
M4VJD7I"4TFKZJI"E]&4445X9[)\#?\%%?VC/CE^RW\!9OBU\%O!WP^\1IHFO
M^'(?'&K_ !"U;58[7P]H.M>*O#?ABV30O#.BK;7OB?7=7O=?$4'G:WHVG:+:
MV=UJ%X]^_P!GL9>V_:G_ &MO"_P"^$OQBUOPE?\ @WXB?'7X;_"[4_B'I7P&
MM/%FFOX\U:VM;.*Y35+OP=IMS=^,AX9L+><ZUJ]]8Z/*XT.SNYK5R_EO6U^U
MM^RIHO[7WP]M_A=XM^)_Q1^'_@N34(+_ ,1Z7\-;[PGI_P#PF(T^_P!,U?1;
M3Q!/XF\)>*)_LFB:WI%CK%@ND2:5*U[%B]EN[8_9Z[-?@)H3>"QHUQXF\1S?
M$H^"E\&2_M%1V'@FR^/$BI9BS77_ /A+K+PC!IL>LX59&CCT!=$=@8GT=K9F
M@(!^;?P*_P""FNH:E\./VS_$WQ2\2_!OXF6W[*WP]\&_$O0_B?\  FR\4:1X
M#^(=G\0?"6L:KI'@V'1O%>JZWJMIXITOQAI/_"&F2#4YX-7EO["3[+IVH+=V
M,?T[I7A/]L&Z_8.\&:(OQR\-^#/VIM;\$^'->^(?QG^(OAZPO]-\"S>(+^+Q
M1\0A8:%9V=EH<=]X,\/WVI>&?"DFJ69TFS?2K'4-9^T"*>:3SWQ5_P $Y+.\
ML/#_ (?TOXC>(/&=IX\_:(^%GQD_:O\ '/Q>U)=;^(/QC\)?!2UFU'X>?#'3
M(/"VA^'/!VB^%[#Q38>&V.BV6B:/I5IHUMJ^R&[U#4YG?ZY_:F_9S\/_ +5W
MP5\4? KQ;XS\>^"/"?C2338O$NH?#G5=.T;Q!JFCV%[%?7'AV:^U/2=:MQHF
MLR00V^M6JV8>_L1+8R2BVN+B.0 _$'PQ^U'^UOJGPYL?AOX2_:/\2^,O WQV
M_;W^'G[,G[.G[9^N_#?P=8>.]>^%%[X0U3Q!\6O&GAW1(M&L/!OB2#3_ !1H
M5[X2^'GC.7P^=+UJ!]1O[9;J&RM9(?2[W]I3]NMOV$OVK9O!/Q"\$:U\2/V4
MOBQ^U/\ "OQQ^T5XVT6#3?%ESX ^"6@+XA\,>*/#?@'0=+D\*ZC\4_$<%[;^
M'99]06R\+Z+=6TGB"YL=2EVV<GVZO_!-KP3J/PBO/A#XW_:$_:?^(=GI_C'X
M?^/_ (6>,O$OQ"T"W\<? ?Q9\,K2XL_">I?![5/#G@S0]/\ #4=K!<R17-A=
MZ5JMC<P?Z.8(XL >J>%/V'OA'X._9:^)/[*.E:OX]NO"?Q?TSXE0_$GQYK?B
M&#6?BAXN\1_%N*]C\;^.=8\27NFO8W/BO4GOFDBN6T?[!;"WLX4T\P0"-@#\
MJ?VN?VH/VKO"_@O]DS4=*^+7Q=^$O@+Q?^Q=9_%6X^+/PO\ @99_&+4?B7^U
M+!X9T#5=$^&?CU1X:UO3_"GA77--DO==O[B*RT"VO7N+P-JEG:V#/9_L/^QK
M\9M=_:(_94^ 'QO\46-EIWB;XF_"WPGXJ\16>FJRZ;'KM_IL7]KOIR,SLFGS
MZA'<7%DA=]EK+$H=P-Q\=^+W_!/7X:?%WP?\)?!LOQ9_:'^'5E\*/A:OP2:\
M^%7Q2NO!MQ\0OA7-HNEZ%JOA'XAV,&FW>A:S#J]EI,/GZG9:1IFL6C7-\FG7
MUG;W)A3[,\ ^!?"OPP\$>$?ASX&T>V\/^#? OAS1_"?A;1+3>;?2]!T&P@TW
M3+*-I&>6006EO$C33/)-,X:6:1Y7=R =;1110 4444 %%%% !1110 45\7>/
M_BK\:;KQ[XV\'_#W0FU6U\(^+_"NFN-,\*:ZL]EI_P#9'PQ\8->ZEXNN[QO#
M6JIXAE\2:YX:U+PWIMK:ZMI&@P'7I;NW2"2X?GM0_:4^*EOXB\*:?/X2@\.P
MZ]K/@'2-*TCQ#X,\46&L>,M0UV^\!Z1XSTRW&H:KIUWX0LO#-]KWB22Q\6ZG
MI&J:/J!TV.)8)XK"XN-1^DI<+9G6IT9TZF DZN'>)]E]=HJM3I/#PQ5-U*3O
M4BZE&;G%*DXQC3JSG.-*G.JOGJG$N74:E6%2&.BJ5?ZO[7ZG5=*I55>>&FJ=
M5?NY*G5@H/\ >*4I5*<(0E5G&D_O*BODNU\:?M$MXYO8)/ EMH_AF#Q!X3GO
MK*ZM=2\4/>Z=KE]\-M!URST+Q3;ZGI.FVEOX;T_6O%?B:6YAT6[BFN-!NH9;
M:.-;V:3ZTKR<=@*F =%5*V$K>WI*K'ZKB:6)]FFJ;Y*KI.483M4324III-J2
M:<(^I@\=3QJK.%'%4?8U'3?UK#U,/SM.:YJ2J)2G#W&FW&+3:3334I%%%%<)
MVA7@_P"TSXZ^*/PU^"'Q"\<_!SPMX3\6^._#'A[4M;L+#QSKE]H/A2QL=*LK
MG4=6UO6)M+L[W5=1@TK3[2>YBT/3$MKS6;D0V":CIJ327]O[Q7DWQP^%;_&O
MX9^)?AG_ ,)_XW^&UKXJM?[-U3Q+\/9O#UOXE.C7 :'5M'@F\3^'O$^EQV>M
MV$D^FZ@YTIKQ;2XD-E=6=R([A #P?]GS]K7PSXW_ &;OV;/B5\6/%_PW\+_%
M;X]?";POXUT7P OB72/#.H^,_$NL:+97MSH?P]\-^(-;FUK699M1O;>PLK&R
MDU:Z2XN[6W>6665-_P /?L3?\%,OB#\>_C=X4^'WQ.D^"Z:7\2O@[\2/BM+X
M:\!VOC/1_'7[-NM?#3Q+H^F:I\+_ (U2>+KZXLM8UR70]8^W76IZ;I_AIK'5
M-+U"$Z0^E3:??W/Z'? ']DSX>? ?X8> ?A>=1UGXL6?PI1;'X9>*?BQIO@K7
M?&?@+0;2WT^VT;P]X9UO1_">@'3M/T&/3;<Z9<K;MJXD EO-3NY(X6B^:OB=
M_P $]=:UCP9\9[_P;\>/B/XQ^/GQ0^%VI? KPU\5OCOK>FZVGPI^$OC7Q!IU
MS\1=*\$Z5X$\(^%;2+7-:T.*Y \0:A97WB#5-6L- 75->2QLY0X!V'['WC_X
M\_'G]G3XK?'F/Q7:1ZU\=/&WQ5\5?LP:7XRTZ)_"OP[^%UL\_A'X+#4[#1;.
MSU74=.UM-!B^(>N&>YNM1OX_$K06]Q!$($C_ "\U3]JS]L7]G#0_VU[ZQ_:5
M'[76B? C]G+0'\8_%+5_ASX6T7P)\*_VT/%7CS1O";_#KX>7_AG2]+M/%OAW
MPMHFMS^(]>\-:E)JMYX;EM=(TS7KNWO[F[L)/WSF^$&A6OP1_P"%$>$-6U[X
M>^&;3X;1_"[P]K/@RYM-/\3>$M!MO#J>&-/O?#E]=65[:66M:7IT<<FG7TEC
M<"VO8X[H0LZ 5\0?"C_@EK\*?AG\,_&'P-U3XU_M&?%+X#^,_AMK_P ,[OX,
M?$7QKX:NO >DV'B'4K;5[GQ+H5IX<\%^'-3LO&MKJ4$E[9>))=3N;Q+R\NKN
M<7%Q(LJ 'S)\-_%O[;4GB+]KK]CZ']KO2=0\:_#3P;^S;\7-#_:D^*_@'PE8
MZIX%^'WQ4L-7U'XOZ:-'T'3]/\)7.HZ)9^'=0N/ FK:_9-I^BQWC/KLMPEK'
M/#1^"OC[]K[XN?LQ?&+6K']LVT\(? [P7^T+<#P=^W'\3?AWX5T'QQXY_91\
M+>'$N?'WBGPGILNBV'@5KIO&RW6D^#?B%K/AR/1]9\/66H7=K!<%]/D3Z9N_
M^"4'P9O_ (-?%GX0ZE\9?VDM9NOCGJO@&7XJ?%37OB'I.M?%/Q9X2^&%HUAX
M(^&=WKM]X4DTR'X?:19B*&71(-%274U1UU*\NHIY8FN>+_\ @F'X<^(/P6B^
M!7CO]JS]K?Q?X/MOB%X5^(-E/KGCGP+<ZGI\O@K2CI_AGPE9I'\.(='C\#Z9
M?"V\11^&Y-)EM9-?T_3KN5GALH;8 '=_\$U/B)\;_BE^S8?%WQLU[6O&BW/Q
M*^(-G\'_ (C>*O"-IX#\8?$_X%:?K"VWPV^(GBKPE8VMA:Z1JGBC3TNKV 1Z
M=IQOM)_LW4FLT^V"6;] :\3^ OP<U'X(>"[KPAJ?QC^+_P ;[BYU_4-<7Q?\
M:_$6D^)O%MK%?6]E NA6E_HV@>'+.'0K V;3V%F+ R037EV3.ZR(D?ME !11
M10 4444 %%%% !116'XFFU.V\-^(;C14DDUBWT/5IM)CB@%S*^IQ6%P]@D5L
M0PN)&NEB5("I$K$1D$-BJA%SG""<8N<X04I.T8N<XP3D^D4YIR?2*D^A,Y*$
M)S:;4(3FU%7DU",I-176346HKK)I=3<HKX=\/^,/VEO 5MX:UCQWI>I^,](U
MOP_]LU#1['0I_$.O>%[]]&T(G^U[GPIX0T">>^O/$SW=O8:#9Z+,=)TR]O6U
M#4+Q=/6?3[OAGX_?%;Q<_CS1+?P%:/XA\.>%K>_OM'T1[RUU;P7KMW=>*[%-
M'U*\U;[7IGBK4'&@V%]';>'[=+BR.IMI][;27%G([?0SX9QR]K.AB<LQ6&HN
M*GBJ&/H^R5\0L-)M5'"I%4ZK2E*<:=.7-#V56LZE-3\*'$>"?LX5L/F.&Q%7
MFY,-6P5;VKM0>(BDZ:G"3G23<8PE.<;2]K3I*%1P^U:*^1+[Q_\ 'W5/AUXH
MNI?"UKX;\2B[\"W&F7.D:3K<UWIOAK7/$?V3QK&-*N(/$&HZMXA\'>'K6?4+
MHZ3I=S<3?;[<V.BFYAA6Y@\*^*_COIGBKP3<>*=+\3:_X;\6V7A*75--M=$L
M(;GP;J6J:(+"ZMM;O;;3(8YK2UNX=2\0:U-!%8Q6MP-)MI[C2I+D:+=9?ZOX
MA4JTY8S+%.C*O!48XVE.=9X>A3Q$_93BXTGS4YR5/FG!3G2J0BW-0C5T_MW#
M^TI06$S%PJQHS=66#J0A25>O.A'VL9)U5RSA%U.6$W"%6G.247.5/["HHHKP
M3VPHHHH ^3/VX/C!\8/@)^S-\4OBY\$_"?@GQ7XO\ ^%]>\5W2?$'6-1TOPU
MHGA[PYH.JZ[K&N3V>CP/JGB2^ACTZ*PTSPW9WFC_ -H7VH0R7.LV%G:W#.EK
M^U-X5TOX'^ ?%OB77_!-Q\:O''[/NG_&#PU\%K/Q1H^D^-?B+K#_  ];Q=<:
M%X \):CJ4_B/5H]0U.UO=*TXV-IJCQ/&R223R6\QKNOVE/@+9?M+?"3Q'\'-
M8^(/C_X=^&_&$,^E^*[_ .'-SX;L];U_POJ&G7^EZUX2O;GQ-X;\3VL6B:Y9
MZ@\>HM8V5IJ@\F'[)J5J/-$N;\,/V:/!OPX^'?@WP->ZSKGQ%UOX?>'+GPEX
M+^+'CO3O!5Y\5O#/A\P7-GI%AH?BC1?"6BQ:6/#FGW"V6C36FG1S+%!%+J#W
M]T]Q/. ?G5^Q-_P4O\3?&GQGXLT/XP^(/@?JWAW3OV6+3]JO4/$'P?L_&>E?
M\*<AL]9_LSQY\&/B9:^,M1U"74/%O@6&>SN;K6K%=&$LD.HP7FB63"U!^KOV
M0O%'[1_Q+_9"B^+^O:[I,_Q@^.5QXS^+OPUT?XC:;/%X2^''@[QWK%SJ/PA\
M$ZG8^%HM,UJ[T3P]X$.@75^!<_VW>ZC>Z@LNIJ726+R;XH_\$W[KQ)\/_BGH
MN@?&OQ]XW^)WQXL?A[\*OB?\8/CCK-EK'B;3_P!FW1?&4'B#QY\-? =AX#\+
M^$O#VD77BS2Y-9M)[F31HY=8U;6)=5\0ZK=/;6RI][?$[X2:3\2/@YXK^"MI
MX@\5?#?0/%'@V?P+%KOPUU*W\/>*O#&ASV2:9M\*ZG+97\.E7,.FH;&WG%G*
M;>W=O)"2".1 #\B/"_\ P43_ &FM1\-^,/!HT7X&>+_B#?\ [<7@W]B[X,_'
M7PYIGC2Q^!?C*]U[1+S7/''C:7PS)XCU/7=6'PM;2M2T#4=.T'QD=.UOQ%]F
ML;?6+=+6^D?=\:?MT?M5:/\ LG?&CXU)J'[,?@OQO^RE\6OC9\&OBW;^*M"^
M(FK>'OC%XX^&>KZ-I_@71OA!ING>*].U;P[=_%!-8M[&+3]8N_%6J67B.YL[
M"PM;JT>>YA^D=$_X)J_#_2?@QX?^!]S\;OCQJ?ACX<^)_AWXU^!FJKJ/PST#
MQ#\!O%?PR?5'T'6?AS<^%?AEH6GRSZA_:]VGB6+QGIGBR'7TDE>\3[3<W=Q/
MDZY_P2Y^%>I:/\)M/TCXS_M >&-5^%'Q*\??&U?%-EXC\#ZWK/CWXX?$:\6\
MUWXO_$*T\8?#_P 1^'-=\<6!-Q;>%[VWT'3['PM:74D>B6%I+'!-$ >._'S]
MO3]H3X/^+OV6(I[7X):%JOQTC_9_CUO]F_Q?X=^)%G\2=/?XHW<.F?$:^G^,
MTNJ:;\*/""_#R].H?V7I6OV4^HZR=(FMKA%O+VRM9/V7KX'^*?[ ?AOXY6WA
MC0?C%^T#^T=\0? &D'X>WGB;X9:OXL\%V?@OXB:_\-KRSU/1?$7BJ#1?A_IF
MLVE[J6JZ?9:IXDL?"6L^&M%U>^MUF_LRV+R!_OB@ HHHH **** (KA)9()XX
M)OL\\D,B0W'EK+Y$K(RQS>4_R2^4Y#^6_P K[=K<$U\?:=\#/CII]Y)=P?'"
M>S%_K$NHZO!#%?7\UV3IL=C'*-3U5;F?:SPR2II/V>/2M-;4'>R1I-,LS-]C
M5X#XJ\/?&"^\0W,FA>-8M-\&W?B:YGNE2,'Q)9:/<>!H]"M=/T"--$EM#%9^
M+VDULI>RB6:9TNY=9BM+=[%OF.),)@ZT<'B,3ALVQ4\/.K&E#*<PKX&=-5(T
M74K5_8XO"J5&*C"%2I)S=*E*:<)PGR2]'+ZM6#JTZ=3"TU447)XJA"LI<KFH
MPAS4JK4G=N,4ES24;2BUS+"\"_"CXQZ1XKT'6O'/Q??Q;I&CI:2'0X[*ZMH)
M;N'P_J&C/([O*6FF$UX]]+?W$CMJ4]Q+YUC:BUL!#]-UYQ\/7\86'AV.R^(5
MU8WOB"RU:?3DU#2I[FZ35H)$@DM;NZC-G:QVUT?/E2>V@1K2VC@24RA_-$?H
M,UQ#;H7FD2-1U+$ ?K[5U</X?!8?!N&"^O+VTJ>(K4<QQN(Q^.HU*E/V2I5Z
MF(KXFI"4?JU2$:4:LH?NY3IKEFG+/'5*TZMZWL7R*5.$\/1IT*$XQES.4(TX
M4XR3]I&3DXJ7O)2=T[2@ 9P,9))]R>IJ)YXXY(8W90TSO$F649D6)YM@4G)8
MQ1R/@ X5&)QQGQSQA\??AIX+9X=4\1V1O(\YLK9S=W>1_";>U$LJ'UWJH'<]
M:^>O$?[<7A+2[6^NM*\.:YJ@L[6YN\B*UL_/%K \YC0W$^\-((]BF2,<L"1C
M-?!<4^/?@EP3G&&X=XL\5^ <EXAQF/P>58?(,1Q-EV)SN68YAC<)EN"P=7*L
MJEG>.PE:MCL?@L.HYA1R[DG7BZ_U>FJE6E[.7\$\89M@JV99;PSG>*R[#X>O
MBZN/AEV(IX*.%PU"MBL16CB<2L'1JPIX?#5ZC>'EB7)4VJ:J2<83^Z0Z^8%\
MP,9$WQH,?<3:&8$9W EUY/'( ]:EK\3;O_@M)\(_#6EV6J^-?AU\0-"@U/5+
MG2]+CTFVT;Q)++]CL[6]N9;H0W^F"Q2-+N%(HU^TM*PD/R!!N[_P9_P6?_8S
M\3S0VVI^,==\&S3,J;O%_@[7M-M8R2!^]O[.WU.R0 ')=YEC&#EQ7]+8GPO\
M1<+"I4J<%<1SI49U*=2KA<OECZ:G1?+5BI9=7QKDZ;M&?)3G::DKR:=OR_!\
M;\(8Z%*IAN),IE&O"-2C[7$O"N<)MJ,N7&4<*XJ3C)QYW"\;.R33?ZYT5XA\
M,OVBO@Y\7]/34_AU\0?"GB^S9 [3>'M=T[5?*!&1]HAM;B2YM3@C*W4,+#D,
M 1BO:XIHIT$D3K(A&0RD,.?<5\17H5\-6J8?$T*V&Q%&3A5P^)HUL/7I36\:
MM#$4J%:G)?RU*4'Y-:GT].I3K0C5HU*=6E-<T*M*I"K3G%]85*4ZE.:\XSDO
M,DHHHK(L**** "BBB@ HHHH **** "BBB@ KSGXI^+/$/@SPC>:QX7\/-XCU
MDNUK:6IBU*>UM9I+.\EMKN^M]'L=1U2>V>\@MM.2*RM&=[N_M?/GL[07%Y;^
MC5@^*=<_X1GPUX@\1_V?=ZM_86C:EJYTRQEM(;R^73K2:[:UMIK^YM+**:98
MBB27-S!"A.YY% KDQZD\#C%'%3P,OJU>7URE3C5J851I3G*O"G*%13G3A3J2
MC'V<W=)QA*:A&6M!I5J5Z4:R]I!>QE)QC4;E&*A*2<6E*4HIOFCINTFVOF.U
M_:"^)\*K'J/P'\6-+;W6D6=T(EO8KZ[:^MI7>:QT]=*GM0MU<*L=BDNJ@6\"
M7,VIR6KQ)#+ZQ\(O'OC+Q]:ZOJ/BOP1=^!X85TK^RK&]%V\UR9TO?[0?[5<V
MUEYZP2PP1%$M(C#+YJE[B)X9FX:\_:3TG3VO9?\ A#=<FTK3)K*&[U6WO]*E
M@TZSO)-6TZWNM5@^T?:=-\W7=&N;**":-I9].\O6E)A:.W?Z,TV^L]4L[;5-
M/GM[JPU2UM;^RO+:7S8;RUN;>.6"YB? #120O&T; ?,A5B!G%?*Y'4JXG&Q<
M.+L3F]/"J7M\#/ 8+#*4:D:M&E6J5J>$H5ZM.-6G*,94FZ,JU-<]1U9^QCZ>
M-4*=%IY52PDJK7)65>M5:<7&<H1A*K.$).,DVI6FH2?+'E7.\SQ0NHV_AGQ1
M-X>'D:\VB:O/IDMO8QWL[:S'I<L>FS?8C);KJ$Z3Q6J1VTL\7VA8H[8S1H0R
M_%EK>_M!Z5I7@WQ9=:?XJ\9_V$-5L;_1I_#\-CXHUJQTS767_A*;9=2TJ35?
M"NH^,;:]T_2O[!EL9-2L]#M-8G0_8&^VVOWH2%!9B  ,DDX 'N:\V\=?%7X<
M_#72KK7?&GBC1/#FF6>+BZOM2OH+.%"2(5=RSJTK.66)%59'=V1%5F*BOTW+
M<S>#B\.L!A<=+%8FA3BJ].4ZU25>$L%3P5"4%[;VF*G6ITZ%.A*5>IB/90PU
M"M7E&$OD<RR^.*:Q$L?B,###8>K*4J56%.A35.I#%RQ5=5)1H<N'5*4JDJRC
M25%S=:M3I)M>C0R-+#%(\3PO)'&[PR%3)"SH&:)RC,A>,G:Q5F4D$J2,&I*_
M,'QE_P %5/V;O#4DMIX<?Q5XTDA9P)/#^@3Q6,K D[H]0UR;3$E5FS^\2.13
MG(RN#7CR_P#!8/P.9=0N)_A7XTM=%TK2-8US4+[[?H-S>QV.BZ?<:E<+;Z7%
M.%N;F:.W,4,1OH4\QU+R!0:^AH>&G'V*HRQ%'A+.8T4N=/$4*6$DXMQ45&EC
M,9AL1)MU(1C'V"G)RBK<S/"J>(?!%'$4\)/BC*:F)J5(T8PP]>KBTZDGRI.K
MA,+7H1NT[R=;DC9MR45<_9^BOQ,\-_\ !<O]E/5)XXM:L?B;X:1V4&XU+P0U
MW;IN.,R/HFIZE(% .YF\GCT)QG[=^$?_  4%_92^-,UO9>"/C'X+OM5N"%CT
M2^U,:!KK.Q "+H_B!-,OY'SQLAAE8G %<>;<!<;Y%2G7S?A'B/+\/33=3$U\
MHQDL-"*WE4Q.%ACJ%.*ZRJ5:44M7)+4]C!<3<.YE-4\#GF58JK)VC2IXZ@JL
MF]E&E6EAZLWY0A-ZJT6?:U%4++4[&_17M;B.4, 0 PR01D'&>A!X/0]1Q5^O
MDM]M3VPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\/^-_Q \:>!=+T8
M>"?#1US4=9OOL[7<FGZYJEO:""]TM&TZ&RT+3K^5]7U6RO-0N-,FU*73=%@3
M2+U[^_5_LT$_?^/O%)\&^%[[7ELDU!X)]-M([:6X>VA,FIZE:::DT\D%O>7;
M06S78N9XK&RO;Z:*)X[2TGG9$/F^F?&6^OXM)NI_"$NFV&NV&ES:?JEYJ:1Z
M8]]=S)]N26^:T2&.RL+"+4K]Y&*WT4>E3QWVGV4UQ A^$S;Q;X"X-XHH</<1
M8Z4LUAE^"SBIECRO.\50_L_,L9B\KP.)Q6,R_ U\)A:%7,,/]7YL5BL+2C6J
M8:G7KTGBJ*?KTN$\^SK*:N,RV+HX>=>M@X8R&(P4*L:^'IT<37IT:&)K0J5)
MK#S<OW=*I/E525.$O939Y19_M'_$^/R_M?P'\4LJZSINF7,2#69-;F^TZ?=L
M1%IJ>'QI\=YJ%Q:VVH6Q74TTZRTC4HFOI(KJVNHU]*^"?Q$\5^.)O$&I^*_
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M]K7A37K1Q):ZUX;U2]T35(77!!6]TZ:WF91@9CD9XV'#(PR*_9/]E#_@LO\
M%[X8WVF>&OVA8)_BCX+#Q6S^--,M[>T\?Z-!G8;G4+*'[/I?BV"),&4)'IFL
M,H9EN+V4B)_Q5HI<5\#<*\;826$XDR;"8]\DH4,<H1H9I@FTTIX+,Z,(XR@X
M-J2INK7PTFK5,)4BY)^MDO$>=</5U7RG'U\,N92J8=R=3!XBS5XXC"5).A44
MDK.:A3K).\*\6E;_ $(?@K\>/AK\>_!FD^.?AMXITGQ1X>U>+?;:AIMP'59D
M53/97ELX2ZT[4K1F$=YIM]#;WEK)\LT*Y4M[/7\"G[*G[6/Q1_9'^(5OXS\
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MIQC4P.*JRJ5:-/1.6 Q564ZM"<8W<:-2=7"3LH2IT;JI'_1O1UD4.C!E89#
MY!!Z$4ZOQO\ ^"9/_!1VS_:;T/\ X5A\3IK'2?C=X6TY)KU(O+M;#Q[HL'EP
MOXJT"V+#R+R!VC7Q)HL19;">5+ZS']FW 2U_8]2& 8'((R"*_P _.).',XX3
MSG&Y!GN$E@\QP-11J0OST:U*:<J&+PE91C#$X/%4DJV&Q$%RS@Y1G&E6I5Z%
M'^G\IS; 9WE^'S/+:ZKX7$QO&5N6I3G&RJT*]-MRI5Z,[PJTI:QDDXN=.=.I
M46BBBO#/1"BBB@ HHHH **** "BBB@ HHHH R-<T'2O$FG2:5K-K]JLY)K:Y
M"K-/;3P75E<1W=E>6EW:2P7=G>6=U#%<6MU:S13P31J\<BD5S%W\,_!UWI5E
MHK:;)#I>F:=<Z=IUK;WEU&EDEW>VNH7%W"YE>1M2EN[.*634)GEN92UPLLCK
M=7(E[ZOGGX\?&[2?A9HGD13077B;4X[B/1M)\]%GNGB13/<F/>)39V(=)+R2
M-6*JRH"&<%?@N.L'X>97D?$W&G'>3Y)4RG)^&L9B>)<WQV2K,\2N&LEAB,UK
MX>M'"8/%9ECL+AYQJ8C#X"C3KN6*G1=*$)1IUL#[>2UL^Q.,R[)\EQ>,CB<7
MF-*GEV%HXSZM2_M'&.GA85(.K6I8>C4J)QA4KSE!*E&?,VG*-;3^(GQ;\$_!
MCP]9V,LH+V=E#8:+HMJ_VB]GBLH$@@AC21B_EQ(B))<SNL:XR\I<@-^;'Q'_
M &A?B!\0I[B'^T)M T20L$TO2YGBDDBSP+V^39-,Q'WDA\B#.1Y;=3Y)XB\1
M:UXKU>[UW7[Z74-3O9"\LTI.V-"24M[>/)6"VB!VQ0IA5')W.68XE?\ /7])
MO]H#XD^,&)QO"'AIB\R\+?"+"PEE>7Y3DF(EE?$_$F5X>DL%0J<39OEM:EB,
M#@J^#H484>%<BQF"RS!81TL)F&-SJO"NU_=7AWX'</\ "E.CFG$%+#\2\4U&
ML37Q>,IK$Y=E^)G)UIQRW"8F$Z=:M"K.;GF>-HUL36J\U6A1P<)03_/_ /:'
M\)#P_P"/)=:MXMMCXOA.JF0#C^UH2D.K(SGEGED,%\=Q))NWQD+7@]?HI\=?
M"7_"5> -0DMXO,U/PZW]O:?M7,C1VL;+J=LF.?W^GM*^T EIK>#TK\ZP00".
M01D'U!K_ *<_V57TC'](GZ'G -?-\Q>.XZ\)E'P@XX=:LZN-KU>%,#A%P=G>
M*<YSK3>?\!SR"I+$57)XC'</YFW4J556/\=_IB>%_P#Q#'QPXCA@L-]7X>XT
MOQOD"A3Y,/3CG&(K?V[@*/+&,%_9W$4<Q2IQM[/#YIA?=C!P/)?C[_R)?@+_
M +&SQC_Z9?"U?+-?4WQ]_P"1+\!?]C9XQ_\ 3+X6KY9K_4CAO_D62_[&.:?^
MID3\/H_[IE__ & 87_W8-#1M6U?PYJMMKOAS5M4\/:W92++::SH6HWFCZK;2
M(P97AU#3YK>Z0A@#@2[3C# C(K]A?V4/^"Q_QK^$=YIGAOX\+=?&#P$KQ6\O
MB6);>V^)&B6V0IN))%%OIGB^"!>7M[Y+'5I$7Y-4GDQ&WXU45R<4\%<+\:8*
M6"XDR?"9C%0E"ABI4U1S+!.2=JF!S*C&&-PLXNTE&-:IAY-)5<)5BY)^YDW$
M&<\/XA8C*<?7PKYE*I14G4PF(2^SB,)4<L/635TVZ<*J3]RO!I-?Z#/P+_:#
M^%O[0_@C3/'OPO\ %FF>*- U) HN+*4I<65VJJT^F:M83!+W2=6M2VRZTZ_A
M@N8F^8(\3)(WM]?P"_LO_M2_%/\ 9-^(MKX^^&VI/)97,UM%XR\$WEQ*OAWQ
MMI$+@O9ZC A*VNJ01ESI&NP)]MTR<KS-:-/:R_VS?LM?M,_#W]J;X4Z!\3?
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MTMX5%U::I?WH@CCDU";6+Y;J6X5(4FU!G20-]MNS!&US)(TH*;[5 ME)+;.
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M''5F8LS'J69F)9F8Y+,Q+,Q))))-?TO^SV\->+O$'%XSZ47BK*55U?[3X?\
M!OA]T9X;)\FP,Y5,!Q/QCEN75)2C&OC.2IPKD^;8CZSF.)PM#B/'+'1IXBE3
M7YO]-GC#@WPYPF$^C?X648T8T/[.SOQ:X@E5ABLZSS,81AC>'>%LTS*$8SE0
MP'M(<29GE.&^JY9AL9B<AP?U&57"U*K6BBBO]83_ #="BBB@ KT_X(>%I_''
MQJ^#_@ZV1I)O$GQ.\#:6$4$L8I?$>GR7+8')6.UBGD?T1&->85^IO_!(#X*W
M/Q3_ &N]'\73VC2^'_@UHE[XON[AH]T \1ZM'-H/ABV+$$><&N-4U-5^\%T[
M?Q@&OEN.,[I<-\'<3YY5G&"R_(\RJ47)I<V+K82M@\#2C?>=7'8["0C%7;:E
M9.SM[/#N73S;/LGRZ$7+ZUF.$C42OI0IUZ=?$S=MHPPV'KR;V6E]S^Q'2]6T
M/3=/AL[C6-*M9+5!'+#/J-I%+ 1")PDT<DRO$PMBLQ21580D2$;?F-P>*?#1
MO&T\:_HWVU&C1K;^TK3S5DEGDM8H2OG<3R7,4D"0?ZYI49 A8$5\L?$?PA^S
MMHOCG4!\2)]6NM=\3:1KOCB:TDNM3_LO0]#T32[BUUC4HX-'6W,,4JRZA)$;
MG^T=0GO7G6R"QPI%%4T;2OV7-:UF+PU;Z)=3Z[JUL=.ET;4;;Q9'J4$[:C=^
M&[G0KR&[NC/8ZEHS17R7L4A2ZTZPM[G49+WRHVN*_P Q:62X-X6EB$L_J4Y8
M6%:52CE%!T(KD7/.%6IC8NI1IRIXB/M90IQG[+F32;/Z_GF%=5ITO^$R$E6E
M34*F.J>U;YGRQE"&':C4FITGR*4G'VEFFT?95O<V]Y!'<VEQ#=6TR[X;BWEC
MG@E0D@/'+$S1R*2"-RL1D'FIJYWPIX7TCP7H-AX8T"V6RT32DDBTVS5YI?LT
M$LTEPZ--<33S3N]Q-/,\DCY+2E0 JBNBKYZJJ:J5%1E.=)3DJ4ZD5"I*GS/D
ME.$92C";C9SC&4HQES*,I))OUH.;A%U%&,W&+G&+<HJ=ES*,FHN45*ZBVDVK
M-I-M(HHHK,H**** "BBB@ IDJ[HY%_O(P_,&GT4 ?SE_MC:))H?[1/CQ'7:F
MJG2-:A." R7>FPP2$=<XGM)02. 017S'7Z=_\%*_ UIHNK^$OBC<S_8M.GCE
M\*:G,EI<WDLMTQDU'1UCBMTVEY -1A#W$UO$ J RY95/Y*WGCNSBRFCZ.9G'
M2\UV3S!UZII5BZ0#CHMS>7:],H>17YEQUXP^'_AW4>$XESODS7V%/$T\CR["
M8G,<WJ4:T9RH5'AJ,*5##TJZIS]E6QF/P].:C*45*,)'ZIP!X+>(WB72CC.%
M\AY\H^L5,+4S[,L9A<LR:G7H2A'$4EB:]2KB,36P[J0]M0P67XFK!SA&3C*<
M;]M!;7%TS+;02SE1E_*1F6,=<R.!LB7U>1D4=R*S;W5="TS<-0UBW>=,YL=)
M U:\W#JDDD+IIUN>H)EOBRGK$>A\KU/Q%K>L#R]1U*XEMP?ELHMEII\8/9+"
MT6&UQ[M$[=,L2,UC  #   '0#@#\*_E3B[Z86;XGVN&X'X8PN5TWS1AFO$=1
M9GCK:I5*658*>'RRA+[26*QF.<792A*S3_KK@WZ%F387V.*X]XJQ>;U5RRJ9
M1PS2EE6 NK-TZN;XZ&)S7$1WC*6$P67J2NXSC=->AWGCXKE-%T>VMAC O=7<
M:I=D]F2T"0:9 1U >"\(/61L5QNI:OJFL.)-4U"[ORIRB3RDP1'MY-JFRU@
M["&% .PK.IKG:K-_=5C^0)K^8>*O$/C?C:<I\4\3YMFU+F=2."JXJ6'RNBU=
MKV.4X+ZGEE/D^RW@Z]2*2_?7O)_U9PCX;<"<"TXT^$N%,GR>MRJG+'4<)'$9
MM63LFJ^<8YXW-:G.W[\5C</3DW_ M:*^9?VI+T?VG\,M%4\:=X(U#6)4':;Q
M-XIU21&([,UEI%F#TRJH>]?+=>\?M*WAG^+VL:?NRGAOP]X+\-*O3RY=/\+Z
M;=7B$?WEOM0NMS#[QY/.:\'K_JO^C1PX^$OH\^"/#TJ?LJN7^%W!<\13:Y7'
M%9GDF'SW%\RLK2>)X@J.5U?FO?74_P";'Q]SY<4>./B]GT:GM:>8>(_&#H5+
M\REAL%G>+RG"M.[O'ZMDE'EL[<MK:6"BBBOV\_(PHHHH _9W_@AOX3GUG]JO
MQMXH$1:V\(?">ZMWEP=J77BCQ%I5K#&6 P&>VTR\8 G.$R 1G']//Q;\3^,O
M">K>"+GPM:W%YI^H:A<V_B6"ST#6M?U*:RBDT^&UBTZ/3]+OK"W2T2^U#7M5
MAO;W1;S4],T6XM-&OVU 1P-^1_\ P0L^"MQX6^"'C3XQ:I9M#>?%?Q9Y>BR2
M(5=_"7@R.;2;*>,L!FWOM<N-<F0J2LB0QN,@BOWAP,@\Y QU.,'U&<'\1QVK
M_.'QLXAPV8^+/$.)A2HX["Y5'"\/JE.7[JK/+,O>&Q?O14K.EF&,Q*C)*7+5
MPK:3<;+^K_#W*JN$X)RNC*<\-6QKK9GSQ7OPCB\4JU'1M7Y\+0HW3:O"M:Z3
M/C71_BI\6X]/\(^*KG2KGQ%X/UFZO[2^LK3X?:[HWCVQTRV\00Q6-YJ_A[4(
M+2#2K^]M;FSTZ73UFEBMA=2R11W5QIMW?'[(CV[ %*G!(8H HW@GS/E!.T[]
MQ89)!SDD\TH10Q89!)+'YFP25"\C.#PH !&!C( ))ID,,5NGEPH(TW.^!DY>
M5VDD=B269GD=G=F)+,Q)))K\GS#&X?&N$J. H8%PE5NL.W:K3G4<Z2JQM&#J
M4(MT_;0C!UD^:=.FTD?;87#U<.I*IB:F)4E#^*E>$HQY9N#3;4:C][DDY*FU
M:,Y)MDM%%%>:=8445',91#*8%1YQ'(85E9DC:4*?+61E#,J%]H=E5F"DD D8
MH>B;UT3>FKT5]%U?9=79=06K2T5VEKHM7;5]%KJ^BN^A)17R5;Z[^UE:R0SZ
MQX>^'$$%U;R&XA&J6P>TN8+>62:+2TFU>VCN)?(2>[MOME^8+E[14O6T>UDN
M+F#2TOQ)\>[>]%SK4O@:XT.#6KB+49([K0[>^T_1+FZM+K3+RX5?$RV.9D>[
MTI@;Q;FUL+*6_BM]9U">&$_/1XCP[<5++<[H\SM+V^6NA[.-HR]I-5,6I*FH
MRYI22?(HU'-)0E)?22X9Q"4G',\BK6C>/U?,XU_:2O./LZ;IX-Q=1SAR1BVN
M>4Z:@VZD8OU/XP?#S3/BAX \2>#M5CW6VLZ9<V>\*&DMY70M;W<6>1-:7*0W
M,1&#YD2C/.*_FE\9^$M6^'VO^)?#WBWR-&E\)75Q!K.I:C*MEI<%K#\\.J/=
MW!2);*\M3%=P2!CN255^]D5_07<W?QVAUB\U.RU/1M3TN/Q<8;3PK<7WABQ.
ML>&-2NYYM/FLM82-[G3-^FQ:=!IUI?VLVJW=P-=FE>-#925\K_\ !2?]AF#]
MJ;X6WDW@Z:/1/B9X>D76O#=WYTMKI?B"XLH9@OAGQ2D1$=SI=ZCNNG7ERDQT
M'4S!?Q 1&Z5_H>&YX+/\VP67X_&U^&,OK9EA,+F&=XW+GCHX# XBK5A5S"AA
M*.*C#%2IJE%1AB*U*CAU7CC,92K83#SH8KQ<XPU7)<'4Q<*5'/:ZP6)Q&%RS
M 8Y86>)Q=&G1G3P6(Q-?"NIA83=;WZF'HUZM7V4\-A)T\5457#?S3?%G]J]8
M1<^'?@X[Q'$EO??$2ZAVW<N<I(OA"QG3_08F!8)K5Y&;IUP]E;Q$K<U\-S33
M7,\]U<SS75U=2O<75U<S27%S<SRL6EGN+B9GFGFD8EGEE=G8G)8UJ^(_#GB#
MP=X@UKPGXLT;4/#OB?PYJ%QI.NZ%JL#6VH:7J-JY2:WN(G[=)(9HR\%S \=S
M;22P2QR-C5_J=P#P!PEP#D\,'PMA(-8VEAZ^.SRO6I8_-L^DJ:J4,7C\UA!+
M$47&LZN"PF"6%R?!4J_+EN I0G/$XK^+>*N*\^XJQ[K9U6]G'"SK4\'E.'IS
MPF6Y3%RY:M#"8&4I2IU6Z:ABL7BY8G,\74I<V.QM1QAA\.4445]T?+A1110
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M4G&3@X'M48N-*"=2=5VO[2I;GDI-R3E:%-)I22MR1:22:YE(****P-0HHHH
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M.6UT*RA31O">G3?ZS3_#EE)(UJ9P.!J&J3RSZSJSCEM1OIDR8X8@OGE%%?\
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MWMX(HX8XH8TBCCCB18XXXTC"I''&BJD<:*J1HJHBJJ@#3HHK^:OZ_K^OUO\
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- CD# 2(  A$! Q$!_\0
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MPG%\</%/Q3_;,U/QOK?B:SUV]MO%'PE^$OA_Q9I.OWWB7QM'8W%Q%I6A>-/
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M[=4FO(M0N8I&,;[12^'O[)7[,'PGU[Q[XH^&GP ^$?@;Q!\4(+ZT^(.K>&?
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MRMC,\=Q=WD,?DR2&/'YRW/[-KZ/^S=\)O$_BC4XM#\6:OXDUSQ:OPVNM*O\
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MT7PO\2M-DA>UGT[QG&=9A9/$?AK1-/MM5.H>'(+FU:YD'VB9+V*%H![_ #?
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M3X/\-0ZIJBQ''R#^W/%=_!.H/S26:,>BX]ZH **** .<\8QZK-X1\4PZ%/\
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M^!O$%UH%SHD\:2NJ:G?RVK7$+J[VMNK>5-(74D\2O[33:7JWBCQ3=6/BO6]
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M\:^%_%UH\0F\WP]KFG:L8XV.,SQ6=Q+-;,&^5X[B.*1'!1U5@17\;=7]&O\
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M3/C)IET>Z^TS:_<74OA<WHS(NL8#PM"&%PFF, <0,N1QMW\"_B)-HW@FWO\
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M)/$^I>/O$47BCXG^%_&7C;XVZ%^T%IGC;PIXCT?3/$GPZ^)'A[P1:?#NTN_
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M?#+5_"FD1>)M0TG5M'U_P[-K\GB/P=XJGE_X1O7=#L=7TA-.ETU!=K)]O%]
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MC:6^I:GJ-W)))'IFD:9I\$:Q0VUE#'& ?6: "OQ&_P""L_\ P4T_X9=\/R_
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M<DI1EAN&KI.\-4C]YM6UWP]X8M?-UW6M"\.6<87YM5U+3M(@08PN%NIK=0"
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M_P"/&]_Z]+G_ -$O7YE4 ?H;\.O^1%\)_P#8"T__ -$)79UQGPZ_Y$7PG_V
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M:5.5::J8G$U%%^RPF#H8W&5FK4<)4>JNU4N+VWMA^]D&_&1&OS.?^ YX'NQ
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M]CI%O%::9IGC'X7V,.EV=G';1*!&;[P,=$,<DA9[AM(N2[;D!?\ ".O]!/\
M;L_94T?]K_\ 9S\=_!V[BM(?%C6Y\2_"[7+E8PWA_P"(VB1RS:%,+B3_ (][
M'629O#NM'<B/I6J7#.<1*1_ !KFAZSX8UO6?#/B/3+K1?$7AS5M1T'7]'OHF
MAO-*UK1[R;3]4T^ZB<*R36=[;S0/D ,4W+E6!/\ )?C)PK+(>)IYEAJ,:>5Y
M_P#[7A_904*-#'4J=&EC\(HPC&%/6G1Q=&$5&+HUY\L4J;4?[&\$>+H\0\*4
MLKQ->53-^')?4L3[6HYUL1@*TZU7+L8Y3E*I4TG7P5>I.4I*OAX<\FZL7+)?
M[I_#^8KJO#7C74O#EQ'MEDDM5(.P,=\8!_@))R!UV_EZ5RS=#]#523M^/^?U
MK\>J4*.)A*C7IQJ4Y+6,EL^CB]XR71K7U6A^S4J];"U8U:%25.I%NTHM]+NS
M5[2B[:I_AN?;'AOQYX;\76B6FK"$/(H07 "AT8\#S!U&.N6Y_E65XP\ RZ7"
M-0T=AJ%O.#)%% 0Y*@9+';]Q1T)QUX"DYKX^M[VZL)DGM9GAD!SE3@-C'##H
MP^OX5Z1H'QJU;1;]8KJ8M"J0H8I/GMW0*,\-D)NR20< $\'.2?V3Z,?@CPUX
MF^+F"R3BG'8JEPEE^3YIQ#FN787$3PF*S?ZA/ X?"93'&4DZF%PU?%YA3K8[
M%8=1Q7U+"U*&'G0JXMXFC^._2=\=.)O#'PAQN=<+X#"U>+LPS?*^'<JS+%8>
M&,PN4?VA#'XC%YO+!U6J>*Q6'PF75*6 PV(<L*\=BJ=?$4Z]+"K#5TU"YU#>
MT%RKVP!(:$*R X)&&8X9QU')Q_LBLJOI33M:^'/Q)MXX;X0:/JDR@+<+M\EI
M#P23]Y1G&>H!/7%<OXE^"?B/2T>]TE%U?3CETFM&$OR8R#\F2..<'/>O]Q.%
M^!^%>",GHY)P1D.3Y!DM&TH8')\'0PD:DU%1>(Q52"GB<?BIQ253&8_&8[%U
M->:ND_9Q_P ->*..>*N-\XK9WQQGV<9_G=:\9X[.<97Q<H4W)R^KX2$W##8#
M"QDVZ>#P&#P&$IZ<M!M>T?B=%6KNRN[&1HKNWEMY%)!65&4Y!P>HJK7N--.S
M33[-6?XGBIIJZ::>S337WH****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH *0@,"IZ,"#]",&EHHVU734#]?\ X!^)QXL^$G@W4'D$EW86#>'[\[B6
M^U:%(;$%\\AI+5+6;&2 ) H/RU[#7PU^Q;XF,EEXT\&RN/\ 19[+Q+8J3@^7
M=#^SM01/51+#9RD#[K2.Q^]Q]RU_@;](;@__ %&\:?$/(:='V.#EQ#B<[RN"
M5H?V5Q,EQ#@U3227LZ4LSQ^&BHZ1^J\FG+9?H66UOK&!PU1N\E35.?\ CI?N
MW?S:C%_,****_&3N"BBB@ HHHH **** "BBB@ HHHH **BFGA@4O-(D:CNS
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MT->[_!8?Z'XB;GF]L%SVP+:5L?7)SZU^3^,TN7PZSS^]6RB/_@6;8=_^V_\
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M@>.)4\+AL/.>&POL,%]:>,SG!X_&RQ-/$X*KF,_[0IX:EBN;$5*$YX&&'5+
MT\NJXW"8JC#$8C"T\/\ .O#Y\XTJ5.4J5'V=#VOM\=1Q%=U8U:$\3+ZS&E"M
M>I*G*6'C34,/##3KT:T%4J4HTO.M*_;<376\-IHWP$^+%^_CNQ\=2_#]DNO
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ME45.%4+VXKWCT3FM+\-65@JD1*&'?'S>G?I_]>ND1$0 *H '3  _S_7O3Z*
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M:KQHQIXR5YUZ5OJLXUJE:G5]C1CAJ4JBC7AB*E+%J%66(PL8K"3E*-IT^?\
MH(HK\!-2_P""I?[3GBGP5KWQ2^&7PX^"&B^$/ O[%?P;_:_\8Z!\0!X]U+Q)
MJ"^,=?\ $ND^*_ ?A34]!U;2M--O=V_ARXN_"OBW4]/,=FC6;WNBZQ%J+/IO
MTQ_P4Y\3_%WQ'\%/V7=#^!WQ0\;_  3\8?'3]I'X4>"[7Q/X)\07.@ZQ;P^+
M_"'C#4[#2+_4+%HVN=(EUFVTE=5LWS:WD,!$L3J M1_J=F=''Y=@<?6P6"_M
M#$5\-*LZ[Q<<%/#87%8RL\72PL%4CRX;"5:RC2G6<X*ZDG[CI<6Y=6P.88W
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M>-[_ ->ES_Z)>OS*K]-;_P#X\;W_ *]+G_T2]?F50!^AOPZ_Y$7PG_V M/\
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M.)G2KN5:I7HP>'@ZS@Z7[,6G[+W[/.GQ>18?!_P-8P_\+J7]HSRK/18+5/\
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MBBB@ HHHH **** "BBB@ HHHH **** *E_\ \>-[_P!>ES_Z)>OS*K]-;_\
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MBBBBL#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&@#ZKHKY4_X:.OO^A5M/_!K-_P#(-'_#1U]_T*MI_P"#6;_Y!H ^JZ*^5/\
MAHZ^_P"A5M/_  :S?_(-'_#1U]_T*MI_X-9O_D&@#ZKHKY4_X:.OO^A5M/\
MP:S?_(-'_#1U]_T*MI_X-9O_ )!H ^JZ*^5/^&CK[_H5;3_P:S?_ "#1_P -
M'7W_ $*MI_X-9O\ Y!H ^JZ*^5/^&CK[_H5;3_P:S?\ R#1_PT=??]"K:?\
M@UF_^0: /JNBOE3_ (:.OO\ H5;3_P &LW_R#1_PT=??]"K:?^#6;_Y!H ^J
MZ*^5/^&CK[_H5;3_ ,&LW_R#1_PT=??]"K:?^#6;_P"0: /JNBOE3_AHZ^_Z
M%6T_\&LW_P @T?\ #1U]_P!"K:?^#6;_ .0: /JNBOE3_AHZ^_Z%6T_\&LW_
M ,@T?\-'7W_0JVG_ (-9O_D&@#ZKHKY4_P"&CK[_ *%6T_\ !K-_\@T?\-'7
MW_0JVG_@UF_^0: /JNBOE3_AHZ^_Z%6T_P#!K-_\@T?\-'7W_0JVG_@UF_\
MD&@#ZKHKY4_X:.OO^A5M/_!K-_\ (-'_  T=??\ 0JVG_@UF_P#D&@#ZKHKY
M4_X:.OO^A5M/_!K-_P#(-'_#1U]_T*MI_P"#6;_Y!H ^JZ*^5/\ AHZ^_P"A
M5M/_  :S?_(-'_#1U]_T*MI_X-9O_D&@#ZKHKY4_X:.OO^A5M/\ P:S?_(-'
M_#1U]_T*MI_X-9O_ )!H ^JZ*^5/^&CK[_H5;3_P:S?_ "#1_P -'7W_ $*M
MI_X-9O\ Y!H ^JZ*^5/^&CK[_H5;3_P:S?\ R#1_PT=??]"K:?\ @UF_^0:
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MMI_X-9O_ )!H ^JZ*^5/^&CK[_H5;3_P:S?_ "#1_P -'7W_ $*MI_X-9O\
MY!H ^JZ*^5/^&CK[_H5;3_P:S?\ R#1_PT=??]"K:?\ @UF_^0: /JNBOE3_
M (:.OO\ H5;3_P &LW_R#1_PT=??]"K:?^#6;_Y!H ^H+_\ X\;W_KTN?_1+
MU^95?2,O[1%]<12P'PM:*)XWA+?VI,=HD4H3C[$,XW9QD9Z9'6O!/[-3_GJW
(_?(_QH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Q /\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH ***^<_VHOVM_V;OV+?A7J_QI_:@^+_@[X._#O2%9
M3K'BK41%>:S?@*8M$\*Z!:I<Z_XN\07.Y?LV@^&M,U35IE+2K:>3'+(@!]&5
MF:SK6C>'-+OM<\0ZMIFA:+ID#76I:QK-_:Z7I>GVR$!KB^U"^E@M+2!2RAI9
MYHXP2 6!(K_/J_X*'_\ !YYXNU.]U;P#_P $U?@[9>&M&BDEM!^T!\?M)BU;
MQ%J"JQ7[;X,^$ME?MHNBQ,5\RSU#QQJOB":XA<"]\'Z=,"@_CN_:B_;^_;2_
M;3U^Y\1?M1?M+_%SXQSW$IECT;Q-XLOX_!FF$R2R"/0O .DOIW@CP_"K32!8
M=%\/V$84A2I"J  ?Z[GQ;_X+D_\ !);X*>($\)>,OV[/@3J/BJ35K/0AX?\
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MRC9<T;.\7>][Z']%,?\ P6+_ &8VE19/"OQ@CB)P\H\,:%(47GYO*'BA6?Z
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M4E[]:M%2J5))2J58IS<ZD%4Y.OU'_P""2W_!1;Q+_P $[/VG-(\77]]J%W\
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M'X!>(_V;_@WXUGNM0\"?$[Q)\,M?OIKF\G\/_&6TE\8>&+N_N97N)OL_Q/\
M!NGIK=L;FXED<S^)? T@W_O+O5F,LDD&O\)O@Y^T%\"CXOUG4O%/PG\"?#/6
M_P#A$H?%?BOQ=X/7]H3X1>.]&T;7)=2@MXI/!_@;XG:5:W&D3;KW['XDA\':
MM*UY9I:3Q7!1X.[\$>"O$/Q$\4Z7X-\*V]G<:YJXOGM5U#4;32-/B@TW3[K5
M+^ZOM3OI(K2RM;2PL[FXFGG=458R.I KU'P5\,OBSI?BC4$^'7C+PO8:CIA\
M.VUQXK\(?%71+7PW>:GXNNI[+PYX8M_$UCJ$6EZQK^LW%O<10^'F:>0I'))=
MQQ0 O7Z3E7C'Q5A\-]1S>EA,_P '5A&#>*PU"&-Y*52C+2I3BL/B>65.G%1Q
M>"<7-0Y9NJH6_7O&O]D3]&+,<XQ.>>%''V>>!7%.$P\\XED=?-<PXGX,5#&2
MQ>#IU*N'Q7_&5Y#@<77J8C#0_LKB;&U*T(8JE0R[&8>GC/9_/O@K]JWP-\/?
M'7QF\1^!+RRLO@SHWBWQ3=?L^_"2?P?I%WXD^S_$CQ%I[ZQ-IWB*^TV_U3PA
MX T*ST5/&6K^"X_$L U[78?#/A^:WN;2;791Y+^UIX@^!OB6]T>_^%LW@?5-
M?U#QK\5-6UK6? >C>*](MK[X>:SJFD77PT@^(!\706]UK/Q816\27/C35K87
M27$EY +O4+Z8H\7UCX^\+>'->T[1=7^/GP4\):A>>*I==CT[Q5X/GM?A-\7)
MH_#VIR:+JNK:B/"UHWAW5K8:O%>Z=9ZAXM\&:BNJWEA?"WNY5L3)'\VZ[^R;
MX/\ $!>X^#WQCTZ*ZDP8? WQPLX? FM&1V(%KI_Q!TEM3^'VK,OR!9]9?P5Y
MF6/D)M42_I_#/B#P#F&,P>*GC\PR#,:-&AAYT\TG'ZMBXTL+2HP6)S/#*I0Q
M,ZDW];K5\5"C5Q%>JI57",*<E_EKXZ?L]/IF>'&19U#!\"\/>-' E3&YKBZ'
M$OA#.IQ+4RR3S2O7Q<\'PA7CAN)<GI8.%-950P>78+.,)EF$PM6AAJV*E4Q,
M%^?'[0'P0^!G[;?PYTSX4_M.P7FD^(O"VD-HGP4_:E\/:4VM?%/X)0HTLVF^
M%_%.GK<6T_Q@^!,=[-(U[\/]3NT\2^#8+J\U'X8:WI4S76@:O_)Y^V)^Q5\<
MOV(?B3;^ /C%HUA<:5XBL)/$/PP^*7A"[DU[X6?&'P9YY@@\7_#CQ:MO;P:O
MIXD*VVKZ5=PV'B;PIJADT+Q;HFB:U!-8)_9I\1/@[\5?A))"/B1X!\2>$[6Z
M_P"/#6KVR%WX8U13NQ)H_BW2I+_PQJ\3;7VOIVK7(.Q^A1PO%:G'X#^(?PWU
MWX$_'GP':?&7]G_Q9>_VKK'P\U'47TG5O#'B7R3;V_Q)^#_C&*"[OOAG\3]-
MA.R+7M,@N-'\260?P_XYT/Q+X>N9K =G&_AIEW$]*IGW"]3!TLSJQE6J4\/6
MH2RS.'K*4XU:$ZE##8Z;_P"8B$O88B;MBZ=*K+ZR_P"<_!WZ1'$7AGC:? ?B
M=A,YJY!@:L<!"69X+'T.)^#G!JDL/B,#F.'PF98S*,/;EEEV)H0S'+J<9/+*
MM?#T_P"S8_PEU^D'_!(+Q_9_#;_@IO\ L3Z_J1)TK5OCQX3^'6L1^8T23Z-\
M76N?A3JUK-(I'EP76G>,[F"=R0J0R.[$*I-=?_P4!_X)@>/?V0H3\8_AEKES
M\<?V0O$>NQZ3X8^,%EIJ6/B7X?:UJ2R7&G_#/]H'PE:2W1^'?Q#BB26#3=22
M:Y\"_$.&UDUCP+KMYG4=%T7\X?AWXPU#X>?$#P+X_P!)ED@U3P-XQ\,>,--F
MA.)8=0\,ZW8ZU9RQ'(Q)'<64;H<C# '-?S36HX[*<;*E7HU\%F&7XB$G1K0G
M1KT,3AJM*O3NGRSBXU:%&<)P;4H\E2E4G%TZC_T9RS,\MSS+L)FN48["9IE>
M8X>.(P>/P->GB<+BL/532G2JTVXO>4)PDH5:56%2C7HT:U*K1I_Z"-_IUQH]
M_?Z/=J$N]'O[W2;M =P2[TRZEL;E PX8)/;R*#W S@9JLJL[*B(\DDCK''%$
MC22RR2,$CBBC0,\DLCLJ1QHK/([*B*68 ^I_'!+$_%[XAWVE16\&D>(?$<_C
M31H;202V\6B>/K:V\<Z(D4@X=1I/B*RR>S;E[5XQ\5_C?8?L@?!MOCQ,MG<_
M%_QA<ZOX4_9;\,7T<-PH\6Z<JVWBGXZZMITQ(G\*_!X7,47AI9X7M-?^*EYH
MEHJ3V/AK7EC_ -S\\\0LHR'@+#<=XQJM0Q^391F&6X.G4A3K9KF.>99@L;EV
M685OF2GB:^+G[6LHU(8/!8;'8VJG2PB5;\WS/%X7*,-CL;CZOL,)E\*U3$U&
MKR4*4Y04(1;7/6K3]G1H4TTZE:K".B524/DS_@I%\?4^&'ABZ_8J\":A'_PE
MVJ3Z-K_[6_B#3YHY#!JUA)#K/@W]G&SO(MVZP\"7'V+Q7\58X9=E[\2/[.\-
M7 9/ LJ3_BK5J^O[_5;^^U75;^]U75=4O;O4]5U34KF6]U'4]3U"XDN]0U'4
M+R=GGN[Z^NYIKJ\NIG>:XN)9)9&9W8FK7^=V<9QF7$.;9CGN<XCZUFF;8J>+
MQE6*E&E&32IT,+A:<I2=' X'#0HX+ X?F?LL+AX<SE6K8JK6_C?BCB+%\49Q
MB<TQ-X0D_8X+#*3E#!X*DY+#X>#T3:BW4K5.5.MB*M:K)+FBH ."".JLK X!
MPRD,IP<@X(!P00<<@BOVS\3?'/XU^*-._P""*_QHEL?$/[27QM\*:Q\;]>T#
MP;=:RX\0>,M0^'_[2WG^$?!=O+IT$LNBV4>G:)96&EV6G:=%%:Z=;*FGVF ,
M_B91^)[$8)!!'((P?EP>>,<\]:\;$X=8A8=WC&>'Q4<33G*"FU_LF9X2I"+N
MI05:GF+C4E"49.G24->:#I99+G=7)X9M3A&K.&:Y=3P$_9UW1=*5'-LES6CB
M+.G5A6G0J91:E3JP<(U,0ZOV)1J_O5XCT-/AA\2?A%X0T_X-?%K3?B9^W?\
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MY^%-O:Q:Q;:;>OIU_<V/D:U;RR6]M?QRV;W C2)KF*6*)Y&AD"8[?%;2Y?\
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MM"]".'I-PYL-/FFY>YH[/F/V5HHHKX4_: HHHH **** "BBB@ HHHH ****
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M\6?!S_@GWITFK1_$K]LCXA3_ +1GQ(L+637+SPYXH\8ZQJWP9^'MI81&XO\
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M(Y-2U&5)+'6/BOJMC+F#6M=MR?.L?"=E,IE\+^%)&PH*:SK2S:K+'%8_4/\
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M7J]%.-"A!WA0HP?>-&E%_?&DG^(IXO%U5RU,5BJD=N6IB<1.-NSC.O*+^:8
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MTN36+S0K.Y&@07WBSP[+_:JZ?$UU<V]Q=?V7$;*V#\;IG[-GC*'XH7VH>*]
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M/J4L5@L13IT8U)TX5J'U>="5"6&DE&C"E.47AU3<%&5%TH./+R.$&K+\5/\
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M:/9ZIIFI6&J^)=5MV@M].O+TQZK%JEB;[0KGR/L"'P3X2B\*:7X'E\/:5?\
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MK/,,PS#&+!8.==T:+K3P&31P<<QK481PF-SNMB<?1=1N<PHHHKZ(_/0HHHH
M**** "BBB@ HHHH **** *E_=?8K&]O-GF?9+2YNO+W;?,\B%Y=F[!V[MFW=
M@XSG!Z5_+Z?^#D&X!8?\,DGY7=?^2O1<['9<_P#(B]\9]LXK^H#4[>2\TW4+
M2(J);JQN[>,N2$$D\$D2%B 2%#,-Q ) R0#TK^,H_P#!OW^V^6<_\)3\ _F>
M1A_Q67BKHSLP_P"9(ZX(S[YY->#G=3-J;PW]EQJRNJOMO9TJ=2UG3]G?VFWV
M[6WUOLCZWA>CP]56-_MV="#B\/\ 5?;UZ]&Z:K>VY?8_%9JG?FVTMNS]T/\
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M@[7KOQ[\'_"GQ%TS6= UCXE>,/B9I%QH^D:UJ5N?"WB7PWJ7CC7].M]7@O\
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C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Q 54# 2(  A$! Q$!_\0
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MR.+^P'^Z?T_^)H^P'^Z?T_\ B:[3["/?]:/L(]_UH^N_WW]\O_D@_LU?RO\
M#_(XO[ ?[I_3_P")H^P'^Z?T_P#B:[3["/?]:/L(]_UH^N_WW]\O_D@_LU?R
MO\/\CB_L!_NG]/\ XFC[ ?[I_3_XFNT^PCW_ %H^PCW_ %H^N_WW]\O_ )(/
M[-7\K_#_ ".+^P'^Z?T_^)H^P'^Z?T_^)KM/L(]_UH^PCW_6CZ[_ 'W]\O\
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M_P#DCCOL _NC]?\ XFC[ /[H_7_XFNQ^PM_=_P#'Q1]A;^[_ ./BCZVN[_\
M O\ @A_9;\ON?_R1QWV ?W1^O_Q-'V ?W1^O_P 378_86_N_^/BC["W]W_Q\
M4?6UW?\ X%_P0_LM^7W/_P"2..^P#^Z/U_\ B:/L _NC]?\ XFNQ^PM_=_\
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MUWS?_DW^8?V7+R^^7^1QOV$^GZM_\31]A/I^K?\ Q-=E]@_V(_\ /X4?8/\
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MV>?^>9_(_P"%=K_9[>GZ#_"C^SV]/T'^%'UU=U_7S#^S)_R_^D_YG%?V>?\
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MFO\ X*PO_P U$_\ $!>)?^AED/\ X.Q__P Q'C/]G?[*_G_]:C^SO]E?S_\
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M"US3HM0GU^\BOM1TK6X-2MHU@EL94DC99/,/@Q_P5U\)1R6/AO\ ;$^%^J?
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M'_PTE\%\R+(P_P",:O%V<)LSC'[1I'&[^(CMC/-+_B)?#?\ T$8S_P (*_\
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MG@'0?$'B**]FT+2=4UV.:"UO-5BTU);]K**7 G^R123JI+)&Y&T_R+_LN_\
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M>\2>)/"]GX>&DW'A'7KB^N0^@RSM<C4+17EO;>UB@:2.1F^C?^"//_!6-/\
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MX674?[77PY)X[\,:;XCDT1=5-K8G4ETQ[]K1;XV5F;H1"8VL!<QK_%]\5/\
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M)V<$?\)/QC'(8@\\ \T)_P %/?\ @FP'E8_MY?L>88J1_P 9#_"?L@4YSXH
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M2F/+N#T/K#[T 3;E^V#YE_X]CW'_ #U7WIR,IN9_F!'DV_<?W[CWJL;2V^V
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M37<#3M%<;)Y+=I8RT9<!'J)0E"RE%QOJK];:=V--/9W/@?\ XB6/^"N>,?\
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MXUC%=^)=52RTN!8X799;OQ EK;(D<BQD++<-/.9I$$F<@4 ?T(ZQ_P '%/\
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M1?\ QK^'.H741W_;-3TGPIX*^&_BOQ+I.EK'^\_M+6/#^DWV@Z>Z8QJ>LZ?
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MO&\VDW^DZ1XEN/M-Y>7'BGQWX5:PM(O)M;+3[&R34+R;QCKCVD?FRW]C9YO
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M  [:175M(3!J&FZ3.UU#<Q*\MC!J&J1W$!2[MKRQ_P _&X^&6I>'? &F:/\
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M"07%S;22HJ(H8A$VY']BZ/Y0@_LZR$*PI;K&%VQB"*Y^V1PJJRC$<=V3<H@
MQ-\P./E$&AY?XTU+6)K6\T?6?%'AGPS9:B+:R-AI33ZOXFU2-D*ZKIMG;M S
M0+J]M))%I]U);1W=BXCN&CE&]!_3A^QS_P %8OV0_P!A#X'ZA\._V;OV4O\
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M.X@>CP?\$J?VV90_F>&_@Y8.I&V*?XFV5T[I&05D1[#3I(U16.U$D(=6!90
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M)K>+6$E$80S(88A+?RA(XR6D4?9=;%I<A0D-MKGB;49F5?\ 26_X(NM%9?\
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M7-.>./Y<^Q]>F"/P'!&#\0!SC'( SV' [_BIZ#H5 ],>G&<9X'\\<\\[3ZT
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ME(&-V,\\GG!Z@>V2V3@#@#!)IO'3D<$G&0>3GGDD;CUR/08%.)SZC&<X&><
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MC'0 X [>G''893N3QD 7_/;H?; '/0=1GJ%)I,@]-W7G'8D''H<D9ZG_ +Z
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C %W/\A110 H^['_U\'^;T_\ C'_74_\ H*T44 )1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (S ^(# 2(  A$! Q$!_\0
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M@ %)BG<T8H ,48HQ2XH 2BG8HQ0 VBG8HQ0 VBG8HQ0 VBG8H H ;BE"YIW
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MOJ%_K]GX6TB8V\DPWSSJ>0O)P/3@$^_%1W/PZ:SM&GTS6K]=01<JSR\.?0X
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M<\"Z=K-\+U7FL[[O/;OM9OK_ (]:@TOX>Z=9:@E]>W-UJ-RF"C7+[@I]0/\
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M[1I=:MJ5S:(<K;22_+]/_P!6*Q3ES2LNIZ5:%!TJ+JR:]WM>ZN]C&\%6,_\
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M%/\ DDEW_P!<;C^;54T:UDO/@O=01 L^)& '?:^[^E=MIWABUTWPV^AQRRM
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M'_UZ7(U&S5SL>+IRK.<9N+LDFO)*]T<K-;:GX"\1:3;VFK275G>2",V\G89
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M-R]V&FN[U^MS.VYO?'I_.DXS<>5HTC7P].M+$PDVW>RMU?=^1SNO<?%O0_\
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M8Y.T^'>A7MK%<P:C?/%*H96$PP0?PJ+PQIOANS\67$.F7%Y/J%O&RN9&RF.
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M*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M)BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M "8HQ2T4 )BC%+10 F*,4M% "44M)0 4&BB@!*2EI*  TVG&F]Z $--IQI*
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M)O7U/;=PI%8.%>9I1M92JG=GL,MM^HIM]XOT>UT:XU*&[AN8X&5&6.09W,>
M?3U_"@#HJ*R8]9M3]KGENK6.TMU1_.\\?=9<@MG[O7CGFG1:[I,]F][%J-LU
MLCB-Y?,&U6)  /H<D=?6@#4HK/T_5].U59#I][!<B,[7\IPVWTS4=_KVE:7,
ML-]J%M;2,-P260 X]3Z#WH U**RKWQ#I&G/LO=2M8&VJV))0#M;.#].#S[4^
M[UO3+ P?:]0MH?/&Z+?(!O'J/;D<T :5%96C:N=6\/6NJF'RO/A\WR]V['MG
M%8"^*]97PW'XAET:R_L\P"Y<1W[&58R,_=,04D#MNH [2BLJ[U_2;%X5O-1M
MK=YE#HLL@4[3WYZ#WIU_KVE:6R)?ZC;6[.NY1)( 2/7Z>] &G16;=ZYI=@8/
MM>H6T/GC=%OD WCU'MR.:9HNK?VMX?M-4:+RA/")3&#NV^V>] &K17):?XCU
M>\M;35%TB*73+MDVB"Y,D\:L<!V3;CC(W -\O/H:V+GQ!I%G>BSN-1MHKDD#
MRWE ()Z ^F: -6BN:M_%$-SXCU+3_,LTM-.CW3S23X?./F^7& J]"2>M2WOB
MW2+;0;S58+N&[BM5RRQ2#)8]%]LT =!15"#5+&YAEFBO(9(X5#2,'&$!&X$^
MGR\U:BFCGA2:)@Z2*&5AT(/0T 2T5EWVO:3I<ZPWNHVUO(PW;)) #CU/H/<T
ME[X@T?3GV7NI6L#[5;;)* <'.#].#S0!JT5&)4:(2*ZF,KN# \8]<UGV.O:3
MJ<[06.HVUQ,J[BD4@8E?4>H]Z -2BLRTU[2;^:2"TU&UFEB!9UCE!( ZGZ>]
M%GKVDW_G?9-2M9A"N^0I*#M7^\?;WZ4 :=%8%QXIT[^Q-2U+3KBWO390/,T<
M<HYP"1] <=:M7.OZ58R0PWM_;6\TJAECDE .#W^F>] &K16=+K6FV^H1V$U_
M;I=R$*D+2 .3C/2H;?Q'HMU+(D&J6DCQ(TCA)0?E7J?<#UH UZ*Y[1O$L.M0
MZ?/;^2L=W%)(RO-^\0KMX"XY^]SSQQUS5VSU[2=0EDBM-2M9I(@6=8Y0Q"CJ
M?I[T :E%9=IX@T?4+D6MGJ5K/.4WB..0$D>HJ2XOOLM[;PNT"I*DCL7DVL H
M!^5<<CGGGB@#0HK+L]?TC4+HVMGJ-K<3A=_EQRACCUJ*^U^SL-;T_2IG GO0
MQ4EL8QC'YDX% &S17.Z%XMTW6K>U475M'?3IN^RB8,Z^WUQS5]-<TJ343IZ:
MA;->*2I@$HW9'48]?:@#3HJI>ZA:Z=;FYO;B.WA4@%Y&P,GH/K5,>(M%-FUW
M_:EI]G1@C2><-JMC=@GUQS0!KT5CR^)M#A6W:35;15N$#Q%I0-RGHWT]ZLRZ
MK8017,LUW!'':L%G9G $9(!&[TR&'YT 7Z*P];\3:=H?EK<SIYKS0QF/> 56
M1]N\^PPQ_P" FH+;Q?ICW]Y:7=W;6TL-U]GB5YAF4;$8-CMDOC\* .CHJ">>
M*U@>>>1(HHU+.[M@*/4FL2^\7Z5;:#?ZK;7<%TEHA)1)1DMC*K[9H Z*BL%M
M>%IX3DUR^%N1% TS+;2ED;&=H5B!DG@=.IJL/&FE)J'DW-U;6]N]G%<QSO,,
M.79U*@>VSK0!T]%9EWKFE6$4,MWJ%M#',-T3-*,.,9R/4>]7(IXI(%F21&C9
M0ZNK94CU!]* )Z*RK/7])U"=8+/4K6>5DWJD<H8LOJ/7J*L)J5E)#;3I<Q-%
M=,%@<-Q(2"<#UX!_*@"[17/:)XKT_5XXHS<V\5](SK]E\X%QM8C\\#.*?IFO
M'46M_P!U#%YLMU'M:;Y_W,FS*KCYLXR?3(ZT ;U%9ECKFEZE.\%C?V]Q+&,L
MD<@8XSC/TSWJM-XDT^VU]M)EE2.5;8W+NS@  =O^^06^@H W**Q_^$FT/[,]
MR-5LS"DODLXE!&_&=OUQ3V\0:0EG%>MJ5J+:4D1RF4;6(Z@'U]J -6BLK_A(
M-(&G)?\ ]I6OV1WV+-Y@VEO[H]_:B3Q!I$=G#=OJ5J+>;/E2>:,/CJ!ZGVH
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M0TJZM%@FV_NG=HY)-JE>67JK @]*DO?'$5G)J3G2;Z6STRX\B\ND\O9'PIR
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M3:3INHK!,(K^[%I&IQE6+LN3STRM '145Q\?CJ&2TN;PZ5?K:1SM:Q2_N_\
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M<1^6%MHC%$<8W M@LQ.,\&@#OZ*Y;4/%T5C>7T<.G7=Y%IX'VV>%HP(OEW8
M9@7(4AB%'?UXK2U+7;32M EUB4M+:I&) T>,N&QMQG YR.3@4 :]%<P?%B6^
MF75YJ.F7MKY)C")A)!<&0[46)E8JQ+<8SQGGCFF?\)G;6L-Z=4LKFRN+2))C
M Q24RJ[;%V%&()+87'')'8YH ZJBN'U[Q=JMEH\[Q:%>VE['+;8$QC9#')*$
M)#!BN[^';U!8'IS5ZZ\7&W:\\K2+ZYAT]1]NEA,9$#;0Y4 MEV52"=N?Q/%
M'545S=MXJ2_UYM,L+"ZN4B2*26[0H(D21-R-RP)SZ &K6JZO<6-S';VNDW=_
M+)&SDQE4C500/F=R%SSTZT ;5%<@GCB&YBTK[!IE[=S:E#-+#"IC4IY3*KAR
MS8&"QYR>GN*DC\9PW5M8_8M-O)KZ[>9!9917C,+;9=Y+;0%; Z\Y&* .KHKF
MO!^JW>L:??7%T)5=-1N(DCE50\:*^ AV\9 X[_6LC5/&5U*EA)IME=QV4^K6
M]FM^1&4E4SJCC;G<%/S -C\LB@#O**Y.7QK;)--)]ANCIL%S]EEOPT>Q9 VT
MG;NWE0W!8#U[#-2:GXM.F//+/HU__9]O,L$MXVQ%R2!N568,R@D<@>N,XH Z
MBBN?\/W]S>ZCXACN)"\=KJ/DP# &Q/)B;'_?3,>?6JC^-]/B33C+#.CWNH/I
M_ED#,4BN8R6Y^[NVC_@:T =717'7?BL-?;;)+LLBWR1QCR_+G:#8&))YX8D#
MD=&SVK*TWQ;K<]UX?WZ=<WDE]HIN7MHC$NZ3='^]+%@%4ACQG^(#% 'HU%9.
MDZQ%K6AQZI:P2[9 V(7P'#*2K(><9W*1UQ7%:=XQURYC\,SR6-Q+)?-=K);0
M^4/.V8VMDG"JO/4@\=^,@'I=%<FOC6![*W9-/NS?S74EF+ E ZRQYWY;=MV@
M#.[/<>M:NBZQ'K45P1#);SVLI@G@E*EHWP&ZJ2""K*00>AH UZ*X.V\;7<,%
M_)J&E7,C#6&TZTC@,9+'!VK][K\O)/'S>@.-*_\ %ES8VLT[^'=2\NU@6>[8
MM$HB!&XJI+8D8#KMR.V<\4 =517FGB#Q-K(UG4[C3DO196&C"]@6-H1'(SB3
M$CAOF*C:/E'/RGCGF]I?B,Z/:2MJUUJDTL.G6]P\<XA<LTLKHH78!EF(  Z8
MV]\T =[16-I6KW%]<S6UWI-YI\T2J^)@K(ZMG[KH2N1CD9S5*[\5"WOKR*UT
MF_OH;%UCNY[=5(C8@-M52VYR%8$A1W[GB@#IJ*Y2Z\906SWLZZ9>3:;8RF&[
MODV;(V'W\*6W,%S\Q ['KBH[_P ;Q64NJ%=)OKBVTIPMY=1&/8BE%?< 6!;A
MN0!V^E '7T5RNI^,(]/DU%H=+O;VVTQ-UY<0%-L9V;\ ,P+$*03CH#^%$WC)
M!*T=EIEY?&&WCN+GRFC7R5==RK\S#<^WG ]O6@#JJ*Y*3QM;O<B+2["[U-1:
M1WCFW9 WE2 E2J,P9S@$X4>W7BL_4?%5[;ZAXEBFBNH;'3[6WEBGA$>]2Y;)
MPW<^XXVGI0!WA%%<M>^+XK.;4&ATR^N[/36VWEW"4VQ$ ,P"E@S;5(+8'YFH
M[WQO%;7&HK;:5?7L&FQI+=3P&,(L;() R[F!;Y2>!Z?3(!UM)6=?:Q9Z?H<F
MK3N3:1Q><65<E@1Q@>IR./>L:Y\9'3+&ZN=4T/4[3R$CD"E4?S%=P@ 96(W
ML,J3GTS0!U)I*Y";Q:-/GNKC4[34+,P6"W#V3F%@,S,BG<I^\<#JVT#'3FI;
MOQ++_8]Q<7-CJ.FM'/:J'3RI!()954;'RR,.<-W /T- '49I#7/6WBI+S59K
M2VTN]FMX;MK.6ZC*,(Y <$L@;>%SQN(]^G-=#0 TTE*:2@!K4TTYJ:: &T44
M4 7AUI1312T .HI** #.16;K^G/K'AS4]-CD6-[RUE@5V&0I="N?UK3HH PH
M=%>+Q'9ZF9D*6^FM9E,<DET;=]/D_6N8'@.]BCTR-FTW48;2T:W-O?QLT*N7
M+>:J]&.#C!].HKT2B@#CO#?A"XT.;29);N*46-K=6YV1[=_FS+("!VP%QBH]
M,\%OH]_#J-E/#'>F\N)+PA"%N8)9&?8W^TN5VM[$=#7:T4 >>:3\/?[+N+&&
M.ST'[-9SB5+T:>INY%4Y52Q& W3YP<\<8/-=)X<TJ[T>.^M[B6"6"2]FN8#&
M"& DD9R&SW!;'%;]% '#77@Z\:QDMP-,OH7O[JZDM;^#=&XED+J0V"RLN<<=
M<GVK<\/:(^D>&X]*NKC[1@2;L%MJJS$[%W$G:H.T9/05NT4 >?:)X"?2KG3T
M6TT$0V+Y6\33U^U7 4$*&8CY6Z$N,DX[9J]8>%;[3M3;6#J(DOKO>-4!!\N9
M<?NP@_A\OA1Z@MGK79=*6@#SGPIH>KZCX;\++JTUNMA8117"1I&RS.PC*HCY
MX4+N[=<#I4FC_#YM)NM/B6TT(6]C*'6\73U-W,J_=5F(PK=,N#DX[5Z%10!R
M.E:!KFE+::9#J%LFD6DV]&6,^?)'DD1-GY0.<%AR0.@K(_X0"Y.GZ9'<)H]]
M-I;S10Q7=N7AF@D(/S YVR CJ,_K7HM% '#P>$+O3(;&[L6TR#4K6XFE$,-H
M(;9DE 5H\(,\!4^<Y/R\\=-KPUI-[I4.H-?W,4]Q>7C73&%2JKN55VC/IMK>
MHH Y&Q\)SVFK6EZUTC+!J%[=E0IR5GW87\,UK:'I+Z4^IL\JR?;+Z2Z7:/NA
M@HQ^E;%% '%P^%+]+Y-]S;FVAUM]5BPK;R'63<C=L@R#!]J9K/@AM5GU*=GM
M96FOK>]@BN8?,BW1Q",I(O<,-W3ID>E=O10!S'ACP])HLEW.]KI-HUR4 @TV
MT6)$50>K8#.22>O3MWS#+H.MVUYJ:Z1J%K;VNI3?:'DDC+2V[E55B@^ZV0H(
MW=#ZUUM% '$W7A/5GL]4T:WOK5=(U.>6661T8SQ+*<RHO\)R2V"<8W=#BI[K
MPE+/I7B&R2YC7^U+Q+B,E3B-56)<'_OV?SKKZ* .2U_PG/K-_J%Q'=)&MW9V
MUNH92=IBG:0G\0V*2\\*3W6A>*-/6Z0/K%P\R.5.(PT<:X/_ 'Q^M==10!Y5
MXIDN;-/%.E:9<[7U/<PM);*1Y9))(E4^2RG:RM@#)^Z=U=_?_9+3PW+'JA M
M!;>5<?*6!4C:>!SWK6HH \WT?P9-JGP^6#49 =1NY8KO?=P[@?*VB)9$/4%(
MU#+_ +35./ UT^FZE'#'HVE3W$<<21Z9:"-,*X=@[@*Y#XVD#  ]:]!I* /.
M6^'MU+'JFP:58"^T[[&(+* JB-OW;V;JY//.!VK;\4>'[K6YHB(-*O;8(5-M
MJ,).Q\_ZQ'4;@>V/IR*ZRB@#G=%L]3TC^SM*>87=G!8%9;IU;S&F#*%Y+?=*
M[N.3\HY]:WB/PM/KEQ?RQW,<8NM(ET]0RD[6=@=WTXKJZ* ,632)'\3:?JGF
MKY=K9S6Q3'+%VC(/_D,_G69XE\)SZ[-J4D=U'$+O2C8*&4G:V_=N^E=;10!Y
M7XI>ZLQXHTG3+DH^IAF%I+92/+)))$JGR64[65L $G[IW5U4'AF=(M=#7"YU
M.TB@7@_NRL)C)/KSS7544 <MI7A^]TO7(+I;BWDMO[,@LIU*L'W1;\,O;!W]
M_2GWFD:O;^(+G5=&GLMUY!'#<17BM@&,MM=2OLY!7O@<BNFHH Y70O";:+?:
M;,MUYR6FGRVKEEPTDDDJ2,_L,JW'O5K5='O+KQ#IFIVLT"K;P3VTR2ALLDA0
MY4CN/+[^M=!10!R=MX4EBTGPM8O<QM_8Q7S2 <2@0/%QZ??S63HWP^?2;K3X
MUM=!^SV,H=;Q=/4W<RK]U6)&%;IEP<G':O0J* .?\3:1<ZQ;010QZ?<0HY,M
MG?PAXIAC YP2K*>016/I_@_4-.71##>6[26%U-*\+!_+2*7(*1Y)(VC[N?TK
MN*3 SGO0!YQ8_#Z_@N=-DFDTQI[*]2XDOA"S75V%)^^[?=X/09&<=*LW/@6Z
MN("DS:9<BVU.>^M8[N R1R),7+QRJ?3?PP_NCBN_HH YSPUH+:+:W8>'3K66
MYDR(M-M5BCB & !QESU.6]>@%9&B^#[VR\1VNIW!TV%X$=9IK&%HGOBPP#*H
MPH_O<9^;TKNJ* ,>32W?Q;;:OYJ^7#8RVICQR2[QL#_Y#/YUDVGA.:#2?#UD
M]S$QTN\:XD(4XD5EE7 _[^#\JZ[O10!YYH_P^.DW5A$MIH2V]C,)%O5T]3=R
MJIRJLQ&%;IEP<G'&*BA^']\MQ9R2OICS6NH1W;Z@8&:ZNE67=M9C]SCTR.!T
M%>D44 <(/!]\_B6WU&1]-5[>Z,[7UO"8KJ>/)Q%(%PI'(!;G('3-+!X0UF*+
M3M.-]9_V=IVH"\B98V\V1=[-L;G QN/(ZX'2NYQS2T <7<>"C<^$%T6:6WDF
MCOY+V-I8?,B9C.\H5T/WEPVTU#:^#[N"TU PP:!I\]R(T6WM-.0P%5;++(2H
M9P_3MM[<UW5% '+>$_#<V@2W\KBUMX[MD*65EN\B#:#DKN[MGG  X%5-0\)7
M]WJ6K3PWMO&MS=6]]:LR,SQ3PK&H##.&0A/K\U=I10!SNEZ1J)UR;6M5EMC<
M-;"UBAM0VQ$#%B2S<EB<=AC%8^M^"&O-=OM3M[/0[MK]$#G5+,2M ZKM#(<<
MC 7Y3CD=>:[JB@#FM*\-OIM_<SB6)HY=.M[)52,1X,7F9;:OR@'>.!TQ6;IO
MA;6/#\=F^E7=B]PNFP6%P+F-MA,6[;(NWG^)OE/7CD5V]% ''Q>'_$&EW<]Q
MINJ6MQ->01)=2WL1!\Y%V^:H3CD8^4^G6H;3PCJ6ASVQT2]M@BZ;%I\QNXV)
M&QF82+M/)^=OE..W-=M10!R7AOPI/H<]A))<QR"UTF/3SM4@EE<MN^E8ECX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@#"U_Q'8>&K(37C$LQQ'&OWG/M7&K\6HA*"^C3" _\
M+029./R_K6MXI\#S^)-9@NCJ"QV\:A?),9.><MSGO5[Q/_9%CX6N;:X$*PK$
M42/C.<< #UK"?M&V[V2/9PT<%&$(RBYSEOJU;_,U='UFRURQ2[L7WQMU!&"I
M]"/6N7UKXE6FC:I<:>UA+(T) 9PX )(K,^$4<XMM3=O]0SH$]-X!W?TK!CN-
M.C^)U]=:J\0LTDDW>8NX'Y< 8[U$JLG"+6ESKHY=0CBJU.2<E!72Z]--#H%^
M+]F/^87+_P!_17::7KMOJ/AZ+66'V>W>,R,'/W0"<Y/X5@V6M^!]1N1!"EDL
MC<*)( F?Q(JWXU@^S^!;^"RC"(L8PL8P NX9P!^-7%R2<F[G)7I495(48TG3
M;:W;V^9B2_%: 3NUOI-Q+:(V&GW8_3']:[/1]7M-<TZ.^LWRC]0>JGT/O7$>
M%3I__"M+K?LX23S@2,[LG_ZU9'@W7'\/>"]6O6Y7S0ENI/WI".?Z5$9M-<ST
M:.C$8&E4A-4(M2C)1WWN=P_C"$^+!H-K:R3RC_62JP"Q\9.?I74X (]JX+X<
M:&UKI[ZQ>?->7QWAFZA<Y_4\_E7?=:WIMM79Y6,A2IU?9TOLZ-]WU'44459Q
MA1110 4444 %%%% !1110 4444 (:*#10 &DI324 )333J:: "FFG4TT --)
M2FDH :U--.:FF@!M%%% %T4M(*6@!:.]%'>@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH BQ][Z5YCHVE: -)U:/6_+-U;3R+(9CAHER2
MI3T!SD$=2:]1K-NM&TR\G2>ZL+>69/NR21JS#\2*F4;G30K^R3CKK;;R*GA!
M[J3PIISWI8SM"-Q;J1V)]\8KFIY8Q+XY@9U$C1;MF><>0.<5Z >%QWJE+I=A
M/<27,EG \[H8VD:(%F4C!4G&<>U)QND.&(2E.37Q?AJF<;I4"R>)/#9= Q31
M]RY'0_(,_D35W1+2'^U_%3>4GSW 5OEZCRP<?F3^==6EE;1RQR+!$KQIY:,$
M *K_ '1Z#VIT=K!#)*\<2(TQW2%5 +GID^M)0*>*NFO*WXW/+(?M'V#P<_VJ
M*WB$,@CEGCWQK+@;<C(YQG'-:S6\4FL:P^H:O'<G^SFCNULK1E 0]"3N;+@;
ML#KBNW?3+&2S^Q/9PM:@8\DH-F/ITHL]-L=/B,5G9PV\9.2D2A03^%"IV-9X
MU26UM^W5W.!@NKC3Y-$66?3]7L7GCCMF$>R:+/ 8 $@X'7I7I0Z9-9UOH>E6
M=R;FUT^UAG/62.%5;GW K2JE%HYJ]6-1II#J***HYPHHHH **** "BBB@ HH
MHH 9QCI65XAU&XTO1+F]MH?.EB3<D?/S<CTK6YII&1[4/5#BU&2;5UV/%?$'
MC?6=7T::RN]+$$,F-T@#\<^XI/#WC;6='T>*RL]+6>&,G$A#<Y.>PKT/Q];R
M3^$+R.WA>61MN$1"Q//H*3X?6TEOX/M8KF%XI SY1T*D?,>QKB]G/VGQ=#ZG
MZ[A?J/\ !5N;:[[;FIX>U*XU70[>\N8!#-*N6C /')]:Q_&,OBF+[.OA^/<C
M*WG$!<@\8QN/UJQXTUR]\.Z3'>V5O')B4+)O)PJGOQ[XJ?POXAB\0:'#=;XU
MN ,3(I^XU=#:?N7U/%IPG3_VQ03A>UGJOF>9>"KFWT[QF3KD<RWTC%8WD_A8
M]=WN?6K'BK#_ !8MU?E?,@&#Z<5%XXGAU3QY;QZ>1)(OEHS1\Y;.>OL*G^(E
MO)IWBVQU/:=CJAW?[2'D?E7(](M=$SZ>+53$0JO252#5NVVQ[!PR,.V*\>^'
MWR?$.[C7A-DPP/9QBO3)]<L(M ;5!.GV81[U8-UXX'U]J\\^%=I)=:S?ZI(O
M"#9N]68Y/\A714UG%(\3 Q=/!XB4]%9+YGKM%%%=!X84444 %%%% !1110 4
M444 %%%% # W'7-<5KOQ'LM"U:73I;.:22,*2RD8.1FNT'/O5"XT33+R5IKG
M3K::4]7>)6)_$BIFI->ZS?#3I1G>M'F7D['B\7BNW3QZ?$+6\GDY)\O(W<IB
MO1?#_P 0;/Q#JHT^&TFC9E+!G(QQ7(1:=9M\739?98C:[F_=;!L_U9/3I7J5
MMHNFV4WGVMC;PR@$;HXU4_F!7+04]=>I]!FU7"\L%R.[@K:[=B:<)%%),(@9
M%4D =2<5XIXJ\7:IKL$5G>V@LX=X8KALDCOS7HND>.K;4_$<FC?9);>1&=0\
MC##%3C ^O6K?C:"SD\):@UTBX2,LA.,ANV/QK2HN>+Y6<> DL'B(JO3NW:VN
MU^Q@7J6EG\(98]/G$T7D@>8.-Q+C=]*E^$T:KX<N) /F:X8'\ *YGPM;7-_\
M/?$$'S%%(:,>X&6_E6_\)+M&TF\M<@.DV_;WPP_^M40E><7Y'=BZ3IX2O33N
MU.[^97^+\">3ILO\6YT_ @?X5-K^B7?B;X?Z5<6R^9=01K($[N"N"![]/RJA
M\6KL2W>G6$9#2+N<J.O. /SYKTC1K7[#HEE:_P#/*(+S[4**E4DC"=>>&P>'
MJ+XDVUZ'E.HZQX@\2:1;^'TT>=)@5$KLN =O3KT]:2>U.JZMIWA=+@?V?I<>
MZZE_AR.7.?T'U->A>,M?7P_H$URF!<RCRX1_M'O^'6O.KS3+C0OATUU(3]JU
M6=/.)ZA>2!^.,GZFHG&SWOW.O"5_:03C%03=H]?>>\ODMCO(/'?AB&9+*&^1
M$3"*VT[!C@#-=5&ZRQJZ,&5AD$="*\OE\-Z7_P *M%X+>/[4(!-Y_P#$6SZ_
MIBN@^&UU-=^#X%E8DPR.BD_W0>*WA.7-RR/)QF$HQI.M1;]V7*[_ )G;4445
MN>0%%%% !1110 4444 %%%% !1110!&3DXS^-><:_P##%M0O+S4+?4&$\[F3
MRW3Y0?2JGQ"75M)U^VU>WGN/L;%=R+(0@9>Q'N*U9/BIHPT\R(DYN=O$)7O]
M>F/>N><H2;C/H>YA<-BZ$85\(^;FWLMO)F?\-=>N//E\.W2K^Y4F(@8(P<,I
M]?K5R+X8VLNLW%[?WC3Q22-((57;R3GDYK'^&^CW=[JMWK<Z-'$ZNJ-TW,QY
M(]A5/2M?O_!GB>XMM9EO)K8@H"[L_&?E=<GFLHM<D>=:'H5X5'BJOU.5I65T
MNKZV-/QOX%TVPT634M-B,#08+H&)#*3COWYK?^'M\^M>$O(O?WWELT#%^=ZX
M[_@<5S7C+QW::UIATK2HY)#.P#L4(XSG '<YQ79> ]%ET/PW%#<C$\K&61?[
MI/:JARNK[FUCFQ3JQRY+$_'S:7WL85Q\*]/:Y8P:A=16['<T QCZ9KG+JVM-
M3UZ+1K3,>B:0K23,.=Q'+DGN3T_.N^\<>(?[ \/.R-B[N/W4 [Y/4_@*R?#7
MA1[/P1=1N,:AJ$)9L]1QPO\ GUIRA'FY8KU"AC*RH^VKSOK:/ZOY+J8=IKWB
M_P 1>?<Z)Y5M96QPD6!R.PY')Q]*ZSP/XKE\1V4T=XBK>6[!9-O1@>AQ^%<A
MX%\4Z?X<TJ_L=39HIUE+A"IRQP 5^O%7_A7:3//J>ILI6&:3;'D=>23^614T
MY.\=;WW-<?AX*C5YH**C;E?>_GU/4J***[#Y<**** "BBB@ HHHH **** "B
MBB@!#10:*  TE*:2@!*::=330 4TTZFF@!II*4TE #6IIIS4TT -HHHH NBE
MI!2T +1WHH[T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 T( 20!D]32TM% !1110 4444 %%%% !1110 4
M444 %%%% !1110!4O+.WO[22UNHEDAD7:Z,."*\]NOA- 9V:SU.>",_P%=V/
MQKTNBHG3C/XD=6'QE?#7]E*USDO#?@/3/#LXN@[7-V!@2R#[OK@=JU]<T&Q\
M06+6UXA*YRKKPR'U!K5- Y%-0BH\J6A,\56G4]K*3YNYYB/A&GF8.K2F#.=H
MC&?YXKO=&T>TT33TLK--L:\Y/)8]R3ZUI9XXHQQ4QIPCJD:8C'8C$I1JRNAU
M%%%:'&%%%% !1110 4444 %%%% !1110 4444 5A:0";SO)C\W^_M&[\ZLTE
M+0-MO<\]\4^ 'U+4?[4TBY%M=DY=3D D=P1T-8S^"?%NL%(=7U-5MD(_Y:;_
M -/7ZUZP1Q0?05DZ,6[GI4LUQ-."BK.VS:NT9>BZ'9Z)I26%JG[L [BW5R>I
M-<'J'P]U?3M4>_\ #=Z(PY)\LL5*Y[9YR*]0QVQ2]:<J<9)+L84,=7HSE-._
M-O?6_J>:Z!\/;U]675/$%TL\JL'6-26RPZ9)[#TKT<A<$YI]-S\O6JA",59&
M>*Q57$24JCVV[(XK7?"=]K_BJVNKF:(:7;D%81G<QZG/U./PKH->T2#7-'FT
MV4[%=1M8#[I'0UKXYHYS2Y5KY@\55?)9VY-CR;_A"?%QLQHK:C%_9(/!R.F<
M],9_#->C:)H\&B:3!I\!+)$N-QZL>YK1QTR/PI?>B%-0U1KB<?6Q$>6=DM]%
M:[[OS'T4459Q!1110 4444 %%%% !1110 4444 03P1W$1BE17C88*L,@UB_
M\(;H F\T:1;%\Y^[@?ETKH*8<>E+E3W1<:M2"M"37H-BB2% D:A5 P HP!53
M4-)L=3C$=[:Q3*.F] <?3TK0-)VHWT)4I)\R>IC:?X9T?39/-M+"".0=&"<C
MZ$UM4E':A)+8<ISF[S=V4+S2;#4)(Y+NTAG>/[AD0-M^E7L#ICBEHJB6VTDW
ML8M[X8T?4;@7%UIT$DO]YER3]?7\:U(((K6%8H46.-1A548 'TJ;&*0Y/O2L
MKW*E4G**C)MI#Z***"0HHHH **** "BBB@ HHHH **** $-%!HH #24II* $
MIIIU-- !333J:: &FDI324 -:FFG-330 VBBB@"Z*6D%+0 M'>BCO0 M%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5%+*@+''S,0H'U)('XT 3T444 %%%% !1110 4444 %%%% !1110 AHH-%
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M5B>PL61"2B_9UVJ3UX_ ?E3YHW%RRMN5-9O[BUN=-EMY@+=FE>5 FXRJL3,
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MMW'4444Q!1110 4444 %%%% !1110 AHH-%  :2E-)0 E--.IIH *::=330
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M6/"NGW&F:7)#<1"W$EP\D-J'WBW0]$S^!/''--;B>QT-%%%62%%%% !1110
M4444 %%%% &=J5])80+(D F)+97=MP C-Z'^[C\:I2Z\_F2)#;"1HP2X,N,8
M+@C[IY^3I[UNT4TUU1+3[G._\)!/&TX:S5BDA0(DO(QP6.1]S(^][]*LPZK+
M+:S7+6H18RJ\RY!) ).0,;1N^]SP#Q6S2#..>M.Z[!:7<P5U6[>"XG\N)(XY
M(DC)8[2"P#-NQ]W!X/IS2'Q"P1B+7,B\[3-@%?D^;)'W?G.#WV_EOTWYL#@=
M>>:+KL'++N<_)XCD57<6/R* 06F"_F,;A[<<_I5J^U6:TG=8[82A8PX!8KU6
M1CV/_//'XUK-NVG;C=VSTI-GSAMJEL8+=\4778+/N8LFNS1LZ-:#S%#$KYV,
MXW],CI\@R>VZK.EW\E^9F:-$52NT*Q)P1SV'?//?%:0W<Y SVYH^;<>!M_6A
MM6V!)]QL4GF/,N/]6^WZ\ _UJ6H(8V1YF./WC[@/08 _I4]2-"T444#"BBB@
M HHHH **** "BBB@#D9M9O+.>_6.6&<K-*$@8%G3;#O!^]]W( QC^+K5F77W
MDO##;W-FD6X+]H?YD'R%L'##G\>QKH HW%MJACW%)Y2;-HC3'ICBHY9=R^9=
MCDM.UV\6QL5>:%F*6R&.0,99M\:DN#N]21TZJ:6#7]0O(H)&>"!6E@9V 4X5
MR04.)#Z#DX[\5T;Z= ]VMP0Y92&"F5@H(& =O2K/E@*<1IR<D>IJ5"7<;E'L
M<_J-U=VVN2.MPBQ+#"BB3=LC+NP+L P!^[CD=QR.<RZ9J5Y?7WEEX#"BDNZ1
MG][\[J"IW<#Y0>_?ZUN;=V=RKR,>N:4*% P%&!BJY7?<GF5MCE3?:G_:LZQ7
M<),1N#L9&("J(BH*ANO/7W/K4UIK]W<ZJD'D1K$[A-I*[@/+W[OOY/TV].]=
M)L7=G:N3U-&Q0VX*N[&,X[4N5WW'S+L8%SK$\&H31*;?$<ZQ" J?,<% V\'/
M09/;HIY]**^);SR(6!MIVE$),D*X6,NKDJ=S@9^0#EA]X<>O5O&L@(902RE2
M>^*9!;106ZVZQJ(U4*!UX''-#C*^X*4;;'.KKM\T+S-]GCC2*+^'?O>1V0$$
M/M X!Z]_O=ZK#7+V9HY'FB"[)D,:Y7<RRQ@'*N><-V)[^M=@44@@JI!&",4>
M6O'R+^5'++N',NQS#:_>?+L:T9I"0$V',!$J)A_FY^\?3D5M:;<SW"3K<&,R
M0S-$6C4J&Q@@X)..#ZU<V#+':N3^M.QCH!SUJE%KJ)M,?1115$A1110 4444
M %%%% !1110 AHH-%  :2E-)0 E--.IIH *::=330 TTE*:2@!K4TTYJ:: &
MT444 712T@I: %H[T4=Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH QM=UZVT&.UDNU8QW$PB+J/N<$[C[#%6+C4XH-1L;/:6:\
MW[&!X&U=U9OB*))M4T**50\;W;JRL,@@PR9%8EO'<Z=XOT?2)@[P6_GO:3$Y
MW1%.$/NO3Z;:R<FF:**:-W_A)H9--M[N&UGEEN)WMX+=2NYV5F!Y)P!\A.<]
M*GTW69+J]DL;NQFL[M8_-".RN'3.,AEXZ]O>N7M7L5\*6 U.&46K7MP3=Q.R
MFV?S9-K97D9Z9]^:TM!OG_MUK.RU9]6TX0%WE<JYA?(VKYBCYL@G@\\5*F[J
MXW!6=C;U'5187$%O%;2W-U.&9(8R!\JXRQ+$  9'YU+IM^-2M?/\F6!@S(\<
MJX964X(]#]17.Z_! GBJTGU*Z>VT^2S>'S!*8E,@<,%9P1C(R>HSMK1\*2S2
MZ5(7EDFMQ<R+:RRDEGA!^4Y/)[X/<8JU)\UB7%<MSH*6D%+6A 4444 %%%%
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M5L<G\ZV*AJSL4G=7%HHHH&%%%% !1110 4444 %%%% "55%[:->M9K<Q&Z1
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M& /F8*(]JG(.X\&NCTHL/$&M*H(A)@=@>TI3YOQVB.FG<3C8WJ***HD****
M"BBB@ HHHH **** $) JI;WD%U),D+,QA<QN2C ;NX!(P?PK(U[1[C4IG:.*
MWE#VS11F9B#;R$\2+P>?I@_**AN])>S\,:U#%!&TMP9I L:X+[LXS@=:EME)
M(ZC(JI]NM\73>9Q:DK,<'Y2%#?C\K \5SBZ+?P323VEM:1"0RJMJLI5(PR(N
M00O]Y,D =_6JZ^%[Q3(/)M%D8J?M0<[R!;+%L^[T+#UQCWI<S[!9=SKH+B.X
M7?'N*\8)4KGC/&>O6G&>);A8"P$K(7"]RH(!/ZBN5/AVZ68N]O9W0(<+',Y
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M(.HWXO+$L8+XR*TWS=0V5VL#QP1V%6]*T:'21.ZRSW%S<OYD]Q.07D;&!G
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M@ IIIU-- #324II* &M333FIIH ;1110!=%+2"EH 6CO11WH 6BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 (:*#10 &DI324 )333J::
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIIH ::2E-)0 UJ::<U-- #:*** +HI:04M "T=Z*.] "T444 %%%% !1110
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M1:X;4Z%XEDT81;O,"1;O,STK TSP1X[L]4M;B[^($]S;QR!I(#;_ .L7N.M
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M::: $HHHH NTM(** %I:2ES0 4444 +1244 +1244 +1244 +1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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MUSP^JR*59DB.0#Z?)7JE% '-^!?"B>#?"UOI"SF>16:267&-SL<G'M72TE%
M"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
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M-JG'/OFAP:U8*29HT4VBI*'44VB@!U%-HH =13:* '44VB@!U%-HH =13:*
M'44VB@!U%-HH =13:* '44VB@!U%-HH =13:* '44VB@!U%-HH =1FFT?C0
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M_P"1YL/I)_Z :]RKU<)\#/SWB7_>U_A7ZCLT9IM%=9\T.S2')4@-@GOZ4E%
M$4<,R.&>\>0#^$HH_E4DJO(F$F:)O[P4'^=.!I: (T218BIN'9S_ !E1G\NE
M,>*=ONWCI](U-3=\4$XH 0!@>921MQC Z^M1Q121R%GNI)>,!2J@#\JEHS0
M@##&9"<'G@<TD:LBD-(TASG) 'X<4*V[=_LMBEH =FC--HH =FC--HH =FC-
M-HH =FC--HH =FC--HH =FC--HH =FC--HH =FC--HH =FC--HH =FC--HH
M=FC--HH =FC--HH =FC--HH =FC--HH =FC--HH =FDS24$XH 6C--S10 ZD
MS2$TF: %S29I,YHH ":3-)F@T (32$T4A- "&D)I33: $S1244P+(-+FF TN
M:0#A13<TM #LT9IN:,T .S1FFY]J,^U #LT9IN?:C/M0 [-&:;GVHS[4 .S1
MFFY]J,^U #LT9IN?:C/M0 [-&:;GVHS[4 .S1FFY]J,^U #LT9IN?:C/M0 [
M-&:;GVHS[4 .S1FFY]J,^U #LT9IN?:C/M0 [-&:;GVHS[4 .S1FFY]J,^U
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M_P#%4?\ ""^)_P#H$R?]_$_^*KW#-&ZCZI#N/_6;%?RQ_'_,\/\ ^$%\3_\
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MY4>1%_SS7\J** #R(O\ GFOY4>1%_P \U_*BB@ \B+_GFOY4>1%_SS7\J**
M$\B+_GFOY4OD1?\ /-?RHHH #!%_SS7\J/L\/_/-?RHHH /L\/\ SS7\J/L\
M/_/-?RHHH 3[-#_SR7\J/LT/_/)?RHHH /LT/_/)?RH^S0_\\E_*BB@ ^S0_
*\\E_*BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D 40# 2(  A$! Q$!_\0
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M3@IJ?RZ=Y?O4W*2(,<=*4+4_E4OE5%QV(0G-." 5-Y5.\NE<=B+ IP4>E2!
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M*WS?9/,Z_P#7-CU_W3SZ$]*X$W91T:-R&0Y#*<%3Z@UW?AWQFLQ%MJ3HLC'
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M4N7W+TX')K'DUO6;>!3]K/G-T!C7C]*Z95$CE5-L[L1#%)Y0 )KSF?Q+K,6
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MECD\FG1RO$VY#M8=Q34VA.)[U:B2YLFD%M+#($+%)0 1@>H.*P)CFT)]9/\
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)<#':BBBD,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 +\# 2(  A$! Q$!_\0
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M  DM];6Q\F\BD^1B>)%P#@_G^%-/34+'HIEL-O.HPC'M3%FT\LL:ZG"68[5
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M(FV^ _%@_O31#_R,AI-$5C8(!<2I\[<*V!5<1N?!GB%D+.BR1[SN_P"FB?\
MUJZ>ADF?2'G.YVY &<8' IZ ;@2,@'L>#4:)P.001VJPD;2-B-<^N* $PNT
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M)[<5YWKGC*^OIY;?2I#;VL?#SCAF]\]A7R6$P-7%3Y:?3=F9Z;Y3_P#/5?\
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ML2:=\O\ M4 2@C_(I<@#'>HLXY&<_6CZ YH FR1B@'D9_G40/4$4X$8)S]*
M)?K^E9GB%A_8-T!WV_\ H:U=XSU(K/\ $!']A7(!_NGZ_,M)@,[=*7BF9H!%
M,!_%+BF\=J7KUH >!]*./;\*82>G2@&@!V12YIF1G%&?PH D!/TI?>H\BDS^
M- $V[TI0V>N*C!]J.<<#% $V_P!J7<,=!4.X@XXI0_6@";C&>*4%:AW9%.W
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8TEMY88"L@^]M.5.X'(YZ\8^A-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A W<# 2(  A$! Q$!_\0
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M&_[Y- $E%1^:OHW_ 'R:/-7T;_ODT 244U2&&1G\:=0 4444 %%%% !1110
M445'YJ^C?]\F@!]%8/B3Q)'X>T]+@Q-(SOM5>F?6KFE:Q;:O81W=LQ*L.0!D
MJ?0U3IR4.>VA/,N;EZFG14?FKZ-_WR:/-7T;_ODU)1)14?FKZ-_WR:/-7T;_
M +Y- $E%1^:OHW_?)H\P?W7_ .^30!)14?F#^Z__ 'R:/,']U_\ ODT 244T
M'<.A_$4Z@ HHHH *:Z!T*MT88.*=10!172[-?*/E9,9)4DD]?7U_&FC2;15V
M!&"9+;=QY)K0HHN!0&E68*GR0=HQSSGW/J?<U8MK:*VCVQ# )R23DG\:GHH
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M;%WXW8YQTS3J** "BBB@ HHHH *KW7GF,)!PS'!?CY1ZU8HH H_V3;_WI_\
MO\W^-']DV_\ >G_[_-_C5ZB@"C_9=N.0\X/8^<W^-2VIG\@"<8D!(ZCD9X/Y
M59HH **** "BBB@ HHJ">XBM+>6XGD2*&)"\CN<*J@9))[ "@">BL.T\4:1>
MP7LR73PK8*'NUNX9+=X5(W!F6158*0#@XP<'T-/MO$>E7.GW-\+GR(+;_CX-
MU&]NT0QG+K(%91@@@D<CI0!LT5C#Q)I"^&U\0O?1II+1"87,@*+L/3@@'))
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M87!:0]&_ASWP,&X\!^)-5_M$ZC)ISS75I;*SW%W)=K+-!*TJ[D,2*L;EL%5
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MCIP>Z/-CX;\2Z<=UIJMPX'178D4'7O%^EC?>117,2<D!,''UKT>F201S(5=
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MMV >PH **** "BBB@ HHJ*=E2"1GSM"DG'7% $M%<G',^VQ>"3SVWOMC9F#
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MWS0N_G<![8H =1110 4444 %%%% !1110 4444 %%,;?GY0N/>E7?SN ]L4
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MT 245'B7_8_,T8E_V/S- $E%1XE_V/S-&)?]C\S0!)14>)?]C\S1B7_8_,T
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M>[EL=1FM4GD5%>1%P5+! JY^;' '2NFH **** "BBB@ HHHH **** "BBB@
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M&?O$=LGHJ** "BBB@ HHHH **** "BBB@ HHHH *CE_U3_[IJ2HY?]4_^Z:
M*^E_\@NV_P"N8JY5/2_^07;?]<Q5R@ HHHH *HZ5_P >TG_7>3_T(U>JCI7_
M ![2?]=Y/_0C0!>HHHH **** "BBJLT[QWEM" -LN[<3UX% %JBBB@ HHHH
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M %V_]E-7JHWW_'U8?]=O_930!>HHHH *HZ5_QYM_UUD_]"-7JHZ5_P >;?\
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M_KFO\JGH **** "BBB@ JC??\?5A_P!=O_935ZJ-]_Q]6'_7;_V4T 7J***
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M -7;_P#7Q'_.KU4=3_U=O_U\1_SJ]0 4444 %4;7_D)7_P!4_P#0:O51M?\
MD)7_ -4_]!H O4444 %%%% !1110 4444 4=7_Y!=Q_N_P!15T=!5+5_^07<
M?[O]15T=!0 M%%% !5&P_P"/B^_Z[_\ LHJ]5&P_X^+[_KO_ .RB@"]1110
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MY7^V_P"='E?[;_G0!)14?E?[;_G1Y7^V_P"= $E4KG_D*V/TD_D*L^5_MO\
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M>Q_Z!<?._P#JF[^U $EI_P ><'_7-?Y5/56TC_T.#YW_ -6O?VJ;RO\ ;?\
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M?[;_ )T 245'Y7^V_P"='E?[;_G0!)14?E?[;_G1Y7^V_P"= $E%1^5_MO\
MG1Y7^V_YT 245'Y7^V_YT>5_MO\ G0!)14?E?[;_ )T>5_MO^= $E%1^5_MO
M^='E?[;_ )T 245'Y7^V_P"='E?[;_G0!)14?E?[;_G1Y7^V_P"= $E%1^5_
MMO\ G1Y7^V_YT 245'Y7^V_YT>5_MO\ G0!5U/\ U=O_ -?$?\ZO5G:G'^[M
M_G?_ (^(^_O5[R_]M_SH ?14?E?[;_G1Y7^V_P"= $E4;7_D)7_U3_T&K7E?
M[;_G5*UC_P")E?\ SOU3O_LT :-%1^5_MO\ G1Y7^V_YT 245'Y7^V_YT>5_
MMO\ G0!)14?E?[;_ )T>5_MO^= $E%1^5_MO^='E?[;_ )T 5=7_ .07<?[O
M]15T=!6?JT>-+N/G?[OK[BKHBX'SO^= $E%1^5_MO^='E?[;_G0!)5&P_P"/
MB^_Z[_\ LHJZHVC&2?K5*P_X^+[_ *[_ /LHH O4444 %%%% !1110 4444
M%1R_ZI_]TU)4<O\ JG_W30!7TO\ Y!=M_P!<Q5RJ>E_\@NV_ZYBKE !1110
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M -7;_P#7Q'_.KU4=3_U=O_U\1_SJ]0 4444 %4;7_D)7_P!4_P#0:O51M?\
MD)7_ -4_]!H O4444 %%%% !1110 4444 4=7_Y!=Q_N_P!15T=!5+5_^07<
M?[O]15T=!0 M%%% !5&P_P"/B^_Z[_\ LHJ]5&P_X^+[_KO_ .RB@"]1110
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M_P#7Q'_.KU !1110 51M?^0E?_5/_0:O51M?^0E?_5/_ $&@"]1110 4444
M%%%% !1110!1U?\ Y!=Q_N_U%71T%4M7_P"07<?[O]15T=!0 M%%% !5&P_X
M^+[_ *[_ /LHJ]5&P_X^+[_KO_[** +U%%% !1110 4444 %%%% !4<O^J?_
M '34E1R_ZI_]TT 5]+_Y!=M_US%7*IZ7_P @NV_ZYBKE !1110 51TK_ (]I
M/^N\G_H1J]5'2O\ CVD_Z[R?^A&@"]1110 4444 5+^\BT^QGNYF"QQ*6)->
M::'I+^)=5?4]04[;LR;%/8 =JU_&U])J>HVOAVT8DNP:<CL/0UTMK91Z?)IE
MM$N%1''Z"NF_LJ6F\OR_X)A\<_)?F<5)8ZWX,N3-IS-/9$Y: \C'M78:!XGL
M->BQ$WEW 'SP/]X?3U%;4D2S1E9%# ^M<5KW@K?+]NTMS!<J=P*<52J0JZ5-
M'W_S#DE#6&W8[FEZUP.C^-9[*==/\0QF*0'"W&.&^M=S%*DT8DC971AD,IR#
M7/4IR@]32$U+8EHHHJ"PHHHH **** *.J_\ 'M'_ -=X_P#T(5>JCJO_ ![1
M_P#7>/\ ]"%7J "BBB@ HHHH **** "J-Q_R%K'_ '9/Y"KU4;C_ )"UC_NR
M?R% %ZJ][_QXW'_7)OY58JO>_P#'C<?]<F_E0 6H_P!#@_ZYK_*N U5F\3^.
M(K%,M:6)R_IN]:ZG6-671_##79QO$*K&/5B.E97@'2FM=,:_G!,]R=Y)ZXKI
MI>Y!U.NR,9^])0^9V$:".-448 &!3Z**YC8**** "J-]_P ?5A_UV_\ 935Z
MJ-]_Q]6'_7;_ -E- %ZBBB@ JCI7_'FW_763_P!"-7JHZ5_QYM_UUD_]"- %
MZBBB@ HHHH **** &2_ZI_\ =-5M*_Y!5K_US%69?]4_^Z:K:5_R"K7_ *YB
M@"Y1110!1D_Y#<'_ %P?^8J]5&3_ )#<'_7!_P"8J]0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1U/_ %=O_P!?
M$?\ .KU4=3_U=O\ ]?$?\ZO4 %%%% !5&U_Y"5_]4_\ 0:O51M?^0E?_ %3_
M -!H O4444 %%%% !1110 4444 4=7_Y!=Q_N_U%71T%4M7_ .07<?[O]15T
M=!0 M%%% !5&P_X^+[_KO_[**O51L/\ CXOO^N__ +** +U%%% !36.U2V"<
M#.!WIU-92R$!BI(P".U &6=93?; HJ+,6!,C[2,'& .Y]J=%JX>UFF>%D*,
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M??WJ[YJ?WU_.J>IJ/+M^!_Q\1]O>KVU?0?E0 WS8_P"^OYT>;'_?7\Z7:O\
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MH 6BBB@ JC8?\?%]_P!=_P#V45>JC8?\?%]_UW_]E% %ZBBB@ HHHH ****
M"BBB@ IDO^J?_=-/J.7_ %3_ .Z: //YO!]Y<>7?V5[-$\B \-TJ$0>,M,^Y
M?/<@=!(,UWNE_P#(,MO^N8JV0#UK=8F=K/7U1DZ4;W6AYVGC+Q'8G_3]+64#
MKY7%78/B/8-_Q^6=S:^N1N_I79/:PR?>C4_A5&XT#3KC[]NI_"G[6F_BA]V@
MN2:VD8W_  L3PW_S^R?]^6_PJM9^/?#\$3J]XXS*[#]TW0G(K8_X1'2\_P#'
MO'_WP*IZ?X6TV2!RT"$B5Q]P= :?-0_E?WK_ "'RU.Z^X9_PL7PW_P _K_\
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M )BKU49/^0W!_P!<'_F*O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4=3_U=O\ ]?$?\ZO51U/_ %=O_P!?$?\
M.KU !1110 51M?\ D)7_ -4_]!J]5&U_Y"5_]4_]!H O4444 %%%% !1110
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M_P >-Q_UR;^56*KWO_'C<?\ 7)OY4 +:?\><'_7-?Y5/4%I_QYP?]<U_E4]
M!1110 4444 %4;[_ (^K#_KM_P"RFKU4+_\ X^+%NPFY/I\IH OT444 %4=*
M_P"/-O\ KK)_Z$:O51TK_CS;_KK)_P"A&@"]1110 4444 %%%% #)?\ 5/\
M[IJMI7_(*M?^N8JS+_JG_P!TU6TK_D%6O_7,4 7**** *,G_ "&X/^N#_P Q
M5ZJ#\ZW#[0-G\Q5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;3=034;03HI7L1U&?8]Z6_NFL[8RK'O(/.3@ >I/84K#)][_ //)OS%&]_\
MGDWYBL2/Q792LK*K^20P+D=&49(Q]*'\56D.F2WDR,I0*1'U)##*_I3LQ71N
M;W_YY-^8HWO_ ,\F_,4J-OC5Q_$ :HZGJ7]FQK*T1:+^-LXVC^I]J0RYO?\
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MFBS8[FC]DN?^?V[_ "3_  H^R7/_ #^W?Y)_A6=)XKM4MY93&V%V%,G 8.<
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M-$DBYVNH89]#69<^(K&SGN(9EG$D"JQ B/S G V^M*P[D_V2Y_Y_;O\ )/\
M"C[)<_\ /[=_DG^%0GQ!9"0(1,,PF<'RS@J,9Y]>>E.L=>LM1GCA@9R\D(F
M9<84DCG\J=F%R9;&X(R=0N1[$+_A5N&%((A'&,**DHI %%%% !1110 4444
M%%%% !6;<:4D^HM>^:ZR&V-O@ $8+9SSWK2HH YL>$[86L=O]IF*!V>0X&9-
MW4$_X5JV>F16-Q<S1L29RF0?X0JA0!^ J_Q1Q3NQ6"L>?0HYI-0D%Q)&UZ4+
MD ?+M7'%;%%*XSG6\)V;)!$TLI@BCV>7P-W.<D]<U<TK1(M+EGD29Y#-M^\
M, =.E:U%.[%9#'4.C*>C#%8<GAB"6"&!KF7RHV=F7 ^?=V)]*WZ*$[#.?/A>
M$R7,HNI1),@C!VK^[ (/ QCM6GIVGQ:;:"WA+$;BS,W5B>IJ[Q1Q1=BL9.M:
M,-:MXH'NIH(TD#NL>/WF.Q]JKOX8MY)G=YY"C*X,> !N88+?6M[BCBB["QSC
M>$K=D.;F;S64))+@9=1T!_(5T*J$0*O0# I:*&[C,>ZT%;O6H=1DNICY*[4@
MXV#/4_6JB^$;=8U N9O-12D<O&40]0/S-=)11=BLC+BT6&&\LKE9'S:0- J\
M88'')]^*U***0SG5\+QBXN[B2]N));B42!F S&1]W''09H'A6V C N)L+&4D
MX'[SYMV3^/I7144[L5D9&CZ*NDR74OVJ:XDN7WNTH&<_AVJ_=0M/:R1)*T+.
MNT2)C*_3-6**5QG.0>$H(+.VMUNYSY.[+D#<X88(-2P>&XK-R]K=30XC,<0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
.%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  N )\# 2(  A$! Q$!_\0
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M_K*II^K:;<%H]WE7$#W%C=VUS/\ +?\ P4<_9>^#_P"WG^Q1\3=,U+3=,O\
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M@TOP7X0U6PCFT33-+MM%U;R=1U6^F9M3LKEI?.\N0E(HU7Y+_:F\;:Q\1?\
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MQ_X2U+4;G39?$-AHLYEGT35-+NXX;+7-/BN[NR_TVRU"Q-M%-);P_FE\#O\
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MPU\0>IS@_>_ G@GM_6U_P5D_X*@?!W]CS]GKXG>'?"?Q&\+^(?VE_%_AO6O
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M^'6GWL6F:KJ?P(M['Q=?R?9C&]QH,?B637=6TG0+PVY1E@-O>R6ADCG%B\8
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M,/ IL]('@;1/%/\ PDBKJWB>[N_#=W;S:% DFL6MU%=VYLQ+;R*/W*U;XD>
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?Y:(N%'M C0=%'KT[]<\^_/UYI^,=/<_F<G]:!G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>fin_001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( #T# 2(  A$! Q$!_\0
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M2\ZN-J6Z*.PI5ZTXQA.M6E"/PPE5J.$?*,'/D7R@O4_J_"8 '3U [_R/3BG
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>fin_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $] B8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HII<!MISG / S@$X!/H,]^W6N8UCQAH>CY6:[
M2>X4D&SL]MS<D@?=8*XCA],RR*,D#J<4 =03C^O3CW/\OK36<*I<]!DDY
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M<-X!_P"0G>_]>1_]'6]% 'O]%%% !1110 4444 %%%% !1110 4444 %%%%
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MO?\ KR/_ *.MZ* /?Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%(6 R20,=?RS_+GZ<T 5KR\AL8);JX8)!#&\LTI/RQQQC<Y/<G&0J@$LV%
M[U\UZ_KDVO:BUX_F)"NY+.!FR+>WSE2" ,32G,DY!Y=MHPB*H[3XB:_YMP-!
MM6_=P.EQJ#J2%DF)+06C8^\L(<3R@@#SC$#N92&\Q'X=2>.!R<X'3@?0?04
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 55OI?(LKR;_GC:W$O4#_ %<3OU/ ^[WX]>*M5@>)IS#X
M?UEP=K#3+G:>X:2*1/<9&1QCK[<@ ^9=YD/F$Y+C<QR<%BSY(SC )Y QT-+3
M5& !Z #\!G&?H#M'L!3J "BBB@ HHHH #_GZ=^O&<=,\9ZUZE\+;/=<ZM?.J
MXAAM[.+*@G,I,\A!QQQ'$#GYB3STY\L.,<]#Q^?']:]R^&D6S1)9F^_<:A=>
MO(@V1@GZ D'MDG !.* /1P,# Z#@4444 %%%% !1110 4444 %%%% !1110
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MHH *Y+Q>Q/AK6#GEM.FS_P !=0,?@376UR?C%2/#FKH 3_Q+;@YQZ/&?Z_\
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MZKV<=2HY5AU@:<E5QU>'-C:T6FJ5.5FL+3:5TGK[7K)*TGRRY25%5$55SM4
M+DDG Z<GD\>O-%.HKM5[:[]?7J>$DDDDK)*R2V26B2] HHHH **** "BBB@
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M(^$JU*E>K4K5I.=6I.4Y2=GK)W:326E]E9622Z!1113("BBB@ HHHH ****
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M$")BSW,H!W0VR'#R+U5G+A8E!&-S9(V@U] 64$=M$+>)0L,(2.$  8C51M&
M ."3T YR<#-<UX0T+^S-/$MS&!>WP2>X(_Y9C&8H!E03Y:DM(3UE9^,*I/8*
M@3.,\XZX[9] /6N[#4E3CS<MI5$N:^\%'51W=G=WDOYF[[(^+SS,GC\4XPLL
M/AVX4U%^[.:O&=96;OS6M%MV<$G9-Z.HHHKJ/$"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$\?Z?]NT&ZE0,
MTVG/#=I@?\L\B.X4=B&@9F)SD&/CISX%W([CVQD<X(]CU'7ZU]87,$=Q!-#*
M-T4L9CD7&=R,"'7'4AE8J>X'(YKY=U73I-(U*\TV3<3:S%(W;GS(#M-O(6P
M=\31DGKD\\[C0!1HHHH **** "BBB@#=\-ZTVA:K'=-O:TF"VU_&@!9K9VQY
MJ@]7MG83)ZA9$P=Y!^EH94E17C*LC!2C(P971E#(ZD<;64@BODL@$'(SP?U'
MT->L_#[Q01Y?A^^D4.6VZ7-(QP\:J9&L<G(!B0,UKER&0&!,F-<@'L%%(K!A
ME2".>1[<$?4'J*6@ J-_F4A6&2&Z'DY4@8Y]2"/I3MZ'/S#AMI]FYX_0UR'B
M'Q';Z';D[DN+R>-A;6H8@@_=\Z0@';&IW-G&78!4.22L3G&G%SEHEO\ U_F:
M4J-;$5J="A3=6K5FHQC&UTMW)]>6*U;V2U;2W7Q!XA@T&V&6\Z]=2+:V,APS
M=!).5Y6+KD#EW&P$G->(W=W=7]S->7LAEN)FR7(V@#KL1>0L:D_(G(5<@$GD
MEU=W%Y<2W=W*9YYCND8D]<Y5%!+!(D!"(B\(.!DY-5\9Z;OR_P#K]<"O+Q.*
ME6<E!VI73BTFF[=;Z67EY>J/TW)<FHY;2<Y.%7$U(KVV):;M=W=*AS17)2C)
M6E+E3J7>JC[H<\=<\G&../3'U/09STYYKM_!6BG4+O\ M*Y3;;6+J80P*K/=
M@C:1Q\ZVZ\LW"^:%5LE37*V%A/J=Y;V%MGS)9!N;!'E1Y_>3L1G A5MP SN;
M:HP""?HC3=/M]/M(+6W0)%!&(@-H!<\%I7(X9W;+,PS\S-R<U>"INI^\E9QB
M_<3C]I75U+[2[J[LTM3@XGS-X:BL%0:5>O&\I)M>RH-ZKE4DG[;51=DXQ4OB
MYM+J*0<DY!48Z]<Y/';KVJ2BBO4_X<_/$K?F_5[_ / 70****!A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT2:?J$H35(MVUMA4:A"@#&2/ VBX7.)H0=\NUI44!L#T(2J3CD'./F&.>X_
M<GT^HKQ3P=X,EN'@U;5EEMX8W6>TLP3%<3,FUHKBX(PT=OQF.)&62;"NX"8!
M[KQ%XDAT6#RU*SZDX8P1\84L#BXN K 1Q!@/E!!EQB,$@Y4I**<I-)+=O_):
MOT2;?1&M"A6Q5:%##TW4JU))1BE)I*_O2E))J*C&[;;27JTG-XB\1VNC1_(
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MW8_),5B:N,Q%7$UI.52K)MWVC%:1A#5VA&-DEWYG;4****T.<**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG""@FDK-OFEYRLD_R/@:U>MB)*=>K.M)0C",JDG)J$$E&*;VBDE9+U=WJ50
M/\>Y^M+115&04444 %%%% !1110!W/@'_D)WO_7D?_1UO11X!_Y"=[_UY'_T
M=;T4 >_T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4C$ '/H>/7@G'Y TM(1G'.,9_4$?US^% /8\"\7,[^(+[
M<V[8+>-6 'W%B0\$=CN)Y]QR0:Y? ]/_ !Y?\*[?QW:-;ZM%= DK?VRD;5X$
MEL0D@X]%>,G/10?O8&.(VL.WZC_&O$Q5_;3>[;=WUTV[_+RVT/UO):L*F68*
M4+)1P]*DTVDU.DN2HK:7]_U;>KNV&!Z?^/K_ (48'I_X^O\ A3:*Y]?/[_\
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M,NTT?QMX\N--647=T+W]CBH;&>QR/R(_K3!%&#D* <Y. !GT!P.0,?*#T[4
M?EUX+\*>-_ WCO\ ;E\!:O\ #_Q7>3_'[]I/PY\7?A?XML-!O=3^'VN>#M;^
M%GP1\&ZC+J'BNQ@O-/\ #^M>#M9^''B==>T;Q -/N!;P:5>6'VRTU2&5.Y^,
M7A;6]0_;R_8U\3Z1\/O$NJ_#WPM\,OVMM'\<>*-+\,/=>"M!U7XH+\*&\.V?
MB/4(8_LUM<>+;KPYK[S>?!)&\L!FU:2$W4#S_H:(T 8 !0Q)(4  D[>2  "<
M*!DY..#2+%&@PB*H]%4 ?H.XX/J !0!^/VI_"KXB>"/!W_!3;X9ZG\*?$'Q0
MUW]J;QEXR\2?!76M%TJ*_P!"\:^'/B?\&?#7PQ\+^!/$^LW&_3_ UO\ !?6]
M"N]+U0>)Y-.TO3_")TWQ#H"7TUW>VL/"ZY\!/VA? _C?X(?$/X4:%JOC_P#:
M1_9;^$?[,/P5UOQ=XCM-1\->!_CY\/\ Q%X9\3_#KX^Z,GC74XA9:RG@KQ%J
M/A+]H.*"4/<+JO@R;3+*.6YUJ]>']O#&AR-HP>HP,$^I]3[G-)Y4>W;L7''\
M(XVC"D<<%1]W'3MB@#\L? 7AOQ]\+OA-^T9\,OAYX3^(.F>*_'/[36I>%O!7
MCG6_ >M3VXTWQSX%^'>D^*/V@-9-G)9W5]X6_M2P\9ZUJOB*UNX))]?>*&![
M<7=G,N;^SWIOQ)_98G_:J^"WB;X/^(?'?P<\.,GQN^ L'PD^'FKOX!UJT^*R
M7C?$W]G'P;H^JZGK4O\ :&C_ !'M-4\36]E?7<^E+X=^(]P0;6PT*]M8/UA,
M:-U4<<?AQQSG@X&1T(&#D4ABC/\  O3&<#.,$8SZ#)('8G([T ?DI^RG%\5/
MV3+O]H+X0^/OA+\6_BWX5\+^&=-^,?P3^*/A3PO/X@U#Q5X+O+#4;R']DF&?
M4]1MX/\ A-?@)=H?!WPRL[G4;'2O$_@K4=$=Y=,\367B""?H_@AH&L_"OQ_^
MVKX;^,?P=\;>.=._:9^-5]\7O!?BRQ\('QCHOC[X9^,OAIX+\*6'P<\97,4E
MU;^#]=^%+^'=<\+7WA[QA=Z9X<71;F#7-"O[FWO-7%K^I/EQ\_(O/7(![[L_
M4GDGKD ]A2>5& 5VC!^\,###&"&'0@_Q ]3UH _,[X9Z-XK^ ?Q&_;HOO'/P
MI\7?%"P^.?Q)TSXQ?#&\\(>'!XKM_&?@M_@A\._A7;_ '5&B,^G>']3\$:]X
M(UVWM;/Q#)8>$;GPUXO@U^TNW0^(UMOEOQ7\+OC9\/?^">7P _8_U7X:?%?X
MG?%;X+?\,(ZYXH\6>#?#9\6>"M5'A?\ :(\(>)/&7AGPOX@BU#[7K-[\)_"G
M@F^N-<DFTVSMUT2/0;BPENKG4H;*/]UECC4;510I&T@* ".XP !SW[<GU.6^
M3'Q\HX&.0#USU!!'<T ?F+X)U_Q+\)OVL/\ @H'\0]8^#GQI\2>&_B _[.E[
M\-;SP?\ #;7=<M_B#/X'^#']B:_9^'=0BA2PBGT_7Y8]&EN=:N-*L([OS)?M
M;64,]S'[)^UE<SW?@'X#W%W!);74O[6G[(TMW9F1;E[">7XR>$GN+)YX T<Q
MLIFE@>=<(_E^=G8P)^V/+3!&/O=3W(R3@GTY_+BH9K*TN%C2XM;>X2*>"ZB2
M>&.58KJVD$MM<QJZL$N+>54D@F4"6)T1T964$ 'Q=\>O@/\ &KXF?'+X'?$7
MP#\?]2^&/@'X;ZE-=^-O =E:ZA/'XW5QJ(9Y&M-0LHD^W6UW'X?N 1'+'93S
MWSS71M;:R'Q;+\,OCSXT_:_\3?%_PQ\"_%6D^'[?]EG]HSX4/HG[0T/PH\(?
M#OPMXH\97OA'4O W@[X/:W\&]1E\5^*]!^)7B3PO)J_Q,\0^+Y-7CT7P[)%<
M:+JNDZ_+<Z5+^U!AC/50<]B 1SR1SV8G+#HQY-(8(3UC3&,8V+C;_=QC&W/.
M.F23U- '\M'@C]B[]J=/@5\7_!=O\!/B!J0O?V//V7/@I<0_%VX^$WAWX@^'
M_%/P=^-EGXK\4_#W]FVP\%ZW'X2\8^#?ASX(NO$GC+X8Z[\6+VX?Q3\1-)\%
MZ%K?B+7=#U'Q!9P_4_A?]F7XL2_"GXG^-_$O@+XU:3XAT#_@H%X<_:^^"FH'
MP?\ "KQ;\?OB+?6OA?P_X4U;Q/\ '#X,Z;XM\#?"_P#LNW\S6M T?0?"FM^$
M_$L'A71M \80:;8^+()#=_OAY,6&!12&^\,##>I88Y+=&)Y8=:/(BZ%%(XR"
MJD$#& 1CH,<#W([F@#X8_P""=GP:^)?P2_9OM?#_ ,683I_C/Q=\6/CW\7K[
MPX_]C+/X/L?C)\8/&'Q&T3PI=V_AJ6?POIVI:-I6OVT6LZ1X8GN/#VC:O)>:
M5H]W?6-G#?7/W92 !1@  >@&*6@ HHHH **** "BBB@ HHHH JO$6<@Y*,0"
MK(C(PQC# XX'4C!R:S9_#ND73;KC3[.5N[F!5<GKR4V_UZ<8[;E%)J+WC%^L
M8O\ -%QJ5(.].I4IR_FIU)TWVWA*+.?B\-Z) VZ+3+1&4'!, D[]0)-P)ZX/
M7GUQC7\G8 L>%3[NQ$55 ..<# XP??GUYJS10HQ6T8K?:,5OOLEN$ZM6H[U*
ME2H[6O4J5*C^^I.=OE8:B[%VYSR<<8Z_B:=113VV("BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>fin_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "@!!4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9L_CC.DP34=$7 .',$Q#+Z_*PY/MD5WNF>/_  ]JM@]U;7ZCRTWR0R K(O\
MP'O^&:F5"I'=![6%FV]CJ:*\VE\2:_XCOC;:.KP1 _P\''JS=OH*TQX7\1>5
MN_X26?S<9V[WVY^N[^E=#PB@E[6:B^VK_(\Z.9>TO["G*2771+\3MJ*\VN-;
M\5>'"R7X\^)OE25P&&?4-_C60/&?B'J=0/\ WZ3_  K6&659J\9)KO<YZF>4
M*;M.,D^UE_F>P45X_P#\)IX@/']HG_OTG_Q-=CHUOXFO;..ZNM9,(D&Y8_LZ
M,<=LG%37R^="/-4DE]_^1KA\WIXF7+2A)_=_F=?14<898P'8LV.3C&:YCQ"-
M<L;2ZO[76"L<?S"$PIP,] <=:XZ5/VDN6]CT:];V4.=Q;]+?YG5T5Y);^*O$
M]W,L%M>/+*W 584S_P"@UW&D6?B(-%+J6J@CJ\ A3\BPQ^E=-?!2H+WY*_;6
M_P"1PX7-(8EVIPEZZ67XG1T4@SBEKA/6"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@]*3-  1D$
M5R/C;P+8^++$L D&I1C]U<A>3_LMZK_+\P>OI"*J,G%WBQ-)JS/"?"'B^_\
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MLZ%KMOKEF)87VRJ )(CU4_X>]>+F.%G";J[I_A_70^GR?'TZE-8=Z2CT[_\
M![FO12*<BEKRCWPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M O\ 9K6T4&G*#N6"7: LDG&,N/NG^'('4UZF5!4@]#6:^A:?)H(T1X U@(1
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M(\?EIG.!M(Q]?PIJI#L)PD<9%XWUK6/#6FO:7D5IJ4K3"1(K5KB241\91 ,
M'N21BG:7K,NO^)_ VIW"*L\UI=[PO3(&TD>F2,_C[5V$O@KP_+!90'38UBL@
M1 J,RX!Z@X/S ]P<YJ:R\*:-I\EC);6GEM8"06Q\USY8<Y8<GG.>_P"&*'.%
MM$'+*YM"EI.E+6!J%%%% !7,^%XS;ZIXEMC_  ZD90/9XHV_GFNFK-M;=8=;
MOY%'^NCB=OJ-R_R44T]&A=32%%%%(84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !BC%%% !1BBB@ I,"EHH **** "BBB@ HHHH **** "BBB@
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M-:BLG^R+W_H8-2_[]V__ ,:H_LB]_P"A@U+_ +]V_P#\:H"YK45D_P!D7O\
MT,&I?]^[?_XU1_9%[_T,&I?]^[?_ .-4!<UJ*R?[(O?^A@U+_OW;_P#QJC^R
M+W_H8-2_[]V__P :H"YK45D_V1>_]#!J7_?NW_\ C5']D7O_ $,&I?\ ?NW_
M /C5 7-:BLG^R+W_ *&#4O\ OW;_ /QJC^R+W_H8-2_[]V__ ,:H"YK45D_V
M1>_]#!J7_?NW_P#C5']D7O\ T,&I?]^[?_XU0%S6HK)_LB]_Z&#4O^_=O_\
M&J/[(O?^A@U+_OW;_P#QJ@+FM163_9%[_P!#!J7_ '[M_P#XU1_9%[_T,&I?
M]^[?_P"-4!<UJ*R?[(O?^A@U+_OW;_\ QJC^R+W_ *&#4O\ OW;_ /QJ@+FM
M163_ &1>_P#0P:E_W[M__C5']D7O_0P:E_W[M_\ XU0%S6HK)_LB]_Z&#4O^
M_=O_ /&J/[(O?^A@U+_OW;__ !J@+FM163_9%[_T,&I?]^[?_P"-4?V1>_\
M0P:E_P!^[?\ ^-4!<UJ*R?[(O?\ H8-2_P"_=O\ _&J/[(O?^A@U+_OW;_\
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M+FM163_9%[_T,&I?]^[?_P"-4?V1>_\ 0P:E_P!^[?\ ^-4!<UJ*R?[(O?\
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M_H8-2_[]V_\ \:H"YK45D_V1>_\ 0P:E_P!^[?\ ^-4?V1>_]#!J7_?NW_\
MC5 7-:BLG^R+W_H8-2_[]V__ ,:H_LB]_P"A@U+_ +]V_P#\:H"YK45D_P!D
M7O\ T,&I?]^[?_XU1_9%[_T,&I?]^[?_ .-4!<UJ*R?[(O?^A@U+_OW;_P#Q
MJC^R+W_H8-2_[]V__P :H"YK45D_V1>_]#!J7_?NW_\ C5']D7O_ $,&I?\
M?NW_ /C5 7-:BLG^R+W_ *&#4O\ OW;_ /QJC^R+W_H8-2_[]V__ ,:H"YK4
M5D_V1>_]#!J7_?NW_P#C56[*TFM0XFOKB[+'(:=8P5]AL5?UH&6Z***0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>fin_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/!!$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ?2NVYI9@H_ !0 ![527PAHB3>8+-B/-\[RVN)#'OSNW;"VW.>>G6G[5;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[3_OMO\ "@+EW%%4MVI_\\[3_OMO\*-VI_\ /.T_[[;_  HL!<Q1BJ>[4_\
MGG:?]]M_A1NU/_GG:?\ ?;?X4 7:*I;M3_YYVG_?;?X4;M3_ .>=I_WVW^%
M7+M%4MVI_P#/.T_[[;_"C=J?_/.T_P"^V_PH"Y=HJENU/_GG:?\ ?;?X4;M3
M_P">=I_WVW^% 7+M%4=VI_\ /.T_[[;_  HW:G_SSM/^^V_PH"Y>HJENU/\
MYYVG_?;?X4;M3_YYVG_?;?X4!<NT52W:G_SSM/\ OMO\*-VI_P#/.T_[[;_"
M@+EVBJ6[4_\ GG:?]]M_A1NU/_GG:?\ ?;?X4!<NT52W:G_SSM/^^V_PHW:G
M_P \[3_OMO\ "@+EVBJ.[4_^>=I_WVW^%&[4_P#GG:?]]M_A0%R]15+=J?\
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MI_WVW^% 7+M%4MVI_P#/.T_[[;_"C=J?_/.T_P"^V_PH"Y=HJENU/_GG:?\
M?;?X4;M3_P">=I_WVW^% 7+M%4MVI_\ /.T_[[;_  HW:G_SSM/^^V_PH"Y=
MHJENU/\ YYVG_?;?X4;M3_YYVG_?;?X4!<NT52W:G_SSM/\ OMO\*-VI_P#/
M.T_[[;_"@+EVBJ6[4_\ GG:?]]M_A1NU/_GG:?\ ?;?X4!<NT52W:G_SSM/^
M^V_PHW:G_P \[3_OMO\ "@+EVBJ6[4_^>=I_WVW^%&[4_P#GG:?]]M_A0%R[
M15+=J?\ SSM/^^V_PHW:G_SSM/\ OMO\* N7:*I;M3_YYVG_ 'VW^%&[4_\
MGG:?]]M_A0%R[15+=J?_ #SM/^^V_P *-VI_\\[3_OMO\* N7:*I;M3_ .>=
MI_WVW^%&[4_^>=I_WVW^% 7+M%4MVI_\\[3_ +[;_"C=J?\ SSM/^^V_PH"Y
M=HJENU/_ )YVG_?;?X4;M3_YYVG_ 'VW^% 7+M%4MVI_\\[3_OMO\*-VI_\
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M_/.T_P"^V_PH"Y=HJENU/_GG:?\ ?;?X4;M3_P">=I_WVW^% 7+M%4MVI_\
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MU.&<217DYE\MHP&#*3TZXKO*B4;6\RT[A1114C"BBB@ HHHH **** "BBB@
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MEK UZQN\R6XN[&.!08O-=4QN#94C=GD<XKH4N]4B\5R:=)>Q26]Q9RW$ \@
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M@KY=R\L0PAQARF[(&#GUI;R.VU+X=7D6A11/#/8RK;QVZ;58E3P!@8R:XO\
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M3]<5H#6-,-W]D_M&T^T[MOD^<N_/IMSG-<1<7]EJ%YK$UE(LD<\NG2(ZJ0'
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M=T[8IM*S!/4W9M=TZ#3)]1DN MK [QN^TYW(Q0@#J3N! QU[5?CD62-7 (#
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M/0GG XX%-T[;_P!?U8.8]!W"C<*\RTRW\^S\/327%V7U'4;F&Z(NI!YJ*9B
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M+10]0$Q1CVI:* $Q[48]J6B@!,>U(10S!%+,0 !DDGI42W=N[!5GC9CT <4
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MU%8SVT>S,-I D(AM[242Q0Q *F1G&0.P)SCU J:]T^TU&'R;VUAN8@<A)4#
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MN['Q/X>CN1"9+*]BYCF4<J>""*Y+0O#NCWWBZ35-.TZWM]/TPF*!XEV^?/\
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MQD@9YK9ETZXN?%,%].(C9VMNRVX!);S7(W,>/[HP/JU.Z6HDF9GBB_UC1?\
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&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>fin_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &$ ^@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBD)"C)Z4 5[Z^M]/MFN+B14C4<
MDG%>0>)_BG??;#'HTH2(9PX ;=VX%7OB'J;:S>1Z79B5BAYV,<$\\>_%<?-X
M4:T2TCGA=9G<#;^->MA<-!+FJG#6J3;48'KGP^UC4M:T W6IONE,A"G '%==
M69H%JMGHMI"(PA$*Y'OBM.O+G;F=CLC>RN%%%%24%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M49H **** "BFLZKU('XTJL&Z$&@!:*** "BBB@ HHHH **** "BBB@ HHHH
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MQ:?ID44*%5 Z$UYIXDFNM5\6K9[LQA\+M7/&<5M']]6<GLC&I+V=-16[.O\
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M0EO![,FM':2Z'9 Y&:6HK=Q) C#H14M<QN@HHHH *S-=_P"0<PK0DD6-=S$
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M1:LWQ$1O^FZ_^AU[U ,0)_NBO4Q56480C%Z6.&C!2G)L@M]-M+6-$AMXU"#
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M\3W7A+PS')9-LD?Y P[8KY6U+4[K5[^6^O)GFFE/S,S4(#W[7_CY9VT_EZ5
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M5J- N?;FBZM;:YI-OJ%HX>&9 RFM"O&_@-KMS?Z#<V$I_=VC%8Q[8!_K7LE
M!3)1N3'U_E3Z#TH ^3/'33:3XRDDAWQ3*^ZN.U/4KR\OOM-S,\LW]^O0/C<R
MQ^-SMZ[/ZUY?(S._S5;=]PLCI['XA>(].2-(=1EV+_ 6XKV_X?\ QC@\07*6
M&J!;:<@*K,1\QX_SFOFEHI$3=LJ2S=X;R)T=T(<?SJ/S!'W<6#)D'((R#7Q]
M\196B\?7TD;[760[66OI#0]>9_APFHXP\-MD_@.M?*/B#5)-6UNZNY/OM(:
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M<<"0,OWO:K/Q;UZZU+Q7=6LNWRK4[5P,<5P'AAV'B.T_WQ70?$E\?$'5MO\
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MFO/=7^"?AK5=3:] EM\XQ'%@*,4 9VEZO90_!J=GG1=T#*/KBOFB9MTSNO\
M>-?1/Q1\)Q:%\.8K#2HI&ABEW-M&2/E/-?.A&SY: /<_V?[&UN_[0:YMH9F'
M&9$#?S%<O\<+2"S\;%;:".-6&2L:!1]U?2NR_9W&(M1^O^%8WQNB5_%PW+V_
M]E6@#R/369+^#^_OK[8\.2/+H-F[MEC&,FOC:WBC&HP?+_%7V3X;&/#]D/\
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M%VB[C$P_0YH ]P^/FAVTEM::^I_?. F/5<5X1:%4N%:3[G\5>M>-/$NH^-/
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MC0X9U4^Y H ?14:W$3?=D0_1A4E !1110 4444 %%%% !1110 4444 %%(2
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M]OD_U6_YJ /J?X,Z9':>"X+@.S-,<\G@<#I7I%>.^"_B9X6TK2+/2(9F+ A
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MHHH **** "FN,HPZ9!%.J"\.+60C^XW\C0!\J?&J6-_'UP8WY&,[?]U:]=^
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M>N6FIM)?$2P,<^620!74^!/AU8:EHL5Y?KO+C(%>:?$/14T#Q'<VT,;>1O\
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ME=:;=6<4<DT3IYGW=WM76_"O4KRT\>Z9##,RQ2RA716^]FO7OC#X2L)? O\
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MHW''?%;=%%<\I.3NS5))604445(PHHHH **** "BBB@ HHHH **** "BBB@
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MGX9W99O^74<_A0!\>M_K_P#@5?9WP]_Y$C2O^N"?^@BOC)_]?_P*OLWX>_\
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MXUA_'/6]+UCQ-:QZ;,'>T1DF(7 SE>_>NM_9UYL]5;_:7^5 '$_'0Y\;_P#
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MFG(<SI"0/KBOF+5_ WB-]6N&;3KA][GGRS0![;\!O^1'7_KHW_H1JM\=@/\
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M7V)X*T%=!\,6MB<,0"S'KDGFO,/"WP-.GZU%=:G*)8X^0 3U%>X11B*)8U&
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M#;SMS_,UZKXG^&FA^*M0^V7\3-)MQD,14GA7X;Z'X2NVNM.A*RL,$EB>/QH
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M4*!T %+10 4444 %)@&EHH 3 HV@]12T4  &*3:#VI:* $P,48%+10 4444
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M*@TBT\R.\N2LHF4C 4$Y&*]AKQ/]H'2+&71[;5'N%%[&5A2+C)4DG/7/7VH
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MBT ?67@SQ=8^,-%6^LW!9<"5/[C>E='7B_[.O_(N:I_U\+_(U[10!Y)\?_\
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MI^[Y462OKA#E%/M2 =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7Q)=28U"9O\ IH?YFON>]MEO+.6W;I(I6O M0_9^U&;5I98+Z 6SN6P<YYH
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M;P;\)-.\+:RFJ;_,N(@?+^48&00?T)KJ?%WA2S\7:0;"]'RY#+QW% 'S_P#
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M0OA+X=T/4%O(X#)(OW0X&!5SQ'\-M"\2WXN[V$^8(Q'\H'04 >:_L^_?N?\
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !9 F,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[:_:U_P""
M\_[;/P/_ &I?VA_@UX.\.? BX\)?"SXO^-/ OAJ?6_!WB>[UF;1?#VJ265A)
MJEU;>,K.WN+]H5!N)H+2VB=\E8(QQ7S[_P 1'/[?G_0K?LZ_^$/XM_\ FZK\
MV?\ @HF W[?W[9BGHW[2GQ.4_1O$,H/Z$UX%XD\2IH_B'7-*LO"7@(6>G:G=
M65J)_"\<\PAMW\J/SIFO0TTC*H,DC ,[EF/)H-K*R:BGMZ;>9^T?_$1S^WY_
MT*W[.O\ X0_BW_YNJ/\ B(Y_;\_Z%;]G7_PA_%O_ ,W5?B'_ ,)M/_T*?P]'
M_<I1?UO32?\ ";3_ /0J?#[_ ,)*'_Y,IZ=W]R_S"R_D_"/^9^WO_$1S^WY_
MT*W[.O\ X0_BW_YNJ/\ B(Y_;\_Z%;]G7_PA_%O_ ,W5?B%_PFT__0J?#[_P
MDH?_ ),H_P"$VG_Z%3X??^$E#_\ )E&G=_<O\PLOY/PC_F?M[_Q$<_M^?]"M
M^SK_ .$/XM_^;JC_ (B.?V_/^A6_9U_\(?Q;_P#-U7XA?\)M/_T*GP^_\)*'
M_P"3*/\ A-I_^A4^'W_A)0__ "91IW?W+_,++^3\(_YG[>_\1'/[?G_0K?LZ
M_P#A#^+?_FZH_P"(CG]OS_H5OV=?_"'\6_\ S=5^(7_";3_]"I\/O_"2A_\
MDRC_ (3:?_H5/A]_X24/_P F4:=W]R_S"R_D_"/^9^WO_$1S^WY_T*W[.O\
MX0_BW_YNJ/\ B(Y_;\_Z%;]G7_PA_%O_ ,W5?B%_PFT__0J?#[_PDH?_ ),H
M_P"$VG_Z%3X??^$E#_\ )E&G=_<O\PLOY/PC_F?M[_Q$<_M^?]"M^SK_ .$/
MXM_^;JC_ (B.?V_/^A6_9U_\(?Q;_P#-U7XA?\)M/_T*GP^_\)*'_P"3*/\
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M+:Y_^1:/^%41_P#11?BO_P"%M<__ "+0!ZO17E'_  JB/_HHOQ7_ /"VN?\
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M\<=?^)OPHUC1[[Q-\+?&=SX)N]*'@31-=F^(.G_VYJ-CJ$VFWVH:%!IXALI
M]RY>,L#L_NM^.Q^G=%?#'P[_ &T[CXM_\-L:5\-?@GXP\5^-OV./BOK'P?3P
M7#XD\*:;??&'Q1IG@WP_XOM1X4U35;NST?P]!JB>((-,@?Q-=VL=O<P23W,L
M=NRL/$OV1O\ @IO<?M,_"+XZ_'[Q?^S)\0_V?O@U\"]+^($VI^./''CGX=>(
M+?Q%K_PGO?$%A\3/#&FZ;X8U6XU*RO/"5UX>NH9]1U."WTK4I9(DTN[NU#N
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MXZU36M$.IZ-I5CJMGXIT-8M M6OI]5E<:?= 75M'8N9L-<1  'V;17RO\?\
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M7]N;78-6NM$TW]G_ %BUT"Q.J:[<Z5^TS\(M0@T73%+!M1U:6TUV:/3K%2C
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M^$?B7X:D\*:'KR^+=+/A[Q;-9>(/ E^?#=Q=WNC:7<Z?XGMH[O4(X\#X@_\
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M_$?B<7NBZ[IQFBG-EJ-J+2,36[30Q2%-ZY:-23@8/R10-7ZV^05^T?[&X/\
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M)&V58T U=-=S];OV??\ @J)XU\%?$'X[_L_?MI>*/B/^T'^Q_P#&_P 5^.?
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M8Y) H08_[-?[0$'[0?A_Q)XABM_#^F)I^NR0Z;HFFZGK=[K]EX<NGN4T*_\
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M^)NI_'W5="FUW2DEAO=8^&4OPANS=6(A2_M_"#>'_-E25_+==75IO[3,:&U
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M?]BGH_\ Z21T4 ?YQ'_!1+_E(!^V7_V<K\3?_4BEKY<\;_\ (Y^*O^P]J/\
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M:7_AJTDBLEN(S^O*\@'U&3]>X_/.1ZYIU% !1110 4444 %13_ZB;_KE)_Z
MU2U%/_J)O^N4G_H#4 >;?!;_ ))-\//^Q3T?_P!)(Z*/@M_R2;X>?]BGH_\
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M/["\-_\ 0^:;_P"$[XG_ /D&N3HH ZS^PO#?_0^:;_X3OB?_ .0:/["\-_\
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MX._^6U?P2?\ !#3_ )2<_L_?]@GXK_\ JN-=K_0DH,I[KT_5GFW_  EOCO\
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MK_\ A5^#O_EM7I-% 'FW_"6^._\ HE.K_P#A5^#O_EM1_P );X[_ .B4ZO\
M^%7X._\ EM7I-% 'FW_"6^._^B4ZO_X5?@[_ .6U'_"6^._^B4ZO_P"%7X._
M^6U>DT4 >;?\);X[_P"B4ZO_ .%7X._^6U'_  EOCO\ Z)3J_P#X5?@[_P"6
MU>DT4 >;?\);X[_Z)3J__A5^#O\ Y;4?\);X[_Z)3J__ (5?@[_Y;5Z310!Y
MM_PEOCO_ *)3J_\ X5?@[_Y;4?\ "6^._P#HE.K_ /A5^#O_ );5Z310!YM_
MPEOCO_HE.K_^%7X._P#EM1_PEOCO_HE.K_\ A5^#O_EM7I-% 'FW_"6^._\
MHE.K_P#A5^#O_EM1_P );X[_ .B4ZO\ ^%7X._\ EM7I-% 'FW_"6^._^B4Z
MO_X5?@[_ .6U'_"6^._^B4ZO_P"%7X._^6U>DT4 >;?\);X[_P"B4ZO_ .%7
MX._^6U'_  EOCO\ Z)3J_P#X5?@[_P"6U>DT4 >;?\);X[_Z)3J__A5^#O\
MY;4?\);X[_Z)3J__ (5?@[_Y;5Z310!YM_PEOCO_ *)3J_\ X5?@[_Y;4?\
M"6^._P#HE.K_ /A5^#O_ );5Z310!YM_PEOCO_HE.K_^%7X._P#EM3)/%?CI
MXY%_X53J_P R.O\ R-?@T<E2 ,_VL<9)QG!QUP>E>F44 <-\,M$U+PW\/?!N
M@ZQ%%!JND^'=+L=0@AG2YBAO(+9$GB2XC CG6.0,@EC 1\;E^4BBNYHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q +P# 2(  A$! Q$!_\0
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M/FE?%>QM?"EC91C3?%C_ !4T?0]"+ZYJH<R?\4X-"$T*1I*Y$@,BKE6;ZMH
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MM3B@M[_5+%+R\6"W:T568GJKNSC@*22P!!X  Y["BB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>37
<FILENAME>sprcy-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 20:39:31 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://trpx.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:sprcy="http://trpx.com/20241231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="sprcy-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedBalanceSheet" id="sprcy_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatement" id="sprcy_r_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedIncomeStatementAlt0" id="sprcy_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>002 - Statement - Consolidated Statements of Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareholdersEquityType2or3" id="sprcy_r_ShareholdersEquityType2or3">
        <link:definition>003 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ConsolidatedCashFlow" id="sprcy_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/General" id="sprcy_r_General">
        <link:definition>005 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPolicies" id="sprcy_r_SignificantAccountingPolicies">
        <link:definition>006 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" id="sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements">
        <link:definition>007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Cash" id="sprcy_r_Cash">
        <link:definition>008 - Disclosure - Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Inventory" id="sprcy_r_Inventory">
        <link:definition>009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivable" id="sprcy_r_OtherAccountsReceivable">
        <link:definition>010 - Disclosure - Other Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVentures" id="sprcy_r_InvestmentinAssociatesandJointVentures">
        <link:definition>011 - Disclosure - Investment in Associates and Joint Ventures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssets" id="sprcy_r_InvestmentinFinancialAssets">
        <link:definition>012 - Disclosure - Investment in Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Leases" id="sprcy_r_Leases">
        <link:definition>013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNet" id="sprcy_r_PropertyandEquipmentNet">
        <link:definition>014 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAsset" id="sprcy_r_IntangibleAsset">
        <link:definition>015 - Disclosure - Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayables" id="sprcy_r_TradePayables">
        <link:definition>016 - Disclosure - Trade Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayable" id="sprcy_r_OtherAccountsPayable">
        <link:definition>017 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstruments" id="sprcy_r_FinancialInstruments">
        <link:definition>018 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilities" id="sprcy_r_EmployeeBenefitLiabilities">
        <link:definition>019 - Disclosure - Employee Benefit Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncome" id="sprcy_r_TaxesonIncome">
        <link:definition>020 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens">
        <link:definition>021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/Equity" id="sprcy_r_Equity">
        <link:definition>022 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactions" id="sprcy_r_ShareBasedPaymentTransactions">
        <link:definition>023 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenues" id="sprcy_r_RevenuesandCostofRevenues">
        <link:definition>024 - Disclosure - Revenues and Cost of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLoss">
        <link:definition>025 - Disclosure - Additional Information to the Items of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShare" id="sprcy_r_LossPerShare">
        <link:definition>026 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegments" id="sprcy_r_OperatingSegments">
        <link:definition>027 - Disclosure - Operating Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" id="sprcy_r_TransactionsandBalanceswithRelatedParties">
        <link:definition>028 - Disclosure - Transactions and Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" id="sprcy_r_SignificantEventsduringtheReportingPeriod">
        <link:definition>029 - Disclosure - Significant Events during the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsAftertheReportingDate" id="sprcy_r_EventsAftertheReportingDate">
        <link:definition>030 - Disclosure - Events After the Reporting Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AccountingPoliciesByPolicy" id="sprcy_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables" id="sprcy_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/CashTables" id="sprcy_r_CashTables">
        <link:definition>996002 - Disclosure - Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InventoryTables" id="sprcy_r_InventoryTables">
        <link:definition>996003 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsReceivableTables" id="sprcy_r_OtherAccountsReceivableTables">
        <link:definition>996004 - Disclosure - Other Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables" id="sprcy_r_InvestmentinAssociatesandJointVenturesTables">
        <link:definition>996005 - Disclosure - Investment in Associates and Joint Ventures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetTables" id="sprcy_r_PropertyandEquipmentNetTables">
        <link:definition>996006 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetTables" id="sprcy_r_IntangibleAssetTables">
        <link:definition>996007 - Disclosure - Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TradePayablesTables" id="sprcy_r_TradePayablesTables">
        <link:definition>996008 - Disclosure - Trade Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OtherAccountsPayableTables" id="sprcy_r_OtherAccountsPayableTables">
        <link:definition>996009 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/FinancialInstrumentsTables" id="sprcy_r_FinancialInstrumentsTables">
        <link:definition>996010 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" id="sprcy_r_EmployeeBenefitLiabilitiesTables">
        <link:definition>996011 - Disclosure - Employee Benefit Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityTables" id="sprcy_r_EquityTables">
        <link:definition>996012 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables" id="sprcy_r_ShareBasedPaymentTransactionsTables">
        <link:definition>996013 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables" id="sprcy_r_RevenuesandCostofRevenuesTables">
        <link:definition>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" id="sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables">
        <link:definition>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LossPerShareTables" id="sprcy_r_LossPerShareTables">
        <link:definition>996016 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegmentsTables" id="sprcy_r_OperatingSegmentsTables">
        <link:definition>996017 - Disclosure - Operating Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesTables">
        <link:definition>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/GeneralDetails" id="sprcy_r_GeneralDetails">
        <link:definition>996019 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails" id="sprcy_r_SignificantAccountingPoliciesDetails">
        <link:definition>996020 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" id="sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable">
        <link:definition>996021 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCashTable" id="sprcy_r_ScheduleofCashTable">
        <link:definition>996022 - Disclosure - Cash - Schedule of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofInventoryTable" id="sprcy_r_ScheduleofInventoryTable">
        <link:definition>996023 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" id="sprcy_r_ScheduleofOtherAccountsReceivableTable">
        <link:definition>996024 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails" id="sprcy_r_InvestmentinAssociatesandJointVenturesDetails">
        <link:definition>996025 - Disclosure - Investment in Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" id="sprcy_r_ScheduleofFairValueoftheInvestmentTable">
        <link:definition>996026 - Disclosure - Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails" id="sprcy_r_InvestmentinFinancialAssetsDetails">
        <link:definition>996027 - Disclosure - Investment in Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/LeasesDetails" id="sprcy_r_LeasesDetails">
        <link:definition>996028 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails" id="sprcy_r_PropertyandEquipmentNetDetails">
        <link:definition>996029 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" id="sprcy_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996030 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/IntangibleAssetDetails" id="sprcy_r_IntangibleAssetDetails">
        <link:definition>996031 - Disclosure - Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" id="sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable">
        <link:definition>996032 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTradePayablesTable" id="sprcy_r_ScheduleofTradePayablesTable">
        <link:definition>996033 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" id="sprcy_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996034 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" id="sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable">
        <link:definition>996035 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable" id="sprcy_r_ScheduleofCompanysFinancialInstrumentsTable">
        <link:definition>996036 - Disclosure - Financial Instruments - Schedule of Company's Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPH1ELcI9xyt3K1DchISeFlf0gxWybNUtM0z5SubuERPcsyFjjcRvlY0woC4Gu3fMsvVXVWKV7wODmQlScdq8DcGYwOT7maUpClVnfueBWSE6BHhwo0f0EXUnILvWj74PXyhBesuwkl8ZeR5liO5Mn8y8G9pOpuap6+Bpxh9NEvKZg==] CSR-->
      <link:roleType roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" id="sprcy_r_ScheduleofDefinedContributionPlansTable">
        <link:definition>996037 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TaxesonIncomeDetails" id="sprcy_r_TaxesonIncomeDetails">
        <link:definition>996038 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" id="sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails">
        <link:definition>996039 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EquityDetails" id="sprcy_r_EquityDetails">
        <link:definition>996040 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofShareCapitalTable" id="sprcy_r_ScheduleofShareCapitalTable">
        <link:definition>996041 - Disclosure - Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" id="sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable">
        <link:definition>996042 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable">
        <link:definition>996043 - Disclosure - Equity - Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" id="sprcy_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>996044 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" id="sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable">
        <link:definition>996045 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" id="sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable">
        <link:definition>996046 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" id="sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable">
        <link:definition>996047 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofRSUtransactionTable" id="sprcy_r_ScheduleofRSUtransactionTable">
        <link:definition>996048 - Disclosure - Share-Based Payment Transactions - Schedule of RSU transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" id="sprcy_r_ScheduleofCostofSalesandGrossProfitTable">
        <link:definition>996049 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" id="sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable">
        <link:definition>996050 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" id="sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable">
        <link:definition>996051 - Disclosure - Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/OperatingSegmentsDetails" id="sprcy_r_OperatingSegmentsDetails">
        <link:definition>996052 - Disclosure - Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable" id="sprcy_r_ScheduleofOperatingSegmentsTable">
        <link:definition>996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" id="sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>996054 - Disclosure - Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="sprcy_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" id="sprcy_r_ScheduleofTransactionswithRelatedPartiesTable">
        <link:definition>996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" id="sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable">
        <link:definition>996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" id="sprcy_r_ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable">
        <link:definition>996058 - Disclosure - Transactions and Balances with Related Parties - Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" id="sprcy_r_SignificantEventsduringtheReportingPeriodDetails">
        <link:definition>996059 - Disclosure - Significant Events during the Reporting Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/EventsAftertheReportingDateDetails" id="sprcy_r_EventsAftertheReportingDateDetails">
        <link:definition>996060 - Disclosure - Events After the Reporting Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://trpx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract"/>
  <xs:element name="ScheduleOfCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCashAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheIntangibleAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
  <xs:element name="ScheduleOfCompanysFinancialInstrumentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract"/>
  <xs:element name="ScheduleOfDefinedContributionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
  <xs:element name="ScheduleOfExpensesDueToShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfFairValueForShareOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
  <xs:element name="ScheduleOfRsuTransactionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRsuTransactionAbstract"/>
  <xs:element name="ScheduleOfCostOfSalesAndGrossProfitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
  <xs:element name="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOperatingSegmentsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfTransactionsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract1"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfSharesAbstract"/>
  <xs:element name="a2024Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_a2024Abstract"/>
  <xs:element name="CostOfGoodsSoldAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostOfGoodsSoldAbstract"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_UnlabeledAbstract2"/>
  <xs:element name="AResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="BSalesAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BSalesAndMarketingExpensesAbstract"/>
  <xs:element name="CGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="DOtherExpensesIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DOtherExpensesIncomeAbstract"/>
  <xs:element name="EFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EFinanceIncomeAbstract"/>
  <xs:element name="FFinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FFinanceExpensesAbstract"/>
  <xs:element name="ContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ContinuingOperationsAbstract"/>
  <xs:element name="IssueOfShareCapitalNetOfIssueExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
  <xs:element name="AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
  <xs:element name="AdjustmentsForIncreaseInRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdjustmentsForIncreaseInRelatedParties"/>
  <xs:element name="SalepurchaseOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SalepurchaseOfPropertyAndEquipment"/>
  <xs:element name="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
  <xs:element name="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
  <xs:element name="DisclosureOfInvestmentFinancialAssetsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
  <xs:element name="DisclosureOfOtherAccountsPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
  <xs:element name="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
  <xs:element name="DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
  <xs:element name="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
  <xs:element name="DescriptionOfAcquisitionOfASingleAssetCompany" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
  <xs:element name="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
  <xs:element name="DisclosueOfCashAndCashEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
  <xs:element name="DisclosureOfInventorieExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfInventorieExplanatory"/>
  <xs:element name="DisclourseOfAccountsReceivablesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
  <xs:element name="InvestmentinAssociatesandJointVenturesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
  <xs:element name="InvestmentinAssociatesandJointVenturesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
  <xs:element name="DisclosureOfTradePayablesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfTradePayablesExplanatory"/>
  <xs:element name="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
  <xs:element name="DisclosureOfIssuedAndOutstandingShareCapital" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
  <xs:element name="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
  <xs:element name="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
  <xs:element name="OperatingSegmentsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsTablesTable"/>
  <xs:element name="OperatingSegmentsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingSegmentsTablesLineItems"/>
  <xs:element name="RelatedPartyBalancetextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RelatedPartyBalancetextBlock"/>
  <xs:element name="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
  <xs:element name="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
  <xs:element name="LeaseholdImprovementsMainlyRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseholdImprovementsMainlyRate"/>
  <xs:element name="CashScheduleofCashDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_CashScheduleofCashDetailsTable"/>
  <xs:element name="Governmentauthoritiescurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_Governmentauthoritiescurrent"/>
  <xs:element name="ReceivablesInRespectOfDownpaymentOnMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
  <xs:element name="InvestmentsDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentsDate"/>
  <xs:element name="InvestmentAchievementOfFirstMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAchievementOfFirstMilestone"/>
  <xs:element name="InvestmentAchievementOfSecondMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestmentAchievementOfSecondMilestone"/>
  <xs:element name="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
  <xs:element name="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
  <xs:element name="DepreciationOfIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
  <xs:element name="CreditFromOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CreditFromOthers"/>
  <xs:element name="WarrantsLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsLiability"/>
  <xs:element name="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
  <xs:element name="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
  <xs:element name="IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
  <xs:element name="ShareIssuedToAConsultants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareIssuedToAConsultants"/>
  <xs:element name="IssuanceOfShareCapitalInRespectSEPA" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
  <xs:element name="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
  <xs:element name="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
  <xs:element name="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
  <xs:element name="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
  <xs:element name="IncomeStatementsLocationsDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IncomeStatementsLocationsDomainDomain"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
  <xs:element name="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
  <xs:element name="EffectOfPotentialDilutiveOrdinarySharesLossPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
  <xs:element name="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
  <xs:element name="ExternalRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExternalRevenues"/>
  <xs:element name="EquityLossesFromTheInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EquityLossesFromTheInvestment"/>
  <xs:element name="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
  <xs:element name="CurrentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CurrentAsset"/>
  <xs:element name="SaleOfMinorityInterestInSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfMinorityInterestInSubsidiary"/>
  <xs:element name="KeyManagementPersonnelCompensationManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_KeyManagementPersonnelCompensationManagementFees"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
  <xs:element name="OperatingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingTerm"/>
  <xs:element name="InvestmentinAssociatesandJointVenturesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
  <xs:element name="InitialInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialInvestment"/>
  <xs:element name="AdditionalInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInvestment"/>
  <xs:element name="OutstandingSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingSharesPercentage"/>
  <xs:element name="AdditionalInstallment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalInstallment"/>
  <xs:element name="InstallmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPaid"/>
  <xs:element name="CashConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CashConsideration"/>
  <xs:element name="PurchaserRemainingOwnershipPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaserRemainingOwnershipPercentage"/>
  <xs:element name="RemainingPurchaserAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RemainingPurchaserAmount"/>
  <xs:element name="IssuedAndOutstandingSharePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuedAndOutstandingSharePercentage"/>
  <xs:element name="InvestmentinFinancialAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_InvestmentinFinancialAssetsDetailsTable"/>
  <xs:element name="ShareCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareCapitalPercentage"/>
  <xs:element name="ReverseShareSplitRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReverseShareSplitRatio"/>
  <xs:element name="SharePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePricePerShare"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeasesDetailsLineItems"/>
  <xs:element name="AreaOfLease" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AreaOfLease"/>
  <xs:element name="OptionToExtendLeaseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OptionToExtendLeaseTerm"/>
  <xs:element name="MonthlyLeaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MonthlyLeaseFee"/>
  <xs:element name="IntangibleAssetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_IntangibleAssetDetailsTable"/>
  <xs:element name="PaymentsOfAdditionalDeferredCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentsOfAdditionalDeferredCash"/>
  <xs:element name="PurchaseCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchaseCostsValue"/>
  <xs:element name="GrowthRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GrowthRatePercentage"/>
  <xs:element name="LongTermPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LongTermPercentage"/>
  <xs:element name="DiscountRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DiscountRatePercentage"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsTaxAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingLossCarryforwardsTaxAmount"/>
  <xs:element name="DekelLicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DekelLicenseAgreementDescription"/>
  <xs:element name="AnnualInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AnnualInvestment"/>
  <xs:element name="AdditionalMilestoneAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdditionalMilestoneAmount"/>
  <xs:element name="InstallmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentAmount"/>
  <xs:element name="EstimatedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EstimatedAmount"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EquityDetailsTable"/>
  <xs:element name="CapitalRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CapitalRatio"/>
  <xs:element name="ReverseSplitRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ReverseSplitRatio"/>
  <xs:element name="IssuanceOfAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceOfAggregateShares"/>
  <xs:element name="AggregateUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnits"/>
  <xs:element name="AggregateUnitsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateUnitsPerShare"/>
  <xs:element name="IssuanceExpireTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceExpireTerm"/>
  <xs:element name="WarrantsAndExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsAndExercise"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePerShare"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateGrossProceeds"/>
  <xs:element name="CommitmentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CommitmentAmount"/>
  <xs:element name="SaleOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfOrdinaryShares"/>
  <xs:element name="SharePriceRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SharePriceRate"/>
  <xs:element name="InterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestRate"/>
  <xs:element name="InstallmentPayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InstallmentPayment"/>
  <xs:element name="PaymentForPremiumPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PaymentForPremiumPercentage"/>
  <xs:element name="AggregateIssuedAmount" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateIssuedAmount"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="FairValueOfShareOptionsGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FairValueOfShareOptionsGranted"/>
  <xs:element name="OrdinarySharesGrantedDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OrdinarySharesGrantedDiscountRate"/>
  <xs:element name="NumberOfOptionsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOptionsOutstanding"/>
  <xs:element name="ConvertIntoOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConvertIntoOrdinaryShares"/>
  <xs:element name="NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
  <xs:element name="OperatingSegmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_OperatingSegmentsDetailsTable"/>
  <xs:element name="OperatingSegmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OperatingSegmentsDetailsLineItems"/>
  <xs:element name="SaleOfStockDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SaleOfStockDomainDomain"/>
  <xs:element name="TransactionsandBalanceswithRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
  <xs:element name="InterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestPercentage"/>
  <xs:element name="DeferredCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DeferredCashPayment"/>
  <xs:element name="BonusAmountReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BonusAmountReceived"/>
  <xs:element name="AcquiredOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AcquiredOrdinaryShares"/>
  <xs:element name="AggregateValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValues"/>
  <xs:element name="AggregateValueAdjusted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateValueAdjusted"/>
  <xs:element name="ListedSharePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ListedSharePrice"/>
  <xs:element name="ComprehensiveLossOnInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ComprehensiveLossOnInvestment"/>
  <xs:element name="CooperationAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CooperationAgreementAmount"/>
  <xs:element name="ExchangeOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeOfCommonShares"/>
  <xs:element name="OutstandingShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OutstandingShareCapital"/>
  <xs:element name="LicenseeIssuePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LicenseeIssuePrice"/>
  <xs:element name="MilestonesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MilestonesAmount"/>
  <xs:element name="LicenseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LicenseAgreementDescription"/>
  <xs:element name="PercentageOfAggregateNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfAggregateNetSales"/>
  <xs:element name="NumberOfUnitsReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfUnitsReceived"/>
  <xs:element name="NumberOfWarrantsHolds" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfWarrantsHolds"/>
  <xs:element name="WarrantsExpireDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantsExpireDate"/>
  <xs:element name="AggregateNumberOfOutstandingOrdinarySharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
  <xs:element name="SignificantEventsduringtheReportingPeriodDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
  <xs:element name="EnterpriseValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_EnterpriseValue"/>
  <xs:element name="EventsAftertheReportingDateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="sprcy_EventsAftertheReportingDateDetailsTable"/>
  <xs:element name="AggregateLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateLoanAmount"/>
  <xs:element name="RepaidOfMonthlyInstallments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RepaidOfMonthlyInstallments"/>
  <xs:element name="PurchasePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasePricePercentage"/>
  <xs:element name="VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
  <xs:element name="VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
  <xs:element name="ConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ConsecutiveTradingDays"/>
  <xs:element name="VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
  <xs:element name="NumberOfWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NumberOfWarrantsIssued"/>
  <xs:element name="VolumeWeightedAveragePricePerWarrant" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VolumeWeightedAveragePricePerWarrant"/>
  <xs:element name="WarrantExercisableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WarrantExercisableTerm"/>
  <xs:element name="AggregateInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AggregateInvestment"/>
  <xs:element name="PercentageOfFullyDilutedCapitalStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfFullyDilutedCapitalStock"/>
  <xs:element name="PercentageOfFinancingProceeds" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PercentageOfFinancingProceeds"/>
  <xs:element name="RestrictedStockGrantPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RestrictedStockGrantPercentage"/>
  <xs:element name="VestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_VestingPeriod"/>
  <xs:element name="IncomeStatementsLocationsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_IncomeStatementsLocationsAxis"/>
  <xs:element name="SaleOfStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="sprcy_SaleOfStockAxis"/>
  <xs:element name="AccumulatedDepreciationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AccumulatedDepreciationMember"/>
  <xs:element name="AdvertisementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AdvertisementMember"/>
  <xs:element name="AmazonFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AmazonFeesMember"/>
  <xs:element name="August2023FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_August2023FinancingRoundMember"/>
  <xs:element name="AutoMaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_AutoMaxMember"/>
  <xs:element name="BusinessDevelopmentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_BusinessDevelopmentExpensesMember"/>
  <xs:element name="ChemistryAndFormulationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ChemistryAndFormulationsMember"/>
  <xs:element name="ClinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ClinicalStudiesMember"/>
  <xs:element name="CostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_CostMember"/>
  <xs:element name="DebenturesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DebenturesMember"/>
  <xs:element name="DepreciationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DepreciationMember"/>
  <xs:element name="DirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DirectorsMember"/>
  <xs:element name="DrugDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DrugDevelopmentMember"/>
  <xs:element name="ExchangeRateDifferencesNetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ExchangeRateDifferencesNetMember"/>
  <xs:element name="FinanceExpenseInRespectOfLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpenseInRespectOfLeasesMember"/>
  <xs:element name="FinanceExpensesFromInterestAndCommissionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
  <xs:element name="FreightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_FreightMember"/>
  <xs:element name="GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
  <xs:element name="InitialPublicOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InitialPublicOfferingMember"/>
  <xs:element name="InterestFromLoansToRelatedPartiesAndDepositsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
  <xs:element name="InvestorRelationsAndBusinessExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_InvestorRelationsAndBusinessExpensesMember"/>
  <xs:element name="IssuanceExpensesRelatedToWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
  <xs:element name="JeffsBrandsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_JeffsBrandsMember"/>
  <xs:element name="June2022WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_June2022WarrantsMember"/>
  <xs:element name="LeaseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LeaseMember"/>
  <xs:element name="LossFromSaleOfPropertyAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
  <xs:element name="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
  <xs:element name="ManagementFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ManagementFeesMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MergerAgreementMember"/>
  <xs:element name="MitoCareXBioLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXBioLtdMember"/>
  <xs:element name="MitoCareXMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MitoCareXMember"/>
  <xs:element name="MizaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_MizaMember"/>
  <xs:element name="N2OFFMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_N2OFFMember"/>
  <xs:element name="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
  <xs:element name="October2023FinancingRoundMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_October2023FinancingRoundMember"/>
  <xs:element name="OfficeEquipmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeEquipmentsMember"/>
  <xs:element name="OfficeMaintenanceRentAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
  <xs:element name="OnlineSalesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesMember"/>
  <xs:element name="OnlineSalesSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OnlineSalesSegmentMember"/>
  <xs:element name="OverAllotmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OverAllotmentMember"/>
  <xs:element name="PreFundedUnitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PreFundedUnitsMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PrefundedWarrantsMember"/>
  <xs:element name="ProfessionalAndDirectorsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ProfessionalAndDirectorsFeesMember"/>
  <xs:element name="PurchasedGoodsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_PurchasedGoodsMember"/>
  <xs:element name="RegulatoryExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryExpensesMember"/>
  <xs:element name="RegulatoryProfessionalAndOtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
  <xs:element name="ResearchAndPreclinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ResearchAndPreclinicalStudiesMember"/>
  <xs:element name="RightOfUseAssesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_RightOfUseAssesMember"/>
  <xs:element name="SEPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SEPAMember"/>
  <xs:element name="SciSparcMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SciSparcMember"/>
  <xs:element name="ShareBasedPaymentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ShareBasedPaymentMember"/>
  <xs:element name="StorageAndShippingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_StorageAndShippingMember"/>
  <xs:element name="SubsequentEventsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SubsequentEventsMember"/>
  <xs:element name="TwoThousandTwentyThreePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_TwoThousandTwentyThreePlanMember"/>
  <xs:element name="WagesAndRelatedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_WagesAndRelatedExpensesMember"/>
  <xs:element name="OtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_OtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
  <xs:element name="SegmentReportingRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SegmentReportingRevenueAbstract"/>
  <xs:element name="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
  <xs:element name="SignificantEventsDuringTheReportingPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
  <xs:element name="SignificantEventsDuringTheReportingPeriodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
  <xs:element name="SignificantNonCashTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_SignificantNonCashTransactionsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="sprcy_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>38
<FILENAME>sprcy-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 20:39:32 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatementAlt0" roleURI="http://trpx.com/role/ConsolidatedIncomeStatementAlt0"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentWarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_SharePremium" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_WarrantLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_RetainedEarnings" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_NoncontrollingInterests" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatementAlt0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPH1ELcI9xyt3K1DchISeFlf0gxWybNUtM0z5SubuERPcsyFjjcRvlY0woC4Gu3fMsvVXVWKV7wODmQlScdq8DcGYwOT7maUpClVnfueBWSE6BHhwo0f0EXUnILvWj74PXyhBesuwkl8ZeR5liO5Mn8yObWEwXLGRaYWpJ+3RfVpAQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_FinishedGoods" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:label="sprcy_Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="sprcy_Governmentauthoritiescurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_NetDebt" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_Accruals" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherPayables" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_OtherReceivables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_CreditFromOthers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="sprcy_WarrantsLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>39
<FILENAME>sprcy-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 20:39:32 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVentures" roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVentures"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShare" roleURI="http://trpx.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDate" roleURI="http://trpx.com/role/EventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShareTables" roleURI="http://trpx.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCompanysFinancialInstrumentsTable" roleURI="http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofRSUtransactionTable" roleURI="http://trpx.com/role/ScheduleofRSUtransactionTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsDetails" roleURI="http://trpx.com/role/OperatingSegmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDateDetails" roleURI="http://trpx.com/role/EventsAftertheReportingDateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Inventories" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_SharePremium" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_WarrantLiability" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_RetainedEarnings" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="31" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_WarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_OtherEquityInterestMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ParentMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20241231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20241231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Cash" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinAssociatesandJointVentures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/IntangibleAsset" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TradePayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableAbstract" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OperatingSegments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EventsAftertheReportingDate" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/CashTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInventorieExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInventorieExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="sprcy_DisclosureOfInventorieExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/IntangibleAssetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TradePayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfTradePayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RevenueAbstract" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OperatingSegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_RelatedPartyBalancetextBlock" xlink:href="sprcy-20241231.xsd#sprcy_RelatedPartyBalancetextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="sprcy_RelatedPartyBalancetextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20241231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovementsMainlyRate" xlink:href="sprcy-20241231.xsd#sprcy_LeaseholdImprovementsMainlyRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_LeaseholdImprovementsMainlyRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="sprcy_CashScheduleofCashDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_CashScheduleofCashDetailsTable" xlink:to="srt_CurrencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_ILS" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_FinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_Inventories" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_Governmentauthoritiescurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentsDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="sprcy_InvestmentsDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfSecondMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeEquipmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="sprcy_OfficeEquipmentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightOfUseAssesMember" xlink:href="sprcy-20241231.xsd#sprcy_RightOfUseAssesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="sprcy_RightOfUseAssesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostMember" xlink:href="sprcy-20241231.xsd#sprcy_CostMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="sprcy_CostMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="sprcy_AccumulatedDepreciationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_NetDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_OtherReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="sprcy_CreditFromOthers" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="sprcy_WarrantsLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="sprcy_WarrantsLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultants" xlink:href="sprcy-20241231.xsd#sprcy_ShareIssuedToAConsultants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="sprcy_ShareIssuedToAConsultants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPH1ELcI9xyt3K1DchISeFlf0gxWybNUtM0z5SubuERPcsyFjjcRvlY0woC4Gu3fMsvVXVWKV7wODmQlScdq8DcGYwOT7maUpClVnfueBWSE6BHhwo0f0EXUnILvWj74PXyhBesuwkl8ZeR5liO5Mn8yTGGHNAwNe7UyvcphGPFREA==] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofRSUtransactionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRsuTransactionAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRsuTransactionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20241231.xsd#sprcy_PurchasedGoodsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="sprcy_PurchasedGoodsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20241231.xsd#sprcy_FreightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="sprcy_FreightMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="ifrs-full_CostOfSales" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_IncomeStatementsLocationsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_0" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_WagesAndRelatedExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ShareBasedPaymentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ClinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ClinicalStudiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20241231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ChemistryAndFormulationsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdvertisementMember" xlink:href="sprcy-20241231.xsd#sprcy_AdvertisementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AdvertisementMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_AmazonFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_AmazonFeesMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_DepreciationMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageAndShippingMember" xlink:href="sprcy-20241231.xsd#sprcy_StorageAndShippingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_StorageAndShippingMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ManagementFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ManagementFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ManagementFeesMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_BusinessDevelopmentExpensesMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_RegulatoryExpensesMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:href="sprcy-20241231.xsd#sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_LossFromSaleOfPropertyAndEquipmentMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:href="sprcy-20241231.xsd#sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20241231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:href="sprcy-20241231.xsd#sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_ExchangeRateDifferencesNetMember" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20241231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_FinanceIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="ifrs-full_FinanceCosts" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:href="sprcy-20241231.xsd#sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20241231.xsd#sprcy_DrugDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_DrugDevelopmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_OnlineSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20241231.xsd#sprcy_ExternalRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_ExternalRevenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromTheInvestment" xlink:href="sprcy-20241231.xsd#sprcy_EquityLossesFromTheInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_EquityLossesFromTheInvestment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CurrentAsset" xlink:href="sprcy-20241231.xsd#sprcy_CurrentAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_CurrentAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfMinorityInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20241231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20241231.xsd#sprcy_OperatingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="sprcy_OperatingTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXBioLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MinimumMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="srt_MaximumMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20241231.xsd#sprcy_InitialInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_InitialInvestment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_AdditionalInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_OutstandingSharesPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInstallment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_AdditionalInstallment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_InstallmentPaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashConsideration" xlink:href="sprcy-20241231.xsd#sprcy_CashConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_CashConsideration" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchaserRemainingOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RemainingPurchaserAmount" xlink:href="sprcy-20241231.xsd#sprcy_RemainingPurchaserAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_RemainingPurchaserAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20241231.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="sprcy_IssuedAndOutstandingSharePercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="sprcy_InitialPublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseShareSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseShareSplitRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_ReverseShareSplitRatio" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_SharePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="sprcy_SharePricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20241231.xsd#sprcy_LeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_LeaseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AreaOfLease" xlink:href="sprcy-20241231.xsd#sprcy_AreaOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_AreaOfLease" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OptionToExtendLeaseTerm" xlink:href="sprcy-20241231.xsd#sprcy_OptionToExtendLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_OptionToExtendLeaseTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MonthlyLeaseFee" xlink:href="sprcy-20241231.xsd#sprcy_MonthlyLeaseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_MonthlyLeaseFee" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/IntangibleAssetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_IntangibleAssetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_IntangibleAssetDetailsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ifrs-full_OtherIntangibleAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash" xlink:href="sprcy-20241231.xsd#sprcy_PaymentsOfAdditionalDeferredCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCostsValue" xlink:href="sprcy-20241231.xsd#sprcy_PurchaseCostsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_PurchaseCostsValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_GrowthRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_GrowthRatePercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20241231.xsd#sprcy_LongTermPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_LongTermPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DiscountRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_DiscountRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="sprcy_DiscountRatePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20241231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_DekelLicenseAgreementDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AnnualInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_AnnualInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_AdditionalMilestoneAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_InstallmentAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20241231.xsd#sprcy_EstimatedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="sprcy_EstimatedAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20241231.xsd#sprcy_SEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_SEPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitsMember" xlink:href="sprcy-20241231.xsd#sprcy_PreFundedUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="sprcy_PreFundedUnitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OverAllotmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="sprcy_OverAllotmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_June2022WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_June2022WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_August2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_August2023FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_August2023FinancingRoundMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_October2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_October2023FinancingRoundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="sprcy_October2023FinancingRoundMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="sprcy_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalRatio" xlink:href="sprcy-20241231.xsd#sprcy_CapitalRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_CapitalRatio" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseSplitRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_ReverseSplitRatio" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ServicesExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_GrossProfit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_IssuanceOfAggregateShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateUnits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateUnitsPerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpireTerm" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpireTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_IssuanceExpireTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsAndExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_WarrantsAndExercise" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_PurchasePricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20241231.xsd#sprcy_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateGrossProceeds" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_CommitmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_CommitmentAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_SaleOfOrdinaryShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePriceRate" xlink:href="sprcy-20241231.xsd#sprcy_SharePriceRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_SharePriceRate" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestRate" xlink:href="sprcy-20241231.xsd#sprcy_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_InterestRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPayment" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_InstallmentPayment" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentForPremiumPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PaymentForPremiumPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_PaymentForPremiumPercentage" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateIssuedAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateIssuedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="sprcy_AggregateIssuedAmount" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DirectorsMember" xlink:href="sprcy-20241231.xsd#sprcy_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_DirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20241231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="sprcy_TwoThousandTwentyThreePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20241231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_FairValueOfShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20241231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOptionsOutstanding" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_NumberOfOptionsOutstanding" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConvertIntoOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_ConvertIntoOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_ConvertIntoOrdinaryShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/OperatingSegmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_OperatingSegmentsDetailsLineItems" xlink:to="sprcy_OperatingSegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_OperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesSegmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SegmentsDomain" xlink:to="sprcy_OnlineSalesSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_OperatingSegmentsDetailsLineItems" xlink:to="ifrs-full_OtherIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockAxis" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_SaleOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockDomainDomain_0" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20241231.xsd#sprcy_JeffsBrandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_JeffsBrandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MergerAgreementMember" xlink:href="sprcy-20241231.xsd#sprcy_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MergerAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="sprcy_PrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SaleOfStockDomainDomain" xlink:to="sprcy_InitialPublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentage" xlink:href="sprcy-20241231.xsd#sprcy_InterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_InterestPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_Cash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayment" xlink:href="sprcy-20241231.xsd#sprcy_DeferredCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_DeferredCashPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_OtherFeeAndCommissionExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20241231.xsd#sprcy_BonusAmountReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_BonusAmountReceived" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ServicesExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AcquiredOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_AcquiredOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AcquiredOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValues" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AggregateValues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValueAdjusted" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValueAdjusted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AggregateValueAdjusted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20241231.xsd#sprcy_ListedSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ListedSharePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20241231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ComprehensiveLossOnInvestment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementAmount" xlink:href="sprcy-20241231.xsd#sprcy_CooperationAgreementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_CooperationAgreementAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentInvestments" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_ExchangeOfCommonShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_OutstandingShareCapital" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseeIssuePrice" xlink:href="sprcy-20241231.xsd#sprcy_LicenseeIssuePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_LicenseeIssuePrice" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MilestonesAmount" xlink:href="sprcy-20241231.xsd#sprcy_MilestonesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_MilestonesAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_LicenseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_LicenseAgreementDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfAggregateNetSales" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfAggregateNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_PercentageOfAggregateNetSales" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfUnitsReceived" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfUnitsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_NumberOfUnitsReceived" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_PurchasePricePerShare" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsHolds" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsHolds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_NumberOfWarrantsHolds" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExpireDate" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsExpireDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_WarrantsExpireDate" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MizaMember" xlink:href="sprcy-20241231.xsd#sprcy_MizaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MizaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_EnterpriseValue" xlink:href="sprcy-20241231.xsd#sprcy_EnterpriseValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_EnterpriseValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_ShareCapitalPercentage" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/EventsAftertheReportingDateDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_EventsAftertheReportingDateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_DebenturesMember" xlink:href="sprcy-20241231.xsd#sprcy_DebenturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="sprcy_DebenturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentEventsMember" xlink:href="sprcy-20241231.xsd#sprcy_SubsequentEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="sprcy_SubsequentEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMember" xlink:href="sprcy-20241231.xsd#sprcy_AutoMaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_AutoMaxMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_SciSparcMember" xlink:href="sprcy-20241231.xsd#sprcy_SciSparcMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_SciSparcMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_N2OFFMember" xlink:href="sprcy-20241231.xsd#sprcy_N2OFFMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_N2OFFMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="sprcy_MitoCareXMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_LoansReceived" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateLoanAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_AggregateLoanAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaidOfMonthlyInstallments" xlink:href="sprcy-20241231.xsd#sprcy_RepaidOfMonthlyInstallments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_RepaidOfMonthlyInstallments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NotionalAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_PurchasePricePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_ConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_ConsecutiveTradingDays" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsIssued" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_NumberOfWarrantsIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePricePerWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantExercisableTerm" xlink:href="sprcy-20241231.xsd#sprcy_WarrantExercisableTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_WarrantExercisableTerm" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_InvestmentIncome" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AggregateInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_AggregateInvestment" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFullyDilutedCapitalStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFinancingProceeds" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFinancingProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_PercentageOfFinancingProceeds" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_RestrictedStockGrantPercentage" xlink:href="sprcy-20241231.xsd#sprcy_RestrictedStockGrantPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_RestrictedStockGrantPercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sprcy_VestingPeriod" xlink:href="sprcy-20241231.xsd#sprcy_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="sprcy_VestingPeriod" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://trpx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>40
<FILENAME>sprcy-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 20:39:31 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total equity attributable to equity holders of the company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Profit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Total adjustments to the profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Decrease in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash for immediate withdrawal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl3" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl3"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract_lbl" xml:lang="en-US">Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:to="sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Total inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl0" xml:lang="en-US">Other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl" xml:lang="en-US">Investment in Associates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl1" xml:lang="en-US">Investments in company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Investment in Financial Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property and equipment, net at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl1" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Intangible Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US">Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OtherAccountsPayableAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OtherAccountsPayableAbstract" xlink:to="sprcy_OtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOtherAccountsPayableAbstract" xlink:to="sprcy_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl" xml:lang="en-US">Investments in financial assets at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total financial and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US">Employee Benefit Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDefinedContributionPlansAbstract" xlink:to="sprcy_ScheduleOfDefinedContributionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitmentsAbstract_lbl" xml:lang="en-US">Contingent Liabilities, Commitments, Claims and Liens [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssuedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Balance at January 1, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Balance at December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Received common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl2" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl3" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl4" xml:lang="en-US">Number of shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl5" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl5"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl" xml:lang="en-US">Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl" xml:lang="en-US">Share-Based Payment Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Number of Share Options , Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Number of Share Options, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price, Share Options outstanding at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRsuTransactionAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRsuTransactionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRsuTransactionAbstract_lbl" xml:lang="en-US">Schedule of RSU transaction [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRsuTransactionAbstract" xlink:to="sprcy_ScheduleOfRsuTransactionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Balance, January 1, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Balance, December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Revenues and Cost of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalInformationAbstract_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_AdditionalInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsAxis" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl" xml:lang="en-US">Income Statements Locations [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodAbstract_lbl" xml:lang="en-US">Significant Events during the Reporting Period [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="sprcy_SignificantEventsDuringTheReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Events After the Reporting Date [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Short-term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US">Investments in short-term financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl0" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Bridge loan to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Investments in short-term financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other short-term liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0" xml:lang="en-US">Engaged in a mutual share exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax Income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Attributable to:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic loss per ordinary share attributable to equity holders of the Company (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted loss per ordinary share attributable to equity holders of the Company (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Issuance of share capital in respect of investment in affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20241231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl" xml:lang="en-US">Issuance of share capital, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to the profit or loss items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Loss on impairment of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Impairment to its intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Group&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl" xml:lang="en-US">Working capital adjustments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US">Decrease (increase) in other accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Withdrawal of (investment in) restricted bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Withdrawal of (investment in) short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issue of share capital (net of issuance expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Invested amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl1" xml:lang="en-US">Gross cash proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants (a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl" xml:lang="en-US">Payment of issuance expenses related to previous period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl" xml:lang="en-US">(a) Significant non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20241231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Investment in financial asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Equity losses from the investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Equity losses from investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl1" xml:lang="en-US">Equity losses from the investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Equity holders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US">Finance income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl" xml:lang="en-US">Increase in related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment_lbl" xml:lang="en-US">Sale (purchase) of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investment in a company accounted for at equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl" xml:lang="en-US">Bridge loan to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Investments in financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Interest paid on lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share capital and premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xml:lang="en-US">Reserve from share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantsMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterestMember_lbl" xml:lang="en-US">Transactions with non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US">Foreign currency translation reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParentMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20241231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl" xml:lang="en-US">Straight-line basis over useful life of assets at annual rates mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl" xml:lang="en-US">Leasehold improvements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseholdImprovementsMainlyRate" xlink:href="sprcy-20241231.xsd#sprcy_LeaseholdImprovementsMainlyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseholdImprovementsMainlyRate_lbl" xml:lang="en-US">Leasehold improvements mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovementsMainlyRate" xlink:to="sprcy_LeaseholdImprovementsMainlyRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInventorieExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInventorieExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInventorieExplanatory_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInventorieExplanatory" xlink:to="sprcy_DisclosureOfInventorieExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl" xml:lang="en-US">Goods in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_Governmentauthoritiescurrent_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Governmentauthoritiescurrent" xlink:to="sprcy_Governmentauthoritiescurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl" xml:lang="en-US">Receivables in respect of downpayment on merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl" xml:lang="en-US">Investment in Associates and Joint Ventures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentsDate" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentsDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentsDate_lbl" xml:lang="en-US">Investment date March 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl" xml:lang="en-US">Investment following achievement of first milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfSecondMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone_lbl" xml:lang="en-US">Investment following achievement of second milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfSecondMilestone" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl" xml:lang="en-US">INVESTMENT IN FINANCIAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationAbstract0" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl" xml:lang="en-US">INTANGIBLE ASSET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfTradePayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory_lbl" xml:lang="en-US">Schedule of Trade Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayablesExplanatory" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDebt_lbl" xml:lang="en-US">Open debts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDebt" xlink:to="ifrs-full_NetDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accrued vacation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xml:lang="en-US">Total financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract0" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract1" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CreditFromOthers_lbl" xml:lang="en-US">Credit from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsLiability_lbl" xml:lang="en-US">Warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_WarrantsLiability_lbl0" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Company&apos;s Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">EMPLOYEE BENEFIT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl" xml:lang="en-US">Schedule of Defined Contribution Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Expenses in respect of defined contribution plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfSharesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, Issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Schedule of Issued and Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants (Note 18h</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareIssuedToAConsultants" xlink:href="sprcy-20241231.xsd#sprcy_ShareIssuedToAConsultants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareIssuedToAConsultants_lbl" xml:lang="en-US">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultants" xlink:to="sprcy_ShareIssuedToAConsultants_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl" xml:lang="en-US">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Underlying share price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Underlying ordinary share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Underlying Share Price of Polyrizon Ltd. ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl2" xml:lang="en-US">Share price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0" xml:lang="en-US">Fair value of the ordinary shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Expenses Due to Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US">Expected life of Share Options (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Weighted Average Exercise Prices of Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_a2024Abstract" xlink:href="sprcy-20241231.xsd#sprcy_a2024Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_a2024Abstract_lbl" xml:lang="en-US">2024:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2024Abstract" xlink:to="sprcy_a2024Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, Share Options exercisable at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">2023:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of RSU transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US">RSUs granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl0" xml:lang="en-US">Granted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Expiry of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Exercise of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">REVENUES AND COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostOfGoodsSoldAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CostOfGoodsSoldAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_UnlabeledAbstract2" xlink:href="sprcy-20241231.xsd#sprcy_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl" xml:lang="en-US">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">a. Research and development expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BSalesAndMarketingExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_BSalesAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BSalesAndMarketingExpensesAbstract_lbl" xml:lang="en-US">b. Sales and marketing expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BSalesAndMarketingExpensesAbstract" xlink:to="sprcy_BSalesAndMarketingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">c. General and administrative expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DOtherExpensesIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_DOtherExpensesIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DOtherExpensesIncomeAbstract_lbl" xml:lang="en-US">d. Other expenses (income):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DOtherExpensesIncomeAbstract" xlink:to="sprcy_DOtherExpensesIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EFinanceIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_EFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EFinanceIncomeAbstract_lbl" xml:lang="en-US">e. Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceIncomeAbstract" xlink:to="sprcy_EFinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FFinanceExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_FFinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FFinanceExpensesAbstract_lbl" xml:lang="en-US">f. Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FFinanceExpensesAbstract" xlink:to="sprcy_FFinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ContinuingOperationsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ContinuingOperationsAbstract_lbl" xml:lang="en-US">Continuing operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Basic loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl" xml:lang="en-US">Basic loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl" xml:lang="en-US">Effect of potential dilutive ordinary shares, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:href="sprcy-20241231.xsd#sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl" xml:lang="en-US">Effect of potential dilutive ordinary shares, Loss (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Diluted loss per share, Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl" xml:lang="en-US">Diluted loss per share, Loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">OPERATING SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">Schedule of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SegmentReportingRevenueAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SegmentReportingRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExternalRevenues" xlink:href="sprcy-20241231.xsd#sprcy_ExternalRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExternalRevenues_lbl" xml:lang="en-US">External</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl" xml:lang="en-US">Segment loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityLossesFromTheInvestment" xlink:href="sprcy-20241231.xsd#sprcy_EquityLossesFromTheInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EquityLossesFromTheInvestment_lbl" xml:lang="en-US">Equity losses from the investment in MitoCareX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromTheInvestment" xlink:to="sprcy_EquityLossesFromTheInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRevenueExpense_lbl" xml:lang="en-US">Finance expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Segment Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US">Segment Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RelatedPartyBalancetextBlock" xlink:href="sprcy-20241231.xsd#sprcy_RelatedPartyBalancetextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RelatedPartyBalancetextBlock_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RelatedPartyBalancetextBlock" xlink:to="sprcy_RelatedPartyBalancetextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CurrentAsset" xlink:href="sprcy-20241231.xsd#sprcy_CurrentAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CurrentAsset_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CurrentAsset" xlink:to="sprcy_CurrentAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">Schedule of Transactions with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfMinorityInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary_lbl" xml:lang="en-US">Sale of minority interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of Benefits to Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20241231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl" xml:lang="en-US">Management fees (see also note 25a)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Cost of share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants fair value ($) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl0" xml:lang="en-US">Warrants fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl" xml:lang="en-US">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">EVENTS AFTER THE REPORTING DATE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Depreciation of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share Options, Share Options cancelled during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl" xml:lang="en-US">Other expenses (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_ILS_lbl" xml:lang="en-US">NIS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CostMember" xlink:href="sprcy-20241231.xsd#sprcy_CostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CostMember_lbl" xml:lang="en-US">Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostMember" xlink:to="sprcy_CostMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AccumulatedDepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AccumulatedDepreciationMember_lbl" xml:lang="en-US">Accumulated Depreciation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationMember" xlink:to="sprcy_AccumulatedDepreciationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeEquipmentsMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeEquipmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeEquipmentsMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RightOfUseAssesMember" xlink:href="sprcy-20241231.xsd#sprcy_RightOfUseAssesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RightOfUseAssesMember_lbl" xml:lang="en-US">Right of use asses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightOfUseAssesMember" xlink:to="sprcy_RightOfUseAssesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOptionsMember_lbl" xml:lang="en-US">Share Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasedGoodsMember" xlink:href="sprcy-20241231.xsd#sprcy_PurchasedGoodsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasedGoodsMember_lbl" xml:lang="en-US">Purchased goods [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FreightMember" xlink:href="sprcy-20241231.xsd#sprcy_FreightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FreightMember_lbl" xml:lang="en-US">Freight [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WagesAndRelatedExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl" xml:lang="en-US">Wages and related expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentMember" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share-based payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl" xml:lang="en-US">Regulatory, professional and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl" xml:lang="en-US">Research and preclinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ClinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ClinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ChemistryAndFormulationsMember" xlink:href="sprcy-20241231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl" xml:lang="en-US">Chemistry and formulations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdvertisementMember" xlink:href="sprcy-20241231.xsd#sprcy_AdvertisementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdvertisementMember_lbl" xml:lang="en-US">Advertising [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdvertisementMember" xlink:to="sprcy_AdvertisementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AmazonFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_AmazonFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AmazonFeesMember_lbl" xml:lang="en-US">Amazon fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DepreciationMember_lbl" xml:lang="en-US">Depreciation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationMember" xlink:to="sprcy_DepreciationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_StorageAndShippingMember" xlink:href="sprcy-20241231.xsd#sprcy_StorageAndShippingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_StorageAndShippingMember_lbl" xml:lang="en-US">Storage and shipping [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageAndShippingMember" xlink:to="sprcy_StorageAndShippingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ManagementFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ManagementFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ManagementFeesMember_lbl" xml:lang="en-US">Management fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ManagementFeesMember" xlink:to="sprcy_ManagementFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl" xml:lang="en-US">Professional and directors&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BusinessDevelopmentExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl" xml:lang="en-US">Business development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RegulatoryExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RegulatoryExpensesMember_lbl" xml:lang="en-US">Regulatory expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl" xml:lang="en-US">Office maintenance, rent and other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl" xml:lang="en-US">Investor relations and business expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:href="sprcy-20241231.xsd#sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl" xml:lang="en-US">Loss from sale of property and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:to="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:href="sprcy-20241231.xsd#sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl" xml:lang="en-US">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:to="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20241231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl" xml:lang="en-US">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:href="sprcy-20241231.xsd#sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl" xml:lang="en-US">Interest from loans to related parties and deposits	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:to="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeRateDifferencesNetMember" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl" xml:lang="en-US">Exchange rate differences, net [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl" xml:lang="en-US">Issuance expenses related to warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20241231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl" xml:lang="en-US">Losses from remeasurement of investment in financial assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl" xml:lang="en-US">Finance expense in respect of leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl" xml:lang="en-US">Finance expenses from interest and commissions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DrugDevelopmentMember" xlink:href="sprcy-20241231.xsd#sprcy_DrugDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DrugDevelopmentMember_lbl" xml:lang="en-US">Drug Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesMember_lbl" xml:lang="en-US">Online Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US">Key management personnel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl" xml:lang="en-US">Other related parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xml:lang="en-US">Classes of ordinary shares [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockAxis" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingTerm" xlink:href="sprcy-20241231.xsd#sprcy_OperatingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingTerm_lbl" xml:lang="en-US">Operating term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialInvestment" xlink:href="sprcy-20241231.xsd#sprcy_InitialInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialInvestment_lbl" xml:lang="en-US">Initial investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInvestment_lbl" xml:lang="en-US">Additional investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingSharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingSharesPercentage_lbl" xml:lang="en-US">Outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInstallment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInstallment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalInstallment_lbl" xml:lang="en-US">Additional installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPaid" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPaid_lbl" xml:lang="en-US">Installment paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashConsideration" xlink:href="sprcy-20241231.xsd#sprcy_CashConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CashConsideration_lbl" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchaserRemainingOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage_lbl" xml:lang="en-US">Purchaser remaining ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaserRemainingOwnershipPercentage" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RemainingPurchaserAmount" xlink:href="sprcy-20241231.xsd#sprcy_RemainingPurchaserAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RemainingPurchaserAmount_lbl" xml:lang="en-US">Purchaser equal valuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RemainingPurchaserAmount" xlink:to="sprcy_RemainingPurchaserAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20241231.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl" xml:lang="en-US">Issued and outstanding share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl" xml:lang="en-US">Share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_ShareCapitalPercentage_lbl0" xml:lang="en-US">Share capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Ordinary shares par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseShareSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseShareSplitRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReverseShareSplitRatio_lbl" xml:lang="en-US">Reverse share split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseShareSplitRatio" xlink:to="sprcy_ReverseShareSplitRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_SharePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePricePerShare_lbl" xml:lang="en-US">Share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AreaOfLease" xlink:href="sprcy-20241231.xsd#sprcy_AreaOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AreaOfLease_lbl" xml:lang="en-US">Area of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AreaOfLease" xlink:to="sprcy_AreaOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OptionToExtendLeaseTerm" xlink:href="sprcy-20241231.xsd#sprcy_OptionToExtendLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OptionToExtendLeaseTerm_lbl" xml:lang="en-US">Option to extend lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OptionToExtendLeaseTerm" xlink:to="sprcy_OptionToExtendLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MonthlyLeaseFee" xlink:href="sprcy-20241231.xsd#sprcy_MonthlyLeaseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MonthlyLeaseFee_lbl" xml:lang="en-US">Monthly lease fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyLeaseFee" xlink:to="sprcy_MonthlyLeaseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_Cash_lbl1" xml:lang="en-US">Cash payment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash" xlink:href="sprcy-20241231.xsd#sprcy_PaymentsOfAdditionalDeferredCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash_lbl" xml:lang="en-US">Additional deferred cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentsOfAdditionalDeferredCash" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchaseCostsValue" xlink:href="sprcy-20241231.xsd#sprcy_PurchaseCostsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchaseCostsValue_lbl" xml:lang="en-US">Purchase costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Acquisition of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl" xml:lang="en-US">Amortized over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_GrowthRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_GrowthRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_GrowthRatePercentage_lbl" xml:lang="en-US">Growth rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LongTermPercentage" xlink:href="sprcy-20241231.xsd#sprcy_LongTermPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LongTermPercentage_lbl" xml:lang="en-US">Long term, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DiscountRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_DiscountRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DiscountRatePercentage_lbl" xml:lang="en-US">Discount rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DiscountRatePercentage" xlink:to="sprcy_DiscountRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl" xml:lang="en-US">Tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20241231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl" xml:lang="en-US">Carryforward tax losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DekelLicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl" xml:lang="en-US">Milestone payments, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AnnualInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AnnualInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AnnualInvestment_lbl" xml:lang="en-US">Annual investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalMilestoneAmount" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AdditionalMilestoneAmount_lbl" xml:lang="en-US">Additional milestone amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentAmount_lbl" xml:lang="en-US">Installment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EstimatedAmount" xlink:href="sprcy-20241231.xsd#sprcy_EstimatedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EstimatedAmount_lbl" xml:lang="en-US">Estimated amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl" xml:lang="en-US">Capital purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalCommitments_lbl" xml:lang="en-US">Capital warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Units received (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_CapitalRatio" xlink:href="sprcy-20241231.xsd#sprcy_CapitalRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CapitalRatio_lbl" xml:lang="en-US">Capital ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ReverseSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseSplitRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ReverseSplitRatio_lbl" xml:lang="en-US">Reverse split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseSplitRatio" xlink:to="sprcy_ReverseSplitRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US">Services rendered amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ServicesExpense_lbl0" xml:lang="en-US">Services expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceOfAggregateShares" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceOfAggregateShares_lbl" xml:lang="en-US">Issuance of aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnits" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnits_lbl" xml:lang="en-US">Number of units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateUnitsPerShare" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateUnitsPerShare_lbl" xml:lang="en-US">Units per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IssuanceExpireTerm" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpireTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_IssuanceExpireTerm_lbl" xml:lang="en-US">Expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpireTerm" xlink:to="sprcy_IssuanceExpireTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsAndExercise" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsAndExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsAndExercise_lbl" xml:lang="en-US">Warrants and exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateGrossProceeds" xlink:href="sprcy-20241231.xsd#sprcy_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US">Purchase sale (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CommitmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_CommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CommitmentAmount_lbl" xml:lang="en-US">Commitment amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SaleOfOrdinaryShares_lbl" xml:lang="en-US">Sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SharePriceRate" xlink:href="sprcy-20241231.xsd#sprcy_SharePriceRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SharePriceRate_lbl" xml:lang="en-US">Share price rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestRate" xlink:href="sprcy-20241231.xsd#sprcy_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestRate_lbl" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InstallmentPayment" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InstallmentPayment_lbl" xml:lang="en-US">Installment payment, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PaymentForPremiumPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PaymentForPremiumPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PaymentForPremiumPercentage_lbl" xml:lang="en-US">Payment for premium percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateIssuedAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateIssuedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateIssuedAmount_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Commitment fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FairValueOfShareOptionsGranted" xlink:href="sprcy-20241231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl" xml:lang="en-US">Fair value of share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20241231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl" xml:lang="en-US">Ordinary shares granted discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOptionsOutstanding" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfOptionsOutstanding_lbl" xml:lang="en-US">Share options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOptionsOutstanding" xlink:to="sprcy_NumberOfOptionsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConvertIntoOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_ConvertIntoOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConvertIntoOrdinaryShares_lbl" xml:lang="en-US">Conversion of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConvertIntoOrdinaryShares" xlink:to="sprcy_ConvertIntoOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US">Vest over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Exercisable of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIntangibleAssets_lbl" xml:lang="en-US">Intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssets" xlink:to="ifrs-full_OtherIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InterestPercentage" xlink:href="sprcy-20241231.xsd#sprcy_InterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InterestPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentage" xlink:to="sprcy_InterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DeferredCashPayment" xlink:href="sprcy-20241231.xsd#sprcy_DeferredCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DeferredCashPayment_lbl" xml:lang="en-US">Deferred cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayment" xlink:to="sprcy_DeferredCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl" xml:lang="en-US">Other fee expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_BonusAmountReceived" xlink:href="sprcy-20241231.xsd#sprcy_BonusAmountReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_BonusAmountReceived_lbl" xml:lang="en-US">Bonus amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AcquiredOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_AcquiredOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AcquiredOrdinaryShares_lbl" xml:lang="en-US">Acquired ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AcquiredOrdinaryShares" xlink:to="sprcy_AcquiredOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValues" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValues_lbl" xml:lang="en-US">Aggregate value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValues" xlink:to="sprcy_AggregateValues_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateValueAdjusted" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValueAdjusted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateValueAdjusted_lbl" xml:lang="en-US">Aggregate values adjusted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValueAdjusted" xlink:to="sprcy_AggregateValueAdjusted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ListedSharePrice" xlink:href="sprcy-20241231.xsd#sprcy_ListedSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ListedSharePrice_lbl" xml:lang="en-US">Listed share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ComprehensiveLossOnInvestment" xlink:href="sprcy-20241231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl" xml:lang="en-US">Loss on investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CooperationAgreementAmount" xlink:href="sprcy-20241231.xsd#sprcy_CooperationAgreementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_CooperationAgreementAmount_lbl" xml:lang="en-US">Cooperation Agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ExchangeOfCommonShares" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ExchangeOfCommonShares_lbl" xml:lang="en-US">Exchange of Common Shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OutstandingShareCapital_lbl" xml:lang="en-US">Outstanding share capital, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseeIssuePrice" xlink:href="sprcy-20241231.xsd#sprcy_LicenseeIssuePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LicenseeIssuePrice_lbl" xml:lang="en-US">Licensee issue price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseeIssuePrice" xlink:to="sprcy_LicenseeIssuePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MilestonesAmount" xlink:href="sprcy-20241231.xsd#sprcy_MilestonesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MilestonesAmount_lbl" xml:lang="en-US">Milestones amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MilestonesAmount" xlink:to="sprcy_MilestonesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_LicenseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LicenseAgreementDescription_lbl" xml:lang="en-US">License agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseAgreementDescription" xlink:to="sprcy_LicenseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfAggregateNetSales" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfAggregateNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfAggregateNetSales_lbl" xml:lang="en-US">Aggregate net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregateNetSales" xlink:to="sprcy_PercentageOfAggregateNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfUnitsReceived" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfUnitsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfUnitsReceived_lbl" xml:lang="en-US">Number of units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfUnitsReceived" xlink:to="sprcy_NumberOfUnitsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US">Aggregate consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl0" xml:lang="en-US">Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsHolds" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsHolds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfWarrantsHolds_lbl" xml:lang="en-US">Warrants holds (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsHolds" xlink:to="sprcy_NumberOfWarrantsHolds_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantsExpireDate" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsExpireDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantsExpireDate_lbl" xml:lang="en-US">Warrants expire date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExpireDate" xlink:to="sprcy_WarrantsExpireDate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl" xml:lang="en-US">Aggregate number of the outstanding ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EnterpriseValue" xlink:href="sprcy-20241231.xsd#sprcy_EnterpriseValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_EnterpriseValue_lbl" xml:lang="en-US">Enterprise value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EnterpriseValue" xlink:to="sprcy_EnterpriseValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl" xml:lang="en-US">Cash position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US">Loan amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateLoanAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateLoanAmount_lbl" xml:lang="en-US">Aggregate loan amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateLoanAmount" xlink:to="sprcy_AggregateLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RepaidOfMonthlyInstallments" xlink:href="sprcy-20241231.xsd#sprcy_RepaidOfMonthlyInstallments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RepaidOfMonthlyInstallments_lbl" xml:lang="en-US">Monthly installments (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaidOfMonthlyInstallments" xlink:to="sprcy_RepaidOfMonthlyInstallments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US">Aggregate principal amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PurchasePricePercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PurchasePricePercentage_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePercentage" xlink:to="sprcy_PurchasePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl" xml:lang="en-US">Volume weighted average price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl" xml:lang="en-US">Volume weighted average price during consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_ConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_ConsecutiveTradingDays_lbl" xml:lang="en-US">Consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsecutiveTradingDays" xlink:to="sprcy_ConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl" xml:lang="en-US">Volume weighted average price of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_NumberOfWarrantsIssued" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_NumberOfWarrantsIssued_lbl" xml:lang="en-US">Number of warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsIssued" xlink:to="sprcy_NumberOfWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePricePerWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant_lbl" xml:lang="en-US">Volume weighted average price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_WarrantExercisableTerm" xlink:href="sprcy-20241231.xsd#sprcy_WarrantExercisableTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_WarrantExercisableTerm_lbl" xml:lang="en-US">Warrant exercisable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExercisableTerm" xlink:to="sprcy_WarrantExercisableTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentIncome_lbl" xml:lang="en-US">Investing amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AggregateInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AggregateInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AggregateInvestment_lbl" xml:lang="en-US">Aggregate investment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateInvestment" xlink:to="sprcy_AggregateInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFullyDilutedCapitalStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock_lbl" xml:lang="en-US">Percentage of fully diluted capital stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PercentageOfFinancingProceeds" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFinancingProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PercentageOfFinancingProceeds_lbl" xml:lang="en-US">Percentage of financing proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFinancingProceeds" xlink:to="sprcy_PercentageOfFinancingProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Financing proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPH1ELcI9xyt3K1DchISeFlf0gxWybNUtM0z5SubuERPcsyFjjcRvlY0woC4Gu3fMsvVXVWKV7wODmQlScdq8DcGYwOT7maUpClVnfueBWSE6BHhwo0f0EXUnILvWj74PXyhBesuwkl8ZeR5liO5Mn8yuKee6yOoQ+8e1eqfyeatTQ==] CSR-->
    <loc xlink:type="locator" xlink:label="sprcy_RestrictedStockGrantPercentage" xlink:href="sprcy-20241231.xsd#sprcy_RestrictedStockGrantPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_RestrictedStockGrantPercentage_lbl" xml:lang="en-US">Restricted stock grant percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RestrictedStockGrantPercentage" xlink:to="sprcy_RestrictedStockGrantPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_VestingPeriod" xlink:href="sprcy-20241231.xsd#sprcy_VestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_VestingPeriod_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VestingPeriod" xlink:to="sprcy_VestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl" xml:lang="en-US">Basis of presentation of the financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl" xml:lang="en-US">The operating cycle</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl" xml:lang="en-US">Consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Functional currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl" xml:lang="en-US">Acquisition of a single asset company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl" xml:lang="en-US">Investment in joint arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US">Investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US">Finance income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXBioLtdMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXBioLtdMember_lbl" xml:lang="en-US">MitoCare X Bio Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MitoCareXMember_lbl" xml:lang="en-US">MitoCareX [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_InitialPublicOfferingMember_lbl" xml:lang="en-US">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialPublicOfferingMember" xlink:to="sprcy_InitialPublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeaseMember" xlink:href="sprcy-20241231.xsd#sprcy_LeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_LeaseMember_lbl" xml:lang="en-US">2021 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIntangibleAssetsMember_lbl" xml:lang="en-US">Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssetsMember" xlink:to="ifrs-full_OtherIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israeli [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sprcy_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Pre-Funded Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_PreFundedUnitsMember" xlink:href="sprcy-20241231.xsd#sprcy_PreFundedUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_PreFundedUnitsMember_lbl" xml:lang="en-US">Pre-Funded Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitsMember" xlink:to="sprcy_PreFundedUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_June2022WarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_June2022WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_June2022WarrantsMember_lbl" xml:lang="en-US">June 2022 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_August2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_August2023FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_August2023FinancingRoundMember_lbl" xml:lang="en-US">August 2023 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_August2023FinancingRoundMember" xlink:to="sprcy_August2023FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OverAllotmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OverAllotmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OverAllotmentMember_lbl" xml:lang="en-US">Over Allotment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_October2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_October2023FinancingRoundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_October2023FinancingRoundMember_lbl" xml:lang="en-US">October 2023 Financing Round [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_October2023FinancingRoundMember" xlink:to="sprcy_October2023FinancingRoundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SEPAMember" xlink:href="sprcy-20241231.xsd#sprcy_SEPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SEPAMember_lbl" xml:lang="en-US">SEPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20241231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DirectorsMember" xlink:href="sprcy-20241231.xsd#sprcy_DirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DirectorsMember" xlink:to="sprcy_DirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary Share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Common shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xml:lang="en-US">Restricted Share Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OnlineSalesSegmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OnlineSalesSegmentMember_lbl" xml:lang="en-US">Online Sales Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesSegmentMember" xlink:to="sprcy_OnlineSalesSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_JeffsBrandsMember" xlink:href="sprcy-20241231.xsd#sprcy_JeffsBrandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_JeffsBrandsMember_lbl" xml:lang="en-US">Jeffs&#8217; Brands [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MergerAgreementMember" xlink:href="sprcy-20241231.xsd#sprcy_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MergerAgreementMember" xlink:to="sprcy_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_MizaMember" xlink:href="sprcy-20241231.xsd#sprcy_MizaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_MizaMember_lbl" xml:lang="en-US">Miza [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MizaMember" xlink:to="sprcy_MizaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SubsequentEventsMember" xlink:href="sprcy-20241231.xsd#sprcy_SubsequentEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SubsequentEventsMember_lbl" xml:lang="en-US">Subsequent Events [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentEventsMember" xlink:to="sprcy_SubsequentEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AutoMaxMember" xlink:href="sprcy-20241231.xsd#sprcy_AutoMaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_AutoMaxMember_lbl" xml:lang="en-US">AutoMax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMember" xlink:to="sprcy_AutoMaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SciSparcMember" xlink:href="sprcy-20241231.xsd#sprcy_SciSparcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_SciSparcMember_lbl" xml:lang="en-US">SciSparc&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SciSparcMember" xlink:to="sprcy_SciSparcMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_DebenturesMember" xlink:href="sprcy-20241231.xsd#sprcy_DebenturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_DebenturesMember_lbl" xml:lang="en-US">Debentures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DebenturesMember" xlink:to="sprcy_DebenturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_N2OFFMember" xlink:href="sprcy-20241231.xsd#sprcy_N2OFFMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_N2OFFMember_lbl" xml:lang="en-US">N2OFF [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_N2OFFMember" xlink:to="sprcy_N2OFFMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xml:lang="en-US">Components of equity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesTable_lbl" xml:lang="en-US">Investment in Associates and Joint Ventures (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesTable" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems_lbl" xml:lang="en-US">Investment in Associates and Investments in Investees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesTable_lbl" xml:lang="en-US">Operating Segments (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesTable" xlink:to="sprcy_OperatingSegmentsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl" xml:lang="en-US">Operating Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xml:lang="en-US">Classes of property, plant and equipment [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeDomain_lbl" xml:lang="en-US">Range [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems_lbl" xml:lang="en-US">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_CashScheduleofCashDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashScheduleofCashDetailsTable_lbl" xml:lang="en-US">Cash - Schedule of Cash (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashScheduleofCashDetailsTable" xlink:to="sprcy_CashScheduleofCashDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_lbl" xml:lang="en-US">Schedule of Cash [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US">Carrying amount [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable_lbl" xml:lang="en-US">Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Intangible Asset [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl" xml:lang="en-US">Levels of fair value hierarchy [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Company&apos;s Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems_lbl" xml:lang="en-US">Schedule of Company&apos;s Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl" xml:lang="en-US">Types of antidilutive instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl" xml:lang="en-US">Schedule of Fair Value for Share Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable_lbl" xml:lang="en-US">Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems_lbl" xml:lang="en-US">Schedule of Cost of Sales and Gross Profit [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsDomainDomain_lbl" xml:lang="en-US">IncomeStatementsLocationsDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsDomainDomain" xlink:to="sprcy_IncomeStatementsLocationsDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable_lbl" xml:lang="en-US">Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl" xml:lang="en-US">Schedule of Additional Information to the Items of Profit or Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsDomain_lbl" xml:lang="en-US">Segments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsDomain" xlink:to="ifrs-full_SegmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable_lbl" xml:lang="en-US">Operating Segments - Schedule of Operating Segments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US">Schedule of Operating Segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xml:lang="en-US">Categories of related parties [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties - Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems_lbl" xml:lang="en-US">Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable_lbl" xml:lang="en-US">Investment in Associates and Joint Ventures (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="sprcy_InvestmentinAssociatesandJointVenturesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xml:lang="en-US">Investment in Associates [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain_lbl" xml:lang="en-US">Classes of ordinary shares [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl" xml:lang="en-US">Investment in Financial Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentinFinancialAssetsDetailsTable" xlink:to="sprcy_InvestmentinFinancialAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US">Investment in Financial Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsTable" xlink:to="sprcy_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_LeasesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeasesDetailsLineItems" xlink:to="sprcy_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_IntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IntangibleAssetDetailsTable_lbl" xml:lang="en-US">Intangible Asset (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IntangibleAssetDetailsTable" xlink:to="sprcy_IntangibleAssetDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Intangible Asset [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasDomain_lbl" xml:lang="en-US">Geographical areas [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_GeographicalAreasDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsTable" xlink:to="sprcy_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Taxes on Income (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TaxesonIncomeDetailsLineItems" xlink:to="sprcy_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_lbl" xml:lang="en-US">Classes of entity&apos;s own equity instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EquityDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityDetailsTable" xlink:to="sprcy_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xml:lang="en-US">Classes of share capital [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xml:lang="en-US">Types of share-based payment arrangements [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentTransactionsDetailsTable" xlink:to="sprcy_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsDetailsTable_lbl" xml:lang="en-US">Operating Segments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsDetailsTable" xlink:to="sprcy_OperatingSegmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_OperatingSegmentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsDetailsLineItems_lbl" xml:lang="en-US">Operating Segments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsDetailsLineItems" xlink:to="sprcy_OperatingSegmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SaleOfStockDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfStockDomainDomain_lbl" xml:lang="en-US">SaleOfStockDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfStockDomainDomain" xlink:to="sprcy_SaleOfStockDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl" xml:lang="en-US">Transactions and Balances with Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US">Transactions and Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl" xml:lang="en-US">Significant Events during the Reporting Period (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="sprcy_SignificantEventsduringtheReportingPeriodDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantEventsDuringTheReportingPeriodLineItems_lbl" xml:lang="en-US">Significant Events During the Reporting Period [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="sprcy_SignificantEventsDuringTheReportingPeriodLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Classes of financial instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xml:lang="en-US">Non-adjusting events after reporting period [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EventsAftertheReportingDateDetailsTable_lbl" xml:lang="en-US">Events After the Reporting Date (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EventsAftertheReportingDateDetailsTable" xlink:to="sprcy_EventsAftertheReportingDateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US">Events After the Reporting Date [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AcquiredOrdinaryShares_lbl0" xml:lang="en-US">The number of shares acquired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AcquiredOrdinaryShares" xlink:to="sprcy_AcquiredOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInstallment_lbl0" xml:lang="en-US">The amount of additional installment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdditionalInvestment_lbl0" xml:lang="en-US">The amount of additional investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl0" xml:lang="en-US">Adjustments for increase in related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0" xml:lang="en-US">Adjustments for losses from remeasurement of investment in financial assets&#xd;
  to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Adjustments for group&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateGrossProceeds_lbl0" xml:lang="en-US">Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateInvestment_lbl0" xml:lang="en-US">aggregate investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateInvestment" xlink:to="sprcy_AggregateInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateIssuedAmount_lbl0" xml:lang="en-US">Aggregate issued amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateLoanAmount_lbl0" xml:lang="en-US">Aggregate loan amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateLoanAmount" xlink:to="sprcy_AggregateLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl0" xml:lang="en-US">Aggregate number of the outstanding ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnits_lbl0" xml:lang="en-US">Number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateUnitsPerShare_lbl0" xml:lang="en-US">Per share of aggregate units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValueAdjusted_lbl0" xml:lang="en-US">The amount of aggregate values adjusted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValueAdjusted" xlink:to="sprcy_AggregateValueAdjusted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AggregateValues_lbl0" xml:lang="en-US">The amount of aggregate value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValues" xlink:to="sprcy_AggregateValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AnnualInvestment_lbl0" xml:lang="en-US">Amount of annual investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_AreaOfLease_lbl0" xml:lang="en-US">Area of Lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AreaOfLease" xlink:to="sprcy_AreaOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_BonusAmountReceived_lbl0" xml:lang="en-US">Bonus amount received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CapitalRatio_lbl0" xml:lang="en-US">Capital ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CashConsideration_lbl0" xml:lang="en-US">Cash consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CommitmentAmount_lbl0" xml:lang="en-US">Commitment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0" xml:lang="en-US">Company&#8217;s share of losses of company accounted for at equity, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl0" xml:lang="en-US">Amount of comprehensive loss on investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ConsecutiveTradingDays_lbl0" xml:lang="en-US">Number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsecutiveTradingDays" xlink:to="sprcy_ConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ConvertIntoOrdinaryShares_lbl0" xml:lang="en-US">Represents the share of restricted share units convert into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConvertIntoOrdinaryShares" xlink:to="sprcy_ConvertIntoOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CooperationAgreementAmount_lbl0" xml:lang="en-US">Cooperation Agreement amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CreditFromOthers_lbl0" xml:lang="en-US">The amount of credit of others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_CurrentAsset_lbl0" xml:lang="en-US">The amount of current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CurrentAsset" xlink:to="sprcy_CurrentAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DeferredCashPayment_lbl0" xml:lang="en-US">Deferred cash payments amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayment" xlink:to="sprcy_DeferredCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl0" xml:lang="en-US">Dekel license agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">The amount of depreciation of intangible asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Description of accounting policy cost of sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in Consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy changes in operating cycle Explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for acquisition of a single asset company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl0" xml:lang="en-US">The description of accounting policies for basis of presentation of the financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">The entire disclosue of cash and cash equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about defined contribution plans explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of expenses due to share-based compensation explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0" xml:lang="en-US">Disclosure of fair value for share options granted explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInventorieExplanatory_lbl0" xml:lang="en-US">The tabular disclosure of inventories.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInventorieExplanatory" xlink:to="sprcy_DisclosureOfInventorieExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl0" xml:lang="en-US">The disclosure of the investment financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0" xml:lang="en-US">Disclosure of detailed inforamtion about issued and outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory_lbl0" xml:lang="en-US">The disclosure of trade payables explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayablesExplanatory" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0" xml:lang="en-US">The disclosure of accounts receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_DiscountRatePercentage_lbl0" xml:lang="en-US">Percentage of discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DiscountRatePercentage" xlink:to="sprcy_DiscountRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl0" xml:lang="en-US">Represents the par value of effect of potential dilutive ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EnterpriseValue_lbl0" xml:lang="en-US">The amount of enterprise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EnterpriseValue" xlink:to="sprcy_EnterpriseValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_EquityLossesFromTheInvestment_lbl0" xml:lang="en-US">Equity losses from the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromTheInvestment" xlink:to="sprcy_EquityLossesFromTheInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExchangeOfCommonShares_lbl0" xml:lang="en-US">Number of shares exchanged.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ExternalRevenues_lbl0" xml:lang="en-US">Amount of external revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl0" xml:lang="en-US">Fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_Governmentauthoritiescurrent_lbl0" xml:lang="en-US">Represent the government authorities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Governmentauthoritiescurrent" xlink:to="sprcy_Governmentauthoritiescurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InitialInvestment_lbl0" xml:lang="en-US">Initial investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentAmount_lbl0" xml:lang="en-US">Amount of installment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPaid_lbl0" xml:lang="en-US">The amount of installment paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InstallmentPayment_lbl0" xml:lang="en-US">Installment payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestPercentage_lbl0" xml:lang="en-US">Interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentage" xlink:to="sprcy_InterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InterestRate_lbl0" xml:lang="en-US">Interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl0" xml:lang="en-US">The amount of investment following achievement of first milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone_lbl0" xml:lang="en-US">Investment following achievement of second milestone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfSecondMilestone" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_InvestmentsDate_lbl0" xml:lang="en-US">The amount of investment date,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceExpireTerm_lbl0" xml:lang="en-US">Issuance expire term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpireTerm" xlink:to="sprcy_IssuanceExpireTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfAggregateShares_lbl0" xml:lang="en-US">The issuance of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl0" xml:lang="en-US">Number of issuance of share capital &#8211; in respect of January 2024 SEPA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0" xml:lang="en-US">The amount of issue of share capital, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl0" xml:lang="en-US">Issued and outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0" xml:lang="en-US">The amount of compensation to key management personnel in the form of management fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LeaseholdImprovementsMainlyRate_lbl0" xml:lang="en-US">The leasehold improvements rate used for mainly.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovementsMainlyRate" xlink:to="sprcy_LeaseholdImprovementsMainlyRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LicenseAgreementDescription_lbl0" xml:lang="en-US">The description of the license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseAgreementDescription" xlink:to="sprcy_LicenseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LicenseeIssuePrice_lbl0" xml:lang="en-US">The amount of licensee, reflecting an issue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseeIssuePrice" xlink:to="sprcy_LicenseeIssuePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ListedSharePrice_lbl0" xml:lang="en-US">Amount of listed shares price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_LongTermPercentage_lbl0" xml:lang="en-US">The percentage of long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MilestonesAmount_lbl0" xml:lang="en-US">Milestones amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MilestonesAmount" xlink:to="sprcy_MilestonesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_MonthlyLeaseFee_lbl0" xml:lang="en-US">Monthly lease fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyLeaseFee" xlink:to="sprcy_MonthlyLeaseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOptionsOutstanding_lbl0" xml:lang="en-US">Represents the amount of options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOptionsOutstanding" xlink:to="sprcy_NumberOfOptionsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl0" xml:lang="en-US">Number of Other Equity Instruments Vested in Share based Payment Arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfUnitsReceived_lbl0" xml:lang="en-US">Number of units received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfUnitsReceived" xlink:to="sprcy_NumberOfUnitsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfWarrantsHolds_lbl0" xml:lang="en-US">Number of warrants holds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsHolds" xlink:to="sprcy_NumberOfWarrantsHolds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_NumberOfWarrantsIssued_lbl0" xml:lang="en-US">Number of warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsIssued" xlink:to="sprcy_NumberOfWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0" xml:lang="en-US">The amount of net operating loss carryforward tax as of the reporting date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OptionToExtendLeaseTerm_lbl0" xml:lang="en-US">Option to extend lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OptionToExtendLeaseTerm" xlink:to="sprcy_OptionToExtendLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl0" xml:lang="en-US">Ordinary shares granted discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingShareCapital_lbl0" xml:lang="en-US">Percentage of outstanding share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_OutstandingSharesPercentage_lbl0" xml:lang="en-US">Outstanding shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentForPremiumPercentage_lbl0" xml:lang="en-US">Payment for premium percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash_lbl0" xml:lang="en-US">Represents the amount of payments of additional deferred cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentsOfAdditionalDeferredCash" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfAggregateNetSales_lbl0" xml:lang="en-US">Percentage of aggregate net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregateNetSales" xlink:to="sprcy_PercentageOfAggregateNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfFinancingProceeds_lbl0" xml:lang="en-US">Percentage of financing proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFinancingProceeds" xlink:to="sprcy_PercentageOfFinancingProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock_lbl0" xml:lang="en-US">Percentage of fully diluted capital stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaseCostsValue_lbl0" xml:lang="en-US">The amount of purchase costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePerShare_lbl0" xml:lang="en-US">The purchase price is the price an investor pays for an investment, and the price becomes the investor&apos;s cost basis for calculating gain or loss when selling the investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchasePricePercentage_lbl0" xml:lang="en-US">Represents the purchase price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePercentage" xlink:to="sprcy_PurchasePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage_lbl0" xml:lang="en-US">Purchaser remaining ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaserRemainingOwnershipPercentage" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl0" xml:lang="en-US">The amount of receivables in respect of downpayment on merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RemainingPurchaserAmount_lbl0" xml:lang="en-US">Remaining purchaser amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RemainingPurchaserAmount" xlink:to="sprcy_RemainingPurchaserAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RepaidOfMonthlyInstallments_lbl0" xml:lang="en-US">Repaid of Monthly installments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaidOfMonthlyInstallments" xlink:to="sprcy_RepaidOfMonthlyInstallments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RestrictedStockGrantPercentage_lbl0" xml:lang="en-US">Restricted stock grant percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RestrictedStockGrantPercentage" xlink:to="sprcy_RestrictedStockGrantPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ReverseShareSplitRatio_lbl0" xml:lang="en-US">Reverse share split ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseShareSplitRatio" xlink:to="sprcy_ReverseShareSplitRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ReverseSplitRatio_lbl0" xml:lang="en-US">Reverse split ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseSplitRatio" xlink:to="sprcy_ReverseSplitRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary_lbl0" xml:lang="en-US">The amount of sale of minority interest in subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SaleOfOrdinaryShares_lbl0" xml:lang="en-US">Sale of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment_lbl0" xml:lang="en-US">The cash outflow for the sale of purchases property, plant and equipment, classified as investing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareCapitalPercentage_lbl1" xml:lang="en-US">Share capital percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_ShareIssuedToAConsultants_lbl0" xml:lang="en-US">Number of share issued to consultants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultants" xlink:to="sprcy_ShareIssuedToAConsultants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePricePerShare_lbl0" xml:lang="en-US">Share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_SharePriceRate_lbl0" xml:lang="en-US">Share price rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VestingPeriod_lbl0" xml:lang="en-US">Vesting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VestingPeriod" xlink:to="sprcy_VestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl0" xml:lang="en-US">Volume weighted average price of ordinary shares during the consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl0" xml:lang="en-US">Volume weighted average price of ordinary shares of preceding the closing of trading day.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl0" xml:lang="en-US">Volume weighted average price of ordinary shares on the day prior to the closing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant_lbl0" xml:lang="en-US">Volume weighted average price per warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantExercisableTerm_lbl0" xml:lang="en-US">Warrant exercisable term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExercisableTerm" xlink:to="sprcy_WarrantExercisableTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sprcy_WarrantsExpireDate_lbl0" xml:lang="en-US">Warrants expire date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExpireDate" xlink:to="sprcy_WarrantsExpireDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SalepurchaseOfPropertyAndEquipment_lbl1" xml:lang="en-US">Salepurchase Of Property And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SalepurchaseOfPropertyAndEquipment" xlink:to="sprcy_SalepurchaseOfPropertyAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfAggregateShares_lbl1" xml:lang="en-US">Issuance Of Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfAggregateShares" xlink:to="sprcy_IssuanceOfAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investment in associates and joint ventures [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl0" xml:lang="en-US">Financial assets, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DirectorsMember_lbl0" xml:lang="en-US">Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DirectorsMember" xlink:to="sprcy_DirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StorageAndShippingMember_lbl0" xml:lang="en-US">Storage And Shipping Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StorageAndShippingMember" xlink:to="sprcy_StorageAndShippingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightOfUseAssesMember_lbl0" xml:lang="en-US">Right Of Use Asses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightOfUseAssesMember" xlink:to="sprcy_RightOfUseAssesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl0" xml:lang="en-US">CGeneral And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CGeneralAndAdministrativeExpensesAbstract" xlink:to="sprcy_CGeneralAndAdministrativeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOptionsOutstanding_lbl1" xml:lang="en-US">Number Of Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOptionsOutstanding" xlink:to="sprcy_NumberOfOptionsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IncomeStatementsLocationsAxis_lbl0" xml:lang="en-US">Income Statements Locations Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IncomeStatementsLocationsAxis" xlink:to="sprcy_IncomeStatementsLocationsAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SegmentReportingRevenueAbstract_lbl0" xml:lang="en-US">Segment Reporting Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SegmentReportingRevenueAbstract" xlink:to="sprcy_SegmentReportingRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateInvestment_lbl1" xml:lang="en-US">Aggregate Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateInvestment" xlink:to="sprcy_AggregateInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ContinuingOperationsAbstract_lbl0" xml:lang="en-US">Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ContinuingOperationsAbstract" xlink:to="sprcy_ContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1" xml:lang="en-US">Adjustments For Losses From Remeasurement Of Investment In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:to="sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl1" xml:lang="en-US">Receivables In Respect Of Downpayment On Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReceivablesInRespectOfDownpaymentOnMerger" xlink:to="sprcy_ReceivablesInRespectOfDownpaymentOnMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FFinanceExpensesAbstract_lbl0" xml:lang="en-US">FFinance Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FFinanceExpensesAbstract" xlink:to="sprcy_FFinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SEPAMember_lbl0" xml:lang="en-US">SEPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SEPAMember" xlink:to="sprcy_SEPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SciSparcMember_lbl0" xml:lang="en-US">Sci Sparc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SciSparcMember" xlink:to="sprcy_SciSparcMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl2" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAchievementOfFirstMilestone_lbl1" xml:lang="en-US">Investment Achievement Of First Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfFirstMilestone" xlink:to="sprcy_InvestmentAchievementOfFirstMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseholdImprovementsMainlyRate_lbl1" xml:lang="en-US">Leasehold Improvements Mainly Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseholdImprovementsMainlyRate" xlink:to="sprcy_LeaseholdImprovementsMainlyRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl1" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentsOfAdditionalDeferredCash_lbl1" xml:lang="en-US">Payments Of Additional Deferred Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentsOfAdditionalDeferredCash" xlink:to="sprcy_PaymentsOfAdditionalDeferredCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaseCostsValue_lbl1" xml:lang="en-US">Purchase Costs Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaseCostsValue" xlink:to="sprcy_PurchaseCostsValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AnnualInvestment_lbl1" xml:lang="en-US">Annual Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AnnualInvestment" xlink:to="sprcy_AnnualInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ResearchAndPreclinicalStudiesMember_lbl0" xml:lang="en-US">Research And Preclinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ResearchAndPreclinicalStudiesMember" xlink:to="sprcy_ResearchAndPreclinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RestrictedStockGrantPercentage_lbl1" xml:lang="en-US">Restricted Stock Grant Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RestrictedStockGrantPercentage" xlink:to="sprcy_RestrictedStockGrantPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1" xml:lang="en-US">Key Management Personnel Compensation Management Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_KeyManagementPersonnelCompensationManagementFees" xlink:to="sprcy_KeyManagementPersonnelCompensationManagementFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotionalAmount_lbl0" xml:lang="en-US">Notional amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CashConsideration_lbl1" xml:lang="en-US">Cash Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CashConsideration" xlink:to="sprcy_CashConsideration_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl0" xml:lang="en-US">Other finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 1 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingSegmentsTablesLineItems_lbl0" xml:lang="en-US">Operating Segments Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingSegmentsTablesLineItems" xlink:to="sprcy_OperatingSegmentsTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValues_lbl1" xml:lang="en-US">Aggregate Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValues" xlink:to="sprcy_AggregateValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl2" xml:lang="en-US">Investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ListedSharePrice_lbl1" xml:lang="en-US">Listed Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ListedSharePrice" xlink:to="sprcy_ListedSharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ChemistryAndFormulationsMember_lbl0" xml:lang="en-US">Chemistry And Formulations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ChemistryAndFormulationsMember" xlink:to="sprcy_ChemistryAndFormulationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl0" xml:lang="en-US">Interest From Loans To Related Parties And Deposits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:to="sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OverAllotmentMember_lbl0" xml:lang="en-US">Over Allotment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OverAllotmentMember" xlink:to="sprcy_OverAllotmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RepaidOfMonthlyInstallments_lbl1" xml:lang="en-US">Repaid Of Monthly Installments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RepaidOfMonthlyInstallments" xlink:to="sprcy_RepaidOfMonthlyInstallments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl1" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1" xml:lang="en-US">Disclosure Of Issued And Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfIssuedAndOutstandingShareCapital" xlink:to="sprcy_DisclosureOfIssuedAndOutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfMinorityInterestInSubsidiary_lbl1" xml:lang="en-US">Sale Of Minority Interest In Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfMinorityInterestInSubsidiary" xlink:to="sprcy_SaleOfMinorityInterestInSubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl0" xml:lang="en-US">Loans received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for restricted cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0" xml:lang="en-US">Reserve of exchange differences on translation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExternalRevenues_lbl1" xml:lang="en-US">External Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExternalRevenues" xlink:to="sprcy_ExternalRevenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl1" xml:lang="en-US">Volume Weighted Average Price Of Ordinary Shares Of During The Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AutoMaxMember_lbl0" xml:lang="en-US">Auto Max Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AutoMaxMember" xlink:to="sprcy_AutoMaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1" xml:lang="en-US">Description Of Accounting Policy For Consolidatedfinancialstatements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:to="sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Cost Of Sales Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:to="sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0" xml:lang="en-US">Adjustments for finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsecutiveTradingDays_lbl1" xml:lang="en-US">Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsecutiveTradingDays" xlink:to="sprcy_ConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPaid_lbl1" xml:lang="en-US">Installment Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPaid" xlink:to="sprcy_InstallmentPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl1" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0" xml:lang="en-US">Finance Expense In Respect Of Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpenseInRespectOfLeasesMember" xlink:to="sprcy_FinanceExpenseInRespectOfLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DeferredCashPayment_lbl1" xml:lang="en-US">Deferred Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DeferredCashPayment" xlink:to="sprcy_DeferredCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Current restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl0" xml:lang="en-US">Israel, New Shekels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInvestment_lbl1" xml:lang="en-US">Additional Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInvestment" xlink:to="sprcy_AdditionalInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EnterpriseValue_lbl1" xml:lang="en-US">Enterprise Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EnterpriseValue" xlink:to="sprcy_EnterpriseValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Adjustments For Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl1" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl1" xml:lang="en-US">Effect Of Potential Dilutive Ordinary Shares Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:to="sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl0" xml:lang="en-US">Non-controlling interests [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesMember_lbl0" xml:lang="en-US">Online Sales Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesMember" xlink:to="sprcy_OnlineSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasedGoodsMember_lbl0" xml:lang="en-US">Purchased Goods Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasedGoodsMember" xlink:to="sprcy_PurchasedGoodsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WagesAndRelatedExpensesMember_lbl0" xml:lang="en-US">Wages And Related Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WagesAndRelatedExpensesMember" xlink:to="sprcy_WagesAndRelatedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateLoanAmount_lbl1" xml:lang="en-US">Aggregate Loan Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateLoanAmount" xlink:to="sprcy_AggregateLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1" xml:lang="en-US">Issue Of Share Capital Net Of Issue Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssueOfShareCapitalNetOfIssueExpense" xlink:to="sprcy_IssueOfShareCapitalNetOfIssueExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ComprehensiveLossOnInvestment_lbl1" xml:lang="en-US">Comprehensive Loss On Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ComprehensiveLossOnInvestment" xlink:to="sprcy_ComprehensiveLossOnInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Exercise price of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OptionToExtendLeaseTerm_lbl1" xml:lang="en-US">Option To Extend Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OptionToExtendLeaseTerm" xlink:to="sprcy_OptionToExtendLeaseTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Categories of financial liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeOfCommonShares_lbl1" xml:lang="en-US">Exchange Of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeOfCommonShares" xlink:to="sprcy_ExchangeOfCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract2" xlink:to="sprcy_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0" xml:lang="en-US">Impairment loss recognised in other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract1" xlink:to="sprcy_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract0" xlink:to="sprcy_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateGrossProceeds" xlink:to="sprcy_AggregateGrossProceeds_lbl1"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Operating Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfOperatingSegmentsAbstract" xlink:to="sprcy_ScheduleOfOperatingSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0" xml:lang="en-US">Disclosure Of Significant Events During The Reporting Period Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:to="sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterestMember_lbl0" xml:lang="en-US">Other equity interest [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentAchievementOfSecondMilestone_lbl1" xml:lang="en-US">Investment Achievement Of Second Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentAchievementOfSecondMilestone" xlink:to="sprcy_InvestmentAchievementOfSecondMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl0" xml:lang="en-US">Gain On Sale Of Patent License Netnet Of Polyrizon Ltd Holdings Sold Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:to="sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentForPremiumPercentage_lbl1" xml:lang="en-US">Payment For Premium Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentForPremiumPercentage" xlink:to="sprcy_PaymentForPremiumPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0" xml:lang="en-US">Disclosure of transactions between related parties [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl0" xml:lang="en-US">Cash advances and loans made to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl0" xml:lang="en-US">Earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCashAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCashAbstract_lbl" xml:lang="en-US">Schedule Of Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCashAbstract" xlink:to="sprcy_ScheduleOfCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Interest paid, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Profit (loss), attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsAndExercise_lbl0" xml:lang="en-US">Warrants And Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsAndExercise" xlink:to="sprcy_WarrantsAndExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl0" xml:lang="en-US">Other cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MizaMember_lbl0" xml:lang="en-US">Miza Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MizaMember" xlink:to="sprcy_MizaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentPayment_lbl1" xml:lang="en-US">Installment Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentPayment" xlink:to="sprcy_InstallmentPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LeaseMember_lbl0" xml:lang="en-US">Lease Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LeaseMember" xlink:to="sprcy_LeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestmentsDate_lbl1" xml:lang="en-US">Investments Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestmentsDate" xlink:to="sprcy_InvestmentsDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateValueAdjusted_lbl1" xml:lang="en-US">Aggregate Value Adjusted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateValueAdjusted" xlink:to="sprcy_AggregateValueAdjusted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Schedule Of Companys Financial Instruments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:to="sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl0" xml:lang="en-US">Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl1" xml:lang="en-US">Adjustments For Increase In Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdjustmentsForIncreaseInRelatedParties" xlink:to="sprcy_AdjustmentsForIncreaseInRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_October2023FinancingRoundMember_lbl0" xml:lang="en-US">October2023 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_October2023FinancingRoundMember" xlink:to="sprcy_October2023FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsExpireDate_lbl1" xml:lang="en-US">Warrants Expire Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsExpireDate" xlink:to="sprcy_WarrantsExpireDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl0" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0" xml:lang="en-US">Financial assets at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentWarrantLiability_lbl0" xml:lang="en-US">Current warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of finance income (cost) [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl2" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_UnlabeledAbstract" xlink:to="sprcy_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0" xml:lang="en-US">Payment Of Issuance Expenses Related To Previous Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:to="sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl0" xml:lang="en-US">Tax rate effect of foreign tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SubsequentEventsMember_lbl0" xml:lang="en-US">Subsequent Events Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SubsequentEventsMember" xlink:to="sprcy_SubsequentEventsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract_lbl" xml:lang="en-US">Schedule Of Warrants Fair Value Was Calculated Using The Black Scholes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:to="sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EquityLossesFromTheInvestment_lbl1" xml:lang="en-US">Equity Losses From The Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EquityLossesFromTheInvestment" xlink:to="sprcy_EquityLossesFromTheInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfFullyDilutedCapitalStock_lbl1" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFullyDilutedCapitalStock" xlink:to="sprcy_PercentageOfFullyDilutedCapitalStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl2" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIntangibleAssets_lbl0" xml:lang="en-US">Other intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssets" xlink:to="ifrs-full_OtherIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0" xml:lang="en-US">Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalInstallment_lbl1" xml:lang="en-US">Additional Installment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalInstallment" xlink:to="sprcy_AdditionalInstallment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfWarrantsIssued_lbl1" xml:lang="en-US">Number Of Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsIssued" xlink:to="sprcy_NumberOfWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of depreciation and amortisation expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl0" xml:lang="en-US">Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareCapitalPercentage_lbl2" xml:lang="en-US">Share Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareCapitalPercentage" xlink:to="sprcy_ShareCapitalPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract0" xlink:to="sprcy_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US">Disclosue Of Cash And Cash Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:to="sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1" xml:lang="en-US">Description Of Acquisition Of ASingle Asset Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany" xlink:to="sprcy_DescriptionOfAcquisitionOfASingleAssetCompany_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostMember_lbl0" xml:lang="en-US">Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostMember" xlink:to="sprcy_CostMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl0" xml:lang="en-US">Non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialInvestment_lbl1" xml:lang="en-US">Initial Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialInvestment" xlink:to="sprcy_InitialInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DekelLicenseAgreementDescription_lbl1" xml:lang="en-US">Dekel License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DekelLicenseAgreementDescription" xlink:to="sprcy_DekelLicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1" xml:lang="en-US">Description Of Accounting Policy Foroperatingcycle Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:to="sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1" xml:lang="en-US">Disclosure Of Detailed Information About Defined Contribution Plans Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:to="sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl1" xml:lang="en-US">Consideration paid (received)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CooperationAgreementAmount_lbl1" xml:lang="en-US">Cooperation Agreement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CooperationAgreementAmount" xlink:to="sprcy_CooperationAgreementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_Governmentauthoritiescurrent_lbl1" xml:lang="en-US">Governmentauthoritiescurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_Governmentauthoritiescurrent" xlink:to="sprcy_Governmentauthoritiescurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl0" xml:lang="en-US">Option life, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingShareCapital_lbl1" xml:lang="en-US">Outstanding Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingShareCapital" xlink:to="sprcy_OutstandingShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXMember_lbl0" xml:lang="en-US">Mito Care XMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXMember" xlink:to="sprcy_MitoCareXMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostOfGoodsSoldAbstract_lbl0" xml:lang="en-US">Cost Of Goods Sold Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostOfGoodsSoldAbstract" xlink:to="sprcy_CostOfGoodsSoldAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl1" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_GrowthRatePercentage_lbl0" xml:lang="en-US">Growth Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_GrowthRatePercentage" xlink:to="sprcy_GrowthRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantsLiability_lbl1" xml:lang="en-US">Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantsLiability" xlink:to="sprcy_WarrantsLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0" xml:lang="en-US">Losses From Remeasurement Of Investment In Financial Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:to="sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesExpense_lbl1" xml:lang="en-US">Services expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl0" xml:lang="en-US">Fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfWarrantsHolds_lbl1" xml:lang="en-US">Number Of Warrants Holds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfWarrantsHolds" xlink:to="sprcy_NumberOfWarrantsHolds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RelatedPartyBalancetextBlock_lbl0" xml:lang="en-US">Related Party Balancetext Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RelatedPartyBalancetextBlock" xlink:to="sprcy_RelatedPartyBalancetextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ExchangeRateDifferencesNetMember_lbl0" xml:lang="en-US">Exchange Rate Differences Net Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ExchangeRateDifferencesNetMember" xlink:to="sprcy_ExchangeRateDifferencesNetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information To The Items Of Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnits_lbl1" xml:lang="en-US">Aggregate Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnits" xlink:to="sprcy_AggregateUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_WarrantExercisableTerm_lbl1" xml:lang="en-US">Warrant Exercisable Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_WarrantExercisableTerm" xlink:to="sprcy_WarrantExercisableTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Other Accounts Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfOtherAccountsPayableTextBlock" xlink:to="sprcy_DisclosureOfOtherAccountsPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfAggregateNetSales_lbl1" xml:lang="en-US">Percentage Of Aggregate Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfAggregateNetSales" xlink:to="sprcy_PercentageOfAggregateNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AreaOfLease_lbl1" xml:lang="en-US">Area Of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AreaOfLease" xlink:to="sprcy_AreaOfLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl2" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Other Equity Instruments Vested In Share Based Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:to="sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Revenues And Cost Of Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:to="sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Fair Value For Share Options Granted Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value For Share Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl1" xml:lang="en-US">Volume Weighted Average Price Of Ordinary Shares On The Day Prior To The Closing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FreightMember_lbl0" xml:lang="en-US">Freight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FreightMember" xlink:to="sprcy_FreightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of general information about financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OnlineSalesSegmentMember_lbl0" xml:lang="en-US">Online Sales Segment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OnlineSalesSegmentMember" xlink:to="sprcy_OnlineSalesSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BSalesAndMarketingExpensesAbstract_lbl0" xml:lang="en-US">BSales And Marketing Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BSalesAndMarketingExpensesAbstract" xlink:to="sprcy_BSalesAndMarketingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdditionalMilestoneAmount_lbl0" xml:lang="en-US">Additional Milestone Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdditionalMilestoneAmount" xlink:to="sprcy_AdditionalMilestoneAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0" xml:lang="en-US">AResearch And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AResearchAndDevelopmentExpensesAbstract" xlink:to="sprcy_AResearchAndDevelopmentExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LicenseAgreementDescription_lbl1" xml:lang="en-US">License Agreement Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseAgreementDescription" xlink:to="sprcy_LicenseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PercentageOfFinancingProceeds_lbl1" xml:lang="en-US">Percentage Of Financing Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PercentageOfFinancingProceeds" xlink:to="sprcy_PercentageOfFinancingProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Current receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ClinicalStudiesMember_lbl0" xml:lang="en-US">Clinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ClinicalStudiesMember" xlink:to="sprcy_ClinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfUnitsReceived_lbl1" xml:lang="en-US">Number Of Units Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfUnitsReceived" xlink:to="sprcy_NumberOfUnitsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl0" xml:lang="en-US">Purchase of interests in investments accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInventorieExplanatory_lbl1" xml:lang="en-US">Disclosure Of Inventorie Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInventorieExplanatory" xlink:to="sprcy_DisclosureOfInventorieExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl1" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0" xml:lang="en-US">Office Maintenance Rent And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeMaintenanceRentAndOtherExpensesMember" xlink:to="sprcy_OfficeMaintenanceRentAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1" xml:lang="en-US">Operating Loss Carryforwards Tax Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingLossCarryforwardsTaxAmount" xlink:to="sprcy_OperatingLossCarryforwardsTaxAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MergerAgreementMember_lbl0" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MergerAgreementMember" xlink:to="sprcy_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl1" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0" xml:lang="en-US">Disclosure of additional information [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfOrdinaryShares_lbl1" xml:lang="en-US">Sale Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfOrdinaryShares" xlink:to="sprcy_SaleOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CommitmentAmount_lbl1" xml:lang="en-US">Commitment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CommitmentAmount" xlink:to="sprcy_CommitmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl1" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareIssuedToAConsultants_lbl1" xml:lang="en-US">Share Issued To AConsultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareIssuedToAConsultants" xlink:to="sprcy_ShareIssuedToAConsultants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl1" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OperatingTerm_lbl0" xml:lang="en-US">Operating Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OperatingTerm" xlink:to="sprcy_OperatingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PreFundedUnitsMember_lbl0" xml:lang="en-US">Pre Funded Units Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PreFundedUnitsMember" xlink:to="sprcy_PreFundedUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentIncome_lbl0" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentIncome" xlink:to="ifrs-full_InvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateIssuedAmount_lbl1" xml:lang="en-US">Aggregate Issued Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateIssuedAmount" xlink:to="sprcy_AggregateIssuedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl0" xml:lang="en-US">Sale or issue of treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl1" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DOtherExpensesIncomeAbstract_lbl0" xml:lang="en-US">DOther Expenses Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DOtherExpensesIncomeAbstract" xlink:to="sprcy_DOtherExpensesIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConvertIntoOrdinaryShares_lbl1" xml:lang="en-US">Convert Into Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConvertIntoOrdinaryShares" xlink:to="sprcy_ConvertIntoOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FairValueOfShareOptionsGranted_lbl1" xml:lang="en-US">Fair Value Of Share Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FairValueOfShareOptionsGranted" xlink:to="sprcy_FairValueOfShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReverseSplitRatio_lbl1" xml:lang="en-US">Reverse Split Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseSplitRatio" xlink:to="sprcy_ReverseSplitRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0" xml:lang="en-US">Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:to="sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl2" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DiscountRatePercentage_lbl1" xml:lang="en-US">Discount Rate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DiscountRatePercentage" xlink:to="sprcy_DiscountRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MitoCareXBioLtdMember_lbl0" xml:lang="en-US">Mito Care XBio Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MitoCareXBioLtdMember" xlink:to="sprcy_MitoCareXBioLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl0" xml:lang="en-US">Loss From Sale Of Property And Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LossFromSaleOfPropertyAndEquipmentMember" xlink:to="sprcy_LossFromSaleOfPropertyAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AdvertisementMember_lbl0" xml:lang="en-US">Advertisement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AdvertisementMember" xlink:to="sprcy_AdvertisementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SignificantNonCashTransactionsAbstract_lbl0" xml:lang="en-US">Significant Non Cash Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SignificantNonCashTransactionsAbstract" xlink:to="sprcy_SignificantNonCashTransactionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitments_lbl0" xml:lang="en-US">Capital commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl0" xml:lang="en-US">Current trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl0" xml:lang="en-US">Issued capital, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ShareBasedPaymentMember_lbl0" xml:lang="en-US">Share Based Payment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ShareBasedPaymentMember" xlink:to="sprcy_ShareBasedPaymentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0" xml:lang="en-US">Short-term employee benefits accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BusinessDevelopmentExpensesMember_lbl0" xml:lang="en-US">Business Development Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BusinessDevelopmentExpensesMember" xlink:to="sprcy_BusinessDevelopmentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CostAbstract" xlink:to="sprcy_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIntangibleAssetsMember_lbl0" xml:lang="en-US">Other intangible assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIntangibleAssetsMember" xlink:to="ifrs-full_OtherIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="sprcy_ConsolidatedStatementsOfChangesInEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OrdinarySharesGrantedDiscountRate_lbl1" xml:lang="en-US">Ordinary Shares Granted Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OrdinarySharesGrantedDiscountRate" xlink:to="sprcy_OrdinarySharesGrantedDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation rate, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MilestonesAmount_lbl1" xml:lang="en-US">Milestones Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MilestonesAmount" xlink:to="sprcy_MilestonesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParentMember_lbl0" xml:lang="en-US">Parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl1" xml:lang="en-US">Warrants [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for investments other than investments accounted for using equity method [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl1" xml:lang="en-US">Other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0" xml:lang="en-US">Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestPercentage_lbl1" xml:lang="en-US">Interest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestPercentage" xlink:to="sprcy_InterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LicenseeIssuePrice_lbl1" xml:lang="en-US">Licensee Issue Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LicenseeIssuePrice" xlink:to="sprcy_LicenseeIssuePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl2" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EstimatedAmount_lbl0" xml:lang="en-US">Estimated Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EstimatedAmount" xlink:to="sprcy_EstimatedAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RemainingPurchaserAmount_lbl1" xml:lang="en-US">Remaining Purchaser Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RemainingPurchaserAmount" xlink:to="sprcy_RemainingPurchaserAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherRelatedPartiesMember_lbl0" xml:lang="en-US">Other related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRelatedPartiesMember" xlink:to="ifrs-full_OtherRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0" xml:lang="en-US">Issuance Expenses Related To Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpensesRelatedToWarrantsMember" xlink:to="sprcy_IssuanceExpensesRelatedToWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_EFinanceIncomeAbstract_lbl0" xml:lang="en-US">EFinance Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_EFinanceIncomeAbstract" xlink:to="sprcy_EFinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl1" xml:lang="en-US">Aggregate Number Of Outstanding Ordinary Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:to="sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl0" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0" xml:lang="en-US">Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:to="sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CurrentAsset_lbl1" xml:lang="en-US">Current Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CurrentAsset" xlink:to="sprcy_CurrentAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_lbl0" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1" xml:lang="en-US">Disclourse Of Accounts Receivables Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclourseOfAccountsReceivablesTableTextBlock" xlink:to="sprcy_DisclourseOfAccountsReceivablesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0" xml:lang="en-US">Reserve of share-based payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationMember_lbl0" xml:lang="en-US">Accumulated Depreciation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationMember" xlink:to="sprcy_AccumulatedDepreciationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0" xml:lang="en-US">Finance Expenses From Interest And Commissions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_FinanceExpensesFromInterestAndCommissionsMember" xlink:to="sprcy_FinanceExpensesFromInterestAndCommissionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInventoriesInTransit_lbl0" xml:lang="en-US">Current inventories in transit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInventoriesInTransit" xlink:to="ifrs-full_CurrentInventoriesInTransit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_TwoThousandTwentyThreePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Three Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_TwoThousandTwentyThreePlanMember" xlink:to="sprcy_TwoThousandTwentyThreePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl0" xml:lang="en-US">Borrowings, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_a2024Abstract_lbl0" xml:lang="en-US">a2024 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_a2024Abstract" xlink:to="sprcy_a2024Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_MonthlyLeaseFee_lbl1" xml:lang="en-US">Monthly Lease Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_MonthlyLeaseFee" xlink:to="sprcy_MonthlyLeaseFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DebenturesMember_lbl0" xml:lang="en-US">Debentures Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DebenturesMember" xlink:to="sprcy_DebenturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AcquiredOrdinaryShares_lbl1" xml:lang="en-US">Acquired Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AcquiredOrdinaryShares" xlink:to="sprcy_AcquiredOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePriceRate_lbl1" xml:lang="en-US">Share Price Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePriceRate" xlink:to="sprcy_SharePriceRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl0" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl0" xml:lang="en-US">Profit (loss), attributable to [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfTradePayablesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Trade Payables Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfTradePayablesExplanatory" xlink:to="sprcy_DisclosureOfTradePayablesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Of The Assets At Annual Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:to="sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of redesignated financial assets and liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl1" xml:lang="en-US">Reserve of exchange differences on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl" xml:lang="en-US">Schedule Of Cost Of Sales And Gross Profit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePercentage_lbl1" xml:lang="en-US">Purchase Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePercentage" xlink:to="sprcy_PurchasePricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl1" xml:lang="en-US">Disclosure Of Investment Financial Assets Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:to="sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_N2OFFMember_lbl0" xml:lang="en-US">N2 OFFMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_N2OFFMember" xlink:to="sprcy_N2OFFMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuedAndOutstandingSharePercentage_lbl1" xml:lang="en-US">Issued And Outstanding Share Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuedAndOutstandingSharePercentage" xlink:to="sprcy_IssuedAndOutstandingSharePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_BonusAmountReceived_lbl1" xml:lang="en-US">Bonus Amount Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_BonusAmountReceived" xlink:to="sprcy_BonusAmountReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AccumulatedDepreciationAbstract" xlink:to="sprcy_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRevenueExpense_lbl0" xml:lang="en-US">Interest income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_June2022WarrantsMember_lbl0" xml:lang="en-US">June2022 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_June2022WarrantsMember" xlink:to="sprcy_June2022WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SaleOfStockAxis_lbl0" xml:lang="en-US">Sale Of Stock Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SaleOfStockAxis" xlink:to="sprcy_SaleOfStockAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl0" xml:lang="en-US">Number of shares authorised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CreditFromOthers_lbl1" xml:lang="en-US">Credit From Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CreditFromOthers" xlink:to="sprcy_CreditFromOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryExpensesMember_lbl0" xml:lang="en-US">Regulatory Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryExpensesMember" xlink:to="sprcy_RegulatoryExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceExpireTerm_lbl1" xml:lang="en-US">Issuance Expire Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceExpireTerm" xlink:to="sprcy_IssuanceExpireTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl4" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl1" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0" xml:lang="en-US">Proceeds from contributions of non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl1" xml:lang="en-US">Descriptionof Basisofpresentationofthefinancialstatements Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:to="sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2" xml:lang="en-US">Intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_SharePricePerShare_lbl1" xml:lang="en-US">Share Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_SharePricePerShare" xlink:to="sprcy_SharePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl0" xml:lang="en-US">Proportion of ownership interest in associate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OutstandingSharesPercentage_lbl1" xml:lang="en-US">Outstanding Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OutstandingSharesPercentage" xlink:to="sprcy_OutstandingSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PrefundedWarrantsMember_lbl1" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PrefundedWarrantsMember" xlink:to="sprcy_PrefundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Non-current receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl2" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect Of Exercise Of Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:to="sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl1" xml:lang="en-US">Volume Weighted Average Price Of Ordinary Shares Of Preceding The Closing Of Trading Day</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:to="sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CapitalRatio_lbl1" xml:lang="en-US">Capital Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CapitalRatio" xlink:to="sprcy_CapitalRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DrugDevelopmentMember_lbl0" xml:lang="en-US">Drug Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DrugDevelopmentMember" xlink:to="sprcy_DrugDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ProfessionalAndDirectorsFeesMember_lbl0" xml:lang="en-US">Professional And Directors Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ProfessionalAndDirectorsFeesMember" xlink:to="sprcy_ProfessionalAndDirectorsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Depreciation Of Intangible Assets Other Than Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:to="sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Intangible Asset Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation and amortisation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_OfficeEquipmentsMember_lbl0" xml:lang="en-US">Office Equipments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_OfficeEquipmentsMember" xlink:to="sprcy_OfficeEquipmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Disposals, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AggregateUnitsPerShare_lbl1" xml:lang="en-US">Aggregate Units Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AggregateUnitsPerShare" xlink:to="sprcy_AggregateUnitsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_AmazonFeesMember_lbl0" xml:lang="en-US">Amazon Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_AmazonFeesMember" xlink:to="sprcy_AmazonFeesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Exercise Prices Of Share Options Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0" xml:lang="en-US">Key management personnel of entity or parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1" xml:lang="en-US">Rightofuse Asset Recognized With Corresponding Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:to="sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_LongTermPercentage_lbl1" xml:lang="en-US">Long Term Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_LongTermPercentage" xlink:to="sprcy_LongTermPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InterestRate_lbl1" xml:lang="en-US">Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InterestRate" xlink:to="sprcy_InterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 3 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl4" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InitialPublicOfferingMember_lbl0" xml:lang="en-US">Initial Public Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InitialPublicOfferingMember" xlink:to="sprcy_InitialPublicOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_NumberOfSharesAbstract" xlink:to="sprcy_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl2" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl1" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl0" xml:lang="en-US">Restricted share units [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ManagementFeesMember_lbl0" xml:lang="en-US">Management Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ManagementFeesMember" xlink:to="sprcy_ManagementFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ReverseShareSplitRatio_lbl1" xml:lang="en-US">Reverse Share Split Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ReverseShareSplitRatio" xlink:to="sprcy_ReverseShareSplitRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of accrued expenses and other liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0" xml:lang="en-US">Dilutive effect of all instruments on weighted average number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VolumeWeightedAveragePricePerWarrant_lbl1" xml:lang="en-US">Volume Weighted Average Price Per Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VolumeWeightedAveragePricePerWarrant" xlink:to="sprcy_VolumeWeightedAveragePricePerWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0" xml:lang="en-US">Regulatory Professional And Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_RegulatoryProfessionalAndOtherExpensesMember" xlink:to="sprcy_RegulatoryProfessionalAndOtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDebt_lbl0" xml:lang="en-US">Net debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDebt" xlink:to="ifrs-full_NetDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) other than changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_VestingPeriod_lbl1" xml:lang="en-US">Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_VestingPeriod" xlink:to="sprcy_VestingPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0" xml:lang="en-US">Communication and network equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl1" xml:lang="en-US">Issuance Of Share Capital In Respect SEPA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_IssuanceOfShareCapitalInRespectSEPA" xlink:to="sprcy_IssuanceOfShareCapitalInRespectSEPA_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_August2023FinancingRoundMember_lbl0" xml:lang="en-US">August2023 Financing Round Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_August2023FinancingRoundMember" xlink:to="sprcy_August2023FinancingRoundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl0" xml:lang="en-US">Other fee and commission expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl0" xml:lang="en-US">Transfers of research and development to entity, related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOptionsMember_lbl0" xml:lang="en-US">Share options [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0" xml:lang="en-US">Investor Relations And Business Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InvestorRelationsAndBusinessExpensesMember" xlink:to="sprcy_InvestorRelationsAndBusinessExpensesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="sprcy_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl0" xml:lang="en-US">Receivables due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchaserRemainingOwnershipPercentage_lbl1" xml:lang="en-US">Purchaser Remaining Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchaserRemainingOwnershipPercentage" xlink:to="sprcy_PurchaserRemainingOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:to="sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_JeffsBrandsMember_lbl0" xml:lang="en-US">Jeffs Brands Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_JeffsBrandsMember" xlink:to="sprcy_JeffsBrandsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl0" xml:lang="en-US">Level 2 of fair value hierarchy [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_PurchasePricePerShare" xlink:to="sprcy_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_DepreciationMember_lbl0" xml:lang="en-US">Depreciation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_DepreciationMember" xlink:to="sprcy_DepreciationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0" xml:lang="en-US">Disclosure of associates [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0" xml:lang="en-US">Categories of financial assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_InstallmentAmount_lbl1" xml:lang="en-US">Installment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_InstallmentAmount" xlink:to="sprcy_InstallmentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1" xml:lang="en-US">Companys Share Of Losses Of Company Accounted For At Equity Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:to="sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>41
<FILENAME>sprcy-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 08 20:39:31 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedBalanceSheet" roleURI="http://trpx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedIncomeStatement" roleURI="http://trpx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareholdersEquityType2or3" roleURI="http://trpx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ConsolidatedCashFlow" roleURI="http://trpx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_General" roleURI="http://trpx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPolicies" roleURI="http://trpx.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" roleURI="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Cash" roleURI="http://trpx.com/role/Cash"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Inventory" roleURI="http://trpx.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivable" roleURI="http://trpx.com/role/OtherAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVentures" roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVentures"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssets" roleURI="http://trpx.com/role/InvestmentinFinancialAssets"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Leases" roleURI="http://trpx.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNet" roleURI="http://trpx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAsset" roleURI="http://trpx.com/role/IntangibleAsset"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayables" roleURI="http://trpx.com/role/TradePayables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayable" roleURI="http://trpx.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstruments" roleURI="http://trpx.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilities" roleURI="http://trpx.com/role/EmployeeBenefitLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncome" roleURI="http://trpx.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiens" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_Equity" roleURI="http://trpx.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactions" roleURI="http://trpx.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenues" roleURI="http://trpx.com/role/RevenuesandCostofRevenues"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLoss" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShare" roleURI="http://trpx.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegments" roleURI="http://trpx.com/role/OperatingSegments"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedParties" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriod" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriod"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDate" roleURI="http://trpx.com/role/EventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AccountingPoliciesByPolicy" roleURI="http://trpx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesTables" roleURI="http://trpx.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_CashTables" roleURI="http://trpx.com/role/CashTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InventoryTables" roleURI="http://trpx.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsReceivableTables" roleURI="http://trpx.com/role/OtherAccountsReceivableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesTables" roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetTables" roleURI="http://trpx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetTables" roleURI="http://trpx.com/role/IntangibleAssetTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TradePayablesTables" roleURI="http://trpx.com/role/TradePayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OtherAccountsPayableTables" roleURI="http://trpx.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_FinancialInstrumentsTables" roleURI="http://trpx.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EmployeeBenefitLiabilitiesTables" roleURI="http://trpx.com/role/EmployeeBenefitLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityTables" roleURI="http://trpx.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsTables" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_RevenuesandCostofRevenuesTables" roleURI="http://trpx.com/role/RevenuesandCostofRevenuesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_AdditionalInformationtotheItemsofProfitorLossTables" roleURI="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LossPerShareTables" roleURI="http://trpx.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsTables" roleURI="http://trpx.com/role/OperatingSegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesTables" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" roleURI="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCashTable" roleURI="http://trpx.com/role/ScheduleofCashTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofInventoryTable" roleURI="http://trpx.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsReceivableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheInvestmentTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueoftheIntangibleAssetTable" roleURI="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTradePayablesTable" roleURI="http://trpx.com/role/ScheduleofTradePayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOtherAccountsPayableTable" roleURI="http://trpx.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFinancialAssetsandFinancialLiabilitiesTable" roleURI="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCompanysFinancialInstrumentsTable" roleURI="http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofDefinedContributionPlansTable" roleURI="http://trpx.com/role/ScheduleofDefinedContributionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofIssuedandOutstandingShareCapitalTable" roleURI="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofExpensesDuetoShareBasedCompensationTable" roleURI="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofFairValueforShareOptionsGrantedTable" roleURI="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWeightedAverageExercisePricesofShareOptionsTable" roleURI="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofRSUtransactionTable" roleURI="http://trpx.com/role/ScheduleofRSUtransactionTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofCostofSalesandGrossProfitTable" roleURI="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" roleURI="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" roleURI="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofOperatingSegmentsTable" roleURI="http://trpx.com/role/ScheduleofOperatingSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofTransactionswithRelatedPartiesTable" roleURI="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofBenefitstoKeyManagementPersonnelTable" roleURI="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" roleURI="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_GeneralDetails" roleURI="http://trpx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantAccountingPoliciesDetails" roleURI="http://trpx.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinAssociatesandJointVenturesDetails" roleURI="http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_InvestmentinFinancialAssetsDetails" roleURI="http://trpx.com/role/InvestmentinFinancialAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_LeasesDetails" roleURI="http://trpx.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_PropertyandEquipmentNetDetails" roleURI="http://trpx.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_IntangibleAssetDetails" roleURI="http://trpx.com/role/IntangibleAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TaxesonIncomeDetails" roleURI="http://trpx.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ContingentLiabilitiesCommitmentsClaimsandLiensDetails" roleURI="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EquityDetails" roleURI="http://trpx.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_ShareBasedPaymentTransactionsDetails" roleURI="http://trpx.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_OperatingSegmentsDetails" roleURI="http://trpx.com/role/OperatingSegmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_TransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_SignificantEventsduringtheReportingPeriodDetails" roleURI="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#sprcy_r_EventsAftertheReportingDateDetails" roleURI="http://trpx.com/role/EventsAftertheReportingDateDetails"/>
  <roleRef xlink:type="simple" xlink:href="sprcy-20241231.xsd#DocumentAndEntityInformation" roleURI="http://trpx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://trpx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentWarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_WarrantLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_NoncontrollingInterests" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherIncome" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_0" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ConsolidatedStatementsOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEquityInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherEquityInterestMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ParentMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_NoncontrollingInterestsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="8.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfShareCapitalNetOfIssueExpense" xlink:href="sprcy-20241231.xsd#sprcy_IssueOfShareCapitalNetOfIssueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssueOfShareCapitalNetOfIssueExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForIncreaseInRelatedParties" xlink:href="sprcy-20241231.xsd#sprcy_AdjustmentsForIncreaseInRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="AdjustmentsForIncreaseInRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalepurchaseOfPropertyAndEquipment" xlink:href="sprcy-20241231.xsd#sprcy_SalepurchaseOfPropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="SalepurchaseOfPropertyAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" xlink:href="sprcy-20241231.xsd#sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfIssuanceExpensesRelatedToPreviousPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SignificantNonCashTransactionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantNonCashTransactionsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="SignificantNonCashTransactionsAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" xlink:href="sprcy-20241231.xsd#sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="RightofuseAssetRecognizedWithCorrespondingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantNonCashTransactionsAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract" xlink:to="ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Cash" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinAssociatesandJointVentures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInvestmentFinancialAssetsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="DisclosureOfInvestmentFinancialAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/IntangibleAsset" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TradePayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAccountsPayableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfOtherAccountsPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableAbstract" xlink:to="DisclosureOfOtherAccountsPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenues" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAdditionalInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAdditionalInformationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfAdditionalInformationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OperatingSegments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriod" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EventsAftertheReportingDate" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBasisofpresentationofthefinancialstatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForoperatingcycleExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForConsolidatedfinancialstatements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAcquisitionOfASingleAssetCompany" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAcquisitionOfASingleAssetCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAcquisitionOfASingleAssetCompany" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/CashTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosueOfCashAndCashEquivalentsTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="DisclosueOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfInventorieExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfInventorieExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="DisclosureOfInventorieExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsReceivableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclourseOfAccountsReceivablesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclourseOfAccountsReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="DisclourseOfAccountsReceivablesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandJointVenturesTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesTable"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesandJointVenturesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesTablesTable" xlink:to="InvestmentinAssociatesandJointVenturesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesTablesLineItems" xlink:to="ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/IntangibleAssetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TradePayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradePayablesExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfTradePayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="DisclosureOfTradePayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_OtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EmployeeBenefitLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIssuedAndOutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfIssuedAndOutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="DisclosureOfIssuedAndOutstandingShareCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/RevenuesandCostofRevenuesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdditionalInformationAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OperatingSegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesTable"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsTablesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesTable" xlink:to="OperatingSegmentsTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsTablesLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyBalancetextBlock" xlink:href="sprcy-20241231.xsd#sprcy_RelatedPartyBalancetextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyBalancetextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract" xlink:to="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CommunicationAndNetworkEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CommunicationAndNetworkEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_CommunicationAndNetworkEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable" xlink:to="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRatePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRatePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DepreciationRatePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" xlink:href="sprcy-20241231.xsd#sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseholdImprovementsMainlyRate" xlink:href="sprcy-20241231.xsd#sprcy_LeaseholdImprovementsMainlyRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems" xlink:to="LeaseholdImprovementsMainlyRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashScheduleofCashDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_CashScheduleofCashDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAbstract" xlink:to="CashScheduleofCashDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_ILS" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashScheduleofCashDetailsTable" xlink:to="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInventoriesInTransit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInventoriesInTransit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_CurrentInventoriesInTransit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_FinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_Inventories" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsReceivableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="Governmentauthoritiescurrent" xlink:href="sprcy-20241231.xsd#sprcy_Governmentauthoritiescurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="Governmentauthoritiescurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivablesInRespectOfDownpaymentOnMerger" xlink:href="sprcy-20241231.xsd#sprcy_ReceivablesInRespectOfDownpaymentOnMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ReceivablesInRespectOfDownpaymentOnMerger" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentsDate" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentsDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="InvestmentsDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAchievementOfSecondMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfSecondMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="InvestmentAchievementOfSecondMilestone" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAchievementOfFirstMilestone" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentAchievementOfFirstMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract" xlink:to="InvestmentAchievementOfFirstMilestone" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CostMember" xlink:href="sprcy-20241231.xsd#sprcy_CostMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CostMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="AccumulatedDepreciationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeEquipmentsMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeEquipmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="OfficeEquipmentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssesMember" xlink:href="sprcy-20241231.xsd#sprcy_RightOfUseAssesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="RightOfUseAssesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract0" xlink:href="sprcy-20241231.xsd#sprcy_AccumulatedDepreciationAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheIntangibleAssetAbstract" xlink:to="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationOfIntangibleAssetsOtherThanGoodwill" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="DepreciationOfIntangibleAssetsOtherThanGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofTradePayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_NetDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_Accruals" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_OtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivablesDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentReceivablesDueFromRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditFromOthers" xlink:href="sprcy-20241231.xsd#sprcy_CreditFromOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="CreditFromOthers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysFinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable" xlink:to="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsLiability" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="WarrantsLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofDefinedContributionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDefinedContributionPlansAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfDefinedContributionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedContributionPlansAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfSharesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="NumberOfSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumberOfSharesAbstract" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedToAConsultants" xlink:href="sprcy-20241231.xsd#sprcy_ShareIssuedToAConsultants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ShareIssuedToAConsultants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalInRespectSEPA" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfShareCapitalInRespectSEPA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="IssuanceOfShareCapitalInRespectSEPA" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="ifrs-full_NumberOfSharesIssued_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesDueToShareBasedCompensationAbstract" xlink:to="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYIvd0mBgnvjBkG0luuptZVTo0nRrG0seDFa6GfGyBZFGmRX8iWVFeXa0L/vAww6wW/7SyWoUMu1ICPHNEcRHl2WslOK6k+GPH1ELcI9xyt3K1DchISeFlf0gxWybNUtM0z5SubuERPcsyFjjcRvlY0woC4Gu3fMsvVXVWKV7wODmQlScdq8DcGYwOT7maUpClVnfueBWSE6BHhwo0f0EXUnILvWj74PXyhBesuwkl8ZeR5liO5Mn8yO1XSjPE4LDzrvaXZAAsRBA==] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable" xlink:to="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueForShareOptionsGrantedAbstract" xlink:to="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="a2024Abstract" xlink:href="sprcy-20241231.xsd#sprcy_a2024Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="a2024Abstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2024Abstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofRSUtransactionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsuTransactionAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfRsuTransactionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuTransactionAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfSalesAndGrossProfitAbstract" xlink:to="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PurchasedGoodsMember" xlink:href="sprcy-20241231.xsd#sprcy_PurchasedGoodsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="PurchasedGoodsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FreightMember" xlink:href="sprcy-20241231.xsd#sprcy_FreightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="FreightMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable" xlink:to="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems" xlink:to="ifrs-full_CostOfSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsAxis" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="IncomeStatementsLocationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementsLocationsDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_IncomeStatementsLocationsDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IncomeStatementsLocationsDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndRelatedExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_WagesAndRelatedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="WagesAndRelatedExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentMember" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ShareBasedPaymentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryProfessionalAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryProfessionalAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryProfessionalAndOtherExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndPreclinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ResearchAndPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ResearchAndPreclinicalStudiesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalStudiesMember" xlink:href="sprcy-20241231.xsd#sprcy_ClinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ClinicalStudiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChemistryAndFormulationsMember" xlink:href="sprcy-20241231.xsd#sprcy_ChemistryAndFormulationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ChemistryAndFormulationsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvertisementMember" xlink:href="sprcy-20241231.xsd#sprcy_AdvertisementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AdvertisementMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmazonFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_AmazonFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="AmazonFeesMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationMember" xlink:href="sprcy-20241231.xsd#sprcy_DepreciationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="DepreciationMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StorageAndShippingMember" xlink:href="sprcy-20241231.xsd#sprcy_StorageAndShippingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="StorageAndShippingMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManagementFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ManagementFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ManagementFeesMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalAndDirectorsFeesMember" xlink:href="sprcy-20241231.xsd#sprcy_ProfessionalAndDirectorsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ProfessionalAndDirectorsFeesMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDevelopmentExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_BusinessDevelopmentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="BusinessDevelopmentExpensesMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_RegulatoryExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="RegulatoryExpensesMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeMaintenanceRentAndOtherExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_OfficeMaintenanceRentAndOtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="OfficeMaintenanceRentAndOtherExpensesMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorRelationsAndBusinessExpensesMember" xlink:href="sprcy-20241231.xsd#sprcy_InvestorRelationsAndBusinessExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InvestorRelationsAndBusinessExpensesMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossFromSaleOfPropertyAndEquipmentMember" xlink:href="sprcy-20241231.xsd#sprcy_LossFromSaleOfPropertyAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="LossFromSaleOfPropertyAndEquipmentMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" xlink:href="sprcy-20241231.xsd#sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" xlink:href="sprcy-20241231.xsd#sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestFromLoansToRelatedPartiesAndDepositsMember" xlink:href="sprcy-20241231.xsd#sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="InterestFromLoansToRelatedPartiesAndDepositsMember" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateDifferencesNetMember" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeRateDifferencesNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="ExchangeRateDifferencesNetMember" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesRelatedToWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpensesRelatedToWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="IssuanceExpensesRelatedToWarrantsMember" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" xlink:href="sprcy-20241231.xsd#sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="LossesFromRemeasurementOfInvestmentInFinancialAssetsMember" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenseInRespectOfLeasesMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpenseInRespectOfLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpenseInRespectOfLeasesMember" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesFromInterestAndCommissionsMember" xlink:href="sprcy-20241231.xsd#sprcy_FinanceExpensesFromInterestAndCommissionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementsLocationsAxis" xlink:to="FinanceExpensesFromInterestAndCommissionsMember" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable" xlink:to="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AResearchAndDevelopmentExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_AResearchAndDevelopmentExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="AResearchAndDevelopmentExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AResearchAndDevelopmentExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BSalesAndMarketingExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_BSalesAndMarketingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="BSalesAndMarketingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BSalesAndMarketingExpensesAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CGeneralAndAdministrativeExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_CGeneralAndAdministrativeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="CGeneralAndAdministrativeExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CGeneralAndAdministrativeExpensesAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DOtherExpensesIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_DOtherExpensesIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="DOtherExpensesIncomeAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DOtherExpensesIncomeAbstract" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EFinanceIncomeAbstract" xlink:href="sprcy-20241231.xsd#sprcy_EFinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="EFinanceIncomeAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EFinanceIncomeAbstract" xlink:to="ifrs-full_FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="FFinanceExpensesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_FFinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems" xlink:to="FFinanceExpensesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FFinanceExpensesAbstract" xlink:to="ifrs-full_FinanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ContinuingOperationsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract" xlink:to="ContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfPotentialDilutiveOrdinarySharesLossPerShare" xlink:href="sprcy-20241231.xsd#sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="EffectOfPotentialDilutiveOrdinarySharesLossPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContinuingOperationsAbstract" xlink:to="ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofOperatingSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingSegmentsAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrugDevelopmentMember" xlink:href="sprcy-20241231.xsd#sprcy_DrugDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="DrugDevelopmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsScheduleofOperatingSegmentsDetailsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExternalRevenues" xlink:href="sprcy-20241231.xsd#sprcy_ExternalRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ExternalRevenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" xlink:href="sprcy-20241231.xsd#sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="CompanysShareOfLossesOfCompanyAccountedForAtEquityNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLossesFromTheInvestment" xlink:href="sprcy-20241231.xsd#sprcy_EquityLossesFromTheInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="EquityLossesFromTheInvestment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_InterestRevenueExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_ProfitLoss" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_OtherLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_OtherRelatedPartiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrentAsset" xlink:href="sprcy-20241231.xsd#sprcy_CurrentAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="CurrentAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfMinorityInterestInSubsidiary" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfMinorityInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTransactionsWithRelatedPartiesAbstract" xlink:to="SaleOfMinorityInterestInSubsidiary" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationManagementFees" xlink:href="sprcy-20241231.xsd#sprcy_KeyManagementPersonnelCompensationManagementFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="KeyManagementPersonnelCompensationManagementFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:href="sprcy-20241231.xsd#sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable" xlink:to="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingTerm" xlink:href="sprcy-20241231.xsd#sprcy_OperatingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="OperatingTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinAssociatesandJointVenturesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="InvestmentinAssociatesandJointVenturesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MitoCareXBioLtdMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXBioLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXBioLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="srt_MinimumMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="srt_MaximumMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinAssociatesandJointVenturesDetailsTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InitialInvestment" xlink:href="sprcy-20241231.xsd#sprcy_InitialInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="InitialInvestment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="AdditionalInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="OutstandingSharesPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInstallment" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalInstallment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="AdditionalInstallment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPaid" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="InstallmentPaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashConsideration" xlink:href="sprcy-20241231.xsd#sprcy_CashConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="CashConsideration" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaserRemainingOwnershipPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchaserRemainingOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="PurchaserRemainingOwnershipPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingPurchaserAmount" xlink:href="sprcy-20241231.xsd#sprcy_RemainingPurchaserAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="RemainingPurchaserAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedAndOutstandingSharePercentage" xlink:href="sprcy-20241231.xsd#sprcy_IssuedAndOutstandingSharePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="IssuedAndOutstandingSharePercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/InvestmentinFinancialAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="InvestmentinFinancialAssetsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_InvestmentinFinancialAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="InvestmentinFinancialAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOrdinarySharesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="InitialPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentinFinancialAssetsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ShareCapitalPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseShareSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseShareSplitRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ReverseShareSplitRatio" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_SharePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="SharePricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LeaseMember" xlink:href="sprcy-20241231.xsd#sprcy_LeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="LeaseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AreaOfLease" xlink:href="sprcy-20241231.xsd#sprcy_AreaOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="AreaOfLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionToExtendLeaseTerm" xlink:href="sprcy-20241231.xsd#sprcy_OptionToExtendLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="OptionToExtendLeaseTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyLeaseFee" xlink:href="sprcy-20241231.xsd#sprcy_MonthlyLeaseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="MonthlyLeaseFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/IntangibleAssetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_IntangibleAssetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:to="IntangibleAssetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_OtherIntangibleAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetDetailsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsOfAdditionalDeferredCash" xlink:href="sprcy-20241231.xsd#sprcy_PaymentsOfAdditionalDeferredCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="PaymentsOfAdditionalDeferredCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseCostsValue" xlink:href="sprcy-20241231.xsd#sprcy_PurchaseCostsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="PurchaseCostsValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrowthRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_GrowthRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="GrowthRatePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermPercentage" xlink:href="sprcy-20241231.xsd#sprcy_LongTermPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="LongTermPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DiscountRatePercentage" xlink:href="sprcy-20241231.xsd#sprcy_DiscountRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="DiscountRatePercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="ifrs-full_TaxRateEffectOfForeignTaxRates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsTaxAmount" xlink:href="sprcy-20241231.xsd#sprcy_OperatingLossCarryforwardsTaxAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="OperatingLossCarryforwardsTaxAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="DekelLicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_DekelLicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="DekelLicenseAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AnnualInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="AnnualInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestoneAmount" xlink:href="sprcy-20241231.xsd#sprcy_AdditionalMilestoneAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="AdditionalMilestoneAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="InstallmentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedAmount" xlink:href="sprcy-20241231.xsd#sprcy_EstimatedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="EstimatedAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CapitalCommitmentsAbstract" xlink:to="ifrs-full_CapitalCommitments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="June2022WarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_June2022WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="June2022WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_August2023FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="August2023FinancingRoundMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="October2023FinancingRoundMember" xlink:href="sprcy-20241231.xsd#sprcy_October2023FinancingRoundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="October2023FinancingRoundMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SEPAMember" xlink:href="sprcy-20241231.xsd#sprcy_SEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SEPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedUnitsMember" xlink:href="sprcy-20241231.xsd#sprcy_PreFundedUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="PreFundedUnitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OverAllotmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OverAllotmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis" xlink:to="OverAllotmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalRatio" xlink:href="sprcy-20241231.xsd#sprcy_CapitalRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="CapitalRatio" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseSplitRatio" xlink:href="sprcy-20241231.xsd#sprcy_ReverseSplitRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ReverseSplitRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ServicesExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_GrossProfit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfAggregateShares" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceOfAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IssuanceOfAggregateShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnits" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateUnits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateUnitsPerShare" xlink:href="sprcy-20241231.xsd#sprcy_AggregateUnitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateUnitsPerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpireTerm" xlink:href="sprcy-20241231.xsd#sprcy_IssuanceExpireTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="IssuanceExpireTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsAndExercise" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsAndExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="WarrantsAndExercise" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="PurchasePricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="sprcy-20241231.xsd#sprcy_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateGrossProceeds" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentAmount" xlink:href="sprcy-20241231.xsd#sprcy_CommitmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="CommitmentAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="SaleOfOrdinaryShares" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceRate" xlink:href="sprcy-20241231.xsd#sprcy_SharePriceRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="SharePriceRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="sprcy-20241231.xsd#sprcy_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="InterestRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentPayment" xlink:href="sprcy-20241231.xsd#sprcy_InstallmentPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="InstallmentPayment" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForPremiumPercentage" xlink:href="sprcy-20241231.xsd#sprcy_PaymentForPremiumPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="PaymentForPremiumPercentage" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIssuedAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateIssuedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="AggregateIssuedAmount" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_FeeAndCommissionExpense" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/ShareBasedPaymentTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyThreePlanMember" xlink:href="sprcy-20241231.xsd#sprcy_TwoThousandTwentyThreePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="TwoThousandTwentyThreePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="sprcy-20241231.xsd#sprcy_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="DirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfShareOptionsGranted" xlink:href="sprcy-20241231.xsd#sprcy_FairValueOfShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="FairValueOfShareOptionsGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesGrantedDiscountRate" xlink:href="sprcy-20241231.xsd#sprcy_OrdinarySharesGrantedDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="OrdinarySharesGrantedDiscountRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsOutstanding" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOptionsOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertIntoOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_ConvertIntoOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ConvertIntoOrdinaryShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/OperatingSegmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentsDetailsLineItems" xlink:href="sprcy-20241231.xsd#sprcy_OperatingSegmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="OperatingSegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OnlineSalesSegmentMember" xlink:href="sprcy-20241231.xsd#sprcy_OnlineSalesSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="OnlineSalesSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsTable" xlink:to="OperatingSegmentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingSegmentsDetailsLineItems" xlink:to="ifrs-full_OtherIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="TransactionsandBalanceswithRelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="sprcy-20241231.xsd#sprcy_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="PrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfStockAxis" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="SaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfStockDomainDomain" xlink:href="sprcy-20241231.xsd#sprcy_SaleOfStockDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockAxis" xlink:to="SaleOfStockDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingMember" xlink:href="sprcy-20241231.xsd#sprcy_InitialPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockAxis" xlink:to="InitialPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JeffsBrandsMember" xlink:href="sprcy-20241231.xsd#sprcy_JeffsBrandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="JeffsBrandsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="sprcy-20241231.xsd#sprcy_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MergerAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransactionsandBalanceswithRelatedPartiesDetailsTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestPercentage" xlink:href="sprcy-20241231.xsd#sprcy_InterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="InterestPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredCashPayment" xlink:href="sprcy-20241231.xsd#sprcy_DeferredCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="DeferredCashPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ShareCapitalPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_OtherFeeAndCommissionExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAmountReceived" xlink:href="sprcy-20241231.xsd#sprcy_BonusAmountReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="BonusAmountReceived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ServicesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ServicesExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquiredOrdinaryShares" xlink:href="sprcy-20241231.xsd#sprcy_AcquiredOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AcquiredOrdinaryShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValues" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AggregateValues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateValueAdjusted" xlink:href="sprcy-20241231.xsd#sprcy_AggregateValueAdjusted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AggregateValueAdjusted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ListedSharePrice" xlink:href="sprcy-20241231.xsd#sprcy_ListedSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ListedSharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossOnInvestment" xlink:href="sprcy-20241231.xsd#sprcy_ComprehensiveLossOnInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ComprehensiveLossOnInvestment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CooperationAgreementAmount" xlink:href="sprcy-20241231.xsd#sprcy_CooperationAgreementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="CooperationAgreementAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CurrentInvestments" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfCommonShares" xlink:href="sprcy-20241231.xsd#sprcy_ExchangeOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ExchangeOfCommonShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingShareCapital" xlink:href="sprcy-20241231.xsd#sprcy_OutstandingShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="OutstandingShareCapital" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseeIssuePrice" xlink:href="sprcy-20241231.xsd#sprcy_LicenseeIssuePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="LicenseeIssuePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonesAmount" xlink:href="sprcy-20241231.xsd#sprcy_MilestonesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="MilestonesAmount" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseAgreementDescription" xlink:href="sprcy-20241231.xsd#sprcy_LicenseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="LicenseAgreementDescription" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAggregateNetSales" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfAggregateNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="PercentageOfAggregateNetSales" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfUnitsReceived" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfUnitsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="NumberOfUnitsReceived" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="PurchasePricePerShare" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsHolds" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsHolds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="NumberOfWarrantsHolds" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExpireDate" xlink:href="sprcy-20241231.xsd#sprcy_WarrantsExpireDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="WarrantsExpireDate" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumberOfOutstandingOrdinarySharesPercentage" xlink:href="sprcy-20241231.xsd#sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="AggregateNumberOfOutstandingOrdinarySharesPercentage" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SignificantEventsDuringTheReportingPeriodAbstract" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsduringtheReportingPeriodDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantEventsDuringTheReportingPeriodLineItems" xlink:href="sprcy-20241231.xsd#sprcy_SignificantEventsDuringTheReportingPeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodAbstract" xlink:to="SignificantEventsduringtheReportingPeriodDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MizaMember" xlink:href="sprcy-20241231.xsd#sprcy_MizaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MizaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsduringtheReportingPeriodDetailsTable" xlink:to="SignificantEventsDuringTheReportingPeriodLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EnterpriseValue" xlink:href="sprcy-20241231.xsd#sprcy_EnterpriseValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="EnterpriseValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_OtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ConsiderationPaidReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConsiderationPaidReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ifrs-full_ConsiderationPaidReceived" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareCapitalPercentage" xlink:href="sprcy-20241231.xsd#sprcy_ShareCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantEventsDuringTheReportingPeriodLineItems" xlink:to="ShareCapitalPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/EventsAftertheReportingDateDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="EventsAftertheReportingDateDetailsTable" xlink:href="sprcy-20241231.xsd#sprcy_EventsAftertheReportingDateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="EventsAftertheReportingDateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DebenturesMember" xlink:href="sprcy-20241231.xsd#sprcy_DebenturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="DebenturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AutoMaxMember" xlink:href="sprcy-20241231.xsd#sprcy_AutoMaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="AutoMaxMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SciSparcMember" xlink:href="sprcy-20241231.xsd#sprcy_SciSparcMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="SciSparcMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="N2OFFMember" xlink:href="sprcy-20241231.xsd#sprcy_N2OFFMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="N2OFFMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MitoCareXMember" xlink:href="sprcy-20241231.xsd#sprcy_MitoCareXMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MitoCareXMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsMember" xlink:href="sprcy-20241231.xsd#sprcy_SubsequentEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentEventsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EventsAftertheReportingDateDetailsTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_LoansReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateLoanAmount" xlink:href="sprcy-20241231.xsd#sprcy_AggregateLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="AggregateLoanAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaidOfMonthlyInstallments" xlink:href="sprcy-20241231.xsd#sprcy_RepaidOfMonthlyInstallments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="RepaidOfMonthlyInstallments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NotionalAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePercentage" xlink:href="sprcy-20241231.xsd#sprcy_PurchasePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PurchasePricePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsecutiveTradingDays" xlink:href="sprcy-20241231.xsd#sprcy_ConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ConsecutiveTradingDays" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsIssued" xlink:href="sprcy-20241231.xsd#sprcy_NumberOfWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="NumberOfWarrantsIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePricePerWarrant" xlink:href="sprcy-20241231.xsd#sprcy_VolumeWeightedAveragePricePerWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VolumeWeightedAveragePricePerWarrant" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExercisableTerm" xlink:href="sprcy-20241231.xsd#sprcy_WarrantExercisableTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="WarrantExercisableTerm" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InvestmentIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_InvestmentIncome" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateInvestment" xlink:href="sprcy-20241231.xsd#sprcy_AggregateInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="AggregateInvestment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFullyDilutedCapitalStock" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFullyDilutedCapitalStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PercentageOfFullyDilutedCapitalStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFinancingProceeds" xlink:href="sprcy-20241231.xsd#sprcy_PercentageOfFinancingProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="PercentageOfFinancingProceeds" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockGrantPercentage" xlink:href="sprcy-20241231.xsd#sprcy_RestrictedStockGrantPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="RestrictedStockGrantPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="sprcy-20241231.xsd#sprcy_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="VestingPeriod" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://trpx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="sprcy-20241231.xsd#sprcy_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>142
<FILENAME>0001213900-25-062110-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-062110-xbrl.zip
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M9(P?B,U--=Q!)'&PM^(BE>*_4E]LO1'MK;?;^V^W=\37BP/XI;W+CX\3 !(
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M9XD9F^(4^!F)I\2D8K*K7:->0E&*<G.4$JZOW0@MAS$6W(@&7DR1BP1*6!S
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M!O4FT'*4(M]H9$WD"!2/^UIF78#Q: R]>) BMT&9QT!3$5$)##-!TJ,V=5J
M06*_#"G-WB6OERJPFU5O<8.L#&R8)GC?49H#:UZ.F362H!30L*:24Q;I'W$1
M/9WVH%%)& \#_X;#0PGSK%?POHLE]GWW-UW Z[;[WIR]_CNJ(C*R]W-)XNM0
M=-#/[W.5OTX<AS N"9<JP!(W;""':>3ZSF7JH4P:*/<G[A-<_7@=@'8^B9D%
M&"ZA5!=D<NRFS9=&L"+C420OU$2O4_GF&.#*SZ^MAZ)'?.3]P.UER\6.*F&M
M6I=AT#^\3V5EM)5!)TJXR>QF<<1KHCR) 9 D*;Y&C:$KPDWX,BDK5T;EK;D*
MNSX[ND([_:[N%"PJ">?&4E\4I"695[FTL,1(HE3YSER&IC!:MEZJR;O4:LH9
M3B<_EY@S5\.Q=F0XNP)@/)IM434B"RJ$83W+RB_AY-RIG9Q/ZN1\4)?$'7)(
M3/I(TZ$P"% _*1'@2O(C=(W&'J9WP'Q_J0"@ B=202YBPV2&(#>!VY6L,B^%
M2L+ 0[6!F296+=0^7,0!F?Q>"B^KB9:O6FUI8R91"<?<X0I@]G-:.2L\WV9.
MLMW0,[#HL,QJ&\[4!^5=>B33;W@O=>?-*JS$<Q-.&HH(O \@[3 6,)@MLUUG
MO+2JX&O#\4C-4!T1"IN!)6/'+ADA>"]<WV3N&@&R4+(6O@M]-G-M( :I)X)*
M?SA2[\**+/>)*0F+85D;GL8*Y;Z&6 =N)O6(M*Y@LVI1E6L9TGVP:$F.M01%
M:NXE"$MQ,F^QPU!R_6<LSHY<_CKD=< T Z+H]F^ZGVGN;E!33,EA8+<=X=>_
M@38?8.E=Y"4KI+8(D]I"JB2^R>N&NYJ$5K*-8[Z6)*4P]A"B@1%)K6PHG9M%
M!B,7^Z^F496UZ>VCM1][$L\L3:IKZ#[RM*7>IJ;E:N+0 J!]CBWXY(=AU' >
M&4KC[])^+N7W>F0P_O?^Z_;F]N;KUNO=UZ]?/_+DZY/DV04U'>O4X_&?8A,=
MXV0M%>:M=$PCVRH=-S9)DL*D9%J9F%FJ99:%"<SEDEI-$R_A+]#_)GTY'2LK
MB4X2ID!A1& @DQ43,ZO49K5LU C2@/*=S.(?)2SI+JG :YB?M53.0)9+-3<K
M($N&NL\H_X\WV,F()043WH^_'!HUFH/_%^11S%UIV;+N,WW+CF>X=SBMS^YC
MO J%KU]4^.YSD[.LHJ7S8IYR/_,)4&L+II4@LUQRS'J #<+&)@H;#25MK#&H
MJX;?ZR!\A"07>_?0*4H_:ST+3+\W8<D?3SOGA^+TDW-X=-ZE''KQN=,3A]V+
M[OF7HY/NH>B<'(J/W>.C[A_=GKCXW+D0W<[!9PRDQ(&XLVSGN"=.OUX<\PL?
M3_^@GK*=PS^.>IV/QUUQ<=J@<8Y.Z*6/W=X%_ Q3P _PYJ>& <BAQ^!#.R23
MWD6P.F<PWQ\P!X'0^PI_:0":HG1=(EL7_'OZY4OWY% MPSR;FPH;XNJFH)].
MSW6A^I()'V8OYV2R+;8X[M86Q\>V.)8%)2_1]GJ-PJ4_G'<_P4D\.<#S?0JG
M]O (LR@ZQ\[1"9R +QW*J7AJQK4&OJB+!<F27C (HRF6*)&6D3?SC* F.#*M
M@JKKORBG,%O)E#^:/,@8L\?1<!A!R9$&F"<7#E**,1!_AJE#;M<^.2WI6WL>
M? =G&H".>"F%K5,ND:1JBKAW#QKB6O9C+Y%BX_KZNAG+0?,RO'J)3V!LC4.:
MZ'6$<1T$=HA=6K3['51;92#3GNJJ-DJS<<M5P<1EYAW'-N^(*GM+0]G-0=PA
M VG>(/*T#MCUDAM",0*UU_<H!QGCI?P;QX[.A)V,I:%&J@F3Q5S$0'C^$"T2
M$VQD$H2J]2O%]>C^EVWEG^42==+C<-;)G,"=)\S<71N^](EZ>YN^-=QC+E8%
M?:@W%-EW!H!H8#_#>96G='&Q6#*V8Y6T;7RRNCZ3]^$;#8Q9"@<P\"<<F.I:
M'66CLY.%ZS M49^J3EWJ?P#A^>L%R*<@/A^>'GS%+,<G/_MK0.*+.U>I^X&;
M8%ZC;VK$F0,<)JA#/A3]JF25AA;O=:,C?0X*GU_+XB=POYF/0M/(,8W-ATSJ
M5QYW%"7.R*2/#4\C#[VD%7414! ?>*I\ 89+P55:W@1 AR=RK)GQ@)8&J,$H
M3DF &B7]E*3V""Z'.5#A6!4Y0<J@O%KJC[-\ZD]( 6]+1\TL$-!,J+:VP3N6
M#5[;R[-* >36MD.U;A\N,^-DM;"+&3JJ],#M3!^S)1#6,V+F\4$P*70NN9YA
MYV#;'!(N_!N.?[S)W896J#$E-UE?Y2HMANB -L(^!342OT$MG)O]+FQG?Q)2
M'*1I16Y28(B85'PHW=O$&&Q0M'HP]$8T9\*M+.GCU<!T%E94672D;E&FHY)J
M29A0<B*J/FX<@R291>N6;L<2@@4%UU(9&3RAQ#FS@'$*4(/I(CTSN<+FS%R)
M46>9C:^ A3O;Y:E/=[NC .#<K)G"AZ$XR+%,]*L7.W,F!_B,B]#$>R#CHU['
MD22@ BIP:UHH%@KHU K1(HFD:W)*:']!(:?NC.$45>&@T/G0B"^<B8(7..4Q
M ;UM)M<PX<TFLHF-%GW2;KW$AMVP;2IF2<2P48G1S,_5=SWUZ0@+=3JJ#!,%
M^UCQ-(4X3#P$V+A<7+E^2KD0_$53? VHOK&F D &UBR&5V)*2AXBI4C5G/K:
MBU$N\/WL7"#9.3-1V S^@#M8VEFE_ 45EM(@"'<2II@L&EG]X!>?^P8Q?ZLN
M,>7J77I7.(WN^1G.(FXMKL\UHO3^0LN7B>G"Q&,0DE+B(U1=*^+$+%])<WGI
MEKA?]E@_O6&C05;@S)#VS'L,3X/R;^"5O^"%&$B14I[A,U8$0M7F&9]049(P
MS_48/N*DBS3PW6OL  (?3]SOS/Z(XS)4>"_8,\/(]*T]W0-Y NCOUV0_7B5\
M9@DWP5[M)O@IJB^MCUGB@MQXIY^PB/=%]^2B=\\0S?65E--_7;%Y2>>4WLO-
MK6:KO8LE-15B-K%Z*+)Y];%:\GZQ\C(E796%IK#;?A_Y0EG1WSO7@&XM"\CJ
ML08*Z,()JX;]/HL %S>9!\WP_UL%PY]7$!_CO*5:X5VP@0RO'!=K4T9W-;*^
M1W)1$U/-%-0'WXITBD'K;BSOD_P?]:15T>)" EP>K'LF'&"Y</8N(] (ALB1
MPP@8PV5_H[VUTVAOOVFT=W=?/B5QY4^4*\:@M/S]Q;]-_M_65NL.Q#B']/[O
MUVX/??0]6C3&RG1.>M\H;D9Y$[K%HF?T%/7AZ)[_WCTWF^;.98*_.@5[WI-0
M[[>QE\B:'_YJU%3SPT7\L/TP_+#W]<N7SOF?-5,CL%K/DZ<]T-;\K%10,Z-%
MS&C[89@1<*+_[E[0BL_.L0(M2EZ'1W\<'78I(-J*L*S9%;*KK9I?U?RJYE<+
M^=7.P_ K;*=(ZRVV5'SF;*D6HVJV5+.EQ6QI]V'8$HA)WSKGAYO'IZ?_C47[
M<>FF#TC-I!BL-]LUDZJ95,VD%C*IO8=A4A>?N\R8"L9V[#!2EFQ:LRUF6[LU
MVZK95LVV%K*MUP_+MFI?H,V4WM1,J69*-5-:R)3>/ 93$IW?S[M=SH:LV1.9
MR?=K_E3SIYH_+>1/^P_#GPQ#XJBK\^YQYZ)[B 54ZK"J(J_:KHWG-:^J>=5"
M7M7:>J@8A(N+[CDSJH]=M$CUOG[\<G2A&%:'BI[55JI%7*RVKM=<K.9BB[G8
M X6YFQ*1Q,:^]HY.NKV:.6GF5)NK:N94,Z?%S.F!8LX[7R].OW3^4?.F$M[T
MNO;OU;RIYDV+>=/M0] +TM&7SDGG=[).J7HK/7%XU#OXVNL=G9ZH#,'.\9^]
M(RR^+3X=G71.*&#AX/2$B__2,^?=WM=CJL\M3L^ZYQ2E7C,UQ=1J_V#-U&JF
MM@13>Z X=5O@JMG=@[.[_9K=U>RN9G>+V=T#Q;^;-B:T:&17IY\^'1U@D0?;
M;O_I]/CX]!M:^&LO9 $LH)V:A=4LK&9A"UG8 T7'JQ )6C(PJXL_Q<5YYZ37
M.2!!*]^K"1E<]Q_=@Z\71W]T<ZP.^=K!Z9>/U&H*?CCKG-25'A2'JW.G:PY7
M<[@E.-P#!=)_/>E\!852\[CS4T'5'<1!B*O IK^&<V5*:)W%.,/&]FHV5K.Q
MFHTM9&,/%'I_<GK193WSXE08GF;SL].3P^Y)CP6P(C][AB5MVJW]FE7]TCM<
MLZH[LJH'BL(_E/$@\J94]!^7C0TC,715''!CB6?#@=K;-0?ZI7>XYD!WXT#M
M!XJM)Q/4^5'O](16C<;X+'9>G!_]_KE6[+1BMUW;IVI>5?.JQ;SJ@2+HS\Z/
M0$<[ZQS3HNT<']N)6',KQ:UJ?V'-K6INM9A;/5!(_7QNI>*_:F:EF%5M,Z^9
M5<VL%C.K!RKS/I]9'823/C5E'G"G])IK*:Y51Y767*OF6HNYU@,%T1]W?U<<
M2Y6(J!D3,Z:=VE)5,Z::,2UF3+LO/G3_<=8]1R-WS3-JGE'SC)IG+.(9#Q1?
M_NUS]YQKAOYY^E4<=$XP*.E0?#D][S['H*2:7=7LJF97]\"N'BA8_//IUQ[9
MB'0[F]-/&&+YCS]1%^N>'W6.:VU,LZJZ?FC-JLK ^L6YE&%#H\U65?OX'(9R
M16".+PZ;(/@<=O^!<=P'IR>]T^.C0ZI2O##[Y%>DKD^;K4<CFIIUK#OK> Y2
MCN$?;LKL0SG-02<RI016YA)W9@]Z+Q[QX._NU">_/OG/Z.3?5E\IXF^N!I/Q
MEX^*O9R<=+DB4R=KV$*Y_&?'G1-4<'0W%RS)=(@=T+]^^?4-QQTE>-2*RZ^Z
MPS4/6@\>U+9YT$?*5D6NXZ:P<^Z/7&9&[^O9V>GYA=U8ZA=G0Q]K-E2SH9H-
M/0(;VK'9T %I5U].CCX='72XV.2S83D'-<NI64[-<AZ!Y>S9+.?0Y'*9>K@=
MX#>'W4-=Z/:"##P=1*0/$(4CX<9Q./!<S*1'MB1^::H]K/E2S9=JOO0(?.FU
MS9>Z(L&*C\<L!H%B]D?G^"O_<MXE;0P^ZS8/FQ^;6#,M3OT$EB'<8"B\X$K&
MR006&HOC9(@LJOE+$W"WE$6]2MR^+S^\'WI7'YSWK_"?]]/5 9FXT:47; *%
M GG@?JH/&"#U6>FQ>C55D]]A]MF!5X&H@NHRP#1D_VMS4WSRI#]\*\[<2_D.
MIO]G*H,![.WK=^*4BL;$;Q',GAS@+^_$'ZZ?PM<ML;FI1F/LTWCPEUYK/XR&
M,C+ ??3AE(L6$HR(0]\;YM?3:I<L:(\"31X/>R]R"-&H>"<N;J:PXN/P6D8T
MW3MQXDXDH^PD1$1X]HNO])N$(D2Z04XELB+I?M_L2]@S&'=*6V$#O%<",*+,
M1@]_K1:BCV3EY#:\N(YL.RNHMA_ZPQ4.#L$AMN809/GIL0#/04-_N<(;PD*5
MGY\TPR<$]?]^!2$1Z_(ZW#ZA]PU3V3H?3[]>4 G>WEF7/(-?NMT++#>.3]DE
MQ^^!390M0$'Y5QHGWNBF< %N->F:J\+R(X)P,99P:?I^>(WW5\SL14RC\,H;
MRMB!38#C%H.$($81G:?$OP$)_+L<"O@M)LXDW'Z8)B*!H;[(Z%)&= ^&\'L$
M<"4)#A!)WZ4K$D;"!WM3"3*\#R](_+@I+L9>K.=OB#&<<KB#&ADD80 3Q^D$
M%GH#=RR2!JD 3?$IA G%!,XL)2WZ,I$P73P%R*2:#GZPH 7@1O@.B![X"4!A
MC0=3^A*(#888 ?P*W$$4QO$F?80L9>@H2..FZ V\WM2-!B*%I<?"@VL_'KN1
M' /Y*]0!6QG",+# 83A(432 &>E)^-&+9'(#Z_1"FFWB?F=)XD8, 44Q+G$A
MA=SIJ.7)9&FJO-<YOXU=P$ELT=!_/O>3>1J(#E"%#Y,T1'NKO=,PI.8@"7?2
M)/SB_A#$!B7*G8I6U1GL7$92(JT!1:=1G+I =?#$]=@;C/4SO;0OKCW?%Q/\
M'7Y,QDJ&A2?5! W^6$\7I]&5=P4DZKAPE& X8!XWF^$UY@S':3_VAAZ>4"QO
MIZ!MBM,(A'S\E Y&;'_)T_<E;'Z<PA#9O,H@4#A-+O,9.1KA ;R23@+(Q@'C
M%)9%RP"N@4?)8 )YBQ3='X.Q&\ BS_&8FVF'P"VB"64\VUARD4-,4M^%![!N
M7Y\0S$P&7G$]Y!G6'([!-N$/>!U@EYX H@8>]@/6GL"'^,0K^#T&]I>DP#V^
MPJ8SL 4 2^<OWUYO,I& ]43Z-T[&R[-G&W-1VB"(\>G.\,J+0X)[$ :!N@MH
M]^W!X%4A?^ ">+]@[X4[Q45Z$P9B9[^YO_^;O<WYF<6 :Q["1@6(ZA1):.CY
M*8[8=V,/@ ):^@NFP D&H(RX )3\,9 L"S/,0("C-*)K9BA'M(<5F\+/EP-C
M*&O1LL3N5G.KM<2R2E;E++,J)E2UOV-875_*0*2!&WB3,(WQXD5XKA!)-[3.
M?NA&0SI/0[A&!DD8T2\@FXY5 K\G^<)#>G> WJ=P_I!CJ"N0Q@.(U7@YA,!
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M$!10['#N\AZW503._HL9[II%DSLY:L^2Q#-QEV,(2F&SSAB+OX6O^]*-*LR
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M3:98UP&#.&,4MM(9'*OF3P6;73KFX1?@!UBR,H2+/Y!\ < O07C][ ]^5EP
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M/W9:#B-8)^&'D<U5U*>=2PSN3QJW*=#C]N.$F\+1):O[IYKR](H#!6&P29
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M0R[C-)'/,=\JO(/MDO:*4JK[<(#K-,,?7PC:N(*S)MD/PP\T3TMX"3T?JC#
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M%P092N_43-B9&7+S@N^'H/W[U^MOB+;BL7K'"(6GVGDQ'"5;=8: 6X1-P^Y
M+14Y-(F7/;/PU(5>9%(7\_2'2NPJ&MT16-WQRM,<WQSPF[_$A1B8?X.]@<M
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M7$S\,>Q&F</#*N;J0PH<2K0QL0[1-BU-?3?=1R# E>3KNO2) FL&U0FK(T\
M5:?*A08YEPKA6XS*Z:'$Y)<-A953W[8+O$,-1UPU@]=H!<>,V3; /$LC)0H!
MZ+B0+HO$/!:B1\L+T5D;O=P.%@-^:Y,$MF(WDB\'6NWAMQW8NL:54^:/L<!G
M*H\U)1!#FV5*/M!C'>$PUVJIA4%JW$0^[!;4D>F>=:^UT=68.L8&^5D5Q9PM
MO9@;I'0)WX9O"_SNMQ+!G.\41LU-;]SVAW!<3*JE"<9;,:8;^?@55($@PR $
MTZ96HNYZIMJ#X#/<J6W_N#T'<2+XUT'?_'MFKI5-TI ^1==0K"!\GQ4E7O&5
MD#;RR?.GL 0*N_MBS7%#FAA,GBP3U<"T57I(6@[^'*I]>H</:EHV:!;NO2*S
M<E_6%'Y\(;JH2L^44)(9BIQY6L)+Z/DP=  CZ*@A87.[HZ(M"!9>@_[)[LXO
M&BT9GYR@N5DKYSWC!2;Z#$>\MSR1CL07J)[Y\='%SW\>^1,XT'2 P>4F !9F
MN<WS#_SG[^\8.D+S_&#3YQN\,"*TF$,;;X#,3@>/3L\D7D0F7R4S"9\?7'HB
MDU;W\0$N[:$3#K<7F@ N$(4 V 82&'C'O4\O>!S&@TJ"4]6M/T_A3C6DJXRV
M)<@9#'8P>?T+Q4Q04!:3H,^7^^WC,?P4'3Q_2?0 %<[\B4\Z^<>#Z."U_?-3
M?(F^A6U-C)>E:J\+PU@M<E)R@@A"TE5@0Q3,[:@#91P[#IGG$]VH$XW9B!NZ
MQ>[6S?D9>?16X>YK?:I0'<EQ.-+"?JY*I4$:3(!]$N<F"B,A7HRZKKNG'/DX
MZKV;S*]);(+.W73DW*KZ7KJ2VR@TMQ&E?-^I&35P"/9W66/)9:1_'\KO7Z^_
MCMI:SBHY(X'>/<*+X6CT*F@/ 5<6@P"Z [7T\= D7O;,PM--1XYN"N;I#Y78
M5>Q35*]<-44#F<]Y2XS!%9SYWV!OX.:A^7H+2DM/JPT'!U=70DY!5^F]?![M
M'^P;K1:UF':?_!&TXMZ+G8W5WM%=4GLWKO?NJ=^P;>Q=S&X3>;#QAD!"#/T>
M@JWFZ(5_AQ<''Z[H9;VUV[8^]>4(D!@"2.SN/$"$Q"4.VZ47W9EN&Z7Q%P>\
M\%S "[T3O"%<Q=>/Q_\G^'!X].WSU^/NA&]2\;;#1;<YDV]]5Y=&\,WCF2:]
MC35UDLK/TK+(K=<]0ZXQXJA=EBI)J?T66R2(J\_/B@R[QB#[)#5'@:]1?7\$
M ^9T>_I&&7>EH.",E-),@H]>3RN.QE)\T$T:X:>9;_OB! PUO=#M-PS1@*4C
MH&(AS;?&= 0&CP<+ _=ZR#*/L::4C(53^)TNZZ&.&MU2P$GX7_:IU"&E2X3
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MS^+S:A)^Q+*\RT7=";2_XA@8 ?))R\"C]:6,)/4]#XV&_)*?613KSV I]%
M_A9<E?N;>4<#JJ_]]9AF'S7KW=6LVQ8F=7JB]#2/"M<VCUI'8[B=8L?"3$0'
M"??ANFY3HYTS2N,]D,9/0@F@/?=-_T>!B@72Z3I]]?J)0KWK'-L(V9:3;O-R
M- 2F:NMYA,MFFJ4SHQTP\%'599RNEWLT/XJF) \,SCD<D![@[78SJ;&(6^,%
MG$BNDQV!SV#7=>DL0E0,V"(SG:<(2Z0FZ@MJQKB]IW2U?<T[T3(_6L>JHMUH
M9)-JQ-=C->)@->+>6(UXTR1!O3:U;C*S@16-%5.@?&ZC>=75TA^\M:W+AMJ+
MV"ZLFMPBP4%TFS<58IB(JAYB\3/Q#RJE5DAK>R04W92R\^?^MB;!E;<UZ;0T
MN14>BELAP>COWG7(W>HL61#%[XMYX#9UYT[(3J]>WCF;.S#]!*G8IN3S(I)&
M/"0,$.0MB,.\H6;$3NU,V^R.\ M3%1#Z9Z'[#/:1$O@'>?+8N[%]LSS4AQJA
M1=Y4@()$MES"#;TI+(QC+21913W$"XQ27;P_+%V]1-GZ*)C>@\[6UT6 >XA-
MH7$*.E(E0MFFIA]ZN-/[/%M%[E<]==!M"6D&"K1SQYW6ETU9-;%=!=,W MZ$
M 7#:Q>Q[SN :2;-RDBB7'SPK$ R+FI9C<&?T'<O9J=NC;_U F:3F$-4]&VV/
MQAO2<G= #OZ1ZX::OH((L-%ED\6VPVBK9XF1F@A\GX5*4FYU[O<7UXJQ]T;3
M@O"$6WF"I.1FRR0C&PA%) R,GZZ<8(,,^=2DB0^3L[1">2T=*A3D?#O/6^W8
MG[^>O'[]2V])HM]!N[>@V9O[Q0\[V)GL[&[R,'260F*,?49L]N@%Q16<S"=.
MT%RN]T#]$,K;ZNFC5^6>@_;LNU)@WM=EP\TTNP9<P,ZVVYC#'MI9G,TD!_ K
M_<FJ>%^CM"_Y:JO]"YW]"S@^1Z5X\$8[.[M1"))7IPC1E=\^?_G\-2GP/'0^
MW9V?:4+4F5Z$CQ3,1().'VAQ_9<,*]36#-;2GJ?@X^#C]6*\ 1>4[KF(;(]\
MQ<;O.KW@FU%1J.U8QU+J6>$G+5&/PFE3ASW:XVG$=Q(.:SN0;BKV47#9K=S\
ME2?7UIIT$\'9:WNTMVF%#5DS0<=,R)/(;:O#%LU%GLU@DQ)M:PT8-?9^"Y#6
M>*I ]@R4 <^D3T6NO:BN47D.WU8_U*S1+<@Y2(>91'#:L'=O8BB]7(IR_3 <
MNRR:D]/ MUD,$9FTSG7<-=_N:Y8V[M_[>1."1#./O(8+#*A EJIO;3T[T^N>
MM-Y&UN:PF)IKGH!G #O%F#8R[IZSI0CCP/HCE(L4 ZLXUA%<6Q56\4+)0!O;
MTY[=:)<OZ-_KZ (S$V?2^83J;RK7P\@ UOVQVUJ1782 3S9=;F0;QP2\536U
MCQ9HCH-0 X%:%'":28EBLMMZ&ATEV1.9@"<M1:OIG#8NDTEA!PAZES?&-+??
MLUY;E$Z_Y\HT@7;WP5F*-P@@3BN\HL]4I%/V1<F]!AA<G,#]DQ5+BJ2_$3+R
M+.!=QG=/0"7)%TS!N\FNPS?<U78ZI7 Q#:IS3U'@-N+JG:<$(;"?<8Z14QO^
M)F!AIR,7XWI5)N2/HV;I=Y6EIT61='2*#1X( >$D=$-5:S1AUT,+-C[T ]Y9
M6MEY##3;-?&Q[WEQCJO@D,":@$7@CM^R/'I)3(:\O5YUT(EKD3+L*,) *\[C
M=)%F<8EJTRS(]N\4]KS3,;?.@&GR:_21K0WJT767',9_PF6<KM>9-CV[(#I<
M1],/>OT7W8R<1RJMMF[/=LB"-/TN*<>%%A2IG81[R>,?&GA2$EC&;MTJ0)[P
M>U/4&E;L4.ITSZ[;F+.;L-8;AI/8K*7\^2G9DCBSLZ*6 !%UTD0/SCV(!GG(
M+73C#/%+N2$9B\)*L3Q5TBG)Q('P..SMO"$02TEZ+OR"46/2]I]X ;Z@V 8?
MD0]Y00LA]B1]=_<-+"S88_1>,#)F/\)7>Q<[BK<8P;^.1W_4,?#A'L;!3_<P
M?MR^]S?11[1VCCXU:_ZIOV^TAP.T;B>&_,@--[=QU,+Z&V%S'-#>L%)D/AK
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M*.10)/X"X_OP@I'UYK)BQMG"19,3'"PS#._8$)[':' 4#.W4*?R,6>8MZQ#
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MP'SY_4RLV0Y(\J=[@:/G$RQ/5Q4<7WC*[+0@;G_WFR=-FB@DY:\<W:/9Z@P
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MEC3I"B.#0.JT!7LJ;N]]:LU_GFO-IVK-+Y[-M>:GQE#C$AWWCWH5R[7)RYU
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MY7B*RT;.#";EN3/D^/EU<CS"!,O,#5+%R61EMW-FGYXL5VW0 $4(N<-/#[#
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M=O<%/3ANIW() ;9HQYX-%-I>YTOGHYN;R5,IS!?0""%T<9!= UY([0=;R/P
M_.T S&.I\ DTCRN=\O8I/I1B7*:WZ2WICE%;7A2\\;C>E]$L@EEWP]T9VV+M
M1Q^>'DAA-LG(,\"5I^6J%I!:9"PJ_>&L[3C8/%D2\ 3!4]50SOOC1AOD\*7G
M*]M/D?L;1",(\RQ^ZTE]^0<6VO/RNY!:"@V$>?#J@\WE>3)WKH4BCX%&.->*
M:JL6:Y*,XR;MA)]$9'OQC#:=[19^P.M:A450L?9]?NYUZ7F9P;K$&^KBQQ0W
MGG-Z4!..?&M7TBN*.JSVB45)BD/16#J6P=QE>*%I?P8!%TMA:Z:12TLK<8/I
MF9O2O[O>G='#T61G8J9UCY^PU-@\VF#(-=4(#5Y3'!X6,8,LVD'PX="M^(8K
M@/3LKT,)3HO 2K]_$0MR\KD+_CP[:XB$R?')V]+)?,04\)?_]5KN%JY3<3';
M;=;,%:.3'D;+^:8,UH*"EPJNY,G=7>'J?YISIXED8*EY+],SQI="5C&*P3R[
MM2H6AP)'5-B8[B(('B!*FKAE>+6#Z(1XR'09<;EXNNSHVBLU9A(@N-?O<E)+
M=M2X8HU73"KHXWO=5XA<C5J6ZI"S4\4&^RPX9VXR-X:F*D\B,1*T@?:::0X@
ME9<*V71'JW!+SU>6ELUE4T2O<I(%8I!GNJ5VO5QH;9=W,/V!K& GD'EQ8?+4
M+\D"LWNXZAQ1>W+9G8IMFGN^AC4"TL+4JQ*5"UWYS%;^U*HD2Q%7R+1B8A_'
M9:$WJ=2=75@50DBSK=W01<O4OM*[2DB8FP9' ?CWNN#> DAY6.%[?/AP+1G:
M^([7&;IS7$S3UA1W0K2P-K&?$2IVSD0L3^W*20;[Z&^2!=<N9Q'0.68C))]5
MGGKZBQWVEVN5D(EJ&BG9Z:JT](_M)E\Y7^D$;J'<L$9!,Y?2/Y*$8M(4H"PW
MM >T([FGW^OAG%!;"!Y)6!ZS):-SXS9K]E!;C?IQZ%]W]IEM)'Y.LPUXI5.0
MCVFCG4E1.(\[]:05"T),1IK0G+H(D(CG:]E9 ^U#R*NI%UAF'BXEAV!77+LH
M,[TS/5A%  .L %7D+1Q;<[P$7=,J)1'S*6!Y.>'1[[$F3N."Q35RET9"PB?X
MORK19@_6WFJ,E&PR.5/L9W$VLR OH1*1*D]$D0]DH29"GD!8DYUX(I/D*15&
M'K1&-!TDH*;A1 @7GX)ATQGVV;()<<G 4)&-ZBBCK,Q3,4GW*>_^:2[OGBSO
M_G4N[SZQ\BYY2K?$D\L!--7?/FF@9!6=T(5[0C;6PKB W(GWP]0-?$39,Q"&
M3A"XA0S%=//W!/]0;N2^'D>J&N)5<9.AV5BOMN5 !R]H.$KYX125T 1 Y^YB
MZ&36.@N"JHEU_3FIXWXQ7EY"BI25&TN%H&VOKIQ8IM_;H!!BP\E5%\9"\1Z(
M\,?TLP*<<L@Z1&:;$G&^I"8DG:)9DHPL:+46]X&[(,A?H:W%5_D$NGI3"K69
M+X#$!O6-R#%*A"'Y@:D,28":!:+/,"M9:+78*+1B. ^^<R9-;":;/V!&AOFG
M/(3'/BQ2,!D*#VVV*]\74G",[Y9KU6F*#&8$Q-#^ AM8Q&(\SEWYF$\,\L><
MVD#\H<5 M'][1#^9X+Y)$8NR!O'C;/9#$=(@EY9D'14.O:%G&G50[H':0/MB
MH@;VM!KHJ23+0+2TU XCJ0#[6XR+11YEF[(W^3)WR<QZED4!XT4!6\()@+H)
MT-J]./SV0RB [XI!8CH7V5B?+W 6@6<V!;AFHQ:. &L=B-3N^/[T%5> ,>>2
MZ+U*HJ&E.&T+\_%1 +E)7T2[S16"0SMH#2:4INA"[=H LP*/D,J^(@C040*/
MJ>C08B@M)RIER9_?9X;4&CT_,,W2D<$1.322']3*/^^"N8OTX\?VJ7!?9,-Z
M\Q062^& UB*:X+*F2I 1>-[S,<\%1,B]9-A+PW7NMISAW+O$++/!*&:DYBJ2
M_=*!==@Y4T!_N:WH?:YPC_)0N:Z24E)"AWHM5@*5A]A!06,59?K@L"\C !
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M"TMG,)P6\D.T*ENL!YN,+8_$)@S1+9MDFKF)*[R$V*OC*5:9$Y16/U,7QR^
MI^3ET%O-IE;X=5I+?JT7QLMP8<PD)O<;E7"*:.]P5@/4T%=EH$+ )7D7_9_@
M@_:,@V^D&2O<NI?"!=!*&UR.J )X?NEV,M#GB/E_&;@& G(1+%D]_7LSNV@_
M&.H<?'9:S>\=W>)EK;7C".P]%/6!0K& Z(5;+5P<9#UQC2V-DPQW[U:R%T7G
MOQT;;NU+"48XB\$7_(^JV)"S((11=%5VB ^#;W/GCI1K$;?-HIY(BF!;;I0;
MGN9Q'^"4;,+M+QQ1]YK6 P J'E&^N,[Y=CL*A 38;0^WPPQ$_@SR%#E=*0R=
M?7-='-L8US,.F.R<I+1HO5R#*LZD\POUYI$LK:3/<-5S/3Q$[DLDIGS@JQ3@
M/"A[,_0DLF>R*J2!H$ ,O2KB36^K)!A3MQMDL/)H>J=*^FXQFEU]8P; &FLE
MT4:7(H.E'*@[/@>+&O;$V%W'\F=(,BX*\%0"^C>$TQNY 7IQ@:,P)O-N>OQ"
M-9?LKSW[I?PB!B8?$,5G$H[J1F5KM5XWC! #H8JNXJ$^&*87Q"V.JN5N0ZKV
MT&"V@I((?;8T2!0";%8>?BBJ-;9'LHCJ8:I/2ON781@E=ZQP=M&O&0WG*A<P
M);TU#<,"=G&=AE;\CL;;7VH!],]S ?14 ?239W,!=*( ^O,XB+]Y-$YG,-H;
M,E=MQM6C2OMJ$&]9P2\_E.L8M\*JZ65FZ.I1;G 0'@L'J0:+035GS#\G$'5&
M%@72:\VM+"5-3;:-,YOKD+>6.*^$]Y)K&.PB%;.,*"=-V<5354['#Y"!:?@V
MQH2I%/[L&_\0E-ME6;M$"4#TZ;5*#^N9;56C'J[JR,I8JL#WR>W!<IL^  Q1
M%3))Z8_%?\A$5DXQ_.4UFA\J8=X.:&:7F;NBK_W3;E9L2JZ,5%?Y5>PH2=Q(
MWXL=2RPI[$OW?S;%0S*Y[1[CDC[V[;8IFY9^^:N79Q*KI'N%DU\'+EF0,[!V
M E6N>EOE@M'_F@(2VD>+W[JXH\+M&V4_?L?*44%P1MH&<MUV3!D*UN#OJI+[
MG-,$2RLXC\6F%V"(MCF'QH-OK!'E)1O)9O&JH@GI>J9(?E4MGO_U+W]<AA%2
MM%(@E$*W0F!P9CQ(<&K1C+3:%OM:#//QK-$,4<4%AAR;^+HF)QD='^_J-0-0
M[1=*XT*3 5Y<7OZC+(0P<O&VK%;6V9OVLH1O6\)4GK',%'&>3HBTOI3(D=/R
M:3J0<0,:+NH<6T;<X([@>RD90<BF(#^0<RRMX%Z=)62QT6EN[Y*Q4/8_7NK2
M++0QY.)]33&8D&%^7:SSQ<6GX9B^+%K: MWBM_SD75T5O^,=U1XK>B-NQD)0
M*]4'&@&]AL94^*L/\K4/Y;[>M?@B14L[[DVN^.^YH4Q Z8E8#Z]C)6_7'AH&
M6B0599W:RZ+M)C.WG BF7<C"%7NN>QQV1;2+BW W:WH^4]L6AN0[S>AS>8#7
M'_JF[0<2G DYD33$3%;$00B:,XQUN?CROX<G8_'ZOUXN.5S_\K_CG<\+UMH\
M\M21+YI+$5_'6M7E6J9IWZ_J-H["17:<7#CD;0>!T862185I:5>[HJG;$G@
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M'N(4>EGQQ:V "843'1?DRK# [(I]A*;25%*&Z8%;L8EGU.:D0M)<4$ R%:R
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M/QE6?DV'I0XP5>8S"MZE#K4]B8N4;@:IUI%-L\LA#6*S)(AU>1O%^>@*ATO
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MW7<AK1COB>O:1'#8MWZUM;MRQ(MQFN[&@W "GYUQ K,X@2_/.(%?#2=PIPU
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MA;NF//3R:-FZ%&-(>57BR+-#SW$7YM:I6$3&)+AL.\_8B8U8#KLJCN Z+(7
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M_6LWCK<2=3D/5T!0Y)+9B:149I;G;^'G"$L(#S3QQ!LH6P%0E=Z&6R$N,F/
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M75I[""'9%(4(X)0+'P@GN(KZT"L3PG79@TK!3Q>3(S)F16_/4( &'AA%3D%
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M;D+K)*#%>)?HA4JILXB A$FN$[V7GU1D02N9CDE]AHAC7A>EO*3RSZ>YQ<Y
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M#49.0;/,MY"(P9KZ.K7EG%M!W[P5U.E[,<=$\E[0?EY>5DO3M9W'%A_;5?3
M<RHB.=V@5\>"^78'*E&RAQ)N%([(V'J5'C%(W<BQW\FI*J1P$CGZWQU,A@>+
M<X5"(+-/^."SZ+5/!S[".LF(W?6,Q%=!,MF7_EF9W(#SD'IWH^B;_>.J1*SA
M1PU/X1YWJOH(9A\TFT$$-K1=I_Z==X6:DL.(@'Y0H+ZSDWJ;(XMDQ0PS 3D<
MY(2(>,I(D.'X,[KH_6%TH8WKJKB6BR@!6(1IB*_'D1&>@[U6E9&+69/TJLV0
M6XQKR]YY)DX^Q%XQ?N4O]?HM?JR62,>WO2QC*Z@JO<-Y1A%T>RB3EF1(Y91=
MR&!.*XTBK\S]]6U3/L+$1K8-']2V' 'VNZFWRVT*/0/EB;N"*![NY7Z'-2 <
M'Y&R@1QPNN>JI"Y@J<ER!OY1DH&OD@93W14:79>R>R,5)&U0(2Q!&$Q>-QT1
MS"_ 9T9HA?3/ 1RCN/GDB3:,LE+:SL22&) 3F93>>,ZAB=&B)46$^0!<3U$?
MJ!'V1O;L?3:K[GT?DCU:4\E<&$)LG(],_XN^*[ROCM@ML$!*T6K&4MU_( 2_
M(!5UKK]07RR),6W04'G/F(#DJX-TN3/%!<8>^<=@8E7AYM%5-7QTJV;/;Y'7
MO/]?>HTT&[;%.F7/,BR^-/X8?(6&S;E3[Z$A5Z5WGR0J# 0H;I+H) ?X-UO[
MTX5?;0S\0YSZJQ7MW\OFLEBL(O:V.]LR26[B1&,,]02K[PB#C0.UWFM*+:XU
ME(7/CND;.J9#7Y"-*P,Z.0W&'.1*'#IX.\5Z5W)>ZIZF. ]85L7EY@Y9(,J1
MY )1VR&[<@FI.JFPW'5@?H%Q8F980)5BY6@AVHLXL_86TO1^#39::N7OF*>6
M+E+%,RYT6\H1FUJ1=]=R>^(-P 0X*[]A)I&2Q_I#9 2QR+>_)11]IV0/9ZWT
M.Q[7@ '#12:Z& ,1$A*I0^#WRTMR#N&V<B*ZC%T]X2U9RI;(1C'[IB*^(AB=
M] ._9%_N;]V.OVA< K=_:N'VTE6UROY1UO6>7I@_93_YXNE7.36?6-[F10>D
M,$)U0M$00'6S?<3(E<#>* OAV:;X-S!F9(6WM7^1[TON^(3&-B(^,.$[A3T:
MZO,Y1N%25R%12S6BL!,GR6 XJ;($/GPBL3+J5Y@R"BZ(0.)@I!;/<*]K!4X1
M7:DU))H5H-!7,8TJ$".M:G3T&JI$-3E:54UO1)A>Q_$M%M_(5S1I YX^K$][
MC3S$'I2O7A;H$^P/3>E?IT1V-';Q)4*GA(]Z%@BC AV>>Y%0*\Y$%A.AA/#=
MA(@CA$V:(*+@91#&4'!M["D%>4ST.33=P63S[(9]SJ 5SMVI Y;R;'&;C)G
ME;\TYX\!I;ZJD-H9)&?\4K[)'=).G$\(')A#;DQA,'M='D1VHBGKG"BIQD1&
M^.QF6U1\NSB'D;?A79_S#ZI"?7*N0LU6H3X_5Z'>/8?(N^\.N$/E*QQVKKU+
M7$!)86".QUZ*6OMUQ=U.A*>:^91B-4+'Y/!3N1O_+K:EJ4)-U&D,Z?%]S["^
MN[#)GXJQ.R&WR7JR[#<%[Q1<FH0LIEQ&2\2!H(B;7PJPN2(]PZNB1"]?A24T
MO3B8CE&K4N%K+GP:@<[SKY_EV:9=E37J"KB1DJYH,YH0.\ZL+PP0EXE!'#6#
M#,D:#<6@<I<[5B0UZVU0_NG+L$(OLE>4'@FTYZ.O2@:DJ!E\2^4,Z1[VGN2Q
M+=!Z;\6?]LNNY(J*D="1O<44X9%?MM\)_TMH*38#S=-MB>;+9DD4Z#R#B[V?
M8X7FJQP<S9+C0E'4HF5\(F.:;-4[R2SR Z=N"MYGI%LV5?)0_C$OFEZ3PF;A
M\CG41=#.HL6O>;6<[&]M\VCP)/9=)^^(:V3R!LGMCT3I#-K:$ (-=VA*I\IG
M8=\$IW<S6'[]OH<L!CMWUG & U=6R!8.Y(-N)9YV(__/3$.J3W0.+1^2$X@]
MS&@2B''!#6J&:!8:+B^#3^2-';G?PN)J_:>9-5=T5'QLV2[!^\,7N:[ V0IB
M5+\M-G[W+PT'[D\2GHGEP(7!8[OB?"#MZZ:5BW-':8,ZV2:/@1/QVM;%(;9J
M!A6"8D%!1F73%$X2T+#+(3"-W^$NO*WRJ&)[LY9EGFVO.B)[#BI<-"%/'W_U
M@]_]_U/Z7?Z/$G(6?VW](OZO_69SR+XNBR[[L?17]E][MMWZQ]_!*#Y]\A4W
M]\8Z*W7M5HPJI5/"1Z;%"@J(]([$8B%%JHV"R;CW@!YSN8_83P_#46*$<50]
MGNV9^PNHZ _97ZMUB:4JH[O(ON5S*: W>G3\F^D!'[!T"(76''F3FN;7_K[D
ME="6+FNH&_@[M*]=7UX#=7M3EJ^9V$W@2@4L9U=>R>V!+P@T.$1\DZY,6DO6
MN%O=0:! ;KQ)MJ_=/(\+<\PY%H7J1H,HS^9?S$8:X(EBI6<-UWY+Z'(_^L-6
M=&%V!6@,].%6A!,F;"M>]T7VP]I/JA*'A^][>UQ=2KLRRQCN?;#"F*!#3YJ'
M>4;18&P-*T"+8*BGEY!R+$LT95"R*/ U@+-OSQ(5/[594UQ7E\RXS-VF(/[W
M'Z?=3<=>\&J1;U(UF;*Y+"YY*5)O7;^+[D?$VA<K,E;R$IY%R$,.K&TX;."@
M>6?)6*2RDS-*AM\7WG68/922A24#W&]A/G)P,_%#<3?4MFC 13E<;@K<D=S,
MOE=6-'_KD.8,0R3"P!V$/VDS=@5U@?,;7Y7B@JPY%78E%!O>K:J0J],D6G1H
M+ LR4RKJFT4G^@#\$/-^WG]H0R.0FBB<EP-;SA<FPD!F:*?^H)55GTDU<R^R
MO[0WI0IU!HC#@,!;&60PQMX)8H2 W%5?JL%5 1SK"A"M(1@C@Z#+)MUC]OUB
M$F_S.?*8+1.&:25%3!R*!#K'8C.GD$@ZY;+^FT3;*ND<21)VY?(*)Y/&%6+.
MCNI'6I$D8KNG=4IGJ#=FG'?5U"6IKHBJ%M._L:] B)!BR\V X?Z$<T\Z!9C9
MA//2A+VA]+)ZKF>-M[<.,3 9_+[=DI0:27>CE?/VY9+'OQR2902C379WE!+P
M=G[15RI XH_U/LH_.3$C_E#UMZ*1],.T4$0.!CC?-;J9R9KN&\B.ARSZRKM?
ME6I'X>!+PQ=DS%GJ_-\D,;'T?Q+G&.S[N'!:D:&3W"0+P.@&I5?2N66>Q4O"
M]S&*2V:#E_3:^ZL"PL#6:*D#)4,O#0XJLI3-'K5"UOWH]WY.'I7-%?K]7;2Q
MZ[*(@O'K?;-D4RI\KF-26LGA4Q^K'&?>,@0%!:42NE1%^>-#/\=\;UY.%"$%
M57="3<=LQ$%=A]((SRY>7)![7D^]$IO F=TY67"4V 6H2]9;Z',J7&W*DEBI
MMM6*6KJD)\G4,L40LV(,A802+WH'JKM$=8 JA)27:9!'"7=CG(YX\TE.Q^;;
M^)APPE?+E T0DHGVY2*%<0ME>2RX(8:L=H%RFB;6%#.Y:XV%<7!JM9W$L"NB
MR$*X%HT<*W7I21A\=LH]+3N**#<$[/0VPDQ1>.+0D!T1MZ/,4G*PQJ*:OR&L
M+GP_OT#31LI*C_*"[$44H%[6[9X!Q=R<*!WK](""Q*Q[(=BJ"(#?D_EDZHPP
M%Z:E'MI&Y/@QV]^N=<2>W7G3]FA--"'6Z".[-H?/MCJ-0Y7%I/RIU@:*V.QN
M6NIK^;-CN14XJYRIF'5C_*3X!;=\71\8^MSOTI?8#XDZZNHU@9SOY[BX6QT7
M+B;<3QCPGM5KY24Z.]"_G /M(]@B\D"@TY^8DP*- UJ&6P9:)0$6X40D_(JG
MM!ZRSEB,<<H[+D#Z_DW7\L9&H-9VD\7ZLS_\YO[P'FFC\'H/WBM>[VX*-@H!
MPJ\H5W,LWM")H78SX2?QYC$]T!.4"+=O5WV\D7@";NP)2)L%.YI2HJ*U:1T
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M,/'VK-=SI%GC+CWGF <J!>VNDFS:.9?RL+%]'TM/+BXQ/>'&B\P?\20UMH1
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M0-?=,NOKZF-8/^WFBEJGJ4#) ZSH?(JR+T0@CX^A"$\%3?G\35>1=5^OA]^
MZH3Y%MQ=E6;KT2Q]_/Q+)1*+&F@":<7CCG13=^?7[-92\@C3NSB80PFK2FNN
MTP)#<?;Z*Z++O>19TE_B:<$B8+SZ5!7A-#?P*1N7%VN7BG\,MTU0+-2W+YL:
MBY&]+_@M-67<=U?Q\U=EO3VRNX3HCSQ5<@6=9<T+;SK^W: 1802/K]ZAW,74
M@3;%)^225<A:@@"PQ/6H?'AWUPT\>BHNPNHX'5_C-#V@!V2WAK%P3 E %O!
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MU,&7^[KH0C;9$($W=,JUS#VY[_=8W5IJX]-NL'LT/VK;7+E0MM@?I(S&F$\
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MG\G*W@#Q?HG\^PIT A#7C@^%B_G)8F8KICN(A4,7]_*:F"B(($4W,.L<\ON
MV5;[,-,%./5^9)WQ"TI?RZF<<J=Y]LZ@0D(S['CV[]X,U4-%A%IB#!3@?!B_
M)2E >[R$F2;!"\C!A!V];LD/#QN%SJ)$I@@MKZMI)NGQRU\A^0;T]!55D$FV
M'O=FB&L BZB8D3UUES4 _XP][/N1 8Z?'0$\UE77[\(S]*CK<H^O4VG:X8/*
M*4ZEHJK=]]FA+#H.;$T$4$TEA9?:RRN2K2&>4Y= RGKQIDYOFG"@!$K4E/M$
M/JL<?TU#MG#"Z4FZ]]&C4?L%56;-?K/@YXMQIJ)BY] NHVP%3"C.4%T -%_4
M#K92M2P]X_4],WZ'@O4D95D8^BL+#T3LIH6Z2K2APC?)L^?9Y;KHR@ [V-E
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MME0Q#00:?_CDXJEW7'Q<0[7R4(1V]DS!O@V#.+YEL5O-N("OYFMAO[(PDKU
M/K\AW9ML2$1Y,0'ZT)TV.A??F7]SOQ/D)$=U>LVXUH-U4ZMK4*PB)FOOYOLC
M55ABA!"&<AN3/2GSV8X"F>)BT5Z7QG_R'W7>\S_3&[\9]\<P,KD]ZNO#&P5E
MSYS!DTM6[ Z/J'835DH'9N1$W 5DL_VV)0HP:O^VO*M$^-BF$"WFS:#.*O^O
M/Y_F=,\M!6&+]>M_2T%I<_F?'SS^X/[C]7.XNZ*//O[C["#\'QBT@G+)MB__
MG.E/X4\](9[\)/H'__FK#PA.\1^[[O[#P:FX+&J=LUV[_4"P&;O5@Y\.<QRG
M<K=Z&Y=\BO<V\8(' 09=^E%?_;ODZ],POOSL\R^_"@[E&PWG ?=70%< ;@F'
M*H<;) C>@2$'M>9^MU\)"UOXW0Y=R\D#^/_I3N.EOZ77/#FOO\J53V<J?_59
M..U]TY7,+XPTH& B(:^L^\;T:I@2[7CKQ#:G5"?,?.E$-]>[W!?G'?>[VW&1
M0-,T*H0,/(9"Z33O=YSWRWF_G/<+8<Z8#I]2MUQ$*DQ7$ ;C ZA-!0&KP&8[
M.(8FD4:A U#/OH3]IN/2775=KB8_<&-$[S$*011+FQ+ +T5"1F2&*1(#S[]]
M1C?Z;M^UV[( ;.Y97Q&J8K^[:CF+<+8#9SMPM@.FO4\$<:B.<] =B;%()Z)H
MS1!32T*U,&D#SKOKO+O.N\OL+H#/LA1\AK&DX'<(X\SL22K(7'9 V%MQKH0L
M<%.LRO/>.^^]\][37>1=0E-!.+;Y A94.+6IXD1\4:%5GWA$&G!'2F_.KJR)
M5X3(L(GJK015$/#ZYSUXWH/G/6@47<!2R8R#2FK)SB736DF95AI:U+<\[Z+S
M+CKOHB2WV2\)7[S?T@F$46RL0B'X)!9*YA%AR9;U**@Y<H5[*F\JW!]!7ITE
M!)79VD9^1(C*-0TK[>J'V:(+)(J5HEH_M:']_]('WF(]?6H^U\6FJ@]_ONT:
M$^^>U]P T?>6ACFZWC'FB*=GYHA9YHA/S\P1[VH+G-$E#[/ZOPCDY/A]GN)&
MIW[8[?AX2:GP<>!@('3HF"9H;?$RDK)GK_'L-9Z]1I-%W)0E"F_ES\NR7'$Q
M/'!N^<U%*,DTE<@Z6& ST_H;M^&=]]9Y;YWW5D1E*2 RFU"*DL"(I C*5?9C
MJ3R7%*>]K(OFO)?.>^F\EXZ?4RRDJ6<5Z^-JI8QI4$B\L=\!.B*,KKO#>6>=
M=]9Y9Y'Z&HF],PD5,<4;SC?DWDT9.<^F.5'R[)^M/\.(\WZG1Y[2'M!^JW9\
M^7,8=MZ$YTTXOO^JZHG"W7 Q&[ CNXA6.F:L&&:[T+8%$1WZ7U&"G[GVB'UY
M!\KI9C52/.)\/G\K2,0)FC-1FL!1:ZGE!O\Z@[U.YLJ_X_D][9VN[082%=(A
M*IT[&,;K\I#UT!$'=26X*8,0^=;OX+9IROJ\E<Y;Z;R5+$T2 4?V57(.8BQR
MJA&D*Y*ZF8/QO)/..^F\DPP"RU#?@5PX8K 0&K)4<*"]/&^?\_8Y;Q^S?:##
M;#5J0C,W2)?\K]O-(<IFA9PE;[FP X]H&*M";9]-BHNRN$97$IHFVS>@9O*W
MDTP.0,@4G;5T+$*-I]N4*PC)U<0IZ6_WHN^*LK;ZU(5TJ=/(OJ]6J[K,OBOZ
MW7GSGS?_>?/WRDD\6=@S?%2#%H/ ):QD:8DXRU>T_\[[Z[R_?O?[2RG^6-$U
M4)P8FN3S-GD'V^2MX[&W;TTW.B@5Y3%0"4R18F7[7;M\K8$..":C<B9T'DD_
M5\CC(*_.>L().1P8!IAJ>^W=J6Q1^O\AEPMNF*/\7M53JK[M0#"R"R@IT36D
M7'TJ,\[\Y&'4%]G775L$[7K60EWY:>D.2C_'-(8C0=48QKD[D^J1].)ET7GW
MK@_;3%W&J0&?/E?X.QW5#Q/,X"K6/61M!KF@:$K,4;>"G)4(+] 9=0V5WZ9@
M)3?1T-BT)"=NV%?I%48RYN3>+OP>K(@LB-JJD% Q<$Y\.%+53!>KOYKAF!8%
M\>//<J;+?/#8_DYOPIEW3%M]YAV;W]^VN/9;$GN/Q/9WNFQ^[W%,K37+Y:(*
M5J/A^<MT]0'J'"G#N(]M)VYTD?W]00^$3^E#T98JB7I=-),H9-[5'&';U2\/
MPC(6DF(FTO^AYDU#]KEG76\NQZZAWR2*T!2U^^]D5"UE70H_SC41 NRLZ #]
M^41IC$]YWP15Q5O7*-Y3!RD0IK67%VR-] 0[<*%*=W3>YG)8<S:G&*_ W($L
MB17MZ%O^L=L5/N7GX2)[)>IU15T?$I-^IVV6BAP*_SB8.%E\<5L7@OAQ_K??
M^P]=$7OYXSS^_"3/_GO?E/3C4]SG!^]OD"B+_\7'^G2T5?_67I<;^<-C_.'9
M_M*_(OZ@Z+*DHH6#HP.SZX[-;@,!0196E*^R6[,MQTS-'TY,^^1>_\/C"_^<
M]%K]3Y]^\AE=;4 8/O4:.2L6+T,:?F28UEV[R?[P)/_DXT\OOOP"EWWR<?[Q
MYY]?/'X\,="/<L,]G!4K6M8H\Y(I=DL?BQ L@QDA<QA)D'!YTTGJGSW?CB>0
M+<8:+YH\LSQ*SQ-*<JMM,O2+^%+C$[ )@IGS;C"]@9[NZ](;C6[SOEBA.S5.
M?GQNG)QMG/SLW#@Y6JFG1H\?57\)T;ESA=^D7<DJ?E>B^3LI!NDC73(T0WW!
M3+G\8.U,'M-;%-0[?GT?_KWT.^;%@7YH'-1^GGP&Z9!/<J,S6RKWH3]>=Q!2
M)",L;\;?VCL&# 8<'/10-/!ODU((HC@;CH)-U52;_29;5.*D^-O@O*53!^Z(
M4N.OL!I8_!MBD/X*55@8?Y6__;BOR^S33S]]_&'QT8=//])C1"[:ZXHR2P>>
MK]#D%!/C:=?N#T_TM,0:]7X\>?[3M_[BR>,/EQ]]^/%''S[[R$S>#31^*RIO
M^=F%F"UF,KI83[YXG!%#0K,JZ/ \]%PSNRR2F7-WFSF(S7%\_-]%LZ?M]>0I
MB\%<9#\T\9>?C!1BXFNV/+39C9\N2B@U>/7NV*NO* .UXM23/&F.V:/M3H,L
M^UT^N+Q_^D<K4G*/:X2GQCX)%F88\:YUH^FYX\)B>89;A5HFHB5<6Y[[&P:3
MN^\E$Q9<X67=LE<F.3+_M51"BU;#'SZ[^.SQ67'IO1O*^VG7OT,*UN]KQ\M4
M5^;6[]'1\@RV@(6-8*C:Q@<K;?=H=^-'<GCD_YE]^ 2_>?KD(^AX$QTNQR>]
MWXUD@CC7)Y$>:O<Q_3@40<HI^>)O"H1/:8SM+\)@<J\)?U_?>5)UP$NF*.NS
MX5N..D4VN5ILJ8L:KW[=>=_[INU>,Y=R?-GTFD,SV^1;#A;4I<JHD)AGT5PP
MV-&/B]*O+;\<G_R98WO_WT\?YZ*($U<B)S]65;_L2HDA\TQ%_OAB$I="NDP?
M W=$JIM4F.FS4<^U:I9\+O2<(O$7Q2=$?;X(NDVKDD3G62'M,)[ 15MT.,M7
M_ISA2H@,Y<D7V<8OD:L^2O$X&[WR,(OZ!%;[;\[TD4NK[L[GP7D@>:;OOC'+
MW+LC?@FLD.WP:^Y6Y^[#ZMH[>,5RB26.%ACXFGE6T;+F>MD!E*B]MHBZ6SV3
M ,/2[Q,UJC'#$X8V\^/O5/Z+>G6\I:8D27"@[.5NH"DL$F.EGW#(\RE'^LC[
M"L/1>?B_>_^6UG#WJ-SX+9H%A/W<QVVP GZ8WY;JK'\K6P9?X)1YG$PW3+/#
M?Y2Q3NBGD=_FXPF.]42C#P1?T,'29Z0T$;V$Y+GA?T]ZBOX]N(GWP':&$I^1
M.KX"#>#H#4# ,)I:^_Z'#S%8$#H 48^[\T*@XY?Z,-JNC -"^1@#ZH=K8G?3
MVC7!#^\'N=]HX2Z886]TU5CK':@AJRFQD)ID3!+;W;Z..%TJ>VI#B=C;5@J-
MT U7AD[B+V<FWU<C]TSM4'W(74*&XO>YYO/]VTE>%]6U_(N2]1:#L>2 [[&@
M965Z:[*WL>]4S,L1MW"P](Y#PGMNB7'0;[<&+;-[65%W^^8QVZ:LD%YZZ.[)
M9G9/V\'\?U_\C(%_$[_](WT;@>Y]Y^GA9XF;\./H,_(DMQ\IJ26 +;[[L=)S
M)<D/(Z9PIM:2/H&N@G^EQ\]JYOA9!:.R.G;\I(H=(R.#)($,KJ/O@/&54T;C
MTP8>8W'' V?J9>&-NB,'#A\U JO(;28"H],=QT]13+X:OZ]Z_YF.Z\6H>7,.
M!7CK<9)I>JB#LW57O$8]C( YH@I?+*\J/VS[^!_R!/7# .(C><D@W<3W1;//
MB0O_S?QVJ*'^ K%B?-2[]'Y]+8D^M.PIDI$ER/GB"5,R\8Y)\Q<&DQ!79=,#
M+X_AU:7Z)K0(K&0G99)*,GPURH<'6BDE*:&1BV_6XK*BRUUDUEJG[B)OS]$D
M98O]SAF((:1C>M0\=C7/1$]Q%ZV<V[)A]DU*>%*,=WBU"Q ##>WBH[AT6WF;
MP0:S(, 9/6I,<([V_D5*^Q^L,@WS1WGF5V*-AXD)K&NUM>[IDS\_N;@EC&6I
M9GJG;SF@%2OO[AO0#EX^X!R0@LVZJG^=Z6EI,I[\])^+6"S>%YU@>%L\5I?,
M6UHD$5[J":_5S#U74\GRT&+V_YW(#@QSH;SF>>\A0>Y"S@;3^O%C6!MBHJ<S
M;K'OO97I>Z2V;6+\?@?'G>,1=Z=XA&YTZY/Z4)\MQ._5[1QU$3S[]E4?';WR
MNFKWO<6GE*NITI[_!BWV45$/JT\Q'D\^#^3/6/T$X$#)XE6YW0FFXTG.P!!8
M1!H+7YC-DRYGN;@<.'2B@)33KS3RGE09.3$6(@-O#"1RI?+RLZ]E/W];+E-P
MB8O@DB=YE@[J7_M6GI9N]\-/W_S?KQ$N3GSE1SK"O>7<P'G092HV*+VJWUD$
M#.=C?)AC:QN3KR53L2CZJL==S22&&X^6NW<(&DF[R>AIFVBUQ#Z).%0<*"]?
M^Q]IB3Q]_-6KES]^\QP_/_GJPKU(Y^S)':P+GK(K'XT6"S)X/$(94!Q#?]@L
MVMJ.08=PFOOJE/?\WUJNUL/X+G&P9Y?5-=Q^6]ZUY7H;6"[&&]WXKHMR6>P3
M)!1LB'&6Q 6F)6^+C7"7PLV/^CWJU=G=G/0SW6$92@!-<9RKJ]<EIYH2A7:Y
M3[A$? 2_FTD""4NV\0[(G:?3_TUE)485S@OWC 40Y29+2NBI'&'$VD_SZ4AO
M)^'"F %?O=A"T5@P" RLI_.4!=3H#F)"90+KM@>TE'HT?3Q!#T4T6B"T@_[\
MTB^Z=J/L/J4??7LH@;$^Q<7.&W&,T;H#1.N3,T1K%J+U^1FB->'IS?:'O!N,
MUO/(8BE1.ZID 1-3:N48A+!=PXWDN^[_L_>FS7%;2=KH=_P*1,?XAA0O1&NU
M[/;[W@B-9+7588]]+?5T3-RX'U %% LM%%"-A53YU]]\<CD+"D616BR2KHD8
MMTA6 6?)DR>7)Y]L:U:GD@#Q6O>U$G4]OO_8M/OKO%OD9/O?^^5=3;[Q,S!P
ML4X1YPS \Y);AKN.X_S*I-TGIG5N1&91 @:_FL+B'G2N?MW5NT_B\^1!=Q8>
M\T7GD24HXP.,(PE4G(*+_1ND6SKI4S.&+S,OLZ N#3LY^4*U1+?&EO'@AWT1
MAKO:E+BGL>"A/ZBD=LPDWM%]RU?R=._U?K,7U#NV93A(W>5C&.RH>A=$3[C3
MS'+T05HP(EACMG!\8D,4HZ;.^0+A7CHD[OUJIQ4:L;MRJ1.H ILX8%S>-"-S
M/CAF+[)7:%7<8QFX;?-L@G*\O3%S\'CFD.RGR5S]@X]LF]KAY#VW\UGN#KV)
M4_,<5N3P3-X5LI^;MN#@<B;]?W@ZDO[@%._% 8^$BQ<E(&%66-DP;C4VU6#%
MT4# =U&RSX6XS&G+$4DX7)./^V#7G"Z=+%KB%NT].O8D?5'UP)M)@'%5@:=M
M64GZX9RN3^R4",_\"F+E-7T-&2HJ+@GEDL_P<<G>XW)>-PX^]FO3O?YA%@&.
M[I+\HNN$5OFLZMJ&A0^;("Z",RH!^&-@W;Y&EM7"OCJIJQHN"151^QS*6;UM
M$NI5.L$Y7T9M,!UEH"FRT/3F(+5<;S)HDL4ULZ*<S)BGM\XD<4<QO<+_X7SQ
MVN=5(8FCHBT->PPF>];G^2Y+:=$@/@5'2N8B(/1EC<S"\LRN-(RQX5)E/)8C
MI!'6&#'H<LE'C"27D6Z9GDL3<J]]&CI^@V@JF"7&'G?9_]LC)#A:#Q]9I!=*
MF(2G2?.]7YI(-;.FTIJGP"1P IJ3";JLMEP%EW-!Z<SCPV=/X'00T[XL1=6,
M4G[],_T.ETH6)-$@@S_EY\CZMU#C5M %1B92>,H!VDRC!T6YK*WN#"5O;DPG
MR3,?7LT"*:[FER(,]N<N4!0(>GO>:&06N0I_</1426698E=%12_*94O;GYR2
MKSA8$LIK<-XK0_SY\6D:8<?F@HVD+VLM)P\11U/=/JUAP3^D2HT6.XE"-_S
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M#%,<W1D3^*ZE2J<KXNS_3.PG;R E>XXGISL"J^XD?=;LQ%,(TBCR!MW^/8=
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MG>YC2!;;PKE<]G1!-R/G9C@VI5)QDKZ(1"L JGO[1M'O*D%"CG"'[("$LX^
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MD09L-YD=GGY).CSAP E_MVP8 ^ B*G@MQQU#/I>H=L_8T,U",.(N!XFB3XO
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MK1!G7A@WUR0A_QYSKBY(Q$XC1<&055',?R^[$4#D3>;".=&=HA17U1!TA\;
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M;*^_N#0,C9VY99W3M;_2<H2891;75'6F!7H>D"36D'1;Q?7'N:S+O,NA@S2
ME"MH-:\#4D0VDPKKNJHPSVX:>X)+:1#0;.;]MKEQ]!45I-6@6.:%:]^J0.,
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MNQQ[H6]GBU!C\0RWJ#C3MT"4!Y_/)WUX3M)_KE%GZ<K37!6?2TD&#TVL.C*
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MGB^Z@O$JPAXGOJWK,$,#^%=;-8,1%V0:V [87J ]YF?2=HQ0_3L_X+D]0)M
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M54 .2@Y$M>PX"=%5U+@/_EMX30B%MZR8,X6J(W9&TKV?T^O"M//&OI]^3:#
M)V*Q]RV!?_Z;L:<>"4T?,)U\8>%7-?UN?UBL&PAL\M?[&Q]P[7Z52C]6O!%#
MTC(8NAV:QFK]$GSYFY=/S@II^WF-OFJM%"QXND0W#:_9E)ERT-KA!M"KRA?'
M( OFV3GX;\;RN=C1Z@^I<KGWY4&C!+=!ZE6UIQOU3=>;),B=@-\KG5189]0;
M)1PH'K<AIJ"S 4P:]5"ZDQCW?TZ]EE_;Y+O199;$$-%!9?VY*;X@0B1@+XE9
M'_%38B@NHN![1.^:IILH[")MM&,NWU!IZ<PTRU%>2@S--]PR@>>0(N4W8HR0
M C$)_KZ3JOHV4B3?4KKG]<QGY:"M%_!Y I;5%>ZI5K;B2:XIPIK"S:"F8OHW
MQ+1K4QO[.9/JKR_O4)Y\PK=3'A%A .J;"'Q%>IFQ_8BP4OC-3H;>^SEAX%:W
M$$;S(6VN]^:\LRC""RTKBF\2K78AN1H]8B1[V5QGFL#>LVSL6=8#.WPVV5X;
M\,@QX"MT.*Z]G!N.-7+&0=,V2J.VAT+V3%'ZS[GN(L)8%BF+>C6F^DTBP:?*
MVO.%&G*&PBR^UY9)6V3D6H."$,HA&XP7I=Y\-G8.G&2>M3DWR5?6B6-M%GV_
M)OZ4\K(XA[FE_<5S[0DY,46!<NOV$N.C%5OF1F(K:HNM2^8(YYI\%56X:MWI
MU=X$)ZAL:[<F0V@E;/8%)F1M+0N2QWS^V0:IL%>C<(->?]O\+5<[(?;;/!AF
M0=I .A,EZ5V(YIUF[Y_+SQPE,KY3-!P[&4QF]8&NA<PU.MP[M+C1;H8./CG8
MVSN0@Z05FQ+^T6(Q&=*U,"WO].U4_[V?DQP0L]D!<4 A+O/N]ZOT.:].7'/>
M0J&O7F4Q-2ZME3X0T<GVU$LU>L2]QS?.YKJ&CWR-Z@TSQIUWF,%+YE,GXRR5
M&N;4*=%?F<(,QWXLQ3OP"NS 466+Z.<LY\RWUA6S9VB;L#NG5%GG^@$O8/Z4
MV/@J#1L*L.F#L(D5U84BH_%%!N>!^G.UP["#T^RVN3=,F./ZW*LRDTC2^&K@
M](RBGSC%+@/A9$;-%/)^BT[N?C1#=<RFR41M,C!R.'!DR(U=I--,"JL7W?CW
M3NK<BUSXLUTN?"@7_GQOEPO?7:[/ED.9]0/=K3_BI2+#-.=6VA8K4IGK'^L[
MDDJJB1;EE"+NL4&& \Y(<VDQ7 *8LG2%UW0M_E_+G-KJT9P6I+>51Q=92F%0
MV!>,BB61PT.Z=I'<MU\D/@RU)#8'@WVZ_3QH'IE^\VC82^=>/:WFWNH"7XGE
M1)]M;C*9GCG'TGF,D*3<?]!1@G#&U=8JXH.[N=?!5L^!=QJUG KS!9R*^^WT
M?4L.[&F2I]2&* F@&\6**M*PB90$>(;R@L)8PQD8B4""/<E,-4))%#3-X$/5
M&_(P=Q;?V"FK>W)TU'=)*^'FM)G &LFO4"@S0W2)(4;!RR#;7:5251[$,321
M?:TXL8!L>I$Q58*T>%K@U<R)>9(+5.'M1--M86(1.E"-'X8>F77%=(0<UIPE
M.%Z9T/>DRN2#P76>(S4]OK ][1 ,DY#WV9G?.N'KI9UVLO?>S>6LA^*G+TEC
MLP53T.IUHW:8H&N8%=8R U%(XLK'W[AJ%A7':O7MA.R]G],[B5FA:@SA5%QP
MH%U7_4)J6[8Q"%,">;V 0Z,'(A1JOK#DB);6^,7&Y^IM<8]@YR^JPE69!,]
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MC^0H_/GJ>DG*I^HRQ8@$5G5)6;F&(\(N"P:)0'K.;<^PMAK5/Y("NQ/Q'NC
M[G0OAHX#6RJ3-,^7&+LHSO_WG_;^U'):)V#7),L:I+'^ZT5TF4V;.0YY[T>6
MUYL-7YX(<GP"[\)I?'SQ)_3"_MI4^E8*JH*2TWFQJ?TG\=6:J7ZOS^K6:3;3
MOWG?)'W"1X([?;^(9+;.=417//B]?1U,&O7.__[3P9_6/+#/N[[.Z7?)B[^.
MJS__+7KPB]7P#]MSZ!VPJ$I_)%_?&HCH_9Z7X!W(QI])-IZ(8KF=N?^YJ6YX
MN:Z96I[.B*&>P(P>+\,5=O#AZJ6.9![T:W2NFRZ[/Q"*/+<W?,U_WO_G;KIG
M<*[@'"'M*KB#\-:R@J>?CQ\<[!W&!X^?QP=/GCSL[JO([:>'/W8WM*4Y'AWA
M"=.#AU_X2W1$ 8E;L^M?HB6 (V1KP"I@68]ZM?S;@WV0 _@/:_V'%T,5T8_]
MM[;]K;YC_,/ ,X]:WY:]VW\V>GPX.(R^%_2+HR\_\KW1WO/[,?"U#QY>][V#
M&P__4Z[5[W.P8-<;(-O<G]_;QJEOE8JA^@!#.Q,A8:3<[\.U8F=@2$,KW;.\
M!\^>Q8^?[ZW[9M\3/]-H]O<>QT^/]N.CIT?W9$1/#I['CP\[!_#SG;KKA?FM
M'4#B0G3NSZT=OHY\ZCMW3T=''7%ZNWN\R3! -N[?DY.VOS]Z]NQFY^S/Y,^I
MCW=G?N:M!Q^Z"9B*3=.]ZS,RO%J_E4WZEZ_/!=]\6(%'OHF?O?FCVS(+-J/?
M8]AJI >'RX]]QJ1O(++U9^V^F[^S'UCYJ;N_KLDM12[W7VR5KT-[N&T+4U8@
MR2<KIDI8U1IOQ! 5_!&W X%_:Z*FB(+;:AR4#4IRJN"HYU1J1JY>UZ>;4E=*
M!J;UA-@ZO]IJ&!(V<U'_-;+N:TYO!&"8+Y3EL,&)CMUQR=9NF'9VJ63SYOC]
M?[\ZB]Z]?WWR*GK]V\]OW[^!K[S]C0?_&47^M3GW>Q#SMO&-%N+-V#(UJ2N%
M!4\Y9E)?+<9E'N&=/=A[<?KN_0G]<_]%F/MM(>B"LC=L@SWXQ.,W_Y\\\(Y"
MT =M_,V]N+&!L,:< >MASB5AZCZBU#V# L% =KRS2Y]P(-P7;X,I*V^%N,O4
M=LN9O#V$?Q_#2Q#0I8EA_ P39P:;WZ92R42 <:2^68&(]H@!;7TP=00H6GVL
M\0NH1;!A./8)E3IA2LLQTLJ^C9^783:KI/:#*X8&TW*@6@$MA:]U*W+M/!\D
MM0_-[DEP=Y?9/K2SWEIKTIOW?FA;?U,)!T[H;O&37^,5F)>7(+8T;>KMN<V@
M+ACF@+7Q8 1P*IBVK?\($-^4<O(*-O\'\+L.>X]]29\]Q@^-?XPQP9>YYZ!Y
MA%7F"))?I0IE<9]*Z;F'J>T[37I&O70N5JMSR<"L@G_NSL\&YT?M5%<B:=[T
MG1'8LS&=@;(-WG8[TQ,3\VHYJ_01-A7'BIJD0E!W_= U<^FB8_J>EG[4ITTQ
M]8+U%((<QUY;]D,]R_+A/,U)=NE \;5DY88'F!X2'ELLTS#) DO/KYLIGF]G
M6,/2[^WM,Y\"2\Q,/SA\=GBD/7D1EH'/D-D3SUM:^ _Z JLAU2@R31U#.&Q[
M(8V]D AF6Z-2291[S!;,YNH*_$)@1^^1\\42/?=> .J_P;3\!IG#35*BPX+F
M)]C\@630YAG>=7Y[@#7[4BG@X0'9>\$9<GL[^#_Y(M*_:9P=&\K[FJ3802?^
M(#?TX<!";IYNWF8AO_6="I ,+=-BLQV*=EOT>;?H5=>,Y25GI<$;%"@._MAN
M4]NTO4_7Z^Z@ VMO16 879_&O]%IVB0=?,-[L#XK/?S0QT]&!\^OF^[MC_-;
M6D)P )\=/MVMX2>NX;67[I.'^070%>M&Y#M:K;E^TC[>VN9MM6-/1T_W-GC.
MC0;T%2X''N"CH2/\G2[(X\^T'O<,1W#GY0L^#5+M1VU,.W*X+E=#Y22S?(55
M/IC#K3.FQO-#[>F:<'YT?%ZET@JHF#)CC=+2(+&)?;3PG0S'\&U\U'NO]2^%
MMHJX1:5 @KZ@TVI][N)ME)[PABMU;-A=?JI?JE*J/!S!KJ2:F7J?U1^BGQ/N
M,/PH>IDZ=H0PGH]/G&4?Y6D^U58RQ3VTO#V&NY@3*OE*>MKC1RV:Z#ZZ_,@Q
M1_=]'(?1(\NOSOT'QABLJ8APL62^2\S6(.FCC4IQ%9'O66AL_4I()#B4)1%K
M7DI-W$6_IU%:3,H5P;6NRI7'QTIE)S!I)'A,+1^K&8QQKSFI=UJQ]'7GT[>D
ME;BWG!9'.TZ+04Z+@QVGQ?VXX-?4 ]/_)%$VA>7Z__?VGN =2/[6/^$MZ5(W
M0:40JQ>BL_X2K9;(*9A@:/[SDD3\_/;][\?O?WKTZ]NW__WZM[^;T[/CLU=O
M7OUV=GHOY-\W6 E^FWRB68U- S^"&F[ E$)#[\^>S6;-K'*RHHZ&U-8>:YP3
M80JHTAD86-R1B"P\-OJ&'HBV(UH.<$8ODVKZ*"_+#\KH+CT3S1GU !G^!I%T
MVB2NVB#,NY@X L1QFF?I3#GZ+LK\@M*S:57"."JP__@CM'O)?'(DH'ZSWE9]
M/'%=SV9$X&TI\LCT]=]/>='U<ZCG5.XM%ARV<4*$Y1)Y-FKM&8*/PKXK4L-.
M!B85_UH#2VQ (KT6X\RB)OC;2,&85;![F'9%3T**BJW=BH1I;EA*29E,YAD\
M@3C,\6^&^4>C_X%7(-FV[0.Y9HJ2;UTQ+WC[BXS&*?/R_,KCG17SG/;N DZN
MXM'D[[S(]L]&_@Q&;/N;..CVWWC-.W]-TP^=%W'K@<Z?F:>Y_<>J-%2TW1DM
MW&$\)NX7L)KR&3):3K(E?NI]2! ":17N.EM?EM2Y#5%=\XJ8YRS3XT4"9U![
MEIDU7Q?>%V*N=RM_+S+1.Q&];D['</F\2\7;3C2>_E]G/D7+#(06"4GO&TZP
M<8,9;-"Z3@IC43#(M 1]Z;C]17] F73[([K28$3DBS*Q>=V@PCC7_@'E^-_<
M$(^^Y[4;]O@2'<.'STO-[+3IA/@-C?3+/1>OEIL<P[LP)D%H*B9*5"WF[MP4
MX572$67&S7Y?M&> ?0Q3XF= A8;M#9B=%/X#^_;BK-+J J,SID3FUXLT+Y?T
MT\ZC*KC2%8U?13D\O%P0\V[!M(VUL).0("&/8/ 9.!7L:36QL1KN0OSHEV21
MU 8V"O4B4<TJK5+I=U.T[WS1VC#6F+1<P<LIJ $J9K'DD1+<E[&31&$]TZ*
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M*O8=;?RM:"\^L\-$5'C6Q('?Y$F86(/OU<SU!&X%,5&!@B/3?)C>($:#&8'
M[25!:BVOF, 5"*@B'BA)Y%(&YFYM%TT[#Z-54<U=G(PSXF<]ZZY/:"\\XGPL
M(^Q?L[_YI+!__7/V-R5F&J=P\BC9B(ADS#_L[^\(.N[]G(ZG[)8EN0FN*+,@
M;4GOUH!'FWIW13S.:UCJY&;0]PV;CT@GG/O7XO35B=_'*J IAD/Y.Q(8$^_:
M":S+S[!:T1MLE_BZH!N-$UQ_5@\.][ZQPWK_2'9O<VJO9\:9"W#FF*H0!&W(
M5*@'%'Y,GP:_\<T0HB42XD:,O7"\1D]\K\ 4'N>VO)2;,WA#UEV'472<Y^NN
M"UVHM>21!F^4TCV6V'8QL?$F9A4OL")FPM?*)S7$&[1(INFH7_%,2Z+F(7NM
M23XP)U4YAHU/F"V[E+ZG\,K5DBC'2<D.38;;PQ'-XB -(U&2]PP]M"BIP^24
M=+;W3/P5\3$2\2:RH*T*OS2&WSGZK+?C*U(^6X-']G?@D4'PR.$.//)9[\)F
MNJU%,_WT%FFF0^VW.:'TV2^OS.F[5R>OCW^-WKQZ=?;ZM[]';W^.3D]>G[X[
M?G_"'=Q_>?OK3Z_>GUY[QS]IS.V8P88-/6[UG3]1FU#\'6F:=R 7TGO9[O/>
M-/ ]!26/0=8WT@*DG+D^$D'?"R6^H@:P9<$3.UZ=PZLC;#7.#<?!9 $-.J'@
M2\/?>?R7O;UH.5J,HKQ$FM0&9A5'0I=\TO+%2V1[A$D;^/Q@+WJ?K/+H=S!V
MTF(,GF=TVE0P3EB9\A*;I, _TCPZO@ Y]_3HV?[1_E/)LH'9@PH=76EA^; ,
MR])SA5R))'I/S@&:,S^#9(3%C-Y5V06:!J_!EDLK Q8"?+*(GC[Z;W#OJR*K
MYXY($GP(S[8!JZ%."TD5KN?CAM]G31TN,'.:%1*CMGZ*4&$FRKRJW)?"7&3?
M/B[!*,*)<*H/W2X,$Y"WQ6O=WFJ-I"73?Y<PLX5:3,NR;I9E$98JMWZ,=.'K
MIT@-7*H:>;89V^"M73#OH#-R03;UN%S)X8GX_VS^O[&AWLL=$7X+]V[K:^__
M[Y>5@^]6%=97#>W>]RX24? M^Y?(V-L!AM+WOD[[(Y"T <6N3YUKNBR+Y"(Q
M539:,%H"@(F]=+',?<JU=J.K-MUT!O*7 Z>SH4;A5&>@O9?:W>%5ZKD\(RJ>
M5AQ3Y'A;'CFVMN][_P\Z^X\V*=H(K^&+BR(#9<V^NNM7ADK'J2#BLR"=7K6"
M'H0A07V0U*"LB_1C=!)=W\DB]O83VS:8Z[98>I;!+%;-O*S Y&\Q7^#'TS2'
M7U<4R2&C87AZI)?!()%91<KYY9]2>-N8VGK)=S*PB:88E<>8C5(,7W\X.1PD
M;=2B5-I'H'Y<+DM,FEL[1'6_<0OOC>?;.\9;O/XQ&&@K(E2A0\"<Y"C@X4N&
M&G_XI.6X;.^H-AG^_5LYBO9CGV0\ 0,E?41;!1[9'-:]8&.NPV5^,L=<Y2L^
M9?#+MWP'8O@@R3 CQ/X)R#!JZ6'<H*+NH&C4TD,\."*"5;BCI;WCG3U<L[,]
MB]B[LR;E:"%((OS"6;F F_9K>G%%S_N?)*F2>72<SS*R6M/J(I74UUJ[V[Y\
M[?46N82,.[,KDF.3/*G!*9!&"MUVC=U7C;ZIS=]2LOR>1A^*\A(7I"A;C/\L
M@NO5>)$UU).RWP7RVGJ &D(=P^7)*':S8A2]YK:2_#6;[60-M424032NRM7Y
M'+T<#*WUO21F"X4*GNNH2!:L\]2/P\SU1=F0OK"M%/#]1,GDX9VL2YC!4%)P
MK/Z]FIZC3KK^$'SU<9WW*0<6IHE/[VTOQDO5?S_IQ;@W!91#J[6#5GUN:)4%
M1-TJ$NIL2YK9=7IB#F)@FG)?*.ETJQVX7$.QX68EV]$GK2KTIVR;EMX^P]OX
M79[/M1T2<PO_+$9!N:'SN!V>3' $)$<)?PK_"$-12M09^(;X1]PU,0BG["UD
M,#YN/N>Z16\SF)ZC4:G DY/0'Y,EO:&8A3&VA,3TA6(2U-S9:BQD&K4;ZZQK
MXW/=P1K=4Q#M3C#O!/.-!7-&&(%D>I'5W-NOC(6-+MJ6A[PC@N)K9)#OCV($
M?UHN&S\VTPY>;#6:+Q;'V:ZM0Q#SV41M;![SV1:&O$E\*(P-11O&AK:K@]HX
MCO0B4$SNN+<&Z33.EE5AZ[737T4?[;T [22:"954Z(P?])[J&]UG&X(9WJ,M
MC]/GTV!W6F:[$2;G8(?)&<3D/-EA<GHP.5_2KI(C-P%9F"QK6$3]USVWI@Z?
M+S]^HC%U< B/V)E2P?_[!%,JQECAFECRUI72Z^+.-TXC;#6*:U(.0V;!]3[H
M=I7T&UD$$9H$P3(]OC;OLMV6?'J.)N[++VQ7$GMM0F?G+-] J,,>W*)<QXWZ
M9-EN%PQV\Y.?R**^:Q!>4_UY\_=N6 +:ZLJ[3I;06#Y1%=R*>#<B#&Z4+D0_
M(1=\WB>G#&DDGYHVC&Z<-FS5P.(=^AH$SN=.,L%"(8:85OE?)>4(WR'6])N#
M4-P:B/@M5@1YD8Z*5M&LS1Y(9B/'VCZL[+9EI(442=%&3 G,+1#C0T488S42
M$DLW.>-?"M@ERE;8J ]9&0D77)DV;C4ZWN;E@U.@VB9,E8@@*U<-EAA-Z16O
M4#9T?FKHIRSIKLH5-AG4B=1"WH.+:)._,!.P>G@V*G XO>WEM3%*Y\D\*[^X
MG)&P;2JP9,V,&%_OJJS RJ4\.AU XZIM=GV)& TC<Y61'FF2YKTQ4U]HCF!A
M>QKUX*98U&/[5MHX[L5(G9 XP0[G\,F/*N2\=1_<K,\"!OX\5_A6Y9G(+SR>
M[].+<F+3-^\8>O"]R[0S;OP+9QI!%E2'H-A]LQ[8+IA\1.,5<%;G23[3 ]GC
M1_E'?#TD_Y;A/%_?EKR>D6A$.9GX<LU8Q1+F:"UZVY/:6*^95A5KAV1,UA\^
MU ?:L%0:1 55_,7QE9R/52V!=I,6I#BF\L$$-GL4_2Z]Y>%W6-"*+\,&:O1^
MD-*26&_#@MPT5A42M^+/5'O9-\,?TJ)&JPX^EF'!\9R4*\1_CJA '2>&M&_Y
MFK>1%&C-/N/%GB?H8>=5FDQY@:;V]: MZW CG(;_#.#XK\ YW65R/W\FMRFW
MBJJ$IYI*T%);H-5S"^RUHY*P<W2S2.9$XR3/X?I>SM,"_[)=:*>JX$&[\,WN
MAGP1K,,-;@C(=";:P_K)\Q)OR.7EY8CD/'YA!/=F=WYWY_>^2GAK@WFF5QS5
MR)QUA7OT ?_C7+ =: :2P>2^JTVI5E6!@4;X8+%LM@1=2" 2"V3!?WVT3#)L
M>4E]ZFA8%]D4C3*Q8N5E- X<6F U^AD) 8]OG6,:MBA)M=&R\=LE[L)&)GLF
MN[N^N^OW]:XCRC?-T^6\+,!YFV"Y'9[WILSS1[,* UOZ:52L%F-P2_8?/=_;
M>_3TB/[_QY_];-_,J_Y"I3FO9UNM.$F(X5AM)90/L"?TS7%5?L! 8\W_B9T*
MBC2-)8-#C.<*2:Z)K6&KP6!Y3*R!1\J%J,-]40H%,"<Z,)1%<I19%QI%AN/G
M6<,P/QH2^JT\UNWSUO4H>I>G29T*W,Z^04902\TR!X+H=9Z$=T'0.?ZTM+_<
M?GMDT34\L';+K/X1?JUSYECV!@V/V7H]> 1Q,)Q)4FPP'H9$VM*F4D\'DO2!
MBD2FP.I*MGP[;8RP^VB\:FB: V\IRN)1WYL4M*])/KB#94UIOH/ML*F/R; X
MI(O2>9G6HTD@A=G?8O TBP]P4W@9!5Q+$22Y3<RVLMW%@26@2(Y[OSTN9=$[
M31WZZ"X#XRB2/U$TWH,PYQ:O1SX^6SW(D&0Q#+.T-B1#^"@U<%PNX(!,+7<-
M!^?6L;DT-R9T:7&K6_J90'!@QCRAY+U:PAPEQ#+)R 4(!R6!3+?V;'&\%A*$
M1\.]A ]QZER*>67H6EQF=1H[H@9$)B$?:%K8BB K>,.EZN*,PIS^YG4NYD[8
M+5H54J8'#K">P6+C JH7UZV5C] V:ZH-;J>"X-KA/([->L#>ERWK-T,8._S/
M:Z9R>!WV<).I$"[%W'T=.R5)/JF._0ZP#?<JZ69N$8N])0'GXQW8?Q#L_W0'
M]M\"[/\%+U!_[5$Y,Y(2ILX S '(W D"#R)+B<29HV[(-&"8U>N-+:S?*D2P
M83SB,KD"J_IGY+N+-\I<H^N$9('PY<L*H3R% IE$H0]HFN A"$]@@X+!DY?$
M$YUG'U*F+4;KD5"1;*:94^PL.(V',KK= 1+,*"I@RV19?&,PS3CIC32*[BOD
M^6("/4N\*(VT8'@M"0AB#ZRV&,E6B6W$>.'7R;Y*<GP_F87.I%:;<V2(X(,Q
M1FM-L790@P(5JLX1V*I+@V>F[:[C%@P]F5%J_BHL$.XF\096D+3<\(\TPY)S
M8OW&1[JWV/.-F#9_D[X+:I _5AFB/?X%2WV_5/E=09K0-6+7HKD,R3;-Y;PD
M]U+\)P\- E=481^,I,2OXL_P$^MPH4#$B!B<T&S6I"G]'+5O]&#_R8\/U=23
M8%V5G<\;VR90N%YC7J>L-@4<Z;K&NT ]2"1RA[?SCU59K19#**GH>%PWB&?$
M>T$P<KX)&'[!"^?(:@4G \]'ROC:/IE<5H)M)8698_0*[W!*9093QZM/ZJ%.
MV949=+IUM!F[KK)2<>\/+ TMN^B6PLVX>MYI<F7I<>MD(:,@Q@VD,XZ%E3Z1
MA@"X]@Q630C^SL_W</;B\?78]\2 &Z@=7Q#5XM?WSDX'Z.;124;A<!KR.06$
ME40PH&RQ(K<1I;+WLAAA%Z1/Y 5FX&1Z,TR%2<F>'-H1W>%O3A1L$V/J<18Y
M\F?V.>87PY4FN<G0XP2L"\+N7BC@&'>>DJN(UOUW64D'H<#(TK/PH'>O'JIJ
MQFUY@&?'AD!,XB[P0R9.\?U;=6-;0<L#>N#C&XZ<!8.-O(&CWQ@:%<D('*,H
M>&]LJN!A5O)A6]+H-Y):7H#/?0@W=64-I ?9PS5K69MUAF8<I1_]L)%8(_!C
MZ9684P<,;U-BA/51DR4.N+1(O%&F$]Y/-@Q>I14U)NM&&AA:"1X=)51(]#S(
M8#Z<C6O@2Y)_L]-A-K;BT=#X!H?%V0HS-#I5(FXT>K22\P1-GC7C=F%%6,T4
M92ZH1=5;/4!R?K!9$LDXO-?V"-I%*>YN"/_J5>SC*^,"B>0'T3?J%/["A*OT
MS9X8G!>9._[[\>O?3L_T$[K(<'^N,3(",\0,FR%THHM2&ZF1::7N2(^)(N:3
MWB],;^FD5S7;"U:Y6Z6I6L]D=5M#;PTQ_^H]@E./,7]7[M -E,AQ2K0M8DU5
M.%+30#4[O&!@_X&!*-W<Q$"L%7ZE;:CJN!LE#X/^F'HHKU*ANH1?E/HNRX'I
MT+LFA'ZP.2'4GFE2B.I;+%:%Y!M&T4\#;_,O&2&U.#6FS>FHNU9:U'Q,J([*
MKH"Q*]#;N,K.HTJSQ7A5P:+PU<<H&YHCM:1XO<QN<D[)-W4D<-5Q+M+,2E?=
M6U=DI^V407T'M_<M+=<;SIM_[W?VN-5I;>95XIE^?O3KDCK6%E+N7+P6M@B2
M2_!<=O5:WER#;AY[R,U<C33Q*3ME56M*"%M<NX*; #.18IK.;"^#@&V[:T,L
M->1H-5(W $NCV9\Y5@$4IHW;4!*B_-(1]7/R6C)>;8J@=8]BI&JR/$L_]QW>
MO'74E[C=FX]FRUS5X2Y7-9BK>O;MYZKN^(K0_[A&<,]NL1'<-6CD+2> [>'>
MO'K_]U?O/U>*.;.+E-UQ-]CL;]232@O>%;$C_VTL:8!X?6<],)@M2MZG:3VI
M,JE75ZLM2NACJ[65C])%OOK -]BDM9DCCWR_O2DL*:K,,GWYDE&PY061G?C#
M0/^P-0B['@)H\J%)W#^=@V&$\)(.)X( <W7] O+%?N6@[X7U]ZI<<2&J*&NL
M),4\8#I;89=:&C N?I6N64_I:4XU_K8=.;6&M6&9==,91EIUB:X[<*-CMIIP
MFJB^O;IYW0&/(B$ZA2N'/>/6/?%E;,<WC(_J8TZ57S'N#6RUR8I!>UBM18UJ
MM3S:%CEKJX(AO@<][ALTM&Z=_C5%\*.-;OM7[XO\'?RO*LF_=R^D3RC%$6F8
M=&K UNYG_@ZYP?GXRG=.5V.VN1?XW])4B9B>X)OV#?1GO8+UJKK(+NAB8A[O
M$FYC?O4(W6)D81_7V31#DA4OB7]7*2!21F$_V;L<ARSY"7@C&<BOA%O7W^FH
M[L&9/A[H/F!\M=U&@82P560!0M*%NK?]7/H1[#(A,J-CO>9AUO\41J&FI&'8
MHQ\D9=%N>?51(!_O<3LI>3W&9+R7]O7O7D*Z;94GUFHA!#<I6_A)DN7JN;?O
M,,6UT[Q.+TE]7&\7C:)_%L)BU!IEO*8/FBZXS-A&$@/LP@,E>3M&ACAB'.KM
MF,H/>\A,41^7W#8--^"RX"31QVS!@S@\&AT=_=CF/')O!BMFF35)'C/*B>R9
M1],L1\B^&2<UECMYV-T)]K&'06&6B6RSFLT V)W9JF*-GLY\_'Q79/H,!;W+
M$$S+]$[KR=YH;_^&TXHVF=;]#$/>UNN^W(O&?SL#8[E92!Y2[_OO(D/BZ*T<
M(X-/A=>]C%Z6Q52.E?SMA/\6BO1O8H7NJ4'T N[(Y,-Y58+$1YK2LOH+6C=-
MBO%:HU5>;1>00 VZPZ(EX (NK:^JUPQ$&M4)H^(0 !47,B93>;1"E!#%F($<
MU*=Z52D&,1GT2HP-.'2-4!1=I#4\Y:'UY_SL-XYE58CZ0E'E26U^G]A[H>[T
MH#D3#(WFR#6WX6\I+5(P!LS:*%_*?.LSUN[#61JF7#RF^#-&$[:I$)25MZ&!
MMJX-18SU7UM_/JL0GOI3FDYC[^.M!J*/4J-GNN(#L+2,A%6Z3*X6@D^<(3SO
MP>%#/)1_K(@]N5@1,@2.;)Z3?QRS>[%=(RIYO>0&\9EP2IE2[.=T7*W05CMX
M3KR3CR/$".7XSZ<28*@SII6=S%V2@1J>;]>62^;)T(4$<Z13JLWICL !)%&S
M6@;$Y/P<"XV;U%N_9(&@@FT[FW1W.]:(0HGH0QYJ?/U8#V-_L%L-8__)!A-;
M-]@&@>7=L6XUB*%Y/0GF%3W>9!/"L=[DGKA0$MX$<93!BH17V&GB%>H9\-.8
M3[F'K3U\\N--SL6VFS&*?@X,_%ZV\^T*K7N$$4VN2A>H-MLJS#-@ W'2D[S;
M;AA^:'50.$HWN/!CPEQ80!N6H&#5'*5UGXR.MMN7)85 "X0R<Y+X'RN07H_U
MG/[V^A3^%3\Y?(95 :L:5^1!Z"7\\"1^<N0^?D@H#-W<[<C/[$%H39BWIFM>
MT+ZA/<*)W'%*:=TDRK-DG.4"C]QV8^ 98_*M).G<<C$EJ-RI[.VRPWYAE^:>
ML#AOM=9ODJMH_T@/FW<33E1FM0F2QR ]"K10.93/[N_9\>DK.+]JSD1;<L4$
MYDQW$&T3YF2M">-^M243DYHO-S5:!@P1M/"W&L=/Z20E+.[C?1;^8K.T_W[4
M:[582Z2M,&ZF+ZP@"4P(WA!/0=>=UZ%EH_CO\$';B:1090Y-[IDS-^R+ M%]
MXHON6?9Q2W/&[GJ?S'_^HR_%SRC5)M\+CH22?_\#SA(8'3BWFQ\,<ASI=(!B
MQ-,PK#^>'<:/GSRV"B)N19D>_  *YN#IWI97MD_;=#7(R4TTR'9;T]$VMZ=!
MOFRUQRU0J-QS)O.7UD<.5_[:46"4,YO<233R<[P:901FS/!$\AF]6USSNNC%
MN T-N;.,TW4CO9^C\DVU:U99H_RZSB-;$T']=)A,)\E!T$WRK" "0B*PC);S
MI%HDDW1%K(0J]D;=M,&LG##S_03CU2J$TV(.?A17W2$D L1E5M(-32?S @9Z
MCBXO9T#J%"N6DYJITB:@]$#X%F5&:KI*EH2V_IT=LDQ>Z!%:XJM7%18[(FM2
M<0ZCMTD4KW0R)2Y.4O6@JLZK9"$O-246<!_M/WUQ]*A)P0R=7TVKT@XC)ZCY
MV2\GY&S_N>0BCF5]-9F7"<<IY;O33+Y\\O(G^V5&:_B3PFKM)>)MY;OOX;OG
M99'53?T7<WKR^M'^_IX%@S=^$N ,+):T 0NAOBI@B M&P9^=QOU?+\=2[0U#
MK'.PZ$%+%VE"/WI[>LS!@[Y?FN/\/_,4#G'EX?9K(KNC'3N7"@JNE,$A'PP-
M^1C.3[T@+&Z#I:(_879NR@G4Z/CT)TE7P//@$+U:9CFFD6A_R\J@!^  !HBJ
MIP;KME*ND^+'U#\B[A6R3$<EM?U;ZB0GZVJ>+N >@Y$/GV3Y(SYZ<"BF*\1G
M66 ^_>YXD?RG+,R;I/J0-E1E>_<]0];(ACO/@/C%),1]  X<"  L]C4KF_[-
MDTOGF35B]+ZNJR3-:=&YL<\!V9Q[ASU2IX^+,L_J1ND6T^BWI)XF?T0GG,^,
M> ,9-D89]/IJ 0I8(5"G[]Z?",;I;LN#[YERU %)1L"J$4T1&-(B:A2KU$6X
M+NXH8P%5)RQH"U@G7"1@RTOU;0JN+C8ZHD"_%G=B)Y0''ERO2J8I#.UAS$I
MR#7QMB+!?D+H'GE2A-WG:O9DD_HO4;T K_E%Q$V2Z</I"]!695TC/!)<WG2:
M8#[^])__J@/L1K[ZN((C9@=(P0H4*/>L@GPC5/R3'2I^$!7__-M'Q7^=#$ZO
MBZS)*.9ED7\LP3-*?:>8$A?U0K0[6!Q6+J[ !P1[(/H[:,AE]&LS'<6N"Z0:
M"QF7_!,O>RB0Q#Q$X.L$BZN21U/LX%$@R4:#:"F;4V3[@E7.91E1LH%L0A@U
MP[BF)?UQ418@^?Z3V(S^HAR#K0-FU3EIIV1*>?V:*$S.J)82J?BR22K]Y/ I
M!(VJHG^.3D?TC%<K+'TR;+YX3Z""PDE&A<K+I5J^6F O(]JT:/";AFO@ ?,R
M8WO[SRW.S"C2' _'<C5&A[U$4A5)5=4<C#H.,!EY28I$V1)L8LS%L#!XMK_W
M. )5E.-9:"=>#@Y'3_3#AR/S,H59%4(KYD5+M:T8#!G3-!45"-A@'OSU*'80
M00PS(/P"C[]W.JN4:3^Q:ER.H=70H^AM$?TC*7!=#"<,]V+/FTK@&B9%!M.J
M.^0*8QB@99S006 $/).XZPK&,DW'33MJR&NS/[ VYH>#9Z,CMS;?Y,F5Q@C[
MMIQG[6 >/QD=H;: O?H-3!G:^Z/8\&;IR@L6FX&F0JJ&>#V&7R:VY( RGG_/
MRS'LI/Y60^6"JHR5K(UJ'AR&TZM6^:<VOY:L+N$(P?8&4^R ^W3NNZ%92*LK
MP_1X:EMCV<>0\K.C^/'^0<?ZMZ6;]$;B)E46W=BT ) 'HR>/;62_OTVG!\,-
M >=>B;@^O_:SR7"T9QD3FRAD"\YK6C<@_NO8<)/C),M=@&)X)5\7=I?B]EJ$
MK8RIXHLK/J0=0F;[>CC,/%UIV@FCN)&X%<4&BQE9MV 6K8 V5[FZF;1W,"G\
MI=E_^CP&>S,^>/*\LU-(==_4/D6-"2EJ.._E8RE:N%Q&K^)#UFV>XEA;,]1=
M&\ @:(7NT*YT-F*<3A)*3W/-0=0)2+@C%% F@--1.K;<#^F5XS_."A.^)"8.
M'+("8"G*C(NO:_\7WE>]W"H#"&G-ERO8=XS?@#T$_[F_'S]_LA\?'NSU0<]5
M SY(IBAW^(96Z2RG4P[C?4+/0,+$% D.>,'K99XU#P-T<"<)JWZB,C'(3\&9
MP[M[D5)O1'=0,0!@7!ZYIHR73"K]N$1J/TU1]=?!]\+08QG*  F1![;%[O(,
M103U0WQWX5E\>C0ZY"RA_.)_;78H/X/NND9QW"JJ8#LE)1IS2Q0!)30%1G P
MJ,S^C;<!_/."N*03=TU%3WD7E^3W3TD^WS)U_J8D:@1V(N"Q_(B>^J4XT)K\
M-:JM( N21MI3E+1=ZEJ>ZAC<-7Z/PUEBZ-/>L!I[VV3U/'4A7OW.<&!FVW3^
M6;JHD^CT0SF%_TW&(%G_*UDL7V1%.2WA</PS3^B_ZPFX8_D+_[,%.N/_]?\>
M/-Y_D2>5_\E68S@>T4]/^044#<<AQ1RF0<G(0<66\ WPQM92"5=WJW&TSN4,
M5/($I%#'ON(%XWI6\,BR<NJ(@J_2!!5@YV!]P@E1QBLD=:?(.7-]R/8S-QL/
MJ;->/W-5"M8!Q3>Y-T/F)WNUG*AGI/N5MTB\,J@S!M=E6V S&Q29 "?$XR=_
MNDD+Y@'VQV+=[ID>)EX;"@S20*=D8-ZD.9R=Y^VSQ=U()G\);?!Y?"7^_[:<
M[FO/32(HLM%#RCQ1T6NZ%@R@Q2@Q'U[VOO'TZO9)WZ)_')\0<RFXR;.$VAE4
M'#[*+LCIIW8-BP462X"$UBBR2];Q931\&6-,L355-E[9&)'>%3]&3G]?$DUO
M4C6U_W)BK8$QN5ML]2#^U>K"F@PL%RQX%J]=#4LNC28WX\'J>;;4!)\=6<](
M?/^B2L]7>0*Z],H&#&JO#8C2!E!UA_%A?ST3<*HV'"H)NGI0TN%#QA77$ML5
M4A<7/PPDA*J!\!6T\8.[H3L;I#2\M =^/:&B3_O^'MBQ(,-L%A.-XMHX\3-.
MFTNLZ"2=#N^E_/A9>Y5LBB3&\),2,\%_3>".P.6JKGBJM5"(:T,R*PD[DQE?
M&=I4=A67V%P3?4,W?_YHNFJ(M1F9GF97R/"[0A*)?+8JA*_\ :PH>*KU0[TC
MX#JXZ7/&7)A<^;I52N0-YRI/+N^3^+S#\,^]BD5I[71P,8V]-9A0FR;+AJ1(
M^A%$'7M%Y655EHNZST:M4_;.\%3;,ZAA4/2KF+:;[T1'PW8O!%RA*EUO>WF^
M:Z^$L>GG]IG%6UT'0KN 2UI6']!/A=N+(OV\1)'GRK!->\Q2SD&+19J'U0Z,
M&)4 AO^I_SC]!D4H*!K4,YP&2(I^$<N$(-H? ";O+R>:Q<:9Q:0\:D</@L*7
M!HNO"8;J^O^4$P;?L)ZR]< 7=&]M?D6FVA;C"0.'5"#ABG#6UON.3>,^2!XB
M@?& Z >/"DEG.%ETD948VZ[IM)7@!YTG+'D< B$<"BI*F /QK5:U4:]JDE63
MU0(?/$FEU)):)O(5R*B OTH38G/#M853A*PVLF84PW8I[/4G:I9D.3JQL.8+
M;"(!(S=\JNC<Q-<>+*MI)-9 ?WWX(GHP?JC+3[M"V\1Q+<<5[<60PO&]((S6
M@TGW&<AB6:V6S>0J1K8 /'?9:A'K8:O02(BC/ /)/4TL1;2C\:NS10:N7[C&
M=QP9N5O[E,)>5Y$6E!F7.Y'KRUCT-,\6'++S,R]XGE%86,\3H5]",SI/DXNK
M:RPU^+\:3]$8 L4JD'75#VS@OQ<E!>M>P=8N6=B&0[_V!Z%7J'P6G6_]7#++
MDUP2XT7'?X:SY(@3,*9N45Z;/"I@HN$VKG6:4N8^>O89NEY^'?;%/;,E IPK
MOOC198I%[PHDH: B!XKW'VM&HQ4 :84? J^@'9PYSN'7,).,)D6!O^A?>FG.
MI#SIUU_)Z?MGD6%@'!$ET:M%A@"$VOB>(+7>Z[AV6!:,#H"+NC'%!C?IJ[*)
M-PC?YM&H3#@[AX9S*DY =J0UVSZ0FR\%H\O"IFS*0J2,)D2LQ=WOMVD7E#<9
MXE8YSW&&>2CKQ!FUZ&2M!UQ%(G%V<X8U4\>(XS;"D-Z A=8PC\TY>B>: =DF
M[K]Q-=^GG^X66O/^7[4PB6(V2:*X&X:(:SJE0W _?^_M8>Y%]S'.6TGFZO1<
M2[73OO?)^:;^-TD%EE^:2P,A>^8T&!.X[)PA=>/KA ,83T':T$AVP<$Z0AG"
M@5-[;LDRHC^UM:P$ICUXH3;*U=R<#0_ ,PA69 ?]P"V0M0JX>?DU2P#W*P>C
ML< !;7!I:7@M'B*1@'C6.##Z*ST0LP6_)I<<S7K\S&(O*<!"IPD158@/6933
M-*]OE*C3N2)ZB>QYW9H".QR0>6S&9/' 9WDY(3P+C/N7))O!6A^#;(7_\QO8
M!\45_.-]\K^2 OX_^%<&KF<1_9K^'YKU<3V?EE-P@-)JA4\%,_9EBEQT\_0B
MB1ZP**I2&$:!U"BXVK^D2$8"#E3CI;[S*V.'FL"<2J)]KZ]JF)LTA)+_8%(+
M;$5!747\>!$.P.)K&?%></D?^Q38645\ $K-+\$357"7+UGKV'A+PEXB?>DW
MXN,^7H#PF"3TEQ.X<HDP(DAD)VO'NH@I7+M*R2XSD@VW%WX,-EA9"9T6XD<=
M1E@--9V+N&R\$O128G>IF1P5#@"XE&*<-<'Y9&L6_B?WB+,GZ715:9TMVG+A
MBN*I9P^3$1AZ^RQ86'8)E@TK_K) X=Z!"7:]U:.:XS-IL\]A>&[-X?UTAU8>
M1"L?[=#*7Q"M?"/CSN&CHF35S,L*TTE&&ZROT;\-=9^B!NJYZEED!EAJK\^>
M0"E9V0R41G,=GYTH<LO976P/T" RI)7VE%8<:!NRLMVHHVM'[3R=(!DBS;\G
M284_6C76(" (-=J8PG@@L3DF'"LNRAQ+ZC!"I4+>B6IM&_Y HH+Z"$X54:)I
M7I8?ZL\!#_VZG&=')U<+"F6@_*INE5]E 2)Z[RDGOJTA+<&AV NE$O#^9 7G
MAMM8(58F"I.M>T>Q]PU#W^ @).<5Z1$8=9_6XA;_??1FA$\2Y'[!) 0'>_O[
M]H?P_0&X/\:CCF'$(+V?*^C4QY_)$TSP:EDP#_#3];-;8#E&V]D:A;  [5?P
MK^&?ITT)^LAB";V9',K4C(] ?QH2H/R,YHN?M=Z#SZD;F&<=MT9%/C/=8G(;
MIJ@&$:X&#Z:'?A;U_D7*UMI5S79C?LG0C*-*Y2%"@*AG6+?:[>"^%>Z=S7L[
MNR)%2)T6&>4+"E#&FLFW=9L<\L%,1I5>9#"L;O7E4H@8$<V0(8J&,&BLN"RF
M!L:S(HUA(TV4FX<MP5Y65R9A<=$EHD7]!7IL(ID-Z6^++P-S!)P_)%S!/^:8
MUL9L2RR)9*:(Y +T"S ?2;(MG>)T5>E^&W;\)N.CT,^:ILN4%M)*"R]0P0M"
M,0WOL57"=3?(\RQ)[207?^U"O#J;S6<F$5&<CI6S1KY>'E\ A8]H=.0]H\XC
M/#V!(RTVTF$L.BO9L_T+;=/$$7O$UO)C],>&,1Y)4< =FFB?)&HJWGT:-=*\
M8%G,<A"!+WP)R#7COE%RCI8E]42$H^*VV%\"Q].,&X\6PB+YF"VR_[1V3-;D
MBY& WH,Z)>I@XO,93.9523P*5X;X$[C)5@*'9+$0X#DNI&W[(1E9\(_I(#,.
MG!)Z']/)JLM<XY<B4.\4]T+7)XR,T KSY6:2@!U6GJ\H0\AW'I. UA#%W!_!
M4 A?/]R$+);Z@,4B:YHTE?^V!1YRHRRQ@N)?OF"+F?MQ'CI1 BYO_LOZ%U+*
MY#1=-FQ/[!_J[4>F^H1#IH30F.%YHKM+>>:I"'3D^ "G [_B+C-;;!XC1R>[
M]WN:2[O=X\D?*Q"6E"$X#M,O;T;OP>9SB*Q@@\E,8T*0-&,_*9E0BH(C//QC
M/BM"C.RJ'N)P$" >#Y\?O. @5FS$H7J)_T5VJT<<3^_#T?E\(QZE 39)AY4>
MJ/Z0=O;VE[^M0-HII4I-DZ"J JR7PL<(%8K<0QG0F?Z3 #$UD5>T*"MB1U01
M^405!'KN:4C78MRT"V.\W?& 9#-_A20OTX"7Q4WG\=WN1#W>:^L3)BK[X7#T
MQ!;OM9Y(1\N6@O%.FA_V;1UD=$FR#49K.RAT2UJP!*FGWO+Y07RX_[R7[[YE
M-ENPI!PE95H?&5>.\E0Y;.4[ CZBA5UQ)YX$\\Y:;2E'T;E*K6=+//,B]3^T
MD[1<V;A>IL.!'7VV".#]%7NN*E7(0?!_VSMK>@R5.3)2)-;Z 2],SC$:H].L
MGJSJ6A$695UGCOTM\4K,D8"/0Q#4E35/"GMJW@<?<=TZZJK8"),C];\23&:+
MFPB\QB4"G*1[NN: VIT;;-6B^GDXI_&5+YFB(5GC"N:'9!6>WG^ W+<0B9<<
MX[>5+ST?!GHCD>)DNE(PA1=>/W@I4;0=,$-R*:\H&2\$$_OQPB0?TG73X@XF
M3@1WZVLB?_FMSLJOC-]>" _J24DV"K;  A,I*1ZI\SQ/<\M_Q8Q',"^9V*I.
MSFT,C@Q>)!6RF3;/X V6IKW6YJ7+IW2?-%M1S$LK&M';$*>"'!8D[%=N41&*
M7*+ME[A9^DC$&^/S9UE#\+4&;F)J?9UOLZKZA@+F25O F.V=(JI:27LDQ#L2
M'EY)/PH!/4F#PD0J@B1*ZM7^TAZC539XL^BFT#EODVIU9B4]<M7\P[2>6F/V
M0,.=,R5UNUL5](*X?8W=R>3.N#[%1LU+-8JXI3-V"_9]#[T'\-OJRIF1I\NL
M>%3.9M&O;U_;=GA@%Q93Z82'UEHY\VR/.<4;,.:<<'<+=5*G%CU&PI?)$+R"
M@^YFW3XH;*V:O=.[T(\^6YNP>[9+V TE[([V=@F[K[HAW%L_)=(Q.TV[Q)$"
M_@[5XS7P L&XX.;CCA7C0)_'-64]%M@OX"."%*I!$4S0/QXRX="ZZC?20%3V
M?M!MPGCM^]7MECY#5M(^>29FJ2%4^6)1%K(2?F@Y--]D0OQFF$WM7-&_UJOE
MW\[>@(L#_[=#*H!>,U(@!M8OO&=_7YTYXU."=%J[;<[_L=U,R"8+26L>C_:L
M'XL=G)(:8[@SF72;_6?D.;UD6B/M>^,[[==TSW"1EE.T,UVS/G?@GK</<.2H
MCL@OX1J_#<R1473G6NH>2(=CYP*1KT,D]KA\YEIKKEPK6-:%\8?\V3?5B)?D
M?Y(/6?0R@1M,S#,N_P#N37Y5(^Z=[P<%L23IBGR(%*F7'.2",-":?I<O!<6+
MFAB1SYJ*[,:RZ 5>&N'1:H&Z!.8I@DJ+6)@2%B9MH=&N:NELGG:&C$1M=&G0
M9RQ8.ED((G\7)TP$." <*+S)X\'63A=)EJ,_-(JD^Z>L;.Q65!:3;69_\6R]
MA%T]5Z5$C2DE_RI_>\@)=9F-L4!-;UW%9X7OR4\M.[(=J'*2>2VX-57N>G*[
MPJ_*H<9Y^=J#-A*:F':2WI*K(79/7=#:!NOM"5#XJ0?X5C+/1TCFZ>J?M9Z>
MVH>V]A81>C0S8JYPM2?]>TY;,3APG")L8B.B-UQ<2R#:@Z U>N)U;^H>!MJ^
M2YE(Y-KZ150(F]0?\!3I;8S _*N;5M6MP&(3=[",W,$$RUE(7KB$*D5-J:ZV
M;WFTJ#8XDRY_(KJ%?3Q-W1'BJ'^.)IBCC,J=?U'-LJ%34%CL9W&@"\=0I50&
M7W 9V(YS4(JE)%0^'%_H9&6&%4G&/2 =/Y1_WF"#QYRS^=>[Z%1O,^[62U4*
M/SEV]-A(3(R.#?S6?Z?5(IK %5]?P+/B0J-AA3.&%1#3!"-T]K=!V& 4#'6)
MF6(0,& YV=I1R\@1]/_V+_&T+1C4=.,N")&/A=) &*.BD>$)+E+% [>]QN6$
MHSR@O AAU3":P:AM>Y'" (8_$7P*_O?O*9B8#%N@>7"/\@4E2VRFQXJ2DWG"
M'1S>E_"3;*(F-S_,N%7"I>$@7ULD^JNEU;C"06_7 P=VO(#MNI+Q=8D3,,$Z
MBSFB@BC&HK1/T>2841Z"P7F/@I5GNS+#F.1T-6'!XQ+!5QWQK:V<DUDCV9->
M-(O<&+/N@NQ$CH!&G+?Y*4D3D#9<"\;4?V$(FNO$^YE/#P=Y3_='EO?SH7'%
MR"/O$L&HJ"IFGBWJ-)^Y*/LTG1"+1:" *&^,'82:U!7N4)J'  E@U9:*@Q&<
M1(-%>]BQ"].R66TL%;F-G8^QLAPDE] 3V.N,#X"KFR'VJ7.G/=4Y8T'@HJ_%
M-%3@W1]I@J!-LNJM.2,\?9\P5+CZDP3LM,8A*V))#7M!SQ,K(:BR1];"[H".
MI;LPF;^(/)76VQ@/4K 1VSJ* 1N7Q2<-+2-9Z%@=;RUT;.-)YW)(@GAG@6Q*
M6+S, JY[QDJNMS5P;-J<J0P%:2: -M/=#__T#JP$97$E[L#8*/&]^U[1L^7<
M-2_/T@LQ%0R6ZU"*:XQLE.=EZ<?? X,48Q3!"42OB>Q4/C235(+A%I"E0OR\
M2J;4@,[KRX?@<;N$QDW2Y4"TE5SO"G4%0\;(HBF&+:9BNB2%MFEX]1'L#INX
M/W/8,>G=X/5W" ZS:'7);O"-'?/)E2.LS)^Z,H3&LQP<-HG);XLYJ6#O&5\\
MF:@>6>-I*9:6HP&(#!?>$T:@; G4=HFR+IM>HB>.R972@:&\/1@],4,2]^G1
M0;RWM_>-$BEO,827'IW2 MXVEYYW16JX6LZ!KV&=S\H%_/O7] (./IC3?1:T
MU <FTS]6"7F/ 9'P(I6]?/L?$% Y*IV3>9;.HE<,Q ,_[RTSNVII7CHS/UN0
MK7[FQR*1;"D]+P5]24J0-!WU7M*$G7=\72'%76W^/=GZM[;5C'/&R#C&?6%B
M8I'_^%?<=+Z>7&LSK< TC7+LR$3[01ZU, _Q9W7:"#"3*RVT?,4!!K"&9QJ*
MEM"U,8GEV6VJ+"D(FDV=WK!V7HXN02"P:-.'IH4LQ'U&1QP*%;%DZA48-A>N
MCQRYBF8MQ;$^G&#*..!ZE3=^A2]/DT?-"F.8L=F+GEF5)B3[1)HDXIBP50PN
MIB"7EPAH [N\[$$2'8V.,/Y/[0_FV3(:Y^7D ZSE VO>3@@R" ; (P1TIU.'
MR-+Q&,D;P$] ":\>MFRIQ%%W1^1!BAYSW$_6),5:ZXPN?>+Q\^$)<B,$>PMS
ME '2)'W$BVG+P7T.8\W?4&LM796^+\PUL^-#;&"O&GDZ%[BP/@Z'#MM*1YS&
M:OBTVXRZ=^I;.C&TAOM?26LL!<&6.)H;O-&)+ 6@V(/IZW-B,D?\2C8F]ND0
M]WN:UB CU"KLX^E6J[3W"/???PI*FC:DS.* ENB/SV:]B,0V>(/AH,*;2L&(
M%%YWGN1,T?7%T#KW158[F*F05F[GQWK^'\D]D U++ZDHY\^WE4/Q2#2QO9[!
M:CFE4^2?"&-/A!_/'XS(ZX5RG&DS;+C0/KU\^2E&QM^/ X =X_#:TL:(5>A5
MN5G^ME;^L'70@Q:!K<NWY;UN2C-.%3&+[&S5-4+PG>\6THO\;H2ZD\Z%TC%U
M+V0Q[5>UAM"?4L0G5-WPL[;#&UWC\/I1 T=PS,IT<FU8P*P-"WSOQGG?HA"P
M,2M  9O \G4.]!K[BG/]1?06%I^M^L&T*](!UFGN;F0WP41?T( Y'L.Z)07:
M=J%^IW-([4M(9\[6Y?C[[B@BX7!9L+,"B2+O-X0$50TJY7I8RX8UDG%G4LZV
M"/LB$"UE3Q.$YXQ+[LCAL./!^LF'>;S$M1JQW=F=Z+IVH#ACOQ^)>=8[P);5
MR712&;CSTXPG%NY!QP((^!!ITZPIEB)_28>$V @33P_J)FNDN"/!<Y. @-G?
MVW.I<QL@2QS!)GIY=.A;LC[0)3"C]EH;SY*CP(T-&" T)8P.H>Q5Q>+ICA"0
M$LL0?K!-K>ZGT%J+7GR^0R\.HA?W=^C%KUR)HNS5.CJK.]$@"W4GM;<3#2H&
M\CEQ+*N!W);*K?@!<@:F=1,$0[N2?&SS,80Y*&>FS].6G#6[V1UCE: C'Y%8
MOR8L3)N;E@3;9([Q\87W)S>82V:9>_Q4(WYHCAO_%2A<[Z<@^[(^E[63.M40
M5M.KG23Q,E"^H3\T8)?'SG^RVDQ=C;6;QV?CFKU3M400RO# =0@SZ'P1HPR=
M(#96^BZ,V PTK7IP7L:!HO2"M= ^JL6QD[RMT.XW79VYH<_4'S?(+X0TY!-Y
MOB(7; -V="TLU[H2%GC=3G90'.^ /][7 XZV])H*]79:G/IG<KR=C@.R_S7A
M;G9]@>/<IG(;K,K3;'*(#%D[#/);)1C!-EEFZ1V&TLFM4D?U9T.OW;;*]:QJ
M):MOG<O!]P39R5ZO1>)\>%93R;W4#3,[!%9H:*]KGT"3%B3Y@WP=5ZI[;4X)
MLXB7K!59JY?P;T&L:;\/-'\?S<#BCSC(<9%Z-"<!5@4C>!5GZV+C]=; '2C.
MD1)EY05>AZ)[/H>*S4YV?5 -?*)Q;J,OA Q=828H8^?(,(M#.KA'%9E?\2",
M1N$<)(W;C!#]KFRW[VL'+,@NE'H:^GT.V6P$4>CICC(,5*"Y2ZC&^(E=#Y#D
MX"2?!!11'TBN6STP :,BN0?&\+V+WK-VM,:>,F-#(AIH]8. [>@^!PVX>OJ6
M<V7F9KFR]>U ]>%>>;1PI7@7P<N.F<'LV/:I,.3-NSX5]M K<$8:<.R*ALT]
MS7!H%RTM# 2AX.Y$R42$!4$:7*8#^<&@T/-_@<MU 3ML;C4V%-TL-F36QH:V
M#PU%-PT-F5Y'QO>58-UPV5B!^&D"%Z\)JJ@&XSS6#J<YXF/IPOE!1W-]T-&*
M<%DJX586I]-F&ZV5(DO9UD /Z?V= 01$ ]>FUVRY<KPFQ^9&S+P0>1HV:K/"
MR_TD#(%:6"U:&4QE^"$K O1KKXDC5 ,7<A77)E(E.S.FJ)Y*(N^&&IM(WS0%
M_;UK)[^E^OY@BL#PMJL#[-H\3+LXD;*?72NX<&*]RO-VF^!SB.YWJB4P>2^V
M)=KX</K)/^YD%WS%';<Z107YW&$SH^SZB1YMD>&RG5KXQXD2"<R,\A%QBXZ3
M.K- =549'&C8;;#K0_FLTY/>L(O0#&3-K=0,+R%N2Q!V\<L4%'-GZQ1\.%]'
M'-.#3>_M;B7[KK_<_:/ULS5!GT;K2TY3JLPUX,"EU&:M#0@):&$"5>XIX"'J
M+X]O0UX4M5_DV0QF<Y6Z#K7B >0H\5>EB]*UM_):4CI*CH[15Y-M;IF );@'
M]K[.S!+NOE< %@7X!(Z%ZI1UHF#5'"2Y5QE'#W17$H>40EQ':62)099P1PY1
M^NZ!#ZU<5SPZ=DBX+#I5Z6R-?TJFTK@]#9N\=N RMO*]);E",54[:(M-%4Q#
MKTW>]ITAD5SWW$XU?0N(1/Y@JP*  H@NR$"'13'WJH0L';6[H3Z:UUG4_<:[
MUC&;5CU%)\+BH$DTJNUJ,2RKMDPLC"YZ 2(ZF"^K;'J.O-A)$>AD+RI#5RJL
MUP@C+>WRC>&B(&]Y<?$XBF/*L%+%@GV)YRB1K+B\DE/C7A=+?ZD=IU\P+;6S
MZ[0AIJ+D/$&*>I90NF<6CV5#65=4E%"VFP\'_F 'WM+6-O$@JNN-%ZQMAZB\
M<A2*)7CM+!.0$0NU6/QI=NI/!A9"IX/-:BA((B+,LWFI[H0S+%3"Y_$4M A'
M60I2@#B&PXH!0?G<]@F@X+$?J@UDN&N ]$5EUBW"%(YV,(5!F,+!#J;P]7L#
MRKVW;YE6.VJUK4Q)%G4]-EMOV$K/#=DQGO :13]U$PI1*Z%@.(O0 H*2FKZF
MK+)'#8/V21PDRT<K!M&M7IUCV'AWH"X0J#E(;NR]WGX::/FM"NFZP]^@]"\
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M4C7/REA*7"]5>:U4:N/Q!!R%(,>]9\ZW+MPWEU-73<B6C!]7W\:I%:K>I9%
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M &KZ:[@6,-:$D?QW8%<1;+@$XL=T,V#VJ/]L@N=QC$9[GQ5Q#O(&_,H4\ZI
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MQL!A2_W=&@M)+]4Z,R7<:9EG!JVI)EUA-=BU9M=8U7?Z_JTMNL X?1:(*I@
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MXV++*M!5_,(CV"\!W/D_]/D?SQYJ$5N)T>$O.@YX. Z8. YXXAQPXCC@B7/
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M 4N,9W 2(&F<O"I8)F_ !@T+$+ "U<0TJ4CH0?S@,S'P7Z_5)/$4!=L\D.)
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M &VZ=V]_"IH>G%Q9_):BP\*0"R<EH[U8S.!1'O)3).\HT$84*9 [A?QAJCG
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MXTNI!R>;4LE'?7DU##S2/^R/255&X1FU"E?<,JZ65 \(VL32(#I@S$8<ZY.
MHQ=@DS>,!9WWU*'E1J);,OEX^4EYC&Q$K111#E&!3-+3KI+%JP8N1]2%E]D5
M7,#_K2N6PJZD?%Q:_J9VY<E4I<1*@QK26Z$MU63M$4A*Q(DAUO_P;XKR-A1M
M'4YK)MOI/BC,^NOH\RQ6^50U$QRYFN.!9^"-2Y+YE95*]G3FJ0589LI&ZY(*
MR9[HZ'9]0^L[O*CMAP8%7N&FR!=/597'@E>0QZ1B.*Q>>$V: <W5"F[5.OL=
M@_U";C35E25XYR+R 1QGDF%>#C/R[*8T7S[P?[3,H,(Z],U03%AZGV-F?X.9
M6QQ\.W^V$QZCX;.CT?A9,[2"A5(>4*#*.6QGV3C-I6F9X&?7>?O:*&E8\ [L
MRO6N'4#OVK_06>C3*V;Y(3/+16B$;@K""C(>S^FSH/Y'%):A;XH\?PQ3JJAG
M@>W7'4XA<!W9'@?2,XM/_>>''W_]5U,\.7?"R6RT]..R0HT,*VXVV3Y4Z]K.
M]HR3T"<FH6!=])*+EC^-DD@>+G9HGP16>5P[!%XH K"[0G\= TEU$9QEZO5:
M2MWM8IE *(?-G@OQH<G<W%)V*9$.';@,^[6/X^QE;H@_@1M^^,R8"VB'9"OM
M9&,<8]H(>\C[P/1-@%\O$]5TLG>#L^"X&CT3#=SV@<%BX*">?=4>6J=^G/H1
M]?-&HKS]Y5[;";8&&MJF0,B-6(0#*<"5*(GP^NW%U_TD;EN0SC+*-_+RJ!^H
M'8)J9K&W+*]2RY4E.-L^J]@P>N9)=HGH^Y9[7=2OQ*(N%4FOAMUTT;F;GN>R
M1M]7W$)"JS88=+AMT_\&/A+N.M#EPW9AVT97*V>\^JS#N,A<]@9*5]=:Q>F,
M,ZY\3UPR5@BK8:9".S]1ZU$L1E3Y%;GU_6Y,"=,B";07UV09_5,K)7SPAN(#
M>I,=PFIJ8RR2F9H53B'926!]-W+.2(J.K9*\L,ZWR[$3@OLBO**DD)5J;:2H
M-.MX#0]=GH#J:#!&?_^WA$!I*)>YN07&RB5\7U897%R#)3UE.%UPP/Y-FJH;
M_SW'D*@I+RNP&+DJ7!)S(XML)\ *CY"1D[4.@KY[^U.C@RXL)&CB\,&=170(
M%E%O?/#KL ,@/+!#SG3C2FFU@');O[4!PD%P$+&Z%.CL7NO0Z %[A ?O;Y,A
ME'@W/#@W^Y?97%&4AFLV+5QPN"K@]P)TUD(%AZ_U!A3[HXIBKNBN 1,L\D[!
M$T[\*F4/4.XGP5' B!7"*ER'ILI^EE5YS_,0A$4P=H'8O!^L)8] &@O%6*9L
M=6V"5G#[K2[OU"DE76+8DQ0Z4R)OQL>OT):BEC*> *43."UH<HU*OE!+6/&5
M,H5 7P)2WMYM"[2<RYZWPY8;K/)2XY<CQQ)J2-_XH@0%E"#ZV^;#0P'/;<LL
MN]O(W4:[@I?7759;<,NI]ZNNW#6HC2T8<_8>M??4]R*P$91UR:%_Y!O$RF3M
M9,S)V$'(V$X@RFP0;,(H(ZQ&6-3R9?=P6]#*+41SAFL24/->:R$<<_*U!0E=
M7^*FTEUN20I-63#FNM@?+8,4F"5>&<P$#;'<:R&_-\ M0WB7PKH!,PB%4&]/
MG- [H7^R0M_$4Z=^$@%5Z9NC[X1?OQU1_;(JFAWS1LPMT>VG>IR8.S%_;&*.
M LVW9J=4EZU;SH)@UZ&+!J@Z-^%8B.I]!YS9;1VM3-9@_.R%E,SI!0DJNPZN
M;.*R<SQJFJUZEP61_FN M#LA=T)^$$+^!F=$]P-HIZXXC<QN83P5W9=YV49N
M1QFD\MHV;'O?.<<K..AU-\A["[B]9<\W8-98S5CX[?WFW(J>@(T2;$)P?FX!
M!SSTZ#$G[D[<;Q7W?TDXJ1>/ZV#Z[Z:CC9JQI*7+'FM, D]!,H-O!<+]Z[3,
M+A6/01!$GH1F^\U4GO<?G]J.@B/&1 O^4RYKM-OCVKYO#SXS,7N.*/2+T>ER
M^3DU_U'3'4@0-RYNKG$;[J&-JO@[KQC7V.]\B)H4[,\557QD*<?Z&UV(-$!6
M2"XE?T<4O:^[6=& .X+_G0_T6?>L*JJ;-SFS9\-^C*F,IK:F&&+53/0ANTLC
MD1FT53[7OO86EJLP0$/!KMQ?TIS">WM3"*PZM=#PD'NLG&24\B:1"H("M^&*
M>BVFD1[1Z1H+,LD"5[#2FM3Y4U8118\)DUQ$*YO2,_ N([R-K.II%"^4#45A
MTFBR#(/S+:!; _\G6+J^X@3LW=]$IH_[K8*1H<J,<-)"K#9'/ 0\?VPP[AA_
M;IA3UDTA =8MA*7+8?;KGM-V#?R-S:55*DCH)6/R%=5E06V&)<A)6BX*&R=!
MS(FVN=//@&"D842@+"UD\%J#D3Y@&3>^TW01 UM$PM(7NDJH86WUK,1+UCHH
M09I4YRY.GVD1I49<%.L9!G(0%+FU[<97)9C1KQK #JT0Q-KI,Q.8L1^NXT(D
MVDK*)TT.YO2(:5*[=_W8 A4IELLIEOXFA@OR1+LYT<(^V4"(J*6DMZ!N"H+!
MDBL9)T;J0C'73B2A4^34KY0JXN)U?(E;R_HQ)WJ[5'J!7#KP?T/4<ZLK#EYR
M+4LR=RG8T 2I()TK_G.J'FA-,GC1=XP\2 $- I]:O-Y^I09WW"P3:)=ORC3Y
M'0;(4X5#@1V72A>>7%:EI28(0QEMTIH'>+))8>I#J5&(=2FP4V^^X"GPB#4/
MKUDSV^-2-CH2ZH9WYWPXY^/K.Q]OLQR,WKYM=0;%!U,&Q_??_>&XV7'S7;A9
MP]SU+ZC7_D#3LM!>=@. : ,)RY19!5*C[2=H'H9]KS*!F!N;$+RVNP(_'JA!
MX)]3 ;@3-B=LAR!L'PR*0]\AO=J*UFW86LQJ6 5R8BP09RUJ[6]>KM',*_-P
MVGMN\;;"S23F3#/Z_P9M3O]20M>F*0Q_1V&=RS )V?I6JA\]N$@9*]1X3JK>
MZL7!2OH#MC'T!&H:.Z"F[4!-)PZHZ1OO36K!T5C1N*!&->5N12L$M($13&"6
M12O]3IC-%\>#TQKC.4/PYN'9X-S\Z'.HS]YG49\W<,:WHSYW!#4WMB+#'2@^
MI,<[>/HUG2,T"<"W@6DG^EL*YW6,RG1]8BN?QB3_$ZVR,GOI-UZ!GPC8YJ,/
M6S=(X$D2\G@X#,XM_/)7S4=8F(7ZS87<!W52M77Y2=2%D$DS'?U3Y@&M"=MZ
M6K:LYV(2')]=6,NQ$K_M2U83MG/BEIXB")K$GD78?H9,-*K[$YXCV5^84&+3
M[L9?7KRH9\*T06GM%LHM=KEF*X+E/P[.)J-ZLYYY:V:AP AEQL?#8(RC'>33
M!]81^34:9JE[E5,P%L(]2!)S57NF<"CX%>FFO%KXK$Q\?!X-#S@]'DRTGB%0
MUK]-)K7F"9KGW^JZ/+ C>N@E@ L$QLN<PKE'4Z!(_A*56*D8CJ7=@QX75DZ#
M!CO[STD\F=\+T>6!7Z6DT[ S.)Y1#A.US#6<YHN':V[=NK5[]D/%/B2\N%6!
M]X#\K>6B=GN?8,5L.*"7&=Q4NWBA;$Q])Z91V_&[\V.%'+5MAL9NBY^.AH/1
MF%A*?SI1,^(S^?&FS5J?1)=;NI?5;7^?(0F<#OI*__>[\7=WM_![+K%K+3^K
M,/TJ.S\ 2I\^+*E_$H"%KT-N=+^=5']]J7Z4PG5(!'X064;CWU'Z@2@]<91^
M($J?.$H_$*5/':4?B-)GCM(/1.ES1^D'HO3%8?D0N[L/7?&1?'[Y?#R<!./C
M\V!\<O+BBUV,?KZ$1$?&&!RQ"8(?^^[U[QCTH_40%,CNN6P=A'G6S5R[/Z]K
MU;>)2X^'G[4>GB/PW]Z>WG_I=^: /L3N_]#[7O86LD].CH/3T9=>;X[XNQ'_
M?!B<'W^I9^*(OQ/Q3T[.@K-3Q_E?A?BGH^/@9.(X_^L0_VP2G%]\J?GGB+\3
M\<\FX^#X_$N]'$?\G8A_/CH-3K_8F;_S+A[&U?D/IX)WM_IW3Y/PEO\EE4UO
MJ7J&UO'\7[^^??%%9-XGV]T3KW4PV&@X.![N\;&\VF>[ND5[<@OW[PO>@P-X
M+X?\;7+AZ6#X8$SXJ DY<I3<GV)TE'24=)1TE.Q+R<-*&.S;H/Y2P\>9>(YV
MCG:.=HYVCG:.=HYVCG:'3+M'&!%&^)RB]'^=<3'+_WF"[L_)R7EP.OS2NM>G
M+'7'%^/@8K0E*^:(=SOQ)N/C8+2MC,01[S/$.[L(3L^W!"\<\3ZC^,9GP>G$
MB>UNQ#L?!I/1L2/>3BFNX_-@<N)TWD[$.QN.@^-M =MOQ<AU =MOW1ERM'.T
M<[1SM'.T<[1SM'.T.T3:'4# ]IY:%#?W_7>:)/P;#1I]@E'<\XM@>/:E@!RN
M"K5VT8?!Z1=WF3AZUO&BL^#L'JJLGBP]S\Z#X?F7]H(X>M;Z\R0XO_A22!)'
M3T//BTDP.7?TW!L]1\/CX.*+NZT=06N"CB;!\1<#MAR"_?U5T4+J!KHG:WJ/
MC@=GKA)_3Y1T/0W[H>3847)/E)PX2CI*.DHZ2CI*?C5*'D @VU5B'&J6P]'.
MT<[1SM'.T<[1SM'.T>X0:?<M1X(C-<7Y\G$&[X:7J3R)4_7E!1N_KA0^56;^
MOK]9J;10_O-?5^]OGB+XVMZ?ZP38*3]'.T<[1SM'.T<[1[MO@W:/,M+[*T[=
M?8(V[5EP\L UGX]+U$8GP<FV(0^.=I\KF N&]]<E_+AI=^9(YTCG2.=(YTCW
M+5BS7P], FM_GZ!=.QJ,W9R,G2AW/)CL5=B>8J75>#!R)6O[$>.'&W?SR GI
M.')/A'35J'LAY'!PX0AYZ(1\A+'>KMT2LK ?II'_)J)E%_"U)\A*QZ/@Y/QA
M(2H>E_&,>*6C+01TM'.TNS?:G0<7%P[J=3>E-PPF$\=WNUX8%Z<.)7<WVAT'
M)Z=.9G>CW6EP,=J"_>1BPBXFW,DTDP?T.!^7N)UNC1XY-_VN-#QQ$"3[(N3#
MI78>.2%=*'-/%XL3[3T1\L01\M )^0ACPM^]_OM_A<O5JS=/D%7&HV#TP#"Z
MC\LX'IT&YY-[\T4?.>W.@Q,W66Y'VET$D].1H]U.2F\83!S?[7QA3$ZV#"-U
MM/L,[<;!R39$6T>[S]!N$IR=WYN^<S'?1VG='@^V9%B<:7LGZFT+;#A7_.XT
M='5N>R*D"P[M2R<Z0NZ'D"X3L2="NDS$P1/R .*^_39Q9]OX]ZP,DR?(+:?#
M8+S-H_JZR_UFZ3F\YWDU3XJ>)Z?!:.(F5.V/GB?!Y,0-J-H?/<^"\S/'G_O4
MGY-M59V.GCO0\S@87KC[?7_T/+_W":DN#/TH.>?"Q:[V0\B1B[GLBY(C5[6X
M+^%V$?X]$7(;](PC9$]"NGCJ7@AY[N[M?1'R_D3[  +3^S>4GTZ1P3X?^=0*
M-!SM'.T<[1SM'.T<[1SMOE7:'5;0]UZ*++I(T!PO]UN>S>+R";I&X_/@S&5I
M]IBE.7/$W%^4.#AQ%0-[E/5Q<'K\L!T)CYN>Y\'P'O)!3Y:>QY-@N&V<D:-G
M?WI.AL'YQ,G[_NAY$IS><X7E 423[ZG,&6LO_&SV="WMB:L=V \AAVZ:P+X(
MZ5JQ]B3:CB/W1,A31\A]$-*AZ^V-D*X&8T^$O#_1/JP0MBO'.-14AZ.=HYVC
MG:.=HYVCG:.=H]TATNX (L /47[Q>WCC/]%VO/%# LX\+M$;[Q7Y\RFZX0_*
M?(Z2CI*.DHZ2CI*.DB[RZR*_SB-UM'.T<[1SM'.T<[1SM'.T>X*1W_]D^2?X
MH/\V7,5/$_GX!+P(UW.WQZK!47 V='T.^Z/G<3 ^VQ)I=_3<0=Z'#S[D\G'3
M\R08.Z3>_='S=!B<3=Q]M#]ZG@;G(Z<_]T;/L^-@<G&_2.>/.XY\!S.<%O*O
ML(RS)\A@#XE8^;@\XKU.GGZ*V3$'ENH(Z0CI".D(Z0CY31/R$4:O76K#I84<
M[1SM#F!9CG:.=HYVCG:.=M]X^<7!X2#_HDK?82%K?-31J<LK[C'O[8HR]D;,
M43"Z<-BH^R/G63!QT]+WJ#M'P8F;1KU'>IZ"B>!J,O9&S^-1,)FXNWU_]#P)
M1O>,)?\((\I=6WZG5KF:QF!_9RFM(DPC_\TR@PW\13]\@MQU%IR?/^SE_+@\
MY7%PLBW3XTBW,^LYTCG2.=(YTCG2.=+=*^D.*Q3]$$;P3_&-BIYP2^#1)!C>
M0VW.TY''H^/M/1>.=KLSGZ.=HYVCG:.=HYVCW?W3[@!"O@]6>/$V+!:S)+NF
M9<RR7%N_3S?J.SX-AB</F^-^7,+YL,5ECYH73X+AN6OAWF=YP/'(E0?LCYXG
MP>34C4;?7SI[&(P<I,A>RP..CUVYVO[H>1$,Q_=;#O2X@\[.#'3^K:.=H]T!
M+,O1SM'.T<[1SM'NWFAW ''DAPDAVQ%C6D?^-&?JC8:#\7CO[M&3@'!S6LS1
MSM'.T<[1SM'.T>Y;I=UCC][^/<^NR\43M&S'#IOX( 7.T<[1SM'.T<[1SM'.
MT>Y;-VP=KO WR1R.=HYVCG:.=HYVCG:.=HYVATB[QQZ9%?#@+ T3_]]A4CW%
M\H/CB^/@Y('[A9P,.MHYVCG:.=HYVCG:.=H= NU<L-8QAQ.L@UBDHYVCG:.=
MHYVCG:.=H]UA&;!?+UC[4UQ,GR; [O%P&)Q/W%")0Y4\1SM'.T<[1SM'.T<[
M1[MOW<)]X!#MA_1*%>42/EP\0=OV8A(<GSTL>*&3.$<[1SM'.T<[1SM'.T>[
M0Z#=XX[==NW^[2),Y\J/4ST[@I;RK[",LR=H!A^-CX.SR</.3'?RZ6CG:.=H
MYVCG:.=HYVAW"+0[@ CO@PU1^ST#J]=_4Q3J249^P>0=!N.1&QQ\J++H:.=H
MYVCG:.=HYVCG:/>MV[QN>-FWSB>.=HYVCG:.=HYVCG:.=HYVATB[ XC?/D3H
M]GU:JGR5QX5BV#!:R?/W_WZ!]0R_?/CX!,.YH]/CX/C,P8@=JF0ZVCG:.=HY
MVCG:.=HYVGWK%K"+YG[K?.)HYVCG:.=HYVCG:.=HYVAWB+1ST=S4_Y^/[YY@
M-'<R"<Y.76GNH0JFHYVCG:.=HYVCG:.=H]W]&\#?E^%EHE[_$,57KSWOA^_Q
MSQ]6_=^V#/-Y#&_"CPZ;+_^C*LIXMFY9L\-!(^BZTDOP]K:*[UY;CY5G_J^C
M(_^G6"712_^W<*Y>P1?_K%0Z5?#\\?$KMI+A[_[1D7R3F(2_#/_32[K,\DCE
M1VSZO_1_3,#V]T>#$WAOD25QI)=R5&8K?/2J-#_1WSE=P9&T-YEF^3),>I_O
M5*&AWWSIL..=0WJG102]_5?^[^L5;/Q-'E[&TU?^+^%2,8E^R9 6H^&I_;7O
M]?>(3DAE0Z&M%,M5^.GH4LVR')Z\(N+;RSWM6"[2S::1=;P-SNE^N;U>W$E]
MIOOCL WV?7@)^GVA?"3J-"Q*>-HJS_Y04YS\5WAA&OD*OKH,2WAS-O/?5&7V
M<WB#'[J*(Q7Y9>:_'[P;_#CPKU6NP(4MX(=9ZJ?54H$K6_A781ZCABA\?%A8
M%-5R10_WRT58^F&.0"<+^&Y:)FN_ I;(RS"&S<7I-*G02PV\Z[A<9%7I)_$R
M+D/\=N#/PFF9Y86?JP061PN9JU3EP/QJFJ79,I[2&Z?9<J7*N(RO%/P]C6)Z
M^<!_,YV"",+CDW7@P[,J^&*NBBHI"_A<!7X<K'SM%T"_> ;>.B[/F^79$M:=
M@3M<J!*I5B[0$^8?643\K2:BWR#B0).+**&BH"99%!?3JBCH.[AC3>S_^M_G
MX]'9JP(.. 4N1#C$P"/BE7!RUG'5IQ+"5L(B2Y'P^(*X\*L5O.)Z$4\7>@6\
M2UCTTH]+/*BD(MK"=U>P,5JW?%3=K( VN,XT\Z]BX, 0SB\#_@ *55.D 3Z'
MOY[EM##[J.%'N$T\<SAI^*@A QQ?S-L/DV3S6?KDD657BO@6PR=T(O(R6$28
MK'&+N. HQC7B%WQ<'*QZ!=01:IL?P9KBRSB)RS4N+0$&Y7_,]-JGTRH/I_1;
M9*!$E<!;A:P_FPV^JL >@,Z0T]/4%OY ^GK9*D[Q9(A#-GAX5I45B/Q*Y73(
M> /@"63I_ @NH"4PESX+2]O(J:SR&#X.?,]LC#^"P[F,4\5B#F_7[_%(MDF
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M42,*<UM;=SLE'Q=%A4_;&OJ03NFC644VP379_V7K:$Q4C>OM-3:'P Y0EHN
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M#8^F9709;C1@@"VOF(PR165I)9^I)3.=%7QA3]SU!V+W^R@:F'C6%2T6T=4
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M01,K,4D-Q8YHABR*9K%=0R(7PD5D)P3* 1^_K''A5*J,6RF5SN+ZN?L(8VU
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MPET@XBG!?>@G-C6RO&* 1?X6@>X2E]X=Y!/KJL%:B@K H&#_"-(9<&M 3[9
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M.MFL;-,4"RV/"#9YJ[T2D."<$$WR _UI_^6&MB2"(6JMD .V2@R#5 I3\EV
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MIS#7 +&^H3!!* )DJ*TQDZ)QA-YVW:3L*.G#T6J+: NXO'G!T;?@09-^&%D
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MK_!2JQ!@J-BB %9CJ59%14F"1A75#%;*0S=D">ZS]6ENJQ*#YC97M%&+8E6
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MTN*NB,85..WK);OG,'KY7@O#F7!-/DFRVA%X1U&-Z%UCJ$8SSF<<I/#/%IR
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M0[BL)\6:9DDT"Q-/R=#(EI)R%Y(J,%!L;=@?Y63@5(HQ1>HXRY> 3]:]QR[
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M.'@]L7=I(DE:,W>X0,]Y#'A\G'M5R9NE%;TVV419(,"2^15U5CK3H5P8<:Y
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MRF*')E6(C!W.,79/S%U&ZYC#U-:O-Z,QZCV6IK"[=3]P2S'F+Z8%;]U->"#
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MS3Q-*NFT[N[\R2H-%_&8_++?D$I4Q]7300@"V9>M).W>$Y3GP2&43>(ZO K
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MDV14;CR0SES%DXH9[(5V4 ZC4%,*HK$^# ;<3#M_$G@TR^/("2ZF&<,MR(T
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MCXB\CB:8/-U49_(,!.*$&%2Z"7<& GBFRT@TB@3.6.]H+H(.>6.C)X5(G=7
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MN*_'U^ CK4D:!_ZPKDKK<S;MM%QG^=O(:<3D,G";VC*'+KA7X2R9]<>6A"/
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M+Y2*S"D7]-6&/0^#J5.E8[N%\$P\FLTHMI$-[19\L.M/PI5]P7!RQ9Y:FI5
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M-\]0[4,>W4P7Y(1,ZW#I1^Y6I\Y8XX=WG)CCNE*HS#YD=YC"$#;33"^[FS;
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M#E7T[;@JW/ECH[?Q2Y]HF_:_PVL0X,_O\#I$E?!MJX0OO11^0C)Z)E'=],7
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MP=)G$_Q& _>*AI/3^!OZEQL(?,,]G = CD3;&/K5"'Z1F"G,!?X#7Z@3QD7
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MI >@T>\,K*0.!%F83]>P[?H_9L<4:S^0K9>I,CC*B,B(!&0UGOMS36:OMF]
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M$+\07\UX^2;QV1T'6 S?$GG.=9!WI)VL:G!8??B0<AA[D']\!9C<%@_$YGN
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M%,O$XF2M;V\)*K40DPL%O0H)3/L4$ZF*L=3K/G];?^0R!$'UT!<GL(P<(OG
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M&JN_/)M65LDD_%QN.^- DZSX_$H]_0'W6J#T[AIZ8>+909)Y&;ERG'6V.EJ
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M!6*6@#W-S9TM+&3@%VJM[9K-^R00'HQ-X#Q,P?6?IZBS*,_CJ)@03(_'7]B
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M!NV$?,]]U=30J?X+:A9X_]G@>3=O7WVE/ERKY*KQ+JQ$-R9^),TI.D>>=M^
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MA'&%$V?SQ0)562>+F=BYR$M*#H'=&HQKK434:*+Q78;SQI=9F,%FR2]3]&Z
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M0DD5<HEH[P*)OO%MJL) D,^?C5GJ!21D)ZD%\S7S\*0RFA:BL!#)]F@]0=6
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MFA4>D.MJD)2VOLK45LFC64B8D8-+%B XNC6&\.HQ6/"H7H)^[P@\1-0"Z![
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M,U_4V%27R!?L*)+4%/Q 'Z6;M.M1R#-"U7;$E'5G,)MD9;T6X65<% (?;;:
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M+FRN'1>A%]ERB@3[NC1IZJF*N(FJ/& ^Z=@K%.IJ. K9-"6BVH31G&^@V[R
M@O87(DD0@-M7 J K6&:8GUF=VOH\OM2OV4)=UNB;O3 Z;5OI_2#&UO#+'Q,U
ME#BD0W9(]WC:Z0"B[>,8W)"?\UQPRB3JK'^YHT_9NMHM 8_UZ!"; DH.E5DA
MOKN\F)E$BMQUOW3</KF<KM48X-II@+U*%T>MAH%W$R%I4UYAPMM42:[2Y#/(
MKWG.MBPE8M:3"3K)Y62+B'C8^_HA^[Y!VW=9<;3W7$85EU!'@H*J4AIY6^4,
MV?T*J?^KU\:E<@8D?J[=_FCDMK M1?TZN; \WIBF=;W;O4R^]"K0E,9?-#BT
M6:Z_UIN__U*?MB[UP+_49\FTGE"T>%H3K5W?Y:Y81;F,7[V*&I6P8^4TF\ 5
M)NFI!'=!/+MD7(49F$AY\5GSL8/8CU1C$G:-=32/;1$'/NT]JQ*U\L/&4E\E
ME>R_\*_/AT.Z?29Q.;?>'9N6X&8+%:5&? [K-,-M@VG 5+_;T;/I&6275=]>
ML1J4LN$EF8@MKNB+-Q0K!';7' I-)G%?$L4T0:,=.YW[.NVMUP8D18MYJ62!
M!9VGOW9F\)/M:R3O2P(I K)[4O0#&G\)72]G:OTV\U@E*8_HJ(D2EPOZP?#.
MTWR,10F9'P_+5<!\PD'%T<"?3S\X^AB$BE=,]&YI_"AWTJ/0"\3EA?5*"1U
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M-)G-B+>_ "6<P(;-1RUI-)?'FM9&43F-*EL)",*80',[A(L;EUK^#+&D88I
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M:4Z1E[BP:I%ZSV#2: :(CB!@_C(L) U*ER/3!"%F(T;MH]/IKL.:T]>)AH!
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MKT9%:PO@'3JK"^I9C6B7*OYL\/J,*UK@-H25+EGH;&'BTDB1C)6)BP">CQ$
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M>K"X'0*PJ:0&,(9XRN4WTO__V=WS]RU?W'*O-8C@K;O7W^>.XG-" A4+>U1
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M4B\6=R [MPND!;B?D=L^(EY$3T6Z+<S+PI2")%-%:#>O!('R&ZFQ04CH1(#
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MLV/7DO@%KOQR'Q[6P2ADLQMC8%&5B53A,O%::MQ##QN!0U3\CCF/[^A;LH.
M',CB)_WS_&(1QJPXEP5]A!8,1Z&74.Z@T1E*;X\, _E5T]A RB$L1 R& 1;P
MI(?/X$S<,H6E929'39G)XC*3DZ;,I'*@[WQ.Y>YEZ(U@).=G\'^0Y]%/Q:KV
M+/W'=X,A+,O_;K6[6%3E_U(_L3XF71^L%>?"H=>=R?NT>;BXO/IR_O7"^7C^
MZ?RW]Q_??_HF+8TK]]WEU<4?5U>7GS^YYY_>P?_.?__WU>65^_F#^^'RT_FG
MB\OSW]V+SY_>77Y3G_GZ_NJ/W[_11SY_>?_U'/]PM3ONPF/&6 K">-%,@E_^
M'>>(*B"&-.%S>%/W1G20G3HG= 2KUL@/YQAT!25\-0BN0+<-M*?+E".8I3$]
M];CB FM7Z#O&,P75-19DD9%F6_*P%-Q\-KL=$W[E@MXHSCCB(GP"X(HP%1(#
M$6E'_<?</.(GX[@7=#;5TH)5'B>R6YO5PQ<?4UP&1R\#QE_!,"5,TXV?# _"
M.*:6=F;0$O 57<=8R)0$Z7<D 8^D2<LQ=JKR46U"8&25U9#MZ-5*8AZ-C5Q'
MX2C!Q):54!AF5A\TO9>(D9O0Y($)Y"\9M9PQM9"$LW#H?H QQ(F<SH#."U<2
MQXE#86ALR,D]Q["XR]13ZRZ 'OA+''W"=!P2.[()X\E!,Q",\,?T3AEMQS^9
MT4B(CNS[:M#DTC7Z"NOKJ*'2\G7>NOC+U/TJ#PV,T%Y?=)WN>H(J^V3.B5.X
M+@H'0;52(L(\I69![$H22^:8D,"'6S[<P30J@B7 @*3NC&0&GE.. "9*=J:D
MO8";E.*97O9JCZ!]0T.Z?O7^HD3WV3DZ9*&EI-43"*O;).6:&G(K\A7;,>;/
MUPB)$S?/V6MXTAX_3[5^?7!IQ@D*B8-!',;)S^A>9F"?*M'E4&L2PK/Z(8)P
MPX @K@<ID97/)CXHPH'(.0 F:7!J)-\H!L%'1 P$9):1&!%-4(MS/UT02F!8
M!'&QFX.0\-F4:),U(P3(MPB\F BK)]%,\&?HV[I_LH0*Y L]/9 B!X2(QO[8
M: O3ZWF(&,>848T@R<&/GIJ7.O_K_SQK'[\].\@$6,:3^3")]3"X[<NW?UQ0
MC.$G25XV2^>#2>PSR%M^=AC(#U_\^DY_F(-/]J20Y&?&]*CTV:_PV7&,28[T
M9P>LYH-VNZ7U1H:+JM(DW^(\$1GHVG0>P1 Q8H9#N_+J/Q[W928!AIB&V%[#
MGT7"IR]]OCJW$]7%;SKGX5\3 6<RL?4;,?61<AL'G(!Y2S_BD#N+AGP.YR>=
MNE>H.)-\ZKX+4LD8 Y\^O^)UPNP0J%7W_0R4T0Q;(]+:.%?OS7GCB"0'5J;^
M?Z@DX0 9WH8F"#*7M#8ZD$E'16C:6E7@.Q%3N)9$=1,'X0&? M6%@7FB<-?H
M>^=3_R\X( ST);!M-7#XPN3,(_,>+I1D]TG>?&9_!!R=KVPQ;T>"9A.SW1;M
MN(FYO<L3U=%@B9E[9&D+E"!C@FED5'EY+:*<\N/4\+485)V;KWW*03$H;:A+
MHT'^<*[\3R$3QR PCTX[;QW*-AR"Q,[(>Y-O =$?CR.J!I(*:OFHF7V3'8/7
M;:_;.D:W*$_QV8^]H1NYAH^7^;W=SU@RQ6^Q@RB TC%"9[9RE-@9QV,T3/*B
MV6'4DF(N40J)>ID6#2ZICM!R& 9#[B"&YM(P%OQF;H.#)T.-@7J74W$25HG*
MX2AO5K]<XF>ILAT6@4^@JF=3N(?E-PCC(%@?D$\EOQI"008!=S(K%)Z^/NFY
M<!9"@E143,=8">$R[M!$+S@>P*3=TM,WHOO]CQEE10ZE.__T=^$YJ,:O4EHU
M&G$7YW89/8 VE/+!D#\WRF?[IW,1IQD6A(V)1!0K]9H;O(MS^T;DH(PI-'M)
M$1CL9),JJ",2TA3:EUK^:U;DV<#'I>7X=Y'+3+OO"TQ>C0ZB],GM(H:JS*NS
M*%BTIZU6(U*V>3I54ZL1*;LXM_*U=Q3_@[' A=Q@YKSA>SNBX";(G3BBU. !
MIA<%-<,BM)WEVZBO>\PNQ]4FFLG._#68SOP@47%&[ \<C8E"@L/ GK1&0@XT
M#J<,_O:92T,_18?H,,,83Q^[IF5#MZT$$G@F,@1F]56>&DJ-OK-.S7N]HY'(
MGFK6C7AY</%RJYC04@9,&IA'P.8,B Y",DKP",<6# NFN?^%Y\\2H7)7,/A\
M2(PM@PDV_D;6,9GDF!I:0U/00M7#D@1$RAP6*^KEMTYD"U#$S6E=W[XV><&,
MZC\1OA'&J>!H+H$=A_%-Q'V/;CD"/S_/9;KE"/"Z(4W #+%4T?COKUJOUI^O
M1.(BR8<_2\7/KOK76_<F&&83?$KKC?X<# :3RK@^/]Z^0KSHW[)D_;=>([<8
MYKKETC) \I7$GV;#=9]H5BL;_E+Y_LI(#[F2!D![V+.ALO!L/4!8)MR8O[\Z
MUHM^.ZAYS>'4P4&5IT<# 6]OXS.&_R3-/O_]5>=Q]QF=^,WO[3-?P>YSNAU!
M!A\;K'1)_KAZQR%D#NVD]<NPYG5;MJ&KS[ENIY:=R/O*A&<YR8<_='4&3#+N
M[W5:1UZG>^IU>KW]NXMM;4N<'+\IKDXH1G"A_O3'):=#Z'#7W=;+6"]OZO?W
M[L^KF\#]-E<__*ST<*JX?/5+]ZSU .NPP7$_CT7N/,(B/\[-_9-=C[OO0W42
M5TAOHY!Z_IQ*%1Y6XC[ (.][0FJ.Q5'O81[W$ /<I77K+K!>[S_ W5-^U?E\
MO3T"=E\-N$N'Y1@YZ)I;MO["G;3/=ON:;4!3?;TE-OT2SD6GW5RH.RU<N[6Q
MA7L.>NOB)=ZED^/F+MUIX7H[;@,^N'):&%&\4-E2MYPMO?L*KA&B73,L^Y G
M;%/OU/+\'F>P=@4W<7F:K<*M.KJ'ZKW35FV71KYS5J+#IX5*G1XXX=&YVT$\
M@C<-X[P?BGME<M8^C _T7G4@O9/6R286=%T1TFS?W;;O>)%$V>SV*;'R$T$T
M%&SC)6!2MF)NZY'6]1K2NL6D=:<-:5US_QX;Q.IP8:VB[R*6[=O0K-3!RB+D
MD@2XB&I'%MI9Z!/O&;&&!5B5JX."R$,>IO:3J2..*N;9)+QTYS'LBR= X[C2
MA0BZ2Y]KREC4Z%X.CT;=$"KU8+IZPZE6;]2#MID@Q1T)*LP8DF."U,]<=.9A
M=[8$.89,(9KG(M\><6QCS_9)P$2W\F]<.1+YS''OX',/7_HV?2M0&94@RTX%
MLKRL!$?7^<U@2%B6-T/QAB5Y/V^ T.89RY@&$;URH+A!1.\HYG.K][E!1._>
M"C:(Z 81_1PGN5VA_/40T:]^.3=6^XY@<5]O#(9[O"#DOBWPX1U?W]Y]T S/
M'^9L.=,O :)Q=-; F^^87&H=W:->8!MNS\,I,_3!3(SI)6Q_][C!A-U-X)QN
M;.%V5N=<U01C7\)9:-_'U'O)EZB]N:*D75,]:V L/^J<QKW,NP:MQV>P<X^:
MU 98^9A;U>G>0UQL,;!RJ2INT)3U)[ 26'@4)%ZOO> (-D#*K=ZYCG=T^M!)
MEWM@*)NT^*8G\!NS?Q)IWWF1_;,*W7F.*+0=0-C9>[2 H74YO6.IYCS%#G0#
M058QH5/\P0!)HN'2>G UQW[HP6V/OW\78D:_"Z)K@0@B9FLA3D='!DZM-DW,
M@>USM\@J.HFK<^-I3'_7C9[L)]A,D69JID1^,56M8]%#;N,6/N?C^5B\D"L0
M%;],9LBMF%N#SEHYVM2@LW84?[+5^]R@LW9O!1MT5H/.>HZ3W+VL0L-7N<K#
M%V&,%I5-;\NXG\,B'RT*J39 K@5\E2\A-7RT.4*XY[UPQZ=-2GWQ?+Z4.2J'
M02(&69RDLG#QQ2 FNUZKU5RQ.R:3>F<-(UAY$K^JOM!UA>TOX5BT6QL3O<][
MX78=2OE8%,LOZS;UFMMT-^W4VG$\_P9TT^?1"!/#V.\X$Y$?<4H6]-/+I"EO
M=YJ[=;>%:]\#++H-=^M) ,N7%9@%W3O5!_P!8HX-/!8/Y]D]HI4-DODQMZI[
M? _7NT$R/R\\[),1BQYYO<X"UZN!,V__]G6]TZ/GB&F^/VAK4T1K!"Z^B*<S
M/PG2F,![B.:;"Q_\!Q@;]J1GE! BA%R$DB!98_$S3ODS77<S!((;7H>_!=BA
M)@^S%-?A\TPDOB3Z?W)&Q#L<C0;5M\@E:U!].XI;VNI];E!]N[>"#:JO0?4]
MQTGN7NC-YES[*JY%E.\,8F]CA&!MK]MZ#$JPE[O"'>_TY!YQJ^>/U;N(TXPJ
MNF+DPP;=.WP)29'3UL:2(L][X8Y/%UA4338)Y_-;$J<I5?@&+P+RVKN/^GK)
M]ZCCM<]V'$*TZ?;1+Q:3M[CU77.K;ENZA6WG=N56;58_756;H[R,<[&0!*FY
M4K<IJH4L1+MRI3:@J"ZG,S](2#6![Q1$F1^- \S&^&DJ7H3EU_:ZBS*YS96Z
M;>D:_NKE7M3M[#(OX9PLP;HT5^S..)-=N6*;@)03:CR(!O%4O(13L-?V.B</
M&NC;?PG+=K#;%V>SNDF"AJ*Q&\;IBU!#)UZWW:BANT7+O=/-^9T[JX;>_S</
MLCG='_CB*(FG!#=D9DORJ8+(_1AD\86?B/]Y">?DJ-.4M=\M.M$4-RV;SX<
M"P<#<*78Z//<Z&5$)_8ZO0>]42_"[@-SN7W\H%[3_@YIJI<D-A_RD2]-Y6QV
M[9Z#UL%JDT1,1)1BQ.[EN$E')QN+ZC[OI>MYI[L.*]J F_1)9'1Y7#_+DJ"?
M<[E/%KN3.!R*A$N8DB&8>,G<)<J]%W'/CKW.YA*2SWOI>EZ[L_'$4['"<A?J
MZ#;9$:;RLO_CX,#]$(AP^+/[Q1^+M_#$_^8B&HB?W4[K^*W[+S_,X=]M]^!
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M8&<U# ^FY(7$,R9=2[F2::@@'14QY\EDT @&2AZ]88(!F: !'H0I<2(QCK.
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MO)<CB0!!X A.1X_1*P3PN D6Q:\H6#84H3_'6"RX.)RL3 =@A<$M(H(7@3S
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M!6B<:H"&G$HM0XT<3[FGQT R0Y(K59:_# (%_RM/N=[$!"7\X760$M!Q0HQ
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MG<(BX7OL7RC"I4 '>:MA 0568X\?C2YDI2I8!<BL7(?HU>&46K/#DV2%U>'
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M',8^ O1/75I&D'D2NH>&V\<1GQ_]$E'T',0*$NXXG*38 /S#>O'R5C2TK09
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M!HAQ&A!C!VSS!HBQEH+\Q$]1&KD(X,X(M\%H!-8#7'BP9<"63 2+L@#AZN]
M7,!E-@!\4GK=!; N1,E5UB>9)CUI?8Y!RHCDSL=RR&?!=I[S')\#C8_.[RR,
M[],&FZZ$39<:<+H2-ET/#VZ !T?J5OB@-Z3L9\67,M^@0EXO^MRTLVU O*:%
M/4J_?TL@7@A<28LX+4%Y/_OFGR%P^2I)WN!YO;X3;/"\&CROU[2AUY=D-7A>
MTU)';'1AQ&5CDE)$8%,A ^?&Y3X](_"&P*DV=O:]@V7JQ6:N_<D)IC=UQCM>
M>[>!_WHDX4NW5MY7Z82OYKJ^JESEH;>WT]10+'QL.WO/4;;U^I1C<2M3#4I]
MXXR*M%-H.M]&2UF%RES ?%_09%\E%S[7.Q42Y)[7/ERB@J/R$)_CCC74XGJ;
MW8,E&A#FIM9KJM=Z3W7?#5A:7<_N+6KFCM',>D3BAAK5C.U?K+"QZ@170?_
MW-6='V+N:G5RJO,T8;\+;^K'DVXH7DS6+_]*W7^X1&M,Y?FMV!MN: 0T.ES"
MB5Z42-6UG35*S%6G?9^05S:P"<>6G5_#5.0++J$4D-#Q0\<J<IPQ\Y;W4![W
MR]&V&=.YM[WM_;U-3T[LZX43?&HQK1R)S+%G]5+GQ<R1WX>%&<*(@X8GH"NX
MHCC:8OU"!5!IR_TL,=EQA\6_N@@"T)\()XNQEBH1O<!7XP>#T3A.L."IQX,*
MN7[S&Y;((89AZFY0P=NV=W!P:%5*XM<R_YL9<$A?V_'V[3'#'A:-WHLPQ/_;
M&_K1K<"*#9JW#%L&(LFJC##PNT&(-1I@[8Y2K)GD@JO0QY*<="B$KKW;/?2.
MCLS$])9; P:LP1+RH?2J +HS[P78L2X QD*GL^KA_N$<S&\/JG:X?V;6!.V#
MP_UGX7XL!J+VDZTNF&A]9^P_\!.)=0GKRG[OTR[*KK=O'1C?$[T@JRY:7AM'
MOOMHQY[.77EKW*5NS8YW: TF?[Y+\S)#[<]UP-E6@B\VS[ZV0N#CA(J-IUQR
MQRBX:)X0OI8"%.:>-5Q^9S>GL+CB-A&#4/2H-F^2 !\S_HQCWQG%AS4XNAHL
M83[J[2Q*O9V]G>FT.SJ<EW L[)R7(=S+B)$S+8\;,;*<&"&CPZBW"B[D8/H,
MJQ>DR&&.&>5H;8(M'7#GQICT63H$1;R5B61$#65A#(XB_DNVV%C-2,ID!.5^
MT)[Q[K:W?[!COYMZ"'2S"#T13^-$8F>I-I ]KW-TX,RP9=I'!_9CQWZ2!7X(
M?TM)-0\P>R/M$/70?>]P=Y;+X1WF#'$P:G!E2'$P)SY0;Y9LO&7;"?M"] OB
M+I#?-S.70XI;^;>)$-JZ8A?E<&?F(O:WS7ENKK<I8HHDFJM!XK!ID)C>(-%N
M&B3JV2"!G6Z32+B=/6412*_+(:8@FP#D@H]-$7?8)C4&9J4+;JXZMTGTP)GP
MM0$1H\R@1K.HLL>*9&EK>VKO6[O5-JUO#G=PD/^B8R^I'W(?*K:2DI<"CSWT
MMK>W\?\OP@2  ,MP%](*P>WP+W A<!98E<]?K8,$6C=+Z*KO]M&R;.$;CGB,
M']K;,QBBTSI\"D.T=[W.X:YWT-Z=QA'$")KZJ>&)@[?,$T]M:-_Z*@3(VRR9
MB.]^.>[UZ%!OE>F IA-Y9L70#=L4[@?W _9[<\A/FQKZXYL$U@',)_I>U9]5
MWR4&8)#HNC'3,DRPT3*>).[&[J8#<HUZ5[E;-M>Z6FSEI'Y7_AXPFT]<<":Z
M";4 =P[Y$KC JT&(_[GO<90J!9M.]K1G0V G7#1U@6I+##]VT' =^7UJX"X_
M%8W3+,@FZ"6UMW7OJ;DE9I_FOI2/AX\L%?"XOGJ]Q\M2[W<JWK_KY1>PM^0"
MLF&03'N_O7]'OG\O__Z=90Y L15R (D>Q@\(S7*0=2H6L>\Q)YB5@)/QY(6T
MW#/3* 9_[85Q*ET/_.=GD=R*)&]J6PR>B!&J41L_ #>23KI_@B>--RW'[3[=
M01)W)&_M:SC[CG%WN/JSPW_&)G.#.D 24C67[[6.?B"1B/=DI( +?IO A=E1
MI*00Y+:WMSLCQK/G[=FN#&ZBU$4.#RZLFX\E+9T+G1D"Z#.B8U<@5BJLVD0T
MY3G Y]T@$GV-6CS($PD^#86,T#J&3JTZ '*\J%5 \8P3QMCXA!@;:X]C/',
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M+]\Z=4+8ZXL!14MD6#Z9A$+5>M_2"%4JD.6"A^O3DSIHI 5K #K;30W ]!J
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MR.?HO84685?">ZX.C= !YPIZ)#3*R \HS+I.M@7GUN F5E58ZHK*8JGE)0%
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M6O@9? 6,HZTS7!#]H[V]]0]^@+DC 68#-9UA;1XQ")?9,E8#3K-CN\ONR,R
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MG2Y'-.:'4&E1$(Q&HA_@I"W&576'OI%L0Q UBPE+>73X!+A3_-^(E9H@T$F
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M&DPD+(Z92D5./;?^:!VWL'V80"K*&,.//\BC0(3$874',8.^2K8PP4JU5/5
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M!+AW9V-M;\31+EV(#8OF5G%X:ZG/:W""]WKO ]%OMK77W11#4S:SV>NAO_4
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M'DO.EMY*#U^ 84+U6?B-K#Y*"JPJCJHX +F@F.D':)4/D$KX@)U=6SNO,95
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MU-U-^02K=GW9Z1\^H:CI*M95C_*EE)R5TVH$0X&IFN_T6SBQ'_K'_;X]!T-
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MCQX<D5!ZK18SOLT*)STMX*P0/Z7)DMWQ'-%' C7:-XP0<2?A90 ,3>,_+ED
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MO_FQRL 7',&^H'X:<J0,XU?I=LE:EIQG @R$(/(1FP+Y*/!$#4KBQW$Z_I?
M[T+]NBC0> VU=YLQ$ZBZ8L:GHW-*&&ZIX)9,M5BE*?.1/CF FPPTM !]">*A
MN7N+=N4,> 8>D@B*XT=P#$%T]XU?,&0=^![\-+94X2@>( $\@2'B48TL*%JP
MFJ^\L2?Z;%S@XBMJ9(3/I%@IXV!OH>]-B-?!8)#*.4K%*UT@> @>O!H!C16_
MA.6D5;0BX)./6Y[R M7(G3+>+QC>!"R*K[P%/O@Z3$1%;A6B/JP/M34!5TG
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M8A_Y.X=R\;%\")9D^US75[]XV4GFL90]:6<B! 2_$_B2!35):?#W:9\ LDS
M*@[)%)[B!#XEH])B%IL/THB.F @IMZ.."KG?@^<MT@A[XQ1F<TZB^9U%L0S>
M?B9ZZ*11"+<<V;&1?'/$YN$U$RBB@F1HEJ-E+/E-+VY0JFPT?)X7.&%*+\(;
M$CNKGJAT2U<< ^J4W <Y>"=8Y=0*2%JD3F$WBDEJ-_CCN.]:+N$=MX9ST;;:
M!CF'+UA-*A.!*OV Q)8:/8X 8Z[IH#AXS#4=/KIP7CRW8V_N^7@A("9/]F.A
MK+P,:-)ZP\!'P@OG%^*@!"4 \R3X-Y  B>LK[KZ8W@=\3;#;X/KH?%UQ=1\
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M2N-[IC2^OC1^:$KCMWZ'_XZ*_HX;?'5#QG;B;GZ0DYMOU!<&G:J]JBJ%EZ@
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M3BB'+QV!5,BK7V<XO ?[=%4O"YJU?-?\:LN!:MI%R@C_4-R=V'R0SN=\&E/
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M;_M49'G+1VG$_TRQ &D,F9:R7$N9:G!L!VEZ9U<W!=)81(I1"Q)&+)=<(W<
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M@%O<P$=I5XLCUTYOYQ,S$BA-9M;K4[Z-BK)JG"50]0$9XEY"<W/0%$\XWG&
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M[3DB*T3%.B["F\83/XRK2PS$]%TO$7A>]LSS:4*+0N)$\$TOF(31 K%2>-&
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MGQ@ZY@D3PYD+U.FZ8OZVP!Y^!6Y56#U'! R"X\D XV:,I(!O!5W5(4?<EW-
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M=OA@BL9$T&PXIYH>30@@:_99?0V[+_T;]EW+N*!XZE_,XH;^\]@V&9?%0E6
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M/3$3'80+KYG?%%Q AQ-@PX&@F1A5Z#\>G(_V$2&U@_S;X"9"SY'ZRF\X_*
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MA@^6'4_(_O2&A6V%>K.5.7J3+A"I<9T"-+,HD23^,G8PB3^)OQ.]83.6>C-
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M3L).PD["3L).PD["+LNP.^V,EWP'6S:< Y5LZNLHEV)P=IPS.VX,Z+($=#J
MKDA IP/HJ@1T.H"N24#O!>BW YZ5PPS]JI77CY&)#\D[QS-/"+_[!;1WQF]%
MXC=M05F7@C)!1CK,N*U:-44^.LG8U_4+<S3#9=C<Y/G-\NS3HN:WH[S[47//
MTARFNNR*\9^#,6#X<>R#^F[DU\%O$PX&/2^J9:B49 E>&0UY9:0#Z*8$=#J
M;DE IP/H./+$)*#?!W1%^J@35(3V-(\3483J4A%*G<ED?")!)LN@L=%(D\=.
M.ZR\>OJUW24N;=>C38$MSAO344NZH!O=SO#?HHF'>/>F?3OBY+"DUDS!XN_J
MV""9.K'?V'SF Z'NGF/.W8SKL-2N%2/;1:(]"8DGZ>M=^MJO(4<\] 7&7ZL6
M9P6Q)+!4"6Q3;2V.) >)VDRB-HZT"HG:3*(VCD0.B=I,HC:.T+-$;6:4N3V]
M8O$H<UBA'FM?#DE@F90=<<0@)6HS(SLRX&>HES(A.DXRG>9\7-JR3$O"3L).
MPD["3L).PD["3L).PF[S39YZS'^-(;PT+N&*:6PR9 Z'3)5/32B?COF]V7"$
MM+QVU;1:M]7+?"9"K&4I9^O#R181I=;_KUZA/O.M./O,2QK*! WMYP/<AH:J
M\<\JD#24"1I*;<!/O1;WW %)09F@H-0F]=3K<8\0D!24$@6]TSPA[J$[[Q=\
MUQOY3J-:J#<.(I#V& !P[I3T-B&E-D6GW@3Z*=1D%NQ1TM"F.1-QE!-+K&9!
M,E3C'CBS7C*T,B(99%Z$])O+F$,F-BEA)V$G82=A)V$G82=A)V$G\R+VM0-D
MB_TE5X5LR)42H&5#KG0 794-N5("M&S*E!*@Y="(_0#]=A2QNE\@>M?6T?4V
MY<949 OVI/&[7Y1X5_PV2A*_Z>!WO^#MSOB%ZZ_9B',ZLL1N!';WRW?=&;F4
M_-IJ)=N$\'3[^D>=M@_@Q\Z"$\.R'<-[I9T8@&J'N1[\HKBSH6OHANJ\G@/9
M;ZS]R4E6*0&Z)@&=#J#E))P] ?VF.K3W)!R-,=V]<>S));S7,88S7,2]&]W:
M%J[DV*8) K\G)/=F/3\:."BGGJRV=$8$L"FGR0$B*0%:#A!)4J3M;<$G(M)J
M4J2E10![F_B)$$ =A[\UJS5) LF3P-Y^@$0HH($4T&[5Y:R"Q-P&/=>=8<\"
MQ1[1)F@P@:*I4\-3370; +JF3//0M6!83XRWI\,_J*.181JJQ\Z>>:J5O;B'
M^OPA'M@#,P&>.@Z*V(Q!0"^JM.*<*7#6 G)3;50F=:0$:)G4D0Z@:S*I(R5
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MY]& E?#14,G4-.8W+QX+/>'&Z#7?&8R9HFJ:/9FJUBO 0K%L#]Z)M8VJI1B
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M1]59U]+O$ D/ =BW=5FTL?V"3*\^HDSZI$BABEFE">>2G04II-B$8Q=*6$\
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MF0WL$MZ*LTNXM$72MT42H@U,E2C4I1&RZ0WU5CW$^Q>7CU _5]*P/-5Z-+#
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MYZ?S@*4ZUP1?I: [MC>?!Y+BX\D''JB@_=VKCB?5OGBO$5%HL2BU:F&I)3!
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M:^9E?H(B8)WO9T^YDM:]\FX_WQQV:7)0C5\;-("[2/.+_C8H^%,^ABLO/UW
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MNN092'876P!C1W)@8\HO%4NN-/CCS&/3#)S( UXH? QSQ&O6?D?!_IN*06?
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M.7^Z4")H1HS61!>);\6[.,)ZP=D?A"5L'#W*<#*E;\'C6%FPAQ_A2"*&(.:
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M^$]HI$\765C+;-P=<0FL6)6X;8*!KB$8*"08.#<$ X9@P! ,&((!0S"P7:?
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M XN:X(1LC 4*8 VK/CO4_!-!4@XR+V';!#M/!S9#YB1K)3#K+T&CJP!!K>Q
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MQOFSCY),)T.Q<+D!Y;ZG=CVI8TJ_CO"R,)5=+M+F:HYGQV/,0.E"UN231J;
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M;3"T!D-K,+0&0VLPM/5Q) V&=BD ]GI]#.U5Q1C:.Q4)?Z?ZD&XF$#;_);E
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M.L#C39WYZ)8(A3,4BXVIPI Y_N08:5<1#)]XD-:;0A_S[;03Z4@WDGA7==U
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MOO]DL:(/\'@^@ M"EG.*B!I+W?NW0@1]I%K-HD9/^\W_X*/^TUH%CKK2*[(
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M+IK$UEFZK_:=E21E ;I]>+C3#$";I!G>#;)Q/2FO4,;7EN^<WER;@WOMIU6
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MNXP>M#HG-]UZ:#430CA6=\2LG5D[LW;[M79[$4)8T&FX4SL16*.G\.K6[7I
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M<")?'_]Q]UT20[]___5W.-$:,+('>)%B@-6<U$ F)S /2')=X2DR0!(#)#%
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M#MLI^+A/EF1;1BV:W-E(48(;!%O=_^$\P3"> KR WXS@U,&.-V0W!AMF[31
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M\+6[GZP?DP?P?NAP[-:BU8)L.H)/55\EK<A']OLA9X/TA_;7 <@9"^$U :7
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M/L5R,677[;H'."'37(,F8S@]I/;BJ/!^L8H.L7!KK7XXM>J4/9,,_9+4/DG
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M*D?&QF1/7"R+-U!0Z'=CJ4TKST0RR82HO$^!!<J8AKHMB]C@N8.+H-(O6*X
M9I9*FNHDO6*NJ"Y1M:I]L)_PP,4SL=\1@A@F_ ->1!-6)^J".OH\\W].%&0N
MFG2+OG-QD,+ *<Y&%-CQ D:]!G$PYNH$U@[VY]30C)>/HKDN.3JL%T(*(,3J
MK)[BF[>-]S-D..JXW\]^-XRI=6\Z=]R/G,DB D\L=>&!0DS[U(</8G;0;!0#
M,1L=FG*25V:PN@H3)X3YA\-_LM0H>#:F?+/D"QI_X) SX\FKH6$&*5TNE3W\
MV=R8$LW!/K>5'S1W![.O)Q.:=4#E5#&!]C9MT6!)4T9W&.B9:,8[AK8J--S+
M<+FIB.,\:BB1O*$ _Q 'QLG"+S$@AIET-HT+^^^W:.S*=W% WVV2A6'22#*-
M;-';00HD[_91 "6QG+.M_'1X@+OE,!M7H7F3OC'*//*;/-L!0 H8*0+8=R5L
M]QP.VZ4)PV7L5CEI5&R)K6:-0@4[EF0[*P]1[.7>][*UO[V,@"9*JU:B0(S^
M^_+R^OKF)@-?M=OU=5U&B)I/TL -?*KZE.#[ZH,00%&J';SB!:%T]A\85Y;.
M?CG/QOM<!V2=HR#N>=!V#&#L= (7.WLR^74F9G&"]<@98H37ZZ@QE)>HVTWW
M9K,N^ZXV%TN\C???]@VJP\WHE@>ZTZ<SZ'YYNET^GNXT2LG3!9UW[T'XQ.1#
M%7W".4Q 9_QF@(/)@BT9'7,'862F"AP?T"%V1:R)J5*A1OAVMO'_=/<\A<PW
MJ\/>YB81Y=_68QSI8,^F_%A5+A&K'HX35O2Q]*A:/^HSDQ#>]HQ=]V!#22*.
MIG+*>^!H:J>1=]S\&]A[YY;OT:E*V$WB6]5A^Z(5SAD]K*T]QI%*<SQU2L2N
M[>JP==$_M3/JX!RG[SJ]AX8AZ9Q9/A^[\#[[FSB@=I;X';L^)#4P_Z!M$\ET
M!"SJQ#NRJU7H=,#*O.AT2R+#8J1\.#"5BY,S!V(=5R.R[.^HSY$#]'6<4BDZ
M8W&"',H)DGV%6V=3A=MA[=(QCE2:DR,'SNN7CO.$WQ%]6CAI@G3&,R_E5AP9
M"0775Z>(%;MU]6?]59W"IGV2V']ABR9VO=D89+E]=7=!-,T^:P+N.JVS_ST_
MQ)W=-P\5$ZIJ)<*X86K]S]Z?R+Y;W0XWAWKDSZV^VA+"6L7(&38'Y8I7N0A,
MZ9*$\\D%CE70&Y4PO)(5G%4EV9HTZ$J:'(V&JE=_':9Z0T3J/&M-!\IJM:G=
M;F+LJY;X^6EF&+:.V(]<@%I_.I]4I9]S[9.FX'[#L?!]7!U^1<AU^Q4X\V]-
MM[J72H#S$.=[RH[K^N)EQ)T^'CT 5$@Y.2IDLR^GP85,TV"QVUP+\[,=$M4%
M7MF*X-5O[8I>Y-B#(WWJ^ 6QUR;'@3!R,)T"<*BYX1CPSY@U'>!#QZ!N; %>
M.-[JC9,N^GTYC*)?AE+O)O@7BQ:9$$BU'(#^S784@C:O0(.G:8N1=U.U;:)+
MB^6SIDX\%$D_AARE]P/[P3W_@8OOO%T#E[ A0+=%X2:;S0@HMI73I\9!YAR4
MM=AH<SM$HMC!\\"'HE&HW<#FNHA.V!A<R.&$X4H8RVL52M(%&_2CRRT7^.>6
M-9<0LK_;P0A<KQ^^,@S9&3MN=&#1\8!2L]MH>AO5O^AV(D U<:?#VUJK("ZJ
M!X(:AH95L,+^)\S7)MI',CZ/"12[ JOHH,72&<3"B^W2B'ZK$>;O&NX@UL-2
M<$2_FJ.UKBX"OE/:OMIT;D1>5$OB( GPC;FH.,#V]"L/:!:?=%]..SO1CZ*T
M98T6WTY=S=Q@FOD"?N?-%1^&]\PMQ\KUS[SBSCQHY5-D_1<610C-2)':G?I4
M^7!*E\/RC!@!;L><;=)=PK8*W7YLZ;8,#=F9(LF# 5C!_X%S53-LVDNK)JF(
M#OQ1"[0T]+3 NJT%UQG$)\!D6.>-)> ,HW=BS.?@BV&TI_#&!\)D/TJ3_?4P
M3/;[B6U@?$+8['0XL,PY1:1F*\(T!VVA UDF9%K!3]%0YP# 'LK[0E,F[/SR
M8-[A]?:2:W 7])U^S8[VB6*]>N<[/VB<,1,?]^EPX9U#_L8TYJCI88$KL.@;
M3_T!QE4:<EC;UR0&AED!0V<YH5IX1HB[6H]LR@O]7[<=H^OP$-:] RPAY8,J
MRN>//+K+EHXKUWN2MW3O=<+8P 4.X:Q8<6D:&79,AK/?WP&'/ILP9*]1'0Z:
MM4%4XP$.J4]A5/#?*[#<B*D=Y37Y7><'^/Z&?;^*OWY109B:B!\X\-)2"%YZ
MJW .DKLB>68_])K58>.B(8?CH#7:E56=S\E497IG,V0T(PDUCY$.,_6-A<(M
M"MQ<B01N+@^,>-E@S7/K,M4<I.HSE4J09? $>IU:,TJ2L[Q1&#3W<*/0:VU8
M780.\3-_WGCE"0$0-P&&#P1@>"1@>%\ AJ?F.P'1?3(0W:'NEP*R.%8H1(!R
M;YCXGD&YM_+T*K!PQNB_[:H0F^.)(/[[,"*(_U" F\T/%Z)1&MMPDCQ_2(Q?
M)><&31HYMR.B:R0CF21'.7$5WO>9(]5N)Z?;U'E\_3#RKKX42P(3E7H<H&EN
MR+/)QNPZ8])HT;]&TNVM]'!70\/(?=._O/=4&,@MZ]@([W(:-EK@$J$CQNZH
MM@0]!G*Z[KTPUKU)?<W[V9-)4W4_$L0D>Z 8Y4:M$7$5N=+2C^,/6R%OU!\P
M&DW?:-"#S<"-%4DC>BL8X:+S,?(@$O-:+_'^BMZ1C6@[Y7A4Z:RG"@%V5O$@
MP=;C!+VU:>#.%I>#[!:@BS<+B4TC> _K!"F >]D+DY CB0]/V67ERC*V$]\%
MHO1:M78W',"NK#(%E04#[Z 3=&T=),MH3]NUM=?#'J5R)]RCE+6'"S(SWV_G
M!GI*<>G=/T +@;Z(Y /T%FC. J--Q0V';B'&SADX7LDP0D[$Q)?H]:O#02]$
MB5\<"74P]/&U#FRX:L$,9ZJ. 7.&[*\9[XC',U7@O$38N.6<2.^\LD!26&E!
M\%)ZG7:I<$::>L$^^Q74.HUBD\G2QABJ;2I3A@W^8=&;:L+NYPR6R^#[.A"L
M]<##:>05)!IFQBZ3,*& [;IN@+U%*K"3_QKM]^8[_^'6W)4@^P8/X#E0TL3X
MC673RP/:F(%3S/)M:5#9U7B/!M[0/MZYV"E8Y;/+N2B-?T:O4!3_I<@#KIOK
M!^^4N\;?.5]7'/5!^T6"YB 43G/"E 7>B1J86 %.BD3+"T*CN%_?P=>A00+?
MLC%0"7[ UML@VQ)8FW,@Z*M5\;@=>\X&[B5 QN Y93(QL3F'@Z;%I<=8VA8:
M6/@DB*R.G3-@(8I&'T>WB\ O:=:9&>N:;-#=5:/Y(71BZK,^N)QAQ?X+S2I3
M=!@-F9+F\E ]8%2VS+U7Y-RQG7BXX-8W>7;'!")U_89B1FVKF;+4P.)5/*7,
M4[I6F 5XZ L![:#CPIN=!M.>R@Q3K@+]&.C5_<K#M8K?7F'\LU!H7A*<?PKC
M.>V#WNO#=U0)P/=S/LN-1)9W)[$[V ,;*RZA\=8E+/'NH6>88.OIU(AQ^)_K
M,/Z#53E$H6+B-*TX\E1S[^1A/V@V Q@#H *LY3.H*9;7MWKLX F+G6B!IE2T
MC=D,6^'@D'P"TZ5C@;K-<7P;0Q.Z8(3):X6]4%)>%-P3>C'[US*TD*A]4[CR
MYAEEH9.:7J]>2+>!@QSL8SA&6/*M\N$LF;%-^.6.!L(T0*"PMISB/:G#,'#"
MS%5@=L['WHRS1F_@":ULV!O#?& #>[C'<?FI%:UT.)'7<5&$L% +M++*7KA.
MW,;(_9C :0ZV@(DG-%#.PIG3"W#6M9A=K:F$_8F]A&UZ8D^9XCC-#!$G>[06
M:;H'E1V_0>::+DF"R ZWRBLIQNPR><6<V>*O]=&UKW5;K4C/'FT!QP_D'DY-
MX@$,GP'G? ,B: $W63.^/GB#3ZW3A"_WH<J,Q$CW:*3R]6X(&>G32S<Y]9KE
M/\4R]?K4NP^K_8PJV<HJ",Y9@FH9E>ZS:?Q@#AG--0.M4/$E^S+[4)VK&F98
M.-EE:K2C0-/0V!,\]K7"6AO\8^9K.T*&,ZQ0@X)F-?!AG:NW\)2E;5,^QW-E
M:9HTJ6L*JO%%M=#2"4T%?$I,@(;7CFA>1:4Y:+7\L<+:FJ7BIZO+C0P$4!I<
ME#"G87,WMBTM'I\Q_L&/SA&>,2\T]&I%W<(TD_1VB_MV?XNV5KLI+GK*<3\Z
M.*S[T?'?1X_7]2^C\?45G>;#Z%^882 ]/8[NQJ/+I]O[N_&V&]/T6ES4/!SI
MC:5R&#>6Z'3@W":&10T[:E;6J1)V[3V33(P7'1YR PPS5A@!?@WX,393T)_V
M?Y69O,DHL[K]AQ"W*ZVK)7DRZ(GT!8F!Y@I\3L]NWU'T! -\T8S)C\"9U!D4
MUC;4M9AX>,"_?Q/?G"O.727+0@YFT$K>]1RM>T%CAP%TQ-OZB/Q4EC/EM"#5
M%)U_4?&<*_B-\:Z[[_5"],@Q-? 5P//56/!T2K"5K\-FHA@M$Q2\-+HYJE]B
M!BHZ^B5N[\>F1_*#:O[X+Y YNIJ@V'F](#/K_N@C7PZXB8?',0?:+33;]JZ"
MS.O)G&'G54'F]626#T7%Y=N[MM/?0^]:S)U5S,DKG3V:=E/R1C1C06U[QW[,
MO"]CE@Y;=)_'7>GQMVS7VMQKXT^Y,4@55G>88Z1/KSRV2!1<[U:'[? =6.D9
M2C!H,0S:3'?ODP&#]JK#5AAN2#"H8%#&H,U],VB_.I2[Q7*H0-6/9I7?B4Y,
M17-M)64Z5W75LDV%YI]F:2YME/#L#/R"ACED(XAO.DCP*+#=B808TTGE?(0X
M1]]2L%OQ)DT6[#9H5(?-;EY8^X+=2L5NZ0R43-BM61U&)9:=<$@GGF62MR05
M^I)(*2C+Y,KS$D&F\I#IN/R<O9S+;7I@3HWELT:2',P%Q1LRG/,A^S"C*28N
MT!2)&\,,I5+&*PX?8".0;AAD_H"M2L&]A^ 29<.]"#HWR*O7MN#>(^;>=!Y6
M-MS;K@[[$07Y^;E8:YJ1A?[.%A:J&+P[-Y$A"9YCNR'P'"/Q' <"SS$NPPDX
MQY.'<TQ8C'54J<6'5[S$MN48JY?V@OO(\^KCI-4+,1"E3\=1^@22!F]'22N[
ME&5PM&Y%<LVP?EBNKL&%35:$++1+U"+DQD&JE^9AJ1>YT>CPBKIF1[H>WS\X
M]74MZ<$KC', $7(NH\P'A**WL8N46V8H]_UMI+X8BHD)5L;")M-*L+.?#J.C
M(->\/G94[*5;'1TM3,6BM NW?85/7>BT;!=9+*['!I(&>'3M7=23K]A2-R3-
M !5ILM:+")SQ(2GO0'_>"I"3V6502U)MZ1W!29<+8H*J97687E-!NC>*AM[5
M"R+BDC<5_"SMP^WMZ'][)?AVD\P5.$W]<',47F/Y_&^L(.4(&N[O+R0N$M]]
M,W7GX ?L0;!".CX%NR'SA69\.+ AM'U6Q2+F&X)C<0A?K(2E4,+\V%==[N+3
M=^&$*?/Q_D(GQ5^K>,V;A+E"6[.],<PDDT&V4R34>!SKXM MPQN]#6EP;PVY
M!IWJL-VK=:-:,Z^ Q+B,G NXZ"$5,F=H!F5A L7NA 5'<OGM(_DB_7QWQW%O
M4:T@KY[,LD2[LDE7B@=M&C #7,WQ2K@.WPXO.LA"Z!%+TEQ2YR'06L+]E+>3
MBU0((4# 0;<Z;$4T?)0")TCDH0LZ<ZJ"PPF^BX4XZ3,XJ/!?P7,,T9"7FJW0
M%L"6,:>(5 R=&7%Z59/3D!%4T1SS\H5E 4IS0MR&@!&8@E3#O1H:/1O#>\A?
M\HV]Q-M(-@%CPH&W_"#[O'FTS&"_G*YW'+N9@?93L&Q-6Z$1MR08E[#G=#X0
M?H*-0W$A8$.8]&?O'))ZA=O8N"N]":EI0VQ$NMP,6@?6>QHF"_0HO)_=>R:/
MOV%A\DZ% ZQIJG7:$8<.0L;Z"7D1<B@.$)7E1E%->C/GW*\&6SUN0V3IM+K9
M(;)LLIQ4"LHR@]E*;SA=RMH!MJZXS<\-CJ+HR#-E2F3J.>V]OK0<O')ZMU@?
M3T L8:[W#]\\'#X/-66AF$ [&[@%/$@U*]OB8"R*<@-=A ]W_X$=-C)VO^??
M>:1#!QEPSAM^G=.H_?9L_CIT.O%DB#\@]C+WO?2W46J59B,/IS3!N3[J9EKU
M2\,OV@<H73JS8 ,89E=E7K%:E+#M=]!!C +H@+^U)9MM!UQ]SV3]@W=O&;'F
M+5YOF4Q:; ^PUKG6D]L7G0(*GD^#?8Z"9ULEYMD!.EO='O!LN$?'WG?R,"I<
MLCR(KE3:6&=*Y_*!.7[2V2_G)V/=95%F55AB=:JC""M4)R"RSH:/+*]!1X1D
MQ^O9T6LTJL-P+X##VM1C'&F_C)KJ_,F)49OE8=1#<7ZRY!AG5^E<W@Q-L54-
MV\Z*PZ:D,ISJL+DBUL14J9PR%'#<^G^ZNYY"C+'G6&[8"<?'0Z?"K:E.G/RX
M%8LH<X++*^VQ4R+GYE&U?M1G)F')@VZ+3MIP4QP\)17EP,'33B/*N/TWL/O^
M)J(IA!D[PEU$=#X[K,T]QI%*=/:4B6$[F-_=SJN&OZ3'3WF]'DV=T72=8&;.
M&6TB(\ZB4HJVG"9?*2#:;+N_ @ML$NA-Z7"]1K<Z+(LPBY'*PJ*M4K%HKSPL
MN@V:HYB$KGU6&*RDS_$LU>@,.B.4=5S;.;$S2=MP-QF15PS$X+IU=XN]1A_O
M%EMRYZ(9]KE#N9PUF@)L;Z>1Y*-1*!.W5DE I68IJ#3 K(%VHW?1CTBM#F6\
MTHQ?_R=NLC#\5#6F+I?8AIN(+)G$-@U\Y1O1/J29:<RET<)4-4EFS?&:C/AX
M[PAD"WS5SJ61] ;Y*5A<KY:FDXN*EE]$]\ *ZQZXKOO@2H/ (*MN;1P.[]X[
M/%.OV:@.P^!,E),F\,:78$8OIM31+%Y?DT26];XPR2N0!6O,-,.R,JXAB\LS
MI<C9%55 .58!M8JO MJN)GB347_-IDJK[?QE+9NK?N1&*NOQ5I^8!(0?9D7_
M>ZL[=4!.L=X.18"]9A,(WJCU>N%(VTJ>Y&JO5%Z0:L%GF%Y)INSPXK]]AT^\
MBEHXKZ6I:DV,I<X#PMM*I'8V<8+$X&?V%1\;0SPQXSG@C0[E<'.H7QQ=Z<L=
ME?Y:&MQBL7V%0D29O#(2,,K8AJUH$>;/*IE]919^WD)]O>VT::<Z;59RT5PS
M:&1_ X8# N%I<+4E2K;Q),(;FD:8J!L*?>AO_1@=N:"1Q#I\LH4CB>%J) (
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M^S11-]\6;3B&%YYA9]*30[]L26?_\]]]66Y\?AQ_M^@_FY_/L6V8!X6MT B
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M];0L^J:59:N$,X0"<S71!S1XA:OKG3'GD-(<>&FTIM2R0OD"[[CQ0*;$=*:
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M&59 *+M+#7:$"0Q*$A-(%'PWB@I[,;<J_DWC\LVB.Z!>^%.NK.'FTZ?85H-
M!14#3%V1,+!JZ%1(L1_:\>XS$IPI8%=]4_):0!C35,FT@FI4656*SM[P9SAQ
M73T2T*A_5RUGB*D!4_<'P2=@@RG $>3G@N@6\8D?_LHD&MT2:P%J?8:VFO91
MX3/ 2ZTW5&0P!:+ H1*<"N4EPR+>F_&E"Y@W>L:H^N'M8"9/5$UED?MG8K\3
MHGN,XC&PLUH<VK"!9=VO*LY7L(9(CLYH(^,PRZY.A7O29N9,;'ICP(F0Y=U"
M'3LP^>^FL5RX#.HP.67XZ_M*T'39D[27L//Q[M[4IH:6<=X8"/V&GL<.%;&F
MM:9:+2JL[#8/:7I4WQ[/2SB?J.(I[(I,9[&F,[+$6NKF3(>(A/F3W'VYV,V_
M ON>30+[VM%_77D>0/Z[?LRTO:>NRPIUQ^C("+JFH>L3&D''I)!8>Z,T\PY$
MR"C-IF!>,F?ZTQ+TNHFL6!T^@FR#%;:IE7*\!:9CDVST<$ZB(I9_2LO/7LIW
MJ^A+'.GOMG^I#J]_LGCH[B3RH8IFF>P0#43YM]3S7(<S&ALBH4^!$*(0$#):
M8UJ>/9(-V90F+0]Z.R1*6PMS\O')X7CG)/.G)Z_/2D:(\%JKT8W(2A9,L!\F
MV*4(,@T+M/;( L4<,AMZ:R:R,5?M1\EG0&ZPO1,>Z-G<$6<C;JE.E$$&)TK6
M2SHH2F=_5'AQ8:XCXJF(=O8J0FQL+C7PB;:U4_2V'II/<4I,F>4K3TV@!>W*
M2KMC,3 3H%_SRUVO].SL15'U\T*"6@FCW5DR85YCQC/&NJE.[=OY0E%-W#6L
M,GX$!GC155J/3(N5\?K;)*]$M]0W<DNS=N(=\-WJL%WK]Z+P%3)EACQ4A>"Z
MO%V O+BNAY7N[;;@NJ/DNG3^25X\UT?8K%8S2U=F)YX3'LZI6IJ"=H)V)^KA
M[+8(!LQ#711X<&8:<YKKR4J<>3Z[]$VUC4O%)/^O8!0A9()V!Q*/YM>15,"_
M4OE&X*ZG5S#I'.&.9]8-P(&5HZ#>#EF79IGS$E[/#2UW< LLI#-6YG->DW2R
M)F_UN+A9: )!NWW0+D]HZUM,\ 7-R:_WKIEL)T,@[#:J0[F3KS(]/VB;=&WX
MYTGYR:LEBXPL'4IX+!=-4N*(WZ$LXM3VY0@CL?F>*:C00+7QTR0*5S?A"=.L
M#IOM?81@"SUW1/15F):"=H)V!V3IKBI2V7^88H0F.QTMYV@_R449&Q$#Y60_
M%;LDL2_E7%)RN];?J*$@LS;]D/GG%WBM(A*:KO+ZOEN%LM0JO%XQ&#4"XB2V
M57YR$">MW.F0@Q5UD+LO($Z.AK8"XD1 G B(D]*#7(CEG_+R#RU<+"!.4A6D
MMQL"XF3OZ!;R8% LOD6WA>4H_<B&H8()]L,$N[0^3L,"[3VR0 EN" 3$2<+X
M9.P3I2D@3O*+!.]V5.R&A='M9*\BQ,9FJ/YWW-9NT=MZ:#[%*3&E2*,0M#L^
MVAV+@2D@3LI<]B\/^F4L_._VJL-.K95I68-(<2X1UZ5S ?+BNCXBY[4[>X>;
M$%Q7/O\D+YX;5(?=6K_9V3?/"0_G5"U-03M!NQ/U<'9;Q&H?5];:W)@YH"?P
MKXG3<W@R@<E@"T0X;"2%^3:$(BB(RGTA@8)VAQ2L9G>57/JM,4K]_8P!H=S/
M^,<C1^!O#'-D,ZR4.Q(/%Z6'I?S-A@AJ)UB/P$41&D+0;@^TVUS#GM+7S@ 7
MI8=5Z[5F-\O"]9-"1N$:M<B(U*&$U4X-@N-0%G%J^R(BN'DBHZP_6F2PT_,L
M*14!VP,WCH1A*6AW?+0[$"MW#12#P$,1N!N'M(A3VY?3PD-)9\KNBH?2:V%>
M5;^?9Q.?7?!0G.G<+>?PTDE1^"@YC?&;&KMZ&\$:_/ ,$L^!=*NYX56YSK4(
M>MSJM 7$!U',%402B8.1M&OT%_P.I6*R[)K_P"\-3*[A*+W8.0)_ILSQB@6O
M6?^V.<TLE8S1M)Y;W5;T%Q5X=&19Q([I'[8Q]"CW^R$IDQ1+4B236$N-SE^1
M+'@;_9<.JW/&@I_!8!>Y<ZFS^7DS60*!8 @;#%/CV(7!6B,-K1JPPY3)105_
M_,7$OU$J3/P]ZGEU!M8T" %+.;B01C3M8+-<2:_ ?E-B$W,.-)[B5R;P&OP_
MOI&^ #:%TI]+VINB+9$]?;-P9L+E4V&9VBM\K;K)<I)M2*IMA9@[AO0..ON2
M7]9!N1V^.I#.E$@ZMZ3ZEM6T]K66+JZET0Z'J\ZI?ED]>;%($KF?53_F+F>%
M#!<>Z+_J=>E&)=KTD_2@O("A-R9_+8D^(9^D=N^S]$]D>QA?JM?Y@]169<_Z
MJDBWQT+9].JVL8#7R6@7\4^<9[H4ZV6'A8=A=(*C-2(&:^!@-W7)OWYGY9^E
MIX\%+'ID*L_JY+-T!RS(J'-G(!W:7?]3OSJ/X5<28R2'.FNI91+E1_V9 .?#
MFQ>4[OX9=R-FC#3ST\>WW0$VBA[</V%<B;>?1\;@S\/QY>WX8?1X*7U]NH+3
MX.Y*NGT:2^/O7\:W5[>CQ]OK\6^_/D=(0GXSNKM_NAY+3_?2Y?W=^/[K[=7H
MZ?I*NKF]&]U=WHZ^2N,G^.#;]=U3X3/[/KYB!YRQM. XLZ0S\G-"4&AI(M]4
ML97S0N>TCETRPF^, FF, G/,%[\19#P#C)R>#)-:L[-^$Q-?7)\I<U7[^+3M
MU?2W%I@S;"8N][)MD5N?ZHP;/("M;,+ ^<S\_N'Z<?1T>_<[ Z>[_IW*F'0&
M8OAT<;ZZDI G3ADP%W9WP-[6<3L8(A-V)4>] FK%_'FE6A.P,)>8:L>OZ?07
M[A=8US\7FJ(KMF%^U">-/_'I/YO5&&^ZAB_M#^N1+ R3KGO;&P62ZA;C(XJ)
M_8SI;/H&D+JT2']))[!_G-;-,XZ#XBJ7BJ(YW! )+MTW-N?F"6, <PW0;(F(
MN/<)E'P76=0M!&E;(@+N?0(EWT&.XE4B@A5X&&2,MANVJG?%XLT'DC=+UDUW
MPYE6B/>I0,0&B TXK0TXM(S1(##RYN5>N[#)*8GMPVG=F<MV'S0J;V+S-/Z6
MU8K7(;[Z1]\,FRE'!*3JV6U(<MID)'^")9(HO<W7H(UFL2#!O1Z[R^U%9#P)
MQA2,Z3#F+KD&:=BR?R!L68*<[XQPKM/ZSW$J!8J3PCUIG'0&0BL7 V$OI!![
M7<C)OQL^=&^0FW85S'8(S)8N<S )J_4;96:U0_/XA33M29IR&%=H1[&?8C^/
M;C^/Q2%,@(:SF4:KJ/5E"?<7"Q:2@GWS1A1)X[.D:UN?$V9TOUD=]FOM1A1F
M=!Z\MS<U*22A0$G8#.B6UGU/)PK;*YO[,OAAS7#%95DDXEP(PR$)0X[1A;P.
MA18>"G(_AT!$?H?"H<4GDB]Z"U8XG<@&O/ @5KAPJX[6K1+[*?93[&=!5_;Y
M0;CWVV"&-J+:ENV?)4L0N<ECI5L0X(5,"ATK]E/LY\GLY^8X3DK?-0-@_GZ'
M8M#E$:M)%Y0Y?&=TQR!1 .V_G%&J,@0K<IK-WBM)RD4<P2N"5T3T^WBCWUDU
M8>@CL%U4<Y_2LOU!^-_";!=NF-A/L9]B/TN[GX?GIZYI!A!GY5_SR*A+,'X^
MCL9:C/R]V-+KVTV493K[)H[@%<$KQ?%*KIU0LO9)LVN7LB^7=-=F*OU>=2C7
M.H.H3H"E9?,5N-?#[J40&$- M*Z5L","ORP71.O(3>"+1&=MEXJ8.3@.@D'+
MC0HIT%F/81<%.NNA[^!)H[,>_J7# :)&EG0005)!TG0D/;SHMP=BFMR#Y\7E
M$NOXECJN(  #,ZP-SZ"]:()&?OT^*_HN/6*@X,L]\V4&K2:3\"7%6NMU<TC%
M$7QY1'Q9K+8<("Q;H];L-<O.E@>1%98+6,Y757E6-=56MP0S]A%&2!@ZR.,J
M;ITLES<S-!.3R,<5\22]B>=/<W!0J:""Q0^6Q3.PKA*SN%P=RG)7,+A@\-P9
M?!\:O(4:O"TW#HG!]Y-'(7(<3N$*^:!R'%JE(F:IKK6.ED%+=;<J<AR.81=%
MCL.A[Z#(<1"WQZ6_/18D%20M/TE%CH.XLRO#G5VKT2[VUJY='?9JC6X.^(GB
M+OFH^#)=Q5=BONQ4A^U:L]D2?"GX<A-?%LN5B(#3K#7[.10@BAP'D>,@[L?R
M,HD2WY#1)N;M=@[)3.(*6+!X'M958A;'AN@=D<0C&+P !M\#>],LZ<[@H%JV
MK>0XT*DC(55]J?"YASZ9JF^8J/ K_C?_E(A"A@L/]%_UNG2C$FWZ27I07LAG
M>-M?2Z)/@)CM_F?IGXJV1+I*]3I_D(HK>Q;^)[Z$L.G5;6,!KY-Q6_DGSC-=
MRNP[+#Q\OQ,<K1$Q&.63F[KD7[^S\L_2T\<"%CTR03 FGZ4[D!I&G3L#Z=#N
M^9_ZU7D,OY(H@5WJK*66290?]6<"P@IO7E"Z^V?<C9@QTLQ/']]V!]@H>G#_
MA'$EWGX>&8,_#\>7M^.'T>.E]/7IZD(:W5U)MT]C:?S]R_CVZG;T>'L]_NW7
MYPA)R&]&=_=/UV/IZ5ZZO+\;WW^]O1H]75])-[=WH[O+V]%7:?P$'WR[OGLJ
M?&;?QU>2JDOVJ[&T%'UJ26?DYX2@T-+>7E/%5LX+G=,Z=F$GS=UR#J^:!(_
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M\00R"OX(N(B 6>A,>V6Q./5_*#H]JEI-.OEVS5/B,3<5)Q1Y9OAG":H+C[&
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MC]R!L[PMJ9X^$3P^GMOW#S7^34QGDR."_BU'Y]!V,!;:P40*2_EDD)FBAR\
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MS/)XFK0*HZ =ECF63S^]LZMNX[*Q.@WD5;%$L ,)O#7JH_-ERSK280G+6LF
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M,,;<F:S%;'<ZK=Y%HW4!1TW=&VX5UV1CB.B6[DG9!4Y+ ;&FD[J1X%@C =)
MU!U:BS'UZ5@+VN$FCQV?)%'MISJMQ)WPTY_8@VDTA\.A*3:^21\7\X$V[LP;
M_[6P16) [H+'JD^1Y<,U\0^>_P,K&KW%'0[??J)K"(L(J7ZPV6>'WRET'9#O
MK&X9TVW2"9Z 5'3L4*S1DS 2Y:H(3DJS4+-8')@8(Q&:2T% \.TITN>(@F;V
M;#8F7]<W)I<V"_+BFLQFQCI5D4]BC\3>% !($R0M*XRZ&=2>0GPYCGR?V4'
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MXYV6(N^#&@.^\)Q(VR5#'WO--_0:/,*-._9FFTR6 <['?3#K9@K4945<JN#
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M<#<@P6E8''2&(W:QX]OP(G+S&<I86ET%1\/5#*':V4Z7;=:M\Z7[+"U_J"5
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M.[&Z<DE>%92%B)Y7A@,A'SY\E1T(C8ORBS_ZN09Q5"W?TS N%<91&7MI(*Y
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M:+MFH]TM Z#;BAF-OIW40Q],M35R1^.O^OC#AIM>T35!IS9B2D<>==16P^[
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M4=]1WS'CCJ=7F+?QO//V[N61^YP(>?5_<I]SW11>LST8%@"$,AH8C@/"O3Z
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MG5Z^8*O!"YJ*-/-IL&FP:;!5'6PML]O)T7=VRJ#3%*<I3E/< 8"M5(H[D;S
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MKVKP3_SON_GV48@9\^]L>$\C?LE\Z:GT)F/,'4>>]V]GC1U6>TFDC#W'8?.
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MZ$ WGV[/E\Y0"7%YO-O)<^<WUMH/)>?5 &9(LG\[:\8H*"O7%9%L0HAO?2G
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M^%3+HQ_./)>']G\(Z73(F3>R'6Y8]AT5.#.+(@\!VF#8;:7^S7T\9N*7H--
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MM%E'F_?QNKAD>%U=3K+LV*;:F1_2(XC+G")+)Q[-IZKT,(L?_33$>2_2:Z"
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M4W/4B!QAX3DHP;(*![@^/1L\4M^&:MJ4.U(8%#-^/&QW+.-$C0LZ;A0E1?B
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M:'?X1AQVNDM2U58L87$6!*W076=,+?Y!56GODB!AH2&W,*C?DF+8RQPZ?__
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MF.Q02,5(D1:V68K/=8UST-T6-&L%P=1-P =3[TPCX'[Q*%6Q(Q4OUZI[A%M
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MMAR%W_L[^S35%<$--=:L(V<6KO>2WVGA>B>&/GHM_+=PO=.CH(7KK15$/!<
M7R,)XN-]PQ/)PJQ&\VD+S<+ZEF1A*[J.'-?.7P>9N_TMABZ^6FA?U?OL!&1Q
M2FB<BX[7WP9=NS2/_LK)-ECL4;0#HIW(M;<V9FD;[*Q%OY"D;74Z+5!IKZSJ
M[W ,]89--T[IRK6XI?WB7I9:VQ:T=/S,JVR+>#C,T@DFLBC7L@(F8.;IG!.
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M2(1"\%_?=+O?;+1L=?#Q9U!PQJVQNXW3]?O:6?76E><@3WF@UEF?@R\GH7;
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MGU@\/HO+JS.P@8N-"-?K+FG <BIGZR!=&//3ET9XQD2/DB1E7Y0=29N0$YO
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M1^ZO')[JO@]'+?<"M]9MO]6_I'_OO+W$.;4SCM,NL,TCR!P<R02C!SX+'[*
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ME,4Q!M9G+,UB/_6YG0.U7<ECW[ON;M&^RM:G[I-9%UVOW=YB=-_:W+H\55/
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M*-Z(21.(=L'3 G\.G L:&I3 "17S%2KZIE][-"!('5B]2SG*@OI<\7"<JY^
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M/$[,#7BNS#PE# UPM,+EY4ZGTI@2!?=^5'=L7>$X%T==T2$%^K!0K2P^K>:
MX78"_L@QQQ/[\(\DR38?GD?SO/!UEDTH0_IH%\S<H0R3+.-9/469R(S4E(4/
M%0Z0X>00+90^!0IRJOI9:8#5VLH+QAIP2TPK$S/\0E1=!6F@_3WXCXO\K4>1
MXDRV@JU$ P]QNA]:H7 J*#?:N&MTG.%")F&3RP(!:UGGU-03&5XRS-,%8UHC
M=?!GXBGL"\_OZF7&KC.'\X$VMXC4(5^1D](6%_;P%Q]-:I3SYSE7T \QBA(_
M\DL0@=IR99<'*06XQ^@I;"(I:UWAXW6%=QZWV_1*-Z+16QXTFJP8\TG,:OK#
M=%G,&(W'8RY<\6GL#\60RPNY#QJGYR\,:'VG8FCN!_;DN8.;P=U5Y^[NKHA_
MJK69'$];7%UAI"[1W1\%F0B3T?A(]>Y(EC''X:2@13 M@'UNU=O4XXZ IQ'M
M%\?2%O9UV7)_BU(,>X)M%H[S@:W1HU!V23;\-]ZO"+T%-59G%P$2=2$R,113
MAQ%QA(O.4'V6V&;,Z35>!;9/&C*:U-J%5*!"/$'ZICP@W)ZOQUI7155%>"/F
M*G="6EWB[X1FKK>)-!I]<?E78=]X>0-IC6_B?V:8/"W#RP7.3TJWF,Z9$\IS
MQU%-ZP:%+!];CD$2ET:H(@+ZNJTF=C=N2] _!W>MWD(;E0-5<=0P.E[H/^V4
M^D^[C?>?KH^27@L[-;#8J6KL5-]BIXZBOF'_S:]K8K%J:6:+V]HS;NNU27Y-
MU%:W;:"VT.)!$X?/YD'TS+7WFGA.R--7"-Y:_M3[EOLQ2M(K00K*?RMBG $!
MT'%YG\2,!SZX!W"OHY- QO G##A1T/0CV.;XTQAMUI@[IHF/6 KX=:(_G".?
M(LH3*@E+W&R.AC1X9J U1  -$4RI+\)>5%,3TQ59="*PUB/@,A(;Q6#;SR-R
M7)Q 0Q#!Z6'NO)J+HEA'U?D8@;M1*? 9%!"-"R>#_,DHY,5Z3X<0)(] UK%K
M/)M<##9*)5H#?8\DK^?4-)'/=A,&7J#R0HQE9 63\*U9XB>J,HO\*:+)# CM
MR(+,(AMV;WG>#EKM@3*9US'CVZV[>8/UP<M/TH\M]R?I!8\YM=USYP$+S^%$
MW[M8\67(^2]QE,WSNN&%D^HLG%2<<D0Z :76" @(P"-XL@GA?V#]A(M61IV^
M>MJ"VL X2[=WU;F[[K7<^R)D"):?LY@]Q&P^]1P%6*##(UU>TB-S'B:$&,OP
M=I<A51]A3^)%P" 9X>FALYC_/'?N^5=XN32GAH@AP:F)'D+_+PHD8?DREM3P
M6.L5G\P>3!2A;9%P@T*H(9ZFL$:"<2WA8"<BVB7EC8];[B?\9>%M/,I\<$1I
M)>J31&]4:TAEH"+HPRR4I=9P'QM%.^,JD3[G8_XN/^8J_'XNQQPO->.@%XZU
M2&!@<:0H62V((![W2D'R7+-0EB*"'BH <0'K8G]Q@.C&'5?0OH@*%#F+_&OJ
MR/'$$;DS=>6JA"S+;T=U.>H+6!RZXH)^8KP=GF-Y%.%(%8R%"G71P,&Y;G7J
MG)NK=NOF, ?G)VD5&3UIL6QSP>;1#'+F0$M.31ED%%4VMG,_33E'%'D#LE];
M$5UU;RG$^%)G9-OX=FE([="#5NR8G7/FOAVS<WH4/,DQ.\L.S!;C#GY4EZ;L
MU6%&.B:F5S]$##-">\C]^F[3S/[:@M"8*JBYQ[-XQY/6[:^1(>?PCB?;S'EA
M(IE0I1]_>F^H2-LQ%#N&=FU7UN:[LKZ:@61;CPQ<?(E/#%,.VQ_+'<G)[H6C
M2B*6&+>'V. IT:W3OFV*<*=WUY7?9ZG+\RL+V0/?[LJKX3/6]!-W*5Q-/5.)
MWQ:7924!FS@VEE.'X-2)7K_K3'BTTR-W,CUR8"=_GBSO.OTE)OQY3?Y<B?.^
MMCCO:ISWP.*\UX7<VJZ8%EW]:KMBJMFOQG.."\D->MM]%V&KS0?1X$?CU3R7
MAP_2ATP\!_17-AL2[$5@2_,F@7N4I%+ >Z_0[G4)^RY@_DS0*. /<.;@8Q+F
MZ*N>_*!F7R$RGO[9Z;>Z2RKS!-1,H*UF- #"Y5_G42+*.8E8SCR.1IRCW21(
M.!+47.QKQPCPF:HF4@KQ.<P2X$("NF6N@(\M]Y]4:T<EBZKQ1I9B P3"NQ'N
M<B1!E2C\LBN=@WL4#1TX_@C^XL_F",7.IP4H:#F!V&*>9$&:@\)Q8 R+@?=8
MY(<OD/?=2G23NI"+UU? :R4S$QXF5$?K&-\2^&VP#9($"*LZ[,UTL >W$&6Q
M.J,134:8P);A!FNJ?' EPVV=_P8U^KLI]"_H*USE:L)F?O#\W<NQX;OKF[NW
M6D'MM%O QKOZB;H<UZJ+Z[8[ ZR: +W[R!-UKMTGAIH8SKF8U2('@3"$IR?^
MV&?QL^?^';2.^X$_/KN?8QP^\CXD U"4]Y.RWZBX'Q3PXLJHC/-!*%@7LJ2?
MCJHV1WU"M>FJWU#][GORI8M/<#6"4W7EH5]TWKH_(?@]H&U[[KN__?[6_=]^
M")^[G_DI_&#J\XG[H]2\M3;S^V3BCT!'X:9^\D$'@J9ZFU/?DT02X>Q8*\U$
M(&&,;;W%WWGN+TSNLM8N_OB(J\$M(>MZA/;\$:V=*2CH]"F*OZQXMB=Z68C?
M9LG<'TFDSB1FV;C>5L#A@Q<5+9)F( O/;L!H=6!ZRRUTK:&+:X%E.,E(-HGX
M%;@!>E]NM;:0*%K*WAO4D3J.'NC4J!8SYMO"58E/-=I;@O=$)*#E8D'>**[7
M"@(]X=%4E62HX@:X,/75BX/;18F%*-X"NS0(L.)DAJAV3CV4'OG4'V'2,:]!
MJ=?N:J%>!7_R,8YP K<L<HL??;QX/V5S_"N5F?Q.'<DO_A!/=]_3CNCC']5B
M=1OR41.?B*P1]<A++(SI80.2FUM30]$>I>:AG>B)607=WEBO!F$9'*0%U(N-
M#>YE[XQPK)A9N"0\V3/)T3V3*FX$I1%*#;<6CZ2>326FC,GS\FO<,L[8PM0S
MX\[X*%=TY(KFC9&/4$RRV4R6.3%WRAFJ#&]9$04#FR@&]9*W8R9-+*L@:$(C
M?@>G0O*1*(B@$D%X56?QH"\2 6>&@0$+VN?W4(V<&X@YDL*(1>/=IPJQQRC
M[>OW8%AT@GO1G2X_PVF^?_0?X8K %B9PXNY+VW?$1>)>?&9?Q2V/S/D;O$HT
M>[ZLHH)JD*))Y9+K,1;M 7%Z'&@3ZOB"Q2+%#EJ:\Y)HDBV.H7MSQN)G%X5'
M="ZB,IF1:.>"+H!035/NQ\KQ$6.9 B[,F#&\.]GYZ@)'GC1EV,L*B&,[N;D\
M=;5 :9%!;U!3R4'ZYF(E259NAK;B8)=/LBAU4:*-9TAT6-+=#''"0Y(7MN1;
M\1RZ0QF6'@5!])0T,"RA?C,7ZXRM]*-VX8N1*\9VW7--7DYU3 >ENOQ$2RD<
M%JG#*4(A+4\MWKE1^Y%CUW!9@=O#"MR;FRTZG1F7FUXY=X"$Q5CY\&26/3R0
M^Y/_^AW0) )%^3NJ=ZJCK[.5_P_I_@<<;3CE___R.WCA(?KVK;+3-0EK.F;E
M(0B_TKH?\G7!:)SZ0Z&2L(T"#H&]N6Y?==OM]O+-TS*U=K+\D87W+G#G;6/&
MI.T-?7P:;;AKC8:W<#T9+=S89:T6HE]F:C4*VU8J%:%OMO +C;5$LXXA'HX5
M&LHCSYBBV_)76N=>R'ULTHMYX3E%[2;,;LK7N_=C-#G!5M9*_1J5^D ,B![]
MF?G"\*D7S)'KN1>_1)'HKE!T43M=>,B@^X+2-"AW#][$U5;J2[6@L:KJ;%75
MZ- -;Q?B =@<U-!6N8HJW?\+2JK\B5K;J+2C%IZYJ$16']:MNL>3#1.J4)JV
M,S V4C9]%@ZQG45Q3H=XO.M#_"\_G=826=&OE::D/5("-^8!DZ[_?3!DL8ZD
MR;8F(BQ=G4LJQH]J[6.)$C%,'I&ASO7*"JNG]*N:M^PN#9Z2_JF71-JAP5,R
M8FHG36H8/*4WSXV="@-F<Z/T;3%IE.?M3)M9QJM*,=P12[CLA#6;8Q:&@FIU
M=E(=6L< \]R/V8B:_HD0!,YSC G7@:3RDS'L@X51++K>1<,DC;.1NAWH%-<\
M-TMNUW?1F!_55=+$LVK">F\LK+<:UGMM8;WK47XO F^!OA;H6Q_H:]&W1X^A
M?CEYKQ$850+O(C82/=(Q3542T T>^-A#!\QAF>XU)S 4<W4"[J*FQH^%!:*_
MI9$O0QQ[DN*C.<T9&6&SNP=*T[J_LG@TQ=QD;_?)V6-&5932Y"*A+1LN3V$E
MGCA&YEI;P-I,U.E2[+Z(808"L*93HCS0-4#\M^8]HV2YF!T$/^NV.]?T"X&Z
M$<G?.5@D><=)"<1Q-%CG _PS3*2AK09C,<K0BBTI#!'VCLV J6@2:S 1 100
M@R1 MRWWDX]B %\,A=2,.1BZ<-)+=!ER%$_A,!6QB80:9_A ]#+%!R6P0[B:
M.5SA2N[V2?6!_1)&3Z'.'?DA8B5H+ RXG6!PPWO(9R0212SQ6*!=:$(V'PMC
M/] T$5-\<CB3/G0(BP!VB V47DX KX$Z5R]M).8A?^("'0;2Q($>8Z>XFG:J
M!2/DW@@V8K3.=C7 1B&MEC&8'D4#]I(DPT=+QX@%Y2<X^-$Y=MX2'<B+^VJY
M[\'"G=+TI2&U\P7)\/\RQ_)40,XJ%0UV6 7UQ%FBAKLJ)YFE#L,95[B3,%(;
M'$=P%P@P.+ 0:2LQB]3)^#&BUZ:5X<$*H%,,[L%+3*/83Y]+B,(2)\<^C9;"
MOL%P166$O9?<772GBN1;=;2%U/"OX (*UQ-QNK03/-&>JP;2,Q?Y%N"7$2*#
M( K8] -U0E.(>C$N#WX6BJBDNT1\\FJ M^6WQ)'<0/T8#QB6"" IBU>#[%8_
M1J!]R&,G#[>(F(: Y4I/&>^?;#X/?#$(5+1LUV="G7DXX2AS&G*DX8TJR%35
M5EZW@J</._HQ@A1ZJ)_24XD6P:."_N_[$AK"U0]'GHY+\"RF<#D%=(\L(1&5
M%VP,RBZ*J=1"S%C#B%OB/D01CO5ZR/1, M'-V+S<U/TA)LPN/P,'X<<^BG]6
M&FVFQLAI/>(:HN7 +5U&9\G(%,5<Q5@W. 7P+:&PC"(@T!9HGHIH(W(W0X@_
M3C* &T+=>Q,6XQ\E"1&8QQ$G%3!"G>[(4AZ\90P;$WM4D_X"MJMAG67PIYBS
MBDVCT50H[9B^M1PN@I^<^,E(7(\S]NS W<*")$)937S,,1AO+"Z9&(6JI,>'
M' &<2<7^B#8QP3RI](K0CCB?#[X]$S>UJ'3*P9##9^=E@T(W^VYT4MEQZIN"
M8*LQ!K>*0R^9G$:;<O65%:1.<)5\2N9/?)ZES[IRPOV%8[O_@,0,OHG9!5=X
MXCA^06S-R7'%M(3\;@%3/)7K,V4H"'CJ) .1?D#'D\0V%A:<F)ZI+GZYNJ]&
M&HN?,KRJ1O!%6AJ'(SOR5(CTA8C^^G@GRM.@4+IC87>@@H:+/\.9+D $/\H2
M+#:AJ<HC/P:3"-VQ$3(1YT(F[M2?P6V+O>0Q94/.-)Y*,3X1MRPO1R<1C/&$
M_80%!'$T@:61W"HNGF/N08EGQ)N\A;RT$'BBH-#RI<6*DQ)R%\WUB>B++STA
MV*F#JU70 #Z;JQ8JW"%M%(#PC1]H.20G6I#/7,Z<UO.CD>6H@UJ2J^X]*)(2
M$OJ3&KK1OF"7%S>73E%HEYK1IN!0*6?,'R.:QJG?'4M#N+!^Q-1KBA23@@W'
M,M>"%^4D"X < :HF=-'QQG5(LDC82.Q QERL,Q* ;7A!99@IZ1(Y,1I[/L>S
M@JJ?1)8EP-U4D(+PU)Y;$DSY52FU2CA=+9Q.23AC,7%TY(,\4SA!LDJ9M:O%
M=6-I=49P<ZV0U!JRYFXL:["<HV1MN9B]%V<FFH,6RWW&<BU;WJ!,U!J5KGT]
MX&C1,)-+./(!LB867E-Z -5 ^?(#Y.V=QQ" ]+(F.5=,Y9*C5*&_1UP5<SNF
M9X-^2YADJ'9]+N:DCAB)L7E><E4*?R-M2E.=BNZGI^4^H=?![^;1"'W*Q+GS
MT%ZAP@C/K3@[&*'0CC,]4+B$99I(V26Z$$H=*8K%QD1E$%HJCWL$*UK0C^;Z
M2@;/&@"T+XD^-G/#]P:;5#M8X$=SP(]N,]CYNO M#540"MX8HO1""',<T<T<
M<#8N*@!QSNJF]/W8N%& 9S2M#L,/Q?N$C/$$M/LP'[V3IXI&04:&#:F\[:H(
M\-T$!7QQ"H;1^+EX?>5QH3RZF;" FQ69^QD8#:=[W7G1PLFP1_YP1W[GX/*Z
M1WZ% X9QR2>T6U67#V5&+<;Q=;1<629U$9LOFC$M]^_1$^H"&325 5M,=U&\
M!,P*"@UJE\VPQ&HBFQ:-$&/:I31&Z%DBD$]SLE*7* '_?(CP!W+N9&1$W6OM
M0JH,-'LQ^(J%M12*F45)NMQ($M.^%KY+$7(5>:I7J*,<7\H-DD\B*V)UK:'0
MBZ(<5P6*9-Y&@,%VPQ9I,ZHL!;TG(V?#39_G/"E6OE-NRD]5EC(M]LC!RL:\
MD<PF*"]5D"^NF;'*CY$#C?=0GAI9<;[&$1=72\+K'98%G!F^G7)E2GF7HD]4
M-H/E%^"^55&WFD!1#!V*FU@N\$Q&@)$LJ;Z)R[>KOEGUI5I3?8CTB.Z(-"E<
MQJ=\!S<>TZM -:R$S-U:R%PU9.[&0N8V**]?.HR0MOT* %,6IF=A>HU*W:(^
MH]Z1E=C4ZJ[,-3GMK(WF<U>@^=P+!;887QX1LL^ZOGMR?7=>K'B_37U>[@]H
M9P_MZUF.J\0!R,]KY"V%WP<>"(:3ZYFQB(+AJ4!JY'U51!+.#U6_'8'RI"S=
M0M)!>>-B#'$H_")E%K?JE3A/LZ24G7B(*(F"@?) 3( 7\(,8.YNZZR;4ZH4#
MT;5QL[F),U/.(!R?+YR0"^^3F/% EM@H$DKW)G*#Z$F6:R'\[QG>*8X13%2W
M6QW5[_"8;C.Q!=WG5N],LDLXF8HIA/!2?A'!)M3WC.UNXO!HZ9#@*TKJQ5&&
MT%%P1+.46K7"=C%Y$F1*L/R4]A>3I2G$FU0\1E9K'Z E62^C4RN>",*NBG0-
M"_)L4,D;U'$,RKG4]$55#BG/*STIT**)Q#4/V1IN>KW@$?:Q0OPL'<\&JZV^
M,]S,&I.^Q1=LP/=PM][.JWL_U^_B,82;;06 %,'5 1\_8/9%@;Q!<S(945JB
MYNL5U*[ 6"B8!_^*JA9O'XSWYO <2L8H_:'BDP8<HW8=J[]6%C_79U)ABALO
MR1 %J3?WY <!*IQQ%-:[^D'R,60:"%7^B,7,(X8*.TN"Y_T$K6X'2R%G%4YZ
M_Z!!JY^S&-%],[J_EJ%@G1P%ZZZ/@E4\K0 )RF;M%$]/V1<P3-3%@I@=['*H
M+AP-8H1;#$X;L,Q/IK+QLJJE40C;XB)%,X^60=>*;B8VFL*;"1#:F >,S @X
M)R-QLU^(<*Z E)/A5B@N<41Q"?9=SCO'KGA-<6?'TC9X8ICQ'+-GCTPA_I5A
MT9 R1O67\M,S\PFN@TUI!?G?L;F?LL#YE<PVSWT?)EFL^VY\HKR" =AW@2U7
M__D?W6[_[=4C(F]B>$2JD$&)! R!T7*Y>PSFSB_6Q@]$7J-!(-HA%5N8-1HJ
MZ;((01*-_QD:CDSD$"A\(S5>3***!2(:@47!'*Q1IPP]$WAQP]Y+GI.4SV2M
M"QH3!!"BAA#428*@3$[>H-7T74I;XU\5( FM.)D@@/,) I!,LB# H?!,UB.
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M7H<XKSV*L?>N:LEB%.G]._)119,SH8.?]3%7"_!'SPQ*+DR"?)I&A4%N:?3
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M5C:5AF@G29X6@OD1?I(EYC?SDY)@0DAV^ZF9VH%EP3OW@X*Y64I@&YUQ6+R
M>RPWM#$;#-7$^7U>U(%BZ/@"WA#1?U-&N-!G'9TCV$R^M2*BO.8](M13P@L$
MEU//U$ NV<%+S6,OE((FRN,UC,8\(5[7^DTRG'9&^$DC*9B;YE48(J^JU[L
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M)297/<F07H&3/3>V!.S) 'Q4X>R< K-2^1V%-\^&S'??HYD0,DG(GW6>[IT
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M?)8WBRW>QL5E54/3\QX6\\9JBZ&NMBBNMACH:HM3<MMTR84NN= E%V=?<G'
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M+^_N;S<'K?HFOYZ?9M&^J?9-M6^Z@R_0OM,Y:.V25E<5M0:KHA(M=(8^X?6
MD!5B8_YGU=B8]^4 (0FN=VJPL??(P?%,0V910R53\']IG"J%O3B1X(L$"<CO
M'K!]";^M_-1R^)BM=F<#W&)%?2N='K7!X8_;X<R*+[P(R*A/0\G34!\DW_CM
MSTW!I$H/5DG061FH&1*<:L<441S1J9Q"5C46/$P#8+I>TY XK^K0Y>$M2ZUB
MS,,GSMWT*TWC%\<;,\= J/(%^RZ@.<- ]!S*V06&7&8(=#%N"$ O\GT$TDS_
M5<G)"NE5W JM\;GYC^9GW.)DSA[MT/@;/!C$.$@-RB;X3L1&%^NP73NT6>CY
MBCXI7,Y;L]2*TGR0\394A:Z!)QB?!T1*31LRX*39+O.?57>F7(!Z1,$(B#T(
M9"(N&D@0 A:&=AC1TA"9]+N]@'4ZST;7>I5;0HS3:P=!1%N9&DMF3^^B9;E+
M(8L-3AUI8080MFG<Q_M'!'B"/83S$G>G%>#!"[364NM(D3)/;0P=<^#Z(Y("
M_R9'G5ZOV>_%!*J4(-F5U X1O/.5I2VW,[BK/M9Q5\78IZ7UH0 _3H3\@;O<
MAW\N. \%ZE>APDG?"B9.$/C,G@WP&NGJ\\K>G,]&VY+?+7J9SQ_L %W&:5Y3
MR9ML];2+/RRU#/70)^[GAEW W<@,LHR1'-;K'L*/&T$$VIH93[!Z@4<"(OH,
MBA#LZIO>;?[RV 6HO!0=X#N;2*'^MMR-^33W @Y&RL+&NU%T'ML!"'C+PF2$
MP=ED;A90##Q\CU!M;ZQ;^7Z"_V;J6:56(=X++^W%+VT:!%B..L$1-S,+ F\B
MRIK%@MA"P(4*D'*09:=.U5UF)E.5F.Y"]Y?S;%96LG$XU% /ARH>#C70PZ&J
M$\K#P%;L/N!)#VVJ<B_;#&VJ>PV%T9UC'X/RHYT:+X]V,@X[VDG[+Y?LO_QR
MVO[+RQ.,R%WY>P3&J0K6@>/2:M%0V]AJ+Q\M6 E8H$V:,YWAHXP5*PW5.!0%
M2KL#MO,C1@=]G+!3:AG\NYBL(>K)X&&H#<33**8FU*S1C3=+?HVH+H+?]5K&
M_8/G>Z&QY+XTVL?/Z-^4]5WHH8\B2C3C_A$#)A(<4*N;LU4W\Q,([?\]<IZ-
M=E]%]HO#R(-.Q^R-VL9->J#9;1ZB/H[R,AS,4O)XBY(NZ5V#8P__56_='*HV
M\4]_Y='"!@?&#UTN#5D:?[6$3W:)3J!I:8.\"I<['K)E!Z%OCR,Q/YG[CZ!=
M:"S0LX&*VIX*-9>F(8T)<UU.(?URX0DU4BRO]<<>141 ^6 ,*YDB)\(&^0%P
M@AD9 I=:QBQR'&5JJ> X_&QGJGK1+!.*&=2K[=&=U!T:"Y#D.1$(G$$,O)ND
MEMUX-:56$BOS#JGZ6)'KF+56PGLHX4\G:O.-G\O8?*EI0=+NLW $9<\<X 3.
MZ@R_G%$G;*@"NRAG?PW2]E?Y95!,.C8!\6U8QC$+>"A>K?*Y$Y]/;?HLB)9+
MQ^9D: HW$3W&&7!468BE5H$*Q^>.,F3A]6A[PE7EB\V/O2@T1BTX%7,1M%W)
MC2\C3 L',GP-K./VXP%&<FK==<FZZ^]UZ*Z?OR^Y&Y3,ZI"U OIB"3J)3@C.
MNY Y-E5I)4^BF/]'A['=CB-E=,1(N\#9\!Y<^Z\8_KYLY547WP1:=(:JP#<<
M+PB:AMK5ZDI=L=B-*\5YQZ.2NOS%?0D]O;K6NG7"B<>Q=YP#WS$P_*^"P#A"
MV8\.'06N"Z9Z54_2FPIS<FOZ]L9O8^(T?#OX9LP860\UCF1N6\W.&@D[U$SH
M5=V9&0K]B^]%R]BT\I;2X0NP7-0#]\0F#?'(P*>)@E2* 0D(+Q99<AP7"^_^
M!L8($?8&4U[PKL1@P8]-\BE!(GUI%>'I^BY_I8K&J7N%/KLUE3&#_VJ@(G'L
M/R,;/GFFCX2W1QM 8.W @.. ]A>FZ&=%QP 5#5VAN"5X=#3!:]P/&9E6L-W(
M%ZD5VESU4Z&'@V:[E"72:@ZT(5*1(5*G'6(U*S9 MM7['\4Y*U<(0Y["1)RA
M0\T-IO]V1\W^6FU8:QD%L?\E+6C8BZ7G@YJ(71B:\!S[40TV]CTV%96NMM*0
MRAM*5)U28#(62%I)/4P6XI.J22M6R10;=[$ ?>3$]:<\\CTQ6YO^W?C#<^Q@
M;OSE>.%ST[@O?''FE;,HC*B 9[' D!.HQ%2)+;PN992Q /S)0+EGZE/'9F/;
ML4-;.758>O5GY(E*H-CWG,0UKG;@RAM%.(#9.V;!&>Z><A;)-\6(<:HW3:T.
MGZ_NDEAN$S7?2"GWIO$Q\C'.MO#06UY];YKL*\]D3N"M<@H-!+'E@*$\Q,X\
M_E))26/"7!?<^C$'2KG?,!$?.8)_:A2ZFH*>YE0<5\BM!:C<-#XE1<LF$EA\
M33Z&5D%?=^$$J&68#4%\S.NPV0Q,>Q&<2*UA9=?9!:'D24J(!XAMIN=19"DJ
M7YT$ JJ_,G=1'%N5/8UTV5-QV=-0ESWM6V5R*J5"NK9)US:=6BCB4%5*1PM+
M9+PF^1D2$3Z)35#EX+76&J4[M[>GIDXU;/3+ _Z A&?IQL\Q<X SZ#';P<3Q
M1$YT7://ZYA-5;)(@U.5L0!2$0%+.*$*+DF*EOJX)##3?NA8+P!+=1*V;3O!
M<NOU%"E&<(9I$?E$X)H._0KW7@. PSXBLX5L*)I5(AQ%1NI^2&0'D9??/-#,
MY+'14N >/PH=KH[N[YG+IC834:LI:N4UTT\UX:LE_']_T>0^(+E_CGQOR:6<
M8QA/D_T09/\#,8]^&OL_BJ5@1R5H^0=-_,,0'Z/3M R*4&NJ'X+J?XO<!^:K
M*W7F^;:[!GU+4[Y:RG_%+HSCD/H$Y_+N[JN*,!-14V:AKFCHM=ZCWJ/>H]ZC
MWJ/>8]D]GBET[-9&@HS5MUN%8.[OF70VL&1E O\P^)^1_<@<D1^\)BC]03&4
MOF5V^WL,[C[$RB^!S'N@ &L2;T?B/<#_-8FW(_$A9FY<.8GW&*^H2;P=B=N:
MQ)K$9T]B,-R&AS#<SFGBR3ZA19]-N6PZQ@*CG;V#<YI.T1Z:PV&GFD=6L<AS
MHMV=)ILFFR:;)ILFFR:;)MO)6B&7'@!?W?WOV.5X;:8LHA8-*YWX>#T'4.LM
M339--DTV339--DVVT[5"KB(4N[:V]5<//L/QU:(OB"^]P-ZGB*-$];!\]K85
MPU6*8UWOC+,([>X>R9I"&M9QUC2S]E/*FE&:49I1FE&:49I1FE&:49I19\.H
M8YCHUY0TJ;[IXL2#%%W+[ _VJ#.]Y@#/'G7\UTRV/6KSKYEL>]3;7S/9M&[;
MK0Y#DTV3[:!6R*BVDWH"J9*#H6+\FN"O5PR*<9J24^4CK^W4:=IIVFG::=II
MVFG::=J=*^VN*3PK:]IAV5.?S=; %EZ6\-Q8E79#W%X#S73!HB:;)ILFFR:;
M)ILFV^E9'R<0D#V$G?I>3"3&"9&TB#%SO^'0RHGG+STU.AG!".4@)?@5#K^R
MPXA^=1WR->R;(ZO2T+\V<;4^TV339--DTV339--D.YX)<GVAV2_1<NG8W">[
M5HQ4XOXC#D)?^MZC/87?7(5,]8$;E=8"7851>V.9K4ZEY:'70;9VRQQVM0]5
MFFZCSAZ@J5=*-&UE:+)ILITXV6[:([/5K>,FO9+0K8#-8Y,)K"H,:!U+]HP
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MW("'8^D7EF%ACBN>#91418EG&"P(>"AKJ)[8LRB[>K(=AZK5GJA.#1^X]'G
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MIM;JGYU&[,[I&L[IZ(G/Z1?0"C?NX9$ZI">OO<.3,Z]W<.3&-%_7O?,3M"K
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MZ3",$>;B<^ /@->SMJSJS8J4';81T/F!: D$@9&FHB7I\<1D7M)-7+^?>"E
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M<?7&EPX]-9E79N5-+!TZVH RN*,62H>N+LY5Y=#;1ZL<.MJL</#1QE8.'6U
MY=#1BZD<*E#[CV7F.[Y9"J#5NG8U>-63@[?N-P+>3=_@!E\)1J-=*^)1'>C0
MXP.M]J-(_'+[>_/05C_'=R*AQU815X-&O-7VH)D>! NU MKJ$KSVLO""2@M?
M'O[E:,W%=!7\E\<K_BJ@P6R&'FBAV.[1BK^>FL(KFS0M5-H]61W8T09DO(_:
MJ+Q[I.*OH\W*$AZU46?WJ'5@1QN0,CQJH]JNY>*OIZ;KZHS<0GW=(Y<8'&]
M4]91&P5WK98C'6]69?]1&Q5UCU:.]-3$7I*%6XBCM%P:\]2$73T-N?ZBNG_"
M[T;NIQ2G/+],6;$<^[903?=M&D026*XB*%XBH5=GY_4[@<^BZ.MX ^I'NTJO
M-;'V\?RBK_.+RQ_]3U_=\V__O/C:__I# T-][U]BV=>6\M^6E'2M*!*/6ZCN
M^C:5L(X&X%1C;;[/TR 2Z=8*P>,V"KML>M<!G+9)])/-JCLZ;J/H:S@$XE+<
M]U-T*](LN&ZM;.-D X(+QRW4=BF<Y#C:NXK#8!AD+Y;$*W-T&QC@/!/V4<C]
MQ+4QRW'T^L.27^,L&,,2E> ^AQ7[0=1F-/ADLP",CELH__H>I]F>P@.7/C*.
M1FR!V!N0@NY<LC6Q[\E\EZS_X<,G[,#I?W;UD-+'<,LV@ <[MZSN8)ZTX):=
MQWF2N?WI-(EO_=!S+\5UD&;2<]#UKV3&6BDSC&7%22LM"QO G; 1Z_?7E'7U
M18@L: DU_F2S*AA.6G#+I,M $VRPY R,*ND1*\J_5<,HKO*!/A@O<3>6X_3U
M>VT@8G#639S,-'G;F:^R64&(DS9<-EPL^1-4!=[>(+BGIO5RO-Q"2XZ4VK*^
M_"62=F4V;F%4DZ2R3)>]2#(OQ\'K+Q\AU.0/8N\SF'T!C\/23)W +WP0T^W-
M>SO=K*Z^DS:Z=.!CV7UM2H=?(JV7X_ 6<'P_<.M3GK125_+49%W=B5R_%RF%
M1RODW8"6U),V^@A:+@)^:KJNSK9M0#,]U@39IZ;VDER\?F?O!_9C1)5\AM%T
M1/K+X/JF):6W<6S>1N(NGK8X4_-T [+/)VWT$/3#,):I.LO1QI:8NPCDR$TP
MM3]_B:1?G;O;<PX?"[;AJ6F^)+NOWU.T8J;NYZ#->I;3S4+&.&FCZ4!KRM%?
M>=I>T^A3D[I+2#\B\YXNJ!'^]I4STE?N]\N+\XL/" +YXYO[[?WG3W^78)'?
M/KH7_?-_4'ZZE6FR&\"077:Z[I2>MI"=_AJ[EP+3T<$6B[_3%K+-MBYO,\?Y
MU/1=F8?;0">P*RQ>(I&78^(68@O^+_<R#]NJECC=K,+(TXW.'S\QK9=CX3;J
M?5T-J7$3#(+6/*I-X^7UQPG>Q]$H=7\DX$V)=H(Q-HW_> [ =[T.XZX&XZX#
MN7M!('?OSI8NLE[2O7VTX0>GS[_2M7U/]_?GJ)-*IV%YY,2S]?K %>#$_G"8
M)_YPAL98"4Z@9>S$#6!6H/[Z'>7O(@$Y/_$52G%\*Z+62M V"SWQK 5GN=7Y
M$T]-W^5X>/U^,M@]NKL /+E$XK^()!7NQ7@LAJTT<IQN%@S,60ON<ZGX@?O
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ML_@F(AIA6.XE4G5UWEZ_^OZ7']RV4Q'\U-1=DF?7'_2\ #&0"),C?NN>P[J
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MNS6F-27A/_8#=.Q@ET? 7A3BXG-&OQV OX]G#A1WFJ66QJMC=L_9"6 -YL#
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M@'4L$0CJ?M&T %<5"SH/*A8\MXL%JU;K''B/LD6>@T$2<FJ '2+]-JFR63%
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M,M^Q[HH.12V/DO7.C4OP=$T&UY#!<R3JC%I+"1*QP'?31.R-&=K\CJ'-Z83
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MWDZOLT6OE"EU A=8ML"B/"@*V6F,?9YF>(I$@&+^ G,=T6Q ^L>4/5ZT&;@
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M @O5L6F5Y=5MW .Z>O==[.F3>&YZ979C0!-5#0@HFKM@#EF%DZ57;.H$1;/
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M5!01%_0Y[KM]]!)I7= E0U)IZ@FD76LXNLA!*&^KJ3RI_$#+H&I11]0?P3'
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M^1G1C$\3;92FK>10 U21JA!(H$I*N,H470*_S@(M^=E;S9QB+G/Z;CH#MX*
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M&GR+*4O+^Q4Q+4V;%CF@B,]69#U'&H<W$E/<!G)><"G)=J='::6X__2.J*#
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MB\?'].TW?B@N3I\<[%RB&R%^QM&'C#GCBL6B0IS-34F*$Q)8;E7\2HYA8'4
M("UTX6)MDUA?AN(A-;#%=J,N7UE3>_4H3TKNA!4AT/,.X\ME6U%#ZB109)^%
M5H &=8.[&YFER$.W;CKFUOU,,/G3TPO$(W+BC-)E?<BW;#0WXM >*VU[1_KI
M9W!HU8\H-P )"<3/OB(;_1BJ':Z@:*8;;GT)*.[[1%THVX><S;U.Y1#!?<?T
MSI3W6RXY^T#\>ET@?.YQZ_<PJ[WP#GL%/8IF-C)E<-:KQYN:8K+@$D3F<7_@
MD"NB<08ZZ<N X7G5;%OO>S"H@8&RUX9Q.C=TTZU$B\*H(A\AF/]1 )JZ(!)(
MUB_.0>34HP&0V\HOR4A=\XD **56(]!&+HLU4M4XR'--OA*V_W>2>Q7T^4PD
M38G.U<+OC8V3*31LZ_T&C+QZR$796>K2T:Q&\*JB+?(UY^'K+\3TMRP$)I:O
ML&W98%$V+ <29V 0]QHBK/75H4$!1Q$=JK[RLJ&=51T]L(4P#''LH0CF#Y=5
MN2!Y2&G>GZC&E-B]\%,(/D&([-=MS17\OV[G5\)LXO4B=$/5<="F<8E<B;/-
M#/U0L <@/,9E4M6%>'ZIQ<#W@*V[I%]#N+U%P#SL'3W[4J*%PYNM*%F1(@?M
M^K:\:0 X 0^>MU!$TFT[H+/-'9$!YUEH\@7%",W<OUC>OW7<!D*8S"!5$?;9
M@;O)_^F.N^E^(*%NP-[#B"ENCJ[:E-K!0]L4=9),%_O+6!Q4^!(%97\;)908
MY]&'W@&(/_#O(P"^<1QBG@V=G6S/V6DUNT\GQ/YL7BX*^"-(9:>*6TY="E63
M68J/&Q/.V#,F63K,>)F'83N8OKH(3-<LV'M/E.2:):]DQACAJ9$>V,!%DP,]
M=;$D'>4_!A57U<%VU3KG],G]=WWI* 55S+QDP!X?C#S<;"EFT#.#=]Z-F ]O
MA'=\4-00\JHD^IM=LZ+")2%>)+JA^E$"\LAE':+IP6<R?AZ&]Y!ERX%1Z"?'
M*/3>*/39,0K]#1^(DY*5;5 =&(M8K9NNHD9=7L!"YM^HC=>U]^^F1/./"5'V
MO5-6?K30[V>@9R>F$.0M]CH$@\D\J3O&%E_K%(7(#45[W,Z(EO0U,=P\ W&M
MWQZV<I\3MLHU5"0MU?@Y/Q?=O/A']K/I,((/I0XADECNVX+4A82NSAE?$H?&
MLM'0&$-2O/KF]I5D4'I?H@##H@L]XY"K;DX?1;TW\ZA37)<S+J@(&!D9!4).
M[R(*Y%Z[SD4Y1[PT @VP]KX+5,?46%2J[Y,*I0@1ZO"$^BV0\"T#PMS,C-J;
M:OMI?Y&<HP'&[><8M6FJ/M #K]_A#N <GQMSQ%$ 0&-L<^Z/<;@TLDB!C\7>
MGJ39;8F=*I$+IJQ## 208 >TJ@RU[^YS:]]WORHV.03>1%@-W#5;LC[;0)\-
M,Z"[S(VPC?'CX[ +R8^# 28/779?G#X[."_TBA*!+%F^?BKH=V*R%*:(** Q
MQ8G"Y$_&4P<[\/G3_/'CQ_"_D5PN$+3RGCW/GS^^R)\]?S*6]L4:+P1&2?<B
M; 46IXP+K=A#XBNX?>@C25+E>_G[!R\ M$,!M%T"]:8@0N&H2-%^/#IINHY9
M9TO8%U=_,E08 )S=MGW@S>LE^GZYU*:AMJ/#WG5'0)S9=I:B)]D3T*<-ZLX8
MJ.8]=FIQ"C(7A'1=#HQ ]O$ X*"4%CV )PC!,>IMZK?&&G$/&*-A[FWLU":E
M<*1K]?-5@0VP2-&2B(^8MQ$(5^\<Y! J(AF8/BZB!L<N=L4-]0*A>YUF@:,S
MHD$!>&-5Y]1YG KNY/%:4)?VWV-"]29MVZMALDU;S5)><[0;U]MV=ET ^4 .
M[?^6^(\UT#'3#5VHA)M7'7A)9+%"M_"(+%T@_ F?>6IF<SOPX?G4@\YEAAK-
M<@'L2.E6*/K9C%0;6@SQSII#KFC@*<#6=H"[C4B9LV*&YB.-8O^."+3U:K<^
M;/DCN9+7,?%!I+W>+@MP)'I2OF"KG'!"O,/\,:EC]FGX))=NE7G<0\"TS.*F
M@K!X4LA)Y "/L,46<I*5WK"C+E[\"SHKI]EE5*4V9*F;RCIJY.?/\EG^^/QQ
M_MVH*L;'J$>)V]TR+T2SHTK[>?[X[$)O*,4(;9F*8U,@'O8M5^,4WKJ'XPD_
MYQ:$&LA>>UF!=7C_Y^S9L]/S[W(C@=+QRV/1>5.P.#)KDSSJRHT7X5)&,7"
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M<>Y]=QLYTD[E)G+OABW3A[V)%[&$1Q&!A0^%Z^Z\+X!,E>FT9L@O-+1)C7\
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M:!8%$BM:^L8(+CY:EUW7S)!&X,0_!%[/'UIP1&?%NI@AX+'#8S^Q$"E&,/5
MJ[?<JW<;D7>_9'^$AS6#%NEEC2A,E)T%@,;N/M<G<3M]DGQW2O]A;_3I#NZ3
MSR"8B[E/0#@%LR;^[CY,*".%I$/<$])]ULG1B^,=&3>EZ2B98*VBT,KGV* R
MKM0VD@T]3&_%M542&9)X40@.!?XRD3<2$*<%OZ?$@ =STJ!?<>QBB=EK$F8N
M%D@TO4%VOS> S2*A*))]F>E1)KTZ'';*P^H;%$:U%,<R%)5B-C7A0$':()@6
M(Y@<M$K-KP%'A3)Z<:(BGC@73]S1)#H]>WJP2?2A^ 0VYN9H! V4ICYT'(S
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MEX1Q"/Q'Z0%^3/FI0%@FVL<#H!G2PJ&-!>1;[E#5'O?AS8#A53=88\&M?5&
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MQ[A?M2SUYRT5RW#> B%7[9W-&1'W,'U,938L(V^11?G*ZRSO>S]L)I+9D(6
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M=A+BE4LFYQX"HK\*X?+45E,+^"#,I1O#7/8?F&"8-5)_D:&+2[EKF(%>G*6
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M6(E1L'?(JKM-"6_R:J!^?T0/*6F+F38*R_40;L!WXM%!<*O'VD1CUH4]8G@
M85>,0LUIV6FH"<>"YS%>!K\F J^6A'@)[>KQ^^*)'5[N&/P.#AOQ&FT.M&>Q
M\BG6U(F-PJ]W!MJ1Y/C >;ZL(W)BQ&()3N,Q"&K:4D1<GA=%?A-+2R&9C/Y/
M\ >NHP87&5>>#9"]-R/KD)+;32&=!OH>T<V:L))?FJ4>UV#HXUTA3P?NT[KF
M@^<5UE '=MF#$<5-^ \Y+N&_)S9&P&$2=@G3W*VM@],5?Q&,'KVV&7IY%3C4
M\&M#:B8)5J=M=I'-4^:CL>U61;G$ZXZWKRT;B*5\R@K>FE"M6^]":+U1X1LE
M=#*):C[:;$WU]H\QWV2I"NBZ@]GFE?C5M0>4RJIX_DL0"-#D$[03,;+EF(C:
MVX=DG"2U)@6)(I)=M$7T;G*+N2R]4BZA9>=T4WQM74Q*HIW7F5,ZETKP^,1P
M'0DV-*<FQ::A43F.2A#EF#2LZ\EX97]H'R G?84YN+&#P96&%)4TQC/.98UM
M@)?=R25,";D$BJ4MEHM.)-1KO0FSA+D8%&!X+"FXS&1B9VDV(W"1C%\\E[@L
MJ&>: 8>^RNG2H4J0@XHX.QR&*(50)W5J1CFA5GG=WI>1GF!J9SFRU)K$MZST
M=.*X='E5QAZ5+;*CO(CY0/[UZ"0\.#C '4W5 H8+Y#KAU/-)?IEI#RJ7PJHS
M,EJXOHEKCWCN&[YEAGE,8,,V)*L6@<HQJX:)^C+RO-9FDD@#I)WE*)N>7IF
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MSV=I9TH0-9>Z$=,[W"XX:[3D^7R>3^W6$+\3$DS3E>S>V[)E<WWOVK"9 \J
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M-B^WX/"$N;9G,P]QH^@QYP^!Y=O/1(Z_]\GE'4+RCF\M)3T2+G )&CQ@II9
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MJ0)T@51J1K')C#TLEBZVQ"QFR[O_"E.JBA@.#'JBVD@:0BV3ZHJP93QZIJ(
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M^(%?XL+2Q#3H@DS[@=L^-0-&2%)U$E:K#J-DX)MNG)#MBH%I6J'A2+0R0?L
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M5YQ-+>*VK,$,<_&V5&U@RNM1Y2IR6$"I!SSQ\DZ')V'#CKZ[.-4==38"EJ"
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M&: H"8/*-LBB(KV@E0F5(Q.(F>+-VX#IK:PRZ=) Y<$XL=1^U*!@%MCWR2R
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MQ+CK(VJL?"GKN#KH_3XIK^9XY -ZS$0C?JVFPX+O^(B:"\XK';R)V8FT N&
M=(;3@.WOM_&XJ+&VU=%Q",;ZT1$I JA9C./J!MF\W"B5=CJZ.RR0'39LF!T?
MD;MAQ).CWD3=( -AF-)J/@<Z6UQ4UCU.?S2YJ()MN*A4!Q?5L*5V?$3.EGH=
ME5=DD> _@K-_U\DUT@M63>5#[R_00['&!):3"/;0;6T-,X27% E!./#K$8D=
M>C"VS?;_2-&/P-0;CT#2D4.SA+\F(_$J$D#6\=-CZ\A,7L*VK-AV!)LKAA>-
MB<@72X@AI2,YXG6E6H[*-*%?[]Z>7W"D*RF1F"M=*N&P'[;RCH_(W<H<7&EJ
MS;<WG@[WCX?UW_$1M=<?+L>6,^P.%O2P"79_1!V;P$18^_4D@@I@+0H+4""6
MY(CI;C6N<;R4WY"KC@E6G=\2[R5>&T@5K5V!^EL5$;DFIFA0/6W)C.!O&6B&
MI,.DBYF/3='4G%/12P<GQOO8W&::VGQZG91<S]:/]PNOM/R8]O<U7+AY@: Z
M+I(;$?C2%I"=6H)99EN'Q@JZ$RU,6B9Y.!<[/B+W7.335H3 VI?OT*^?16EP
MCI53:[0<IYQ/\?+%LQ!) JGJPJ /[?R(O"5'ZQ_$@ (#K=^WH#/5S.-HSX7!
MR?.3ET\.7[Y\&?H5,N@OITB&@UL*Z2F[6;R\"X7_'[;/CH^HM7V6RDE8Z=Y$
MVLLD#TDIL4+*54LUA;(>_R[H;9N?> 2VWMX1&XJ-3X]'K0R<8?/L^(@Z-L\I
MY4O!Q?(^PFH:K1UTM\C69(AL[?J(NO9$#V+!4<U=?$)2!GN(3I-2AG$:7U-2
M-%XK-U$Y"GHA!IX/'#\0:*;L,D1(F#)@3P^?@M@)T=\$_YFS3-K+1S;,-HU#
MB]YU[C^I!&6OP6%/?GO@VN$ 7%L+7'LQ ->&$_;UI'Y9YI/54E\\#>AWP*14
M$.J8T98C&08"L.)%3/TU>*>\"+6/A&'0S$;90$8,XGC'1]2Q67[*HV)%.'R,
M7^,RZR5OHF&&-=_Q$76L.=MYQ3*XP*2R'EN3W*+Z0<H^@]<LHD)2#CZ\NP@.
M]@].@@4792KB<-@9W]>(.G8&\L E,ZPHOFIK&#>$OX]LJAAG<^O'Z-M FL;B
MQ -6;M='U+4U1!7H5RKT$S\2;J'*)>[AFH:4^DFI28P^&"\['I)$0,IF:L@4
ME5!F%8=2P [%"PHL0?R,;=-V:U=1&39^8SUDPFO $!NP,3EK<C):U1H\HK Q
MR0ME6SFYO*I,==JXK(8=ON,CZMCA;V'1(RH>FGKE-7O=L>R?\!XDO\4-U<5U
MPH)F^WCL<=YP:+13S"FFAGZD#9@F6?R7?QC/B?CCY']'^X=*UF3O38W>6YO&
M_<K+^!N%&[^K^8IC>4.P9TB77@4_)9SL^P%1;A2\,GQY=WC54_.J_\ZK&%:
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M52F[!2KH>$ %K4,%O3@84$'#07OH@?']C9<W;)-)S/DK2W5&0''M_Y!K'"?
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MP_/P)#P*S^#_'<&_?UF<)_  8[[+P^<GMT62F&B3'H/II$>39I@7%W$&NNV
MX]D"CKPV8>JS"@O7P1]\F/B\K5;:E5L/6K,BW5I%\$.$H?;K M^03G21' RG
M&_0NS3I6X"$!T)XV&[:DS>*(QY2VR6C;:Y!#!H<KD%WW$#4/F+QFAF :UP7F
M.U#=*WI_)$*)X+\XANP"TRPJ2F]K%@YREH?0O"/\FT=/B1.9]$\F*K+5@_34
M"9H9YR7F(D=G=7&57.$''YUL5KUR(:U<T+IRN0O?Q1\YL.JI_,?FM+1/FR<$
MF^\/G)IA5 )IE>8H8QAV2CS1,.:Z@$_'N+1XV6"AJ M^U,4FNW.25*4GWS'?
M.<)L%7A+"B8NF&\1/=2'>R<A>4^MVA2<:%9Q)Q^#+26<2K#<=ND5!R_W_&P;
MS*GY$E^'+U^_?/M\[^W;M\&,4]A(M:9B:'!+<,\*=2$EI&B+C^KT@F[>RM3)
M:F9D>ZV[B_6P<FT#12LI!8Z<B *+Z$']AJ[G?,AUSTH$TW]0F1HFZ"> 8_?U
M&M8$]]+1=U %; &T=[APW5S[<XV<!E8:$ W!*$;I'R/">E#W^5R+V&#I9=+5
M4)#"_&94'B_G:\-*TE8Y M]AWD,]PE981B%;1]RW*24Z 2Z@L]2;X,GOI_5
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M ZL9\@<8..FG.8FPG$/O=99P_ ?WE-Y/HO2V*:A1FWJJ330G.^U#'A>#\'"
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M480((-9.'#!%8AX8\HM6 !AO4!;W5H%SNC%I#3BW[+*FHH:>KDK0;,&<SC:
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MP@2A$Y<WM/,-G:HVMYJO >V$AVEJZL_8WQ,NH5$_1GR? P.Z#.0DM$)0Y$[
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ME;9T55MGMLW1)C!=R@%1,U;'RQFQ'OUOL/]TR: 21'DBT$IJ(AO\E!>..R-
MFN>*5H_X!H?L31'Z5I])4"JO<5@71L;E%Z0DD"0D#.,K=,R \<5>1SS]V((.
M0[(-($@N-M9<F12@(HYPJ!!L;9!K6(4/WS=&[T&1$*@^UY<+->AT:E;-C1G5
MZ[<T+A,O"K' >CD%=0*/HG:RW7)@^&2(W<0!8M_^@VZSRP7->S/)C3"L[")#
MXDA,O?KAP.P??T/@'%% W+>?FSA9Z#+59N#]<*7LHN&)ZM=<85BD]H)%#[Q%
M;^M+RY(WBGFY6UJI;Z6_6_F7^B^I<L$_E',J%0>G-1:[(;SJ%)4A:V;ZZ"ER
MST:XP3MN<II=%G2QYJATJNP3G\IXTLJIJ>U1/H#>*+NK< ZK[NXZZ<TU:.A=
M\#LZ28I9P6]VUK @7P1AM95(T-BWI'(]=EY*(@QLE+I1!%:#)@)2=UW$A\./
MU$ (^5X0QNTT<2I-W,ZTQX<\1"1ZT\3ZRMW"K=;YR2$C73;1A,J8F+)!.&NA
MLQ+'3^1K:I!8];SDR5FC#F347B# ML/#'J@TIJ,F[.X:W<[.[]822*UD(K'N
MG6Z#7M"=R3EG<IU4UV=H%<C59T!_QZVJXYRL&X.O<B./8A5&@L]C51#=^5CR
M5R*R"S41SNQ 9I,+Q'@0-S#6.\I,I%G7LV#>U8$.G'H[CXND+JQ$JRWO1OR4
MJF3;T6/TO+)$K'Q&DP*N<L2H] EWHHG6)(N&(LQ<!\^4]L +T\:,\-&LFA(P
MYX[/50B0 U.4%53^-.Y+P<;6F9FW9IILFHON.MZ"Q@\YPHPC @F(5-@1IS%:
M 9>796*609/G1C;]Q"*5W%R 97K=B8$Y8F"=;,^'E,7#=_.92?!YASA,N)N+
M :IE<,.8J@]%XA0DL>SMWOXRK,5#&Q6E,#%S27,1BE:;@*F-\?8O[07LO$J?
M"+ETMYP['Z.;YN *YL*!2VAC@]Y"6#.-(S,,YFYJM#0D*>([X5FST#&81^)F
MR00+TR9Y8"3:'\.)RB"&;%ZA<YDS5;1W$ 6W$E_$>%<'[O!;"R N3M3"VQO!
M;Z-QI?3'6@.8+NN^#N[] '>K'R[OJ0;ANULF'INQ'.,M28!"/$TWRH@*XT5X
MM9 0';"=D.L,.W&^X<23CB4);@W<R]PY;<RDG6*94]J;+68F;?G(+G AO@A=
MR5[ Q[SIF>?2UB[>Q!),MO%.$%M!O/:JW.S="#[&X[COZ&6>-N#Z",4UT2S@
M0-$PLI!0BQ(3QG5U6=0;_I;!(F%?6N522L0! $8SINO:FC\AE0:85V&U69:[
M#8%C.TLNLJ3/=P(EZ)8NG 3KIK76/=)==_L<"_M]3D<J)[J^PBEN))FJ\3=Q
M-CGM;&$8)4Y2$<[PZ;:^>=QU:6LTLRT53@=L2:5VZ@O/$)I5]F,CSO[]1.TX
M@OOL_3_A.CAO5>J)XT?+>@.N2=409C:-LV]X=_SO^KMY=Q.P:C3^U6X7C6]$
MX_>Z:/P2^_5![NSCD_#WX_.3H[.S\/=?CDZ/OGZ.7'V+ZY<0<EFS.)B<-#\#
MC^H:M7Y#8L&]%,[J,3&->*PB+F/-,"G*RF:0]/(K=0=$-?3?@YV#)&M,S?-=
M_+#MW-]YD[.$&.NK?96F8PQ 9!=_>;;[;/7.7">#ZA(?W?W3NU#$4#]/TWA<
MPL'2_S)?E7B!9A?8^>_OGN$)^7-5Z%:O$&'<CU.]S> D/I-#5 T\3:JUPE\U
ML ]#PWB!_N79P;/9/UQ4C._]^2]'X6^'IT<GYS^S BJ7,K0$_RD>N/O.#S>@
M-PLG\^SC\1E,YL?PR_FGG1]Y.F\XA1\F/[LS-CVX_6?+JP.K-OY3^=,T4_L:
M9\H(DE>[?UIIULP/7]SP=R__M&CLI'PTROVLTL+!WL(F]-2&]W<F[F/+GB-L
MHGW7WO"-'S]_;9^CG^@^>S0F0+L-!";0/\],ACJIB: AS55T_I<==/=@_*Q/
MF5S9_MGK[)^&_;/?V3\/=5@[XV?5^7]LIL8B'7()7?<7L!I^^?KET]'IV:U-
MAX7=V2Q#X!?,8/JBKB;A>1$/U//C3.HY;4;W'H&:']ZEGO_3V4_AIS@#44R+
M]&-I\>TSNY0"?U=S]M#:^4I3LNB5GR0,\A14=-#0)"UER.5JL0C4'53 NI^2
M+O]TKZ3__7.O^.E]\$]NV/WO[&_".PBQN!UT:GJTMTX=DZH9#]"_^U@DPF=)
MAM42Y=B>1FW(E7;A@V["A7OPOK?@K4SR&QNN"[T4P1UZ*6[<ZXT)YNYWSHR&
M,^.@<V9LF#.C<V5TKHS.E;%@<@YWPO]),@21[>_NO=PF+\<]!G Z;\?MHYIG
M/\D2'HZ2ZH>,:]["(S+_[7<[KT_2:_(D(IL_@-LDG&VQ>E_=I\LDG&.HWFNG
M.C_)??A)PC87R:;LMT>ZW1ZG0^1A"X6OYOHXZ%P?#=?'B\[U\1![N'."=$Z0
MS@FR#B?(;_5_X-+/K\+C[$J5%5.8,-ZC<X0\*D<(:&]9K5*XG?X3ZE7M7"+K
M=(G<UPQWSA%/M1'];5I[>SHWG'YHR9.ESQ$^!K=;^[[LK>]VNXWTG3>.18)P
MGF#K7&R;[&+;*%_'/"!2PP_RZ"WZ'].UUN;-VDC7VB/=;H_3M;8^K-$#YDZ]
MZ'QN#9_;RR?D<[M_CUCGDNM<<IU+;I-=<FC1I<DDOJS##W%!A27(']<Q+CP^
MG]PD3F41?TA7W)UYXNYV7A_: 7<_*5W!)D_331_FH3VD;.^]_Z!2U#;REIB*
MYY3;)-'=">[E!?>3%]OZU0\@O#=9)FV.Z.X\WD_=P&J$>O:7BPB]V5UX^AKN
M^C4;78L:;T'>WBKE8DU]N.<N+$I377MOEH^H+HR STZ=I4Z[SK -C3[>+$8R
M,]YX+[#,^X@+="*RDU(/*J5N*7KN]XP^^NC:AD[&NK#J+[NX62-N]NH)Q<T>
ME)VC!V?KM@$RO>S3-N'9QU^./OW]RU%XO/ \W6U'YA9  >6(ZW1[GH+UVW,S
MV.BB.[%16Q+"[Z*=UNC.^IN9XX9<?V-S<.1W,(&MB,"'Y-"]XY.XVM7WJKOZ
M&E??ZR=_]=WM!EQ2OWO ^\@IR'7TW[\<?S@^#P^7O99^M+F;LJT^?SW]-?CZ
M.?S;U^.33T>GX>%?3X^.?CTZ.?]QREC-[0+6M:(-)K4ML5(;(8^P]+(#/<+Z
M9(0]^EO.); LWFA<%V4=9U*(,JY@K0HL_3P?IA01.FD@:*7#<9&D,- HW-_=
M?Q%N814S*;8=8#TV?#3R2VV[M31M06ZL)-W'&G&FEK53]-T4 <:/L#C</LQ^
M[_W<?F)@DQ[=>[<=2/W+GJJNE8(!]I.S<5ST66_#NFO'91'#A''9.#6@0L)Q
M-HFXI*U3M;NT;?($U%7^:_P]_#6OL++CHA<&6_X0I+";V]D(?E-67#G[K'^I
M!G6JPF.> ZQ3.G,.2O<M.^$1]KH?CY,*]M-_$((&<QDBABWHU14Y%@=J2)6^
M=2V]Z3W"3DC"OW$9/U/.<J3BC,IUE_TBZ3$PCBKK43,)%\2<NT)WH(<]KC/\
M86+/;.B?V6#&>DBUUP4GM&H(!]PZ< 2VDNTP'N3C2FJYCK%$LBJ7>&.PE>!O
MR[(>21E&JA]=<O7!T3B=2"%HV"QR4-K*.;J%>G5Q]P5-XTZ271?H(PA3AC7F
MH?G2+Z4K);?19PRF659BR5;L+/0>NT]=CJ1@-NYAZ#JTT:<:CIE%7K*TD7JW
M5%X\&R1<0Y)K5NN71XP&Q<+D\!C5M8=/6&@P3K27U]E E]]U9XHK_TJ%:I0D
MT1)S8<<73&\$JHK,$P0B&#9EAM4U80#)<&I#7,,(J=QDD<#.C=.P))==7DR6
MVF$__,EMWK[V@,&MAU6%R=;$-;^."]@L54DW;-2X<UN/N*X?O^",)U2=-<9*
MQ%)'6.]*I8)E#Y<<CFV8B&]XL.WQ-<.0X^J,A0Z>JC!N#AL9]MPANM7AS!VT
MG/UI=V^$59I'-;ZX#/%_X7"55*RYVU7^KG*J\Y:!*W2Y4F]#@(2ZO/:2-LGA
MZ?GQQR]'X3]T3>WIQ6O;,2 XD@S>-\97RM9/,JXZC9N/ZI?;%0Y^M!5VB\^>
MNH5GN>:L6W VO/."L^U=N]^)6-%3]+KS%#4\16^>O*?H<>SKAC@Y)',5=,=T
MTJ)QH\7DI@(%C52@EGO?I/_\"_\/5-$)?O O_K](_^,A:LP^47C&JW;<Q3 >
M)>GDYT6]GG)925KO8J2JY4I8SB]VTP[]N??^MZ/37X_/SX\^A>>GAR=GGX].
MCXYNG=FT[BF[+4!U?:UO]%2L!U;^<)/U,$MZGZU/)1AU4]1MHQO([24MN!,"
M@X;'&6AV(_K6]+B;WFX+WJ9UR8WHA-G<UG^[S+-.X,]OG4"R#\I"?U>,%DN!
M8Y;R>;SI?!X-G\?;SN>Q;G '_2<.D\%?GGWXU^[N"]RF\?O[/AF]]X<G)T?_
M'7QD*_0^7) S^J'G:8ENW H(4U%8!C2TG\-Z/%9%/T9?1JNG=$F]#[$QX=?/
M(8YHE"5#N%WPD2"VV(=[0!DM/ZY[#:T\>W_^R_%9B*BA7T^./Q]_/#P__GIB
M\4-- $4K8"0*7)#+O\S_,<PE(K0-CHVP$QCI719?(C"0\/HR+U482P8JO&Y_
M-SR-ZS3\/4Y3E?54<1&>53M1<)Y?HY<0&H;W?T[SO( I46EX> 7"[M7;UWMO
M]UY%\OKFT%K!)3J\Z'HK#2$J_/^O0]A/'+' Q^0= 7<XP\AR#*L=(_I%HLTF
MVX,B' )3R>4UC2X=\Y:ME/+ *O>V-V[AR5SQL,R]'6?X,MD3^I=GZ D%<;!(
MAYQV*>X^^^G]]*=[*/&(V.KP+&(=K*'[-:=I6OV[5LG%9848>S UTV?.0M(M
MN.S_8<@ZDST6_L)!QBV]/1*P:$O89;\FL)TQ(N;LVM(%%Y4^<DGO4J3J6J4S
M7^+K*'SY^N5; JCLO=M[^_8M-240-G_SLDSUNKYXFF0$*W5+GU"_83-$[/;2
M#4<.9"N=@%Q;I2.^"'@WG6^X9A7^AN56G_39?;V[\Q8'O^;C"^.Y7&DO.!N!
M-J@]_[##^OE%!B8?/91D?="]D2FO2,ION(?2I!+4%_V2P)]A/XV340DW)H+=
M5CH=("$*NILOXB0K*U^8T'W=-T>%CU)<A9<P_'1"WZB*P*_P+.(F*%#'$*Z5
MNC$"PP)&GM;]2N \T"V"E#$R@D$S(*CD:N6^R*U8XD4+HDNF(L:-1+":.DM!
M'UAU82:$RB P"$HM1N(-P&9",!M\7.'YI]NZR.L+A.R4=4$X6^B&>;"I3:ZT
M*+(6248A47P=KCZO!J\TX5?Z,B_R./1]!'U/2D+@U95(G*2@R8296FTF!'F'
MK5SQ?,*@>^HR3H<$L#/[HA-E#R3*WKQT9-EB*15YRW1KH0=;:Z4-);@VQGF7
M9=Y/6(KY]V(8U]5E7FCYIS\%B:!/%$O,>'!%9TY]'ZNL7%%5P;=595/6X6OE
MV!.+C3W8!%O_WJ]A'PEPM>7W"!A=J1>*(>6EBC1,=%B#N0(G&19$I*J $=$B
MLFC<-+[NSMPFG+EUZ0^K'B5]*B[Q2E2HQ9/Z3G<SPM)]S6&0X#ZMTVI">2%5
M5:!,%Y \F)=P>^!?YC9?J2OZYB<KHBH2M/WC5&_HGJ)K#&W[LBH;1]T V;TL
M$*UDW%B?*B_S.J5["WN!*'NXSLG<T7W5B,\"4V/2%)'E=K8D;:<BN!#^;+7I
ML/J!&%/#&JWYR(*#&6J,K>49'I8(?E0/-'XX4WW06>)B0B+(]1FLTHT^[#)<
MY9J D>A X%P!A7)+P07NRE.#L&_*U,:%O_IDZ/E>5;I!6[E9I0DO$BN$,"<X
MMB2K5]5FY 7N3AD6H&\/BWR$[IL:M4T8?9$U6\;<'M@BI9VR1 W>X:1U,OCI
MR. 5+V\QT[0&8PTX(]4R!5L;#W%9]THT:Q*0BXY\T&H[GQ+X+DWB7@+FW6I'
M'0V?@O(3C+!KZ8P^- -M"^A#J<\"W@R9D\S#"2^K>EHH:08S=R*O7UJK<LQ<
M,JO0EX(FDBNO>! DA_0Y7'$^/,,KFJ/&Q<,A=I$$$,[%+ U5+HG5)N,J3E(Z
MA\3/H,<=>9-^G927G/9%_N,J_J9,]J"%LNJ+X#8FI21@45H727FR$8=6U'N]
M7$UBK]01D.XZ%<S+>FF,>7E=W#M\*_H^YG5ANC[B9@CW.W+E_[GW_N3K[_!+
ME*J?OYX2KM6KVZ!C$107"V)D^DS3_/HN6#[7'VYXE%?=_IN= [KJ]G:6N^1Z
M[Z<"=2>?PN.3L[^?'IY\/&K04V_&?G[\BP?+] )&V+:"DMRPM[/D"IX[EX-D
M09J;8747AW&8W%2RD[1&\8O]N9EZPN*:+AE]W7.@Z4R)^U(2[7".]HQ3U?GP
M!5R](&?@(A^-\Y(S^6\H\5')1V.(W,6@<V2BBK&/-R.;$:8"P_ \%60VNK>W
M2LC)/"Z2O)!7Q<-J146ID1I-NE*;SL:>[ G%T!IA/OQ-/ZWQO$34??3W$CL"
M:SVK7H2Q<:U'VJT.@QV-TWR"PXXO<)? 8(?)H :UJ)@T;/F(M@AJNLF OA:2
MB=64%-YHXL>WKO^(LU9ZYD^\D4 [+2^3<13^.P=K/;R"#I*=715PF PM!@,+
M8+E*M=J<P)(P<:QS=LB"A+FJJ)M5@M'[2O)[_ZCQ.#5\F5,( LGS7,W9(]O
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M5&#4@**"&TK:G9E[G=;,+\ (]RUCLU;-_39<Q[K6=+BVI1A2/:^ND9N8!OB
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M3OJ?4(]FYHNH2D1[&AJCQ7D*2<^@1>I/K\P;J.:,Q.4M=/-9N+A 7#I]\0G
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M-%0OCQ^J[W+$]%(S[@1E?&&Q6#0YJ_-J8B./;C.#YG23YF*/ZXU='EO-2^>
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M3CRJ9TV*3<9\0H5>%3L%A8&)^O6Z)\V[L^/R9/^C11.Z9U?M6I4=&#7D9UT
ME75DYWY2RVXL*]CG7B2[>WHOT#X9AQXY 1$3Q<@#GC=&^YF<.6NH3J!1:N:@
M5HHU0;BT0UZ(G>B6&2.-CVP>GB 0LU6()-Q&<@'RA\--V,GJ\#?*">_OD/0@
M7@[D#!_E97@?;[]>63S *$%DSH#Z8FE5*=< +9>C>05947P,G1I.*V/8*Y(R
M3PV#L;Y(DTNK/Z7A*P$747!OYI\9CO T_UP2@ZNGOGNP;(]]V,6#UE'/KUU'
M_2,M,CY?1AD!7:8T*Z85GMYE*<C)V)P%VZ9/;]=\J*E(,Z ]6JZHOP0<O9J\
MN3A!BF5 6D8Q$(# %&QJ))[C6#TP?DH/XG@_<U.:)MN9!XDM,S7XAXC)XHIU
M+8TM=!91P?7P 1!)'E#Q"&J49@PZ@H ZL7R[;NY&_PT%P*5&([(B89V$2QGZ
M>JCF'NFM0"BI:Y8*[;,0!R^2$><7D3 DFHVZB&86?7HA;U/]3<ZC?%0T)K<A
M:<RY5I9MY6.,5C3% PL3-,W#(Z\+)DA<G-$POP[<JDZ\U[KVQ5199,GXS7Y&
M(@I*._=\:]F8C:K.61F2_23VIY4O4?:IK)<Y1UJ:RM%$:+"NQ3]X#>S<GVH'
M=+IA"#Y3[(-WI+Z].255,5&'LLLX#IOGHU:..QE>A#-;"OGOFR=J#NAO!@C=
MA'K'4=(^(FTGA:75#5;Z_?'I8TWJ? 0TQ13N'/QP>"CDE?BQ8T%LTH?@ \\L
MST*PCB5Z7D9-;)X%YJ8;$YT5R)1,BPF'M@OZ+3"CXRYFD3^B44P0/_OHH*3J
MXJT]E*WVQL-JV]Z3@#*:+*DP^*=T0#*M ^NW^5Y<L83OVG^>.VIY=U.D;UU1
M@#BMO4X;S]D-G06SSA/2CL(B:$T+RF<@S92YY-ZZERYM-.=]3RV#!$"1F^71
M8  C)K2=I-3 *=7N,>V&B=,:"97=&\+TB'DL8TU*5,#5$O!42#J+/\WG8*GA
M&5+J<#!11[0T2\TX.^<[GNJV;>\=5^&""[DKO7F5[FOM[OZ+OGW *#FM4%<3
MW\[<>('Y#/5U64;L=U0T",;91OX4#W('UOQ<4I3T +JS6.8%.KD*H&<E*2LK
M%%:"S!JKRD5,%YZ*01HETO021,DL'C;JQ108R717!\B49T4X007.$ Z<X#-"
M)^Q_^6;,3SND8GJLGCN"(3M>\Z34 4'WG1JU9L=GO[ Y$J \R(?<))&^T,Y:
MH$/'-U)3+L3[@\>H5\N6O,*_[+&[(L"#^YZ5$9U7.O!@?U$\]"MWGIFLS:HR
M%D4$Q(N<V_WICWC56AT7A6ZAUAG0HO4WI)%PNLA=2Z]&#@:NV+I&5D11NT.S
M.Z<\.?O)#(V(W 1'9T9JRW@\M9[ J54#VQ)\8F[RQ'7(ZO6.J<>VLX[H/FA@
MX5>=M;I78(^1J'TAT:!A5SIO"R^1<ACT(H5JJ'M\158' D&U(9UW"*U_%?7&
M\4/,U( 6[!T B>:QX-Z;ZG'7KFBRL47+#3#OZK-;(A.^&Y$)/C+AAWN,3-A
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M&7)\/W0!_^':!?R8015S(;9<!Z= #>;B]^*2Z0E$OH5@QH7+K>0#,F,E/L6
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M,!$>#&-'79:49<%$J<@L(JWP'O,5-%Y /!G3(O'0"=,<#J3>2_:MI#W"!CD
M_%1 ^$X]#=(=[ BSD1#;V0P<E;>D+"]I53;(YBO 3&1B1S*XL  ZIM^(X,Y
MHVK^54]B%U[ #FPFO*:.S?(,$=R(80_3/Z&["@RT,BHX1%HQODH(?I[@*T(;
M18>4OH]A^%F4D?E$G'Q9PQL#4EOP>-68=4B"0WA3[2LA8%W2Q1B&\KIA%"$&
M8X0D0Q/M1,AC#I@G?@$E-BK:1O:(8),O[J.(M]7)U8MI];<X825C%+(;H=>
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M_S&X-!MOV?" &\4X>R4#:J*L*CPJ@&4&$\G)-T026Z#-C5[P4(HB-P%'#X'
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MD,$8?F2TZ7]0N1:+SXP/QR3;'1#J#65Z%@D0MRZCO)IS4_W&@C3O$=7IRKR
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M/5>M8&T&%1WLPBL;:QU45L*JPTE58!6'.K"L,RJC@!PF'I-CE+7 P-$1_<K
M8IOMZ.>7UDF6#_H6I*PG4V_X+;N?VG@X/ '/4)H6#:5_JL1V9IE+-,:^I0Y-
MA._!:R9SG*9,0Z>-F[:YVM8")Q>^064X<K)0/%O]2[>%WO6%$:C8+'^BE^\]
M=KI80H:21RS:=^\9QR2V?>TL&='969DFBBG ]]?-HN)H88QW1?2=^+QGT)58
M3W1TDGR:94V57B39:IR^>^N&[OL[;^C>)Q!.6B+(<9S#K1HOA4DF@%'OZ+X)
MCNZCD:RE?7\R-:YO0A]H$_JD\^RIOM$W-Y6LC#?--+)A?G16)I0SF";U9<))
M$$<)$RM**Z?#[=)(.:=E=\3 #:BSOH1KWPD<.D0B!^X8[-P2/[!3,2G<I.P;
M7.Z#KAQ?H^'XX1X8#E>$$QRH".-H/W:D?O;D.4TRT+''I%T155X_)XPC;@FP
M]/FHN'MCF;V4HJV968)9?[D"F[&PK!EHB/ W-I$%!*%U,1F(J_"+,!(UG;E(
M2:7FL8(K$UAL\?<\3>;!,09>,.OZ+7U]W\4&QH[R6/36]#7@! 'PF7T@XX+G
M]7X;G\QPAQ(TE=$;"'BSLV'0Q-&C)E@#YS0XC%Y;D\?W'G7R98^*\2A/H$6B
M+PT.A]43\Q<_/(Z6AW<E+2$=6,9$NI49D@&.R:MD651$\/JA-*_;5<AI"_,"
MAO2JF$;VM!1*N#8I.D:ZA?%JQ$?!X"]NT%? FTZ&;@I  2%XD_LD*ACT$";;
MQ(,*I5*Y<P,5&B\.P]J1V<8T;Q+B:2-DBEI.88LX@% N)0T\Q <7#DZ=LN!U
M@-DDR63.P_X\'(0'?*!85!'IL7@NC$@7%%N;NQ9G>?J_PL_2@YG 1'1,LXG-
MR84\L^"_S:>1"MB76INLJ#RPS6E=S#X:F:4)1K<1M@YIQM$I49;UZ9,[[Y2<
M-A747)1+HMV4T2VYQ;"V/X<JK343UUK3PBE:Z'F>S(QO8JQ6&,RR@O.D@TH=
M-9RO'D7#54K%(7,5I.C2(G:#YN/)NK%NV-GN7;T:NKQ?CF]!U8R=8^-LQ[[A
M*NC72.$Q66^XT$3A9L1C]/S9T?,BK5!C?.4(>HO3.YJJMJDZN/.FZI519_"*
MA8?O_J9?KTG0OT)MPW)9Q4EDPI,V/Y4? 9!N%S>:S!%&P7$:Y1V@DH06"5%-
M%0[U('^Y3(%*4<WCC*:5A))@'Z@\E467\R:;0 JU\L(5P55(R %%)&4,:TOF
M+-&# .+G_,38K1RW+N;Q-@,T7^);,M(3'C#N9H<@,V2E3.F:*5K7&>N/Q;#;
M5\I/[[Q2?@^2;C:QXD:,.'B=_KM)8T0CW3.U_! S^ ^O]ZM5473VRK8:E2SS
M "846<<6L-3<,2I)/\/()H:[4 [UTLC'HV890I=Q5607_@Q'>RE(69F#MBR0
M.<"W+8!PH-XO2.PE"23 \NB,)K-NO29C-&&F5-DLZ]F**XVS(C=1(\9_-M]8
M)D5Y%ID=D+@PM+PY?'&'59$1BY0<;$^IE;PGT^>D.-8"TH_P33:,/O:QZDE+
M2H;5DC>H.]Q5T..=Z!/Z;NP3\ON$OAO[A$8L\(/M$SHEPMFNW:%,\DW;0U=(
M7&,-N0GU:UC$'FM8>>:0+/<&)A%Q1N87<8.X6GQ&&T8.5T?WMHH.B7OIBFHP
M^#^(@:H:W"T(6HF86F%*HZ8^+Q"_"@\W<PWD)I@P9XPZIS!D\/A(N(\#UV%W
M%L8:J-:0&PZ!A5-:6D3Z;T?%:E4U/BLC&B=1)G. 'S/7531%:JA$D5[MAT$'
M)+R&U\RURPB'65%V4&T.,VS)9FH%5V!J6JBT1I!-"-V?[L$\PYN+Y;9/A?^:
MY# [>?);D@#DX[9@9#=29KA#AO<:TS&'=SX=(S()2W=R>:^R, ^O"O3P<C!'
M )'+@9N2!5J$&=>Q!P6@IV9'IA"]]7P*1!T_<_!"-5:>)UGLS<FFA K_8FF"
M5>.3)*F%L%%7:='4%0PCELH!%",$*D&3N$,UW'*3+/Y=M;WCB=GA8.PHZYR"
M2O$TX7B4_L.B,!<\>\T=KU.8Q]+S%77 U@UK14;9%@TL+L=XIQ?FDN +]]^A
M>T[Y?*X_F%L=2CG%X\&\YP?S5ID13N8 .>J(X$"\"4G^@7.*D>_@>6%11QM7
MGY=%<T8!-<2GW%:Y2"+"7<V*Q:+)N8N4JAI7SF0.'2L^* L^=,#^E<[2981K
M\*!6,_,@YTE4$C<=]U>EBR:KHSPIFBI;/0Z.VB,D]#IXY?VKQK W@KQIA?,G
MA\C*%%TSX0"@412F&"7.\I_Q5BZ4BX&>@1>HM^\ $&-$V^6V7[7_>C@,!AK!
M8IO,D;_H%[7F[3256BU_=]15-ZRK>H[R-4::S]9&FIW8\"Z$GN_AMV147^%$
M=*.O.G[YO8I$=PM.O"8VAH:F3G^+FSUBQXY,[$RL5ML+=^HC;65QV4ZY6N/6
MQE957E'7T5T1G<%% <E](H-HAWG<#17%?Q9-F3NP%*?:]64YU]]FU8^97--U
M]\: +$NG3-Y?2AJ7/HY(K\J[^(2H*8!T.U&?:76_,#5#]#&AN<_4+LSI6LV7
M&A ET5I^C'GZ"8T6G"0:6&A.$6+H6ALD,QD]FH4%T**CIX\&)?IDS.U"0-(R
M7LQ-2\0/I;G^T!+>8\V)<V,PP43+VR5[U(L:Q^5N]*H[?@L] '1JKX2D5K]T
M]C/8Z+T(-E5&;M0B*H5PLND7[4A&^A[L5'WU&\O-,6V]-0(DTJ.837%F^^L?
M_KMLBX& XF9-\?/[9XK5"<7G>5<6RZ(RI^Y]@N-"1CM\=P_$EH'TC9Z=[9/$
M-[H<.^%-B7Y1=NR5]E[@UYQNRI*HXOE'U!6,YA"J:P"4D?JU?!7Z;U]'EW(]
M8^"(M!0]!/\F5.%&<\TVLNKP#$)C-/HR>.>V@Y7FLZR)(9Y=0"1IR;>A\SJ.
M"'7?-JQ[\ &7R2,5(.&M?V<O72YMT49-=,K.WJ.OMXWKERRIM^ZR*7#'- ;#
M_>8-#3"V^8=UM[6N:.4^Q@M(*THO+,L4>W)IV/64, <I#__K<U'VHLX^:E7J
M]@[G2U'_KS@ /4LT3RAW-#>3Z^%B^)H\D)J:Z=7K5P^#/1$Q^<1I;OL?AN4A
M;+'-MI\C6)@#*CL"2=<,D!\9@&@(&-/N1'?D.@&2ZPB/3>^%(:FQE#E2ZHA9
MWLW:FWI(51YZ;,J3J#$V3Y\3AP"ZBMXB"!&$K=,)MTX'99-9-A^+F:"<=?]*
MB5E,IC<PS/6,$W<J]64/5/L8+Z*/-M%C#Y+=2EMA<GDC"!M6&B2RB-+,R'M1
MH>99E@E0@H8V+\4!CTW6G2:06P=R@KVB#-N],#9LN@(*X^LL(\L?BM;A(*G@
M=0SOGET>I^JQ^1VR^!1C5'JRW+3]"NG-1'E>-+FCAS3VP0L*2MR<99$[*N9>
M9>*B(TBJ$7P*?76U'H1-\5P&F3'%?]JWQYA?'P]+Z#PZMN_P,]'VP( \5 ?@
M1TB/+EP^!;K$!>'&K)TAI<?'?+/3-K#_? VN^4 @ @$[.AY[Z;Z%3P-M;&Q>
M@S&F=9(ERW.SE4'>+*8 GIM'G_AG(N4%<93/KY5^VDI(]PY:&]MM-8-!CY2T
MQN/,,[/)0M+D;%PIC\S#9#,>%[24H-HQ-U%D%6&D<B0")*@<7N*%>6!Y8GP8
M$1/&E:.)X3,Q=)8!FPAJ.V,PH/W7GEOQRJ=$I&'A;+_D\YC53SXMLRB/-/O/
M.>525NX[L.%F49?GQ6+?C_%)+_$$,7PY>:&"^0B;F[5$_;N)<'X90LYZGY"/
M\FS&9AUO;8&&+?H9SR>1]C@*><6):FW$%9L+"]/TS%R^Z[,A^"[Y9;(!9,W:
M/3Q7NT8TOM,_B)F%1 KE/-U'QJ=$2%5Z;I/PUJ58XE+M,J:8T*]E1EUOYH82
M:\8>)N"&&-7CMM,KAE@'IO^P\9V%? Y2+#R"A[_6?6PL:AAS0J4+>O;U=S'O
M"=>"Y/0QD^I!5:=MOLQJ/JWDSC9=LY=>[,-$9%2.2\NZ AF?L@3[S X XT,E
M/0DM(8XI;U"95-8/H 2;4Q![1G58(^S623]5^T.X7GZMN"5\FOIDC(ZO)V>T
MM32TA_;5=QH&#X'9#O'TW,%:("M/Q.N-,F\VDUNH> 2HB2IH(_5V&O.4(+AH
M-HQG#'I<SFCGTN9E#;VK5\8:7D3H+6#[/R4R*Z,%P>[-D?Z!/$=C:_91B7A&
MH/W,S-> .KTT^J9HC!!?)@ !WSMX:CPHH]F%W"$,M!N8>&JBUHLQ^V"MGGD+
M8-HJ<P5V_EAEPM,[CL<TOP#<.6AJY[^:K35?,QMC=!OP,\TL[V)(.S>P&R_P
M"GL7Z3X[2%H84**4\ZB5CY:VE"C%^D--7]BO='UQ&;WN+XNS"ZA\Y=YS.#R-
M2&8O=,Q1 Q="7VZPSJVH3+PIP5=SF?"QO%ISR<*L$\9AEMY]>UVHTA.4NA.Z
M;A)=#</R*:#F<^@HQ^YH_?9.-*I]/S:J^8UJWX^-:G?Z6)BWKW)0_19(9:(F
M!";!#(F0#X?:Y5)CZ]N^ER*%!S.QPI(H3 U,3!@R%]9_T'53HP/G:8V6$6[5
MJX:ED@NTQ4;3'\WG:0;Y-YE44LSP7VK:HBTH8CD5;@& )Q._'E  <!%E34)^
M$T1'*?@@97K!4S?-71/NW,+1A$0.:.R0_1IR;X*#@+T]Y"* 7S#,!>VG1L)@
MS_@H='/7KL:FIN+:<XG57Q<S!L5R691UDP-/OME7X*G'^R-#)C."XB_E87#A
M4<!I+#9!]B'6K>Z0]BF9S^TB:DZDV"VKB\G"?/T,O*FLJ"KIG8.Q6Q_=SM?J
M7BNY.X0>D$FDI5'-?.^9;(G=B-KRIT@!&)<R UN(/\<)_3Q1"72<:.U\K?ZP
M-=A8IMK-Z%(@Z'W/D_9.T@-M?X+ XK,306N 0:Q9ND@IY*+34BSIYTN\**8(
MIW6 U)T(D\W-CH7!M #W'N&R99TB9SF_#;-#E]$R9*</,ML #*1P%G8=,'%&
MXMP5X<W &Y5U&P<NB<_,/>Q+$LB$V3EZ'1/U[,8=1Z_)V(U''"\#M29NN=L6
M="V+LBPNX0\9Q(R\X>UY2:JTP,@-<-AKIL8)'?*B*"?T_!4'-9;^K76*>=@2
M0UO@N('+5R?J3<W7B)6<L<&C-9&4$9Y5=@#A*>'-)CC%MS:_K,[3I151^9N;
M(C<3Z;+'<=V2JJ$45#B)[!KXQC81AC*80, S<OS<Z?+JUAT%-[J<#W[@2O&E
M+94V)0PEX%*A*M?8[&6SC%%I4-I/LM$:-</'K1-;82)W#N[.M*F@ME?1-$7R
M1VW4WYOOHL2A334.),7:J"._P" UE+L:LXWG[J8;!F[\W%FL9B6U PO5?/I\
M+Z**J/EINJ\1=6'PM_2G10-N1Q7 _QKS485_^R;]2;PAR7A>F4-O]1WH!E/G
M57);CZ\-(INP:;,#!G'C59F[>:@^^G,O*38>R3L-@__V_F'OWB#,0DYINW'N
M1?"6R7-!VG\%FT9?&"%Y=_R@[(KMVBU(WH<6#"ZE@=FZ3GT&A\"!DWIRZWJD
M%]JL',E\NAT,HVUXD"*_>V&2\5L@DU*SHU0HG7^5N'MY*I7P0B!+D3]2U,)\
ME8KS+IVA\ [_Q&4OG-0I TDT356KN5"R%ZI[4IHF,12*ZO%L/9"SM5NAT)NB
M _!F,$O8CT@)I<$,87TR/V( *$B#@FT34Y4D'QFKEH/$1-(X9@\261Z&8:R\
M$X7L8')ZJD[/<:>WFV*=1O6O)9B^%\Y3JS"\<XJ)6%(:-@V"3\H* TD3O,XY
M#*SJ9 '=: HO-+86/\"S'>_4V59@60'BX:$"$48+9;GZ/'KF!71>1A=1FN'K
MG^/!NTC-;:<K'RQ&S03FG&O,G<7OZ=.*Z1 ZUN[<]H,^K"?KC:I1+1+^:LT3
M*C2*/-R\W:6"K2#P$(X1L&^A&AR%P]/KI,P3<YK-"?]ZI_CN3KW9#E7RPX@J
M\5$E/XRHDOMS%C9>XCOGY4R,6NRCAAI'0=VM-.QW]R\-^_\U1=DL[EE6]:%)
M_:XXRKN54S7&5^K@Y!YZTX,IKNOW5R'^JX>)57B6-?BL_\;CTX-)5UV:Z+;:
M(1P];&7HMW8H,/I:P$)JI2%&K<MS;OR0*)?C:O++^<G'(/6!G+W=2NZ>Y+9A
M30V;L]/!79F>$S?JN$@KF3E1$)_)$9MS4F8P)>4%AGM0/4&4Z#QJ,LGKMKF/
M*CRZ-(2;.AHL'.?@,*#COM_#8.>U<N6NL8^QL>8QX9K(:2<(@3,8X\V,N(I$
M(2WKU:/Z' :,PX6*/'D$O[24"L'>X>'_^W^^?WYX\.*OML&SA0'UP9C29!(&
M3-'#_ ,I88D&]= E=$;F)N"6>0"PGD&@0B??/3R+C]%%^]+T1GDWQ>'?2>QK
M;$/%_9DIO:&&I_,"NJJBN@#CO2$X,N(-F-L+!#-659.4#/1FO?S[J48M9M%E
M%4HZ,.^7NHVDZQHDBU*TZZ7K]$KI<I(U3^<UMAR)&!T\WTA^1G/Q0,S%;M4K
M3N;,@H +P08*H$4U#I%M3&"&8SN#1KHKQ/F)Y,ARZ=S6._!P"[H<SN:\*1%@
MS;4"?1$Y[IS3%(^,J2@0BTG8JPIFJ\6(7Z>Z Z1*+Y/D8RAJ#C]!:W:LS-1J
MSR5(^+IF5O<_;+P_MEHQ<)RJL6Z])0[J+DBWNC[S7$1I*9JG%_NIG&?'8,@3
M89A.-XE,.$G(:D"\EX$ESL,RJK8>LRP")0Y[B>P/^X\#Y:@/.NF,B^AXR=#&
MF9B#;2_ ZT*LOJ6R/8\ %(N-TMYE/0&"8E1J%%0$WR"*[\?!4=URSW$9=M-3
MVC'YHKT86%-K/,&8^BWIO; _LE&GW$_Z[6$O6"/L'>>'&$#-H"%V /@J .X.
M3?9>R7NM4Q-Z=@?6<&[VDXV%LRI$/W/P9"/+8FOSML/8#B[DV&F.N/P>4AB2
M"6!8J=.ZP4E7=-9#\]JM;^=:?C%@:F$#.C9;\R)?X>.M6<%H+^]T0N_[^Y?0
M4_I\ %RIDGV/@SN;G+OQ3M(/_<:Q&^%,2#N "L$F^JK]M00ID3J)']_Q#D[F
MDG1:Z$!(7<KW;(0WBEW]B7'Q]X&GMH$&/QJO;MVF>?J)%:Q6Z@K%9"[=Y# G
MGO_=$!D&#ZKS'RE4#!R.. E= =Z#27</]/WVU"AZ]WW4'OL_&M4J.]LSH*Z/
M(:$>9NL*)^Z/OQ@#G2,V7_[H.3LOBR:O8!Y&[5&%<=:!'\1?D+<-)@(K !2B
MWJ/VSR8YFN+6IX5I1:?UX(Y(_))L\TIPU3I&E<OM:9,V$9,F[0^S\Z*HDL%1
MBY]6]CHM;XDZ(=02B)&,QO_!<^KW;_%UR*YFKIUD\W#"&"+R+^C.G&*]@O7:
M7$GF#*2U0)%HM^4ZX%=5P$R"[='&(<#OX37W)!8P'RS.(J*OL[D2&VXXBDJ\
ML'X<N[KVD$)L^85-ZW1PI',$7@%-5-AWKJ.L*B:=BPF@P;ROL4-Q!]V''^Z?
M^W 44\.U^ [O-3BOKXI]KPJ'8SO&6#J$*QUC4H$R#E=@USBN]0H8%FW63VL@
MF>##'X@*+/13ZC*H2UESOWXI.7<@F&H-)%+TS1&,$5IF4#K\D\8.]P7IEN7.
M)43:UM8Z$*036MEIOAI9[AR+EN#I,+48?").*TA/EP2_FU9 LH'ZQ-I:"^CM
M+,]Z'_9.CW$5?^AM%7^6^_S5HUI'J[7%'<(+R[XLXR?066XC*>656V;6BCG,
M.#WB=MK/\3!!ANK#(9&BO&7[RY=%D\4J9>5&-;G?&0F36=_$0"-U#$\.IV:'
MUCT'3BFIVN5J8)I@0C#'V[*G9)I35%5P^/0[:JA]IADJO7OLAUVYQ7S8=0NG
M%DPA_/OZPCFF@QZ&N=JM:OLQ)!AP$9@Q15K-9LH3:E"]#5;-C1>(E(1T)H%H
M%_AV(R2W ?6Q68D @W];'&!=A-@:I73[[PD,XI!3GH(RJF&0CO\;*3&@NEB0
M+E"LL3UP;XBGD.45UX&=&Q#1+HP2A>(V3+:SV1%-/FF)OSM/:Z[=9&Y> 09_
MW0VCT-_^E1^#&#_I48!0*OIH'HT60%4:MX)PBYNYW<0&-V:Q<O2</?OB.Q'J
M)> Z6N]A5&0/0Y'M5AWXB-NYI*9#)31.@$$VIYG5O9UI7H>'](3128)?66,.
MG:'S)ING6:;A&JI!FN[CVFNJ!'THXR]RQG)S[U_<3' OI'!L=B&G\M?0L_6Q
M[ZBC"QE@X[18UG*__71I')MA9PG);^U5(B*^0S685K.F(D 6,<XQ.HL]QZ+X
M2%5C<3/'WM8'I"-VJ__M2)M,LJZ#AKL++6L[)9:<>1:598H(7G.X%SAX-Z3<
M,?T>33#-\6W,W6W@ A_"590)D"\ \(ZHLB Q+1,!S%V99E*(R;%.8\3&'*PV
M@L^:Z&69+B+(&:>)&S<@D2T4 22Y8-07 ^KXKU)D+Q7#GW8H*N83(U3)/+HH
M2AY"& &Y9E5+!5[VZ:Z>];M P_S#D[%ASF^8.W@R=LR--O#F"SB'3^Y? ><=
MI*:D,?R(4&MCE>;6V,@'IMK0L+!(1@4KBL&"1CT0IZ!EM-'E@7S-QSE9(JR<
M6/VVT$6I;@,B!-P2P8/";R=,@5&0GT]CL/H=JVXVR9(.:!"N!2 @EE (3N,"
M!DBD<Z;K=94+(4QT@YN%R!!V2\TX]DH<&Z>/AYLW^"O,Y2@)-'PKKOEKG[)A
M^49(U8&&KL^'JDXV@*I2UUJO6'3*'73CO/!*(I''ON+C@^1>$[K7"P8;[Z]I
M^[ \UL:+I>'6W%77EIX1VK"+EO'@_EG&?Q06S8Y&\IY9Q;N"JSSU9^6J5D#'
MUCLY?"IDO4)O8S-T#!%3;5 5<^XR9(NF$Y%:#YE@JBY3EUWSIBV$#,_4T"M2
M[:"))U NQ!3\7&8VX@>]L8@>:DO&<H2@@^G23LLZ/(#+"MH!MI+LYVHE$P5#
M6M!8@-[ZS*J5M0_9N#DH/ XX&17L#BK8I_=:P;['H_BX1\7>P3#ASDCLKB2,
M=PO,U4.&V,MCN YQO(>C?@@+0K,9*!DL<0>'/5P9V;<<$8BQ-O^OHC;$9;1"
M69I2M?X\78#&YC'7XJ"#@D\K^0-W27G%)QTEP,SKNYJ='0_6G8:=',F0'@$&
M<ON=(-/,NX@A'4%%V9:7I*49T2,PXR!JC'=4FEOHI@L>NE!7WDC>BZ35+J/K
M'[KGL( 12;.FYEE:.$2!L'@ U*<XF8:V/0Z.W%UAS*6L)NY7&&[TDAO[IG@-
M] /#M]';A< C5( \_:&9 _[)I1'DF4)K<9D0=6$,PZ>:*'L<_+XL'&L!SXUH
MI6OTGG0R4>([ZM(292[XN0D6 PTD0+< Q*O)LI8FE-:=]C6R1 VJ,"I.I.,<
MYRR-BNHA**H=@Y7XO<"XG([E!R6$/W"W?W_&<._RO CRQ'P/(!333NN4IW_V
M(2"S3>+^P#)&#L^<INK3GACDM=6>4TL:9"RH<IAM@YWUXV%[((=MM_ 9)T;:
M+PM1^L@\(%V.D#@ID[.THLFIQHO^$]@\O)2^'-70)43X4)D3D"*8O0 2 IIK
MSRF<=6W[!!%)V'RY\4G)IUG65"U@!(^:1TX'/(YZ@>:/CX-?A#*\*0%@29]6
M<]P.GYKW$?)BH3+A+<)B9&WR" 63TD:P,8Q%Y37XV\,QP'O>0<NAP'\?S_L#
M.>_)KIWWJ&-=H:450$Y@_HC7Q!S)FOI&C$V+\H]ELZQI]ND95K&@HV6Q3&KD
M["GLE%'D\L!2GQA&O$):4<0\2\#5A%&B-&'TWPW/&R#(9(KP<7\RCG%2"RY,
MZ<QSJPE&QAW&Q:R! B!/*H#,KFH(H]!$*-=ZV1]I(9S8+8OF[!RB^S X=XW6
M=6E>4P)[+ \4VD>!#<RCN@'/_:R!/I4HIZ9T>@C</ON7?LY(\RR"V[2J. ,5
M$I.CX%R?7CUZ6PSI5V:2;^AV6Z*W#D;T5@N]=3"BMW9*LC^+N_Q3FHP<Y7>P
MKG1X_^I*)[GQB]$*2S[KB&@ X5=C%?^N'H9GWRT_;>)2'SXU-WI ]:HC2/-Z
M$L^LEY1'ISR4S;8:EPT2N7Y[SQ3H<*95;4Y=RMYUBVT),KH_C@%C6[AG9H.,
M>C+O0GZZ,2.PUB$8/@T'AW^]8:T-JT!*Y9-UIZ+EU4Z[7JT<WX.A!5_]L,]N
M_EF+^?4\Y0\;/*4]8UL*SK:[]R6?'W86/W>'_Y;^M <Q0BM?M0_SU;?4N[?\
M%$=Q7$)5_XH'N4NO^>M=_L9WQ6AL> ?_\9=G?UG[W>N3B9^YM%VULE\@'[/T
M=!F5L^!U'3]&S"+@\LB.5W=!6*[6?->R@MU1Y*/RODIYOT,FPCNMMOL?X2Z]
MVE%A?X$T1%6PT!Q14OM'ZG$9P0(?83C/ (]""V5$50!$A#,BYU__^A?2[YL/
M_HO^$\H/0LG?FBZU5^T[;H5BWI]Y^((7@9CWSWH-W6_>0\$X-1?&J>T,S/A7
M]PWJMWCO7\\7K^<:LS.G2+G<E'9J$&?_BG*?Q_M<G<?8S43&C??:4!T55$U3
M-4:!(=/,8E$PH@__/$','U43">=721MIFUVRV^;W.#BU',7_/WMOVMRXD;6)
M?L>O0'C"$]($)&NMQ>YVW'*Y_+9ZVG:-J]Q]W_OE1I)(BFB! !N+)/K7S]ER
MP4**+&NA*%1'N*LD$LCEY,FS/H]7 8BUG"4?*?FJ,GMFJPPYT8@[>/SZNS)H
MUG^BBH0/9WIA2ZBX--$^AKIC[JB=,F ;C+F#D3*JNTPJ&ESI)7?Y%R/8N#)(
M,$]\R4TYU#FIX':$\S,A'A8N4K'#Z\/XD5FXKE0&#8<?Z8?HQ7G>4>"MJJS8
MKOIJZ90SEDH'?"J2 B+AGG%!X[Z ,74'C_/YPH*LBU ;+'LGTGL61,[PN)A?
M-0N]K9S3^23L&JZ X--$!]8;E(7:8<VPK&+8MZSVD+@.CB<C]A.W$OR31C$O
MDFR<S TY/([2-%8; L_* M*3[<\5Y%QD1;47U& ]P8E<FJH3PY5D*9(<VY+?
M$0WZD>N\L?-PLMBG8E A!56D7.'P:VHSW#M[LT],5B4UD=#32U@V+. "%9CD
ML:G9D%?QJM@G>UB'5=*@<K!$0#(J)%*J4!UAW-^2/%"%1Q=SWK4X-ELB;U1R
M[;U-*EUH_VR9"Q>-^$WE1D3QF6[':=7GG$JVO9Q4A=?W(;BC0&*Y3'X$VY1E
M8FIW.L81)-*H;D_4I:*V=1==PX'E]>)FS&Y;_C*LJ-PKT[>O*S027#W;6KMG
M@8=T,E34M"IJ3H:*FF>;4GQ.Q2-GNU<\\F%B 471<=$*;BU70<+FS6=C")C$
M#D>"BO W?9V/;47V[E:=#*W20ZLT=W1B.)1&@9Q)%#P88\VSPNN&G>'L#D>C
M97EE/38I0P+%?!8+6PX^M@YSRZAK\#AR",'KD#;."8CI 1,L&6\$6T4D#-%R
M1O8MLE;EG7W;I=5JQR8[T)90<Z5T22MD&[U-,V6;G97@F$K?W"872 J]6Y0B
M"RF[[@'=:G")B?_#W:WT&T8)IW0D#NNYFJ>#^MCQ@,7ZVD-83PJX@:]T3'!T
M!.5/)P=1U#H'IW5J!#2['I5D+I-WN^S+D[9^B.C8-\]T,Z!I_&CX86(8:[VI
MV8/<46#>I!V_&YQ:T+"I==J=I<'A&HZK[,DL78"QRS+3'@CBNDG Q49O)JOV
M(4[ 8BK$X;^5:) 7([9!4Z=G;3\,#].VPIUB+ZH)5809R)$WL?U(])A$%?@S
M5GWR@J1B?!5K#Y<ZY<O<:5@)!$E$!^8BO)DFQD&CF#AL 'L)>6\T4EB90@Z,
M)"'\%(>LX&G-.7.$S7!R[YL.8&_@S69@ Y;(34NV":>%P^>H?#K29D(HN-LV
MFA;UGYCE%XLG]#02V0U"C>Q &EAN#-]$]H/T,]O*->%U1P24SF,8CMK$W68N
MPO,HEH@_^H)[.@OLB_*ES_@.K8-I+0C>NW&K>\KO7%VR[X2&V-W<A ]M03VN
MM(MD8H@ZZVR\KRMX^QN*LV?AJFF#@K35!N?WLIY1,WG%0.)L;U@SB.*#SO@@
MQO-'-3W^;).+N<$?L,?ESPZ1$FZ!GW ;6G*>7U3E?/>B*@2@6?J:L9L;WK$8
MR4L[$]OBXFQ7A.2S$74;4;2(QU@T82&A*(='YCV=%.8:S-V/U;B2G-@4>71-
M#K '2!E;Z5U9!!AQ*=,.\3=H&,:/:7[41Z@RK\?:LX)2C:8FF1T5?&:KJ]U!
M4*%MC#BH3:1NEXW[+,-P;HF LVI;$-<S+WJ:;VR<-YJ7EF/$]N?!O99['HPT
M\(.94SLOP@.\)A!VXGNT5E$# $"PL'L@TWM K"/KQT2AX1(72TD1;+CPJ2P9
MBY"99V2H8I$)0]XF3$=J5[]%*ZHL4=-R)4R#8+NRS2O*5K&IK%DZMJDR6$=(
M7,>K,L277HCRW:[XDK#^TC#69_Y=HG\(&*1SNB,B?%-(S\ ENC.$_"18H-HB
M[,%9GY@ZE%8M,"&#HD-87&LY2/C7DOP[.M6,&X1/=.4%W>%1\1I!^(_H)#)'
M6Z$9_D2X%,#3"V$@@G72H)UK<TZ#A0=_3PVHGU#?5D4RLJ33HSRK2\$;91(K
MO-% *2&V(-,:S#"RXA8H,5046%]GM6Y78\8:-*7X[#'HG6)A'%E\-E>!R(@,
MIA+!M,B*(<YJ94(J^#D]FZ?YPE$MN/66032_9.H +?%":\_,>G'\? 0;3G?@
ME=9S+M_#_H=2SQ65%M+TI "JA+5H/\[AK>#RP4U&B(TB#&!.<S&@-LQ]1E X
MXN#>EU.D,.4K=U(CY2=-A]$8+?Z+B%-$"]8R(F@03?NDNS=H?URA%#U7G?XL
M2EI.AY*65DG+Z5#2,M@ZCQ!\>;5[P9</XID9^X.#,3L>B.&XRE"Q\N0NP7;%
M8][UP7_W6/LK*<IZ<B0F*G'F124L0&$SM"+0WB;ZD1C,/S_R8VWW$"U>3LM@
M23(_1#@!EO78/,$1>WFWT+8<K^WRN-]YD2"3KD=_(VZ![Z\X>>V*#A-82R:-
M_K(NEY][A)S3R()V-YIW/1*_2JB37*K9"V3A@:\E<(9?',[52SI7VX5(?T<:
M@<Z()[NE(PX;Y]FUSKC,X<[#%_GP8*X95+C!N"URCH#4526'JE$9)?'UX:"\
MI(.R76CRK98V$]^CK)E)#\&1P):^1<CQL<@+A38*TLKP])6A%82_C?8C6P^&
M)PL^F5\J+L;!,)D[*7Q/J=0A/_-=Z.5B6MDCB=Z! *#TI:97T^'O*8+"-K>C
M/);MR,DD*6:*J!X\ZEN%#898"55-"ZT/_E,K;"'D&/3>Z3=G^]UKL\);$ U-
MZH'DR&F;]4)NS$># MSB(]Z(>?7%CM;2 JM5P)( 0]"#\]=>&P96^.;[95H!
MCFZRS_MW!^3&NVS1-NO6_8..#W7-8!,^W4#%)<*5HZ#FJ<%>!^D&>2X3^<=,
MI9=J)K^R07CPID9)I@R>>UGKC4:")P;9%?2X9J>+Z9U&E?\CNBQA$U ^:,3R
M+=O"7":@EE1AN98W78\]A(E$6/MKG6+D/Q3HQ+^,OO_L'HF1%X&JV*<KF8A$
M":.=\L.<F2W@>.<9R#)B+VRV%K=SYM*F$N>R3JMP[]V^N>VE)G&O"6J N:5W
MH!C2!/M9L<\8-H3R92:%!8_9:!2F_-.;.*[(2&<:] \2M.8W:'#L49&BY<%(
M,C[7+0^<?_A;G6K^V_%I?'"ZT7@L&C\<<"L1'V['4Y5=@JKFUH[CMZ=G/.49
MUEO&I$8GR:0B;CWPSHG"_/C\ZWW+9B*)E77_X !^+4 M*<,R6[*XQ]QE5E>V
M(C69@8.$^P$BX*X*N>+*>C9KU-EN- IO4Z@J^8=]DQ6#RQ(E3]LL66N_F%QA
MTID#D[5L-(CU)!&[=OR5L)TNRQ;"G]Q&X\$ZW/+.W>9J5[I+^[>MM3)BP=$M
M^H H-)T+XK&8=W?@GGR4BS(F0RQ=L.-E_U7"^J/&P3QPQ#<4W!RF#2TB*T_;
M&^H&0XR2%\>K8S.-G-&#2ETD?& 9O2#VK[LR\M+M3=!H^J%4L/=ENC<:"QX:
M/.GXB@2.-@X)IJVNL*H(;QPX]BD"5>3>I34<I>T_2H]C=%(7MU2;@.F MY-<
MY+9&T.#!+"GSB'S+%7N1,)E6;FKAV(>3X8:UE&8\<&!<+Q+76;B7&Y@KOD?
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M[L;#@,W*8"HC>T&FP[WC_7"!"-=[S6'*IY:G*UT#W+Y#KZ:"?N*^L<TDG2X
M-\CNJG1'FR97V@RF^1ISNP2$@2.2$;G0/&SE1">5E(SRCPL,E-@28%G2"(M4
MU]4<5&8<Z]B>YN3[C;X_S6]P#(VO6UJW'HQ=:O4@6*.24(S 8*%&^:7='79A
M5\I?9)HE,8?CQ(?YR]@&P-C^C84(#@@BN%/CBP#%UIM J>45]ECRI+Z(STJ1
M9(BBE(9[5,:;I0;67GZ^O^H8L1P%#8&QNYU,S+&,;%+&3F6[.TBV#:?X].AX
MJ/]MU?\>#_6_0V+MO@WK'02E^EF/IRI+QJ6M'V'S:,<LZ^W+J:VPK=>(;2 @
M,%4%]!K646A)/BIUZ^"#A! TJ:934#2(L%#6*F/LH?D\A9.&QSQ% "DV8\JU
MRM]P,&CNE%@NZ-L\IMX"OCF>:KAQ,/ZA"NR<"DOFQRV0JE20KK#".2=#)]43
MQ.$UA!R725DQ7T,<%S@S@_+8M!8"V\C$H TVK(&6Q4AE5\YHYX)%CYE.'K6'
MW'0(UBA<'BV8+ZJ=\,=3AO\F7"-;13()FA&61K$%?99-*!HG;B(\U5Q.-H2K
M*BKWP"$7];P:6Q8@">DTBWLD<2J8QMYLD/#!AXUN+(&A1W.VHV^;SI1D4['Q
M]S*#PVM*0_*;C"-%AD^M8V(VXF/AR7% X;'00]EPPA998Y<'(C2_96.L^UR!
MDW?@J@S=")\0(QPRT&7"04[GPC*%QB3%?M6HR=YF,M$^MY-KM_Q"F/ #06K3
M>#K"[MQB74W9ES-NJ#6(R=_UDN&TV%11U91V(1/$"C+DYB'2H)[EZ5T$LT>!
MCVW*Z7I9!B*D=QXR=4ZV9R.* +?(8,MY(XH+=9-Y[8Q<&8MJ <[$I6[[&4%G
MW>Q7?33N(BFOEAQ[\T2N 2BTX'B;V8X>HE?B!>"=O./#-\"=/$-#=0=QOW[(
M\RMKI(IL[IB1^GS"OY^= G<W-FX0&:&\.8Y+\$K/K1[_U5(D- )Z:"DU+O,6
M N0=\*'(*W%E2JECQNBFUP<JO5$+@A3/YSKC9GCN6$>VWQ:A+W$AEG["CNMW
MF4'7D1=[&*VV^]][-%>H.3L+5R9P/2W(1:Z*,,['M7_-VK70MV-:L!+^AG92
M4J4&R%5:?L!"IQ5CX-4_5MGFPA(BX7 >^ P),\;Y7-IJ$JJASFJ5P@IF*B/@
M@[("HX;K!=2U@@&C7IV0D>0O7Z>,6K;9!0X9!+1=.W<8>,-JUDK[WDJI"7!T
MW9'VU'5O5^1PN)[P2:]V$(WK71TG+3JG(<QQYQWBX2]'/HYT)(@JQ)XH4-.B
M0!0O-,(UMQ6GO7# 0Z]3)1A9[<B&20A%H:1V))^#?8&WNAASZPVI&AG0(B!F
MSEN)1LSJ3+M467-,45<CPG-;N)!<V 7WQ)[TY= S1J4) O#U02_@"$'&"I==
M6&H*\MH3]8QU)5U')3'9ZWB?H@+F?EAV=>YQ@Q%=7Y0$3/6E[=3I@<AD/S.
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M,)X'PV^UI?5J!Y'_/.%]2G?\^=(FK6W==<TX1")J,OFUH*"8SYCY?;JF'*D
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M9;76_="U\@WNL^^Q;';T>HPZ9]L(.[N<Z;:R[%Y73>[YC74 PSUE""&9%\:
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MB0(=')]@ ?U-D><S?!/A=&'^4;0$MA60EIJH<9)RM B!""NLQ'9C4>'''R]
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M75LT7:BH998<GD_5C5V]$OD )61?(G^;70_>U@1+D#$$ *_(4PY7S#2ZJ65
M=$=]Y>VML H7H;G!2$0B,J6'6:R*F!_="8T0 XU$"^G?ZI;EBY(.=G0!$<[
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M#4,[SN<H6(H9Y%*T@_.T-IR6H/P*2IQZ9JW)MIBG-=,#W,:HLW;R@',+(?,
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M8;!F%QG1MR8(Y?O8\(O1PJ5@G[Y1\8%$?QE%Q"M+$?%49_ Y:Q:[F__K!R.
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M)NUZ3G]9T:M?,>IC/L U:E\:WU0XW9(!UW9+S6SA$15]21@O"KH#-,;L=^F
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M]^&*WOWPGNDP^VD^^2SKQMYZ;CK#F9T\N=\L4[/:S:.55/C"PJBZ;YYON=^
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M@4*:O"/--RJD!GY<BOWG_;BX@F@#N3V#Q-5& 8^?'JX3?0#;4+K>G/L<Q3;
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M:RQ!Z B;!A/'X6JXO%K.1QYOD@([:S0 P6BH.&3YT>MNR]#8! ?J80J1Q*8
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M#Z"([PU(+X3(DNWO_/VIL8\#F!T4FA0?3919;S=[Z &,4Z=&7FJ_Y=YO&?F
MLE'O9FI5W%-15PI71AX5X/SZ\&-=.%VYCS)BC*D9NY?M.FUB,\R=*PF=-N!:
MNY?%.VW -16I[NK^4H#;C<=E%Q98<L UE*%H-\"I,*8=+6P-1:J[ >X0'J(R
M JZMX+:;-*(XW&[B;V9"7+']^[[]2$.&!19. 0M:NQ?P/6WR45JW8M<'A9O*
MTMX-;DJLV@UN*L0Y9V)5N>%F*+CMYG)2_&VW& !UG^X&-R6_*3FD''[ATH1A
M2)/%"=52:&IMQ8AV%!B4H+43W#JJ^-)NAK+=VV6=.. ,!;@= :=LL[L!KJD
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M%# M1(T%D8K$(4;3Q>)12O8'*,X1%5$8L0/5OD!@.$6;"9 ,=07]N #8ZQ_
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MP,2/)Q8XA5M#KQ+Z!I*^U\32-1+0 9,&1;%CCJQB8?!Q?](+29<&#[Q_(](
MKE.X&BI+'& SOM);UJ<N'M ?/^#O+]]^"$R[PBQ0#W ?2<=QYG8:C\A<.$Y&
M@F?@72,^;DP&70I'!\@^A4IE2G!XM #Q'K>$1)^7%J/QG 161ZQ &HF%,T:X
M6N6)LWZE^XS!A9-N8/=M"A"$(_Q5W# R(.AU%!CTQ4/.5VJXQ7<'@DD$1W*7
M,DIW''DP' KPRO7""GJ(&>TCP!)Q9\)107UT<#M1Y-GT $X/>N$0Q %@CW,P
MJK"?=B!9[,"G<%-->" ,.0^&WI/O>4C@PK'3&U+790[\^]O'&TF^&AD"[*L\
M\H3%(;P8FGFAR1-*BD_SDT@RJ& @ <@JW*54WJ I44U[@?0Q?@&Y;43?4\!7
M9/RJN#NB#T$D1/UB&A8X<.B]$ #EEW$P&O=EEQ:>O[O3L-[9@.H85@FO;&4&
M*-H\.\'?N"Q\\OP''C_RDWLVYP<.$J*YN!UA%)]?NESHY<_D0986[HFHL]AG
M2F>\IB+\C/0H,")X7$&9@H?A5^$OZ_B V9/!8,8JD,J MMQTL-YRP$T+\U:"
M>LVP;!?5]56_@LUWFJW.0GKYRB,-L2!Z3 ^1M,<-[&G_1)+./<B"P8PFO* .
M8=BG(X3&1(@9UXJGH351U 7(.UNM@Z=JB$ QT*9A-R,>QD,#&^AVQ%@H%6"'
MX<RH8;E]ZO<#>/2O"0CH7+.M32TA>S:$;'#;**Q-B;4W@4]1NN.!'R X\UAY
M;K?9#ENBV.1[$)2>Z',4FPPCB0 R?I^.4*2*T#D9,AP'8_%XY$GW+R:B_1(,
M<:OE\* :M##$B2DK:$@A:-X1]'(FG:RA:WK=E'&TN_#5 $U5?<$E_PX8"'IB
M]9:-00[O\@!!P$&><_:$J58)%.4&1IY!0\[U9JWYZD+H"/";K9;!I1O/A:WH
MAM8RFS/QEQS[,= ?;2B>4 3&/GODECM<5N[0-2O+<J\'Z,@#F[T%E70F'9!'
M_E6NDNH:3_$1B6XBEU&8$&8C1N%N\T'M>D:P_V]#Y#=&0:E"5PMAG6@8"N8R
M&AOU>L(@!'J%P^3!P8.*_"K*CD3&!D@6SQN-C77@N"EU9FA#2P[.<066UQ#A
ML/L4^0Y]VAOF4W[=8OAU2Z6");W(*CI/1>?M*3HO7^%YN@K/6QV>9ZGP/!4U
M=Z2*.9E7(%@:I:>DJY.5KDH;J_D-$UU=].5TF>,]15:D+@WL($JX14WQS=$%
MV7S$V*6H]+JB *_-'9!O2+5>T]&0,RVLB[%X:-Z1CP75X9<H#OHCZJPJU+JD
M6.WBQUL5\ 5@H*#YRYEQEEZR2;F,9;P>+0>[5^8],4A9"E(I(96V6<>)0^H[
M&POV;S\*<_ _&/6S ]T!JIRG9K)11++Q:FXK$;PVP5 $4/.("KZ2\_^=8$6V
MD =._9!&R(6*^-$5DW[6M86^MQ\N?15P.79GU[&CXNOUA1+Y!UCU"0&XK0"<
M+8!UK:E G"V(N>LF>Q!GU1=E.]%^MWW(*R4.F\1U7-U\(I>P!52YKW@3%MLE
M=T-O$HA<B]N%^V<?^+1W)'H1]UL0BH^U/ 4S!3,%LX/ +$^*Q NV=#D +:QZ
M1W^*7G9\'7?4MP<#R<TCWHZO8"P6=<EUE ,C[P/2J+_2HJ]:K\K/\'6C53--
M18P*;@IN)PNWH@CRP.,E"[^5T73??,SE.+^\_78"K-K2:U9;D8Z"VZ'@9M4,
M!;=\P:V LKKL1ES^<U]PD[U@>:\4N!2X9L"U3XZBP+4+N%*VUHVC<LH5?!-[
MT_76V8M@F@A,_.9[Y!.^0CY0AU=XN1UB-N<2PWOW??XNP#UYO2/W-E\,!I"Z
MH><_*S=66[.4IS!C9VQ+JRL89PMCLZ%@G#6,+?TP,"Z*I6QI<!4F")-O%(LA
MKKQE2B<(PCVO3!C;D],"+2F@;;Q+M;JAP+8#V"PS*[#E25EXP98^V3]9GUP&
M 0ME=.RO%-T@H C*"F'E]WXL4044;6T4/9=)10IL"FR9@&VIGI,#3GYLP?LC
M&WGDBOKE=X$H87L7LEG,1%- VV@;M!2#SA'02B)HWV$I+"EHEQX;.I:F]/Q=
M+KFZUC$5R]Y>JFYK[9;"M^TUWY9FMK-FW,JGO2^?]FU(0U%P&%.7;US><FCJ
MZ$ZZMODZ2N_>%B#@2^&=MD79_$1:MW)?->M:<S&Z6[D(]PECW= UH]E20,XT
M\[C1UAJ-C@)RI@$%+4-KM@[ +HIB=#M[SQ/\X$KA=TOY)4+40 PE26]]!=1U
MK=U<J)"E +=9Y36UELH%V8%5URW-ZF1%JGE2%EZPI:\L)-_9(W.Q:29H"'PA
ML9:0#%O"<&#A^D9U$?LXE9_9 \O2%P0J17F;P :8W5"<?GNC,$@6BL]O3Z1M
M4."S0K>BB.'+]L%3_["_[< .RX\%NF:I$, =Q$M3:S86+#,*;AOUP(;6M)1L
ML#7<VI;6TE4UI0V^C!-!ACV.>%)$I."FX%8:N!59Q/Y"_0?&&]!,Z]Y=]OGZ
M WA:>L10T=J[^9P5V!2VE0)LA9>XHS0![#!-L7G0;_];>H30-4/1T2Y@:S04
MV'8 FW)?[F*8T^HM9=5>W,=WF$%(VP1_Y.OX8#M.$&7F<D_EZ23GZMJ2MBF*
MO!38%-A. VPE$<'O?/K(',Z\/]N/,#9?R?7/,7,#%I#+KN_1?ND115&7 IH"
MV@D"K<@B^4=LOMFS:6A[+E\$,O'+D0?K_S=_6'J\T!N-FJ&B ;:&F]4T:KH*
M%=P:;LV.56OI"F[;PJVCZ[5&'ENY'*T_P"?;I6[O%'R5S2;0C"*9[577!@"N
MH8HN[&#!;1GU6D>)V5M#KJ'5]6:MJ63M)6827B8G,HN4'A-:6E/5R=F!:1M:
MO:F<;MO#K:ZUU%6W$[XUZRK5<L665%2W(B(%-P6W4X);D67L;SZKAO0G5@X[
MA=1)4^LH&7L'F4?7K):R^6^OW".^*9O_]JJPJ>EZUK;KN5J4"\4H<>1TQ21%
MV<IJZ(VQ0&08/Q!LGS^;+F&^H&56\^UQ)CXBJ<\"]J])$-J#YV43_4>U2C[9
MS.F_(=\G#JM^PU#%:I6_%:TAQ1YF2G&>S7PMRW+RKS\X<*L2O6;!&@//L?L1
M4MC_!IS0D[#GJUM8X^N%11X!9AE-M'>L2[VOC*:*%,RF56TVR0?JLP<6DMO0
M9RS4R!?V2(. ^?#HG[;GDDZ]U6Y9=0&%]7]7[I@#,QI5RS3-MM7*&F;11JY'
MU(:)WV&%V!GQK\]ZGL]C"I"SN2 ELJYO/^CU_[['3VH];_3N-7X%A]PVS,Z&
M_6W[=^6*.0@0RZB:;;VE&XWDX68*D@6D/28'0[[P%D;[UX2Y/6 HIFF\)3^H
M,T'F,F48_#H5'R_RJ8BI+6%523ZH&TL889,S\QUVO@C9E#?'I>NRG^2ZFH1"
MM/^WY.YY##N_]&G7[KTE7^F("1A]]1 81G.&LT:?<3@AE&,(K828S^A#M<L&
MG@\#CSGPDZMN+EDUPNUL61GIN7MW^>3)]1[T$CBL1+"<U-YUWU_7/M8^D"O/
M#28.S^_%DM'8N3$(17WISV&_)DI''WFE5UX-.&&-6'JC91EZQ]KSJC9PB6Y\
M8H><54E7QY2N=D'4@]U;!Q;N;D)B!X2.L5*B&Y)P2/$O!JQC!%+(,THA>NMM
M0$(8BX45>#?T".T-;?:(F4KNA#HDX/460_3L<E8S'OO>3WM$0^8\$T-KU.OD
MMW]<77XEC[)J.Z'DF5$?D#4<VBYI\'\%I/M,QCY\Y]OPW00+$"Q="OMI!\C3
M*F.'AG"EC,AY(-.E8.]B,6/F!QY<>8Y&6-BK76CD":8>XEY'C.)&$[N 61G:
MR^1V1,4QK!\YNY.;S[>D99*1[3@@O]7**N[_Z@-\6%_CL+\)?,H<.SHY8H_&
MGA_B."BAVT&E"P+M"$]J!'<[#YSE/\##,0OMT ;X3L\4SAH'90[KA;[=BT<-
MV#V_E30^ (.#@5'<<$B>8$@??\]P"A>V-?+ZS!'5/'L<+VP65,YQ5% 2<&%_
M>;X=/N/IB1/'[Z\ RUC +@BGYIF-B9UHB46&0]^;W _Y6PYB_=SF ;-*>_:_
M>4] $;Y&^BP8VR'C0,#4<GM@]Y!LXG/UW(HX S>PX5Z):'5 >Y*)7$Z HP)1
M(7=Q0/[KPYD 55(NC4A$B( /U :DQGE S( D4^%L)\D&R) &@! AW%@^?!@P
M9X!<"69PD"WT>)<,_B_  AC8=A\]YY$%<\1<K[5?(9+@R)QS1=0_>]B<W0E<
MN>!(9W-^V6-^2&T7QA%,!(U.E0AQ8!K8J-P<[O;)\Q]*BS(@0:U5<R<NH ?<
M"Z#J7@WI&.GOFE3)%75Z$X>_$AW#-1(GT&' *EP5DXKP026S P/OD^T'@/\W
M<!,Z#F#M +F3)ZEN-':0JSD3 :41"X=>O^(#]WR4-]AXTG4 XV-&2) $6)]X
M@KSN+F^O.=(FQH-%349K;WK)VW%BADM"9@UC2I+ECRMP8D!Z)!@"=PUP.CX5
M"@=+!D1BE,/A8N1FV4^XOF'0IR'<K*1O]T$+ **V!8T!^OBLQS>9@ I,$,.C
MM 1U-T2P4Q!? GYY ;L;>([C/05OCK[E/35J2B6&+^W2)/2;7\ZD?K/:.PMC
MG[VO)!P-4C&JU]"]>O;Z_<I?S;(SKA<-* A]SV_6;^OL?37F6+,^CE7'[(O.
M1FG_V$C?80@'@*1EU-]*\A\X'@WY(_VM1JQJ2]#ET', ?D'$7>>I$F[NT >\
MBC)5T_Y!5_>8>$_1#3Z5MR0W.)^]:-OU5Q<U@D@=^A11AL!]#"QH5@9 47*;
M50!$?3;"\8$P:E,?T)P#Z$CN'T4F^R23K1 CDNN#T.L] )KTAM0%$=YSI3JP
M_((:P4V$J"E1&-DN8BM>>P&_E_H@%CL@UO45KI47UV[<K5!-*(B@=(9/GK1@
MA,C4N89RSUQ0=AQ@4%W&7"'/2'&WR\(G?"8Y'S RMQ_$<EK?1L$GRD1-^T<R
M>8Z_"D45BLH_@$HHZ\\BYR,3.#E"UP#J!-@_!:1YP2#'/O^G%$'YR4G9/0A8
M$ COP?G5[S]N/E;UCK8]Q;![RE4=--Q%2/]$_0N%MN5%VUUO\1X=VVB;D:Q2
M&)!@57U[ $HAH"*WU\$&T##D(8*C]65DNXC!<Q]3'J.Y-;X^>;ZC;GV%F_$?
M(5G&:@M!"V15VBL2MDW'<^^K_L3E/.[>\_J2"W/9$CDQ.L.!$>,G^&./HNE&
M(5IY$>WO\,-6F$:Y:>WOU)U0_YD8ND:,.OZ]3(<1=W1D^&,.N7RT'\DMQ]7K
M2 OJT1%:N[=;Q((/S&BU(R<8.>_20!@<J1 ^T9'28[Q]-;QJZO4++3(B<M]@
MM-#!"Q;QQ^U'TF[46LM6X4YU/KPJ<"%FS6A?"->2G0!GW3 06%NMXR507P))
MO1/O8:ME;("Z8:R$^A)(-LV:]=)5P/^ '#$<8 GT]0M2E8QN:-\/Q5HB<;/O
M<?U:+G89:F\I\$:VYK<D\ #JWG)R<;RGZ>%%*"$(K+'\/+=:QO3LA7-TZ>F;
MS;1DU)@]S^U(9]W9=VJ=U$34M& 1W)L7\#/;\EQ KPA *J/<)2S]!]/3RMV]
MIR*X58Q1:5Q**H);17#G,8)[:UZY-H3;5"'<JT.X6RJ$.Z<R@8KA5C'<2K[*
M3N I&K/8$*\MHJ=<T%^E1L5UU=XTG"Z.^(A#I8)*K-JAJY(Z0+>N4,1$4)GG
M>/<V*V]8*W ($54UHX3*.&_I!K,Q9#.&QG.9HPX1%M<?;NX^7B8W'_GB%L!2
MX29K0!P CV_W,'1H-/)<'J,/6(6V#>X:G,8'<F.##$M\KI$/7CB,/QXQ&DR$
M#9QP.3KVA\<.;&G\B!;4F[,'B05JI#L)T7P4>&C6BSU"Y(D^EQ>3EQ^=A&FP
M"-1*2J!B6!><X#1"6P!9!&XM_UT4[CD_DORM$!4QH%/49ZTP6?-/(R']R43
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MHS<)*Z'G.8%@!B)[2KSN(5;;U.%X.9B$$S_:6XF/SPYF03^B#_Q.Y(F:"',
M( /1KH<B>X53;(#^(3L81CEG"\@N2 _/AO4H,-[D<.((^QX3<;U BQB)SK-!
M>\!+A#8E)EP1.5^)\D]G$N- 1GH"*9>Y]YAJ*+S-TP3$..=4H&(4(Q*EM/4]
MC.2'$6%[/'V2)]>(!+B)[WJ/DLAG$E0K,GN6D@$< 0\N*2V>?/5"W"V<O(O,
M&3.F>!QC'T24OKA8$]IP11*\.$!Q])AN*I*)N)^9D@?,-,*LA9#Z0JKU;'%&
M]W1RSY9G'I\*6[TAO:$7",D3*02!$7GXHZ3))T\J@I6E?-)FDK-*=07Q=^%2
M#J*\[)OH]N(93^BG!C"CZQDI?FGZ"LC'M ?'P9,^RXOYEP'"1EY<P+%0UND"
M0Q"P->J&&7,%&-3K5WHH%*'Z)41.&@A!(VGXX+GW_4FL6/#S""=]?K8CVO.]
MV9!@D'DISP&4,M&(^3V;!_'&9#9"-C9-R(X2O>&"\T:8]]US)CSW1V8%"X6%
MA^#,K!Z4]R 1'<>1T"54*DE+=A&A1R(XN;2H@"Z!>=7_],Q4&($2Z:X8W"M8
M.^)Z9;T,/&>4$H4O$MI 0OB?U<Z6:0)264%K:_>97]=S1I)(B3D7.[@H+59^
M\GPX'?IFR5']LG &E=?RM;)"0P)!VE^ 0V%:6;!@#)N:7"HA_:G-6%N$I)?H
M/B?E68GI?08@Q0CWY2:>>2L=[=J\$@(<@L>SJ*.915H;3S9RGBL\.4D(4HC,
MTU$H"MYV6&;;Q!H^,_;&@-M^!'LXQ KB,0)FFG0?V.A)1[L:S]*6YB!AZ+$#
M=+IP]7]$^RRV=4^_1KDV8;V.DA:"T)_T4 4,:N33<K3!;:Y%'&Y]2"@IH(+*
MJ+Z%96B1!47>O(A:J#D!^T,;#.S0$T&L,A<HPCL4-Q)*#?P#A 5<4< 2$-@G
MZN3*=Z_B^92_6<7SJ7@^%<_W4@ZV&,[74.%\J\/YVBJ<3U5D5=%\2KHZ!>EJ
M%4H<1R]T9^I'@H8#:A]S*G,5,@/0JT$/]%'="F)]RT 5RJQ9POZ)7B&>,2P=
MBE.E4$XB!TF4HTGDB276!%H:B \UJQ+R7<.GMK\JHJ>L,O%=PD6Q>%S1,47E
M'2NSQV3/EX<T\(SB:IBB<@;U65)OCYU[\FC@ #&]$8_#Q_Q"](8D'1WQT<7*
M?@6K97KXN]A ?OP2;QD>#S*S.8.JQLU-,Z8J+9$.7Y%N<.%=U6:<#W;P4%Z;
MU#?AZ4"*9YBKRJO@H@F&_:0\ @GAN,"<@DHRF&@5JYHOYBMHH+28]X>+*NH7
M#RF-L]J87!=X:*U=5B!<.WVTS:W?O5G6W=]BJ<#UNS=K1EEWOXR7/%+?]B8!
MD3>0O,U&]+DBG+U)S_UFX>?$.,K5M CVK*2F2?LZ9[WW&+;CHFY7&8-$WWN>
M^>U,@CU,_^AA]@9WU7"/0 11'@%<WGONSINZ8*/@@+GJ&HEZ[)5EH>_3J*[U
M!<D7:HB+TC8)3RZ/VPVFA=^#D(P=^BSPGH=D\5/&Z 9! 5$84A2G,,]3,')!
M%+Z8C5TH[7'*1)N%.)^RARDL1AO/A2F( /\,HA02(<FSDG44EX#NNYFXP=(B
M7QR)\&WA-'XA7Z9P>@W3A)62 V,Y5L(3P!T8>R(=SR@4NGV[QSD@:@]#$!!&
M$PSZXJ9)3U8L ^Z%:0LBTI(^3T/G@R%[ $8(7\Z$84M43>!CC5Q&^O'29!@W
MBJJ.YN4)0TGF'2$V3X#$\M6V*V+84#N4Y9UZ6+:2)93*6 L2FB2N0NCF*Q,$
M(GCP,C65Q3LD6H:L#(R3R]#=1%0XC\M%1=_NH6M\R@C&7F"7.J<F-II(0'")
M4$8_L]$8;EZT D30K"SEG#RYD&)@Q;V#)^PY&_(;YKCF76RO$34A(RF7SQH,
MO8G3YZD@4E9@?:U2?@O,I]BJ0C985;1DFQ>M O/1>X:";&F1]K,]LD,ZDSV]
M@)BE18SE5\7J%(FEJ5'R=T! I462E8)>'!\--QY\B,GUSM2V&^!M*D.8;>1;
MJ%?,!DB?'L@0L:B#J=I$AHN=&@Q>XD:R\#K4Z_OW(EE5O4ZX$ZDBG$B)'&,5
MPZ>\S&7V,JL8/A7#IV+X]AO#9ZD8OM4Q?!T5PZ=B^%0,GY*N3D&Z.F(,W^JH
ML!717Y76(:*_B(K^4M%?+XC^6BRFH**_7A+]U2YO!%"*Z*]F>6/?4D1_=6IZ
M67>_/D2EO2I$A9=:BJIUE!4V'Z)+6980F8S&P@<TCAFP++82/Z@(CHPB@YNH
M.A)=; N.R6YRBBA\:2YF:4EQD[6U:8_/K/?4%4Q*SSW/<>@X "$Y^FE&XE[1
M& PUTS7MP(3\?B;UUVEKKLUV!BZT/S&0YD(<QNG/ L=A Y#D/[*@Y]L<7>:;
M?RWY7D)IJH;C?%/PPO?Q,@$$:*GZY<PXV]N2(\60VV+FE[MT;4N&G%DN[]23
MY@#@\&"U][SW(AXTB!K$O^^>&_6&9IAMS;"LB\5#DJ??;K]:NA!)1U@_:'XW
M$=Z\V@KHZT&1&',1$9) 23M29VXD'S=W]MYH:&V]O>V.-BWJ)2?UY] .V>+Q
MI**0W^/,(QF/]241#I@"6KN<U N/9\F9F#M\NM\SV$PM6QX'YP+D&E@\JKNH
M)]P-O4E L0LU7&-?;VX+=#ZMAM:P&D<_I/T0RH:3^8BWHQ\4Z'2,NM9L+_#H
MXI.0X&@%.@B]KC5,_>@'H>Z3A>N]^,10JOND;6J-QO$/2=TGR^\30VLW2W.?
M7$K'1)D/3-=:K?T>V&Q[V'(9I.P:JVD+>7#S1B6-1]OZHDV!-U^<N8O==F9;
M]*PJT"RJE,L\$!F<'T3&JF36P\;RZ95D^?3Y6LTN$^D9Z^JE+U1@P/;$AEYK
MI>WR??/YMH)-BK&2,/]8+V_-U4N>O3A7"]KK_B6JY,=ES^..)!4LJQQX#L(5
MTS"B"OJ88S%;_ERD4"8J5WK.M'0H0';@^2/1O(+7J<=7?39D;H#S3CN@"/=H
MR&OY+X2.SZ-'=Q(@#@28;!E]*ERBO+CF*IPI[>E^X!;F&VP!Y#AQ7?MD@YFD
M43ERDD9M4F+_:5G!\ZX+^(]V=UX0==[>'F4+4_+QZE.2:57*G(/ZARNZB,SQ
MZ2>63)J:[Z,F$2?98T>T?K(#P<OM,*H0+Y&PM"1W$[7,DN5O7=8#J%$_8I="
M')NF!5403@[65TKT:N$M.( 7/X]%0RG^.YPBV:)#(Y@EXR3&BBLT8X(OG03"
M/RF*/%-'E+D73/%).JD2WB+1E0H8,VP<N40BVY>.\!!+>V3S,1+"(\=^XB4B
MN"3<C9.%[IB5J'V%AU66>U[ 77=1U>6H2Y?(UV1+*VQ/*V*3\S\OKZXNICWU
MIM-$_L"(EF#8F,906EJ=RGA\YUZ&,4 (+W(N]"*47J34.G<,%YAX2Y.)MHLG
M)N"]RZF5.)&%@Q<)@:.72$B+D5(6#."5WM'!+TXAF O)B@'69UTA#K)_37A<
M%A<-YP:+3H.G@D<==>2QE!C.*J15A;2JA"&5,)1)PE 9\H7B3(2\)B8U56+2
MRL0DLZX2DU1BDDI,4E+<*4AQI147 <'7R3T3-!EBNVJL9RFU.*[I2<&GS.;2
MNZ3JRC<=&1E NIWXV-$*GOI<@5Y:[288@G \]!P 81 5Z8N]*LD"&XLY7F(:
M.WA RP_(FJS/JTMR7LW+>+BS&5(T($\@+59D!9FQ%P0V!E_+E:*=R^$E9[B_
M..;XI;7[36M[135L>169V?I@\G KD>TB1QEV>PJ=GXF/3W55+ ^B7Q/_ ,.=
MO:\L1B+7:X9ENV>OEP0IRU_-<AY^UPSHR':>WZS?%D*MTVQUWL8\:#9N8"F@
MKX2YB8N#:?\@JH2\MBZ2W,CK,X><7UU^^W(QC368"S0XD@E+H<N>T>7&E06Z
MML&7*,B _U>BR\WW[PI;RHXM,D3KQ<ARF4-DR4[PC 1*]"&<BAS)_24KI4@>
MJ3$O13K,W2A )KSOT^J!$88%-N ]]8'ZW'ZI);Y9*,M"O0#926]:9SBD/SE@
MM(IHR#M7JY=S1I 2^_A5.%N-$4</R,#W1KP@ 8Q$A8C]R-Q)B2.-@%3_Y%Y
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M\G96+:R1R-N1ZUIX=8Z.%WY_P-MR PO:>NDS+.@P&]M@F3!2IM;FZK VJ+W
M5Z)$*S:;L7-BI]NJ=<I\N'W6#2.Z/<T#-LSRD>\=_<DW@<6H3O5<MU)&BW"H
M?W+A;Y8KGS;I;A4!6+PC[B=CWDIWM*F5U'P<W(D*MZA/%HW&3O2HWG6QRH^!
M?1>[:2Q6N3JSC5O[4YH^A'];UMV.S![S.R[7L9> 4Q[28'?P;J!T1*(2[F/1
MG3.N*]^C 9KKX#_#@>,]542S3SK UKM#^@@ G?8IE/5A8QO?;,W>J"RR'"$D
M@M95)S35K:/4W3I4)S35"2V#3FB'[DU6Z)9KZ3CE8L^UCNJYMKKGFJEZKJ5&
MNQ7*02NY;"G]J[YLQ>C+MNY(YUSN^SY9)0T65AI\"=IDO#3LY?8(MYT(V!!J
MFAU$&B'H<UT&&N#A&GV\A&GN*6YC3:C&LI".K6K:"L):C+>;M5/4:[IAV:X$
MD>WV>1>LJGP\:ZN8CL&A)?1PG,CI+]I$.'TN-\W )A&LOYP99^FEFR53+N/;
M7QAUYU>[=&E+1LQZMQEL]Y,TH>Q[R[N=YLZ#I8@=S1*=7X:[Z_2.K0%1!!HS
MZD8GKS26R6[;)[7;UDGMMGE2N[5.:K>-D]JML9_=IKV*02J%Q=[[WL3MHP3K
M^6^(?]\]-^H-S3#;FF%9%R^[KJ=",';KV@ ('%#F9I!;ZF *XBPTHK%>;75F
MZT&9&'-Q+5O( /%([;F1N-]QU5";=I1^48F17H;BJ<&5ZC1WA>"&P250VWI3
M:R[>=INA^H*UGR2@6PTL9;X@1"E [QO0S59#:W<69',%Z+T#6C<UJ[$@7BA
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M311-Y-V"HHE\6U TD6\+BB;R;4'11+XM2$,3F=*]E]0;',D@TD:]7NTVCWL
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M8 4[,"UK7C"T-C9 ZR5B"$0-D-1,B ]#I.>;8#^'U 4&Y%((VHTKNK,)Z )
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M)6WFWS'A3;W]",@:2_+<FC.*AG#@,'O*8@I$"/'RR;N\!-*A4($.*7D*.V:
M46>@D-"ACS%L)<ZPZ"^4 #W;I ;I%$3'\O_VYHWFN8._O:%3<TS^MVX8)W_.
MQE$'O\AWM5O8:*]-Q#@9H]6;/;UY+Q%G27;T_M4'$IX;YI#Z93?9VO3QS'%G
M#LLX^.833SW4-*/Q4\$ZMGH;=&R=B[P'WVT8O2?S);5$@\.BP3'>A<VZCJI
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MHT+52YY UU+DM<?)O,(U86K0LSD#%8[PLUFIF;-[)\AO\ SP@!CJ?@^L??H
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MK,L PBXR'#.DX:%^/!H(S'NB?7/$*4"/![6,A.R8&4B#4!KAD_'SA"-,X.7
M[*HK4_4-''TY7W5E;KH1U959M*[,ENK*7-V5V5-=F6MR^5Z[_$(&8)]15DJ'
MWU&;@7%S>GNO75T=' Y)T''U[?+Z]NOI_=7U-^W;];UV>_%?WZ]N+\XK5]^T
MF]OK?_Q3N[L_O;_X>O'M_CW\_>[FXNS^^]U:8/<=:[AOV[[AFB^X9.(SO-.
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M$]JG" QP.!VR88^ 9>KQSBPQV)3E,C@1]Y:_+H!H)B6NDI0X*E3=/%,.L%R
MLQ2%<(T<RW(>D30AL<+Q1U&N"I@"<R)\=H$Y\-G0&QP%&LTJXXM4^")5C5"6
M](H)'9+<9N/'?*3R8M'PTRKG-<:HSXD%3:EQ[.\ O)MB !#*1L6,,7=,-O:5
MHMV,?7@+X@"B'G&GS]_>U-_D=.PDEMCX61-! H1RF"/#7SS]#([(XOJ\]1=/
M7[0'4*PPQY78'4;KOU_ S3'Y_N/KWF&TTLY">%-2K]WI+=W4M%WDDWT?03Q!
MQ*($<Z.A_(O4^D*OXD14T:,TH5.4+2%Y(_/!<;G<\69B/JA*FP6N%XC19R;
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MW_@!:SMF548_;J'[S%()]Q;C(^'H;JA6V-1\>QC@O$WN'J\$*.9AL[E^;ZE
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M+>T>@R33]]GM=%G61B[?0:_+1/1F7>^TC#8C>KW>Z ')]7JM$]'< O.>I_O
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M$%9[H>G#_8N#_)5G1[ E)J7=!&.+>E3[=W,*2O_4\YP!94?P4X/3-)?@N&>
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MVS7'NX,]3)2<8>B(P21>#GT]VE<PF<6VC6P7_N"@9K%WMJM_<%"S>#!#5<L
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M4%X^D,XN=,J<3?P,X>.U+;@ ?FG[7R"H!,_@&_%MXL.'CC5WZ5^._<4?_NK
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M-K&5)S+%>LQ3W@+,8TQ_5"'J/72_AAM+8V3>@EBPY OL-XXHZZJ[=]D=_@8
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MV5/YS#+:G/F:;AA1JEUY24AS=2*&U:V#@!>.&M/#=NCPL@2..Q0%N K7!9\
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M'XJQ-A-D&YJIA@%TB_#'^O?%C!+4YGFIUU6WLY#(9VCYDFHM7\[A PFUTY9
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MA1W#-.^E>)WVZ,K2(IJ:U)@J39QRF3F\K#.EK:>2.5T:+%45QC9TLR!U7&4
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M9==%]TIXVB^[$_K, W-]J3=O;FBB9S7S=(%X8"%;5>*?==$=:N/-T]1%VH,
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MC_7E!*AC\RRA&9Z$"\4PJY]"K,BHAF$(L='KM((\&XC4#8W$=#F6DKZ^[J/
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M8J+Q14(0,V5=)83)CDR[EJ;CXH/QD>]>U*JZ#N++$%-2-"N P'ZKO -XLS)
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M1'9R^"78).4DX.P;CH>+>GCC)V8L)7D6E,P(FIWHL\S^G[*O ?(G$/$J/B
M "@@RD4/@&[*OR#._0>@Q'[V)LJQ]/!BN68W]LIH=2^AP?FR7BMYX1P;UJJ;
MO:;W(R.C<8#70)F]NR S:T)N1,;%3T4>$QU004=GG;VGW\.V+>PQ(PF?W-1(
M0H6]M-[\V2%'O2:?SGSB@?Z6>B4P!P]@!K! OS !W;]/A@*FDU&_[$4G7]=S
MU,L.X-$VN(JDCXF)[NC"Q#]4/4A)5@UTU09&6+_/P/5RH^07_1K'X9Y:%U Z
M0)'[;BQVE:$7 UV3>Z5 3CD302PE\N6+HV4<4=/;\O*X (8?OH<.X2[Q8[U/
M%X;ZR?(EY);0?-$!U(2I6.4-R"D!4/.7.K7_!B$)(SQ<?@7P &CS_<>::6IP
MO'-P)HKG"F7FU>$(B*X0\,3I%CVNV5];>*HV.$@BL;V98C?*#$:%]9X 2AB>
M[1O<_%W3V;4N,^DC)>_[/+)\7?H]24/-/==6G#NI^XH[Z!,5+51 T@3_!D73
M6)'M@!?:082^0RX$6%F_Z7XUU3>S&O-3^'42*7/3?#)\$WQ4HPDS_]U7=TV$
M<>(G0UTRL!+@713*5W7@2SDR-G-UB*GLTBWPYNSYC\JM#EKJ3D*LSP&Q33;2
M.]#@(J6/-8"J-,&_'!IZNS[1K -MVS$5W2T2#X 6?MO;]ML6Q,5:A28DLH@+
MX:_CY/YU@L,]>[4@ZM45*2FY:54]-7C+8.OE%G[BNBMY)A';-9U0.U,\]Z_Q
M"75CT Z 1'?.R165_4JP]W<O@7-]X['?ZSPA9EGQ(;5S_L6,2.U9Z1J)_<':
M8) K"V^_9!^Y[%/AZTBQ\^VA)]RC+_NV^RZJ7!#61,-X.AG'"S;$ALT1 C*/
M;E D#Q.=0$*Y.+)@,#AWY;\CI2)'(4=ER$*R*G^.>K8?RYHU?9$\,2U$JYY]
MOXML@8XB*AE0S1<24=WA9E[5V=P_K$P EIIZ]SM?T39ZH5ZUCZ8$FRRB],DW
M!O6S#.[SU?("LV,;E.%\&NQ0%MK:Z)'X(;$H^JRXE[R;!;BPK/@249HX^@*;
MS]$"6PQ<-L,5?/961S7V5C<5?+X:T7\L ^4O\?L;S8;="%MMX<V:W>\/ ,@-
M3!7(/SW#M$Y(UY7>!"@C%1R>.._ <_8?@.E<G,R=?PI0.$K<V;.[V<L5W@]
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M:.Z!^?H>66_#H5A6G%44_E[N/$N$61V]D6W<X*>6M7>0DKH+1BS7*^M>#+2
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MA"S=AWBQD#\7,J=62IIRFI,S3>ZZUR^3IR9;QX\J#\8G5]9\AE>+RPG1DS_
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M&6::!:9*M6K7>,&$-;^(0F)>7>K5G=Z''W4DE#F(FP<@]'^7 E';,Z/'#T#
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M&/_01)%5TU7T5KW\(9(J=Y^X?6[WPTSDYOC[^6NU=_:NU&%JN93STI[;T0^
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M^&V@OR"5<EF_RY[<_<W@%1S T<AK%NU\ &I&#^#K]E2]K30G_GU4(=F,)P]
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M*K'I$"-L'^%G@4SS1V2Q9LUNHU6XSP&,?KIE&*45..!_[GGVA7;[G[^GNOO
M.G,^BF4U)W/Y]5L4*;U!M=RX,ANL$6+M968:)&&"SB,QXL2<^R3H_Z-(P:SW
M8+'%31C7(8 PT,1L)B>K?'OT#&7D-_ESY$^GLA1JJK[/J^)SK!U&-98=RW,7
M/J2<D>Q09L_1GN5'4$&DT$E.@(\B3@\5M@\F(IRM/@>+WY'28$]D:B3.U_I6
MW#.XLY4HT6VBAIWGD,^?S/-T75%'>O%7RUWL<S+2 Q=Q6O$*+FD284S0B!)
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MZ+U =E:AT6R,P?P<5!@'C.N?'TJMUA9#;OBH-?W:0<GM:3OQM#Z6=]=:4>S
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M<IX@DE"#FNWT%GAC%1:QX5:U4;<CG-J'-K H?5Y&A%# CQ320R(F>&0\Q$;
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M5<;A'7"VNMS8P]<G$2+-P,+(O&E_:)QQCB*.1LTN25%1/BHX(":P" >@%''
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M.P.F\5S/WP70Q%S-GIQ?7%FAP']T\ :F+SSA%N4SA'?Z?Z3KI94]_5ZZT4"
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ME <J2F)VT_A6^A>3UR<_%J;#G3(GNKU GKJ@^!WQ[QZS/Q5;DQN_TNM<'K[
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M"0<\_GA+]B5)^/GE5=0F^# <-I!4<"(:E+;[(BN4E^I1J9G>:(.ZP\-6!NO
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MV>OW_.\?@"=J2JI* #0T-(#%GPOP&P5X"<#%QL;!QL+%P<'!P\/%?T1*^(B
MX!$5R=/'I'34#/1TU+2TC"Q\[(Q,/,RTM!SBG#P"@B(B(@SLDK(20C)\PB)"
M?QE!P\7#>T3PB)*0D%+H&>TSH?_/XW<7@!@7$(=)C('&!$ G1L,@1OO="V
M -"PT/XQ /\ZT- Q,+&P<7#Q\ G^;( ^ :"C86"@8V)@86%B_ED-_+,.P"3&
M(GDF*(_]5-L2A\F=5.A30CXNLT+==S*=R6,68:OW(7CXY!245-2L;.P<G%PB
MHF+B$I)2+U\I*BFKJ*KIZND;&!H9FUC;V-K9.S@Z>7AZ>?OX^OE__A(:%AX1
M"4Y,2DY)34O/@!04%A67E):5?ZUO:(0VP9I;6KM[>OOZX0.#0U/3,[.(N?D%
MY.K:^L;FUO;.[M[)Z=GYQ>75]<WM7UQH  RT?QO_CUS$?[C0,3$Q,''^XD)#
M]_EK S$FUC-!;!)Y;1Q+]Z=,0I]P2142\NN^XS$+ZQR36;V?Q"=G$5EE/?D+
M[1]D_VM@(?\ELG\'^P\N). 1!MJ?Y&$0 ^0 5[><>.@5"\O%A\T9S! !51J[
MR$(7(BD![&">23VHAA(OOWKKM_2G=(T:W%A[+ZBZBJ:/7*I!Y*;#Y WI.9:.
M9 ,,^FM1CN[ #D4A51V)A:60K]%UUL$X'1Z?>^?2+(:+?3]>GL[<#X<E2AC(
M[^7/D\@><Q8M=R&5-12M=J5^^<?TINJ:C-N6O?J$1*S3@.W19D)>\OD.R#J!
M'AO'F4PC=YD=NG*,O.L&AR2!#Q+Y)2%;Q618LUVP1LA[ MR)%OIFJJ^WSXL@
M37'V95PBSE[X0T^R4AX)ASB:JD=_4[0?+.?:K]W-,:5(7#@2WPXF2W"/NZ8/
MPO^6L/^"0)%M\Z+0+0^KH&+)C/5KH9#:W=(;W'5[QAPA]PG_I*ZOK>9?(<FM
M(3Q*<G5FH@TD'LVA!@.7-]_4O ,^%2N2Z@ *P!S_>\^D]['G+NC!Y&"-[F@P
MP(13'%\<XX\L=D'.[+]8WB[0F[K>\2/;1TYB[MSCS"^*F_TGSM$<*E$:QGP7
M@4K?K6V=V6*,(U=A)4=8XN8(YDF12/YEMA3M=0VPF^:5WE@@S"X[^X!"E*,D
MC+2%-/B/^<<F!(_>H$\:5=7 [VN*YPG\/LTPI>H[DN:_^.1K*[-Q=,_MX%DR
M+>]6 .8$+-JUI[V,<$(&A?+RYQCGY;[I)"E/"3LN4$!CW/CQR;PI,-36Y-I#
MO9[<:GF"?7XC445@]%0XA/(T8./!RRV-:^YV,5)IF[#,\?+$^'I;64O\@-P@
M 8CJM7M/C&1G3_2(+I.0"3"HVHJS6>:<:D1GHS9JA*P/G*V0J% ILWMKHK%3
M_31[W<J6*[SWF+66M^P54ZMTW,\GZ'E>ZR'^_E-.)JQAU9;. ^*J>&R<V@OT
M,A?((7FJKI_ZAU($::99].4TNTBY6)%,MF1C4Y0B"]>4\(V=HJL NJI$%PY=
M@\F<1NEO@,NKUK >.Y&(A^Y$CZ>2=DN-GOR?Z*5_G"!: V0IM&KK(6,$MJ?V
M+".T:4*) NKD+$W*M!!X5#<R)N1&ZFTD/ZB*(N)'*L<6<>Q0<=@+ND]LN3+F
MGX8F1Z[MD%M7>L>>DS_Y2XW&6C_3;JH3?HUY0/A]WXZ>E;?$@@6+\GICB/BG
M0 ][XT>2))"*WP&@,=Q+N.BNE-F72_*#-.K0OO-J%,0X)*X+"X!VJ)?63<VD
ML44@QCQZUM[4' __)@U[QPN3W"XU^3C[[C>@ZC=@1)+(Z_PNT-7@! B)A!@T
M<-.U1AJ_4M\(^\%)I\J^G#=]WI;YD^C:SKL^4*E;EO>E*>MXHH'"D_ ]<3?<
M[=)UL\#M,,_,NQ:^4NASSZ_D!JIF,A/8 +<B[/58CS[Q!V(0_X$!PIET%ZL^
M.=*Z-46@93?%0FM='<D=9/9),2OE",JL95V^0QXC^-";.QASX]"5RJA*=0/^
M<?Q8 NZ_)V()<EZM<[?VO^KT!,DA;20=LZ*38E>.+G>1C;SG433*L(  FPA4
M-V@-%4\NI)<0][5F4W_M&)&"=6Z88(()X61)%:*KC6-$&P#^L*<]T>5D+Z".
M4I;^$4@]=*<P+7I7TMP\LZDK/':E0]NDTK^$<I.RIJM@=/2..SZX3AYWOV_8
MH,GWNDP;A^!)NV=9R_$M!A@Z.Z]J4/<?NH#>C?!5&NNSN5.RER^TN0:IV?]Z
M=LN8.4HN0>^:N>DWONDZYN/GA\HZFZZ2<ZSP>6C#X>:\'K-7I^. <QH\(!H-
MD/,_F@<D+L[+/W#^!C!\9/D-J&W/O>7CZERFFUI6M1%S,C%-;O/H:,D0A+9>
M=E6(0<RJLI=&1XC3-UI!9U9*7*/!PC )',!['"?@<.IW^X T15)MXU12;47
M_\[3XZ/PV>&YKQ>!MP5"W&VQ<QHA,.\6V-3PT7QVW.3M$O*Z?QW8VNI>M*3J
M[I"?NR&/'T))M" X>A,PEP=$]?F >-MWZ*G>].\%1:I\9TBQ'5\%46^_BE*&
M])ET,Z>O+:YP;G=Z+%Y5/6-)R2#BS?J8*WWM)$M@/&.7-OP-UGQGZ<-#6BM<
M2A>!EEK.NG046;!B-.PCDG8[6O04%6ZEIBZ<OJ%_CNK K7DU*R(K;30=&I;O
MD&02@AN=**#\VN*DC\*$/CL@T#[ W2$1:$P"FM_>8*?[AG:CSQ55<S$/K,GO
MW\,.Q'@@H>,;\SGC.\P#R1H/<HU'X&+>"NC^!J"7-?X&P%@@<N&VS2D;=;-V
MCD7VK!#<M!$%>/-SF[=#;0%+!!HSHC3J=Q6*J7L329A?XG7E7H[+(S+DPCW;
MHH:'6T!DI>V?#\XZUPC@T:!]N(MR,?VDD:3Q^,JNM\FW7E;P(;5*6$*+@MH
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MO.@X5[!RR%4_$%M#"2HZTE'6G:KKY*"]YB/9[(YJ)A#:9K1/ZO/H#$R^[3A
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M()O_C^&Y<(DQX &0.S]24&4.=F5A+M)^Q6V=+D@,TPF;S6K_IIH-0PC]5TI
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M/OQ%;0W/+=$L__WR/V'K/O1)M.0_&#^EY!ZWOXJ69F(>-TB90,X='N\'+&A
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M./%1(E5I(FNBY',P"2Y07GBO"YR%C_]1E6/ IM;5Y=6G,DAW+<.R3%KLTQ4
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M?O_7A$%8FN1WG[$UO74:LN@MHQOOKAL0SDH7&67IP<BM3Z;^$23G!7*^/%W
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M[/9@"4XGTVR.>FJ/&RQ^^@#8+?-OL;BZA0BA7KE6/@ &2&O>HQPGT;8;?K4
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M)^,-;.Q8K=O3[KGUYQ[U4/W&]/+*WX#,_A9+[,F5;B&0? =\\> #86/'4\.
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M3L;FY,R*?*V+NUP=Y4MG;;9^C>W+MCN*GK9#Z-^M1![%"_.J*7A.#:PI\TC
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M*#,52>[@\IE23FTI_S;[1#OU]_MFH5J"-@[;1KJ'&VH>*\N-MVBW>@ZN7XM
MXL'SL\'S?M*B4MW\3WIC4Y_\V=@8#I!08B54&C?AJ[\U=V8)#WT_'JRM0^;
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M(7-DP;A,@R;W-/Z7K,<Z=%;!$!?;-LY-X_>R]:;>_.T;XO:7![@_4^S-G6Y
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M@]<;.$7%_FI>G%-M+ER??+W/BA&14/ZIRG8V9,+3I?6^S1@CA1E9-81_,35
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MH E\]2#)%M^=ZZG)"*0#;D6KEVALY/O.T]"R:ODA%F5!B@R& X$19+C"'B#
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M/H[_5+8C"YUN*QB%^%]C$I.Q_>DYT/B,V-&VX?&PONY'F<^K(4-=1M1BFFV
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M%E+N+^%'&/9@MQBF_93LCXGWV=IO"W;LB+-C\V'SV48$GY-/<+4(#S!X$&5
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M\'USSK%-/<88NRBZ?>>(K.%;&UD7DQY&S+_FV7K9!H_R+X#D3VGZ\]8:QB5
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M_&*N -3_4^?L_RO_5_YKX:&/_3=02P,$%     @ >(GH6E>>_H,;*P  72\
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MAQ9!:4G=KWKZW@(JY]=_.MNZK^Y=W7N;3+!]R11:8_/>+,'I8*,"<D&SY ?
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M#3>(S$GM&;,8V(@7?UUE?XR]+8N_/NAR0<J'A!UWG6\5FG$+*_Y\SGJF1/3
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M(Y/Z2_4/JP<4.[<XAL;?^WAI]]C&4TGA3/FG^KNOXJJFB?L&R@.P':J+_\Y
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M@<Z^P:J58]3'.1_7R:;AA_-N/2@^\K7+2-;IMFFP_^XKU]<2\6*0R*SV3'S
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MDKOKJ2UY&WULUGSVCA%?^/Y+0X=0+]&@,1%2P(;^/K(LQT0!+N@=5>^_E H
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M.$+(KXF2D[+)T14U?'>:D,;6@579A $-R1/MVHWJK#JF6,GU4U2IW+!5.9I
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M5'<1:Q4[I^+K/-NE<[^N;&CCNL.GHI!6M<!=2UK[=D+-.W;7UU$M8@<B3F2
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M<&UMZCJE$BB/;AN0^NLD\7UY7I<WU?'W,+!3YV^;HA[@++YDW^O;R(X3>NW
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MX9H=";BA%WGE*?W(VJ.7U;58IR]D $)+.7S0=KR\&(D2(0,,VYY.1]/[/63
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M!Z9QY2/J8!M!H(I?7SX@3F,UJY8* A 8#(IB2RS3]UEK>7TD[!!V^&X C<&
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M)HWJ_83WT#>PR3;N0P^F'4A8&67%T>74ZU<+PZ=Q+O"H9+_>AJD>?LUGGN<
MF9'FI-C,Z#LK1?>CU5W9V"7R3E\-GC!QWGI@8:'PQ)CW <MBY$['*[Q=@"W6
MZ50/+.9W*<Z@YM)E]T*6Y&(*O5H;C8#3DGKY)MPKNH[KY=)MM4C7 Z'@0N]F
M]M:03'E89+BLG.#7SV>\:AYRJ@B6,HOP-Q2%BT>K\/-_B^N[DH"/PIW[#>/
M0_)\)L456JHF&9#M!QM:\ %D0'XQ'('].@(>R%6,_ A8# L-3OO%^UP.%%CD
M-FJ]>MNCS:M]V;[F_67)DU]8N0(#=#=T\Z]Y^P;/5[!Q13MQK9\2%S2(HUN4
MICQ)UVM5U\+.T"#^]5DZ,31*Q<\V-Y+ 8YFO"!\=$\3?H2\N4N'QNY3= SI9
M;:6_<V*.=/%2E>WWRE/[D'G448EP\)B*=]Q4][@-QQM,7T0O^>*R24Q&FV2
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M<CYN->%\O6].<HAR%H[.,>BCS'$9G -<UU'S!S"+KM @%[M!?REK>9[:DG.
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M768?#D&!D%J91VS*OP<$>D1*@AEGK]5,_D1#C>E)#W>H)!-MG>TUX]ZJLJY
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MN9)2-T'X@Q6-:JEG'/"6(D^"N8[C2K;>?O^96;UTP_OO9J)MV=TFA\\$V8R
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ME<L*L5S;'JKB\.7)UC/&OQB9;\E_E=EE &,3\ZPO :E_(QCQ1_/1GQ5IRD$
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MFNX$Q3KY/(1B15S.Q9Z[8F9#J*BG#K!<UZ/4RN>L<E@O2\=6=@ ?2^&4*1X
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M >KI8L3VV7$5<)#UO*\ N\ZQH>(*S9H+]_UT@EXUZ+;9CBTA\JH?O40T_"4
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MF2Z"PZ"%X=QX'__MZ=,/&3;+RQS%IU7<(U8MC2ER;4N>RLWIEX?A-8N+%H0
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M(NJ;$.=W5F#S@L!CX[F:UQ#PT=TV$J#6"/8'7DH;KUJ>Z'59QD_LF#C2/E^
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M>^T1!/)X:[GB=<&,8UZ7VVO 59U&-.! B=((YD%LK 9>[S/47EJ%R;P))YN
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MP@7EA[>?..\FVL(FFE@YKY,E"4!)_)WRW^RBP+\>2"HD]FGQN=ZU=M 0KA*
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MM><X>BJAO)SC.I*[N 9)=@D7(&SV,MHZ7 <5S]^S#WQ>+390HS/_(5Q%/4O
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MHQ *FR(!T.3E;8U\1T5#/[J1R>=L& Z[4U8Y[4V&_L4<LNLY_BF14_G]>65
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MJO72H%4=AULK!)'_6"#\O@3ZKPAE#;'>E21;8*UDD$<UAT<Z5KYM+&KP9"W
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MN4+L2,QCAF2PXDL?S$F28J]:O_T5Z&^Q%6O(1CO/:.'P_P)02P,$%     @
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MN8$)E36/L&:TV9,L*!A'D_'U; ;$:^=3!-KUH2GGP!T:\L@,9L@CR4+[7F[
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M.0PGVW$Z2*S&7J:\ H2>5(,+%UA*<^;-%VM6"J4F#!_XHL@=M/W)B8#I=HZ
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MBJ5G@BOVAP&(V8-="O%A^[ TW*DTQW'#<S3J25"&PM;HF<9ET:(L._%U@V6
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MV_H?K#!0!QCJ\I0;Y:G4HUAWI,!:I$(R!^:^FLV<GHUFF97[2SN/:V)8:%K
M*8^1+QL[EV&.H^?K&>J/+@2>7$)DTPU4"K3IW<Q-WW;8R[ 9;=!L#IF8&]0U
M"UE>H5NFI3@971ANMBIE_5R/B"L4Y^$\QH@G>AE&1!(8T2ZKF-/)7_$1,_3+
MR*@9T)U%\J^/<)V-6TR5,6YCN47,M3Y9Q"C[GRQX8%S\C,9#S!LY==EGA5/F
M+6R3&Y]3YN;U[P;G.VBWE,[S=5G*OZW4?TR,6RR0<+ G;OB9!C,OMEN'U*VU
MB\3)&PCJ#A;X/\[2ZZO ]>6ODA^C]R/_QZV 7:U_WPHXA5G[!\5[D\C1;34
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M'%2LZQE(;9\59EVMQ%0Z4Q@>D[$L#]I&T(;^/6J%"<DOHE!JG*5Q.7_/Z(]
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M[&NA;)FD?8&6\0W[$K5KNA:E/L;DY_Y-*1:/\ZN5]!/M_5LO!!CB1%2[='(
M]G5-)?HR7=F6Z$#W<G18@J)L[&.4S,2NT.W:+<)0UOEZ16+F'<)7(N"'.6=P
M_3P8/FP(HU%3FHQBYA'"&._NO8U/:;&&QE3)]3JVCBF#W E]Z%BH,)%S _2H
M FV^D+W ^T48.K-]>M[]=>JI:FTY3G_C6&#8!\M!'7IVVKZZOZPD8!0'1'0A
MCVVKUZW]@9J1YWD[@+=$5UK546]GSC&J)")W$U3#"$)HV!$"K2Y2AW5.Y]X-
M4*&]858D]<\PL<9A I*W-MLG6M6*6_Y:"(X]ZYR(>1MVNM*^9GG?Y\*E NL
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MA#- ,D$(Z@AC*86?ZJ+(<6WNFEV(8H+O%>]0W3%F&'8KW=S@)Q9.(DS5E-X
MW;,P^G3!>[*VH'("-2H;U_6$,EF#9D"D&P8DD&.T5:02TR]]-H/,6S[BP;7(
M">+N[O'&.5*&43*5#^0<8??ZIB>];QU9^1FA5Q:*UN00[QFFGYQ:='M:/WR
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MUQQ,S%1*H6J.$CP(P*^+T7W@7# N&B>-3'F]CBP>Z!;!<C18<0[]\VC#I.P
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MEAZ0:<(J9&1OQPYZ SO8LQ# PP=8B:X"9L *">-M?G^QTP?W H9='D19(MN
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MY1Y*0%HMHDKXYS3\RB7<<>K74>J&G@1T_R/^C3X]%"QX3-P:ALKJ"C=6ODI
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MK.2W0<6V3R2H$\\,DTBQ/_'<BYD29SWSOP&%(]Z\50G)O\PW[5!"RAIITZ$
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MZA[:GD?3,AHLNZI/P1YR%57^"D<9"705[ F@H-;;6SQB=0%0YCA&V_0:HXO
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M3]:A\EY!5HH\%JI8M]^QL:4*C?*7&1\N("T\1^713_$2U$^LPP@,'CQ,%3,
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M\"A;"F;,M1>Q,GT!"/, 2GCSE$CI8_P3MM'<X8:^TCA=4HK(61AF;=#!VD+
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MD3RG;B=E?6_EE58U7!-R\.T_(BQS;49V_3]H_P/9_S=@+_Y_(?M?P/XO7*,
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M(I:04VS@Y\HP[-]'BMSB["HG:H/Q/LQC&,XDB-N'A]E,&R"QZUIE[2;KQ%@
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M1C9K&(\XL8>?!4A)4;TA>+()&YA175>&+!%SV<#;G78?*G$T>7H\ZU_J S9
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M0_"_4_!R3)_]2WF0X\T!U1$Z&F("!AI@VO[SX+=%6FY0@D]-WG#-5G><6.E
MO]?\?HAH0GTDM]]JTC@J^G' (RL-L%(K=5G .CR\GGAK^Y$&))E7;"VX-Y1$
M%%'+O*90 R9[=^$-X=):,5FSR46GG_ZB!GA%Z9L6]C.++Q2/+CMT?2Y_I]S'
M1^ONPB/'C;U$<#UX]\"56XSA%*O3K., &9B+I/.[PBH*P+*)HDOA/A2K^J;R
MO>;I$Q?S*LO#J:S[,FDK]^=%<08&FK1%(BC? !L-BLZ9,5L +6Q/Q_E%$B4R
MH45(G9\<+[QYY<[]Z*(M,F@[A4\?J1ZOU8!$)?B&.FZ5D"RO!KET7*[W&F\=
M0 <L^+%68MF ^IC?Q99\^;9Y[I,\<W%;D*@I\=#M0I4QJ@RPY]?R2&?.N4R.
M"$&?&4.>3>V6$P?!46W8GT5=GY,U'<4;"TFQ+]/U]&NJOVP'2#=<SBVEP*7Y
MQJBF4EIL8$:$# GXISSH+&:B87_[*$<OW"C.:8V?=TD5#TE$!L4][986%9G>
MP:,((ML]IFE ^\5.G\6$W>GM1;SU5DFJF^UB_5BA2D:H[R\EVVU=UO7!^848
M ;33-Q"0DI!=#84R3$+.<7.\^NT<H1KG$S7N#(O<*DVS>J2<U*MR>'4!(4!D
MNC:(:]EJ[YE+%\Q_Q].QG54F1KI_*0MO*E:50CM0J0D&5KXY3X,<P4OFCE%H
M_@@RF@UH9EV[N^+0JKT6B8=&<ML[RV5M"PW]YHR,ZO75=IQZ$4J&#(OWU&]<
M!9W]_N_TYVEDXZ'G.:.-4Y-PQ5#47!(;D/Y4&[$;GY0Y(LJ-/JGBQ\0O4FE>
MRU=FK;!\R/Y)_A=*/Z?:)4<ESC2+RB>Z%(Q8<XLHJI.-8QZD^J0TG7(X4G1D
M-V%1TG.V5E0L"G.;)-[4W$>L8?T^XD!G VO5CW1\9B=.%8A)!)PUT:!QG]3Z
M5/J0F%9J\9'PWDMTVL>%2A P=:$.&,\2T^]_Y.E->!)9)/D]_N??T1X_L_S#
M33X%,@R+"L:C.S],&F_*429CW>V6B(N)74GWD-S(7F_L2=B<91,;*#W)!OX=
ML^MA SBPL-UK!$E"KQH#+",?,)T)*8M3)2@=R?^G96]-YP.4.BY]TUYR*QX:
MLAV[M8ZO9652QF:6,+]5\Z^-5HG=KINR]($4+_#G<?I8U57:35P/CK7BR^)-
MB1"P54Y)FN*"O6$,5P;^"9RYO9$MD<U%+$,0$G[+OTS0%I5RC.-Z$8(GC5;.
M5CT+.&OF>;,7)-)*(93!]A%[!0X:Z7Z>!L/P<-@=TK!$3U@0]3<; #ZGC7\>
MN7HU2) Z)2TQ/C17-5=.!>5S2X!@MK3"M*ASY5=]>:2.@TJ5B35-^E8)0^_W
MA\8-0*!=_T4ZB^O3=M^F6H)X?7UM;N-RQI8!<5>TVUU7?/^6""CA[PX;.%,O
ME./V(ACJD\"_\MFYQ@#-2LT2^J@QER:6^-!?8Y&%>K!N&;JAW$J6F(HA5B.X
M=(<3JGTVZBMVB]+O'),M]-2S^U4ZW&AHT'FKQFYF>H^_:2+<QTPZVOQPF&?O
M[(VX0,@6C@W85B7WO*&VX &)ER9=Q4TV9  =U<)5"GK$NZS5X!@WC+**LRGK
MODRQD?S4]T_VJ)K,ZGK5,V95W^^*FO/^HT7=G;<6WZ'VS?$H:[,%&%/X]+U^
MB%4>L@7+WZ /,66)K>=3G^2XC))Z06FC3M5U'JF#OL*[D!_9#6Z!BCSGC;;*
MAD*M'ET^'C3>&#$M <_3EI'\XY-$=V$#(&[7&DVO-M1?>:NC/]Q7E[7.!Y/-
M""M9[SJ4\K+RGS,4JT\_JA5-L K-3.Z0ZK(0,H_C%!!']*?H*=FNEZ-.9<X-
MZ+JM0@6KJH9&5G^O#0E?B-8MO7>FD#IQ7P&.,.C54S;T2XF3NVS^(%GP@Z+=
MO#;5:.\VDF!9PSQ58SMP+1Z%PXBM!T4@-2S#U.CB:V-MC.KO>2ZVQ]><7P9
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M3P$7$V4;?&B43(^IO>OA*O,Q2PA0JZQ<X,=/._:=[=$HSQ0ZU5<G129#WO$
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M7TW!"5K<U.2/"ST(>2@@?@<@QSO@-&^Z:YTBK=0'99_DENJ4+Q,_[YC=[$R
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M:G?P&_YA$,U/Q^S <M-Q&/^'P^L5=JS,CL$KC!=CR^@?"3@!V:.*-HYFA ]
M(&R(\Q055UB_J5(D"F1<T(-4C?BZ3M8KBZ49N>/=NB!ODQ<<I=$M1_M.#'@=
M\$XWZR)-M)GR)/(J39P(9/X,AY$B8U7L XLX\DZEI0&:L.M;F49@+R36NJ4]
MZZ,)\C1KL\E^ 7?/1:KQMTDW\=[D'SKPN==GWN-ZI$T=-=C@VX&6$6G1#MJ@
M989")(,:L;BW@+KF2(B/H! >&F3G/;'4RZ_R9L!55^05H=.W@2WQ64ETT:U
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MBNF9'[69;M7KWS=)-2[B:2G>,^G3U6?:(6TU8+7VZL]J:C\EE78G@\*$;*F
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M=5INI 9V1,;IM_MIZYP_=:.!852BHNC"UR\<V"7)/,B6T^1&6,=((G(.KDX
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M8_$<[Q6O)D+1K9:EQ6\<A5OT[S(PG3P8K[7PU=:\B]][U2CO?[,DW)]CJ#C
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MT8*.URR]:]G" HTR"KJUM4<ANKL:3?$2]/Y!YEWNA[N)ZLU?TM?,-](]^)[
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M;XIEJS^Y/S][3^TQ'O..L'TNE1-?LU4QFUJ!15@Z5?;S[?V>3Z]=;ATX0W0
M^K=Q0F_,>X*)WAGR.C3 ";?B4@7!%T:;/8LM<'4:8(]%=IY;[0!L,?P>I-:)
M&);@O))\6RW.GXK"\T*"$-(%YN_ZU5[/-:QD1CR!DZ&EY!'GZ@OS/Z^T!T7!
M'*FO,GO Q_8K<A\>DH)*_X3?">.%,I!@<)( :$(<"ECUY"3I]5CDY\^$"13H
MIZXLN!FX9A$PJ*'J^W+B92*#.BP\34E+SYMINCOJ-SII:"'5^%MEK660OJYV
MRI90)BLYW.5Z>5@R.5M8TA::67T8D>Z&C=IM&/5R)]?Q&.8X%8;^'%'3NQ(
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MN(L;W-?3SE+Z35"/Q_%_ZS12(D'DK^P;7Y<8+GD<?**KCW/\"ZY/MLB^P*2
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MK8E=.RD]+W'1VC)P8$@<;[36P3CC$V+>D@?S60'ZWW?RNNH[T'N8AI.)I7W
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M]E8I>>->2_-[&"VIM?<#PO?.+2H$F:W0GVS*XRSDU9?E-M;JIE6+W'^GSN@
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M' ,.$Y6-1:I%)+ZVWU-D-HST#8JP=.N059$V"]U#@^V3/Z:0RKB_]PH+*6Q
M+KWH3L\0SF[U3&EPNCL<)*#GZ>WO(^T]B;5YJ9"P& 3TBA 4DBN.C5$PM7T,
MXB1<NSN1F.<M#5AR&3[P)FUU;'U8-+B/P84UYS(I3VC#ZR<M4EXE^HN*U5K>
M=%<GZCD]S?K<4SUP%=B@EJ:??6B;< OS)EJ9ON3L7DO+^<P7RWU)&^U1D1C'
MD_@H%=;66Q>!%^-_Z/BP+F61D_B<*!U>8IV#&3DZQ_7?29+J.QV[L..\&B;P
M@T]=,^A%:1]Y$/_#=F1O[;8#\FL.<KYFZ^=XMTXRSB]R'(<Q+-I]'4 ^(\86
MK4A%RL&S_]#U\X <8G445[41K""XA'")EX;617G-CC+<!W\:NC+))B\Z21)/
M79HAGA[PUXQD?6Q^GWKT<Z0PV;Z^Z]N,[10L%-A"WJFQQ[2_Q]H*Z#BWA4:B
M:";-&?D%I!M Q9?FJ BN+L\*,W(<,68+6J?R65 +>I55-?<#>:9!/A_7(9<Q
M7..QKO'^!/OC?9X[2Y[W&WC>O!#GSY8TC\IY*%]@);M#ZJ$EU"D+J+T(VR]-
MU:<3MJV6J;\LJ)1F<AZ'6"$N"T5.%?&44"6)0G,-O;G<3?54 /%:@FH#*URV
M/W=T5]V?*MG]$I>PFFC.X3 YATK<.GJGVN0+\;LU(K_F?_\F.=*?JKDBA(<Z
M4H)?GQE<+.'0^[VX5^I_Z/@QL&?C6(8S(^K&<B^)V/;>)PBF:$V&);F Y\-U
MTPPG00/R&KW;I;931T7H_LJM8#*F?&6G+CJ;SP^E7FX-!-HDMH<$@RIFEHYK
MW$=*\ZHGD@NXMS3$25)MYOHR\FVV26;98XO!&2=H,_>?;G&%_U!S*,9]RE3$
MYTC!61WS6H-'+2<S#YWRWJ$[M466>-7XV_AD=;6DRX*XJP_[#JO>SAN(& I;
M' X(-4D."L79@X(&DR,%EK>D:W?L\1)I(MM:07WMS:A*O?D(A8$!AKF]!L4;
MI4#&%_?O*]4B%]Y],'H;^?EBS$T0]Z@A3N_?O!ZWZW_H((BY,=?&23L%-=B3
MD56WWNP9+)CHV8Q +T*M]3KYP69BZ8/0BFZQ%$\47B>XN8;SC@K@,.6O&_WP
M%UX2X26^T1<,0DW+?366'#M%MW0B*#PKRREZHN&:'1VX9K):2^^\^8U]9ZH\
MV>@4+YGX"^-.9 #[\L-/],-2+ ?XLNH&DAY'".8)O95?6> J5W"%=D@9&BF&
M!--.^P?.EEN;M ZK%$QO<%95F?Y2'),J6YSTAV@Z>4V7AH%.A?YS]%H2PQRJ
MGH,$;#'57X4_M;>EJ4]HCLB\:]I8#(\)G\FV2WN43"XV/&E)%8FS_M3.5M+/
M-R0VMBDCS>SX^[H()/7 Y ?JQJ7@N]Z'8S]V>KO4SHMPGIJ!EO@>%F:X=G_1
M31B-G@B(+F2>5MC;TPD@_Z'K>YE/7VJP,OH@1STWN&%UO^FO@EA6PI]<]X2I
M$XDV"/&Z'QU6IT5GHA??0EQ5IGZY)41JDFDGKMR3I&1!ADF?Q] 1!*=YJ&_2
M>?".A1>7H(#<H$)!>:]8TZ#X5%JP*2Q6Z4OEL,U:HGGSWFY6 =JW Q$Y>-_O
M4S;/CIWFA[V2#PVR+9ZE0"?9/W3R+9Z;$3-5$>[/9T[=YOK+QFZ^>X]GR(LO
M#O9:?71_3%9T:..FF5%JM\OG%]=S'GJT38XVHY@J)^O-6!08C'.#(VHPF:)"
MPN]C]]-7W]Z27BB;W8JC<8(ON!IV)\_DJ?O$\(O+WY\?=5XVGOJ5$F"/GI1#
MC^0QJ0#1/.IX]:)*.:B?>SU\%9QC0H[-"WK6$/18L*;2^R$)V2\F]&ULM^[,
MBKJS6O1Z]]?R39H,I3ZI&@IJ;JC]60B8)!W!& C?ZKQ:6(UPS*JC5TF[O\ X
M;JJ_?<=<C==,R*E>>;FC21"]/(8A%-7:$E/%,)(E<?+2L$->X<AG"!),6I-Q
M_.E0666Z-01X5I:?]U*B?K:]H6L6(?JS$]ICR#(OOW<=$['FN-B\:*1J*-[2
MMRQK_.KF'1B-]H5.C#9/R3AVI')1CI>-+),!C#25U:I (323\*]Y3>L=\]0=
MJ/,@-,PS"*H#U4Q4ILAF!C^<#WDZNU^TRT8VTZ=F$?:YJ7\]Z.M)F\1YQS2#
M[^X4A2*&\M[N?S5"3K+)1ONWT@UU)YSH%;B<-IM;X01NTK_(R)CMY4MZ#!IQ
M0>; KIMPM3IY],A(E%PAUT<#QH?](B,JO/(S]QWI0IWR;IJ,,";N]^HW)GO[
M=Z#Q,Z,22&H=HJW\]/>/7&H(R-'W2;6X6"XRO-XJC*:-JG8 ),(8+NA[SUCA
MB(<MN*;S7#U!,]V"KSQ*:C2^K%,#58MZ)*:KM-*Y5V1@A14I:O2#UWZ(ZY@+
M&WP'#.2*2;XC9F/&U"@ERV[H<U^:4:FD,E7,I,<H(>;^PTK.2VE%(N<?,#BA
M<./QE0D=X1HOUVN4D$&A5)!X6A)RZ3/\F@,9]T9>#:C*P@2_%\VZG#<BAL%D
M6'=E Z-S+GU.-U 6]#U.I<Y6T7@QL8>@R8P>'(N"7J_<,J>;<^,AH4NC?Q^K
M[4'X!-,K%XLS-\PX<V/A-W_1W$P!2DMTN//:55D4[&M:**6I-HQ(8[A_P>I^
M0;S;?[S(8M21F4)=UU=*+K>V786V&OX=Z\0W6MAW6"Q:EM8KJ(2(IJF.'#]Z
M]ZS/XWZ)LK,GL]%*]8>]F[UW1I]^=B7[(-!F9R?)L8_YJBQ71=0/[>(,;=,S
M\AUZ'U[,(QHC-G(JW30&.C:G2,]I%-0"9)GU<?:*-L<Z7IOZ$*PB5]=9D8Z\
M(ORNJV]U#O$L[1;\A!A<%!J$\LK&[_?>;PQ+X2>*=[6?QG;4[@2X\3)GA7P
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MZK>'Q#3"(@4COY^>1-6C\GO9[H41]GGTV[FV36IN/58LZ/LYC"R]LNCF$DW
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M E.$5<S'OX$@5X\#R.)G-RD&S=-AJL.X;BQOGW*&O! Z.\B(!1FC*A?TFF9
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M'690,$Z=!A*D2?+W,;CF(#3AG_?NJH.5A"#3.*UG[OWI_;(H_.L&>RW5M($
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M;=TF0],9J6)<<@J2WU@49IE@272\^K80D@ KO'TVQJ:7Q4"N?%B58 -2W=D
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MS$1$&!=ZGBFSVKT@"S^R< Y);0W(J'X>VDIXWTS_M(L(=&]@3W6,$T9+6H&
MS7)N>0#AXA^MC1'!BJ0(Q;A#\].RK1@.VM2 ]M3I1HI151>YX?VQ94T?C0\5
M6TN:]85V'=IMJ0_3K:RKW:U=%A\/HKB!E8F%D@=,I0=OK!_\@N^T_]Q_M!0
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M%$ENXSQQLYF#R.=5"^A*+T=0T3,$E3]/."OX2IPZQQ(4 ,:>X>8&DZP^D+2
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M?:DC*\CWU4Y6B,$%]9L]?DXG_%2W>A'OE[(7MR)BLD2US\KX9.P=*;AFH:&
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M=SX.]J&B;Q5%=7CO^70)(YM\.E!I1?J933XVU+LG;C)&Z]TM*(0;EDMK\K9
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MS(.K^7G64$P],<4H@%HSUBE&Y<TEF> 0K"XQNW0"Y";-:)*6O86#AB6A_/@
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M:VC?R-U2:1O%W FSI" CM%-D\W\"&GPD)DX\4=]G(W+?]WBV%I4B=Y.?;;S
MSA.]04P?=T43UPY/#+C,SE=A*C<S#/E3&2K,HKNP#^3_N4DTGVX" Y*,UEN/
M8=],8!G:(D>6GF]Q?P8#]X-HARNJKGT,:-.*].YXH]@%8#S5_6(9Z7$Y[BS%
MVZQ&KBY+>;'.1F*EPJ0S#<IH9\ LF: *#KU'E0DD/AGG  -J3H.CQN0]T:*U
M'9PU$=FNST)Q?&-GEQ<.V\)J2EE7@:K2&0./^(.3%CTVTBZWCI]4F-]W<2.Y
M\JTJS&7F7);BQSO8HCH-.0F.E/CPIGK[))0$C@DMJ(=F(W=K9:DPP<=]J:Z\
MPT"R_^E"<6L(_SRR&GZV.4NBJ71J()AJW@.^XY2$ F7UJ!1;6%PP^G)(4T3
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M2_D>C5:T BU9];'<H6[BAV? E"F[$V^JPMQ,YXD^'U5AN@EXF*@'O$M]Q?W
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M5B[U^=2&<N:0"I.#]JLU[U68N@O< V <<A"'!?K14G<4_C2H0#O3&Y;HB6L
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MV?>B)/QR#W4/%1K\XVI/2:GY(H3R V^!N:D2'VRD.MT^RI$A-!M6WGLX=99
MU$OZK<7OG;J5S9;V7J//-_!J/\VNU&[7>R]H:+1BJ@)->>(_Q&&AI\DERCLC
MW<\C#<GT^)6WFC?U F&%*W7UG8%2,PI2K/_X:+05V7WSJ=E%BG.((118!AW]
MA&18[N0/%)Y/+\NU3L$6[!LF?7]_Z?,IU.>@+[N_U8YO;V46"A#PD>R8<0^A
M*V7S@7SI^]W<;<PVD]E]O!'YZIL#=?2Y"/GN4,C7T4((D6=8D$DD/>07K/*^
MMH<?S+'5)/'SIFBSPD(/UMHB)OF\L,I[=.5)4:(8X+]$Q28P-B[=+;ABLW4F
MS#/'C2K39CZN,/!Z7E)>DX23_9NJSLQD>KC /R"#LE1!G:M9+[A1<KXI*U?,
M[!8(-OU65N9C0WBMF!=69FD&ZN,  (NIBYTEZGZZ84V88HZ-80WDLF_&5ECG
M0(X=15"E>X4;3_9S%^1B#;-"+++7%'\9W*_>/T4IC-TV#$A1=+&&,[3RT05F
M6&2XF >MB]5Z8X:6[T&Z+@!XYP&FJZ<.Q.Z55QJ!)7J5OVP8&K4E[MI#0%:_
M[92/RU(^8MXDW35K<>O@><_%HJ(C/TJ5]O "(!#Q\*Q+DW5>P"Y"DQQ#/#Y:
MW56 =+Q.[%*&93Y]H=N"'+!=$E"_%BJ2>WO^VQ"#3KY!#7EK;X$21&J)571B
MG.ZZLS%)'][MUO\'.?^F_V%X_IS,3C#,\*[!(L+U/B9 0&A Z.%K=I,:8)HA
M4I!)#3(%QHM9YB%R((I;4PAD4C./3(V#7*BN_\NB+4+#T_6KK\W?\D7X&.<^
MJ=L,A-UG[%$1Z_MJD6-\7Q[%;5Q6R-V$)4[<@*OS4T"!!;$UIT^659NQJ%W8
M=O-P]?EPV(S82,L1Z(W8C>5-9:YPHR_WE]RB][VSO0E)M@($R\8)I3'LHJF@
MD>*^1L/G;;ME Z[.3@46(X5Z3Z$T Z$T8QU'KV0V,QV T^2AY)+,&D\G3U9-
M>6NV&AY> I\3CE]38W\7G79[?)@MX49NL?A:K[DF782>;WP/:_+F'TH0=BPD
MK/ QNXR!-<>?D0^ )+_ZCD5=P,..Q"@Q+J! E 1TF__[NEU#!XD?S<=QW<6K
M$_O;F6'B>;&>N+^KK^_A6FMG%H4X[RQS\2V+DP&@^!.V6D\(J1?6L[^ZO;-X
MLIPH5FU\/U'LPY7_ TS(WJ=[<]61,Q> 1E2*)E4*<#.*:8T$ 2O,PS,?Q=9B
MFG=?5\UM*;=TY$4OSK44%CN;NB,[\HH<M047/GLD:DOI,^TOD7C.:8I)OJNO
MDTY5.U(NT]1U>(S.E&=CYD!8US+CC/- CP")BN%@>#4I0';G;B961DGQU<*G
M6?K :X50?\%YA:4'TM5:<\T1KT]"X>4838:S=$UY<GI? <,:N1EO?'<@53EO
ME<SY.,TS-%A23&B6\$;/^S#!G=ADKA5?;"RBCSK]H@3D+K0*M2"0,V-5G94S
M#G)/*.S9+63[++L?W8MX"AFZ'G?4EF,Q@/.0]35GRK=<K5 S,=:N*"\_Y'^A
M9<!?(AN749?/#K\WJ&;RX"7!1[KOH\??98M^1,!\UE'D_NE+JT&OW >Z,2-^
MMMF^U$8\"37O)P=<Q"V0(KG$]!0ETY_"O:M9RUKDSM4+ "-44[*.*+M-PEO<
M(T"<V-+[L^-J4,:^98K9UV-G*H*?=NA4"YH9B3?;W8Z;?Q#L[]>*'4G&LYWH
M'<F=O?4Z2^_%J;1WD>.7%;I(:6#DVI Q=OV;AI;+M?<'(YF>(WC\FGT>R#.O
M"%KD9EN3.?)X35>2)-O?NR!Y-$?2V08R)5P <->)>8C6=*93X0O C4@N\H"%
M50)V-\"WO&E6R@L*E0P7SS;JE7$5S<8NNP)W/!P*.*+Z[D>!OW :?#MTIH-<
M *C/A6J+/T([@L]Z8WLXR&,MKT7>1 EGF(:KG H]>S?>482>#2E;>FL$(>JG
M+PIM$ YR"Y2( \)H%X5<&>>"B3O]%AF"R54Q:-UF4&+:P"SJK( !1A>!3?(-
M->\;>1NZF!82D/('E7#.%_G5F6W?1X"(BH=/].5J49%NRL<),O>'>K&Z3P<L
M,G*$OCT80XD[@-_B'A& 'W$D;M<@C_?^]Z1&.OH'DPR;SBH+[?]X)IYNGL5J
M0;22HYKN70!2I"*E3K4:OC9-,-K^:@W32_R-8H)J NO:IF1V2^*>7\'/VK9U
M<#XS>EITK+8C9)UXRQI^U- =6C"40A9'EA-S",\2SAF]M:B;SCQ.Y:H7-EB@
MFN(DS>)"HX_+HPRL]\Y*8^.RX -ZDJK*?RC'LW&"SY*5A1^?%VBJX4;41.CC
MY51SK5EEQN24[KRW21@EO4-/,!M/6<3T#^9NZH!R2X&U3B/^C:_6]K@N  6J
MOD6<R:$%B:=6JSW:[X@7 !;_H:L_;$V$\72A_$#BH*A@OWO;)ES]?81#X#%Y
M3)FNQNEI,!U['7/A66%L[4\&:];K_%Z@WJWK['^AU#LX4MFADBCVG/&4>YK'
M"-D_XRVM*;M5O[0( <:>SKM;*W/,YG,T(_?U]V"U MF;=Q0/];.=FQ&W;-XL
M7 #Z'#6TO? _B!/QD53>=-(1#R.TJH9P>[R;P.3*](&/><H[0>]%L,CY\S6U
MZ?,OW'Z9]O>+KVQ"$\L3(G@,)JT:-72$K2%L/RTDQ]QH#89U%S?S=(HC#QH;
MC/>;FH\7.;_R_]++>L GU?A2_M%(J _0MLN#@3/>@=6&7?<5V*0A?6!J<'53
MQ?P&)"W@%<3$$K<#'GGV>N?=IL)D=V1\Y##P6JP;<6T/G1V95V@/.9<F7:MZ
M7N7\*]J_ L)Q_/S'O/6[8$QGLN2;\#9IJ9$!")M]3DCR_CVLTZ.=O].^\HL+
M]@Y%1D!'>_LEH<#"1#AVC6O=MCS^!T8#>LN@2&-(HN.FY:SOZ@H?.>73? FH
M+.:C,50B.FWH%9(G7O_6@ ;KM41XCVN_VC7V3_!Y\?LCO4&SBD'A<^6UE;..
MK<;W;& <+>=W&\O5= TJ[IN_*MJ!C[!DB.3E(@AB)C)8""DD U$J^QTB.7 .
MC @FHM!7L@/KL$KXVSIU>7-%W:F$E-#Z7 R7E*A7RO9^;"8=4#F+UG^7/=W8
M^[>B\;WH1+&2._^%JJ \N  <Y9-S2)2X"T"2^839^1RVAYW\^E%CXVNT=* ;
M9YQOLWAQN[%-_Y_9Q_;WUE)"0Z&LW4VM^_VMWYH_MV0[2SW@1Y\S$4T'5N)Z
M;C814?T3#**O-.38EVNJNE]Q3CK7+%>A-I^!>HH_<J])K1I+KR#87/42[\*+
M;%_YQR9%P4XM<%H,Y)4'/<2)MXI\LNA\_JE4MQZL4HZJ;[6,E:TZ]ZT\1Y7!
M58T ,3M!/VYN6TIG1!2PAQ'^>E6WRK]R85XGBFBR3QPHAH2%+7UY1ESFW+_:
M@L#W-BD>&!<9^"O6@>?W)Z1"4G6NMQ3=\DSXZ5^N:P6>":HX<T6H-U58^[VI
MH@O.4P'=^$B8X)H.J@C7US54./+K\!'GH[\SYOWS^V(94HO;5'S,WY8AQ 7Y
M@!6DRN"I()$LK^8IRQECQ<'#'#]*>$^8H6L&653$VBZ:%XM)',JN[PCVJ'0J
MJ_L(O2SX)\Q&LHHLV*=YNQ,8U[LZ00O-?I$D<!)9C^OF,>^1TY7C]=S?'X'&
M)<NAO;'LVOTO5&N1*@9FP@E8VQ(K^,\$I/X/74!52;P=']<-JPS$K1\LXF3-
MU_M*U;\F*]LAD^76*J;(&O5@M^#&GU4FU3X=FO:U25Q/2&V+':C6T?K+6Z]0
MQ4E$+_?;T:T3M87\@M9/KD2E[MR_-O>T8-OK(^V_AC$!Y"]_MK^<:&W=5"5F
M8NCW:# N^#TJ<+X ]O<.CRZV*4>6!NJ_)==W5A"*^N77QP:,77NCM>#>E/:3
M?YC3QU4O$+$-TP2>JM1U1!\/X=9?2NW!2NQJ4-(1@CBR3\VZ148V3_SO0Z1:
M:H\[@MO=^B\B)M"Q@BJ8ZCE8,@UIG_DX#Y+AQR41B++?8B_E%>%6FSVZ=(3U
M,M_^1%J26#F39Z8 1,(FMR=%CC"N^J5NSH=)@7!38L@E( )UPBH]@%=-N8>0
M$C$[[!JXN4\>5,-H0>/@7;-R-6+X?.6 XR5#\RHI]=*X(I9+967P(RW X)Z!
M:)II0-@W'?;YB"S(R/&>24?<T0C>'IH3RF);%FT@D,K'[<CMGI Z5579@/#P
M\& HN4/U/)#XYZAT1AJ%:R M^J_\,F6[<]:#I;D,-.]T<%ZJ<NE>SHM)H3@U
M P:2_JXU-7D_T5BT PA[&CD*#\3T\)$\LIWA45;-4RZP.=NYXO;XLJ6M>R5;
M?%/"SPK/M@VY'?F,!*MN)O9R1]S#&WOU'R-JJXJ='>P<Y_5OBC]Y7OVA0>'#
M9P]Q$0R+[B;)L-C]VS"WNR\V):: .V@O 0AO[ FW9V*=&Z!I;V!YH<1NZ\:Z
M8E<L!+\9E;4.*G\_L^GF-T%?-1,0VPQ"88"ZX(W?45F[EF8ZVBXZ;(\I_E?8
MS0\6,-:4;((\,*6QI\#8V*7<%E!-6\>D#!9/';^PR8%FOI?;V>* >3M,&\R;
M"E(T.P/W?@;/E;MO3S8A\-N3C38V)C.0S5_-P>$H?#'^V3;I G UF1Q<19XU
M!ZJ@O\A^ZN&;:0[_H\44C*)1B9%JTMH1]Q%.'^"XX]3]^R9_(BW0_J&WJS('
M!>@'J(3E?7L--=YKQP-OR@4?PNWF%$5B6V\J$%%9E9!LJY1D*7=UT3BE)5K^
MOK D#&:YG2-/XT_'IH%0JOVF>L:S,+UYX6@W*0&QWM8LP63O97$SX41+[Q_)
M.C;)^DN&'>IW)#8V#1OJ)$;T;\4XO]=JXOPT1=92FDCN$BV'VYN2+?Q:.)9O
MQ4W<3UY +W-TA\^M8G]DVC:UIJU;$1T"-TWI^J+D-'D.OCWAG_.^VKH>16*"
M2(P$M0TDMD-<A2V8&4S<I(R"A(%[<[@?6Q9'5@@[+*2$(*;N_S%/V&S2[WRW
M_/=*W_0HQ$7!M)CSV^S":H,ZEU0ZZSL_*]ZX7(4P]OWW4C[/7I<C",LNF5.C
MQ*Q7PM$#KF)X7!+:14*/7X-/ Z;A?$ Z4?!>(5I(^KX]9\K!8_:2F084.W/)
M7S1O07J /5CA;Q$)#_3 U[*D_@R!#MY2FX9[_-- +:\:,V9Q(J0]_$EU>%!/
M=<<9J=72@CAY#M%B"<I)F1O\@]'#I<,A0]M$.-T%0+NIW=%OV.\XHX,\=;1D
M."D):LF3,CDJ6Y!X8=B0?A!7$74"@@L:$!&]&*W$E6;9Z"X[@K&Y*1W9AV;[
M-\S7>+;+^4Y=CM%DM1M6D>=/ZXG[]<J'TKLHI%[VC&2J8DC14[\GC1M$AT:-
MLE!GOG5%O^^S:E[<7;^L!RP#DV^^$GR)L8[5EU("(<0KS8)1H*9)LU?K0-]=
MU<:^D17#2MZK>&M^-'\1=6Q[66C_U_[+FFR 5\0MT^N[&*[*RZY%I)73[\@F
MOL^U/'_U#ESJ*>FP$+GO,6?-\ACAX,1SW9G?]$\@]==SW;1>RJX'N *R! 3J
M3M8\.(IQ%!IP/2*@U=>C/;I:>KP%5>J6C*E"CB87M)]ULWBT6L(!0I\U0\YZ
MR+[\2<5$IF@\.57ZU<H-SH&P^_!!F&)A?3I: 'N[0N,Z2_5#[C_<H*L<:[Z*
M"R]IM9T]!DZ--8Y[9%ZU16D.GU?0!5HU/A7R=B%I'/)I/KJG _0)%O3U)GR>
M;8R8?>. ^NLVV NXTW/])Z]2CLNI-S$<?0$X3.%\VS\J25R/W_2<&]>M>R]A
MBWDS7L>"2D[FI':<@JL'(V4NY9HENSHIN\:TL:A76N/YY4?(TTT<&C+EB>"K
M)S_'U7 ,]87EG:=KO=&\#2\W_^;6TSZ)8U%"AX44E#@:L=<<G&:'VLD 'WJO
M(XH-KE2#,D_9))VQLHI5]$N2J]&.*PO#@5&\6C<B]/QOQG)-HH)YW'OR^9F:
M%!:7AV"^[-W=Z6,GS9(<[SZ D3(2/;>)"&!;HL)892#.G]T/\=?/MIQKMMC:
M4D+;T# ]4]K61,*0-^U'1M$BI]RA*E,A$]94;G3_T033IS:E6#QOB@Q>HWR>
M9,-4^?UM@=+H1\\V7H=?+LN:BGQ/KTE>=[(-:RN/+R*Q>5N7,ACK?XVJ9*\J
M@H)>OVXVDG8V:@N';M''U\)^OGUG;FNK 4M.:GYQUY;-)2/8W=/BKVCUI5S5
M.V1BV-1D->JE/54BE16@R#EZQ)^'!0,HWBU@08(4O]5#L(QTT,(.G=@AA>NV
M],JH1QS^5W$T[? []?,J2>J'P8Q50OZ?JP2V4Q_&UW)8"F6D/H"ETHZH>FC$
M.,T8HT.U;CP'>UR*1+BX6;*(?+%U>OEAO$F0XZ;X?8A_N?DXNQ >/T6@]O$=
MZ;(@*J#WKLXRF:)-^,O3S/&5=J5/XYIY9V7&*@AN:7B_-H=Q&54#<S0.X@)U
M\TL8XGQ9"/R*HGL/(<=7)F8N+W.=U2B&XNI:2;JO_6$A0Z,]W9-"3+Y]G]J2
M1P@,+U!?A+1@[RJH'F)9ZF=G0"95;K7@%E!/ELJ\E!*]=VV-YW=29IP50VEQ
MJKG^=\HX/2N/)]KLY'K'"T#,N0A\M(]EZ"RVQFEAOJI8*27;O<$/Q=.FG$X+
MHS<49.X<]A7\ZQXKL6#W///JI!XYZI.6B,7S8"TG;]1MLBS)9 #?&^LQ7?.C
MY;F1WI3GU\,?3?!YFF8C>&'>M)E(UJIG:UNT >R'ZU?#O1NA[)0%3M7SC8T;
MD+Q#.K&B=U?9S/[Y-ZQZZANFMG>;=@RQ\Q< TY[6;.S1X!%-+4QFQX>Y*']^
M;=D#[A7M/5>,%#=+>^A:7<(B,<U&<3IRZ6;34^83M_/1X_.7%9$C':;QA[W1
MZLUEQ56;'7F9KSZ0$'LOF[."N:<CQ -#?OG+9.'LC:B;,A]D[[,QE(7;R7J$
MWW<^2/QSE'%6$W%[]3D_IH#M]'DMV>NQ>G[&45A4@I;7'J.S3 Z^HNE+ %1K
MVWX'-%8]7U3]0*^QH27S46_;5+-W6>+1W?!0#M.=\WWLS#EV\U_KKMZ#K35U
MMN11O5NT=]#].D%5WV*%1XIZ_[A/X^'*=*V7_UPN0O)265\ .)CB(M4G@[02
M@!R%X2Z$ L!&CVSR7G!S7&PM_1D'C9.X5;#D"HW3]SXO?[746I]JT B>Q%Z[
M6/!Z7/6!PA@I-$Z%'C.WQ@)_KX-K6+>Z 'C@*K4?)_Z,NUE#-Y(=5&H]DSMM
M(*YF4"H6Y4JV^5VP>O,JKI8!=U/H6)%LC,Z0ISLDY/M_D6I))U''W['-;K_4
M$:R)X_NG*Y)(I0%^O2N;X8^4;\*!YD4?O\;D\[.?GI%7")<I0U;_C4XWT:20
M1(W^"EF!(->-.\BR8([2#PL8K^)1;R4#UTG!INSPK=%N$%7<G*4>([*A\4Z[
MGE:-,^6I/:'; D<]<.9%*&U)7=U+F*]]?53 LC'+R:&N;13;T9:\C*L6[ECP
M\G_FVM)J$V)VM[0&C7VH3' ]>9NI<*GT?(,.A)Y];U"S7,:TB'M*-VO/=R;<
M_6=85*17X@+@[?N=>O "P!7EG:4I/W_ZS]=F7SKGY0U.4.:+4V>1;M^?MN [
M]@M.Y$"3SDG!SNA[HH_UW9$J-[25FOX$MK/DWO,X2R\@HIK'Y$\]HP81_N:%
M,:$F=_GOQW%>-;18K\K2GLH+F\SE95<Q27HX)6FZ5$&#T9N-%"3+_7YKRTA+
M\.$B^FY49/H=,JPD_"*G]COPY7B>:F-LCU6C*I^H<K+R,O*(C1"_.SC(60P.
M\;W'B=*U5;?2=;<P,=NPFJ,V=%%%I_PD/@($>(X@MCI/<9N+]L[ (FY7+C=<
M%A.^P6&-X]9W #K@.R\  /8^A\CQE8;D5L(>8\3CG(%S5DUUXMK+&KC7(^)1
MIL=J\>H7N^#P-UY-4\W&'+??++D]2O"%5:\I-W0,P4>Z*AO.?2'.]2IH:1YT
M) O1IY7X#+>'SM'BVUP6;,%&!.-"(_1P.SRXLLRB&)0,@J#6="8BOE<]^)+M
M'::R)&#+YMG]7=,F= T5\\&RX 4@VO;4DL04OZWDJ(7G'/"EG+M_*]'[5([_
MS:-WH>IY.U,@1(:\SI4H[P7PP9PM)N=]FM=D43O23*BA_J!J/4([*2/C5+$\
MN2)N$%<.8I=\7&Z.E"@0$4'866.>%!I6%P+?U0#?H1)+_DY!6E4M"TUW WQI
MN[AP$$4)E_/\ORDT3Q26.2;NM/O(4B/7VK:ON0Q\GZAV#TUV-I7$[4IB/%7I
MN+ITJ9F1UGVN#9%\8[>(C369%K9/3:B5,>=#ORX US5Y?G'60=1M!GJO@,.2
MBA.D?7]? &C@D2-',U;C0JT=+9/X?%JV]-=)TQF_!3J=NJ$JNG7I!M^:GHM
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M$<_Z^T)2#7PE#(!&5[\T#2HCE^%+^O \?,+WV\G_?"LT<'O"%?GF5(R\A+L
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M^H:?[1V=7=T]O7UCX_")R:GIF=F57ZMKZQN;6]L[QR>G9^<7E[^OKO^("PE
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M=CCHDWDSSWU-G:8F3'-ZRZR,4]M2.>/-T> MGP%IN6DXTXA$+@4[F)^.+M]
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MI3P]@"Y)[]-S7K1T%*419F8>AKVSWE3)\6@]B-=V6LZQT5:8XU#\OK5\-W_
M P'H3IW#XIN)5.5;0]Y7:M8I=[#)_5Q^O(.#@N-!E3T]4?0O\O[OQ?^..LDQ
M5GU?@L)$0A/JRXAD5D8N.V(E&71PIEI3X\7;%G^_B()Q991 !YIQJ:!6O!M5
M:[!.$C -^.7%):^)5%(?KAQ;66D34V0%.%%W?-JZ12MM+:L!Y9^O.\*WRCDM
MR9F%GUTJ?/<EX3&>HA(T-U#X+F(*Y%-\WQ^FY-!,YZZ(7GT_>F U0BD.[Q<B
MH>:*1:KQ(H_Z/>I%\* BA6?O:RNF1W5LB?9F52I*=BOG&.&FE37.X9^$_*-5
MH"H' -(CPSH>CQNU*>KWONW[%^S]M@7=V#$YN.M]5"_LL*Z22+KI[(?[' 2>
MX.P$KR* %0;XX]%H+H.+H((7Z888BY;Q*)?>!UV<,W-^)Z$'.;633=(BD;7%
M=_$;TF2$;\+\$M1)I;'&@*67,;5V(AO>?+=BV)<BE'#K?3WSS>2%U7 >8]1X
M5!PUGZ7)^I0([ 7U*[[X^,KYIMI(V0OMT?(90G9W.QF]]0 W8?OSLABQ"?3\
M?/&3^=E^EP\?0P!FGSIOEPH6D6V*2U",1NR%?D/%SUDWF_/J+\F;[W2YM8>?
M3V8>A+)EVK49T@E^:5.L#D!??)F;'V!36N+4DW\T\$%3$Q-_9XPWD _?\!$'
MJK\>N&NUSF:(OQR:E2"#L_DHUTU%=Y]9L=@\W:-;GXP\@D<*/\<_UM3EEY*>
M3;?%)Q]]SRQM>7LJ'WJ3Y<ZGA_2A/=(.6I7=D7V9:US>W5^%F6N+NA4KGQ8;
M7R0.]IOBH?>N)EM<CL2/::0N!7%+V_($-%C3.DL]_\Z[2VK6%B#;$7C5LYJ>
M36_HHVQZ5-)ZS%IK?K!6G_1A/YKI;BSNB\2)*>EB_PF.9TQH<*7GKSG_J%^^
M,P8OW\;0]H*V(-?G42*UA5JF7FO>'K1SM\7]Z:829!*'UZ?"4L;5^<7?[YO"
M(D!YV903?=JL.S^_%37,!V*]P+G""UBU6<AP7=]>XIFTT57L[=8Y7Q^3I<^_
MC!9$ $T=\)9G"" *:_B^M?5"M=1.;;AT4JG4EDO(!G>G*DUSJ>=LEGGSM\V!
M-0* :\D\O0E7O5*IS@\YWQ6R@AM'29I7O'AXEB[%(VN3KI08>63/%I2#QUM>
M2.6PY1J4"/;:V,$.8^Z?-0J_ZA#0^0X9.1C-.23X6 9!N6..SL6*O:=W$J]B
MJ.3>R@KN@/_?V-)9WB_SDO0I]VH+#:UJWY?-,. QNE+8:9+2^5PI,6=N;6,K
ME,485+QF2"%[Y(05<;?,\=#J8#$B^]<$YJ@OD!=KL_4]\DL=)&I@3CU?PQYG
MRQM%+[>H==A>_:!UE_JV=Q/[?"8C)<-BK)QWTEA^OUEG:C#LX^Z-*B_^JVOH
MJ':&D&SZTXB#C(;Y,C?B;929RFJU*O+&FRFILYER9'=5*R(RT=:%F!;^+2^F
MHVT-[@8#S39]O0N<-X5DX@$O#D@ CL/DE6K-1_M,9;]$WGRIJ<7O71>T\72D
MC3U<7:=?0>=J,XP::Z3&L>#CF[Q4U'X$XQRS9?!J()(@)PI 8B!9",_/Y2FJ
M$^[OEAD?O)P+\R]L[%J"].IR4:54I"K!ICTDIV4C+K03IOMM>1& J3Q+;=F\
MH<CYIV!1Y>KQDKT<=];2[* T99PV;Z)/.S[3V.D@B@R-:B@AH*S]6K%ZG#7T
MTN&S3GLCM:C@A*RC=NTH:RUD^*'@BK]0R=>?$6T(!&0[%RZ0AQ0^JM\29#Q#
MJ78:S=PLGE[N-*237 C_SEL=0;*X%!\,3]%T[.[[Y'*=ON2O/Z,C;0A[/._^
MBB!@=PK^2?AE,]%6%U[P=TD?@0D&-G=AN?8.!9H6F1YWWWW4 LG=.]Q5M?/2
MO-Z[XA52Z]Z!:T];K?-I!UCW"5&,;L:&&TS_2_36.>1]7X4,@7_H]1Z188?N
M":TZ IBZO.\[UREQ"[E_PPRYOD< ,SH-#J\N.PS38 V0#P%9P<QG7,L_XRBS
M[;8ZU>7$0*AD;QE1JD9$:+1G"/V4%IQMQP<10'P( NC\)'0SE:NNJ['#6^AH
MSME/X&0,^7K&L\R3G[5;VT"TG#YQ_^'^^XN;,F$$T%5GN4(GK)\ML&V@Y11?
M<"G S/5ZBI5G%\_>:EJ_(XKC*O(& 8293T4QUC5RC<GR.!$J0FG]"15%T?X"
M\#1AW260 ]QU*/'2\2[NC=^5HBCJGW9'5L:=&@+P@IS1OA]!@A(J_*^ *C&+
M0A]-8KCT\G-436A#Z#+!O .,2[:JLOI;K::GH)GULE84!2.>A,<1?^'6/PKY
MPAVRW/@$"EM/ATB6<#KQ.TS(^%)F\7N!3G*I/2)"8A-A@'*W0^A#>>L7GL!4
M?-;L/M' []=W\KH]+J6%[R\B>@JZ-BZ#6)S)O: 'KW2'U,,-TS[MXOSP\&(F
M+OGMV1G0A;LWJ,+EFEO7-=X//6A97$IHB2_/##%[JC"^_E3#RH_YY8GJ]%0V
MYLG-=Q$8N4\:[R:E8A"44*4[UMI-Y;>Z912(KK>.ZIWWS=F=_6^3$@N5@&Z%
MY/DSB2OYHG/J7,?,Y355TR+(15Z8?C$V*=85U^I->^MFQH#JT&:=C<?;H@5J
M[7:U%HUPO]V*(!4A* )X1I1Q!X/ME2OO=']I71.O1 #EAW=QN]T]K4MX9^Y3
M-]GG_!:,6:VO1;#_1F4CH]4AI00*,HTF:W9;'@*7Z,WY;^'[YV$"S',F??QK
M5$6>?@?,;<5Y1[I?Y$**OIA\5)^/_&YT%%@)BZ@=JSM6$LYQC]_::9]<^UAN
MXOF0<!VFG;]2%O_YTJ!CA[)TH*'0IT^TFRW2U0L$% N2)\7_FBBWUFL(EU(6
MQ^>EXUQ%>V<4U]/[(NYGMS/4@:PVF <I;SZ%7,TP4:W-)5IHYD?4%SIR7#KJ
MB&I9]U_%_02N&]MVW[>/<Q(&*6<$44RI=!1L?X:F[I^1%M74$ WE!:\/!Q]D
MU\$$9<*L#>'$G>LRI8/Q<Q6^>Z34[#T]W59PV5^-(06$>1G?9\]-9<#^DU,F
M86JW[?HSD25B: W8/N\7$\C@NV9E/$+RKOIYXG3C@P,*VXI+W..+]\<QU.P,
MIJ^Z=0)GJZJ\Y)6:IYS5& *FU<6>L5B]$(233'C/?3,%]U[5;0]KY%5_BQG;
M%(/JNQ7FA\C7IC^J7V%VM<DUU/O:_LY[;548DV0(O,D#"K+.BY>*[[H^Y@&K
M?QHD=(P+0_[&MI>-E$#I:OJ-(EG*:INQ#.M0<<)IT&7'\&(R6C*>7MKU+LT'
M<RUVN/\'SF!M*OJPQ5831]%K6#X+H\U Y#-BSR;;2/;Y\C8A/BUG2G9&C6*_
MT<16O.KR"G/IO)_3R8>'JU6&Y1MNMX_=H=:_:S\(U :Q;3Y.C&HJ0  +.I /
M,;\GGWM4Z?>CAOTJ\:UI@OS2'$1V7/^E*8U[6+IT4'<8\3H< :1;$@>/YDPD
MSM9OJ6K(II<;.>OB5KA=#UK>VE/KWT%8IL#J#3K%[ME+SQ=B\\!/?2'^W5\I
M.UTQN ])1:>(D5B=C4CC9\)1TW?O(1FEXC$!T7.M5^G$?&PW3BV')^#DG8\,
MG MB7ME2H@3Y2<2>_ B !@'\L$Q*)F7=<#.1D'ZR$A> P<.;X7;]Z2O:K"D'
MOP'(?OX3W;,T"XM2/A#\Y-M$&M9H00.76&PVD7X ")6J*__XZ>T7%=CY'0+X
MWJQ[3/1=LN!1HA2[-F,<B1/XX2K"%/[L\#% 479L $PMDY%E4DVDA2NP:_@'
MK1]&!/ZY-1#V^S';.^'T/%AEL+/LV<=SYEN&D]6CLN0FV(_DI/%;:<)WT\%;
M[BQ<\W=+4Q%=S;Y-+,HB;\/GN*;:A]/)SA[.4!_V\T^SS/\9_F,SSC^ _*A?
MRG9OO:H.1S_.I4Z:%),JZ3W&[4[(;]=WT9I@'5+UDE_L[2E)&!@2&'0NY'1E
MCLD36=[LJT<!@83R^+-@R=H;+O2ZJ$IBAZ?Q^W/C-4S[*]JD"Y2E)'$*I3=7
M'(P@N@'R"@;ZC!1A2Y-@8.-LZ3%2T9+NCEW7B?!*78W:@9&18A4CRV>T>8XI
M4+G.RU]NNI+2QE&LVN]\NE!/K&41P,?,A<\,#,_M+ V"A;P[$,!G&8F34)TW
M-X_+IWMNM)9V'-,R/!_(<2Z7P$U>*NVRBO- 1,UP4] 6;]7&04X>L+GIL$^>
MRPKQR2C:JA& *W9_K!20F(LSK(NFC11#W=./QD US;<H=U[Q8CL1/RU=Y?@L
M.MV2YIHYA*)_;Y-?YIC^\+M KD@2VN">*]=30PI9? GYOL:&5(]E0_#V>4G@
M^/)11F U>8C[9K(8@'7ZC1Y-NZ+@!PK*Z?F+AK?K(L_DUWZ_51J^WE:$:"_=
ML&KSN--SEPU3/=3)E, _Y"ZGMBYYTBD=DPQL*!@'7_93'!6E\LG?):9Z%2#(
MJI!;5I9MI4JC;WP&6IH[.2L)>RU7/\Z6O+C#&0X&5>(J> :O%U>-?E2VA5DU
MR'\YI1>F;;KGC[B1'%\Z';:JSJ]9:.TY.4[$F+Q<R6GELNB2W]?%X#9-"0-_
M%WYG>IMQLU'PY_ZDBKN?Z19<WA&#QY;A(127Y*ZR<.D8?M6]+*MZG%NL]EM$
M\-/Q4EK+JF74M4%3)U22/<QL;YPW5^=]?ZXXC%!]$Z[R1O]C"E,6C9;4M,G!
M/,7F9"SW=ZC)(+TM0TH;<\]*P^FPO$W<P8WNJUWY4Z%AXPU+1?6\Z[7/4JL2
M,3AJ%U=R@E&W.]#Z>D<F*E&U(RG#G?K=5.<B98,+AIG>IP5%-;4X-_$FHBLU
M_BCFVZG.D*]YVE"*&#8 '[EDC. 2N%<_*W(<V])JF$DP*ZF@2_'C<K=^Z'88
MF2C*K<)A5'$X,S020=D_C'79;:CY^(=O,:*NR(;GW)_N-0U.&[N]"#<;HN+%
MSA_QB]*YL;2K5;&;9YB/YW&^QDN^VEG4%6#M=(GLE!JR$^OTA/GEWTA^/KL4
M5L:"+;&H7JNR@1E(>BE)),WY*QV"&<L9S_ZMS?J?V[#_*LKH?GE2[SV"[MGX
M((!NC4:/]F/9EB3[_#?.4B^246.?5/#B[%$UA0M,2.28M[A;!:2ES:R<J68]
M@F%(^B:S'(C=@U,00' ^ZW#@*H0A8+\'%'9B>A4\NE%G#&^U)!@R*W]+EI=
MA:U#,1[K%_G.0O[>3UX7KY?T;C(MOPNI9PY7?O*[>R=:=>=^U(9%R1Z1F($'
MP*5B.&Z[WIU@['"U7?,"?,<\VKK" A?]R=J >V&( ';A#!VS]?1WY50_>1
MUN"F4@,T9C_!,#"B?78@QVK,-MSS+LW[]EC%\ CVA;YK@<T^XU ?EE16VB16
M5*LY=0M0]R@[%NV@KBW-(X"E201 -KAIF0/=OPWY1/+M6"0Y0[]U;+ K@7:#
M+XF+NN%V*7^UTXF*:]3FO)F*W)(FX$VJE&L-/U;[=?#ZOE%+:U/PM+;<()UA
M$F9WX>ZVNH[01+R7#JO 1$_M>$(_*I_J/5V&%=(Y>K"[7\I%$6_MAO5KW//Z
M.NN%2.K Z[,/7"\2J'[9:1M';-PY*D!\G NN!'BEK&X;<46:J">_?WC?$G*G
MO=^GM[D>%WA>C/?;3_V+;W+U4=N0R,CT;:6V)7>"6G;N$0*P\%OZV1#]:;^*
M.969"JT8+T.Q"T(6=B8X79LP5D8 P]:8#UOL#K<8<VOOP+M;4'$<^F3%=TID
M J%RB^:$_#*L\^!F=$0 X9,A/+H]1B=8S2\<?TTRIB)A?16W^VKOMQ2A(5'C
ML^3YFAQR&8QL623_9?9ZU5%3^OY,=QDJ]!$*3T'V@LC&.<8D:D*NB30&F<Z#
M0GKLF<U?-:T+)38M\?7+<]W,2< $)&J#.GP21$P7UT[OB28BR&8J%OC\S_(-
M'*1"L>\#4H6TO_;Z\'TN%1V2#A>%R%;G7Z0];>!T?\$*:T_-L<^1PD,G]-QH
M]ENY(5CA%]M_T,A3^#SE(/! .F6=N)Q<?P#DAKW\S5'QM,S*;^-QUK7:JJC4
M' =>J:LOPL/VBIJD;ZO >F_LB(X.TXM&9A]H-'3D_YS,_Q?H.>86<?$307]K
M;?^;"O9NLAGJB#4_VX_B-?.D\!8*E3H5ZZY+[XX;E8LB Y/QD1C3XQTPXRRI
M<EKR/0EZKU;#EX"/U\1)03W,0'I6GA1*46X3P,M;4#)=G;BAILYJ(Q7/1?/3
M5W2(710\!!L&X5%*K[=431L%<-%'#1+Z>!1M%@QOF=\P.3\B.U-1G,I\4I6W
MN,P0:R*N#'/S*]3Q.O7S"ZZU_%C[7H8D6&V1/2<(6*/ZK)<A7\H@)ZW]5:T:
M2D3_I'FPPTZ"\X1=\3<\U]4(O?3S;I:9Z^R>MZWR22D< 1!DW+=N/79/:93:
M.^A,"U=/7(O9L:PXOL@,L;?\.L=QPJ) "IF-C-C"O1>R#"W7EHQ^^2A_P\M&
M/?!"R3W]Y.$6^8W_B_MU"7NDZ17S\]KJC=X5UIIG[0 LS2T^R6@V/-_2)&G@
MI,C(!?4$AJ0K5E3T+"OT92C2%G,Q3JUI4(J\5/L&*Z&BMN3G![$*_%N 6B,
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M9Y<)CQO44QNI':<]52U7+2ORS(EUJ/V]HP(SG,,WO]V>7F$M[TZ$"J<2BB"
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M(U:T=35?3D[FZD-.%G7C( ]%$F">L_@E:(A=->8[AV7=4;EW'ISTE;.RF;5
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MUVMKK,)[U3&G+25'OJB]X=?_N*<P_(Z*8H(R/S"T,-\>T5]A=JW7A1EIVHS
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MTL;7:?$[T%0FZ"1*_8PE$9^R<*(=*A,DD]*(29@_/T[5RXNU":XNBN7*6[J
M;T7S8[J\"(ME"$[O6B8H.IA:QR+S1*TYW5?82T!)#KQW[JROW=/ "Q2W%.J;
MTV&R3K-K6=NJQF8:>I5'*%*B/_F3D'=&N9PMJ#'.NHFB&ZWCU4+S,_US5G<1
M5ZMBJR9":- <XJD9ZQJ(X--^^;EO+=8VW1/^2H@'UM93%E3H^'PBXQS!&P/H
M8?M$LA^ZQQVXH4?VW<O+<&?GF2"2Z/LYTY]#-D^5*V7ITRQO(^PV-SM_R]+@
MV6J!?(,NR#AH8#EX=9QJ12<P0;=QL\'&CURH]X$!XJB8OV-6G=NZ.T];FA47
M"1QG>_U[ /KHY-2T<TNJ1JE,1W/+NW$=HNW?CV+ ]_'8AJK\"YZUVM(F^H^\
MDYR2SU/AU>;F=IU9U+K2MJE]2"5Y!4+.%M8=_[B=;'C-/I-1F #CQ,YLFAV-
M#\D," B/JXC_]NZ&Z\'91'D\]\&I_\P-]K\"+!IN8X(&!S#D2\'[>\ 3)J@\
M)8A0L\:X@EFL(?RI6Z#QNS Z&*<PJTLN^/6VQT;V4Y@?@)$D$_3MS7_4 -^1
MCW56XC.U<7^-P'%0JC].'+,;1&/'O_GUWS/PU3,VF<5CYH:@72WX-LMJ<?%A
MNLR;(-_,%A_D'VC23D_+C3'T&%_$SQ>UE;TK<],2Q_8L1/LI^;51ZP*UE!N<
M PI4WVH"]RZ_T##G+'FX23/Q;FX.^>45$22M,T"LIREVN%[Y&Y$3)%0Q,%_I
M7-ITO=3*(G1M05FT0PN99X9;U/64'5B)2/Y[]ZNX*NJYGWTO'-<:U_VE,[7F
M3$.,KN^$786M95H&_F\=2Y8,LN9C=MU(=:K=[T $/3"OG&M!#GI^+XRU19D@
M\7;-UXUPAM+$*>^6*:.3 !^\+D,;'Q<H<]P)6=GK:,>SFQ2-,QOWQEI9?L0S
M06DQ#A>%+X)\0)%Y:9%IYC+IK)9FKO6F\"*[X5_6JPO*GT)OO$C[],E2\_@G
M<YFQZ9TLJ_2;]0;"!E+'>&XHP*ME.FK.MBC:5CJ:NS7_+N3XJ]#].<I<1VU1
M2H7T:3;YWL._-7[.L!S;6#"/F.7:UR-JFO?) %+G=EI#A<W #+QRV+$J+\^>
M=W^ :@X,+>*?SBM0;N,$57]O=8HC&\R_W&=E'TT7%FLD"F26HUR^:%GY&P:B
MA"N@";N&VB@A[[98A2H#KY+&_3+L Y$_,](J[1%_]1)WU(5.)Q3"P;:,D49)
MV8![,AM_BV;2[)*2O7A"6WCZ!5/*N2V,I+C$X&I]G_L_VX3=W:8^L_MY-W0Y
M(U"6I]LVI6Q+ZG9)7K$,\4(_HFC^!+T"+4C3!4P6"2#4!9C +[W,E;ZA8 E@
M+2 XME/$20O/X3\CTD'$2B"5>AO\<WXW^%"H)#=V%W&S*'R[33'P$ +^-@N3
M&9+9^[,Q2&>MH#\F&M.X%X?2)*FH$2<78CO5+[UQFEG+>5D;-35ZE?P ZU?E
MC/$\VQ#XQA*2(-BK.>>[/^-RE,L4V].6WUSOF07XEPZL[ KW29;SB$_4\<U&
M^CN4.FN?O'&OU>)<N?R(HVV%U7BY]?$4,SE9D64YQ4Q9J#=>V#NS-I.LD2IP
M2_V$LY/Y9R?? ]W+217R]J5BUC:ECMJ*DQ5BXS;7,Z9E[/ULK\L7)>Z,Y@ID
MWK"H/5+%[76*_])B%)A#8 *^8\,$<7BQ-N T@*?J442>'.BAQ^9/3])<#I36
M]V-J7A(7COMGP_7*FLB\#*I7E%+NA?*(H""&F+G6D]T4?LV6.+9'<%.'%M$I
M4>A(WVE0%#<'_R6.V_S(4T^[..Y>6G=_X)>YN)U\TE5$+ZW"H@A57^\@/V'^
MQ[%87\>Z1*(MP%RIV_]Z1E'D=YW>UA;>GV]1L_*]@S$/-2Q*S_\@ VW'S"=Z
M/"KNR4\6.RJ4E;06JCIG+/,^BYX^X%_5JWF)]WL8U%+D+^+<F5+E-..?8UU9
M]KTGLGS-.9 F,.>T\'7>I3UKSS'\P5@?2UEP8%D^,\UT(YGG,_Z'/N-H)2MH
M+ *9;34!7<3A1)M6M\*"^59SXI*@/H8^#FUI?K]1LK=-!A+1)Q)6?,*#C[RT
M)A!?A'MIF3<%"!TZJ3JF3D=.;S\(SR!I7!L2R"89KEA8V/N7^D[WC/S.]*T.
M'#XI)]%I\:R"[U<N@TZ4DNL*01M'C9XS^A'"?[>7F)=1_K1_;#E5CD^G&#T2
MG),WXSX68^&@G)N38"($3WLD;V,B!(+_;4&/XOZT0OJQ!VJ$1C"C8LZ#,&;Z
M;XI%B(WQ_!GF=1RCU8P)>J5B:7.)40397X8P'C>I_*??<^<\@*''%GA8C("(
M<M<!]BC%O0*^4EQDT[QIS4WUCV\"VJK^)IF1!^+NN"T]@O7J[:ZF#ERKC5_^
M\:# .W9L_B=)1<&VPKU:3^N68I/_B-;J>+1K^841"_5HCZ;0C!QSU*SY^;I>
M#_E;\HY]'I5V/<3:B3=PO'OCI)Z][UATN6VI^<?2$Y<% EM^I 7V:XS37Q%\
ML4\Q]:/=HP(H;V!KJ1I"9()ZMHYTE^W!)[V,PC9WNF)2$PI7/R>H-75$VF<>
M$0_"EG6%1(:=)=7%%^<XL;01%E! T$1'J;'T6NV3D43\QNYK))8:0<^3_.XW
M?#C]H=96(NYX%0\R9[N/(3W^XP 6NY,$O,@D9\<%GY$RYM[-A]FB^D3?+Y!M
M((#\W@ "D!_H:VT/IB@R,&":#GES]P_J+*!?-O=A7HQ\%JO9&#(_UU_J.47S
M>SU39>9*D1W3^O3CZVJE3YGQT5K:7_QWI,N3VM;;"I[WG.]3;J1;A!1KB[^X
M(_C S_2HKF.OV:9#6L9I%?F>.2H>V.K%GM@^PJB1EB.^V:W?2-3(5'S19IM_
M!.V?K>6C8)]<;,<75= Y"K:^7NEXU%+0=IPJ<.W(NU!G,S^9![(%YI)9$?_\
M-_.X,??1V\/RN+E6HPVB$!?=/!O8/#O)>MX+G"/D\LH7/?Z/MH826,*)TS0I
MWDE+"W%2JA3(8UHP<>CM5B-$!#!SZOR,NE3J=J5KRM+*TCJ'+\/Q%,]-GX#(
M:!4ABKF$1H%SXDM3S>1"W?Z[:2$97L+R@RI:2_(?+32LSN?XE>5::;GI9<I/
MQ#@[R%E47U 8K[ .+;<53+)EG6 AF%PTYF^3YE<R;@7YAJ,=GV8<TWSJUDIF
M@MYC 'G34J\R_ST-9S^IX_0RE3N;.YO@ZR\'76:^HES'JCP2IZ^T9R::=IX?
M6\2:%UR6<*L;GRN=^,'H4,;?V572MS*S?M=,&-_:?-51UUE?H%2I/ZO_.BW2
MY9WE:ZFKJH$U-Y^?C4*ZD7+DS*4?F'(P0:FM;$\<V3*?'"DYQ"W-P8*G5&X#
M <08CB:@QN!S(&&_)?6A^>F94'^(\%P H0$2CZ]NARY")=:GC\^M8=B:\B\3
M3X]7JS:)O?RM:B3L[F91Z_9M9 S"9:FQIA=A);<YY?FG0&51+RC?=52Z=&.%
M4_%M7AO/'VN%"]9EQQ1IF<>M;7O40OV@'H5:%:/[GCU@L?6#.VK@D-C3D^6.
MUWL6-6?JW:<R9J^7&FOEMC25GEWB]BP]&+0-<2JWS0U;98(B)^Q%IL]/-T_M
M987SNWV;ZQ(>KIYLK!L-O!=H$* L*K+=.RKTV4JPY+FEA%:HZ>"O3U4\!00(
MM"+XD6/%6LZDUJZ5]OUQ*ZUQO[*<6R;_W'269NF.,!:(L.3P8M3"[A:%Y7!@
MXG,8MTE:/,O$NF&6/0G J19Z).TB$S3>WX*8#@.A*JJ8H(]DU 4FJ,$>&&>"
M*L,73SZ"(Q0#H']0D&.8C4DC+29H;0[@0CA\9F,-\T_C/&EG5_OE_K"9TV10
M8=W83JY$!\RVXVW(R8[\F)CV;'BVW0?DU<!-4IJ?*_EU\L 3Q/(-UJ7QTBN:
M\+.:U'Y@B;)EVYFS93)-<\.\HADU9PZ9E-"TR57;OIU'QS?Y*4*VJ\T]]GGR
M4F'4XK"[!P6.GHQ8#-D)E@*'LD$7<Q>:8"D[ZUF-T]K@.+@1^^>S9NIM:P3^
M+14#2:Q$,C_9.4 T6Y%K_ES@%F)Y]SAW<:KZAQ1A-D/KSX=AT\+[>[%B]R,T
M):="K(/NOO^<;D%)3,3'ASR2+%4\%QA4[(U1I9^Y-U,P?H;89N>?W5"9YWDJ
MU^)>QG)TEZF?OC:WL:"C0KD?[&7 ZWWY(H(S],7E_V8Z_[.!'0%A"JX?TE#>
MCXGY1QFQ1VICDSJ%D.-7*%F9,JKP3?/2.6E_9ZOW'#S*3=4*^/N57Q$**DT_
MXA>?(M9/DX-)V-C.\S0Y()B"Z9H.<0<\28BH=ITE-Q'D[>/E7U$FI2[^-N]'
M6J7"BEVUJ[MWS8G/P8H!M-B'N_@=2Q9^AG1JNJ/^*0'Z(S6[]TL_MDX8<2.9
MH $H[Y+R\@^KXS/[8"'@$42F/OZ.@175:2)/V?&#X#((/$2S&BJT8X\:EA9Z
M0ZR#.%3*9"X;'R]5](<]*'3/7WK449)MMZ_Y:[M@HCCW)TW?-I!(^0K=5#:0
M0-7VW2SE#<MSV,AW5?$:]JHL%J%"(WR+$FFNC,;_@"HFZ/S6MVT&7!KXP@1Y
M[5%9WF!2OPJ^?W7Z7\CP,71,X[]Z<']YZ(0Q$^1:S 1]%BG]CRD^;*E\UTQF
M_.JS?TJ/0TI5(7V2_N[F,L\_V%^Y?F,NWN&Z^:E# ;2?T,4V"-DV #>;3DUO
M!4+(ZRXYB&\-5,QD$^P8H*I_H]1-?V#^0I0Y:W\+T:Z^35(Z.=F2*Y0#B2ZX
MR@2%%'>%8/C-M1.VZ?:8KD?0P#ECZB5Z@C;V*%+.)A!*&MB$1#XB9W?M96U'
MP-M$XVH:5W DKD25Q'//Y6K)M&+S^A<*_&OBFR5K@^1J#!NN0;1+"8%=$-7"
MQ887G'I'[GRI%H>Z10JT=*IO& _Z/3;0-7^R8WJY+G8),:FE=L1/1_S=C;+<
MP^](<^$FY)'<D##)_>;R8('K3% 5,B)MK-Q2H/?%UQH+WB8#48VV:+]+[>X*
M2FX?E3Z73!'Z0O9*L#_QDF_QPO&]B[I<\A4'&W=J)[=]Q!-Q^GAM.BY[),@F
MV>\C$]3L(91C]<A=P\ITM$L>/Z8"HQXE4W&O&9_WE1<$47;E:N\1)P"=JZU
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MS(P^:3<CD_807S#$XQ2IEP&O\HUFNV>T2PHDR<.=N<3-LTO=G4=:HS@P?,@
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M&@35_O$D:"LT,72%%:Q/*D[NUBDCTPX6W9D*7?*U:Y_:_?Y>VD^IZQ:<0]!
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M$*6.QHD;10!:D:S5".R?U9>0;9[*?? #XK%M=XY^>&H;Z482SC#>4J7P]OU
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M $$G64JDG+2X,(KXMC6IDE[J\D#)4-K21[V@R>%SU<;HYWEH-9^0W@1%![$
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M>O,+D?S&^X6TVA(.??O)4(XX38DJ^^W7H%3T/;V2%>=+M,52.T[I)_L&" ,
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M*<P0YE?MS]+RS?V4ZQTJTZ(3]R H\:RCY^2/* :3R.ZG\]?;CJP@G*>^OKW
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M*:#2E=C%PRRY5%5,_3Y]#CFR3PC DI_<X$A$#' M"PD=25@,YT;F2Y<QTHF
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M0SHB*GY A*9_<AB2YMHNRS@[=SXAWUTGT8.8S3QG[_,:"M27G=\ %OGI\T1
M/T!HMHHY0@N=\@@W$ 0M!]/I[ENEVVTX4$RT:!B.$G+6B^RK!$8!MK[^[>=W
M(_8L73B7G+M4R!Z:M\>\>'7K*R%MG$L_PV$OI"7/*LV51CG(+MF#%,>,-/H6
MEA3*)N?]IU(-][0KWEMDK /BH$),353@]51-$I.]5LS\-!UL OCVO(F:0; :
M8)'!PF):H6W'EI*@A?<L22ZQY;+H*=.DM[<*LBSNF ,Y8+C]LJ/\"_&C-S"F
M\;*$!/3(X\F]YZ693VG:2(.^U[L#!9VK/G;II<E\MF:AIG);^'$BK_$=]QMM
M<[)BN7RD4IYN-,TNY:0;HM=_V.W]QF%I<SR>S>(^F]657XE[M )I*_VP^T0"
MJ'!W(#XY(TF9Y;FL]I(J\UGF,21\M/?%QD+&=,BJ]GM"NM'*(" B)0\;I!OM
MZGJ]; <Z3]MHP/$*WJSJM8\]MTISNT]7W=4"U1K<HD[#@OHRB;F)B=TFZF0P
MQ.ME67]8@S7P.ZB3S)M@OR19%R#BP]J08Z7PPRK7RS*+R;+(6E)\^,U/Z$<U
M@*-$(L'>Z[X5T#2!NZ:Q"N0CQZ&?\_QY8'"<*^\CRQQ.YU[AP'K3V^;FB5TB
MAT[PPO0D& ^/@[$RC/!BCM <PQ,D,[V8+M._.$3SX2UAPP)GIA$KC&./Y,L7
MK2E/%MW+R&R85_G6U]K)JZ!R"U.)SUZ-[?NK.UA#ARO>SW1[P:H-U1OCJY]J
M!!OZZ=J%6\N8U,_=V_1,/54@G<]!@S\:T@=Q+\JRTG2X(T"X,7NW5I>FBNHJ
MGUG5MPFQGQN+;J$6Z!>-^@H_S#BH//D@GW[ONYCE2;2V<O]TI1%%IOA4,J,L
M.Y>]":N?\WCB?#2XQ":=PZA"Q#JS#0YH(=9;9,.-U**(F<G2&?%J)@;*(UDQ
M*6G6 )_\ @]S@I7'+67QR>8"$1K?^3&;YG4;9DC3?_)L7U#IC=/00T>[_&Q/
M'SOP^,KEV?C:M'/7,T.!/#J-E#(3X?[O-]0^:S^]=0F(ZCK_(5-UQL,^\:CB
M1H;J=GL!1VL8QS0I\'LMFVE91?FLB K>8G'J^Y:%GP3B^M"HY5 __KS:.52K
M19*2(C=OGJ<DH!19^V)D.0/GB /TKRPW0__?@EB1?V_\7PR"?^36CG?OGO*=
M3]ED+5 BS@HA[)2_.PN?"2S,GG,U37;;TPZ7<_EU.Y7*YA/L1"PBR@RJJ 0V
M)(,?G.!29M*CR)%5[5'3WE89T^*7Q^V+L]J\Y3"\%_%DL_\?XKMM!<Q:8/MS
MCUM;DFHU6KPF$E&32*,:N8VW;[=$.BC?*=:7X.76NUJ,4@36:?.!,M<R^ZH[
MGLG6>T.46TB05)JL8EDMG8%Y&R3D]K-5OF=O!M4XD7DM.F3EJWC6M]7>%U2M
M!OT:=JKII&THO28?5"YO47JF$P7+/^/L:XZP=)GI8=N?6&,0+6'C].*L%&EK
M.5(N/K]N$U=.08J"3<70^XRDD!RC;IE<_>"6\[H&-;NM^2(!#IJ@%6= 4*\5
M5$*=D<*==:HYO_1 ++G7ES&]<PEV3W$>J,U,E$LL?V]@Y=#A/LM_.Y(G[HGO
M3\8X :)_)H5%#!]V6%>)!&N09@?\'GZ[>XOD0KA16^D]JA#L 64D>^K0;EDF
MW/'D^29W=^V*2B[U,2 EA6*+!;UKGQZ3[ZY5FI9\4Q)Z;/(5;N3R1UVU#^3W
M"4234L<3WU@,9(=SV99H.J0Z*/,Z@1^QN!SNG2@.H9@IU&0I(L>#3/0%U74(
M*T6';/^A5))/]1.*=:);E14?E- =K8!;?K$5?$71>21(\3;MX\=L.TKFSM<V
MU;-RC+(*#8>6+2OOFP9'K]\?#LXZ"/::FR@S8#1E#?P-?%IF(CX)?YBCKE3"
MUNQJE*-NM9KGC98ZN+PXY5__AV__?T)(4BV4'_+-I4D.P\BV772#=$$U8':3
M[-#?*3=G6EWB$^(BLY>Y4.O6TWR0RR/ASA]=3AS+?Q;P5D^,.N7S_WT/LU>Y
MU_>"BBP:,6B66=QLD'DN3=;M%Z#?U=0@Y!")D[N'"Z/A6C8"N\6,WX"V CX9
MD\9%2Q&+@,^DR!!M-TD'^M=:/_G[GGW;]0#8+[M+-]'R*FU;(CFN;3I9(3AQ
MW3]F;0)S#('7SE:29006 D7-T9$S?LEH4D*T96+C?&2TT6_Y['4CA>KT=+"F
MQ"5OB>\?P)6I3TM7#MA6U"HA.4Z&\/OSJJO[:92KE11CHECJ'B42+R-FGXC)
M4T4Q-:&FZX1G?\H^EQ&<V'L>WVVKRC&N#7]6*KXF>6V[_Q.=0=DW\CAFULNL
MK:,W46_Z4$;K\#'X/M+$#P[*D%++60;ZA_HF]W^7^LM Z$L_E]"C",_Y-(-/
MQ8VVNPZ$"ZHXER9H,NHFQ6R&<O]%&($Q>63MOC_XWDG.3+%L)OU^HIQ^H=22
M:%X$V^CLD?3,KZ&KC'<]#=W?O#>:G8C:W]UGA]?XZ,QUKA>]QQ<:;9I.ZY7]
MV#C&1GF6E8-\S.B_V6U!A(K(XQR)1>S&U2.W7-\2]'T7O.O*$I^^J[/;53$W
MX$K#X.5;I/!;;KX&M"F-,&1".C=#=K&,FBXL# $X0MQ8,]0+5BG_-1:\S(+>
MZ,BEEA[S)1 YGT-D.:5'^VPRY*[>_,>&O=3JASE<,JO0\=GW$OUL!+=\G(<A
M8D_+W9H,7S61.KT"Q0OAPB2Z36JV3O@S \I] .%E09%A'U=:85EZ=!P>ZTUM
M78:"W>U)CUOW6%\E_)@S<*_<[H2D>Q_/PQ=M;)(^9VKVQT@]7C W?#HH/7@U
MH^7 4:<I\2B\&@]4B@[0;9A0TNA-B,I9SP*9SI@\6@:K-IQ>N^<=%>.$[50I
MK*WP1[JR'[/T18LLDIY<4/FW4R]>?M[3<19R\.;C^K<WZSQA\WHO<L.2I!42
MGV<;/'^M1A4<]<8Q3.*?J1_Z.9%C+ 73P"'Q=MU"<6UG9SN4M83&_9]%*1/:
M7JH)+/3Z"L-54P/31YPI;ZW=/R]9VWR+\F=*5^OO-#SX.!81GM?L.)'FT4R:
MC0OX^:&Q:;;&7[8.;N>WJI\%;FP-+]VXIQ 8]5IKQ[4E5:_[A3('<[>PS!3I
M[WV@9[_FUS9;N]MHM*;&7]C2QKR%=J^^;E5B)A:FWUNVG:<*LUSXYJ(;IJ G
MTI=3EJD1YUI"XU"D>ENK_\633I&):%/.@#(351O@>F?;VX4O[2F^^5!!]X!
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MHVRINURZV'Q#O5]XT3X3?7XD2+&T-^QZ6^9N[(#Z,E9B$CD].-;6@YB),6F
MQN(JB:^-Z*Z*$V1VA3@9-WU#GT;Q$NC=2?GTI>5J>/9\3OY],;^G]EP+-958
MXS'$MD\Q?L5P2U.[A9COB]Z!<ZQ6]Q:Y=")*X+^/3U\3E4JGNYA=_FJ[P= X
M?_U$N&E:L84W,DC"I7(SRF3T=Z$6KT*^B)@U;M55?<Y:R <BG.E$Z13[+N]
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M%I;*19:Q0$$,)Y(/3_N-?#IX4<8NGQT5ZOR@>"G<;R52=F/T"C4TX=JC:+.
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MX#-UJ*W1XAE%O)@HCJQ!EGZ<%J(EXSBFHL9I_0F3)LU8*BR&$!HYRC=7FQ6
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MV0SZ1"D@S7R12V]G@?BE7K! 7]\]A=3W*/Z]QDGL".,$"W3S*T!A@6)2;K)
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M+A]BDG\=VLJ+GT/QS:9P,F[1O*+09U'Z=-F46?!!8/;J8+,=A5\8^617TLR
M+A>]/2D?)"D.'=CFN1<:NJIE\Z$^?.WKDLA]7+CMBU.EAUSM0'_OB^GEO3,1
M-9]6X@S7?CY @)9K[TS>&NE+UXX=)'"M%L;W6VN'M7=S )4-]]>2TC?.:1FH
MGC6V?>S.^,#L(-.<L!-I#L/-&K/@";_122JLK<]RQVZ_A'D9P!L &)KP,J6N
M(V==D-D'J=%OH,U3^W?</HP23YOSKRH6.3*4![!=&)$M+-^U ,A3#:X'SI,=
M#@[:Y761[YCO@\SU)6&WA@-+X_"KJ]LZ/"WZH4FJ5L2![<MG6NI2)YQJ5J%F
M]37#-4U JGVHN;%%8RVQJMYQS5?E3'W\%9'-X#8RS0PVWC]CD76D94_FOC#D
M*%$3>>ECGAJ-\^-Z'.;DMFH\MF8LALC]"R. NCM]!<CRI("C28)$Y:)7N F4
MX9@*(90D"CZV["8R$M2;Y!S<,C)?8_GATX$EY_55.BWTZGZF_@7TN(.^))"
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M('$SSR+[9P-WUY^N,]6\R8<Q%&< <[MQK 8<+:*O!"0=J0HR-VM[/#JH7$C
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MK(S/$A?GR]B<T>Q"]=%'J'\^WI=S)O YX$'H*MXKME"5 64RRJUH\2N!^F:
M4&.^G34*CWSSDO3/?&F5"QSKS0I3'W>=_@NZY7YJ642X9IBS8#,E[D5K .[
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M8C_/V+=H'I-X;^?98G6]L6_Y5YD+@.9?DB"88Z#BHT>[58PLS;;_OK?6U,N
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MG%;CEB[>8K4T<W]>Q:\D<"+>6IQMJ\*3*ZYO\$;OB8LNWJC8Q0) #9(1\DL
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M>]/!<+]JY!I*X.Y/>T(:9B/&C80!@2DCPTM/A:SY!IX=W\7.-]YR[)$:7C3
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M93Y#53OE)Z_.Z#C>WY0P=*\IUA9<%N= \IOFX0R-YX=JFHQS_:P(B)&YIH0
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M[MB":4%6,>NOKM* IVV+7Z%9P4XWNP3LF_G0O7%FT/61>SX]T7EA1.^B!Z)
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MX97PPG&[+G"QO8TP_1&0G'D_,L;T2MC[R]^-A7Z*LBLJIG^U6Y"A^$P+GH=
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M.\YZ]@=[3=%T(^)!W-ZNBCYW9QSDA\G _K>V[WL/]F7F]UL'%[7W]_G[QS,
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M-W:/GL,X4\\$/CZ.-_$I.R[<_+,];O?!PE_-3?H.SVH7QPP*74:C_23."8@
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M9^<VW=$9K(9\,_[#=#/NXY6\?4><63O,C(\;;I*H"NL=>7LZY>$+5^[:NY@
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M%8J#6$_>ML+(%X'5;_)#]-O@LN<!UP\-!<BNI#2FGID<_3X:_C3'TMKWR5G
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MM^W62&*0L2,)>LK4V$-Z0N#OU[\MA5-9%LI,.&;^G8KAG4GT07.+9_RF8R?
MP!"=$6P"'YF=2X0_EU4*YJ3^O)'VP5'*[@,UD[#S1ZW?([SV6=/]>*W?HBP:
M9^)R_6"2EN00M>;=5.QJT!@66GF+2-^\=K@;W$ 4^VBZCZ]C<I"GRYJ!GQII
M@=>/=*:]&<)S8--2$_38ZU477EI'!?/0<- .(1 ]]-L W.SFAF2Z*.)WO$4A
M=>!0K;X0>'3*+\1L6H2)=,LN7D8B,*H$6J6CQ:F7D@0@"YEY8[=AFVO8*.Q6
MO8DP\D8HR87;3-Y+-.SQRZE?T)*9?<][\32G?\@_Z-3H9M7*6(OD<KM,.,>8
M)^"M@#&@)IKKZG:$T,?XXS#(;N<?D*_[EO?;XA(Y<46_H]"C,;&\N(/DGF(K
MW<ZRSPP(+;8ODC7.X19951B5/S]13E;((,GZXMYI1(HDA62:2L:<M T=VS*E
MF>%G=95D?VB$WM=P.5=-7J/6QZ#B^OG2&6X-%65Z%,.> N,E\1>A*IVT(+W8
M3UKX*VJ-:?+HI.EYV1SKN$\LGD:@FEN:16"";^Y$T@W-Y%GC(8M[32G!6_B7
MH>[AXH<WYNJI<H3]D-5<DWOR#7IBL+$N3Z2I6IJ9$(9+;M9R:)0U.D,./%SQ
MK/&2MG'QM.7W2SYSHWWJR^1W[Z]7DL?1#2G34ROB7/*,7]:([8,GLU]J.S+5
M'54M1ZH""]6EU-3+][U/;QTTM,MW#BDR3RZJU@NP#=O746!_M4AG-*V4G9'1
MHZOTE&24&"B;Z."D?N)XX0G]'R^.'XRQ2K0*VRW7'))[[C$EJEL(^#-35IX2
MN>^;!^CP3NX@O<&7][ ]9F%F\Y3[]]OL=V0)OGGW]X4T%6B@467?FVX/SQYC
M/_;$I9C4RI+:;QNGK"HJ.N&/99O;Z*K/\9>@SM) M<8;C"8AD&A$CT^+"\;_
M%B9PH<,:7?JO65J60S86#<S^RAOE"-GBI@;LL-88&B=>@#]4A__I/_W$[QR^
M..(&?)N_;VB(^D@(B":ZV=H='VK5K#M6Z+9?<^.&-@M)=]?</TR><#/59YW)
MALY%F(&(_8XCEQ)/%RHX&1.T2?24YO??'_BSBY\-9>I;953M/K-]E&2EOIVH
M9I3",!DY8LJI!R7@G?S#510*%,)A*O!-:[N^F=\O&L*AFHS&HK]7*.L=#'M)
M(1ZCO,R:;?',MO:(O2M][L,SL</@:TQOQZP_]4^P[[%_84[X4TACV/)IGO^>
M'/_1;(N$D1S_)]?NNOE>\[MK*?]P,.FHS!X&;Z_;RZNXF0YJ!:KWXUGTG\%]
MN<'K4.OY:X^"GV10P5:PWXJC7;Z*$BN 6VBE/W5%15V_6-W1YTRY_Y_2TONZ
M2T3M2MSU,IX4-9>XESTM5+5QL/>'WPTW6;;J?_2OSO2US7,ZUI [:>LX435J
M%Q(Z455].<3?\.WQ;4%J:GO3L2Z1O[",X"($ZNV%0(!X"O$U)IH@&D#<4.,2
MR/*8D8,JFV^XQ#]]Q_U^BZU**?L\KZRRBHDUJ%C=>ORH>>SD]W %#Z=$2[/H
M._<E?A<<GJ,OT2=@::@ X>O$3B*6._/M=7[3LPDCSQQZXXRB?\+SP/YH(_.8
MIQ6+MU@#5\"2@,[;&Q\4]H?'1DQ-F*E65%MJ: 3U@[EXY;J1ONP$3ZVHMI>X
M4S3MDO@/*CHBJ32:='2);:KU _:.DK@BT;^*Y6RC YJU<_L?[K,ZF,'91.TQ
MF)-(:KB<%1)?QRB);>HLC'748$V^3PD(R?.^5;A:79;AJ51@?SHX1R/KJJV5
MM@TA5 C0$."_1%S1Z+> %=%Q1'Z[G1 0=Q!4@^-D?Q1T$58!YTS.>'/2>@<:
M\S9UP-N@>EB/+\* I?"!U;Q+1!8S^08FL<;2?UA+UIZ[Z\N11*3/'> E"&/)
MTZH=C"_/.RJG-R,^>6CJ>F*6@KWG(.92.IJ.+2/'$Q1QC#H8Q2,W,V_VBT>9
M[L'KO8(JAHDILI3]O$-X0Y[([9GOT^6KUSJG&0U:G(@4?_*E8;/'I.@VMKM\
MQ?ZU;NYG+$66M(S3ZZLI]#YN^\8V]LZTAYLL8B6+G$:<5#&'\D6QO7D]KA^D
M.*KQK8*<#]YRU<33F3I#Q(]7/^!@E4[BD79VD?56A;OA;?D;DA/S9)Z0! 5_
M/SNWB_&J*43@;#,K\,5\,=&%54BKB$^?SW2@N7U\8R$P>B,-ND&<[A0")R).
M(A/HQYT3 O<GER,X,]\$G/8^.GN4Q VD5YY1>L>33C;:(,A[_2APUU1#_\<D
M=I)KL)[6U58GZFW;NPS;=V_N6>I.9O4<ZHT?#7S+244?K 83A<"KL218(A#<
M&.H5C.B:S?KW" 8X<QUYR*?IAFR*./\W(^?4E<'%VWK]0B"Y(O*H=8=WQ>O:
MSDM?'SAW#ISN(%7\D?-^<KQU!]K)5(:;]>+0^XRW'E'/'3Y>KN!5.5F%;Q.]
M3&<=Z,66,LAQ&0=VV*=HJH>-R*^J?RG+B54I/&F;<24KA'X@ZY#D1X/8'77.
MI+CF9K="7.M6]Y+@XDZ2D[543DA)@#\];_/;*J=H7WDJHD+BBA#2-.]2GL8_
M#(JCE_/(@RAH+SB]@>>QF "M8>LH\<_RI*D)?#L2WY$G'AND+^8E:?%I=]J)
MEY^,M2(#+UPL/VHM=N3"]PJ-OJVT!L8VU4VSKRP4R',3.M]T>1L[.8N5J^@
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M8 NW-[P?6N?HA[+_Z>R/RS]G!(_\NDG6SXC)._$K9%1_!=03;:H.FH[R0=3
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M:/'BLZ HR!'>_V=UY*7_'UMHV8O":S8.BL8Q#(+>AW=_&6/;OXQ9I+L/P/J
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MV1_X29W3PY:X+#?-!7LL'_K2&"J#$JH^'<E-?M:3/C:\U#/I3P(]-/CGFI@
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MJOVY>[534X>UE%HOOLA(@ST!_E,L(A5K%2 $D$-2&&P)$_ECKCR/+5T(WL%
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M3IH0OVU:0DBQUV]@LOR&'K/L1/@W#MV$YX3"<S7YNWAVA6(O2L,3=B@\G^S
MNCH?STT>:+J?>0Z<;^:1?JXE/O;<DU6Z3?$O>T7JE<&CV7OO[<E7RJZ>0VJ3
MB]XI7R6/R+"L4DA9\!2SB__/P&TPVOOR]H9/89M>OMG[,K'VR":4_S2K/Y$
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MFA^/WGO@=R0W]>UZ%[YPC_\I:O[A*_@TL_L?.^LI7\S1"/!>WXRM'A !0H.
MWXE!_!WE_TJ'\7#A#4S.TFUN(;8=;K>P:#*VKDF&LFN@Z)+MH%*W5"BDFM,=
M:!"P*F#[>2R&?_!%&B<6O9C@W%ZQHN&2(5,)\C_P-2>'=L@],VFZ@:0+LA=[
MPU\Q.9;!H"M-CFP4S@&"*#J4K^V;I,D&,A3D^"0_R&P7EQ[<0BVG->?Y#MAR
M[0/)T^'57W-UP@EA+*_>A>YV?C&W;ZHNWIKFN935I_C2B$7+'^Q_*" *W_-Q
M@91ED.:$B:.HD;?E"(P%\I7@;%)0N88V:P-E4^\3_Q/5B21,A7+"4D%HD'<X
M?F9Q69LC*>C FP9N[ F7LW<\B>KT09-B%Z$)U R<$IM"@X@37%0R0V(*R5#B
MS8[0V Z(Z-5!#2S1RH;06F4@AG2-7<9JG]D J[9+#A0(U(NK:"[NKJGN+54/
M>1Z[J8=?!P4$.> ]U5#D7!X;6J=7%0Y\D]\O?8Y=3IZ'U81 ST3)X5Q!4[['
M;%I':-E\VPY&Q!F^VQVR#=?ACI5M=J.WFM.EGXIO^4:!%[H#'.R>=)&2BR-9
M^]\FX.VD23@/PIT$10$[&*M*WL2"YY&W-F3@7-@+*4WM:P0Q54X*AQI',!J.
MT"5_M7581=+^NM:*]F74W<.=]WB'647[U'\5IO:<"&B*[SP7HU/<*?2G?5O/
MPLM0@62((=3@YU-;='=5:2@(G*->D@^Q#.0NZTE<>=3%3J1\!""*^.WQJ2=F
MYA<U#0XZL_;E-]QM.9Y;_*[HX7/?,^'"9](PB:^ C8=L4T@^7+VR0G7<>P)Z
M%(=B]P#*E.DD?RY\QS7U9\O!D+N@$D7]()!V3C08A(#/M?8O1[XZ.SG8\(MZ
M/9=XJ*[I;XKZ\%Y#+-Y"/IV-]-B-'@1H;+AZC2\A*!9->PJ579SYPFB718.A
M0L"3S(?J]:N*/RMMBS.Z)JS_$%6M6V"Q.BLIXI,YL[^$C7"8BZ-E*28H01F:
MPP<X]%+BS-AF,ST^H[1%+RC'_XZ%9&"/D+TW]]B9!N\Y2\X;"I.]NG\J4PZ_
MLO+T6E5V>Z&%1K+0LP?0A VFW?[-#HF_K^L N&F$3BB:9L8SA,.^RD=*' GA
M=NP%17BM]QF:I=M8E=&Y@>A9QR66#:.ZFJ6;"=_;'4H]4_O&MIG'=Z68Y\6X
MK*F1G'"-L_GXTFG'S'"G9H;I=ZW.]BP9:N8,B,FO/BC-*)K_REFR%AKD#=[0
M,)0F4)0@-2[KNF1=.F3$*4D4V L#65Q^)?,&V8-#*K+GIBG;0O:^FN=%G\Y1
M5KM[J^EI68,'=0[YN@2-&@EC(0^! Y?Q?A!#-H)T!'O0@>R%9JXO+)\A@+'$
MM99HV HJN.?[;-Y8Z)5XO/F\WP%^G\\)?,LK@[9]1)N<=[\H;8MS^!;40+/Y
M,M2,!@$E7KS>0X9ZXW-;XL$GE+<KO2GAVT=B52$&1[Z,KG*.LN4-5-T!+G4@
ME>G=IBW5*_(4F%;=%B BY7C3U1K#T4=[:\^^S?7H,[[T-'?KHF/7KU)F0K7B
M4U#Y<>D+X&S;7.!Z^VII$N F0V$D*^NHE>:VY? :/E >/AA,4Y(8H<-6"VH8
MY?[F7A4^+ T]?G".:DDLD:-=Y."13 KL4M-Y/!IOKGH5J_P,9H.JH\1Y$)T#
M!_GS:5SYBG+Q)0@CW BYBW=!0-F)FI12FN)W*+V\CTM8"@WAISM Z4>BAP]!
M+AYNK\ZU9 8G04T7U>R;-.LCME5<MC+-SR2-P7.D8@M2-0<8P,P,'3#GT&=3
MOF)RZ1%%\WT$5*[/S1*U/A$FI!^[C"1?+E?VA%BN%]JRE&+R3K U5"D]97>Y
MHT"1'9XYJG9KU.EL2YLN[TD;I[4..(F^92.9AK#U38C1@2LO)@JO02G\,>Y8
M/_.E1!TRYTJ5RRBJ LL;2H+,>BX0:N8DP%7ZT:C/!>$$=BE71XQ;>$[U52_@
M1;J45'(L&:71*-8@7Q;D5^F@(Q/F0DEFF[T%ED(B-,"E!6KH">2##-)KY,NQ
M!N'[ZW/B?<I+-M=+3($T#WOL<MJQ6N];LU*>R5 >/R\?8[=^TJ6?O=W ^@:Z
M"J4XL>HX3WA<&F>(OKX-75$]J$3*JV;0EE*,),<%1E74L(3UM1*<47"1N2>7
MOGB7RZD%5 X1_?U\0=NO& X-?4[D&A*3;)'FL>U%\I9*W<:!_NP#.Z46_^TT
M,_><T4N\+,SK];H:/5R<D9,=$*T3FWR[I;W=@;Z>D&UA5KKJ'N_3@_>1=;>2
MUF6!6HG25S(4HHH#P1Q$N"I2ZE1I[\'E! 3<.<H,O8@$8^@4WW2G8&;^+=!-
M;QY9FR]EW9:8I_XL,6@<[:OE@0N@+PIV_(83+S(X1'FVT:UEV%@7[_.%G=*K
MC;K>ZPR*]YLK^5L=/'L0*S37&+3)C1[&YS0ZMQRM_T5_Q7G2[E!HZI\]C[6U
M%C_C?AEU\4$U8\_Q?>(-0"FVQ)B\1*!5J6O%9592 VEJ:L*;6-U082!T/X"?
MSFC":) ]$TG4/0TYK9BY/0G&#=CUY]O5^2DW)=BQNVL?<\1H^;R$Z$W+6C2O
MY>5?>[H\Y3VN%2.,$Q##8+E>++:V9"$I$&C5$9Z'[@L&.[2"<\QU*C1FRE#!
MWESZS!.]?NUW^$Q&POIW369XO; 1<Y=ROU_QV#2>CI/"GH8-ACI6T,!5AUB[
M$,L^BBK< .8H!P'(,UP",S'JF115B:< $PJ>-2<(0P5-L6)#"'.\?I0=E+"V
MWE!A[P4*VNG$3\HZECU#.<$@MY D44AMM^0<]#E:F!OBG['X"^-0B%T=9#OQ
M CQ4R/_$*SL12_GJK,+*I3>SA10H2(RC?#@1!1%\7EAU',0Q]GR97>0K.(!6
M9I?SZ,KG5+%1B>?L[O9L(ME:%.?F)/P:JJ%O[/)J@$O!+$(5T#S]H@]>8%]!
M1+S*X@MF%WU>08E<H,(4'4+!UF/-)8>A&\"5^[WP*@&M0F\1^;  ^]#GU O&
MFK8<575:R(57 Z=(8'8)8V6A_]/YN&]$X7V((;;L8^>N2:G2"[7#S1G$+I8X
M?373Y.!"S[0Z02EE[2HLLYF)T!L67M"5?2H@X,5Y6/=,0T=A@PR5;=?.VI_0
MY:1N47[<\#,(_".YNIDW<-F9S_@^W)@!>\'BX<JM?M+\ 34!T0**27'?6F!1
M1</=',BA33_GO"!@E>B7@SAUU+<[=J__:%%^8)DQ[ZV#UZ4!E<=PPG_?PBQ!
MTND%(+0A1,M0N3$#BN(C\.?VU3G0C9<$R33<O")+ <BAE^&#@&QIWGTN9B'Y
M'#28!)7;U>90%_4U.6\YZ+$WJ(RR\6M58NIY8<*R>HDFUVDQVZKN-/R-=?+)
M^&)\T^9+^A^,!Z][4;^ VI(=XGEPG8@V$,/5:_F%CV!/(U],;35052X%%"0G
M()Q H?(:,(VLL/Q63!Z /O45UH4(%CF"Z.(+:R]Z5=EO,Z\9&?/Z(*QU<,BZ
M?MUW+!R\1+NS3?X.^:)@CP(^]!#E,X"0T$7V?$I%BPQUXY=D\ZMJ@>GQF",E
MM6;Z=(ECEJ!',&^;4U /O)F5,9##GH56<#I!Z!':ZW_OVSJVI>I..]E.^AP\
M3[R!4:?,[0$7>Z.OGZ"&@N?0+1;8!21YX54^ELK5)7"_00>OY"?"RBYDBX*F
M_E7O&B2FBD6J8 39T.C&27[78_>K&RZ2+3TOO_1X*I"7+(FU;Z*L)86T8\)/
MN(+]3!YQ0M+F&867+,5W',\T\_$4^)1W'RR.+6\A5*P6K-[FFE\>X%_AMS6&
MZV1E7<"/;RHF>LUK4J5DS4RNN,DEZTM#0'>:'-Q$,9.FF^$%M ZM2CTE:*S"
MW6U!,@\,8B\<U5,D;X*V/8D"H*,T>>_9V(TG2$#IY7V)M&RG/AK_#J']Y[;;
M]P8/.<1ZA,>N>[]*H#4Q\F2,-!GG1@LE*--A5-\U,(=1A5Q6;3LDQZ_?)U"4
MH2H %%F[SD!Z7KP/8OD*5,4G;I'"FLITMY9*/%ZT0\J[:ON3&[7>U'H[C%\=
M/X%K(+[AY04(6#*4NN'X#;Z\4$6:C%T$UVN82I/('H+8#GPE6QG)M%. ,@16
M K.Q*VH$.N6$N7:]+:T<HS(G(JSTE0]>'U%0T%RJ-(BY280;/569+RW];IS&
MI!.FX'_[,MH4]4RY%\/\WWP1$.>'F9SK/HTDEP;T!2=H@;RX1@/'>>R;,E0.
MM9001#&"9D6#"Q 20&-(01QZ.?6V'[YB0/.XP+&%'5IDBKN]D;R/3MZ<QQ<!
M9R -*U-WJY]SN-5MA(/AKE592;W<O8DQ@QP4<T74]Y,1<.YXC:MX+5R;1?D&
MKY2^&&6'$V::>3TE,#$WS50XU&7D=8(:5AAV$7EQ @=3H:$ G<KH!9<@:3^O
MAZ(KN+#CA<"2JF>V)NVG:F7=#J*9W)[@JP4H#AF)YYGR N4[N3)4B)<#Y8OJ
M@XD0/U<]&%Z [@>YU<#M@GD)*Z$H+G#SXRN\-)X'S&OON:;J4VYNRK#SFT5/
M)=G: 8M)]S_EYA$&TDWGO A;V\8G#!3S,OQ8PE3^6!@BKTQ+<4M!5\(B:,DN
M04!FNG@[Z1*S(TZ(6WCU[6B\J7-#B6$?,A)/^0-@Z$CO8E[E-B=6\"7O5%4/
MAXOZ>/!=W&YCPEP9JM2$8DC2J'_OC.&S!E9RCDETQ88.Y L-P!G28,GB[VVD
MH-(2?:C</:-7J"I#5<;OQ"^K?D$2L3@O8KD'S]>7M5RZG0@=.:^_S]4_DWFU
M*>% 21!?36@N3:3,)2\4Q)0=@[4H7[:UI]'/YR5LB*E2S7]/5R-%CW'=[HS.
MM[NXB]&^ I)BPK$;SP]#OP:K/ ,BEQ9_)9KI>G.ZLO-##]B^<&AU_XKRQ84"
M'4FPD8 54C)_7P>A>;C4+_0.10^!-2:?>%!UD%$8@.D8'28OXY<*]J3PP!ED
MIQS(-UTK0J+"G7VX^\#7W-EDW5/"#.LO_J2B.EM<&F5QK',C69=38UNYS3KJ
M&2G&IO9J7YN_Q5?#)H%U:/+Y_*VUU?ZG$J&'.37JN=)M+6?/#1A>J[M:57)K
M0U<5VR<:IU>T!F&\IU\1W:')GP4*/"K !92UO4IL#&6]Q ]ZQG^!#U[DCH1!
MKMK@+6#^*;Y2# <=0D,;SO=QK"_"/(7\1'6ME4:'?[[I8VUK?[VZ,&[7-8M*
M2NZY!/7:(L-$=^QROO#AJ6<0L*/^PD@ >G?=!>[KNI$[6M8W=*]*]0]FY1T;
MZ.^_D/$\LKVI9<;>IR$&D89'#Z%F F_$%)KT#F8JNUK_813L[VJ!26LZ<<2J
M!/>CKB]?:OH1KJ'XV_>J=\KU^\1AH.'"?J"['>\G^?X4_143.F9WNX,Z-RGF
M6FKOLV\ZB=]W9V9TIJW_Y+"^W'C%]1T?-%<5R%!YQP'F  V>43FQY6579;<D
MX" \#N],/R3?&]JZ >P6,F6HZ:=E*&ZJV#5& C?+4!T'")*C%+?:[9@7F MO
M9"A:*TXR)UR&"DL<B"8,BQ&#<&,S(#@Z3K- 41X%O*F&@0LR%'^M'KR>^O?-
M I9.$YT25NN-2[-EJ/>/0.@EMME5AL+E = 291E*D?!XY/^WXO^WXO_M5B2Q
M6-%[/O$56K<<3/X@-[!I=--;#..GQS#118;R!@?OPTNUV(2QF/&PWE0Y6?/_
M %!+ P04    " !XB>A:CN68JU:A   &S@  #0   &EM86=E7S P.2YJ<&?L
MO D\E._;-WQ)$:I)MJQ3(2)D+TVF$I*0/>LDR?:3;!F%J[+O12C;)%NRC%W9
M)L;R0_:=P@QESXP8@UF>J_NYM_]RO__[\S[O\WG?Y_/^^5PUQN&\CN.XCO/X
M?K_G><(<9\X"1V_HZ.D +"PLP!WH$V!. 5J_O_I?^O@]R/_J&"S,SP#W01;D
M/AE6EE/ /FX65FX69BL !P"6 __3 /C7#Y9]K/L/L+$?Y.#D@@RJCP+[6%A9
M]^UG/7!@_W[HNT'0]X']W >.G52\PL9C[,!^RHM7Z=G+[(/B5\N;^4P&2!+*
M=[V?<W#R"QP7%)(\+25]1D9%54W]_ 4-K6O:.KK7]6Z8FIE;6-ZVLG:\YW3?
MV<75S<?7[Y$_.N!Q2&A8>$1D5'1BTJODE-37;]+>Y>3FY1>\+_Q045E575/[
M\5-="[ZUK;WCS\ZNP:'AD=&Q\8E) G%N_ON/A<6E9?+&K\TMRC9U9_=W7"P
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MA*UD!$B9(Z&39F*B01=M^/TKW/US#,,Y3D>#LNE4=3($*)7;+<@8.$>P^/+
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ML!4P@=BQ7W)_EQ ?WX7>Z&PD\D%%$B_.!,P^6>[ IYB @<+.!1%U"(D-!9B
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M@<4%Q%O9R+UR<W09Q5XQB7/;^N92YRMSH4M>YIAQC$&G*MV4J!Y*<R#8!>;
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M#'D.]9D):"7LB)_O8'1]46!4CCONX98@]B*)V\\$)N Q3& TE=?WE:4J_5D
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MI"- _>S0O3.8IOS'L)N1U)T$>O2'G&8^A8<Z/C%RE6<P6\Q#"#]*U\IJPY;
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M]>G*;GI03W=,+)R++O(!3#R +X>6EV)ERJR<45BT&+6BR(.^1&P$5XIHY8_
M=S3=%>%V*!'<79/:7SJ"[KK(&.D %.#7=Y1J2A=N_"+A=2$25T='+,S56;U1
M+.GU;S KOQH-OXY$(R50WU>&$U&BG4 0AY!WT0F"Z!E,+72.P?4*!4U\O4UK
M+_O'RG*NBFQE62HBSBHX,BFS)//^ORDYZACA.5V:( 6LPL4!<'3JUD6S*([
M?,**&4P9F/2^>HH1:!<'/C:G_$H?_0&H3FS=;3#WSVJ@*??;T.VB.O2@.AB+
M'+^=L@)V/?1$VK^O#:80&] LXK0F8&_V@,1[&8@TN[.UD;OS9C"-=3J3# ];
M:<I'B$O_ !CWI#7LEB!]=A7F4CDXQ/)A/R$'*"^E]WC)1F5;- 9,^6^VX[!$
M Z[Y0@:_SXE)A8=6I1):Y\-SD6507U0O3J*[F2%N<*+^F,$\KY;&2X$<<J&
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M<O]8!">$08)M[&[$QLU=;/G'(C@]%"?0X1 1^_X]LW#"@%GKSI &P+@^=&\
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M'VYH8(32QH^9X^"V";8! IUF"0P)U<9_S>^,,__8*]4-&(V,&V7-PHWVWME
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MZ73AMGYQ;.O0B^%Z[T"9$60#7'M&16#T2%CA5^Y:K/\ 6TWH8Q4YH3]8S]Q
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MSP:&[PP2=$97\B@]IY\&X#8!L7.AZ%FD5!.VS>^\K,2F4;ZO@"MNY&&-8#1
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MN/2P^&7G(24]1Y;DS;O#AZ5.Z=.4V?^ ]M^0_<\!B_U?0O8O8/\=%P5T9*_
M;O#VBH(@(-Z/ID+_]:[O=J,;.P8&<AT6NG[..3]NE69J2O[QYFK&$<Y3X@]*
MNQ6H8+.:2O'6YH.*O0?XH,,'R3]AUE5\T)L96L@VFRW-2QNMJ:T#:_F*W-5^
M-=,R&/W=.CS+4_GCH*JJ[GV;D0;;G(F&F)M4[T7UG7(Z=5OR&YGU+(T/RM[
MP)$MO(1H7:Z:(A_T)28BW'$!]E:$B^.#'H$U>5%\T#R.^^#=WZS ?UN)EY=$
MF.Y\$@_*![U-^K?7O[W^[?5OKW][_=OK_Q*O@4\K>05Y1 _[JM+>RK>AOF'1
M^UXL6Z-JFQNF>Q6-ZPC[#QD==O[22$B/K"]IM<7_E-?'<D (\+9[A9O;Y9$M
M#VOO0P0\8M:V)J1D^1QUUJX%KI_?Q PDI>C@B]\N8]:-D)X\(LJ"#RK96%[1
M?#2V.^MM5LL.$M@ML19+XQ,.%W9+=1P?%/*DE,@']?-!S3UJ^,'V#H5)VYTZ
M^W*6QDI?VV,^2)@(9D-[R(2^FB@&3!+!$YG\098*U QC3=(R^@IK@MH2XTW]
M?&M[I5.UOQ&$Y(VAAX"@$3E$0TW]M,=;%JZ7FFRF!T X!KP!""&@.T0!Z(.F
MD0EFN1>2^NS0(=(KQKVDRC)@I7NE&NCO37L&HWHCPWYM!:QB3N*Z6R@ZCRHN
MTI*9O@0B%82<;BX2&,\^UU=M7QT;6V@D57G.I;K409UTI2V\_-R F[(&>C[J
M0Q1])Z^@W*X)^O1M'WSV3/8Y(Z'>, /CU+.9J3IZ6SCUG8,., 'NV8^$7?"8
MIB7 84X8UG,6=8YM]>TC691K6[PRJ\,63-<.YX-D JG';A'U2H&&64X/I0@?
M53X#X*W(8W4&:LQ5YL;.33LQH3=,L]& 4$U42R0>44E#%W*<I@%L[UEN=,CT
M65C2@!\X+6*T_ ;@968XRST=$M??&4K%'C7<#<%!_3USTQG'5JR?]\TJ&E'A
MU#/)<S_G'P=Q&C*D[>V%C31XTUEZ6*/5$634=]L\:]4#C^QO$-BF-=>CAR,D
M1O(:G#L>/4K[<F-U_"9#SJ*Y#!\-VXQ-Y6%XNB@+-KF+.F4^M\:,8W%Z9[7:
M=HI)*DA&GZQJQN^XWKQ9?#D0=WEB8RBE!@_'SK7GK^".3'F@--.Z/?RK2@HU
M+[_,_37D<!4Q>R+&B@FYB](<#C83XXWNKA@ESOK>4Z0Z@5)F>VX&LG4S>"?=
M5XI.[^[6LS&N%:TNK#,4B*1#\^N#\IZ-_(")8;JLZJ][#Y7GRVNZ7I3M_5VA
M3TE^[/6Y2TZ;5=,KHK99-M^[[G+"IQ\18KY\*P]@&A!_NWKFQHC#9C#L4_//
M1X10Z4T['2]8VTY9^/S(!S>(E5I)S>?!4Z(AJ13/RL^"V>*7\7$%S7[(T;TG
M,J86_T ,4;=;%B)RU&HQ3,VU[3TP#'4%S+,IY=AP>'_D4K>V=U,\J[H5ELO;
M#_XN.8G[O-NH?BIYR0<1\.2OAV+X($PMYJ<&]B^^V3\Q<PY\T.FV[QS<3SD)
M5\AF]M:.@"YY[0>6#U)VV"G?=?O5=HVSX[M[M)WODG6YAR$+TMZ8,#Y(Z69J
M/V^$Q <]4][:X>U.,U\-^<M,F6Y?^* '5MRNE:%5S/PMA^M\$,6-NK%OUX4\
M >%F.UV,CM2J.I'G,M-F&&EWJCD])>&4E.B'U;N_.C1!3P7L/:7SEP'@#A8!
M0=M]CV@[.GR0YV23G<GEX? :=WS3!9@;J7DTO,/PW<R11[,PZNR <'EA[4&A
MP=!0K5#+/QK;_K [F:?OY#!BX6;I9N42'O[;NZ^O)?U^N^+WVT77?;$'?Z$7
M_KI?PN&_WY*O43I )8L/8D ?$# I,"&BG1]#9"\R-MB?:LF6*I2<-XS\CHSV
M'N.>J>V7\$AH*J3D"T=;CFU,H::1W78!2I=_3RA]R-D&J55[Y)17!E(B>/@:
MZA3<PSXW(.SY\OV*\HC]F865\,UK'8-??NPPQQYZND]1//M/;1FYB?7O.]:W
M_NYK\GO-K_=G<^EV2O:3!$]\\Y)Q4VUD6\1<(GU_&^')[43ZN?J2V%")MRF*
MD2F77YZUR2\-ORE08R&YR <)H=6Y$&!RSDZ('M)%%7=']K\N4I%]^I%H56D1
MO;^H1#_&]]I' XB*]J6)#VSTVUJX1T)Z400ANKSI'A9E<>HWD5]+4M?7TJBR
M)$GN7E9A2R;I-#!YA242'V+J1 /OFT:T3;5).0(U_44G7[ JX_4M#',F'=,Z
MHGL\*G!E4[?3+]^N+Q$;$!.;VSL6B(>P%GNA23P=]E /)K%(CFV04\/ Q3L"
M]B+)//E8S1XBJXQD_)%,4V'EP08N$%P?R8=<XH-2LEL^W=:)O\-M43E$CO0J
M7"WWJ=3RWUR6NX=C[J&HWOKLU5%7WKO38^CZMHV^2=?4M,VO:&E*A;^7^GY%
M25/NF,"]U"[64 KW N."H!T;DA"1)HSY=7P.D6'B,GI;;&'DBU*.;=1'XX+^
M4$3$D<W(YD:M2%>CYBVIR#O=$?L^5AK-45/)(NB3"#Y(E*L]1Q6?0E#XH"Z(
MY#0 IIL]14A^"P/<>B/1\L-$]Y 2:M-X[;'!,-TDE'EI4)IR>HMKEQ#PL$*\
M]J6EP%=]1S'0J3]!^[+L07NSK$U!@J>*LN=G!0 .2Y/>DLBU98 3J+)H<90U
M"QNG$U)+]*'C0%Q+%B;=]#S-=O#LVX@+-J,];=2DI@PKNX_U!.;YW&NDEG&=
M8']"@U_;JRMSBC:@']6:7RQVVLD^6X3AIGT[#1@_JQ=LJ<JP$N3]GYC D/C@
M #S","1$?O9AR6>L]),(.\<)VX'+K2]>1JW.1=?XY4C Z<++'BW]Y ?W!3,G
M:??:V:4TLS3VF0T@(@*(J$%9L-"%C(J1^DL&I J2&''BY.0'W)WZC/USH[PA
MM8@S;U['_:K0:"%__Y\GR"7Z:5FLTBG7$:]S?@K.=F+G]\V]T#.%)RQ;?F,\
MTQ?XKVBCYC\YZ8Q7U,X0-R-5$_P7@GO^-^?S_\%W0GA(*Q_T\*7%+E'!89B/
M8AP>'[3+..LNX+^0CI7F.A_TNI3G$[&X!5DW_/_DTN=?T#!  O->A\A;Y%GV
M2F+_1H>8OTYT K_;#^W!_DSX)_62#<R4N/X[)2AY/FC_D9VG)/&W]"$1*Y8)
M Q)/.K-\%C@PT&4HA#</W:6:KFV_+^6\1H;)-&>@]3;.A93S16L#$6/\SD0R
M]I#%YS5-[(/=@@VH]?=SH!2,^3#7BFW;W>R16<.!XZ8JW7:2U\RD*I[20T2X
MBA,&<G4B7;#CHW3G80SB1A"E]FT WO/I*A]$.S'&O#W1UW7@X&KA1L-[B\"J
M2\X>R(@4UX+\+V'XHZZ/Y<O*DYZ7G_=(OS"N4?7!:+[(.,,(WE?2%&!UO:SU
M,=SZK;?-\KA/8,U8+G%,-KUN1VP8E@(^3$;H4@Y3>8>5R]%#:"6@5Q?+%<8O
MX:0$T[A*##[H#]5-3".K/QEUTA3"2H=#0*9>]3NX:P"ER/V5[(_QCLW&VQ27
M=L3IS[\\](W[B@?4I?MP%-6YR"[(8:X-H$?/$'R]*861(!U'PGKOW2?'[^Z#
MY,JL4@.[,C/<:X^GO,8JQ\'8/BDPQ\CHYC*3L#)C:5W1(I7E46VM9#M08R6:
MU-TZO-#3):G^]IV-5-70NT+:^W*D09E'9'KK8^\,7_4VEYJ[8U^*SU\*)=S
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M"RV8V^>1F2\=MP\FP@,'29M=&#<#+]65#3)LM75FIYV?$NK.K@OAOY;M<KR
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MPJU6ZEMHN^WIBT_3R+@KHS_R8XQ<1YNF#QK(!=;3FB;"TQY$EB]?Z]5HT%[
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MR\NUMY*TRUI?9G9?>Y6SHKDM9W&>\>7<N6BUFAV?RB'5 2V8[H1\WHVWZ_@
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M0[8U6@=UY%%W?[<T1H ++4:2[5ENW9X'4?YM3>]Q8AMD402E.5^JYGF@%*7
MMFP@HD9FPRU33FG[,+61BEV%!'8X,78[Q5ZF68R2*^O4KOH/8,FW=+^ZY0<5
M:&Z*H<LA E%>(JGYU[ ]IX-:/@S6ZQ0I15\?.;[Q]?<]H31'3.?Y#=UC2-O7
M5&$4AFWNR%;MQL;G2:?JPQ*D9(WB]6&'D*._YO888OT":H"T?BGIW$@%U3&"
MVGOIX>2-.MDA[TEM[2:<F,=RKNB3Z=%2)Q YO>JM\;G MTZ5%U2/C[G4%H2H
MO^68W79W"IXMJ69(6Z(BE-(06_;PZFR/L(*(] +Y"TXC9VYL+J2/N,8E4*K
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M^P>JZ#7!Z$GH(W=V1\>W+9)R$TL?K3:IS+HA!C<.;W9SA+?(9O<]#\\/Q\
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M_K5?3'QKX0_BCH5_]]ZE(<BF^V#(&7I/6@Y3[^1('3H^U>LHY2T.B^DU"+F
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MXC]F*TV['R?5!1=1(4^M_.? OXCC:[\7-DX5VL<$_8<WW!?:XC=0BDJLSE<
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MZ\'8:T$?N!C<L((0[J'^D7*-N "_=B+4*)R=L_J"G_797S+$>^Y\_U?!GJR
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MR 7HG(<3<7/MH(X-.FZG68P TO"5 UDI9SJB?+H+:*IB_,Y0P"M%,Q6HK#8
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M_<H_:?JBL/N[+96N5EP$:]IN'58"@V[ $>]D TKR78UK8\:YN07N)///,\0
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MPX(SB:+,V[;><QDB KJ)@A+?Q>G$/\_7;H!'R:JL[8'Z)^O >'MN!J67=E<
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M]/VP%)(N8? RH!-C&F7=U;=CT2(5,XNS&YS5O.7.34>&CT;$;+57R&7&9'C
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MF%ZRI('_.74,J@#T-LH^^)FO)#7LLD?;1E>KP<J3:04:4;U\JJ0B\/0\ZB3
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MZ9PZN/. Y'WBWX3PVJ)%E$+N6X\"*2 #!M<=70M"7AG!>U/D? ,>9H=%'&S
M8,O?R8R=>)-E4B!VXYF,I3N!EIL&\Q09^$D0]I9<J_R(C-TIC*:!ACBQ]RNB
M&S(9QD+D>@-Q''7M ?Y GQ-(+L.B+(2[11IGTCM&#@6JHF.*&P:-@D:131X(
M%]*D.?21D?@B@../)I),QHE'A2:MR*0(Y42X&N')>MLZ"EXOA"28M9QU Y+G
M'GN\5<6HCB::B#UXRSCWUX-&=5)XVKE5JPJN7%;(: =;F2:1(@T@U"1*:,*5
MKFVI(^P[:#5"LP#:9J) R&TC*[-V$2\!T*?D@&7DC(158 A\H92@P+ZK@"C;
M7VC>/3 @<!Q<&Y>S941Y6Z=9GIS[;;BPCJ&4?\-Z\@""'9^$Z3FBYVCZ;YD+
MQG4]7$$M=[9,KZTNJJ&Z[$)GR?G!0"?.83_WAF:K[L D5S^X9R],+KPQ+>%+
M]&W]H$%1=9*/EIX!8KQ)7+O58FKR)(?<:?*(9 F6")*E+YB198F>X%F:^,2(
M! KV\.^5"'?Q3%(-5[VGXYM&.5N:;]U5J?$6F@*RK/=7$>PP80HK&QH9I?U]
MW9&5(ZM=+R\I]9CK6_9 </[S@_4ZF:79S<N+%$43)E0H<V50' GT.8#88B)B
MA*0/)@J0CY@.6\_X)HH$_[:"0P 3AM(9)%XJG@9QUD,\(2D?^\"/^NO )^QA
M6QQ9'B:]AQ'OCC>>][!U0>8$#606XE7>Z)G2G6S6B:_S^>D9$4);<V-QEDOQ
M>.[ZK<QK4^[!">FV\]);FV^X#J_8./#HE*RY#4>7!0DL.#+"VC6_XX'J\I5Y
MYTIX/<W-FV5U-#E::,4_:Q??N07YV0<$A38'.%T.K%ZXONBT^. *0=%@/@*T
M$7FQ0=M*HC58PH=$FZ,[4J4Q!7KL;:GH[/;_D.,IL?D.3UD:< J,AS4?+;!T
M (\XIE]AP !'.?6 WBO"7P'+^%);VGPOJ=\+M:",(D\.'WWS?;AVCGW*6_1,
M/SL]CU)75UQR\=T/QS.SN>O\ER4]RG%A5/+#B5YCZPDCQ:-5WJ\8:E9>1CJ*
MWYK?3'[__TSE_/^94I$DHDH@6ZP[S__W3 H%)ZM+-ZT4KO_TGP^:PF[H?#&C
M;F /&@C)OB / T#YZ#9T_&@V0MK"YA5HMRW%WX'(G1!U<;RR8QFX/5-BT_ZB
M]':-7Q)1'^\T^K(TSFUT_OF[Y".C^9%A#/O7"AYB'-:JH<42PI8&A>36'%@2
M W=$?  L+ ?33O/HTESQY<$C'-(IH&,TUN(FE@Y>Q38I-3\X5UCH.W&)UXOE
M!$\MJ$K754_VWK;,2T]8:#5];;IB[+;900X>:-&O&&,'E.Q1K1HJGE714FGH
MGGP>JRWI?)AZ=MUTO8YQ#8[_9ZCQ;_KYXD&F>YG/O]VZ:[AD%U(O6PD1D,J=
MYD&2X'+SB#K(XQ7)D:^(/205+$L)IRKYJ!2R&(%^++;D3X;YCHH=JKZFE@2>
M"41P-13-'\8$-R77?@)CO^PM"E!;^\)6LPB:@3Y!:[ LQ<9"1"LN-4*Y+=D!
MCA ;@,/"1%$4^)1'\VY3I;0CCXK-L[XXP-I)1X#IA!/ -_I+HLV0H;^YSC.\
MI6J7QP#3$X.AOBLK'*H#UU2VI?Y8O(NGQ=5FH+4\EM05K:X[5R@5]1RU/I*Q
M-6]7J>5L9B2K(X?ILC!:<1=EM^Q9=K/QX#*D<YO3,URCAH_:_7*?F>X\@/M!
M%0'U "R:L?)H^I@_^*-4+ /V IO>0FHLZS!J$24]+-&?USB?VM4DUT)/MC@1
M!0QRXJ=T1@3I=@-!>,1RJEQ+50GOQQ\Z:5\])WH/L#Q?CJ&('L*5I7QANBA^
MJX(E#ZZW_DET>M.\E;M#0?:\;W1>OD'GMM31>V)-?N^Y$WRT?&#$>@+^IG8,
M;TVHF\Z14X[C/75Y\F7:]V%3K?WI;Q0&)9IHY2=,%?T.;O(LCW1YU5,!G)=P
M.*ME6VHO^\D),+&$_<@BK!2C2DX*W5R1XRXVP9[=96R.&QGOXN'DO_X2V%/B
MVQHB3:/VWB1^G39U  9GJ)T0;N3,7 IICY@$C#Z^2[PH[!P7I+;WC=$[4= A
MI@$?<EA\A0'8Q#//PA(L]O/8\E=XRV3.U,D10WR+Y%Q"G\U0*/)07VEIY?<K
M9?MSFZLJ+R9RG)F?&P-NX3R=J&[]Z.7]"PM.5/,Z-\> ;C.M7N7EBLNK+DGO
M=SBXW.MT6(7UT*1MJRNY<>M'$E45[Q/NE:'9H[4TWSU\ET_J])C%+<=4@+"9
MAF5E'C*9I+Q5*CX!( 1QB23Y7F!;RA-(366I$;+YHS%$WQURF=)M%!XCG1H*
MI<C8!_$A/UWB)9-O-">057M>>1*" W"H<0]/AS1;R$(F*8QX<P#'4I)\XIHL
M'[*X*#SB!L#9@*%8&ZSBFG!L25I?E;T.YO-]<>VH8[Z_@)%N<'V@BE:ZJ$IK
MEYS"B$]7!7A)'C_8K5M6]LFJ(>[G 9I!_6AU90OEV[+G]];R,Z+RZW7+4;?&
M,XYG&Q#[YSNTYSM'W"L<?K B!T?03)]D.R$[-,-/>^6>1R)0T79FDC2T+;6?
MI$<D;;UDR@H1 F,V8,]7I"QM\2#1$KDF@/[(FX<7E<TD>_,A2;>&3XU8.#W@
M]XPWQP+1Y]9A.?\9WW+;T'G>/+1F8M*'/N]+LI'TH67@"E.2$98<6 3HB.*!
M6#:0SF,_(IT)*#BVE4<WTAX4AP%=SB"]BG#%7:C%>GRSK#Z?;VG FV51>:_#
MJ2#6"UBK 8/GW'+Z[)LD[['8:P@?/0%M64]+Q^#ZDP>A47$UZPL,6^?/":F&
M/CZ-OM>Z0_**G!^DS=[P_N[PIB2BAMA-98@*EDT7S%.<@[]@2O#214<[VHPN
M2N!$;R$LCO03:9BL4+I#)"BB$8@6L),'P5WM4&66*O'FCL/ :8 >EX6J 2,2
M.0 9C^Z2J Z%7C2)I0#I\UGNH@=?6:8C+P?Q>LNWF8-[:B<1N:LV2Z,S^Q&R
MI/YMJ6-K[&?;4JJKE 0V YW @A*-<KMR$#',$P]F<#($$QXJ-XH_CHO+RE%*
MU)JJ6O=W&J*T-\":.DOH"UZTCK8ZN%MRDKL0EAN88Q++DB/U0QEPJA#9*KDX
M@O"?YKH@@?RN9,TAR:$%Z"&F00@_^6Q;%OPPLRFU72+'',6K(?9,$H*'#>G$
M"WSD7@[^9M4I;DHNR?#>'V:P)1N S(&K@Z/",'[#8S(&?4 <#D95$D^#MX&&
MMUXG?:S"A5!>5S1Q?P78X-;/O"C8NHJRC:JPI]KP/>NBU%Q&32=-4-F_#1KQ
MAOF-+4^P99&!;YBFTQ;9FUI[-]&W'9A7:7$,60^J0W=.L4#7+M_3ZH/"JW=N
MZ8XO^G9O,97UMZ4(Y5N4NAS7-#S.S3EO(+O.P=91]E5WR=7YXJ&^P05QD)#\
M;#7UT73=2B=DGUAFZS5<G@!I1QP51[T$1_ED#C2)O%^,% 3M;T,K,#T+OW*-
M_QK9EE*PN% .DJV!F*ZDU67M-GNH-('C$8Y:.!^;9#2RY-V[J87.J"@DF,Q,
M=T"YZQRTF@54T&LC"MDJ9GKO($5*.;XOVIR>5 <![1BX@_,1T&<KREVD/4U"
MN?<DN9::?M/&.O6S*& JG08BO1J:FNJ'G"?&/USXQ4C'US['=B#NFRL&.4[:
M@*T'4E7LTNY5'F_T*<X+Y].CA!X,;9J:(YH9G!=%^38K*JL3J+ GNQT7]*@]
M.@T-I&[2K@&QRDX+^HLII'1>A"22Z]83=$"G<F*P@TQ;#:C3QCK8'\0T(/L!
M]"O 7-QO&PE=_MJ/-4KPQB5AM(6-^L*+M>@>J82]-I.9_[[>E"5J#8BU=I"!
M"^'[Q[$Q)OLE_21E, ZSP]0D!59USLABI^00T,=!'%ST.A=7*+9E,5K>F-/C
M!=5#M^I]4:(^NV&SHX866XX=N*3OB'E+_^2&D5,9D_:7$X)#)T_EE.SFJ3HJ
M3)X?K(G^7?#MU7@.^1A=CGQ;K>/R]U<#+F[&^;9F.F9Z9=UDA>("VE0_>!O,
M!W)]AT@JX(_VZ5KEI>Q-K/A@.D<HM@'C+4QF*(E0&0M?OCJ:@S(=(5ZJ(+ [
MIZ2 ]0XYG78-!2"NW=?F\HA9T&4@X/DD"BQMX]K25DH*+I[Y?9,JT@?0CYDR
M,ZD)&\HQ$IT^85@G;O.2V&D8;D'H]CUA<7$W6\/,.U__1U<.*I_W]41*SY5!
MT[\^]R\;UFW*TFEIBD=8A6%AEN^I?+8TX38/U[8M]91R:%OJ#HX+G^;C'L,U
MK(0NG2P8:")8#N,]K"T-W):"W&/051909@-B&TC'RIX^_LJ!";""0S(>_K:&
MDR.T"22'QY2OG./ZQQO-.D4&Z8RBJ]$<-78<5$ZBBYXFW@5@79OT!#*4=%+L
MM4-GG,U(-0>--;%'$&_\]NTH3&F@>6E^$-V;?/M?;KL[C.RW:?4IX/<&Z\,F
M#T]W]%<-S59^]4)UYFR,(U^,Y$>X_ON'0&E6WSE/9Q]K;;'T<^/]45'&8%)H
M,CJ,Z[#EZS7UP;0<^4)[P*[XMFYW :4)8[6%$_1! N#& "))K,<ORYGF:.@
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MS+>F2K<H_R#^39C?3+*U (OY!OWN/TK'"4>@;[+KA8:B@'HNZ<]U7'6:@&?
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M&SVM.Q\@4YXXTA$,1^-78#.Q<@)^7/Q+<1\SF(56HF)AT#<'EEA_WH^^'_=
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M_Q!3B#KKQ,<<I1-0@DAFD3WVCJM[P/"Y>%/9]VVYIBW(9[XZU1R6+CW>.='
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MBWCX Y_)UEO?K\M0!8.,D;6 VA6*/F:J_ZWB"0##[C@^:4.C* /6X--W<7\
M&<6N2&(. T1-Q%VN 4*Z6[DTG5D-G8LZ/3)AMVA6YZ\'3EZ&R@4.Z^V\0NJH
M^0>6:(U(F#N4J:N?9@N](<]O=L'613;@Z>SR/^9U-=8>,8A7646(ZE<3O[PA
MV/=GT8=<,HA0R8OXM4G,6\%AI#R:HL[97H>S"J,C33N:ZS-<:-H45>"!(Z>E
MC=1PTS>UA/.>=91.% O._7!CK/^!5QFHB\5,>/FA?TV37[A7S#?:/<003'CU
M"0R!4,->2&JPQW_BK8 2SM);)1$2)#6$T1\'<E5NX1B^ )]W]08?YY[@S-87
MO7\0;&I8!8\H7W79 1>99?48MAHU7KKW/"G+NG15=P;&2-%T"JUAC?M8DK^Q
M;>%61OHE.FYM-R=/_;PGLTM-U=S2=,2CR_.>XS=:M'\Z3:>!2%;3D -;(R]<
MMB/_&&N_QWT^/]<'NP(ECDU;<26Z"?I?P9JNB^&D]GV1F)'K#5Q((@YRXM_S
M9+38NF*$CE9"-O=XAM_+?N3UR7?(AO*Z765T/3"[RGO$03YO/U2[')+KD<"%
M=#$PW4:1I[$;YN/2LVY[2C N-68+=J1[]@\BQ*NUN7ELL:,AO8OYL"4"O!+1
MF+7#:^C1<L[]DF7R=/8*7M0>GF7P68-\*'SF*L55K92LD]1QE>(]O+U=8N28
M-%&M =,P08S\ZZY/^\3?Y6YT4F-EY 1U-8 +KYC$\:"""=7N,]X>II._]@?G
M1*3B@\)H*])_8UU8R8BFLM?F4OLBN2HT/J3.^_Z['#+)#>1>LCSRUPX^B:3T
M^\H)++DOZF@[EF%;&S@DB03,T"'EW@U?/]YQ!;7+#2> .UCAOC)WXUS^@3XH
M7PW)_NW=U/NCS]Y]Q"_B$XBZ@+IA7)1W7<JL.ADP">?B>V;_&">N2B1'R@(A
MN[JK47+MYYA*B8AKUCI%=3Z*RISMOT!)VF)]"$I&!!K#6I=[[YKEIW/QO^,@
MM'S$P[O6AE_A:_T5@J'<N>Y*TLA4 )1C\'+^[/4>XQIC4EJTJ;92-)W6)^<:
M#Z6OF4*9.6,_W.&67,L"7]^U+?FSF%O$B7.)6O=4/*[_.325D)QUM*G^BG,I
MV[Y),>:T0G%>O*GJNM.ZMU&O9KU=>EA;P$?41+IMC/N*Q^EJIXSTY)JR]Q<V
M33 ZKH:V+DG@9Y14!EK^'49ELV:!U)RZ@C1;Q[5YQ=)#P6-I\M-K+]I"EU4P
MQTU[ S7/1 ;Z((]0%+Q#.#YSOU/1F-]1DP8$C&K32VXJFQG2'W%:M3T.&HXE
MP:7OWL%9UI,<P39G(?V\[^<O>GJ"[]Z+LJQUGEJO/<7];[AAM%,K]*6\&ZC1
MLBNHV=4\X;5W4L*-9WT/+BKX#D6>QXIV"XZ%SXMMO&@$W.9C-WH+X^7FTMK-
M619<O[]VSV/Q+*NND?C)AIM-@BNC?$.NC 7@'X6.8)J8A8W<GLC5,IEY !M=
M;&LGC7X3C^[&G/YO9FX->RMNLG'[PFB)L^3B4YAC4-F9/F>Z6.[WNP/J*HD]
MQ'R37:G(J+ RFS>9CS-L1=,STBGIOB"9P9D,R'_!TCZS:G2^1,D*^-(D6 G(
M06;.]H?4\G6S=Y"'?.PZ(_S%"<.9K2D\?(C?!EKAO&!T2]M<6[?WPXE9^"GE
M K)[$ZU.'W9_Y$ZS02N,GE/AYI-S3>!^<1KUG0&56F,[1*-11+9XH_4?E#C6
M,5_1O6*C8FQW72'_5-[\UE+7W!$?I$@QYS'RZ%;$)1^!F#!W?QOLAW%J6H-+
M3,GVL/)/RQS$-$,_Y^E=^>G@INA%L0UB=^CO+G9#<CMJ=8H9!AE5%G5JA6KQ
M.OGABHV*-4U#9=:E'<3JBO)R\C.&00']D6>'VVO?E/I,6]/BB0$SS<'13&V[
MW5I-R90RSJ96Q:"V6XYC*:'!6)EP=:4,JQWZJD2K/]++2X5&-5@W*<S?1A[#
MB3/S;>9< ?===ZS>[+>A=1WM'W4I"1PR.ZZ@;]3?]Q20<:?]8Z3ZU WEDU4P
M-'O#"%=1JN9LT3^#/ Z"G%A5/,)9Q+,Z7#H12R_\UDR''%R (+/UD>@@67IH
MB4RD8L[MYK;VW=.C*H\?%'Q;?MU\Y4\=KYMT%SX:>"#!/S7";$IB8=8DH@WW
M14Y%GO3 MO7,7AREJ$E\VA?I ^L#[O,I8O;-N[9U15^C3M50Y&;ZJ[&2?TZP
M)G2(,^:U('2$\3!GZHZ/H;%%V<LTGA83SM<R /SG!RCB5LR;%&GWKP8N@D/(
M YWWT$QEYKJY^'IFKA3E7P7G2ZZW=.0\$X^6'%-^5R=G<];*SUA'TW2T9Y!&
M]&%=^H$R:/&;G]$PTBC?PMM?1F>]1RL(W6!PH!,[1!14-6[]W2V7EIB4M'S5
M@ 0-9_3W$&2Z!.>%!8((ET.'>"APAHM0"L;E+0]8X=3#'JB726VAVM\(./B#
M<+P[2K*,Y?:B]GQ[3-O+ S]?#HY"^M/-66D'0C?Y6GNMIK*UC#]U5,B<D/4C
M(?.%+\(>I__S+/4(EQH?1#V,%0Q(WU!:EFF-?W%0\]MB'Y/BO%/-#B)WF8S$
M1)W4IIA9,%T%XM9,F)M ^D:DH5LPIYY3Y4;,S4#_MK1]_W3*P;^)4<O0X*;U
M^Q9?R:"?NIPN)* FT1TE@D5V>V@"&D%1\[[G9\6UK($M;AK/A M^/K_G=H-*
M]6[7TB%SY1T!SWNE SX7Z_3WU*9[&$N?['=F&=K7[[2[EK6T!L4\S]*@W+6
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MM#[-6<A8^K1$](/O:;W4ALEU"^[*7#=%;*\,#,;IC5-.+8-U.%$I01OB.&4
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MI! #5. \7=<6& )]FP8$MO>0Z>1>./$Y#(K<[JTVDIZE)5$<YPOO#0&/_)=
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MT/(M)F'OH64*''LXOI;= M%!93U(Y,X)YH\'D5E1J?,S=7YN=<Z$G4' Y/Z
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MI+)LWJJY6M)A"+-STFVQP?8W4E-MQ(5%Q]X?+W"P1()75QL?T;F0B'Y ="9
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M"\>4\&/*(I 2@TV'@9/M<"H=Y:PLG/(@C\+^8A%)IG^(7.PRI (_OQR>C@;
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M)YE>A)[Y[42[ZO+_MY[V*#5RL9M=$FX%9])Y!<&KEF16B/]8?DDO-_3KMH8
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M1VEN6NAREE3KBG1FQ;80 3P:*BW5JQPS*_*O1C>?71WP3.JO%/2+23GYF6X
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M:FI;7'.Y%SXRS/*+J6%EHE?W1]URNVP4#,6V-34I86Y]0RMF1)(R':S/9YY
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M!-.<C$WH]9@NQG)KFVK:6U[]C;BV@27/#I3[)FN:P7SQ]Y95L264<TK>YR<
MS3N1-OU2B7LQ6!W<C2%1Q-&+ B.2DM4"?L2$AG+80ID'O*)/(.H=.%7F1(@R
M?_^!,B60WAK'$<"B_Z[P.U^ YIG&S,EVO)E8I*QH0Z;A9TEVO*TB%^AN?%72
MF(]?OX-$RTJ5O8]).NG$Z'FX8Z@U49QN&<G=?*]0CT1!'L9\=SSW:H2'&HGT
MC-OYXD4J.UE$I+4,>A'EONHEP2F%>I\+8XKW9[#M<5WI&PH- >Y^<WIA=D0
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M$0'PMQAN(B#[#Q"9VGT%^OUC!1& [,&E$ 'CH:%<:@ (\C_CU]_"3=JXZT3
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M'6<]E+0V!&OI=)5K"U/P%[&9FD>E7:X/S(\^-6K21HP8$WX!_OOGQM]%;>P
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M**64E&J%\FG*@K/X:K8D,G9M3*DYRF$2=P/XD5J]1<*=NI=,,QB_H<WR7%F
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M<@]K5JXM<SQK5.ZUR _R5S3>6K%+]AZ?JMC8^+L]H7(,R8 !QF.IG3J3*"B
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MJY+*W CP]BS%8*#: 4#1RD;7TOG:=@_>U"@1!_"CP"6*, V6N'<@CB>F"=@
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M^#_/ID(+%?2S%O^TX%'T0,?$1@W#&D:6"/.()&%5BK(AQ8G8DM2I0-6>HK(
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M&R6",IV2I=HM(QA!C]YCR'F5[;,H91!+3F'5]ATC5D//ZSY]0E1@0L; .+Z
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M:),<NVQ=_N&K*\ QQ&EX;=JY-577);4FED#RB)BKX7]HF=(0]*AX]XF&B66
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MM68_>9F2WZ\%Y_0^0"1HPXG5Z(3JMQM6/L*Z0,UTX4R'>G+(-LL2"+>>:.J
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M V\!2PS9^%KN&2"$.M?-XH*5!UNE0"SE0'#>O4 H[$[(&Y<Q)SG<D)TC^O*
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M_>W #)[#;:C7=GV$0S#/_MBP0T S5:=3"(*#=!$DEFRA*@,$\BEJ4 <!, B
M@!%24DT#S#.3K;@";RE)DD]E@),IH/I@Q0<Z5D-<<"GJ5<R2LYC.+_8^(MTK
ME592478B4TY(N\#@I4=(Y$N)JY)N3K%2Y%L\[4'!ES9$:A(U0Z5TDHPW<\Z>
MEU:ZBUI1M:2X;0367:]A$U?'0H_R&&&US_R$7H1)XISMNL1THNH0,P<9^A^
M8HJ#9HZ.11U55I>933X?D&UF2DZ.J<#)6_ @G/PG#[][G^Y$V$R7"DZX(N3V
M4'DC8[8A4C^@%'T;""E'7P%D: @R/AO<7NE*Q M8TL3;PK2!P(G?3ZG6-Z/Z
MX;3C*>1X%,Y,P[F)VI&ABZPOUNPO,2\0=RIW15M9[ET!(DP'51FPZEZ?XJ5W
MO>#HK<)#[\8F.JAGEX139"[3.BK%9:\/E%T^6B@ .27] 1*>9?[2CQI$?M&@
MZY+CJX+G_,88]WQ?GVYB:J^BYA84FSE.EA=6,?&*39@_(G#@3^&N$<!E!21I
M];&9 K%S_9&CO$!\AU@L39TXKOE):]RU@=K=YB5^/=7,U7QHY2OV$2FVQ/*!
MO#?RSKC2VT^5/_%B@ )-F.S9B>%Q<6%^FQ&$J@-0^G:GD&Y5(LU!7P\3>KC!
M<P[#E2WI>J65RHPM$K=M; @T<]2+T+<[EB+BFHPXL]>583Q0I#;HK>M6-1_?
MDBY49=_47N60)6W?-#E9_H/1>TC)7/IBS><B;SX-$_F7)1JU&K6XQ'(-O;,L
MO1-3$X0:F*IMS!%\E7[C(@=%?=4E5V_(?]6.*,4)F)8Q'##\#,,1%9P3MW*7
MBQ35@!DM6=TYPW%/S*,,\0:5 [%H_("TFA@1N7/FTYLO<CEB($J+.!W^K<6N
M&!T O'R#O@0XT8S(U;&X?CXGQ&.U% I&#'#MSF4?J',VG?/L\&9<*4*Q.*[]
M.5$JTR^ ,HP?PG'#[':O]_O*]?W,T-1UHWTD?,! *BI4&>)%MYSLQ]OT&":
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M-)3_#!+N3.K-EY)NJ8!7DUEH,I"67Y5+XYDJ8)+M@FUB\M=VC2\&:!_GSZF
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M:]X?)LB$*7@ .0C]?F;18]DX)QP=>*QLP2ZWCPI5;Y*NR"H,,8HK+ARL%-[
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MUC+Z6N1@*_T/LHD%S'HQA%_6B;C)2+$J8!G.1?9V"AO+6$9SE8D<IW^R):D
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MLWE8['O4#[%G(U1 TS+%&G3TGSPI.8#1:OC_!C>,HX/M.N$\&A6K3B<L^'U
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M.VD?2>**EP[ZMXI4K*>*300A[K^(\/)Y=7WNV8ZFYT]A&:YZRFVR1S%%@!R
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MMEK^#"AHLRXH^J5V+9!V=5CG8FB4S,XX[51!?@/^+^/HM23FPG7(H+>JV%S
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M-R)XL"YS.AG$!=;2^PH]1J@>6?]HT3N-^S,&HT5:ZP$?\M,//6=;IK<7@6<
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MS83#X#+EXU'\B0FU#R@(<FL36.,U(5*'H%>)@HDD[?96U3&JNFN.=N+GT[)
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M0^6]F)>,4^;+HA)4UL:06.+'W&>!98E_7COBV7L@9^#6^+!>,),7_Y+ A3I
M*9)UFVA7%M\@Q]Z7$."#8X9PV<!FML+KO-K8BG.^$P\PL+8Q_G$%OI"Q1A&5
MD7OV3QX])+SW(7H2/D] A30M%GE_A)ARPO:(*?BP'E]]=%F/]S[\%J"%W67_
M<M\;P2(?4KFQN].PS3QDKSOI5_ACK^C3#^6D0>'0Z=M6;8T3M? K$RYJ?=S$
M5\FK A/W,WAP)>*"Y:9+4>\LW(L@X3(.=4=%EW<?K$KIF:6)O7NXRB UU&UR
M+3 Z0VOVAL$WMOM'KBM#X-#[D)M6Q*&A<J-V#]7RL5GZ/ G5@$)&4:-[YW-?
MV,RZ>B2%?[SZ\.9+KY3RS6WAN]-$'RX'<LJJ3SF=3^AY/5_;P5W[5Q<9?W*)
M+][<7>B-=(.9$OV W@]P0_Q(2O#(N1G/J:-(Q>E&&FRU?4\G_Q2)'8_"ZM66
M;QWMPR31][L\X9;+:?%-!PM#B%)8-#9B<OI%<<O4S]'&KT@E8[[O ]]A040H
MT/HA"::<%J.NWV,:*R2>G13,S@17('@DP)G=5IRK@21T&WUF=@]2%$B[F3K2
M%:G<.>K7,&1^<QQN'W &?M>8VZ9E:J_Z4"2X0<\08@N?H8+6"Q]3[O^9)GN0
M#K9/0[B9D\5)4&>=CW^3W&I% [H9$],C,??(+4OO /W')N55YO".M!5K5!GX
MC?8%\BMM#:>-H\@S]83,JK:0?K2Q0E\=C&C*Z<VQ:'IBL@EE<09TM<9FE#O:
MHC;L%C-2<+DIH5C)="U7_1#Y7#DJZ(WKIB;D1,9G.D<2+:)JC7_?BXI[A/+<
M5<65I6C2X]Y#O]S?R#&)+H'+3,,O_]S($P%\2KPB.=1]CQ+$1@^-/H,B.GQ4
M4X*06P/T$^,S>C3'>N<N<.C0G3FG1B>J0_=81X153IGSTNU498O3[^V_>#DY
MZ"TM!9@^?J#_.S$<X&1/L,>6%A T#,>5AB"XL)ZTF+TR;]8(^1+\M,UX@Z^1
MF=[S93[UF+Z"XJUN(S&/@RDI,S[%CXKM4K,.;XZ!*A6VSW"^,[9Y\N]XRA]<
M3.I^()Z0KWEIL\I=_7KW/>_K[_YL]W9]]&,,&F;P@]YB3.S#X@%2MZ 56]6\
MSQIWUXKB.>R# C69-/IG&0%ODH:OE@W<-/2:,/=/YU;1O@PWP?-W0U@-5M@3
M1"7&2>+8<N2CW^N3C1<?3U%!?JA0(PU+HSOR'D\\7!\GOE)E^CYC*18(949Y
M(J/RA4+DK.\ C@1F74)J6<&L3OE6D]VC\!?FLS/SP[X?VE[Y5U73WCZH2 K6
M)7;2TL^W @AB-CE>6QHVB,W=6&0$L 0$+J]%\U;AHD),IQQL^[8_8V-)_7Q$
MY7VP.WXHH\BRSI:WBK&%\>"[X/G,_I>1WY8^L?=#Z6!EO6&+VH2EA$Y.FR58
MY/"(Z60G*[!M*#2,A.5DY\OG5^56GR5#ZI:?,;\Y(V;B]U7\6U09?F<PC>2$
M!IYG_(29,GVTP#ZR K-JAJJMX&<^-FQ-H-<L9:4(HOR<IK%X0]['P)V/-M]9
M[3(F]4VJ2LQY8S(AB_LC;!V"/4#0.P]@A-_+'#<O<9G;E":[7[[766JRQ)0[
M<[QP%2W0H64BU:\VVK/BNK4<\-MK(KC(+-G%B#$I!8I)/)CS3UQB5[CR6^/$
MG\?&V ,'/0UJ67]KQ*0>N!>M1+ =0#]-=FB<W7Z@NYJY'G,(B#^Y'5IU[-:5
MBIWH&7L"15-!L^L.>(7$WTO<"Y11: -[JN_OPW9;N,(*@G<C'!G;J- P9^!7
M2AF>0ZNH<BE7WFAM\O3#NN8I/;15O0RS2CJ1@XWHB=(0>!NR]W"[#,0W0 4!
M8C:N#(ZGB+?C-;5Y"285A/ ]])$*A??$-8=%-; ?AV11WFUZ6X(NMQ5.L;*1
M]"F0-3K1,T_^7MOB-3ETW>XMWR7E$A,!P[>EMKF&)>("AC=B$KX5L&CRE$BC
M9X:>VK3YF?DIQJ!8AQ_;.C%P,ZF9/#&%H+\E>YL*&DD/!<+&J]9O#++A9SNV
M'DI@!;HC,5S$ZY8\ES*P&N3Q2EA[=QN/E>*VD]B/AC<A6MY+Z)S@MMA*%R_>
MHWCYV:EIW<;T)Z,>DY*>/VVJ7.0"5P6NN%;T^2=1+@#67Z8P$=/Q(>!+6D8]
M%'[\"V9?ENQZW6J@WZ)Y3$F@!MMH*U;?U-;1FO3]<ZO-;O7R4I!2 IW?R@'S
MZ1C7E?5I?&T4>=J?S](A7)F+B,^OS^ZYB-^4CP1C/#&QK<N,<#<W@MYV=UMH
MMHLO=DC)FV_QPMC/'XVF/- 17!KWII #!ZS>,MH\5JKH]T]RKF9 )>"WWA4I
M!7A@/^O;^J=I"Q)&DBDR"[!LXW1HDC9C/3"O^52D>O>=X>)%@V %!F''2X[\
M]CX^LEX-):,=VM,YRMUW\@I^YH<YP'7P)<W)OQ$TQA7T!#X4-L6H]]CBH31K
MS%1"B3=&(BE$QON!,+BALP#'>EW6'J*QJ^IU)7VN7^RQX>!T]5"[";%24RZ(
MQ^M*UK:,X$KBS9MW\+$'7*HR72(9LAQ_B45#,RG7R!G:EY3&9FU(<OBR9"5F
M1S"Q"H]X5B5.2,EZQ8Z^HRT/-_C1H8^O[VDSSEQ O1*)BPF>TYAKE5.:Y;;%
MO[*YC/]<,C36ZW\^[RHY!^6%X@*H(-O.VLX?P4;EFJP$_BX^*-?O!7W=T5*"
M8VH[/E<7?Q03 N%R]&JZ#M>;(.E DJL4:C1OM[W_[03&SV0-6N!C4B8G K]_
M !<%P&_C,R@JB+@?6P^AG/U8,4)]_WDS[3Q-[>.?B^>YJ2#OC[FT@<J>XLT^
M%R&8EPIO1E]<F/:'9F<CZCUZ/M_"A:%1"4Z"@#YV)"Z2":\?UW&M=/LTN!])
M:F#X$7G!:0; R.GMW9N4Q/_6-VV>U+P4"Q:&R1L@_8*'_.U'<=&]H?<=EWHE
MLH_C_J+G19-NXGV74DF:&-;L%$WG9>D<XM3>R=,OQS&EN35T3?)V7QV=9KRO
MR95,+<O??V![_A)]YMGEI6O $O$Q\-X-*Q>Y_@71H-^_X-]WWVN?"NK6*-G.
MTQJ]HO2TVN ME_A$31&^>U"DV'M$J5 RU8 NTLQ ^,9CFL/.:)P_.U H<G,%
MW=8;6W\VL\I;_6R12O[C[&NSVW9WNUF-C-\7B8E/OBL6&WV=.5_%:&46YK,?
M1'Q"3D=X+C%NYPR_78&* O78]>A#F%](PEZD(/SF)_[I2!DOW^E=H<S,M:3(
M;*.GWAY<\Q^BW+*D<FS%Z*1.S-'0>DHS=H_#\WB'"FI0Z$=RH$N@ND_D8Y!
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M? :YJ"U$D@!6\ ?]B]) "A*@Q7GTY;,":5T4=;SHVTK8GTA1>WC8].$2-X#
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M*S^E0($&FM8T-7 'P!R;D6[*>:HB;+&U9UPIDX3(YP^^,D@&.FQQMGS9WB=
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MU&#BX525TM"E<=.IM4DDZ:;"[P 7X<WFU[WT1[OU^+J1NU"AFK>XIVG1Q->
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M:/(3W?0F@R+!/DYZ? (I4Z)$2UAH2?[Y@/77EU@ZI8RHR-X]->W._.$CVIJ
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M9/DZ"NKS@6!%6'7)^;8 :X+L<6O/73-_\&F@+W5%].+PX_5EX.G][>,_5)=
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ML;>K<VRQJ1ME&7YANCFT)%@;M0E2 K'"[Y"AR$BL(T#2BYV9\S192Y3@M/
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M:BL8-)^8#.5B5+Z)CR=@UXBM^FA7:*O'=%="#CRDS+?\V$OO8L^6"?PI1?@
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M[$S&#H46155:%O@HH<\4FZ;5M#+C EX%G&/ZF@UK\8RV;&^0FZ0YO3[3RS.
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ME=JE#5>]*ZIQ@VRO=J25 _AJ$<>4NA;A.=M"P*&.YAN*HNZD')#M)2,%U*-
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M^>P6I%QE6RUWWES-^JS+Q\^'?XXRO29AG^-:9_EOXX0^Z^Z9L+N84Z-<5B^
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M"/N&?GOJ61;5W45C.WV2G<GNT7Q?[KQ:JC HJ&GEK61M1<4M,%39$R\QV!F
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M,!,3!X^ISJ"2O@K<HP%]CZHD2B-"Y8R MN30S/9E':<(>1ESM)ECX3HUN(C
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M%9>7[]=RQ=[:B[R$CG2&#I;ZC-EJE?6E:+CIGO\H7WT:LW%"0>YGWVAKPA"
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M>Y6C/^=/$]XHN,IE)67$/5%JJ< *I4CNO].9 HU:\/#W.,@9:!/UQ4BCCRE
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M30KWM..XM:;>J+KTJW(QDWP G.;$.6;^CH;'WB4FIIZVY\25/ !LW+>N8 ^
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MUQRE9:ER*8I\9U:L[ 4)]PY^XEX>-,O^O]&H;H) CLP;OYD_^912.LUZ/+R
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M-.C_WI5Q_"Q=X.E# /.N"?,@,;4?M"N6IWW.ZWY:J/!JARAOT4R:> ?ZI4M
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MFN?EFTOH'"$\5>\*U=55ML1,GZ2MSS(%T]$A+F&B=]64)J!8"+>$UF:;CZ7
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M@XT4W/,/X0?+:M6_<.QK\(F;W"I4]+X)&16IP++[IF@_FK+__,;J:]WR2N>
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ME,=/JAG@HO520&S9SVGWJ9CS;I*0<(O_[L*Z>7*V8.NZ0#]\>_%4J>@6$-6
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M?CRO1+/,%N=$8QOH5T8P2.:*"&5QSOM[\7>;B8TX_"S!NAY4.TPZO0344^+
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MK $RUO74 0Y@0YMKRK/!U-A"?\Z&D%/,BA49U_OPVR7JL:G?3<_KYXO8OSO
M%*J#E7KD9&XJKVT?PK1/>WM#26LX->SJ.W#",G]AWTWZ#R_RJ:=^6[S9E1Z-
MC2FH"@CY_<66TK4-F*/B4$MG<9,7(HI?NS4KB).GY\$Y?%I6PDM)'WGWK!%\
M?*F]N[^Y.?.M6*FS\_1/7I:U68?J 4AHF+JTY;OK\$! KY%PMV[?=N<]_%*?
M#A4FYJ(NAD&-W'J_9^%B,<Y3D.YCX!2RTOJL<OYK=:4B,CDGA&E'M*$UD><I
M;CWF\G4OUQ%;U$"G0-]\IBE]P':V)0?P8A2;UK_W[L=,)H[+;K* $LU_=2]
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M&%O^)(&).7C'_4-:%?>.H'3,1LS C3AOX4RHFV"L?B MQ&6PKX \Y%E RIN
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MJ57$\GY\/-84^HI6_(\YU]?&KK&P[-G_]3^G!]RQJMIK5#B;<% YIJEM8 G
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M@QB7ZVS3E7_"[Y0'^'N872:G8TC9K,INBW^@8UV?A8' E^8S7VE]FHYIK;-
M5P9<Z)%GU<./TEBC;NA#-:&K=]#-@CA409P[I9XN2[-L?BZVXS&]"EI\FY7J
M1Y)/;"PG;%[$HZCQ#F I_"'GO8>Y?DY7X]GW)YL?$#M+@Y3)H\) _C?[E5('
MXO,7;2U_8_+T_E';:.G(L\A.KAQ<"_%4%2N?=3U#'87-C&%3?&\;3RE2+B=?
M-7ESC6//G2Y?*WZ!A*#$G0/I#7V&E7R'L^%G/62*LH5N@B%W )=T^%OV.<%?
M>8^'?W^$&C1,^?R@<LW^+3U\A*AZ1?72%M6F?G+\O#GZD7$\OKCG3/CU.6%7
MBUHFZ1U >'PC!9/6IT'6%=LI?2UP*E?P,E]0&CO8V]Y^H[FLW44EECKS>X+N
MX,\D"3&'-BJDU6>X9*K4SNK%<SN#-NLK_FO.- /&KI0N[ O\\*9RN_&;8EQ,
M?R8+#TSZI*E;V*3W"^(4KZ^-$^_3\#$!_8+/"/YSADRX@R'?'EH[^8]P,EF_
M-?745D"[\+?M5A?_*]U1K_AKC;S-ZF:/A&_<-Q,NN5X))H2/-V2O]Y+JLP::
MC5E(1\Y)_U#K+0^8E'DK19TQ<ZU._P>W61BH&.9BD'Y[4QW"L&*QZM3UY#!8
M%]=DU1A7E*F.U\:N*O4SBDK;QP[;!F[^S/(Y(5'"%B T.GL-<PTE<K@P0V$/
M*:LANG6AKO+,%$!1G9@"@(^)?3*E[V;0Y2W/M>HYY:0)[?2O)=$3HOU.8,"S
M@8*/_I66H]7PENA=D\<5\F^,E_9S5/ZC900U)V=:TV7+-L-C')U+E]6V:9!M
MK4TS'.J0XF3ZS&$<3PS+\Z]%X.6G(C3 !IV'\0_ KCL)K\SDO(9=+YC&!X10
MXL+#6)+*IV2T=X 'NE,""9?=;/I1MW5[E\EM?VBWK#4-=T<#P&0ZT?5^/]\$
MUI@X,NO$I2QY)4OS>1FYB-8Y=?U.B?%:?14442]2Q73F\)]M?&7_J^6:K_HC
M?&I<6"W1NA->\+W_5)\,C]3D9H[_,]*X$'6M+>-_!Z"_]L8Q;?E]J?,77$0;
MU>J4X<493&VY)A9#6/#&/S ,\!YU (XNZD1E._X+6N\[CA :='H2A>;;T'[E
MS$)QNAYUS5>JYG8.BDZRMB_=3X"^/+<$ES6U*'EB2>*8LWX[G@LBF&;(&@SB
M-'F4I(&.3OY4H@T8&M=8^'ZM];L@:2NA93M+_D214.N#[9L8DT]'7>FP2!2#
M=3JQS(^)DUH>#5!XUO6B?8# ,004=GEL_=86)Q]CQV(P%FXV^E#XN=C!CKE0
M[R67R:;76#%AS,!<"LAMQ"-?1+Q/H(KZ/P>Q)N :"FK$F)U3M@QYFQP7*-E%
MX\D2I$KOMB YL.DA6CJNQ!^)#1\^G2CNV<ZV)ZWC[FUNS)"IF=7@_#GJ=TX,
M5^IP'XNVBZQN9-)6& F+0NN#F8K, L)LW_]51=6TF#48-+2F-_%5&'I-/](C
MH<NJ;(H+/I%4JAG%.%=_+7]GH"!CABU;)EQ2[$"2<WL_;>I]G"%BHO+4KT?I
MHBJRM0',7[1CN?M^=S.4R%PGK%PGHM*9L>'=>WC8I\8>81.+LG.-^"584'KT
M95ED(!(YO<(1^-*U@5#8F7'(&EIC=M3<D;K(5^=SB4M,585IDJ&^+E^6(%($
MX/!I>)J$&UAV(HK+[0;V,4D^BN><DD-] ..UZX63SS')?\5@5S#:[DB?/"\]
MBG#ZGEM-M+V*_>@NL5RU1+35_ED=&ZEK 4Q[3EV86MH&%X]Z3T<0Y"R3N^1S
MI;#,]#9,SHKA!RRE:?6Z:7]D6NCIOETX[[-Y,TYUR)JA,Y>P<\/2*C&G(WHM
M>/3D\<K8 ^4#QCN 0ONR>QBH=^.^=",5#>^8R1XY0SPE<XVP.NE)B3%R.T%?
MD4!&!=M"N;RFRM.5*"T"3.---D:/82Z='S>F^[?.&,ZKDF7X"G668TWLTZNI
M4<T3T2?#J;H<2:_G6WT"W&U3MU=XFA!PR6-VL_ETL,L%$I5^*@FV\%'C"R7_
M^3(5&F3WOJ4S5"Q3G#//8'908APXHY5$%,4-=WH8%RB0Z<Q'XAKZ4"ALLX;V
M/?*/H0;70'Z-],LO]W)''2-/'K%@B&E=/V?F1GPU[:]<"QZ0M672B?S=NAK=
M=@=@68"%*[U+8+!IC/"P%P3&0PJ%S!%3GV9&(=9M-BVS-I11.,$8<9*/UA*6
M \G=Z?U,RZ*40_:-E#7UJ>H9I3.P^4,"Q\@J!H%KD"^W3,Q[*%K2$Y'TF31:
MM()AP_%>9+T)VLCH+==>5G!Y0W-'NUK/SW$&A]/\.B8B*/#\23E/7N.G9\Q#
MWZRK(U\3^%)0!Y:#BA$0#C6FY[#S[@G.I(OLY1O^7DPEY>MPBL=#."#;\-K+
MBXLSDO:R!YZ\\,GUU9C/=P WTNC3DSA]'GU]:/G*2-L*BZGX"]PHA];T\,LK
MWN0UW/%S%H.^>?AT*I2@%,I(]/N(&.=<T<-RN\3H\*&&;$R@8NUC=+?S1913
MMCW"C#\L!DX?(9K)0IH?7%0=U@RBUG5^!D FJ0,R-%J[;=F\^8>O*K[]M\(K
M*%W-W_ >]]!&)B"W5_ECFAYRY32.80ELJ1*E.@.I-QU_N38 %D/X&67,> V=
M!7"K9G1B(C\6]YS31U(2S?E1-RH7*E$V'QWF<:$2Y4ZG;N*_[SJZ^Z:B"TCP
MT?*PRWB5BB&_6JNGE>+T6N#<N!(":M8<]R-+XV-[]:=9:58MQM]P++&]AU*H
M2QB&O_7Y)YD>KHGL79B6WR%7WF;K\)AA_80O<RQ'YV+\&CU.,^\/Q:/&M@Q&
M56Y!R>LIQ/ NPVI8<QQ'NVM)Y#!;]%#9XK4^XX.;MB^?06*R0+%?]MO<4O&N
M645ZAD&<22![%-.V1C7MB(%JS@8<*@Y]-"YM<SR[ISO5S*UX/T%]+BK36(.W
M#SYFF$33OS::@B8K+?FC*]??_OPRGQGWU(ULQ&;@K\+EP_OB290L]B\?F?EG
M-5ZF[2= V.Q@:G%+B6M/,[*C^F/@,P$.AS*3195/V)'6G!HD!-W1W^E,:I^<
M5N=;5!NU-$0%21(QG(;&V7J"1B+(1HNY-2[".+\$]I<$[KY@NQ+UWSV;X[Q2
M6_JRNET7#RHVD..:R67TJW1L!"N<B=2(2[Z/_\XP;:;0L)@ V^< EY=63Q[G
M;SKMOO@30M.:)H^AE5G[(<'4.59%_!H ;'#21(E>K06:"L=RH((JBF&J4I J
M:/)Z/^4+RJ_.#T%E7>X\G02O-9\FJK$3/S!U2^;C5'HLNP:O%W%+/4K/@.CT
MNI_3S"+VWXYB;\ BBO3J>LHNHGH,MOZ&]-'S3F4H7;EAS5Q^R)L#.CEE6-7)
M:4'L<^OGS91F+E3 :D6C_XAM^8#CG.=M2M +ISHN=$L\5'3_HNEE_&@?'*=,
MT&1SY7-C]L;$\9/,-". 84R;4_GT4;5>S1%V[>NQX3S(Z&UO@Z&]$I:5DB/;
MO5:AOBU@EFJ:**'E/[EY!YCJ9_JM*[DO?U[RYJM&KX\9NZ%5G@A5[X<9+O0A
M ].)O7=FWXZZ3PY*C=LV6,-V)3XA_IJ:O0'D!*D/"_IBVU9'+!<UR=:B?%&[
MJWIB2;TLQE/Y!*GW52$0^_B#,VX[C7(2:VC%.O^),Q>A',G\!K?!<Y7*1J%N
M0"KW0T 2I%[%H[NFF,Z0U5%XD&8,#J_./0D6WWW=R=Z0]J>393:6=LB(BB.?
M*^K94(H31?^+]=6A?R_<:]9?:97IYVO+*!&-?A/OH+CC/"/S7ECD5O4RXY@E
MD$N@$SQ(4,ZU6NWV';+E9V:F0VE:_=Z%%I0D;]E,L",S #*P;HN+EYJP>:LD
M.PMUB1,KPK1S^M/1&B9J9<K1.IMLSOVZ#$//B(EPSL<^-\[_Q*,J<K/E]=V1
M<X-3HNR =_KUF_&$<CR2<T]O.OTFS6*F/L2OU9ZR'4C",O")+]J$ IO4T.+P
MKA7>PTTE$F#1FUJW3QX7+'V+P@"CWC?)O"P&X%X4+9MJ"@C*#'$DF[PU-7.A
M>X+=HQ(BPZ90?#/5]7B/[/)H&'K<SSY"[,R05^NQ9J;<XO!WDM93F.^L!FWF
M0B%>99,U(_9# NCP>@SP(-*9/7QQ8+'0&O@=D*Q'N\8GJ#M7VNS]N"7RVEA^
M&J)A%K@F[K^^A@]NF&$7O,B[_;@!1:JF6FQ;C)%C;+6^_.>3FI[*\4#@S=_S
M87?;6 *3FLA0QS:T*@&?6^=8<%WSJM+3FCW6QTU#O7T?9++0T\<FEMW*GH5R
M4=C)JI)O%(!PLYI/YF+31U?OEOW,&QQRV%]:I\;9$BNLOQ2]-X9?P.KTIL0N
MY @4;A40.,GQS,J\0D5^("C\NL3Y!R/ZH7&9NY(E-^"Q^=)@16G>5RNUAQ69
MSM#';QJ!+H^"ZB(*'D.;4RCPX7^P>Y&"8G6TSM1.<ERSM0A^DH0\;_4V9$L3
MJF%VS<G<HM_?T='1U6\Z&G: &?E.$@/C!_NDL&Z>]'?AWVU]H]+86*? E\T,
MLE*B.4[__M2=*I\ZJI;A#+:J,7$2-SUNYZZL,#6?<$(E%SM":9)37"L.)/34
M=]['$SGDR5@-%"#%PS8^OMDXD"-8. [F"<+1F>)!&^O42P<YBFG]70P(UX+#
MJ8V*7R;;T1^Y!]_-?YG]I2W2U]("<<%$IX0L(/W$0;:!'^X=>UV3XB7EDK G
MY#JG$]W>/_*?S@J(0<F=FWZ(4YLY?T@Z+ JZ:J55-\G1UO35:-:1++5XH[X9
M]+O5J9A_RJG@2? C;!WESUO!TSM I(QL<4!Q/ZE9'^-%7JFIZ<&'*IDJF8'C
M UZXJH01;Z91N^8-ZHBC'7U^K,O%*F9Q.W^VK+U90*YR6F?:@8\Y79OI_[O7
M3TZ P><JG5V+8.4)3/#0=^T+" N_@ TD3BOG.&-SG/%G#\;<+T=[H%#X /[A
MOQP@RM/Y+S2JJYDG)N3%SWSB%+73M5+7C90$*9U$L8*(6^FTMPVM2%Q'9IA
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ME_1T;W33[1D3&/='A!,SU(A5O?[:LR/.INV3>^_S';/#F'3$AU2$(1UMB*:
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MQNL*?C.#?TFT@R'RNJ627G"E5Q?ISNG?;RCR)3V5;/F';AXGA^@J6)E6L+$
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M.3G6>M;YCR"G5+U$[5C1+!@Q.S0O1KDG2#2#,ZS 2XRL:#[X3S7O!2P+'H\
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M8*/'O/1KOFMTLZ4Q45>;]IAX&$%$*D?I7IO4%<3P+#=$^!9X+M52\57?L)>
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M[%F'X"'>+^DL!F4^OJ>]Q SJD3GC=/2J,#?JV^6T#Z7_A,3^YJC[2_I*]$2
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M*Z+HX4EG<<OND<2_@0[^O R?CK7+H +W]369D\8&3!]!E/^[<3+NV-7FBO=
M02%2%=W1VL$ \A0&O$8A]B0P+X\@)W74CB"# S"2V!1QS8C"2#^#.0X][>WT
MW>OGDF@2MM.'S*(7CB ?1]AQOW[][^#^=W#_.[C_'=S_S\']6!1OG]X?$OYM
M\K*S9;*M$>^>X-[4#@!A%]*>F/PR746I?*ZW4)>0\.X79#&N,LZ+A1S-_A]0
M2P,$%     @ >(GH6EPUH Y$@   MX(   T   !I;6%G95\P,34N:G!GI+H'
M4%-MV"T:%*2+] XBO8E*QT ^0'KOG0A("0BA2H1(%*0WI4H7(4" @/060+J
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MV,8@I0TM+$]UDTA-QD3PGFP0T<YT"AJZW"UM.AL -T"->%?Y=-J6;4RP]ET
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M_8+[]/1.-7K%6X+EH68DL?J!,_&-D?ASZA5R (F((GG@)A,O2W)APZNZ,WU
M_>H@B )C1Q@]U/L25A*OK,%.\BR%_)ZL0OBM5B:Z$XOS\!_##C+L,&;-*ZLK
M9IEUB+[;4>P[CJ!^?Y ^:?+T'YB'#<F"*#VRSFLWI.0J3-!HJR4=;\8/^@UA
M%J+DR%K-Q/C+$,Y,"G$A#KU0YECC[&[[$GHJ2._H8B"0Z :1"32Y09U&AI]U
M@WS,8LYOG^7<*E[8R(FM)H>F'R'2G<X*R&#<>B('@B7TF%06?CV/R'."2)G>
MR8?VI]/(#8S/5"$\MQW/LD[2&D,3T77,4+G'Z$=GN?4OSB7//T3QDK[YXU*I
M-SGWKI[JP34)UUY%":S!"G Y]?A)JB62'%ZLEX#]/6DU!=?!5RF XT^\FB"1
M*-_.9SDHO)$@K9\&SU18Y&Y8P>F]1<R+<]+;*TD2_P&:.A:'F\4J8J? W]JW
MM(.^U?8\J$UIF/@&&I7+^@K*N0!([V%76,&"D/6K&FJ0XPR7/F)_Y%U$K5'5
M#D&;_9"\\&B[87%$8O;0IJ/$#WC/,-]L:7.Z>7Z6_^?K\AF93^L>=L])-0/K
M7'(8[1"QV$W[YO5KJZ3\K4BD?A]1-"<]:,/G0-H%]$^J@H$_@VV4'$2Q,;<Q
MT2MO^I>+E[11> /T#=Y8['IS("S%E%=IR(Q)K0')4'FG_D61HJ6"B^'<69H<
M'5)7ZDZL849(*,H0TA]8(M+-UX.V5VO>GNV?L6%S+I9Z*2T9W%'5SS=;W2+^
M9),M5R'+7Z+ETWL,/:%L4^ UOIO:D3@Y=$P,>%V&+(_73AO;P=(&X CGI67
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MEO8T\P\WKC*\TM4<CK@!4V>R& +79ZS[_V=P^W^#],"Y,OD?8N6+T&XNF/B
MGO-L6,%^4\M*?E1'M1.61BZTV5^-5Y;>M#?[\)GMV!_S]AFQ6>1,J#VK?G?D
MZ2&B21.$V-QG*[E&<CUU=1*9%: ]6-;?0[9'^ACG%R,A%>4SHU3=WY8U'R^X
M;\%J']=#*Y+$TZ:GGR[=^-N31\PY.9<5VT'0&%4L^K7R.&.C4$]1Y1$>ZRZ?
M2@(,H/E30FEC_?VRAF=?W=NF])!F_$<EGHJ#-%&L2D3H\W;E)(G 8V8/I,P\
M=Q2]"BH'6']_R/Q\\E/#&TS]U<0ACWMD1K@81ZSS --AU&-;:7I#Q6HWU$*]
M ;ZJ<G<:!SQ5&_/=O+?8J?)T 1T3=X\KA4UJN$>@B,\D(M3'W4\+:5 +7.D-
M-RS_:V-@];([:^D;!Z(9,4@B][:0J8E&4KMJ 7DA+(Q>)@'0YNWCQP\<?6%P
M"''-EY.C%1O;X&*BL"LK;)E87YZT@]U1/*B/1C #[383,9HH4OV'Q U>ASV@
MW.T2BH;>-!,GQ]XNHDDK6GA'&1N5IWC0VHKU2O:687&0:977 59L1=Y?OE>B
M.4S\F'BY%>K=2A1^S:6FIJ]<4Q9M\WK@FJVE-8H*-J03I-C2SNH,M$@88,\P
M>5LES-B2+BP<U\?-Q[>PT_('V,4:AS)C?(T+;+G+''];G"EU>"$H.4M*;[&_
M_+LN?%M'*M64@(J N++D?C0?;Z)CW[:N+W(/LO[1L<YD1QM3QMW&/7"<B:29
M<V[KE0HZWNA8=IXRE4%)46=S3O *I;92/V4#9K!]YBX8=VZL"VS(^<"-JOF&
M2.QM6?CYC>#?,XZ?3!#@;9S]F:&/GY(14^MIX]!U59P.S>K&O%@D/"#V%6Z\
MIUP8CA*_ $1WP7EFMC+D&$CR(VNB-B*B?>]G%(S"^U0>ALGJ[=UWJI_PK5.A
M4MWLE=XHOCTI1->AQWCI<%E<?XD^]#4?,'%!2K@'!?>9Y[?42X5)#1\WY[>0
M0F[?Q1GG!"/SB=?-8NJI]]V^I58ZL5)[PB:98M/N842*]KAGD")M2>%&A]-)
M9*WY"\!&<R\#61RYG=^;',4%.Q]>MY\[Y)?JEQ5JY@^ DK*7MH]S[90=>F<H
M)<91VGQW=;TA/*I&"AX^ 2-]8(*3W.+Q8,@0M&Y7XR[!Z*,U-]QJ VTK+3$>
ME"<7JCM?FJJY,_'RZI;H/V+=ACT<L%3=%")3='MT"UT(RC0L$":QN5%I4#67
M=)(FS:ZJ%NQ[[VO9?</M$(5/A)60/E+[=/9UX;%\-,TL<J]F\M)KJ4J,+6(T
M^'6,,FR_9]W./C !']U+(H!B0<W?/^RG/C%X1IC$F[T$>K#>^CCZUJ^5\]A<
M&J"'#25]XXDM%1QLLWW?>/"0YE;WFN2[HJL#M_3CRX2O"98J$KE2E,2I72MX
M.>,'W>XJ>([;,2:5@ND3D'+?:K19]9@<"Z:VU2QZC=!F%4C;[(A M!9:ZL!7
MNA_-T[QKF;]/UUQM4ZGXG7O\\Z26H\2[!@4ZB7?/_Y^HIR-M$M.-2#:XT0!:
M([0O0;TGLU(Z-F/K1ZE0"67SDR]71#H*H!_?V'Q*>TZ^ + 3[:X30(S?"]V&
M.GJ8A'!U?.-!JJUA!9L[D4 E^JNQ\8J&&8W9AG.^IM;O%XUO"Q0]=E7F3>Q_
M^#Y+&M]@#='XV20S\ETUCDEJC- 2U)'FEE 9VX?ST<M'^LZYE+%'ZMY(LD+9
MH@VTLGD4=N9K5"R1JK*()# W4)+09>37[4YT/3(?]ZA89L\Y.7JH\?5&@*!4
M!G"T7))!.X\?1OU''*^WQ[YY 4B07]%D/UCC_[):9&4\(Q[:GG/+=+UUO6ZI
MW,OJSQ!U)HT(RH%:_"/9 E\4,NPXL=:-Y]V&MM"WN3LL_K4E!HC*^M\2J>68
M\J;E.50-EQ.6;P.!_[0=(,]*HT1)$V^V"N_BZCP*2'XX9U^[OJG2;'RU)\9M
M:-%&*JM8.;&IEBH"]JF+-K6B&ZG!-1JT"+S-RV2K$/)X7&4(8PRY #R%03<N
M;V*.(.,;XC5!^D&@\29=$RH1R:=KDSW7[/DS>(4?9I@:T>SY:_S>L 7:MGSC
M>^P 3C)2^>;7IKNB>8E>7B)-\GPY7JHR!E\S#,31>C):>.ZWPH'%DF[29S@I
M!1@YW+V\4FA \N AP@+\O8>:'TSQYF&3FGSN_'LNLH"G;EE6X7G3BQ$W>3JK
MD #+D)/AZUE_"X*WC@N"NQ =[A)6@VX-7+Z):O8IZG!%_26'Z7JM5H&@%K2W
M:?.FGZBWGY,VH7*3K,M$3S*]=OH%-CEDKLRUQ2^LET!<SJ[/V?W)A"U>^$GO
M[=GFTTHJV/R1%=HO6E?0E!XJ%;2,A"/ )]8$74\C-5Q*C5JIJ!KW9YZX$-V@
M\)2J[UQ\N2I(B9YJZR;?8+-JR"%H*ZF5!4:+H7HP9TQ9LR$EWEE\5;#@H5=)
M?C&=0?XY'Y$I <A?LTR*Z><Y:L&91$P-YG0NQ!T:K;):QRY0LG?/5+3E93WT
M4N7>=!L09D@ZRSS+ FTT7@ X>[C6(<4\9Z4/2_#IT0-#C\\59F3W]H"(,LVB
MN._FC?$_3\#)#Q/O>-(*Y-7>B_-L[\Y**"':)CG;?5B1'EXT<%/)%.OW6!<I
MU>8KY>&NH&V>+J:7+Z/9E%!1*D=UMA"F?>?N9-_Z6H+.( J$#<S-P2L%P0P=
M6=5N*T7& K<F7%521 W4V-DRFO)CU4;O]V,<;2\ 6H+1O0(:/.1(@E?F9DG<
MFN0TW *WYRI[A(TK".2W?60CO^3JI&*$OF_9[,6\!FG[LKSF./I[@NZ;4:0Z
MXDI)8^6>!U'O2(\4"]T$ < F3]^"G9?E4LE7P\)%')E2%!;?4*\*.*K?'^1X
MGZNFVTV)\&G-?<RIM=7WK0VT3/US_%2/=/4HG^2"6T]TI9@=^I5;N^R?CW5_
MO1.A@8*VJIMIS?NSYZ$5GTE]?2,GI)K:E[:S^K6Y/=KN_ H1W ]<&'@<!M11
MRY8WY1J9SP:V*8?.2GU!0ZP= OQ,\T.K/&Q4QJRE9[[U;RF@/B.IC)C-F&,J
MSY3[G(.B\2O ;<,;?5LD>TEW O"7.<IT1XXS.FM=W?A^@07*U X=6UC&4Q=:
M:8CI27Z7)/W[ZJ_H_]%^^B_DR5A,LKT:2Q2QTB4:\2759>C=R@H-?6@S-9OM
M^=#FQ<UH6K83285\2/F,B<*AB<*,29B)4OY.@69K31@J":Z,.U)^^2-"4RU9
M>(=R.T=O[[>>SV/AG ,NFJZ<^]?\)-8V]*>6NI:%;MP70J%]UP0):85A)KI^
M)O<&#!M\F//*6EJ:&U,>&$-X?L9)9&G2W9)Z_DXA[4[9-WE2YJ :-$XA>=7#
MIC-I^O/8FE-B15Z_[NO!V+R\](?4FJ,J )9_0*_ O!I*?B#VEKQW27[)(-JE
MS^M+G0%;*6L_1<1*JR1 P#0-O\@G8TY"E#%WO03'P89FY?L4SSA)MXO#"W&!
M?[]S>Y?8(_OXF&/11O0IGXGMMJO.DW?K30MWOCDK9N&E+8L]\SO9I6T'Y^(<
MLBR&O$BHV?$+@ %A?:!V?Q"^9F\LZOA&IHSJY[?"[^Q"4EGO0WUK]!CC7R*Y
M\$U\-BJ&*G!EH!M=4(XXIYJ]HZ'B60%^82^DUH_5^<<%@(EBII8-(U>_HE-0
M\"*#?OLH@_%]);=1,C)<W98*E]Y_KMS:27J!],-"$Z"_6E0/=^EK5*&*M%\[
ML\7R:-M*X+5#.BT?X\*LL=4>O-8/;;#2YS"X]HDS[!#OG:!*G8#1'G'(9AAX
MJ5(IAC]G^'@O8C&E_B7,2AGW<Y.BZ&M+<)W @'O9RQHGZN3Q.TD5'OF89>7A
MF9-/0:HIPLEH3438UW/V0"6#@8Y<1K=[0$5G@;"LS<;'NYPIL4!32/Y&$_"Z
M.$5:9?+(;,7.,/L/]]U@'&'=IM\BLV+;;;F,+OYKV!QZ*'9N+A7+5?<SP+NI
M,S6.(5RI$<-:RO=LB3E><YA1,^P"<.LXK?=G$6G_ F!1I-L]<Q1+Z/L2=7/%
MUWRH<61(J6&'R&YY UPA&Z;?MXV9Y M_3$T^O[JNB L'_Y:#[9Z/KJ==  ZY
M9_W.=^'<1"M1XDA?.B/P(6[?FZ]RL)@6%W"[+!YI89,&3I[P\0S^?"_1=*^S
M0_R&&RQ>I+K2-\G!FE]_.(P']#T^6>6^(.XX\>DQI9?S)'?_BEW:J+=MT#=8
M/I>Q"Z+*P[+1^0VYL=4A/=EUU[ZCJO5=^N2W'QHQ?ZT<5590CVP?/?PXR/AQ
M++@V]?AUUN_:\CO :$;5"*:WY]8M9QKNST9.E?]M^(,@ZTL5O_N7_R&BOZ=A
MF'VFRM>9R(BG3]&0Z#G]58Y$M)%(_GZ\%XU2_WRNU:(0G>B,ET72^;M>#R:2
MQ'Y?.G;9Q$3.&)/9#V9Y+,OQ+ 2WD%#9EN[<9H-M O]HHVU<'NR\U?'=?,;:
M+("&)S4UV2.<*.IX+DB\UHV3C=0GFL6&H<T&HL0(9P=JQ?'U/Q8L[7<Z;<B,
MG=(U]ZL28"O!C4*K#$3Y/F#P@/#P>C(L<0-!&S3$H"M''3= V&=1^1P: N]B
MI%-Y;!.I*N&M&B6@X.,A.5N<?3<4XO9'ROESK1]^Q86GY&U@?4+'^O59I#:S
M8YU?5B77[ =\]64,5#@PM6>P<3!%TPXK!Y59A@5F-KY$376B! ^@>@YL:G<\
MW5Y]^'HC@MFT?O@"0!(S([,]F3PJ^'(!P-G#3?-'#$BK.']5L6Y]3)<3D\"/
M]T\#>Y.:Z=T'/F)>8!6)8LG,GN^+K7N:!)?:*&01'K-Q%"\^"M],N@" 5#+C
MY=-8/P=U7(M\F<-T]\.L!8K^SQ3:$#(6)T?KH'MG<(-HG8&.&]0,_GS=HA!B
MBW2-%=PF5RI]\'X:)2@_[E=-<C:&<COE(%6'Q]!T!\O!2->42U>(K'V4F5RD
M.H.R\'F71)A\\+\+I!\7%/BE!_-#\VV;_(YJ5,5:.^B:S/R!G+9VS*M+KHXN
M6".JU:)O1;-WG1U7'2?8""8\F&!)]D\N9'E"V%JVY[O6 A$UU[Q*YVUL&+K[
MVRSD46YX:V?LT,IMSZ>\ECF_/DL^FA5[&N I&]CX<3<L6'2_YGM)NB!O<TEL
MOOAKMB\NL *K-+PZK\&?*>].V&OC8S%UO)6W.[\()D/1O7KL>5R@W4;[+C5N
MR^XU49DG:,TLPWHL.(IGV!V6JSSRJ$9^L(YGU"UAP@^WJT<;,^1E__.V0! J
M86!#8J;N6U(1I^&-+,C\A].GLH]/65/&&^&YG"EIXIQOIBMSW7PV-=!&IWI<
MVS@WR^MH7_L(12EQ+NMZ54TIBQ)YR)AB\_DMN!/!K"^=R6%Q7$+.VY,Q+OD=
MMA<KYYTT1AE-XV' U9O+<DLD5[YSN'U\S/GY>H$@\P7 !YP@>*.R/?Y4R__J
M@U?O3>2,\O 9^DT?NGM,,HT'GWV-_QBC*N 4IF& EV/V<Y6>^W6X&G7BHFW5
M_0K39&BZ^"7#<FT-F!V-O?EDB,[-.CA<U4LE^P*@CC#HQ5[%FZ5P%4)I8)#D
M3QA90C(]K>?3**L,=]%L(HC%$Q9A1*55R>KUU]_7/N4Z7<_U6"X+G',R=_3X
M'7L](]HW'B'5A+J%8[OX*.K "P"=55E^$)4,B(5HHMN@2(2-^;'F>I+R1N<+
M@U?$Q%@K'9NE/@<\+59*?6SBBYGSL>CK-S?[<P$XBB>\(EP TD7GT?AE#SS)
MM/K1U?0]'T/M&F'5;\4.#)PC02(%;<-:"S$+/RI'P+2(?IL-1BTC&&;"; !]
MUEVYY_QQ"CL\CEH64ST[+Y[N^4(+06\<U']^KPE(T^2FGN6Y %2"EFP.4A#Z
M):7? 0L3?SC3-NMIL^ W-^,=FVI2Z^UB[ZCH]"VM27X.02N7$/A^TV4,V@3#
M4L*9MOQG43:VH!%$A7CL!8#(  _$JSQ\OVZ'^Z70R_N5CNWOG8/-0G=I1,"&
MQ._A.^"E%1V^(:F@MJ:!K3?@)W<"@;F;^^3$J"L7@(:F8="))Z$%W@2V@C^[
M +R6^P ^4H*-7 ",>SCJ<_S.]'&]?SF,SH=5*\\K'I UTD\KP!> AUS@LT4%
M!7\G.\)6C7\=*<1V#JB.7M)OQ/JI<90]+=MIG1:^9A=O/K/5UJG%=?7%[9F4
M.\*W>MT0GDPD&<1P[\OP?.^X<Z#LPC 3A?005"[1W2D2FL@CVJI5D"AB :V
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M_"\*HOCF5E,#A36'" %P5:1$T[1>E=2P>1\$@%T=/)?N"6P]N9V.J&H78;P
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M-[SL8B@VUSG@LL2VV'-A&*M-P0,B(B8LTA^J-5OJ17';O^ XITV?AI/G25G
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MXOT9Q^20IH5F0+XP4K**0&AGB/' T^<ZG&^<TTE."Q.EP<C[6'>_'LJ@YCL
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MC>_=HG%]4Q1YFEM9F;L4[7XLR-G6EG64@?835=NNX0_@32"EX&7]5%[Q#X$
M*L&)?J(MHF?JB:"0+Z/2!GK^[ZTM4X[_LHY)W"L;!Z+YI_*_PZG8'ZN2OF64
MG0^]_5$@*4L5B=?[5=8ZIRL:<7 63 -T(#.$N';XY>!%FGT>UJQ^F^QR6:7\
MT*EF)^/D?K,?OL5HL%+7@_J)$H\XTQ??I-6RAOW=N4B!%PEBN+;T"MMECD]]
M6LB"+;$^?=_6>O[NV02MM Z06FJ_@_]7@I3S?;Q8A9K;I""1C=M[.)U\+"P
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M!#J"1K4LB$YQZ#@&6QS2-^L5)_PG@IF_3]\3%E6IS9R0]NYIL.A3R//0D"?
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M.G#@ .CV_@O$G0:9_>OJ?VO[UR3_NW,<X+X#B1X]8'/PPJ$#IT '10\<$CW
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M9W_WKZ07.;LB_^8?RW\#U*[&.;4ZQ;NFQ?3MW)E[GS%5U,,%242=8 =/4&0
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M'AKV3 \3+Y0;FHD8CN<5\9FWSR#^L[_\ =2^O^3V"C&.+/OYIA1(I-Z\)R#
M^KT]"-3NRON!>4-:H1(]NV; 00:-/'NQ)H;NFT2VT4G69E\DD+.C#F0[L%#1
M\TRII^!XC %=08YE8A6AF9O&!0&:3D6[EV> F&T=)G1MCN5,Y^W4 :/Q/5@%
MMEE)YSQ*/( "3NBFG #@S--=[1(FJC2PI*M_TS$S.E0$:307?VKXQ^9%&^U[
M.J='E=*O6CWH2S.5Z<;ZS]=]\CC-%XN><JD@B"T:;9[E@NSP=NB77A<SC8)3
MEQQB_1T?.*KUY(_B7=O40Y5N_4J%CK)D6B0(="G%D!-+9=WYUNTN+R1E[19?
M%#+LS@4G&"C-Z2B5C^31,[Y@_Z/#. 'Z7- T@8Y8-]CUCOH ;H!V8A/!XB3H
M9#RCV[7GO1LTUE1Q(C1-M1,JQO:DH2;MNQ''*>=AU6@[-7H=ZWPY#77< \#2
MTC."*]QFM!H)-"VKM>@@S8("+HAY S>MTPT]RH82VQ.Y(%\;.?C4W/:)O5(N
MR!\7W8059$/I_;!N1+WYP'NL@ LZ9PX&/-&N9KA;7ML_%A6M#/N) J5"I]^?
MIR@"^?B&O%GP^.;NA4H=XX '%D@;&D/]B^%HN:V.N#71^H5O3%=$P#_5L65M
MF2BDF\#E7"I=P< Z!Q^N_]U9+%/V5V=BC?TVT;Z*QO?1+N^T;(\H;++#897Z
MJ_-9?L!S![7@X(^]8TIOS%N><J+_/:_]&\DCF4V=[8U-Z[5WYT6B$<+Z&TES
M]8IO6.K3'#Y@KLDY@W(.X\B$I@2:7&3,";H): B)T]+37B]AQ4G-ZR9N@6+P
M,HP34-C2W_W4\^("KFP9*DS:13)*S;ZPC??:N:! >(91]G[\L!6!2*:&+1/7
M.?#EUS9FKW#-5 ;SE^+I$?)C!CQQCB3=@1!#IUP"W$72J]@(V@ _VOM2#>M1
MKN\CBN:X_N/F4=)XPV#1R+K*&,)CY()OQX4\2:N6250M7DW-*0LR'.WQE;9D
M[3$A(,V3_.Q%F9H*XZBM"Z[B)T2KJ.#V-QK8-V7[N55%4.>O7LY'Q[)L99_B
M)94BNWY554G+Z6#WJ$$NZ#^EOM[V&NEU<7K[%'S>?2*9<W+5%#P:I8*V[)E5
M!X)8IZ\.1<D"/32>W]$8?QIV[1<1+4\M +'P261?;!& [PR>VTO?B32@MG#B
M*F]B?9%&H3-@5"Z\;O<16=!'K)%7,O']Q W'FK&[UOC3#V->A"'TE1B\9ZSU
M8FG:#GB^CB"R+Q]LI',"G_0&)FK-^4R2H'UZEID_5OP\LSCOKJS%>O>-%^YY
M=XK^5U)XL/S_OYH!D5 @U,Q,SYYO$^F>/<J*^P1N4,3OWEKER(^$K(.[=TJ+
MZ' )]'UL6GA5-M%/486)1$IG/4?;BAQ,LUBANYM=;:@?(=[3TF&T1ING+>RD
M*]":<,,]-EX5GB5QA"=OX,]Y[*6MQGK,]//4&>HC!)OY&OW3F:/H/.^TJT-I
M?@XO(O/4$0OUG),W):])>,@5G#+,04]M76"]8#8XFDC4?;'.$LZW=I32DW>]
MF0])Z%"SS_2U?I#Z=M%VKG:1MOCWJ!2*WT^]@L_GO-0\Z(B54A7HT#,XR.'\
M[&$@+.*PLU.4///K5U(?13X%";.:SSQGL52::/)0^Y)\9N*'TQ<D__3,;TP%
M,[!IG',!.9+S(R>9H3U=<TDXP=#V0[,S&.UA> +9F-:J$#5G/:%?DMNM2N=4
MTS\JCVAN7;05&#BJ$X_2_WHYN#BQ*%F@E)EQA#,$EHX"LY4 7N8O6LGWA(3*
MM79?)R -/S>3$<>\B6Y%H&2 &!LY84(YYCHK(79-RT2GU-R;=[L#@&RPO93&
M"IOC#;48*0,[_%&RBWK6SZG?![MA*PT.IK7]\25QU='$%(+1%L/F,Z2LW]._
M.U\.LNR$3RQ0D8Q,ER-$2<)%ZQ(-'#V#^3Q/;^5@N"#G[UV.74/=-SJ&T_C%
MRMZH0UZS(,IV#:Z2:@YO!/67U;\D^T=][)F')SSL#PJ4CF<;:%'QF=L$]+J6
M(A)U4?"?O4+E3__\^2! 75#_DRB@\I<*_G\(GX7S^2QL=PYXW;EJ6B#-@+:0
MPGK<!:UW;.^"'D^)-.Z:BDJJ'&!&[;H-4>1N_EE &EM13@0$!K]9+CA+]K^W
M?KOIS@C[J^V/_GC<NG\%DB.W5Z&ODY2C0B">!"29JE> VO(EUZB2",G26IH
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M\() $GUT2[+>QI8+<F@8YDP'[^4'!BB?^MMD96*[]2UEA+BQ'L4'_#0K9U_
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MQK;!+<*K$\_<4383=R@&_YA)N-[/?IB5>J3AWFZ;!WC*N7/AYP"LE?F#Z$O
M)5),F8I-^(MC+^K0X0.TST\?TQ4BJ!,#X@:YA8UQBOEE4Y;WJT,?M%!?G(FW
MF?='9VRCF/ DB,AQ]QFDJ>[(FNF)KV@W.Q9O JG?M4/A\*KI,=R5Y];C]P*U
M]5,(N;#?34Q.ON<C*5;E0KV5I-:I_*YEHO0[<$(M^SH+3DT*;- @1G0K*N9V
MYE R@R/D 3^WV9N3_BV9>Z5964-]*$) RWT<TK-L=J^VGUHA\7,T_]VA5,!X
MUPX-98@D8VF2(R&3^H0^+DBXGSXG7(].Z-A9:\EZ$AB&\KTPKHDQKE@QB!(;
MIQLT.@N]7BWGV9C$^Q^8.UQ;/3)&YX($.;QH%,V]]^/KU5F=T7N!^A-#)!MY
MCU'2:IM>YXY;GV#A@*V4JVD^-N2T%+-3Z'-K9*5')THF62/3.?O3=C*H',L%
M*1JT;RT'<T&%'NWG")OC7!#'!(5='5[D@JZT1=V]SKN$ZJS^(XI1Y8)N:T'W
M;RH_"NW^'__AR"-QXW]HBF:L77IJ^V$*']L>:#V2 DY< %#SJ&- M]81M^UA
MQMC<Y9$%BOO%+652.U+YK6Z8Q;>;[C)FJ&-6::4DZ'&R+#*(:6#.4NC:@29S
M3)<?&Q3P#=VN'X5HA&V$X'@[&3;AO9%V4P-K659X?SMC\^"R7*4V=-=UM?RN
M4P,]^\+A%^8>H,R"TR3D/D4IY-*A3]AF\T##9*6;?8I59# \AXKZ-C*\\G%#
MZDO?@GQH:^.Y]2F5:PL4A[:]+*Q?Y/V)^4<-!'8(X(EDR6^'3VQD=*Y'7 %T
MB3VT5VSY:H"'?("NI=-%D1TS/;-B8)212.FV=Q@*;54(AM74MSWQ;!W2"2Q^
MBIQOC@%W&Q[_@5+NK;U9Y6R"4\TTM,=GPT0$0[4U8P88:G0]S5;QXZ$>X@3[
MW7/G@M\[= _%WC6"..0C@@^8J57'P&23\?%=E1Y:5KTN<78.RIE]*UKJ:(RY
M@85LL?=6U@ND1>JT=9"_F?0M+B@Z%6,P;*H,"':C(. GI@: -*,Z^?RLYK )
M+TO @]4\3A9BR9(E"7]A= N7G9O&3:5'-$E[$0[C$!LS\V1CEQ :&O6L?Q#V
MU3UJNEV8#&% DZ4YNJR,&/OYICBRP:XI4E&"91 ?@E-$4I3)V8PNUU8_@YP9
MIW#E_557B!3R]]HY/"N/7"6@[^2M/IWZ,+Z$@=KLFQ7&MF/>CYG/A](FUD5>
M+^7TQ%$.8VX  A4!4[\[L.L QO+U?HB\(@"+]N/46$6]88N42G^GG!>B_M'C
M](7^AMR308]1YS/U<UR^9G/X^A5B#5K@\5$J)?'1_T1UC\LIR67$+[2/$C6A
M=X4LZ-O>V BIMTB%KXMIX[?%7+363PXNS-(5+FL]55TTQ#Q.SRJW:X1?&D.7
M^>B6.-V\=W94P[GWC'V6H]7@YT7[LQ_]O&>UR<PQ3E%BAY>_)\WRW"<_>OX]
M@W8C$^D?W89ORW95$QXF=QD]C]4-5:H]M_C^S"#U<W3)T=&$)KQ3WLH%&O-7
MR4?[)96]MU#?N\S&7'H<2R1%)=*^9V>Q4P!UU VC!R0%LTYB FEIT%UDERMD
MH!-MHJ>:%HBX,B@8=7*T2G5(;&KZ2H["I>\_[U[[Q1'=J]F$#:2!Q2GB0-L]
M+>U[IAIH/5K/^VFPD'_4B7&,#<.0;,ELL@#2*E;#%UX%9 _[MY@^D2K26.&<
M>C9Q;9!D UU+(=SJ##-!ZF1CG/>BR98L7ACP'K^,%<,HE,RPG8#5"C:"-!XZ
MD&!46E^-,>$,,W7BR>"[D?,*$5=9<_$0G,A^[=29K0@.M+_*@A"9P]ITLI%'
M$ZW-XK-678!_>TU!-6T@HRYJ:%8>J#P-I&*0-./<-'M7YGIWB4$217**K3=(
M :,W:+]3%14>#E^TVZ6ZQL?Y,R(-NAH';U)BZ&<\O?%S'3YBX5OU8)G%E]]3
M=N6/U*"O#1S:>^,F("C$C_Y45?BY1C;?.8Z8[Z7N57N]!*;VN4;&*)0I8V)Z
M6H*9J>N2T^PL:*GI]^#9FT2L&V&]@D:(..H8NF*=I0*UKX[/:(@7SO.W"\[2
MX/6H?.-!O&KOZ&V;IQYLOQ.\[0T0"/M$H4H320K_1A''V;$D.&?2_3&BX*13
MS+Z>0G2K^Z!6.@Z<4KG)!1W32 G45J;LAA9;3_W=@K39MD&=COB*J66ZS4]T
MZ4S.;4<RG3O@AY"*0JSJ1+96.?#D!P0G94D$$.;D$1,S.DX,G6,OU)@!3MQX
MTUX?Z#7<J_\X(B(N>N%[\=_DZ\(3[PM,@-CV8SY * MJP?3)+T>@K=@(&A'V
MWK7Q;=GR[^V6**+B4^+RA+?'<$@Y8U338Q?6FA:8Y?>-U.KC):=R:$M8]F8%
M[5.<;VU><,/S[P3#--<:HMV%G [[G9_EKK@?*_U>D8695R.>(W.,]!;JP023
M*,A\GH<0G05V#$J)W<^M?5^:.SPV[?%]?GV.]:._U<\4MG6FGBE,!OT9Z)RK
MDUYKH.FDA&?TX 0Y ^U'-\&I+:3?38^Y(+&0]H-+4E&:.;OV[CD%A2V5YV$0
M"K[\9.AHJ#%*A?/G;I[[S#5MU5^:0-&V[=XK=B"3"[H$.#)$GB $V#9,1@='
M#2L/8-_GS,7JI\$N#6,\S^.QE5_1.</=*U-7;.YS08YCH<;KL!O&5:'&:19[
M#7S:49,/E':$:\AF] PAM*5-M@L+D4C2$?0_%KBO-D^.;>Y)V\0V7DY"-6BD
M(%U^'[N\D1D<DY[YI78R=<7N63<#[XJKBY/5=-(.]5PK,KR>)JO^LQQ\5R[S
MI+7^U+<TJ^X\+[RR]N/XCF[Q_4HY[4)P;V&(GX78=OJYLH7\,^]_-5^V#X:_
MZM"V::82RQCI,HQXF>$SA5?2SQ297V6D2:A;RIWA3TP^6'B&OP($ O&8MD--
MU;B@]XY<T#X/'KE__QXF8A?!EFD<)?+N6&32<&+@1+E*R\-QD0;OI&95VRY_
MF6J=O^ZF\<^E0[]^]\PQ'^+8XAD=R&!P'(*1017XH!02#^7'G'UN5==Z-&B!
M6HZ><V&2!.2W+B\=3\V^8L@[^IZ)%_?A@_'^X[/%T(#8K\@DAWS=CIH0%=24
MBYA[5=6T$C3QN0ZC$4#Q?5(ZG@Z]67)!(^1;B?IP>V;VF[V#0X@/$VG[IJZT
M"UAN)T;)<;HI:I0+J+H 12.@NM#_:*\\__V0?6+POH6>S,X2#?C)8W+D@0'X
M*>8N%\1K'O5EJCD+>AAS8*_ 1"IM0?/AJMX^A?1(7ZWD[_YD?XN91KCZ2B2C
M7J9/J+(2#]E$HP0,IT5]?K88.NS0?QV75,G..VDO#EE&_E&T\="CK3@WGBOQ
M:;G>X:6*M3QCET''WL&"?A&^8,Q9N^Q%.B]51VI%2@_7IAU#RTW$\+U^P@5=
MHV;'L;\DYZ?7AY4_55GXW<L%&6O9<X1%]I/12YBO8C8-?AP#!E!%[X@*!<_G
MJZ--C\5W=T@_+3[[I:<J+7AMN2V_KKC6][&/-C4C#LCE")AS03Q76/:M[IPO
MBB9#XS;3;YBE3^9%A"P.W:?)VS*?S9C_W>.?3)-]4'Q672C" 2-##YN>]GYX
MZ^)O+LB?.H'D@@[/TW&]ECRVT(\,MHFIIS.'=KT4Q^%-#(SLV;D]A/A.)6#?
MVV#G"\-G:66<:00IE_=$31V07^7'.'$[4$X_!WTI_2-)_*/L KG3>:^>"[KG
M'IFRBFO(6%<EU(,$ L#R4:=OU1Z2^?B\2RE/TGZB(L-Z4PU0SFFG+T[>@:[.
MBI\MXX)^^MM;:I+-WNO$:';#V([,&O:+20[QA?,?"'P7QAE^K.W!V$X$UHWK
M8K5TJ'/@MV<.'+ *Q+";E;SQ*I3]JBLZ"N,%=!* /KJ):Q-U([FE\CI@?_69
M3(-.XJQN>[HL^&:(_RE8F\_=M$E3IQ!^:I1=$/6Q)X:OVPLY_(93-S^_<OYM
M>QWKX8V <UF$U2 4K3'_Q[;)S #UN*G;DRYO#U@B\;C):0,;[[++]@OEMODO
M"A1O.&UGM\*1H=#ABF2.AA=0S;([* @5YYSJNKS&8X*B.YXTE'\(@;;^;;C\
M;I-H#$]'R-^3@61W0Y,?I9X[T,3B@I*]3@<IUS@['+Z3EZ>(G,@>ZM&K_T8G
M-U#R_CAY2O[Z3K7B" + WHF'NU51TI_$5OMR;LO_4?,LPK[C#"Q5,UIZMJOV
M\"%C KZ[?[%O77_;,V6"JIP#OWSV$/5#.^D;JSF_**[C;XWZ82[H_L#4[M5,
MY1C&0*IVQ\'#1FWM"0U^\A>_HD)N*CTT]O$P^AE\"Q*53H9)?%4\\4$#4I>O
M.1Z3'>@NUVOPJ\4R5 >,#K>)N)=B4A(YH_X]=/A7'=&\[[L/UG[6!,BG@1.N
MW^2"4+,#IM6$#X'LBS1WL7%W;^J^#EO2TE<X.!"Y]2OF">3CU4K-]V*(6=?.
M5[QY;GYSQSDGZY%&/2G:IKQ^G]Z0$$<!UYX.SAD6TN(;K@$]X,$2SJSR>^"N
MCU9[ SRDTNM\J-UO(T])@#\WQNU'O.A^X0T]-H.N;9@[N&JJ1!Y9#\EM>^P,
M!-%*QZM"ID^?=KL)J_ARR1NCY>WOWD^V-Q=\!CYWY?&!!/(2F.E</06VE0_E
M@@YA-%CJT:9^1!,KVI_>7\WZ_R!=7\BG6R@$2CH(RGS)FTA)8HIDE*DL56;(
M!V8*3MJ]:)/2X;F$: GVJ-QB<@P?F/MDHM8KE7^'UC4Y:8S1@C+SR:,>T^#V
M%IWH'!U!& UW')D-E2@L^ '+S1V0\Z-(>P?)%&CDPJPV^\%7AC=OGAI9B%-J
M>$IB/%!RS+(JN&+IT<*P'?FQ4-O<4E/W%@?+KR)]_*%U.R?0Z/OZ=U)$BJQ2
M6L'P8U)SP61ID]\W9%A);&VZI1/;C/F;+>5YL+M $^ )(N/F;@&HGD<;<B"\
MBL9%^[^2OBO7@) ?:MY>\ *9<D$T!*"!71NJ+(;1;>3IB.@?=P*K=# &2.+D
ME;^^IRT\J4!<]89V]/ND6\ZFB?0A#%*9U5T8"I1,J^PE&EX@,2697Y94#7^.
MOC@9T].+G+KTL+\[^L7\"Q^\_)4=0=6D C"CY$>0,,*Z>%3<944F52(G]FUY
MMSWUM@-8:4Y?@F#88=,K+$;.&)'7$?&3NX^O0+H^2BCZ@C2B-06BG.I&-(FA
M%SV)QZA^H3#@1/KJ]?.USQ7>MF9Y\XL]7;<SO^?\L4!RKZ7]#DY&WF43EQXE
MT/26K%OL%,[^39%I^77GP[&79'/?TD.G_G%LU,/+9T[RU^YXF^U7!FQX@ X&
M0A<2[SIO63*;4/$E8!RO]"0E12 E\>V)C/91L!F"Y]4-ZO<OP/?)-A,+7GTT
MVCG]T+G%3A^Q#@N[-[;DLR][_^F&\<G>R.</+1\LD#2R*[&MV+Z?9[JH4Q[_
MZ:S8IX?E-[J_(T6-Q'N^]QJF4@S?6D!6KA?H\5FC#>DS 1T-UA#=8U2($R3
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M/:0)(MM19:K1OQS:P@JF+EH(6:,K&>C3<B$IQY_5M,]C)[VZ40FF!X;8@15
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M\!NL.U4+#/\--8M2P'Y(H4%W#_AS03LG->JK]&@3[$2*.!=4(X7C@@K%6HU
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MGPY]Z%JN%7@WL7].4W"\MM91YIIXBR_/F*2"D=.I]CWS>>.6SJ(W% \Z^4=
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M< YY+XO4H&+]5J_I>(N@(NN*%P3L&P^;LHR-UYDLRC-?VB<M&;,L?H3Q?9$
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MS36XD;[/N-K;+)<4GL(O$OUZ^;VG"+7HT$:,/8B)J']1"7*72BEE:J4E&$I
M50+1SA10ZBD%$QIN'W3/06_ZO!TLQ5>^ML._K+VKT)QU\:-867L;@QVB@N!!
MHCC"@9!_"*I_36>O%/$T&+>6H2$'?8"_WXDU@NG-AIBDEH@2#M=WH&38O4M
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MJ^?&?!\L&N6P8G.0U!,\0X)H4*-=:[A%F;%\]72N=ZN/Z@LOG16X]IW:!-'
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M9X%"8U6M:BS3/2@&CKVJ6-FOV(BR9>GNA<%-!@==_N1G)ZY$8<2JZ\_($"%
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M,-[#]X9O(,($#-O(=+]P;E]F&/.@$;+$ K0)!="=K8,X=1&-GQZQL9Q$73B
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MVF6(S[/^,YMWF99^*D&1@>/P^LDK$!N_'_/GP*_+7.5'1Z.('RA48MNNQ-=
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M-/KE,:M@%;VN$^-D@AP0>88^M]6GJ6$I8J=I1ME.J&!%]&WB2S7S'%@,H3E
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M7C<_7Q+Z>C7GZVK;2!3Y1N^2=B#O!3)30;P\%\3><?-%PL2,".=;_N]O@>-
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M"S,;_ZXXWH$YN&C+QB'5SL96$C9A,GODI"SZ.7K<3W[<QEXT:>/T)C9;H$!
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M/@"H.?;#CCQ2>V$<50<I-XEQ9I."XP5C_"D[?VF+\Z#)(.KBP&D@Q_-S%$@
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M%L6&=Y"_DDQ.1J=6?/;'M$FU^$SLP\L0')\ H^*QRV4*ZAF[F3+ R\_NZIV
MQ47ZRD+$8 :BB74!KD%0S"KN:&M^[0J;?'G[DD%^==,1]2+Z-K;Q>VUR<//H
M0TW&W4I =G-"Y&[97N<".]P2TQ26UF_<&)[K\A1O).3Y/N3..4]UV:&_T)DO
M72DH=V?WC:\K,<N)Y7LR783B9^PW S 2\MG-29[P>@BE=R1;F&2+\Z+_L5;D
MGO[^*^O)4OC,K7/?7]*_W\E8Y%<6<*H2%&2BKTH%O2]WQ!MM?<$R/(PU(L@K
M.MRHNB'TSN.=9$+?,.;W*^_WV4?'&<0F9-1"-;C+!3@;*)3-B<[2^>CSS*RM
M2K;]^95O3UZ]O CK"5:WL8IC$G:($!!#5]^JV:V&E,T9J>1+ON"KM66^E3X3
M$TCI*V\C=<2<J&P0_?"@Z.$_9!#I;?Y<^OENMP"5![)"?\7Z_5;H$AVS)7["
M=4Y4X(_Q1_[4WF#MZ5</B71;E]K\^1TV5^@JNCW6]&&[ T@_%.EJ<2?$1Y.8
M8D,V'Z+[6G? S+@Q8UL%7KL[^2LO='GVQV>6J:26ED +"0FQ3C'3U;;0(^Y(
M+AU8[7K. 2FC4-M6%Z3](<58ZU''_[H?YC\S OTI&>3'\URD=DS\'F?) ;$1
M/["Z BTKOGP]J*U/58'S^?3+RXP)MVU!I4)/WP4F,"+8K!W^0.K3 E-S:_P#
M_>9J*351W7S2DLOZ4=96K_)TN7>5V4]"/T,MY@6'?<%7IRN@GEYZ%1,"@KP,
ML^XKSV[J GH%FY]_SBK)-Q) ]\O,7&BG <RP"1=PC6R>^FI]E7]D/TS$268[
MOG,"U;R:LH!8#Q8893H5FBZ_,.2\RW;DZ'+P2=EFOY+S]0%*:2*$NJ75KQH@
MU@XZ@4W^D[6RK_'N?V:G?'OV/>3&XZ2>#QMIO @^*--AMXIZ3++4SV?G>I:
MV88Z2^:<AB]&PO).1.N/&;5-7L?9(G31?7SL-V]JZP*8\M[1+4.[:X?B,O@_
ME-?!M.?O6+D)*J][#RGAXIZ=D(]P,C/^AE4Q=N">M^>0_>:<Y]0!-UZOC*$O
MMMC=TOGH+)0JJ:"O6/(';.M;.:LCW3T%34HI.3X-YS].+$[L1_?W7;\W1K'3
MB7.R]MI]6KQRN-R<VX7FVE<7$%,KQ%XX!^\>SZ:C$WF[SJ3BUXVP(^&(91E+
MR[%&V= TU3>RE=/)ZW-T#7TW$K+1,J1D[$XL_/ZN5TO2C(A4:OQL -U$=?NQ
MY=P2@M>I^-40#\B%PW6\YC4-0#]!W@R^R!HA;CC:I9\*\3VL_SI. 9*23\RG
MIR4)O=_.KKR\S/O1"[LHJIK@LS9;"Y?%(6<XNEH% KY6ICVZ^:YBCR_AD?*2
M&?_W7I&%A(F]7V,#KY:MEY(@G$D.VI)=V<W)QI9KRF[T2\K/G?ON*WAHSY.Q
MI4C14HV3'./PGQ4?K/*Y/4S 'KI>?]&#2_US]P^-/Z):&M*P%D)I[_O]-L\H
MG?MMKB):GJ>K)<R69".4I"LCE*2_K2Z49*'77_5/IMP%!/5493*= DHFXXD>
M7+>.4HBXL\HHTP8*XQ<,)W-]]7A]*&L+MR(5YAI<V,H0J($P?5E$GYV3Y#@^
M8A:N*RYG8&1,>_1T@EWC-@T0XH%L5]00/'V@IH9(R_=@HW8P ,X:[+' 3A47
M+M"[./TR^R)>WQ#M.D[V*YD%IE,\41&;?+7QYH:26S*@X;L8C@ZO\W !/%T(
M]1I9&C]7'HX DLYI5N*GPM7475J^5HQNFGK(5S?(.8#G'[NVCA\P1 1E/3!N
M:&SY[IKV6H&H)O.NG\."*T(ZYX2/R^=)V-3)@+N^[JO:4GH3NU&ON6(3V9#E
M./&[VR[*/J5*6*C.X55_%)<,=D"=+WM_<6(VT%!7RUY,;D)>2@5Z4M'M?SWX
MU\O;NLJ+XHM,S4_/_#C'69[KJW^ANDZSGLY]G_?8>^@)LJ_,J ,!O%XI-/C!
MB2TNP2=!Y=.)WUK?5J*.<0U U7)M99+AOV;4_F_)-_VG/7M?$F/^1IGS+](!
M30G< ['#'*6-EZ(O;EY?]%TD]O)F!^%.N=KHV]]H89.2,S\$<Y![._N?F:/(
MWHN)S#!TY_Q-/"A!336?5-S!+S:Z(P^Z1O*RJTXX>319D[GZZ^[KNY-5(55:
M N]^;%0%!:2I9D*<OD<HFY).U7=($K)=E'H#\6,F 4V 8AC32@ET1'#V4GD>
M.JXN%[L3ZK3[6E";T%*B]\(/>-E&-;_N/>Z'<Y+0FW9/K+=+X(6EA<-_"C3J
M^)9*ZD9V\H;O_$8$>__&0SL.XMF$_"WN$E_:3]NWJV=M92W56%I8UOFS--]5
M3$]++JFPF_ES?XBQN[;KU0.UQX0?"24/X$A.O*%1SX<+$;]NK.)N$S+[]U1D
M8[N?%AG8]]J*DVR2C/WPJ<)]JCYCJ=SK"N 9O!'?BAWCAV8'6P7PA:A4A0]+
MYBO"8;VFH55IZ3"XO5*#.&>C\4HX)<MJJO.G62[5J2OB<>'YJYQ7-<_[G6=Y
MI\D;HJ007E+F^!;=)%A( [R]0@,8]2I0=)#MFLC%2'_+0ZH :>"$>=KJ_I0K
MSI(@LCFA-KPV&;$8D;&[LCA9^FH#\NSP%:LXC,XF;<$HX3Z!%&16JQVI#_PE
M$BL?;WNO94)-'<LG:($_C"*#"C6RRF#^X+$7^\'^#\=O2B9->\P8D)\X_+;[
M ES?%C 68!%Z3*AJ0N@LT@",;JU TA[FEX^=JI6=)8M9_\OIU MBB]XI>VKE
M*FTR;N;E<Q/)Q?HY#.#IJ8+90W$M[3ST<T)0C!*RR^B,FDYABI,30<F!#_41
M6_7K09C<%4:[>H4^[YV9$?2.F,[TI!D!AH1$?DOR\,T7,TED%O'J/39W6]?(
M&9](YSVWDSA$ TR8_RM"]6@ &U3]PA%H%_0#6WU !O44@^9!D;OL+L>)J ,%
M^W^O?:#8"4%WLL08^><_>JHP/X&X/;UWH:MR,>1L0]OB:S43D/$^M: 8#>XD
M>YA"YA1S?&>0@>[%(KFZQ:7<!E[3!0F]^J1PK#V_61#T:+SPO/RK/M:XP#NW
MN19?DTGE@7C45@ !V/GC75D3?+C@3,Q:_"\8K[.TU=8V[/ 8GOFO]:!2O[%?
MWC7L:U@1%T^AH_0_?=FV(5W@F2?A)]VO6H*9Q_@$B7^XDR[!33%;YVRT.W[L
MSCY,JL"I:_M\8@VY^*BL2B8.6(V.G>(>"IO5SK:[F-'=IB7USDH4EW"O#3B)
MOO4M9GO]W(<RX;B$3/M(H^<XWOU5:%T.*TYLS>23>"FH\9C<R!_LP-.AMYVJ
ME[+@.>4PLP^R!G<@JY<;\VL2N0T*?I"+[ 'L1D]MW_8^Z/7X]9W$\=4^?H8N
M41XZK&TLE*'@G-/(?./OW]=\U-HC?^9HA4R?78='K[/O^FS-\C4=+->5(@1(
M,7T1LQ^5VB_<>L]L]Q<PY]-[JQ'7#?//?R[_=:Y65_U@S3G#3BX*W-$E]MJ@
M%M'B"[KGU7J!U#%[:WI39JQ:\V58_>(I5:OMEUGL8!+C-ONNN>\I<2W?X?4>
M>@$2G&RUK" 1L/WL,XUI*$Y3,L>+SKB5"*]^E%=G80VEH-F:Z=P&Q]]GO(]L
M-*?00@@E?FKM&+]@OW!3BKHI.*,RK.K*((^P\-^O.X=R4]MJ,E@&IX<S!NNX
MPJO59TAOH%*;,KE"ZOD=[\<YP8ED__)ZFZ6GE$*%#L6A8-Y/3X^&OQRV2^9]
MH@0//5]CGK%? CS.>!9V,'?VRO'*+!EWJRXA(+7_^7T'@U[RJ>OMYTAQ-9Z/
M'3NIHK!2:^4?WRF?C]$\T ;^,GU=L5X".D=ESUZHX<^Y_:M.Q?:8_-;GR"V.
M!GC_&,3CJTRE?D11S-XFP33F-%J7:ZQ;[8A=O3N1-("0Z^Z?P/G0@YI1LA/D
MZ3'PQTCH*E+0R@0.QI^X<0=GK/SQ&WJJ<M!MDHR=C/")5779[Y$;2U!%BO-[
MII<?124N\*'Q4NTNOP]I@-L[-, M&N"O83'=,%4[[I^*4-AGI,H\GSH>EPVR
MGO?!C>,3!&=) U4:LL@7,NV=C?M" R@=4QOZ5?J=R@A7:8"VSVCBLMVKD@Y;
MQR4:X,T #;"%RO<4J5_IW2N?8)XV[8HO)PN.[:_I0LLOKUO.,&P[Z=:X<4=D
M:ZJS/8 -OVUH"-N_8(80'B)$_'H6,"PS$NF G,%M[ _Q(0HH']$0?3#3&D*Q
M*ECSFMC.?N:XP4^Z#*FRTKETH7?6]\_>T6Q3OZ= SMWO[=_=EL9; GDEPN%C
M-['2?(-5L_(K'*8<8)%?@NS\I^Y0YM=,T@C(^2*5+6B:R?CC R##R"='BRR;
M5X<BG@(HGCG?%!!0CN@799SF G9J"T3P43R:YF9U#E>B P^\?S_;UT@]JBY"
M3+X.?6D[S;M"8F#I$XD[0WK=*R*(REY'UOH.-&L1TX>^HM7\A=[V+2+?E.]Z
M)%YP8_<,M$O?+CVJ"2;?N?*\/E1_="$++7A@@^M2,:CXE>[]U*_S' 6IM[RC
M(>"N^ 4]RA(UJ.&E.17GO;\R;OE7L?+$<&.*IW6 C0**[R D[^08%3"K;_3[
M>27,R[5(57E?5:W\R/?C /?V""E.K&CEPWG8SIJ'J<Y# K;8IN?T(Z#ZN"2'
M*OU=]$'EB4P1'#(BV>F9S3Z;@[4C'-QJCNT"UQ2DN@,Y1@!-C2K$(748<6L3
M2C@T(;W'GF [[&U<+"0OQ;WO'4]>#Z !-J98 HH\[B;TK!^OOPH\2GZD^8.O
M_LRQY=A3LE)[QV"+GTB0C>RKR:EY"]L _BPF[LYNE E\9J8O %S^Y=@+FS@S
MTW%.H+=0@O?=6=WLE7=L"3J<U.__5A<V7[><'3/BN,;ZCC,I=JA!N7?L -NJ
MG)S5=3 $[C)C/U R9.FK2(,R;W'755<936@A4)4ZHFTCM85B"N39X/Y==7T[
M4@M."I+C=V+;TT7@D=-@0D8GR VI.<?L%;=H4X]BY^W_V,GVW;*VCU1'F+S>
MVR\RLQPV[G3$KVG'<YLEC;RZ+T8AHK&!5U&&&34W.<M%\TDS-$"4L19[@^-_
M[*:3O&IG;V=K/6/[9]YAWH@]/S4UM7G*O[[>YWL"@[ZJZK.TY>WU@$N/I$JQ
M29!/8?%<46QGV!%YI^I4";V8!N1">Y5?:\=RG+AU@J?['XZ3$SGA#N.2'W-L
MD@:?<<RSD]P<E>+5]+&Z9Z!!68]!1+K(RQ _B8]EH^J*7L-@TNGX)%^%]B*O
M*8"8X"Z4>M]8&B!R@>%+D*?S0]*UPVM6Y(>DL+<6V"$J:WVMU]VV[&L-S%>F
MN!]EP>V+V_@'8;ZBP@%YU XR^ZGX(AEUSM"%P!DQ \ .Q%5\:R;T*PG:0>4;
M*]TO9;@_ZLG17SNVWZ(X(EA?4QO]ZO575QT9^0&A*EW!X *MCEI90\Z20=;<
MB%$S?!F^-&H:90HQ_GJB83-Q/=HD]!6""$[^66Q>Z9TBYL5M2,@R+!PJN;F4
MMS3#X@\'MB6^13+2 &X+$1I,)"F\?P=QGI6$7"P^XYR[9M$YD(V%6.E_@ZIT
M;XAFFD_59M8%;8'-FZ2\ _QN"N6)73&F^&- #.<9U-;^\)N]DCLZB4/<\TWN
MY+]J==] 9??U)Y;5B^K!0<[JLAD'[C<>714  /@ N./3\&&Y]B1,K$-^K>=V
MF"#G_:MZLF%.*<Z<W4(I3DFZPL_2%PYD8V*,8XSC3.*<4I-TK872HH5*WE5T
M57S6 @!DVWKY<U:.S6J,S?[K(LS_QYQ]KO\V60Q@,];Z;TUAQ([=\1V,!E!'
MR]J]:,($04F_HWJP3)<.>AT -(!&1Y.>RC!=?^-4A/3^H1/+QS-J;W>V57S5
M@Z%[#XC8?^"(.HBLUTX4[NUBO+71AN:0+!F=ZLSAA3-[NGCBH)<6Z:5J=J[-
MV@FL96O@-SU:;=RI0M:NE?'3-9[Z^NG+H/K#1I<6++LOG7J@SV 0)1BIMUN*
M; NO[W_>HJNT<L/Y"]?6IY7U8/$O(H9U0!8&\=^/#:ZX<I=+NJAPEDA9378Z
MB2EKVZ5^,X_)4GFO9^Q?78/B*I0.M(JY]HIHU:PH2!==D*_4T\K*KF?FK>11
M="VQ)M?AG]FY5(S2#*'9413Y";SUD08XWT@I!3GY3JCIXQ+IVPDBBP/Q7:U&
MO<SA^'F/>:[*2KE+6R*$E<AL10)'Y^Q'DT>3$ 7](#1S:3MLZ^!H@H%Y4%;2
MM)MWN(]W^,<77)J(M:#?4_HJE6LE>;[BC\H/5,;WE1>MMUYL"7ZO;8BPA68&
M?7#^7MM8]_&QCZV][6#YA>YF0F4"-" 7YAK_44A;6QQY!?U\@733<K/]1&=A
M ;:RV(VAI+:*S_7Y!WP;6(P_.V5&,L6>''W]980UBNA9,:H=WK99,B_S2SQO
M[SZFEV2G/OGQFUWC3W3=RYU8*5%'6%*DXHAU-E-VDPVI1,B!XF)ZY:3A"8@+
MR\S NM*%WPKR$DEW6H=,S#+&)HWXQJOIS?19N!%X_M6/ :H(T&@KA5*,7/P(
MK,O9#)(N+H3KD0R0.*.(#.L[Y3V)H00P#-?&Z 3VL-^HJTOKQY9?^/XS^"OP
MVFI:75WWN'3N2W0S*,?;;G:N*WEFB/V73-/SBD=5VK^5E)X)/>._I!;:#B"
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M,/4\$TF^Z<#@J< ]KK0G$/ID\D",/=I:)$UN:6K3LL,K!,Q I2<A9"Z1KY/
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M0GY%ST\C/Z_Y?1LOAC-!$NR2\QEZ)7+#RTV2B*4.^>[8+]P&#K+>R1G5\33
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MOS$(6!E%B]( ;LRS',0) KB=!OA=C,&1ZA>98S04$:,T (.&,-PE%,?<M<!
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MB..+:-]Y>&1#C7ULNHD)\>I$%@U\=UVNO4#74#A)83E\ QI*@#PF!\5),IX
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MNI_41Y,G^+[KWH)S*1O/0]S(8D<>VKM.J2'")#^:U([>,<@$3D;1+6#)4/K
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MGA@QY$?[0P)YI.C2*T)9^>Y5[QIK5UO5 A9@;4F[]U<%QR;P4HGJJP&EK _
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MHW,_9SYP#ILN:[1;95F> R(U^G6-(%_*B5X._%FL:<?L -:V1)"F"A">0'7
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MD0#>AAK&]7%J1A1GN]L9X"EU-EC L7BEV3ZV(L]XG*Q5]AF7ZFDT2(JMSIA
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MG'=J !Y'$"M#W-5;^0M/RNZ<#(Z=D=*D"H-)=!I%#3AM?J)2!P"#[Y+&4=<
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M@&-I WVH11G\L[(LXC3?_X3DS0..1YM'D-3V:4Y I(;9A#C@.+4:$1^__9:
M.E_^?<H4[_N&U#KD\OUVZ?4$>^/S"K",F[\@)YLA+V<:#C@^P5+=](;1TDA!
M.T!^/)'D;V&]TR=M2ON;_<YGP%<D."KB(;G)ZG1  U"3ZKA@2H/(.:"/)6FD
M-+Q\['BZKU3FI?<UDY2+-[%Z&=9YY"5+A\R,YB>DT0S3$8!O,#KQUWUYM";3
MD+,IEP(__2'--X%YVLWJG76;D5SQ"UQR43H^ ?O6NEA*Z(I8KF/"^(Y]F,JM
M8@LSYTT:WX0HXS===@(VN[CVC@!?F3FK+WPH':-/;]VX[C@J%\7I,+9I(+2:
MJYB(4B/ JYZ'^&4/=Q#!2/.1RZKKV%WI3\\)ER\6#OE^>$,%BU@++BV]<&;\
M<WUI1K PRB>&06ED4>F/P<WVYH68V1;,:23.=1 1Y6T!<"]'P!.*(_D:ED4B
M,M=%XX.V5?ZKQ)B^^-G)>\MW;K 1+,*ORNB.DA49P4?]<G=R&%'H+CI:'7 Z
MS(%89Q_GK.EW[I4]/Y;&)U^L3A):"_/*'2WD.UI3K+[U:%;[+K"F[O84S08G
MZ8DFUP<J[_^-TJ'_K:K12>DMC$%43%E$:1?,$@56W&1&2(Y90T-.JIZ[0J+A
MH<DA)Q);XZ9]WS5\5DRU$0+.%./M;?Y^ ;167+OY*P&NP8Y^8PL7?K.18NM[
M\Z'O%][/B5VR260]\LV>Q=LYW?<=HL_6)G3J1C3=?Z1QXB7^5I6._-\^45X7
MZ12:<IA2M ]C+JW(8K"$!4X.QJK:7;)GP3C0[0<<//IJN_HH09"/H-T2J=@&
M7UN/_ <8CSTD-N(Q)*V'R4\:]00@R?6&@LAPYUI X=T!!Y=0X05 +6L!<YD8
MSML?OYU8;V&Z/D97/&0+]!?J20.AWMD),@_#/U6:?:24?6](7]D+$$W4\L1]
M93\$X@KF^A,2-7,[*Z(O8[5;F07*_38Z$24Y.4_O9M ];Y!%!;L4/RP=< A0
M9) QL#&M0,$N X'1,"K?^1RWD0#]F]AO7Y<&$@K=0_#?3<,&)ESTU3]KANOP
M20ET2&687KR@+O4T!NC_E+N!G:.+4!E-9/G92#C7??,Y8T &HYT<"4GR&'GK
M3*9[M69UY._PNZA"PC7'GTS?P@L%6,D/-6ACG4:SH+^1[\:(5I?DN?0&\OT^
M=Q@XTL(6E5W*=*F//F*?_F&1^=[]=+!%>E^A&)L?,>)?KZT,4Q?3T0.5KZ%E
MK(C_8IT=5[9KWD+?!JCZ1J')_E$><1*ETE!;=L;OG;-[N424X0>DG;XBTU6#
M/FE*]]WG<_-UYFO')%!D24 T[8_WZ :#99K>F<I,5@3Z$G%NJY.CTV]$$S%6
M&&B.W<A<==.+*2O*"^9&W>Y9=%_S#L&K?$5&%! S5R&^_%N\]!3.CS[G2Q$>
M81NS]&!\T30"\.@CP]6PO6'R9".3R.V,M*'_M:.TE#NZNDTOZ[EF8\K-(H/]
M@VJBC(O]G0T3ZGMN^/\SJKGG;SIRX=<:PN+R!L\J3U/C5='&YH:,.UYVKV5T
MOOXH20":'.RMYC!2T3XS<?"Z#DP\A"+OYB_R=%^9/**J&3>DZ=+K5=(T',AH
M;A;$OE?X?MNFTVHF42S+S7;<0@+\F_6^S+Z]KZ6LW,9V4<=J)'U3:,X[7->E
M4*#EL7\NYN(H.SM*1H)!;I%-83H_LS?+FA]P#.BF!)N(26ESYU7 CFVC/-JM
M7E9_'L/#N*Q3H9K?RJ&:_L-YOSUGV 9@. ,2.RV;1]OG'GXX5.^2S@]2.S(F
M>Z*BRC3\*=<!^YHYF.!T5+%54W.3'140:2V'R]=VJU4.S3H[=9PHN4*7[9XY
M5%AK1HSTR9W=3PZ4\\!B EEL^A@)D"941HCD8>%5'R@7<HRSO9OU,K(3"9:I
M9U_>^B=$O_#14X*[#ENH9<?)^)'>3$IUN>,!1P=?Y1;'&[;,"TH:T-^5S@W*
M,A9?H!4MW"O]*"( !3O[54VA]H52U=;WBYW:]'O)\!&UR]BDV[5#8;3)N(I@
M\<BF0&;>PZ#!UVZ;9[SS'3[]67!MU[^>U/'CW8+D)./)&LJ',6^-&:M.AN!-
M\D/JU1V]^V/R'X_A3:!"?ZYY<8KU&9QQ9?+%ZQO%]&(S0[SYO'7U\T[5J3*\
MD/,I3N@SI<K^JV_+D<X&8P7*;YM'7?+=K;HK*\RZH+7I\VPJRQ@65]NA:CJ'
M:Y<7, &R9:18'\_I9?W7[7GQFOC<&-5UZG^O@#;J^X_X3I9H^%FP%G[?&25?
M#QON]Y5S[DQ]/P,^G;J7>]W,(^G)Y%-\V<5)2X5Z2,C",Y,[[F&+J! @^A^6
M:3):'*D=>?T[W XLJ#+(PC7D[J0&ESAV^<JM5ZW4FNOQX\Q"=USUOKJH#KNZ
MNA(SXW2]PY8N'N9[YB/@:-L<D=MR7RBU%%"^6;5<][F(EL/K\W/%5YC>6F(6
M1O"7RR@O"5<>V^BYFBGS6Q3$,V$R=&6,"&#@F=^EA']GVXVSCCO&HR\%9/K.
M3^3C>R[W5&NI.:?>8:A$!OGHCA3H3HS@H]_3YW0CXBY*QA0G?[)J=U]Q9X'=
M6NI7<'XDED!OF15,T+E ;_@92CXM\\IP.S1;QF"LMB0[/\"PKHNFZU$XB%)U
M@>;*)FC7+,$J_/G>?_V*LC87!L9RL,LG#[W,V2VKRMQ=>&8G""/<FET0J?5]
M+(LWLS&T;A,IR.![L2_MU[S0RE@B36QO"BPWGWQ=M8J^"#@DZCN4KSR5$=T?
MEC@M*DJY.*IUZ9]AC]'-![$?U.MH2W7BSEKNCPR3J3Q>@U7ZQK+MAIS:L;[E
ME^-#*Z)I-TMYQ!"X%]>Q0W)-_O_&6&L/=87N2.V5N#2];;_XIP+#FNGB.[:"
M%A@FPYDW(NEHONHQU$UF 8])E$M[[I/)E0H&E=_/68Q23<F?H(>>6--6]Y.C
M$84K=4)4OMUI>?1FWG_QFT5R41+-(Q0UQQ_?H6Q;@XP *RWN> 1;YR];$[A?
M/R%<LL5!ZV+>%#C1LB_4MD,U5\N?=?&98"&@=?>U\D%B>JRCYV.!DNHM>;'1
MCCZR>EJJA,$0L2XV@G1I" ^?',):VRV/XOAR#&=Q_SN:D,YY2$BPZ(?!(NC_
M]O7 1"8\=EH:\$Y"\3*3,:)(<^@0J<!O+/@8&#?>KMWPZNLJ1#J9'JU5/M5_
M43=#+A#8N.@?K6X('(>L'<:]:0>P>\#!.TZG[IL1U[>=7.T&LP8SK]:^ZNZF
M*W?3S^&/G[UY+N9U!QJ-'L"P;((G'';<04P9^SQ(K$+V=77FNKW^X)_S=!+R
M?+O@:=MAQ0I6Z\M?+INXU)CAD"1ZM1T7IGJ4*N?P>4$\&YYUSS&_7S+ND_OW
M.X>B!V$G$50Y\NT2WDRK7]XRT&0<E;'6/X"$Q>@VIFM<^T$6IC_K%W[$:AO[
MHIC]PU'B7=Q5W=.:9;<HZ@-8:P''"(UVQIPU42/%-0+:7W!UDRUX?8>;E<,6
M--JY 2)V99&R7?L7P3P&-3Z"FHZ(A(B!Q+O#FE'!5F^Z*+KCY.!PWMZXM'YW
MH:>BSEMCVNN"(MFG+F;<O?.%$U&&IAO6=?3'&DB##F8#;*_98E9AL%0C?48$
MI0\6 9*?HL^2=;P ';<F -*NQCW3-2T":+]C5E!Y0:I#TZY;'>.[N0UY<#YW
M&-KTHF]ZTWCHLBHZ$HPZY.7HO62T OBK+9J7K<(TE.UG1LLB<4:L\/@'K2""
MZ#C12P"3K6+,AR\TM[Z[K9V]&1XJT!L*V6#<>AB=91%5,W? D3R.E@!N$/_5
MYY^]$<F,;Q??T@*,-^.W7(V,!L(V^9"/7);KIVYXME/D >GUM'>E5<0R9_C$
M4@2B>@019>^J8Y,M>:)V>&.#.4];_*C@#BU5//+678,[S-^ZZ-HL5O7^G)L5
MWBU+F%L(9V\G;1CL=.M*SD8K>='/DJA3@T&Z,'6X'SFJ8I*:=&XP4/0KG^8T
M[LK()E[)_'EGM.<*PH>A/I%9L>#8[ C5E=)ZQJC^FN**,I:P!01I0\G9%Y ^
MY@O!PNC.7'B" 03]WU^WY%E8O SW7A[5TV7=E&GXKUI8JXM;,S#V$;CPBY[[
M^^46_+19L4%.,,YWFF?@T:@-TX!*7)51!@P^S@7+^A8*DUN&*C>V_'O]=D<W
MJ![]$QN_F(B9CFMD")$79@4LY %P6U: @0$P(LNE%9R<:_BU+^=P"+S)EV##
MZ#A4'RJ7--<-=@P%[B,#-TK&-'?Y^.]SD4V]_"N,6@-W39"AID#8-!]8(1/#
M2K9.;IOA(]^Z"'BGDF_\6BV\/LIV+3[4W2J\7ZZ6OGL6@NUE(!U7["521PES
M?CNLA/5"K5W3RA5#_GW991F5(39/.3A.FPQ/U6H:<[U(:VS>R LDKJ@W9;8'
M:GX,$OGI^5AM@[>VQ+@JEM0_T4[USO,N,I6.*RO20^9:WNMP2,HLIPEG:[<Z
M^Y4H2F1=U!W/K]9%#I4LW[K_5EFPR"CW90C_GTIOWD6D\VLL_%)GGVY*LV[S
M51JC8NXQXB=97GE;V:/Z:[Z(K&ALN_L55H>'_UR(9HC=LI7C1(]X0K&Y,#<"
M_7B$Z@Z;6+QWZ"9N,Q;@<\:>C15(+V='# >SY8%#5XL-8HL"IAT2:"(6_-4N
MRQ>D"1'^VC/K$IQH;W >.&W(7\_'2\$P-L4^$_T:G3MS;LSW3PI.[I]"\8.^
MN]?8ZJS%MOZ8?9EH;O9U5F8S>UIV0-9^##%6'2P OG$ @JK/5#!Y]FP<6T3U
M-EKPW^,HU(\9ZH_/FY[MDKA<F I$,V )_[MC]E30<T#QT^1,,JH%#XNK)PHM
M-<<UXSU^\T^+#JT'R[>:D"+-B_3TE0$>WXD154N'FB&M5MEVD0SX4@0VKL93
M> =;:O:L]'M;9$!S7'IT"':EP20R/ -2OSR9A1V-7;O>..7F @M6KJS1(PP2
M;CTVY[-/82B5$=WML^YTBT5[6QCKV2E?,HFQ=7_XS9=DIB6N["T#@7RI3HV*
M/HPCB52]U=4FU2#AGW/2T9Y.JO:"O!O,;^IN-,+'$*DFC+M>M];ZG]Y=W\/T
MK:4OO.N+,F$UM@<+L*V Z.=$E-IL)LM6PCN^/HK'JKZ%9!%N/VZ\]7,E81C;
MEF.7\:U+_">YS*JF-9=R=X@Z^Q+.HTF FXX6[[VGR/<JI%?Z.I,?4^-0%_":
MN?9%@66FIU-J@AP7(KU2)]!>]O+/CE(?Z7L!#C29XR.!8=2SW^!&X<\>:IT2
M&8<5KO/6%+H$U+_F+=\/N*PM$Q*WY)^5O), ^FI6TW)R:YXM))UJ&ZSZ=-7B
M0ON_&5>.A(LK_GL5!OVELJ< ^K]4&6%(P9/)6J^9/Y]5-C28)O=>;=8EGX F
M"8L(D"0F OT&*N3?#F>DK%H&>N!)<E@9>-\OV6(=SI"GGHG,;]%Q6J$IZ!#7
M1XXITX93]YNZ1T;%5*%_*:'Q]$D5"%;V^P".;R<<J=.W.(R"@N8,2%(-$H&R
M@"16!K'E*[[Y%TJ/LB\R-P60D/M#VY*M"@<<1BT9,XXL"@X[\[:JGF"YT\><
M-)N>=ER0+[Z<T"."87DS^K(8,R= !]@ ;T/R+)_@%-A/MY^S&?5J2NZX8H[_
M1OF(]Q.<[BGS;T[=7JC#S_CE.(^.LINQ>S_&<V/NW]=YYVI"9;9 SJR@)8>)
M#PIRVG-^+0^ZF7CNWD@9I!%YOF\\8*J\^Q$W*'WL>*X/N[?\B8J?FT9--2"!
M=/?X!<F[-8+X'%1:J!*HW7W]7*D29"/O2^339ANYJ?:KI]2*GOVP)HB%PU-J
M\T^'B#E/?%.*?K0 ZE<U2.;6>QOI?F%I:>B?D= <%>NVJW&4#4S"6FLIQJ8(
M/^L7C,T/$<#]5F<0"?:.\YG#!!?IYP2;56LL5W?#L2/VV3+UV&NVF7;Z-QSO
M8;76EL=RY$\YDR^:Y/XBBJ+[9$^3@YFMX1U_M]#JN\%)6WL7S8&@K!+4;: _
MG@QAMAK>:FRN'P[4-V6D\L"'ZUV=3Q&"+ZL]2ML8'/LY:12(5(SYC5@RN @B
M9C>%D6[T-F=*\A%6X;M(1EZ/(=_RIO9K;*>^;+GO9'_\FD55CGQ)8(GCC*]>
MI/2Y]+75!+6,PQURN35 2H9)@A&1NP3E0$L:KPD=6CU*C)\Z[Z^TONF>[3'V
MN\K#)8$P!-%V2K%2>A'IE' TL(+D5>4SF=#HSVM-8[F:AJHU3FP4Y?0G]=V.
MV[CSXMKE[*'/4J&U+RZ$&S^I_"1#A@C.JN_3"@4-VIA>L03K+&[-.E6Y"G=
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M5ACQV.:]7"F9ZA,"32&;@RPHJDZ3$*N".-MQ3*P4CKUY*5&I]9V,=MQ-<RW
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M[#RX=@Q67_\-EI,+W_[\D@E\+SC/!!J"59C B\[A?Q.+&=+!;7#[/"?=BNS
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M2L6^$,&8N-ZE>1\K E*&";2T^R)6.Z4"Z,N_VVO#H70$XW5C1"XX$3@JO8^
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M9+29;>V'F0&#^$>3(7-1FM Z!4%7A;O<R&TC)$QP%^*JSGZEKI/Q;MPL7YC
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M"BF^>#^NZ&\N5U"N.NGS738DYE=M7%3G<%<5HP<Q=DVZ"U&!)=9@"F@N=8?
MPLU%Y>[7,!4.14V^^>QQ%/&C<_1REQ$[^7U^BK-7KW7V>_RA)SV.6<6Z2(T4
M\,E+BB'&XLDK>!2K]+$P@1.(FUSTK9[_ TH^5D$B8< N1W!-X8/SPG\!W">@
M]P_^!\CL -LMY6)P$K<,D/1P3;KD!W#&F@FTP?7Y4YD2<(8)F,J"VYSP*Q=
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M#JJJ*_OL25+UHTH:1][C-ES)J^;/+N]1'S&G)[U.O#*,^3ZA,:T_\+D;EI<
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M)]X9"3848?EVVZ>\[4*Y%/T0JO'GBPQR)T[P35FX0E';P["Z<;]0WD<SA[4
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ME+K,$A(4&K8)2 R#*W).V)VV*.DK&W9P*M5.*6Z6YP+(+N<C(N@#)LEL""'
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M>/<EC3>?+R:"9[R$#!$YK$N([EO"4$6K??Y@5RM618>>3=MEQ*9KX@NW>4L
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M 3BW\P&6CP40>3/ZF4U1JSCD=MP%:O2O5&$,78FH^^.H0:2.CT)L6F>0%'T
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MC9)IL>/T[%U^MLO UF]8&X@]25J8^G(M(!"ULZBTKF5M<+A%;*\)N1=3G33
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M];Z[^]5^N[6[?V]/U=RNTZ=/GU\?O57W<>9Q!4"DHJ"L $!!00&8/?T C_.
MMP L# Q,#'0L3$Q,;&PL'#Q2?#Q<7#RJYR2$I'34#/1TU+2T+YAYV5XP<C/1
MTK*+<G"_XA<2$F)@$Y<6$Y#B%102^"<$!0L;&P\7CQ(?GU+@)>U+@?_7X_$/
M@!CKF2 J A6%$?",& 65&.6Q&\   *"@H_QG /YKH#Q#14/'P,3"QL%]8J@E
M CQ#045]AH:*CHZ&]K0:^+0.0"-&?_Z2_S4&B>8G3$974H$O\;E83&^J.LBT
MQH^8!<W=0K%QR"DHJ:A96-G8.3B%A$5$Q<0EWKZ35U!44E;1_O!11U=/W\#B
MLZ65M8VMG;N'IY>WCZ]?V-=OX1&1WT$)B3^3DE-^I:;EY1> "XN*2TJK:Z"U
M=?4-C4V=7=T]O7W] X,3L,FI:?C,[-PJ8FU]8W-K>V?W^.3T[/SB\NKZYA\N
M%  JRG^/_R4NXB=<S]#04-$P_^%">>;]CX$8#?TE/\;SUYJ8GUQ)& 6^8)&^
MB<^MZL!F$M0Z(C-W&\<A9Q9:93G^!^T_R/Z? 0O]_X3L?P/VO^.: ^"AHCP9
M#Y48( NXE-)"1&DA0E"40=Y"YB%XFB!^51! A6,FGQ0P]S__Y^  G#C>;&;^
M ?>#72AU2=,#2^7D25'HR%CG1$"\:![:%Q.('U_H*$OXY2F>26EJ$:<!6\9=
MJ.250?SR?V) B:3F3ZND=YH@7E1^>0F0F0C(B[T'(!*E7>(JA]=#QBI=@I6#
M80Z*P^&7(Q[_QQ["E$]Z1VB@&0L!*"IP AMS\#30?/+ >THZ<<3C6N@]:)HN
M3'D%J*1DA4^'_P'W_.-ZP][SXHG(F/Y/O@LI%#!<-!'UX:<9-2 FNK  %V2D
M]8R3_TFU9_]4)7MI-$9!:H1U9%-2I2370_&,D^.6PX7]G_*(N*AQEZ?SCZ#[
MVL\X.=_CX(RA>3B6\(/^LVJ>)O]/\2H5#':47_ED+&A:SR0X;GW!3$)&6-L]
MLH[L3T*W2_@5.+[0 :PRY,[!ST*(BGN$GA2!HI"1L0JJD&J@??@ =E<"_.?^
MV'NXGI1AY7C"KZG>P\NQ\+09D -Y(K)RRK'W4*#\*D2 >UCG>%&Q"GJ40;:D
M1AA:'WY=%/35 A1!;SC6M<Q_X?4(@7Q))]A1&@IA_86($"H0QTS>+XHG%69R
MM% X;&UM4!KR27?949XH-CEH/93@O! 24O-D$."]UI<>4@U,'H0IP1YUZ[K
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MKK?(; 57 J6!2]BR;N'-)8_QZ(6_LE6O"H>9M M7QA%OLR>"[KG]4#NW\I9
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MWZ6.OJQ^DW&K P]W.)?D>2X9J+/CY-3%;TOVXYE@'_-39F#7ER$QEN#7T3O
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M(H7H0/WKG^$9\B_)%"PX"K.!0H Y#IM"]#$.5WG2$/8>'AX Z[\IP#Q*4QY
MF4^J*8?!WD.J@0+B?R+V4B%:8 C^1P"HIHOA_/@14 /V<[+/ADMQV5;8>5'
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MENLC:%6U<U/SN]P?EL"@HYT].6JHSN>FI23\K]X3N^1#]KQH[KYA]MGRTH\
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M//.G>H4_6:A.M&=K:<M'P^"-V-"S6X7OGUI DWPI;"]-:5%CIEI'")GF09X
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M)L7BBA2KBJ=EMM_E[O3X-R2QP.DWKA+&/-0DG$PAYE*5(!GG5M+_8@[WRZI
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M<KR"(@$8X3=1$"M.ASQ5>UL%B03T7DPF>A9HK5'=]GOBX>&YK+;WAVCNVVW
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M\ 9Q-L#VSI\_JA*GY0Q?F8R!=/UFTBS[TSY@G"@U-: S2D*'##U'Q/TT"U5
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MLWYU;!K)(5I8,;X&34VMF9@L\_*B3>)BW.\ M<=\9Y?1E63.C*<HW2PN7>_
M9HOD79&,Z+):=@":5/%5Q<XE=<F%9,"4 V7.,"L['5*>U$HPMWEM9C!KCJ@^
MQUV\WF. G;+T#(_7>#B1*?H6:6AN\RR#O2D0/JN.U=P#^"ZZAA<!MN7T4$:6
M:QZUU-"5P-W?1+<DE\Q$F7&NZ5>T@Y.RG./@F2A$<GU(L(Q(\:.AOKSU#J7R
MF(\1PCC#049N@IC(\.M^DVV1KK2&TJN:2"A3@20;_H6N4#'-=9%$,42\IK !
M)I_"6"MP)5#-%(S4[__A-C]-UZC^S-7UH>P**-Q +V* &)V"4>&PW!^=XTM.
MSH_&WO+D/$KB\V>$VJ^\AV1@3(XA<M9.(BD04;55D^"QYK=IH9N*%<2LG\#M
M6)NE,,!*[4*&TNV6YII#*-&8'58PN:%0K\TA0F%60>9/XH20U1T>0_O/(_:Z
MHW3_[E05+DS%3PA$P3 A-& &].?W-8L#>"=<X95KA=*DN*P=MA'46G\!X6?&
MUV9<>(?ZG -EJR..=":4P?('OSW(@]%K$1Y)YU%TN+(<T)--K<G(@W_2;\.Q
M/$=^?T"739H/!?MB'#8WXP%=4CZS<S:.!$4;E74CB?;0$'-_35\L&WM'1\TA
M 7U:M]EVOA5Z1A^MF#5_RPXZE/^=]_<L+V['%UULWIV"KD]M!6QSUD(,D^BV
M!89:R#PY3:6F,[Z"YNOQSBI1,.WP5U>^6SZ^NK<&39%8 6 " =BM2H_90T"R
M4'-5"G8Q,U,']1J7+OV^45\?EF=KHXN='KM?V?S4D;,20D8J9IFHJTU2"#0\
M^YF9BYHR"RGT9/P\\Q>-)P'>VKD6+_N@*U:3S5U-7GBG#B;V:]?0;?P"(;PN
MB.R( Y6UF=.>I'W0**FH2IU+)R))C48[Z^_?A87#89.3IK+3EC7SA)MK)-CC
MRAV#JU#3T!U3V'70),Q6?D8?FW3S;C;J/<9X/"O"#C.01U 88MBOJ28B*/%)
MR2?0>7A"2(W)PL@6PI%><,GG320T1=4>P?YL3P#G/+5*<5G&_8K;DGWG&TY(
MDB#0;LR@+-;A3$<#N$Y=B=ULBSR61B @*%;:2J7C4&N,&GZ9/(7J2;<*7J8W
MRR/!8@+@WFCS*$_L7S8&40PQ=->@A\S&5BSW=N2>%$!BR_-: H2S'2>?>"WD
M8AN/6'N'S[Z5O(Y"LUN3[!_-XLEH\;R%&5)-V)\-EJKV$B,U6F4U- 0@\H3/
M!\VXLX?W5]Z@6%!\Q>K )Y#*RJM#H8Z0@@L,F6[*'XV">W9YDLZ^R>DC#(G/
MW;0&7ZR>+I!"!SSGPHK_6;OE/CTMFRG*7G[?6C^+-F;GO=?3#?/$4>5K4X%^
MUEBDQ-OE&0;+FCD'&*PHS_HFX8Z?71;C7<8[B9EV4YOZ\"2E2PJ: G\8J>\@
M\Z<KBIVL90J@0[AVCTDS$S+^,'6ZT-/0PVQ/3EODM+^ &C,0EC-GXZ"%U5_
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MI-A=(5XDOE9+O5#^N'C#/FCF()#YQG VSLC"G?&50K XQ][5)LSP3$:_R;^
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M0FGA@._*(O/5@WXXX%4*]@64;PLRP$,URW+0.V10%;*#>OO0JR>\$HCSPG
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M>I+&,NY8I($KOW.*X>1V> CF)>.77S/H/73VE'+C<3:P$%U@)#;-@%%4>/*
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M40<ZPZKT[ETUJ&0=#-],5_FIP5V1B.!5AP(.#+4;J2T:&2+?["7G00<?'7^
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M<\7#IR\55HY%O_:4-&6"&!'#2GW6?3+)RY]/$64H'B+(G_S<-1,7J?_B24O
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M034,&K7[)>./Q[A5(T[^,:-IKUMK_/]?*045P4&#ANZL1X*^W&HN;NQY1C]
MD!+WV@3!F\5EGH$^(9"2P\>$3?H.1)+VCOO(1^E^7"\/@JSUH"'D8U&3V#0O
M,A%.!Z(<! ([*=0B$/F_XD#[/+C\ND&IY7A:H\4P-O%A"KG!O;NGA3=CEIFT
MQ]3!QBI1A.&Y)*,U2X@@UN<B&>;-"EYH@P/+.7#@TQ/$SLF#2!@,00+P=)=J
M@^! PB3-^+/9*X'3>#QH"13<=P '+H3<Y>" 8*S _C+X4!G<@K8,OKK;#0?
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M_^Z#U>%(0<RT^$@Q_B_ K:2-D5M5H0ZZY:MS8P9#?U%%= M1-ANG'8<(G6M
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MCP4]^M7.OU5 F^8E )_Z/U!+ P04    " !XB>A:=P@#3KPG  !W*   #0
M &EM86=E7S R,"YJ<&>=F7507$W7X(<,8;! T !!@@5)< @."027R>#N(3C!
M-4@($FR0 &%PA^"N":[!&=S=7088F/EXGO?;W=JJ_6-WSZWJNN=T5]?]G=-=
M?4Y?] QZ!?!4459!%H"!@0$P>7@ Z'F -  ;"PN$]1@;! +AX&#CXI,^P<?#
MPZ<D)B$DI:&BHZ6AHJ9^P<3)\H+A-2,U-:L@VVMN'GY^?CH687$A7C%./G[>
M?R;!P,;!P<?#IWCRA(*7GIJ>]_]9T&T (FQ +L9[( 8#X!$1!I ( ]T%H ,
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MQ:S7K'Q?92?_N=^X47)%H$ZOR(;E3G4=7KC:$F&6Y+XN1-;1&1:4;QMXA#'
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MGF.08[I E.FM[2DUUO?-,@?>NJB\:*QR^_XT>=-900QWH[8U3$)YB%1E6Y$
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M22@D?UFHI?MV.U\@\C>DMUH:A6]3?6VN$<#W,@]KDO+UWAYHO:Z1R,M5Q&!
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M._#.EEI/$-&[J8JD*\G($PWOBSN'-/S^,C$PSDU!>2 >K(D-6*:_Y7)1CQ
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M&W8?*[ ^\\R%L^;RH6?_"U!+ P04    " !XB>A:O%0V&W<F  !+)P  #0
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M&8J]QL@ $HS-EB;:9/QPFYZV'-EG0G^BJ_&3DUU)@&Y]ED]2JE-Y6<I,UDL
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MK'#6%^P!?)R5;];K=6&LRMU:%CN7]$W=!KSOW8]MBD)[EEI9H_Y8$&VZIEE
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M^*<;9,XSY^Y*Z2C/@^9YPPWB"F-8+;!+A/$876%-4UPP(/.DZ(>9&?Y?4H:
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M!6"%-81LPN=!BU.4@'M2I)?L<<MD:K:X,FIP4VNG[4_N8],NH)-:&:J@*[\
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M0W+;W3 2?\2AMU*&*-W:KYP%(P+V%23T/,5@('@.W7VS<YZ'IWN)HV+&A4O
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M.MKUWDA2&$V)H^0A=0/[M,(#9G\C)F.15=90$:NN,M_A-=P+!BP=]@H0Y>[
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MR@^F6D:3IHZ1-ZYPWF2&8<QB/WYJ#X/3(H'FW61XW54K?84 5E@)'[/.ZS"
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M@,$YHOD*=]E&1Q9QBG!:*[P7R+Z,V&T/),-!BYA6W0F;;Z<5+B/O?II7WGM
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MFI69T6$Q?3+N$,1NNJM8_V2$ERJ]0/*$A1;&9:"2>;QA,FW849VF^+5B*/+
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M;XD]M6RY5=[!535Q<VE374/JBXDM43D%KU9O#;/I$7I[4>DJSAT]R1!$_O+
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MR .-U\P'LB:9N9]3;/4W\>:\%#>D;-*?\(Y1[_C)L6FG^1#"]?7")46B(OG
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M!!V- Q/+M,IPB6./[7+JKUIC[B=D 6&U0N0KS&A$-QM>;#\\.0>PN*EE*CY
M=+&>R!7[8"QC8N,KIQS<>..N"AH?^<)N;@#E-,R'PYC!@W_UZ8G_#A?Q^=#_
M 5!+ P04    " !XB>A:3Y8F;?4B  ">I0$ $@   '-P<F-Y+3(P,C0Q,C,Q
M+GAS9.U=ZW/;.)+_OG\%SU=U-UL[CF4[[YW,EOP<)W;DL^0D,UM;6S0)29A0
MA(8@;6O^^FV #_&!%R790<[\,A-3>/P:#30:C>[&3_^XGP7.+8HH)N&[K=UG
MO2T'A1[Q<3AYMW4]W.X/#\_.MO[QL^/\Y:?_VMYV3E&((C=&OG.S< [);#[T
ML#.*W)".231S?HAG?W6VG6D<S]_N[-S=W3WSH SU<(0H22(/4?;!V=Z&!O,F
M#R/$&GSKC!+DO$\"I_?:V>N]W7_S=G_7N1X=PA][+](J?_GIGKZEWA3-7 <%
M:(;"^ 2Z/4)C-PGB=UM_)&Z QQCY6P[0%4+9*-Z.%W-$WVUEF,8NO7E&HLE.
M\=,.M/]\RXG=:(+BC^X,T;GKH:)"',WO&6A>;'=O?S=O.\#AUZ(4(_7^)@IX
MTWN]WOX.^_G&I2@O?M\H?[?/2^^^>?-FA_^:%TVH#'3^2X8Y(W(>>0L]WGLJ
MZAVP[NY\N3@?\E$MR@(I?ER4+U/V8B?],2_JQY%X%."''0:6 =G;[NUOEZ!
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M_EZV& .ZLCLHQ\=MR!SA=@;123$Z&4B'H^QFW*K!J&*?<Y,:)C[GSQMF27U
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ME\57"4\VV7C&K$$EY]I'!/L?_YZ-396V&0E1[$8+$75C-Z :\M+?;E)S!/R
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MQI$)D6FO_?E+43;=$PA0264&#\ZQ=^D(X"D#H6RTE4F J?3$"+F#,:]7GD_
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MW/JT/2$2P24I5VAZ\)\;QE^7R[07C,?.4W$F\;3!I##)S#[]'U!+ P04
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MJ]/&GT![7<892KT@%$9T&[\V7_Q0)D$ Z0.-H7/WPM[3@=3+#:8W(X.3PJY
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M ?*H\\:(JPV:NWGW'2X9)W=5<\(Q= ?]ZJT0GD6+6\3:@)4W":E[4?\8+G.
MI4Q"M:][+U,,=:EL8==("8'WM;NT T7F<]F@&X^OO*.M: >\.'FAIQO"F!V
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M&6"V#GR?R0@:GK5CR$!83]Z!BMMI^HY)80/3>!21BGLZJIF$*!Y#ZS4U^];
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M.II\8$DETB CW<AS%0U?_)85.!47<7*YV7I!0O^-@D_DB8->2*AL_-V/5U'
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M%&R_J*\H6*W)A+-'E'@KM#MC9NDU*T1FU)^5 &5]1[7![3Z(R,-R!71)3@B
MID6=;A'E$7$MR9K3Q//3C%;++$=R%]!"[('9)-VB%,.]J1PYNT,NGZI" ?"L
MZ1G@T)P%,<< &&TJ&!,149ST,DIC)?@#_O>'9="%W(( N@W809VQH2\(DYU_
M&;722BJKD=UIZA,=^(X<( %03KV6DWR/*N$:6U.:L-_+"0T0D7Z4NW;@N5N?
MBZ@C34$KE)JS9NM/!D/I/33K9$"BP&;A^@K=YUNR(U+JD.;EN^+B=J5#E#=-
MBZ^BR(=P',53GC>P3 UY_Q@&2]=:A>.23*^$6/K9H*$(7+7;Q,I^ 4MM4D,1
M<V#6,D@]F[TEJBPS5<Z]H\=N%G)C6I,H9,"\XRX-[18(.*=8AT0L)A!WR,1I
MMK"L1*"9P J'2T3^ABBP'RZFE.M6R/O<-?A>]^:OG";<=1O2?>9_748I<:@"
M8AAG&".+KZ[=LSOQ>A4< "$70?G"^CS3:EV.%RU.O) "^..G(%TW,M'%'JL&
M0*8*-2<H?4(HJE/!\61M(3#!R5//N)<4B(SKK#:VL7@%%(E)6BDJ^?EJW!SN
M@1\QF#3[YH/VA48\)@-P/FZ%.Y*"PB,BDQXANBX>/"(R24MT$HA,&NVO)G2F
M(S23+>-\A&8Z0C.-%9JIVL[A+HW];VW3+6AIL?]JZBXNAQ>@5]9!/,^EVV4\
M(;RO?6W#A>DP=KUJU,G;^IH-U=]SYFO:+#4N.W$5AS':*+;;$=G'\CU\,,J/
M*4"8$<AZ)-?R(\[/$>=G'#@_/Z/E$I\0Z[.00_II?^>R+$\>ZJ=CW7KW3S[-
M-4I6*)FM$H2DGTZ[OW6<B";/:0X+A/I\!/#Y/0#XE&V:+4NJ,:WK9 1UX)<F
M_TP8L1LBC8P^2/<)B]\RC?/UM,"2!)P0G\[R;+^D+/'"F^PA#/SY<HF2(%I)
ML;YO!/O'-2B^4>T+V+-\W0:IWO11NBU@QX<CJD<8\-+?Q1&#D>53#Z\M7B;(
M9*XM_W!!-;EG"A 4D1V8H 6=1*Y;:=>7TV=[#U>$>#J*+>,*]TW:.G$^'@V.
MR@#^\_@B1LE11@BE"8:N6VCV$C'UDP?*:P <CL)..XFC#.<]6&^1CXA?" 6K
MZOKR4.Q<)U>$,#.J10#)8^ C;'M3-><=3P7ZP&W48J@0:489VY7,1 @^?_;7
MM"[P+*!N.Z(O&?.(K8)077D!L0'U"J1H3/6= \4M(08A/HR" 9WY_\H"XA(I
MX4%P/CX$5X7'%S/8*;NFX@PM",S^QE<3-X$<5HB14(;R.\?R WL.G(\/0NLY
M?(&DA*NZZ#=)O(T32NY\.7^*4(+7P;:,9%Q&=]D##A8!V8+6SB$X10=T#DF(
M 8)P(K\GKP)< J(SP S@;FQ]-GF9\-AA*(6-W-6V"5K3]_)'=!5CXG5<1H\H
M!S<%"J%_C$.Y5@DX!4C549%.G)=6$GZ5C[+YS0XL&NX ![)3^EA4RD1;V*$2
MO\T2XJ6G>PVPF!W7GOIPPDA=?"W%V(.1JV3[RCO7?$DC5G$D=?OA?'P(?B"/
M+Z4<]*'>%N7C#;C*(D8,% 3OZZGO"0%O2F'HP8LMO0Z?!IT0PZ:6<\-:'QX&
M^[LX4G*>'P50R#T+0F+OX@AAJ>.]]=F!'.IM=I1,[X-$5=?XG>=PAK"?!-MV
MX%.D^ITC',)AT,NA\O54=]''_GEPOMQ%)3ZAE$&\  73/\:AW$H$G"H%I#79
MJ40A9)W+)!_>NK\]$+/%84PI!,U7]YLL(7Y:T3:(Z 'S#Z";H_/; Q$#AS&E
M& PD&AR;LHQ"_.H"*75#?[^>8]]%8T+N;;3X05-'G4IH@I 9+(I8TXT7++J/
M/I.1'RX%!R/3'B:7@NT)/ZC[,F62^-_B< 'U,+N_G;P5[65,*82>- 05,92S
MG#]O@P2=P5M4=7QX&)&'+HZ4S-<3>:@4ID ;%XVCM:PF<@_&9NH27ZE>9I(M
M=@[8/J)9]\6D<Z65ACZ$F(P:3\L\:V&P1A^VZEVPBH)EX!,%.W^DNK;(:&40
M4<-;Q/(-HA6A,(@7FK%5BX3SYNQG;/;[UNPM5HN2].4'5ML\LOR3@4)5&]L>
M%.I0&58*#]2XJ*$)P1&&Q1P,RZ"]H0;#8@ 3]0C#<H1A<2[8(PR+=/D$S8^P
M:HSW,[I'0M5H>BN,- 9XRN:P;$^K<[J'+VVI:X<0+("15N:Q: $;HG!JZN""
M, 84>AW\VY/#-MI_X!8?1Q[.J+)4DQB[\9901$5G&1FG-;'CV'.'H6T@Y+8X
M90ZMZ"1.TWCC1C!=<[O..!$*IY-A)L!RSFE=R38)<%YH!#1#S:\<V")](8D6
M"\SM Q;TI9@7M#*?_(/&?Q^]T&K*>A\-SL"-!HD1R%^#5Q VKXO.8^[[C6D5
M7:/MF+8DK6/B@!49BA,&=($G'Q*ZC\;@>C^J#S^A2NM#4T[^;$E.U6H4@CYZ
MZFXTW?V<]RF./%8P36:M$ -[:++4O$^61O7"*J$T9!ZJH*,9=+"!??H4E:#B
M%D(9YZQ!]@ZD]B*(O,@/O-!5SR@Q)<8BV\ PJ>0VX/0%XS,:\"QE0,BN.O;U
MT&+,B9%MW2?:%!(BE@C'&A.RBYY^ C&[?JHR)FE0O'>@I(\]5<V8:'X756T-
MW@6S'MNH@I7]V$85)L2Q6-IC&]7#:J,ZR.1"F U!2C(AZF/GU*Y]#-\>Q\ZI
MQ\ZI=CNGRJ:@_<XS;H<YRQI:'1Z3;(])MO"9CTFVQR3;"2?9#K*V'6FU^J$-
MCGFUQ[S:D3B>3O-J]_/ '@"MFC0)D@P)T8:]DV&\&$[4I/ MVTLIHDRFJ (M
MJOP.4E$$L$TVKPD6#;:T+C@UZ38U >K(RJ?"G*$',G7&Z6_<TX>O\9GCS'Z)
MC(!JP[WFVLUE.1]K,,98@W'L\#V%#M]%(F?V@-&_,E3F@DK9*\['+L%65-RQ
M2EHKAQMF>#_+TOC:>Y9B>?T;MZ!7\J5YC15KSG(J9.@'=UNR#CE-KG_DNFI+
MGK/-59OQ:SY]F%]<2#&V^H5K;T::J;7E&N@9?!VD\2FQ\;](5N;6OYI<>6YC
MT9!.P*H0=P6<GF4?I#&M:VLBD\#0P)AK\,_<H\[ON:O\@ *")@L-AINO8B_B
MX+X;%%9]UO& ?&J168.E9L[L'6P@G4VJSTC7EP>R;WI8H_6<WQ-^$B=)_$2H
MPF6#Q=L6WJU1;(+.Z<>"BZEE._%8;*0BE)#F!8OY\CJ.TG7(D%6],.SH"<?=
M7GTC'(!< &P25HL.>)*C+//"+GMG--9>F_9 C"6?K84 =;?H:[;RD"NWYGU]
M$,Z#@$&%0'3WZOL2A^2RT$"<9I,W6VO,ES<)<6@6>4'Y*9F=HA-3W.,%>]9]
M 0I1YXRC@?P>+'>M<BATI0?3WZRB[& '*)@#\MF]=$\?]!35.>/O4U&$<B@4
MA=]_0$%1!LF<+[[#D)Y $)J[(4KH2D2TA)!"_F.<W,=[PZ)_KW)G.A@A:V$[
M!*-:1X.<K@Y6X XY^PY4AR$Y'G- Y;]:-R@AM2!B\ ZL##6B7D8&=UF5=Y#B
M0?7^1N?/Q$,/,,UCO$?)!B@JSL<'LXMXS &5!"F&!?8-YB\C/][8"[^U)CZ,
M/=;'6=T5"(V0[7Y"V6AVY<L#"=#TL$:<]JP:83MVN#0;:NMK<_E>:S?$:C?I
M"S+WRQE])4:+(E7M+HW];]#8&V2HP[!],KPKQ::Y?V)M\CQ%EY"<Q#Y"X':6
M_6,<E($4L*L4DJ8XQWX1Y1079''[-RJ6%AHL ^*5XATU,Y]<^@.:/F/-EJI1
M=Q#!],$B*E6F-R*C]+B(4W)'(7:$&1#6JU'Z'40PR"$<ES!NE2_Z>O-,OR"\
MIPYZ_:Y]<Q![J),9)<=[,>WTX0"?Q3[+99M%B_,H97U.EW&R8>#0KVO<5&\N
MN4#!K^4\E>%;/.FPUQCY?UC%CV2Y ;/4]/\P[6":(1Q86C\Y(W:@[PXGTSX(
M+U005#G[.6&[U2.E)M?/V6)!G'J,</%_:(:FH#Y8+!W!T,Y@9"#J6 I+Q!YQ
MO%M6()4IA$6Z8AFT1W,"[@+7M)+Q'6S0GDO:.4]O):PBPYW4L&K@N0&4 CK/
M28:)<<3XE)@WST^%R?!BKG>/Z.1>W[N'2TYS.*"Y_HB10G1DP3JO(^PGP;;J
M@J@I>-> #GQWV6.WFQ$&.%X21:6OQ;MA ]E_9E'U:_)U:P=DVINS6[0*R 6+
M7*H^>;U/)E 7I3'@!)2YFQ& WD%J'*=/* FY>C&B[E(O1:<TWS)Y.8T7.@30
M/_YDY"%@D^:T[];Y7OR#$OE>G^->&W4RHNAD"2"]6Y< /A@1P(<I"^ #*#U[
MD !.R?^=)_?QTS 7AS>FB_C8(.Y7^2',Q![$^9N8UE'\,]AJ.A$ZAW7FSRL+
MH,$6<8;ST V0GS<:M;\8<&IV9\<(<:ZP-,?IKIHER!NLZK6!QN_@U]<-R?V5
M9NT5^2_AS3J.4)YN,(B]K<$F83_:+-"?4\NDF8<>;E""XRA"X>"[5.> $[ ;
MW8S0WCJG9:+8!6&>W"3Q8Q#Y&@_-YL"3<UM:G &DPZJ)XGR#DE40K3XF\5.Z
M/HTW6R_2<7IVCSM^$]_+%7$B+/\1]:]OZ3P/'D945O\?4$L#!!0    ( 'B)
MZ%KC<-2I&-T  (3'"@ 6    <W!R8WDM,C R-#$R,S%?;&%B+GAM;.Q]_W/C
M-K+GSW=_!2Y[MS53-Y.Q9]YN-MG==R7;\D19V_):FDSR4EM;M A)3"A22U+V
M*'_]X0LI?A$  B"%YF1?U=N7L4T C>X/&HU&H_LO_^_3)D1/.$F#./KK%^=?
MGGV!<+2(_2!:_?6+#[/7H]GE9/+%__M/A/[G7_[7Z]?H/8YPXF781X][=!EO
MMK-%@.:)%Z7+.-F@%]GF)7J-UEFV_>;-F^?GYR\7Y)MT$20XC7?) J?T%^CU
M:])AT>5E@FF'WZ#Y#J/O=B$Z^Q-Z>_;-NZ^_>7>./LPOR0]O_\";_,^_A$'T
MRZ.78D3HCM*_?E$9Z=-C$GX9)ZLW;\_.WKTI/OR"?_G-)_J+VO?/[]C7YU]_
M_?4;]M?#IVD@^I!T>_[FA]N;V6*--][K($HS+UK0 =+@FY3]\B9>>!GC9"M=
M2/H%_>EU\=EK^JO7YV]?OSO_\E/J?\'YAM!?DCC$#WB)&.7?9/LM_NL7:;#9
MAI0@]KMU@I=B0L(D>4/;OXEP1@?XF@YP_D<ZP._(KVZ\1QQ^@>@7'QXFTKE\
M?>B#-WCSG[U2MJ*@.*:._7H>9UYH2F:SY9N^>:FDF"PQ;$=QV=(IQ5;$-ND,
MZ<\WA)Z<*OJM8G&PKO*E6)D9_I3AR,<E^FG/\:+V34B77IP4#=G ?_W"Q\$_
MQU$69/N1[Q,=E.(T_\><M!I]"M)C?J6$-$96BA=?KN*G-Z030M[;_Z#_>$W_
MP=BDT76^(@H^U.@M%.(7)ISA(C&<X3_#QY"I-M*$:G4<O?XP^^(_>2-T:/6J
M^">B#=%/M.D__L+'_$]4F\@HJ?/>2Q8%5>2?+3/)OWBSB(GRW&:O:Y-:)O'&
M1&I9K,V!-\;@"99)^GJY"\-_7NZ2!$?9B/2=J1!#6["99MZG.(HW>X:;UT2#
MO_WJ#>N)?E'^Z_4B3OY9?L)P)1OU34,(G=&4592HSKPE.&(:%2WXE\ACGU9@
MXQ0X+1*C:%%-KN_UFE64OBZ'SP0LOOP-,/>L!F##]7='J )9@D<#U[2(JV78
MI$*Y$J,X>BU;C2!HD0FO#ACA'/O7>>TK4D2(:%'>_7;X?-9I<W2\)"$7HL;R
M&XJ.5F% LL+LC**;P'L,PB +L'/+J#HTH'E4(4/+1@K+[^%Q(I>B<$-OSA7.
M9&I0HK*;?D,,[V1&C?^UHZ>D+$N"QUWF/89X'D^?(\+RZ?+>HZ,Y6\$:I+PY
M$I*+-=U.F'*-8]8<>97V*(N+7Z_CT"<]H7B)LC5&U#?J1?LJ)D$@J8^+.D0U
M>=7%N.!#.(8EC''!Q]9 %[P.JTM%!(K3F.];G 2Q/\N\)-/EI6A?N/!"ZKD'
MMM?UF'AV C!R-HXC7Y>)YSI,'#88SWM00R/",0!K5SAX[X:7]M98HT.IKBIV
M%_(B?V#J2RQ-X0YW/&7"?CLDO4_B-+U/XF7@SMBJC@FRM54(D "&?8&V[!-X
M@ B$5,=%<T(0CJH&#:*-[L#5!<9^BEX$$;J*P]!+TI<')G\6#.[FH>+]W) >
MKPD=TRV-8 BBU6B1!4]N57D[)?TA27KQ;<TFR=H]?(E"TA866-JBKL--;^H
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MU2><E4C%=\>A3-6#[=Z_%1!:)I(LG70/Z:[BC;;V[4JZ 7C5*:9$PU_[,/N
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M^H<QRG+)_;N>S%JG#Y"'8IB<,%SYJN/9O]'I3'=Y#>%\IH6 ?JX.R82R??J
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M24)ST=*]5/<$5&WB]EEX=6C9:85_@KR&(0-Q[!#PMG*::,ZEGZO.>5FD)+W
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M8.G4J+M'\@ZK26PT,=/>C_/J)&T4:3XFR.&"_&IB(M"*);HBJV1;T.)%EY3
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MA.F"BL-@L;^.DSR)8[1:[!<A[@1VP_[!(&Y&IP38<_ITLFB#6*.A0-=.SD+
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M^5(+RO&<F";5V9=ZE[WW\0E4ANQ4"6R";_185J!,W-$J+V?5')Q%.Z9",&>
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MUI7\P-93_2.ZBN7ES[PA L42<0?8:].OMWTH'G:&GRIV9&UV%/(H:'J"4@P
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M46&26$X4F(,?\R1Y!= =G[-\"WR'SW4G]#I'"Y V?S_ 9\#W^MA+@/$<=D^
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M7,Y(%^%:"\Y9&7O1%I?#XN4MS"OFRF^)%0>?<0Q:D=H@D2/L8>^J,=%:(UJ
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M0!+3P-BUZG(OSTCP++68H$E)GLAIGF=*S*QY770Z8IZ&NLK(!R\CC6LVN!$
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MYGPCICG^K)$&O'1&3IW6J2T(=SYP2=OX\$%\]YRQ2$ROH+E27AR8B]?&<RE
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MD6_S-"D:89#B.NM-T<%S3,_.[9!0%IHC-XEI_US/D&'4*+8K-H3'LLH!,'V
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MBE=9 U+%UXQ814"EWX%J0N4W5E7ITET/DCU4LV#UK0&U]2 %3IX@JRJ%W2N
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M8U]W=2CPO48MEI#?8@T('NU-E3>S<@K-K K#ZX",TWR7&X]'N M;(<A9%R1
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MXR>X,=YR2O>/*@]7<U]'P7W[0#B0EMYKWA"23S[?[WX>Q733-$[=;B-O%<"
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M^LB9PZ*=K L7[EU@A4DKT5E=PH%&;8VF@T6+D&[3)M Y]%\"IE[$8QPFLQF
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M4=)G.Q-!T5IR['*CAQ^,2I="<^>;D"S8/]&%X]W%B4NU"=>]$D9<4(-8"JA
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M"),5T#:TPK7I[:6GVQQ=E!N[&Z I>DWJV 9H<#@H3^#<X"H@X;I8NO*DSQ\
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MJ>< <8F>A<3I+3ZEA:;@*Y5/#I>CKDN!*_8OWLTZ\$F:@-2+"K7%)J*ZZD@
M2T/7EH@TH'G#%@E\GWB]O=?&!2>AK9I1 9E*WN\N$0[9/+P)@T?J+P"O_^K"
M$S35:K@!3"HW(]KYAH0KZJ\^AL%3O#X--EO'A[ #FM>=PA74BA>XG'#CV/:%
MYZQZ$:B\TC2DJ')ZN+QO>1++W]YP"!Z<B/"__?]02P$"% ,4    " !XB>A:
M%6"*\H\M#0"/E(  &P              @ $     96$P,C0X,3,X+68T83E?
M<V-I<W!A<F,N:'1M4$L! A0#%     @ >(GH6E2)N)7G @  ^0@  !X
M         ( !R"T- &5A,#(T.#$S.# Q97@R,RTQ7W-C:7-P87)C+FAT;5!+
M 0(4 Q0    ( 'B)Z%K>U21.C0L  %LO   =              "  >LP#0!E
M83 R-#@Q,S@P,65X-2TQ7W-C:7-P87)C+FAT;5!+ 0(4 Q0    ( 'B)Z%JH
MZ#8.] \  ,E4   >              "  ;,\#0!E83 R-#@Q,S@P,65X.3DM
M,5]S8VES<&%R8RYH=&U02P$"% ,4    " !XB>A:SASW3+ @  #?(0  "P
M            @ 'C3 T 9FEN7S P,2YJ<&=02P$"% ,4    " !XB>A:"EU%
M>L0-  "9#@  #               @ &\;0T 9FEN7S P,6$N:G!G4$L! A0#
M%     @ >(GH6AR1C7G=-0  ^CX   L              ( !JGL- &9I;E\P
M,#(N:G!G4$L! A0#%     @ >(GH6DQKH#I?)   @3,   L
M ( !L+$- &9I;E\P,#,N:G!G4$L! A0#%     @ >(GH6I//Q>*&7@  "&<
M  L              ( !.-8- &9I;E\P,#0N:G!G4$L! A0#%     @ >(GH
M6BYP1@;)N@  @,0   L              ( !YS0. &9I;E\P,#4N:G!G4$L!
M A0#%     @ >(GH6E>>_H,;*P  72\   T              ( !V>\. &EM
M86=E7S P,2YJ<&=02P$"% ,4    " !XB>A: AWTXNK1   UX   #@
M        @ $?&P\ :6UA9V5?,# Q82YJ<&=02P$"% ,4    " !XB>A:+/\_
MV+\- 0"X,@$ #@              @ $U[0\ :6UA9V5?,# Q8BYJ<&=02P$"
M% ,4    " !XB>A:/'!'MS^2 0!OE0$ #0              @ $@^Q  :6UA
M9V5?,# R+FIP9U!+ 0(4 Q0    ( 'B)Z%JI/.\(R%T  ,%E   -
M      "  8J-$@!I;6%G95\P,#,N:G!G4$L! A0#%     @ >(GH6H/P9BFE
M1P  +UP   T              ( !?>L2 &EM86=E7S P-"YJ<&=02P$"% ,4
M    " !XB>A:=JTDB54L  #"+0  #0              @ %-,Q, :6UA9V5?
M,# U+FIP9U!+ 0(4 Q0    ( 'B)Z%K3 9WLFBL  %\W   -
M  "  <U?$P!I;6%G95\P,#8N:G!G4$L! A0#%     @ >(GH6L6\'5?M9P$
M1'X!  T              ( !DHL3 &EM86=E7S P-RYJ<&=02P$"% ,4
M" !XB>A:6P5\0I1_  #IE@  #0              @ &J\Q0 :6UA9V5?,# X
M+FIP9U!+ 0(4 Q0    ( 'B)Z%J.Y9BK5J$   ;.   -              "
M 6ES%0!I;6%G95\P,#DN:G!G4$L! A0#%     @ >(GH6O[KW:CG-0$ 'E4!
M  T              ( !ZA06 &EM86=E7S Q,"YJ<&=02P$"% ,4    " !X
MB>A:_$:NUSH[ 0"\4@$ #0              @ '\2A< :6UA9V5?,#$Q+FIP
M9U!+ 0(4 Q0    ( 'B)Z%JL#YQU77T   Z,   -              "  6&&
M& !I;6%G95\P,3(N:G!G4$L! A0#%     @ >(GH6M&N?2S<?P  L),   T
M             ( !Z0,9 &EM86=E7S Q,RYJ<&=02P$"% ,4    " !XB>A:
MAV2A0D!! 0"53 $ #0              @ 'P@QD :6UA9V5?,#$T+FIP9U!+
M 0(4 Q0    ( 'B)Z%I<-: .1(   +>"   -              "  5O%&@!I
M;6%G95\P,34N:G!G4$L! A0#%     @ >(GH6MR:L:4_"@$ 5AH!  T
M         ( !RD4; &EM86=E7S Q-BYJ<&=02P$"% ,4    " !XB>A:X0E*
M5GB:  "CG0  #0              @ $T4!P :6UA9V5?,#$W+FIP9U!+ 0(4
M Q0    ( 'B)Z%K>H1V..GL  #F/   -              "  =?J' !I;6%G
M95\P,3@N:G!G4$L! A0#%     @ >(GH6E)[65;!O0  YM<   T
M     ( !/&8= &EM86=E7S Q.2YJ<&=02P$"% ,4    " !XB>A:=P@#3KPG
M  !W*   #0              @ $H)!X :6UA9V5?,#(P+FIP9U!+ 0(4 Q0
M   ( 'B)Z%J\5#8;=R8  $LG   -              "  0],'@!I;6%G95\P
M,C$N:G!G4$L! A0#%     @ >(GH6JL5K&RV9   RWX   T
M ( !L7(> &EM86=E7S R,BYJ<&=02P$"% ,4    " !XB>A:3Y8F;?4B  ">
MI0$ $@              @ &2UQX <W!R8WDM,C R-#$R,S$N>'-D4$L! A0#
M%     @ >(GH6@28'NEK#P  W<@  !8              ( !M_H> '-P<F-Y
M+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !XB>A:F]>K@5U;  #.V 4
M%@              @ %6"A\ <W!R8WDM,C R-#$R,S%?9&5F+GAM;%!+ 0(4
M Q0    ( 'B)Z%KC<-2I&-T  (3'"@ 6              "  >=E'P!S<')C
M>2TR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ >8GH6D@%=!6W7@  >D$&
M !8              ( !,T,@ '-P<F-Y+3(P,C0Q,C,Q7W!R92YX;6Q02P4&
2     "< )P!="0  'J(@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>ea0248138-f4a9_scisparc_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sprcy="http://trpx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sprcy-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:CommunicationAndNetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-25</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-25</startDate>
            <endDate>2023-11-25</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-26</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-21</startDate>
            <endDate>2023-11-21</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:LeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sprcy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:OfficeEquipmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sprcy:RightOfUseAssesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2017-04-11</startDate>
            <endDate>2017-04-11</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-02</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-08-18</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:PreFundedUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:June2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfEntitysOwnEquityInstrumentsAxis">sprcy:OverAllotmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:August2023FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-13</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sprcy:October2023FinancingRoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-01-21</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sprcy:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:PurchasedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">sprcy:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:WagesAndRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ShareBasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryProfessionalAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ChemistryAndFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AdvertisementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:AmazonFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:DepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:StorageAndShippingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ManagementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ProfessionalAndDirectorsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:BusinessDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:RegulatoryExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:OfficeMaintenanceRentAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InvestorRelationsAndBusinessExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossFromSaleOfPropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:InterestFromLoansToRelatedPartiesAndDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:ExchangeRateDifferencesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:IssuanceExpensesRelatedToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpenseInRespectOfLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:IncomeStatementsLocationsAxis">sprcy:FinanceExpensesFromInterestAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:DrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sprcy:OnlineSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:JeffsBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sprcy:SaleOfStockAxis">sprcy:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">sprcy:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2024-12-30</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <startDate>2024-12-30</startDate>
            <endDate>2024-12-30</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MizaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-18</instant>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:SciSparcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sprcy:DebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:AutoMaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:N2OFFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611746</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sprcy:MitoCareXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sprcy:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-25</startDate>
            <endDate>2025-02-25</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0" id="ixv-85099">Amendment No. 9</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-84">SciSparc Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-85100">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-85101">20 Raul Wallenberg Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-85102">Tower A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-85103">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-85104">6971916</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-85105">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c0" id="ixv-85106">(+972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-85107">(3) 717-5777</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-160">Puglisi &amp; Associates</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-85108">850 Library Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-85109">Suite 204</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-85110">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c1" id="ixv-85111">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-85112">19711</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1" id="ixv-85113">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-85114">738-6680</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-291">false</dei:EntityEmergingGrowthCompany>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85115" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-85116" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85117" unitRef="usd">20000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-85118" unitRef="usd">65000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ixv-85119" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentTradeReceivables contextRef="c2" decimals="-3" id="ixv-85120" unitRef="usd">10000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c3" decimals="-3" id="ixv-85121" unitRef="usd">22000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-85122" unitRef="usd">1079000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-85123" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-85124" unitRef="usd">517000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-85125" unitRef="usd">4224000</ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-85126" unitRef="usd">113000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c3" decimals="-3" id="ixv-85127" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="-3" id="ixv-85128" unitRef="usd">7503000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="-3" id="ixv-85129" unitRef="usd">6445000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-85130" unitRef="usd">1479000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-85131" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c2" decimals="-3" id="ixv-85132" unitRef="usd">952000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c3" decimals="-3" id="ixv-85133" unitRef="usd">781000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-85134" unitRef="usd">354000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c3" decimals="-3" id="ixv-85135" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-85136" unitRef="usd">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-85137" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="-3" id="ixv-85138" unitRef="usd">2844000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="-3" id="ixv-85139" unitRef="usd">4737000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="-3" id="ixv-85140" unitRef="usd">10347000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="-3" id="ixv-85141" unitRef="usd">11182000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-85142" unitRef="usd">816000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-85143" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-85144" unitRef="usd">205000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-85145" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentWarrantLiability contextRef="c3" decimals="-3" id="ix_0_fact" unitRef="usd">191000</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:OtherCurrentLiabilities contextRef="c2" decimals="-3" id="ixv-85147" unitRef="usd">341000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c3" decimals="-3" id="ix_1_fact" unitRef="usd">341000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-85149" unitRef="usd">37000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-85150" unitRef="usd">52000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="-3" id="ixv-85151" unitRef="usd">1399000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="-3" id="ixv-85152" unitRef="usd">1571000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-85153" unitRef="usd">9000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-85154" unitRef="usd">24000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:SharePremium contextRef="c2" decimals="-3" id="ixv-85155" unitRef="usd">70886000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c3" decimals="-3" id="ixv-85156" unitRef="usd">64526000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="-3" id="ixv-85157" unitRef="usd">5746000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="-3" id="ixv-85158" unitRef="usd">5282000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantLiability contextRef="c2" decimals="-3" id="ixv-85159" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c3" decimals="-3" id="ixv-85160" unitRef="usd">5190000</ifrs-full:WarrantLiability>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c2" decimals="-3" id="ixv-85161" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation contextRef="c3" decimals="-3" id="ixv-85162" unitRef="usd">497000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:OtherEquityInterest contextRef="c2" decimals="-3" id="ixv-85163" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c3" decimals="-3" id="ixv-85164" unitRef="usd">810000</ifrs-full:OtherEquityInterest>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="-3" id="ixv-85165" unitRef="usd">-74975000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="-3" id="ixv-85166" unitRef="usd">-68691000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="-3" id="ixv-85167" unitRef="usd">8154000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c3" decimals="-3" id="ixv-85168" unitRef="usd">7614000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c2" decimals="-3" id="ixv-85169" unitRef="usd">785000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c3" decimals="-3" id="ixv-85170" unitRef="usd">1973000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-85171" unitRef="usd">8939000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-85172" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="-3" id="ixv-85173" unitRef="usd">10347000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c3" decimals="-3" id="ixv-85174" unitRef="usd">11182000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-85176" unitRef="usd">1306000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c4" decimals="-3" id="ixv-85177" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c5" decimals="-3" id="ixv-85178" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-85179" unitRef="usd">800000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c4" decimals="-3" id="ixv-85180" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c5" decimals="-3" id="ixv-85181" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="-3" id="ixv-85182" unitRef="usd">506000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c4" decimals="-3" id="ixv-85183" unitRef="usd">2196000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c5" decimals="-3" id="ixv-85184" unitRef="usd">1025000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-85185" unitRef="usd">1707000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-85186" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-85187" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-85188" unitRef="usd">1515000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c4" decimals="-3" id="ix_2_fact" unitRef="usd">2484000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c5" decimals="-3" id="ix_3_fact" unitRef="usd">1082000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-85191" unitRef="usd">1344000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-85192" unitRef="usd">1042000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-85193" unitRef="usd">4526000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ix_4_fact" unitRef="usd">3844000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ix_5_fact" unitRef="usd">5427000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherIncome contextRef="c0" decimals="-3" id="ixv-85196" unitRef="usd">1270000</ifrs-full:OtherIncome>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-85197" unitRef="usd">-7316000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="-3" id="ixv-85198" unitRef="usd">-6815000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c5" decimals="-3" id="ixv-85199" unitRef="usd">-8287000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-85200" unitRef="usd">-429000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-85201" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-85202" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-85203" unitRef="usd">612000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-85204" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c5" decimals="-3" id="ixv-85205" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-85206" unitRef="usd">353000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="-3" id="ixv-85207" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c5" decimals="-3" id="ixv-85208" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="-3" id="ixv-85209" unitRef="usd">-7486000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="-3" id="ixv-85210" unitRef="usd">-5861000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c5" decimals="-3" id="ixv-85211" unitRef="usd">-2578000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-85212" unitRef="usd">-14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c4" decimals="-3" id="ixv-85213" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="-3" id="ixv-85214" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-85215" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-85216" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-85217" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c0" decimals="-3" id="ixv-85218" unitRef="usd">-6284000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c4" decimals="-3" id="ixv-85219" unitRef="usd">-5122000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c5" decimals="-3" id="ixv-85220" unitRef="usd">-2592000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c0" decimals="-3" id="ixv-85221" unitRef="usd">-1188000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-85222" unitRef="usd">-761000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-85223" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-85224" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-85225" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-85226"
      unitRef="usdPershares">26.94</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-85227"
      unitRef="usdPershares">303.03</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-85228"
      unitRef="usdPershares">311.22</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-85229"
      unitRef="usdPershares">26.94</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-85230"
      unitRef="usdPershares">303.03</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-85231"
      unitRef="usdPershares">311.22</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Equity contextRef="c6" decimals="-3" id="ixv-85233" unitRef="usd">58541000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="-3" id="ixv-85234" unitRef="usd">4331000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="-3" id="ixv-85235" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="-3" id="ixv-85236" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="-3" id="ixv-85237" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c11" decimals="-3" id="ixv-85238" unitRef="usd">-60977000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c12" decimals="-3" id="ixv-85239" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="-3" id="ixv-85240" unitRef="usd">8141000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c20" decimals="-3" id="ixv-85241" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c21" decimals="-3" id="ixv-85242" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-85243" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c15" decimals="-3" id="ixv-85244" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c21" decimals="-3" id="ixv-85245" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c5" decimals="-3" id="ixv-85246" unitRef="usd">3000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c15" decimals="-3" id="ixv-85247" unitRef="usd">48000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c16" decimals="-3" id="ixv-85248" unitRef="usd">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c21" decimals="-3" id="ixv-85249" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-85250" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c23" decimals="-3" id="ixv-85251" unitRef="usd">58592000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c24" decimals="-3" id="ixv-85252" unitRef="usd">5180000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c25" decimals="-3" id="ixv-85253" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c26" decimals="-3" id="ixv-85254" unitRef="usd">559000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="-3" id="ixv-85255" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="-3" id="ixv-85256" unitRef="usd">-63569000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="-3" id="ixv-85257" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c31" decimals="-3" id="ixv-85258" unitRef="usd">6449000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c37" decimals="-3" id="ixv-85259" unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c38" decimals="-3" id="ixv-85260" unitRef="usd">-5122000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c39" decimals="-3" id="ixv-85261" unitRef="usd">-761000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-85262" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c35" decimals="-3" id="ixv-85263" unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c38" decimals="-3" id="ixv-85264" unitRef="usd">251000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c39" decimals="-3" id="ixv-85265" unitRef="usd">2734000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests contextRef="c4" decimals="-3" id="ixv-85266" unitRef="usd">2985000</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ShareIssueRelatedCost contextRef="c32" decimals="-3" id="ixv-85267" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c38" decimals="-3" id="ixv-85268" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c4" decimals="-3" id="ixv-85269" unitRef="usd">288000</ifrs-full:ShareIssueRelatedCost>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c32" decimals="-3" id="ixv-85270" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c38" decimals="-3" id="ixv-85271" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c4" decimals="-3" id="ixv-85272" unitRef="usd">5552000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c32" decimals="-3" id="ixv-85273" unitRef="usd">94000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c33" decimals="-3" id="ixv-85274" unitRef="usd">102000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c38" decimals="-3" id="ixv-85275" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-85276" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c40" decimals="-3" id="ixv-85277" unitRef="usd">64526000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c41" decimals="-3" id="ixv-85278" unitRef="usd">5282000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="-3" id="ixv-85279" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="-3" id="ixv-85280" unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c44" decimals="-3" id="ixv-85281" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c45" decimals="-3" id="ixv-85282" unitRef="usd">-68691000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c46" decimals="-3" id="ixv-85283" unitRef="usd">7614000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c47" decimals="-3" id="ixv-85284" unitRef="usd">1973000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="-3" id="ixv-85285" unitRef="usd">9587000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c53" decimals="-3" id="ixv-85286" unitRef="usd">-6284000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c54" decimals="-3" id="ixv-85287" unitRef="usd">-6284000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c55" decimals="-3" id="ixv-85288" unitRef="usd">-1188000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-85289" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c48" decimals="-3" id="ixv-85290" unitRef="usd">6255000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c54" decimals="-3" id="ixv-85291" unitRef="usd">6255000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense contextRef="c0" decimals="-3" id="ixv-85292" unitRef="usd">6255000</sprcy:IssueOfShareCapitalNetOfIssueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c48" decimals="-3" id="ixv-85293" unitRef="usd">105000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c49" decimals="-3" id="ixv-85294" unitRef="usd">464000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c54" decimals="-3" id="ixv-85295" unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-85296" unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:Equity contextRef="c56" decimals="-3" id="ixv-85297" unitRef="usd">70886000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c57" decimals="-3" id="ixv-85298" unitRef="usd">5746000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c58" decimals="-3" id="ixv-85299" unitRef="usd">5190000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c59" decimals="-3" id="ixv-85300" unitRef="usd">810000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c60" decimals="-3" id="ixv-85301" unitRef="usd">497000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c61" decimals="-3" id="ixv-85302" unitRef="usd">-74975000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c62" decimals="-3" id="ixv-85303" unitRef="usd">8154000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c63" decimals="-3" id="ixv-85304" unitRef="usd">785000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="-3" id="ixv-85305" unitRef="usd">8939000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-85306" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-85307" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-85308" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c0" decimals="-3" id="ixv-85309" unitRef="usd">482000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c4" decimals="-3" id="ixv-85310" unitRef="usd">538000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c5" decimals="-3" id="ixv-85311" unitRef="usd">187000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-85312" unitRef="usd">1344000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-85313" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="-3" id="ixv-85314" unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="-3" id="ixv-85315" unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="-3" id="ixv-85316" unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-85317" unitRef="usd">897000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c4" decimals="-3" id="ixv-85318" unitRef="usd">2205000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c5" decimals="-3" id="ixv-85319" unitRef="usd">6585000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c0" decimals="-3" id="ixv-85320" unitRef="usd">429000</sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c4" decimals="-3" id="ixv-85321" unitRef="usd">210000</sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c5" decimals="-3" id="ixv-85322" unitRef="usd">109000</sprcy:AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c0" decimals="-3" id="ixv-85323" unitRef="usd">305000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c4" decimals="-3" id="ixv-85324" unitRef="usd">1048000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets contextRef="c5" decimals="-3" id="ixv-85325" unitRef="usd">770000</sprcy:AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c0" decimals="-3" id="ixv-85326" unitRef="usd">2232000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c4" decimals="-3" id="ixv-85327" unitRef="usd">829000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="c5" decimals="-3" id="ixv-85328" unitRef="usd">-4622000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c0" decimals="-3" id="ixv-85329" unitRef="usd">-535000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c4" decimals="-3" id="ixv-85330" unitRef="usd">-409000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c5" decimals="-3" id="ixv-85331" unitRef="usd">3000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="-3" id="ixv-85332" unitRef="usd">25000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c4" decimals="-3" id="ixv-85333" unitRef="usd">-397000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="-3" id="ixv-85334" unitRef="usd">20000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c4" decimals="-3" id="ixv-85335" unitRef="usd">-8000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c5" decimals="-3" id="ixv-85336" unitRef="usd">39000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <sprcy:AdjustmentsForIncreaseInRelatedParties contextRef="c0" decimals="-3" id="ixv-85337" unitRef="usd">15000</sprcy:AdjustmentsForIncreaseInRelatedParties>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c0" decimals="-3" id="ixv-85338" unitRef="usd">12000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c4" decimals="-3" id="ixv-85339" unitRef="usd">55000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c5" decimals="-3" id="ixv-85340" unitRef="usd">-77000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="-3" id="ixv-85341" unitRef="usd">629000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c4" decimals="-3" id="ixv-85342" unitRef="usd">-74000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c5" decimals="-3" id="ixv-85343" unitRef="usd">-668000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c0" decimals="-3" id="ixv-85344" unitRef="usd">136000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c4" decimals="-3" id="ixv-85345" unitRef="usd">-833000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="c5" decimals="-3" id="ixv-85346" unitRef="usd">-703000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-85347" unitRef="usd">-5104000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="-3" id="ixv-85348" unitRef="usd">-5887000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-85349" unitRef="usd">-7917000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-85350" unitRef="usd">45000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-85351" unitRef="usd">-5000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-85352" unitRef="usd">-15000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="-3" id="ixv-85353" unitRef="usd">3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c4" decimals="-3" id="ixv-85354" unitRef="usd">-3000000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <sprcy:SalepurchaseOfPropertyAndEquipment contextRef="c0" decimals="-3" id="ixv-85355" unitRef="usd">-8000</sprcy:SalepurchaseOfPropertyAndEquipment>
    <sprcy:SalepurchaseOfPropertyAndEquipment contextRef="c5" decimals="-3" id="ixv-85356" unitRef="usd">8000</sprcy:SalepurchaseOfPropertyAndEquipment>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-85357" unitRef="usd">600000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-85358" unitRef="usd">400000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-85359" unitRef="usd">700000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties contextRef="c0" decimals="-3" id="ixv-85360" unitRef="usd">4078000</ifrs-full:CashAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-85361" unitRef="usd">689000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-85362" unitRef="usd">1500000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c5" decimals="-3" id="ixv-85363" unitRef="usd">4861000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-85364" unitRef="usd">-1625000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="-3" id="ixv-85365" unitRef="usd">-4094000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-85366" unitRef="usd">-7084000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c0" decimals="-3" id="ixv-85367" unitRef="usd">6255000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c4" decimals="-3" id="ixv-85368" unitRef="usd">5552000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c5" decimals="-3" id="ixv-85369" unitRef="usd">9005000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c4" decimals="-3" id="ix_6_fact" unitRef="usd">2985000</ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c5" decimals="-3" id="ixv-85371" unitRef="usd">2770000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod contextRef="c5" decimals="-3" id="ixv-85372" unitRef="usd">3000</sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-85373" unitRef="usd">8000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c4" decimals="-3" id="ixv-85374" unitRef="usd">7000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="c5" decimals="-3" id="ixv-85375" unitRef="usd">8000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="-3" id="ixv-85376" unitRef="usd">54000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c4" decimals="-3" id="ixv-85377" unitRef="usd">47000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c5" decimals="-3" id="ixv-85378" unitRef="usd">70000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-85379" unitRef="usd">6193000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="-3" id="ixv-85380" unitRef="usd">8483000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-85381" unitRef="usd">11700000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="-3" id="ixv-85382" unitRef="usd">-536000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="-3" id="ixv-85383" unitRef="usd">-1498000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c5" decimals="-3" id="ixv-85384" unitRef="usd">-3301000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-85385" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c31" decimals="-3" id="ixv-85386" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c14" decimals="-3" id="ixv-85387" unitRef="usd">6875000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85388" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-85389" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c31" decimals="-3" id="ixv-85390" unitRef="usd">3574000</ifrs-full:CashAndCashEquivalents>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c0" decimals="-3" id="ixv-85392" unitRef="usd">75000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability contextRef="c4" decimals="-3" id="ixv-85393" unitRef="usd">102000</sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c4" decimals="-3" id="ixv-85394" unitRef="usd">288000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c0" id="ixv-34912">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    1:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GENERAL&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) (&#x201c;SciSparc&#x201d; or the &#x201c;Company&#x201d; or the &#x201c;Group&#x201d;),
    a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc
    and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#x2019;s
    own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing
    on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in
    development programs based on &#x394;9-tetrahydrocannabinol (&#x201c;THC&#x201d;) and/or non-psychoactive cannabidiol for the treatment
    of Tourette syndrome, Alzheimer&#x2019;s disease and agitation, autism spectrum disorder and Status Epilepticus. The headquarters
    of the Company are located in Tel Aviv, Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#x201c;SPRC&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2024, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#x201c;Evero&#x201d;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#x201c;Brain Bright&#x201d;); and a company incorporated
under the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (together with Evero and Brain Bright, the &#x201c;Subsidiaries&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
board of directors (the &#x201c;Board&#x201d;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1,
which became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these consolidated financial statements for all periods presented.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2024, the Group had an accumulated deficit of approximately $74,975 as a result of recurring operating losses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2024, the Company&#x2019;s
cash and cash equivalents totaled $1,540. In the period ended December 31, 2024, the Company had an operating loss of $7,316 and negative
cash flows from operating activities of $5,104. The Company&#x2019;s current cash and cash equivalents position is not sufficient to fund
the Company&#x2019;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its
liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past,
there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially
reasonable terms, would have serious consequences on our financial condition and results of operations. In addition, the Group has started
recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing
and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue
from its products. These above-mentioned factors raise substantial doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Definitions
    and Meanings:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Group&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SciSparc
    Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Companies
    that are controlled by the Company, as defined in IFRS 10, &#x201c;&lt;i&gt;Consolidated Financial Statements&lt;/i&gt;&#x201d;, and whose accounts
    are consolidated with those of the Company (if active).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Associates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
    entity over which the Company has significant influence, as defined in IAS 28, &#x201c;&lt;i&gt;Investment in Associates and Joint Ventures&lt;/i&gt;&#x201d;
    and is not a Subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
    Parties&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    defined in IAS 24, &#x201c;&lt;i&gt;Related Party Disclosures&lt;/i&gt;&#x201d;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International
    Accounting Standards issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International
    Financial Reporting Standards issued by the IASB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 48px; text-align: left"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On July 3, 2025, the Company effected a twenty one-for-one
reverse share split of its ordinary shares. All share and per share information has been retroactively adjusted to reflect the reverse
share split for all periods presented.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings contextRef="c64" decimals="-3" id="ixv-85395" unitRef="usd">-74975000</ifrs-full:RetainedEarnings>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85396" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="-3" id="ixv-85397" unitRef="usd">-7316000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-85398" unitRef="usd">-5104000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-35078">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    2:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT
    ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following accounting policies
have been applied consistently in the financial statements for all periods presented, unless otherwise stated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint
    ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint
    operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="text-transform: uppercase"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Mainly
    %&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;33-50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;7-15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;see below&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
    instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition
    of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized
only when:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the
    financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred
    control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation
    to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;3.&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Impairment
                                            of financial assets:&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company evaluates at the end of
each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss.
The Company distinguishes between two types of loss allowances:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;a)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Debt
                                            instruments whose credit risk has not increased significantly since initial recognition,
                                            or whose credit risk is low - the loss allowance recognized in respect of this debt instrument
                                            is measured at an amount equal to the expected credit losses within 12 months from the reporting
                                            date (12-month ECLs); or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;b)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Debt
                                            instruments whose credit risk has increased significantly since initial recognition, and
                                            whose credit risk is not low - the loss allowance recognized is measured at an amount equal
                                            to the expected credit losses over the instrument&#x2019;s remaining term (lifetime ECLs).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has short-term financial
assets in respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to
the lifetime expected credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company considers a financial
asset in default when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial
asset to be in default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual
amounts in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition
    of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting
    financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound
    financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue
    of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and
other service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
    employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment
    benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
    extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
    modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company&#x2019;s Brand sells products directly to customers mainly through the Brand&#x2019;s online Amazon stores.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory contextRef="c0" id="ixv-35090">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis of presentation of the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s financial statements
have been prepared on a cost basis, unless otherwise indicated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has elected to present
the profit or loss items using the function of expense method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#x2019;000), except when otherwise indicated.&lt;/p&gt;</sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory>
    <sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory contextRef="c0" id="ixv-35111">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The operating cycle:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The operating cycle of the Company
is one year.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForoperatingcycleExplanatory>
    <sprcy:OperatingTerm contextRef="c0" id="ixv-85399">P1Y</sprcy:OperatingTerm>
    <sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements contextRef="c0" id="ixv-35123">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyForConsolidatedfinancialstatements>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-35141">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), since it&#x2019;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <sprcy:DescriptionOfAcquisitionOfASingleAssetCompany contextRef="c0" id="ixv-35153">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of a single asset company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.&lt;/p&gt;</sprcy:DescriptionOfAcquisitionOfASingleAssetCompany>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-35202">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#x2019;s office facilities lease agreements and its credit
cards.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory contextRef="c0" id="ixv-35214">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment in joint arrangements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint
    ventures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Joint
    operations:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c0" id="ixv-35254">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments accounted for using the equity method:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Group&#x2019;s investments in associates
and joint ventures are accounted for using the equity method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#x2019;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-35319">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Mainly
    %&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;33-50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;7-15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;see below&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory contextRef="c0" id="ixv-35331">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Mainly
    %&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"&gt;6-50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Computers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;33-50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;7-15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;see below&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c65" decimals="2" id="ixv-85400" unitRef="pure">0.06</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c66" decimals="2" id="ixv-85401" unitRef="pure">0.50</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c67" decimals="2" id="ixv-85402" unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c68" decimals="2" id="ixv-85403" unitRef="pure">0.33</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c69" decimals="2" id="ixv-85404" unitRef="pure">0.50</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c70" decimals="2" id="ixv-85405" unitRef="pure">0.33</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c71" decimals="2" id="ixv-85406" unitRef="pure">0.07</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <ifrs-full:DepreciationRatePropertyPlantAndEquipment contextRef="c72" decimals="2" id="ixv-85407" unitRef="pure">0.15</ifrs-full:DepreciationRatePropertyPlantAndEquipment>
    <sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly contextRef="c73" decimals="2" id="ixv-85408" unitRef="pure">0.15</sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife contextRef="c74" id="ixv-85409">see below</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c0" id="ixv-35384">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c0" id="ixv-35399">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of non-financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-35448">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company classifies and measures
debt instruments in the financial statements based on the following criteria:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company&#x2019;s business model for managing financial assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contractual cash flow terms of the financial asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    instruments are measured at amortized cost when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;The Company&#x2019;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
    instruments are measured at fair value through profit or loss when:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
    instruments and other financial assets held for trading:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition
    of financial assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial asset is derecognized
only when:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contractual rights to the cash flows from the financial asset have expired;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the
    financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred
    control of the asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation
    to pay the cash flows in full without material delay to a third party.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;3.&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Impairment
                                            of financial assets:&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company evaluates at the end of
each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss.
The Company distinguishes between two types of loss allowances:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;a)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Debt
                                            instruments whose credit risk has not increased significantly since initial recognition,
                                            or whose credit risk is low - the loss allowance recognized in respect of this debt instrument
                                            is measured at an amount equal to the expected credit losses within 12 months from the reporting
                                            date (12-month ECLs); or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;b)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Debt
                                            instruments whose credit risk has increased significantly since initial recognition, and
                                            whose credit risk is not low - the loss allowance recognized is measured at an amount equal
                                            to the expected credit losses over the instrument&#x2019;s remaining term (lifetime ECLs).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has short-term financial
assets in respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to
the lifetime expected credit losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company considers a financial
asset in default when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial
asset to be in default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual
amounts in full.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    liabilities measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    liabilities measured at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify"&gt;After initial recognition, changes
in fair value are recognized in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derecognition
    of financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Offsetting
    financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compound
    financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue
    of a unit of securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-35787">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Research expenditures are recognized
in profit or loss when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c0" id="ixv-35802">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance income and expenses:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c0" id="ixv-35814">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#x2019;s or the liability&#x2019;s
principal market, or in the absence of a principal market, in the most advantageous market.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value measurement of a non-financial
asset takes into account a market participant&#x2019;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c0" id="ixv-35922">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#x2019;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-36012">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s employees and
other service providers may receive remuneration in the form of share-based payments (&#x201c;Equity-settled transactions&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Equity-settled transactions:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#x201c;OPM&#x201d;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#x201c;Vesting Period&#x201d;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#x2019;s best estimate of the number of equity instruments that will
ultimately vest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0" id="ixv-36043">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0" id="ixv-36099">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee benefit liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has several employee-benefit
plans:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
    employee benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-employment
    benefits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company has defined contribution
plans to its employees according to the specific laws per country.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c0" id="ixv-36138">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision in accordance with IAS
37, &#x201c;&lt;i&gt;Provisions, Contingent Liabilities and Contingent Assets&lt;/i&gt;&#x201d;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following are the types of provisions
included in the financial statements:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Legal claims:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-36161">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company elected to apply the provisions
of IFRS 16, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;IFRS 16&#x201d;) using the modified retrospective method (without restatement of comparative
data).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accounting policy for leases applied
effective from January 1, 2019, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company as a lessee:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#x2019;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#x201c;&lt;i&gt;Impairment of Assets&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
    extension and termination options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
    modifications:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c0" id="ixv-36317">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#x201c;FIFO&#x201d;) and the cost of inventory includes shipment and freight
costs.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c0" id="ixv-36330">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;w.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company&#x2019;s Brand sells products directly to customers mainly through the Brand&#x2019;s online Amazon stores.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Under
the Company&#x2019;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock contextRef="c0" id="ixv-36351">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;x.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
accordance with Amazon&#x2019;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Cost
of sales primarily consists of expenses related to Amazon&#x2019;s commissions, storage costs and freight.&lt;/span&gt;&lt;/p&gt;</sprcy:DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock>
    <ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory contextRef="c0" id="ixv-36394">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    3:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT
    ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Judgments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discount
    rate for a lease liability:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental
borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar
security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there
are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk,
the lease term and other economic variables deriving from the lease contract&#x2019;s conditions and restrictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    control:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#x2019;
meetings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determining
    the fair value of share-based payment transactions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable options pricing model (&#x201c;OPM&#x201d;). The inputs to the model
include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest
and expected dividend yield.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates
    and assumptions:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal
    claims:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on
its management&#x2019;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are
based, among others, on management&#x2019;s familiarity of and proximity to the circumstances, and also on the legal counsels&#x2019; best
professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the
outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value of financial instruments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;When the fair values of financial
assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value
is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken
from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models
are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disclosure
    of new standards in the period prior to their adoption:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18, &#x201c;Presentation and Disclosure
in Financial Statements&#x201d;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In April 2024, the International Accounting
Standards Board (&#x201c;the IASB&#x201d;) issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS
18&#x201d;) which replaces IAS 1, &#x201c;Presentation of Financial Statements&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 is aimed at improving comparability
and transparency of communication in financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 retains certain existing requirements
of IAS 1 and introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals.
It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation
of financial information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 does not modify the recognition
and measurement provisions of items in the financial statements. However, since items within the statement of profit or loss must be
classified into one of five categories (operating, investing, financing, taxes on income and discontinued operations), it may change
the entity&#x2019;s operating profit. Moreover, the publication of IFRS 18 resulted in consequential narrow scope amendments to other
accounting standards, including IAS 7, &#x201c;Statement of Cash Flows&#x201d; and IAS 34, &#x201c;Interim Financial Reporting&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;IFRS 18 is effective for annual reporting
periods beginning on or after January 1, 2027, and is to be applied retrospectively. Early adoption is permitted commencing from January
1, 2025, subject to disclosure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is evaluating the effects
of IFRS 18, including the effects of the consequential amendments to other accounting standards, on its consolidated financial statements.&lt;/p&gt;</ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-36571">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    4:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CASH&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,383&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in
    NIS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,540&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-36581">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Cash for immediate withdrawal - in USD&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,383&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,866&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Cash for immediate withdrawal - in
    NIS&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,540&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,076&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c75" decimals="-3" id="ixv-85410" unitRef="usd">1383000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c76" decimals="-3" id="ixv-85411" unitRef="usd">1866000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c77" decimals="-3" id="ixv-85412" unitRef="usd">157000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c78" decimals="-3" id="ixv-85413" unitRef="usd">210000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85414" unitRef="usd">1540000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-85415" unitRef="usd">2076000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c0" id="ixv-36639">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    5:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;104&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;669&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;113&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <sprcy:DisclosureOfInventorieExplanatory contextRef="c0" id="ixv-36649">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Goods in transit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;73&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;104&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;669&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;113&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;742&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfInventorieExplanatory>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c2" decimals="-3" id="ixv-85416" unitRef="usd">9000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:CurrentInventoriesInTransit contextRef="c3" decimals="-3" id="ixv-85417" unitRef="usd">73000</ifrs-full:CurrentInventoriesInTransit>
    <ifrs-full:FinishedGoods contextRef="c2" decimals="-3" id="ixv-85418" unitRef="usd">104000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c3" decimals="-3" id="ixv-85419" unitRef="usd">669000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c2" decimals="-3" id="ixv-85420" unitRef="usd">113000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c3" decimals="-3" id="ixv-85421" unitRef="usd">742000</ifrs-full:Inventories>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c0" id="ixv-36707">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    6:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER
    ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;350&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Receivables in respect of downpayment on merger&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Related party&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;540&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <sprcy:DisclourseOfAccountsReceivablesTableTextBlock contextRef="c0" id="ixv-36717">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Government authorities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;350&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Receivables in respect of downpayment on merger&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Related party&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;540&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclourseOfAccountsReceivablesTableTextBlock>
    <sprcy:Governmentauthoritiescurrent contextRef="c2" decimals="-3" id="ixv-85422" unitRef="usd">78000</sprcy:Governmentauthoritiescurrent>
    <sprcy:Governmentauthoritiescurrent contextRef="c3" decimals="-3" id="ixv-85423" unitRef="usd">62000</sprcy:Governmentauthoritiescurrent>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-85424" unitRef="usd">449000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-85425" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="-3" id="ixv-85426" unitRef="usd">350000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c3" decimals="-3" id="ixv-85427" unitRef="usd">275000</ifrs-full:CurrentPrepaidExpenses>
    <sprcy:ReceivablesInRespectOfDownpaymentOnMerger contextRef="c2" decimals="-3" id="ixv-85428" unitRef="usd">187000</sprcy:ReceivablesInRespectOfDownpaymentOnMerger>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-85429" unitRef="usd">15000</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:OtherCurrentReceivables contextRef="c2" decimals="-3" id="ixv-85430" unitRef="usd">1079000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c3" decimals="-3" id="ixv-85431" unitRef="usd">540000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory contextRef="c0" id="ixv-36807">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    7:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT
    IN ASSOCIATES AND JOINT VENTURES &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;MitoCareX
    - Joint Venture Transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#x201c;MitoCareX&#x201d;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid on March
11, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 26, 2024, the Company
signed a non-binding letter of intent relating to the sale of its entire ownership interest in MitoCareX to N2OFF, Inc. (&#x201c;N2OFF&#x201d;)
a publicly-traded company in the United States which is a related party (the &#x201c;Purchaser&#x201d;). Pursuant to the terms of the letter
of intent, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute
27% of SciSparc&#x2019;s ownership in MitoCareX, SciSparc will receive cash consideration of $700. Subsequent to this first phase, SciSparc
will transfer to the Purchaser the remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based
on the valuation of the Purchaser equal to $8,000 and a valuation of MitoCareX equal to $5,000 (the latter of which includes the $700,
in cash consideration for SciSparc&#x2019;s shares described above). The letter of intent also includes provisions for additional milestones
that, upon achievement, may increase the consideration paid by the Purchaser to SciSparc from $5,000 to $7,000. The details of the full
terms of this transaction are subject to negotiation and execution of definitive agreements.&#160;As of December 31, 2024, the Company
and the Purchaser have not closed the sale of the ownership of MitoCareX and the Company still holds 52.73% of the issued and outstanding
share capital of MitoCareX. See also Note 25(d).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;During the year ended December 31,
2024, the Company recorded equity losses from the investment in MitoCareX in the amount of $429 (for the year ended December 31, 2023
- $210).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;591&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;400&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;781&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Investment following achievement of second milestone&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;952&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <sprcy:InitialInvestment contextRef="c79" decimals="-3" id="ixv-85432" unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:AdditionalInvestment contextRef="c80" decimals="-3" id="ixv-85433" unitRef="usd">1000000</sprcy:AdditionalInvestment>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c81" decimals="4" id="ixv-85434" unitRef="pure">0.5001</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:InitialInvestment contextRef="c82" decimals="-3" id="ixv-85435" unitRef="usd">700000</sprcy:InitialInvestment>
    <sprcy:OutstandingSharesPercentage contextRef="c83" decimals="4" id="ixv-85436" unitRef="pure">0.3148</sprcy:OutstandingSharesPercentage>
    <sprcy:AdditionalInvestment contextRef="c84" decimals="-3" id="ixv-85437" unitRef="usd">400000</sprcy:AdditionalInvestment>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c85" decimals="4" id="ixv-85438" unitRef="pure">0.3148</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c86" decimals="4" id="ixv-85439" unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:AdditionalInvestment contextRef="c87" decimals="-3" id="ixv-85440" unitRef="usd">600000</sprcy:AdditionalInvestment>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c88" decimals="4" id="ixv-85441" unitRef="pure">0.4192</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c89" decimals="4" id="ixv-85442" unitRef="pure">0.5273</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:AdditionalInstallment contextRef="c90" decimals="-3" id="ixv-85443" unitRef="usd">600000</sprcy:AdditionalInstallment>
    <sprcy:InstallmentPaid contextRef="c91" decimals="-3" id="ixv-85444" unitRef="usd">600000</sprcy:InstallmentPaid>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c92" decimals="2" id="ixv-85445" unitRef="pure">0.27</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sprcy:CashConsideration contextRef="c92" decimals="-3" id="ixv-85446" unitRef="usd">700000</sprcy:CashConsideration>
    <sprcy:PurchaserRemainingOwnershipPercentage contextRef="c93" decimals="2" id="ixv-85447" unitRef="pure">0.73</sprcy:PurchaserRemainingOwnershipPercentage>
    <sprcy:RemainingPurchaserAmount contextRef="c93" decimals="-3" id="ixv-85448" unitRef="usd">8000000</sprcy:RemainingPurchaserAmount>
    <sprcy:RemainingPurchaserAmount contextRef="c94" decimals="-3" id="ixv-85449" unitRef="usd">5000000</sprcy:RemainingPurchaserAmount>
    <sprcy:CashConsideration contextRef="c95" decimals="-3" id="ixv-85450" unitRef="usd">700000</sprcy:CashConsideration>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="c96" decimals="-3" id="ixv-85451" unitRef="usd">5000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents contextRef="c97" decimals="-3" id="ixv-85452" unitRef="usd">7000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <sprcy:IssuedAndOutstandingSharePercentage contextRef="c94" decimals="4" id="ixv-85453" unitRef="pure">0.5273</sprcy:IssuedAndOutstandingSharePercentage>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c83" decimals="-3" id="ixv-85454" unitRef="usd">429000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c98" decimals="-3" id="ixv-85455" unitRef="usd">210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c0" id="ixv-36882">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The table below summarizes the fair
value of the investment in MitoCareX:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 88%"&gt;Investment date March 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(109&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;591&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Investment following achievement of first milestone&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;400&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;781&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Investment following achievement of second milestone&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Equity losses from investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;952&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <sprcy:InvestmentsDate contextRef="c5" decimals="-3" id="ixv-85456" unitRef="usd">700000</sprcy:InvestmentsDate>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c5" decimals="-3" id="ixv-85457" unitRef="usd">-109000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c31" decimals="-3" id="ixv-85458" unitRef="usd">591000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sprcy:InvestmentAchievementOfFirstMilestone contextRef="c4" decimals="-3" id="ixv-85459" unitRef="usd">400000</sprcy:InvestmentAchievementOfFirstMilestone>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c4" decimals="-3" id="ixv-85460" unitRef="usd">-210000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c3" decimals="-3" id="ixv-85461" unitRef="usd">781000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sprcy:InvestmentAchievementOfSecondMilestone contextRef="c0" decimals="-3" id="ixv-85462" unitRef="usd">600000</sprcy:InvestmentAchievementOfSecondMilestone>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c0" decimals="-3" id="ixv-85463" unitRef="usd">-429000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c2" decimals="-3" id="ixv-85464" unitRef="usd">952000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory contextRef="c0" id="ixv-36968">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    8:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INVESTMENT
    IN FINANCIAL ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Clearmind&lt;/span&gt;&lt;/i&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#x201c;Clearmind&#x201d;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Shares of Clearmind are listed for trading on Nasdaq Capital Market and the Canadian Securities Exchange under the symbol &#x201c;CMND&#x201d; and the Frankfurt Stock Exchange under the symbol &#x201c;CWY.&#x201d; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company holdings in Clearmind decreased from 230,769 common shares to 7,692. As of December 31, 2024, the listed share price of Clearmind on Nasdaq was $1.38 and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2024 of $11 on its investment (for the year ended December 31, 2023 - $727). &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c99" decimals="-3" id="ixv-85465" unitRef="usd">1500000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c100"
      decimals="0"
      id="ixv-85466"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssued>
    <sprcy:ShareCapitalPercentage
      contextRef="c101"
      decimals="4"
      id="ixv-85467"
      unitRef="pure">0.0933</sprcy:ShareCapitalPercentage>
    <ifrs-full:ParValuePerShare
      contextRef="c102"
      decimals="0"
      id="ixv-85468"
      unitRef="usdPershares">0</ifrs-full:ParValuePerShare>
    <sprcy:ReverseShareSplitRatio contextRef="c103" id="ixv-85469">1-for-30</sprcy:ReverseShareSplitRatio>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c104"
      decimals="0"
      id="ixv-85470"
      unitRef="shares">230769</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c105"
      decimals="0"
      id="ixv-85471"
      unitRef="shares">7692</ifrs-full:NumberOfSharesIssued>
    <sprcy:SharePricePerShare
      contextRef="c0"
      decimals="-1"
      id="ixv-85472"
      unitRef="usdPershares">1380</sprcy:SharePricePerShare>
    <ifrs-full:OtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-85473" unitRef="usd">11000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-85474" unitRef="usd">727000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0" id="ixv-37014">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    9:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 1, 2024, the Company entered
into a two-year lease agreement with for a total area of approximately 240 square meters, whereby the Company occupies approximately
120 square meters for the Company&#x2019;s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional
three-year term. The monthly lease fee was set at approximately $3, linked to the NIS.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <sprcy:AreaOfLease contextRef="c106" decimals="0" id="ixv-85475" unitRef="sqm">240</sprcy:AreaOfLease>
    <sprcy:AreaOfLease contextRef="c107" decimals="0" id="ixv-85476" unitRef="sqm">120</sprcy:AreaOfLease>
    <sprcy:OptionToExtendLeaseTerm contextRef="c108" id="ixv-85477">P3Y</sprcy:OptionToExtendLeaseTerm>
    <sprcy:MonthlyLeaseFee
      contextRef="c108"
      decimals="-3"
      id="ixv-85478"
      unitRef="usd">3000</sprcy:MonthlyLeaseFee>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-37028">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    10:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PROPERTY
    AND EQUIPMENT, NET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Office&lt;br/&gt;
    furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Right
    of use asses&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif"&gt;Cost:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;225&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;77&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;99&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January&#160;1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Depreciated cost at December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;47&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;59&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;122&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;225&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;65&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;47&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;28&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;108&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Depreciation expenses for the years
ended December 31, 2024, 2023 and 2022 amounted to $37, $52 and $43, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-37038">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Office&lt;br/&gt;
    furniture&lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Right
    of use asses&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif"&gt;Cost:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;225&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;77&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;99&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January&#160;1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Disposals&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Depreciated cost at December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;47&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;59&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;122&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;225&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January&#160;1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;59&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;65&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;47&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Depreciated cost at December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;28&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;108&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c109"
      decimals="-3"
      id="ixv-85479"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c110"
      decimals="-3"
      id="ixv-85480"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c111"
      decimals="-3"
      id="ixv-85481"
      unitRef="usd">181000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c112"
      decimals="-3"
      id="ixv-85482"
      unitRef="usd">225000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c113"
      decimals="-3"
      id="ixv-85483"
      unitRef="usd">2000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c115"
      decimals="-3"
      id="ixv-85484"
      unitRef="usd">75000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c116"
      decimals="-3"
      id="ixv-85485"
      unitRef="usd">77000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c113"
      decimals="-3"
      id="ixv-85486"
      unitRef="usd">1000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c114"
      decimals="-3"
      id="ixv-85487"
      unitRef="usd">21000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c115"
      decimals="-3"
      id="ixv-85488"
      unitRef="usd">181000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c116"
      decimals="-3"
      id="ixv-85489"
      unitRef="usd">203000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c117"
      decimals="-3"
      id="ixv-85490"
      unitRef="usd">12000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c118"
      decimals="-3"
      id="ixv-85491"
      unitRef="usd">12000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c119"
      decimals="-3"
      id="ixv-85492"
      unitRef="usd">75000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c120"
      decimals="-3"
      id="ixv-85493"
      unitRef="usd">99000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c121"
      decimals="-3"
      id="ixv-85494"
      unitRef="usd">6000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c122"
      decimals="-3"
      id="ixv-85495"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c123"
      decimals="-3"
      id="ixv-85496"
      unitRef="usd">106000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c124"
      decimals="-3"
      id="ixv-85497"
      unitRef="usd">117000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c125"
      decimals="-3"
      id="ixv-85498"
      unitRef="usd">4000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c126"
      decimals="-3"
      id="ixv-85499"
      unitRef="usd">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c127"
      decimals="-3"
      id="ixv-85500"
      unitRef="usd">28000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c128"
      decimals="-3"
      id="ixv-85501"
      unitRef="usd">33000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c125"
      decimals="-3"
      id="ixv-85502"
      unitRef="usd">1000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c126"
      decimals="-3"
      id="ixv-85503"
      unitRef="usd">4000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c127"
      decimals="-3"
      id="ixv-85504"
      unitRef="usd">106000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="c128"
      decimals="-3"
      id="ixv-85505"
      unitRef="usd">111000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c129"
      decimals="-3"
      id="ixv-85506"
      unitRef="usd">9000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c130"
      decimals="-3"
      id="ixv-85507"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c131"
      decimals="-3"
      id="ixv-85508"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c132"
      decimals="-3"
      id="ixv-85509"
      unitRef="usd">40000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c133"
      decimals="-3"
      id="ixv-85510"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c134"
      decimals="-3"
      id="ixv-85511"
      unitRef="usd">9000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c135"
      decimals="-3"
      id="ixv-85512"
      unitRef="usd">47000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-85513" unitRef="usd">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c136"
      decimals="-3"
      id="ixv-85514"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c137"
      decimals="-3"
      id="ixv-85515"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c138"
      decimals="-3"
      id="ixv-85516"
      unitRef="usd">78000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c139"
      decimals="-3"
      id="ixv-85517"
      unitRef="usd">122000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c142"
      decimals="-3"
      id="ixv-85518"
      unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c143"
      decimals="-3"
      id="ixv-85519"
      unitRef="usd">103000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c109"
      decimals="-3"
      id="ixv-85520"
      unitRef="usd">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c110"
      decimals="-3"
      id="ixv-85521"
      unitRef="usd">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c111"
      decimals="-3"
      id="ixv-85522"
      unitRef="usd">181000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c112"
      decimals="-3"
      id="ixv-85523"
      unitRef="usd">225000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c144"
      decimals="-3"
      id="ixv-85524"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c145"
      decimals="-3"
      id="ixv-85525"
      unitRef="usd">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c146"
      decimals="-3"
      id="ixv-85526"
      unitRef="usd">59000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c147"
      decimals="-3"
      id="ixv-85527"
      unitRef="usd">65000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c148"
      decimals="-3"
      id="ixv-85528"
      unitRef="usd">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c149"
      decimals="-3"
      id="ixv-85529"
      unitRef="usd">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c150"
      decimals="-3"
      id="ixv-85530"
      unitRef="usd">47000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c151"
      decimals="-3"
      id="ixv-85531"
      unitRef="usd">52000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c121"
      decimals="-3"
      id="ixv-85532"
      unitRef="usd">6000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c122"
      decimals="-3"
      id="ixv-85533"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c123"
      decimals="-3"
      id="ixv-85534"
      unitRef="usd">106000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c124"
      decimals="-3"
      id="ixv-85535"
      unitRef="usd">117000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c152"
      decimals="-3"
      id="ixv-85536"
      unitRef="usd">5000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c153"
      decimals="-3"
      id="ixv-85537"
      unitRef="usd">28000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="c154"
      decimals="-3"
      id="ixv-85538"
      unitRef="usd">75000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-85539" unitRef="usd">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationExpense contextRef="c0" decimals="-3" id="ixv-85540" unitRef="usd">37000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c4" decimals="-3" id="ixv-85541" unitRef="usd">52000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c5" decimals="-3" id="ixv-85542" unitRef="usd">43000</ifrs-full:DepreciationExpense>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c0" id="ixv-37565">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    11:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;INTANGIBLE
    ASSET&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On September 30, 2022, the Company
announced the closing of the acquisition of Wellution&lt;sup&gt;TM&lt;/sup&gt;, a top seller Amazon.com Marketplace account (the &#x201c;Brand&#x201d;),
American food supplements and cosmetics brand and trademark (the &#x201c;Acquisition&#x201d;). In connection with the Acquisition, the
Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#x201c;M.R.M&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#x2019;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In the years ended December 31, 2022,
2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline
in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023
- $1,042).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 7.8
years (2023 &#x2013; 8.7), commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections
were determined based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#x2019;s
expectations that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter
of 27.8% (2023 &#x2013; 13.8%) and a declining growth rate for the long term, reaching 2% (2023 &#x2013; 2%) at the terminal year. Theoretical
royalties arising from the brand were capitalized at a discount rate of 21.9% (2023 &#x2013; 20.6%).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,344&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,479&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;During the year ended December 31,
2024, the Company recognized depreciation expenses in respect to intangible asset in the amount of $366 (for the year ended December
31, 2023 - $486).&#160;&lt;/p&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:Cash contextRef="c2" decimals="-3" id="ixv-85543" unitRef="usd">4540000</ifrs-full:Cash>
    <sprcy:PaymentsOfAdditionalDeferredCash contextRef="c0" decimals="-3" id="ixv-85544" unitRef="usd">1120000</sprcy:PaymentsOfAdditionalDeferredCash>
    <sprcy:PurchaseCostsValue contextRef="c2" decimals="-3" id="ixv-85545" unitRef="usd">321000</sprcy:PurchaseCostsValue>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-85546" unitRef="usd">4861000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c0" id="ixv-85547">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="-3" id="ixv-85548" unitRef="usd">1344000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c4" decimals="-3" id="ixv-85549" unitRef="usd">1042000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c0" id="ixv-85550">P7Y9M18D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c4" id="ixv-85551">P8Y8M12D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sprcy:GrowthRatePercentage contextRef="c0" decimals="3" id="ixv-85552" unitRef="pure">0.278</sprcy:GrowthRatePercentage>
    <sprcy:GrowthRatePercentage contextRef="c4" decimals="3" id="ixv-85553" unitRef="pure">0.138</sprcy:GrowthRatePercentage>
    <sprcy:LongTermPercentage contextRef="c0" decimals="2" id="ixv-85554" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <sprcy:LongTermPercentage contextRef="c4" decimals="2" id="ixv-85555" unitRef="pure">0.02</sprcy:LongTermPercentage>
    <sprcy:DiscountRatePercentage contextRef="c0" decimals="3" id="ixv-85556" unitRef="pure">0.219</sprcy:DiscountRatePercentage>
    <sprcy:DiscountRatePercentage contextRef="c4" decimals="3" id="ixv-85557" unitRef="pure">0.206</sprcy:DiscountRatePercentage>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c0" id="ixv-37624">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;The table below
summarizes the fair value of the intangible asset:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 88%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;4,717&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,042&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(486&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss on impairment of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,344&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;Depreciation of intangible asset&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,479&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c31" decimals="-3" id="ixv-85558" unitRef="usd">4717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-85559" unitRef="usd">1042000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill contextRef="c4" decimals="-3" id="ixv-85560" unitRef="usd">486000</sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c3" decimals="-3" id="ixv-85561" unitRef="usd">3189000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-85562" unitRef="usd">1344000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill contextRef="c0" decimals="-3" id="ixv-85563" unitRef="usd">366000</sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c2" decimals="-3" id="ixv-85564" unitRef="usd">1479000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="c155"
      decimals="-3"
      id="ixv-85565"
      unitRef="usd">366000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="c156"
      decimals="-3"
      id="ixv-85566"
      unitRef="usd">486000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-37693">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    12:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRADE
    PAYABLES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;208&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;264&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;816&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <sprcy:DisclosureOfTradePayablesExplanatory contextRef="c0" id="ixv-37703">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Open debts&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;208&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;264&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;816&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfTradePayablesExplanatory>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c2" decimals="-3" id="ixv-85567" unitRef="usd">608000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c3" decimals="-3" id="ixv-85568" unitRef="usd">538000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:NetDebt contextRef="c2" decimals="-3" id="ixv-85569" unitRef="usd">208000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt contextRef="c3" decimals="-3" id="ixv-85570" unitRef="usd">264000</ifrs-full:NetDebt>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="-3" id="ixv-85571" unitRef="usd">816000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c3" decimals="-3" id="ixv-85572" unitRef="usd">802000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <sprcy:DisclosureOfOtherAccountsPayableTextBlock contextRef="c0" id="ixv-37785">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    13:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OTHER
    ACCOUNTS PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees
    and payroll accruals&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;104&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other
    payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;205&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;185&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfOtherAccountsPayableTextBlock>
    <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory contextRef="c0" id="ixv-37795">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Employees
    and payroll accruals&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued vacation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;104&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other
    payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;205&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;185&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c2" decimals="-3" id="ixv-85573" unitRef="usd">75000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c3" decimals="-3" id="ixv-85574" unitRef="usd">48000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:Accruals contextRef="c2" decimals="-3" id="ixv-85575" unitRef="usd">130000</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="c3" decimals="-3" id="ixv-85576" unitRef="usd">104000</ifrs-full:Accruals>
    <ifrs-full:OtherPayables contextRef="c3" decimals="-3" id="ixv-85577" unitRef="usd">33000</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="-3" id="ixv-85578" unitRef="usd">205000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="-3" id="ixv-85579" unitRef="usd">185000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-37864">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    14:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FINANCIAL
    INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification
    of financial assets and financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;Financial assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,239&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets at amortized
    cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,248&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,344&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Investments in financial assets at
    fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;871&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;659&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;123&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;315&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison
between the carrying amount and fair value of the Company&#x2019;s financial instruments as of December 31, 2024, and 2023, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"&gt;Investments in short-term financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;517&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;517&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#160;&#160;&#160;&#160;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x202f;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Management believes that the carrying
amount of cash, short-term deposits, trade receivables, trade payables, overdrafts and other current liabilities approximate their fair
value due to the short-term maturities of these instruments.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    risk factors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#x2019;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#x2019;s
financial performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
    risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;Foreign currency risk:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit
    risks:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity
    risk:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2024, the Company expects
to settle all of its financial liabilities in less than one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory contextRef="c0" id="ixv-37882">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#x201c;&lt;i&gt;Financial Instruments&lt;/i&gt;&#x201d; (&#x201c;IFRS 9&#x201d;):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;Financial assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Cash and restricted deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;2,141&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;203&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,239&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets at amortized
    cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,248&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,344&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Investments in financial assets at
    fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;871&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;659&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financial liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Credit from others&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Warrants liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total financial and lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;123&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;315&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85580" unitRef="usd">1560000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" id="ixv-85581" unitRef="usd">2141000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c3" decimals="-3" id="ixv-85582" unitRef="usd">3000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:OtherReceivables contextRef="c2" decimals="-3" id="ixv-85583" unitRef="usd">449000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c3" decimals="-3" id="ixv-85584" unitRef="usd">203000</ifrs-full:OtherReceivables>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties contextRef="c2" decimals="-3" id="ixv-85585" unitRef="usd">4239000</ifrs-full:NoncurrentReceivablesDueFromRelatedParties>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c2" decimals="-3" id="ixv-85586" unitRef="usd">6248000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost contextRef="c3" decimals="-3" id="ixv-85587" unitRef="usd">5344000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c2" decimals="-3" id="ixv-85588" unitRef="usd">871000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c3" decimals="-3" id="ixv-85589" unitRef="usd">659000</ifrs-full:FinancialAssetsAtFairValue>
    <sprcy:CreditFromOthers contextRef="c2" decimals="-3" id="ixv-85590" unitRef="usd">75000</sprcy:CreditFromOthers>
    <sprcy:CreditFromOthers contextRef="c3" decimals="-3" id="ixv-85591" unitRef="usd">48000</sprcy:CreditFromOthers>
    <sprcy:WarrantsLiability contextRef="c3" decimals="-3" id="ixv-85592" unitRef="usd">191000</sprcy:WarrantsLiability>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="-3" id="ixv-85593" unitRef="usd">48000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="-3" id="ixv-85594" unitRef="usd">76000</ifrs-full:LeaseLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="-3" id="ixv-85595" unitRef="usd">123000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="-3" id="ixv-85596" unitRef="usd">315000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c0" id="ixv-38119">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The tables below are a comparison
between the carrying amount and fair value of the Company&#x2019;s financial instruments as of December 31, 2024, and 2023, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"&gt;Investments in short-term financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;517&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;517&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Carrying amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level
    3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"&gt;Investments in financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#160;&#160;&#160;&#160;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x202f;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;659&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&#x202f;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-85597" unitRef="usd">354000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c157"
      decimals="-3"
      id="ixv-85598"
      unitRef="usd">354000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c2" decimals="-3" id="ixv-85599" unitRef="usd">517000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c157"
      decimals="-3"
      id="ixv-85600"
      unitRef="usd">517000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c3" decimals="-3" id="ixv-85601" unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c161"
      decimals="-3"
      id="ixv-85602"
      unitRef="usd">659000</ifrs-full:OtherNoncurrentFinancialAssets>
    <sprcy:WarrantsLiability contextRef="c3" decimals="-3" id="ixv-85603" unitRef="usd">191000</sprcy:WarrantsLiability>
    <sprcy:WarrantsLiability
      contextRef="c162"
      decimals="-3"
      id="ixv-85604"
      unitRef="usd">191000</sprcy:WarrantsLiability>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c0" id="ixv-38376">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    15:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EMPLOYEE
    BENEFIT LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Employee benefits consist of short-term
benefits and post-employment benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Post-employment benefits:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#x201c;Severance Pay Law&#x201d;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#x2019;s liability is accounted for as a post-employment benefit. The computation of the Company&#x2019;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#x2019;s salary and employment
term which establish the entitlement to receive the compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;i&gt;Defined contribution plans:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Expenses in respect of
    defined contribution plans&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;105&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory contextRef="c0" id="ixv-85605">These contributions and contributions for compensation represent defined contribution plans.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Expenses in respect of
    defined contribution plans&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;105&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="-3" id="ixv-85606" unitRef="usd">106000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c4" decimals="-3" id="ixv-85607" unitRef="usd">105000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c5" decimals="-3" id="ixv-85608" unitRef="usd">115000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-38435">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    16:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TAXES
    ON INCOME&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
    rates applicable to the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2024, 2023, and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
    assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The assessments of the Company are
deemed final through the 2016 tax year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carryforward
    tax losses and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company has accumulated tax losses
since its inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;As of December 31, 2024, the Company&#x2019;s
net carryforward tax losses are estimated to be approximately $62,000.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="c163"
      decimals="2"
      id="ixv-85609"
      unitRef="pure">0.23</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="c164"
      decimals="2"
      id="ixv-85610"
      unitRef="pure">0.23</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates
      contextRef="c165"
      decimals="2"
      id="ixv-85611"
      unitRef="pure">0.23</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <sprcy:OperatingLossCarryforwardsTaxAmount contextRef="c2" decimals="-3" id="ixv-85612" unitRef="usd">62000000</sprcy:OperatingLossCarryforwardsTaxAmount>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-38502">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    17:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CONTINGENT
    LIABILITIES, COMMITMENTS, CLAIMS AND LIENS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License
    Agreement with Dekel Pharmaceuticals Ltd.:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#x201c;Dekel License Agreement&#x201d;). The Dekel License Agreement became effective
in August 2015.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments
include: (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 14, 2019, an amendment to
the Dekel License Agreement was signed (the &#x201c;Amendment&#x201d;), which encompasses the Company and Dekel&#x2019;s original intention
to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect
the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Amendment also prescribes for
a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined
under the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment
also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#x2019;s former Executive
Chairman of the Board and former interim Chief Executive Officer, towards the Company&#x2019;s field of activity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 5, 2024, SciSparc received
written notice from Dekel for the termination of the Dekel License Agreement, effective immediately, based on SciSparc allegedly breaching
its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the licensed products under
the Dekel License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 16, 2025, the Dekel License
Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc&#x2019;s former directors, effective as of February
5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents,
know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License
Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License
    Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#x201c;Yissum&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#x201c;Yissum License Agreement&#x201d;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#x2019;s share in such joint patents shall be automatically included in the Yissum License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agreement
    with Hannover Medical School:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#x201c;MHH&#x201d;) to conduct during 2018 a phase IIb clinical
trial titled &#x201c;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#x201d; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount
of approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of
the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under
a new agreement or will be paid back to the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Agreement with Yale University:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 2, 2023, Capital Point Ltd. (&#x201c;Capital Point&#x201d;) filed with the Tel Aviv-Jaffa District Court (the &#x201c;Court&#x201d;) a suit against the Company, case number 2050-05-23 (the &#x201c;Suit&#x201d;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Suit challenges a certain warrant issued by the Company to Capital Point (the &#x201c;Capital Point Warrant&#x201d;) to purchase $16 of ordinary shares of the Company (the &#x201c;Warrant Shares&#x201d;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#x2019;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of December 31, 2024, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <sprcy:DekelLicenseAgreementDescription contextRef="c0" id="ixv-85613">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#x2019;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.</sprcy:DekelLicenseAgreementDescription>
    <sprcy:AnnualInvestment contextRef="c0" decimals="-3" id="ixv-85614" unitRef="usd">350000</sprcy:AnnualInvestment>
    <sprcy:AdditionalMilestoneAmount
      contextRef="c166"
      decimals="-3"
      id="ixv-85615"
      unitRef="usd">75000</sprcy:AdditionalMilestoneAmount>
    <sprcy:InstallmentAmount
      contextRef="c167"
      decimals="-3"
      id="ixv-85616"
      unitRef="usd">122000</sprcy:InstallmentAmount>
    <sprcy:EstimatedAmount
      contextRef="c167"
      decimals="-3"
      id="ixv-85617"
      unitRef="usd">776000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c168"
      decimals="-3"
      id="ixv-85618"
      unitRef="usd">1385000</sprcy:EstimatedAmount>
    <sprcy:EstimatedAmount
      contextRef="c169"
      decimals="-3"
      id="ixv-85619"
      unitRef="usd">370000</sprcy:EstimatedAmount>
    <ifrs-full:IssuedCapitalOrdinaryShares contextRef="c2" decimals="-3" id="ixv-85620" unitRef="usd">16000</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:CapitalCommitments contextRef="c2" decimals="0" id="ixv-85621" unitRef="ils">10000000</ifrs-full:CapitalCommitments>
    <ifrs-full:CapitalCommitments contextRef="c2" decimals="-4" id="ixv-85622" unitRef="usd">2750000</ifrs-full:CapitalCommitments>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-38660">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    18:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;515,631&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,652&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Reverse Share Splits&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#x2019;s share capital
to 75,000,000 ordinary shares with &lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, &lt;i&gt;inter alia&lt;/i&gt;, a reverse split of the Company&#x2019;s share
capital up to a ratio of 30:1 (the &#x201c;Third Reverse Split&#x201d;). Following the implementation of the Third Reverse Split, the Company&#x2019;s
authorized share capital was adjusted under the Company&#x2019;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;no&lt;/span&gt; par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On September 14, 2023, the Company&#x2019;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
    in share capital:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,652&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of share capital &#x2013; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;175,110&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share issued to consultants (Note 18(e), and Note 19 (a) (3)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,770&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of share capital &#x2013; in respect of January 2024 SEPA (Note 18(i))&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;276,099&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;515,631&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rights
    attached to shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Voting rights at the shareholders
meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capital
    management in the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s capital management
objectives are to preserve the Company&#x2019;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional
    issuances of ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 2, 2022, the Company
issued a consultant 44 ordinary shares in respect of services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 1, 2022, the Company
issued a consultant 68 ordinary shares in respect of services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 22, 2023, the Company
issued 660 ordinary shares in respect of the stock purchase&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;agreement entered
into by and among Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo&#x201d;) (see also Note 25a).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the year ended December
31, 2024, the Company issued 30,770 ordinary shares to consultants in respect of services rendered in the amount of $105&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;June
    2022 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#x201c;June 2022 Financing Round&#x201d;), providing for the issuance
of an aggregate of 6,495 units and pre-funded units, as follows: (a) 614 units at a price of $1,542.48 per unit, each consisting of (i)
one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#x201c;June 2022 Warrants&#x201d;),
and (b) 5,881 pre-funded units at a price of $1,539.09 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The June 2022 Warrants have an
exercise price of&#160;$1,435.98&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven
years from the date of issuance.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.38&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.872&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    share price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;102.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,435.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,435.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    fair value ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;192&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Less than $1 thousand&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the year ended December
31, 2022, the Company issued 5,881 ordinary shares in respect of the exercise of 5,881 pre-funded warrants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.25in; text-indent: 0in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;August
    2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 14, 2023, the Company
closed an underwritten public offering (the &#x201c;2023 Public Offering&#x201d;) of 10,119 ordinary shares, at a purchase price of $109.20
per ordinary share and pre-funded warrants to purchase up to 1,786 ordinary shares at a purchase price of $108.654 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#x201c;Aegis&#x201d;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 1,786 ordinary shares solely to cover
over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;October
    2023 Financing Round&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In connection with the private
placement, the Company issued an aggregate of 91,910 units, each unit consisting of two pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;).
The Pre-Funded Warrants have an exercise price of $0.021, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the year ended December
31, 2024, the Company issued 175,110 ordinary shares in respect of the exercise of 175,110 Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January
    2024 Standby Equity Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 21, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;), as amended on February 26, 2024, with YA II PN, LTD (&#x201c;YA&#x201d;),
which provided for the sale of up to $20,000 of the Company&#x2019;s ordinary shares (the &#x201c;Advance Shares&#x201d;). As of December
31, 2024, of the $20,000 eligible to be sold pursuant to the SEPA (the &#x201c;Commitment Amount&#x201d;), the Company has sold 273,466
ordinary shares for total proceeds of $6,255. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share
price of 97% of the market price, which is defined as the lowest daily volume weighted average price of the Company&#x2019;s ordinary
shares during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice
to YA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000 (each a &#x201c;Pre-Paid Advance&#x201d;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#x201c;Promissory Note&#x201d;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to
18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued
interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such
notice against an equal amount of the monthly installment amount, at the Company&#x2019;s option. If the Company elects to pay in cash,
the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The
Promissory Note contains the Company&#x2019;s customary representations and warranties and events of default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of 2,633 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $200.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-38676">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Composition of share capital:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;515,631&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,652&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c2"
      decimals="INF"
      id="ixv-85623"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-85624"
      unitRef="shares">515631</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c3"
      decimals="INF"
      id="ixv-85625"
      unitRef="shares">75000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-85626"
      unitRef="shares">33652</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c170"
      decimals="0"
      id="ixv-85627"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:CapitalRatio contextRef="c172" id="ixv-85628">30:1</sprcy:CapitalRatio>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c173"
      decimals="0"
      id="ixv-85629"
      unitRef="shares">75000000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:ReverseSplitRatio contextRef="c172" id="ixv-85630">26:1</sprcy:ReverseSplitRatio>
    <sprcy:DisclosureOfIssuedAndOutstandingShareCapital contextRef="c0" id="ixv-38838">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Issued and outstanding share capital:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,652&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of share capital &#x2013; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;175,110&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share issued to consultants (Note 18(e), and Note 19 (a) (3)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;30,770&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Issuance of share capital &#x2013; in respect of January 2024 SEPA (Note 18(i))&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;276,099&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;515,631&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfIssuedAndOutstandingShareCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-85631"
      unitRef="shares">33652</ifrs-full:NumberOfSharesIssued>
    <sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants
      contextRef="c0"
      decimals="INF"
      id="ixv-85632"
      unitRef="shares">175110</sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants>
    <sprcy:ShareIssuedToAConsultants
      contextRef="c0"
      decimals="INF"
      id="ixv-85633"
      unitRef="shares">30770</sprcy:ShareIssuedToAConsultants>
    <sprcy:IssuanceOfShareCapitalInRespectSEPA
      contextRef="c0"
      decimals="INF"
      id="ixv-85634"
      unitRef="shares">276099</sprcy:IssuanceOfShareCapitalInRespectSEPA>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-85635"
      unitRef="shares">515631</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c174"
      decimals="0"
      id="ixv-85636"
      unitRef="shares">44</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c175"
      decimals="0"
      id="ixv-85637"
      unitRef="shares">68</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c176"
      decimals="0"
      id="ixv-85638"
      unitRef="shares">660</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c0"
      decimals="0"
      id="ixv-85639"
      unitRef="shares">30770</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ServicesExpense contextRef="c0" decimals="-3" id="ixv-85640" unitRef="usd">105000</ifrs-full:ServicesExpense>
    <ifrs-full:GrossProfit
      contextRef="c177"
      decimals="-3"
      id="ixv-85641"
      unitRef="usd">10210000</ifrs-full:GrossProfit>
    <sprcy:IssuanceOfAggregateShares
      contextRef="c178"
      decimals="0"
      id="ixv-85642"
      unitRef="shares">6495</sprcy:IssuanceOfAggregateShares>
    <sprcy:AggregateUnits
      contextRef="c178"
      decimals="0"
      id="ixv-85643"
      unitRef="shares">614</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c178"
      decimals="2"
      id="ixv-85644"
      unitRef="usdPershares">1542.48</sprcy:AggregateUnitsPerShare>
    <sprcy:AggregateUnits
      contextRef="c179"
      decimals="0"
      id="ixv-85645"
      unitRef="shares">5881</sprcy:AggregateUnits>
    <sprcy:AggregateUnitsPerShare
      contextRef="c180"
      decimals="2"
      id="ixv-85646"
      unitRef="usdPershares">1539.09</sprcy:AggregateUnitsPerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c181"
      decimals="2"
      id="ixv-85647"
      unitRef="usdPershares">1435.98</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <sprcy:IssuanceExpireTerm contextRef="c181" id="ixv-85648">P7Y</sprcy:IssuanceExpireTerm>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c0" id="ixv-39108">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The June 2022 Warrants&#x2019; fair
value was calculated using the Black&#x2013;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 66%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;72&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.38&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.872&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    share price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;102.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    price ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,435.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,435.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    fair value ($)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;192&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Less than $1 thousand&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c0" decimals="2" id="ixv-85649" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c4" decimals="2" id="ixv-85650" unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c0" decimals="2" id="ixv-85651" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c4" decimals="2" id="ixv-85652" unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c0" decimals="4" id="ixv-85653" unitRef="pure">0.0438</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c4" decimals="5" id="ixv-85654" unitRef="pure">0.03872</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-85655"
      unitRef="usdPershares">7.56</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c4"
      decimals="2"
      id="ixv-85656"
      unitRef="usdPershares">102.48</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="2"
      id="ixv-85657"
      unitRef="usdPershares">1435.98</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c4"
      decimals="2"
      id="ixv-85658"
      unitRef="usdPershares">1435.98</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c3" decimals="-3" id="ix_7_fact" unitRef="usd">192000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c182"
      decimals="0"
      id="ixv-85661"
      unitRef="shares">5881</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c183"
      decimals="0"
      id="ixv-85662"
      unitRef="shares">5881</sprcy:WarrantsAndExercise>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c184"
      decimals="0"
      id="ixv-85663"
      unitRef="shares">10119</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c184"
      decimals="2"
      id="ixv-85664"
      unitRef="usdPershares">109.2</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c185"
      decimals="0"
      id="ixv-85665"
      unitRef="shares">1786</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c185"
      decimals="3"
      id="ixv-85666"
      unitRef="usdPershares">108.654</sprcy:PurchasePricePerShare>
    <sprcy:AggregateGrossProceeds
      contextRef="c184"
      decimals="-3"
      id="ixv-85667"
      unitRef="usd">1300000</sprcy:AggregateGrossProceeds>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c186"
      decimals="0"
      id="ixv-85668"
      unitRef="shares">1786</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="c187"
      decimals="-3"
      id="ixv-85669"
      unitRef="usd">5026000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c188"
      decimals="0"
      id="ixv-85670"
      unitRef="shares">91910</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c189"
      decimals="3"
      id="ixv-85671"
      unitRef="usdPershares">0.021</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c190"
      decimals="0"
      id="ixv-85672"
      unitRef="shares">175110</ifrs-full:NumberOfSharesIssued>
    <sprcy:WarrantsAndExercise
      contextRef="c191"
      decimals="0"
      id="ixv-85673"
      unitRef="shares">175110</sprcy:WarrantsAndExercise>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="c192"
      decimals="-3"
      id="ixv-85674"
      unitRef="usd">20000000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <sprcy:CommitmentAmount
      contextRef="c192"
      decimals="-3"
      id="ixv-85675"
      unitRef="usd">20000000</sprcy:CommitmentAmount>
    <sprcy:SaleOfOrdinaryShares
      contextRef="c192"
      decimals="0"
      id="ixv-85676"
      unitRef="shares">273466</sprcy:SaleOfOrdinaryShares>
    <ifrs-full:GrossProfit
      contextRef="c193"
      decimals="-3"
      id="ixv-85677"
      unitRef="usd">6255000</ifrs-full:GrossProfit>
    <sprcy:SharePriceRate
      contextRef="c194"
      decimals="2"
      id="ixv-85678"
      unitRef="pure">0.97</sprcy:SharePriceRate>
    <sprcy:CommitmentAmount
      contextRef="c195"
      decimals="-3"
      id="ixv-85679"
      unitRef="usd">5000000</sprcy:CommitmentAmount>
    <sprcy:InterestRate
      contextRef="c196"
      decimals="2"
      id="ixv-85680"
      unitRef="pure">0.05</sprcy:InterestRate>
    <sprcy:InterestRate
      contextRef="c197"
      decimals="2"
      id="ixv-85681"
      unitRef="pure">0.18</sprcy:InterestRate>
    <sprcy:InstallmentPayment contextRef="c2" decimals="2" id="ixv-85682" unitRef="pure">0.10</sprcy:InstallmentPayment>
    <sprcy:PaymentForPremiumPercentage contextRef="c0" decimals="2" id="ixv-85683" unitRef="pure">0.05</sprcy:PaymentForPremiumPercentage>
    <sprcy:AggregateIssuedAmount
      contextRef="c0"
      decimals="0"
      id="ixv-85684"
      unitRef="shares">2633</sprcy:AggregateIssuedAmount>
    <ifrs-full:FeeAndCommissionExpense contextRef="c0" decimals="-3" id="ixv-85685" unitRef="usd">200000</ifrs-full:FeeAndCommissionExpense>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-39341">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    19:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SHARE-BASED
    PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    cost of share-based payment recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;524&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;196&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;897&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    2005 and 2015 ESOP and 2023 Plan of the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#x201c;2023 Plan&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. &lt;/span&gt;Under the 2023 Plan, the Company may grant its employees and other
service providers equity-based incentive awards (&#x201c;Share Options&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On December 28, 2023, the Board
approved to reserve for &lt;span style="background-color: white"&gt;issuance under the 2023 Plan 47,619 Ordinary Shares. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 3, 2022 (the &#x201c;2022 Grant Date&#x201d;), the Board approved the grant of 326 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#x2019;s shareholders (the &#x201c;2022 General Meeting&#x201d;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $3,549 per Share Option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;February&#160;10,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;January
    3,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    ordinary share price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,724.54&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,674.58&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;134&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.46&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life of Share Options (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair value of the Share Options
granted on January 3, 2022, was set at $3,325.14 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $2,407.86 per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end
at April 21, 2024.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;During the year ended December 31,
2024, share-based compensation in respect of Share Options of $7 was charged to the consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the year ended December 31, 2024, the Company issued consultants 30,770 ordinary shares in respect of services rendered. The shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $105.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement
    during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt;
    price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding
    at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,491.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,354.83&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options exercisable at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,354.83&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,488.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options cancelled during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,035.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,491.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options exercisable at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,477.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life of the Share Options outstanding was 2.99 years and 4.03 years as of December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The range of exercise prices of Share Options outstanding at the end of the year was $3,549 - $444,759 (inclusive) as of December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"&gt;c.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Restricted
                                            Share Units:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 1.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.5in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 20, 2024, the Company granted 25,238 Restricted Share Units (&#x201c;RSUs&#x201d;) to directors and officers, pursuant to the Company&#x2019;s RSU Plan. The RSUs will vest at each recipient&#x2019;s discretion and taking into account personal tax implications and convert into 25,238 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on June 20, 2024, which was $18.753.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 1.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 0.5in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 8, 2024, the Company granted &lt;span style="-sec-ix-hidden: hidden-fact-117"&gt;25,238&lt;/span&gt; RSUs to directors and officers, pursuant to the Company&#x2019;s RSU Plan. The RSUs will vest at each recipient&#x2019;s discretion and taking into account personal tax implications and convert into 25,238 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August 8, 2024, which was $6.636.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50,476&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expiry of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50,476&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total exercisable RSUs as of December
31, 2024, are 12,619. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $456 was charged to the
Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock contextRef="c0" id="ixv-39359">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 58%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;264&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;524&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;162&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;633&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;569&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;196&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;897&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-85686"
      unitRef="usd">45000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c210"
      decimals="-3"
      id="ixv-85687"
      unitRef="usd">34000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c211"
      decimals="-3"
      id="ixv-85688"
      unitRef="usd">264000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-85689"
      unitRef="usd">524000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c210"
      decimals="-3"
      id="ixv-85690"
      unitRef="usd">162000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c211"
      decimals="-3"
      id="ixv-85691"
      unitRef="usd">633000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c209"
      decimals="-3"
      id="ixv-85692"
      unitRef="usd">569000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c210"
      decimals="-3"
      id="ixv-85693"
      unitRef="usd">196000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c211"
      decimals="-3"
      id="ixv-85694"
      unitRef="usd">897000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c198"
      decimals="0"
      id="ixv-85695"
      unitRef="shares">47619</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c199"
      decimals="0"
      id="ixv-85696"
      unitRef="pure">326</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c200"
      decimals="0"
      id="ixv-85697"
      unitRef="usdPershares">3549</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock contextRef="c0" id="ixv-39536">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&lt;i&gt;The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;February&#160;10,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;January
    3,&lt;br/&gt;
    2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Underlying
    ordinary share price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,724.54&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,674.58&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;133&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;134&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate (%)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.46&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    life of Share Options (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c212"
      decimals="2"
      id="ixv-85698"
      unitRef="usdPershares">2724.54</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c213"
      decimals="2"
      id="ixv-85699"
      unitRef="usdPershares">3674.58</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c212"
      decimals="2"
      id="ixv-85700"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c213"
      decimals="2"
      id="ixv-85701"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c212"
      decimals="2"
      id="ixv-85702"
      unitRef="pure">1.33</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c213"
      decimals="2"
      id="ixv-85703"
      unitRef="pure">1.34</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c212"
      decimals="4"
      id="ixv-85704"
      unitRef="pure">0.02</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c213"
      decimals="4"
      id="ixv-85705"
      unitRef="pure">0.0146</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c212"
      decimals="0"
      id="ixv-85706"
      unitRef="pure">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="c213"
      decimals="0"
      id="ixv-85707"
      unitRef="pure">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c200"
      decimals="2"
      id="ixv-85708"
      unitRef="usdPershares">3325.14</sprcy:FairValueOfShareOptionsGranted>
    <sprcy:FairValueOfShareOptionsGranted
      contextRef="c201"
      decimals="2"
      id="ixv-85709"
      unitRef="usdPershares">2407.86</sprcy:FairValueOfShareOptionsGranted>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c202"
      decimals="-3"
      id="ixv-85710"
      unitRef="usd">7000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c203"
      decimals="0"
      id="ixv-85711"
      unitRef="shares">30770</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:OrdinarySharesGrantedDiscountRate contextRef="c0" decimals="2" id="ixv-85712" unitRef="pure">0.25</sprcy:OrdinarySharesGrantedDiscountRate>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c204"
      decimals="-3"
      id="ixv-85713"
      unitRef="usd">105000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0" id="ixv-39721">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; Share&lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt;
    price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding
    at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,491.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,354.83&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options exercisable at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,354.83&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;336&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,488.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options cancelled during the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,035.55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options outstanding at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;334&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,491.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Share Options exercisable at the end of
    the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,477.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c3" decimals="0" id="ixv-85714" unitRef="pure">334</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-85715"
      unitRef="usdPershares">3491.88</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c2" decimals="0" id="ixv-85716" unitRef="pure">324</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-85717"
      unitRef="usdPershares">7354.83</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c2" decimals="0" id="ixv-85718" unitRef="pure">324</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c2"
      decimals="2"
      id="ixv-85719"
      unitRef="usdPershares">7354.83</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c31" decimals="0" id="ixv-85720" unitRef="pure">336</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c31"
      decimals="2"
      id="ixv-85721"
      unitRef="usdPershares">3488.94</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c4" decimals="0" id="ixv-85722" unitRef="pure">2</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c4"
      decimals="2"
      id="ixv-85723"
      unitRef="usdPershares">3035.55</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c3" decimals="0" id="ixv-85724" unitRef="pure">334</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-85725"
      unitRef="usdPershares">3491.88</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c3" decimals="0" id="ixv-85726" unitRef="pure">279</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c3"
      decimals="2"
      id="ixv-85727"
      unitRef="usdPershares">3477.18</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c0" id="ixv-85728">P2Y11M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c4" id="ixv-85729">P4Y10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <sprcy:NumberOfOptionsOutstanding contextRef="c2" decimals="-3" id="ixv-85730" unitRef="usd">3549000</sprcy:NumberOfOptionsOutstanding>
    <sprcy:NumberOfOptionsOutstanding contextRef="c3" decimals="-3" id="ixv-85731" unitRef="usd">444759000</sprcy:NumberOfOptionsOutstanding>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c205"
      decimals="0"
      id="ixv-85732"
      unitRef="pure">25238</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <sprcy:ConvertIntoOrdinaryShares
      contextRef="c205"
      decimals="0"
      id="ixv-85733"
      unitRef="shares">25238</sprcy:ConvertIntoOrdinaryShares>
    <sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement contextRef="c205" id="ixv-85734">P2Y</sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c205"
      decimals="3"
      id="ixv-85735"
      unitRef="usdPershares">18.753</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <sprcy:ConvertIntoOrdinaryShares
      contextRef="c206"
      decimals="0"
      id="ixv-85736"
      unitRef="shares">25238</sprcy:ConvertIntoOrdinaryShares>
    <sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement contextRef="c206" id="ixv-85737">P2Y</sprcy:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c206"
      decimals="3"
      id="ixv-85738"
      unitRef="usdPershares">6.636</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c0" id="ixv-40110">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50,476&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expiry of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50,476&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="c0" decimals="0" id="ixv-85739" unitRef="pure">50476</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c2" decimals="0" id="ixv-85740" unitRef="pure">50476</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c207"
      decimals="0"
      id="ixv-85741"
      unitRef="pure">12619</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c208"
      decimals="-3"
      id="ixv-85742"
      unitRef="usd">456000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c0" id="ixv-40211">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;20:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;REVENUES
    AND COST OF REVENUES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s Brand sells products
directly to customers mainly through the Brand&#x2019;s online Amazon stores.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the Company&#x2019;s standard
contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue
based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant
revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it
expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates
of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2024,
the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right
of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In certain contracts, the Company
evaluates the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining
the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis
based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible
for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other
factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore,
sales are recorded on a gross basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Purchased goods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;798&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;672&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;301&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Freight&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;683&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock contextRef="c0" id="ixv-40227">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Purchased goods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;798&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;672&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;301&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Freight&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;683&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock>
    <ifrs-full:CostOfSales
      contextRef="c214"
      decimals="-3"
      id="ixv-85743"
      unitRef="usd">798000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c215"
      decimals="-3"
      id="ixv-85744"
      unitRef="usd">672000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c216"
      decimals="-3"
      id="ixv-85745"
      unitRef="usd">301000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c217"
      decimals="-3"
      id="ixv-85746"
      unitRef="usd">2000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c218"
      decimals="-3"
      id="ixv-85747"
      unitRef="usd">11000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="c219"
      decimals="-3"
      id="ixv-85748"
      unitRef="usd">21000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c0" decimals="-3" id="ixv-85749" unitRef="usd">800000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c4" decimals="-3" id="ixv-85750" unitRef="usd">683000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c5" decimals="-3" id="ixv-85751" unitRef="usd">322000</ifrs-full:CostOfSales>
    <ifrs-full:DisclosureOfAdditionalInformationExplanatory contextRef="c0" id="ixv-40341">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;21:-
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ADDITIONAL
    INFORMATION TO THE ITEMS OF PROFIT OR LOSS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;392&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;436&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;45&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;34&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;264&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;681&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;719&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;101&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;703&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;254&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;369&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;104&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;141&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;281&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,707&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,641&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,803&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Sales and marketing expenses:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Advertising&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;367&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;576&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;363&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amazon fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;495&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;454&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;486&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;144&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Storage and shipping&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;167&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;145&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;91&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Management fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;120&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;235&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,515&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,484&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;General and administrative
    expenses:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;507&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;415&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;437&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;419&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;68&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;633&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,009&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,468&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Business development expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;108&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;86&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;161&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Regulatory expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;158&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;162&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;110&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;197&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;369&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,526&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,427&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Other expenses (income):&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss from sale of property and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gain on sale of patent license, net
    (net of Polyrizon Ltd. holdings sold) (See also Note 25b)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,270&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Finance income:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net change in fair value of financial liabilities designated
    at fair value through profit or loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,205&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest from loans to related parties and deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(421&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,219&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;f.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expenses:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Issuance expenses related to warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Losses from remeasurement of investment in financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;305&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,046&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;770&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expense in respect of leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses from interest and
    commissions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;353&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassified&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAdditionalInformationExplanatory>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c0" id="ixv-40351">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;392&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;436&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;45&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;34&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;264&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Regulatory, professional and other expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;681&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;719&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;750&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;211&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;101&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;703&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;254&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;369&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Chemistry and formulations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;104&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;141&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;281&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,707&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,641&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,803&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Sales and marketing expenses:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Advertising&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;367&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;576&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;363&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amazon fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;495&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;454&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;366&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;486&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;144&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Storage and shipping&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;167&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;145&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;91&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;*&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Management fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;120&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;235&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,515&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,484&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;General and administrative
    expenses:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Wages and related expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;507&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;415&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;437&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;419&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;68&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;633&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Professional and directors&#x2019; fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,009&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,468&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Business development expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;108&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;86&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;161&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Regulatory expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;158&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;202&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;162&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Office maintenance, rent and other expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;110&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Investor relations and business expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;197&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;369&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,526&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,427&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Other expenses (income):&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Loss from sale of property and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gain on sale of patent license, net
    (net of Polyrizon Ltd. holdings sold) (See also Note 25b)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,270&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Finance income:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net change in fair value of financial liabilities designated
    at fair value through profit or loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(191&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,205&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest from loans to related parties and deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(421&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(612&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,219&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;f.&lt;/td&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expenses:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Issuance expenses related to warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Exchange rate differences, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;18&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Losses from remeasurement of investment in financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;305&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,046&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;770&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expense in respect of leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses from interest and
    commissions&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;353&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,055&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,014&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reclassified&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c220"
      decimals="-3"
      id="ixv-85752"
      unitRef="usd">390000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-85753"
      unitRef="usd">392000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c222"
      decimals="-3"
      id="ixv-85754"
      unitRef="usd">436000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-85755"
      unitRef="usd">45000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-85756"
      unitRef="usd">34000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-85757"
      unitRef="usd">264000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c226"
      decimals="-3"
      id="ixv-85758"
      unitRef="usd">681000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c227"
      decimals="-3"
      id="ixv-85759"
      unitRef="usd">719000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c228"
      decimals="-3"
      id="ixv-85760"
      unitRef="usd">750000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c229"
      decimals="-3"
      id="ixv-85761"
      unitRef="usd">211000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c230"
      decimals="-3"
      id="ixv-85762"
      unitRef="usd">101000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c231"
      decimals="-3"
      id="ixv-85763"
      unitRef="usd">703000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c232"
      decimals="-3"
      id="ixv-85764"
      unitRef="usd">276000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c233"
      decimals="-3"
      id="ixv-85765"
      unitRef="usd">254000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c234"
      decimals="-3"
      id="ixv-85766"
      unitRef="usd">369000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c235"
      decimals="-3"
      id="ixv-85767"
      unitRef="usd">104000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c236"
      decimals="-3"
      id="ixv-85768"
      unitRef="usd">141000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="c237"
      decimals="-3"
      id="ixv-85769"
      unitRef="usd">281000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-85770" unitRef="usd">1707000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" id="ixv-85771" unitRef="usd">1641000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-85772" unitRef="usd">2803000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c238"
      decimals="-3"
      id="ixv-85773"
      unitRef="usd">367000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c239"
      decimals="-3"
      id="ixv-85774"
      unitRef="usd">576000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c240"
      decimals="-3"
      id="ixv-85775"
      unitRef="usd">363000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c241"
      decimals="-3"
      id="ixv-85776"
      unitRef="usd">495000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c242"
      decimals="-3"
      id="ix_8_fact"
      unitRef="usd">1042000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c243"
      decimals="-3"
      id="ix_9_fact"
      unitRef="usd">454000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c244"
      decimals="-3"
      id="ixv-85779"
      unitRef="usd">366000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c245"
      decimals="-3"
      id="ixv-85780"
      unitRef="usd">486000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c246"
      decimals="-3"
      id="ixv-85781"
      unitRef="usd">144000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c247"
      decimals="-3"
      id="ixv-85782"
      unitRef="usd">167000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c248"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">145000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c249"
      decimals="-3"
      id="ix_11_fact"
      unitRef="usd">91000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c250"
      decimals="-3"
      id="ixv-85785"
      unitRef="usd">120000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c251"
      decimals="-3"
      id="ixv-85786"
      unitRef="usd">235000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c252"
      decimals="-3"
      id="ixv-85787"
      unitRef="usd">30000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-85788" unitRef="usd">1515000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c4" decimals="-3" id="ixv-85789" unitRef="usd">2484000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c5" decimals="-3" id="ixv-85790" unitRef="usd">1082000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c220"
      decimals="-3"
      id="ixv-85791"
      unitRef="usd">507000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-85792"
      unitRef="usd">415000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c222"
      decimals="-3"
      id="ixv-85793"
      unitRef="usd">437000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-85794"
      unitRef="usd">419000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-85795"
      unitRef="usd">68000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-85796"
      unitRef="usd">633000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c253"
      decimals="-3"
      id="ixv-85797"
      unitRef="usd">3009000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c254"
      decimals="-3"
      id="ixv-85798"
      unitRef="usd">2594000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c255"
      decimals="-3"
      id="ixv-85799"
      unitRef="usd">2468000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c256"
      decimals="-3"
      id="ixv-85800"
      unitRef="usd">108000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c257"
      decimals="-3"
      id="ixv-85801"
      unitRef="usd">86000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c258"
      decimals="-3"
      id="ixv-85802"
      unitRef="usd">161000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c259"
      decimals="-3"
      id="ixv-85803"
      unitRef="usd">158000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c260"
      decimals="-3"
      id="ixv-85804"
      unitRef="usd">202000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c261"
      decimals="-3"
      id="ixv-85805"
      unitRef="usd">162000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c262"
      decimals="-3"
      id="ixv-85806"
      unitRef="usd">128000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c263"
      decimals="-3"
      id="ixv-85807"
      unitRef="usd">110000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c264"
      decimals="-3"
      id="ixv-85808"
      unitRef="usd">80000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c265"
      decimals="-3"
      id="ixv-85809"
      unitRef="usd">197000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c266"
      decimals="-3"
      id="ixv-85810"
      unitRef="usd">369000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="c267"
      decimals="-3"
      id="ixv-85811"
      unitRef="usd">1486000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-85812" unitRef="usd">4526000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" id="ix_12_fact" unitRef="usd">3844000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-85814" unitRef="usd">5427000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c268"
      decimals="-3"
      id="ixv-85815"
      unitRef="usd">-17000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c271"
      decimals="-3"
      id="ixv-85816"
      unitRef="usd">1287000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c0" decimals="-3" id="ixv-85817" unitRef="usd">1270000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceIncome
      contextRef="c274"
      decimals="-3"
      id="ixv-85818"
      unitRef="usd">191000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c275"
      decimals="-3"
      id="ixv-85819"
      unitRef="usd">2205000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c276"
      decimals="-3"
      id="ixv-85820"
      unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c277"
      decimals="-3"
      id="ixv-85821"
      unitRef="usd">421000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="c281"
      decimals="-3"
      id="ixv-85822"
      unitRef="usd">14000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="-3" id="ixv-85823" unitRef="usd">612000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="-3" id="ixv-85824" unitRef="usd">2219000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c5" decimals="-3" id="ixv-85825" unitRef="usd">7832000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="c285"
      decimals="-3"
      id="ixv-85826"
      unitRef="usd">1204000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c280"
      decimals="-3"
      id="ixv-85827"
      unitRef="usd">18000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c282"
      decimals="-3"
      id="ixv-85828"
      unitRef="usd">4000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c286"
      decimals="-3"
      id="ixv-85829"
      unitRef="usd">305000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c287"
      decimals="-3"
      id="ixv-85830"
      unitRef="usd">1046000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c288"
      decimals="-3"
      id="ixv-85831"
      unitRef="usd">770000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c289"
      decimals="-3"
      id="ixv-85832"
      unitRef="usd">8000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c290"
      decimals="-3"
      id="ixv-85833"
      unitRef="usd">9000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c291"
      decimals="-3"
      id="ixv-85834"
      unitRef="usd">15000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c292"
      decimals="-3"
      id="ixv-85835"
      unitRef="usd">22000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="c294"
      decimals="-3"
      id="ixv-85836"
      unitRef="usd">21000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="-3" id="ixv-85837" unitRef="usd">353000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="-3" id="ixv-85838" unitRef="usd">1055000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c5" decimals="-3" id="ixv-85839" unitRef="usd">2014000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0" id="ixv-41156">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    22:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;LOSS
    PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Continuing operations:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277,380&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,472&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,413&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,883&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,379&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Effect of potential dilutive ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277,380&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,472&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,413&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,883&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,379&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the
    loss per share (anti-dilutive effect):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    Options to employees, officers, directors and consultants; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 120px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable
    warrants to investors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c0" id="ixv-41172">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details of the number of shares and loss used in the computation of loss per share:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amounts used in the computation of basic and diluted&#160;loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted&lt;br/&gt; number of&lt;br/&gt; shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Continuing operations:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277,380&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,472&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,413&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,883&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,379&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Effect of potential dilutive ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;277,380&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(7,472&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;19,413&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,883&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,379&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-85840"
      unitRef="shares">277380</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c0" decimals="-3" id="ixv-85841" unitRef="usd">-7472000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="INF"
      id="ixv-85842"
      unitRef="shares">19413</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c4" decimals="-3" id="ixv-85843" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="INF"
      id="ixv-85844"
      unitRef="shares">8379</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument contextRef="c5" decimals="-3" id="ixv-85845" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-85846"
      unitRef="shares">277380</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c0" decimals="-3" id="ixv-85847" unitRef="usd">-7472000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c4"
      decimals="INF"
      id="ixv-85848"
      unitRef="shares">19413</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c4" decimals="-3" id="ixv-85849" unitRef="usd">-5883000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c5"
      decimals="INF"
      id="ixv-85850"
      unitRef="shares">8379</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument contextRef="c5" decimals="-3" id="ixv-85851" unitRef="usd">-2592000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0" id="ixv-41704">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;23:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;OPERATING
    SEGMENTS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies the principles
of IFRS 8,&#160;&#x201c;&lt;i&gt;Operating Segments&lt;/i&gt;&#x201d;&lt;i&gt;&#160;&lt;/i&gt;(&#x201c;IFRS 8&#x201d;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#x2019;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#x201c;CODM&#x201d;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#x2019;s management determined that it has two reportable segments &#x2013; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#x2019;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Segment performance (segment income
(loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items
that are allocated directly to the segments and items that can be allocated on a reasonable basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The review of the CODM is carried
out according to the results of the segment&#x2019;s performance. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Drug
    &lt;br/&gt;
    Development&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Online
    &lt;br/&gt;
    Sales&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;External&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;Segment
    loss (gain)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,873&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,443&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,316&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Equity losses from the investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(259&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Tax income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Drug
    &lt;br/&gt;
    Development&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Online
    &lt;br/&gt;
    Sales&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;External&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;Segment
    loss (gain)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,456&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,815&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at
    equity, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Drug Development Segment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the year ended December 31, 2024, the Company
recognized other income in the amount of $1,288 as a result of a sale of an intangible asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Online Sales Segment&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the years ended December 31, 2023, and 2024,
the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of
the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 - $1,042).&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Year
    ended December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-143; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,405&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,287&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Company&#x2019;s share of losses
    of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(5,818&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,407&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,171&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,194&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;226&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,420&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,069&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,113&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;11,182&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,441&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,595&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c0" id="ixv-41722">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Group&#x2019;s CODM is the CEO
of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Drug
    &lt;br/&gt;
    Development&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Online
    &lt;br/&gt;
    Sales&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;External&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;Segment
    loss (gain)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,873&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,443&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,316&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Equity losses from the investment in MitoCareX&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;429&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(259&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Tax income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;Loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,472&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Drug
    &lt;br/&gt;
    Development&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Online
    &lt;br/&gt;
    Sales&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;External&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,879&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;Segment
    loss (gain)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,359&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,456&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,815&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Company&#x2019;s share of losses of company accounted for at
    equity, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Finance expense (income), net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,164&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Tax expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,883&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Year
    ended December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-size: 10pt"&gt;External&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-143; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,405&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,287&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Company&#x2019;s share of losses
    of company accounted for at equity, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Finance expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(5,818&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,592&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,407&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,764&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,171&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,194&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;226&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,420&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;As
    of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Drug&lt;br/&gt;
    Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Online&lt;br/&gt;
    Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Segment Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,069&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,113&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;11,182&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Segment
    Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,441&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,595&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <sprcy:ExternalRevenues
      contextRef="c297"
      decimals="-3"
      id="ixv-85852"
      unitRef="usd">1306000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c0" decimals="-3" id="ixv-85853" unitRef="usd">1306000</sprcy:ExternalRevenues>
    <ifrs-full:Revenue
      contextRef="c297"
      decimals="-3"
      id="ixv-85854"
      unitRef="usd">1306000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c0" decimals="-3" id="ixv-85855" unitRef="usd">1306000</ifrs-full:Revenue>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c296"
      decimals="-3"
      id="ixv-85856"
      unitRef="usd">4873000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c297"
      decimals="-3"
      id="ixv-85857"
      unitRef="usd">2443000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c0" decimals="-3" id="ixv-85858" unitRef="usd">7316000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:EquityLossesFromTheInvestment contextRef="c0" decimals="-3" id="ixv-85859" unitRef="usd">429000</sprcy:EquityLossesFromTheInvestment>
    <ifrs-full:InterestRevenueExpense contextRef="c0" decimals="-3" id="ixv-85860" unitRef="usd">-259000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="-3" id="ixv-85861" unitRef="usd">-14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="-3" id="ixv-85862" unitRef="usd">-7472000</ifrs-full:ProfitLoss>
    <sprcy:ExternalRevenues
      contextRef="c299"
      decimals="-3"
      id="ixv-85863"
      unitRef="usd">2879000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c4" decimals="-3" id="ixv-85864" unitRef="usd">2879000</sprcy:ExternalRevenues>
    <ifrs-full:Revenue
      contextRef="c299"
      decimals="-3"
      id="ixv-85865"
      unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c4" decimals="-3" id="ixv-85866" unitRef="usd">2879000</ifrs-full:Revenue>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c298"
      decimals="-3"
      id="ixv-85867"
      unitRef="usd">5359000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c299"
      decimals="-3"
      id="ixv-85868"
      unitRef="usd">1456000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c4" decimals="-3" id="ixv-85869" unitRef="usd">6815000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c4" decimals="-3" id="ixv-85870" unitRef="usd">210000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c4" decimals="-3" id="ixv-85871" unitRef="usd">-1164000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c4" decimals="-3" id="ixv-85872" unitRef="usd">22000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="-3" id="ixv-85873" unitRef="usd">-5883000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherIntangibleAssets contextRef="c2" decimals="-3" id="ixv-85874" unitRef="usd">1288000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets
      contextRef="c295"
      decimals="-3"
      id="ixv-85875"
      unitRef="usd">1344000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c3" decimals="-3" id="ixv-85876" unitRef="usd">1042000</ifrs-full:OtherIntangibleAssets>
    <sprcy:ExternalRevenues
      contextRef="c301"
      decimals="-3"
      id="ixv-85877"
      unitRef="usd">1347000</sprcy:ExternalRevenues>
    <sprcy:ExternalRevenues contextRef="c5" decimals="-3" id="ixv-85878" unitRef="usd">1347000</sprcy:ExternalRevenues>
    <ifrs-full:Revenue
      contextRef="c301"
      decimals="-3"
      id="ixv-85879"
      unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c5" decimals="-3" id="ixv-85880" unitRef="usd">1347000</ifrs-full:Revenue>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c300"
      decimals="-3"
      id="ixv-85881"
      unitRef="usd">8405000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome
      contextRef="c301"
      decimals="-3"
      id="ixv-85882"
      unitRef="usd">-118000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome contextRef="c5" decimals="-3" id="ixv-85883" unitRef="usd">8287000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncome>
    <sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet contextRef="c5" decimals="-3" id="ixv-85884" unitRef="usd">109000</sprcy:CompanysShareOfLossesOfCompanyAccountedForAtEquityNet>
    <ifrs-full:InterestRevenueExpense contextRef="c5" decimals="-3" id="ixv-85885" unitRef="usd">-5818000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="-3" id="ixv-85886" unitRef="usd">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="-3" id="ixv-85887" unitRef="usd">-2592000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherAssets
      contextRef="c302"
      decimals="-3"
      id="ixv-85888"
      unitRef="usd">8407000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c303"
      decimals="-3"
      id="ixv-85889"
      unitRef="usd">1764000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c2" decimals="-3" id="ixv-85890" unitRef="usd">10171000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c302"
      decimals="-3"
      id="ixv-85891"
      unitRef="usd">1194000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c303"
      decimals="-3"
      id="ixv-85892"
      unitRef="usd">226000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c2" decimals="-3" id="ixv-85893" unitRef="usd">1420000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherAssets
      contextRef="c304"
      decimals="-3"
      id="ixv-85894"
      unitRef="usd">7069000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c305"
      decimals="-3"
      id="ixv-85895"
      unitRef="usd">4113000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c3" decimals="-3" id="ixv-85896" unitRef="usd">11182000</ifrs-full:OtherAssets>
    <ifrs-full:OtherLiabilities
      contextRef="c304"
      decimals="-3"
      id="ixv-85897"
      unitRef="usd">1441000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="c305"
      decimals="-3"
      id="ixv-85898"
      unitRef="usd">154000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c3" decimals="-3" id="ixv-85899" unitRef="usd">1595000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0" id="ixv-42667">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;24:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TRANSACTIONS
    AND BALANCES WITH RELATED PARTIES&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,
    2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,
    2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Key&lt;br/&gt;
    management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Other&lt;br/&gt;
    related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Key&lt;br/&gt;
    management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Other&lt;br/&gt;
    related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current
    assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current
    assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,224&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current
    assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;108&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current
    liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;55&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;245&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;95&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research
    and development expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;63&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale
    of minority interest in subsidiary&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term
    benefits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;765&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Management
    fees (see also note 25a)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;120&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost
    of share-based payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;779&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 23, 2023, the Company entered into an agreement with Jeffs&#x2019; Brands and Jeffs&#x2019; Brands Holdings Inc. (&#x201c;NewCo Inc.&#x201d;), a newly-formed wholly owned subsidiary of Jeffs&#x2019; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#x2019;s wholly owned subsidiary, SciSparc US which owns Wellution, for $2,500 in cash, and additional deferred cash payments of approximately $489 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#x201c;Price Adjustment&#x201d;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#x201c;Holdback Shares&#x201d;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#x2019; Brands, the Company holds approximately 51% of the share capital of SciSparc US.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the agreement, at the closing of the transaction, Jeffs&#x2019; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#x2019; Brands provides management services to SciSparc US for the Wellution brand for a monthly fee of $20 and Jeffs&#x2019; Brands received a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31, 2024, the Company has recorded management services expenses in the amount of $120 (for the year ended December 31, 2023 - $220).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, in connection with the closing of the transaction, the Company and Jeffs&#x2019; Brands, engaged in a mutual share exchange in the amount of $288 of ordinary shares from each of the Company and Jeffs&#x2019; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#x2019;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#x2019; Brands and Jeffs&#x2019; Brands acquired 660 ordinary shares of the Company having an aggregate value of $288 which was adjusted from $300 according to the 4.99% ownership limit included in the definitive agreements. As of December 31, 2024, the listed share price of Jeff&#x2019;s Brands on Nasdaq was $ 2.57, and the Company has recorded a loss in its statements of comprehensive loss of $17 on its investment (for the year ended December 31, 2023 -$180).&lt;br/&gt; &lt;br/&gt; Mr. Oz Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#x2019;&#160;Brands.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company&#x2019;s Chief Technologies Officer, Mr. Weiss, the Company&#x2019;s President, and Mr. Adler, the Company&#x2019;s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#x201c;Cooperation Agreement&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2024 and 2023, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $63 and $40, respectively.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 17, 2022, the Company invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also Note 8).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr.
    Amitai Weiss, the Company&#x2019;s chairman of the Board, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;On August 13, 2024, the Company entered into the license agreement (the &#x201c;License Agreement&#x201d;) of the out-licensing of its SCI-160 program (the &#x201c;Assets&#x201d;), with Polyrizon Ltd. (the &#x201c;Licensee&#x201d; or &#x201c;Polyrizon&#x201d;). According to the License Agreement, the Company granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the &#x201c;License&#x201d;). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $805, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones relating to the Assets. &lt;br/&gt; &lt;br/&gt; Pursuant to the terms of the License Agreement, the Company is entitled to up to $3,320 based on the achievement of certain milestones, including (i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction. Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of 5%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country. &lt;br/&gt; &lt;br/&gt; On October 31, 2024, following an initial public offering of the Licensee, the Company received 684,931 units, of which (i) 320,000 units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (960,000 warrants in total); and (ii) 364,931 units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (1,094,793 warrants in total). Altogether, the Company received 320,000 ordinary shares, 364,931 pre-funded warrants to purchase one ordinary share of the Licensee, and 2,054,793 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. &#160; &lt;br/&gt; &lt;br/&gt; On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of 1,541,096 Licensee common warrants to third parties, for aggregate consideration of $771. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. &#160; &lt;br/&gt; &lt;br/&gt; As of December 31, 2024, the Company holds 513,698 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. The warrants expire on October 31, 2029. The value of the warrants on December 31, 2024, is $517.&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mr. Oz Adler, the Company&#x2019;s Chief Executive Officer, is a director
of the Licensee.&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;General Overview of Valuation Approaches
used in the Valuation:&lt;/i&gt; &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;i&gt;Economic methodology:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The warrants&#x2019; fair value was
calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,
    &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;October&#160;31,
    &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2.17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Underlying Share Price of Polyrizon Ltd. ($)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price ($)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;517&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,399&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 10, 2024, the Company entered into an Agreement and plan of merger, as amended (the &#x201c;Merger Agreement&#x201d;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#x2019;s shareholders and AutoMax&#x2019;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 14, 2024, SciSparc and AutoMax entered into the Merger Agreement addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024. On November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement second addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025. On March 27, 2025, SciSparc and AutoMax entered into the Merger Agreement third addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the effective time of the Merger (the &#x201c;Effective Time&#x201d;, as further defined in the Merger Agreement): (a)&#160;each outstanding share of AutoMax&#x2019;s share capital will be converted into the right to receive ordinary shares of the Company, equal to the exchange ratio set forth in the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;). Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders immediately before the Merger (other than the Company) are expected to hold together approximately 49.99% (minus the Finder Fee, as defined in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of the Company on a fully diluted basis (subject to certain exceptions). The shareholders of the Company, together with the holders of the Company&#x2019;s convertible securities, immediately before the Merger are expected to hold together approximately 50.01% of the aggregate number of the outstanding ordinary shares of the Company on fully diluted basis (subject to certain exceptions); (b) subject to the consummation of the Merger (as defined in the Merger Agreement, the &#x201c;Closing&#x201d;), and immediately after the Effective Time, AutoMax shall have the right to (i) designate two members to the Board if the Board is comprised of five or six directors; or (ii) designate three members if the Board is comprised of seven directors. At least one such designee shall be an independent director, as defined under the Nasdaq Stock Market listing rules. (See also Note 26b).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <sprcy:RelatedPartyBalancetextBlock contextRef="c0" id="ixv-42683">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balances with related parties:&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,
    2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,
    2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Key&lt;br/&gt;
    management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Other&lt;br/&gt;
    related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Key&lt;br/&gt;
    management&lt;br/&gt; personnel&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Other&lt;br/&gt;
    related&lt;br/&gt; parties&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current
    assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current
    assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,224&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Non-current
    assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;108&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Current
    liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;55&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;245&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;95&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</sprcy:RelatedPartyBalancetextBlock>
    <sprcy:CurrentAsset
      contextRef="c330"
      decimals="-3"
      id="ixv-85900"
      unitRef="usd">15000</sprcy:CurrentAsset>
    <sprcy:CurrentAsset
      contextRef="c332"
      decimals="-3"
      id="ixv-85901"
      unitRef="usd">121000</sprcy:CurrentAsset>
    <ifrs-full:CurrentAssets
      contextRef="c330"
      decimals="-3"
      id="ixv-85902"
      unitRef="usd">4224000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c332"
      decimals="-3"
      id="ixv-85903"
      unitRef="usd">108000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentLiabilities
      contextRef="c329"
      decimals="-3"
      id="ixv-85904"
      unitRef="usd">55000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c330"
      decimals="-3"
      id="ixv-85905"
      unitRef="usd">245000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="c331"
      decimals="-3"
      id="ixv-85906"
      unitRef="usd">95000</ifrs-full:CurrentLiabilities>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c0" id="ixv-42806">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions with related parties (not including amounts described in Note 24c):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research
    and development expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;63&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;40&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;208&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Sale
    of minority interest in subsidiary&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,985&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions contextRef="c0" decimals="-3" id="ixv-85907" unitRef="usd">63000</ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions>
    <ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions contextRef="c4" decimals="-3" id="ixv-85908" unitRef="usd">40000</ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions>
    <ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions contextRef="c5" decimals="-3" id="ixv-85909" unitRef="usd">208000</ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions>
    <sprcy:SaleOfMinorityInterestInSubsidiary contextRef="c4" decimals="-3" id="ixv-85910" unitRef="usd">2985000</sprcy:SaleOfMinorityInterestInSubsidiary>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-42864">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Benefits to key management personnel (including directors):&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    ended December&#160;31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Short-term
    benefits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;765&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,204&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;1,940&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Management
    fees (see also note 25a)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;120&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cost
    of share-based payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;779&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c0" decimals="-3" id="ixv-85911" unitRef="usd">765000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c4" decimals="-3" id="ixv-85912" unitRef="usd">1204000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c5" decimals="-3" id="ixv-85913" unitRef="usd">1940000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c0" decimals="-3" id="ixv-85914" unitRef="usd">120000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <sprcy:KeyManagementPersonnelCompensationManagementFees contextRef="c4" decimals="-3" id="ixv-85915" unitRef="usd">220000</sprcy:KeyManagementPersonnelCompensationManagementFees>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c0" decimals="-3" id="ixv-85916" unitRef="usd">157000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c4" decimals="-3" id="ixv-85917" unitRef="usd">84000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c5" decimals="-3" id="ixv-85918" unitRef="usd">779000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <sprcy:InterestPercentage
      contextRef="c306"
      decimals="2"
      id="ixv-85919"
      unitRef="pure">0.49</sprcy:InterestPercentage>
    <ifrs-full:Cash
      contextRef="c307"
      decimals="-3"
      id="ixv-85920"
      unitRef="usd">2500000</ifrs-full:Cash>
    <sprcy:DeferredCashPayment
      contextRef="c307"
      decimals="-3"
      id="ixv-85921"
      unitRef="usd">489000</sprcy:DeferredCashPayment>
    <sprcy:ShareCapitalPercentage
      contextRef="c308"
      decimals="2"
      id="ixv-85922"
      unitRef="pure">0.51</sprcy:ShareCapitalPercentage>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="c308"
      decimals="-3"
      id="ixv-85923"
      unitRef="usd">20000</ifrs-full:OtherFeeAndCommissionExpense>
    <sprcy:BonusAmountReceived
      contextRef="c308"
      decimals="-3"
      id="ixv-85924"
      unitRef="usd">51000</sprcy:BonusAmountReceived>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="c309"
      decimals="-3"
      id="ixv-85925"
      unitRef="usd">10000</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:ServicesExpense
      contextRef="c310"
      decimals="-3"
      id="ixv-85926"
      unitRef="usd">120000</ifrs-full:ServicesExpense>
    <ifrs-full:ServicesExpense
      contextRef="c311"
      decimals="-3"
      id="ixv-85927"
      unitRef="usd">220000</ifrs-full:ServicesExpense>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="c312"
      decimals="-3"
      id="ixv-85928"
      unitRef="usd">288000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <sprcy:AcquiredOrdinaryShares
      contextRef="c0"
      decimals="0"
      id="ixv-85929"
      unitRef="shares">35345</sprcy:AcquiredOrdinaryShares>
    <sprcy:AcquiredOrdinaryShares
      contextRef="c310"
      decimals="0"
      id="ixv-85930"
      unitRef="shares">660</sprcy:AcquiredOrdinaryShares>
    <sprcy:AggregateValues contextRef="c0" decimals="-3" id="ixv-85931" unitRef="usd">288000</sprcy:AggregateValues>
    <sprcy:AggregateValueAdjusted contextRef="c0" decimals="-3" id="ixv-85932" unitRef="usd">300000</sprcy:AggregateValueAdjusted>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c0" decimals="4" id="ixv-85933" unitRef="pure">0.0499</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sprcy:ListedSharePrice
      contextRef="c2"
      decimals="2"
      id="ixv-85934"
      unitRef="usdPershares">2.57</sprcy:ListedSharePrice>
    <sprcy:ComprehensiveLossOnInvestment
      contextRef="c312"
      decimals="-3"
      id="ixv-85935"
      unitRef="usd">17000</sprcy:ComprehensiveLossOnInvestment>
    <sprcy:ComprehensiveLossOnInvestment
      contextRef="c313"
      decimals="-3"
      id="ixv-85936"
      unitRef="usd">180000</sprcy:ComprehensiveLossOnInvestment>
    <sprcy:CooperationAgreementAmount contextRef="c0" decimals="-3" id="ixv-85937" unitRef="usd">63000</sprcy:CooperationAgreementAmount>
    <sprcy:CooperationAgreementAmount contextRef="c4" decimals="-3" id="ixv-85938" unitRef="usd">40000</sprcy:CooperationAgreementAmount>
    <ifrs-full:CurrentInvestments
      contextRef="c314"
      decimals="-5"
      id="ixv-85939"
      unitRef="usd">1500000</ifrs-full:CurrentInvestments>
    <sprcy:ExchangeOfCommonShares
      contextRef="c101"
      decimals="0"
      id="ixv-85940"
      unitRef="shares">7692</sprcy:ExchangeOfCommonShares>
    <sprcy:OutstandingShareCapital
      contextRef="c101"
      decimals="4"
      id="ixv-85941"
      unitRef="pure">0.0933</sprcy:OutstandingShareCapital>
    <sprcy:LicenseeIssuePrice
      contextRef="c315"
      decimals="-3"
      id="ixv-85942"
      unitRef="usd">805000</sprcy:LicenseeIssuePrice>
    <sprcy:MilestonesAmount
      contextRef="c315"
      decimals="-3"
      id="ixv-85943"
      unitRef="usd">3320000</sprcy:MilestonesAmount>
    <sprcy:LicenseAgreementDescription contextRef="c315" id="ixv-85944">(i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.</sprcy:LicenseAgreementDescription>
    <sprcy:PercentageOfAggregateNetSales
      contextRef="c315"
      decimals="2"
      id="ixv-85945"
      unitRef="pure">0.05</sprcy:PercentageOfAggregateNetSales>
    <sprcy:NumberOfUnitsReceived
      contextRef="c316"
      decimals="0"
      id="ixv-85946"
      unitRef="shares">684931</sprcy:NumberOfUnitsReceived>
    <sprcy:NumberOfUnitsReceived
      contextRef="c317"
      decimals="0"
      id="ixv-85947"
      unitRef="shares">320000</sprcy:NumberOfUnitsReceived>
    <sprcy:PurchasePricePerShare
      contextRef="c318"
      decimals="2"
      id="ixv-85948"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c319"
      decimals="0"
      id="ixv-85949"
      unitRef="shares">960000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:NumberOfUnitsReceived
      contextRef="c320"
      decimals="0"
      id="ixv-85950"
      unitRef="shares">364931</sprcy:NumberOfUnitsReceived>
    <sprcy:PurchasePricePerShare
      contextRef="c321"
      decimals="2"
      id="ixv-85951"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c321"
      decimals="0"
      id="ixv-85952"
      unitRef="shares">1094793</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c318"
      decimals="0"
      id="ixv-85953"
      unitRef="shares">320000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c322"
      decimals="0"
      id="ixv-85954"
      unitRef="shares">364931</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c323"
      decimals="0"
      id="ixv-85955"
      unitRef="shares">2054793</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <sprcy:PurchasePricePerShare
      contextRef="c323"
      decimals="2"
      id="ixv-85956"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c324"
      decimals="0"
      id="ixv-85957"
      unitRef="shares">1541096</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c325"
      decimals="-3"
      id="ixv-85958"
      unitRef="usd">771000</ifrs-full:ConsiderationPaidReceived>
    <sprcy:NumberOfWarrantsHolds
      contextRef="c326"
      decimals="0"
      id="ixv-85959"
      unitRef="shares">513698</sprcy:NumberOfWarrantsHolds>
    <sprcy:PurchasePricePerShare
      contextRef="c326"
      decimals="2"
      id="ixv-85960"
      unitRef="usdPershares">4.38</sprcy:PurchasePricePerShare>
    <sprcy:WarrantsExpireDate contextRef="c326" id="ixv-85961">2029-10-31</sprcy:WarrantsExpireDate>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c327"
      decimals="-3"
      id="ixv-85962"
      unitRef="usd">517000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c0" id="ixv-43097">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The warrants&#x2019; fair value was
calculated using the Black&#x2013;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December&#160;31,
    &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;October&#160;31,
    &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2.17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Underlying Share Price of Polyrizon Ltd. ($)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price ($)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants fair value ($)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;517&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,399&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c326"
      decimals="2"
      id="ixv-85963"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c323"
      decimals="2"
      id="ixv-85964"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c326"
      decimals="2"
      id="ixv-85965"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c323"
      decimals="2"
      id="ixv-85966"
      unitRef="pure">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c326"
      decimals="4"
      id="ixv-85967"
      unitRef="pure">0.0217</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c323"
      decimals="4"
      id="ixv-85968"
      unitRef="pure">0.0415</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c326"
      decimals="2"
      id="ixv-85969"
      unitRef="usdPershares">0.36</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c323"
      decimals="2"
      id="ixv-85970"
      unitRef="usdPershares">4.38</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c326"
      decimals="2"
      id="ixv-85971"
      unitRef="usdPershares">4.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c323"
      decimals="2"
      id="ixv-85972"
      unitRef="usdPershares">4.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c327"
      decimals="-3"
      id="ixv-85973"
      unitRef="usd">517000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c333"
      decimals="-3"
      id="ixv-85974"
      unitRef="usd">1399000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage
      contextRef="c328"
      decimals="4"
      id="ixv-85975"
      unitRef="pure">0.4999</sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage>
    <sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage contextRef="c0" decimals="4" id="ixv-85976" unitRef="pure">0.5001</sprcy:AggregateNumberOfOutstandingOrdinarySharesPercentage>
    <sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock contextRef="c0" id="ixv-43209">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
    25:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT
    EVENTS DURING THE REPORTING PERIOD&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2024, the Company announced that it signed a non-binding letter of intent with Miza III Ventures Inc. (&#x201c;Miza&#x201d;), a publicly traded company on the Toronto Stock Exchange Venture in Canada, which references a proposed asset and share purchase agreement, to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals. (collectively, the &#x201c;Target Assets&#x201d;)&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The agreement is based on the approximate total $3,300 (CAD 4.5 million) enterprise value of Miza, when including its $1,000 cash position, and an approximate $11,600 (CAD 15.8 million) value of the Company&#x2019;s assets.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the LOI, the Company will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, the Company would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 28, 2025, the Company entered into a second amendment (the &#x201c;Miza Amendment&#x201d;) to the non-binding letter of intent, as amended by the first amendment on December 16, 2024, with Miza. According to the Miza Amendment, the deadline to enter into definitive agreements was extended from March 31, 2025 to June 30, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock>
    <sprcy:EnterpriseValue contextRef="c0" decimals="-3" id="ixv-85977" unitRef="usd">3300000</sprcy:EnterpriseValue>
    <sprcy:EnterpriseValue contextRef="c0" decimals="-5" id="ixv-85978" unitRef="cad">4500000</sprcy:EnterpriseValue>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c2" decimals="-3" id="ixv-85979" unitRef="usd">1000000</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:OtherAssets
      contextRef="c334"
      decimals="-3"
      id="ixv-85980"
      unitRef="usd">11600000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="c334"
      decimals="-5"
      id="ixv-85981"
      unitRef="cad">15800000</ifrs-full:OtherAssets>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c335"
      decimals="-3"
      id="ixv-85982"
      unitRef="usd">63300000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="c336"
      decimals="-3"
      id="ixv-85983"
      unitRef="usd">48000000000</ifrs-full:ConsiderationPaidReceived>
    <sprcy:ShareCapitalPercentage
      contextRef="c336"
      decimals="2"
      id="ixv-85984"
      unitRef="pure">0.75</sprcy:ShareCapitalPercentage>
    <sprcy:ShareCapitalPercentage
      contextRef="c335"
      decimals="4"
      id="ixv-85985"
      unitRef="pure">0.8453</sprcy:ShareCapitalPercentage>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-43258">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;26:-&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;EVENTS
    AFTER THE REPORTING DATE&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 18, 2025, the Company announced that it has reached a settlement agreement (the &#x201c;Settlement&#x201d;) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against six of the Company&#x2019;s former directors (the &#x201c;Defendants&#x201d;) case number 34426-02-22 (the &#x201c;Suit&#x201d;). The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior acquisition of a pain clinic network through a subsidiary of the Company (See Note 17a).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of the Settlement, which was facilitated through mediation and approved by the court, SciSparc will be entitled to a $411 cash payment from the Defendants, in exchange for the full dismissal by SciSparc of the alleged claims brought against the Defendants in the Suit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Settlement also includes the termination, effective as of February 5, 2024 of a disputed licensing agreement with Dekel, entered into on May 21, 2015 and amended from time to time (the &#x201c;License Agreement&#x201d;). As part of the Settlement, Dekel clarified, to SciSparc&#x2019;s full satisfaction, that SciSparc will retain its exclusive global rights to its extensive intellectual property portfolio, patents, know-how and technologies and is released from all alleged commitments, claims and royalties related or arising out of the License Agreement, including those related to claimed core technologies, ensuring a continued focus on SciSparc&#x2019;s core development programs. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related whatsoever to the Company&#x2019;s pipeline and development program.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 24, 2025, the Company announced that it has entered into a loan agreement with AutoMax to provide a $2,000 loan (the &#x201c;New Loan&#x201d;). The funding will support AutoMax&#x2019;s business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4,250 (the &#x201c;Previous Loans&#x201d;). The Previous Loans were provided in lieu of SciSparc&#x2019;s obligation to provide a $4,250 closing financing, in accordance with the merger agreement signed between the parties. On March 27, 2025, SciSparc and AutoMax entered into a third addendum to the Merger Agreement, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The loan, bearing an 8% annual interest rate, will be repaid in equal monthly installments of $50 and interest, commencing on March 24, 2025,with AutoMax retaining the option for early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the merger agreement, and thereafter AutoMax shall continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax has pledged a first-ranking fixed charge on its subsidiary&#x2019;s shares.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 25, 2025, the Company entered into securities purchase agreements (the &#x201c;Securities Purchase Agreements&#x201d;) with certain investors, pursuant to which the Company agreed to sell and issue to the investors convertible debentures (the &#x201c;Debentures&#x201d;) in the aggregate principal amount of $4,200 (the &#x201c;Subscription Amount&#x201d;), which are convertible into the Company&#x2019;s ordinary shares, no par value per share (the &#x201c;Ordinary Shares&#x201d; and, as converted, the &#x201c;Conversion Shares&#x201d;), at a purchase price equal to 95% of the Subscription Amount. The issuance and sale of the Debentures is subject to certain conditions and limitations.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Debentures, when issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding principal balance of the Debentures at an annual rate of 8%, which will increase to an annual rate of 18% upon an Event of Default (as defined in the Debentures) for so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at the lower of (i) 110% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii) 95% of the lowest daily volume weighted average price of the Ordinary Shares during the twenty (20) consecutive trading days immediately preceding the conversion date or other date of determination (the &#x201c;Market Price&#x201d;); provided that the Market Price may not be lower than the floor price, which will be equal to 20% of the volume weighted average price of the Ordinary Shares on the day prior to the closing.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the closing of the transaction, the Company issued to the investors 172,174 warrants which are exercisable into a number of Ordinary Shares equal to the Subscription Amount applicable to the investors divided by a price equal to 130% of the volume weighted average price of the Ordinary Shares immediately prior to the closing date, or $11.6172 per warrant. The warrants are exercisable for a term of five years from the issuance date.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;d.&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On April 1, 2025, we entered into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement of Polyrizon and invested $100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and Series A warrants to purchase ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant to which we exchanged existing ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;The Company entered into a global guaranty agreement (the &#x201c;Global Guaranty Agreement&#x201d;) with one of the investors (the &#x201c;Investor&#x201d;) through certain of the Company&#x2019;s subsidiaries, pursuant to which such subsidiaries will guaranty the Company&#x2019;s obligations under the Debenture with the Investor and other instruments, agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.&lt;br/&gt; &lt;br/&gt; The Company entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Investor, pursuant to which the Company subsidiaries, pursuant to which the Company has agreed to provide to the Investor registration rights under the Securities Act of 1933, as amended (the &#x201c;Act&#x201d;) and the rules and regulations promulgated thereunder, and applicable state securities laws.&lt;br/&gt; &lt;br/&gt; In connection with the transaction, on February 25, 2025, the Company entered into a Deed of Assignment (the &#x201c;Deed&#x201d;) with AutoMax, and three of the investors. Pursuant to the Deed, the Company assigned part of the Subscription Amount in the amount of $2,000 to AutoMax in lieu of making the payment under the Loan Agreement (the &#x201c;Loan Agreement&#x201d;) to which the Company entered into with AutoMax on February 24, 2025.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 25, 2025, the Company announced it has signed a definitive agreement to sell its entire ownership interest in MitoCareX to N2Off, Inc., a publicly-traded company in the United States (Nasdaq: NITO) (&#x201c;N2OFF&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which the Company and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX to N2OFF. As part of the agreement, the Company will sell 4,961 shares of MitoCareX to N2OFF for $700 and exchange its remaining shares for common stock in N2OFF. In total, the Company and the other sellers will receive N2OFF common stock equivalent to 40% of the company&#x2019;s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF&#x2019;s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF&#x2019;s control.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company and the other sellers will be entitled to receive additional N2OFF stock based on milestone achievements, representing up to 25% of N2OFF&#x2019;s fully diluted capital stock. As part of the financial terms, the Company, along with the other sellers, will collectively receive 30% of N2OFF&#x2019;s financing proceeds over five years, up to a maximum of $1,600. N2OFF has also committed to investing $1,000 in MitoCareX post-closing. Dr. Silberman will continue as CEO of N2OFF under a revised employment agreement, which includes a restricted stock grant of 5% of N2OFF&#x2019;s capital stock, vesting over three years. The agreement contains customary representations, warranties, and provisions for termination if the closing does not occur within 30 days.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Mr. Amitay Weiss, who serves as the chairman of the Board, also serves as the chairman of the board of directors of N2OFF. In addition, Ms. Liat Sidi, who also serves as a member of the Board, also serves as a member of the board of directors of N2OFF.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;- - - - - - - - - - - - - - - - - - - - - - -
- -&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:Cash
      contextRef="c337"
      decimals="-3"
      id="ixv-85986"
      unitRef="usd">411000</ifrs-full:Cash>
    <ifrs-full:LoansReceived
      contextRef="c338"
      decimals="-3"
      id="ixv-85987"
      unitRef="usd">2000000</ifrs-full:LoansReceived>
    <sprcy:AggregateLoanAmount
      contextRef="c339"
      decimals="-3"
      id="ixv-85988"
      unitRef="usd">4250000</sprcy:AggregateLoanAmount>
    <sprcy:AggregateLoanAmount
      contextRef="c340"
      decimals="-3"
      id="ixv-85989"
      unitRef="usd">4250000</sprcy:AggregateLoanAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c341"
      decimals="2"
      id="ixv-85990"
      unitRef="pure">0.08</ifrs-full:BorrowingsInterestRate>
    <sprcy:RepaidOfMonthlyInstallments
      contextRef="c342"
      decimals="-3"
      id="ixv-85991"
      unitRef="usd">50000</sprcy:RepaidOfMonthlyInstallments>
    <ifrs-full:NotionalAmount
      contextRef="c343"
      decimals="-3"
      id="ixv-85992"
      unitRef="usd">4200000</ifrs-full:NotionalAmount>
    <sprcy:PurchasePricePercentage
      contextRef="c344"
      decimals="2"
      id="ixv-85993"
      unitRef="pure">0.95</sprcy:PurchasePricePercentage>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c345"
      decimals="2"
      id="ixv-85994"
      unitRef="pure">0.08</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c346"
      decimals="2"
      id="ixv-85995"
      unitRef="pure">0.18</ifrs-full:BorrowingsInterestRate>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay
      contextRef="c344"
      decimals="2"
      id="ixv-85996"
      unitRef="pure">1.10</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays
      contextRef="c344"
      decimals="2"
      id="ixv-85997"
      unitRef="pure">0.95</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays>
    <sprcy:ConsecutiveTradingDays contextRef="c344" id="ixv-85998">P20D</sprcy:ConsecutiveTradingDays>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing
      contextRef="c344"
      decimals="2"
      id="ixv-85999"
      unitRef="pure">0.20</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing>
    <sprcy:NumberOfWarrantsIssued
      contextRef="c347"
      decimals="0"
      id="ixv-86000"
      unitRef="shares">172174</sprcy:NumberOfWarrantsIssued>
    <sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing
      contextRef="c348"
      decimals="2"
      id="ixv-86001"
      unitRef="pure">1.30</sprcy:VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing>
    <sprcy:VolumeWeightedAveragePricePerWarrant
      contextRef="c347"
      decimals="4"
      id="ixv-86002"
      unitRef="usdPershares">11.6172</sprcy:VolumeWeightedAveragePricePerWarrant>
    <sprcy:WarrantExercisableTerm contextRef="c344" id="ixv-86003">P5Y</sprcy:WarrantExercisableTerm>
    <ifrs-full:InvestmentIncome
      contextRef="c349"
      decimals="-3"
      id="ixv-86004"
      unitRef="usd">100000000</ifrs-full:InvestmentIncome>
    <sprcy:AggregateInvestment
      contextRef="c349"
      decimals="-6"
      id="ixv-86005"
      unitRef="usd">17000000</sprcy:AggregateInvestment>
    <ifrs-full:LoansReceived
      contextRef="c350"
      decimals="-3"
      id="ixv-86006"
      unitRef="usd">2000000</ifrs-full:LoansReceived>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c351"
      decimals="0"
      id="ixv-86007"
      unitRef="shares">4961</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c352"
      decimals="-3"
      id="ixv-86008"
      unitRef="shares">700000</ifrs-full:NumberOfSharesIssued>
    <sprcy:PercentageOfFullyDilutedCapitalStock
      contextRef="c344"
      decimals="2"
      id="ixv-86009"
      unitRef="pure">0.40</sprcy:PercentageOfFullyDilutedCapitalStock>
    <sprcy:PercentageOfFullyDilutedCapitalStock
      contextRef="c353"
      decimals="2"
      id="ixv-86010"
      unitRef="pure">0.25</sprcy:PercentageOfFullyDilutedCapitalStock>
    <sprcy:PercentageOfFinancingProceeds
      contextRef="c344"
      decimals="2"
      id="ixv-86011"
      unitRef="pure">0.30</sprcy:PercentageOfFinancingProceeds>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="c344"
      decimals="-3"
      id="ixv-86012"
      unitRef="usd">1600000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:InvestmentIncome
      contextRef="c354"
      decimals="-3"
      id="ixv-86013"
      unitRef="usd">1000000</ifrs-full:InvestmentIncome>
    <sprcy:RestrictedStockGrantPercentage
      contextRef="c343"
      decimals="2"
      id="ixv-86014"
      unitRef="pure">0.05</sprcy:RestrictedStockGrantPercentage>
    <sprcy:VestingPeriod contextRef="c344" id="ixv-86015">P3Y</sprcy:VestingPeriod>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">F-4/A</dei:DocumentType>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivablesDueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentWarrantLiability
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherIncome
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c13"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c15"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c16"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c19"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c22"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c16"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c17"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c19"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c20"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="c22"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c17"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c19"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c20"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c22"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="c30"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c32"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c33"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c34"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c35"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c36"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c32"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c33"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c34"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c36"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="c37"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c33"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c34"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c35"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c36"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c37"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c39"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c33"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c34"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c35"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c36"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c37"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c39"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c34"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c35"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c36"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c37"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c39"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c48"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c49"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c50"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c51"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c52"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c49"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c50"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c51"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c52"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c53"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:IssueOfShareCapitalNetOfIssueExpense
      contextRef="c55"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c50"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c51"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c52"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c53"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="c55"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="c5"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="c5"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForIncreaseInRelatedParties
      contextRef="c4"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:AdjustmentsForIncreaseInRelatedParties
      contextRef="c5"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c5"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:SalepurchaseOfPropertyAndEquipment
      contextRef="c4"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="c4"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="c5"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="c0"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries
      contextRef="c0"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromChangesInOwnershipInterestsInSubsidiaries
      contextRef="c5"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="c4"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:PaymentOfIssuanceExpensesRelatedToPreviousPeriod
      contextRef="c4"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:RightofuseAssetRecognizedWithCorrespondingLeaseLiability
      contextRef="c5"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c0"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="c5"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:LeaseholdImprovementsMainlyRate
      contextRef="c74"
      id="hidden-fact-91"
      unitRef="pure"
      xsi:nil="true"/>
    <sprcy:ReceivablesInRespectOfDownpaymentOnMerger
      contextRef="c3"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="c14"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c114"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c140"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c141"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherPayables
      contextRef="c2"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c2"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivablesDueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c2"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c158"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c159"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c158"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="c159"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialAssets
      contextRef="c160"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c160"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:WarrantsLiability
      contextRef="c161"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="c2"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c171"
      id="hidden-fact-110"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:ParValuePerShare
      contextRef="c172"
      id="hidden-fact-111"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-112"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c3"
      id="hidden-fact-114"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-115"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-116"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c206"
      decimals="0"
      id="hidden-fact-117"
      unitRef="pure">530000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c269"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c270"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c272"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c273"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c4"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:OtherFinanceIncomeCost
      contextRef="c5"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c278"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c279"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c280"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="c282"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c283"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c284"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c281"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="c293"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c0"
      id="hidden-fact-132"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare
      contextRef="c0"
      id="hidden-fact-133"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c4"
      id="hidden-fact-134"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare
      contextRef="c4"
      id="hidden-fact-135"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrs-full:DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares
      contextRef="c5"
      id="hidden-fact-136"
      unitRef="shares"
      xsi:nil="true"/>
    <sprcy:EffectOfPotentialDilutiveOrdinarySharesLossPerShare
      contextRef="c5"
      id="hidden-fact-137"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c296"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c296"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c298"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c298"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:ExternalRevenues
      contextRef="c300"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c300"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CurrentAsset
      contextRef="c329"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:CurrentAsset
      contextRef="c331"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c329"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c331"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="c332"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c329"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c330"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentAssets
      contextRef="c331"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="c332"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:SaleOfMinorityInterestInSubsidiary
      contextRef="c0"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:SaleOfMinorityInterestInSubsidiary
      contextRef="c5"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <sprcy:KeyManagementPersonnelCompensationManagementFees
      contextRef="c5"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-86174">0001611746</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-86175">true</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-109"
          xlink:label="hidden-fact-109"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than $1 thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-109"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SciSparc Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Raul Wallenberg Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Tower A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6971916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(+972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3) 717-5777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">850 Library Ave.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">738-6680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Puglisi & Associates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted deposit</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties', window );">Bridge loan to related parties</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments in company accounted for at equity</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">4,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">10,347<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other short-term liability</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share capital and premium</a></td>
<td class="nump">70,886<span></span>
</td>
<td class="nump">64,526<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve from share-based payment transactions</a></td>
<td class="nump">5,746<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrants</a></td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Foreign currency translation reserve</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Transactions with non-controlling interests</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(74,975)<span></span>
</td>
<td class="num">(68,691)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to equity holders of the company</a></td>
<td class="nump">8,154<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">8,939<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 10,347<span></span>
</td>
<td class="nump">$ 11,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(322)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="nump">3,844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">5,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="nump">7,316<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from the investment in MitoCareX</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">5,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Taxes on income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Total comprehensive loss</a></td>
<td class="nump">7,472<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Equity holders of the Company</a></td>
<td class="nump">6,284<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit loss</a></td>
<td class="nump">$ 7,472<span></span>
</td>
<td class="nump">$ 5,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per ordinary share attributable to equity holders of the Company (in Dollars per share)</a></td>
<td class="nump">$ 26.94<span></span>
</td>
<td class="nump">$ 303.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 311.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per ordinary share attributable to equity holders of the Company (in Dollars per share)</a></td>
<td class="nump">$ 26.94<span></span>
</td>
<td class="nump">$ 303.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 311.22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Share capital and premium</div></th>
<th class="th"><div>Reserve from share-based payment transactions</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Transactions with non-controlling interests</div></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling interests</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 58,541<span></span>
</td>
<td class="nump">$ 4,331<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (60,977)<span></span>
</td>
<td class="nump">$ 8,141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">58,592<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(63,569)<span></span>
</td>
<td class="nump">6,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Issuance of share capital in respect of investment in affiliate</a></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of share capital, net of issue expenses</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">64,526<span></span>
</td>
<td class="nump">5,282<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(68,691)<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">9,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,284)<span></span>
</td>
<td class="num">(6,284)<span></span>
</td>
<td class="num">(1,188)<span></span>
</td>
<td class="num">(7,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssueOfShareCapitalNetOfIssueExpense', window );">Issuance of share capital, net of issue expenses</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 70,886<span></span>
</td>
<td class="nump">$ 5,746<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (74,975)<span></span>
</td>
<td class="nump">$ 8,154<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 8,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssueOfShareCapitalNetOfIssueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of issue of share capital, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssueOfShareCapitalNetOfIssueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="num">$ (7,472)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to the profit or loss items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on impairment of intangible asset</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of share-based payment</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance income, net</a></td>
<td class="num">(897)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,585)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Group&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets', window );">Losses from remeasurement of investment in financial assets</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments to the profit or loss</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease (increase) in other accounts receivable</a></td>
<td class="num">(535)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase (decrease) in trade payables</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase (decrease) in other accounts payable</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdjustmentsForIncreaseInRelatedParties', window );">Increase in related parties</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">629<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Working capital</a></td>
<td class="nump">136<span></span>
</td>
<td class="num">(833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,104)<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents', window );">Withdrawal of (investment in) restricted bank deposits</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Withdrawal of (investment in) short-term bank deposits</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SalepurchaseOfPropertyAndEquipment', window );">Sale (purchase) of property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Investment in a company accounted for at equity</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties', window );">Bridge loan to related parties</a></td>
<td class="num">(4,078)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,861)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,625)<span></span>
</td>
<td class="num">(4,094)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issue of share capital (net of issuance expenses)</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants (a)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod', window );">Payment of issuance expenses related to previous period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid on lease liability</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,193<span></span>
</td>
<td class="nump">8,483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Decrease in cash</a></td>
<td class="num">(536)<span></span>
</td>
<td class="num">(1,498)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash at the beginning of the period</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash at the end of the period</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantNonCashTransactionsAbstract', window );"><strong>(a) Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Investment in financial asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansMadeToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForIncreaseInRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase in related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForIncreaseInRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses from remeasurement of investment in financial assets

  to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for group&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset recognized with corresponding lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SalepurchaseOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the sale of purchases property, plant and equipment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SalepurchaseOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantNonCashTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantNonCashTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">GENERAL</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    1:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) (&#8220;SciSparc&#8221; or the &#8220;Company&#8221; or the &#8220;Group&#8221;),
    a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc
    and its subsidiaries at the time were mainly engaged in developing several innovative immunotherapy products and SciSparc&#8217;s
    own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing
    on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in
    development programs based on &#916;9-tetrahydrocannabinol (&#8220;THC&#8221;) and/or non-psychoactive cannabidiol for the treatment
    of Tourette syndrome, Alzheimer&#8217;s disease and agitation, autism spectrum disorder and Status Epilepticus. The headquarters
    of the Company are located in Tel Aviv, Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">The Company&#8217;s
ordinary shares are listed on Nasdaq and are trading under the symbol &#8220;SPRC&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company
had three private subsidiaries, including an inactive company incorporated under the laws of Israel: Evero Health Ltd (&#8220;Evero&#8221;);
an inactive company incorporated under the laws of Israel: Brain Bright Ltd (&#8220;Brain Bright&#8221;); and a company incorporated
under the laws of the State of Delaware: Scisparc Nutraceuticals Inc. (together with Evero and Brain Bright, the &#8220;Subsidiaries&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) resolved that the final ratio for the Third Reverse Split (as defined below) will be 26:1,
which became effective on September 28, 2023.&#160;Consequently, all share numbers, share prices, and exercise prices have been retroactively
adjusted in these consolidated financial statements for all periods presented.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group incurred operating losses since its incorporation and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2024, the Group had an accumulated deficit of approximately $74,975 as a result of recurring operating losses.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
cash and cash equivalents totaled $1,540. In the period ended December 31, 2024, the Company had an operating loss of $7,316 and negative
cash flows from operating activities of $5,104. The Company&#8217;s current cash and cash equivalents position is not sufficient to fund
the Company&#8217;s planned operations for at least a year beyond the date of the filing date of the financial statements. The ability
to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its
liabilities arising from normal business operations when they become due. While the Company has successfully raised funds in the past,
there is no guarantee that it will be able to do so in the future. The inability to borrow or raise sufficient funds on commercially
reasonable terms, would have serious consequences on our financial condition and results of operations. In addition, the Group has started
recognizing revenues from sales. However, its pharmaceutical operations are dependent on its ability to raise additional funds from existing
and/or new investors. This dependency will continue until the Group is able to completely finance its operations by generating revenue
from its products. These above-mentioned factors raise substantial doubt about the Group&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities
and commitments in the normal course of business. Such financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty
related to the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions
    and Meanings:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. (formerly known as Therapix Biosciences Ltd.) </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Group</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
    Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
    that are controlled by the Company, as defined in IFRS 10, &#8220;<i>Consolidated Financial Statements</i>&#8221;, and whose accounts
    are consolidated with those of the Company (if active).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    entity over which the Company has significant influence, as defined in IAS 28, &#8220;<i>Investment in Associates and Joint Ventures</i>&#8221;
    and is not a Subsidiary.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Parties</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    defined in IAS 24, &#8220;<i>Related Party Disclosures</i>&#8221;. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
    Accounting Standards issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
    Financial Reporting Standards issued by the IASB.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 72px"></td><td style="width: 48px; text-align: left">d.</td><td style="text-align: justify">On July 3, 2025, the Company effected a twenty one-for-one
reverse share split of its ordinary shares. All share and per share information has been retroactively adjusted to reflect the reverse
share split for all periods presented.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    2:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING POLICIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following accounting policies
have been applied consistently in the financial statements for all periods presented, unless otherwise stated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    ventures:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    operations:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Mainly
    %</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">6-50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Computers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">33-50</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7-15</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">see below</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual cash flow terms of the financial asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    instruments are measured at amortized cost when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    instruments and other financial assets held for trading:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
    of financial assets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized
only when:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the
    financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred
    control of the asset; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation
    to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify">3.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment
                                            of financial assets:</p>
</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company evaluates at the end of
each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss.
The Company distinguishes between two types of loss allowances:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 168px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 48px">a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Debt
                                            instruments whose credit risk has not increased significantly since initial recognition,
                                            or whose credit risk is low - the loss allowance recognized in respect of this debt instrument
                                            is measured at an amount equal to the expected credit losses within 12 months from the reporting
                                            date (12-month ECLs); or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 168px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 48px">b)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Debt
                                            instruments whose credit risk has increased significantly since initial recognition, and
                                            whose credit risk is not low - the loss allowance recognized is measured at an amount equal
                                            to the expected credit losses over the instrument&#8217;s remaining term (lifetime ECLs).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has short-term financial
assets in respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to
the lifetime expected credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company considers a financial
asset in default when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial
asset to be in default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual
amounts in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities measured at amortized cost:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities measured at fair value through profit or loss:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
    of financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting
    financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound
    financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    of a unit of securities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    taxes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and
other service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    employee benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment
    benefits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company as a lessee:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    extension and termination options:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    modifications:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">The
Company&#8217;s Brand sells products directly to customers mainly through the Brand&#8217;s online Amazon stores.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract', window );"><strong>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory', window );">SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    3:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the process of applying the significant
accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in
the financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount
    rate for a lease liability:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When a company in the Group is unable
to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental
borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar
security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there
are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk,
the lease term and other economic variables deriving from the lease contract&#8217;s conditions and restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    control:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company assesses whether it controls
a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting
rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders&#8217;
meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
    the fair value of share-based payment transactions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The fair value of share-based payment
transactions is determined upon initial recognition by an acceptable options pricing model (&#8220;OPM&#8221;). The inputs to the model
include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest
and expected dividend yield.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
    and assumptions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of the financial statements
requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported
amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The key assumptions made in the financial
statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material
adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    claims:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In estimating the likelihood of outcome
of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on
its management&#8217;s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are
based, among others, on management&#8217;s familiarity of and proximity to the circumstances, and also on the legal counsels&#8217; best
professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the
outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of financial instruments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">When the fair values of financial
assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value
is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken
from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models
are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    of new standards in the period prior to their adoption:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18, &#8220;Presentation and Disclosure
in Financial Statements&#8221;:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In April 2024, the International Accounting
Standards Board (&#8220;the IASB&#8221;) issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS
18&#8221;) which replaces IAS 1, &#8220;Presentation of Financial Statements&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is aimed at improving comparability
and transparency of communication in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 retains certain existing requirements
of IAS 1 and introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals.
It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation
of financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 does not modify the recognition
and measurement provisions of items in the financial statements. However, since items within the statement of profit or loss must be
classified into one of five categories (operating, investing, financing, taxes on income and discontinued operations), it may change
the entity&#8217;s operating profit. Moreover, the publication of IFRS 18 resulted in consequential narrow scope amendments to other
accounting standards, including IAS 7, &#8220;Statement of Cash Flows&#8221; and IAS 34, &#8220;Interim Financial Reporting&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">IFRS 18 is effective for annual reporting
periods beginning on or after January 1, 2027, and is to be applied retrospectively. Early adoption is permitted commencing from January
1, 2025, subject to disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is evaluating the effects
of IFRS 18, including the effects of the consequential amendments to other accounting standards, on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant judgements and assumptions made in relation to interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    4:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,383</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,866</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in
    NIS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">210</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,540</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,076</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">INVENTORY</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    5:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORY</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Goods in transit</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">73</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">669</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">113</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">742</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER ACCOUNTS RECEIVABLE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    6:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
    ACCOUNTS RECEIVABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Government authorities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">78</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">62</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">449</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">350</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables in respect of downpayment on merger</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">187</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Related party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,079</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">540</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Investment in Associates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">Investment in Associates and Joint Ventures</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    7:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT
    IN ASSOCIATES AND JOINT VENTURES </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MitoCareX
    - Joint Venture Transaction</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On March 10, 2022, the Company entered
into a Founders and Investment Agreement with Dr. Alon Silberman, or the MitoCareX Agreement. Pursuant to the MitoCareX Agreement, the
Company invested an initial amount of $700, and agreed to invest over the next two years, an additional $1,000, subject to the achievement
of certain pre-determined milestones as agreed upon in the MitoCareX Agreement, for up to a 50.01% ownership in MitoCareX Bio Ltd. (&#8220;MitoCareX&#8221;).
MitoCareX is focused on the discovery and development of potential drugs for cancers and other life-threatening conditions. The MitoCareX
Agreement also contains customary representations, warranties, covenants, and indemnification provisions. On March 31, 2022, the closing
conditions were met, and the Company paid the initial investment amount of $700 to MitoCareX. As of December 31, 2022, the Company owns
31.48% of the outstanding shares of MitocareX.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 17, 2023, MitoCareX achieved
its first milestone pursuant to the MitoCare X Agreement. As a result of MitoCareX meeting this milestone, the Company will invest an
additional $400 in MitoCareX and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 25, 2023, MitoCareX achieved
its second milestone pursuant to the MitoCareX Agreement. As a result of MitoCareX meeting this milestone, the Company invested an additional
sum of $600 in MitoCareX and increased its share ownership in MitoCareX from 41.92% to 52.73%. Notwithstanding the above, the Company
and MitoCareX agreed for the additional $600 installment to be deferred to March 25, 2024, and the $600 installment was paid on March
11, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 26, 2024, the Company
signed a non-binding letter of intent relating to the sale of its entire ownership interest in MitoCareX to N2OFF, Inc. (&#8220;N2OFF&#8221;)
a publicly-traded company in the United States which is a related party (the &#8220;Purchaser&#8221;). Pursuant to the terms of the letter
of intent, initially, in exchange for transferring and selling to the Purchaser a number of ordinary shares of MitoCareX that constitute
27% of SciSparc&#8217;s ownership in MitoCareX, SciSparc will receive cash consideration of $700. Subsequent to this first phase, SciSparc
will transfer to the Purchaser the remaining 73% of its ownership stake in MitoCareX in exchange for a certain number of shares based
on the valuation of the Purchaser equal to $8,000 and a valuation of MitoCareX equal to $5,000 (the latter of which includes the $700,
in cash consideration for SciSparc&#8217;s shares described above). The letter of intent also includes provisions for additional milestones
that, upon achievement, may increase the consideration paid by the Purchaser to SciSparc from $5,000 to $7,000. The details of the full
terms of this transaction are subject to negotiation and execution of definitive agreements.&#160;As of December 31, 2024, the Company
and the Purchaser have not closed the sale of the ownership of MitoCareX and the Company still holds 52.73% of the issued and outstanding
share capital of MitoCareX. See also Note 25(d).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">During the year ended December 31,
2024, the Company recorded equity losses from the investment in MitoCareX in the amount of $429 (for the year ended December 31, 2023
- $210).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%">Investment date March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(109</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment following achievement of first milestone</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(210</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment following achievement of second milestone</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(429</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">952</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Investment in Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory', window );">INVESTMENT IN FINANCIAL ASSETS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    8:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTMENT
    IN FINANCIAL ASSETS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Clearmind</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $1,500 in the initial public offering of Clearmind Medicine Inc. (&#8220;Clearmind&#8221;) and received 230,769 common shares of Clearmind, resulting in the Company holding 9.33% of share capital of Clearmind. Shares of Clearmind are listed for trading on Nasdaq Capital Market and the Canadian Securities Exchange under the symbol &#8220;CMND&#8221; and the Frankfurt Stock Exchange under the symbol &#8220;CWY.&#8221; On November 21, 2023, Clearmind conducted a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. As a result, the Company holdings in Clearmind decreased from 230,769 common shares to 7,692. As of December 31, 2024, the listed share price of Clearmind on Nasdaq was $1.38 and the Company has recorded a loss in its statements of comprehensive loss for the year ended December 31, 2024 of $11 on its investment (for the year ended December 31, 2023 - $727). &#160;</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the investment financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    9:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 1, 2024, the Company entered
into a two-year lease agreement with for a total area of approximately 240 square meters, whereby the Company occupies approximately
120 square meters for the Company&#8217;s offices, in the district of Tel Aviv, Israel. The Company has an option to extend for an additional
three-year term. The monthly lease fee was set at approximately $3, linked to the NIS.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    10:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY
    AND EQUIPMENT, NET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Computers</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Office<br/>
    furniture<br/> and<br/> equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Right
    of use asses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif">Cost:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Balance at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">181</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Disposals</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">99</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Accumulated depreciation:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January&#160;1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Disposals</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(106</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(111</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Depreciated cost at December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">47</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">59</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Accumulated depreciation:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January&#160;1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">65</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Depreciated cost at December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses for the years
ended December 31, 2024, 2023 and 2022 amounted to $37, $52 and $43, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSET</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    11:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE
    ASSET</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On September 30, 2022, the Company
announced the closing of the acquisition of Wellution<sup>TM</sup>, a top seller Amazon.com Marketplace account (the &#8220;Brand&#8221;),
American food supplements and cosmetics brand and trademark (the &#8220;Acquisition&#8221;). In connection with the Acquisition, the
Company incorporated a new wholly owned Delaware subsidiary, SciSparc Nutraceuticals Inc., to hold the new assets. The definitive agreement
for the acquisition of the Brand was entered into with Merhavit M.R.M Holding and Management Ltd (&#8220;M.R.M&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At the closing, the Company paid a
base cash payment of $4,540 and in 12 months following the closing agreed to pay an additional deferred cash payment equal to a multiple
of 3 times the amount by which the Brand&#8217;s EBITDA exceeds $1,120 during the 12-month period following the closing of the Acquisition.
The Company paid an additional $321 as purchase costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company reviewed the transaction
and deemed it to be the purchase of assets for accounting purposes under generally accepted accounting principles. The Company reviewed
the guidance under IFRS 3 for the transaction and determined that the fair value of the gross assets acquired was concentrated in a single
identifiable asset, a brand. Accordingly, the Company treated the transaction as an asset acquisition. On the closing date of the acquisition,
the Company fully recognized the acquisition amount total of $4,861 as an intangible asset, to be amortized over a period of 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In the years ended December 31, 2022,
2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline
in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023
- $1,042).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impairment loss was determined
based on the revenue projections of the Brand, using the relief from royalty approach. Under the relief from royalty approach, the fair
value of a brand is determined based on discounted future royalty payments that owner of the asset would have been required to pay if
instead of purchasing the intangible asset it would have been licensed from a third party. Revenues were projected for a period of 7.8
years (2023 &#8211; 8.7), commensurate with the remaining estimated useful life of the Brand and with no terminal value. The projections
were determined based on the current period revenues, assuming a growth rate for the short term that is consistent with management&#8217;s
expectations that revenues of the brand will resume their past extent, as of the date of purchase of the brand, a growth rate thereafter
of 27.8% (2023 &#8211; 13.8%) and a declining growth rate for the long term, reaching 2% (2023 &#8211; 2%) at the terminal year. Theoretical
royalties arising from the brand were capitalized at a discount rate of 21.9% (2023 &#8211; 20.6%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,717</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(486</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,189</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,344</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Depreciation of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(366</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,479</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended December 31,
2024, the Company recognized depreciation expenses in respect to intangible asset in the amount of $366 (for the year ended December
31, 2023 - $486).&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE PAYABLES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    12:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRADE
    PAYABLES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">608</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">538</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">208</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">264</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">816</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    13:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
    ACCOUNTS PAYABLE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees
    and payroll accruals</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other
    payables</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">205</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">185</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfOtherAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfOtherAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    14:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
    INSTRUMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    of financial assets and financial liabilities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">Financial assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash and restricted deposits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,560</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,141</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">449</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,239</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financial assets at amortized
    cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,248</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,344</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Investments in financial assets at
    fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">871</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">659</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Financial liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit from others</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financial and lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">123</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">315</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison
between the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2024, and 2023, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Investments in short-term financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">354</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">354</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">659</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#160;&#160;&#160;&#160;-&#8239;</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">659</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-&#8239;</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Management believes that the carrying
amount of cash, short-term deposits, trade receivables, trade payables, overdrafts and other current liabilities approximate their fair
value due to the short-term maturities of these instruments.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    risk factors:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s activities expose
it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company&#8217;s
comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company&#8217;s
financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Risk management is performed by management
in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities
as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of
surplus funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>Foreign currency risk:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is exposed to exchange
rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized
liabilities that are denominated in a foreign currency other than the functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
    risks:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">All cash and restricted deposits related
to the Company are held in two banks in Israel which are considered financially solid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
    risk:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company monitors the risk of a
shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2024, the Company expects
to settle all of its financial liabilities in less than one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The carrying amounts of cash and restricted
deposits, and all other financial assets and liabilities approximate their fair value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">EMPLOYEE BENEFIT LIABILITIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    15:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE
    BENEFIT LIABILITIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Employee benefits consist of short-term
benefits and post-employment benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Post-employment benefits:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">According to the labor laws and the
Israeli Severance Pay Law, 1963 (the &#8220;Severance Pay Law&#8221;), the Company is required to pay compensation to an employee upon
dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law,
as specified below. The Company&#8217;s liability is accounted for as a post-employment benefit. The computation of the Company&#8217;s
employee benefit liability is made in accordance with a valid employment contract based on the employee&#8217;s salary and employment
term which establish the entitlement to receive the compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The post-employment benefits are normally
financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><i>Defined contribution plans:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Section 14 of the Severance Pay Law
applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension
funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions
were made. These contributions and contributions for compensation represent defined contribution plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt">Expenses in respect of
    defined contribution plans</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">105</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">115</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXES ON INCOME</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    16:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAXES
    ON INCOME</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    rates applicable to the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Israeli statutory corporate tax
rate and real capital gains tax rate were 23% in 2024, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    assessments:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The assessments of the Company are
deemed final through the 2016 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward
    tax losses and other temporary differences:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has accumulated tax losses
since its inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">As of December 31, 2024, the Company&#8217;s
net carryforward tax losses are estimated to be approximately $62,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Contingent Liabilities, Commitments, Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    17:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINGENT
    LIABILITIES, COMMITMENTS, CLAIMS AND LIENS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement with Dekel Pharmaceuticals Ltd.:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In May 2015, the Company entered into
an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions
and methods for treating inflammatory disorders (the &#8220;Dekel License Agreement&#8221;). The Dekel License Agreement became effective
in August 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Pursuant to the Dekel License Agreement,
the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments
include: (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 14, 2019, an amendment to
the Dekel License Agreement was signed (the &#8220;Amendment&#8221;), which encompasses the Company and Dekel&#8217;s original intention
to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which
are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field
of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect
the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Amendment also prescribes for
a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined
under the Dekel License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment
also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company&#8217;s former Executive
Chairman of the Board and former interim Chief Executive Officer, towards the Company&#8217;s field of activity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On November 13, 2019, an additional
milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical
trial. The Company paid the milestone amount on April 13, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 5, 2024, SciSparc received
written notice from Dekel for the termination of the Dekel License Agreement, effective immediately, based on SciSparc allegedly breaching
its material contractual obligations by allegedly failing to provide Dekel with certain reports regarding the licensed products under
the Dekel License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 16, 2025, the Dekel License
Agreement was terminated, as part of a settlement of a lawsuit filed against SciSparc&#8217;s former directors, effective as of February
5, 2024. In accordance with the settlement, SciSparc retained its exclusive global rights to its intellectual property portfolio, patents,
know-how and technologies and was released from all alleged commitments, claims and royalties related or arising out of the Dekel License
Agreement, including those related to claimed core technologies, and Dekel assumed full and exclusive ownership of the patent application
for compositions and methods for treating inflammatory disorders and all such underlying intellectual property.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (&#8220;Yissum&#8221;):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On July 29, 2018, the Company entered
into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed
technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field
and the territory only, as determined in the agreement (the &#8220;Yissum License Agreement&#8221;). According to the Yissum License
Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in
the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All rights, title
and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights
granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum,
including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such
invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate,
and Yissum&#8217;s share in such joint patents shall be automatically included in the Yissum License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    with Hannover Medical School:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On April 11, 2017, the Company entered
into an investigator-initiated study contract with Hannover Medical School (&#8220;MHH&#8221;) to conduct during 2018 a phase IIb clinical
trial titled &#8220;A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice
Daily Oral SCI-110 in Treating Adults with Tourette Syndrome&#8221; in treating approximately 20 Tourette syndrome subjects aged 18 to
65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount
of approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated
to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed
about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of
the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under
a new agreement or will be paid back to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 13, 2018, the Company entered
into an agreement with MHH to conduct a clinical study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating
adults with Tourette syndrome, which agreement was subsequently updated on December 2, 2021, in an estimated amount of $1,385.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreement with Yale University:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an agreement with Yale University to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled, cross over study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in treating approximately 10 Tourette syndrome subjects aged 18 to 65. The total estimated amount of the agreement is approximately $370.</p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2, 2023, Capital Point Ltd. (&#8220;Capital Point&#8221;) filed with the Tel Aviv-Jaffa District Court (the &#8220;Court&#8221;) a suit against the Company, case number 2050-05-23 (the &#8220;Suit&#8221;). The Suit names the Company as the sole defendant and includes allegations of breaches of contract by the Company under the Israeli Contracts Law, 1973, unjust enrichment under the Israeli Unjust Enrichment Law, 1979 and breaches of the Company under the Israeli Torts Ordinance, 1968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Suit challenges a certain warrant issued by the Company to Capital Point (the &#8220;Capital Point Warrant&#8221;) to purchase $16 of ordinary shares of the Company (the &#8220;Warrant Shares&#8221;). The Capital Point Warrant was exercisable for 12 months from May 15, 2021, to May 15, 2022 and was issued in connection with the joint venture transaction, entered on May 15, 2020, by and between the Company, Capital Point and Evero Health Ltd., a majority owned subsidiary of the Company, as further described in the Company&#8217;s Report on Form 6-K, filed on May 19, 2020. The Suit claims that the Company unlawfully refused to accept the Capital Point Warrant exercise notice as of November 4, 2021 and accordingly the Company did not issue to Capital Point the Warrant Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Suit claims damages in the amount of NIS 10,000,000 (approximately $2.75 million), which accounts for, as of the date of the filing of the Suit, the agreed compensation according to Section 2(d)(i) of the Capital Point Warrant, an injunction order for the Company to issue the Warrant Shares to Capital Point, return of any unlawful profits received by the Company and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December 31, 2024, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero Health Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Approval Date, the Company cannot predict the likelihood of success of the Suit.</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">EQUITY</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    18:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December&#160;31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Issued and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Issued and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Ordinary shares</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">515,631</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,652</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Reverse Share Splits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 15, 2022, the Company
convened an annual general meeting of its shareholders, whereby the shareholders approved to increase the Company&#8217;s share capital
to 75,000,000 ordinary shares with <span style="-sec-ix-hidden: hidden-fact-110">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On August 18, 2023, the Company convened
a general meeting of its shareholders, whereby the shareholders approved, <i>inter alia</i>, a reverse split of the Company&#8217;s share
capital up to a ratio of 30:1 (the &#8220;Third Reverse Split&#8221;). Following the implementation of the Third Reverse Split, the Company&#8217;s
authorized share capital was adjusted under the Company&#8217;s Articles, which as of the date hereof consists of 75,000,000 ordinary
shares, <span style="-sec-ix-hidden: hidden-fact-111">no</span> par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On September 14, 2023, the Company&#8217;s
Board resolved that the final ratio for the Third Reverse Split will be 26:1, which became effective on September 28, 2023.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Consequently, all share numbers, share
prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in share capital:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> ordinary shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-sec-ix-redline:true;-keep: true">Balance at January 1, 2024</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,652</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">175,110</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,770</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">276,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">515,631</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
    attached to shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Voting rights at the shareholders
meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    management in the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s capital management
objectives are to preserve the Company&#8217;s ability to ensure business continuity thereby creating a return for the shareholders,
investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain
level of capital return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    issuances of ordinary shares:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 2, 2022, the Company
issued a consultant 44 ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 1, 2022, the Company
issued a consultant 68 ordinary shares in respect of services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 22, 2023, the Company
issued 660 ordinary shares in respect of the stock purchase<span style="text-transform: uppercase"><b>&#160;</b></span>agreement entered
into by and among Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo&#8221;) (see also Note 25a).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended December
31, 2024, the Company issued 30,770 ordinary shares to consultants in respect of services rendered in the amount of $105</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    2022 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 1, 2022, the Company completed
a private offering with an investor for gross proceeds of $10,210 (the &#8220;June 2022 Financing Round&#8221;), providing for the issuance
of an aggregate of 6,495 units and pre-funded units, as follows: (a) 614 units at a price of $1,542.48 per unit, each consisting of (i)
one ordinary share of the Company, and (ii) two warrants each to purchase one ordinary share (the &#8220;June 2022 Warrants&#8221;),
and (b) 5,881 pre-funded units at a price of $1,539.09 per unit, each consisting of (i) one pre-funded warrant to purchase one ordinary
share and (ii) two June 2022 Warrants.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The June 2022 Warrants have an
exercise price of&#160;$1,435.98&#160;per ordinary share. The June 2022 Warrants were exercisable upon issuance and will expire seven
years from the date of issuance.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.872</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    share price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">102.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,435.98</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,435.98</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    fair value ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">192</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less than $1 thousand</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended December
31, 2022, the Company issued 5,881 ordinary shares in respect of the exercise of 5,881 pre-funded warrants.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.25in; text-indent: 0in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 14, 2023, the Company
closed an underwritten public offering (the &#8220;2023 Public Offering&#8221;) of 10,119 ordinary shares, at a purchase price of $109.20
per ordinary share and pre-funded warrants to purchase up to 1,786 ordinary shares at a purchase price of $108.654 per pre-funded warrant,
for aggregate gross proceeds of approximately $1,300, pursuant to an underwriting agreement between the Company and Aegis Capital Corp
(&#8220;Aegis&#8221;), the underwriter in the 2023 Public Offering, dated August 10, 2023. Pursuant to the terms of the underwriting
agreement, the Company also granted the underwriter a 45-day option to purchase up to an additional 1,786 ordinary shares solely to cover
over-allotments, if any, at the share price of the 2023 Public Offering less underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2023 Financing Round</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On October 13, 2023, the Company announced
the closing of a private placement with an institutional investor with gross cash proceeds to the Company of approximately $5,026, before
deducting fees to the placement agent and other offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In connection with the private
placement, the Company issued an aggregate of 91,910 units, each unit consisting of two pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;).
The Pre-Funded Warrants have an exercise price of $0.021, are immediately exercisable upon issuance and have a term of five years from
the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended December
31, 2024, the Company issued 175,110 ordinary shares in respect of the exercise of 175,110 Pre-Funded Warrants.</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2024 Standby Equity Purchase Agreement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 21, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;), as amended on February 26, 2024, with YA II PN, LTD (&#8220;YA&#8221;),
which provided for the sale of up to $20,000 of the Company&#8217;s ordinary shares (the &#8220;Advance Shares&#8221;). As of December
31, 2024, of the $20,000 eligible to be sold pursuant to the SEPA (the &#8220;Commitment Amount&#8221;), the Company has sold 273,466
ordinary shares for total proceeds of $6,255. The Advance Shares to be purchased or purchased by YA pursuant to the SEPA are for a share
price of 97% of the market price, which is defined as the lowest daily volume weighted average price of the Company&#8217;s ordinary
shares during the three consecutive trading days commencing on the trading day immediately following the delivery of an advance notice
to YA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In connection with the SEPA, the Company
may request pre-paid advances of the Commitment Amount, in an amount up to $5,000 (each a &#8220;Pre-Paid Advance&#8221;). Each Pre-Paid
Advance will be evidenced by a promissory note (each a &#8220;Promissory Note&#8221;). Each Promissory Note will fully mature 24 months
following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate of 5% per annum, increasing to
18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 150 days after the issuance of a Promissory Note,
the Company shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory Note and accrued
interest, payable in cash or by submitting an advance notice, where YA will offset the amount due to be paid to the Company under such
notice against an equal amount of the monthly installment amount, at the Company&#8217;s option. If the Company elects to pay in cash,
the installment amount shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The
Promissory Note contains the Company&#8217;s customary representations and warranties and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, pursuant to the SEPA,
the Company issued to YA an aggregate of 2,633 of its Ordinary Shares, or the Commitment Shares, in satisfaction of payment of the commitment
fee of $200.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">YA will pay all brokerage fees and
commissions and similar expenses in connection with the offer and sale of Ordinary Shares by YA pursuant to the SEPA. The Company will
pay the expenses (except brokerage fees and commissions and similar expenses) incurred and register pursuant to the Securities Act of
1933, as amended, the offer and sale of the Ordinary Shares pursuant to the SEPA by YA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    19:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED
    PAYMENT TRANSACTIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    cost of share-based payment recognized in the financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">524</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">569</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">897</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2005 and 2015 ESOP and 2023 Plan of the Company:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On December 28, 2023, the Board adopted
an additional new plan, the 2023 Share Incentive Plan (the &#8220;2023 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="background-color: white">The
Company no longer grants any awards under the 2015 ESOP as it was superseded by the 2023 Plan, although previously granted awards under
the 2015 ESOP remain outstanding and subject to the 2015 ESOP. </span>Under the 2023 Plan, the Company may grant its employees and other
service providers equity-based incentive awards (&#8220;Share Options&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On December 28, 2023, the Board
approved to reserve for <span style="background-color: white">issuance under the 2023 Plan 47,619 Ordinary Shares. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 3, 2022 (the &#8220;2022 Grant Date&#8221;), the Board approved the grant of 326 Share Options under the 2015 ESOP to directors, officers, employees and consultants, some of which required the approval of the general meeting of the Company&#8217;s shareholders (the &#8220;2022 General Meeting&#8221;), which occurred on February 10, 2022. The date of commencement for all Share Options granted, the date on which the vesting started, was the 2022 Grant Date. The exercise price was set at $3,549 per Share Option.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February&#160;10,<br/>
    2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
    3,<br/>
    2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    ordinary share price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,724.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,674.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life of Share Options (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair value of the Share Options
granted on January 3, 2022, was set at $3,325.14 per Share Option, and the fair value of the Share Options granted on February 10, 2022,
was set at $2,407.86 per Share Option. The Share Option vesting period was set to commence retroactively from April 21, 2021, and end
at April 21, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">During the year ended December 31,
2024, share-based compensation in respect of Share Options of $7 was charged to the consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended December 31, 2024, the Company issued consultants 30,770 ordinary shares in respect of services rendered. The shares were granted at a discount rate of 25% to the share price quoted on the date of each grant. The total fair value of the ordinary shares granted to consultants was $105.</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement
    during the year:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> Share<br/> Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> average<br/> exercise<br/>
    price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2024:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding
    at the beginning of the year</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">334</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,491.88</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">324</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,354.83</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options exercisable at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">324</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,354.83</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2023:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding at the beginning of the year</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">336</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,488.94</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options cancelled during the year</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,035.55</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">334</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,491.88</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options exercisable at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">279</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,477.18</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of the Share Options outstanding was 2.99 years and 4.03 years as of December 31, 2024, and 2023, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 120px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The range of exercise prices of Share Options outstanding at the end of the year was $3,549 - $444,759 (inclusive) as of December 31, 2024, and 2023, respectively.</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted
                                            Share Units:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 1.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 0.5in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 20, 2024, the Company granted 25,238 Restricted Share Units (&#8220;RSUs&#8221;) to directors and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s discretion and taking into account personal tax implications and convert into 25,238 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on June 20, 2024, which was $18.753.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 1.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 0.5in; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2024, the Company granted <span style="-sec-ix-hidden: hidden-fact-117">25,238</span> RSUs to directors and officers, pursuant to the Company&#8217;s RSU Plan. The RSUs will vest at each recipient&#8217;s discretion and taking into account personal tax implications and convert into 25,238 ordinary shares of the Company. The RSUs vest on a quarterly basis over a period of two years, commencing on June 20, 2024. The fair value of the RSUs was established using the quoted share price of the Company on August 8, 2024, which was $6.636.</span></td></tr> </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Balance, January 1, 2024</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">RSUs granted</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,476</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Expiry of RSUs</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercise of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Balance, December 31, 2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,476</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Total exercisable RSUs as of December
31, 2024, are 12,619. During the year ended December 31, 2024, share-based compensation in respect of RSUs of $456 was charged to the
Consolidated Statements of Comprehensive Loss.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">REVENUES AND COST OF REVENUES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;20:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVENUES
    AND COST OF REVENUES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s Brand sells products
directly to customers mainly through the Brand&#8217;s online Amazon stores.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the Company&#8217;s standard
contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return, the Company recognizes revenue
based on the amount of the consideration which the Company expects to receive for products which it is highly probable that a significant
revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration received or receivable if it
expects to refund some or all of the consideration to the customer. At the end of each reporting period, the Company updates its estimates
of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues. As of December 31, 2024,
the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against other payables. A right
of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the goods from the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In certain contracts, the Company
evaluates the nature of its promise to the customer and determines whether it is a principal or agent for each contract. In determining
the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize revenues on a gross or net basis
based upon its evaluation of whether the Company obtains control of the specified goods by considering if it is primarily responsible
for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting suppliers, among other
factors. Based on its evaluation of these factors, management has determined that it is the principal in these arrangements; therefore,
sales are recorded on a gross basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Cost of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Purchased goods</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">798</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">301</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Freight</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">322</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalInformationAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory', window );">ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;21:-
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL
    INFORMATION TO THE ITEMS OF PROFIT OR LOSS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">a.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Research and development expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">390</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">392</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">436</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory, professional and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">681</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">719</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and preclinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Clinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">254</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">369</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">141</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">281</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,707</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,641</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,803</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">b.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Sales and marketing expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Advertising</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">367</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">576</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">363</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amazon fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">*</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">486</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Storage and shipping</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">*</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">120</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,515</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,484</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,082</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">c.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">General and administrative
    expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">415</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">437</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">68</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">633</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and directors&#8217; fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,594</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,468</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Business development expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">161</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">202</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">162</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office maintenance, rent and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">128</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">110</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">197</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">369</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,486</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,526</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,427</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">d.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Other expenses (income):</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from sale of property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on sale of patent license, net
    (net of Polyrizon Ltd. holdings sold) (See also Note 25b)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,270</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">e.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Finance income:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in fair value of financial liabilities designated
    at fair value through profit or loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,205</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,832</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest from loans to related parties and deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(421</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Exchange rate differences, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(612</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,219</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,832</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">f.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Finance expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance expenses related to warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,204</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exchange rate differences, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Losses from remeasurement of investment in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">305</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,046</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">770</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense in respect of leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finance expenses from interest and
    commissions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">353</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,055</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,014</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    22:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LOSS
    PER SHARE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Amounts used in the computation of basic and diluted&#160;loss</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Continuing operations:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="-sec-ix-redline:true;-keep: true">Basic loss per share</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277,380</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,472</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,413</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,883</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,379</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,592</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Effect of potential dilutive ordinary shares</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Diluted loss per share</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277,380</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,472</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,413</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,883</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,379</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,592</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    computation of diluted loss per share did not include the following convertible securities since their inclusion would decrease the
    loss per share (anti-dilutive effect):</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    Options to employees, officers, directors and consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable
    warrants to investors.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">OPERATING SEGMENTS</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;23:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPERATING
    SEGMENTS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies the principles
of IFRS 8,&#160;&#8220;<i>Operating Segments</i>&#8221;<i>&#160;</i>(&#8220;IFRS 8&#8221;), regarding operating segments. The segment
reporting is based on internal management reports of the Company&#8217;s management, which are regularly reviewed by the Chief Operating
Decision Maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated and assess performance. According to the principles
of IFRS 8, the Company&#8217;s management determined that it has two reportable segments &#8211; (1) development of drugs based on cannabinoid
molecules to be approved by an official regulatory authority (the Company&#8217;s operation); and (2) online sales of a various range
of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams,
and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Segment performance (segment income
(loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items
that are allocated directly to the segments and items that can be allocated on a reasonable basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The review of the CODM is carried
out according to the results of the segment&#8217;s performance. His review does not include certain expenses that are not related specifically
to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating
results in financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drug
    <br/>
    Development</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Online
    <br/>
    Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">External</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Segment
    loss (gain)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,873</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,443</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,316</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity losses from the investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense (income), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(259</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,472</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drug
    <br/>
    Development</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Online
    <br/>
    Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">External</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Segment
    loss (gain)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,359</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,456</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,815</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Company&#8217;s share of losses of company accounted for at
    equity, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense (income), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,883</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Drug Development Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the year ended December 31, 2024, the Company
recognized other income in the amount of $1,288 as a result of a sale of an intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Online Sales Segment</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2023, and 2024,
the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of
the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 - $1,042).</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Year
    ended December&#160;31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenues</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-size: 10pt">External</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">8,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">8,287</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Company&#8217;s share of losses
    of company accounted for at equity, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Finance expense (income), net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(5,818</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2,592</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">8,407</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">1,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">10,171</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,194</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">226</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">7,069</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">4,113</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">11,182</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,441</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">154</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,595</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">TRANSACTIONS AND BALANCES WITH RELATED PARTIES</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;24:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSACTIONS
    AND BALANCES WITH RELATED PARTIES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Key<br/>
    management<br/> personnel</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Other<br/>
    related<br/> parties</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Key<br/>
    management<br/> personnel</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Other<br/>
    related<br/> parties</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">121</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,224</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">55</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">245</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">95</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research
    and development expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">63</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">208</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale
    of minority interest in subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,985</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term
    benefits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">765</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,204</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,940</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management
    fees (see also note 25a)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">120</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost
    of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">157</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">779</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2023, the Company entered into an agreement with Jeffs&#8217; Brands and Jeffs&#8217; Brands Holdings Inc. (&#8220;NewCo Inc.&#8221;), a newly-formed wholly owned subsidiary of Jeffs&#8217; Brands, pursuant to which, at the closing and upon the terms and conditions set forth in the Agreement, NewCo Inc. acquired from the Company a number of shares of stock equal to approximately a 49% interest in the Company&#8217;s wholly owned subsidiary, SciSparc US which owns Wellution, for $2,500 in cash, and additional deferred cash payments of approximately $489 accounting for price adjustments related to inventory and working capital, which was paid in five equal monthly installments beginning in May 2023 (the &#8220;Price Adjustment&#8221;). As collateral for the payment in full of the Price Adjustment, SciSparc held back such number of shares of common stock of SciSparc US, equal to the outstanding due amount of the Price Adjustment (the &#8220;Holdback Shares&#8221;). Following the closing of the transaction on March 22, 2023, which included an equity conversion of financing amounts previously provided to SciSparc US. by the Company for working capital, and the release of the Holdback Shares on January 31, 2024, upon the payment in full of the Price Adjustment by Jeffs&#8217; Brands, the Company holds approximately 51% of the share capital of SciSparc US.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, at the closing of the transaction, Jeffs&#8217; Brands and SciSparc US. entered into a consulting agreement, pursuant to which Jeffs&#8217; Brands provides management services to SciSparc US for the Wellution brand for a monthly fee of $20 and Jeffs&#8217; Brands received a one-time signing bonus in the amount of $51. The consulting agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice. On November 2023 the monthly fee reduced to $10 thousand. For the year ended December 31, 2024, the Company has recorded management services expenses in the amount of $120 (for the year ended December 31, 2023 - $220).</p></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, in connection with the closing of the transaction, the Company and Jeffs&#8217; Brands, engaged in a mutual share exchange in the amount of $288 of ordinary shares from each of the Company and Jeffs&#8217; Brands. The number of shares in the share exchange was calculated based on the average closing price of the relevant company&#8217;s shares for 30 consecutive trading days ending on the third trading day immediately prior to the closing. Accordingly, the Company acquired 35,345 ordinary shares of Jeffs&#8217; Brands and Jeffs&#8217; Brands acquired 660 ordinary shares of the Company having an aggregate value of $288 which was adjusted from $300 according to the 4.99% ownership limit included in the definitive agreements. As of December 31, 2024, the listed share price of Jeff&#8217;s Brands on Nasdaq was $ 2.57, and the Company has recorded a loss in its statements of comprehensive loss of $17 on its investment (for the year ended December 31, 2023 -$180).<br/> <br/> Mr. Oz Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer, is the chairman of the board of directors of&#160;Jeffs&#8217;&#160;Brands.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2022, the Company entered into the Cooperation Agreement with Clearmind, a company in which Dr. Adi Zuloff-Shani, the Company&#8217;s Chief Technologies Officer, Mr. Weiss, the Company&#8217;s President, and Mr. Adler, the Company&#8217;s Chief Executive Officer and Chief Financial Officer serve as officers and directors (the &#8220;Cooperation Agreement&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2024 and 2023, the Company recognized expenses in respect of the Cooperation Agreement in the amount of $63 and $40, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company invested $1.5 million in Clearmind in connection with its initial public offering on the Nasdaq Capital Market, in exchange for 7,692 common shares of Clearmind, representing 9.33% of the outstanding share capital of Clearmind (see also Note 8).</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Amitai Weiss, the Company&#8217;s chairman of the Board, is the chairman of the board of directors of AutoMax (see Note 8b).&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 13, 2024, the Company entered into the license agreement (the &#8220;License Agreement&#8221;) of the out-licensing of its SCI-160 program (the &#8220;Assets&#8221;), with Polyrizon Ltd. (the &#8220;Licensee&#8221; or &#8220;Polyrizon&#8221;). According to the License Agreement, the Company granted the Licensee a royalty-bearing, exclusive, sub-licensable right and license to the Assets (the &#8220;License&#8221;). In consideration for the License, the Company received and will receive certain shares of the Licensee, reflecting an issue price of $805, and royalties from sales related to and income generated from the Assets. Further, the Licensee will pay the Company pre-determined fees upon the completion of certain development milestones relating to the Assets. <br/> <br/> Pursuant to the terms of the License Agreement, the Company is entitled to up to $3,320 based on the achievement of certain milestones, including (i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction. Additionally, the Company is eligible to receive royalties, on a country-by-country and product-by-product basis, at a rate of 5%, on aggregate net sales of a product that comprises, contains and/or incorporates and/or is based on the Licensed Patent Rights, or a Licensed Product (as these are defined in the License Agreement), and sublicense income that we may receive until the longer of (i) fifteen years from the date of the first sale of a Licensed Product (on a country-by-country basis), and (ii) the last to expire valid claim of any licensed patents with respect to a Licensed Product in such country. <br/> <br/> On October 31, 2024, following an initial public offering of the Licensee, the Company received 684,931 units, of which (i) 320,000 units, with each unit consisting of one ordinary share of the Licensee and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (960,000 warrants in total); and (ii) 364,931 units consisting of one pre-funded warrant to purchase one ordinary share of the Licensee, and three warrants, each to purchase one additional ordinary share of the Licensee at a purchase price of $4.38 (1,094,793 warrants in total). Altogether, the Company received 320,000 ordinary shares, 364,931 pre-funded warrants to purchase one ordinary share of the Licensee, and 2,054,793 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. &#160; <br/> <br/> On December 30, 2024, pursuant to a share transfer agreement, the Company sold all of the Licensee ordinary shares and pre-funded warrants held by it to a third party, as well as an aggregate of 1,541,096 Licensee common warrants to third parties, for aggregate consideration of $771. In addition, in consideration for the License, the Company will receive royalties from sales related to the Assets and income generated from it. &#160; <br/> <br/> As of December 31, 2024, the Company holds 513,698 warrants to purchase one additional ordinary share of the Licensee at a purchase price of $4.38. The warrants expire on October 31, 2029. The value of the warrants on December 31, 2024, is $517.<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Oz Adler, the Company&#8217;s Chief Executive Officer, is a director
of the Licensee.</p>
</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>General Overview of Valuation Approaches
used in the Valuation:</i> &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Economic methodology:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    <br/> 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">October&#160;31,
    <br/> 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Dividend yield (%)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility (%)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Underlying Share Price of Polyrizon Ltd. ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.38</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.38</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.38</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants fair value ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,399</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2024, the Company entered into an Agreement and plan of merger, as amended (the &#8220;Merger Agreement&#8221;) with AutoMax and SciSparc Merger Sub Ltd., an Israeli limited company and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including approval of the transaction by the Company&#8217;s shareholders and AutoMax&#8217;s shareholders, Merger Sub will be merged with and into AutoMax, with AutoMax surviving the Merger as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 14, 2024, SciSparc and AutoMax entered into the Merger Agreement addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by August 30, 2024, was deferred to November 30, 2024. On November 26, 2024, SciSparc and AutoMax entered into the Merger Agreement second addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by November 30, 2024, was deferred to March 31, 2025. On March 27, 2025, SciSparc and AutoMax entered into the Merger Agreement third addendum, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the effective time of the Merger (the &#8220;Effective Time&#8221;, as further defined in the Merger Agreement): (a)&#160;each outstanding share of AutoMax&#8217;s share capital will be converted into the right to receive ordinary shares of the Company, equal to the exchange ratio set forth in the Merger Agreement (the &#8220;Exchange Ratio&#8221;). Under the Exchange Ratio, following the Effective Time, the former AutoMax shareholders immediately before the Merger (other than the Company) are expected to hold together approximately 49.99% (minus the Finder Fee, as defined in the Merger Agreement) of the aggregate number of the outstanding ordinary shares of the Company on a fully diluted basis (subject to certain exceptions). The shareholders of the Company, together with the holders of the Company&#8217;s convertible securities, immediately before the Merger are expected to hold together approximately 50.01% of the aggregate number of the outstanding ordinary shares of the Company on fully diluted basis (subject to certain exceptions); (b) subject to the consummation of the Merger (as defined in the Merger Agreement, the &#8220;Closing&#8221;), and immediately after the Effective Time, AutoMax shall have the right to (i) designate two members to the Board if the Board is comprised of five or six directors; or (ii) designate three members if the Board is comprised of seven directors. At least one such designee shall be an independent director, as defined under the Nasdaq Stock Market listing rules. (See also Note 26b).</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodAbstract', window );"><strong>Significant Events during the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock', window );">SIGNIFICANT EVENTS DURING THE REPORTING PERIOD</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
    25:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
    EVENTS DURING THE REPORTING PERIOD</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2024, the Company announced that it signed a non-binding letter of intent with Miza III Ventures Inc. (&#8220;Miza&#8221;), a publicly traded company on the Toronto Stock Exchange Venture in Canada, which references a proposed asset and share purchase agreement, to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in SciSparc Nutraceuticals. (collectively, the &#8220;Target Assets&#8221;)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agreement is based on the approximate total $3,300 (CAD 4.5 million) enterprise value of Miza, when including its $1,000 cash position, and an approximate $11,600 (CAD 15.8 million) value of the Company&#8217;s assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LOI, the Company will sell, assign, convey and transfer to Miza the Target Assets in consideration for 63,300,000 common shares of Miza and up to 48,000,000 Miza contingent rights based on pre-determined milestones. Following the closing of such transaction, the Company would hold a controlling interest in Miza, the exact percentage of which is contingent on agreeing definitive terms between the parties. The resulting entity, of which SciSparc will hold a stake in the resulting entity ranging from a minimum of approximately 75% to a maximum of 84.53%, will be active in both the pharmaceutical and supplement sectors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 28, 2025, the Company entered into a second amendment (the &#8220;Miza Amendment&#8221;) to the non-binding letter of intent, as amended by the first amendment on December 16, 2024, with Miza. According to the Miza Amendment, the deadline to enter into definitive agreements was extended from March 31, 2025 to June 30, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than July 31, 2025, which was extended from April 30, 2025.</p></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsDuringTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsDuringTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Events After the Reporting Date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">EVENTS AFTER THE REPORTING DATE</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;26:-</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EVENTS
    AFTER THE REPORTING DATE</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2025, the Company announced that it has reached a settlement agreement (the &#8220;Settlement&#8221;) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against six of the Company&#8217;s former directors (the &#8220;Defendants&#8221;) case number 34426-02-22 (the &#8220;Suit&#8221;). The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior acquisition of a pain clinic network through a subsidiary of the Company (See Note 17a).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Settlement, which was facilitated through mediation and approved by the court, SciSparc will be entitled to a $411 cash payment from the Defendants, in exchange for the full dismissal by SciSparc of the alleged claims brought against the Defendants in the Suit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Settlement also includes the termination, effective as of February 5, 2024 of a disputed licensing agreement with Dekel, entered into on May 21, 2015 and amended from time to time (the &#8220;License Agreement&#8221;). As part of the Settlement, Dekel clarified, to SciSparc&#8217;s full satisfaction, that SciSparc will retain its exclusive global rights to its extensive intellectual property portfolio, patents, know-how and technologies and is released from all alleged commitments, claims and royalties related or arising out of the License Agreement, including those related to claimed core technologies, ensuring a continued focus on SciSparc&#8217;s core development programs. Dekel will assume full and exclusive ownership of the patent application for compositions and methods for treating inflammatory disorders and all such underlying intellectual property, which are not related whatsoever to the Company&#8217;s pipeline and development program.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2025, the Company announced that it has entered into a loan agreement with AutoMax to provide a $2,000 loan (the &#8220;New Loan&#8221;). The funding will support AutoMax&#8217;s business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4,250 (the &#8220;Previous Loans&#8221;). The Previous Loans were provided in lieu of SciSparc&#8217;s obligation to provide a $4,250 closing financing, in accordance with the merger agreement signed between the parties. On March 27, 2025, SciSparc and AutoMax entered into a third addendum to the Merger Agreement, pursuant to which the right to terminate the Merger Agreement if the Merger was not consummated by March 31, 2025, was deferred to September 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan, bearing an 8% annual interest rate, will be repaid in equal monthly installments of $50 and interest, commencing on March 24, 2025,with AutoMax retaining the option for early repayment without penalties. The interest on the loan will be cancelled as of the consummation of the merger agreement, and thereafter AutoMax shall continue to make monthly payments towards the principal amount of the loan. As collateral, AutoMax has pledged a first-ranking fixed charge on its subsidiary&#8217;s shares.</p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company entered into securities purchase agreements (the &#8220;Securities Purchase Agreements&#8221;) with certain investors, pursuant to which the Company agreed to sell and issue to the investors convertible debentures (the &#8220;Debentures&#8221;) in the aggregate principal amount of $4,200 (the &#8220;Subscription Amount&#8221;), which are convertible into the Company&#8217;s ordinary shares, no par value per share (the &#8220;Ordinary Shares&#8221; and, as converted, the &#8220;Conversion Shares&#8221;), at a purchase price equal to 95% of the Subscription Amount. The issuance and sale of the Debentures is subject to certain conditions and limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Debentures, when issued, will mature on the one-year anniversary of the issuance date of the Debentures. Further, interest will accrue on the outstanding principal balance of the Debentures at an annual rate of 8%, which will increase to an annual rate of 18% upon an Event of Default (as defined in the Debentures) for so long as such Event of Default remains uncured. The investors will have the right to convert the Debentures into Ordinary Shares at the lower of (i) 110% of volume weighted average price of the Ordinary Shares the trading day immediately preceding the closing or (ii) 95% of the lowest daily volume weighted average price of the Ordinary Shares during the twenty (20) consecutive trading days immediately preceding the conversion date or other date of determination (the &#8220;Market Price&#8221;); provided that the Market Price may not be lower than the floor price, which will be equal to 20% of the volume weighted average price of the Ordinary Shares on the day prior to the closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the closing of the transaction, the Company issued to the investors 172,174 warrants which are exercisable into a number of Ordinary Shares equal to the Subscription Amount applicable to the investors divided by a price equal to 130% of the volume weighted average price of the Ordinary Shares immediately prior to the closing date, or $11.6172 per warrant. The warrants are exercisable for a term of five years from the issuance date.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">d.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">On April 1, 2025, we entered into a securities purchase agreement with Polyrizon, pursuant to which we participated in a private placement of Polyrizon and invested $100,000 (out of an aggregate investment of approximately $17 million), in exchange for ordinary shares and Series A warrants to purchase ordinary shares, of Polyrizon. In addition, we entered into an exchange agreement with Polyrizon, pursuant to which we exchanged existing ordinary share warrants of Polyrizon held by us for Series A warrants to purchase ordinary shares of Polyrizon.</span></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company entered into a global guaranty agreement (the &#8220;Global Guaranty Agreement&#8221;) with one of the investors (the &#8220;Investor&#8221;) through certain of the Company&#8217;s subsidiaries, pursuant to which such subsidiaries will guaranty the Company&#8217;s obligations under the Debenture with the Investor and other instruments, agreements or other items executed or delivered pursuant to the Global Guaranty Agreement.<br/> <br/> The Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investor, pursuant to which the Company subsidiaries, pursuant to which the Company has agreed to provide to the Investor registration rights under the Securities Act of 1933, as amended (the &#8220;Act&#8221;) and the rules and regulations promulgated thereunder, and applicable state securities laws.<br/> <br/> In connection with the transaction, on February 25, 2025, the Company entered into a Deed of Assignment (the &#8220;Deed&#8221;) with AutoMax, and three of the investors. Pursuant to the Deed, the Company assigned part of the Subscription Amount in the amount of $2,000 to AutoMax in lieu of making the payment under the Loan Agreement (the &#8220;Loan Agreement&#8221;) to which the Company entered into with AutoMax on February 24, 2025.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, the Company announced it has signed a definitive agreement to sell its entire ownership interest in MitoCareX to N2Off, Inc., a publicly-traded company in the United States (Nasdaq: NITO) (&#8220;N2OFF&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into a Securities Purchase and Exchange Agreement with N2OFF, under which the Company and other sellers, including Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, will transfer full ownership of MitoCareX to N2OFF. As part of the agreement, the Company will sell 4,961 shares of MitoCareX to N2OFF for $700 and exchange its remaining shares for common stock in N2OFF. In total, the Company and the other sellers will receive N2OFF common stock equivalent to 40% of the company&#8217;s fully diluted capital stock. The transaction is subject to certain conditions, including approval of N2OFF&#8217;s shareholders. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with its board restructured under N2OFF&#8217;s control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company and the other sellers will be entitled to receive additional N2OFF stock based on milestone achievements, representing up to 25% of N2OFF&#8217;s fully diluted capital stock. As part of the financial terms, the Company, along with the other sellers, will collectively receive 30% of N2OFF&#8217;s financing proceeds over five years, up to a maximum of $1,600. N2OFF has also committed to investing $1,000 in MitoCareX post-closing. Dr. Silberman will continue as CEO of N2OFF under a revised employment agreement, which includes a restricted stock grant of 5% of N2OFF&#8217;s capital stock, vesting over three years. The agreement contains customary representations, warranties, and provisions for termination if the closing does not occur within 30 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Amitay Weiss, who serves as the chairman of the Board, also serves as the chairman of the board of directors of N2OFF. In addition, Ms. Liat Sidi, who also serves as a member of the Board, also serves as a member of the board of directors of N2OFF.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - - - - - - - - - - - - - - - - - - - - -
- -</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory', window );">Basis of presentation of the financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation of the financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">These financial statements have been
prepared in accordance with IFRS, as issued by the IASB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s financial statements
have been prepared on a cost basis, unless otherwise indicated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has elected to present
the profit or loss items using the function of expense method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements are presented
in USD and all values are rounded to the nearest thousand (&#8217;000), except when otherwise indicated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory', window );">The operating cycle</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cycle:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The operating cycle of the Company
is one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements', window );">Consolidated financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The consolidated financial statements
comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when
the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those
returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over
the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such
control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform
accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from
intra-Group transactions are eliminated in full in the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Non-controlling interests in subsidiaries
represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in
equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive
income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they
result in a negative balance of non-controlling interests in the consolidated statement of financial position.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The functional currency of the Company,
which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the
U.S. Dollar (&#8220;USD&#8221; or &#8220;$&#8221;), since it&#8217;s the primary currency of the economic environment in which the Company
operates. The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated
financial statements in USD provides more relevant information to the users of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany', window );">Acquisition of a single asset company</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of a single asset company:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of a single asset
company, the Group evaluates whether it is the acquisition of a business or of an asset. To be considered a business, the acquisition
must include, at a minimum, an input and a substantive process that together can significantly contribute to the creation of outputs.
The acquisition is accounted for as a business combination if the single asset company is a business. If it is not a business, the acquisition
is accounted for as the acquisition of assets and liabilities. In such an acquisition, the cost of the acquisition includes transaction
costs which are allocated to the identifiable acquired assets and liabilities proportionally based on their fair value on the acquisition
date. In such case, goodwill and deferred taxes in respect of the temporary differences existing as of the acquisition date are not recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory', window );">Restricted deposits</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted deposits:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A restricted deposit is cash invested
in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the
date of investment). Restricted deposits are designated to secure the Company&#8217;s office facilities lease agreements and its credit
cards.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory', window );">Investment in joint arrangements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in joint arrangements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Joint arrangements are arrangements
in which the Company has joint control. Joint control is the contractually agreed sharing of control of an arrangement, which exists
only when decisions about the relevant activities require the unanimous consent of the parties sharing control.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    ventures:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint ventures the parties that
have joint control of the arrangement have rights to the net assets of the arrangement. A joint venture is accounted for at equity</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    operations:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In joint operations the parties that
have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. The
Company recognizes in relation to its interest its share of the assets, liabilities, revenues and expenses of the joint operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The acquisition of interests in a
joint operation which represents a business, as defined in IFRS 3, is accounted for using the acquisition method, including the measurement
of the identifiable assets and liabilities at fair value, the recognition of deferred taxes arising from this measurement, the accounting
treatment of the related transaction costs and the recognition of goodwill or bargain purchase gains. This applies to the acquisition
of the initial interest and additional interests in a joint operation that represents a business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments accounted for using the equity method</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments accounted for using the equity method:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Group&#8217;s investments in associates
and joint ventures are accounted for using the equity method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Under the equity method, the investment
in the associate or in the joint venture is presented at cost with the addition of post-acquisition changes in the Group&#8217;s share
of net assets, including other comprehensive income of the associate or the joint venture. Gains and losses resulting from transactions
between the Group and the associate or the joint venture are eliminated to the extent of the interest in the associate or in the joint
venture. The cost of the investment includes transaction costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Goodwill relating to the acquisition
of an associate or a joint venture is presented as part of the investment in the associate or the joint venture, measured at cost and
not systematically amortized. Goodwill is evaluated for impairment as part of the investment in the associate or in the joint venture
as a whole.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial statements of the Company
and of the associate or joint venture are prepared as of the same dates and periods. The accounting policies applied in the financial
statements of the associate or the joint venture are uniform and consistent with the policies applied in the financial statements of
the Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Upon the acquisition of an associate
or a joint venture achieved in stages when the former investment in the acquiree was accounted for pursuant to the provisions of IFRS
9, the Group applies the principles of IFRS 3 regarding business combinations achieved in stages. Consequently, equity interests in the
acquiree that had been held by the Group prior to achieving significant influence or joint control are measured at fair value on the
acquisition date and are included in the acquisition consideration while recognizing a gain or loss resulting from the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The equity method is applied until
the loss of significant influence in the associate or loss of joint control in the joint venture or classification as investment held
for sale.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Property and equipment are measured
at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment
grants and excluding day-to-day servicing expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Mainly
    %</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">6-50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Computers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">33-50</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7-15</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">see below</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The useful life, depreciation method
and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting
estimate. Depreciation of an asset ceases at the earlier of: the date that the asset is classified as held for sale and the date that
the asset is derecognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Separately acquired intangible assets
are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination
are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized
development costs, are recognized in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Intangible assets with a finite useful
life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired.
The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of non-financial assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company evaluates the need to
record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.
If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount.
The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future
cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset
that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses
are recognized in profit or loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments:</span></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets are measured upon
initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except
for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company classifies and measures
debt instruments in the financial statements based on the following criteria:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s business model for managing financial assets; and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual cash flow terms of the financial asset.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    instruments are measured at amortized cost when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">The Company&#8217;s business model
is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give
rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial
recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate
method, less any provision for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">On the date of initial recognition,
the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly
reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through
profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    instruments are measured at fair value through profit or loss when:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">A financial asset which is a debt
instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial
recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or
loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    instruments and other financial assets held for trading:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Investments in equity instruments
do not meet the above criteria and accordingly are measured at fair value through profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Other financial assets held for trading
such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss
unless they are designated as effective hedging instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Dividends from investments in equity
instruments are recognized in profit or loss when the right to receive the dividends is established.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
    of financial assets:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial asset is derecognized
only when:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contractual rights to the cash flows from the financial asset have expired;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the
    financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred
    control of the asset; or</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation
    to pay the cash flows in full without material delay to a third party.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify">3.</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Impairment
                                            of financial assets:</p>
</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company evaluates at the end of
each reporting period the loss allowance for financial debt instruments which are not measured at fair value through profit or loss.
The Company distinguishes between two types of loss allowances:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 168px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 48px">a)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Debt
                                            instruments whose credit risk has not increased significantly since initial recognition,
                                            or whose credit risk is low - the loss allowance recognized in respect of this debt instrument
                                            is measured at an amount equal to the expected credit losses within 12 months from the reporting
                                            date (12-month ECLs); or</td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 168px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 48px">b)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Debt
                                            instruments whose credit risk has increased significantly since initial recognition, and
                                            whose credit risk is not low - the loss allowance recognized is measured at an amount equal
                                            to the expected credit losses over the instrument&#8217;s remaining term (lifetime ECLs).</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has short-term financial
assets in respect of which the Company applies the simplified approach in IFRS 9 and measures the loss allowance in an amount equal to
the lifetime expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company considers a financial
asset in default when contractual payments are more than 180 days past due. However, in certain cases, the Company considers a financial
asset to be in default when external or internal information indicates that the Company is unlikely to receive the outstanding contractual
amounts in full.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities:</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities measured at amortized cost:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">Financial liabilities are initially
recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, the Company
measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair
value through profit or loss such as derivatives.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 168px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    liabilities measured at fair value through profit or loss:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">At initial recognition, the Company
measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-align: justify">After initial recognition, changes
in fair value are recognized in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
    of financial liabilities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A financial liability is derecognized
only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial
liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is
legally released from the liability.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting
    financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Financial assets and financial liabilities
are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off
the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously.
The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also
in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must
not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events
that will cause the right to expire.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compound
    financial instruments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Convertible debentures which contain
both an equity/derivative component and a liability component are separated into two components. This separation is performed by first
determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component
is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the
liability component based on the allocation of proceeds to the equity and liability components.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    of a unit of securities:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The issue of a unit of securities
involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following
order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for
financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual
amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Research expenditures are recognized
in profit or loss when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The conditions enabling capitalization
of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss
when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance income and expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance income and expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Finance income and expenses comprise
interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective
interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value
through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value is the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Fair value measurement is based on the assumption that the transaction will take place in the asset&#8217;s or the liability&#8217;s
principal market, or in the absence of a principal market, in the most advantageous market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value of an asset or a liability
is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants
act in their economic best interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Fair value measurement of a non-financial
asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best
use or by selling it to another market participant that would use the asset in its highest and best use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company uses valuation techniques
that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant
observable inputs and minimizing the use of unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">All assets and liabilities measured
at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level
input that is significant to the entire fair value measurement:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Current or deferred taxes are recognized
in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A current tax liability is measured
using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required
in connection with the tax liability in respect of previous years.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are computed in respect
of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are measured at the
tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted
or substantively enacted by the reporting date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred tax assets are reviewed at
each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and
temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred
tax asset is recognized to the extent that their utilization is probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes that would apply in the event
of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of
the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution
of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends
does not involve an additional tax liability or since it is the Company&#8217;s policy not to initiate distribution of dividends from
a subsidiary that would trigger an additional tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Taxes on income that relate to distributions
of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, &#8220;<i>Income Taxes</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Deferred taxes are offset if there
is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same
taxpayer and the same taxation authority.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s employees and
other service providers may receive remuneration in the form of share-based payments (&#8220;Equity-settled transactions&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Equity-settled transactions:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable
option pricing model (&#8220;OPM&#8221;). As for service providers, the cost of the transactions is measured at the fair value of the
goods or services received as consideration for equity instruments granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The cost of equity-settled transactions
is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service
conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the &#8220;Vesting Period&#8221;).
The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects
the extent to which the Vesting Period has expired and the Company&#8217;s best estimate of the number of equity instruments that will
ultimately vest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">No expense is recognized for awards
that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective
of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If the Company modifies the conditions
on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">If a grant of an equity instrument
is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized
immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled
and new grants are accounted for as a modification of the original grant, as described above.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings (loss) per share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings (loss) per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Earnings (loss) per share are calculated
by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares outstanding during
the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Basic loss per ordinary share includes
only ordinary shares that were outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Potential ordinary shares are included
in the computation of diluted loss per ordinary share when their conversion increases loss per ordinary share from continuing operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefit liabilities</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee benefit liabilities:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company has several employee-benefit
plans:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    employee benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">Short-term employee benefits are benefits
that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render
the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions
and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized
when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and
a reliable estimate of the amount can be made.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-employment
    benefits:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The plans are normally financed by
contributions to insurance companies and classified as defined contribution plans or as defined benefit plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company has defined contribution
plans to its employees according to the specific laws per country.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision in accordance with IAS
37, &#8220;<i>Provisions, Contingent Liabilities and Contingent Assets</i>&#8221;, is recognized when the Company has a present obligation
(legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects part
or all of the expense to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset
but only when the reimbursement is virtually certain. The expense is recognized in the statement of profit or loss net of any reimbursement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following are the types of provisions
included in the financial statements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Legal claims:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A provision for claims is recognized
when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow
of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made
of the amount of the obligation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company elected to apply the provisions
of IFRS 16, &#8220;<i>Leases</i>&#8221; (&#8220;IFRS 16&#8221;) using the modified retrospective method (without restatement of comparative
data).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accounting policy for leases applied
effective from January 1, 2019, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for a contract
as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company as a lessee:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For leases in which the Company is
the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases
whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected
to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the
lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease
components (such as management and maintenance services, etc.) included in a single contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the lease
liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined,
or otherwise using the Company&#8217;s incremental borrowing rate. After the commencement date, the Company measures the lease liability
using the effective interest rate method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On the commencement date, the right-of-use
asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and
initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful
life and the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company tests for impairment of
the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, &#8220;<i>Impairment of Assets</i>&#8221;.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    extension and termination options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">A non-cancelable lease term includes
both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised,
and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In the event of any change in the
expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures
the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total
change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized
in profit or loss.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 120px; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    modifications:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification does not reduce
the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease
terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the
right-of-use asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">If a lease modification reduces the
scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use
asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised
lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment
to the right-of-use asset.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Inventories
are stated at the lower of cost and or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence
and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. Cost
is determined in accordance with first-in, first-out Method (&#8220;FIFO&#8221;) and the cost of inventory includes shipment and freight
costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">The
Company&#8217;s Brand sells products directly to customers mainly through the Brand&#8217;s online Amazon stores.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Under
the Company&#8217;s standard contract terms, customers have a right of return within 30 to 90 days. For contracts with rights of return,
the Company recognizes revenue based on the amount of the consideration which the Company expects to receive for products which it is
highly probable that a significant revenue reversal will not subsequently occur. The Company recognizes a refund liability for consideration
received or receivable if it expects to refund some or all of the consideration to the customer. At the end of each reporting period,
the Company updates its estimates of expected product returns and adjusts the refund liabilities with a corresponding adjustment in revenues.
As of December 31, 2024, the allowance for returns was immaterial. The refund liability is recorded as a decrease in revenues against
other payables. A right of return asset and corresponding adjustment to cost of sales is also recognized for the right to recover the
goods from the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
certain contracts, the Company evaluates the nature of its promise to the customer and determines whether it is the principal or agent
for each contract. In determining the nature of its promise to the customer, the Company evaluates whether it is appropriate to recognize
revenues on a gross or net basis based upon its evaluation of whether the Company obtains control of the specified goods by considering
if it is primarily responsible for fulfillment of the promise, has inventory risk, and has the latitude in establishing pricing and selecting
suppliers, among other factors. Based on its evaluation of these factors, management has determined that it is the principal in these
arrangements; therefore, sales are recorded on a gross basis.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 72px">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">x.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">In
accordance with Amazon&#8217;s terms of use, the Company is obligated to pay to Amazon incremental costs, such as sales fulfillment commissions
which are contingent on making binding sales. Sales commissions would not have been incurred if the contract had not been obtained. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="background-color: white">Cost
of sales primarily consists of expenses related to Amazon&#8217;s commissions, storage costs and freight.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy cost of sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in Consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy changes in operating cycle Explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionOfAcquisitionOfASingleAssetCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for acquisition of a single asset company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionOfAcquisitionOfASingleAssetCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of accounting policies for basis of presentation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory', window );">Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Depreciation is calculated on a straight-line
basis over the useful life of the assets at annual rates as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Mainly
    %</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">6-50</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Computers</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">33-50</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">7-15</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">see below</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash for immediate withdrawal - in USD</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,383</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,866</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash for immediate withdrawal - in
    NIS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">210</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,540</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,076</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosue of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfInventorieExplanatory', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Goods in transit</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">73</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">669</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">113</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">742</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfInventorieExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfInventorieExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock', window );">Schedule of Other Accounts Receivable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Government authorities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">78</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">62</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">449</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">350</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables in respect of downpayment on merger</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">187</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Related party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,079</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">540</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclourseOfAccountsReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounts receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclourseOfAccountsReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems', window );"><strong>Investment in Associates and Investments in Investees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Schedule of Fair Value of the Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The table below summarizes the fair
value of the investment in MitoCareX:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%">Investment date March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">700</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(109</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">591</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment following achievement of first milestone</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(210</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment following achievement of second milestone</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Equity losses from investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(429</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">952</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Computers</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Office<br/>
    furniture<br/> and<br/> equipment</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Right
    of use asses</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif">Cost:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Balance at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">181</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Disposals</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(203</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">99</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Accumulated depreciation:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January&#160;1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Disposals</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(106</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(111</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Depreciated cost at December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">47</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">59</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Accumulated depreciation:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at January&#160;1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">65</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">52</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Depreciated cost at December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Intangible Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of Fair Value of the Intangible Asset</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">The table below
summarizes the fair value of the intangible asset:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">4,717</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Depreciation of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(486</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,189</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on impairment of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,344</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Depreciation of intangible asset</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(366</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,479</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfTradePayablesExplanatory', window );">Schedule of Trade Payables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">608</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">538</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Open debts</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">208</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">264</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">816</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfTradePayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade payables explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfTradePayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Employees
    and payroll accruals</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other
    payables</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">205</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">185</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The financial assets and financial
liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9,
&#8220;<i>Financial Instruments</i>&#8221; (&#8220;IFRS 9&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif">Financial assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Cash and restricted deposits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,560</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,141</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">449</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,239</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financial assets at amortized
    cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,248</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,344</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Investments in financial assets at
    fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">871</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">659</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Financial liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit from others</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">76</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total financial and lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">123</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">315</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Schedule of Company's Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The tables below are a comparison
between the carrying amount and fair value of the Company&#8217;s financial instruments as of December 31, 2024, and 2023, which are
presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair
values):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Investments in short-term financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">354</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">354</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#160;&#160;&#160;-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level
    3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left">Investments in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">659</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#160;&#160;&#160;&#160;-&#8239;</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8239;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">659</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-&#8239;</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">191</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets and financial liabilities that have been redesignated during the transition to IFRSs. [Refer: Financial assets; Financial liabilities; IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 29<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_29&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Employee Benefit Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory', window );">Schedule of Defined Contribution Plans</a></td>
<td class="text">These contributions and contributions for compensation represent defined contribution plans.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt">Expenses in respect of
    defined contribution plans</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">106</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">105</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">115</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about defined contribution plans explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition of share capital:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December&#160;31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December&#160;31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Issued and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Issued and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Ordinary shares</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">515,631</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,652</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital', window );">Schedule of Issued and Outstanding Share Capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><i>Issued and outstanding share capital:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> ordinary shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-sec-ix-redline:true;-keep: true">Balance at January 1, 2024</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,652</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants &#160;(Note 18h</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">175,110</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,770</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">276,099</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Balance at December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">515,631</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The June 2022 Warrants&#8217; fair
value was calculated using the Black&#8211;Scholes option pricing model, which takes into account the parameters as disclosed below for
each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
    2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">4.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.872</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    share price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">102.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,435.98</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,435.98</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    fair value ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">192</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less than $1 thousand</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed inforamtion about issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract', window );"><strong>Share-Based Payment Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock', window );">Schedule of Expenses Due to Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The expenses due to share-based compensation
for the years ended December 31, 2024, 2023 and 2022, recognized in the financial statements in respect of the share option plan of the
Company is shown in the following table, detailed by departments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">264</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">524</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">633</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">569</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">897</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock', window );">Schedule of Fair Value for Share Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"><i>The fair value for Share Options
granted to the consultant was estimated using the Black-Scholes OPM with the following parameters:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February&#160;10,<br/>
    2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January
    3,<br/>
    2022</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying
    ordinary share price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,724.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,674.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate (%)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    life of Share Options (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Weighted Average Exercise Prices of Share Options</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table lists the number of Share Options, the weighted average exercise prices of Share Options and changes in directors (and former directors), officers, employees and consultants Share Options during the years ended on December 31, 2024, and 2023:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> Share<br/> Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> average<br/> exercise<br/>
    price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2024:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding
    at the beginning of the year</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">334</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,491.88</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">324</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,354.83</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options exercisable at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">324</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,354.83</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">2023:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding at the beginning of the year</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">336</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,488.94</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options cancelled during the year</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,035.55</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options outstanding at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">334</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,491.88</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Share Options exercisable at the end of
    the year</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">279</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,477.18</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of RSU transaction</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">RSU transactions for the year ended
December 31, 2024, and for the year ended December 31, 2023, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Balance, January 1, 2024</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">RSUs granted</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,476</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">Expiry of RSUs</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercise of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Balance, December 31, 2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,476</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expenses due to share-based compensation explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value for share options granted explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and Cost of Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock', window );">Schedule of Cost of Sales and Gross Profit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table discloses the
breakdown of our revenues, cost of sales and gross profit for the periods set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Cost of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Purchased goods</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">798</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">301</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Freight</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">322</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalInformationAbstract', window );"><strong>Additional Information to the Items of Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of Additional Information to the Items of Profit or Loss</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">a.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Research and development expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">390</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">392</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">436</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory, professional and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">681</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">719</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and preclinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">101</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Clinical studies</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">254</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">369</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Chemistry and formulations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">104</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">141</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">281</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,707</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,641</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,803</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">b.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Sales and marketing expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Advertising</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">367</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">576</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">363</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amazon fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">495</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">*</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Depreciation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">486</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">144</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Storage and shipping</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">167</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">91</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">*</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">120</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">235</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,515</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,484</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,082</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">c.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">General and administrative
    expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Wages and related expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">415</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">437</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">68</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">633</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and directors&#8217; fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,594</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,468</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Business development expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">161</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">158</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">202</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">162</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office maintenance, rent and other expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">128</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">110</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Investor relations and business expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">197</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">369</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,486</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,526</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,427</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">d.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Other expenses (income):</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from sale of property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gain on sale of patent license, net
    (net of Polyrizon Ltd. holdings sold) (See also Note 25b)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,270</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">e.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Finance income:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in fair value of financial liabilities designated
    at fair value through profit or loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(191</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,205</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,832</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest from loans to related parties and deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(421</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Exchange rate differences, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(612</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,219</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,832</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">f.</td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Finance expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance expenses related to warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,204</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Exchange rate differences, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Losses from remeasurement of investment in financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">305</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,046</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">770</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense in respect of leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Finance expenses from interest and
    commissions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">353</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,055</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,014</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of the number of shares and loss used in the computation of loss per share:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Year ended December&#160;31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Amounts used in the computation of basic and diluted&#160;loss</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> number of<br/> shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">USD</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Continuing operations:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="-sec-ix-redline:true;-keep: true">Basic loss per share</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277,380</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,472</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,413</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,883</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,379</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,592</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Effect of potential dilutive ordinary shares</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Diluted loss per share</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">277,380</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(7,472</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,413</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,883</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,379</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,592</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingSegmentsTablesLineItems', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Operating Segments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group&#8217;s CODM is the CEO
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drug
    <br/>
    Development</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Online
    <br/>
    Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">External</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,306</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Segment
    loss (gain)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,873</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,443</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,316</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity losses from the investment in MitoCareX</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">429</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense (income), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(259</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,472</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Drug
    <br/>
    Development</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Online
    <br/>
    Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="text-decoration:underline">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">External</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,879</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt">Segment
    loss (gain)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,359</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,456</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,815</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Company&#8217;s share of losses of company accounted for at
    equity, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">210</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Finance expense (income), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,883</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Year
    ended December&#160;31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt"><span style="text-decoration:underline">Revenues</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-size: 10pt">External</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">8,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">8,287</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Company&#8217;s share of losses
    of company accounted for at equity, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Finance expense (income), net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(5,818</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2,592</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">8,407</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">1,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">10,171</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,194</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">226</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">As
    of December&#160;31, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Drug<br/>
    Development</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Online<br/>
    Sales</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-size: 10pt">Segment Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">7,069</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">4,113</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-size: 10pt">11,182</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Segment
    Liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,441</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">154</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,595</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingSegmentsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingSegmentsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Transactions and Balances with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RelatedPartyBalancetextBlock', window );">Schedule of Balances with Related Parties</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with related parties:</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Key<br/>
    management<br/> personnel</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Other<br/>
    related<br/> parties</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Key<br/>
    management<br/> personnel</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Other<br/>
    related<br/> parties</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">121</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,224</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Non-current
    assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">108</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Current
    liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">55</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">245</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">95</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of Transactions with Related Parties</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related parties (not including amounts described in Note 24c):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research
    and development expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">63</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">40</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">208</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Sale
    of minority interest in subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,985</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Schedule of Benefits to Key Management Personnel</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits to key management personnel (including directors):</span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    ended December&#160;31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Short-term
    benefits</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">765</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,204</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1,940</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Management
    fees (see also note 25a)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">120</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cost
    of share-based payment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">157</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">779</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The warrants&#8217; fair value was
calculated using the Black&#8211;Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in
which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,
    <br/> 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">October&#160;31,
    <br/> 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">Dividend yield (%)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility (%)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate (%)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Underlying Share Price of Polyrizon Ltd. ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.38</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.38</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.38</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants fair value ($)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">517</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,399</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RelatedPartyBalancetextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RelatedPartyBalancetextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (74,975)<span></span>
</td>
<td class="num">$ (68,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (74,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(7,316)<span></span>
</td>
<td class="num">(6,815)<span></span>
</td>
<td class="num">(8,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">$ (5,104)<span></span>
</td>
<td class="num">$ (5,887)<span></span>
</td>
<td class="num">$ (7,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingTerm', window );">Operating term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember', window );">Lab equipment [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly', window );">Straight-line basis over useful life of assets at annual rates mainly</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment', window );">Straight-line basis over useful life of assets at annual rates</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems', window );"><strong>Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife', window );">Leasehold improvements, description</a></td>
<td class="text">see below<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeaseholdImprovementsMainlyRate', window );">Leasehold improvements mainly</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRatePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRatePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeaseholdImprovementsMainlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The leasehold improvements rate used for mainly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeaseholdImprovementsMainlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_CommunicationAndNetworkEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash - Schedule of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 3,574<span></span>
</td>
<td class="nump">$ 6,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems', window );"><strong>Schedule of Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash for immediate withdrawal</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInventoriesInTransit', window );">Goods in transit</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total inventory</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInventoriesInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInventoriesInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable - Schedule of Other Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Other Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_Governmentauthoritiescurrent', window );">Government authorities</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ReceivablesInRespectOfDownpaymentOnMerger', window );">Receivables in respect of downpayment on merger</a></td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Related party</a></td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other accounts receivable</a></td>
<td class="nump">$ 1,079<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_Governmentauthoritiescurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the government authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_Governmentauthoritiescurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReceivablesInRespectOfDownpaymentOnMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables in respect of downpayment on merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReceivablesInRespectOfDownpaymentOnMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2024</div></th>
<th class="th"><div>Mar. 11, 2024</div></th>
<th class="th"><div>Nov. 25, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaserRemainingOwnershipPercentage', window );">Purchaser remaining ownership</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RemainingPurchaserAmount', window );">Purchaser equal valuation</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (429)<span></span>
</td>
<td class="num">$ (210)<span></span>
</td>
<td class="num">$ (109)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Cash consideration</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember', window );">MitoCare X Bio Ltd [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InitialInvestment', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInvestment', window );">Additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OutstandingSharesPercentage', window );">Outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalInstallment', window );">Additional installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentPaid', window );">Installment paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CashConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RemainingPurchaserAmount', window );">Purchaser equal valuation</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuedAndOutstandingSharePercentage', window );">Issued and outstanding share</a></td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from the investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investment in Associates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional installment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InitialInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InitialInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of installment paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuedAndOutstandingSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuedAndOutstandingSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaserRemainingOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchaser remaining ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaserRemainingOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RemainingPurchaserAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining purchaser amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RemainingPurchaserAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract', window );"><strong>Schedule of Fair Value of the Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance at beginning</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentsDate', window );">Investment date March 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Equity losses from investment in MitoCareX</a></td>
<td class="num">(429)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Balance at ending</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentAchievementOfSecondMilestone', window );">Investment following achievement of second milestone</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InvestmentAchievementOfFirstMilestone', window );">Investment following achievement of first milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment following achievement of first milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment following achievement of second milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InvestmentsDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment date,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InvestmentsDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Financial Assets (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Invested amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="nump">$ 5,552<span></span>
</td>
<td class="nump">$ 9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,631<span></span>
</td>
<td class="nump">33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ReverseShareSplitRatio', window );">Reverse share split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SharePricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_InitialPublicOfferingMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Invested amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Investment in Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Received common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReverseShareSplitRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse share split ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReverseShareSplitRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=sprcy_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AreaOfLease', window );">Area of lease</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OptionToExtendLeaseTerm', window );">Option to extend lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_MonthlyLeaseFee', window );">Monthly lease fee (in Dollars) | $</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember', window );">2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AreaOfLease', window );">Area of lease</a></td>
<td class="nump">120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MonthlyLeaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly lease fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MonthlyLeaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OptionToExtendLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to extend lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OptionToExtendLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_RightOfUseAssesMember', window );">Right of use asses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member] | Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember', window );">Cost [Member] | Right of use asses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member] | Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member] | Right of use asses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at beginning balance</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, net at ending balance</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_OfficeEquipmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_RightOfUseAssesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sprcy_RightOfUseAssesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sprcy_AccumulatedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Intangible Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentsOfAdditionalDeferredCash', window );">Additional deferred cash</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchaseCostsValue', window );">Purchase costs</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of intangible asset</a></td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Amortized over period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment to its intangible asset</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Estimated useful life</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_GrowthRatePercentage', window );">Growth rate, percentage</a></td>
<td class="nump">27.80%<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LongTermPercentage', window );">Long term, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DiscountRatePercentage', window );">Discount rate, percentage</a></td>
<td class="nump">21.90%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Intangible Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation expenses</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_GrowthRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_GrowthRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LongTermPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of long term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LongTermPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentsOfAdditionalDeferredCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of payments of additional deferred cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentsOfAdditionalDeferredCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchaseCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchaseCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Schedule of Fair Value of the Intangible Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at beginning</a></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Loss on impairment of intangible asset</a></td>
<td class="num">(1,344)<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill', window );">Depreciation of intangible asset</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at ending</a></td>
<td class="nump">$ 1,479<span></span>
</td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of intangible asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Payables - Schedule of Trade Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Schedule of Trade Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Open debts</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 816<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable - Schedule of Other Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accrued vacation</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Other accounts payable</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Cash and restricted deposits</a></td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivablesDueFromRelatedParties', window );">Related parties</a></td>
<td class="nump">4,239<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Total financial assets at amortized cost</a></td>
<td class="nump">6,248<span></span>
</td>
<td class="nump">5,344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Investments in financial assets at fair value</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CreditFromOthers', window );">Credit from others</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial and lease liabilities</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CreditFromOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of credit of others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CreditFromOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Company's Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="nump">354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems', window );"><strong>Schedule of Company's Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Investments in short-term financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsLiability', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Investments in financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfDefinedContributionPlansAbstract', window );"><strong>Schedule of Defined Contribution Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Expenses in respect of defined contribution plans</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfDefinedContributionPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfDefinedContributionPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingLossCarryforwardsTaxAmount', window );">Carryforward tax losses (in Dollars)</a></td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IL', window );">Israeli [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingLossCarryforwardsTaxAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net operating loss carryforward tax as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingLossCarryforwardsTaxAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities, Commitments, Claims and Liens (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalCommitmentsAbstract', window );"><strong>Contingent Liabilities, Commitments, Claims and Liens [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DekelLicenseAgreementDescription', window );">Milestone payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid
in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating
net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or
the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company&#8217;s discretion, the
respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are
8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing
from this application would likely be 2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AnnualInvestment', window );">Annual investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AdditionalMilestoneAmount', window );">Additional milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentAmount', window );">Installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EstimatedAmount', window );">Estimated amount</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Capital purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Capital warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">&#8362; 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AdditionalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AdditionalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AnnualInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AnnualInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DekelLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dekel license agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DekelLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EstimatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EstimatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of installment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Oct. 13, 2023</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CapitalRatio', window );">Capital ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ReverseSplitRatio', window );">Reverse split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services rendered amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfAggregateShares', window );">Issuance of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,542.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,435.98<span></span>
</td>
<td class="nump">$ 1,435.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,631<span></span>
</td>
<td class="nump">33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross cash proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="nump">$ 5,552<span></span>
</td>
<td class="nump">$ 9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Purchase sale (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CommitmentAmount', window );">Commitment amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SaleOfOrdinaryShares', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SharePriceRate', window );">Share price rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InstallmentPayment', window );">Installment payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PaymentForPremiumPercentage', window );">Payment for premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateIssuedAmount', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Commitment fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InterestRate', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InterestRate', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PreFundedUnitsMember', window );">Pre-Funded Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnitsPerShare', window );">Units per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,539.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember', window );">SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CommitmentAmount', window );">Commitment amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="nump">1,094,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateUnits', window );">Number of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember', window );">June 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,435.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceExpireTerm', window );">Expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember', window );">August 2023 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateGrossProceeds', window );">Aggregate gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember', window );">August 2023 Financing Round [Member] | Over Allotment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember', window );">August 2023 Financing Round [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108.654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember', window );">October 2023 Financing Round [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross cash proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember', window );">October 2023 Financing Round [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsAndExercise', window );">Warrants and exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate issued amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateUnitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share of aggregate units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateUnitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CapitalRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CapitalRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Installment payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceExpireTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance expire term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceExpireTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The issuance of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PaymentForPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for premium percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PaymentForPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ReverseSplitRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse split ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ReverseSplitRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SharePriceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SharePriceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsAndExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsAndExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PreFundedUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_PreFundedUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_June2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_August2023FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis=sprcy_OverAllotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sprcy_October2023FinancingRoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Share Capital (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfSharesAbstract', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ordinary shares, Issued and outstanding</a></td>
<td class="nump">515,631<span></span>
</td>
<td class="nump">33,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Issued and Outstanding Share Capital (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Schedule of Issued and Outstanding Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at January 1, 2024</a></td>
<td class="nump">33,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants', window );">Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants (Note 18h</a></td>
<td class="nump">175,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareIssuedToAConsultants', window );">Share issued to consultants (Note 18(e), and Note 19 (a) (3)</a></td>
<td class="nump">30,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IssuanceOfShareCapitalInRespectSEPA', window );">Issuance of share capital &#8211; in respect of January 2024 SEPA (Note 18(i))</a></td>
<td class="nump">276,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at December 31, 2024</a></td>
<td class="nump">515,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital &#8211; in respect of exercise of October 2023 pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IssuanceOfShareCapitalInRespectSEPA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of share capital &#8211; in respect of January 2024 SEPA.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IssuanceOfShareCapitalInRespectSEPA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareIssuedToAConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share issued to consultants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareIssuedToAConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrants&#8217; Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.38%<span></span>
</td>
<td class="nump">3.872%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying share price ($) (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.56<span></span>
</td>
<td class="nump">$ 102.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,435.98<span></span>
</td>
<td class="nump">$ 1,435.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than $1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 20, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 18, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,631<span></span>
</td>
<td class="nump">33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FairValueOfShareOptionsGranted', window );">Fair value of share options granted | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,407.86<span></span>
</td>
<td class="nump">$ 3,325.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OrdinarySharesGrantedDiscountRate', window );">Ordinary shares granted discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value of the ordinary shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfOptionsOutstanding', window );">Share options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,549<span></span>
</td>
<td class="nump">$ 444,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.56<span></span>
</td>
<td class="nump">$ 102.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_DirectorsMember', window );">Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issuance of ordinary shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember', window );">Share Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,724.54<span></span>
</td>
<td class="nump">$ 3,674.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted Share Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">25,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ConvertIntoOrdinaryShares', window );">Conversion of shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,238<span></span>
</td>
<td class="nump">25,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement', window );">Vest over period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.636<span></span>
</td>
<td class="nump">$ 18.753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Exercisable of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value of the ordinary shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member] | Share Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-Based Payment Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than $1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConvertIntoOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the share of restricted share units convert into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConvertIntoOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FairValueOfShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FairValueOfShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Other Equity Instruments Vested in Share based Payment Arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OrdinarySharesGrantedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares granted discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OrdinarySharesGrantedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sprcy_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) - Share Options [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Total</a></td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) - Share Options [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Schedule of Fair Value for Share Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying ordinary share price (in Dollars per share)</a></td>
<td class="nump">$ 2,724.54<span></span>
</td>
<td class="nump">$ 3,674.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">133.00%<span></span>
</td>
<td class="nump">134.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life of Share Options (years)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_a2024Abstract', window );"><strong>2024:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Share Options , Share Options outstanding at the beginning of the year</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the beginning of the year</a></td>
<td class="nump">$ 3,491.88<span></span>
</td>
<td class="nump">$ 3,488.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options cancelled during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options cancelled during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,035.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Share Options, Share Options outstanding at the end of the year</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options outstanding at the end of the year</a></td>
<td class="nump">$ 7,354.83<span></span>
</td>
<td class="nump">$ 3,491.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of Share Options, Share Options exercisable at the end of the year</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, Share Options exercisable at the end of the year</a></td>
<td class="nump">$ 7,354.83<span></span>
</td>
<td class="nump">$ 3,477.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_a2024Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_a2024Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions - Schedule of RSU transaction (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfRsuTransactionAbstract', window );"><strong>Schedule of RSU transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Balance, January 1, 2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">RSUs granted</a></td>
<td class="nump">50,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Expiry of RSUs</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercise of RSUs</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Balance, December 31, 2024</a></td>
<td class="nump">50,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfRsuTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfRsuTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_PurchasedGoodsMember', window );">Purchased goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_FreightMember', window );">Freight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems', window );"><strong>Schedule of Cost of Sales and Gross Profit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_PurchasedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_PurchasedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_FreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=sprcy_FreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,526<span></span>
</td>
<td class="nump">3,844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">5,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DOtherExpensesIncomeAbstract', window );"><strong>d. Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other expenses (income)</a></td>
<td class="num">(1,270)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember', window );">Wages and related expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">436<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember', window );">Share-based payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember', window );">Regulatory, professional and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember', window );">Research and preclinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember', window );">Clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember', window );">Chemistry and formulations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AResearchAndDevelopmentExpensesAbstract', window );"><strong>a. Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AdvertisementMember', window );">Advertising [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember', window );">Amazon fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">454<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_DepreciationMember', window );">Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageAndShippingMember', window );">Storage and shipping [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">91<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ManagementFeesMember', window );">Management fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BSalesAndMarketingExpensesAbstract', window );"><strong>b. Sales and marketing expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember', window );">Professional and directors&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember', window );">Business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">161<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember', window );">Regulatory expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember', window );">Office maintenance, rent and other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember', window );">Investor relations and business expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CGeneralAndAdministrativeExpensesAbstract', window );"><strong>c. General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossFromSaleOfPropertyAndEquipmentMember', window );">Loss from sale of property and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DOtherExpensesIncomeAbstract', window );"><strong>d. Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other expenses (income)</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember', window );">Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DOtherExpensesIncomeAbstract', window );"><strong>d. Other expenses (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other expenses (income)</a></td>
<td class="num">(1,287)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember', window );">Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember', window );">Interest from loans to related parties and deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="num">(421)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember', window );">Exchange rate differences, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EFinanceIncomeAbstract', window );"><strong>e. Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember', window );">Issuance expenses related to warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember', window );">Losses from remeasurement of investment in financial assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember', window );">Finance expense in respect of leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember', window );">Finance expenses from interest and commissions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_FFinanceExpensesAbstract', window );"><strong>f. Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassified</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BSalesAndMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BSalesAndMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DOtherExpensesIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DOtherExpensesIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EFinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EFinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_FFinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_FFinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_WagesAndRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryProfessionalAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ChemistryAndFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AdvertisementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AdvertisementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_AmazonFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_DepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_DepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_StorageAndShippingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_StorageAndShippingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ManagementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ManagementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ProfessionalAndDirectorsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_BusinessDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_RegulatoryExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_OfficeMaintenanceRentAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InvestorRelationsAndBusinessExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossFromSaleOfPropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_LossFromSaleOfPropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_ExchangeRateDifferencesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_IssuanceExpensesRelatedToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpenseInRespectOfLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_IncomeStatementsLocationsAxis=sprcy_FinanceExpensesFromInterestAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ContinuingOperationsAbstract', window );"><strong>Continuing operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic loss per share, Weighted number of shares</a></td>
<td class="nump">277,380<span></span>
</td>
<td class="nump">19,413<span></span>
</td>
<td class="nump">8,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument', window );">Basic loss per share, Loss (in Dollars)</a></td>
<td class="num">$ (7,472)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares', window );">Effect of potential dilutive ordinary shares, Weighted number of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare', window );">Effect of potential dilutive ordinary shares, Loss (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted loss per share, Weighted number of shares</a></td>
<td class="nump">277,380<span></span>
</td>
<td class="nump">19,413<span></span>
</td>
<td class="nump">8,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument', window );">Diluted loss per share, Loss (in Dollars)</a></td>
<td class="num">$ (7,472)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
<td class="num">$ (2,592)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity&#8217;s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph A14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_A14&amp;doctype=Appendix&amp;subtype=A<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the par value of effect of potential dilutive ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingSegmentsDetailsLineItems', window );"><strong>Operating Segments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesSegmentMember', window );">Online Sales Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OperatingSegmentsDetailsLineItems', window );"><strong>Operating Segments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Intangible asset</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OperatingSegmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OperatingSegmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Segments - Schedule of Operating Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Schedule of Operating Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">7,316<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
<td class="nump">8,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet', window );">Company&#8217;s share of losses of company accounted for at equity, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EquityLossesFromTheInvestment', window );">Equity losses from the investment in MitoCareX</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Finance expense (income), net</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(5,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax Income (expense)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss</a></td>
<td class="nump">7,472<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">10,171<span></span>
</td>
<td class="nump">11,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember', window );">Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Schedule of Operating Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">4,873<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember', window );">Online Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Schedule of Operating Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExternalRevenues', window );">External</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome', window );">Segment loss (gain)</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">1,456<span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Segment Assets</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Segment Liabilities</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company&#8217;s share of losses of company accounted for at equity, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EquityLossesFromTheInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity losses from the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EquityLossesFromTheInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExternalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of external revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExternalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_DrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sprcy_OnlineSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_InterestPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_DeferredCashPayment', window );">Deferred cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFeeAndCommissionExpense', window );">Other fee expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_BonusAmountReceived', window );">Bonus amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Engaged in a mutual share exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AcquiredOrdinaryShares', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateValues', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateValueAdjusted', window );">Aggregate values adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ListedSharePrice', window );">Listed share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CooperationAgreementAmount', window );">Cooperation Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ExchangeOfCommonShares', window );">Exchange of Common Shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_OutstandingShareCapital', window );">Outstanding share capital, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LicenseeIssuePrice', window );">Licensee issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_MilestonesAmount', window );">Milestones amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfAggregateNetSales', window );">Aggregate net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued (in Shares)</a></td>
<td class="nump">1,541,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,631<span></span>
</td>
<td class="nump">33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Aggregate consideration</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage', window );">Aggregate number of the outstanding ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember', window );">Jeffs&#8217; Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Engaged in a mutual share exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AcquiredOrdinaryShares', window );">Acquired ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ComprehensiveLossOnInvestment', window );">Loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage', window );">Aggregate number of the outstanding ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SaleOfStockAxis=sprcy_InitialPublicOfferingMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfUnitsReceived', window );">Number of units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,054,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfWarrantsHolds', window );">Warrants holds (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantsExpireDate', window );">Warrants expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfUnitsReceived', window );">Number of units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfUnitsReceived', window );">Number of units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Share [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Share [Member] | Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Transactions and Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Units received (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AcquiredOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AcquiredOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of the outstanding ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValueAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate values adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValueAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_BonusAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonus amount received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_BonusAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ComprehensiveLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of comprehensive loss on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ComprehensiveLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CooperationAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cooperation Agreement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CooperationAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_DeferredCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred cash payments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_DeferredCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ExchangeOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ExchangeOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_InterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_InterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_LicenseeIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of licensee, reflecting an issue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_LicenseeIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ListedSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of listed shares price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ListedSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_MilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestones amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_MilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfUnitsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfUnitsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfWarrantsHolds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants holds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfWarrantsHolds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_OutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_OutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfAggregateNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfAggregateNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantsExpireDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants expire date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantsExpireDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_JeffsBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfStockAxis=sprcy_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfStockAxis=sprcy_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=sprcy_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CurrentAsset', window );">Current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems', window );"><strong>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_CurrentAsset', window );">Current assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_CurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_CurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract', window );"><strong>Schedule of Transactions with Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions', window );">Research and development expenses</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SaleOfMinorityInterestInSubsidiary', window );">Sale of minority interest in subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,985<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of research and development to the entity in related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SaleOfMinorityInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of minority interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SaleOfMinorityInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract', window );"><strong>Schedule of Benefits to Key Management Personnel [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">$ 1,204<span></span>
</td>
<td class="nump">$ 1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_KeyManagementPersonnelCompensationManagementFees', window );">Management fees (see also note 25a)</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Cost of share-based payment</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_KeyManagementPersonnelCompensationManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of management fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_KeyManagementPersonnelCompensationManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Related Parties - Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes (Details) - Warrants [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems', window );"><strong>Schedule of Warrants&#8217; Fair Value was Calculated using the Black&#8211;Scholes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (%)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">2.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Underlying Share Price of Polyrizon Ltd. ($) (in Dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Warrants fair value ($) (in Dollars)</a></td>
<td class="nump">$ 1,399<span></span>
</td>
<td class="nump">$ 517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events during the Reporting Period (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_EnterpriseValue', window );">Enterprise value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCashAndCashEquivalents', window );">Cash position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">9.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="nump">84.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ShareCapitalPercentage', window );">Share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember', window );">Miza [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems', window );"><strong>Significant Events During the Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_EnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of enterprise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_EnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share capital percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_SignificantEventsDuringTheReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_SignificantEventsDuringTheReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MizaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Events After the Reporting Date (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Feb. 25, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_NumberOfWarrantsIssued', window );">Number of warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePricePerWarrant', window );">Volume weighted average price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.6172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,631<span></span>
</td>
<td class="nump">1,541,096<span></span>
</td>
<td class="nump">33,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RepaidOfMonthlyInstallments', window );">Monthly installments (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Aggregate principal amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PurchasePricePercentage', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay', window );">Volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays', window );">Volume weighted average price during consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_ConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing', window );">Volume weighted average price of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_WarrantExercisableTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Investing amount (in Dollars)</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateInvestment', window );">Aggregate investment (in Dollars)</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfFullyDilutedCapitalStock', window );">Percentage of fully diluted capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfFinancingProceeds', window );">Percentage of financing proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Financing proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_RestrictedStockGrantPercentage', window );">Restricted stock grant percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_VestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember', window );">AutoMax [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Loan amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateLoanAmount', window );">Aggregate loan amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember', window );">SciSparc&#8217;s [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_AggregateLoanAmount', window );">Aggregate loan amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_N2OFFMember', window );">N2OFF [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_PercentageOfFullyDilutedCapitalStock', window );">Percentage of fully diluted capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember', window );">MitoCareX [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentIncome', window );">Investing amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing', window );">Volume weighted average price of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember', window );">Debentures [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember', window );">Debentures [Member] | Top of Range [Member] | Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Events After the Reporting Date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment income, such as interest and dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>aggregate investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_AggregateLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate loan amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_AggregateLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_ConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_ConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfFinancingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfFinancingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PercentageOfFullyDilutedCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fully diluted capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PercentageOfFullyDilutedCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_PurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_PurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RepaidOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repaid of Monthly installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RepaidOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_RestrictedStockGrantPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock grant percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_RestrictedStockGrantPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of ordinary shares during the consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of ordinary shares of preceding the closing of trading day.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of ordinary shares on the day prior to the closing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_VolumeWeightedAveragePricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price per warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_VolumeWeightedAveragePricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sprcy_WarrantExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercisable term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sprcy_WarrantExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sprcy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sprcy_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_AutoMaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_SciSparcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_N2OFFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_N2OFFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sprcy_MitoCareXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=sprcy_DebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>355</ContextCount>
  <ElementCount>371</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>86</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements</Role>
      <ShortName>Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Cash</Role>
      <ShortName>Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivable</Role>
      <ShortName>Other Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Investment in Associates and Joint Ventures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesandJointVentures</Role>
      <ShortName>Investment in Associates and Joint Ventures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Investment in Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssets</Role>
      <ShortName>Investment in Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAsset</Role>
      <ShortName>Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Trade Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayables</Role>
      <ShortName>Trade Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Employee Benefit Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilities</Role>
      <ShortName>Employee Benefit Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Revenues and Cost of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenues</Role>
      <ShortName>Revenues and Cost of Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Additional Information to the Items of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</Role>
      <ShortName>Additional Information to the Items of Profit or Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Operating Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegments</Role>
      <ShortName>Operating Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Transactions and Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</Role>
      <ShortName>Transactions and Balances with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Significant Events during the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</Role>
      <ShortName>Significant Events during the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Events After the Reporting Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsAftertheReportingDate</Role>
      <ShortName>Events After the Reporting Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/CashTables</Role>
      <ShortName>Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Cash</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Inventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsReceivableTables</Role>
      <ShortName>Other Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsReceivable</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Investment in Associates and Joint Ventures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables</Role>
      <ShortName>Investment in Associates and Joint Ventures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesandJointVentures</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetTables</Role>
      <ShortName>Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAsset</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Trade Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TradePayablesTables</Role>
      <ShortName>Trade Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TradePayables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OtherAccountsPayable</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/FinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Employee Benefit Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EmployeeBenefitLiabilitiesTables</Role>
      <ShortName>Employee Benefit Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/EmployeeBenefitLiabilities</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/Equity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Revenues and Cost of Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/RevenuesandCostofRevenuesTables</Role>
      <ShortName>Revenues and Cost of Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/RevenuesandCostofRevenues</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables</Role>
      <ShortName>Additional Information to the Items of Profit or Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/LossPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Operating Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegmentsTables</Role>
      <ShortName>Operating Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegments</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Transactions and Balances with Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedParties</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996019 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/General</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Cash - Schedule of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCashTable</Role>
      <ShortName>Cash - Schedule of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsReceivableTable</Role>
      <ShortName>Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Investment in Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails</Role>
      <ShortName>Investment in Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable</Role>
      <ShortName>Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Investment in Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/InvestmentinFinancialAssetsDetails</Role>
      <ShortName>Investment in Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/InvestmentinFinancialAssets</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/Leases</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/IntangibleAssetDetails</Role>
      <ShortName>Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/IntangibleAssetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable</Role>
      <ShortName>Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTradePayablesTable</Role>
      <ShortName>Trade Payables - Schedule of Trade Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable - Schedule of Other Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable</Role>
      <ShortName>Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Financial Instruments - Schedule of Company's Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable</Role>
      <ShortName>Financial Instruments - Schedule of Company's Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofDefinedContributionPlansTable</Role>
      <ShortName>Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TaxesonIncome</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails</Role>
      <ShortName>Contingent Liabilities, Commitments, Claims and Liens (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EquityTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable</Role>
      <ShortName>Equity - Schedule of Issued and Outstanding Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Equity - Schedule of Warrants??? Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable</Role>
      <ShortName>Equity - Schedule of Warrants??? Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Share-Based Payment Transactions - Schedule of RSU transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofRSUtransactionTable</Role>
      <ShortName>Share-Based Payment Transactions - Schedule of RSU transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable</Role>
      <ShortName>Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable</Role>
      <ShortName>Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable</Role>
      <ShortName>Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/OperatingSegmentsDetails</Role>
      <ShortName>Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/OperatingSegmentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofOperatingSegmentsTable</Role>
      <ShortName>Operating Segments - Schedule of Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Transactions and Balances with Related Parties - Schedule of Warrants??? Fair Value was Calculated using the Black???Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable</Role>
      <ShortName>Transactions and Balances with Related Parties - Schedule of Warrants??? Fair Value was Calculated using the Black???Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Significant Events during the Reporting Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails</Role>
      <ShortName>Significant Events during the Reporting Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/SignificantEventsduringtheReportingPeriod</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ea0248138-f4a9_scisparc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Events After the Reporting Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trpx.com/role/EventsAftertheReportingDateDetails</Role>
      <ShortName>Events After the Reporting Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://trpx.com/role/EventsAftertheReportingDate</ParentRole>
      <Position>92</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="F-4/A" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0248138-f4a9_scisparc.htm">ea0248138-f4a9_scisparc.htm</File>
    <File>sprcy-20241231.xsd</File>
    <File>sprcy-20241231_cal.xml</File>
    <File>sprcy-20241231_def.xml</File>
    <File>sprcy-20241231_lab.xml</File>
    <File>sprcy-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>fin_001a.jpg</File>
    <File>fin_002.jpg</File>
    <File>fin_003.jpg</File>
    <File>fin_004.jpg</File>
    <File>fin_005.jpg</File>
    <File>image_001.jpg</File>
    <File>image_001a.jpg</File>
    <File>image_001b.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="904">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>240
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0248138-f4a9_scisparc.htm": {
   "nsprefix": "sprcy",
   "nsuri": "http://trpx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0248138-f4a9_scisparc.htm"
     ]
    },
    "schema": {
     "local": [
      "sprcy-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sprcy-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sprcy-20241231_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sprcy-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sprcy-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 243,
   "keyCustom": 128,
   "axisStandard": 19,
   "axisCustom": 2,
   "memberStandard": 29,
   "memberCustom": 55,
   "hidden": {
    "total": 158,
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 121,
    "http://trpx.com/20241231": 34,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 355,
   "entityCount": 1,
   "segmentCount": 86,
   "elementCount": 631,
   "unitCount": 7,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 904,
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://trpx.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://trpx.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentRestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://trpx.com/role/ConsolidatedIncomeStatement",
     "longName": "002 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://trpx.com/role/ShareholdersEquityType2or3",
     "longName": "003 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://trpx.com/role/ConsolidatedCashFlow",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://trpx.com/role/General",
     "longName": "005 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://trpx.com/role/SignificantAccountingPolicies",
     "longName": "006 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements",
     "longName": "007 - Disclosure - Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "shortName": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://trpx.com/role/Cash",
     "longName": "008 - Disclosure - Cash",
     "shortName": "Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://trpx.com/role/Inventory",
     "longName": "009 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://trpx.com/role/OtherAccountsReceivable",
     "longName": "010 - Disclosure - Other Accounts Receivable",
     "shortName": "Other Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://trpx.com/role/InvestmentinAssociatesandJointVentures",
     "longName": "011 - Disclosure - Investment in Associates and Joint Ventures",
     "shortName": "Investment in Associates and Joint Ventures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssets",
     "longName": "012 - Disclosure - Investment in Financial Assets",
     "shortName": "Investment in Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://trpx.com/role/Leases",
     "longName": "013 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://trpx.com/role/PropertyandEquipmentNet",
     "longName": "014 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://trpx.com/role/IntangibleAsset",
     "longName": "015 - Disclosure - Intangible Asset",
     "shortName": "Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://trpx.com/role/TradePayables",
     "longName": "016 - Disclosure - Trade Payables",
     "shortName": "Trade Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://trpx.com/role/OtherAccountsPayable",
     "longName": "017 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://trpx.com/role/FinancialInstruments",
     "longName": "018 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilities",
     "longName": "019 - Disclosure - Employee Benefit Liabilities",
     "shortName": "Employee Benefit Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://trpx.com/role/TaxesonIncome",
     "longName": "020 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens",
     "longName": "021 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://trpx.com/role/Equity",
     "longName": "022 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactions",
     "longName": "023 - Disclosure - Share-Based Payment Transactions",
     "shortName": "Share-Based Payment Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenues",
     "longName": "024 - Disclosure - Revenues and Cost of Revenues",
     "shortName": "Revenues and Cost of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss",
     "longName": "025 - Disclosure - Additional Information to the Items of Profit or Loss",
     "shortName": "Additional Information to the Items of Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://trpx.com/role/LossPerShare",
     "longName": "026 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://trpx.com/role/OperatingSegments",
     "longName": "027 - Disclosure - Operating Segments",
     "shortName": "Operating Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedParties",
     "longName": "028 - Disclosure - Transactions and Balances with Related Parties",
     "shortName": "Transactions and Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriod",
     "longName": "029 - Disclosure - Significant Events during the Reporting Period",
     "shortName": "Significant Events during the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://trpx.com/role/EventsAftertheReportingDate",
     "longName": "030 - Disclosure - Events After the Reporting Date",
     "shortName": "Events After the Reporting Date",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://trpx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DescriptionofBasisofpresentationofthefinancialstatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://trpx.com/role/CashTables",
     "longName": "996002 - Disclosure - Cash (Tables)",
     "shortName": "Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://trpx.com/role/InventoryTables",
     "longName": "996003 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInventorieExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfInventorieExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://trpx.com/role/OtherAccountsReceivableTables",
     "longName": "996004 - Disclosure - Other Accounts Receivable (Tables)",
     "shortName": "Other Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables",
     "longName": "996005 - Disclosure - Investment in Associates and Joint Ventures (Tables)",
     "shortName": "Investment in Associates and Joint Ventures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetTables",
     "longName": "996006 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://trpx.com/role/IntangibleAssetTables",
     "longName": "996007 - Disclosure - Intangible Asset (Tables)",
     "shortName": "Intangible Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://trpx.com/role/TradePayablesTables",
     "longName": "996008 - Disclosure - Trade Payables (Tables)",
     "shortName": "Trade Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfTradePayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfTradePayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://trpx.com/role/OtherAccountsPayableTables",
     "longName": "996009 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://trpx.com/role/FinancialInstrumentsTables",
     "longName": "996010 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://trpx.com/role/EmployeeBenefitLiabilitiesTables",
     "longName": "996011 - Disclosure - Employee Benefit Liabilities (Tables)",
     "shortName": "Employee Benefit Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://trpx.com/role/EquityTables",
     "longName": "996012 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsTables",
     "longName": "996013 - Disclosure - Share-Based Payment Transactions (Tables)",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://trpx.com/role/RevenuesandCostofRevenuesTables",
     "longName": "996014 - Disclosure - Revenues and Cost of Revenues (Tables)",
     "shortName": "Revenues and Cost of Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables",
     "longName": "996015 - Disclosure - Additional Information to the Items of Profit or Loss (Tables)",
     "shortName": "Additional Information to the Items of Profit or Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://trpx.com/role/LossPerShareTables",
     "longName": "996016 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://trpx.com/role/OperatingSegmentsTables",
     "longName": "996017 - Disclosure - Operating Segments (Tables)",
     "shortName": "Operating Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables",
     "longName": "996018 - Disclosure - Transactions and Balances with Related Parties (Tables)",
     "shortName": "Transactions and Balances with Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:RelatedPartyBalancetextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:RelatedPartyBalancetextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://trpx.com/role/GeneralDetails",
     "longName": "996019 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c64",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://trpx.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996020 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:OperatingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
     "longName": "996021 - Disclosure - Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "sprcy:StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://trpx.com/role/ScheduleofCashTable",
     "longName": "996022 - Disclosure - Cash - Schedule of Cash (Details)",
     "shortName": "Cash - Schedule of Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosueOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://trpx.com/role/ScheduleofInventoryTable",
     "longName": "996023 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInventorieExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentInventoriesInTransit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInventorieExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable",
     "longName": "996024 - Disclosure - Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)",
     "shortName": "Other Accounts Receivable - Schedule of Other Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "sprcy:Governmentauthoritiescurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "sprcy:Governmentauthoritiescurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclourseOfAccountsReceivablesTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
     "longName": "996025 - Disclosure - Investment in Associates and Joint Ventures (Details)",
     "shortName": "Investment in Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c79",
      "name": "sprcy:InitialInvestment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "sprcy:InitialInvestment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable",
     "longName": "996026 - Disclosure - Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)",
     "shortName": "Investment in Associates and Joint Ventures - Schedule of Fair Value of the Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "sprcy:InvestmentsDate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
     "longName": "996027 - Disclosure - Investment in Financial Assets (Details)",
     "shortName": "Investment in Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "sprcy:ReverseShareSplitRatio",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfInvestmentFinancialAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://trpx.com/role/LeasesDetails",
     "longName": "996028 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c106",
      "name": "sprcy:AreaOfLease",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c106",
      "name": "sprcy:AreaOfLease",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://trpx.com/role/PropertyandEquipmentNetDetails",
     "longName": "996029 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996030 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://trpx.com/role/IntangibleAssetDetails",
     "longName": "996031 - Disclosure - Intangible Asset (Details)",
     "shortName": "Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:PaymentsOfAdditionalDeferredCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
     "longName": "996032 - Disclosure - Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "shortName": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DepreciationOfIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://trpx.com/role/ScheduleofTradePayablesTable",
     "longName": "996033 - Disclosure - Trade Payables - Schedule of Trade Payables (Details)",
     "shortName": "Trade Payables - Schedule of Trade Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfTradePayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://trpx.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996034 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "shortName": "Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
       "sprcy:DisclosureOfOtherAccountsPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
     "longName": "996035 - Disclosure - Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "shortName": "Financial Instruments - Schedule of Financial Assets and Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RestrictedCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable",
     "longName": "996036 - Disclosure - Financial Instruments - Schedule of Company's Financial Instruments (Details)",
     "shortName": "Financial Instruments - Schedule of Company's Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c157",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://trpx.com/role/ScheduleofDefinedContributionPlansTable",
     "longName": "996037 - Disclosure - Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)",
     "shortName": "Employee Benefit Liabilities - Schedule of Defined Contribution Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://trpx.com/role/TaxesonIncomeDetails",
     "longName": "996038 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "sprcy:OperatingLossCarryforwardsTaxAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "sprcy:OperatingLossCarryforwardsTaxAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails",
     "longName": "996039 - Disclosure - Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "shortName": "Contingent Liabilities, Commitments, Claims and Liens (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:DekelLicenseAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://trpx.com/role/EquityDetails",
     "longName": "996040 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c173",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c172",
      "name": "sprcy:CapitalRatio",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://trpx.com/role/ScheduleofShareCapitalTable",
     "longName": "996041 - Disclosure - Equity - Schedule of Share Capital (Details)",
     "shortName": "Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
     "longName": "996042 - Disclosure - Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "shortName": "Equity - Schedule of Issued and Outstanding Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
     "longName": "996043 - Disclosure - Equity - Schedule of Warrants\u2019 Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)",
     "shortName": "Equity - Schedule of Warrants\u2019 Fair Value was Calculated Using the Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
     "longName": "996044 - Disclosure - Share-Based Payment Transactions (Details)",
     "shortName": "Share-Based Payment Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfIssuedAndOutstandingShareCapital",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c200",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
     "longName": "996045 - Disclosure - Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c209",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c209",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
     "longName": "996046 - Disclosure - Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c212",
      "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c212",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable",
     "longName": "996047 - Disclosure - Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of Weighted Average Exercise Prices of Share Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c31",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://trpx.com/role/ScheduleofRSUtransactionTable",
     "longName": "996048 - Disclosure - Share-Based Payment Transactions - Schedule of RSU transaction (Details)",
     "shortName": "Share-Based Payment Transactions - Schedule of RSU transaction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable",
     "longName": "996049 - Disclosure - Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)",
     "shortName": "Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c214",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sprcy:ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
     "longName": "996050 - Disclosure - Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "shortName": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherFinanceIncomeCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfAdditionalInformationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable",
     "longName": "996051 - Disclosure - Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://trpx.com/role/OperatingSegmentsDetails",
     "longName": "996052 - Disclosure - Operating Segments (Details)",
     "shortName": "Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
     "longName": "996053 - Disclosure - Operating Segments - Schedule of Operating Segments (Details)",
     "shortName": "Operating Segments - Schedule of Operating Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:ExternalRevenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "996054 - Disclosure - Transactions and Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c306",
      "name": "sprcy:InterestPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c306",
      "name": "sprcy:InterestPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "996055 - Disclosure - Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c329",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c329",
      "name": "ifrs-full:CurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable",
     "longName": "996056 - Disclosure - Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Transactions with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable",
     "longName": "996057 - Disclosure - Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Benefits to Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
     "longName": "996058 - Disclosure - Transactions and Balances with Related Parties - Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes (Details)",
     "shortName": "Transactions and Balances with Related Parties - Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c323",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c323",
      "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
     "longName": "996059 - Disclosure - Significant Events during the Reporting Period (Details)",
     "shortName": "Significant Events during the Reporting Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "sprcy:EnterpriseValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "sprcy:EnterpriseValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "sprcy:DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://trpx.com/role/EventsAftertheReportingDateDetails",
     "longName": "996060 - Disclosure - Events After the Reporting Date (Details)",
     "shortName": "Events After the Reporting Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c347",
      "name": "sprcy:NumberOfWarrantsIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0248138-f4a9_scisparc.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sprcy_AResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AResearchAndDevelopmentExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "a. Research and development expenses:",
        "label": "AResearch And Development Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued vacation",
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sprcy_AccumulatedDepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AccumulatedDepreciationAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AccumulatedDepreciationAbstract0",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AccumulatedDepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AccumulatedDepreciationMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Depreciation [Member]",
        "label": "Accumulated Depreciation Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AcquiredOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AcquiredOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ordinary shares (in Shares)",
        "documentation": "The number of shares acquired.",
        "label": "Acquired Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of intangible asset",
        "label": "Acquisitions through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_AdditionalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information to the Items of Profit or Loss [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdditionalInformationtotheItemsofProfitorLossScheduleofAdditionalInformationtotheItemsofProfitorLossDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information to the Items of Profit or Loss - Schedule of Additional Information to the Items of Profit or Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdditionalInstallment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional installment",
        "documentation": "The amount of additional installment.",
        "label": "Additional Installment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdditionalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional investment",
        "documentation": "The amount of additional investment.",
        "label": "Additional Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdditionalMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdditionalMilestoneAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone amount",
        "label": "Additional Milestone Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in inventory",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease (increase) in other accounts receivable",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income, net",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on impairment of intangible asset",
        "verboseLabel": "Impairment to its intangible asset",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustments:",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in other accounts payable",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "sprcy_AdjustmentsForIncreaseInRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdjustmentsForIncreaseInRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in related parties",
        "documentation": "Adjustments for increase in related parties.",
        "label": "Adjustments For Increase In Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdjustmentsForLossesFromRemeasurementOfInvestmentInFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets",
        "documentation": "Adjustments for losses from remeasurement of investment in financial assets\r     \n  to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Losses From Remeasurement Of Investment In Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments to the profit or loss",
        "label": "Adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile loss to net cash used in operating activities:",
        "verboseLabel": "Adjustments to the profit or loss items:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdjustmentsForShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Adjustments for group\u2019s share of losses of company accounted for at equity, net.",
        "label": "Adjustments For Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Cost of share-based payment",
        "verboseLabel": "Share-based compensation",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Working capital",
        "label": "Adjustments to reconcile profit (loss) other than changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "sprcy_AdvertisementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AdvertisementMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising [Member]",
        "label": "Advertisement Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateGrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "documentation": "Aggregate Gross Proceeds means the aggregate of the proceeds from any sale of shares of Common Stock by the Underwriter pursuant to this Agreement, before the deduction of Commissions and Placement Fees payable with respect to those shares.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate investment (in Dollars)",
        "documentation": "aggregate investment.",
        "label": "Aggregate Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateIssuedAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateIssuedAmount",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares",
        "documentation": "Aggregate issued amount.",
        "label": "Aggregate Issued Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateLoanAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateLoanAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate loan amount (in Dollars)",
        "documentation": "Aggregate loan amount.",
        "label": "Aggregate Loan Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateNumberOfOutstandingOrdinarySharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateNumberOfOutstandingOrdinarySharesPercentage",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of the outstanding ordinary shares",
        "documentation": "Aggregate number of the outstanding ordinary shares.",
        "label": "Aggregate Number Of Outstanding Ordinary Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateUnits",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units",
        "documentation": "Number of shares issued.",
        "label": "Aggregate Units"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateUnitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateUnitsPerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units per share (in Dollars per share)",
        "documentation": "Per share of aggregate units.",
        "label": "Aggregate Units Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValueAdjusted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateValueAdjusted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate values adjusted",
        "documentation": "The amount of aggregate values adjusted.",
        "label": "Aggregate Value Adjusted"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AggregateValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AggregateValues",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value",
        "documentation": "The amount of aggregate value.",
        "label": "Aggregate Values"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AmazonFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AmazonFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amazon fees [Member]",
        "label": "Amazon Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AnnualInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AnnualInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual investment",
        "documentation": "Amount of annual investment.",
        "label": "Annual Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AreaOfLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AreaOfLease",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of lease",
        "documentation": "Area of Lease.",
        "label": "Area Of Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r127",
      "r128",
      "r129",
      "r163",
      "r167"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207"
     ]
    },
    "sprcy_August2023FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "August2023FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Financing Round [Member]",
        "label": "August2023 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_AutoMaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "AutoMaxMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AutoMax [Member]",
        "label": "Auto Max Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_BSalesAndMarketingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "BSalesAndMarketingExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "b. Sales and marketing expenses:",
        "label": "BSales And Marketing Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per ordinary share attributable to equity holders of the Company (in Dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "sprcy_BonusAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "BonusAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus amount",
        "documentation": "Bonus amount received.",
        "label": "Bonus Amount Received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [member]",
        "verboseLabel": "Bottom of range [Member]",
        "netLabel": "Bottom of Range [Member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r226"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203"
     ]
    },
    "sprcy_BusinessDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "BusinessDevelopmentExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development expenses [Member]",
        "label": "Business Development Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CGeneralAndAdministrativeExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "c. General and administrative expenses:",
        "label": "CGeneral And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital warrant",
        "label": "Capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of future capital expenditures that the entity is committed to make."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_CapitalCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities, Commitments, Claims and Liens [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CapitalRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CapitalRatio",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital ratio",
        "documentation": "Capital ratio.",
        "label": "Capital Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r46",
      "r82",
      "r85",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r148",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r85",
      "r91",
      "r93",
      "r94",
      "r148",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "verboseLabel": "Cash consideration",
        "netLabel": "Cash payment (in Dollars)",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAdvancesAndLoansMadeToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bridge loan to related parties",
        "label": "Cash advances and loans made to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails",
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at the beginning of the period",
        "periodEndLabel": "Cash at the end of the period",
        "terseLabel": "Cash",
        "verboseLabel": "Cash for immediate withdrawal",
        "netLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r105",
      "r123"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CashConsideration",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "documentation": "Cash consideration.",
        "label": "Cash Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withdrawal of (investment in) restricted bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withdrawal of (investment in) short-term bank deposits",
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CashScheduleofCashDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CashScheduleofCashDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash - Schedule of Cash (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Categories of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/LeasesDetails",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "sprcy_ChemistryAndFormulationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ChemistryAndFormulationsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry and formulations [Member]",
        "label": "Chemistry And Formulations Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfEntitysOwnEquityInstrumentsDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of entity's own equity instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOrdinarySharesAxis",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOrdinarySharesDomain",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "sprcy_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical studies [Member]",
        "label": "Clinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount (in Dollars)",
        "documentation": "Commitment amount.",
        "label": "Commitment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommunicationAndNetworkEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CommunicationAndNetworkEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Communication and network equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "sprcy_CompanysShareOfLossesOfCompanyAccountedForAtEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CompanysShareOfLossesOfCompanyAccountedForAtEquityNet",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s share of losses of company accounted for at equity, net",
        "documentation": "Company\u2019s share of losses of company accounted for at equity, net.",
        "label": "Companys Share Of Losses Of Company Accounted For At Equity Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_ComprehensiveLossOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ComprehensiveLossOnInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on investment",
        "documentation": "Amount of comprehensive loss on investment.",
        "label": "Comprehensive Loss On Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "sprcy_ConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ConsecutiveTradingDays",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading days",
        "documentation": "Number of consecutive trading days.",
        "label": "Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ConsiderationPaidReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate consideration",
        "verboseLabel": "Consideration",
        "label": "Consideration paid (received)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "sprcy_ConsolidatedStatementsOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ConsolidatedStatementsOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ContinuingOperationsAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations:",
        "label": "Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ConvertIntoOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ConvertIntoOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of shares",
        "documentation": "Represents the share of restricted share units convert into ordinary shares.",
        "label": "Convert Into Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CooperationAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CooperationAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cooperation Agreement amount",
        "documentation": "Cooperation Agreement amount.",
        "label": "Cooperation Agreement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CostAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost:",
        "label": "Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_CostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CostMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost [Member]",
        "label": "Cost Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of goods sold",
        "terseLabel": "Cost of goods sold",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r34"
     ]
    },
    "sprcy_CreditFromOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CreditFromOthers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit from others",
        "documentation": "The amount of credit of others.",
        "label": "Credit From Others"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "sprcy_CurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "CurrentAsset",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "documentation": "The amount of current assets.",
        "label": "Current Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r118",
      "r192"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInventoriesInTransit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInventoriesInTransit",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods in transit",
        "label": "Current inventories in transit"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of inventories in transit. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current investments",
        "label": "Current investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r120",
      "r192"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposit",
        "label": "Current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179"
     ]
    },
    "ifrs-full_CurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Current warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "sprcy_DOtherExpensesIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DOtherExpensesIncomeAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "d. Other expenses (income):",
        "label": "DOther Expenses Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DebenturesMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debentures [Member]",
        "label": "Debentures Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DeferredCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DeferredCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred cash payments",
        "documentation": "Deferred cash payments amount.",
        "label": "Deferred Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DekelLicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DekelLicenseAgreementDescription",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments, description",
        "documentation": "Dekel license agreement description.",
        "label": "Dekel License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "sprcy_DepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DepreciationMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation [Member]",
        "label": "Depreciation Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DepreciationOfIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DepreciationOfIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of intangible asset",
        "documentation": "The amount of depreciation of intangible asset.",
        "label": "Depreciation Of Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48"
     ]
    },
    "ifrs-full_DepreciationRatePropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRatePropertyPlantAndEquipment",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates",
        "label": "Depreciation rate, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements, description",
        "label": "Description of intangible assets with indefinite useful life supporting assessment of indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DescriptionOfAccountingPolicyCostOfSalesPolicyTextBlock",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "documentation": "Description of accounting policy cost of sales.",
        "label": "Description Of Accounting Policy Cost Of Sales Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAccountingPolicyForConsolidatedfinancialstatements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForConsolidatedfinancialstatements",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated financial statements",
        "documentation": "The description of the entity's accounting policy changes in Consolidated financial statements.",
        "label": "Description Of Accounting Policy For Consolidatedfinancialstatements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit liabilities",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income and expenses",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency and foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of non-financial assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in joint arrangements",
        "label": "Description of accounting policy for investment in associates and joint ventures [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investment in associates and joint ventures. [Refer: Total for all associates [member]; Total for all joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Description of accounting policy for investments other than investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenditures",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "label": "Description of accounting policy for restricted cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "sprcy_DescriptionOfAccountingPolicyForoperatingcycleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForoperatingcycleExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The operating cycle",
        "documentation": "The description of the entity's accounting policy changes in operating cycle Explanatory.",
        "label": "Description Of Accounting Policy Foroperatingcycle Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DescriptionOfAcquisitionOfASingleAssetCompany": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DescriptionOfAcquisitionOfASingleAssetCompany",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of a single asset company",
        "documentation": "The description of the entity's accounting policy for acquisition of a single asset company.",
        "label": "Description Of Acquisition Of ASingle Asset Company"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life of Share Options (years)",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "sprcy_DescriptionofBasisofpresentationofthefinancialstatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DescriptionofBasisofpresentationofthefinancialstatementsExplanatory",
     "presentation": [
      "http://trpx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation of the financial statements",
        "documentation": "The description of accounting policies for basis of presentation of the financial statements.",
        "label": "Descriptionof Basisofpresentationofthefinancialstatements Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per ordinary share attributable to equity holders of the Company (in Dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "ifrs-full_DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfAllInstrumentsOnWeightedAverageNumberOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of potential dilutive ordinary shares, Weighted number of shares",
        "label": "Dilutive effect of all instruments on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relates to the assumed conversion of the entity\u2019s instruments. It represents the aggregate of the reconciliation amounts for all classes of instruments that reflect dilutive effect on weighted average number of ordinary shares."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sprcy_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DirectorsMember",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosueOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosueOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://trpx.com/role/CashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash",
        "documentation": "The entire disclosue of cash and cash equivalents.",
        "label": "Disclosue Of Cash And Cash Equivalents Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Disclosure of accrued expenses and other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfAdditionalInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAdditionalInformationExplanatory",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS",
        "label": "Disclosure of additional information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Benefits to Key Management Personnel [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://trpx.com/role/Cash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiens"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates",
        "label": "Disclosure of depreciation and amortisation expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfDetailedInformationAboutDefinedContributionPlansExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Contribution Plans",
        "documentation": "Disclosure of detailed information about defined contribution plans explanatory.",
        "label": "Disclosure Of Detailed Information About Defined Contribution Plans Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Intangible Asset",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://trpx.com/role/EmployeeBenefitLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT LIABILITIES",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING SEGMENTS",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EVENTS AFTER THE REPORTING DATE",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://trpx.com/role/AdditionalInformationtotheItemsofProfitorLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information to the Items of Profit or Loss",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfExpensesDueToShareBasedCompensationExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Due to Share-Based Compensation",
        "documentation": "Disclosure of expenses due to share-based compensation explanatory.",
        "label": "Disclosure Of Expenses Due To Share Based Compensation Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfFairValueForShareOptionsGrantedExplanatoryTextBlock",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value for Share Options Granted",
        "documentation": "Disclosure of fair value for share options granted explanatory.",
        "label": "Disclosure Of Fair Value For Share Options Granted Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES AND COST OF REVENUES",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Financial Instruments",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://trpx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://trpx.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants\u2019 Fair Value was Calculated Using the Black-Scholes Option Pricing Model",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Benefits to Key Management Personnel",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/IntangibleAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSET",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Intangible Asset [Line Items]",
        "terseLabel": "Intangible Asset [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfInventorieExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfInventorieExplanatory",
     "presentation": [
      "http://trpx.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "documentation": "The tabular disclosure of inventories.",
        "label": "Disclosure Of Inventorie Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://trpx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "sprcy_DisclosureOfInvestmentFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfInvestmentFinancialAssetsExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN FINANCIAL ASSETS",
        "documentation": "The disclosure of the investment financial assets.",
        "label": "Disclosure Of Investment Financial Assets Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Investment",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_DisclosureOfIssuedAndOutstandingShareCapital": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfIssuedAndOutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Issued and Outstanding Share Capital",
        "documentation": "Disclosure of detailed inforamtion about issued and outstanding share capital.",
        "label": "Disclosure Of Issued And Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://trpx.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU transaction",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Exercise Prices of Share Options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Fair Value was Calculated Using the Black-Scholes Option Pricing Model [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Segments",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Segments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclosureOfOtherAccountsPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfOtherAccountsPayableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Disclosure Of Other Accounts Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://trpx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment, Net"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value for Share Options Granted [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Financial Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities",
        "label": "Disclosure of redesignated financial assets and liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets and financial liabilities that have been redesignated during the transition to IFRSs. [Refer: Financial assets; Financial liabilities; IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://trpx.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "sprcy_DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfSignificantEventsDuringTheReportingPeriodTextBlock",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT EVENTS DURING THE REPORTING PERIOD",
        "label": "Disclosure Of Significant Events During The Reporting Period Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVentures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Associates and Joint Ventures",
        "label": "Disclosure of associates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r126"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantJudgementsAndAssumptionsMadeInRelationToInterestsInOtherEntitiesExplanatory",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingJudgmentsEstimatesandAssumptionsUsedinthePreparationoftheFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS",
        "label": "Disclosure of significant judgements and assumptions made in relation to interests in other entities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant judgements and assumptions made in relation to interests in other entities."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://trpx.com/role/TradePayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "sprcy_DisclosureOfTradePayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclosureOfTradePayablesExplanatory",
     "presentation": [
      "http://trpx.com/role/TradePayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Payables",
        "documentation": "The disclosure of trade payables explanatory.",
        "label": "Disclosure Of Trade Payables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transactions with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DisclourseOfAccountsReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DisclourseOfAccountsReceivablesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/OtherAccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Receivable",
        "documentation": "The disclosure of accounts receivables.",
        "label": "Disclourse Of Accounts Receivables Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DiscountRatePercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate, percentage",
        "documentation": "Percentage of discount rate.",
        "label": "Discount Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "sprcy_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_DrugDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "DrugDevelopmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Development [Member]",
        "label": "Drug Development Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EFinanceIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EFinanceIncomeAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "e. Finance income:",
        "label": "EFinance Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://trpx.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sprcy_EffectOfPotentialDilutiveOrdinarySharesLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EffectOfPotentialDilutiveOrdinarySharesLossPerShare",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of potential dilutive ordinary shares, Loss (in Dollars per share)",
        "documentation": "Represents the par value of effect of potential dilutive ordinary shares.",
        "label": "Effect Of Potential Dilutive Ordinary Shares Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofDefinedContributionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses in respect of defined contribution plans",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r34",
      "r175"
     ]
    },
    "sprcy_EnterpriseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EnterpriseValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise value",
        "documentation": "The amount of enterprise.",
        "label": "Enterprise Value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r19",
      "r107",
      "r110",
      "r127",
      "r128",
      "r129"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity attributable to equity holders of the company",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "sprcy_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EquityLossesFromTheInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EquityLossesFromTheInvestment",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity losses from the investment in MitoCareX",
        "documentation": "Equity losses from the investment.",
        "label": "Equity Losses From The Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EstimatedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EstimatedAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amount",
        "label": "Estimated Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_EventsAftertheReportingDateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "EventsAftertheReportingDateDetailsTable",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After the Reporting Date (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ExchangeOfCommonShares",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Common Shares (in Shares)",
        "documentation": "Number of shares exchanged.",
        "label": "Exchange Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExchangeRateDifferencesNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ExchangeRateDifferencesNetMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate differences, net [Member]",
        "label": "Exchange Rate Differences Net Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price ($) (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ExternalRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ExternalRevenues",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External",
        "documentation": "Amount of external revenue.",
        "label": "External Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FFinanceExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FFinanceExpensesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "f. Finance expenses:",
        "label": "FFinance Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FairValueOfShareOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FairValueOfShareOptionsGranted",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share options granted",
        "documentation": "Fair value of share options granted.",
        "label": "Fair Value Of Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee (in Dollars)",
        "label": "Fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "sprcy_FinanceExpenseInRespectOfLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FinanceExpenseInRespectOfLeasesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense in respect of leases [Member]",
        "label": "Finance Expense In Respect Of Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinanceExpensesFromInterestAndCommissionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FinanceExpensesFromInterestAndCommissionsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expenses from interest and commissions [Member]",
        "label": "Finance Expenses From Interest And Commissions Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance income",
        "negatedTerseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments in financial assets at fair value",
        "label": "Financial assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company's Financial Instruments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FinancialInstrumentsScheduleofCompanysFinancialInstrumentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Company's Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial and lease liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r215"
     ]
    },
    "sprcy_FreightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "FreightMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Freight [Member]",
        "label": "Freight Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "GainOnSaleOfPatentLicenseNetnetOfPolyrizonLtdHoldingsSoldMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) [Member]",
        "label": "Gain On Sale Of Patent License Netnet Of Polyrizon Ltd Holdings Sold Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in financial asset",
        "label": "Gains (losses) on financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "ifrs-full_AdjustmentsForSharebasedPayments",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r184",
      "r195",
      "r197"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r184",
      "r195",
      "r197"
     ]
    },
    "sprcy_Governmentauthoritiescurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "Governmentauthoritiescurrent",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "documentation": "Represent the government authorities.",
        "label": "Governmentauthoritiescurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "terseLabel": "Gross proceeds (in Dollars)",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "sprcy_GrowthRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "GrowthRatePercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Growth rate, percentage",
        "label": "Growth Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israeli [Member]",
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "ILS",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIS [Member]",
        "label": "Israel, New Shekels"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment loss (gain)",
        "label": "Impairment loss recognised in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income. Impairment loss on a revalued asset is recognised in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. [Refer: Impairment loss; Revaluation surplus; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "negatedLabel": "Loss on impairment of intangible asset",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IncomeStatementsLocationsAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statements Locations [Axis]",
        "label": "Income Statements Locations Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IncomeStatementsLocationsDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IncomeStatementsLocationsDomainDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeStatementsLocationsDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "verboseLabel": "Tax Income (expense)",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r37",
      "r38",
      "r39",
      "r66",
      "r124",
      "r162"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued",
        "verboseLabel": "Units received (in Shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_InitialInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InitialInvestment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial investment amount",
        "documentation": "Initial investment.",
        "label": "Initial Investment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InitialPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InitialPublicOfferingMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering [Member]",
        "label": "Initial Public Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InstallmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment amount",
        "documentation": "Amount of installment amount.",
        "label": "Installment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InstallmentPaid",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment paid",
        "documentation": "The amount of installment paid.",
        "label": "Installment Paid"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InstallmentPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InstallmentPayment",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment payment, percentage",
        "documentation": "Installment payment.",
        "label": "Installment Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IntangibleAssetDetailsTable",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IntangibleAssetScheduleofFairValueoftheIntangibleAssetDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset - Schedule of Fair Value of the Intangible Asset (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Intangible assets, net",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r85"
     ]
    },
    "sprcy_InterestFromLoansToRelatedPartiesAndDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InterestFromLoansToRelatedPartiesAndDepositsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest from loans to related parties and deposits\t[Member]",
        "label": "Interest From Loans To Related Parties And Deposits Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid on lease liability",
        "label": "Interest paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "sprcy_InterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InterestPercentage",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "documentation": "Interest percentage.",
        "label": "Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InterestRate",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, percentage",
        "documentation": "Interest rate.",
        "label": "Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r168",
      "r213"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 8.0
      },
      "http://trpx.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventory",
        "terseLabel": "Inventory",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r178"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "terseLabel": "Investments in company accounted for at equity",
        "label": "Investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r125",
      "r164"
     ]
    },
    "sprcy_InvestmentAchievementOfFirstMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentAchievementOfFirstMilestone",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement of first milestone",
        "documentation": "The amount of investment following achievement of first milestone.",
        "label": "Investment Achievement Of First Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentAchievementOfSecondMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentAchievementOfSecondMilestone",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment following achievement of second milestone",
        "documentation": "Investment following achievement of second milestone.",
        "label": "Investment Achievement Of Second Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentIncome",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing amount (in Dollars)",
        "label": "Investment income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investment income, such as interest and dividends."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r213"
     ]
    },
    "sprcy_InvestmentinAssociatesandJointVenturesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentinAssociatesandJointVenturesDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Joint Ventures (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandJointVenturesTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentinAssociatesandJointVenturesTablesLineItems",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Investments in Investees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinAssociatesandJointVenturesTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentinAssociatesandJointVenturesTablesTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associates and Joint Ventures (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentinFinancialAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentinFinancialAssetsDetailsTable",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Financial Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsAccountedForUsingEquityMethodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestmentsDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestmentsDate",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment date March 31, 2022",
        "documentation": "The amount of investment date,",
        "label": "Investments Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_InvestorRelationsAndBusinessExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "InvestorRelationsAndBusinessExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and business expenses [Member]",
        "label": "Investor Relations And Business Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceExpensesRelatedToWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssuanceExpensesRelatedToWarrantsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses related to warrants [Member]",
        "label": "Issuance Expenses Related To Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceExpireTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssuanceExpireTerm",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire term",
        "documentation": "Issuance expire term.",
        "label": "Issuance Expire Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssuanceOfAggregateShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of aggregate shares",
        "documentation": "The issuance of aggregate shares.",
        "label": "Issuance Of Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssuanceOfShareCapitalInRespectOfExerciseOfPrefundedWarrants",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of exercise of October 2023 pre-funded warrants (Note 18h",
        "documentation": "Issuance of share capital \u2013 in respect of exercise of October 2023 pre-funded warrants.",
        "label": "Issuance Of Share Capital In Respect Of Exercise Of Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuanceOfShareCapitalInRespectSEPA": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssuanceOfShareCapitalInRespectSEPA",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital \u2013 in respect of January 2024 SEPA (Note 18(i))",
        "documentation": "Number of issuance of share capital \u2013 in respect of January 2024 SEPA.",
        "label": "Issuance Of Share Capital In Respect SEPA"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssueOfShareCapitalNetOfIssueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssueOfShareCapitalNetOfIssueExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital, net of issue expenses",
        "documentation": "The amount of issue of share capital, net of issue expenses.",
        "label": "Issue Of Share Capital Net Of Issue Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_IssuedAndOutstandingSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "IssuedAndOutstandingSharePercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and outstanding share",
        "documentation": "Issued and outstanding shares percentage.",
        "label": "Issued And Outstanding Share Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ContingentLiabilitiesCommitmentsClaimsandLiensDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital purchase",
        "label": "Issued capital, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sprcy_JeffsBrandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "JeffsBrandsMember",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jeffs\u2019 Brands [Member]",
        "label": "Jeffs Brands Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_June2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "June2022WarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2022 Warrants [Member]",
        "label": "June2022 Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_KeyManagementPersonnelCompensationManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "KeyManagementPersonnelCompensationManagementFees",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees (see also note 25a)",
        "documentation": "The amount of compensation to key management personnel in the form of management fees.",
        "label": "Key Management Personnel Compensation Management Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of share-based payment",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofBenefitstoKeyManagementPersonnelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel [Member]",
        "label": "Key management personnel of entity or parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "sprcy_LeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LeaseMember",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Lease [Member]",
        "label": "Lease Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeaseholdImprovementsMainlyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LeaseholdImprovementsMainlyRate",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements mainly",
        "documentation": "The leasehold improvements rate used for mainly.",
        "label": "Leasehold Improvements Mainly Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "sprcy_LeasesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LeasesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r79",
      "r80",
      "r128"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r128"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r128"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r128"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r128"
     ]
    },
    "sprcy_LicenseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LicenseAgreementDescription",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement, description",
        "documentation": "The description of the license agreement.",
        "label": "License Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LicenseeIssuePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LicenseeIssuePrice",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensee issue price",
        "documentation": "The amount of licensee, reflecting an issue.",
        "label": "Licensee Issue Price"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ListedSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ListedSharePrice",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listed share price (in Dollars per share)",
        "documentation": "Amount of listed shares price per share.",
        "label": "Listed Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amount (in Dollars)",
        "label": "Loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trpx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LongTermPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LongTermPercentage",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term, percentage",
        "documentation": "The percentage of long term.",
        "label": "Long Term Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossFromSaleOfPropertyAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LossFromSaleOfPropertyAndEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from sale of property and equipment [Member]",
        "label": "Loss From Sale Of Property And Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_LossesFromRemeasurementOfInvestmentInFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "LossesFromRemeasurementOfInvestmentInFinancialAssetsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses from remeasurement of investment in financial assets [Member]",
        "label": "Losses From Remeasurement Of Investment In Financial Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ManagementFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ManagementFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees [Member]",
        "label": "Management Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement [Member]",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MilestonesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "MilestonesAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones amount",
        "documentation": "Milestones amount.",
        "label": "Milestones Amount"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXBioLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "MitoCareXBioLtdMember",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCare X Bio Ltd [Member]",
        "label": "Mito Care XBio Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MitoCareXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "MitoCareXMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MitoCareX [Member]",
        "label": "Mito Care XMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MizaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "MizaMember",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miza [Member]",
        "label": "Miza Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_MonthlyLeaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "MonthlyLeaseFee",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly lease fee (in Dollars)",
        "documentation": "Monthly lease fee.",
        "label": "Monthly Lease Fee"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_N2OFFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "N2OFFMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "N2OFF [Member]",
        "label": "N2 OFFMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NetChangeInFairValueOfFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in fair value of financial liabilities designated at fair value through profit or loss [Member]",
        "label": "Net Change In Fair Value Of Financial Liabilities Designated At Fair Value Through Profit Or Loss Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetDebt",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open debts",
        "label": "Net debt"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r112",
      "r114"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r119",
      "r192"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Non-current receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount (in Dollars)",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://trpx.com/role/ScheduleofRSUtransactionTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted",
        "verboseLabel": "Granted shares",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r225"
     ]
    },
    "sprcy_NumberOfOptionsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NumberOfOptionsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options outstanding",
        "documentation": "Represents the amount of options outstanding.",
        "label": "Number Of Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable of shares",
        "label": "Number of other equity instruments exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofRSUtransactionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of RSUs",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofRSUtransactionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry of RSUs",
        "label": "Number of other equity instruments expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofRSUtransactionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, January 1, 2024",
        "periodEndLabel": "Balance, December 31, 2024",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "sprcy_NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest over period",
        "documentation": "Number of Other Equity Instruments Vested in Share based Payment Arrangement.",
        "label": "Number Of Other Equity Instruments Vested In Share Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Share Options , Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Number of Share Options, Share Options outstanding at the end of the year",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r140",
      "r143"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Share Options exercisable at the end of the year",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Share Options, Share Options cancelled during the year",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "sprcy_NumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NumberOfSharesAbstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Number Of Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Authorized",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, 2024",
        "periodEndLabel": "Balance at December 31, 2024",
        "terseLabel": "Received common shares",
        "verboseLabel": "Shares issued",
        "netLabel": "Issuance of ordinary shares",
        "label": "Number of shares issued (in Shares)",
        "totalLabel": "Ordinary shares (in Shares)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued and Outstanding Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://trpx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Issued and outstanding",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sprcy_NumberOfUnitsReceived": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NumberOfUnitsReceived",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units (in Shares)",
        "documentation": "Number of units received.",
        "label": "Number Of Units Received"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfWarrantsHolds": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NumberOfWarrantsHolds",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants holds (in Shares)",
        "documentation": "Number of warrants holds.",
        "label": "Number Of Warrants Holds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_NumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "NumberOfWarrantsIssued",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants issued (in Shares)",
        "documentation": "Number of warrants issued.",
        "label": "Number Of Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_October2023FinancingRoundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "October2023FinancingRoundMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2023 Financing Round [Member]",
        "label": "October2023 Financing Round Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "sprcy_OfficeEquipmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OfficeEquipmentsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipments Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OfficeMaintenanceRentAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OfficeMaintenanceRentAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance, rent and other expenses [Member]",
        "label": "Office Maintenance Rent And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OnlineSalesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales [Member]",
        "label": "Online Sales Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OnlineSalesSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OnlineSalesSegmentMember",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Online Sales Segment [Member]",
        "label": "Online Sales Segment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingLossCarryforwardsTaxAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingLossCarryforwardsTaxAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses (in Dollars)",
        "documentation": "The amount of net operating loss carryforward tax as of the reporting date.",
        "label": "Operating Loss Carryforwards Tax Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingSegmentsDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingSegmentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsScheduleofOperatingSegmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingSegmentsScheduleofOperatingSegmentsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments - Schedule of Operating Segments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingSegmentsTablesLineItems",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Abstract]",
        "label": "Operating Segments Tables Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingSegmentsTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingSegmentsTablesTable",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OperatingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OperatingTerm",
     "presentation": [
      "http://trpx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating term",
        "label": "Operating Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OptionToExtendLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OptionToExtendLeaseTerm",
     "presentation": [
      "http://trpx.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to extend lease term",
        "documentation": "Option to extend lease term.",
        "label": "Option To Extend Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OrdinarySharesGrantedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OrdinarySharesGrantedDiscountRate",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares granted discount rate",
        "documentation": "Ordinary shares granted discount rate.",
        "label": "Ordinary Shares Granted Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares [Member]",
        "verboseLabel": "Ordinary Share [Member]",
        "netLabel": "Common shares [Member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "sprcy_OtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Assets",
        "verboseLabel": "Assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_OtherCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash position",
        "label": "Other cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r26",
      "r33",
      "r122"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in short-term financial assets",
        "verboseLabel": "Investments in financial assets",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other short-term liability",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts receivable",
        "terseLabel": "Other accounts receivable",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_OtherEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEquityInterest",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_OtherEquityInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEquityInterestMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with non-controlling interests",
        "label": "Other equity interest [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_OtherFeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other fee expenses",
        "label": "Other fee and commission expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses (income)",
        "label": "Other finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income",
        "label": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r175",
      "r176"
     ]
    },
    "ifrs-full_OtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Other intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset [Member]",
        "label": "Other intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Liabilities",
        "label": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in financial assets",
        "verboseLabel": "Investments in short-term financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable",
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties [Member]",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "sprcy_OutstandingShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OutstandingShareCapital",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding share capital, percentage",
        "documentation": "Percentage of outstanding share capital.",
        "label": "Outstanding Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OutstandingSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OutstandingSharesPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares",
        "documentation": "Outstanding shares percentage.",
        "label": "Outstanding Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_OverAllotmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "OverAllotmentMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Allotment [Member]",
        "label": "Over Allotment Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares par value",
        "verboseLabel": "Par value (in Dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParentMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "sprcy_PaymentForPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PaymentForPremiumPercentage",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for premium percentage",
        "documentation": "Payment for premium percentage.",
        "label": "Payment For Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentOfIssuanceExpensesRelatedToPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PaymentOfIssuanceExpensesRelatedToPreviousPeriod",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of issuance expenses related to previous period",
        "label": "Payment Of Issuance Expenses Related To Previous Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PaymentsOfAdditionalDeferredCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PaymentsOfAdditionalDeferredCash",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional deferred cash",
        "documentation": "Represents the amount of payments of additional deferred cash.",
        "label": "Payments Of Additional Deferred Cash"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "sprcy_PercentageOfAggregateNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PercentageOfAggregateNetSales",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net sales",
        "documentation": "Percentage of aggregate net sales.",
        "label": "Percentage Of Aggregate Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfFinancingProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PercentageOfFinancingProceeds",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of financing proceeds",
        "documentation": "Percentage of financing proceeds.",
        "label": "Percentage Of Financing Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PercentageOfFullyDilutedCapitalStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PercentageOfFullyDilutedCapitalStock",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of fully diluted capital stock",
        "documentation": "Percentage of fully diluted capital stock.",
        "label": "Percentage Of Fully Diluted Capital Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "sprcy_PreFundedUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PreFundedUnitsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Units [Member]",
        "label": "Pre Funded Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "verboseLabel": "Pre-Funded Warrant [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing proceeds (in Dollars)",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_ProceedsFromChangesInOwnershipInterestsInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromChangesInOwnershipInterestsInSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103"
     ]
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "label": "Proceeds from contributions of non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants (a)",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of share capital (net of issuance expenses)",
        "verboseLabel": "Invested amount",
        "netLabel": "Gross cash proceeds (in Dollars)",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "sprcy_ProfessionalAndDirectorsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ProfessionalAndDirectorsFeesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and directors\u2019 fees [Member]",
        "label": "Professional And Directors Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow",
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable",
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "terseLabel": "Income (loss)",
        "verboseLabel": "Loss",
        "negatedLabel": "Profit loss",
        "negatedTerseLabel": "Loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r25",
      "r97",
      "r108",
      "r111",
      "r163",
      "r166",
      "r192",
      "r196"
     ]
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r27",
      "r113"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatementAlt0": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity holders of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r175",
      "r176",
      "r199",
      "r200"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingBasicEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating basic earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating basic earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToParticipatingEquityInstrumentsOtherThanOrdinarySharesUsedInCalculatingDilutedEarningsLossPerInstrument",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per share, Loss (in Dollars)",
        "label": "Profit (loss) from continuing operations attributable to participating equity instruments other than ordinary shares, used in calculating diluted earnings (loss) per instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations used in calculating diluted earnings (loss) per instrument attributable to equity instruments that participate in profit with ordinary shares according to a predetermined formula. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "terseLabel": "Operating loss",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r213"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Property and equipment, net at beginning balance",
        "periodEndLabel": "Property and equipment, net at ending balance",
        "terseLabel": "Property and equipment, net",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r46"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PropertyandEquipmentNetScheduleofPropertyandEquipmentNetDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r116"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r69",
      "r115"
     ]
    },
    "sprcy_PurchaseCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PurchaseCostsValue",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase costs",
        "documentation": "The amount of purchase costs.",
        "label": "Purchase Costs Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible asset",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in financial assets",
        "label": "Purchase of interests in investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in a company accounted for at equity",
        "label": "Purchase of investments other than investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "sprcy_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "The purchase price is the price an investor pays for an investment, and the price becomes the investor's cost basis for calculating gain or loss when selling the investment.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PurchasePricePercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "documentation": "Represents the purchase price percentage.",
        "label": "Purchase Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchasedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PurchasedGoodsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased goods [Member]",
        "label": "Purchased Goods Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_PurchaserRemainingOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "PurchaserRemainingOwnershipPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchaser remaining ownership",
        "documentation": "Purchaser remaining ownership percentage.",
        "label": "Purchaser Remaining Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r226"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r226"
     ]
    },
    "sprcy_ReceivablesInRespectOfDownpaymentOnMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ReceivablesInRespectOfDownpaymentOnMerger",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables in respect of downpayment on merger",
        "documentation": "The amount of receivables in respect of downpayment on merger.",
        "label": "Receivables In Respect Of Downpayment On Merger"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RegulatoryExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory expenses [Member]",
        "label": "Regulatory Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RegulatoryProfessionalAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RegulatoryProfessionalAndOtherExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory, professional and other expenses [Member]",
        "label": "Regulatory Professional And Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RelatedPartyBalancetextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RelatedPartyBalancetextBlock",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "label": "Related Party Balancetext Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized over period",
        "label": "Remaining amortisation period of intangible assets material to entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "sprcy_RemainingPurchaserAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RemainingPurchaserAmount",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchaser equal valuation",
        "documentation": "Remaining purchaser amount.",
        "label": "Remaining Purchaser Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RepaidOfMonthlyInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RepaidOfMonthlyInstallments",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly installments (in Dollars)",
        "documentation": "Repaid of Monthly installments.",
        "label": "Repaid Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable": {
       "parentTag": "ifrs-full_AdjustmentsForSharebasedPayments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable",
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "sprcy_ResearchAndPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ResearchAndPreclinicalStudiesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and preclinical studies [Member]",
        "label": "Research And Preclinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "verboseLabel": "Engaged in a mutual share exchange",
        "label": "Reserve of exchange differences on translation"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r177"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve from share-based payment transactions",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and restricted deposits",
        "label": "Restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Units [Member]",
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sprcy_RestrictedStockGrantPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RestrictedStockGrantPercentage",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock grant percentage",
        "documentation": "Restricted stock grant percentage.",
        "label": "Restricted Stock Grant Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r177"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "verboseLabel": "Total",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r121",
      "r149",
      "r160",
      "r165",
      "r170",
      "r171",
      "r173",
      "r175",
      "r176",
      "r192"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cost of Sales and Gross Profit [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RevenuesandCostofRevenuesScheduleofCostofSalesandGrossProfitDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofCostofSalesandGrossProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues and Cost of Revenues - Schedule of Cost of Sales and Gross Profit (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ReverseShareSplitRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ReverseShareSplitRatio",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse share split ratio",
        "documentation": "Reverse share split ratio.",
        "label": "Reverse Share Split Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ReverseSplitRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ReverseSplitRatio",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse split ratio",
        "documentation": "Reverse split ratio.",
        "label": "Reverse Split Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RightOfUseAssesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RightOfUseAssesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asses [Member]",
        "label": "Right Of Use Asses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_RightofuseAssetRecognizedWithCorrespondingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "RightofuseAssetRecognizedWithCorrespondingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability",
        "documentation": "Right-of-use asset recognized with corresponding lease liability.",
        "label": "Rightofuse Asset Recognized With Corresponding Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SEPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SEPAMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA [Member]",
        "label": "SEPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfMinorityInterestInSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SaleOfMinorityInterestInSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of minority interest in subsidiary",
        "documentation": "The amount of sale of minority interest in subsidiary.",
        "label": "Sale Of Minority Interest In Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SaleOfOrdinaryShares",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of ordinary shares",
        "documentation": "Sale of ordinary shares.",
        "label": "Sale Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale Of Stock Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SaleOfStockDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SaleOfStockDomainDomain",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SaleOfStockDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase sale (in Dollars)",
        "label": "Sale or issue of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_SalepurchaseOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SalepurchaseOfPropertyAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale (purchase) of property and equipment",
        "documentation": "The cash outflow for the sale of purchases property, plant and equipment, classified as investing activities.",
        "label": "Salepurchase Of Property And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "verboseLabel": "Sales and marketing expenses",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "sprcy_ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfAdditionalInformationToTheItemsOfProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information To The Items Of Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCompanysFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfCompanysFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Companys Financial Instruments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfCostOfSalesAndGrossProfitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfCostOfSalesAndGrossProfitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cost Of Sales And Gross Profit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDefinedContributionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfDefinedContributionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Contribution Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Is Calculated On AStraight Line Basis Over The Useful Life Of The Assets At Annual Rates Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfDepreciationIsCalculatedOnAStraightLineBasisOverTheUsefulLifeOfTheAssetsAtAnnualRatesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfExpensesDueToShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfExpensesDueToShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Expenses Due to Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueForShareOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfFairValueForShareOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value For Share Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfFairValueOfTheIntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfFairValueOfTheIntangibleAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Intangible Asset Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Number of Shares and Loss Used in the Computation of Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Segments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfOtherAccountsPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfRevenuesAndCostOfRevenuesTableTextBlock",
     "presentation": [
      "http://trpx.com/role/RevenuesandCostofRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost of Sales and Gross Profit",
        "label": "Schedule Of Revenues And Cost Of Revenues Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfRsuTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfRsuTransactionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU transaction [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfTransactionsWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfTransactionsWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Transactions with Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants Fair Value Was Calculated Using The Black Scholes Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfWarrantsFairValueWasCalculatedUsingTheBlackScholesLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ScheduleOfWeightedAverageExercisePricesOfShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Exercise Prices Of Share Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SciSparcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SciSparcMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SciSparc\u2019s [Member]",
        "label": "Sci Sparc Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r132",
      "r163",
      "r185",
      "r198"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://trpx.com/role/OperatingSegmentsDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheIntangibleAssetTable",
      "http://trpx.com/role/ScheduleofOperatingSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r132",
      "r169",
      "r185",
      "r198"
     ]
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services rendered amount (in Dollars)",
        "verboseLabel": "Services expenses",
        "label": "Services expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from services."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "sprcy_ShareBasedPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareBasedPaymentMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment [Member]",
        "label": "Share Based Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsScheduleofExpensesDuetoShareBasedCompensationDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions - Schedule of Expenses Due to Share-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareBasedPaymentTransactionsScheduleofFairValueforShareOptionsGrantedDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions - Schedule of Fair Value for Share Options Granted (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_ShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareCapitalPercentage",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "verboseLabel": "Share capital percentage",
        "documentation": "Share capital percentage.",
        "label": "Share Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital in respect of investment in affiliate",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sprcy_ShareIssuedToAConsultants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "ShareIssuedToAConsultants",
     "presentation": [
      "http://trpx.com/role/ScheduleofIssuedandOutstandingShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued to consultants (Note 18(e), and Note 19 (a) (3)",
        "documentation": "Number of share issued to consultants.",
        "label": "Share Issued To AConsultants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedIncomeStatement",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/ScheduleofFairValueoftheInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity losses from the investment in MitoCareX",
        "terseLabel": "Equity losses from investment in MitoCareX",
        "verboseLabel": "Equity losses from the investment",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Total for all joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r161",
      "r168"
     ]
    },
    "ifrs-full_ShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOptionsMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options [Member]",
        "label": "Share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share options."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sprcy_SharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SharePricePerShare",
     "presentation": [
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "documentation": "Share price.",
        "label": "Share Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SharePriceRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SharePriceRate",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price rate",
        "documentation": "Share price rate.",
        "label": "Share Price Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialAssetsAtAmortisedCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposit",
        "verboseLabel": "Short-term deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsUsedInThePreparationOfTheFinancialStatementsabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SignificantAccountingPoliciesScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies - Schedule of Depreciation is Calculated on a Straight-Line Basis Over the Useful Life of the Assets at Annual Rates (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsDuringTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SignificantEventsDuringTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsDuringTheReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SignificantEventsDuringTheReportingPeriodLineItems",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events During the Reporting Period [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantEventsduringtheReportingPeriodDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SignificantEventsduringtheReportingPeriodDetailsTable",
     "presentation": [
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events during the Reporting Period (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SignificantNonCashTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SignificantNonCashTransactionsAbstract",
     "presentation": [
      "http://trpx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Significant non-cash transactions:",
        "label": "Significant Non Cash Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://trpx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StorageAndShippingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "StorageAndShippingMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Storage and shipping [Member]",
        "label": "Storage And Shipping Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "StraightlineBasisOverUsefulLifeOfAssetsAtAnnualRatesMainly",
     "presentation": [
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over useful life of assets at annual rates mainly",
        "label": "Straightline Basis Over Useful Life Of Assets At Annual Rates Mainly"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_SubsequentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "SubsequentEventsMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Member]",
        "label": "Subsequent Events Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "sprcy_TaxesonIncomeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TaxesonIncomeDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://trpx.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/InvestmentinAssociatesandJointVenturesDetails",
      "http://trpx.com/role/InvestmentinFinancialAssetsDetails",
      "http://trpx.com/role/ScheduleofDepreciationisCalculatedonaStraightLineBasisOvertheUsefulLifeoftheAssetsatAnnualRatesTable",
      "http://trpx.com/role/SignificantEventsduringtheReportingPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [member]",
        "verboseLabel": "Top of range [Member]",
        "netLabel": "Top of Range [Member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r136",
      "r143",
      "r193",
      "r194",
      "r226"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other accounts payable",
        "terseLabel": "Other accounts payable",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge loan to related parties",
        "label": "Current receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://trpx.com/role/ScheduleofTradePayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet",
      "http://trpx.com/role/ScheduleofTradePayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade payables",
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable": {
       "parentTag": "ifrs-full_OtherCurrentReceivables",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofOtherAccountsReceivableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party",
        "label": "Receivables due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsLineItems",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofBalanceswithRelatedPartiesDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Balances with Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TransactionsandBalanceswithRelatedPartiesScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesDetailsTable",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions and Balances with Related Parties - Schedule of Warrants\u2019 Fair Value was Calculated using the Black\u2013Scholes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
     "presentation": [
      "http://trpx.com/role/ScheduleofTransactionswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Transfers of research and development to entity, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of transfers of research and development to the entity in related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "sprcy_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand Twenty Three Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ScheduleofExpensesDuetoShareBasedCompensationTable",
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://trpx.com/role/EquityDetails",
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://trpx.com/role/ScheduleofCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://trpx.com/role/IntangibleAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "sprcy_VestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "VestingPeriod",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "documentation": "Vesting period.",
        "label": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "VolumeWeightedAveragePriceOfOrdinarySharesOfDuringTheConsecutiveTradingDays",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price during consecutive trading days",
        "documentation": "Volume weighted average price of ordinary shares during the consecutive trading days.",
        "label": "Volume Weighted Average Price Of Ordinary Shares Of During The Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "VolumeWeightedAveragePriceOfOrdinarySharesOfPrecedingTheClosingOfTradingDay",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price",
        "documentation": "Volume weighted average price of ordinary shares of preceding the closing of trading day.",
        "label": "Volume Weighted Average Price Of Ordinary Shares Of Preceding The Closing Of Trading Day"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "VolumeWeightedAveragePriceOfOrdinarySharesOnTheDayPriorToTheClosing",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price of ordinary shares",
        "documentation": "Volume weighted average price of ordinary shares on the day prior to the closing.",
        "label": "Volume Weighted Average Price Of Ordinary Shares On The Day Prior To The Closing"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_VolumeWeightedAveragePricePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "VolumeWeightedAveragePricePerWarrant",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price per warrant (in Dollars per share)",
        "documentation": "Volume weighted average price per warrant.",
        "label": "Volume Weighted Average Price Per Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WagesAndRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "WagesAndRelatedExpensesMember",
     "presentation": [
      "http://trpx.com/role/ScheduleofAdditionalInformationtotheItemsofProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and related expenses [Member]",
        "label": "Wages And Related Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantExercisableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "WarrantExercisableTerm",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercisable term",
        "documentation": "Warrant exercisable term.",
        "label": "Warrant Exercisable Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "sprcy_WarrantsAndExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "WarrantsAndExercise",
     "presentation": [
      "http://trpx.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and exercise",
        "label": "Warrants And Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsExpireDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "WarrantsExpireDate",
     "presentation": [
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expire date",
        "documentation": "Warrants expire date.",
        "label": "Warrants Expire Date"
       }
      }
     },
     "auth_ref": []
    },
    "sprcy_WarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "WarrantsLiability",
     "crdr": "credit",
     "calculation": {
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://trpx.com/role/ScheduleofCompanysFinancialInstrumentsTable",
      "http://trpx.com/role/ScheduleofFinancialAssetsandFinancialLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants liability",
        "verboseLabel": "Warrants",
        "label": "Warrants Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://trpx.com/role/EventsAftertheReportingDateDetails",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://trpx.com/role/ShareholdersEquityType2or3",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants [Member]",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options exercisable at the end of the year",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Share Options cancelled during the year",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Share Options outstanding at the beginning of the year",
        "periodEndLabel": "Weighted average exercise price, Share Options outstanding at the end of the year",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r140"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://trpx.com/role/TransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "verboseLabel": "Warrants fair value",
        "label": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value ($) (in Dollars)",
        "verboseLabel": "Fair value of the ordinary shares granted",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://trpx.com/role/ScheduleofFairValueforShareOptionsGrantedTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedUsingtheBlackScholesOptionPricingModelTable",
      "http://trpx.com/role/ScheduleofWarrantsFairValuewasCalculatedusingtheBlackScholesTable",
      "http://trpx.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price ($) (in Dollars per share)",
        "verboseLabel": "Underlying ordinary share price (in Dollars per share)",
        "netLabel": "Underlying Share Price of Polyrizon Ltd. ($) (in Dollars per share)",
        "label": "Share price per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://trpx.com/role/ScheduleofNumberofSharesandLossUsedintheComputationofLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share, Weighted number of shares",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "sprcy_a2024Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://trpx.com/20241231",
     "localname": "a2024Abstract",
     "presentation": [
      "http://trpx.com/role/ScheduleofWeightedAverageExercisePricesofShareOptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024:",
        "label": "a2024 Abstract"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_29&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_21_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "A14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_A14&doctype=Appendix&subtype=A",
   "URIDate": "2024-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
